<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="0.62.0">
<page number="1" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="0" size="12" family="Times" color="#000000"/>
	<fontspec id="1" size="14" family="Times" color="#000000"/>
	<fontspec id="2" size="19" family="Times" color="#000000"/>
	<fontspec id="3" size="19" family="Times" color="#000000"/>
	<fontspec id="4" size="16" family="Times" color="#000000"/>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="12" height="21" font="1">1 </text>
<text top="113" left="90" width="1014" height="19" font="2"><b>2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Cholesterol Guideline Data </b></text>
<text top="137" left="536" width="121" height="19" font="2"><b>Supplements</b> </text>
<text top="161" left="349" width="495" height="19" font="2"><b>(Section numbers correspond to the full-text guideline) </b></text>
<text top="209" left="525" width="141" height="16" font="4"><b>Table of Contents </b></text>
<text top="242" left="81" width="1012" height="22" font="1"><a href="data supplement.html#4">Data Supplement 1. Nonrandomized Trials, Observational Studies, and/or Registries of Q3: Evidence regarding the difference in lipid levels measured in fasting and non-</a></text>
<text top="261" left="81" width="1029" height="22" font="1"><a href="data supplement.html#4">fasting individuals, and associations with outcomes (Section 2.2) ........................................................................................................................................................ 4 </a></text>
<text top="282" left="81" width="1029" height="22" font="1"><a href="data supplement.html#12">Data Supplement 2. RCTs of Statin Therapy for Primary Prevention of ASCVD Among Patients with the Metabolic Syndrome or its Subcomponents (Section 3.1.2) ........ 12 </a></text>
<text top="302" left="81" width="1029" height="22" font="1"><a href="data supplement.html#15">Data Supplement 3. Meta-analyses comparing statins versus placebo or various intensities of statin therapy (Section 3.2) .................................................................... 15 </a></text>
<text top="322" left="81" width="1029" height="22" font="1"><a href="data supplement.html#17">Data Supplement 4. Risk stratification among patients with ASCVD to identify those most likely to benefit from non-statin therapy (Section 3.2.2) ................................... 17 </a></text>
<text top="342" left="81" width="998" height="22" font="1"><a href="data supplement.html#20">Data Supplement 5. RCTs of Non-Statin or Combination Lipid Lowering Therapy for Primary Prevention of ASCVD Among Patients with the Metabolic Syndrome or its </a></text>
<text top="361" left="81" width="1029" height="22" font="1"><a href="data supplement.html#20">Subcomponents (Section 3.2.3) ..................................................................................................................................................................................................... 20 </a></text>
<text top="381" left="81" width="1029" height="22" font="1"><a href="data supplement.html#22">Data Supplement 6. Evidence Tables for Statin initiation in patients with heart failure meta-analysis of CORONA and GISSI HF trials (Section 4.1) ................................. 22 </a></text>
<text top="401" left="81" width="1029" height="22" font="1"><a href="data supplement.html#26">Data Supplement 7. Meta-analysis of CORONA and GISSI HF trials (Section 4.1) .............................................................................................................................. 26 </a></text>
<text top="421" left="81" width="1029" height="22" font="1"><a href="data supplement.html#32">Data Supplement 8. Evidence Tables for Secondary Prevention (Section 4.1) .................................................................................................................................... 32 </a></text>
<text top="441" left="81" width="1029" height="22" font="1"><a href="data supplement.html#39">Data Supplement 9. RCTs comparing evidence on Severe Hypercholesterolemia (Section 4.2) ........................................................................................................... 39 </a></text>
<text top="462" left="81" width="1029" height="22" font="1"><a href="data supplement.html#46">Data Supplement 10. Non-randomized Trials, Observational Studies and/or Registries for Severe Hypercholesterolemia (Section 4.2) ................................................... 46 </a></text>
<text top="482" left="81" width="1029" height="22" font="1"><a href="data supplement.html#51">Data Supplement 11. Nonrandomized Trials, Observational Studies, and/or Registries of Diabetes Mellitus 40-75 Years (Section 4.3) ................................................... 51 </a></text>
<text top="502" left="81" width="1029" height="22" font="1"><a href="data supplement.html#58">Data Supplement 12. RCTs Comparing Diabetes Mellitus 40-75 Years (Section 4.3) .......................................................................................................................... 58 </a></text>
<text top="522" left="81" width="1029" height="22" font="1"><a href="data supplement.html#64">Data Supplement 13. Nonrandomized Trials, Observational Studies, and/or Registries of ASCVD Risk Associated with the Metabolic Syndrome (Section 4.4.1) .............. 64 </a></text>
<text top="542" left="81" width="983" height="22" font="1"><a href="data supplement.html#65">Data Supplement 14. Nonrandomized Trials, Observational Studies, and/or Registries of Q1: Performance of the Pooled Cohort Equations (PCE) when used for the </a></text>
<text top="561" left="81" width="1029" height="22" font="1"><a href="data supplement.html#65">prediction of first incident atherosclerotic cardiovascular disease (ASCVD) events in diverse populations (Section 4.4.1.2) .................................................................... 65 </a></text>
<text top="581" left="81" width="961" height="22" font="1"><a href="data supplement.html#84">Data Supplement 15. Nonrandomized Trials, Observational Studies, and/or Registries of Q2: Performance of coronary artery calcium screening to reclassify risk </a></text>
<text top="600" left="81" width="1012" height="22" font="1"><a href="data supplement.html#84">appropriately for atherosclerotic cardiovascular disease (ASCVD) events when used for the prediction of first incident ASCVD events in diverse populations, especially in </a></text>
<text top="619" left="81" width="1029" height="22" font="1"><a href="data supplement.html#84">the context of the Pooled Cohort Equations (Section 4.4.1.2) ............................................................................................................................................................ 84 </a></text>
<text top="639" left="81" width="1029" height="22" font="1"><a href="data supplement.html#101">Data Supplement 16. Evidence Tables for Borderline and Intermediate Risk Group (5-&lt;7.5%; 7.5 to 20%) (Section 4.4.2) ................................................................... 101 </a></text>
<text top="659" left="81" width="1029" height="22" font="1"><a href="data supplement.html#104">Data Supplement 17. Evidence Tables Monitoring in Response to LDL-C–Lowering Therapy (Section 4.4.3) ...................................................................................... 104 </a></text>
<text top="679" left="81" width="1029" height="22" font="1"><a href="data supplement.html#107">Data Supplement 18. Evidence Table to discontinue therapy (Section 4.4.4.1) ................................................................................................................................. 107 </a></text>
<text top="700" left="81" width="1029" height="22" font="1"><a href="data supplement.html#109">Data Supplement 19. Evidence Table for Statin therapy for adults &gt;75 years (Section 4.4.4.1) .......................................................................................................... 109 </a></text>
<text top="720" left="81" width="956" height="22" font="1"><a href="data supplement.html#115">Data Supplement 20. Nonrandomized Trials, Observational Studies, and/or Registries of Q4: Evidence regarding the cost-effectiveness of screening for familial </a></text>
<text top="739" left="81" width="1029" height="22" font="1"><a href="data supplement.html#115">hypercholesterolemia (Section 4.4.4.3) ......................................................................................................................................................................................... 115 </a></text>
<text top="759" left="81" width="1029" height="22" font="1"><a href="data supplement.html#121">Data Supplement 21. RCTs Comparing Screening of Children and Adolescents (Section 4.4.4.3) ...................................................................................................... 121 </a></text>
<text top="779" left="81" width="1029" height="22" font="1"><a href="data supplement.html#131">Data Supplement 22. Nonrandomized Trials, Observational Studies, and/or Registries of Metabolic Syndrome of Children and Adolescents (Section 4.4.4.3) ................ 131 </a></text>
</page>
<page number="2" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="12" height="21" font="1">2 </text>
<text top="106" left="81" width="1029" height="22" font="1"><a href="data supplement.html#134">Data Supplement 23. Nonrandomized Trials, Observational Studies, and/or Registries of Treatment (Section 4.4.4.3) ......................................................................... 134 </a></text>
<text top="126" left="81" width="1029" height="22" font="1"><a href="data supplement.html#135">Data Supplement 24. Nonrandomized Trials, observational studies and / Registries for African Americans. (Section 4.5.1) .................................................................. 135 </a></text>
<text top="146" left="81" width="998" height="22" font="1"><a href="data supplement.html#138">Data Supplement 25. Nonrandomized Trials, Observational Studies, and/or Registries of Pooled Cohorts Equation Risk Estimation in Adults of Asian Descent (Section </a></text>
<text top="165" left="81" width="1029" height="22" font="1"><a href="data supplement.html#138">4.5.1) ......................................................................................................................................................................................................................................... 138 </a></text>
<text top="186" left="81" width="1029" height="22" font="1"><a href="data supplement.html#141">Data Supplement 26. Nonrandomized Trials, Observational Studies, and/or Registries of Hispanic (Section 4.5.1) .............................................................................. 141 </a></text>
<text top="206" left="81" width="1029" height="22" font="1"><a href="data supplement.html#143">Data Supplement 27. Nonrandomized Trials, Observational Studies, and/or Registries of Hispanic (Section 4.5.1) .............................................................................. 143 </a></text>
<text top="226" left="81" width="1029" height="22" font="1"><a href="data supplement.html#148">Data Supplement 28. Nonrandomized Trials, Observational Studies, and/or Registries of Hispanic (Section 4.5.1) .............................................................................. 148 </a></text>
<text top="246" left="81" width="1029" height="22" font="1"><a href="data supplement.html#151">Data Supplement 29. Nonrandomized Trials, Observational Studies, and/or Registries of Hispanics (Section 4.5.1) ............................................................................ 151 </a></text>
<text top="266" left="81" width="1029" height="22" font="1"><a href="data supplement.html#153">Data Supplement 30 Nonrandomized Trials, Observational Studies, and/or Registries of Hispanic (Section 4.5.1) ............................................................................... 153 </a></text>
<text top="286" left="81" width="1029" height="22" font="1"><a href="data supplement.html#155">Data Supplement 31. Hypertriglyceridemia: RCT, Meta Analyses (4.5.2) ......................................................................................................................................... 155 </a></text>
<text top="306" left="81" width="1029" height="22" font="1"><a href="data supplement.html#161">Data Supplement 32. Hypertriglyceridemia: Observational Studies (Section 4.5.2) ............................................................................................................................ 161 </a></text>
<text top="327" left="81" width="1029" height="22" font="1"><a href="data supplement.html#166">Data Supplement 33. Randomized Trials of Statins in Women for Primary Prevention of CVD (Section 4.5.3.) .................................................................................... 166 </a></text>
<text top="347" left="81" width="1029" height="22" font="1"><a href="data supplement.html#180">Data Supplement 34. Nonrandomized Studies of the Utility of Coronary Artery Calcium in Women (Section 4.5.3) .............................................................................. 180 </a></text>
<text top="367" left="81" width="1029" height="22" font="1"><a href="data supplement.html#186">Data Supplement 35. CAC to guide therapy (Section 4.5.3) ............................................................................................................................................................ 186 </a></text>
<text top="387" left="81" width="1029" height="22" font="1"><a href="data supplement.html#187">Data Supplement 36. Nonrandomized Trials, Observational Studies, and/or Registries of Chronic Kidney Disease and Cardiovascular Risk (Section 4.5.4) ................... 187 </a></text>
<text top="407" left="81" width="1029" height="22" font="1"><a href="data supplement.html#190">Data Supplement 37. RCTs Comparing PLACEBO VS. Statin (or Statin plus another agent) to reduce CVD events in persons with CKD (Section 4.5.4)........................ 190 </a></text>
<text top="427" left="81" width="985" height="22" font="1"><a href="data supplement.html#195">Data Supplement 38. RCTs Comparing PLACEBO VS. Statin (or Statin plus another agent) to reduce CVD events in persons with Albuminuria and preserved eGFR </a></text>
<text top="446" left="81" width="1029" height="22" font="1"><a href="data supplement.html#195">(Section 4.5.4) ............................................................................................................................................................................................................................ 195 </a></text>
<text top="466" left="81" width="1029" height="22" font="1"><a href="data supplement.html#196">Data Supplement 39. Nonrandomized Trials, Observational Studies, and/or Registries of HIV/Inflammatory Diseases (Section 4.5.5) ................................................... 196 </a></text>
<text top="487" left="81" width="1029" height="22" font="1"><a href="data supplement.html#205">Data Supplement 40. RCTs Comparing Statin Safety and Statin Associated Side Effects (Section 5) ................................................................................................. 205 </a></text>
<text top="507" left="81" width="1029" height="22" font="1"><a href="data supplement.html#210">Data Supplement 41. Nonrandomized Trials, Observational Studies, Meta-analyses and/or Registries of Statin Safety and Statin-Associated Side Effects (Section 5) .... 210 </a></text>
<text top="527" left="81" width="1029" height="22" font="1"><a href="data supplement.html#215">Data Supplement 42. RCTs Comparing Patient Interventions to Usual Care (Section 6) .................................................................................................................... 215 </a></text>
<text top="547" left="81" width="1029" height="22" font="1"><a href="data supplement.html#219">Data Supplement 43. RCTs Comparing System Interventions to Usual Care (Section 6) ................................................................................................................... 219 </a></text>
<text top="567" left="81" width="1029" height="22" font="1"><a href="data supplement.html#221">Data Supplement 44. RCTs Comparing Small Number of Pills/Day to Large Number of Pills/Day (Section 6) ...................................................................................... 221 </a></text>
<text top="587" left="81" width="1029" height="22" font="1"><a href="data supplement.html#225">Data Supplement 45. RCTs for Implementation (Section 6) ............................................................................................................................................................ 225 </a></text>
<text top="607" left="81" width="1029" height="22" font="1"><a href="data supplement.html#227">Data Supplement 46. Nonrandomized Trials, Observational Studies, and/or Registries for Implementation (Section 6) ........................................................................ 227 </a></text>
<text top="627" left="81" width="1029" height="22" font="1"><a href="data supplement.html#234">Data Supplement 47. Cost-Effectiveness Models of PCKS9 Inhibitors in Secondary Prevention (Section 7) ........................................................................................ 234 </a></text>
<text top="648" left="81" width="1029" height="22" font="1"><a href="data supplement.html#235">Data Supplement 48. Cost-Effectiveness Models of PCKS9 Inhibitors in Primary Prevention (Familial Hypercholesterolemia) (Section 7) ............................................. 235 </a></text>
<text top="668" left="81" width="1029" height="22" font="1"><a href="data supplement.html#236">References ................................................................................................................................................................................................................................ 236 </a></text>
</page>
<page number="3" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="5" size="14" family="Times" color="#000000"/>
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="12" height="21" font="1">3 </text>
<text top="106" left="81" width="229" height="22" font="5"><b>Methodology and Evidence Review</b> </text>
<text top="125" left="81" width="1005" height="22" font="1">The recommendations listed in this guideline are, whenever possible, evidence based. An extensive evidence review was conducted from May 1980 through July 2017. </text>
<text top="144" left="81" width="996" height="22" font="1">Other selected references published through August 2018 were incorporated by the writing committee. Literature included was derived from research involving human </text>
<text top="163" left="81" width="990" height="22" font="1">subjects, published in English, and indexed in PubMed and other selected databases relevant to this guideline. Key search words included but were not limited to the </text>
<text top="182" left="81" width="965" height="22" font="1">following: hyperlipidemia, cholesterol, LDL-C, HDL-C, ezetimibe, bile acid sequestrants, PCSK9 inhibitors, lifestyle, diet, exercise, medications, child, adolescent, </text>
<text top="201" left="81" width="1024" height="22" font="1">screening, primary prevention, secondary prevention, cardiovascular disease, coronary artery calcium, familial hypercholesterolemia. ASCVD risk enhancing factors, statin </text>
<text top="220" left="81" width="844" height="22" font="1">therapy, diabetes, women, adherence, Hispanic/Latino, South Asian, African American. Terms may have been used alone or in combination. </text>
<text top="239" left="81" width="4" height="22" font="1"> </text>
<text top="259" left="81" width="1014" height="22" font="5"><b>Abbreviations</b> 1° indicates primary; 2°, secondary; ACC, American College of Cardiology; ACE, angiotensin-converting-enzyme; ACR, albumin-to-creatinine ratio; AHA, </text>
<text top="278" left="81" width="971" height="22" font="1">American Heart Association; ALT, alanine aminotransferase; AMI, acute myocardial infarction; ARB, angiotensin-receptor blocker; ART; antiretroviral therapy; AS, </text>
<text top="297" left="81" width="1003" height="22" font="1">ankylosing spondylitis; ASCOT-LLA, Anglo-Scandinavian Cardiac Outcomes Trial—lipid-lowering arm; ASPEN, the Atorvastatin Study for Prevention of Coronary Heart </text>
<text top="316" left="81" width="977" height="22" font="1">Disease Endpoints in non-insulin-dependent diabetes mellitus; Atorva, atorvastatin; AURORA, A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular </text>
<text top="334" left="81" width="1030" height="22" font="1">Hemodialysis; BMI, body mass index; BP, blood pressure; CAC, coronary artery calcium; CARDS, Collaborative Atorvastatin Diabetes Study; CHD, coronary heart disease; </text>
<text top="354" left="81" width="1028" height="22" font="1">chol, cholesterol; CI, confidence interval; CIMT, carotid intima-media thickness; CK, Creatine kinase; CKD, chronic kidney disease; cPB, carotid plaque burden score; CPK, </text>
<text top="372" left="81" width="997" height="22" font="1">creatine phosphokinase; CRP, C-reactive protein; CVD, cardiovascular disease; DM, diabetes mellitus; DR, diabetic retinopathy; EC, extended care; eGFR, estimated </text>
<text top="391" left="81" width="1006" height="22" font="1">glomerular filtration rate; ERD, electronic reminder device; f/u, follow up; FDC, fixed-dose combination; FET, Fisher’s exact test; FOCUS, Fixed Dose Combination Drug </text>
<text top="410" left="81" width="1014" height="22" font="1">[Polypill] for Secondary Cardiovascular Prevention; GFR, glomerular filtration rate; h/o, history of; HbA1c, hemoglobin A1c; HCV, Hepatitis C viral; HF, heart failure; HPS, </text>
<text top="429" left="81" width="989" height="22" font="1">Heart Protection Study; HPS2-THRIVE, Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events; HR, hazard ratio; ICD, International </text>
<text top="448" left="81" width="988" height="22" font="1">Classification of Disease; IQR, Inter Quartile range; ITT, intention to treat; JART, Justification for Atherosclerosis Regression Treatment; KDIGO, kidney international </text>
<text top="467" left="81" width="1030" height="22" font="1">guidelines; LDL-C, low density lipoprotein cholesterol; LFT, liver function test; LVH, left ventricular hypertrophy; MACE, Major adverse cardiovascular events; MAQ, Morisky </text>
<text top="486" left="81" width="1015" height="22" font="1">Green questionnaire; MEMS, medication event monitoring system; MESA, Multi-Ethnic Study of Atherosclerosis; MI, myocardial infarction; N/A, not applicable; NHANES, </text>
<text top="505" left="81" width="997" height="22" font="1">National Health And Nutrition Education Survey; NNT, number needed to treat; NODM, new onset diabetes mellitus; NP, nurse practitioner; NR, not reported; NRI, net </text>
<text top="524" left="81" width="1003" height="22" font="1">reclassification index; NYHA, New York Heart Association; OR, odds ratio; P01, first co-primary outcome; PAD, peripheral arterial disease; PCI, percutaneous coronary </text>
<text top="543" left="81" width="1027" height="22" font="1">intervention; P02, second co-primary outcome; PCP, primary care provider; PI, pharmacist-delivered intervention; PN, Peripheral neuropathy; pts, patients; RA, rheumatoid </text>
<text top="562" left="81" width="988" height="22" font="1">arthritis; RAS, renin angiotensin system; revasc, revascularization; RC, routine care; RCT, randomized controlled trial; rhabdo, rhabdomyolysis; rosuva; rosuvastatin; </text>
<text top="581" left="81" width="1021" height="22" font="1">RUTHERFORD, Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder; RR, relative risk; RRF, reduced renal function; RRR, </text>
<text top="600" left="81" width="995" height="22" font="1">relative risk reduction; SBP, systolic blood pressure; SCr, serum creatinine; SD, standard deviation; SE, standard error; SHARP, Study of Heart and Renal Protection; </text>
<text top="618" left="81" width="1017" height="22" font="1">Simva; simvastatin; SLE, systemic lupus erythematosus; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; TC, total cholesterol; UC, usual care; UL, upper </text>
<text top="637" left="81" width="1009" height="22" font="1">limit; ULN, Upper limit of normal; UMPIRE, Use of a Multidrug Pill In Reducing Cardiovascular Events; UK, United Kingdom; US, United States; vs., versus; WOSCOPS, </text>
<text top="656" left="81" width="380" height="22" font="1">West of Scotland Coronary Prevention Study; y, years; yr, year.</text>
</page>
<page number="4" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="6" size="16" family="Times" color="#1b1b1b"/>
	<fontspec id="7" size="12" family="Times" color="#000000"/>
	<fontspec id="8" size="12" family="Times" color="#0000ff"/>
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="12" height="21" font="1">4 </text>
<text top="106" left="81" width="611" height="24" font="4"><b>Data Supplement 1. Nonrandomized Trials, Observational Studies, and/or Registries of </b></text>
<text top="106" left="692" width="29" height="24" font="6"><b>Q3: </b></text>
<text top="106" left="721" width="339" height="24" font="4"><b>Evidence regarding the difference in lipid levels </b></text>
<text top="127" left="81" width="667" height="24" font="4"><b>measured in fasting and non-fasting individuals, and associations with outcomes (Section 2.2) </b></text>
<text top="148" left="117" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="166" left="142" width="48" height="20" font="7"><b>Author; </b></text>
<text top="183" left="120" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="148" left="267" width="118" height="20" font="7"><b>Study Type/Design; </b></text>
<text top="166" left="293" width="66" height="20" font="7"><b>Study Size </b></text>
<text top="148" left="438" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="148" left="619" width="179" height="20" font="7"><b>Primary Endpoint and Results </b></text>
<text top="166" left="617" width="184" height="20" font="7"><b>(P values; OR or RR; &amp; 95% CI) </b></text>
<text top="148" left="906" width="130" height="20" font="7"><b>Summary/Conclusion </b></text>
<text top="166" left="933" width="75" height="20" font="7"><b>Comment(s) </b></text>
<text top="201" left="91" width="139" height="20" font="0">Di Angelantonio E, et al., </text>
<text top="218" left="91" width="49" height="20" font="0">2009 <a href="data supplement.html#236">(1)</a> </text>
<text top="235" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19622820">19622820</a></text>
<text top="235" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19622820"> </a></text>
<text top="201" left="254" width="126" height="20" font="7"><b>Study type:</b> Individual </text>
<text top="218" left="254" width="99" height="20" font="0">patient data meta-</text>
<text top="235" left="254" width="128" height="20" font="0">analysis of prospective </text>
<text top="252" left="254" width="80" height="20" font="0">cohort studies </text>
<text top="270" left="254" width="3" height="20" font="0"> </text>
<text top="287" left="254" width="141" height="20" font="7"><b>Size:</b> 302,430 individuals </text>
<text top="304" left="254" width="3" height="20" font="0"> </text>
<text top="201" left="411" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="220" left="409" width="11" height="18" font="0">• </text>
<text top="219" left="422" width="151" height="20" font="0">Studies with information on </text>
<text top="236" left="422" width="137" height="20" font="0">total cholesterol, HDL-C, </text>
<text top="253" left="422" width="154" height="20" font="0">triglycerides and other CVD </text>
<text top="271" left="422" width="136" height="20" font="0">risk factors at a baseline </text>
<text top="288" left="422" width="73" height="20" font="0">examination. </text>
<text top="305" left="411" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="324" left="409" width="11" height="18" font="0">• </text>
<text top="323" left="422" width="138" height="20" font="0">Participants with missing </text>
<text top="341" left="422" width="31" height="20" font="0">data. </text>
<text top="202" left="590" width="185" height="20" font="7"><b>1</b>°<b> endpoint:</b> Incident myocardial </text>
<text top="219" left="590" width="128" height="20" font="0">infarction or fatal CHD. </text>
<text top="236" left="590" width="3" height="20" font="0"> </text>
<text top="254" left="590" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="273" left="586" width="11" height="18" font="0">• </text>
<text top="272" left="599" width="209" height="20" font="0">8857 nonfatal MIs, 3928 CHD deaths. </text>
<text top="291" left="586" width="11" height="18" font="0">• </text>
<text top="290" left="599" width="194" height="20" font="0">Adjusted HRs per 1 SD higher lipid </text>
<text top="307" left="599" width="61" height="20" font="0">measures: </text>
<text top="325" left="599" width="42" height="20" font="7"><b>HDL-C </b></text>
<text top="342" left="599" width="212" height="20" font="0">Fasting participants HR: 0.79; 95% CI: </text>
<text top="359" left="599" width="59" height="20" font="0">0.74-0.84. </text>
<text top="376" left="599" width="212" height="20" font="0">Nonfasting participants HR: 0.75; 95% </text>
<text top="393" left="599" width="81" height="20" font="0">CI: 0.68-0.83.  </text>
<text top="411" left="599" width="3" height="20" font="0"> </text>
<text top="428" left="599" width="80" height="20" font="7"><b>Triglycerides </b></text>
<text top="445" left="599" width="212" height="20" font="0">Fasting participants HR: 1.02; 95% CI: </text>
<text top="462" left="599" width="59" height="20" font="0">0.95-1.09. </text>
<text top="479" left="599" width="212" height="20" font="0">Nonfasting participants HR: 0.92; 95% </text>
<text top="497" left="599" width="78" height="20" font="0">CI: 0.82-1.03. </text>
<text top="514" left="599" width="3" height="20" font="0"> </text>
<text top="531" left="599" width="3" height="20" font="0"> </text>
<text top="203" left="839" width="11" height="18" font="0">• </text>
<text top="202" left="853" width="235" height="20" font="0">Hazard ratios for HDL-C and incident CHD </text>
<text top="219" left="853" width="235" height="20" font="0">were at least as strong for those who were </text>
<text top="236" left="853" width="194" height="20" font="0">not fasting as for those who fasted. </text>
<text top="255" left="839" width="11" height="18" font="0">• </text>
<text top="254" left="853" width="248" height="20" font="0">After adjustment for HDL-C, non-HDL-C, and </text>
<text top="272" left="853" width="247" height="20" font="0">other standard CVD risk factors, triglycerides </text>
<text top="289" left="853" width="248" height="20" font="0">were not independently associated with CHD </text>
<text top="306" left="853" width="241" height="20" font="0">risk overall, in women and under nonfasting </text>
<text top="323" left="853" width="62" height="20" font="0">conditions. </text>
<text top="549" left="91" width="135" height="20" font="0">Doran B, et al., 2014 <a href="data supplement.html#236">(2)</a> </text>
<text top="566" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25015340">25015340</a></text>
<text top="566" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25015340"> </a></text>
<text top="549" left="254" width="113" height="20" font="7"><b>Study type:</b> Nested </text>
<text top="566" left="254" width="117" height="20" font="0">matched prospective </text>
<text top="583" left="254" width="38" height="20" font="0">cohort </text>
<text top="601" left="254" width="3" height="20" font="0"> </text>
<text top="618" left="254" width="134" height="20" font="7"><b>Size:</b> 16,161 individuals </text>
<text top="635" left="254" width="127" height="20" font="0">(8,598 individuals after </text>
<text top="652" left="254" width="117" height="20" font="0">propensity matching: </text>
<text top="669" left="254" width="105" height="20" font="0">4299 fasting; 4299 </text>
<text top="687" left="254" width="64" height="20" font="0">nonfasting) </text>
<text top="704" left="254" width="3" height="20" font="0"> </text>
<text top="549" left="411" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="568" left="409" width="11" height="18" font="0">• </text>
<text top="567" left="422" width="73" height="20" font="0">≥18 y of age </text>
<text top="586" left="409" width="11" height="18" font="0">• </text>
<text top="586" left="422" width="130" height="20" font="0">Noninstitutionalized US </text>
<text top="603" left="422" width="143" height="20" font="0">adults examined between </text>
<text top="620" left="422" width="117" height="20" font="0">1988-1994 as part of </text>
<text top="637" left="422" width="68" height="20" font="0">NHANES III </text>
<text top="656" left="409" width="11" height="18" font="0">• </text>
<text top="655" left="422" width="152" height="20" font="0">Fasting defined as ≥8 H for </text>
<text top="672" left="422" width="85" height="20" font="0">main analyses  </text>
<text top="690" left="411" width="3" height="20" font="0"> </text>
<text top="707" left="411" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="726" left="409" width="11" height="18" font="0">• </text>
<text top="725" left="422" width="124" height="20" font="0">Missing lipid values or </text>
<text top="742" left="422" width="107" height="20" font="0">fasting information. </text>
<text top="761" left="409" width="11" height="18" font="0">• </text>
<text top="761" left="422" width="90" height="20" font="0">TG ≥400 mg/dL </text>
<text top="550" left="590" width="217" height="20" font="7"><b>1</b>°<b> endpoint:</b> All-cause mortality; mean </text>
<text top="567" left="590" width="106" height="20" font="0">follow up of 14.0 y. </text>
<text top="584" left="590" width="3" height="20" font="0"> </text>
<text top="602" left="590" width="202" height="20" font="0">Secondary outcome: CVD mortality.  </text>
<text top="619" left="590" width="3" height="20" font="0"> </text>
<text top="636" left="590" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="655" left="586" width="11" height="18" font="0">• </text>
<text top="654" left="599" width="193" height="20" font="0">Mean LDL-C 118.55 mg/dL among </text>
<text top="672" left="599" width="206" height="20" font="0">fasting and 118.33 among nonfasting </text>
<text top="689" left="599" width="120" height="20" font="0">matched participants. </text>
<text top="708" left="586" width="11" height="18" font="0">• </text>
<text top="707" left="599" width="205" height="20" font="0">3788 total deaths; 1454 CVD deaths. </text>
<text top="726" left="586" width="11" height="18" font="0">• </text>
<text top="725" left="599" width="220" height="20" font="0">HRs adjusted for potential confounders. </text>
<text top="742" left="599" width="113" height="20" font="7"><b>All-cause mortality </b></text>
<text top="760" left="599" width="55" height="20" font="7"><b>Fasting:  </b></text>
<text top="777" left="599" width="189" height="20" font="0">LDL-C tertile 1: HR: 1.0 (referent). </text>
<text top="551" left="839" width="11" height="18" font="0">• </text>
<text top="550" left="853" width="240" height="20" font="0">Similar prognostic value for fasting and non-</text>
<text top="567" left="853" width="233" height="20" font="0">fasting LDL-C levels in association with all-</text>
<text top="584" left="853" width="197" height="20" font="0">cause and CVD mortality over 14 y. </text>
<text top="603" left="839" width="11" height="18" font="0">• </text>
<text top="603" left="853" width="232" height="20" font="0">Similar prognostic value also observed for </text>
<text top="620" left="853" width="237" height="20" font="0">fasting and nonfasting total cholesterol and </text>
<text top="637" left="853" width="101" height="20" font="0">triglyceride levels. </text>
<text top="656" left="839" width="11" height="18" font="0">• </text>
<text top="655" left="853" width="219" height="20" font="0">Results question the value of fasting for </text>
<text top="672" left="853" width="218" height="20" font="0">prognostic information from lipid panel.  </text>
<text top="692" left="839" width="11" height="18" font="0">• </text>
<text top="691" left="853" width="228" height="20" font="0">Large sample representative of broad US </text>
<text top="708" left="853" width="64" height="20" font="0">population. </text>
<text top="727" left="839" width="11" height="18" font="0">• </text>
<text top="726" left="853" width="205" height="20" font="0">Fasting and nonfasting samples from </text>
<text top="743" left="853" width="236" height="20" font="0">different individuals; propensity score used </text>
<text top="761" left="853" width="244" height="20" font="0">to match fasting and nonfasting participants; </text>
<text top="778" left="853" width="166" height="20" font="0">content of last meal unknown. </text>
</page>
<page number="5" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="9" size="7" family="Times" color="#000000"/>
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="12" height="21" font="1">5 </text>
<text top="107" left="599" width="217" height="20" font="0">LDL-C tertile 2: HR: 1.61; 95% CI: 1.25-</text>
<text top="124" left="599" width="31" height="20" font="0">2.08. </text>
<text top="141" left="599" width="217" height="20" font="0">LDL-C tertile 3: HR: 2.10; 95% CI: 1.70-</text>
<text top="159" left="599" width="31" height="20" font="0">2.61. </text>
<text top="176" left="599" width="197" height="20" font="0">C statistic: 0.59; 95% CI: 0.56-0.61. </text>
<text top="193" left="599" width="72" height="20" font="7"><b>Nonfasting: </b></text>
<text top="210" left="599" width="189" height="20" font="0">LDL-C tertile 1: HR: 1.0 (referent). </text>
<text top="228" left="599" width="217" height="20" font="0">LDL-C tertile 2: HR: 1.21; 95% CI: 0.92-</text>
<text top="245" left="599" width="31" height="20" font="0">1.60. </text>
<text top="262" left="599" width="217" height="20" font="0">LDL-C tertile 3: HR: 2.23; 95% CI: 1.76-</text>
<text top="279" left="599" width="31" height="20" font="0">2.83. </text>
<text top="296" left="599" width="193" height="20" font="0">C statistic: 0.58; 95% CI: 0.56-0.60 </text>
<text top="314" left="599" width="203" height="20" font="0">(p=0.73 compared with C statistic for </text>
<text top="331" left="599" width="47" height="20" font="0">fasting). </text>
<text top="348" left="599" width="8" height="20" font="0">P</text>
<text top="354" left="607" width="37" height="13" font="9">interaction</text>
<text top="348" left="644" width="180" height="20" font="0"> for fasting status x LDL-C=0.11. </text>
<text top="365" left="599" width="3" height="20" font="0"> </text>
<text top="382" left="599" width="196" height="20" font="0">C statistics for triglyceride levels for </text>
<text top="400" left="599" width="201" height="20" font="0">fasting (0.60; 95% CI: 0.59-0.62) vs. </text>
<text top="417" left="599" width="202" height="20" font="0">nonfasting (0.61; 95% CI: 0.59-0.62) </text>
<text top="434" left="599" width="218" height="20" font="0">participants were not different (p=0.96). </text>
<text top="451" left="599" width="3" height="20" font="0"> </text>
<text top="469" left="599" width="223" height="20" font="0">C statistics for total cholesterol levels for </text>
<text top="486" left="599" width="201" height="20" font="0">fasting (0.60; 95% CI: 0.59-0.62) vs. </text>
<text top="503" left="599" width="202" height="20" font="0">nonfasting (0.59; 95% CI: 0.57-0.61) </text>
<text top="520" left="599" width="218" height="20" font="0">participants were not different (p=0.31). </text>
<text top="537" left="599" width="3" height="20" font="0"> </text>
<text top="555" left="599" width="211" height="20" font="0">Sensitivity analyses: Pattern of results </text>
<text top="572" left="599" width="191" height="20" font="0">similar for unmatched participants, </text>
<text top="589" left="599" width="193" height="20" font="0">participants with triglycerides ≥400 </text>
<text top="606" left="599" width="203" height="20" font="0">mg/dL, and for different definitions of </text>
<text top="623" left="599" width="118" height="20" font="0">fasting (4 H or 12 H). </text>
<text top="641" left="599" width="3" height="20" font="0"> </text>
<text top="660" left="586" width="11" height="18" font="0">• </text>
<text top="659" left="599" width="148" height="20" font="7"><b>Cardiovascular mortality </b></text>
<text top="676" left="599" width="55" height="20" font="7"><b>Fasting:  </b></text>
<text top="693" left="599" width="185" height="20" font="0">LDL-C tertile 1: HR: 1.0 (referent) </text>
<text top="711" left="599" width="217" height="20" font="0">LDL-C tertile 2: HR: 1.68; 95% CI: 1.13-</text>
<text top="728" left="599" width="31" height="20" font="0">2.51. </text>
<text top="745" left="599" width="217" height="20" font="0">LDL-C tertile 3: HR: 3.04; 95% CI: 2.00-</text>
<text top="762" left="599" width="31" height="20" font="0">4.62. </text>
<text top="779" left="599" width="197" height="20" font="0">C statistic: 0.62; 95% CI: 0.60-0.66. </text>
</page>
<page number="6" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="12" height="21" font="1">6 </text>
<text top="107" left="599" width="72" height="20" font="7"><b>Nonfasting: </b></text>
<text top="124" left="599" width="189" height="20" font="0">LDL-C tertile 1: HR: 1.0 (referent). </text>
<text top="141" left="599" width="213" height="20" font="0">LDL-C tertile 2: HR 1.59; 95% CI: 0.97-</text>
<text top="159" left="599" width="31" height="20" font="0">2.61. </text>
<text top="176" left="599" width="217" height="20" font="0">LDL-C tertile 3: HR: 4.00; 95% CI: 2.58-</text>
<text top="193" left="599" width="31" height="20" font="0">6.19. </text>
<text top="210" left="599" width="193" height="20" font="0">C statistic: 0.62; 95% CI: 0.60-0.66 </text>
<text top="228" left="599" width="203" height="20" font="0">(p=0.73 compared with C statistic for </text>
<text top="245" left="599" width="47" height="20" font="0">fasting). </text>
<text top="262" left="599" width="8" height="20" font="0">P</text>
<text top="268" left="607" width="37" height="13" font="9">interaction</text>
<text top="262" left="644" width="180" height="20" font="0"> for fasting status x LDL-C=0.34. </text>
<text top="279" left="599" width="3" height="20" font="0"> </text>
<text top="296" left="599" width="196" height="20" font="0">C statistics for triglyceride levels for </text>
<text top="314" left="599" width="201" height="20" font="0">fasting (0.62; 95% CI: 0.60-0.64) vs. </text>
<text top="331" left="599" width="202" height="20" font="0">nonfasting (0.61; 95% CI: 0.59-0.64) </text>
<text top="348" left="599" width="218" height="20" font="0">participants were not different (p=0.81). </text>
<text top="365" left="599" width="3" height="20" font="0"> </text>
<text top="383" left="599" width="223" height="20" font="0">C statistics for total cholesterol levels for </text>
<text top="400" left="599" width="201" height="20" font="0">fasting (0.64; 95% CI: 0.62-0.66) vs. </text>
<text top="417" left="599" width="202" height="20" font="0">nonfasting (0.63; 95% CI: 0.60-0.65) </text>
<text top="434" left="599" width="218" height="20" font="0">participants were not different (p=0.49). </text>
<text top="451" left="599" width="3" height="20" font="0"> </text>
<text top="469" left="599" width="211" height="20" font="0">Sensitivity analyses: Pattern of results </text>
<text top="486" left="599" width="191" height="20" font="0">similar for unmatched participants, </text>
<text top="503" left="599" width="193" height="20" font="0">participants with triglycerides ≥400 </text>
<text top="520" left="599" width="203" height="20" font="0">mg/dL, and for different definitions of </text>
<text top="537" left="599" width="118" height="20" font="0">fasting (4 H or 12 H). </text>
<text top="555" left="599" width="3" height="20" font="0"> </text>
<text top="573" left="91" width="103" height="20" font="0">Langsted A, et al., </text>
<text top="590" left="91" width="96" height="20" font="0">2008 – Part 1 <a href="data supplement.html#236">(3)</a> </text>
<text top="607" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18955664">18955664</a></text>
<text top="607" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18955664"> </a></text>
<text top="624" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="573" left="254" width="107" height="20" font="7"><b>Study type:</b> Cross-</text>
<text top="590" left="254" width="89" height="20" font="0">sectional cohort </text>
<text top="607" left="254" width="125" height="20" font="0">(Copenhagen General </text>
<text top="624" left="254" width="131" height="20" font="0">Population Study, 2003-</text>
<text top="641" left="254" width="129" height="20" font="0">2006 and Copenhagen </text>
<text top="659" left="254" width="128" height="20" font="0">City Heart Study, 2001-</text>
<text top="676" left="254" width="35" height="20" font="0">2003) </text>
<text top="693" left="254" width="3" height="20" font="0"> </text>
<text top="710" left="254" width="134" height="20" font="7"><b>Size:</b> 33,391 individuals </text>
<text top="727" left="254" width="3" height="20" font="0"> </text>
<text top="573" left="411" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="592" left="409" width="11" height="18" font="0">• </text>
<text top="591" left="422" width="128" height="20" font="0">All adults ages 20-95 y </text>
<text top="610" left="409" width="11" height="18" font="0">• </text>
<text top="609" left="422" width="97" height="20" font="0">Fasting (≥8 H) or </text>
<text top="626" left="422" width="98" height="20" font="0">nonfasting (&lt;8 H) </text>
<text top="643" left="422" width="3" height="20" font="0"> </text>
<text top="661" left="422" width="3" height="20" font="0"> </text>
<text top="678" left="411" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="697" left="409" width="11" height="18" font="0">• </text>
<text top="696" left="422" width="131" height="20" font="0">Outliers with lipid levels </text>
<text top="713" left="422" width="131" height="20" font="0">beyond ±3 SD from the </text>
<text top="730" left="422" width="34" height="20" font="0">mean </text>
<text top="574" left="590" width="233" height="20" font="7"><b>1</b>°<b> endpoint:</b> Lipid levels stratified by time </text>
<text top="591" left="590" width="134" height="20" font="0">since last reported meal </text>
<text top="608" left="590" width="3" height="20" font="0"> </text>
<text top="625" left="590" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="644" left="586" width="11" height="18" font="0">• </text>
<text top="644" left="599" width="200" height="20" font="0">Compared with levels in participants </text>
<text top="661" left="599" width="229" height="20" font="0">fasting &gt;8 H, total cholesterol, LDL-C and </text>
<text top="678" left="599" width="209" height="20" font="0">HDL-C were minimally but statistically </text>
<text top="695" left="599" width="222" height="20" font="0">significantly lower for 3-5 H after the last </text>
<text top="712" left="599" width="211" height="20" font="0">reported meal; triglyceride levels were </text>
<text top="730" left="599" width="224" height="20" font="0">significantly higher for up to 6 H after the </text>
<text top="747" left="599" width="219" height="20" font="0">last meal. Adjustment for effects related </text>
<text top="764" left="599" width="209" height="20" font="0">to hemodilution altered some of these </text>
<text top="781" left="599" width="111" height="20" font="0">differences slightly.  </text>
<text top="574" left="839" width="11" height="18" font="0">• </text>
<text top="574" left="853" width="230" height="20" font="0">Lipid levels differed minimally across time </text>
<text top="591" left="853" width="136" height="20" font="0">after normal food intake. </text>
<text top="610" left="839" width="11" height="18" font="0">• </text>
<text top="609" left="853" width="239" height="20" font="0">Limitations: fasting and nonfasting samples </text>
<text top="626" left="853" width="203" height="20" font="0">from different individuals; exclusively </text>
<text top="643" left="853" width="214" height="20" font="0">northern European Caucasian sample; </text>
<text top="661" left="853" width="166" height="20" font="0">content of last meal unknown. </text>
</page>
<page number="7" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="12" height="21" font="1">7 </text>
<text top="109" left="586" width="11" height="18" font="0">• </text>
<text top="108" left="599" width="206" height="20" font="0">Levels of non-HDL-C, apo A1, apo B, </text>
<text top="125" left="599" width="210" height="20" font="0">total/HDL-C and apo B/apo A1 did not </text>
<text top="143" left="599" width="221" height="20" font="0">differ by time from last meal in response </text>
<text top="160" left="599" width="125" height="20" font="0">to normal food intake.  </text>
<text top="179" left="586" width="11" height="18" font="0">• </text>
<text top="178" left="599" width="174" height="20" font="0">Patterns of results did not differ </text>
<text top="195" left="599" width="198" height="20" font="0">substantially by time of day of blood </text>
<text top="212" left="599" width="220" height="20" font="0">sampling, although total cholesterol and </text>
<text top="230" left="599" width="202" height="20" font="0">LDL-C were somewhat lower for 5 H </text>
<text top="247" left="599" width="210" height="20" font="0">after a meal when blood was drawn in </text>
<text top="264" left="599" width="70" height="20" font="0">the evening. </text>
<text top="283" left="586" width="11" height="18" font="0">• </text>
<text top="282" left="599" width="228" height="20" font="0">After normal food intake, maximum mean </text>
<text top="300" left="599" width="217" height="20" font="0">differences in levels were observed for: </text>
<text top="317" left="599" width="213" height="20" font="0">Total cholesterol: -0.2 mmol/L at 0-2 H </text>
<text top="334" left="599" width="158" height="20" font="0">LDL-C: -0.2 mmol/L at 0-2 H </text>
<text top="351" left="599" width="160" height="20" font="0">HDL-C: -0.1 mmol/L at 0-5 H </text>
<text top="368" left="599" width="195" height="20" font="0">Triglycerides: +0.3 mmol/L at 1-4 H </text>
<text top="387" left="586" width="11" height="18" font="0">• </text>
<text top="387" left="599" width="197" height="20" font="0">Results were similar after excluding </text>
<text top="404" left="599" width="228" height="20" font="0">participants on lipid lowering therapy (5% </text>
<text top="421" left="599" width="64" height="20" font="0">of sample). </text>
<text top="439" left="91" width="103" height="20" font="0">Langsted A, et al., </text>
<text top="456" left="91" width="96" height="20" font="0">2008 – Part 2 <a href="data supplement.html#236">(3)</a> </text>
<text top="473" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18955664">18955664</a></text>
<text top="473" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18955664"> </a></text>
<text top="490" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="439" left="254" width="138" height="20" font="7"><b>Study type:</b> Prospective </text>
<text top="456" left="254" width="140" height="20" font="0">cohort (Copenhagen City </text>
<text top="473" left="254" width="138" height="20" font="0">Heart Study, 1991-1994) </text>
<text top="490" left="254" width="3" height="20" font="0"> </text>
<text top="508" left="254" width="127" height="20" font="7"><b>Size:</b> 9,319 individuals </text>
<text top="525" left="254" width="3" height="20" font="0"> </text>
<text top="439" left="411" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="458" left="409" width="11" height="18" font="0">• </text>
<text top="457" left="422" width="136" height="20" font="0">Adults ages 20-95 y and </text>
<text top="474" left="422" width="119" height="20" font="0">free of ischemic CVD </text>
<text top="493" left="409" width="11" height="18" font="0">• </text>
<text top="493" left="422" width="62" height="20" font="0">Nonfasting </text>
<text top="510" left="422" width="3" height="20" font="0"> </text>
<text top="527" left="411" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="546" left="409" width="11" height="18" font="0">• </text>
<text top="545" left="422" width="105" height="20" font="0">Missing lipid levels </text>
<text top="440" left="590" width="178" height="20" font="7"><b>1</b>°<b> endpoint:</b> Fatal and nonfatal </text>
<text top="457" left="590" width="232" height="20" font="0">myocardial infarction and ischemic stroke; </text>
<text top="474" left="590" width="127" height="20" font="0">Mean follow up 14.0 y. </text>
<text top="492" left="590" width="3" height="20" font="0"> </text>
<text top="509" left="590" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="528" left="586" width="11" height="18" font="0">• </text>
<text top="527" left="599" width="172" height="20" font="0">1,166 primary endpoint events. </text>
<text top="546" left="586" width="11" height="18" font="0">• </text>
<text top="546" left="599" width="192" height="20" font="0">Adjusted HRs for nonfasting lipids: </text>
<text top="563" left="599" width="94" height="20" font="0">Total cholesterol </text>
<text top="580" left="599" width="27" height="20" font="0">Men </text>
<text top="597" left="599" width="150" height="20" font="0">Tertile 1: HR: 1.0 (referent) </text>
<text top="614" left="599" width="189" height="20" font="0">Tertile 2: HR: 1.1; 95% CI: 0.7-1.6 </text>
<text top="631" left="599" width="189" height="20" font="0">Tertile 3: HR :1.7; 95% CI: 1.1-2.5 </text>
<text top="649" left="599" width="46" height="20" font="0">Women </text>
<text top="666" left="599" width="150" height="20" font="0">Tertile 1: HR: 1.0 (referent) </text>
<text top="683" left="599" width="189" height="20" font="0">Tertile 2: HR: 1.4; 95% CI: 0.9-2.3 </text>
<text top="700" left="599" width="189" height="20" font="0">Tertile 3: HR: 1.9; 95% CI: 1.2-3.1 </text>
<text top="717" left="599" width="39" height="20" font="0">LDL-C </text>
<text top="735" left="599" width="27" height="20" font="0">Men </text>
<text top="752" left="599" width="150" height="20" font="0">Tertile 1: HR: 1.0 (referent) </text>
<text top="769" left="599" width="189" height="20" font="0">Tertile 2: HR: 1.3; 95% CI: 0.8-2.0 </text>
<text top="786" left="599" width="189" height="20" font="0">Tertile 3: HR: 1.8; 95% CI: 1.2-2.7 </text>
<text top="441" left="839" width="11" height="18" font="0">• </text>
<text top="440" left="853" width="231" height="20" font="0">Nonfasting lipid levels are associated with </text>
<text top="457" left="853" width="89" height="20" font="0">ASCVD events. </text>
<text top="476" left="839" width="11" height="18" font="0">• </text>
<text top="476" left="853" width="235" height="20" font="0">Limitations: exclusively northern European </text>
<text top="493" left="853" width="218" height="20" font="0">Caucasian sample; content of last meal </text>
<text top="510" left="853" width="56" height="20" font="0">unknown. </text>
</page>
<page number="8" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="12" height="21" font="1">8 </text>
<text top="107" left="599" width="46" height="20" font="0">Women </text>
<text top="124" left="599" width="150" height="20" font="0">Tertile 1: HR: 1.0 (referent) </text>
<text top="141" left="599" width="192" height="20" font="0">Tertile 2: HR:  1.6; 95% CI: 1.0-2.4 </text>
<text top="159" left="599" width="192" height="20" font="0">Tertile 3: HR:  2.2; 95% CI: 1.5-3.5 </text>
<text top="178" left="586" width="11" height="18" font="0">• </text>
<text top="177" left="599" width="222" height="20" font="0">Patterns of results by tertile were overall </text>
<text top="194" left="599" width="174" height="20" font="0">similar for other nonfasting lipid </text>
<text top="211" left="599" width="222" height="20" font="0">measures (non-HDL-C, HDL-C, Apo A1, </text>
<text top="229" left="599" width="208" height="20" font="0">Apo B, triglycerides, total/HDL-C, and </text>
<text top="246" left="599" width="84" height="20" font="0">Apo B/Apo A1. </text>
<text top="264" left="91" width="103" height="20" font="0">Langsted A, et al., </text>
<text top="281" left="91" width="49" height="20" font="0">2011<a href="data supplement.html#236"> (4)</a> </text>
<text top="298" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21189274">21189274</a></text>
<text top="298" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21189274"> </a></text>
<text top="264" left="254" width="107" height="20" font="7"><b>Study type:</b> Cross-</text>
<text top="281" left="254" width="89" height="20" font="0">sectional cohort </text>
<text top="298" left="254" width="125" height="20" font="0">(Copenhagen General </text>
<text top="315" left="254" width="131" height="20" font="0">Population Study, 2003-</text>
<text top="333" left="254" width="35" height="20" font="0">2009) </text>
<text top="350" left="254" width="3" height="20" font="0"> </text>
<text top="367" left="254" width="134" height="20" font="7"><b>Size:</b> 58,434 individuals </text>
<text top="384" left="254" width="3" height="20" font="0"> </text>
<text top="264" left="411" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="283" left="409" width="11" height="18" font="0">• </text>
<text top="282" left="422" width="128" height="20" font="0">All adults ages 20-95 y </text>
<text top="301" left="409" width="11" height="18" font="0">• </text>
<text top="300" left="422" width="97" height="20" font="0">Fasting (≥8 H) or </text>
<text top="318" left="422" width="98" height="20" font="0">nonfasting (&lt;8 H) </text>
<text top="335" left="422" width="3" height="20" font="0"> </text>
<text top="352" left="422" width="3" height="20" font="0"> </text>
<text top="369" left="411" width="134" height="20" font="7"><b>Exclusion criteria:</b> N/A </text>
<text top="386" left="411" width="3" height="20" font="0"> </text>
<text top="265" left="590" width="233" height="20" font="7"><b>1</b>°<b> endpoint:</b> Lipid levels stratified by time </text>
<text top="282" left="590" width="217" height="20" font="0">since last reported meal, in participants </text>
<text top="299" left="590" width="145" height="20" font="0">with and without diabetes. </text>
<text top="317" left="590" width="3" height="20" font="0"> </text>
<text top="334" left="590" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="353" left="586" width="11" height="18" font="0">• </text>
<text top="352" left="599" width="187" height="20" font="0">2270 participants with and 56,164 </text>
<text top="369" left="599" width="96" height="20" font="0">without diabetes. </text>
<text top="388" left="586" width="11" height="18" font="0">• </text>
<text top="388" left="599" width="226" height="20" font="0">52% of participants with and 8% of those </text>
<text top="405" left="599" width="168" height="20" font="0">without diabetes taking statins </text>
<text top="424" left="586" width="11" height="18" font="0">• </text>
<text top="423" left="599" width="206" height="20" font="0">Lipid levels were lower in participants </text>
<text top="440" left="599" width="140" height="20" font="0">with vs. without diabetes. </text>
<text top="459" left="586" width="11" height="18" font="0">• </text>
<text top="458" left="599" width="191" height="20" font="0">Overall patterns of lipid levels as a </text>
<text top="476" left="599" width="202" height="20" font="0">function of time since last meal were </text>
<text top="493" left="599" width="204" height="20" font="0">similar between participants with and </text>
<text top="510" left="599" width="96" height="20" font="0">without diabetes. </text>
<text top="529" left="586" width="11" height="18" font="0">• </text>
<text top="528" left="599" width="200" height="20" font="0">Compared with levels in participants </text>
<text top="545" left="599" width="225" height="20" font="0">fasting &gt;8 H, total cholesterol and LDL-C </text>
<text top="563" left="599" width="215" height="20" font="0">were modestly lower for 3-5 H after the </text>
<text top="580" left="599" width="203" height="20" font="0">last reported meal; triglyceride levels </text>
<text top="597" left="599" width="226" height="20" font="0">were somewhat higher for up to 6 H after </text>
<text top="614" left="599" width="214" height="20" font="0">the last meal. Differences tended to be </text>
<text top="631" left="599" width="202" height="20" font="0">statistically significant among people </text>
<text top="649" left="599" width="195" height="20" font="0">without diabetes and nonsignificant </text>
<text top="666" left="599" width="227" height="20" font="0">among people with diabetes (smaller N).  </text>
<text top="685" left="586" width="11" height="18" font="0">• </text>
<text top="684" left="599" width="228" height="20" font="0">After normal food intake, maximum mean </text>
<text top="701" left="599" width="217" height="20" font="0">differences in levels were observed for: </text>
<text top="719" left="599" width="144" height="20" font="7"><b>People without diabetes </b></text>
<text top="736" left="599" width="213" height="20" font="0">Total cholesterol: -0.3 mmol/L at 0-1 H </text>
<text top="753" left="599" width="158" height="20" font="0">LDL-C: -0.3 mmol/L at 0-2 H </text>
<text top="770" left="599" width="156" height="20" font="0">HDL-C: 0.0 mmol/L at 0-8 H </text>
<text top="787" left="599" width="195" height="20" font="0">Triglycerides: +0.2 mmol/L at 0-5 H </text>
<text top="266" left="839" width="11" height="18" font="0">• </text>
<text top="265" left="853" width="232" height="20" font="0">Cholesterol and triglyceride levels differed </text>
<text top="282" left="853" width="228" height="20" font="0">minimally, and similarly, across time after </text>
<text top="299" left="853" width="228" height="20" font="0">normal food intake in individuals with and </text>
<text top="316" left="853" width="99" height="20" font="0">without diabetes.  </text>
<text top="335" left="839" width="11" height="18" font="0">• </text>
<text top="335" left="853" width="239" height="20" font="0">Limitations: fasting and nonfasting samples </text>
<text top="352" left="853" width="203" height="20" font="0">from different individuals; exclusively </text>
<text top="369" left="853" width="214" height="20" font="0">northern European Caucasian sample; </text>
<text top="386" left="853" width="209" height="20" font="0">content of last meal unknown; smaller </text>
<text top="404" left="853" width="232" height="20" font="0">number of participants with diabetes limits </text>
<text top="421" left="853" width="212" height="20" font="0">statistical power to detect differences.  </text>
</page>
<page number="9" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="12" height="21" font="1">9 </text>
<text top="107" left="599" width="125" height="20" font="7"><b>People with diabetes </b></text>
<text top="124" left="599" width="213" height="20" font="0">Total cholesterol: -0.4 mmol/L at 0-2 H </text>
<text top="141" left="599" width="158" height="20" font="0">LDL-C: -0.6 mmol/L at 1-2 H </text>
<text top="159" left="599" width="156" height="20" font="0">HDL-C: 0.0 mmol/L at 0-8 H </text>
<text top="176" left="599" width="195" height="20" font="0">Triglycerides: +0.2 mmol/L at 0-4 H </text>
<text top="195" left="586" width="11" height="18" font="0">• </text>
<text top="194" left="599" width="177" height="20" font="0">Adjustment for effects related to </text>
<text top="211" left="599" width="168" height="20" font="0">hemodilution attenuated these </text>
<text top="229" left="599" width="67" height="20" font="0">differences. </text>
<text top="246" left="586" width="3" height="20" font="0"> </text>
<text top="264" left="91" width="129" height="20" font="0">Mora S, et al., 2008 <a href="data supplement.html#236">(5)</a> </text>
<text top="281" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18711012">18711012</a></text>
<text top="281" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18711012"> </a></text>
<text top="264" left="254" width="138" height="20" font="7"><b>Study type:</b> Prospective </text>
<text top="281" left="254" width="41" height="20" font="0">cohort  </text>
<text top="298" left="254" width="3" height="20" font="0"> </text>
<text top="315" left="254" width="120" height="20" font="7"><b>Size:</b> 26,330 women  </text>
<text top="333" left="254" width="3" height="20" font="0"> </text>
<text top="264" left="411" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="283" left="409" width="11" height="18" font="0">• </text>
<text top="282" left="422" width="111" height="20" font="0">Women aged ≥45 y </text>
<text top="301" left="409" width="11" height="18" font="0">• </text>
<text top="300" left="422" width="152" height="20" font="0">Asymptomatic from CVD or </text>
<text top="318" left="422" width="40" height="20" font="0">cancer </text>
<text top="337" left="409" width="11" height="18" font="0">• </text>
<text top="336" left="422" width="97" height="20" font="0">Fasting (≥8 H) or </text>
<text top="353" left="422" width="98" height="20" font="0">nonfasting (&lt;8 H) </text>
<text top="370" left="422" width="3" height="20" font="0"> </text>
<text top="387" left="422" width="3" height="20" font="0"> </text>
<text top="404" left="411" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="423" left="409" width="11" height="18" font="0">• </text>
<text top="423" left="422" width="148" height="20" font="0">Missing data on time since </text>
<text top="440" left="422" width="53" height="20" font="0">last meal </text>
<text top="265" left="590" width="208" height="20" font="7"><b>1</b>°<b> endpoints:</b> Lipid concentrations in </text>
<text top="282" left="590" width="228" height="20" font="0">fasting vs. nonfasting women; Composite </text>
<text top="299" left="590" width="194" height="20" font="0">end point of incident CVD (nonfatal </text>
<text top="317" left="590" width="198" height="20" font="0">myocardial infarction, percutaneous </text>
<text top="334" left="590" width="208" height="20" font="0">coronary intervention, coronary artery </text>
<text top="351" left="590" width="192" height="20" font="0">bypass grafting, nonfatal stroke, or </text>
<text top="368" left="590" width="124" height="20" font="0">cardiovascular death). </text>
<text top="385" left="590" width="136" height="20" font="0">Median follow up 11.4 y. </text>
<text top="403" left="590" width="3" height="20" font="0"> </text>
<text top="420" left="590" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="439" left="586" width="11" height="18" font="0">• </text>
<text top="438" left="599" width="179" height="20" font="0">19,983 fasting; 6,347 nonfasting </text>
<text top="457" left="586" width="11" height="18" font="0">• </text>
<text top="456" left="599" width="189" height="20" font="0">Median (IQR) lipid concentrations, </text>
<text top="474" left="599" width="162" height="20" font="0">fasting vs. nonfasting women </text>
<text top="491" left="599" width="215" height="20" font="0">Total cholesterol: 209 (185-236) mg/dL </text>
<text top="508" left="599" width="189" height="20" font="0">vs. 206 (181-234) mg/dL, p&lt;0.001 </text>
<text top="525" left="599" width="204" height="20" font="0">LDL-C: 123 (102-146) mg/dL vs. 117 </text>
<text top="542" left="599" width="139" height="20" font="0">(97-140) mg/dL, p&lt;0.001 </text>
<text top="560" left="599" width="222" height="20" font="0">HDL-C: 52 (43-62) mg/dL vs. 52 (43-62) </text>
<text top="577" left="599" width="82" height="20" font="0">mg/dL, p=0.25 </text>
<text top="594" left="599" width="207" height="20" font="0">Triglycerides: 115 (81-169) mg/dL vs. </text>
<text top="611" left="599" width="163" height="20" font="0">133 (93-196) mg/dL, p&lt;0.001 </text>
<text top="630" left="586" width="11" height="18" font="0">• </text>
<text top="630" left="599" width="221" height="20" font="0">There were no substantial differences in </text>
<text top="647" left="599" width="152" height="20" font="0">the distributions of lipid and </text>
<text top="664" left="599" width="191" height="20" font="0">apolipoprotein concentrations as a </text>
<text top="681" left="599" width="221" height="20" font="0">function of time since the last meal, with </text>
<text top="698" left="599" width="163" height="20" font="0">the exception of triglycerides. </text>
<text top="716" left="599" width="214" height="20" font="0">Triglycerides were at their maximum in </text>
<text top="733" left="599" width="197" height="20" font="0">women 4-5 H after the last reported </text>
<text top="750" left="599" width="37" height="20" font="0">meal.  </text>
<text top="769" left="586" width="11" height="18" font="0">• </text>
<text top="768" left="599" width="93" height="20" font="0">961 CVD events </text>
<text top="787" left="586" width="11" height="18" font="0">• </text>
<text top="787" left="599" width="221" height="20" font="0">Adjusted HRs for CVD events per 1 SD: </text>
<text top="266" left="839" width="11" height="18" font="0">• </text>
<text top="265" left="853" width="216" height="20" font="0">Lipid levels differed minimally in fasting </text>
<text top="282" left="853" width="236" height="20" font="0">compared with nonfasting women, with the </text>
<text top="299" left="853" width="146" height="20" font="0">exception of triglycerides.  </text>
<text top="318" left="839" width="11" height="18" font="0">• </text>
<text top="317" left="853" width="246" height="20" font="0">Associations of fasting total cholesterol, LDL-</text>
<text top="335" left="853" width="232" height="20" font="0">C and non-HDL-C with incident CVD were </text>
<text top="352" left="853" width="221" height="20" font="0">stronger than associations of nonfasting </text>
<text top="369" left="853" width="236" height="20" font="0">levels with incident CVD. Associations with </text>
<text top="386" left="853" width="226" height="20" font="0">incident CVD were similar for fasting and </text>
<text top="404" left="853" width="248" height="20" font="0">nonfasting levels of HDL-C and total/HDL-C.  </text>
<text top="423" left="839" width="11" height="18" font="0">• </text>
<text top="422" left="853" width="245" height="20" font="0">Results suggest that nonfasting blood draws </text>
<text top="439" left="853" width="194" height="20" font="0">may be useful when limited to HDL </text>
<text top="456" left="853" width="239" height="20" font="0">cholesterol, total/HDL cholesterol ratio, and </text>
<text top="473" left="853" width="76" height="20" font="0">triglycerides.  </text>
<text top="492" left="839" width="11" height="18" font="0">• </text>
<text top="492" left="853" width="246" height="20" font="0">Results also suggest that a fasting sample is </text>
<text top="509" left="853" width="248" height="20" font="0">preferred if risk assessment is based on total </text>
<text top="526" left="853" width="226" height="20" font="0">cholesterol, LDL cholesterol, or non-HDL </text>
<text top="543" left="853" width="100" height="20" font="0">cholesterol alone. </text>
<text top="562" left="839" width="11" height="18" font="0">• </text>
<text top="562" left="853" width="202" height="20" font="0">Limitations: women only; fasting and </text>
<text top="579" left="853" width="185" height="20" font="0">nonfasting samples from different </text>
<text top="596" left="853" width="212" height="20" font="0">individuals; largely Caucasian sample, </text>
<text top="613" left="853" width="235" height="20" font="0">higher SES; content of last meal unknown; </text>
<text top="630" left="853" width="243" height="20" font="0">smaller number of participants with diabetes </text>
<text top="648" left="853" width="243" height="20" font="0">limits statistical power to detect differences.  </text>
</page>
<page number="10" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">10 </text>
<text top="107" left="599" width="102" height="20" font="7"><b>Total cholesterol </b></text>
<text top="124" left="599" width="224" height="20" font="0">Nonfasting: HR: 1.07; 95% CI: 0.93-1.21 </text>
<text top="141" left="599" width="205" height="20" font="0">Fasting: HR: 1.22; 95% CI: 1.14-1.30 </text>
<text top="159" left="599" width="8" height="20" font="0">P</text>
<text top="165" left="607" width="37" height="13" font="9">interaction</text>
<text top="159" left="644" width="34" height="20" font="0">=0.10 </text>
<text top="176" left="599" width="40" height="20" font="7"><b>LDL-C </b></text>
<text top="193" left="599" width="224" height="20" font="0">Nonfasting: HR: 1.00; 95% CI: 0.87-1.15 </text>
<text top="210" left="599" width="205" height="20" font="0">Fasting: HR: 1.21; 95% CI: 1.13-1.29 </text>
<text top="228" left="599" width="8" height="20" font="0">P</text>
<text top="234" left="607" width="37" height="13" font="9">interaction</text>
<text top="227" left="644" width="34" height="20" font="0">=0.03 </text>
<text top="247" left="586" width="11" height="18" font="0">• </text>
<text top="246" left="599" width="206" height="20" font="0">After adjustment for total and HDL-C, </text>
<text top="263" left="599" width="184" height="20" font="0">nonfasting triglycerides remained </text>
<text top="280" left="599" width="206" height="20" font="0">associated with incident CVD events, </text>
<text top="297" left="599" width="207" height="20" font="0">whereas fasting triglyceride levels did </text>
<text top="315" left="599" width="27" height="20" font="0">not.  </text>
<text top="334" left="586" width="11" height="18" font="0">• </text>
<text top="333" left="599" width="228" height="20" font="0">Results were generally similar for women </text>
<text top="350" left="599" width="228" height="20" font="0">using vs. not using hormone replacement </text>
<text top="367" left="599" width="44" height="20" font="0">therapy </text>
<text top="386" left="586" width="11" height="18" font="0">• </text>
<text top="386" left="599" width="206" height="20" font="0">For total cholesterol, LDL-C, and non-</text>
<text top="403" left="599" width="228" height="20" font="0">HDL-C, significant associations with CVD </text>
<text top="420" left="599" width="191" height="20" font="0">were noted only after at least 10 H </text>
<text top="437" left="599" width="161" height="20" font="0">postprandially. The strongest </text>
<text top="454" left="599" width="196" height="20" font="0">associations for the other lipids and </text>
<text top="472" left="599" width="198" height="20" font="0">apolipoproteins were noted 6 to 8 H </text>
<text top="489" left="599" width="83" height="20" font="0">postprandially. </text>
<text top="507" left="91" width="129" height="20" font="0">Mora S, et al., 2009 <a href="data supplement.html#236">(6)</a> </text>
<text top="524" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19395440">19395440</a></text>
<text top="524" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19395440"> </a></text>
<text top="507" left="254" width="138" height="20" font="7"><b>Study type:</b> Prospective </text>
<text top="524" left="254" width="38" height="20" font="0">cohort </text>
<text top="541" left="254" width="3" height="20" font="0"> </text>
<text top="558" left="254" width="116" height="20" font="7"><b>Size:</b> 27,331 women </text>
<text top="507" left="411" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="526" left="409" width="11" height="18" font="0">• </text>
<text top="525" left="422" width="111" height="20" font="0">Women aged ≥45 y </text>
<text top="544" left="409" width="11" height="18" font="0">• </text>
<text top="543" left="422" width="152" height="20" font="0">Asymptomatic from CVD or </text>
<text top="561" left="422" width="40" height="20" font="0">cancer </text>
<text top="580" left="409" width="11" height="18" font="0">• </text>
<text top="579" left="422" width="97" height="20" font="0">Fasting (≥8 H) or </text>
<text top="596" left="422" width="98" height="20" font="0">nonfasting (&lt;8 H) </text>
<text top="613" left="422" width="3" height="20" font="0"> </text>
<text top="630" left="422" width="3" height="20" font="0"> </text>
<text top="647" left="411" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="666" left="409" width="11" height="18" font="0">• </text>
<text top="666" left="422" width="148" height="20" font="0">Missing data on time since </text>
<text top="683" left="422" width="53" height="20" font="0">last meal </text>
<text top="508" left="590" width="196" height="20" font="7"><b>1</b>°<b> endpoints:</b> LDL-C measured by </text>
<text top="525" left="590" width="212" height="20" font="0">Friedewald calculation or direct LDL-C </text>
<text top="542" left="590" width="211" height="20" font="0">measurement in fasting vs. nonfasting </text>
<text top="560" left="590" width="222" height="20" font="0">women; Composite end point of incident </text>
<text top="577" left="590" width="200" height="20" font="0">CVD (nonfatal myocardial infarction, </text>
<text top="594" left="590" width="200" height="20" font="0">percutaneous coronary intervention, </text>
<text top="611" left="590" width="224" height="20" font="0">coronary artery bypass grafting, nonfatal </text>
<text top="628" left="590" width="179" height="20" font="0">stroke, or cardiovascular death); </text>
<text top="646" left="590" width="123" height="20" font="0">Mean follow up 11.4 y<b> </b></text>
<text top="663" left="590" width="3" height="20" font="0"> </text>
<text top="680" left="590" width="52" height="20" font="7"><b>Results: </b></text>
<text top="699" left="586" width="11" height="18" font="0">• </text>
<text top="698" left="599" width="217" height="20" font="0">Correlation between fasting Friedewald </text>
<text top="715" left="599" width="222" height="20" font="0">calculated LDL-C and fasting direct LDL-</text>
<text top="733" left="599" width="208" height="20" font="0">C, r=0.976, p&lt;0.001; mean difference </text>
<text top="750" left="599" width="205" height="20" font="0">(direct minus Friedewald) was -0.146 </text>
<text top="767" left="599" width="197" height="20" font="0">(95% CI: -0.149, -0.143) mmol/L for </text>
<text top="784" left="599" width="206" height="20" font="0">fasting samples and -0.125 (95% CI: -</text>
<text top="509" left="839" width="11" height="18" font="0">• </text>
<text top="508" left="853" width="239" height="20" font="0">Direct LDL-C measurements were lower by </text>
<text top="525" left="853" width="231" height="20" font="0">0.13-0.26 mmol/L (5-10 mg/dL) compared </text>
<text top="542" left="853" width="217" height="20" font="0">with Friedewald fasting measurements. </text>
<text top="561" left="839" width="11" height="18" font="0">• </text>
<text top="560" left="853" width="235" height="20" font="0">Lower LDL-C measured by direct methods </text>
<text top="578" left="853" width="206" height="20" font="0">may lead to misclassification of some </text>
<text top="595" left="853" width="235" height="20" font="0">individuals when LDL-C strata are applied. </text>
<text top="614" left="839" width="11" height="18" font="0">• </text>
<text top="613" left="853" width="246" height="20" font="0">Associations of Friedewald and direct LDL-C </text>
<text top="630" left="853" width="229" height="20" font="0">were nearly identical for fasting samples.  </text>
<text top="649" left="839" width="11" height="18" font="0">• </text>
<text top="649" left="853" width="230" height="20" font="0">No association of nonfasting direct LDL-C </text>
<text top="666" left="853" width="236" height="20" font="0">with incident CVD, calling into question the </text>
<text top="683" left="853" width="212" height="20" font="0">utility of a direct assay for prognosis in </text>
<text top="700" left="853" width="113" height="20" font="0">nonfasting samples. </text>
<text top="719" left="839" width="11" height="18" font="0">• </text>
<text top="719" left="853" width="202" height="20" font="0">Limitations: women only; fasting and </text>
<text top="736" left="853" width="185" height="20" font="0">nonfasting samples from different </text>
<text top="753" left="853" width="212" height="20" font="0">individuals; largely Caucasian sample, </text>
<text top="770" left="853" width="235" height="20" font="0">higher SES; content of last meal unknown. </text>
<text top="787" left="841" width="3" height="20" font="0"> </text>
</page>
<page number="11" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">11 </text>
<text top="107" left="599" width="202" height="20" font="0">0.131, -0.120) mmol/L for nonfasting </text>
<text top="124" left="599" width="53" height="20" font="0">samples. </text>
<text top="143" left="586" width="11" height="18" font="0">• </text>
<text top="143" left="599" width="78" height="20" font="0">LDL-C values </text>
<text top="160" left="599" width="207" height="20" font="0">Friedewald, fasting mean 3.40 ± 0.90 </text>
<text top="177" left="599" width="211" height="20" font="0">mmol/L (median 3.33; IQR: 2.78-3.94) </text>
<text top="194" left="599" width="223" height="20" font="0">Direct, fasting mean 3.26 ± 0.88 mmol/L </text>
<text top="211" left="599" width="167" height="20" font="0">(median 3.19; IQR: 2.65-3.78) </text>
<text top="229" left="599" width="200" height="20" font="0">Direct, nonfasting mean 3.11 ± 0.86 </text>
<text top="246" left="599" width="214" height="20" font="0">mmol/L (median 3.03; IQR: 2.51- 3.62) </text>
<text top="263" left="599" width="193" height="20" font="0">p&lt;0.001 for comparisons of fasting </text>
<text top="280" left="599" width="198" height="20" font="0">Friedewald vs. fasting direct and for </text>
<text top="297" left="599" width="219" height="20" font="0">fasting Friedewald vs. nonfasting direct. </text>
<text top="316" left="586" width="11" height="18" font="0">• </text>
<text top="316" left="599" width="203" height="20" font="0">Overall distributions of Friedewald or </text>
<text top="333" left="599" width="215" height="20" font="0">direct LDL-C did not differ substantially </text>
<text top="350" left="599" width="131" height="20" font="0">by time since last meal. </text>
<text top="367" left="590" width="3" height="20" font="0"> </text>
<text top="386" left="586" width="11" height="18" font="0">• </text>
<text top="386" left="599" width="142" height="20" font="0">945 incident CVD events. </text>
<text top="405" left="586" width="11" height="18" font="0">• </text>
<text top="404" left="599" width="223" height="20" font="0">Adjusted HRs for incident CVD per 1 SD </text>
<text top="421" left="599" width="83" height="20" font="0">higher LDL-C:  </text>
<text top="440" left="586" width="11" height="18" font="0">• </text>
<text top="439" left="599" width="209" height="20" font="0">Friedewald, fasting HR: 1.22; 95% CI: </text>
<text top="457" left="599" width="55" height="20" font="0">1.14-1.30 </text>
<text top="474" left="599" width="209" height="20" font="0">Direct, fasting HR: 1.23; 95% CI: 1.15-</text>
<text top="491" left="599" width="27" height="20" font="0">1.32 </text>
<text top="508" left="599" width="202" height="20" font="0">Direct, nonfasting HR: 1.03; 95% CI: </text>
<text top="525" left="599" width="55" height="20" font="0">0.89-1.18 </text>
<text top="107" left="841" width="3" height="20" font="0"> </text>
<text top="543" left="91" width="133" height="20" font="0">Sidhu D, et al., 2012 <a href="data supplement.html#236">(7)</a> </text>
<text top="560" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23147400">23147400</a></text>
<text top="560" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23147400"> </a></text>
<text top="543" left="254" width="107" height="20" font="7"><b>Study type:</b> Cross-</text>
<text top="560" left="254" width="139" height="20" font="0">sectional cohort (Calgary </text>
<text top="578" left="254" width="117" height="20" font="0">Laboratory Services) </text>
<text top="595" left="254" width="3" height="20" font="0"> </text>
<text top="612" left="254" width="141" height="20" font="7"><b>Size:</b> 209,180 individuals </text>
<text top="629" left="254" width="3" height="20" font="0"> </text>
<text top="543" left="411" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="562" left="409" width="11" height="18" font="0">• </text>
<text top="562" left="422" width="146" height="20" font="0">All individuals with at least </text>
<text top="579" left="422" width="73" height="20" font="0">1 lipid profile </text>
<text top="596" left="422" width="3" height="20" font="0"> </text>
<text top="613" left="411" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="632" left="409" width="11" height="18" font="0">• </text>
<text top="631" left="422" width="139" height="20" font="0">Missing fasting time data </text>
<text top="650" left="409" width="11" height="18" font="0">• </text>
<text top="650" left="422" width="144" height="20" font="0">LDL-C data missing when </text>
<text top="667" left="422" width="139" height="20" font="0">triglycerides ≥400 mg/dL </text>
<text top="544" left="590" width="233" height="20" font="7"><b>1</b>°<b> endpoint:</b> Lipid levels stratified by time </text>
<text top="562" left="590" width="226" height="20" font="0">(1-16 H) since last reported meal, in men </text>
<text top="579" left="590" width="70" height="20" font="0">and women. </text>
<text top="596" left="590" width="3" height="20" font="0"> </text>
<text top="613" left="590" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="632" left="586" width="11" height="18" font="0">• </text>
<text top="632" left="599" width="216" height="20" font="0">Compared with those who fasted &gt;8 H, </text>
<text top="649" left="599" width="222" height="20" font="0">adjusted mean levels of lipid subclasses </text>
<text top="666" left="599" width="211" height="20" font="0">varied minimally in 1-7 H as a function </text>
<text top="683" left="599" width="215" height="20" font="0">time from last meal for total cholesterol </text>
<text top="700" left="599" width="201" height="20" font="0">and HDL-C, and somewhat more for </text>
<text top="717" left="599" width="135" height="20" font="0">LDL-C and triglycerides: </text>
<text top="735" left="599" width="205" height="20" font="0">Mean total cholesterol varied by &lt;2% </text>
<text top="752" left="599" width="212" height="20" font="0">lower (NS for men; p&lt;0.05 for H 1-2 in </text>
<text top="769" left="599" width="47" height="20" font="0">women) </text>
<text top="545" left="839" width="11" height="18" font="0">• </text>
<text top="544" left="853" width="247" height="20" font="0">Fasting time since last meal showed minimal </text>
<text top="561" left="853" width="238" height="20" font="0">associations with total cholesterol and HDL-</text>
<text top="579" left="853" width="219" height="20" font="0">C, and modest associations with LDL-C </text>
<text top="596" left="853" width="198" height="20" font="0">(lower after meal by up to 10%) and </text>
<text top="613" left="853" width="216" height="20" font="0">triglycerides (higher after meal by up to </text>
<text top="630" left="853" width="36" height="20" font="0">20%). </text>
<text top="649" left="839" width="11" height="18" font="0">• </text>
<text top="649" left="853" width="223" height="20" font="0">Large population-based sample of those </text>
<text top="666" left="853" width="96" height="20" font="0">receiving testing. </text>
<text top="685" left="839" width="11" height="18" font="0">• </text>
<text top="684" left="853" width="232" height="20" font="0">Limitations: content of last meal unknown; </text>
<text top="701" left="853" width="241" height="20" font="0">unknown status with regard to lipid lowering </text>
<text top="718" left="853" width="38" height="20" font="0">drugs. </text>
</page>
<page number="12" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">12 </text>
<text top="107" left="599" width="214" height="20" font="0">Mean HDL-C varied by &lt;2% lower (NS </text>
<text top="124" left="599" width="116" height="20" font="0">for men and women) </text>
<text top="141" left="599" width="225" height="20" font="0">Mean LDL-C varied by &lt;10% (p&lt;0.05 for </text>
<text top="159" left="599" width="183" height="20" font="0">H 1-5 in men; p&lt;0.05 for H 1-4 in </text>
<text top="176" left="599" width="47" height="20" font="0">women) </text>
<text top="193" left="599" width="192" height="20" font="0">Mean triglycerides varied by &lt;20% </text>
<text top="210" left="599" width="223" height="20" font="0">(p&lt;0.05 for H 1-6 in men; p&lt;0.05 for H 1-</text>
<text top="228" left="599" width="74" height="20" font="0">5 in women). </text>
<text top="245" left="590" width="3" height="20" font="0"> </text>
<text top="264" left="88" width="976" height="20" font="7"><b>Abbreviations:</b> 1° indicated primary; CI, confidence interval; HR, hazard ratio; N/A, not available; OR, odds ratio; RCT, randomized controlled trial; and RR, relative risk. NHANES </text>
<text top="281" left="88" width="300" height="20" font="7"><b>Search Terms and Date of Search</b>: Author to provide </text>
<text top="298" left="88" width="3" height="20" font="0"> </text>
<text top="315" left="88" width="4" height="22" font="1"> </text>
<text top="334" left="81" width="911" height="24" font="4"><b>Data Supplement 2. RCTs of Statin Therapy for Primary Prevention of ASCVD Among Patients with the Metabolic Syndrome or its </b></text>
<text top="355" left="81" width="228" height="24" font="4"><b>Subcomponents (Section 3.1.2)  </b></text>
<text top="385" left="98" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="402" left="123" width="48" height="20" font="7"><b>Author; </b></text>
<text top="420" left="101" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="385" left="245" width="83" height="20" font="7"><b>Aim of Study; </b></text>
<text top="402" left="250" width="74" height="20" font="7"><b>Study Type; </b></text>
<text top="420" left="244" width="86" height="20" font="7"><b>Study Size (N) </b></text>
<text top="402" left="392" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="377" left="557" width="111" height="20" font="7"><b>Study Intervention </b></text>
<text top="394" left="575" width="76" height="20" font="7"><b>(# patients) / </b></text>
<text top="411" left="558" width="111" height="20" font="7"><b>Study Comparator </b></text>
<text top="428" left="579" width="69" height="20" font="7"><b>(# patients) </b></text>
<text top="385" left="751" width="105" height="20" font="7"><b>Endpoint Results </b></text>
<text top="402" left="735" width="137" height="20" font="7"><b>(Absolute Event Rates, </b></text>
<text top="420" left="713" width="181" height="20" font="7"><b>P values; OR or RR; &amp; 95% CI) </b></text>
<text top="386" left="932" width="175" height="20" font="7"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="403" left="964" width="111" height="20" font="7"><b>Study Limitations; </b></text>
<text top="420" left="972" width="96" height="20" font="7"><b>Adverse Events </b></text>
<text top="446" left="89" width="40" height="20" font="7"><b>MEGA </b></text>
<text top="463" left="89" width="105" height="20" font="0">Matshushima T, et </text>
<text top="481" left="89" width="73" height="20" font="0">al., 2012 <a href="data supplement.html#236">(8)</a><b>  </b></text>
<text top="498" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22573644">22573644</a></text>
<text top="498" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22573644"> </a></text>
<text top="446" left="218" width="119" height="20" font="7"><b>Aim:</b> To evaluate the </text>
<text top="463" left="218" width="89" height="20" font="0">effectiveness of </text>
<text top="481" left="218" width="81" height="20" font="0">pravastatin for </text>
<text top="498" left="218" width="107" height="20" font="0">preventing ASCVD </text>
<text top="515" left="218" width="81" height="20" font="0">events among </text>
<text top="532" left="218" width="107" height="20" font="0">individuals with the </text>
<text top="549" left="218" width="114" height="20" font="0">metabolic syndrome </text>
<text top="567" left="218" width="3" height="20" font="0"> </text>
<text top="584" left="218" width="131" height="20" font="7"><b>Study type:</b> RCT (post-</text>
<text top="601" left="218" width="133" height="20" font="0">hoc subgroup analysis)  </text>
<text top="618" left="218" width="3" height="20" font="0"> </text>
<text top="635" left="218" width="86" height="20" font="7"><b>Size:</b> 8,214 pts </text>
<text top="653" left="218" width="132" height="20" font="0">(subgroup of 2,636 with </text>
<text top="670" left="218" width="118" height="20" font="0">metabolic syndrome) </text>
<text top="446" left="369" width="157" height="20" font="7"><b>Inclusion criteria:</b> Men and </text>
<text top="463" left="369" width="141" height="20" font="0">post-menopausal women </text>
<text top="481" left="369" width="118" height="20" font="0">aged 40-70 with total </text>
<text top="498" left="369" width="145" height="20" font="0">cholesterol 220-270 mg/dl </text>
<text top="515" left="369" width="3" height="20" font="0"> </text>
<text top="532" left="369" width="152" height="20" font="7"><b>Exclusion criteria:</b> History </text>
<text top="549" left="369" width="88" height="20" font="0">of CVD, familial </text>
<text top="567" left="369" width="124" height="20" font="0">hypercholesterolemia, </text>
<text top="584" left="369" width="157" height="20" font="0">secondary hyperlipidemia or </text>
<text top="601" left="369" width="107" height="20" font="0">current malignancy </text>
<text top="446" left="540" width="143" height="20" font="7"><b>Intervention:</b> Pravastatin </text>
<text top="463" left="540" width="55" height="20" font="0">10-20 mg </text>
<text top="481" left="540" width="7" height="20" font="0">  </text>
<text top="498" left="540" width="132" height="20" font="7"><b>Comparator:</b> Placebo <b>  </b></text>
<text top="447" left="699" width="169" height="20" font="7"><b>1</b>°<b> endpoint:</b> CHD, defined as </text>
<text top="464" left="699" width="192" height="20" font="0">composite of fatal and nonfatal MI, </text>
<text top="482" left="699" width="200" height="20" font="0">cardiac and sudden death, coronary </text>
<text top="499" left="699" width="178" height="20" font="0">revascularization procedure and </text>
<text top="516" left="699" width="202" height="20" font="0">angina (Among those with metabolic </text>
<text top="533" left="699" width="165" height="20" font="0">syndrome: Pravastatin 5.3 vs. </text>
<text top="551" left="699" width="205" height="20" font="0">Placebo 6.9, events per 1000 person-</text>
<text top="568" left="699" width="179" height="20" font="0">y; HR: 0.78 [95% CI: 0.49-1.24]) </text>
<text top="585" left="699" width="3" height="20" font="0"> </text>
<text top="602" left="699" width="193" height="20" font="7"><b>Safety endpoint (if relevant):</b> N/A </text>
<text top="619" left="699" width="3" height="20" font="7"><b> </b></text>
<text top="448" left="921" width="7" height="18" font="0">•</text>
<text top="447" left="928" width="42" height="20" font="0"> Stroke </text>
<text top="464" left="921" width="180" height="20" font="0">(Pravastatin 2.6 vs. Placebo 5.7, </text>
<text top="482" left="921" width="171" height="20" font="0">events per 1000 person-y; HR: </text>
<text top="499" left="921" width="141" height="20" font="0">0.45 [95% CI: 0.25-0.83]) </text>
<text top="518" left="921" width="7" height="18" font="0">•</text>
<text top="517" left="928" width="163" height="20" font="0">Total CVD events, defined as </text>
<text top="534" left="921" width="175" height="20" font="0">CHD, stroke, transient ischemic </text>
<text top="552" left="921" width="179" height="20" font="0">attack [TIA], and arteriosclerosis </text>
<text top="569" left="921" width="57" height="20" font="0">obliterans </text>
<text top="586" left="921" width="187" height="20" font="0">(Pravastatin 8.6 vs. Placebo 13.6, </text>
<text top="603" left="921" width="171" height="20" font="0">events per 1000 person-y; HR: </text>
<text top="621" left="921" width="141" height="20" font="0">0.64 [95% CI: 0.45-0.90]) </text>
<text top="640" left="921" width="7" height="18" font="0">•</text>
<text top="639" left="928" width="84" height="20" font="0">Total Mortality  </text>
<text top="656" left="921" width="180" height="20" font="0">(Pravastatin 2.5 vs. Placebo 5.2, </text>
<text top="673" left="921" width="171" height="20" font="0">events per 1000 person-y; HR: </text>
<text top="691" left="921" width="141" height="20" font="0">0.50 [95% CI: 0.27-0.92]) </text>
<text top="708" left="921" width="3" height="20" font="0"> </text>
<text top="725" left="921" width="166" height="20" font="0">Limitation: Post-hoc subgroup </text>
<text top="742" left="921" width="196" height="20" font="0">analysis among individuals with the </text>
<text top="759" left="921" width="114" height="20" font="0">metabolic syndrome </text>
<text top="777" left="921" width="3" height="20" font="0"> </text>
</page>
<page number="13" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="10" size="12" family="Times" color="#303030"/>
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">13 </text>
<text top="107" left="921" width="141" height="20" font="0">5 y follow-up data utilized </text>
<text top="124" left="921" width="3" height="20" font="0"> </text>
<text top="193" left="89" width="116" height="20" font="7"><b>AFCAPS/TEXCAPS </b></text>
<text top="210" left="89" width="106" height="20" font="0">Clearfield M, et al., </text>
<text top="227" left="89" width="19" height="20" font="0"><a href="data supplement.html#236">(9)</a> </text>
<text top="244" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16360356">16360356</a></text>
<text top="244" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16360356"> </a></text>
<text top="193" left="218" width="127" height="20" font="7"><b>Aim:</b> To determine the </text>
<text top="210" left="218" width="89" height="20" font="0">effectiveness of </text>
<text top="227" left="218" width="138" height="20" font="0">lovastatin for the primary </text>
<text top="244" left="218" width="120" height="20" font="0">prevention of ASCVD </text>
<text top="262" left="218" width="124" height="20" font="0">events among several </text>
<text top="279" left="218" width="104" height="20" font="0">clinical subgroups, </text>
<text top="296" left="218" width="138" height="20" font="0">including individuals with </text>
<text top="313" left="218" width="134" height="20" font="0">the metabolic syndrome </text>
<text top="330" left="218" width="3" height="20" font="0"> </text>
<text top="348" left="218" width="134" height="20" font="7"><b>Study type:</b>  RCT (post-</text>
<text top="365" left="218" width="130" height="20" font="0">hoc subgroup analysis) </text>
<text top="382" left="218" width="3" height="20" font="0"> </text>
<text top="399" left="218" width="132" height="20" font="7"><b>Size: </b>6,605 pts (48% of </text>
<text top="417" left="218" width="109" height="20" font="0">trial population with </text>
<text top="434" left="218" width="118" height="20" font="0">metabolic syndrome) </text>
<text top="451" left="218" width="10" height="20" font="0">   </text>
<text top="193" left="369" width="133" height="20" font="7"><b>Inclusion criteria:</b> Men </text>
<text top="210" left="369" width="133" height="20" font="0">aged 45-73 and women </text>
<text top="227" left="369" width="120" height="20" font="0">aged 55-73, with LDL </text>
<text top="244" left="369" width="145" height="20" font="0">cholesterol 130-190 mg/dl </text>
<text top="262" left="369" width="127" height="20" font="0">and triglycerides &lt; 400 </text>
<text top="279" left="369" width="37" height="20" font="0">mg/dl  </text>
<text top="296" left="369" width="3" height="20" font="0"> </text>
<text top="313" left="369" width="110" height="20" font="7"><b>Exclusion criteria:</b> </text>
<text top="330" left="369" width="134" height="20" font="0">Previous Hx of MI/CHD, </text>
<text top="348" left="369" width="106" height="20" font="0">stroke/TIA or PAD; </text>
<text top="365" left="369" width="7" height="20" font="0">u</text>
<text top="365" left="375" width="141" height="20" font="10">ncontrolled hypertension, </text>
<text top="382" left="369" width="146" height="20" font="10">secondary hyperlipidemia, </text>
<text top="399" left="369" width="138" height="20" font="10">type 1 or type 2 diabetes </text>
<text top="417" left="369" width="158" height="20" font="10">mellitus that either managed </text>
<text top="434" left="369" width="140" height="20" font="10">with insulin or associated </text>
<text top="451" left="369" width="132" height="20" font="10">with a Hemoglobin A1C </text>
<text top="468" left="369" width="131" height="20" font="10">level of at least 10%, or </text>
<text top="485" left="369" width="150" height="20" font="10">body weight &gt; 50% greater </text>
<text top="503" left="369" width="137" height="20" font="10">than desirable weight for </text>
<text top="520" left="369" width="37" height="20" font="10">height </text>
<text top="520" left="406" width="3" height="20" font="0"> </text>
<text top="193" left="540" width="137" height="20" font="7"><b>Intervention: </b>Lovastatin </text>
<text top="210" left="540" width="55" height="20" font="0">20-40 mg </text>
<text top="227" left="540" width="7" height="20" font="0">  </text>
<text top="244" left="540" width="129" height="20" font="7"><b>Comparator:</b> Placebo<b>  </b></text>
<text top="194" left="699" width="193" height="20" font="7"><b>1</b>°<b> endpoint:</b> 10-y incidence of MI, </text>
<text top="211" left="699" width="188" height="20" font="0">CHD Mortality or Unstable Angina </text>
<text top="228" left="699" width="161" height="20" font="0">(Among those with metabolic </text>
<text top="246" left="699" width="171" height="20" font="0">syndrome: Lovastatin 7.7% vs. </text>
<text top="263" left="699" width="190" height="20" font="0">Placebo 13.0%; RR: 0.59; p&lt;0.05) </text>
<text top="280" left="699" width="3" height="20" font="0"> </text>
<text top="297" left="699" width="124" height="20" font="7"><b>Safety endpoint:</b> N/A </text>
<text top="314" left="699" width="3" height="20" font="7"><b> </b></text>
<text top="195" left="921" width="7" height="18" font="0">•</text>
<text top="194" left="928" width="170" height="20" font="0"> Limitation: Post-hoc subgroup </text>
<text top="211" left="921" width="196" height="20" font="0">analysis among individuals with the </text>
<text top="228" left="921" width="117" height="20" font="0">metabolic syndrome. </text>
<text top="246" left="921" width="3" height="20" font="0"> </text>
<text top="263" left="921" width="149" height="20" font="0">10-y follow-up data utilized </text>
<text top="538" left="89" width="68" height="20" font="7"><b>WOSCOPS </b></text>
<text top="555" left="89" width="85" height="20" font="0">Sattar N, et al., </text>
<text top="572" left="89" width="60" height="20" font="0">2003 <a href="data supplement.html#236">(10)</a>  </text>
<text top="589" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12860911">12860911</a></text>
<text top="589" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12860911"> </a></text>
<text top="607" left="89" width="7" height="20" font="0">  </text>
<text top="538" left="218" width="119" height="20" font="7"><b>Aim:</b> To evaluate the </text>
<text top="555" left="218" width="133" height="20" font="0">risk for CHD associated </text>
<text top="572" left="218" width="81" height="20" font="0">with metabolic </text>
<text top="589" left="218" width="104" height="20" font="0">syndrome and risk </text>
<text top="607" left="218" width="82" height="20" font="0">reduction from </text>
<text top="624" left="218" width="135" height="20" font="0">pravastatin in those with </text>
<text top="641" left="218" width="122" height="20" font="0">and without metabolic </text>
<text top="658" left="218" width="57" height="20" font="0">syndrome </text>
<text top="676" left="218" width="3" height="20" font="0"> </text>
<text top="693" left="218" width="131" height="20" font="7"><b>Study type:</b> RCT (post-</text>
<text top="710" left="218" width="133" height="20" font="0">hoc subgroup analysis)  </text>
<text top="727" left="218" width="3" height="20" font="0"> </text>
<text top="744" left="218" width="124" height="20" font="7"><b>Size:</b> 6,447 pts (1,691 </text>
<text top="762" left="218" width="81" height="20" font="0">with metabolic </text>
<text top="779" left="218" width="62" height="20" font="0">syndrome) </text>
<text top="538" left="369" width="159" height="20" font="7"><b>Inclusion criteria:</b> Men with </text>
<text top="555" left="369" width="141" height="20" font="0">LDL cholesterol from 174-</text>
<text top="572" left="369" width="150" height="20" font="0">232 mg/dl and triglycerides </text>
<text top="589" left="369" width="68" height="20" font="0">&lt; 530 mg/dl </text>
<text top="607" left="369" width="3" height="20" font="0"> </text>
<text top="624" left="369" width="152" height="20" font="7"><b>Exclusion criteria:</b> History </text>
<text top="641" left="369" width="133" height="20" font="0">of myocardial infarction, </text>
<text top="658" left="369" width="92" height="20" font="0">angina requiring </text>
<text top="676" left="369" width="156" height="20" font="0">hospitalization; arrhythmias; </text>
<text top="693" left="369" width="114" height="20" font="0">severe hypertension </text>
<text top="710" left="369" width="129" height="20" font="0">(&gt;180/110); congestive </text>
<text top="727" left="369" width="131" height="20" font="0">heart failure; congenital </text>
<text top="744" left="369" width="138" height="20" font="0">heart disease; rheumatic </text>
<text top="762" left="369" width="130" height="20" font="0">heart disease; baseline </text>
<text top="779" left="369" width="53" height="20" font="0">diabetes  </text>
<text top="538" left="540" width="143" height="20" font="7"><b>Intervention:</b> Pravastatin </text>
<text top="555" left="540" width="38" height="20" font="0">40 mg </text>
<text top="572" left="540" width="7" height="20" font="0">  </text>
<text top="589" left="540" width="125" height="20" font="7"><b>Comparator:</b> Placebo<b> </b></text>
<text top="539" left="699" width="169" height="20" font="7"><b>1</b>°<b> endpoint:</b> CHD, defined as </text>
<text top="556" left="699" width="202" height="20" font="0">nonfatal CHD or CHD death (Among </text>
<text top="573" left="699" width="176" height="20" font="0">those with metabolic syndrome: </text>
<text top="591" left="699" width="205" height="20" font="0">Pravsatatin 7.7% vs. Placebo 10.4%, </text>
<text top="608" left="699" width="192" height="20" font="0">event rate; HR: 0.73; 95% CI: 0.53-</text>
<text top="625" left="699" width="31" height="20" font="0">1.01) </text>
<text top="642" left="699" width="3" height="20" font="0"> </text>
<text top="659" left="699" width="124" height="20" font="7"><b>Safety endpoint:</b> N/A </text>
<text top="677" left="699" width="3" height="20" font="7"><b> </b></text>
<text top="540" left="921" width="7" height="18" font="0">•</text>
<text top="539" left="928" width="170" height="20" font="0"> Limitation: Post-hoc subgroup </text>
<text top="556" left="921" width="196" height="20" font="0">analysis among individuals with the </text>
<text top="573" left="921" width="114" height="20" font="0">metabolic syndrome </text>
<text top="591" left="921" width="3" height="20" font="0"> </text>
<text top="608" left="921" width="132" height="20" font="0">Average 4.9 y follow-up </text>
</page>
<page number="14" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">14 </text>
<text top="107" left="89" width="59" height="20" font="7"><b>JUPITER  </b></text>
<text top="124" left="89" width="98" height="20" font="0">Ridker PM, et al., </text>
<text top="141" left="89" width="56" height="20" font="0">2008 <a href="data supplement.html#236">(11)</a> </text>
<text top="159" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18997196">18997196</a></text>
<text top="159" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/18997196"> </a></text>
<text top="176" left="89" width="7" height="20" font="0">  </text>
<text top="107" left="218" width="98" height="20" font="7"><b>Aim:</b> To evaluate </text>
<text top="124" left="218" width="117" height="20" font="0">whether rosuvastatin </text>
<text top="141" left="218" width="119" height="20" font="0">decreases the rate of </text>
<text top="159" left="218" width="57" height="20" font="0">first major </text>
<text top="176" left="218" width="122" height="20" font="0">cardiovascular events </text>
<text top="193" left="218" width="127" height="20" font="0">among individuals with </text>
<text top="210" left="218" width="133" height="20" font="0">elevated high sensitivity </text>
<text top="228" left="218" width="123" height="20" font="0">CRP and LDLC &lt; 130 </text>
<text top="245" left="218" width="33" height="20" font="0">mg/dl </text>
<text top="262" left="218" width="3" height="20" font="0"> </text>
<text top="279" left="218" width="99" height="20" font="7"><b>Study type:</b> RCT </text>
<text top="296" left="218" width="3" height="20" font="0"> </text>
<text top="314" left="218" width="131" height="20" font="7"><b>Size:</b> 17,802 pts (7,375 </text>
<text top="331" left="218" width="81" height="20" font="0">with metabolic </text>
<text top="348" left="218" width="62" height="20" font="0">syndrome) </text>
<text top="107" left="369" width="145" height="20" font="7"><b>Inclusion criteria:</b> LDL-C </text>
<text top="124" left="369" width="113" height="20" font="0">less than 130 mg/dl, </text>
<text top="141" left="369" width="137" height="20" font="0">triglycerides &lt; 500 mg/dl </text>
<text top="159" left="369" width="159" height="20" font="0">and high sensitivity CRP ≥ 2 </text>
<text top="176" left="369" width="33" height="20" font="0">mg/dl </text>
<text top="193" left="369" width="3" height="20" font="0"> </text>
<text top="210" left="369" width="122" height="20" font="7"><b>Exclusion criteria:</b> A </text>
<text top="227" left="369" width="151" height="20" font="0">history of CVD; current use </text>
<text top="245" left="369" width="136" height="20" font="0">of lipid lowering therapy; </text>
<text top="262" left="369" width="139" height="20" font="0">elevated CK (3x normal), </text>
<text top="279" left="369" width="106" height="20" font="0">ALT (2x normal) or </text>
<text top="296" left="369" width="123" height="20" font="0">creatinine (&gt; 2 mg/dl); </text>
<text top="314" left="369" width="156" height="20" font="0">uncontrolled HTN; history of </text>
<text top="331" left="369" width="125" height="20" font="0">systemic inflammatory </text>
<text top="348" left="369" width="53" height="20" font="0">condition </text>
<text top="107" left="540" width="78" height="20" font="7"><b>Intervention:</b> </text>
<text top="124" left="540" width="112" height="20" font="0">Rosuvastatin 20 mg </text>
<text top="141" left="540" width="7" height="20" font="0">  </text>
<text top="159" left="540" width="132" height="20" font="7"><b>Comparator:</b> Placebo <b>  </b></text>
<text top="108" left="699" width="137" height="20" font="7"><b>1</b>°<b> endpoint:</b> First major </text>
<text top="125" left="699" width="180" height="20" font="0">cardiovascular event, defined as </text>
<text top="143" left="699" width="155" height="20" font="0">nonfatal MI, nonfatal stroke, </text>
<text top="160" left="699" width="193" height="20" font="0">hospitalization for unstable angina, </text>
<text top="177" left="699" width="196" height="20" font="0">arterial revascularization procedure </text>
<text top="194" left="699" width="202" height="20" font="0">or death from cardiovascular causes </text>
<text top="212" left="699" width="204" height="20" font="0">(Rosuvastatin 0.77 vs. Placebo 1.36, </text>
<text top="229" left="699" width="208" height="20" font="0">rate per 100 person-y; HR: 0.56; 95% </text>
<text top="246" left="699" width="79" height="20" font="0">CI: 0.46-0.69) </text>
<text top="263" left="699" width="3" height="20" font="0"> </text>
<text top="280" left="699" width="201" height="20" font="7"><b>Safety endpoint:</b> Any serious event </text>
<text top="298" left="699" width="184" height="20" font="0">(Rosuvastatin 15.2% vs. Placebo </text>
<text top="315" left="699" width="197" height="20" font="0">15.5%; p=0.60); notable statistically </text>
<text top="332" left="699" width="202" height="20" font="0">significant findings: newly diagnosed </text>
<text top="349" left="699" width="179" height="20" font="0">diabetes (Rosuvastatin 3.0% vs. </text>
<text top="366" left="699" width="194" height="20" font="0">Placebo 2.4%, p=0.01); death from </text>
<text top="384" left="699" width="169" height="20" font="0">cancer (Rosuvastatin 0.4% vs. </text>
<text top="401" left="699" width="205" height="20" font="0">Placebo 0.7%; p=0.02); median GFR </text>
<text top="418" left="699" width="176" height="20" font="0">at 12 mo (Rosuvastatin 66.8 vs. </text>
<text top="435" left="699" width="169" height="20" font="0">Placebo 66.6, in ml/min/1.73 m</text>
<text top="437" left="867" width="4" height="13" font="9">2</text>
<text top="435" left="872" width="25" height="20" font="0">; p= </text>
<text top="452" left="699" width="31" height="20" font="0">0.02) </text>
<text top="470" left="699" width="3" height="20" font="7"><b> </b></text>
<text top="109" left="921" width="7" height="18" font="0">•</text>
<text top="108" left="928" width="186" height="20" font="0"> All-cause mortality (Rosuvastatin </text>
<text top="125" left="921" width="195" height="20" font="0">1.00 vs. Placebo 1.25, rate per 100 </text>
<text top="143" left="921" width="185" height="20" font="0">person-y; HR: 0.80; 95% CI: 0.67-</text>
<text top="160" left="921" width="31" height="20" font="0">0.97) </text>
<text top="177" left="921" width="3" height="20" font="0"> </text>
<text top="196" left="921" width="7" height="18" font="0">•</text>
<text top="195" left="928" width="127" height="20" font="0"> In subgroup analyses, </text>
<text top="213" left="921" width="193" height="20" font="0">rosuvastatin was associated with a </text>
<text top="230" left="921" width="183" height="20" font="0">reduction in the primary endpoint </text>
<text top="247" left="921" width="194" height="20" font="0">among individuals with and without </text>
<text top="264" left="921" width="180" height="20" font="0">the metabolic syndrome, with no </text>
<text top="282" left="921" width="180" height="20" font="0">evidence of statistical interaction </text>
<text top="299" left="921" width="49" height="20" font="0">(p=0.14) </text>
<text top="316" left="921" width="3" height="20" font="0"> </text>
<text top="333" left="921" width="3" height="20" font="0"> </text>
<text top="488" left="89" width="53" height="20" font="7"><b>HOPE-3  </b></text>
<text top="505" left="89" width="114" height="20" font="0">Yusuf S, et al., 2016 </text>
<text top="522" left="89" width="25" height="20" font="0"><a href="data supplement.html#236">(12)</a> </text>
<text top="539" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27040132">27040132</a></text>
<text top="539" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27040132"> </a></text>
<text top="557" left="89" width="3" height="20" font="0"> </text>
<text top="488" left="218" width="119" height="20" font="7"><b>Aim:</b> To evaluate the </text>
<text top="505" left="218" width="123" height="20" font="0">effects of rosuvastatin </text>
<text top="522" left="218" width="78" height="20" font="0">on preventing </text>
<text top="539" left="218" width="122" height="20" font="0">cardiovascular events </text>
<text top="557" left="218" width="135" height="20" font="0">among intermediate risk </text>
<text top="574" left="218" width="89" height="20" font="0">persons without </text>
<text top="591" left="218" width="132" height="20" font="0">baseline cardiovascular </text>
<text top="608" left="218" width="46" height="20" font="0">disease </text>
<text top="625" left="218" width="3" height="20" font="0"> </text>
<text top="643" left="218" width="102" height="20" font="7"><b>Study type:</b> RCT  </text>
<text top="660" left="218" width="3" height="20" font="0"> </text>
<text top="677" left="218" width="93" height="20" font="7"><b>Size:</b> 12,705 pts </text>
<text top="694" left="218" width="7" height="20" font="0">  </text>
<text top="488" left="369" width="145" height="20" font="7"><b>Inclusion criteria:</b> Men ≥ </text>
<text top="505" left="369" width="135" height="20" font="0">55 y and Women ≥ 65 y </text>
<text top="522" left="369" width="126" height="20" font="0">with at least one of the </text>
<text top="539" left="369" width="117" height="20" font="0">following risk factors: </text>
<text top="557" left="369" width="154" height="20" font="0">elevated waist-hip ratio; low </text>
<text top="574" left="369" width="119" height="20" font="0">HDL-C; dysglycemia; </text>
<text top="591" left="369" width="146" height="20" font="0">current or recent smoking; </text>
<text top="608" left="369" width="150" height="20" font="0">mild renal dysfunction; or a </text>
<text top="625" left="369" width="148" height="20" font="0">family history of premature </text>
<text top="643" left="369" width="156" height="20" font="0">CAD. Women ≥ 60 y with at </text>
<text top="660" left="369" width="145" height="20" font="0">least two of the above risk </text>
<text top="677" left="369" width="40" height="20" font="0">factors </text>
<text top="694" left="369" width="3" height="20" font="0"> </text>
<text top="711" left="369" width="151" height="20" font="7"><b>Exclusion criteria: </b>Known </text>
<text top="729" left="369" width="149" height="20" font="0">cardiovascular disease; an </text>
<text top="746" left="369" width="133" height="20" font="0">existing indication for or </text>
<text top="763" left="369" width="136" height="20" font="0">contraindication to statin </text>
<text top="780" left="369" width="44" height="20" font="0">therapy<b> </b></text>
<text top="488" left="540" width="78" height="20" font="7"><b>Intervention:</b> </text>
<text top="505" left="540" width="112" height="20" font="0">Rosuvastatin 10 mg </text>
<text top="522" left="540" width="7" height="20" font="0">  </text>
<text top="539" left="540" width="125" height="20" font="7"><b>Comparator:</b> Placebo<b> </b></text>
<text top="489" left="699" width="83" height="20" font="7"><b>1</b>°<b> endpoint:</b> 1</text>
<text top="490" left="782" width="6" height="13" font="9">st</text>
<text top="489" left="788" width="119" height="20" font="0"> co-primary outcome: </text>
<text top="506" left="699" width="135" height="20" font="0">composite of death from </text>
<text top="523" left="699" width="193" height="20" font="0">cardiovascular causes, nonfatal MI </text>
<text top="540" left="699" width="187" height="20" font="0">and nonfatal stroke (Rosuvastatin </text>
<text top="558" left="699" width="201" height="20" font="0">3.7% vs. Placebo 4.8%, event rates; </text>
<text top="575" left="699" width="162" height="20" font="0">HR: 0.76; 95% CI: 0.64-0.91) </text>
<text top="592" left="699" width="3" height="20" font="0"> </text>
<text top="609" left="699" width="7" height="20" font="0">2</text>
<text top="611" left="706" width="9" height="13" font="9">nd</text>
<text top="609" left="715" width="192" height="20" font="0"> co-primary outcome: composite of </text>
<text top="627" left="699" width="191" height="20" font="0">death from cardiovascular causes, </text>
<text top="644" left="699" width="155" height="20" font="0">nonfatal MI, nonfatal stroke, </text>
<text top="661" left="699" width="183" height="20" font="0">resuscitated cardiac arrest, heart </text>
<text top="678" left="699" width="156" height="20" font="0">failure and revascularization </text>
<text top="695" left="699" width="177" height="20" font="0">(Rosuvastatin 4.4% vs. Placebo </text>
<text top="713" left="699" width="205" height="20" font="0">5.7%, event rates; HR: 0.75; 95% CI: </text>
<text top="730" left="699" width="60" height="20" font="0">0.64-0.88) </text>
<text top="747" left="699" width="3" height="20" font="0"> </text>
<text top="764" left="699" width="161" height="20" font="7"><b>Safety endpoint:</b> New onset </text>
<text top="781" left="699" width="50" height="20" font="0">diabetes </text>
<text top="489" left="921" width="7" height="18" font="0">•</text>
<text top="489" left="928" width="141" height="20" font="0"> Composite of death from </text>
<text top="506" left="921" width="176" height="20" font="0">cardiovascular causes, nonfatal </text>
<text top="523" left="921" width="178" height="20" font="0">MI, nonfatal stroke, resuscitated </text>
<text top="540" left="921" width="153" height="20" font="0">cardiac arrest, heart failure, </text>
<text top="558" left="921" width="185" height="20" font="0">revascularization and angina with </text>
<text top="575" left="921" width="118" height="20" font="0">evidence of ischemia </text>
<text top="592" left="921" width="177" height="20" font="0">(Rosuvastatin 4.8% vs. Placebo </text>
<text top="609" left="921" width="186" height="20" font="0">6.2%, event rates; HR: 0.77; 95% </text>
<text top="627" left="921" width="79" height="20" font="0">CI: 0.66-0.89) </text>
<text top="646" left="921" width="7" height="18" font="0">•</text>
<text top="645" left="928" width="127" height="20" font="0"> Death from any cause </text>
<text top="662" left="921" width="177" height="20" font="0">(Rosuvastatin 5.3% vs. Placebo </text>
<text top="679" left="921" width="186" height="20" font="0">5.6%, event rates; HR: 0.93; 95% </text>
<text top="697" left="921" width="79" height="20" font="0">CI: 0.80-1.08) </text>
<text top="716" left="921" width="7" height="18" font="0">•</text>
<text top="715" left="928" width="176" height="20" font="0"> Limitation: Metabolic syndrome </text>
<text top="732" left="921" width="180" height="20" font="0">components part of the inclusion </text>
<text top="749" left="921" width="164" height="20" font="0">criteria, but only a subset met </text>
<text top="766" left="921" width="194" height="20" font="0">diagnostic criteria for the metabolic </text>
<text top="784" left="921" width="57" height="20" font="0">syndrome </text>
</page>
<page number="15" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">15 </text>
<text top="107" left="369" width="7" height="20" font="0">  </text>
<text top="107" left="699" width="3" height="20" font="0"> </text>
<text top="124" left="699" width="97" height="20" font="0">Cognitive decline </text>
<text top="141" left="699" width="3" height="20" font="7"><b> </b></text>
<text top="107" left="921" width="3" height="20" font="0"> </text>
<text top="124" left="921" width="140" height="20" font="0">Median follow-up of 5.6 y </text>
<text top="194" left="88" width="921" height="20" font="7"><b>Abbreviations:</b> 1° indicated primary; CI, confidence interval; HR, hazard ratio; N/A, not available; OR, odds ratio; RCT, randomized controlled trial; and RR, relative risk. </text>
<text top="212" left="88" width="300" height="20" font="7"><b>Search Terms and Date of Search</b>: Author to provide </text>
<text top="229" left="88" width="3" height="20" font="0"> </text>
<text top="246" left="81" width="852" height="24" font="4"><b>Data Supplement 3. Meta-analyses comparing statins versus placebo or various intensities of statin therapy (Section 3.2) </b></text>
<text top="276" left="97" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="293" left="122" width="48" height="20" font="7"><b>Author; </b></text>
<text top="310" left="100" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="276" left="243" width="83" height="20" font="7"><b>Aim of Study; </b></text>
<text top="293" left="248" width="74" height="20" font="7"><b>Study Type; </b></text>
<text top="310" left="242" width="86" height="20" font="7"><b>Study Size (N) </b></text>
<text top="293" left="390" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="267" left="557" width="111" height="20" font="7"><b>Study Intervention </b></text>
<text top="285" left="575" width="76" height="20" font="7"><b>(# patients) / </b></text>
<text top="302" left="557" width="111" height="20" font="7"><b>Study Comparator </b></text>
<text top="319" left="578" width="69" height="20" font="7"><b>(# patients) </b></text>
<text top="276" left="753" width="105" height="20" font="7"><b>Endpoint Results </b></text>
<text top="293" left="737" width="137" height="20" font="7"><b>(Absolute Event Rates, </b></text>
<text top="310" left="715" width="181" height="20" font="7"><b>P values; OR or RR; &amp; 95% CI) </b></text>
<text top="277" left="932" width="175" height="20" font="7"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="294" left="965" width="111" height="20" font="7"><b>Study Limitations; </b></text>
<text top="311" left="972" width="96" height="20" font="7"><b>Adverse Events </b></text>
<text top="337" left="89" width="94" height="20" font="0">Baigent C, et al., </text>
<text top="354" left="89" width="56" height="20" font="0">2010 <a href="data supplement.html#236">(13)</a> </text>
<text top="371" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21067804">21067804</a></text>
<text top="371" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21067804"> </a></text>
<text top="337" left="216" width="135" height="20" font="7"><b>Aim: </b>To evaluate safety </text>
<text top="354" left="216" width="114" height="20" font="0">and efficacy of more </text>
<text top="371" left="216" width="115" height="20" font="0">intensive lowering of </text>
<text top="389" left="216" width="89" height="20" font="0">LDL cholesterol<b> </b></text>
<text top="406" left="216" width="3" height="20" font="7"><b> </b></text>
<text top="423" left="216" width="126" height="20" font="7"><b>Study type: </b>Individual </text>
<text top="440" left="216" width="101" height="20" font="0">patient-level meta-</text>
<text top="458" left="216" width="78" height="20" font="0">analysis of 26 </text>
<text top="475" left="216" width="111" height="20" font="0">randomized trials of </text>
<text top="492" left="216" width="77" height="20" font="0">statin therapy<b> </b></text>
<text top="509" left="216" width="3" height="20" font="7"><b> </b></text>
<text top="526" left="216" width="76" height="20" font="7"><b>Size: </b>170000 </text>
<text top="544" left="216" width="111" height="20" font="0">participants from 26 </text>
<text top="561" left="216" width="111" height="20" font="0">randomized trials of </text>
<text top="578" left="216" width="77" height="20" font="0">statin therapy<b> </b></text>
<text top="337" left="366" width="123" height="20" font="7"><b>Inclusion criteria: </b>All </text>
<text top="354" left="366" width="104" height="20" font="0">eligible statin trials </text>
<text top="371" left="366" width="131" height="20" font="0">published by the end of </text>
<text top="389" left="366" width="145" height="20" font="0">2009, main intervention to </text>
<text top="406" left="366" width="137" height="20" font="0">lower LDL-C using statin </text>
<text top="423" left="366" width="122" height="20" font="0">therapy, at least 1000 </text>
<text top="440" left="366" width="156" height="20" font="0">participants recruited with at </text>
<text top="458" left="366" width="122" height="20" font="0">least 2 y of scheduled </text>
<text top="475" left="366" width="51" height="20" font="0">duration. </text>
<text top="492" left="366" width="3" height="20" font="0"> </text>
<text top="509" left="366" width="143" height="20" font="7"><b>Exclusion criteria: </b>Trials </text>
<text top="526" left="366" width="125" height="20" font="0">where other risk factor </text>
<text top="544" left="366" width="152" height="20" font="0">modification (except LDL-C </text>
<text top="561" left="366" width="146" height="20" font="0">reduction via statins) were </text>
<text top="578" left="366" width="60" height="20" font="0">excluded.  </text>
<text top="595" left="366" width="3" height="20" font="0"> </text>
<text top="613" left="366" width="3" height="20" font="0"> </text>
<text top="630" left="366" width="154" height="20" font="0">-5 trials of more versus less </text>
<text top="647" left="366" width="120" height="20" font="0">intense statin therapy </text>
<text top="664" left="366" width="156" height="20" font="0">included 100% patients with </text>
<text top="681" left="366" width="33" height="20" font="0">CHD. </text>
<text top="699" left="366" width="150" height="20" font="0">-Proportion of patients with </text>
<text top="716" left="366" width="138" height="20" font="0">CHD in the remaining 21 </text>
<text top="733" left="366" width="123" height="20" font="0">trials varied from &lt;1% </text>
<text top="750" left="366" width="117" height="20" font="0">(AFCAPS/TexCAPS,<b> </b></text>
<text top="767" left="366" width="124" height="20" font="0">ASCOT LLA, CARDS, </text>
<text top="785" left="366" width="150" height="20" font="0">MEGA, JUPITER) to 100% </text>
<text top="337" left="537" width="154" height="20" font="7"><b>Intervention/Comparator:  </b></text>
<text top="354" left="537" width="3" height="20" font="0"> </text>
<text top="371" left="537" width="115" height="20" font="0">1. Statin (n= 64744)/ </text>
<text top="389" left="537" width="130" height="20" font="0">placebo (n= 64782) [21 </text>
<text top="406" left="537" width="33" height="20" font="0">trials] </text>
<text top="423" left="537" width="3" height="20" font="0"> </text>
<text top="440" left="537" width="139" height="20" font="0">2. More (high) [n=19829] </text>
<text top="458" left="537" width="149" height="20" font="0">/less intense statin therapy </text>
<text top="475" left="537" width="106" height="20" font="0">(n=19783) [5 trials] </text>
<text top="492" left="537" width="7" height="20" font="0"> <b> </b></text>
<text top="509" left="537" width="143" height="20" font="7"><b>Definition of Outcomes: </b></text>
<text top="526" left="537" width="3" height="20" font="0"> </text>
<text top="544" left="537" width="137" height="20" font="0">1. Major vascular events </text>
<text top="561" left="537" width="129" height="20" font="0">(first occurrence of any </text>
<text top="578" left="537" width="122" height="20" font="0">major coronary event, </text>
<text top="595" left="537" width="150" height="20" font="0">coronary revascularization, </text>
<text top="613" left="537" width="55" height="20" font="0">or stroke) </text>
<text top="630" left="537" width="133" height="20" font="0">2. Major coronary event </text>
<text top="647" left="537" width="129" height="20" font="0">(coronary death or non-</text>
<text top="664" left="537" width="48" height="20" font="0">fatal MI) </text>
<text top="681" left="537" width="68" height="20" font="0">3. Coronary </text>
<text top="699" left="537" width="96" height="20" font="0">revascularization </text>
<text top="716" left="537" width="126" height="20" font="0">(angioplasty or bypass </text>
<text top="733" left="537" width="49" height="20" font="0">grafting) </text>
<text top="750" left="537" width="138" height="20" font="0">4. Stroke (any, ischemic, </text>
<text top="767" left="537" width="132" height="20" font="0">hemorrhagic, unknown) </text>
<text top="337" left="701" width="75" height="20" font="7"><b>Endpoints:   </b></text>
<text top="354" left="701" width="3" height="20" font="7"><b> </b></text>
<text top="371" left="701" width="139" height="20" font="7"><b>Statin (S) / Placebo (P): </b></text>
<text top="389" left="701" width="3" height="20" font="7"><b> </b></text>
<text top="406" left="701" width="195" height="20" font="0">Average LDL-C difference between </text>
<text top="423" left="701" width="190" height="20" font="0">statin and placebo = 1.07 mmol/L* </text>
<text top="440" left="701" width="3" height="20" font="0"> </text>
<text top="458" left="701" width="190" height="20" font="0">1. Major vascular events: S= 2.8% </text>
<text top="475" left="701" width="181" height="20" font="0">per annum, P = 3.6% per annum </text>
<text top="492" left="701" width="170" height="20" font="0">(RR: 0.78; 95% CI: 0.76-0.81). </text>
<text top="509" left="701" width="208" height="20" font="0">2. Major coronary event: S= 1.3% per </text>
<text top="527" left="701" width="189" height="20" font="0">annum, P = 1.7% per annum (RR: </text>
<text top="544" left="701" width="141" height="20" font="0">0.73; 95% CI: 0.70-0.77). </text>
<text top="561" left="701" width="189" height="20" font="0">3. Coronary revascularization: S = </text>
<text top="578" left="701" width="172" height="20" font="0">1.2% per annum, P = 1.6% per </text>
<text top="595" left="701" width="207" height="20" font="0">annum (RR: 0.75; 95% CI: 0.72-0.79) </text>
<text top="613" left="701" width="198" height="20" font="0">4. Stroke: S = 0.7% per annum, P = </text>
<text top="630" left="701" width="197" height="20" font="0">per annum (RR: 0.85; 95% CI: 0.80-</text>
<text top="647" left="701" width="35" height="20" font="0">0.91). </text>
<text top="664" left="701" width="3" height="20" font="0"> </text>
<text top="681" left="701" width="201" height="20" font="7"><b>More statin (MS) / less statin (LS): </b></text>
<text top="699" left="701" width="195" height="20" font="0">Average LDL-C difference between </text>
<text top="716" left="701" width="146" height="20" font="0">MS and LS = 0.51 mmol/L </text>
<text top="733" left="701" width="3" height="20" font="7"><b> </b></text>
<text top="750" left="701" width="204" height="20" font="0">1. Major vascular events; MS = 4.5% </text>
<text top="767" left="701" width="188" height="20" font="0">per annum, LS = 5.3% per annum </text>
<text top="785" left="701" width="170" height="20" font="0">(RR: 0.85; 95% CI: 0.82-0.89). </text>
<text top="339" left="923" width="7" height="18" font="0">•</text>
<text top="338" left="930" width="165" height="20" font="7"><b> </b>No heterogeneity of effect for </text>
<text top="355" left="923" width="164" height="20" font="0">major vascular events among </text>
<text top="373" left="923" width="158" height="20" font="0">those with previous vascular </text>
<text top="390" left="923" width="185" height="20" font="0">disease versus those without any </text>
<text top="407" left="923" width="177" height="20" font="0">previous vascular disease (p for </text>
<text top="424" left="923" width="117" height="20" font="0">heterogeneity = 0.3)  </text>
<text top="442" left="923" width="178" height="20" font="0">-History of prior CHD: Statin/MS </text>
<text top="459" left="923" width="171" height="20" font="0">(4.5% per annum) versus P/LS </text>
<text top="476" left="923" width="192" height="20" font="0">(5.6% per annum) - RR: 0.79; 95% </text>
<text top="493" left="923" width="78" height="20" font="0">CI: 0.76-0.82. </text>
<text top="510" left="923" width="167" height="20" font="0">- History of non-CHD vascular </text>
<text top="528" left="923" width="163" height="20" font="0">disease: Statin/MS (3.1% per </text>
<text top="545" left="923" width="172" height="20" font="0">annum) versus P/LS (3.7% per<b> </b></text>
<text top="562" left="923" width="180" height="20" font="0">annum)- RR: 0.81; 95% CI: 0.71-</text>
<text top="579" left="923" width="31" height="20" font="0">0.92. </text>
<text top="597" left="923" width="154" height="20" font="0">-No history of prior vascular </text>
<text top="614" left="923" width="163" height="20" font="0">disease: Statin/MS (1.4% per </text>
<text top="631" left="923" width="172" height="20" font="0">annum) versus P/LS (1.8% per </text>
<text top="648" left="923" width="180" height="20" font="0">annum)- RR: 0.75; 95% CI: 0.69-</text>
<text top="665" left="923" width="31" height="20" font="0">0.82. </text>
<text top="684" left="923" width="7" height="18" font="0">•</text>
<text top="684" left="929" width="178" height="20" font="0"> No significant reduction in CHD </text>
<text top="701" left="923" width="189" height="20" font="0">death when comparing MS versus </text>
<text top="718" left="923" width="188" height="20" font="0">LS (RR: 0.93; 95% CI: 0.81-1.07). </text>
<text top="735" left="923" width="178" height="20" font="0">Significant reduction in non-fatal </text>
<text top="753" left="923" width="190" height="20" font="0">MI (RR: 0.85; 95% CI: 0.76- 0.94), </text>
<text top="770" left="922" width="175" height="20" font="0">coronary revascularization<b> </b>(RR: </text>
<text top="787" left="923" width="192" height="20" font="0">0.81; 95% CI: 0.76-0.85), ischemic </text>
</page>
<page number="16" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">16 </text>
<text top="107" left="366" width="155" height="20" font="0">(SSSS, CARE, Post-CABG, </text>
<text top="124" left="366" width="123" height="20" font="0">LIPID, GISSI-P, LIPS, </text>
<text top="141" left="366" width="70" height="20" font="0">ALLIANCE). </text>
<text top="159" left="366" width="112" height="20" font="0">-Overall, 52% of the </text>
<text top="176" left="366" width="128" height="20" font="0">patients had prior CHD </text>
<text top="193" left="366" width="137" height="20" font="0">-15% had other vascular </text>
<text top="210" left="366" width="103" height="20" font="0">disease (history of </text>
<text top="228" left="366" width="109" height="20" font="0">intracerebral bleed, </text>
<text top="245" left="366" width="141" height="20" font="0">transient ischemic attack, </text>
<text top="262" left="366" width="144" height="20" font="0">ischemic stroke, unknown </text>
<text top="279" left="366" width="133" height="20" font="0">stroke, peripheral artery </text>
<text top="296" left="366" width="136" height="20" font="0">disease, or heart failure) </text>
<text top="314" left="366" width="152" height="20" font="0">-41% with no prior vascular </text>
<text top="331" left="366" width="145" height="20" font="0">disease (no known history </text>
<text top="348" left="366" width="139" height="20" font="0">of CHD or other vascular </text>
<text top="365" left="366" width="60" height="20" font="0">disease).   </text>
<text top="383" left="366" width="3" height="20" font="7"><b> </b></text>
<text top="107" left="537" width="109" height="20" font="0">5. First cancer after </text>
<text top="124" left="537" width="81" height="20" font="0">randomization </text>
<text top="141" left="537" width="111" height="20" font="0">6. Mortality (overall, </text>
<text top="159" left="537" width="130" height="20" font="0">vascular, non-vascular, </text>
<text top="176" left="537" width="150" height="20" font="0">unknown) [described for all </text>
<text top="193" left="537" width="107" height="20" font="0">26 trials combined] </text>
<text top="210" left="537" width="145" height="20" font="0">- Median follow-up = 4.8 y </text>
<text top="228" left="537" width="122" height="20" font="0">in statin/placebo trials </text>
<text top="245" left="537" width="143" height="20" font="0">-Median follow-up 5.1 y in </text>
<text top="262" left="537" width="129" height="20" font="0">more versus less statin </text>
<text top="279" left="537" width="36" height="20" font="0">trials.  </text>
<text top="107" left="701" width="206" height="20" font="0">2. Major coronary events: MS = 1.9% </text>
<text top="124" left="701" width="188" height="20" font="0">per annum, LS = 2.2% per annum </text>
<text top="141" left="701" width="170" height="20" font="0">(RR: 0.87; 95% CI: 0.81-0.93). </text>
<text top="159" left="701" width="189" height="20" font="0">3. Coronary revascularization; MS </text>
<text top="176" left="701" width="168" height="20" font="0">2.6% per annum, LS 3.2% per </text>
<text top="193" left="701" width="207" height="20" font="0">annum (RR: 0.81; 95% CI: 0.76-0.85) </text>
<text top="210" left="701" width="194" height="20" font="0">4. Stroke; MS 0.6% per annum, LS </text>
<text top="228" left="701" width="200" height="20" font="0">0.7% per annum (RR: 0.86; 95% CI: </text>
<text top="245" left="701" width="63" height="20" font="0">0.77-0.96). </text>
<text top="262" left="701" width="3" height="20" font="7"><b> </b></text>
<text top="279" left="701" width="152" height="20" font="7"><b>For all 26 trials combined </b></text>
<text top="296" left="701" width="196" height="20" font="7"><b>(Described per mmol/L reduction </b></text>
<text top="314" left="701" width="63" height="20" font="7"><b>in LDL-C): </b></text>
<text top="331" left="701" width="3" height="20" font="7"><b> </b></text>
<text top="348" left="701" width="171" height="20" font="0">-Mortality: Statin/MS (2.1% per </text>
<text top="365" left="701" width="172" height="20" font="0">annum) versus P/LS (2.3% per </text>
<text top="382" left="701" width="180" height="20" font="0">annum)- RR: 0.90; 95% CI: 0.87-</text>
<text top="400" left="701" width="31" height="20" font="0">0.93. </text>
<text top="417" left="701" width="201" height="20" font="0">-Vascular mortality: Statin/MS (1.2% </text>
<text top="434" left="701" width="193" height="20" font="0">per annum) versus P/LS (1.3% per </text>
<text top="451" left="701" width="180" height="20" font="0">annum)- RR: 0.86; 95% CI: 0.82-</text>
<text top="469" left="701" width="31" height="20" font="0">0.90. </text>
<text top="486" left="701" width="156" height="20" font="0">-Any non-vascular mortality: </text>
<text top="503" left="701" width="198" height="20" font="0">Statin/MS (0.8% per annum) versus </text>
<text top="520" left="701" width="192" height="20" font="0">P/LS (0.8% per annum)- RR: 0.97; </text>
<text top="537" left="701" width="106" height="20" font="0">95% CI: 0.92-1.03. </text>
<text top="555" left="701" width="162" height="20" font="0">-Unknown cause of mortality: </text>
<text top="572" left="701" width="198" height="20" font="0">Statin/MS (0.1% per annum) versus </text>
<text top="589" left="701" width="192" height="20" font="0">P/LS (0.1% per annum)- RR: 0.87; </text>
<text top="606" left="701" width="106" height="20" font="0">95% CI: 0.73-1.03. </text>
<text top="623" left="701" width="3" height="20" font="0"> </text>
<text top="641" left="701" width="204" height="20" font="0">-Although mortality data not provided </text>
<text top="658" left="701" width="168" height="20" font="0">for separately for statin versus </text>
<text top="675" left="701" width="203" height="20" font="0">placebo and more versus less statin, </text>
<text top="692" left="701" width="143" height="20" font="0">the authors state that “the </text>
<text top="710" left="701" width="200" height="20" font="0">proportional reduction in risk per 1.0 </text>
<text top="727" left="701" width="206" height="20" font="0">mmol/L LDL cholesterol reduction did </text>
<text top="744" left="701" width="191" height="20" font="0">not differ between the two types of </text>
<text top="761" left="701" width="204" height="20" font="0">trial comparisons (all heterogeneity p </text>
<text top="778" left="701" width="78" height="20" font="0">values &gt;0.1).  </text>
<text top="107" left="923" width="171" height="20" font="0">stroke (RR: 0.84; 95% CI: 0.74-</text>
<text top="124" left="923" width="187" height="20" font="0">0.99) when comparing MS versus </text>
<text top="141" left="923" width="22" height="20" font="0">LS. </text>
<text top="160" left="923" width="7" height="18" font="0">•</text>
<text top="160" left="929" width="179" height="20" font="0"> Although major vascular events </text>
<text top="177" left="923" width="172" height="20" font="0">reduced non-significantly when </text>
<text top="194" left="923" width="194" height="20" font="0">comparing patients with CHD aged </text>
<text top="211" left="923" width="166" height="20" font="0">&gt;75 y receiving MS versus LS </text>
<text top="229" left="923" width="170" height="20" font="0">(RR: 0.78, 99% CI: 0.52-1.18); </text>
<text top="246" left="923" width="149" height="20" font="0">heterogeneity; p=0.8 when </text>
<text top="263" left="923" width="180" height="20" font="0">comparing MS versus LS across </text>
<text top="280" left="923" width="186" height="20" font="0">groups of CHD<b> </b>patients aged &lt;65 </text>
<text top="298" left="923" width="163" height="20" font="0">y, &gt;65 y to &lt;75 y, and &gt;75 y.  </text>
<text top="317" left="923" width="7" height="18" font="0">•</text>
<text top="316" left="929" width="176" height="20" font="0"> For major vascular events, RR: </text>
<text top="333" left="923" width="192" height="20" font="0">0.71 (99% CI: 0.63-0.80) for males </text>
<text top="350" left="923" width="183" height="20" font="0">and RR 0.75 (99% CI: 0.58-0.97) </text>
<text top="368" left="923" width="180" height="20" font="0">for females when comparing MS </text>
<text top="385" left="923" width="185" height="20" font="0">versus LS among males/ females </text>
<text top="402" left="923" width="149" height="20" font="0">(p for heterogeneity = 0.6). </text>
<text top="420" left="923" width="191" height="20" font="0"> •RR: 0.85 (99% CI: 0.73-0.99) for </text>
<text top="438" left="923" width="169" height="20" font="0">major vascular events in those </text>
<text top="455" left="923" width="188" height="20" font="0">aged &gt;75 y comparing S versus P </text>
<text top="472" left="923" width="174" height="20" font="0">(p for heterogeneity = 0.4 when </text>
<text top="489" left="923" width="165" height="20" font="0">comparing S versus P among </text>
<text top="506" left="923" width="186" height="20" font="0">those aged &lt;65<b> </b>y, &gt;65 y to &lt;75 y, </text>
<text top="524" left="923" width="65" height="20" font="0">and &gt;75 y). </text>
<text top="541" left="923" width="7" height="20" font="0">  </text>
<text top="559" left="923" width="187" height="20" font="0"> •Among comparison of 5 trials of </text>
<text top="576" left="923" width="164" height="20" font="0">MS versus LS, large absolute </text>
<text top="594" left="923" width="186" height="20" font="0">reduction in LDL cholesterol were </text>
<text top="611" left="923" width="191" height="20" font="0">associated with larger proportional </text>
<text top="628" left="923" width="151" height="20" font="0">risk reduction (p for trend = </text>
<text top="645" left="923" width="185" height="20" font="0">0.0004). After adjustment for LDL </text>
<text top="663" left="923" width="187" height="20" font="0">cholesterol differences, there was </text>
<text top="680" left="923" width="185" height="20" font="0">little residual variation (p for trend </text>
<text top="697" left="923" width="49" height="20" font="0">= 0.05).  </text>
<text top="714" left="923" width="3" height="20" font="0"> </text>
<text top="731" left="923" width="73" height="20" font="7"><b>Limitations: </b></text>
<text top="749" left="923" width="193" height="20" font="0">1. Individual patient-level data on 3 </text>
<text top="766" left="923" width="150" height="20" font="0">trials (CORONA, SPARCL, </text>
</page>
<page number="17" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">17 </text>
<text top="107" left="701" width="7" height="20" font="0">  </text>
<text top="124" left="701" width="173" height="20" font="7"><b>Safety endpoint (if relevant):  </b></text>
<text top="141" left="701" width="3" height="20" font="7"><b> </b></text>
<text top="159" left="701" width="192" height="20" font="0">-Cancer: S = 1.4% per annum, P = </text>
<text top="176" left="701" width="201" height="20" font="0">1.4% per annum (RR: 1.00, 95% CI: </text>
<text top="193" left="701" width="66" height="20" font="0">0.95-1.04).  </text>
<text top="210" left="701" width="3" height="20" font="0"> </text>
<text top="228" left="701" width="199" height="20" font="0">-Cancer: MS = 1.6% per annum, LS </text>
<text top="245" left="701" width="192" height="20" font="0">= 1.6% per annum (RR: 1.00, 95% </text>
<text top="262" left="701" width="82" height="20" font="0">CI: 0.93-1.07). </text>
<text top="279" left="701" width="3" height="20" font="0"> </text>
<text top="296" left="701" width="203" height="20" font="0">- Rhabdomyolysis: Observed excess </text>
<text top="314" left="701" width="117" height="20" font="0">of rhabdomyolysis =  </text>
<text top="331" left="701" width="202" height="20" font="0">  1 (SE 1) per 10,000 in 21 trials of S </text>
<text top="348" left="701" width="145" height="20" font="0">versus P (14 vs. 9 cases)  </text>
<text top="365" left="701" width="206" height="20" font="0">  4 (SE 2) per 10,000 in 5 trials of MS </text>
<text top="383" left="701" width="169" height="20" font="0">versus LS (14 vs. 6 cases) [All </text>
<text top="400" left="701" width="196" height="20" font="0">excess cases occurred in SEARCH </text>
<text top="417" left="701" width="200" height="20" font="0">and A to Z<b> </b>study (simvastatin 80 mg </text>
<text top="434" left="701" width="57" height="20" font="0">po daily)]. </text>
<text top="451" left="701" width="3" height="20" font="0"> </text>
<text top="469" left="701" width="124" height="20" font="0">-Hemorrhagic Stroke:  </text>
<text top="486" left="701" width="191" height="20" font="0">S= 0.1% per annum, P = 0.1% per </text>
<text top="503" left="701" width="207" height="20" font="0">annum, RR: 1.15 (99% CI: 0.87-1.51) </text>
<text top="520" left="701" width="190" height="20" font="0">MS = 0.1% per annum, LS = 0.1% </text>
<text top="537" left="701" width="196" height="20" font="0">per annum, RR: 1.21, 99% CI: 0.76-</text>
<text top="555" left="701" width="38" height="20" font="0">1.91). <b> </b></text>
<text top="107" left="923" width="156" height="20" font="0">GREACE) not available and </text>
<text top="124" left="923" width="129" height="20" font="0">therefore, not included.<b> </b></text>
<text top="574" left="81" width="1005" height="20" font="7"><b>Abbreviations:</b> 1° indicated primary; CI, confidence interval; HR, hazard ratio; N/A, not available; OR, odds ratio; RCT, randomized controlled trial; RR, relative risk; LDL-C, low-density </text>
<text top="591" left="81" width="581" height="20" font="0">lipoprotein cholesterol; S, statin; P, placebo; LS, less statin; MS, more statin; CHD, coronary heart disease </text>
<text top="608" left="81" width="236" height="20" font="0">* 1 mmol/L LDL-C = 38.67 mg/dL of LDL-C </text>
<text top="625" left="81" width="4" height="22" font="1"> </text>
<text top="653" left="81" width="4" height="22" font="1"> </text>
<text top="681" left="81" width="4" height="22" font="1"> </text>
<text top="709" left="81" width="4" height="22" font="1"> </text>
<text top="728" left="81" width="1015" height="24" font="4"><b>Data Supplement 4. Risk stratification among patients with ASCVD to identify those most likely to benefit from non-statin therapy (Section 3.2.2) </b></text>
<text top="749" left="116" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="767" left="141" width="48" height="20" font="7"><b>Author; </b></text>
<text top="784" left="119" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="749" left="264" width="118" height="20" font="7"><b>Study Type/Design; </b></text>
<text top="767" left="290" width="66" height="20" font="7"><b>Study Size </b></text>
<text top="749" left="426" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="749" left="589" width="179" height="20" font="7"><b>Primary Endpoint and Results </b></text>
<text top="767" left="586" width="184" height="20" font="7"><b>(P values; OR or RR; &amp; 95% CI) </b></text>
<text top="749" left="859" width="130" height="20" font="7"><b>Summary/Conclusion </b></text>
<text top="767" left="886" width="75" height="20" font="7"><b>Comment(s) </b></text>
</page>
<page number="18" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">18 </text>
<text top="107" left="91" width="129" height="20" font="0">Bohula EA, et al., 2017 </text>
<text top="124" left="91" width="25" height="20" font="0"><a href="data supplement.html#236">(14)</a> </text>
<text top="141" left="91" width="58" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28231942">28231942 </a></text>
<text top="141" left="149" width="3" height="20" font="0"> </text>
<text top="107" left="252" width="92" height="20" font="7"><b>Aim: </b>To test the </text>
<text top="124" left="252" width="86" height="20" font="0">hypothesis that </text>
<text top="141" left="252" width="118" height="20" font="0">atherothrombotic risk </text>
<text top="159" left="252" width="113" height="20" font="0">stratification may be </text>
<text top="176" left="252" width="119" height="20" font="0">useful to identify post-</text>
<text top="193" left="252" width="131" height="20" font="0">ACS patients who have </text>
<text top="210" left="252" width="136" height="20" font="0">the greatest potential for </text>
<text top="228" left="252" width="135" height="20" font="0">benefit from the addition </text>
<text top="245" left="252" width="116" height="20" font="0">of ezetimibe to statin </text>
<text top="262" left="252" width="48" height="20" font="0">therapy. </text>
<text top="279" left="252" width="3" height="20" font="7"><b> </b></text>
<text top="296" left="252" width="122" height="20" font="7"><b>Study type:</b> Post-hoc </text>
<text top="314" left="252" width="126" height="20" font="0">analyses from an RCT </text>
<text top="331" left="252" width="87" height="20" font="0">(IMPROVE-IT). </text>
<text top="348" left="252" width="3" height="20" font="0"> </text>
<text top="365" left="252" width="120" height="20" font="7"><b>Size:</b> 17,717 patients </text>
<text top="382" left="252" width="59" height="20" font="0">post ACS  </text>
<text top="107" left="406" width="106" height="20" font="7"><b>Inclusion criteria:</b> </text>
<text top="124" left="406" width="131" height="20" font="0">Patients at least 50 y of </text>
<text top="141" left="406" width="148" height="20" font="0">age with hospitalization for </text>
<text top="159" left="406" width="141" height="20" font="0">ACS within the preceding </text>
<text top="176" left="406" width="145" height="20" font="0">10 ds, including MI with or </text>
<text top="193" left="406" width="42" height="20" font="0">without </text>
<text top="210" left="406" width="137" height="20" font="0">ST-segment elevation or </text>
<text top="228" left="406" width="140" height="20" font="0">high-risk unstable angina </text>
<text top="245" left="406" width="3" height="20" font="0"> </text>
<text top="262" left="406" width="110" height="20" font="7"><b>Exclusion criteria:</b> </text>
<text top="279" left="406" width="113" height="20" font="0">Incomplete baseline </text>
<text top="296" left="406" width="134" height="20" font="0">characteristics, baseline </text>
<text top="314" left="406" width="92" height="20" font="0">ezetimibe use in </text>
<text top="331" left="406" width="141" height="20" font="0">combination with a statin, </text>
<text top="348" left="406" width="127" height="20" font="0">creatinine clearance of </text>
<text top="365" left="406" width="148" height="20" font="0">&lt;30 ml/min., statin therapy </text>
<text top="383" left="406" width="127" height="20" font="0">with a potency &gt;40 mg </text>
<text top="400" left="406" width="148" height="20" font="0">simvastatin, hemodynamic </text>
<text top="417" left="406" width="72" height="20" font="0">instability, or </text>
<text top="434" left="406" width="150" height="20" font="0">revascularization by CABG </text>
<text top="451" left="406" width="108" height="20" font="0">for the index event. </text>
<text top="108" left="570" width="210" height="20" font="7"><b>1</b>°<b> endpoint:</b> Composite of CV death, </text>
<text top="125" left="570" width="127" height="20" font="0">MI, or ischemic stroke. </text>
<text top="143" left="570" width="3" height="20" font="0"> </text>
<text top="160" left="570" width="209" height="20" font="7"><b>Results:</b> 9 clinical risk factors used to </text>
<text top="177" left="570" width="203" height="20" font="0">define a score. These included CHF, </text>
<text top="194" left="570" width="216" height="20" font="0">HTN, age &gt;75 y, DM, prior stroke, prior </text>
<text top="211" left="570" width="201" height="20" font="0">CABG, PAD, eGFR &lt;60ml/min./1.73 </text>
<text top="229" left="570" width="10" height="20" font="0">m</text>
<text top="230" left="580" width="4" height="13" font="9">2</text>
<text top="229" left="585" width="125" height="20" font="0">, and current smoking. </text>
<text top="246" left="570" width="3" height="20" font="0"> </text>
<text top="263" left="570" width="207" height="20" font="0">-Each of the 9 clinical variables in the </text>
<text top="280" left="570" width="209" height="20" font="0">model were independent predictors of </text>
<text top="298" left="570" width="7" height="20" font="0">1</text>
<text top="299" left="577" width="4" height="13" font="9">0</text>
<text top="298" left="581" width="197" height="20" font="0"> endpoint in the control (simvastatin </text>
<text top="315" left="570" width="100" height="20" font="0">+placebo) group.  </text>
<text top="332" left="570" width="197" height="20" font="0">- Mean number of risk indicators for </text>
<text top="349" left="570" width="189" height="20" font="0">each patient was 1.8 ± 1.2 in both </text>
<text top="366" left="570" width="90" height="20" font="0">treatment arms. </text>
<text top="384" left="570" width="203" height="20" font="0">-The use of this risk stratification tool </text>
<text top="401" left="570" width="210" height="20" font="0">showed a graded relationship with the </text>
<text top="418" left="570" width="195" height="20" font="0">primary outcome (8.6% for patients </text>
<text top="435" left="570" width="184" height="20" font="0">with 0 risk indicators to 68.4% for </text>
<text top="453" left="570" width="186" height="20" font="0">those with &gt;5 risk indicators, p for </text>
<text top="470" left="570" width="91" height="20" font="0">trend &lt;0.0001).  </text>
<text top="487" left="570" width="187" height="20" font="0">-Goodness-of-fit was 4.5 (p=0.48) </text>
<text top="504" left="570" width="176" height="20" font="0">indicating adequate calibration.  </text>
<text top="521" left="570" width="197" height="20" font="0">-The c-statistic for the 9-component </text>
<text top="539" left="570" width="209" height="20" font="0">clinical model was 0.67 (95% CI: 0.65-</text>
<text top="556" left="570" width="35" height="20" font="0">0.68). </text>
<text top="573" left="570" width="215" height="20" font="0">-Risk categories, defined as low (0 to 1 </text>
<text top="590" left="570" width="172" height="20" font="0">risk indicators), intermediate (2 </text>
<text top="607" left="570" width="196" height="20" font="0">indicators), and high (&gt;3 indicators) </text>
<text top="625" left="570" width="206" height="20" font="0">represented 45% (n = 8,032), 30% (n </text>
<text top="642" left="570" width="202" height="20" font="0">= 5,292), and 25% (n = 4,393) of the </text>
<text top="659" left="570" width="175" height="20" font="0">overall population, respectively. </text>
<text top="676" left="570" width="191" height="20" font="0">- 7-y event rates with HR (95% CI) </text>
<text top="693" left="570" width="168" height="20" font="0">associated with the addition of </text>
<text top="711" left="570" width="210" height="20" font="0">ezetimibe, ARR (95% CI) in ezetimibe </text>
<text top="728" left="570" width="178" height="20" font="0">+simvastatin group (eze+simva) </text>
<text top="745" left="570" width="206" height="20" font="0">compared with simvastatin + placebo </text>
<text top="762" left="570" width="82" height="20" font="0">(simva) group: </text>
<text top="780" left="570" width="3" height="20" font="0"> </text>
<text top="109" left="800" width="7" height="18" font="0">•</text>
<text top="108" left="806" width="239" height="20" font="0"> This risk score identified patients with ACS </text>
<text top="125" left="800" width="215" height="20" font="0">at high risk of recurrent CV events who </text>
<text top="143" left="800" width="241" height="20" font="0">derive the greatest benefit from the addition </text>
<text top="160" left="800" width="164" height="20" font="0">of ezetimibe to statin therapy. </text>
<text top="177" left="800" width="3" height="20" font="0"> </text>
<text top="195" left="800" width="205" height="20" font="0"> • Of note, this risk score was initially </text>
<text top="213" left="800" width="246" height="20" font="0">developed in a population of patients with MI </text>
<text top="230" left="800" width="247" height="20" font="0">within 2 wk to one year of randomization to a </text>
<text top="247" left="800" width="245" height="20" font="0">thrombin receptor agonist. The results of the </text>
<text top="264" left="800" width="215" height="20" font="0">current study validated the utility of this </text>
<text top="282" left="800" width="237" height="20" font="0">score in post-ACS population of IMPROVE-</text>
<text top="299" left="800" width="235" height="20" font="0">IT (Circulation. 2016 Jul 26;134(4):304-13) </text>
<text top="316" left="800" width="25" height="20" font="0">(36) </text>
<text top="333" left="800" width="3" height="20" font="0"> </text>
</page>
<page number="19" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">19 </text>
<text top="109" left="570" width="7" height="18" font="0">•</text>
<text top="108" left="577" width="209" height="20" font="0"> 0-1 risk indicators: 14% (eze+simva), </text>
<text top="125" left="570" width="192" height="20" font="0">13.1% (simva), HR: 1.05; 95% CI:  </text>
<text top="143" left="570" width="206" height="20" font="0">0.92-1.19; ARR: -0.9%; 95% CI: -2.5, </text>
<text top="160" left="570" width="24" height="20" font="0">0.7. </text>
<text top="177" left="570" width="3" height="20" font="0"> </text>
<text top="196" left="570" width="7" height="18" font="0">•</text>
<text top="195" left="577" width="205" height="20" font="0">2 risk indicators: 19.3% (eze+simva), </text>
<text top="213" left="570" width="189" height="20" font="0">21.5% (simva), HR: 0.89 (95% CI: </text>
<text top="230" left="570" width="206" height="20" font="0">0.78-1.01), ARR: 2.2%; 95% CI: -0.3, </text>
<text top="247" left="570" width="24" height="20" font="0">4.6. </text>
<text top="264" left="570" width="3" height="20" font="0"> </text>
<text top="283" left="570" width="7" height="18" font="0">•</text>
<text top="283" left="577" width="176" height="20" font="0">3 or more risk indicators: 40.2% </text>
<text top="300" left="570" width="212" height="20" font="0">(eze+simva), 33.9% (simva), HR: 0.81 </text>
<text top="317" left="570" width="213" height="20" font="0">(95% CI: 0.73, 0.90), ARR: 6.3%; 95% </text>
<text top="334" left="570" width="72" height="20" font="0">CI: 2.9-9.7).  </text>
<text top="352" left="570" width="3" height="20" font="0"> </text>
<text top="369" left="570" width="191" height="20" font="0">-Number-needed-to-treat for 7 y to </text>
<text top="386" left="570" width="215" height="20" font="0">prevent one primary event = 16 among </text>
<text top="403" left="570" width="197" height="20" font="0">those with 3 or more risk indicators. </text>
<text top="420" left="570" width="183" height="20" font="0">-Similar results were obtained for </text>
<text top="438" left="570" width="193" height="20" font="0">IMPROVE-IT pre-specified primary </text>
<text top="455" left="570" width="205" height="20" font="0">and secondary trial endpoints as well </text>
<text top="472" left="570" width="186" height="20" font="0">as most of the individual, nonfatal </text>
<text top="489" left="570" width="60" height="20" font="0">endpoints. </text>
<text top="506" left="570" width="203" height="20" font="0">-No significant reduction in CV death </text>
<text top="524" left="570" width="120" height="20" font="0">or all-cause mortality. </text>
<text top="541" left="570" width="203" height="20" font="0">-The median achieved LDL-C values </text>
<text top="558" left="570" width="165" height="20" font="0">at 1 y were similar across risk </text>
<text top="575" left="570" width="135" height="20" font="0">categories by treatment. </text>
<text top="593" left="570" width="3" height="20" font="0"> </text>
<text top="612" left="81" width="883" height="20" font="7"><b>Abbreviations: </b>1° indicated primary; CI, confidence interval; HR, hazard ratio; RCT, randomized controlled trial; IMPROVE-IT, Improved Reduction of Outcomes: </text>
<text top="629" left="81" width="1015" height="20" font="0">Vytorin Efficacy International Trial; ACS, acute coronary syndrome; MI, myocardial infarction; CV, cardiovascular; CHF, congestive heart failure; HTN, hypertension; DM, diabetes; CABG, </text>
<text top="646" left="81" width="916" height="20" font="0">coronary artery bypass grafting; PAD, peripheral artery disease; GFR, glomerular filtration rate; ARR, absolute risk reduction; LDL-C, low-density lipoprotein cholesterol  </text>
<text top="663" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="691" left="81" width="4" height="22" font="5"><b> </b></text>
</page>
<page number="20" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">20 </text>
<text top="106" left="81" width="978" height="24" font="4"><b>Data Supplement 5. RCTs of Non-Statin or Combination Lipid Lowering Therapy for Primary Prevention of ASCVD Among Patients with the </b></text>
<text top="127" left="81" width="413" height="24" font="4"><b>Metabolic Syndrome or its Subcomponents (Section 3.2.3) </b></text>
<text top="157" left="102" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="174" left="127" width="48" height="20" font="7"><b>Author; </b></text>
<text top="191" left="105" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="157" left="253" width="83" height="20" font="7"><b>Aim of Study; </b></text>
<text top="174" left="258" width="74" height="20" font="7"><b>Study Type; </b></text>
<text top="191" left="252" width="86" height="20" font="7"><b>Study Size (N) </b></text>
<text top="174" left="399" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="148" left="563" width="111" height="20" font="7"><b>Study Intervention </b></text>
<text top="166" left="580" width="76" height="20" font="7"><b>(# patients) / </b></text>
<text top="183" left="563" width="111" height="20" font="7"><b>Study Comparator </b></text>
<text top="200" left="584" width="69" height="20" font="7"><b>(# patients) </b></text>
<text top="157" left="754" width="105" height="20" font="7"><b>Endpoint Results </b></text>
<text top="174" left="738" width="137" height="20" font="7"><b>(Absolute Event Rates, </b></text>
<text top="191" left="716" width="181" height="20" font="7"><b>P values; OR or RR; &amp; 95% CI) </b></text>
<text top="157" left="932" width="175" height="20" font="7"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="175" left="965" width="111" height="20" font="7"><b>Study Limitations; </b></text>
<text top="192" left="972" width="96" height="20" font="7"><b>Adverse Events </b></text>
<text top="218" left="89" width="119" height="20" font="7"><b>HHS: Helsinki Heart </b></text>
<text top="235" left="89" width="38" height="20" font="7"><b>Study </b></text>
<text top="252" left="89" width="123" height="20" font="0">Frick et al., 1987 <a href="data supplement.html#236">(15)</a>  </text>
<text top="270" left="89" width="48" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3313041">3313041</a></text>
<text top="270" left="137" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3313041"> </a></text>
<text top="287" left="89" width="7" height="20" font="0">  </text>
<text top="218" left="226" width="92" height="20" font="7"><b>Aim:</b> To test the </text>
<text top="235" left="226" width="121" height="20" font="0">efficacy of gemfibrozil </text>
<text top="252" left="226" width="119" height="20" font="0">for lowering CHD risk </text>
<text top="270" left="226" width="120" height="20" font="0">among asymptomatic </text>
<text top="287" left="226" width="106" height="20" font="0">men with high Non-</text>
<text top="304" left="226" width="41" height="20" font="0">HDL-C </text>
<text top="321" left="226" width="3" height="20" font="0"> </text>
<text top="338" left="226" width="102" height="20" font="7"><b>Study type:</b> RCT  </text>
<text top="356" left="226" width="3" height="20" font="0"> </text>
<text top="373" left="226" width="93" height="20" font="7"><b>Size:</b> 4,081 pts   </text>
<text top="218" left="376" width="151" height="20" font="7"><b>Inclusion criteria:</b> Men 40-</text>
<text top="235" left="376" width="157" height="20" font="0">55 y of age with Non-HDL-C </text>
<text top="252" left="376" width="155" height="20" font="0">greater than or equal to 200 </text>
<text top="270" left="376" width="137" height="20" font="0">mg/dl in two consecutive </text>
<text top="287" left="376" width="148" height="20" font="0">pretreatment assessments </text>
<text top="304" left="376" width="3" height="20" font="0"> </text>
<text top="321" left="376" width="153" height="20" font="7"><b>Exclusion criteria:</b> Clinical </text>
<text top="338" left="376" width="111" height="20" font="0">or ECG evidence of </text>
<text top="356" left="376" width="145" height="20" font="0">baseline CHD; congestive </text>
<text top="373" left="376" width="103" height="20" font="0">heart failure; other </text>
<text top="390" left="376" width="137" height="20" font="0">comorbidities that “could </text>
<text top="407" left="376" width="137" height="20" font="0">have an influence on the </text>
<text top="424" left="376" width="87" height="20" font="0">study outcome” </text>
<text top="218" left="546" width="144" height="20" font="7"><b>Intervention:</b> Gemfibrozil </text>
<text top="235" left="546" width="109" height="20" font="0">600 mg twice a day </text>
<text top="252" left="546" width="7" height="20" font="0">  </text>
<text top="270" left="546" width="132" height="20" font="7"><b>Comparator: </b>Placebo <b>  </b></text>
<text top="219" left="703" width="202" height="20" font="7"><b>1</b>°<b> endpoint:</b> Composite of fatal and </text>
<text top="236" left="703" width="165" height="20" font="0">nonfatal MI and cardiac death </text>
<text top="254" left="703" width="195" height="20" font="0">(Gemfibrozil 27.3 vs. Placebo 41.4, </text>
<text top="271" left="703" width="204" height="20" font="0">cumulative events per 1000 over 5 y; </text>
<text top="288" left="703" width="193" height="20" font="0">relative risk reduction of 34% [95% </text>
<text top="305" left="703" width="79" height="20" font="0">CI: 8.2-52.6])  </text>
<text top="322" left="703" width="3" height="20" font="0"> </text>
<text top="340" left="703" width="170" height="20" font="7"><b>Safety endpoint (if relevant):</b> </text>
<text top="357" left="703" width="144" height="20" font="0">Moderate to severe upper </text>
<text top="374" left="703" width="173" height="20" font="0">gastrointestinal symptoms - in 1</text>
<text top="376" left="876" width="6" height="13" font="9">st</text>
<text top="374" left="882" width="3" height="20" font="0"> </text>
<text top="391" left="703" width="202" height="20" font="0">year: Gemfibrozil 11.3% vs. Placebo </text>
<text top="408" left="703" width="171" height="20" font="0">7.0% (p&lt;0.001); in subsequent </text>
<text top="426" left="703" width="201" height="20" font="0">years: Gemfibrozil 2.4% vs. Placebo </text>
<text top="443" left="703" width="81" height="20" font="0">1.2% (p&lt;0.05) </text>
<text top="460" left="703" width="3" height="20" font="7"><b> </b></text>
<text top="220" left="923" width="7" height="18" font="0">•</text>
<text top="219" left="930" width="186" height="20" font="0"> Nonfatal MI (Gemfibrozil 21.9 vs. </text>
<text top="236" left="923" width="180" height="20" font="0">Placebo 35.0, cumulative events </text>
<text top="254" left="923" width="190" height="20" font="0">per 1000 over 5 y; p&lt;0.02; relative </text>
<text top="271" left="923" width="126" height="20" font="0">risk reduction of 37%)  </text>
<text top="290" left="923" width="7" height="18" font="0">•</text>
<text top="289" left="930" width="120" height="20" font="0"> Gallstone operations </text>
<text top="306" left="923" width="185" height="20" font="0">(Gemfibrozil 18 vs. Placebo 12; p </text>
<text top="324" left="923" width="157" height="20" font="0">value nonsignificant [&gt;0.05]) </text>
<text top="343" left="923" width="7" height="18" font="0">•</text>
<text top="342" left="930" width="171" height="20" font="0"> All gastrointestinal operations, </text>
<text top="359" left="923" width="167" height="20" font="0">including hemorrhoidectomies </text>
<text top="376" left="923" width="174" height="20" font="0">(Gemfibrozil 81 vs. Placebo 53; </text>
<text top="394" left="923" width="46" height="20" font="0">p&lt;0.02) </text>
<text top="413" left="923" width="7" height="18" font="0">•</text>
<text top="412" left="930" width="90" height="20" font="0"> 5 y of follow-up </text>
<text top="429" left="923" width="3" height="20" font="0"> </text>
<text top="446" left="923" width="3" height="20" font="0"> </text>
<text top="478" left="89" width="105" height="20" font="0">Tenkanen L, et al., </text>
<text top="495" left="89" width="56" height="20" font="0">1995 <a href="data supplement.html#236">(16)</a> </text>
<text top="512" left="89" width="51" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7671361">7671361 </a></text>
<text top="512" left="141" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7671361"> </a></text>
<text top="478" left="226" width="119" height="20" font="7"><b>Aim:</b> To evaluate the </text>
<text top="495" left="226" width="89" height="20" font="0">effectiveness of </text>
<text top="512" left="226" width="111" height="20" font="0">gemfibrozil for CHD </text>
<text top="530" left="226" width="102" height="20" font="0">prevention among </text>
<text top="547" left="226" width="137" height="20" font="0">overweight subjects with </text>
<text top="564" left="226" width="119" height="20" font="0">metabolic risk factors </text>
<text top="581" left="226" width="3" height="20" font="0"> </text>
<text top="598" left="226" width="99" height="20" font="7"><b>Study type:</b> RCT </text>
<text top="616" left="226" width="103" height="20" font="0">subgroup analysis </text>
<text top="633" left="226" width="3" height="20" font="0"> </text>
<text top="650" left="226" width="93" height="20" font="7"><b>Size:</b> 4,081 pts   </text>
<text top="478" left="376" width="151" height="20" font="7"><b>Inclusion criteria:</b> Men 40-</text>
<text top="495" left="376" width="157" height="20" font="0">55 y of age with Non-HDL-C </text>
<text top="512" left="376" width="155" height="20" font="0">greater than or equal to 200 </text>
<text top="530" left="376" width="137" height="20" font="0">mg/dl in two consecutive </text>
<text top="547" left="376" width="148" height="20" font="0">pretreatment assessments </text>
<text top="564" left="376" width="3" height="20" font="0"> </text>
<text top="581" left="376" width="153" height="20" font="7"><b>Exclusion criteria:</b> Clinical </text>
<text top="598" left="376" width="111" height="20" font="0">or ECG evidence of </text>
<text top="616" left="376" width="145" height="20" font="0">baseline CHD; congestive </text>
<text top="633" left="376" width="103" height="20" font="0">heart failure; other </text>
<text top="650" left="376" width="137" height="20" font="0">comorbidities that “could </text>
<text top="667" left="376" width="137" height="20" font="0">have an influence on the </text>
<text top="685" left="376" width="87" height="20" font="0">study outcome” </text>
<text top="478" left="546" width="144" height="20" font="7"><b>Intervention:</b> Gemfibrozil </text>
<text top="495" left="546" width="109" height="20" font="0">600 mg twice a day </text>
<text top="512" left="546" width="7" height="20" font="0">  </text>
<text top="530" left="546" width="132" height="20" font="7"><b>Comparator: </b>Placebo <b>  </b></text>
<text top="479" left="703" width="202" height="20" font="7"><b>1</b>°<b> endpoint:</b> Composite of fatal and </text>
<text top="496" left="703" width="169" height="20" font="0">nonfatal MI and cardiac death  </text>
<text top="514" left="703" width="3" height="20" font="0"> </text>
<text top="531" left="703" width="196" height="20" font="0">Among those with BMI greater than </text>
<text top="548" left="703" width="44" height="20" font="0">26 kg/m</text>
<text top="550" left="747" width="4" height="13" font="9">2</text>
<text top="548" left="752" width="149" height="20" font="0">, high triglycerides (greater </text>
<text top="565" left="703" width="196" height="20" font="0">than or equal to 200 mg/dl) and low </text>
<text top="582" left="703" width="156" height="20" font="0">HDL-C (less than 42 mg/dl): </text>
<text top="600" left="703" width="203" height="20" font="0">Gemfibrozil 4 vs. Placebo 17, events </text>
<text top="617" left="703" width="172" height="20" font="0">per 1000 person-y; relative risk </text>
<text top="634" left="703" width="158" height="20" font="0">reduction of 78% [p=0.002])  </text>
<text top="651" left="703" width="3" height="20" font="0"> </text>
<text top="668" left="703" width="196" height="20" font="0">Among those with BMI greater than </text>
<text top="686" left="703" width="44" height="20" font="0">26 kg/m</text>
<text top="687" left="747" width="4" height="13" font="9">2</text>
<text top="686" left="752" width="141" height="20" font="0">, and 3-4 of the following: </text>
<text top="703" left="703" width="196" height="20" font="0">hypertension (greater than or equal </text>
<text top="720" left="703" width="195" height="20" font="0">to 140/90), glucose greater than 80 </text>
<text top="737" left="703" width="163" height="20" font="0">mg/dl, sedentary lifestyle and </text>
<text top="755" left="703" width="196" height="20" font="0">smoking (Gemfibrozil 8 vs. Placebo </text>
<text top="772" left="703" width="167" height="20" font="0">27, events per 1000 person-y; </text>
<text top="480" left="923" width="7" height="18" font="0">•</text>
<text top="479" left="930" width="158" height="20" font="0"> Post-hoc subgroup analysis </text>
<text top="498" left="923" width="7" height="18" font="0">•</text>
<text top="497" left="930" width="90" height="20" font="0"> 5 y of follow-up </text>
<text top="515" left="923" width="3" height="20" font="0"> </text>
<text top="532" left="923" width="3" height="20" font="0"> </text>
</page>
<page number="21" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="11" size="12" family="Times" color="#565656"/>
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">21 </text>
<text top="107" left="703" width="161" height="20" font="0">relative risk reduction of 68% </text>
<text top="124" left="703" width="56" height="20" font="0">[p=0.03])  </text>
<text top="141" left="703" width="3" height="20" font="0"> </text>
<text top="159" left="703" width="124" height="20" font="7"><b>Safety endpoint:</b> N/A </text>
<text top="176" left="703" width="3" height="20" font="7"><b> </b></text>
<text top="194" left="89" width="39" height="20" font="7"><b>FIELD </b></text>
<text top="211" left="89" width="118" height="20" font="0">Keech A, et al., 2005 </text>
<text top="228" left="89" width="29" height="20" font="0"><a href="data supplement.html#237">(17)</a>  </text>
<text top="246" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16310551">16310551</a></text>
<text top="245" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16310551"> </a></text>
<text top="263" left="89" width="3" height="20" font="11"> </text>
<text top="263" left="93" width="3" height="20" font="0"> </text>
<text top="194" left="226" width="111" height="20" font="7"><b>Aim:</b> To assess the </text>
<text top="211" left="226" width="126" height="20" font="0">effect of fenofibrate on </text>
<text top="228" left="226" width="110" height="20" font="0">CVD events among </text>
<text top="246" left="226" width="109" height="20" font="0">patients with type 2 </text>
<text top="263" left="226" width="50" height="20" font="0">diabetes </text>
<text top="280" left="226" width="3" height="20" font="0"> </text>
<text top="297" left="226" width="99" height="20" font="7"><b>Study type:</b> RCT </text>
<text top="314" left="226" width="3" height="20" font="0"> </text>
<text top="332" left="226" width="118" height="20" font="7"><b>Size:</b> 9.795 pts (80% </text>
<text top="349" left="226" width="105" height="20" font="0">meeting criteria for </text>
<text top="366" left="226" width="121" height="20" font="0">metabolic syndrome)  </text>
<text top="194" left="376" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="211" left="376" width="3" height="20" font="0"> </text>
<text top="228" left="376" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="194" left="546" width="102" height="20" font="7"><b>Intervention: </b>N/A </text>
<text top="211" left="546" width="7" height="20" font="0">  </text>
<text top="228" left="546" width="101" height="20" font="7"><b>Comparator:</b> N/A<b> </b></text>
<text top="195" left="703" width="187" height="20" font="7"><b>1</b>°<b> endpoint:</b> Nonfatal MI or CHD </text>
<text top="212" left="703" width="36" height="20" font="0">Death </text>
<text top="229" left="703" width="3" height="20" font="0"> </text>
<text top="247" left="703" width="124" height="20" font="7"><b>Safety endpoint:</b> N/A </text>
<text top="264" left="703" width="3" height="20" font="7"><b> </b></text>
<text top="196" left="923" width="7" height="18" font="0">•</text>
<text top="195" left="930" width="159" height="20" font="0"> Total CVD events, including </text>
<text top="212" left="923" width="176" height="20" font="0">nonfatal MI, CHD death, stroke, </text>
<text top="229" left="923" width="116" height="20" font="0">coronary and carotid </text>
<text top="247" left="923" width="96" height="20" font="0">revascularization </text>
<text top="266" left="923" width="7" height="18" font="0">•</text>
<text top="265" left="930" width="70" height="20" font="0"> Nonfatal MI </text>
<text top="284" left="923" width="7" height="18" font="0">•</text>
<text top="283" left="930" width="84" height="20" font="0"> CHD mortality </text>
<text top="301" left="923" width="3" height="20" font="0"> </text>
<text top="318" left="923" width="3" height="20" font="0"> </text>
<text top="384" left="89" width="120" height="20" font="7"><b>ACCORD Lipid Trial </b></text>
<text top="401" left="89" width="111" height="20" font="0">Ginsberg HN, et al., </text>
<text top="418" left="89" width="60" height="20" font="0">1998 <a href="data supplement.html#237">(18)</a>  </text>
<text top="436" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20228404">20228404</a></text>
<text top="436" left="144" width="3" height="20" font="11"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20228404"> </a></text>
<text top="453" left="89" width="3" height="20" font="11"> </text>
<text top="453" left="93" width="3" height="20" font="0"> </text>
<text top="384" left="226" width="90" height="20" font="7"><b>Aim:</b> To assess </text>
<text top="401" left="226" width="117" height="20" font="0">whether combination </text>
<text top="418" left="226" width="131" height="20" font="0">therapy with fenofibrate </text>
<text top="436" left="226" width="130" height="20" font="0">plus simvastatin lowers </text>
<text top="453" left="226" width="134" height="20" font="0">the rate of incident CVD </text>
<text top="470" left="226" width="98" height="20" font="0">events more than </text>
<text top="487" left="226" width="98" height="20" font="0">simvastatin alone </text>
<text top="504" left="226" width="137" height="20" font="0">among high risk patients </text>
<text top="522" left="226" width="116" height="20" font="0">with type 2 diabetes  </text>
<text top="539" left="226" width="3" height="20" font="0"> </text>
<text top="556" left="226" width="99" height="20" font="7"><b>Study type:</b> RCT </text>
<text top="573" left="226" width="3" height="20" font="0"> </text>
<text top="591" left="226" width="90" height="20" font="7"><b>Size:</b> 5,518 pts  </text>
<text top="384" left="376" width="157" height="20" font="7"><b>Inclusion criteria:</b> Men and </text>
<text top="401" left="376" width="157" height="20" font="0">women aged 40-79 y (55-79 </text>
<text top="418" left="376" width="133" height="20" font="0">y if subclinical CVD or 2 </text>
<text top="436" left="376" width="148" height="20" font="0">additional risk factors) with </text>
<text top="453" left="376" width="152" height="20" font="0">type 3 DM with hemoglobin </text>
<text top="470" left="376" width="145" height="20" font="0">A1C greater than or equal </text>
<text top="487" left="376" width="147" height="20" font="0">to 7.5%; an LDL-C level of </text>
<text top="504" left="376" width="132" height="20" font="0">60-180 mg/dl; HDL less </text>
<text top="522" left="376" width="139" height="20" font="0">than 55 mg/dl for women </text>
<text top="539" left="376" width="156" height="20" font="0">and blacks and less than 50 </text>
<text top="556" left="376" width="116" height="20" font="0">mg/dl for others; and </text>
<text top="573" left="376" width="145" height="20" font="0">triglycerides less than 750 </text>
<text top="591" left="376" width="152" height="20" font="0">mg/dl (or 400 mg/dl on lipid </text>
<text top="608" left="376" width="150" height="20" font="0">therapy). Included subjects </text>
<text top="625" left="376" width="148" height="20" font="0">with (36.5%) and without a </text>
<text top="642" left="376" width="132" height="20" font="0">previous cardiovascular </text>
<text top="659" left="376" width="106" height="20" font="0">event (primary and </text>
<text top="677" left="376" width="148" height="20" font="0">secondary prevention trial) </text>
<text top="694" left="376" width="3" height="20" font="0"> </text>
<text top="711" left="376" width="146" height="20" font="7"><b>Exclusion criteria:</b> taking </text>
<text top="728" left="376" width="139" height="20" font="0">any medication known to </text>
<text top="745" left="376" width="122" height="20" font="0">interact with statins or </text>
<text top="763" left="376" width="100" height="20" font="0">fibrates; history of </text>
<text top="780" left="376" width="133" height="20" font="0">pancreatitis, gallbladder </text>
<text top="384" left="546" width="78" height="20" font="7"><b>Intervention: </b></text>
<text top="401" left="546" width="86" height="20" font="0">Combination of </text>
<text top="418" left="546" width="143" height="20" font="0">Fenofibrate (160 mg, with </text>
<text top="436" left="546" width="138" height="20" font="0">adjustment as needed to </text>
<text top="453" left="546" width="126" height="20" font="0">eGFR) plus open label </text>
<text top="470" left="546" width="130" height="20" font="0">Simvastatin (20-40 mg) </text>
<text top="487" left="546" width="7" height="20" font="0">  </text>
<text top="504" left="546" width="136" height="20" font="7"><b>Comparator:</b> Placebo + </text>
<text top="522" left="546" width="127" height="20" font="0">open label Simvastatin </text>
<text top="539" left="546" width="67" height="20" font="0">(20-40 mg)<b>  </b></text>
<text top="385" left="703" width="199" height="20" font="7"><b>1</b>°<b> endpoint:</b> Composite of nonfatal </text>
<text top="402" left="703" width="191" height="20" font="0">MI, nonfatal stroke and death from </text>
<text top="420" left="703" width="195" height="20" font="0">cardiovascular causes (Fenofibrate </text>
<text top="437" left="703" width="174" height="20" font="0">2.2% vs. Placebo 2.4%, annual </text>
<text top="454" left="703" width="192" height="20" font="0">event rate; HR: 0.92 [95% CI: 0.79-</text>
<text top="471" left="703" width="83" height="20" font="0">1.08; p=0.32])  </text>
<text top="488" left="703" width="3" height="20" font="0"> </text>
<text top="506" left="703" width="194" height="20" font="7"><b>Safety endpoint:</b> Elevations of CK </text>
<text top="523" left="703" width="203" height="20" font="0">more than 10 times the upper limit of </text>
<text top="540" left="703" width="161" height="20" font="0">normal (Fenofibrate 0.4% vs. </text>
<text top="557" left="703" width="169" height="20" font="0">Placebo 0.3%; cumulative rate </text>
<text top="574" left="703" width="110" height="20" font="0">during trial; p=0.83) </text>
<text top="592" left="703" width="3" height="20" font="0"> </text>
<text top="609" left="703" width="192" height="20" font="0">Any unexplained myalgias with CK </text>
<text top="626" left="703" width="194" height="20" font="0">greater than 5 times the upper limit </text>
<text top="643" left="703" width="175" height="20" font="0">of normal (Fenofibrate 0.3% vs. </text>
<text top="660" left="703" width="169" height="20" font="0">Placebo 0.3%; cumulative rate </text>
<text top="678" left="703" width="110" height="20" font="0">during trial; p=0.79) </text>
<text top="695" left="703" width="3" height="20" font="0"> </text>
<text top="712" left="703" width="152" height="20" font="0">Serum creatinine elevation  </text>
<text top="729" left="703" width="193" height="20" font="0">– for women (ever greater than 1.3 </text>
<text top="747" left="703" width="160" height="20" font="0">mg/dl; Fenofibrate 27.9% vs. </text>
<text top="764" left="703" width="176" height="20" font="0">Placebo 18.7%; cumulative rate </text>
<text top="781" left="703" width="120" height="20" font="0">during trial; p&lt;0.001)  </text>
<text top="386" left="923" width="7" height="18" font="0">•</text>
<text top="385" left="930" width="185" height="20" font="0"> Prespecified subgroup analyses: </text>
<text top="402" left="923" width="3" height="20" font="0"> </text>
<text top="420" left="923" width="191" height="20" font="0">Triglycerides greater than or equal </text>
<text top="437" left="923" width="189" height="20" font="0">to 204 mg/dl and HDL-C less than </text>
<text top="454" left="923" width="182" height="20" font="0">or equal to 34 mg/dl (Fenofibrate </text>
<text top="471" left="923" width="193" height="20" font="0">12.4 vs. Placebo 17.3, overall % of </text>
<text top="488" left="923" width="187" height="20" font="0">events in group; p=0.032). Others </text>
<text top="506" left="923" width="184" height="20" font="0">without high triglycerides and low </text>
<text top="523" left="923" width="157" height="20" font="0">HDL-C (Fenofibrate 10.1 vs. </text>
<text top="540" left="923" width="186" height="20" font="0">Placebo 10.1, overall % of events </text>
<text top="557" left="923" width="135" height="20" font="0">in group; p=0.032). p for </text>
<text top="574" left="923" width="87" height="20" font="0">interaction 0.06 </text>
<text top="592" left="923" width="3" height="20" font="0"> </text>
<text top="609" left="923" width="155" height="20" font="0">Women (Fenofibrate 9.1 vs. </text>
<text top="626" left="923" width="192" height="20" font="0">Placebo 6.6, overall % of events in </text>
<text top="643" left="923" width="186" height="20" font="0">group). Men (Fenofibrate 11.2 vs. </text>
<text top="660" left="923" width="186" height="20" font="0">Placebo 13.3, overall % of events </text>
<text top="678" left="923" width="171" height="20" font="0">in group). p for interaction 0.01 </text>
<text top="695" left="923" width="3" height="20" font="0"> </text>
<text top="712" left="923" width="192" height="20" font="0">No interaction seen with prior CVD </text>
<text top="729" left="923" width="49" height="20" font="0">(p=0.45) </text>
<text top="747" left="923" width="3" height="20" font="0"> </text>
<text top="764" left="923" width="178" height="20" font="0">Mean duration of follow-up 4.7 y </text>
<text top="781" left="923" width="113" height="20" font="0">for primary outcome </text>
</page>
<page number="22" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">22 </text>
<text top="107" left="376" width="60" height="20" font="0">disease or </text>
<text top="124" left="376" width="105" height="20" font="0">myositis/myopathy </text>
<text top="107" left="703" width="177" height="20" font="0">– for men (ever greater than 1.5 </text>
<text top="124" left="703" width="160" height="20" font="0">mg/dl; Fenofibrate 36.7% vs. </text>
<text top="141" left="703" width="176" height="20" font="0">Placebo 18.5%; cumulative rate </text>
<text top="159" left="703" width="117" height="20" font="0">during trial; p&lt;0.001) </text>
<text top="176" left="703" width="3" height="20" font="0"> </text>
<text top="193" left="703" width="194" height="20" font="0">ALT greater than 5 times the upper </text>
<text top="210" left="703" width="200" height="20" font="0">limit of normal (Fenofibrate 0.6% vs. </text>
<text top="228" left="703" width="169" height="20" font="0">Placebo 0.2%; cumulative rate </text>
<text top="245" left="703" width="110" height="20" font="0">during trial; p=0.03) </text>
<text top="262" left="703" width="3" height="20" font="7"><b> </b></text>
<text top="107" left="923" width="3" height="20" font="0"> </text>
<text top="124" left="923" width="3" height="20" font="0"> </text>
<text top="141" left="923" width="3" height="20" font="0"> </text>
<text top="281" left="88" width="921" height="20" font="7"><b>Abbreviations:</b> 1° indicated primary; CI, confidence interval; HR, hazard ratio; N/A, not available; OR, odds ratio; RCT, randomized controlled trial; and RR, relative risk. </text>
<text top="298" left="88" width="300" height="20" font="7"><b>Search Terms and Date of Search</b>: Author to provide </text>
<text top="315" left="88" width="4" height="22" font="5"><b> </b></text>
<text top="334" left="81" width="1014" height="24" font="4"><b>Data Supplement 6. Evidence Tables for Statin initiation in patients with heart failure meta-analysis of CORONA and GISSI HF trials (Section 4.1) </b></text>
<text top="364" left="94" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="382" left="120" width="48" height="20" font="7"><b>Author; </b></text>
<text top="399" left="97" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="364" left="227" width="83" height="20" font="7"><b>Aim of Study; </b></text>
<text top="382" left="231" width="74" height="20" font="7"><b>Study Type; </b></text>
<text top="399" left="225" width="86" height="20" font="7"><b>Study Size (N) </b></text>
<text top="382" left="368" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="356" left="548" width="111" height="20" font="7"><b>Study Intervention </b></text>
<text top="373" left="565" width="76" height="20" font="7"><b>(# patients) / </b></text>
<text top="390" left="548" width="111" height="20" font="7"><b>Study Comparator </b></text>
<text top="407" left="569" width="69" height="20" font="7"><b>(# patients) </b></text>
<text top="364" left="751" width="105" height="20" font="7"><b>Endpoint Results </b></text>
<text top="382" left="735" width="137" height="20" font="7"><b>(Absolute Event Rates, </b></text>
<text top="399" left="713" width="181" height="20" font="7"><b>P values; OR or RR; &amp; 95% CI) </b></text>
<text top="365" left="932" width="175" height="20" font="7"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="382" left="964" width="111" height="20" font="7"><b>Study Limitations; </b></text>
<text top="399" left="971" width="96" height="20" font="7"><b>Adverse Events </b></text>
<text top="425" left="89" width="58" height="20" font="7"><b>CORONA</b> </text>
<text top="443" left="89" width="87" height="20" font="0">Kjekshus et al., </text>
<text top="460" left="89" width="56" height="20" font="0">2007 <a href="data supplement.html#237">(19)</a> </text>
<text top="477" left="89" width="58" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17984166">17984166 </a></text>
<text top="477" left="147" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17984166"> </a></text>
<text top="425" left="211" width="90" height="20" font="7"><b>Aim:</b> To assess </text>
<text top="443" left="211" width="95" height="20" font="0">beneficial effects </text>
<text top="460" left="211" width="75" height="20" font="0">and harms of </text>
<text top="477" left="211" width="62" height="20" font="0">initiation of </text>
<text top="494" left="211" width="114" height="20" font="0">rosuvastatin therapy </text>
<text top="512" left="211" width="85" height="20" font="0">in patients with </text>
<text top="529" left="211" width="46" height="20" font="0">chronic, </text>
<text top="546" left="211" width="76" height="20" font="0">symptomatic, </text>
<text top="563" left="211" width="83" height="20" font="0">ischemic heart </text>
<text top="580" left="211" width="40" height="20" font="0">failure. </text>
<text top="598" left="211" width="3" height="20" font="0"> </text>
<text top="615" left="211" width="99" height="20" font="7"><b>Study type:</b> RCT </text>
<text top="632" left="211" width="3" height="20" font="0"> </text>
<text top="649" left="211" width="109" height="20" font="7"><b>Size:</b> 5011 patients </text>
<text top="666" left="211" width="98" height="20" font="0">(2497 in placebo, </text>
<text top="684" left="211" width="113" height="20" font="0">2514 in rosuvastatin </text>
<text top="701" left="211" width="29" height="20" font="0">arm) </text>
<text top="718" left="211" width="3" height="20" font="0"> </text>
<text top="735" left="211" width="107" height="20" font="7"><b>Median follow-up</b>: </text>
<text top="752" left="211" width="48" height="20" font="0">32.8 mo </text>
<text top="770" left="211" width="83" height="20" font="0">371 sites in 19 </text>
<text top="787" left="211" width="113" height="20" font="0">European countries, </text>
<text top="425" left="339" width="154" height="20" font="7"><b>Inclusion criteria:</b> Patients </text>
<text top="443" left="339" width="163" height="20" font="0">who were at least 60 y of age </text>
<text top="460" left="339" width="145" height="20" font="0">and who had chronic New </text>
<text top="477" left="339" width="128" height="20" font="0">York Heart Association </text>
<text top="494" left="339" width="169" height="20" font="0">(NYHA) class II, III, or IV heart </text>
<text top="512" left="339" width="158" height="20" font="0">failure of ischemic cause (as </text>
<text top="529" left="339" width="166" height="20" font="0">reported by investigators) and </text>
<text top="546" left="339" width="169" height="20" font="0">an ejection fraction of no more </text>
<text top="563" left="339" width="163" height="20" font="0">than 40% (no more than 35% </text>
<text top="580" left="339" width="156" height="20" font="0">in patients in NYHA class II) </text>
<text top="598" left="339" width="105" height="20" font="0">were eligible, if the </text>
<text top="615" left="339" width="157" height="20" font="0">investigator thought they did </text>
<text top="632" left="339" width="142" height="20" font="0">not need treatment with a </text>
<text top="649" left="339" width="148" height="20" font="0">cholesterol-lowering drug.  </text>
<text top="666" left="339" width="3" height="20" font="0"> </text>
<text top="684" left="339" width="161" height="20" font="7"><b>Exclusion criteria:</b> Previous </text>
<text top="701" left="339" width="151" height="20" font="0">statin-induced myopathy or </text>
<text top="718" left="339" width="138" height="20" font="0">hypersensitivity reaction; </text>
<text top="735" left="339" width="159" height="20" font="0">decompensated heart failure </text>
<text top="752" left="339" width="123" height="20" font="0">or a need for inotropic </text>
<text top="770" left="339" width="164" height="20" font="0">therapy; myocardial infarction </text>
<text top="425" left="521" width="101" height="20" font="7"><b>Intervention:</b> G1: </text>
<text top="443" left="521" width="134" height="20" font="0">Rosuvastatin 10 mg QD </text>
<text top="460" left="521" width="53" height="20" font="0">(n=2514) </text>
<text top="477" left="521" width="3" height="20" font="0"> </text>
<text top="494" left="521" width="163" height="20" font="7"><b>Comparator:</b> G2: Placebo (n </text>
<text top="512" left="521" width="46" height="20" font="0">= 2497) </text>
<text top="529" left="521" width="7" height="20" font="0"> <b> </b></text>
<text top="546" left="521" width="71" height="20" font="7"><b>End points: </b></text>
<text top="563" left="521" width="3" height="20" font="7"><b> </b></text>
<text top="582" left="521" width="155" height="20" font="7"><b>1</b>°<b> endpoint:</b> Composite of: </text>
<text top="599" left="521" width="145" height="20" font="0">death from cardiovascular </text>
<text top="616" left="521" width="156" height="20" font="0">causes, nonfatal myocardial </text>
<text top="633" left="521" width="128" height="20" font="0">infarction, and nonfatal </text>
<text top="650" left="521" width="44" height="20" font="0">stroke,  </text>
<text top="668" left="521" width="3" height="20" font="0"> </text>
<text top="685" left="521" width="157" height="20" font="7"><b>Secondary</b>: Death from any </text>
<text top="702" left="521" width="148" height="20" font="0">cause, any coronary event </text>
<text top="719" left="521" width="146" height="20" font="0">(defined as sudden death, </text>
<text top="736" left="521" width="151" height="20" font="0">fatal or nonfatal myocardial </text>
<text top="754" left="521" width="163" height="20" font="0">infarction, the performance of </text>
<text top="771" left="521" width="140" height="20" font="0">PCI or CABG, ventricular </text>
<text top="788" left="521" width="102" height="20" font="0">defibrillation by an </text>
<text top="425" left="698" width="155" height="20" font="0">G1: LDL-C 137 to 76 mg/dL </text>
<text top="443" left="698" width="161" height="20" font="0">G2: LDL-C 136 to 138 mg/dL </text>
<text top="460" left="698" width="189" height="20" font="0">Absolute LDL-C difference of 45% </text>
<text top="477" left="698" width="147" height="20" font="0">between groups (p&lt;0.001) </text>
<text top="494" left="698" width="3" height="20" font="0"> </text>
<text top="513" left="698" width="79" height="20" font="7"><b>1</b>°<b> endpoint:</b>  </text>
<text top="530" left="698" width="188" height="20" font="0">G1: 692 (11.4 per 100 patient-y of </text>
<text top="547" left="698" width="60" height="20" font="0">follow-up)  </text>
<text top="564" left="698" width="188" height="20" font="0">G2: 732 (12.3 per 100 patient-y of </text>
<text top="582" left="698" width="60" height="20" font="0">follow-up)  </text>
<text top="599" left="698" width="158" height="20" font="0">HR: 0.92; 95% CI: 0.83-1.02 </text>
<text top="616" left="698" width="38" height="20" font="0">p 0.12 </text>
<text top="633" left="698" width="184" height="20" font="0">No heterogeneity of effect across </text>
<text top="650" left="698" width="61" height="20" font="0">subgroups </text>
<text top="668" left="698" width="3" height="20" font="0"> </text>
<text top="685" left="698" width="179" height="20" font="7"><b>Secondary Outcomes</b> (per 100 </text>
<text top="702" left="698" width="124" height="20" font="0">patient-y of follow-up): </text>
<text top="719" left="698" width="3" height="20" font="0"> </text>
<text top="736" left="698" width="127" height="20" font="0">Death from any cause: </text>
<text top="754" left="698" width="188" height="20" font="0">G1: 728 (11.6 per 100 patient-y of </text>
<text top="771" left="698" width="57" height="20" font="0">follow-up) </text>
<text top="427" left="921" width="7" height="18" font="0">•</text>
<text top="427" left="928" width="186" height="20" font="0"> Mean age 73 y, 41% participants </text>
<text top="444" left="921" width="127" height="20" font="0">were at least 75 y old.  </text>
<text top="463" left="921" width="7" height="18" font="0">•</text>
<text top="462" left="928" width="179" height="20" font="0">Nonfatal MI and stroke relatively </text>
<text top="479" left="921" width="68" height="20" font="0">uncommon. </text>
<text top="498" left="921" width="7" height="18" font="0">•</text>
<text top="498" left="928" width="172" height="20" font="0"> Composite of Fatal or nonfatal </text>
<text top="515" left="921" width="75" height="20" font="0">MI, or stroke: </text>
<text top="532" left="921" width="98" height="20" font="0">GI: 227; G2: 264  </text>
<text top="549" left="921" width="199" height="20" font="0">HR: 0.84; 95% CI: 0.7-1.00; p=0.05  </text>
<text top="568" left="921" width="7" height="18" font="0">•</text>
<text top="568" left="928" width="95" height="20" font="0"> Adverse events: </text>
<text top="585" left="921" width="176" height="20" font="0">-Study drug discontinuation: G1 </text>
<text top="602" left="921" width="174" height="20" font="0">490, G2 546 HR: 0.88; 95% CI: </text>
<text top="619" left="921" width="55" height="20" font="0">0.78-0.99 </text>
<text top="637" left="921" width="156" height="20" font="0">-ALT &gt;3 x ULN (at least one </text>
<text top="654" left="921" width="138" height="20" font="0">episode): G1: 25; G2: 24 </text>
<text top="671" left="921" width="140" height="20" font="0">-Muscle adverse events:  </text>
<text top="688" left="921" width="101" height="20" font="0"> G1: 170; G2: 155 </text>
<text top="705" left="921" width="160" height="20" font="0">-CK &gt;10 x ULN: G1: 1; G2: 3 </text>
<text top="723" left="921" width="154" height="20" font="0">-CK &gt;10 x ULN with muscle </text>
<text top="740" left="921" width="133" height="20" font="0">symptoms: G1: 0, G2: 1 </text>
<text top="757" left="921" width="3" height="20" font="0"> </text>
</page>
<page number="23" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">23 </text>
<text top="107" left="211" width="100" height="20" font="0">Russia and South </text>
<text top="124" left="211" width="35" height="20" font="0">Africa </text>
<text top="107" left="339" width="166" height="20" font="0">within the past 6 mo; unstable </text>
<text top="124" left="339" width="92" height="20" font="0">angina or stroke </text>
<text top="141" left="339" width="116" height="20" font="0">within the past 3 mo; </text>
<text top="159" left="339" width="129" height="20" font="0">percutaneous coronary </text>
<text top="176" left="339" width="154" height="20" font="0">intervention (PCI), coronary-</text>
<text top="193" left="339" width="122" height="20" font="0">artery bypass grafting </text>
<text top="210" left="339" width="168" height="20" font="0">(CABG), or the implantation of </text>
<text top="228" left="339" width="160" height="20" font="0">a cardioverter–defibrillator or </text>
<text top="245" left="339" width="169" height="20" font="0">biventricular pacemaker within </text>
<text top="262" left="339" width="150" height="20" font="0">the past 3 mo or a planned </text>
<text top="279" left="339" width="83" height="20" font="0">implantation of </text>
<text top="296" left="339" width="146" height="20" font="0">such a device; previous or </text>
<text top="314" left="339" width="166" height="20" font="0">planned heart transplantation; </text>
<text top="331" left="339" width="111" height="20" font="0">clinically significant, </text>
<text top="348" left="339" width="113" height="20" font="0">uncorrected primary </text>
<text top="365" left="339" width="148" height="20" font="0">valvular heart disease or a </text>
<text top="383" left="339" width="139" height="20" font="0">malfunctioning prosthetic </text>
<text top="400" left="339" width="107" height="20" font="0">valve; hypertrophic </text>
<text top="417" left="339" width="94" height="20" font="0">cardiomyopathy; </text>
<text top="434" left="339" width="141" height="20" font="0">acute endomyocarditis or </text>
<text top="451" left="339" width="129" height="20" font="0">myocarditis, pericardial </text>
<text top="469" left="339" width="161" height="20" font="0">disease, or systemic disease </text>
<text top="486" left="339" width="107" height="20" font="0">(e.g., amyloidosis); </text>
<text top="503" left="339" width="166" height="20" font="0">acute or chronic liver disease; </text>
<text top="520" left="339" width="92" height="20" font="0">levels of alanine </text>
<text top="537" left="339" width="113" height="20" font="0">aminotransferase or </text>
<text top="555" left="339" width="134" height="20" font="0">thyrotropin of more than </text>
<text top="572" left="339" width="158" height="20" font="0">2 times the upper limit of the </text>
<text top="589" left="339" width="127" height="20" font="0">normal range; a serum </text>
<text top="606" left="339" width="158" height="20" font="0">creatinine level of more than </text>
<text top="623" left="339" width="166" height="20" font="0">2.5 mg per deciliter (221 μmol </text>
<text top="641" left="339" width="137" height="20" font="0">per liter); chronic muscle </text>
<text top="658" left="339" width="147" height="20" font="0">disease or an unexplained </text>
<text top="675" left="339" width="128" height="20" font="0">creatine kinase level of </text>
<text top="692" left="339" width="168" height="20" font="0">more than 2.5 times the upper </text>
<text top="710" left="339" width="139" height="20" font="0">limit of the normal range; </text>
<text top="727" left="339" width="130" height="20" font="0">previous treatment with </text>
<text top="744" left="339" width="130" height="20" font="0">cyclosporine; any other </text>
<text top="761" left="339" width="112" height="20" font="0">condition that would </text>
<text top="778" left="339" width="112" height="20" font="0">substantially reduce </text>
<text top="107" left="521" width="138" height="20" font="0">implantable cardioverter–</text>
<text top="124" left="521" width="139" height="20" font="0">defibrillator, resuscitation </text>
<text top="141" left="521" width="124" height="20" font="0">after cardiac arrest, or </text>
<text top="159" left="521" width="149" height="20" font="0">hospitalization for unstable </text>
<text top="176" left="521" width="110" height="20" font="0">angina); death from </text>
<text top="193" left="521" width="154" height="20" font="0">cardiovascular causes (with </text>
<text top="210" left="521" width="135" height="20" font="0">an additional analysis of </text>
<text top="228" left="521" width="154" height="20" font="0">cause-specific death from a </text>
<text top="245" left="521" width="150" height="20" font="0">cardiovascular cause); and </text>
<text top="262" left="521" width="79" height="20" font="0">the number of </text>
<text top="279" left="521" width="105" height="20" font="0">hospitalizations for </text>
<text top="296" left="521" width="128" height="20" font="0">cardiovascular causes, </text>
<text top="314" left="521" width="108" height="20" font="0">unstable angina, or </text>
<text top="331" left="521" width="131" height="20" font="0">worsening heart failure. </text>
<text top="348" left="521" width="3" height="20" font="7"><b> </b></text>
<text top="107" left="698" width="188" height="20" font="0">G2: 759 (12.2 per 100 patient-y of </text>
<text top="124" left="698" width="57" height="20" font="0">follow-up) </text>
<text top="141" left="698" width="161" height="20" font="0">HR: 0.95; 95% CI: 0.86- 1.05 </text>
<text top="159" left="698" width="41" height="20" font="0">p=0.31 </text>
<text top="176" left="698" width="3" height="20" font="0"> </text>
<text top="193" left="698" width="113" height="20" font="0">Any coronary event: </text>
<text top="210" left="698" width="181" height="20" font="0">G1: 554 (9.3 per 100 patient-y of </text>
<text top="228" left="698" width="57" height="20" font="0">follow-up) </text>
<text top="245" left="698" width="178" height="20" font="0">G2: 588 (10 per 100 patient-y of </text>
<text top="262" left="698" width="57" height="20" font="0">follow-up) </text>
<text top="279" left="698" width="158" height="20" font="0">HR: 0.92; 95% CI: 0.82-1.04 </text>
<text top="296" left="698" width="41" height="20" font="0">p=0.18 </text>
<text top="314" left="698" width="198" height="20" font="7"><b>Other outcomes</b> (per 100 patient-y </text>
<text top="331" left="698" width="74" height="20" font="0">of follow-up): </text>
<text top="348" left="698" width="3" height="20" font="0"> </text>
<text top="365" left="698" width="195" height="20" font="0">Death from Cardiovascular causes: </text>
<text top="382" left="698" width="44" height="20" font="0">G1: 9.3 </text>
<text top="400" left="698" width="44" height="20" font="0">G2: 9.6 </text>
<text top="417" left="698" width="158" height="20" font="0">HR: 0.97; 95% CI: 0.87-1.09 </text>
<text top="434" left="698" width="3" height="20" font="0"> </text>
<text top="451" left="698" width="203" height="20" font="0">Death from noncadiovascular cause: </text>
<text top="469" left="698" width="44" height="20" font="0">G1: 2.2 </text>
<text top="486" left="698" width="44" height="20" font="0">G2: 2.6 </text>
<text top="503" left="698" width="3" height="20" font="0"> </text>
<text top="520" left="698" width="70" height="20" font="0">Nonfatal MI: </text>
<text top="537" left="698" width="81" height="20" font="0">GI 1.9, G2 2.4 </text>
<text top="555" left="698" width="3" height="20" font="0"> </text>
<text top="572" left="698" width="92" height="20" font="0">Nonfatal Stroke: </text>
<text top="589" left="698" width="87" height="20" font="0"> G1 1.5, G2 1.7 </text>
<text top="606" left="698" width="3" height="20" font="0"> </text>
<text top="623" left="698" width="173" height="20" font="0">Hospitalization (total number of </text>
<text top="641" left="698" width="95" height="20" font="0">hospitalizations): </text>
<text top="658" left="698" width="3" height="20" font="0"> </text>
<text top="675" left="698" width="207" height="20" font="0">-For any cause: G1 3694, G2 4074, p </text>
<text top="692" left="698" width="34" height="20" font="0">0.007 </text>
<text top="710" left="698" width="3" height="20" font="0"> </text>
<text top="727" left="698" width="178" height="20" font="0">-For a cardiovascular cause: G1 </text>
<text top="744" left="698" width="136" height="20" font="0">2193, G2 2564, p&lt;0.001 </text>
<text top="761" left="698" width="3" height="20" font="0"> </text>
</page>
<page number="24" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">24 </text>
<text top="107" left="339" width="124" height="20" font="0">life expectancy or limit </text>
<text top="124" left="339" width="111" height="20" font="0">compliance with the </text>
<text top="141" left="339" width="165" height="20" font="0">protocol; or the receipt of less </text>
<text top="159" left="339" width="128" height="20" font="0">than 80% of dispensed </text>
<text top="176" left="339" width="144" height="20" font="0">placebo tablets during the </text>
<text top="193" left="339" width="76" height="20" font="0">run-in period. </text>
<text top="107" left="698" width="177" height="20" font="0">-For worsening heart failure: G1 </text>
<text top="124" left="698" width="130" height="20" font="0">1109, G2 1299, p=0.01 </text>
<text top="141" left="698" width="3" height="20" font="0"> </text>
<text top="159" left="698" width="204" height="20" font="0">- For unstable angina: G1 74, G2 90, </text>
<text top="176" left="698" width="38" height="20" font="0">p 0.30 </text>
<text top="193" left="698" width="3" height="20" font="0"> </text>
<text top="210" left="698" width="203" height="20" font="0">-For a non-cardiovascular cause: G1 </text>
<text top="228" left="698" width="129" height="20" font="0">1501, G2 1510, p 0.82  </text>
<text top="245" left="698" width="3" height="20" font="7"><b> </b></text>
<text top="264" left="81" width="1038" height="20" font="7"><b>Abbreviations:</b> 1° indicated primary; CI, confidence interval; HR, hazard ratio; N/A, not available; OR, odds ratio; RCT, randomized controlled trial; RR, relative risk; MI, myocardial infarction; </text>
<text top="281" left="81" width="390" height="20" font="0">ULN, upper limits of normal; LDL-C, low-density lipoprotein cholesterol. </text>
<text top="308" left="94" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="325" left="120" width="48" height="20" font="7"><b>Author; </b></text>
<text top="342" left="97" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="308" left="227" width="83" height="20" font="7"><b>Aim of Study; </b></text>
<text top="325" left="231" width="74" height="20" font="7"><b>Study Type; </b></text>
<text top="342" left="225" width="86" height="20" font="7"><b>Study Size (N) </b></text>
<text top="325" left="368" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="299" left="548" width="111" height="20" font="7"><b>Study Intervention </b></text>
<text top="316" left="565" width="76" height="20" font="7"><b>(# patients) / </b></text>
<text top="334" left="548" width="111" height="20" font="7"><b>Study Comparator </b></text>
<text top="351" left="569" width="69" height="20" font="7"><b>(# patients) </b></text>
<text top="308" left="751" width="105" height="20" font="7"><b>Endpoint Results </b></text>
<text top="325" left="735" width="137" height="20" font="7"><b>(Absolute Event Rates, </b></text>
<text top="342" left="713" width="181" height="20" font="7"><b>P values; OR or RR; &amp; 95% CI) </b></text>
<text top="308" left="932" width="175" height="20" font="7"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="325" left="964" width="111" height="20" font="7"><b>Study Limitations; </b></text>
<text top="343" left="971" width="96" height="20" font="7"><b>Adverse Events </b></text>
<text top="369" left="89" width="59" height="20" font="7"><b>GISSI HF  </b></text>
<text top="386" left="89" width="93" height="20" font="0">Tavazzi L, et al., </text>
<text top="403" left="89" width="56" height="20" font="0">2008 <a href="data supplement.html#237">(20)</a> </text>
<text top="420" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18757089">18757089</a></text>
<text top="420" left="144" width="3" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18757089"><b> </b></a></text>
<text top="369" left="211" width="111" height="20" font="7"><b>Aim:</b> To investigate </text>
<text top="386" left="211" width="81" height="20" font="0">the safety and </text>
<text top="403" left="211" width="59" height="20" font="0">efficacy of </text>
<text top="420" left="211" width="83" height="20" font="0">rosuvastatin in </text>
<text top="438" left="211" width="103" height="20" font="0">patients with heart </text>
<text top="455" left="211" width="37" height="20" font="0">failure </text>
<text top="472" left="211" width="3" height="20" font="0"> </text>
<text top="489" left="211" width="99" height="20" font="7"><b>Study type:</b> RCT </text>
<text top="506" left="211" width="3" height="20" font="0"> </text>
<text top="524" left="211" width="63" height="20" font="7"><b>Size:</b> 4631 </text>
<text top="541" left="211" width="68" height="20" font="0">randomized </text>
<text top="558" left="211" width="3" height="20" font="0"> </text>
<text top="575" left="211" width="3" height="20" font="0"> </text>
<text top="592" left="211" width="107" height="20" font="7"><b>Median follow-up</b>: </text>
<text top="610" left="211" width="30" height="20" font="0">3.9 y </text>
<text top="627" left="211" width="3" height="20" font="0"> </text>
<text top="644" left="211" width="111" height="20" font="0">-326 cardiology and </text>
<text top="661" left="211" width="113" height="20" font="0">31 internal medicine </text>
<text top="678" left="211" width="83" height="20" font="0">centers in Italy<b> </b></text>
<text top="369" left="339" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="386" left="339" width="120" height="20" font="0">Men and women with </text>
<text top="403" left="339" width="141" height="20" font="0">symptomatic heart failure </text>
<text top="420" left="339" width="138" height="20" font="0">(NYHA Class II-IV). Both </text>
<text top="438" left="339" width="151" height="20" font="0">ischemic and non-ischemic </text>
<text top="455" left="339" width="141" height="20" font="0">etiologies of HF included. </text>
<text top="472" left="339" width="159" height="20" font="0">Those with LV EF &gt;40% had </text>
<text top="489" left="339" width="132" height="20" font="0">to have at least hospital </text>
<text top="506" left="339" width="139" height="20" font="0">admission for CHF in the </text>
<text top="524" left="339" width="88" height="20" font="0">preceding year. </text>
<text top="541" left="339" width="3" height="20" font="0"> </text>
<text top="558" left="339" width="110" height="20" font="7"><b>Exclusion criteria: </b></text>
<text top="575" left="339" width="142" height="20" font="0">Known hypersensitivity to </text>
<text top="592" left="339" width="159" height="20" font="0">study treatment; presence of </text>
<text top="610" left="339" width="153" height="20" font="0">any noncardiac comorbidity </text>
<text top="627" left="339" width="125" height="20" font="0">(e.g., cancer) that was </text>
<text top="644" left="339" width="163" height="20" font="0">unlikely to be compatible with </text>
<text top="661" left="339" width="154" height="20" font="0">a sufficiently long follow-up; </text>
<text top="678" left="339" width="104" height="20" font="0">treatment with any </text>
<text top="696" left="339" width="161" height="20" font="0">investigational agent within 1 </text>
<text top="713" left="339" width="160" height="20" font="0">month before randomization; </text>
<text top="730" left="339" width="167" height="20" font="0">acute coronary syndrome or a </text>
<text top="747" left="339" width="154" height="20" font="0">revascularization procedure </text>
<text top="764" left="339" width="121" height="20" font="0">within 1 month before </text>
<text top="369" left="521" width="101" height="20" font="7"><b>Intervention:</b> G1: </text>
<text top="386" left="521" width="134" height="20" font="0">Rosuvastatin 10 mg QD </text>
<text top="403" left="521" width="53" height="20" font="0">(n=2285) </text>
<text top="420" left="521" width="3" height="20" font="0"> </text>
<text top="438" left="521" width="150" height="20" font="0"> <b>Comparator:</b> G2: placebo </text>
<text top="455" left="521" width="56" height="20" font="0">(n= 2289) </text>
<text top="472" left="521" width="3" height="20" font="0"> </text>
<text top="489" left="521" width="67" height="20" font="7"><b>Endpoints</b>: </text>
<text top="506" left="521" width="3" height="20" font="0"> </text>
<text top="524" left="521" width="154" height="20" font="7"><b>Co-primary</b>: Time to death, </text>
<text top="541" left="521" width="113" height="20" font="0">and time to death or </text>
<text top="558" left="521" width="136" height="20" font="0">admission to hospital for </text>
<text top="575" left="521" width="137" height="20" font="0">cardiovascular reasons.  </text>
<text top="592" left="521" width="3" height="20" font="0"> </text>
<text top="610" left="521" width="155" height="20" font="7"><b>Secondary</b>: Cardiovascular </text>
<text top="627" left="521" width="136" height="20" font="0">mortality, cardiovascular </text>
<text top="644" left="521" width="164" height="20" font="0">mortality or admission for any </text>
<text top="661" left="521" width="131" height="20" font="0">reason, sudden cardiac </text>
<text top="678" left="521" width="137" height="20" font="0">death, admission for any </text>
<text top="696" left="521" width="121" height="20" font="0">reason, admission for </text>
<text top="713" left="521" width="133" height="20" font="0">cardiovascular reasons, </text>
<text top="730" left="521" width="148" height="20" font="0">admission for heart failure, </text>
<text top="747" left="521" width="143" height="20" font="0">myocardial infarction, and </text>
<text top="765" left="521" width="37" height="20" font="0">stroke </text>
<text top="782" left="521" width="3" height="20" font="7"><b> </b></text>
<text top="369" left="698" width="179" height="20" font="0">G1: LDL-C 3.16 mmol/L* to 2.31 </text>
<text top="386" left="698" width="92" height="20" font="0">mmol/L after 3 y </text>
<text top="403" left="698" width="174" height="20" font="0">G2: LDL-C 3.13 mmol/L to 3.06 </text>
<text top="420" left="698" width="95" height="20" font="0">mmol/L after 3 y. </text>
<text top="438" left="698" width="3" height="20" font="7"><b> </b></text>
<text top="456" left="698" width="79" height="20" font="7"><b>1</b>°<b> endpoint:</b>  </text>
<text top="473" left="698" width="3" height="20" font="0"> </text>
<text top="490" left="698" width="127" height="20" font="0">Death from any cause: </text>
<text top="508" left="698" width="170" height="20" font="0">G1: 657 (29%), G2: 644 (28%) </text>
<text top="525" left="698" width="158" height="20" font="0">HR: 1.03; 95% CI: 0.91-1.14 </text>
<text top="542" left="698" width="3" height="20" font="0"> </text>
<text top="559" left="698" width="197" height="20" font="0">Death from any cause or admission </text>
<text top="576" left="698" width="160" height="20" font="0">to hospital for cardiovascular </text>
<text top="594" left="698" width="51" height="20" font="0">reasons: </text>
<text top="611" left="698" width="181" height="20" font="0">G1: 1305 (57%), G2:1283 (56%) </text>
<text top="628" left="698" width="158" height="20" font="0">HR: 1.02; 95% CI: 0.92-1.13 </text>
<text top="645" left="698" width="3" height="20" font="7"><b> </b></text>
<text top="662" left="698" width="184" height="20" font="0">No heterogeneity of effect across </text>
<text top="680" left="698" width="111" height="20" font="0">various subgroups<b>.  </b></text>
<text top="697" left="698" width="3" height="20" font="7"><b> </b></text>
<text top="714" left="698" width="130" height="20" font="7"><b>Secondary Outcomes</b> </text>
<text top="731" left="698" width="3" height="20" font="0"> </text>
<text top="748" left="698" width="143" height="20" font="0">-Cardiovascular mortality: </text>
<text top="766" left="698" width="187" height="20" font="0">G1: 478 (20.9%), G2:488 (21.3%) </text>
<text top="783" left="698" width="158" height="20" font="0">HR: 0.98; 95% CI: 0.87-1.12 </text>
<text top="370" left="921" width="7" height="18" font="0">•</text>
<text top="370" left="928" width="178" height="20" font="0"> Mean age 68 y, 44% older than </text>
<text top="387" left="921" width="186" height="20" font="0">70 y. 23.8% women in G1, 21.4% </text>
<text top="404" left="921" width="76" height="20" font="0">women in G2 </text>
<text top="423" left="921" width="7" height="18" font="0">•</text>
<text top="423" left="928" width="179" height="20" font="0"> Etiology of HF: Ischemic (40%), </text>
<text top="440" left="921" width="123" height="20" font="0">primary dilated (35%), </text>
<text top="457" left="921" width="113" height="20" font="0">hypertensive (18%)  </text>
<text top="476" left="921" width="7" height="18" font="0">•</text>
<text top="475" left="928" width="180" height="20" font="0"> Mean EF: 33.4% G1, 33.1% G2 </text>
<text top="494" left="921" width="7" height="18" font="0">•</text>
<text top="494" left="928" width="188" height="20" font="0"> 10.3% in G1 and 9.8% in G2 with </text>
<text top="511" left="921" width="73" height="20" font="0">LV EF &gt;40% </text>
<text top="530" left="921" width="7" height="18" font="0">•</text>
<text top="529" left="928" width="189" height="20" font="0"> Per protocol analysis: Death from </text>
<text top="547" left="921" width="194" height="20" font="0">any cause: G1 29%, G2: 27% (HR: </text>
<text top="564" left="921" width="144" height="20" font="0">1.12; 95%: CI: 0.97-1.29). </text>
<text top="581" left="921" width="3" height="20" font="0"> </text>
<text top="600" left="921" width="7" height="18" font="0">•</text>
<text top="599" left="928" width="92" height="20" font="0"> Adverse events </text>
<text top="617" left="921" width="167" height="20" font="0">-Permanent discontinuation of </text>
<text top="634" left="921" width="189" height="20" font="0">study treatment: G1: 790 (34.6%), </text>
<text top="651" left="921" width="138" height="20" font="0">G2: 831 (36.3%), p=0.22 </text>
<text top="668" left="921" width="191" height="20" font="0">-Permanent discontinuation due to </text>
<text top="685" left="921" width="173" height="20" font="0">adverse drug reaction: G1: 104 </text>
<text top="703" left="921" width="168" height="20" font="0">(4.6%), G2: 91 (4.0%), p=0.36 </text>
<text top="720" left="921" width="191" height="20" font="0">-Permanent discontinuation due to </text>
<text top="737" left="921" width="191" height="20" font="0">muscle-related symptoms: G1: 23, </text>
<text top="754" left="921" width="47" height="20" font="0">G2: 21.  </text>
<text top="772" left="921" width="150" height="20" font="0">-CK &gt;5x ULN: G1: 9, G2: 2 </text>
<text top="789" left="921" width="157" height="20" font="0">-CK &gt;10x ULN: G1: 1, G2: 1 </text>
</page>
<page number="25" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">25 </text>
<text top="107" left="339" width="131" height="20" font="0">randomization; planned </text>
<text top="124" left="339" width="158" height="20" font="0">cardiac surgery, expected to </text>
<text top="141" left="339" width="141" height="20" font="0">be done within 3 mo after </text>
<text top="159" left="339" width="168" height="20" font="0">randomization; significant liver </text>
<text top="176" left="339" width="143" height="20" font="0">disease; serum creatinine </text>
<text top="193" left="339" width="120" height="20" font="0">concentration greater </text>
<text top="210" left="339" width="162" height="20" font="0">than 221 μmol/L; alanine and </text>
<text top="227" left="339" width="132" height="20" font="0">aspartate transaminase </text>
<text top="245" left="339" width="163" height="20" font="0">concentrations more than 1.5 </text>
<text top="262" left="339" width="158" height="20" font="0">times the upper normal limit; </text>
<text top="279" left="339" width="133" height="20" font="0">creatine phosphokinase </text>
<text top="296" left="339" width="141" height="20" font="0">concentrations above the </text>
<text top="314" left="339" width="129" height="20" font="0">upper normal limit; and </text>
<text top="331" left="339" width="159" height="20" font="0">pregnant or lactating women </text>
<text top="348" left="339" width="141" height="20" font="0">or women of childbearing </text>
<text top="365" left="339" width="126" height="20" font="0">potential who were not </text>
<text top="383" left="339" width="161" height="20" font="0">adequately protected against </text>
<text top="400" left="339" width="112" height="20" font="0">becoming pregnant.<b> </b></text>
<text top="107" left="698" width="3" height="20" font="0"> </text>
<text top="124" left="698" width="154" height="20" font="0">-Cardiovascular mortality or </text>
<text top="141" left="698" width="144" height="20" font="0">admission for any reason: </text>
<text top="159" left="698" width="191" height="20" font="0">G1: 1417 (62%), G2:1385 (60.5%) </text>
<text top="176" left="698" width="158" height="20" font="0">HR: 1.03; 95% CI: 0.96-1.11 </text>
<text top="193" left="698" width="3" height="20" font="0"> </text>
<text top="210" left="698" width="133" height="20" font="0">-Sudden Cardiac death: </text>
<text top="228" left="698" width="174" height="20" font="0">G1: 220 (9.6%), G2:196 (8.6%) </text>
<text top="245" left="698" width="158" height="20" font="0">HR: 1.13; 95% CI: 0.93-1.37 </text>
<text top="262" left="698" width="3" height="20" font="0"> </text>
<text top="279" left="698" width="106" height="20" font="0">-Patients admitted: </text>
<text top="296" left="698" width="201" height="20" font="0">G1: 1278 (55.9%), G2:1286 (56.1%) </text>
<text top="314" left="698" width="158" height="20" font="0">HR: 1.00; 95% CI: 0.93-1.08 </text>
<text top="331" left="698" width="3" height="20" font="0"> </text>
<text top="348" left="698" width="209" height="20" font="0">-Admission for cardiovascular reason: </text>
<text top="365" left="698" width="201" height="20" font="0">G1: 1033 (45.2%), G2:1060 (46.3%) </text>
<text top="383" left="698" width="158" height="20" font="0">HR: 0.98; 95% CI: 0.90-1.07 </text>
<text top="400" left="698" width="3" height="20" font="0"> </text>
<text top="417" left="698" width="112" height="20" font="0">- Admission for HF:  </text>
<text top="434" left="698" width="187" height="20" font="0">G1: 629 (27.5%), G2:634 (27.7%) </text>
<text top="451" left="698" width="158" height="20" font="0">HR: 1.00; 95% CI: 0.90-1.12 </text>
<text top="469" left="698" width="3" height="20" font="0"> </text>
<text top="486" left="698" width="131" height="20" font="0">-Fatal and non-fatal MI: </text>
<text top="503" left="698" width="160" height="20" font="0">G1: 61 (2.7%), G2:70 (3.1%) </text>
<text top="520" left="698" width="158" height="20" font="0">HR: 0.88; 95% CI: 0.63-1.24 </text>
<text top="537" left="698" width="3" height="20" font="0"> </text>
<text top="555" left="698" width="150" height="20" font="0">-Fatal and non-fatal stroke: </text>
<text top="572" left="698" width="160" height="20" font="0">G1: 82 (3.6%), G2:66 (2.9%) </text>
<text top="589" left="698" width="158" height="20" font="0">HR: 1.25; 95% CI: 0.91-1.73 </text>
<text top="606" left="698" width="3" height="20" font="0"> </text>
<text top="107" left="921" width="3" height="20" font="0"> </text>
<text top="124" left="921" width="3" height="20" font="0"> </text>
<text top="625" left="81" width="1005" height="20" font="7"><b>Abbreviations:</b> 1° indicated primary; CI, confidence interval; HR, hazard ratio; N/A, not available; OR, odds ratio; RCT, randomized controlled trial; RR, relative risk; LDL-C, low-density </text>
<text top="643" left="81" width="1015" height="20" font="0">lipoprotein cholesterol; ULN, upper limit of normal.                                                                                                                                                                                                                         </text>
<text top="660" left="81" width="212" height="20" font="0">*1 mmol/L LDL-C=38.67 mg/dL LDL-C </text>
<text top="686" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="714" left="81" width="4" height="22" font="5"><b> </b></text>
</page>
<page number="26" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">26 </text>
<text top="106" left="81" width="563" height="24" font="4"><b>Data Supplement 7. Meta-analysis of CORONA and GISSI HF trials (Section 4.1)  </b></text>
<text top="136" left="94" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="154" left="120" width="48" height="20" font="7"><b>Author; </b></text>
<text top="171" left="97" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="136" left="227" width="83" height="20" font="7"><b>Aim of Study; </b></text>
<text top="154" left="231" width="74" height="20" font="7"><b>Study Type; </b></text>
<text top="171" left="225" width="86" height="20" font="7"><b>Study Size (N) </b></text>
<text top="154" left="368" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="128" left="548" width="111" height="20" font="7"><b>Study Intervention </b></text>
<text top="145" left="565" width="76" height="20" font="7"><b>(# patients) / </b></text>
<text top="162" left="548" width="111" height="20" font="7"><b>Study Comparator </b></text>
<text top="179" left="569" width="69" height="20" font="7"><b>(# patients) </b></text>
<text top="136" left="751" width="105" height="20" font="7"><b>Endpoint Results </b></text>
<text top="154" left="735" width="137" height="20" font="7"><b>(Absolute Event Rates, </b></text>
<text top="171" left="713" width="181" height="20" font="7"><b>P values; OR or RR; &amp; 95% CI) </b></text>
<text top="137" left="932" width="175" height="20" font="7"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="154" left="964" width="111" height="20" font="7"><b>Study Limitations; </b></text>
<text top="171" left="971" width="96" height="20" font="7"><b>Adverse Events </b></text>
<text top="197" left="89" width="44" height="20" font="7"><b>Pooled </b></text>
<text top="215" left="89" width="92" height="20" font="7"><b>individual-level </b></text>
<text top="232" left="89" width="79" height="20" font="7"><b>reanalysis of </b></text>
<text top="249" left="89" width="83" height="20" font="7"><b>CORONA and </b></text>
<text top="266" left="89" width="57" height="20" font="7"><b>GISSI-HF </b></text>
<text top="283" left="89" width="90" height="20" font="0">Feinstein MJ, et </text>
<text top="301" left="89" width="76" height="20" font="0">al., 2015 <a href="data supplement.html#237">(21)</a> </text>
<text top="318" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25684642">25684642</a></text>
<text top="318" left="144" width="3" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25684642"><b> </b></a></text>
<text top="197" left="211" width="106" height="20" font="7"><b>Aim:</b> Using pooled </text>
<text top="215" left="211" width="113" height="20" font="0">data from CORONA </text>
<text top="232" left="211" width="113" height="20" font="0">and GISSI HF trials, </text>
<text top="249" left="211" width="102" height="20" font="0">to assess whether </text>
<text top="266" left="211" width="66" height="20" font="0">HF patients </text>
<text top="283" left="211" width="81" height="20" font="0">randomized to </text>
<text top="301" left="211" width="107" height="20" font="0">rosuvastatin 10 mg </text>
<text top="318" left="211" width="94" height="20" font="0">daily vs. placebo </text>
<text top="335" left="211" width="87" height="20" font="0">had statistically </text>
<text top="352" left="211" width="58" height="20" font="0">significant </text>
<text top="369" left="211" width="76" height="20" font="0">differences in </text>
<text top="387" left="211" width="96" height="20" font="0">atherothrombotic </text>
<text top="404" left="211" width="68" height="20" font="0">events after </text>
<text top="421" left="211" width="81" height="20" font="0">accounting for </text>
<text top="438" left="211" width="102" height="20" font="0">competing causes </text>
<text top="456" left="211" width="55" height="20" font="0">of death.  </text>
<text top="473" left="211" width="3" height="20" font="0"> </text>
<text top="490" left="211" width="70" height="20" font="7"><b>Study type: </b></text>
<text top="507" left="211" width="78" height="20" font="0">Individual trial </text>
<text top="524" left="211" width="89" height="20" font="0">participant-level </text>
<text top="542" left="211" width="69" height="20" font="0">reanalysis.<b> </b>  </text>
<text top="559" left="211" width="3" height="20" font="0"> </text>
<text top="576" left="211" width="111" height="20" font="7"><b>Size:</b> CORONA (n= </text>
<text top="593" left="211" width="109" height="20" font="0">5011), GISSI HF (n </text>
<text top="610" left="211" width="46" height="20" font="0">= 4574) </text>
<text top="628" left="211" width="3" height="20" font="0"> </text>
<text top="645" left="211" width="107" height="20" font="7"><b>Median follow-up</b>: </text>
<text top="662" left="211" width="61" height="20" font="0">32.8 mo in </text>
<text top="679" left="211" width="109" height="20" font="0">CORONA, 46.9 mo </text>
<text top="696" left="211" width="69" height="20" font="0">in GISSI HF<b> </b></text>
<text top="197" left="339" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="215" left="339" width="167" height="20" font="0">Inclusion criteria for CORONA </text>
<text top="232" left="339" width="126" height="20" font="0">and GISSI HF trials as </text>
<text top="249" left="339" width="98" height="20" font="0">discussed above. </text>
<text top="266" left="339" width="3" height="20" font="0"> </text>
<text top="283" left="339" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="301" left="339" width="114" height="20" font="0">Exclusion criteria for </text>
<text top="318" left="339" width="167" height="20" font="0">CORONA and GISSI HF trials </text>
<text top="335" left="339" width="115" height="20" font="0">as discussed above. </text>
<text top="352" left="339" width="3" height="20" font="7"><b> </b></text>
<text top="197" left="521" width="81" height="20" font="7"><b>Intervention:</b>  </text>
<text top="215" left="521" width="157" height="20" font="0">G1: Rosuvastatin 10 mg QD </text>
<text top="232" left="521" width="60" height="20" font="0">(n = 4799) </text>
<text top="249" left="521" width="7" height="20" font="0">  </text>
<text top="266" left="521" width="84" height="20" font="7"><b>Comparator:</b> <b>  </b></text>
<text top="283" left="521" width="133" height="20" font="7"><b> </b>G2: placebo (n = 4786) </text>
<text top="301" left="521" width="3" height="20" font="0"> </text>
<text top="318" left="521" width="70" height="20" font="7"><b>End points</b>: </text>
<text top="335" left="521" width="3" height="20" font="0"> </text>
<text top="352" left="521" width="158" height="20" font="0">A competing Cox regression </text>
<text top="369" left="521" width="152" height="20" font="0">model was used to analyze </text>
<text top="387" left="521" width="46" height="20" font="0">the joint </text>
<text top="404" left="521" width="146" height="20" font="0">and simultaneous risks for </text>
<text top="421" left="521" width="132" height="20" font="0">the following outcomes: </text>
<text top="438" left="521" width="3" height="20" font="0"> </text>
<text top="456" left="521" width="131" height="20" font="0">-MI (fatal and non-fatal) </text>
<text top="473" left="521" width="153" height="20" font="0">-Stroke (fatal and non-fatal) </text>
<text top="490" left="521" width="155" height="20" font="0">-Other cardiovascular death </text>
<text top="507" left="521" width="93" height="20" font="0">-Death from non-</text>
<text top="524" left="521" width="125" height="20" font="0">cardiovascular causes </text>
<text top="542" left="521" width="3" height="20" font="0"> </text>
<text top="559" left="521" width="155" height="20" font="0">Data presented here are for </text>
<text top="576" left="521" width="156" height="20" font="0">(a) CORONA and GISSI-HF </text>
<text top="593" left="521" width="140" height="20" font="0">pooled (b) CORONA and </text>
<text top="610" left="521" width="148" height="20" font="0">GISSI HF pooled for those </text>
<text top="628" left="521" width="159" height="20" font="0">with ischemic etiology of HF.<b> </b></text>
<text top="197" left="698" width="205" height="20" font="7"><b>CORONA and GISSI-HF pooled (all </b></text>
<text top="215" left="698" width="81" height="20" font="7"><b>participants): </b></text>
<text top="232" left="698" width="198" height="20" font="0">MI (fatal and non-fatal): G1 186, G2 </text>
<text top="249" left="698" width="189" height="20" font="0">223, HR: 0.83; 95% CI: 0.68-1.00; </text>
<text top="266" left="698" width="48" height="20" font="0">p=0.055 </text>
<text top="283" left="698" width="3" height="20" font="0"> </text>
<text top="301" left="698" width="200" height="20" font="0">Stroke (fatal and non-fatal): G1 186, </text>
<text top="318" left="698" width="209" height="20" font="0">G2 169, HR: 1.07; 95% CI: 0.87-1.32; </text>
<text top="335" left="698" width="41" height="20" font="0">p=0.50 </text>
<text top="352" left="698" width="3" height="20" font="0"> </text>
<text top="369" left="698" width="202" height="20" font="0">Other cardiovascular death: G1 877, </text>
<text top="387" left="698" width="209" height="20" font="0">G2 890, HR: 0.98; 95% CI: 0.90-1.08; </text>
<text top="404" left="698" width="41" height="20" font="0">p=0.74 </text>
<text top="421" left="698" width="3" height="20" font="0"> </text>
<text top="438" left="698" width="172" height="20" font="0">Death from non-cardiovascular </text>
<text top="456" left="698" width="196" height="20" font="0">causes: G1 305, G2 288, HR: 1.06; </text>
<text top="473" left="698" width="147" height="20" font="0">95% CI: 0.90-1.25; p=0.48 </text>
<text top="490" left="698" width="3" height="20" font="0"> </text>
<text top="507" left="698" width="203" height="20" font="7"><b>CORONA and GISSI HF pooled for </b></text>
<text top="524" left="698" width="186" height="20" font="7"><b>those with ischemic etiology of </b></text>
<text top="542" left="698" width="78" height="20" font="7"><b>heart failure: </b></text>
<text top="559" left="698" width="201" height="20" font="7"><b> </b>MI (fatal and non-fatal): G1 171, G2 </text>
<text top="576" left="698" width="192" height="20" font="0">208, HR: 0.81; 95% CI: 0.66-0.99;  </text>
<text top="593" left="698" width="48" height="20" font="0">p=0.049 </text>
<text top="610" left="698" width="3" height="20" font="0"> </text>
<text top="628" left="698" width="200" height="20" font="0">Stroke (fatal and non-fatal): G1 145, </text>
<text top="645" left="698" width="212" height="20" font="0">G2 140, HR: 1.08; 95% CI: 0.86-1.37;  </text>
<text top="662" left="698" width="38" height="20" font="0">p 0.50 </text>
<text top="679" left="698" width="3" height="20" font="0"> </text>
<text top="696" left="698" width="202" height="20" font="0">Other cardiovascular death: G1 687, </text>
<text top="714" left="698" width="209" height="20" font="0">G2 695, HR: 0.99; 95% CI: 0.89-1.10; </text>
<text top="731" left="698" width="38" height="20" font="0">p 0.88 </text>
<text top="748" left="698" width="3" height="20" font="0"> </text>
<text top="199" left="921" width="7" height="18" font="0">•</text>
<text top="199" left="928" width="159" height="20" font="0"> NNT to prevent one MI = 94 </text>
<text top="218" left="921" width="7" height="18" font="0">•</text>
<text top="217" left="928" width="167" height="20" font="0"> Relatively few MIs in both the </text>
<text top="234" left="921" width="193" height="20" font="0">trials compared to other outcomes. </text>
<text top="253" left="921" width="7" height="18" font="0">•</text>
<text top="252" left="928" width="150" height="20" font="0"> Traditional Cox regression </text>
<text top="270" left="921" width="179" height="20" font="0">analyses (without accounting for </text>
<text top="287" left="921" width="169" height="20" font="0">competing risk) yielded largely </text>
<text top="304" left="921" width="85" height="20" font="0">similar results.  </text>
<text top="321" left="921" width="3" height="20" font="0"> </text>
<text top="339" left="921" width="196" height="20" font="0">CORONA and GISSI HF pooled for </text>
<text top="356" left="921" width="169" height="20" font="0">those with ischemic etiology of </text>
<text top="373" left="921" width="187" height="20" font="0">heart failure (using traditional Cox </text>
<text top="390" left="921" width="68" height="20" font="0">regression): </text>
<text top="407" left="921" width="3" height="20" font="0"> </text>
<text top="425" left="921" width="190" height="20" font="0">-MI (fatal and non-fatal): HR: 0.82; </text>
<text top="442" left="921" width="106" height="20" font="0">95% CI: 0.67-1.00. </text>
<text top="459" left="921" width="3" height="20" font="0"> </text>
<text top="476" left="921" width="181" height="20" font="0">-Stroke (fatal and non-fatal): HR: </text>
<text top="493" left="921" width="137" height="20" font="0">0.87; 95% CI: 0.67-1.14. </text>
<text top="511" left="921" width="3" height="20" font="0"> </text>
<text top="528" left="921" width="183" height="20" font="0">-Other cardiovascular death: HR: </text>
<text top="545" left="921" width="137" height="20" font="0">0.97; 95% CI: 0.88-1.07. </text>
<text top="562" left="921" width="3" height="20" font="0"> </text>
<text top="579" left="921" width="175" height="20" font="0">-Non-cardiovascular death: HR: </text>
<text top="597" left="921" width="137" height="20" font="0">1.02; 95% CI: 0.85-1.22. </text>
</page>
<page number="27" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">27 </text>
<text top="107" left="698" width="172" height="20" font="0">Death from non-cardiovascular </text>
<text top="124" left="698" width="196" height="20" font="0">causes: G1 227, G2 214, HR: 1.07; </text>
<text top="141" left="698" width="147" height="20" font="0">95% CI: 0.89-1.29; p 0.49. </text>
<text top="171" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="199" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="236" left="94" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="253" left="120" width="48" height="20" font="7"><b>Author; </b></text>
<text top="271" left="97" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="236" left="227" width="83" height="20" font="7"><b>Aim of Study; </b></text>
<text top="253" left="231" width="74" height="20" font="7"><b>Study Type; </b></text>
<text top="271" left="225" width="86" height="20" font="7"><b>Study Size (N) </b></text>
<text top="253" left="368" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="227" left="548" width="111" height="20" font="7"><b>Study Intervention </b></text>
<text top="245" left="565" width="76" height="20" font="7"><b>(# patients) / </b></text>
<text top="262" left="548" width="111" height="20" font="7"><b>Study Comparator </b></text>
<text top="279" left="569" width="69" height="20" font="7"><b>(# patients) </b></text>
<text top="236" left="751" width="105" height="20" font="7"><b>Endpoint Results </b></text>
<text top="253" left="735" width="137" height="20" font="7"><b>(Absolute Event Rates, </b></text>
<text top="271" left="713" width="181" height="20" font="7"><b>P values; OR or RR; &amp; 95% CI) </b></text>
<text top="237" left="932" width="175" height="20" font="7"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="254" left="964" width="111" height="20" font="7"><b>Study Limitations; </b></text>
<text top="271" left="971" width="96" height="20" font="7"><b>Adverse Events </b></text>
<text top="297" left="89" width="57" height="20" font="7"><b>SPARCL  </b></text>
<text top="314" left="89" width="108" height="20" font="0">Amarenco P, et al., </text>
<text top="332" left="89" width="56" height="20" font="0">2006 <a href="data supplement.html#237">(22)</a> </text>
<text top="349" left="89" width="58" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16899775">16899775 </a></text>
<text top="349" left="147" width="3" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16899775"><b> </b></a></text>
<text top="297" left="211" width="94" height="20" font="7"><b>Aim:</b>  To assess </text>
<text top="314" left="211" width="114" height="20" font="0">whether atorvastatin </text>
<text top="332" left="211" width="66" height="20" font="0">80 mg daily </text>
<text top="349" left="211" width="76" height="20" font="0">(compared to </text>
<text top="366" left="211" width="98" height="20" font="0">placebo) reduces </text>
<text top="383" left="211" width="89" height="20" font="0">the incidence of </text>
<text top="400" left="211" width="96" height="20" font="0">stroke in patients </text>
<text top="418" left="211" width="110" height="20" font="0">with a recent stroke </text>
<text top="435" left="211" width="65" height="20" font="0">or transient </text>
<text top="452" left="211" width="88" height="20" font="0">ischemic stroke </text>
<text top="469" left="211" width="31" height="20" font="0">(TIA) </text>
<text top="486" left="211" width="3" height="20" font="0"> </text>
<text top="504" left="211" width="99" height="20" font="7"><b>Study type:</b> RCT </text>
<text top="521" left="211" width="3" height="20" font="0"> </text>
<text top="538" left="211" width="109" height="20" font="7"><b>Size:</b> 4731 patients </text>
<text top="555" left="211" width="3" height="20" font="0"> </text>
<text top="573" left="211" width="109" height="20" font="7"><b>Follow-up</b>: Median </text>
<text top="590" left="211" width="41" height="20" font="0">= 4.9 y </text>
<text top="607" left="211" width="3" height="20" font="0"> </text>
<text top="624" left="211" width="94" height="20" font="0">205 participating </text>
<text top="641" left="211" width="47" height="20" font="0">centers. </text>
<text top="659" left="211" width="3" height="20" font="7"><b> </b></text>
<text top="297" left="339" width="157" height="20" font="7"><b>Inclusion criteria:</b> Men and </text>
<text top="314" left="339" width="160" height="20" font="0">women over 18 y of age with </text>
<text top="332" left="339" width="160" height="20" font="0">no known CHD who had had </text>
<text top="349" left="339" width="154" height="20" font="0">an ischemic or hemorrhagic </text>
<text top="366" left="339" width="165" height="20" font="0">stroke or a TIA (diagnosed by </text>
<text top="383" left="339" width="164" height="20" font="0">a neurologist within 30 d after </text>
<text top="400" left="339" width="151" height="20" font="0">the event) 1 to 6 mo before </text>
<text top="418" left="339" width="157" height="20" font="0">randomization. Patients with </text>
<text top="435" left="339" width="139" height="20" font="0">hemorrhagic stroke were </text>
<text top="452" left="339" width="163" height="20" font="0">included if they were deemed </text>
<text top="469" left="339" width="148" height="20" font="0">by the investigator to be at </text>
<text top="486" left="339" width="143" height="20" font="0">risk for ischemic stroke or </text>
<text top="504" left="339" width="132" height="20" font="0">coronary heart disease. </text>
<text top="521" left="339" width="3" height="20" font="0"> </text>
<text top="538" left="339" width="165" height="20" font="7"><b>Exclusion criteria:</b> Presence </text>
<text top="555" left="339" width="134" height="20" font="0">of atrial fibrillation, other </text>
<text top="573" left="339" width="115" height="20" font="0">causes of embolism, </text>
<text top="590" left="339" width="150" height="20" font="0">subarachnoid hemorrhage. </text>
<text top="607" left="339" width="3" height="20" font="0"> </text>
<text top="626" left="339" width="7" height="18" font="0">•</text>
<text top="625" left="346" width="133" height="20" font="0"> Mean Time since index </text>
<text top="642" left="339" width="145" height="20" font="0">event to entry in the trial = </text>
<text top="660" left="339" width="138" height="20" font="0">87.1 d in the atorvastatin </text>
<text top="677" left="339" width="130" height="20" font="0">group and 84.3 d in the </text>
<text top="694" left="339" width="85" height="20" font="0">placebo group. </text>
<text top="711" left="339" width="3" height="20" font="7"><b> </b></text>
<text top="297" left="521" width="98" height="20" font="7"><b>Intervention:</b> GI: </text>
<text top="314" left="521" width="152" height="20" font="0">Atorvastatin 80 mg po daily </text>
<text top="332" left="521" width="60" height="20" font="0">(n= 2365). </text>
<text top="349" left="521" width="7" height="20" font="0">  </text>
<text top="366" left="521" width="148" height="20" font="7"><b>Comparator: </b>G2: Placebo </text>
<text top="383" left="521" width="67" height="20" font="0">(n= 2366). <b>  </b></text>
<text top="400" left="521" width="3" height="20" font="7"><b> </b></text>
<text top="418" left="521" width="72" height="20" font="7"><b>End Points: </b></text>
<text top="435" left="521" width="125" height="20" font="7"><b>-</b>Analyses adjusted for </text>
<text top="452" left="521" width="136" height="20" font="0">geographic region, entry </text>
<text top="469" left="521" width="146" height="20" font="0">event (stroke or TIA), time </text>
<text top="486" left="521" width="150" height="20" font="0">since entry event, sex, and </text>
<text top="504" left="521" width="150" height="20" font="0">baseline age<b>. </b>This was pre-</text>
<text top="521" left="521" width="59" height="20" font="0">specified<b>.  </b></text>
<text top="538" left="521" width="7" height="20" font="7"><b>  </b></text>
<text top="555" left="521" width="53" height="20" font="7"><b>Primary: </b></text>
<text top="573" left="521" width="163" height="20" font="0">Time from randomization to a </text>
<text top="590" left="521" width="152" height="20" font="0">first nonfatal or fatal stroke. </text>
<text top="607" left="521" width="3" height="20" font="0"> </text>
<text top="624" left="521" width="70" height="20" font="7"><b>Secondary</b>: </text>
<text top="641" left="521" width="90" height="20" font="0">1. Stroke or TIA </text>
<text top="659" left="521" width="133" height="20" font="0">2. Major coronary event </text>
<text top="676" left="521" width="155" height="20" font="0">(death from cardiac causes, </text>
<text top="693" left="521" width="110" height="20" font="0">nonfatal myocardial </text>
<text top="710" left="521" width="143" height="20" font="0">infarction, or resuscitation </text>
<text top="727" left="521" width="114" height="20" font="0">after cardiac arrest). </text>
<text top="745" left="521" width="164" height="20" font="0">3. Major cardiovascular event </text>
<text top="762" left="521" width="124" height="20" font="0">(stroke plus any major </text>
<text top="779" left="521" width="92" height="20" font="0">coronary event). </text>
<text top="297" left="698" width="44" height="20" font="7"><b>LDL-C: </b></text>
<text top="314" left="698" width="198" height="20" font="0">G1: 132.7 mg/dL at baseline versus </text>
<text top="332" left="698" width="201" height="20" font="0">mean of 72.9 mg/dL during the trial.  </text>
<text top="349" left="698" width="198" height="20" font="0">G2: 133.7 mg/dL at baseline versus </text>
<text top="366" left="698" width="204" height="20" font="0">mean of 128.5 mg/dL during the trial. </text>
<text top="383" left="698" width="3" height="20" font="7"><b> </b></text>
<text top="402" left="698" width="79" height="20" font="7"><b>1</b>°<b> endpoint:</b>  </text>
<text top="419" left="698" width="187" height="20" font="0">G1: 265 (11.2%), G2 311 (13.1%) </text>
<text top="436" left="698" width="182" height="20" font="0">Adjusted HR: 0.84; 95% CI: 0.71-</text>
<text top="453" left="698" width="34" height="20" font="0">0.99.  </text>
<text top="470" left="698" width="3" height="20" font="0"> </text>
<text top="488" left="698" width="176" height="20" font="7"><b>Secondary and other relevant </b></text>
<text top="505" left="698" width="70" height="20" font="7"><b>endpoints:</b>  </text>
<text top="522" left="698" width="3" height="20" font="7"><b> </b></text>
<text top="539" left="698" width="93" height="20" font="0">1. Stroke or TIA: </text>
<text top="556" left="698" width="187" height="20" font="0">G1: 375 (15.9%), G2 476 (20.1%) </text>
<text top="574" left="698" width="182" height="20" font="0">Adjusted HR: 0.77; 95% CI: 0.67-</text>
<text top="591" left="698" width="31" height="20" font="0">0.88. </text>
<text top="608" left="698" width="136" height="20" font="0">2. Major coronary event: </text>
<text top="625" left="698" width="167" height="20" font="0">G1: 81 (3.4%), G2 120 (5.1%) </text>
<text top="642" left="698" width="182" height="20" font="0">Adjusted HR: 0.65; 95% CI: 0.49-</text>
<text top="660" left="698" width="31" height="20" font="0">0.87. </text>
<text top="677" left="698" width="171" height="20" font="0">3. Major cardiovascular event:  </text>
<text top="694" left="698" width="187" height="20" font="0">G1: 334 (14.1%), G2 407 (17.2%) </text>
<text top="711" left="698" width="182" height="20" font="0">Adjusted HR: 0.80; 95% CI: 0.69-</text>
<text top="729" left="698" width="31" height="20" font="0">0.92. </text>
<text top="746" left="698" width="140" height="20" font="0">4. Acute coronary event:  </text>
<text top="763" left="698" width="174" height="20" font="0">G1: 101 (4.3%), G2 151 (6.4%) </text>
<text top="299" left="921" width="7" height="18" font="0">•</text>
<text top="298" left="928" width="161" height="20" font="0"> More patients in the placebo </text>
<text top="316" left="921" width="163" height="20" font="0">group than in the atorvastatin </text>
<text top="333" left="921" width="178" height="20" font="0">group permanently discontinued </text>
<text top="350" left="921" width="159" height="20" font="0">treatment (20.2% vs. 15.4%) </text>
<text top="369" left="921" width="7" height="18" font="0">•</text>
<text top="368" left="928" width="174" height="20" font="0">After randomization, open-label </text>
<text top="386" left="921" width="176" height="20" font="0">statin therapy use (25.4% in the </text>
<text top="403" left="921" width="159" height="20" font="0">placebo group versus 11.4% </text>
<text top="420" left="921" width="184" height="20" font="0">percent in the atorvastatin group) </text>
<text top="439" left="921" width="7" height="18" font="0">•</text>
<text top="438" left="928" width="172" height="20" font="0">The net difference in statin use </text>
<text top="456" left="921" width="158" height="20" font="0">between groups was 78.1%. </text>
<text top="475" left="921" width="7" height="18" font="0">•</text>
<text top="474" left="928" width="95" height="20" font="0"> All-cause death: </text>
<text top="491" left="921" width="174" height="20" font="0">G1: 216 (9.1%), G2 211 (8.9%) </text>
<text top="508" left="921" width="182" height="20" font="0">Adjusted HR: 1.00; 95% CI: 0.82-</text>
<text top="526" left="921" width="31" height="20" font="0">1.21. </text>
<text top="543" left="921" width="3" height="20" font="0"> </text>
<text top="560" left="921" width="151" height="20" font="0">-Death from cardiovascular </text>
<text top="577" left="921" width="49" height="20" font="0">disease: </text>
<text top="594" left="921" width="160" height="20" font="0">G1: 78 (3.3%), G2 98 (4.1%) </text>
<text top="612" left="921" width="182" height="20" font="0">Adjusted HR: 0.78; 95% CI: 0.58-</text>
<text top="629" left="921" width="31" height="20" font="0">1.06. </text>
<text top="646" left="921" width="115" height="20" font="0">-Death from Cancer: </text>
<text top="663" left="921" width="160" height="20" font="0">G1: 57 (2.4%), G2 53 (2.2%) </text>
<text top="680" left="921" width="182" height="20" font="0">Adjusted HR: 1.05; 95% CI: 0.72-</text>
<text top="698" left="921" width="31" height="20" font="0">1.53. </text>
<text top="715" left="921" width="3" height="20" font="0"> </text>
<text top="734" left="921" width="7" height="18" font="0">•</text>
<text top="733" left="928" width="119" height="20" font="0"> <b>Post-hoc analyses:</b> </text>
<text top="750" left="921" width="3" height="20" font="0"> </text>
<text top="768" left="921" width="153" height="20" font="0">- 492 ischemic strokes: 218 </text>
<text top="785" left="921" width="150" height="20" font="0">atorvastatin, 274 placebos. </text>
</page>
<page number="28" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">28 </text>
<text top="107" left="521" width="133" height="20" font="0">4. Acute coronary event </text>
<text top="124" left="521" width="138" height="20" font="0">(major coronary event or </text>
<text top="141" left="521" width="98" height="20" font="0">unstable angina). </text>
<text top="159" left="521" width="157" height="20" font="0">5.Any coronary event (acute </text>
<text top="176" left="521" width="121" height="20" font="0">coronary event plus a </text>
<text top="193" left="521" width="147" height="20" font="0">coronary revascularization </text>
<text top="210" left="521" width="156" height="20" font="0">procedure, unstable angina, </text>
<text top="228" left="521" width="121" height="20" font="0">or angina or ischemia </text>
<text top="245" left="521" width="116" height="20" font="0">requiring emergency </text>
<text top="262" left="521" width="85" height="20" font="0">hospitalization) </text>
<text top="279" left="521" width="114" height="20" font="0">6. Revascularization </text>
<text top="296" left="521" width="161" height="20" font="0">procedure (coronary, carotid, </text>
<text top="314" left="521" width="80" height="20" font="0">or peripheral). </text>
<text top="331" left="521" width="154" height="20" font="0">7. Any cardiovascular event </text>
<text top="348" left="521" width="127" height="20" font="0">(any of the former plus </text>
<text top="365" left="521" width="107" height="20" font="0">clinically significant </text>
<text top="383" left="521" width="161" height="20" font="0">peripheral vascular disease). </text>
<text top="400" left="521" width="3" height="20" font="7"><b> </b></text>
<text top="107" left="698" width="182" height="20" font="0">Adjusted HR: 0.65; 95% CI: 0.50-</text>
<text top="124" left="698" width="31" height="20" font="0">0.84. </text>
<text top="141" left="698" width="127" height="20" font="0">5. Any coronary event: </text>
<text top="159" left="698" width="174" height="20" font="0">G1: 123 (5.2%), G2 204 (8.6%) </text>
<text top="176" left="698" width="182" height="20" font="0">Adjusted HR: 0.58; 95% CI: 0.46-</text>
<text top="193" left="698" width="31" height="20" font="0">0.73. </text>
<text top="210" left="698" width="201" height="20" font="0">6. Revascularization: G1: 94 (4.0%), </text>
<text top="228" left="698" width="83" height="20" font="0">G2 163 (6.9%) </text>
<text top="245" left="698" width="182" height="20" font="0">Adjusted HR: 0.55; 95% CI: 0.43-</text>
<text top="262" left="698" width="31" height="20" font="0">0.72. </text>
<text top="279" left="698" width="161" height="20" font="0">7. Any cardiovascular event:  </text>
<text top="296" left="698" width="187" height="20" font="0">G1: 530 (22.4%), G2 687 (29.0%) </text>
<text top="314" left="698" width="182" height="20" font="0">Adjusted HR: 0.74; 95% CI: 0.66-</text>
<text top="331" left="698" width="31" height="20" font="0">0.83. </text>
<text top="348" left="698" width="3" height="20" font="7"><b> </b></text>
<text top="365" left="698" width="173" height="20" font="7"><b>Safety endpoint (if relevant):</b>  </text>
<text top="382" left="698" width="3" height="20" font="7"><b> </b></text>
<text top="400" left="698" width="203" height="20" font="0">-Any adverse event: G1 2199 (93%), </text>
<text top="417" left="698" width="97" height="20" font="0">G2 2156 (91.1%) </text>
<text top="434" left="698" width="200" height="20" font="0">-Any serious adverse event: G1 998 </text>
<text top="451" left="698" width="140" height="20" font="0">(41.8%), G2 975 (41.2%) </text>
<text top="469" left="698" width="172" height="20" font="0">-Any adverse event resulting in </text>
<text top="486" left="698" width="191" height="20" font="0">discontinuation of study treatment: </text>
<text top="503" left="698" width="184" height="20" font="0">G1 415 (17.5%), G2 342 (14.5%) </text>
<text top="520" left="698" width="190" height="20" font="0">-Myalgias: G1 129 (5.5%), G2 141 </text>
<text top="537" left="698" width="40" height="20" font="0">(6.0%) </text>
<text top="555" left="698" width="194" height="20" font="0">-Rhabdomyolysis: G1 2 (0.1%), G2 </text>
<text top="572" left="698" width="46" height="20" font="0">3(0.1%) </text>
<text top="589" left="698" width="151" height="20" font="0">-AST or ALT &gt;3 x ULN at 2 </text>
<text top="606" left="698" width="194" height="20" font="0">consecutive measurements: G1 51 </text>
<text top="623" left="698" width="116" height="20" font="0">(2.2%), G2 11(0.5%) </text>
<text top="641" left="698" width="179" height="20" font="0">-CK &gt;10 x ULN at 2 consecutive </text>
<text top="658" left="698" width="195" height="20" font="0">measurements: G1 2 (0.1%), G2 0  </text>
<text top="107" left="921" width="161" height="20" font="0">HR: 0.78; 95% CI: 0.66-0.94. </text>
<text top="124" left="921" width="3" height="20" font="0"> </text>
<text top="141" left="921" width="160" height="20" font="0">- 88 hemorrhagic strokes: 55 </text>
<text top="159" left="921" width="138" height="20" font="0">atorvastatin, 33 placebo. </text>
<text top="176" left="921" width="161" height="20" font="0">HR: 1.66; 95% CI: 1.08-2.55. </text>
<text top="193" left="921" width="3" height="20" font="0"> </text>
<text top="210" left="921" width="145" height="20" font="0">-19 unclassified strokes: 7 </text>
<text top="228" left="921" width="138" height="20" font="0">atorvastatin, 12 placebo. </text>
<text top="245" left="921" width="161" height="20" font="0">HR: 0.55; 95% CI: 0.21-1.40. </text>
<text top="262" left="921" width="3" height="20" font="0"> </text>
<text top="279" left="921" width="172" height="20" font="0">-Incidence of fatal hemorrhagic </text>
<text top="296" left="921" width="162" height="20" font="0">stroke did not differ: 17 in the </text>
<text top="314" left="921" width="156" height="20" font="0">atorvastatin group, 18 in the </text>
<text top="331" left="921" width="85" height="20" font="0">placebo group. </text>
<text top="348" left="921" width="3" height="20" font="0"> </text>
<text top="365" left="921" width="3" height="20" font="0"> </text>
<text top="676" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="704" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="731" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="759" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="787" left="81" width="4" height="22" font="5"><b> </b></text>
</page>
<page number="29" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">29 </text>
<text top="106" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="134" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="172" left="94" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="189" left="120" width="48" height="20" font="7"><b>Author; </b></text>
<text top="206" left="97" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="172" left="227" width="83" height="20" font="7"><b>Aim of Study; </b></text>
<text top="189" left="231" width="74" height="20" font="7"><b>Study Type; </b></text>
<text top="206" left="225" width="86" height="20" font="7"><b>Study Size (N) </b></text>
<text top="189" left="368" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="163" left="548" width="111" height="20" font="7"><b>Study Intervention </b></text>
<text top="180" left="565" width="76" height="20" font="7"><b>(# patients) / </b></text>
<text top="197" left="548" width="111" height="20" font="7"><b>Study Comparator </b></text>
<text top="215" left="569" width="69" height="20" font="7"><b>(# patients) </b></text>
<text top="172" left="751" width="105" height="20" font="7"><b>Endpoint Results </b></text>
<text top="189" left="735" width="137" height="20" font="7"><b>(Absolute Event Rates, </b></text>
<text top="206" left="713" width="181" height="20" font="7"><b>P values; OR or RR; &amp; 95% CI) </b></text>
<text top="172" left="932" width="175" height="20" font="7"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="189" left="964" width="111" height="20" font="7"><b>Study Limitations; </b></text>
<text top="206" left="971" width="96" height="20" font="7"><b>Adverse Events </b></text>
<text top="233" left="89" width="56" height="20" font="7"><b>GREACE </b></text>
<text top="250" left="89" width="103" height="20" font="0">Athyros VG, et al., </text>
<text top="267" left="89" width="56" height="20" font="0">2002 <a href="data supplement.html#237">(23)</a> </text>
<text top="284" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12201623">12201623</a></text>
<text top="284" left="144" width="3" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12201623"><b> </b></a></text>
<text top="233" left="211" width="111" height="20" font="7"><b>Aim:</b> To assess the </text>
<text top="250" left="211" width="114" height="20" font="0">effect of atorvastatin </text>
<text top="267" left="211" width="94" height="20" font="0">on morbidity and </text>
<text top="284" left="211" width="105" height="20" font="0">mortality (total and </text>
<text top="301" left="211" width="69" height="20" font="0">coronary) of </text>
<text top="319" left="211" width="72" height="20" font="0">patients with </text>
<text top="336" left="211" width="65" height="20" font="0">established </text>
<text top="353" left="211" width="83" height="20" font="0">coronary heart </text>
<text top="370" left="211" width="87" height="20" font="0">disease (CHD), </text>
<text top="387" left="211" width="3" height="20" font="0"> </text>
<text top="405" left="211" width="71" height="20" font="7"><b>Study type:</b> </text>
<text top="422" left="211" width="72" height="20" font="0">Randomized </text>
<text top="439" left="211" width="89" height="20" font="0">(please see last </text>
<text top="456" left="211" width="51" height="20" font="0">column)  </text>
<text top="474" left="211" width="3" height="20" font="0"> </text>
<text top="491" left="211" width="109" height="20" font="7"><b>Size:</b> 1600 patients </text>
<text top="508" left="211" width="3" height="20" font="0"> </text>
<text top="525" left="211" width="85" height="20" font="7"><b>Follow-up</b>: 3 y<b> </b></text>
<text top="233" left="339" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="250" left="339" width="139" height="20" font="0">Patients with established </text>
<text top="267" left="339" width="146" height="20" font="0">CHD: history of prior MI or </text>
<text top="284" left="339" width="164" height="20" font="0">&gt;70% stenosis of at least one </text>
<text top="301" left="339" width="165" height="20" font="0">coronary artery on a coronary </text>
<text top="319" left="339" width="166" height="20" font="0">angiogram. Age&lt; 75 y, LDL-C </text>
<text top="336" left="339" width="141" height="20" font="0">&gt;100 mg/dL, triglycerides </text>
<text top="353" left="339" width="72" height="20" font="0">&lt;400 mg/dL. </text>
<text top="370" left="339" width="3" height="20" font="0"> </text>
<text top="387" left="339" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="405" left="339" width="127" height="20" font="0">Recent acute coronary </text>
<text top="422" left="339" width="132" height="20" font="0">syndrome, renal or liver </text>
<text top="439" left="339" width="97" height="20" font="0">dysfunction, prior </text>
<text top="456" left="339" width="137" height="20" font="0">hypolipidemic treatment, </text>
<text top="474" left="339" width="146" height="20" font="0">childbearing potential, any </text>
<text top="491" left="339" width="148" height="20" font="0">significant disease likely to </text>
<text top="508" left="339" width="164" height="20" font="0">limit life to less than the study </text>
<text top="525" left="339" width="161" height="20" font="0">duration (e.g. NYHA Class III </text>
<text top="542" left="339" width="101" height="20" font="0">or IV heart failure, </text>
<text top="560" left="339" width="153" height="20" font="0">malignancies), and patients </text>
<text top="577" left="339" width="129" height="20" font="0">scheduled for coronary </text>
<text top="594" left="339" width="103" height="20" font="0">revascularization.  </text>
<text top="611" left="339" width="3" height="20" font="7"><b> </b></text>
<text top="233" left="521" width="106" height="20" font="7"><b>Intervention (G1):</b> </text>
<text top="250" left="521" width="142" height="20" font="0">Atorvastatin dose titration </text>
<text top="267" left="521" width="155" height="20" font="0">(from 10-80 mg daily) to get </text>
<text top="284" left="521" width="136" height="20" font="0">LDL-C below 100 mg/dL </text>
<text top="301" left="521" width="139" height="20" font="0">(n=800) performed in the </text>
<text top="319" left="521" width="90" height="20" font="0">university clinic. </text>
<text top="336" left="521" width="3" height="20" font="7"><b> </b></text>
<text top="353" left="521" width="146" height="20" font="7"><b>Comparator (usual care) </b></text>
<text top="370" left="521" width="39" height="20" font="7"><b>[G2]:</b> <b>  </b></text>
<text top="387" left="521" width="144" height="20" font="0">Lifestyle changes such as </text>
<text top="405" left="521" width="143" height="20" font="0">hypolipidemic diet, weight </text>
<text top="422" left="521" width="120" height="20" font="0">loss, exercise plus all </text>
<text top="439" left="521" width="143" height="20" font="0">necessary drug treatment </text>
<text top="456" left="521" width="162" height="20" font="0">(e.g. lipid lowering treatment) </text>
<text top="474" left="521" width="48" height="20" font="0">[n=800]. </text>
<text top="491" left="521" width="3" height="20" font="7"><b> </b></text>
<text top="233" left="698" width="206" height="20" font="7"><b>Lipids/Lipid lowering medications: </b></text>
<text top="250" left="698" width="173" height="20" font="0">-Intervention group (G1): 100% </text>
<text top="267" left="698" width="195" height="20" font="0">received atorvastatin, mean dose = </text>
<text top="284" left="698" width="55" height="20" font="0">24 mg/d.  </text>
<text top="301" left="698" width="3" height="20" font="0"> </text>
<text top="319" left="698" width="207" height="20" font="0">-Usual care group (G2): 211 (26%) of </text>
<text top="336" left="698" width="195" height="20" font="0">the patients received hypolipidemia </text>
<text top="353" left="698" width="184" height="20" font="0">drug treatment. 98(12%) of these </text>
<text top="370" left="698" width="190" height="20" font="0">discontinued their treatment at 6-8 </text>
<text top="387" left="698" width="181" height="20" font="0">mo. Overall, 14% (n =113) of the </text>
<text top="405" left="698" width="197" height="20" font="0">patients in the usual care continued </text>
<text top="422" left="698" width="196" height="20" font="0">hypolipidemic treatment throughout </text>
<text top="439" left="698" width="200" height="20" font="0">the study (12% statins, 2% fibrates). </text>
<text top="456" left="698" width="3" height="20" font="0"> </text>
<text top="474" left="698" width="162" height="20" font="0">-Mean LDL-C: G1 180 mg/dL </text>
<text top="491" left="698" width="197" height="20" font="0">(baseline), 97 mg/dL (on-treatment) </text>
<text top="508" left="698" width="207" height="20" font="0">G2: 179 mg/dL (baseline), 169 mg/dL </text>
<text top="525" left="698" width="88" height="20" font="0">(on-treatment).  </text>
<text top="542" left="698" width="3" height="20" font="0"> </text>
<text top="560" left="698" width="191" height="20" font="0">-Mean Non-HDL-C: G1 218 mg/dL </text>
<text top="577" left="698" width="204" height="20" font="0">(baseline), 123 mg/dL (on-treatment) </text>
<text top="594" left="698" width="207" height="20" font="0">G2: 218 mg/dL (baseline), 204 mg/dL </text>
<text top="611" left="698" width="88" height="20" font="0">(on-treatment).  </text>
<text top="628" left="698" width="3" height="20" font="0"> </text>
<text top="646" left="698" width="174" height="20" font="0">G1: 95% achieved LDL-C &lt;100 </text>
<text top="663" left="698" width="208" height="20" font="0">mg/dL and 97% achieved non-HDL-C </text>
<text top="680" left="698" width="72" height="20" font="0">&lt;130 mg/dL. </text>
<text top="697" left="698" width="205" height="20" font="0">G2: 3% achieved LDL-C &lt;100 mg/dL </text>
<text top="715" left="698" width="204" height="20" font="0">and none achieved non-HDL-C &lt;130 </text>
<text top="732" left="698" width="41" height="20" font="0">mg/dL. </text>
<text top="749" left="698" width="3" height="20" font="0"> </text>
<text top="767" left="698" width="161" height="20" font="7"><b>1</b>°<b> endpoints (No OR or HR </b></text>
<text top="784" left="698" width="67" height="20" font="7"><b>provided):</b>  </text>
<text top="234" left="921" width="7" height="18" font="0">•</text>
<text top="234" left="928" width="66" height="20" font="0">No placebo </text>
<text top="253" left="921" width="7" height="18" font="0">•</text>
<text top="252" left="928" width="65" height="20" font="0">No blinding </text>
<text top="271" left="921" width="7" height="18" font="0">•</text>
<text top="270" left="928" width="179" height="20" font="0">Adjudicators likely not blinded to </text>
<text top="288" left="921" width="178" height="20" font="0">the identity of the study group of </text>
<text top="305" left="921" width="90" height="20" font="0">the participants. </text>
<text top="324" left="921" width="7" height="18" font="0">•</text>
<text top="323" left="928" width="167" height="20" font="0">Active treatment (atorvastatin) </text>
<text top="340" left="921" width="161" height="20" font="0">versus usual care in different </text>
<text top="358" left="921" width="53" height="20" font="0">settings.  </text>
<text top="376" left="921" width="157" height="20" font="0"> •Two separate adjudication </text>
<text top="393" left="921" width="188" height="20" font="0">committees (one for each group).  </text>
<text top="412" left="921" width="7" height="18" font="0">•</text>
<text top="412" left="928" width="190" height="20" font="0"> Cost per quality-adjusted life year </text>
<text top="429" left="921" width="170" height="20" font="0">gained with atorvastatin = $US </text>
<text top="446" left="921" width="34" height="20" font="0">8350. </text>
<text top="463" left="921" width="3" height="20" font="0"> </text>
</page>
<page number="30" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">30 </text>
<text top="107" left="698" width="205" height="20" font="0">-Total mortality: G1 23 (2.9%), G2 40 </text>
<text top="124" left="698" width="91" height="20" font="0">(5%), p=0.0021. </text>
<text top="141" left="698" width="192" height="20" font="0">-Coronary mortality: G1 20 (2.5%), </text>
<text top="159" left="698" width="138" height="20" font="0">G2 38 (4.8%), p=0.0017. </text>
<text top="176" left="698" width="195" height="20" font="0">-Non-fatal MI: G1 21 (2.6%), G2 51 </text>
<text top="193" left="698" width="98" height="20" font="0">(6.4%), p=0.0001 </text>
<text top="210" left="698" width="200" height="20" font="0">-Unstable angina: G1 10 (1.2%), G2 </text>
<text top="228" left="698" width="119" height="20" font="0">21 (2.6%), p=0.0032. </text>
<text top="245" left="698" width="199" height="20" font="0">-PTCA/CABG: G1 22 (2.7%), G2 45 </text>
<text top="262" left="698" width="102" height="20" font="0">(5.6%), p=0.0011. </text>
<text top="279" left="698" width="196" height="20" font="0">-CHF: G1 11 (1.3%), G2 22 (2.7%), </text>
<text top="296" left="698" width="52" height="20" font="0">p=0.021. </text>
<text top="314" left="698" width="200" height="20" font="0">-Stroke: G1 9 (1.1%), G2 17 (2.1%), </text>
<text top="331" left="698" width="52" height="20" font="0">p=0.034. </text>
<text top="348" left="698" width="3" height="20" font="0"> </text>
<text top="365" left="698" width="170" height="20" font="7"><b>Safety endpoint (if relevant): </b></text>
<text top="382" left="698" width="206" height="20" font="0">Intervention group: 9 (1.1%) had side </text>
<text top="400" left="698" width="201" height="20" font="0">effects; 7 with liver enzyme increase </text>
<text top="417" left="698" width="202" height="20" font="0">&gt;3 x ULN (specific liver enzymes i.e. </text>
<text top="434" left="698" width="192" height="20" font="0">AST or ALT not mentioned), 2 with </text>
<text top="451" left="698" width="195" height="20" font="0">persistent epigastric discomfort. No </text>
<text top="469" left="698" width="166" height="20" font="0">cases of myopathy. 6 patients </text>
<text top="486" left="698" width="204" height="20" font="0">withdrawn from the study due to side-</text>
<text top="503" left="698" width="182" height="20" font="0">effects attributed to atorvastatin.  </text>
<text top="520" left="698" width="3" height="20" font="0"> </text>
<text top="537" left="698" width="178" height="20" font="0">Usual care: Withdrawal from the </text>
<text top="555" left="698" width="200" height="20" font="0">study in 3 patients with liver enzyme </text>
<text top="572" left="698" width="182" height="20" font="0">elevation &gt;3x ULN (0.4%) [p non-</text>
<text top="589" left="698" width="155" height="20" font="0">significant vs. atorvastatin).  </text>
<text top="606" left="698" width="3" height="20" font="7"><b> </b></text>
<text top="624" left="81" width="1022" height="20" font="0">relative risk; NYHA, new York Heart Association; HF, heart failure; MI, myocardial infarction; LV, left ventricular; EF, ejection fraction; CK, creatine kinase; ULN, upper limits of normal; NNT </text>
<text top="641" left="81" width="1028" height="20" font="0">= numbers needed to treat; LDL-C, low-density lipoprotein cholesterol; ULN, upper limit of normal; Non-HDL-C, non-high-density lipoprotein cholesterol; NYHA, New York Heart Association; </text>
<text top="659" left="81" width="838" height="20" font="0">PTCA, percutaneous transluminal coronary angioplasty; CHF, congestive heart failure; CABG, coronary artery bypass grafting; ULN, upper limit of normal<b> </b></text>
<text top="685" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="722" left="97" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="739" left="123" width="48" height="20" font="7"><b>Author; </b></text>
<text top="757" left="100" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="722" left="244" width="83" height="20" font="7"><b>Aim of Study; </b></text>
<text top="739" left="249" width="74" height="20" font="7"><b>Study Type; </b></text>
<text top="757" left="243" width="86" height="20" font="7"><b>Study Size (N) </b></text>
<text top="739" left="391" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="713" left="557" width="111" height="20" font="7"><b>Study Intervention </b></text>
<text top="731" left="574" width="76" height="20" font="7"><b>(# patients) / </b></text>
<text top="748" left="557" width="111" height="20" font="7"><b>Study Comparator </b></text>
<text top="765" left="578" width="69" height="20" font="7"><b>(# patients) </b></text>
<text top="722" left="751" width="105" height="20" font="7"><b>Endpoint Results </b></text>
<text top="739" left="735" width="137" height="20" font="7"><b>(Absolute Event Rates, </b></text>
<text top="757" left="713" width="181" height="20" font="7"><b>P values; OR or RR; &amp; 95% CI) </b></text>
<text top="723" left="930" width="179" height="20" font="7"><b>Relevant  2</b>°<b> Endpoint (if any); </b></text>
<text top="740" left="964" width="111" height="20" font="7"><b>Study Limitations; </b></text>
<text top="757" left="971" width="96" height="20" font="7"><b>Adverse Events </b></text>
</page>
<page number="31" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">31 </text>
<text top="107" left="89" width="68" height="20" font="7"><b>REAL-CAD </b></text>
<text top="124" left="89" width="91" height="20" font="0">Taguchi I, et al., </text>
<text top="141" left="89" width="56" height="20" font="0">2018<a href="data supplement.html#237"> (24)</a> </text>
<text top="159" left="89" width="55" height="20" font="8"><a href="">29735587</a></text>
<text top="159" left="144" width="3" height="20" font="0"><a href=""> </a></text>
<text top="107" left="217" width="110" height="20" font="7"><b>Aim:</b>  To determine </text>
<text top="124" left="217" width="129" height="20" font="0">whether higher-dose of </text>
<text top="141" left="217" width="105" height="20" font="0">pitavastatin (4 mg) </text>
<text top="159" left="217" width="108" height="20" font="0">would be beneficial </text>
<text top="176" left="217" width="122" height="20" font="0">and safe compared to </text>
<text top="193" left="217" width="133" height="20" font="0">lower-dose (pitavastatin </text>
<text top="210" left="217" width="105" height="20" font="0">1 mg) in Japanese </text>
<text top="228" left="217" width="108" height="20" font="0">patients with stable </text>
<text top="245" left="217" width="33" height="20" font="0">CAD. </text>
<text top="262" left="217" width="3" height="20" font="0"> </text>
<text top="279" left="217" width="74" height="20" font="7"><b>Study type:</b>  </text>
<text top="296" left="217" width="138" height="20" font="0">Prospective, multicenter, </text>
<text top="314" left="217" width="71" height="20" font="0">randomized, </text>
<text top="331" left="217" width="131" height="20" font="0">open-label, blinded end </text>
<text top="348" left="217" width="134" height="20" font="0">point, physician-initiated </text>
<text top="365" left="217" width="83" height="20" font="0">superiority trial </text>
<text top="382" left="217" width="103" height="20" font="7"><b>Size:</b> 13,054 total. </text>
<text top="400" left="217" width="3" height="20" font="0"> </text>
<text top="417" left="217" width="109" height="20" font="7"><b>Follow-up</b>: median </text>
<text top="434" left="217" width="121" height="20" font="0">follow-up = 3.9 years. </text>
<text top="107" left="368" width="113" height="20" font="7"><b>Inclusion criteria:</b>   </text>
<text top="124" left="368" width="152" height="20" font="0">Men and women 20 to 80 y </text>
<text top="141" left="368" width="145" height="20" font="0">of age with stable CAD as </text>
<text top="159" left="368" width="157" height="20" font="0">defined by a history of acute </text>
<text top="176" left="368" width="123" height="20" font="0">coronary syndrome or </text>
<text top="193" left="368" width="147" height="20" font="0">coronary revascularization </text>
<text top="210" left="368" width="127" height="20" font="0">&gt;3 mo ago or a clinical </text>
<text top="228" left="368" width="124" height="20" font="0">diagnosis of CAD with </text>
<text top="245" left="368" width="92" height="20" font="0">angiographically </text>
<text top="262" left="368" width="157" height="20" font="0">documented coronary artery </text>
<text top="279" left="368" width="133" height="20" font="0">stenosis of at least 75% </text>
<text top="296" left="368" width="112" height="20" font="0">diameter narrowing. </text>
<text top="314" left="368" width="3" height="20" font="0"> </text>
<text top="331" left="368" width="117" height="20" font="7"><b>Exclusion criteria:</b>   </text>
<text top="348" left="368" width="137" height="20" font="0">Patient with LDL-C &lt;100 </text>
<text top="365" left="368" width="113" height="20" font="0">mg/dL without statin </text>
<text top="382" left="368" width="116" height="20" font="0">therapy. Other major </text>
<text top="400" left="368" width="110" height="20" font="0">exclusions included </text>
<text top="417" left="368" width="147" height="20" font="0">coronary revascularization </text>
<text top="434" left="368" width="120" height="20" font="0">scheduled but not yet </text>
<text top="451" left="368" width="99" height="20" font="0">completed, active </text>
<text top="469" left="368" width="122" height="20" font="0">malignancy, history of </text>
<text top="486" left="368" width="158" height="20" font="0">hypersensitivity to any of the </text>
<text top="503" left="368" width="146" height="20" font="0">ingredients of pitavastatin, </text>
<text top="520" left="368" width="154" height="20" font="0">serious liver disorder or bile </text>
<text top="537" left="368" width="148" height="20" font="0">duct obstruction,  currently </text>
<text top="555" left="368" width="116" height="20" font="0">under treatment with </text>
<text top="572" left="368" width="158" height="20" font="0">cyclosporin, women who are </text>
<text top="589" left="368" width="114" height="20" font="0">pregnant, potentially </text>
<text top="606" left="368" width="122" height="20" font="0">pregnant, or lactating, </text>
<text top="623" left="368" width="135" height="20" font="0">serious heart failure (left </text>
<text top="641" left="368" width="150" height="20" font="0">ventricular ejection fraction </text>
<text top="658" left="368" width="87" height="20" font="0">&lt;30% or NYHA </text>
<text top="675" left="368" width="133" height="20" font="0">classification class III or </text>
<text top="692" left="368" width="144" height="20" font="0">above), receiving dialysis, </text>
<text top="710" left="368" width="42" height="20" font="0">familial </text>
<text top="727" left="368" width="124" height="20" font="0">hypercholesterolemia, </text>
<text top="744" left="368" width="128" height="20" font="0">participating in another </text>
<text top="761" left="368" width="111" height="20" font="0">clinical study, under </text>
<text top="778" left="368" width="152" height="20" font="0">treatment with a  prohibited </text>
<text top="107" left="539" width="109" height="20" font="7"><b>Intervention (G1):</b>. </text>
<text top="124" left="539" width="116" height="20" font="0">Pitavastatin 4mg (n= </text>
<text top="141" left="539" width="35" height="20" font="0">6526) </text>
<text top="159" left="539" width="119" height="20" font="7"><b>Comparator (G2):</b>  <b>   </b></text>
<text top="176" left="539" width="116" height="20" font="0">Pitavastatin 1mg (n= </text>
<text top="193" left="539" width="35" height="20" font="0">6528) </text>
<text top="107" left="698" width="209" height="20" font="7"><b>Lipids/ Lipid lowering medications: </b></text>
<text top="124" left="698" width="141" height="20" font="0">-Intervention group (G1):  </text>
<text top="141" left="698" width="189" height="20" font="0">Mean baseline LDL-C (after run-in </text>
<text top="159" left="698" width="117" height="20" font="0">period) = 87.7 mg/dL </text>
<text top="176" left="698" width="152" height="20" font="0">6 mo LDL-C = 73.7 mg/dL.  </text>
<text top="193" left="698" width="146" height="20" font="0">-Comparator group (G2):   </text>
<text top="210" left="698" width="189" height="20" font="0">Mean baseline LDL-C (after run-in </text>
<text top="228" left="698" width="113" height="20" font="0">period) = 88.1 mg/dl </text>
<text top="245" left="698" width="152" height="20" font="0">6 mo LDL-C = 89.4 mg/dL.  </text>
<text top="262" left="698" width="3" height="20" font="0"> </text>
<text top="279" left="698" width="179" height="20" font="0">- LDL-C difference = 14.7 mg/dL </text>
<text top="296" left="698" width="124" height="20" font="0">between G1 and G2.   </text>
<text top="314" left="698" width="3" height="20" font="0"> </text>
<text top="331" left="698" width="3" height="20" font="0"> </text>
<text top="349" left="698" width="156" height="20" font="7"><b>1</b>°<b> endpoints </b>(composite of </text>
<text top="366" left="698" width="167" height="20" font="0">cardiovascular death, nonfatal </text>
<text top="384" left="698" width="167" height="20" font="0">myocardial infarction, nonfatal </text>
<text top="401" left="698" width="196" height="20" font="0">ischemic stroke, or unstable angina </text>
<text top="418" left="698" width="204" height="20" font="0">requiring emergency hospitalization): </text>
<text top="435" left="698" width="3" height="20" font="0"> </text>
<text top="452" left="698" width="201" height="20" font="0">-4.3% in G1 versus 5.4% in G2 (HR: </text>
<text top="470" left="698" width="168" height="20" font="0">0.81; 95% confidence interval, </text>
<text top="487" left="698" width="114" height="20" font="0">0.69–0.95; p=0.01)   </text>
<text top="504" left="698" width="3" height="20" font="0"> </text>
<text top="521" left="698" width="176" height="20" font="7"><b>Secondary and other relevant </b></text>
<text top="539" left="698" width="204" height="20" font="7"><b>endpoints</b> (composite of the primary </text>
<text top="556" left="698" width="161" height="20" font="0">end point event and clinically </text>
<text top="573" left="698" width="203" height="20" font="0">indicated coronary revascularization, </text>
<text top="590" left="698" width="126" height="20" font="0">excluding target-lesion </text>
<text top="607" left="698" width="197" height="20" font="0">revascularization for lesions treated </text>
<text top="625" left="698" width="171" height="20" font="0">at prior percutaneous coronary </text>
<text top="642" left="698" width="78" height="20" font="0">intervention):  </text>
<text top="659" left="698" width="202" height="20" font="0">-7.9% In G1 versus 9.7% in G2 (HR: </text>
<text top="676" left="698" width="195" height="20" font="0">0.83; 95% CI: 0.73–0.93; p=0.002)  </text>
<text top="693" left="698" width="3" height="20" font="0"> </text>
<text top="711" left="698" width="195" height="20" font="0">-Death from any cause: 3.3% in G1 </text>
<text top="728" left="698" width="191" height="20" font="0">versus 4.2% in G2 (HR: 0.81; 95% </text>
<text top="745" left="698" width="79" height="20" font="0">CI, 0.68-0.98) </text>
<text top="109" left="921" width="7" height="18" font="0">•</text>
<text top="108" left="928" width="66" height="20" font="0"> Open label </text>
<text top="127" left="921" width="7" height="18" font="0">•</text>
<text top="127" left="928" width="181" height="20" font="0"> Run in period with pitavastatin 1 </text>
<text top="144" left="921" width="182" height="20" font="0">mg po daily for at least 1 month.  </text>
<text top="163" left="921" width="7" height="18" font="0">•</text>
<text top="162" left="928" width="181" height="20" font="0"> The actual event rate was lower </text>
<text top="179" left="921" width="169" height="20" font="0">than anticipated. However, the </text>
<text top="197" left="921" width="188" height="20" font="0">steering committee decided not to </text>
<text top="214" left="921" width="196" height="20" font="0">extend the study further despite the </text>
<text top="231" left="921" width="177" height="20" font="0">original event-driven trial design </text>
<text top="248" left="921" width="181" height="20" font="0">because a substantial number of </text>
<text top="266" left="921" width="178" height="20" font="0">centers were reluctant to extend </text>
<text top="283" left="921" width="96" height="20" font="0">the study further. </text>
<text top="302" left="921" width="7" height="18" font="0">•</text>
<text top="301" left="928" width="159" height="20" font="0"> Final follow-up completed in </text>
<text top="318" left="921" width="170" height="20" font="0">83.4% in G1 and 83.2% in G2. </text>
<text top="337" left="921" width="7" height="18" font="0">•</text>
<text top="337" left="928" width="162" height="20" font="0"> The rate of adherence to the </text>
<text top="354" left="921" width="153" height="20" font="0">study drug was high in both </text>
<text top="371" left="921" width="192" height="20" font="0">groups, although it was slightly but </text>
<text top="388" left="921" width="100" height="20" font="0">significantly lower </text>
<text top="406" left="921" width="159" height="20" font="0">in G1 than in G2 (97.1% and </text>
<text top="423" left="921" width="187" height="20" font="0">98.7% at 6 mo, 74.8% and 76.8% </text>
<text top="440" left="921" width="82" height="20" font="0">at 4 y; p=0.02) </text>
<text top="459" left="921" width="7" height="18" font="0">•</text>
<text top="458" left="928" width="177" height="20" font="0"> Study drug discontinuation was </text>
<text top="476" left="921" width="160" height="20" font="0">slightly but significantly more </text>
<text top="493" left="921" width="188" height="20" font="0">frequent in G1 than G2 (9.8% and </text>
<text top="510" left="921" width="91" height="20" font="0">8.1%; p&lt;0.001). </text>
<text top="527" left="921" width="3" height="20" font="0"> </text>
<text top="544" left="921" width="3" height="20" font="0"> </text>
</page>
<page number="32" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">32 </text>
<text top="107" left="368" width="122" height="20" font="0">concomitant drug that </text>
<text top="124" left="368" width="154" height="20" font="0">cannot be discontinued, not </text>
<text top="141" left="368" width="131" height="20" font="0">a suitable candidate for </text>
<text top="159" left="368" width="154" height="20" font="0">study participation for some </text>
<text top="176" left="368" width="159" height="20" font="0">other reasons, in the opinion </text>
<text top="193" left="368" width="115" height="20" font="0">of the investigator or </text>
<text top="210" left="368" width="93" height="20" font="0">subinvestigator.  </text>
<text top="227" left="368" width="3" height="20" font="0"> </text>
<text top="107" left="698" width="192" height="20" font="0">- Myocardial Infarction: 0.6% in G1 </text>
<text top="124" left="698" width="191" height="20" font="0">versus 1.2% in G2 (HR: 0.57; 95% </text>
<text top="141" left="698" width="79" height="20" font="0">CI: 0.38-0.83) </text>
<text top="159" left="698" width="181" height="20" font="0">-Coronary revascularization (all): </text>
<text top="176" left="698" width="204" height="20" font="0">8.5% in G1 versus 10.1% in G2 (HR: </text>
<text top="193" left="698" width="138" height="20" font="0">0.86; 95% CI: 0.76-0.96) </text>
<text top="210" left="698" width="157" height="20" font="0">- Coronary revascularization </text>
<text top="228" left="698" width="207" height="20" font="0">(nontarget-lesion): 4.5% in G1 versus </text>
<text top="245" left="698" width="199" height="20" font="0">5.7% in G2 (HR: 0.79; 95% CI: 0.68-</text>
<text top="262" left="698" width="31" height="20" font="0">0.92) </text>
<text top="279" left="698" width="7" height="20" font="0">  </text>
<text top="296" left="698" width="208" height="20" font="0">-No significant difference in the risk of </text>
<text top="314" left="698" width="201" height="20" font="0">cardiovascular death, cardiac death, </text>
<text top="331" left="698" width="204" height="20" font="0">ischemic stroke, hemorrhagic stroke, </text>
<text top="348" left="698" width="206" height="20" font="0">unstable angina requiring emergency </text>
<text top="365" left="698" width="206" height="20" font="0">hospitalization, target lesion coronary </text>
<text top="383" left="698" width="103" height="20" font="0">revascularization.  </text>
<text top="400" left="698" width="3" height="20" font="0"> </text>
<text top="417" left="698" width="170" height="20" font="7"><b>Safety endpoint (if relevant): </b></text>
<text top="434" left="698" width="176" height="20" font="0">-Muscle complaints: 1.9% in G1 </text>
<text top="451" left="698" width="156" height="20" font="0">versus 0.7% in G2, p&lt;0.001 </text>
<text top="469" left="698" width="152" height="20" font="0">-No significant difference in </text>
<text top="486" left="698" width="198" height="20" font="0">rhabdomyolysis, gallbladder-related </text>
<text top="503" left="698" width="201" height="20" font="0">events, new onset diabetes mellitus, </text>
<text top="520" left="698" width="185" height="20" font="0">psychiatric disorders, elevation of </text>
<text top="537" left="698" width="200" height="20" font="0">alanine aminotransferase, aspartate </text>
<text top="555" left="698" width="197" height="20" font="0">aminotransferase, or both ≥3 upper </text>
<text top="572" left="698" width="185" height="20" font="0">limit of normal range, elevation of </text>
<text top="589" left="698" width="178" height="20" font="0">creatine kinase ≥5 upper limit of </text>
<text top="606" left="698" width="83" height="20" font="0">normal range   </text>
<text top="623" left="698" width="3" height="20" font="7"><b> </b></text>
<text top="643" left="81" width="1005" height="20" font="7"><b>Abbreviations:</b> 1° indicated primary; CI, confidence interval; HR, hazard ratio; N/A, not available; OR, odds ratio; RCT, randomized controlled trial; RR, relative risk; LDL-C, low-density </text>
<text top="660" left="81" width="492" height="20" font="0">lipoprotein cholesterol; CAD, coronary artery disease; NYHA, New York Heart Association </text>
<text top="677" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="705" left="81" width="537" height="24" font="4"><b>Data Supplement 8. Evidence Tables for Secondary Prevention (Section 4.1) </b></text>
<text top="726" left="116" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="744" left="142" width="48" height="20" font="7"><b>Author; </b></text>
<text top="761" left="120" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="726" left="267" width="118" height="20" font="7"><b>Study Type/Design; </b></text>
<text top="744" left="293" width="66" height="20" font="7"><b>Study Size </b></text>
<text top="726" left="438" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="726" left="618" width="179" height="20" font="7"><b>Primary Endpoint and Results </b></text>
<text top="744" left="615" width="184" height="20" font="7"><b>(P values; OR or RR; &amp; 95% CI) </b></text>
<text top="726" left="906" width="130" height="20" font="7"><b>Summary/Conclusion </b></text>
<text top="744" left="933" width="75" height="20" font="7"><b>Comment(s) </b></text>
</page>
<page number="33" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">33 </text>
<text top="107" left="91" width="138" height="20" font="0">Virani SS et al<b>, </b>2017<a href="data supplement.html#237">(25)</a><b> </b></text>
<text top="124" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28465286">28465286</a></text>
<text top="125" left="146" width="3" height="19" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28465286"> </a></text>
<text top="107" left="253" width="77" height="20" font="7"><b>Study type:</b>   </text>
<text top="124" left="253" width="114" height="20" font="0">Observational Study </text>
<text top="141" left="253" width="89" height="20" font="0">evaluating what </text>
<text top="159" left="253" width="144" height="20" font="0">proportion of patients with </text>
<text top="176" left="253" width="132" height="20" font="0">ASCVD seeking care in </text>
<text top="193" left="253" width="105" height="20" font="0">the VA health care </text>
<text top="210" left="253" width="135" height="20" font="0">system would qualify for </text>
<text top="228" left="253" width="124" height="20" font="0">evolocumab based on </text>
<text top="245" left="253" width="126" height="20" font="0">FOURIER trial criteria. </text>
<text top="262" left="253" width="95" height="20" font="0">The authors also </text>
<text top="279" left="253" width="132" height="20" font="0">evaluated how eligibility </text>
<text top="296" left="253" width="108" height="20" font="0">for PCSK9 inhibitor </text>
<text top="314" left="253" width="133" height="20" font="0">therapy would change if </text>
<text top="331" left="253" width="118" height="20" font="0">high-intensity statins, </text>
<text top="348" left="253" width="94" height="20" font="0">ezetimibe, or the </text>
<text top="365" left="253" width="111" height="20" font="0">combination of both </text>
<text top="383" left="253" width="107" height="20" font="0">agents were used.  </text>
<text top="400" left="253" width="3" height="20" font="0"> </text>
<text top="417" left="253" width="129" height="20" font="7"><b>Size</b>: 631, 855 patients </text>
<text top="434" left="253" width="124" height="20" font="0">with ASCVD receiving </text>
<text top="451" left="253" width="145" height="20" font="0">care in the VA health care </text>
<text top="469" left="253" width="139" height="20" font="0">system between October </text>
<text top="486" left="253" width="118" height="20" font="0">2013 and September </text>
<text top="503" left="253" width="34" height="20" font="0">2014  </text>
<text top="107" left="412" width="161" height="20" font="7"><b>Inclusion criteria:</b>  Same as </text>
<text top="124" left="412" width="133" height="20" font="0">FOURIER trial inclusion </text>
<text top="141" left="412" width="40" height="20" font="0">criteria </text>
<text top="159" left="412" width="3" height="20" font="0"> </text>
<text top="176" left="412" width="162" height="20" font="7"><b>Exclusion criteria: </b>Same as </text>
<text top="193" left="412" width="137" height="20" font="0">FOURIER trial exclusion </text>
<text top="210" left="412" width="40" height="20" font="0">criteria </text>
<text top="108" left="588" width="225" height="20" font="7"><b>1</b>°<b> endpoint:</b>  Proportion of patients with </text>
<text top="125" left="588" width="215" height="20" font="0">ASCVD meeting FOURIER trial criteria </text>
<text top="143" left="588" width="3" height="20" font="0"> </text>
<text top="160" left="588" width="59" height="20" font="7"><b>Results:</b>   </text>
<text top="177" left="588" width="3" height="20" font="0"> </text>
<text top="194" left="588" width="216" height="20" font="0">-154,823 patients (24.5%) with ASCVD </text>
<text top="211" left="588" width="216" height="20" font="0">met FOURIER criteria based on LDL-C </text>
<text top="229" left="588" width="136" height="20" font="0">and non-HDL-C cutoffs.  </text>
<text top="246" left="588" width="3" height="20" font="0"> </text>
<text top="263" left="588" width="198" height="20" font="0">- 49.9% of the ASCVD patients who </text>
<text top="280" left="588" width="215" height="20" font="0">qualified were on high-intensity statins, </text>
<text top="298" left="588" width="89" height="20" font="0">47.5% were on  </text>
<text top="315" left="588" width="232" height="20" font="0">moderate intensity statins, and 2.6% were </text>
<text top="332" left="588" width="186" height="20" font="0">on a statin/ezetimibe combination </text>
<text top="349" left="588" width="3" height="20" font="0"> </text>
<text top="367" left="588" width="237" height="20" font="0">-Titration to a high-intensity statin would be </text>
<text top="384" left="588" width="236" height="20" font="0">expected to reduce LDL-C to &lt;70 mg/dL in </text>
<text top="401" left="588" width="215" height="20" font="0">an additional 28,930 FOURIER-eligible </text>
<text top="418" left="588" width="215" height="20" font="0">patients (18.7%) with a mean achieved </text>
<text top="435" left="588" width="114" height="20" font="0">LDL-C of 63 mg/dL.  </text>
<text top="453" left="588" width="3" height="20" font="0"> </text>
<text top="470" left="588" width="238" height="20" font="0">-Initiation of ezetimibe would lead to LDL-C </text>
<text top="487" left="588" width="236" height="20" font="0">&lt;70 mg/dL in an additional 78,507 patients </text>
<text top="504" left="588" width="221" height="20" font="0">(50.7%) with a mean achieved LDL-C of </text>
<text top="521" left="588" width="62" height="20" font="0">60 mg/dL.  </text>
<text top="539" left="588" width="3" height="20" font="0"> </text>
<text top="556" left="588" width="225" height="20" font="0">-Combination of high-intensity statin plus </text>
<text top="573" left="588" width="233" height="20" font="0">ezetimibe would lead to LDL-C &lt;70 mg/dL </text>
<text top="590" left="588" width="217" height="20" font="0">in 92,538 patients (59.8%) with a mean </text>
<text top="607" left="588" width="163" height="20" font="0">achieved LDL-C of 58 mg/dL. </text>
<text top="625" left="588" width="3" height="20" font="0"> </text>
<text top="642" left="588" width="226" height="20" font="0">-Estimated costs associated with treating </text>
<text top="659" left="588" width="233" height="20" font="0">the 154,823 patients eligible for FOURIER </text>
<text top="676" left="588" width="182" height="20" font="0">with evolocumab would be $2.08 </text>
<text top="693" left="588" width="237" height="20" font="0">billion/year.  Restricting evolocumab use in </text>
<text top="711" left="588" width="192" height="20" font="0">patients with LDL ≥70 mg/dL, after </text>
<text top="728" left="588" width="238" height="20" font="0">accounting for cost associated with titration </text>
<text top="745" left="588" width="208" height="20" font="0">to high-intensity statin plus ezetimibe, </text>
<text top="762" left="588" width="224" height="20" font="0">would be expected to result in an annual </text>
<text top="780" left="588" width="178" height="20" font="0">net cost savings of $1.13 billion. </text>
<text top="107" left="839" width="219" height="20" font="0">-Healthcare systems have considerable </text>
<text top="124" left="839" width="239" height="20" font="0">opportunity to increase the use of evidence-</text>
<text top="141" left="839" width="235" height="20" font="0">based high-intensity statins and ezetimibe, </text>
<text top="159" left="839" width="228" height="20" font="0">which may reduce the need for additional </text>
<text top="176" left="839" width="138" height="20" font="0">PCSK9 inhibitor therapy. </text>
<text top="193" left="839" width="3" height="20" font="0"> </text>
<text top="210" left="839" width="3" height="20" font="0"> </text>
<text top="228" left="839" width="3" height="20" font="0"> </text>
</page>
<page number="34" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">34 </text>
<text top="107" left="588" width="3" height="20" font="0"> </text>
<text top="124" left="588" width="3" height="20" font="0"> </text>
<text top="143" left="588" width="3" height="19" font="0"> </text>
<text top="161" left="91" width="133" height="20" font="0">Cannon et al, 2017 <a href="data supplement.html#237">(26)</a> </text>
<text top="178" left="91" width="55" height="20" font="8"><a href="">28768335</a></text>
<text top="178" left="146" width="3" height="20" font="7"><a href=""><b> </b></a></text>
<text top="195" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="213" left="91" width="10" height="20" font="0">   </text>
<text top="161" left="253" width="77" height="20" font="7"><b>Study type:</b>   </text>
<text top="178" left="253" width="145" height="20" font="0">Observational study using </text>
<text top="195" left="253" width="109" height="20" font="0">a large database of </text>
<text top="212" left="253" width="127" height="20" font="0">medical and pharmacy </text>
<text top="229" left="253" width="143" height="20" font="0">claims (MarketScan). The </text>
<text top="247" left="253" width="133" height="20" font="0">study aimed to estimate </text>
<text top="264" left="253" width="146" height="20" font="0">the percentage of patients </text>
<text top="281" left="253" width="133" height="20" font="0">with ASCVD who would </text>
<text top="298" left="253" width="96" height="20" font="0">require a PCSK9 </text>
<text top="316" left="253" width="119" height="20" font="0">Inhibitor (alirocumab) </text>
<text top="333" left="253" width="132" height="20" font="0">when oral lipid-lowering </text>
<text top="350" left="253" width="142" height="20" font="0">therapy is intensified first. </text>
<text top="367" left="253" width="3" height="20" font="0"> </text>
<text top="384" left="253" width="131" height="20" font="7"><b>Size:</b> Cohort of 105269 </text>
<text top="402" left="253" width="143" height="20" font="0">patients with ASCVD who </text>
<text top="419" left="253" width="115" height="20" font="0">met inclusion criteria </text>
<text top="436" left="253" width="107" height="20" font="0">(database cohort).  </text>
<text top="453" left="253" width="128" height="20" font="0">Patients were sampled </text>
<text top="470" left="253" width="96" height="20" font="0">with replacement </text>
<text top="488" left="253" width="137" height="20" font="0">(bootstrapping) to match </text>
<text top="505" left="253" width="120" height="20" font="0">the US epidemiologic </text>
<text top="522" left="253" width="132" height="20" font="0">distribution and entered </text>
<text top="539" left="253" width="104" height="20" font="0">into a Monte Carlo </text>
<text top="556" left="253" width="122" height="20" font="0">simulation (simulation </text>
<text top="574" left="253" width="109" height="20" font="0">cohort) that applied </text>
<text top="591" left="253" width="107" height="20" font="0">stepwise treatment </text>
<text top="608" left="253" width="138" height="20" font="0">intensification algorithms </text>
<text top="625" left="253" width="146" height="20" font="0">in those with LDL-C levels </text>
<text top="642" left="253" width="136" height="20" font="0">of at least 70mg/dL. The </text>
<text top="660" left="253" width="145" height="20" font="0">simulation cohort included </text>
<text top="677" left="253" width="95" height="20" font="0">1 million patients </text>
<text top="694" left="253" width="130" height="20" font="0">(bootstrapping allowing </text>
<text top="711" left="253" width="129" height="20" font="0">for multiple replications </text>
<text top="729" left="253" width="87" height="20" font="0">per individual).  </text>
<text top="161" left="412" width="113" height="20" font="7"><b>Inclusion criteria:</b>   </text>
<text top="178" left="412" width="147" height="20" font="0">Patients 21 years or older; </text>
<text top="195" left="412" width="154" height="20" font="0">LDL-C level measured from </text>
<text top="212" left="412" width="140" height="20" font="0">January1, 2012, through  </text>
<text top="229" left="412" width="159" height="20" font="0">December 31, 2013; 2 years </text>
<text top="247" left="412" width="137" height="20" font="0">of continuous enrollment </text>
<text top="264" left="412" width="146" height="20" font="0">before the index date; and </text>
<text top="281" left="412" width="162" height="20" font="0">ASCVD defined as (1) recent </text>
<text top="298" left="412" width="146" height="20" font="0">acute coronary syndrome, </text>
<text top="316" left="412" width="133" height="20" font="0">(2) other coronary heart </text>
<text top="333" left="412" width="119" height="20" font="0">disease, (3) ischemic </text>
<text top="350" left="412" width="140" height="20" font="0">cerebrovascular disease, </text>
<text top="367" left="412" width="142" height="20" font="0">and (4) peripheral arterial </text>
<text top="384" left="412" width="49" height="20" font="0">disease. </text>
<text top="403" left="412" width="3" height="19" font="0"> </text>
<text top="162" left="588" width="237" height="20" font="7"><b>1</b>°<b> endpoint:</b>  Use of lipid lowering therapy </text>
<text top="179" left="588" width="232" height="20" font="0">in the ASCVD patients and distributions of </text>
<text top="196" left="588" width="207" height="20" font="0">LDL-C levels under various treatment </text>
<text top="213" left="588" width="134" height="20" font="0">intensification scenarios </text>
<text top="231" left="588" width="3" height="20" font="0"> </text>
<text top="248" left="588" width="59" height="20" font="7"><b>Results:</b>   </text>
<text top="265" left="588" width="217" height="20" font="0">-53.2% ASCVD patients were receiving </text>
<text top="282" left="588" width="194" height="20" font="0">statins at baseline and 15.3% were </text>
<text top="299" left="588" width="179" height="20" font="0">receiving a high-intensity statin.  </text>
<text top="317" left="588" width="3" height="20" font="0"> </text>
<text top="334" left="588" width="235" height="20" font="0">-25.2% achieved LDL-C levels of less than </text>
<text top="351" left="588" width="55" height="20" font="0">70mg/dL. </text>
<text top="368" left="588" width="3" height="20" font="0"> </text>
<text top="385" left="588" width="224" height="20" font="0">-When a 20-mg dose of atorvastatin was </text>
<text top="403" left="588" width="222" height="20" font="0">added for patients not receiving a statin, </text>
<text top="420" left="588" width="219" height="20" font="0">49.1% of the overall cohort achieved an </text>
<text top="437" left="588" width="226" height="20" font="0">LDL-C level of less than 70mg/dL. Of the </text>
<text top="454" left="588" width="207" height="20" font="0">remaining 50.9% patients, 9.1% were </text>
<text top="472" left="588" width="235" height="20" font="0">already receiving high-intensity statins and </text>
<text top="489" left="588" width="194" height="20" font="0">41.8% would undergo uptitration to </text>
<text top="506" left="588" width="237" height="20" font="0">atorvastatin, 80mg. The uptitration resulted </text>
<text top="523" left="588" width="236" height="20" font="0">in an additional 20.2% achieving an LDL-C </text>
<text top="540" left="588" width="228" height="20" font="0">level of less than 70mg/dL (overall cohort </text>
<text top="558" left="588" width="233" height="20" font="0">with LDL-C level &lt;70 mg/dL, 69.3% at this </text>
<text top="575" left="588" width="41" height="20" font="0">stage). </text>
<text top="592" left="588" width="3" height="20" font="0"> </text>
<text top="609" left="588" width="234" height="20" font="0">- Of the remaining 30.7% not at the LDL-C </text>
<text top="626" left="588" width="172" height="20" font="0">goal, 0.9% were already taking </text>
<text top="644" left="588" width="185" height="20" font="0">concomitant ezetimibe; therefore, </text>
<text top="661" left="588" width="210" height="20" font="0">ezetimibe was added in the remaining </text>
<text top="678" left="588" width="238" height="20" font="0">29.8% of the cohort receiving high intensity </text>
<text top="695" left="588" width="215" height="20" font="0">statins and not at the LDL-C level goal. </text>
<text top="712" left="588" width="190" height="20" font="0">After this step in intensification, an </text>
<text top="730" left="588" width="231" height="20" font="0">additional 16.7% were able to achieve the </text>
<text top="747" left="588" width="235" height="20" font="0">LDL-C goal (total at LDL-C goal, 86%) and </text>
<text top="764" left="588" width="192" height="20" font="0">14% of the original cohort required </text>
<text top="781" left="588" width="207" height="20" font="0">additional treatment with alirocumab.  </text>
<text top="161" left="839" width="4" height="20" font="0">-</text>
<text top="160" left="843" width="4" height="21" font="1"> </text>
<text top="161" left="847" width="249" height="20" font="0">69.3% of ASCVD patients could achieve LDL-</text>
<text top="178" left="839" width="223" height="20" font="0">C levels of less than 70mg/dL with statin </text>
<text top="195" left="839" width="239" height="20" font="0">initiation and/or uptitration only, and add-on </text>
<text top="212" left="839" width="240" height="20" font="0">ezetimibe could increase this percentage to </text>
<text top="229" left="839" width="250" height="20" font="0">86%. Adding a PCSK9 inhibitor to therapy for </text>
<text top="247" left="839" width="103" height="20" font="0">the remaining14% </text>
<text top="264" left="839" width="238" height="20" font="0">still above the LDL-C threshold could result </text>
<text top="281" left="839" width="219" height="20" font="0">in more than 99% of the population with </text>
<text top="298" left="839" width="226" height="20" font="0">ASCVD having LDL-C levels of less than </text>
<text top="316" left="839" width="55" height="20" font="0">70mg/dL. </text>
<text top="333" left="839" width="3" height="20" font="0"> </text>
<text top="350" left="839" width="233" height="20" font="0">-In a model that assumes no lipid lowering </text>
<text top="367" left="839" width="216" height="20" font="0">therapy intolerance and full adherence, </text>
<text top="384" left="839" width="235" height="20" font="0">intensification of oral lipid lowering therapy </text>
<text top="402" left="839" width="230" height="20" font="0">could achieve an LDL-C level of less than </text>
<text top="419" left="839" width="250" height="20" font="0">70mg/dL in most patients, with only a modest </text>
<text top="436" left="839" width="217" height="20" font="0">percentage requiring a PCSK9 inhibitor </text>
<text top="453" left="839" width="3" height="20" font="0"> </text>
<text top="470" left="839" width="3" height="20" font="0"> </text>
<text top="488" left="839" width="3" height="20" font="0"> </text>
</page>
<page number="35" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="12" size="21" family="Times" color="#000000"/>
	<fontspec id="13" size="12" family="Times" color="#000000"/>
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">35 </text>
<text top="107" left="588" width="3" height="20" font="0"> </text>
<text top="124" left="588" width="4" height="20" font="0">-</text>
<text top="122" left="592" width="4" height="22" font="1"> </text>
<text top="124" left="596" width="217" height="20" font="0">Addition of a 75-mg dose of alirocumab </text>
<text top="141" left="588" width="232" height="20" font="0">for patients not at the LDL-C goal resulted </text>
<text top="159" left="588" width="237" height="20" font="0">in an incremental 12% achieving an LDL-C </text>
<text top="176" left="588" width="235" height="20" font="0">level of less than 70 mg/dL. The remaining </text>
<text top="193" left="588" width="214" height="20" font="0">2% of the cohort received uptitration to </text>
<text top="210" left="588" width="236" height="20" font="0">alirocumab, 150mg. At this final step of the </text>
<text top="228" left="588" width="216" height="20" font="0">intensification, only 0.7% of the original </text>
<text top="245" left="588" width="84" height="20" font="0">cohort failed to </text>
<text top="262" left="588" width="224" height="20" font="0">achieve an LDL-C level goal of less than </text>
<text top="279" left="588" width="58" height="20" font="0">70 mg/dL. </text>
<text top="296" left="588" width="3" height="20" font="0"> </text>
<text top="314" left="588" width="197" height="20" font="0">-In summary, simulation of maximal </text>
<text top="331" left="588" width="208" height="20" font="0">lipid-lowering treatment intensification </text>
<text top="348" left="588" width="232" height="20" font="0">indicated that 99.3% could achieve LDL-C </text>
<text top="365" left="588" width="236" height="20" font="0">levels of less than 70mg/dL, including 86% </text>
<text top="382" left="588" width="224" height="20" font="0">receiving statins and ezetimibe and 14% </text>
<text top="400" left="588" width="167" height="20" font="0">with add-on PCSK9 inhibitors. </text>
<text top="419" left="88" width="1041" height="20" font="7"><b>Abbreviations:</b> 1° indicated primary; CI, confidence interval; HR, hazard ratio; N/A, not available; OR, odds ratio; RR, relative risk; ASCVD, atherosclerotic cardiovascular disease; FOURIER, </text>
<text top="438" left="88" width="1056" height="20" font="0">Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk; VA, Veterans Affairs; LDL-C, low-density lipoprotein cholesterol; non-HDL-C, non-high density </text>
<text top="456" left="88" width="170" height="20" font="0">lipoprotein cholesterol; PCSK9,</text>
<text top="456" left="258" width="4" height="21" font="1"> </text>
<text top="456" left="262" width="242" height="20" font="0">proprotein convertase subtilisin/kexin type 9.</text>
<text top="447" left="504" width="5" height="32" font="12"><b> </b></text>
<text top="486" left="81" width="4" height="22" font="1"> </text>
<text top="506" left="152" width="38" height="20" font="7"><b>Study </b></text>
<text top="506" left="295" width="75" height="20" font="7"><b>Sample Size </b></text>
<text top="523" left="287" width="92" height="20" font="7"><b>Study Duration </b></text>
<text top="541" left="299" width="67" height="20" font="7"><b>Adherence </b></text>
<text top="506" left="423" width="75" height="20" font="7"><b>Drug Tested </b></text>
<text top="523" left="425" width="71" height="20" font="7"><b>Statin Used </b></text>
<text top="541" left="407" width="3" height="20" font="7"><b> </b></text>
<text top="506" left="564" width="105" height="20" font="7"><b>Study Population </b></text>
<text top="523" left="615" width="3" height="20" font="7"><b> </b></text>
<text top="506" left="742" width="141" height="20" font="7"><b>Primary and Secondary </b></text>
<text top="523" left="778" width="68" height="20" font="7"><b>Outcomes* </b></text>
<text top="506" left="948" width="132" height="20" font="7"><b>Major Adverse Events </b></text>
<text top="560" left="83" width="96" height="20" font="7"><b>dal-OUTCOMES </b></text>
<text top="577" left="83" width="114" height="20" font="0">(Schwartz et al) <a href="data supplement.html#237">(27)</a> </text>
<text top="595" left="83" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23126252">23126252</a></text>
<text top="595" left="137" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23126252"> </a></text>
<text top="560" left="272" width="41" height="20" font="0">15,871 </text>
<text top="577" left="272" width="81" height="20" font="0">Median 31 mo </text>
<text top="595" left="272" width="3" height="20" font="0"> </text>
<text top="612" left="272" width="63" height="20" font="13"><i>Adherence </i></text>
<text top="631" left="272" width="76" height="19" font="0">– Active 79% </text>
<text top="648" left="272" width="87" height="19" font="0">– Placebo 81% </text>
<text top="665" left="272" width="94" height="19" font="0">– Based on % of </text>
<text top="681" left="282" width="92" height="20" font="0">participants who </text>
<text top="699" left="282" width="93" height="20" font="0">continued taking </text>
<text top="716" left="282" width="61" height="20" font="0">study drug </text>
<text top="733" left="282" width="83" height="20" font="0">throughout the </text>
<text top="750" left="282" width="33" height="20" font="0">study </text>
<text top="769" left="272" width="119" height="19" font="0">– 89% of participants </text>
<text top="785" left="282" width="102" height="20" font="0">in each group had </text>
<text top="560" left="407" width="89" height="20" font="0">Dalcetrapib 600 </text>
<text top="577" left="407" width="49" height="20" font="0">mg daily </text>
<text top="595" left="407" width="3" height="20" font="0"> </text>
<text top="612" left="407" width="88" height="20" font="0">97% on a statin </text>
<text top="629" left="407" width="94" height="20" font="0">Intensity or dose </text>
<text top="646" left="407" width="70" height="20" font="0">not reported </text>
<text top="560" left="528" width="55" height="20" font="13"><i>Inclusion  </i></text>
<text top="579" left="528" width="171" height="19" font="0">– Prior hospitalization for ACS, </text>
<text top="595" left="539" width="66" height="20" font="0">MI with PCI </text>
<text top="614" left="528" width="156" height="19" font="0">– Target baseline LDL &lt;100 </text>
<text top="630" left="539" width="157" height="20" font="0">mg/dL, preferably 70 mg/dL, </text>
<text top="647" left="539" width="141" height="20" font="0">but not excluded if higher </text>
<text top="664" left="528" width="3" height="20" font="0"> </text>
<text top="681" left="528" width="147" height="20" font="13"><i>Exclusion (cardiovascular) </i></text>
<text top="700" left="528" width="100" height="19" font="0">– TG &gt;400 mg/dL </text>
<text top="716" left="528" width="3" height="20" font="0"> </text>
<text top="733" left="528" width="120" height="20" font="0">Mean age 60.3±9.1 y </text>
<text top="750" left="528" width="71" height="20" font="0">20% women </text>
<text top="768" left="528" width="81" height="20" font="0">12% nonwhite </text>
<text top="560" left="717" width="124" height="20" font="0">ERC primary outcome </text>
<text top="577" left="717" width="72" height="20" font="0">Not reported </text>
<text top="595" left="717" width="3" height="20" font="0"> </text>
<text top="612" left="717" width="140" height="20" font="0">ERC secondary outcome </text>
<text top="629" left="717" width="72" height="20" font="0">Not reported </text>
<text top="646" left="717" width="3" height="20" font="0"> </text>
<text top="663" left="717" width="130" height="20" font="0">Study primary outcome </text>
<text top="681" left="717" width="147" height="20" font="0">Death from coronary heart </text>
<text top="698" left="717" width="168" height="20" font="0">disease, nonfatal MI, ischemic </text>
<text top="715" left="717" width="148" height="20" font="0">stroke, unstable angina, or </text>
<text top="732" left="717" width="180" height="20" font="0">cardiac arrest with resuscitation) </text>
<text top="751" left="717" width="132" height="19" font="0">– HR: 1.04 (0.93–1.16)  </text>
<text top="769" left="717" width="162" height="19" font="0">– Event rates 9.2% vs. 9.1%, </text>
<text top="784" left="728" width="41" height="20" font="13"><i>p</i>=0.52 </text>
<text top="562" left="920" width="128" height="19" font="0">– Mean SBP remained </text>
<text top="578" left="930" width="143" height="20" font="0">approximately 0.6 mm Hg </text>
<text top="595" left="930" width="145" height="20" font="0">higher with dalcetrapib vs. </text>
<text top="612" left="930" width="103" height="20" font="0">placebo (<i>p</i>&lt;0.001) </text>
<text top="631" left="920" width="125" height="19" font="0">– Greater incidence of </text>
<text top="647" left="930" width="163" height="20" font="0">hypertension with dalcetrapib </text>
<text top="664" left="930" width="154" height="20" font="0">(7.3% vs. 6.5%) but smaller </text>
<text top="681" left="930" width="120" height="20" font="0">difference in report of </text>
<text top="698" left="930" width="177" height="20" font="0">hypertension as a serious event </text>
<text top="716" left="930" width="90" height="20" font="0">(0.6% vs. 0.3%) </text>
<text top="734" left="920" width="174" height="19" font="0">– Greater incidence of diarrhea </text>
<text top="750" left="930" width="60" height="20" font="0">6.8 vs. 4.3 </text>
</page>
<page number="36" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">36 </text>
<text top="107" left="282" width="71" height="20" font="0">at least 80% </text>
<text top="124" left="282" width="108" height="20" font="0">adherence to study </text>
<text top="141" left="282" width="28" height="20" font="0">drug </text>
<text top="107" left="717" width="3" height="20" font="0"> </text>
<text top="168" left="83" width="62" height="20" font="7"><b>FOURIER  </b></text>
<text top="185" left="83" width="112" height="20" font="0">(Sabatine et al) <a href="data supplement.html#237">(28)</a> </text>
<text top="202" left="83" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28304224">28304224</a></text>
<text top="202" left="137" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28304224"> </a></text>
<text top="168" left="272" width="41" height="20" font="0">27,564 </text>
<text top="185" left="272" width="117" height="20" font="0">Median follow-up 2.2 </text>
<text top="202" left="272" width="10" height="20" font="0">y </text>
<text top="219" left="272" width="3" height="20" font="0"> </text>
<text top="237" left="272" width="63" height="20" font="13"><i>Adherence </i></text>
<text top="255" left="272" width="76" height="19" font="0">– Active 88% </text>
<text top="273" left="272" width="87" height="19" font="0">– Placebo 87% </text>
<text top="290" left="272" width="111" height="19" font="0">– Based on number </text>
<text top="306" left="282" width="100" height="20" font="0">taking study drug; </text>
<text top="323" left="282" width="64" height="20" font="0">specifics of </text>
<text top="341" left="282" width="82" height="20" font="0">adherence not </text>
<text top="358" left="282" width="49" height="20" font="0">reported </text>
<text top="168" left="407" width="71" height="20" font="0">Evolocumab </text>
<text top="185" left="407" width="79" height="20" font="0">either 140 mg </text>
<text top="202" left="407" width="100" height="20" font="0">every 2 wk or 420 </text>
<text top="219" left="407" width="67" height="20" font="0">mg monthly </text>
<text top="237" left="407" width="3" height="20" font="0"> </text>
<text top="255" left="407" width="89" height="19" font="0">– High-intensity </text>
<text top="271" left="417" width="71" height="20" font="0">statin 69.5% </text>
<text top="290" left="407" width="67" height="19" font="0">– Moderate-</text>
<text top="306" left="417" width="81" height="20" font="0">intensity statin </text>
<text top="323" left="417" width="38" height="20" font="0">30.2% </text>
<text top="168" left="528" width="52" height="20" font="13"><i>Inclusion </i></text>
<text top="186" left="528" width="83" height="19" font="0">– Age 40–85 y </text>
<text top="204" left="528" width="151" height="19" font="0">– Clinically evident ASCVD </text>
<text top="220" left="539" width="145" height="20" font="0">(prior MI, nonhemorrhagic </text>
<text top="237" left="539" width="160" height="20" font="0">stroke, or symptomatic PAD) </text>
<text top="256" left="528" width="157" height="19" font="0">– Most recent fasting LDL-C </text>
<text top="272" left="539" width="143" height="20" font="0">≥70 mg/dL or non-HDL-C </text>
<text top="289" left="539" width="155" height="20" font="0">≥100 mg/dL after ≥2 weeks </text>
<text top="306" left="539" width="125" height="20" font="0">of stable lipid-lowering </text>
<text top="323" left="539" width="44" height="20" font="0">therapy </text>
<text top="342" left="528" width="144" height="19" font="0">– Fasting TG &lt;400 mg/dL </text>
<text top="360" left="528" width="50" height="19" font="0">– PLUS  </text>
<text top="377" left="539" width="11" height="18" font="0">• </text>
<text top="377" left="561" width="111" height="20" font="13"><i>At least 1 major risk </i></text>
<text top="394" left="561" width="125" height="20" font="13"><i>factor</i> (DM, age &gt;65 y, </text>
<text top="411" left="561" width="60" height="20" font="0">prior MI or </text>
<text top="428" left="561" width="142" height="20" font="0">nonhemorrhagic stroke in </text>
<text top="445" left="561" width="119" height="20" font="0">the last 6 mo, current </text>
<text top="463" left="561" width="130" height="20" font="0">daily smoking, prior MI, </text>
<text top="480" left="561" width="113" height="20" font="0">stroke, symptomatic </text>
<text top="497" left="561" width="33" height="20" font="0">PAD) </text>
<text top="516" left="539" width="11" height="18" font="0">• </text>
<text top="515" left="561" width="124" height="20" font="0">Or <i>2 minor risk factors</i> </text>
<text top="533" left="561" width="118" height="20" font="0">(prior non–MI-related </text>
<text top="550" left="561" width="99" height="20" font="0">revascularization, </text>
<text top="567" left="561" width="143" height="20" font="0">residual &gt;40% stenosis in </text>
<text top="584" left="561" width="127" height="20" font="0">≥2 large vessels, most </text>
<text top="601" left="561" width="140" height="20" font="0">recent HDL-C &lt;40 mg/dL </text>
<text top="619" left="561" width="131" height="20" font="0">for men and &lt;50 mg/dL </text>
<text top="636" left="561" width="135" height="20" font="0">for women,  most recent </text>
<text top="653" left="561" width="134" height="20" font="0">hsCRP &gt;2.0 mg/L, most </text>
<text top="670" left="561" width="109" height="20" font="0">recent LDL-C ≥130 </text>
<text top="688" left="561" width="118" height="20" font="0">mg/dL or non-HDL-C </text>
<text top="705" left="561" width="133" height="20" font="0">≥160 mg/dL,  metabolic </text>
<text top="722" left="561" width="62" height="20" font="0">syndrome) </text>
<text top="739" left="528" width="3" height="20" font="0"> </text>
<text top="756" left="528" width="147" height="20" font="13"><i>Exclusion (cardiovascular) </i></text>
<text top="775" left="528" width="163" height="19" font="0">– MI or stroke within 4 weeks </text>
<text top="168" left="717" width="124" height="20" font="0">ERC primary outcome </text>
<text top="186" left="717" width="176" height="19" font="0">– HR: 0.80 (95% CI: 0.73–0.88) </text>
<text top="204" left="717" width="170" height="19" font="0">– Event rates (5.9% vs. 7.4%), </text>
<text top="220" left="728" width="48" height="20" font="13"><i>p</i>&lt;0.001 </text>
<text top="239" left="717" width="75" height="19" font="0">– ARR: 1.5% </text>
<text top="256" left="717" width="60" height="19" font="0">– NNT: 67 </text>
<text top="272" left="717" width="3" height="20" font="0"> </text>
<text top="289" left="717" width="140" height="20" font="0">ERC secondary outcome </text>
<text top="308" left="717" width="176" height="19" font="0">– HR: 0.85 (95% CI: 0.79–0.92) </text>
<text top="325" left="717" width="166" height="19" font="0">– Event rates (9.8% vs. 11.3), </text>
<text top="341" left="728" width="48" height="20" font="13"><i>p</i>&lt;0.001 </text>
<text top="360" left="717" width="75" height="19" font="0">– ARR: 1.5% </text>
<text top="377" left="717" width="60" height="19" font="0">– NNT: 67 </text>
<text top="393" left="717" width="3" height="20" font="0"> </text>
<text top="168" left="920" width="156" height="20" font="0">Injection site reactions more </text>
<text top="185" left="920" width="179" height="20" font="0">frequent with evolocumab (2.1% </text>
<text top="202" left="920" width="180" height="20" font="0">vs. 1.6%), 90% were considered </text>
<text top="219" left="920" width="186" height="20" font="0">mild, 0.1% in each group stopped </text>
<text top="237" left="920" width="180" height="20" font="0">treatment because of a reaction  </text>
</page>
<page number="37" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="14" size="12" family="Times" color="#424242"/>
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">37 </text>
<text top="109" left="528" width="160" height="19" font="0">– NYHA class III or IV or last </text>
<text top="125" left="539" width="125" height="20" font="0">ejection fraction &lt;30% </text>
<text top="143" left="528" width="172" height="19" font="0">– Any prior hemorrhagic stroke </text>
<text top="161" left="528" width="107" height="19" font="0">– Uncontrolled BP  </text>
<text top="178" left="528" width="150" height="19" font="0">– Uncontrolled or recurrent </text>
<text top="194" left="539" width="127" height="20" font="0">ventricular tachycardia </text>
<text top="211" left="528" width="3" height="20" font="0"> </text>
<text top="228" left="528" width="120" height="20" font="0">Mean age 62.5±9.1 y </text>
<text top="246" left="528" width="71" height="20" font="0">25% women </text>
<text top="263" left="528" width="84" height="20" font="0">15% nonwhite <i> </i></text>
<text top="281" left="83" width="122" height="20" font="0">ODYSSEY Outcomes </text>
<text top="298" left="83" width="118" height="20" font="0">(Schwartz et al,) <a href="data supplement.html#237">(29)</a> </text>
<text top="315" left="83" width="96" height="20" font="0">PMID-IN PRESS </text>
<text top="281" left="272" width="41" height="20" font="14">18,924 </text>
<text top="298" left="272" width="117" height="20" font="14">Median follow-up 2.8 </text>
<text top="315" left="272" width="10" height="20" font="14">y </text>
<text top="332" left="272" width="3" height="20" font="14"> </text>
<text top="350" left="272" width="63" height="20" font="13"><i>Adherence </i></text>
<text top="368" left="272" width="89" height="19" font="0">– Active 96.4 % </text>
<text top="386" left="272" width="100" height="19" font="0">– Placebo 96.6 % </text>
<text top="403" left="272" width="99" height="19" font="0">– Based on study </text>
<text top="419" left="282" width="85" height="20" font="0">discontinuation </text>
<text top="437" left="282" width="31" height="20" font="0">rates </text>
<text top="454" left="272" width="3" height="20" font="0"> </text>
<text top="281" left="407" width="85" height="20" font="0">Alirocumab 75–</text>
<text top="298" left="407" width="107" height="20" font="0">150 mg every 2 wk </text>
<text top="315" left="407" width="3" height="20" font="0"> </text>
<text top="332" left="407" width="96" height="20" font="0">Drug was titrated </text>
<text top="350" left="407" width="104" height="20" font="0">to goal LDL 25–50 </text>
<text top="367" left="407" width="106" height="20" font="0">mg/dL; switched to </text>
<text top="384" left="407" width="103" height="20" font="0">placebo if LDL&lt;15 </text>
<text top="401" left="407" width="38" height="20" font="0">mg/dL </text>
<text top="419" left="407" width="3" height="20" font="0"> </text>
<text top="436" left="407" width="78" height="20" font="0">High-intensity </text>
<text top="453" left="407" width="84" height="20" font="0">statin in 88.6% </text>
<text top="470" left="407" width="82" height="20" font="0">Low-moderate </text>
<text top="487" left="407" width="93" height="20" font="0">intensity in 8.8% </text>
<text top="281" left="528" width="52" height="20" font="13"><i>Inclusion </i></text>
<text top="300" left="528" width="70" height="19" font="0">– Age &gt;40 y </text>
<text top="317" left="528" width="152" height="19" font="0">– ACS within past 1–12 mo </text>
<text top="334" left="528" width="167" height="19" font="0">– LDL ≥70 mg/dL or non-HDL </text>
<text top="350" left="539" width="143" height="20" font="0">≥100 mg/dL or ApoB ≥80 </text>
<text top="368" left="539" width="38" height="20" font="0">mg/dL </text>
<text top="386" left="528" width="140" height="19" font="0">– High-intensity statin ≥2 </text>
<text top="402" left="539" width="38" height="20" font="0">weeks </text>
<text top="419" left="528" width="3" height="20" font="0"> </text>
<text top="437" left="528" width="147" height="20" font="13"><i>Exclusion (cardiovascular) </i></text>
<text top="455" left="528" width="157" height="19" font="0">– Uncontrolled hypertension </text>
<text top="473" left="528" width="154" height="19" font="0">– NYHA class III or IV heart </text>
<text top="489" left="539" width="37" height="20" font="0">failure </text>
<text top="507" left="528" width="137" height="19" font="0">– Ejection fraction &lt;25% </text>
<text top="525" left="528" width="100" height="19" font="0">– TG &gt;400 mg/dL </text>
<text top="541" left="528" width="3" height="20" font="0"> </text>
<text top="558" left="528" width="85" height="20" font="0">Mean age 58 y </text>
<text top="575" left="528" width="75" height="20" font="0">25% women  </text>
<text top="593" left="528" width="145" height="20" font="0">Nonwhite participation not </text>
<text top="610" left="528" width="49" height="20" font="0">reported </text>
<text top="627" left="528" width="3" height="20" font="13"><i> </i></text>
<text top="281" left="717" width="124" height="20" font="0">ERC primary outcome </text>
<text top="300" left="717" width="176" height="19" font="0">– HR: 0.85 (95% CI: 0.78, 0.93) </text>
<text top="317" left="717" width="158" height="19" font="0">– Event rates 9.5% vs. 11.1, </text>
<text top="333" left="728" width="48" height="20" font="13"><i>p</i>&lt;0.001 </text>
<text top="352" left="717" width="75" height="19" font="0">– ARR: 1.6% </text>
<text top="369" left="717" width="60" height="19" font="0">– NNT: 63 </text>
<text top="385" left="717" width="3" height="20" font="0"> </text>
<text top="402" left="717" width="150" height="20" font="0">ERC secondary outcome‡  </text>
<text top="421" left="717" width="176" height="19" font="0">– HR: 0.87 (95% CI: 0.81, 0.94) </text>
<text top="438" left="717" width="175" height="19" font="0">– Event rates 13.7% vs. 15.6%, </text>
<text top="454" left="728" width="48" height="20" font="13"><i>p</i>&lt;0.001 </text>
<text top="473" left="717" width="75" height="19" font="0">– ARR: 1.9% </text>
<text top="491" left="717" width="60" height="19" font="0">– NNT: 53 </text>
<text top="506" left="717" width="3" height="20" font="0"> </text>
<text top="524" left="717" width="3" height="20" font="0"> </text>
<text top="281" left="920" width="169" height="20" font="0">Injection site reaction 3.8% vs. </text>
<text top="298" left="920" width="169" height="20" font="0">2.1%, HR: 1.82 (95% CI: 1.54–</text>
<text top="315" left="920" width="31" height="20" font="0">2.17) </text>
<text top="645" left="83" width="971" height="20" font="0">ACC indicates American College of Cardiology; ACS, acute coronary syndrome(s); ALT, alanine aminotransferase; apoB, apolipoprotein B; ARR, absolute risk reduction; ASCVD, </text>
<text top="662" left="83" width="1022" height="20" font="0">atherosclerotic cardiovascular disease; BP, blood pressure; CABG, coronary artery bypass graft; CAD, coronary artery disease; CI, confidence interval; CKD, chronic kidney disease; CRP, </text>
<text top="679" left="83" width="1004" height="20" font="0">C-reactive protein; CV, cardiovascular; CVD, cardiovascular disease; DBP, diastolic blood pressure; DM, diabetes mellitus; ERC, evidence review committee; FDA, U.S. Food and Drug </text>
<text top="696" left="83" width="998" height="20" font="0">Administration; FH, familial hypercholesterolemia; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; hsCRP, high-sensitivity C-reactive protein; IV, intravenous; LDL-C, low-</text>
<text top="714" left="83" width="1008" height="20" font="0">density lipoprotein cholesterol; MI, myocardial infarction; NNT, number needed to treat; NYHA, New York Heart Association; PAD, peripheral artery disease; PCI, percutaneous coronary </text>
<text top="731" left="83" width="504" height="20" font="0">intervention; SBP, systolic blood pressure; TG, triglycerides; and ULN, upper limit of normal. </text>
<text top="748" left="83" width="3" height="20" font="0"> </text>
<text top="765" left="83" width="80" height="20" font="0">*__________. </text>
<text top="783" left="83" width="318" height="20" font="0">†Outcomes only included coronary death, not CVD death. </text>
</page>
<page number="38" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="15" size="16" family="Times" color="#000000"/>
	<fontspec id="16" size="12" family="Times" color="#0563c1"/>
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">38 </text>
<text top="107" left="83" width="336" height="20" font="0">‡Includes only coronary heart disease death, not CVD death. </text>
<text top="124" left="83" width="3" height="20" font="0"> </text>
<text top="148" left="81" width="5" height="16" font="15"> </text>
<text top="169" left="81" width="5" height="16" font="15"> </text>
<text top="190" left="81" width="5" height="16" font="15"> </text>
<text top="211" left="81" width="5" height="16" font="15"> </text>
<text top="231" left="81" width="5" height="16" font="15"> </text>
<text top="252" left="81" width="5" height="16" font="15"> </text>
<text top="267" left="112" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="284" left="137" width="48" height="20" font="7"><b>Author; </b></text>
<text top="302" left="115" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="276" left="300" width="118" height="20" font="7"><b>Study Type/Design; </b></text>
<text top="293" left="327" width="66" height="20" font="7"><b>Study Size </b></text>
<text top="284" left="487" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="276" left="670" width="179" height="20" font="7"><b>Primary Endpoint and Results </b></text>
<text top="293" left="670" width="184" height="20" font="7"><b>(P values; OR or RR; &amp; 95% CI) </b></text>
<text top="276" left="964" width="130" height="20" font="7"><b>Summary/Conclusion </b></text>
<text top="293" left="992" width="75" height="20" font="7"><b>Comment(s) </b></text>
<text top="319" left="91" width="133" height="20" font="0">Giugliano RP et al 2017 </text>
<text top="337" left="91" width="29" height="20" font="0"><a href="data supplement.html#237">(30)</a>  </text>
<text top="354" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28813214">28813214</a></text>
<text top="354" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28813214"> </a></text>
<text top="371" left="91" width="3" height="20" font="0"> </text>
<text top="319" left="244" width="125" height="20" font="7"><b>Study type/Design: </b>   </text>
<text top="337" left="244" width="217" height="20" font="0">Substudy of the Further Cardiovascular </text>
<text top="354" left="244" width="185" height="20" font="0">Outcomes Research with PCSK9 </text>
<text top="371" left="244" width="220" height="20" font="0">Inhibition in Subjects with Elevated Risk </text>
<text top="388" left="244" width="217" height="20" font="0">(FOURIER) trial that evaluated ASCVD </text>
<text top="406" left="244" width="198" height="20" font="0">outcomes in those on statin therapy </text>
<text top="423" left="244" width="197" height="20" font="0">assigned to evolocumab or placebo </text>
<text top="440" left="244" width="3" height="20" font="0"> </text>
<text top="457" left="244" width="3" height="20" font="0"> </text>
<text top="474" left="244" width="178" height="20" font="0">Double-blind randomization was </text>
<text top="492" left="244" width="214" height="20" font="0">performed with the use of a central, 24-</text>
<text top="509" left="244" width="226" height="20" font="0">hour, interactive, computerized response </text>
<text top="526" left="244" width="211" height="20" font="0">system, with stratification according to </text>
<text top="543" left="244" width="170" height="20" font="0">region and final screening LDL </text>
<text top="561" left="244" width="208" height="20" font="0">cholesterol level (&lt;85 mg per deciliter </text>
<text top="578" left="244" width="187" height="20" font="0">[2.2 mmol per liter] or ≥85 mg per </text>
<text top="595" left="244" width="53" height="20" font="0">deciliter). </text>
<text top="612" left="244" width="3" height="20" font="0"> </text>
<text top="630" left="244" width="3" height="20" font="0"> </text>
<text top="647" left="244" width="228" height="20" font="0">Evaluated cognition using the Cambridge </text>
<text top="664" left="244" width="201" height="20" font="0">Neuropsychological Test Automated </text>
<text top="681" left="244" width="103" height="20" font="0">Battery (CANTAB, </text>
<text top="698" left="244" width="163" height="20" font="16"><a href="http://www.cambridgecognition.com/">www.cambridgecognition.com</a></text>
<text top="698" left="408" width="11" height="20" font="0"><a href="http://www.cambridgecognition.com/">) </a> </text>
<text top="715" left="244" width="3" height="20" font="0"> </text>
<text top="733" left="244" width="80" height="20" font="7"><b>Study Size:</b>    </text>
<text top="750" left="244" width="3" height="20" font="0"> </text>
<text top="767" left="244" width="221" height="20" font="0">A total of 2442 patients in the FOURIER </text>
<text top="784" left="244" width="213" height="20" font="0">trial were screened for eligibility for the </text>
<text top="319" left="487" width="113" height="20" font="7"><b>Inclusion criteria:</b>   </text>
<text top="337" left="487" width="167" height="20" font="0">Enrolled before administration </text>
<text top="354" left="487" width="156" height="20" font="0">of first dose of study drug or </text>
<text top="371" left="487" width="46" height="20" font="0">placebo </text>
<text top="388" left="487" width="3" height="20" font="0"> </text>
<text top="406" left="487" width="141" height="20" font="0">-40 and 85 years of age, -</text>
<text top="423" left="487" width="92" height="20" font="0">clinically evident </text>
<text top="440" left="487" width="90" height="20" font="0">atherosclerosis  </text>
<text top="457" left="487" width="152" height="20" font="0">-LDL cholesterol level of 70 </text>
<text top="474" left="487" width="167" height="20" font="0">mg per deciliter (1.8 mmol per </text>
<text top="492" left="487" width="159" height="20" font="0">liter) or higher or a non–high-</text>
<text top="509" left="487" width="169" height="20" font="0">density lipoprotein level of 100 </text>
<text top="526" left="487" width="167" height="20" font="0">mg per deciliter (2.6 mmol per </text>
<text top="543" left="487" width="86" height="20" font="0">liter) or higher,  </text>
<text top="561" left="487" width="161" height="20" font="0">-receiving moderate-intensity </text>
<text top="578" left="487" width="123" height="20" font="0">or high-intensity statin </text>
<text top="595" left="487" width="48" height="20" font="0">therapy. </text>
<text top="612" left="487" width="3" height="20" font="0"> </text>
<text top="629" left="487" width="117" height="20" font="7"><b>Excusion  criteria:</b>   </text>
<text top="647" left="487" width="154" height="20" font="0">Current or past diagnosis of </text>
<text top="664" left="487" width="146" height="20" font="0">dementia or mild cognitive </text>
<text top="681" left="487" width="169" height="20" font="0">impairment or any condition or </text>
<text top="698" left="487" width="136" height="20" font="0">situation, including other </text>
<text top="715" left="487" width="115" height="20" font="0">mental or neurologic </text>
<text top="733" left="487" width="118" height="20" font="0">disorders, that, in the </text>
<text top="750" left="487" width="154" height="20" font="0">investigator’s opinion, could </text>
<text top="767" left="487" width="161" height="20" font="0">confound the study results or </text>
<text top="784" left="487" width="167" height="20" font="0">considerably interfere with the </text>
<text top="321" left="670" width="83" height="20" font="7"><b>1</b>°<b> endpoint:</b>   </text>
<text top="338" left="670" width="228" height="20" font="0">The score on the spatial working memory </text>
<text top="355" left="670" width="209" height="20" font="0">strategy index of executive function, a </text>
<text top="372" left="670" width="237" height="20" font="0">principal component of CANTAB; CANTAB </text>
<text top="390" left="670" width="203" height="20" font="0">was performed at screening (training </text>
<text top="407" left="670" width="231" height="20" font="0">session), at baseline, at 24 weeks, yearly, </text>
<text top="424" left="670" width="143" height="20" font="0">and at the end of the trial. </text>
<text top="441" left="670" width="3" height="20" font="0"> </text>
<text top="458" left="670" width="66" height="20" font="7"><b>Results:</b>     </text>
<text top="476" left="670" width="103" height="20" font="0">Primary endpoint:  </text>
<text top="493" left="670" width="238" height="20" font="0">Evolocumab:   -0.21±2.62   Placebo group: </text>
<text top="510" left="670" width="66" height="20" font="0">0.29±2.81   </text>
<text top="527" left="670" width="148" height="20" font="0">P&lt;0.001 for noninferiority;  </text>
<text top="544" left="670" width="128" height="20" font="0">P=0.85 for superiority)  </text>
<text top="562" left="670" width="3" height="20" font="0"> </text>
<text top="579" left="670" width="126" height="20" font="0">Secondary endpoints:  </text>
<text top="596" left="670" width="239" height="20" font="0">No significant between-group differences in </text>
<text top="613" left="670" width="154" height="20" font="0">scores for working memory  </text>
<text top="631" left="670" width="118" height="20" font="0">(change in raw score </text>
<text top="648" left="670" width="116" height="20" font="0">Evolocumab:  -0.52   </text>
<text top="665" left="670" width="129" height="20" font="0">Placebo group: -0.93)   </text>
<text top="682" left="670" width="122" height="20" font="0">For episodic memory  </text>
<text top="699" left="670" width="121" height="20" font="0">(change in raw score, </text>
<text top="717" left="670" width="113" height="20" font="0">Evolocumab:  -1.53  </text>
<text top="734" left="670" width="132" height="20" font="0">Placebo group: -1.53 )   </text>
<text top="751" left="670" width="136" height="20" font="0">For psychomotor speed  </text>
<text top="768" left="670" width="124" height="20" font="0">(change in raw score,  </text>
<text top="785" left="670" width="141" height="20" font="0">Evolocumab:    5.2 msec  </text>
<text top="319" left="923" width="85" height="20" font="7"><b>Conclusions:  </b></text>
<text top="337" left="923" width="213" height="20" font="0">In a randomized trial involving patients </text>
<text top="354" left="923" width="194" height="20" font="0">who received either evolocumab or </text>
<text top="371" left="923" width="200" height="20" font="0">placebo in addition to statin therapy, </text>
<text top="388" left="923" width="161" height="20" font="0">no significant between-group </text>
<text top="406" left="923" width="194" height="20" font="0">difference in cognitive function was </text>
<text top="423" left="923" width="210" height="20" font="0">observed over a median of 19 months </text>
<text top="440" left="923" width="3" height="20" font="0"> </text>
<text top="457" left="923" width="204" height="20" font="7"><b>Strengths:   Done in the context of </b></text>
<text top="474" left="923" width="191" height="20" font="7"><b>a randomized controlled clinical </b></text>
<text top="492" left="923" width="104" height="20" font="7"><b>trial of large size  </b></text>
<text top="509" left="923" width="212" height="20" font="7"><b>CANTAB tool has been validated as </b></text>
<text top="526" left="923" width="91" height="20" font="7"><b>a research tool </b></text>
<text top="543" left="923" width="206" height="20" font="7"><b>There was absence of sef reported </b></text>
<text top="561" left="923" width="180" height="20" font="7"><b>clinical change in cognition to </b></text>
<text top="578" left="923" width="129" height="20" font="7"><b>parallel these results  </b></text>
<text top="595" left="923" width="83" height="20" font="7"><b>Limitations: </b>   </text>
<text top="612" left="923" width="121" height="20" font="0">Followup period short </text>
<text top="629" left="923" width="213" height="20" font="0">Patients with mid cognitive impairment </text>
<text top="647" left="923" width="207" height="20" font="0">or known dementia were not included </text>
<text top="664" left="923" width="212" height="20" font="0">CANTAB tool not a standard in clinical </text>
<text top="681" left="923" width="46" height="20" font="0">practice </text>
<text top="698" left="923" width="7" height="20" font="0">  </text>
<text top="716" left="923" width="3" height="20" font="0"> </text>
<text top="733" left="923" width="3" height="20" font="0"> </text>
<text top="750" left="923" width="3" height="20" font="0"> </text>
</page>
<page number="39" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">39 </text>
<text top="107" left="244" width="205" height="20" font="0">EBBINGHAUS study, and 1974 were </text>
<text top="124" left="244" width="187" height="20" font="0">enrolled (full-analysis population). </text>
<text top="141" left="244" width="3" height="20" font="0"> </text>
<text top="107" left="487" width="152" height="20" font="0">patient’s participation in the </text>
<text top="124" left="487" width="27" height="20" font="0">trial. </text>
<text top="141" left="487" width="3" height="20" font="0"> </text>
<text top="159" left="487" width="3" height="20" font="0"> </text>
<text top="176" left="487" width="3" height="20" font="0"> </text>
<text top="193" left="487" width="3" height="20" font="0"> </text>
<text top="107" left="670" width="154" height="20" font="0">Placebo group:  0.9 msec)   </text>
<text top="124" left="670" width="3" height="20" font="0"> </text>
<text top="141" left="670" width="225" height="20" font="0">In an exploratory analysis, there were no </text>
<text top="159" left="670" width="210" height="20" font="0">associations between LDL cholesterol </text>
<text top="176" left="670" width="161" height="20" font="0">levels and cognitive changes </text>
<text top="193" left="670" width="3" height="20" font="0"> </text>
<text top="210" left="670" width="7" height="20" font="0">  </text>
<text top="227" left="670" width="3" height="20" font="0"> </text>
<text top="252" left="81" width="5" height="16" font="15"> </text>
<text top="266" left="81" width="4" height="24" font="15"> </text>
<text top="287" left="81" width="660" height="24" font="4"><b>Data Supplement 9. RCTs comparing evidence on Severe Hypercholesterolemia (Section 4.2)  </b></text>
<text top="308" left="111" width="38" height="20" font="7"><b>Study </b></text>
<text top="325" left="100" width="61" height="20" font="7"><b>Acronym; </b></text>
<text top="343" left="106" width="48" height="20" font="7"><b>Author; </b></text>
<text top="360" left="115" width="30" height="20" font="7"><b>Year </b></text>
<text top="377" left="99" width="62" height="20" font="7"><b>Published </b></text>
<text top="308" left="213" width="83" height="20" font="7"><b>Aim of Study; </b></text>
<text top="325" left="218" width="74" height="20" font="7"><b>Study Type; </b></text>
<text top="343" left="212" width="86" height="20" font="7"><b>Study Size (N) </b></text>
<text top="308" left="365" width="111" height="20" font="7"><b>Patient population </b></text>
<text top="308" left="516" width="112" height="20" font="7"><b>Study Intervention </b></text>
<text top="325" left="534" width="76" height="20" font="7"><b>(# patients) / </b></text>
<text top="343" left="517" width="111" height="20" font="7"><b>Study Comparator </b></text>
<text top="360" left="537" width="69" height="20" font="7"><b>(# patients) </b></text>
<text top="308" left="692" width="105" height="20" font="7"><b>Endpoint Results </b></text>
<text top="325" left="650" width="188" height="20" font="7"><b>(Absolute Event Rates, P value; </b></text>
<text top="343" left="683" width="123" height="20" font="7"><b>OR or RR; &amp; 95% CI) </b></text>
<text top="308" left="893" width="175" height="20" font="7"><b>Relevant 2° Endpoint (if any); </b></text>
<text top="325" left="925" width="111" height="20" font="7"><b>Study Limitations; </b></text>
<text top="343" left="933" width="96" height="20" font="7"><b>Adverse Events </b></text>
<text top="395" left="89" width="64" height="20" font="7"><b>ENHANCE </b></text>
<text top="412" left="89" width="73" height="20" font="0">Kastelein JJ, </text>
<text top="429" left="89" width="64" height="20" font="0">et al., 2008 </text>
<text top="447" left="89" width="25" height="20" font="0"><a href="data supplement.html#237">(31)</a> </text>
<text top="464" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18376000">18376000</a></text>
<text top="464" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18376000"> </a></text>
<text top="395" left="184" width="127" height="20" font="0">To assess the effect of </text>
<text top="412" left="184" width="141" height="20" font="0">ezetimibe on progression </text>
<text top="429" left="184" width="128" height="20" font="0">of carotid intima-media </text>
<text top="447" left="184" width="139" height="20" font="0">thickness in patients with </text>
<text top="464" left="184" width="35" height="20" font="0">HeFH </text>
<text top="481" left="184" width="127" height="20" font="7"><b>Study design</b>: Double </text>
<text top="498" left="184" width="133" height="20" font="0">blind placebo-controlled </text>
<text top="515" left="184" width="125" height="20" font="0">RCT multicenter study </text>
<text top="533" left="184" width="118" height="20" font="7"><b>Size</b>: N=720 patients </text>
<text top="395" left="339" width="106" height="20" font="7"><b>Inclusion criteria: </b></text>
<text top="412" left="339" width="153" height="20" font="0">Men and women age 30-75 </text>
<text top="429" left="339" width="161" height="20" font="0">with clinical HeFH defined by </text>
<text top="447" left="339" width="152" height="20" font="0">WHO criteria. LDL-C ≥ 210 </text>
<text top="464" left="339" width="123" height="20" font="0">mg/dL untreated; if on </text>
<text top="481" left="339" width="130" height="20" font="0">treatment LDL-C ≥ 210 </text>
<text top="498" left="339" width="150" height="20" font="0">mg/dL after placebo run-in. </text>
<text top="515" left="339" width="110" height="20" font="7"><b>Exclusion criteria: </b></text>
<text top="533" left="339" width="125" height="20" font="0">high-grade stenosis or </text>
<text top="550" left="339" width="129" height="20" font="0">occlusion of the carotid </text>
<text top="567" left="339" width="142" height="20" font="0">artery, a history of carotid </text>
<text top="584" left="339" width="144" height="20" font="0">endarterectomy or carotid </text>
<text top="602" left="339" width="146" height="20" font="0">stenting, homozygous FH, </text>
<text top="619" left="339" width="156" height="20" font="0">New York Heart Association </text>
<text top="636" left="339" width="137" height="20" font="0">class III or IV congestive </text>
<text top="653" left="339" width="115" height="20" font="0">heart failure, cardiac </text>
<text top="671" left="339" width="155" height="20" font="0">arrhythmia, angina pectoris, </text>
<text top="688" left="339" width="135" height="20" font="0">or recent cardiovascular </text>
<text top="705" left="339" width="43" height="20" font="0">events. </text>
<text top="395" left="514" width="109" height="20" font="7"><b>Intervention/Comp</b></text>
<text top="412" left="514" width="109" height="20" font="7"><b>arator:</b> Simvastatin </text>
<text top="429" left="514" width="92" height="20" font="0">80 mg daily plus </text>
<text top="447" left="514" width="98" height="20" font="0">placebo (360) vs. </text>
<text top="464" left="514" width="102" height="20" font="0">simvastatin 80 mg </text>
<text top="481" left="514" width="111" height="20" font="0">daily plus ezetimibe </text>
<text top="498" left="514" width="99" height="20" font="0">10 mg (360) daily </text>
<text top="516" left="514" width="68" height="20" font="0">over 24 mo. </text>
<text top="533" left="514" width="3" height="20" font="0"> </text>
<text top="550" left="514" width="3" height="20" font="0"> </text>
<text top="395" left="643" width="183" height="20" font="7"><b>Primary endpoint:</b> Change from </text>
<text top="412" left="643" width="165" height="20" font="0">baseline in the average of the </text>
<text top="429" left="643" width="194" height="20" font="0">means of the far-wall intima–media </text>
<text top="447" left="643" width="160" height="20" font="0">thickness of the right and left </text>
<text top="464" left="643" width="179" height="20" font="0">common carotid arteries, carotid </text>
<text top="481" left="643" width="202" height="20" font="0">bulbs, and internal carotid arteries in </text>
<text top="498" left="643" width="120" height="20" font="0">the two study groups. </text>
<text top="515" left="643" width="188" height="20" font="7"><b>Results:</b> There was no significant </text>
<text top="533" left="643" width="194" height="20" font="0">difference in the change in CIMT in </text>
<text top="550" left="643" width="196" height="20" font="0">the simvastatin monotherapy group </text>
<text top="567" left="643" width="187" height="20" font="0">versus with simvastatin-ezetimibe </text>
<text top="584" left="643" width="35" height="20" font="0">group </text>
<text top="602" left="643" width="156" height="20" font="0">Fasting blood samples were </text>
<text top="619" left="643" width="155" height="20" font="0">obtained for analysis of lipid </text>
<text top="636" left="643" width="176" height="20" font="0">measures, as well as laboratory </text>
<text top="653" left="643" width="195" height="20" font="0">measures of liver aminotransferase </text>
<text top="670" left="643" width="143" height="20" font="0">levels, renal function, and </text>
<text top="688" left="643" width="112" height="20" font="0">hematologic values. </text>
<text top="705" left="643" width="186" height="20" font="7"><b>Results:</b> There was a statistically </text>
<text top="722" left="643" width="181" height="20" font="0">significant difference in the fall in </text>
<text top="739" left="643" width="169" height="20" font="0">LDL-C and apo B between the </text>
<text top="757" left="643" width="175" height="20" font="0">simvastatin monotherapy group </text>
<text top="774" left="643" width="184" height="20" font="0">(317.8±66.1 mg/dl to 192.7±60.3 </text>
<text top="395" left="859" width="200" height="20" font="7"><b>Secondary endpoint:</b> Proportion of </text>
<text top="412" left="859" width="225" height="20" font="0">patients with regression in carotid- artery </text>
<text top="429" left="859" width="232" height="20" font="0">intima–media thickness from baseline, the </text>
<text top="447" left="859" width="211" height="20" font="0">proportion of patients with new carotid-</text>
<text top="464" left="859" width="222" height="20" font="0">artery plaques of more than 1.3 mm, the </text>
<text top="481" left="859" width="204" height="20" font="0">change from baseline in the maximal </text>
<text top="498" left="859" width="231" height="20" font="0">carotid-artery intima–media thickness and </text>
<text top="516" left="859" width="223" height="20" font="0">the change from baseline in the average </text>
<text top="533" left="859" width="230" height="20" font="0">intima–media thickness of the carotid and </text>
<text top="550" left="859" width="143" height="20" font="0">common femoral arteries. </text>
<text top="567" left="859" width="195" height="20" font="0">Results: No difference between the </text>
<text top="584" left="859" width="230" height="20" font="0">simvastatin monotherapy and simvastatin-</text>
<text top="602" left="859" width="238" height="20" font="0">ezetimibe group in any secondary endpoint </text>
<text top="619" left="859" width="240" height="20" font="0">Adverse events: Adverse events and safety </text>
<text top="636" left="859" width="203" height="20" font="0">profile were similar in the two groups </text>
<text top="653" left="859" width="3" height="20" font="0"> </text>
<text top="670" left="859" width="110" height="20" font="7"><b>Study limitations:  </b></text>
<text top="688" left="859" width="229" height="20" font="0">1. Statin pre-treatment resulting in plaque </text>
<text top="705" left="859" width="226" height="20" font="0">lipid depletion and normal baseline CIMT </text>
<text top="722" left="859" width="160" height="20" font="0">may have biased the results. </text>
</page>
<page number="40" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">40 </text>
<text top="107" left="643" width="198" height="20" font="0">mg/dL for LDL-C and 254.1±49.3 to </text>
<text top="124" left="643" width="168" height="20" font="0">168.8±44.3 for apo B) and the </text>
<text top="141" left="643" width="156" height="20" font="0">simvastatin-ezetimibe group </text>
<text top="159" left="643" width="188" height="20" font="0">(319.0±65.0 mg/dL to 141.3±52.6 </text>
<text top="176" left="643" width="185" height="20" font="0">mg/dL for LDL-C and 253.9±47.6 </text>
<text top="193" left="643" width="197" height="20" font="0">to134.6±39.1 for apo B), p&lt;0.01 for </text>
<text top="210" left="643" width="31" height="20" font="0">both. </text>
<text top="228" left="89" width="75" height="20" font="7"><b>IMPROVE-IT </b></text>
<text top="245" left="89" width="76" height="20" font="0">Cannon C, et </text>
<text top="263" left="89" width="76" height="20" font="0">al., 2015 <a href="data supplement.html#237">(32)</a> </text>
<text top="280" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26039521">26039521</a></text>
<text top="280" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26039521"> </a></text>
<text top="228" left="184" width="107" height="20" font="7"><b>Aim:</b> To determine </text>
<text top="245" left="184" width="128" height="20" font="0">whether the addition of </text>
<text top="263" left="184" width="113" height="20" font="0">ezetimibe to a statin </text>
<text top="280" left="184" width="137" height="20" font="0">reduces the incidence of </text>
<text top="297" left="184" width="139" height="20" font="0">cardiovascular events as </text>
<text top="314" left="184" width="105" height="20" font="0">compared to statin </text>
<text top="332" left="184" width="79" height="20" font="0">monotherapy. </text>
<text top="349" left="184" width="3" height="20" font="0"> </text>
<text top="366" left="184" width="127" height="20" font="7"><b>Study design:</b> Double </text>
<text top="383" left="184" width="133" height="20" font="0">blind placebo-controlled </text>
<text top="400" left="184" width="125" height="20" font="0">RCT multicenter study </text>
<text top="418" left="184" width="3" height="20" font="0"> </text>
<text top="435" left="184" width="93" height="20" font="7"><b>Size:</b> N= 18,144 </text>
<text top="228" left="339" width="106" height="20" font="7"><b>Inclusion criteria: </b></text>
<text top="245" left="339" width="148" height="20" font="0">1. Men and women 50 y of </text>
<text top="263" left="339" width="150" height="20" font="0">age or older who had been </text>
<text top="280" left="339" width="114" height="20" font="0">hospitalized with the </text>
<text top="297" left="339" width="153" height="20" font="0">preceding 10 d for an acute </text>
<text top="314" left="339" width="109" height="20" font="0">coronary syndrome </text>
<text top="332" left="339" width="154" height="20" font="0">2. Patients required to have </text>
<text top="349" left="339" width="105" height="20" font="0">LDL-C ≥ 50 mg/dL </text>
<text top="366" left="339" width="133" height="20" font="0">3. For those not on lipid-</text>
<text top="383" left="339" width="160" height="20" font="0">lowering therapy at baseline, </text>
<text top="401" left="339" width="116" height="20" font="0">LDL-C ≤ 125 mg/dL. </text>
<text top="418" left="339" width="161" height="20" font="0">4. For those on lipid-lowering </text>
<text top="435" left="339" width="122" height="20" font="0">therapy, LDL-C ≤ 100 </text>
<text top="452" left="339" width="41" height="20" font="0">mg/dL. </text>
<text top="469" left="339" width="3" height="20" font="0"> </text>
<text top="487" left="339" width="110" height="20" font="7"><b>Exclusion criteria: </b></text>
<text top="504" left="339" width="156" height="20" font="0">1. Planned coronary bypass </text>
<text top="521" left="339" width="116" height="20" font="0">surgery for the acute </text>
<text top="538" left="339" width="85" height="20" font="0">coronary event </text>
<text top="555" left="339" width="154" height="20" font="0">2. Creatinine clearance &lt;30 </text>
<text top="573" left="339" width="43" height="20" font="0">ml/min. </text>
<text top="590" left="339" width="122" height="20" font="0">3. Active liver disease </text>
<text top="607" left="339" width="154" height="20" font="0">4. Use of statin therapy that </text>
<text top="624" left="339" width="140" height="20" font="0">had potency greater than </text>
<text top="641" left="339" width="135" height="20" font="0">simvastatin 40 mg daily. </text>
<text top="228" left="514" width="109" height="20" font="7"><b>Intervention/Comp</b></text>
<text top="245" left="514" width="109" height="20" font="7"><b>arator:</b> Simvastatin </text>
<text top="263" left="514" width="105" height="20" font="0">40 mg daily (9072) </text>
<text top="280" left="514" width="112" height="20" font="0">plus placebo versus </text>
<text top="297" left="514" width="102" height="20" font="0">simvastatin 40 mg </text>
<text top="314" left="514" width="111" height="20" font="0">daily plus ezetimibe </text>
<text top="332" left="514" width="105" height="20" font="0">10 mg daily (9072) </text>
<text top="349" left="514" width="81" height="20" font="0">over a median </text>
<text top="366" left="514" width="90" height="20" font="0">follow-up of 6 y. </text>
<text top="383" left="514" width="3" height="20" font="0"> </text>
<text top="228" left="643" width="80" height="22" font="7"><b>1</b>⁰<b> endpoint:  </b></text>
<text top="246" left="643" width="172" height="20" font="0">1. Composite of cardiovascular </text>
<text top="263" left="643" width="148" height="20" font="0">death, nonfatal myocardial </text>
<text top="280" left="643" width="198" height="20" font="0">infarction, unstable angina requiring </text>
<text top="298" left="643" width="151" height="20" font="0">re-hospitalization, coronary </text>
<text top="315" left="643" width="96" height="20" font="0">revascularization </text>
<text top="332" left="643" width="170" height="20" font="0">(≥30 d after randomization), or </text>
<text top="349" left="643" width="87" height="20" font="0">nonfatal stroke. </text>
<text top="366" left="643" width="3" height="20" font="0"> </text>
<text top="384" left="643" width="55" height="20" font="7"><b>Results:  </b></text>
<text top="401" left="643" width="189" height="20" font="0">1. Median time- weighted average </text>
<text top="418" left="643" width="202" height="20" font="0">LDL-C for placebo patients was 69.5 </text>
<text top="435" left="643" width="167" height="20" font="0">mg/dl vs. 53.7 for those taking </text>
<text top="452" left="643" width="60" height="20" font="0">ezetimibe. </text>
<text top="470" left="643" width="186" height="20" font="0">2. Kaplan Meier event rate for the </text>
<text top="487" left="643" width="172" height="20" font="0">primary endpoint was 34.7% in </text>
<text top="504" left="643" width="193" height="20" font="0">those receiving placebos vs.32.7% </text>
<text top="521" left="643" width="196" height="20" font="0">in those on ezetimibe (absolute risk </text>
<text top="539" left="643" width="188" height="20" font="0">reduction 2%, hazard ratio: 0.936; </text>
<text top="556" left="643" width="158" height="20" font="0">95% CI: 0.89-0.99; p=0.016. </text>
<text top="228" left="859" width="227" height="20" font="0">1. Ezetimibe added to moderate-intensity </text>
<text top="245" left="859" width="235" height="20" font="0">statin therapy lowered LDL-C and reduced </text>
<text top="263" left="859" width="219" height="20" font="0">the incidence of cardiovascular events.  </text>
<text top="280" left="859" width="220" height="20" font="0">2. Ezetimibe therapy was safe and well- </text>
<text top="297" left="859" width="55" height="20" font="0">tolerated. </text>
<text top="314" left="859" width="3" height="20" font="0"> </text>
<text top="332" left="859" width="73" height="20" font="7"><b>Limitations: </b></text>
<text top="349" left="859" width="223" height="20" font="0">1. 42% of the patients stopped the study </text>
<text top="366" left="859" width="124" height="20" font="0">medicine prematurely. </text>
<text top="659" left="89" width="58" height="20" font="0">Silverman </text>
<text top="677" left="89" width="60" height="20" font="0">MG, et al., </text>
<text top="694" left="89" width="56" height="20" font="0">2016 <a href="data supplement.html#237">(33)</a> </text>
<text top="711" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27673306">27673306</a></text>
<text top="711" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27673306"> </a></text>
<text top="659" left="184" width="98" height="20" font="7"><b>Aim:</b> To evaluate </text>
<text top="677" left="184" width="141" height="20" font="0">association between LDL </text>
<text top="694" left="184" width="136" height="20" font="0">cholesterol lowering and </text>
<text top="711" left="184" width="126" height="20" font="0">relative cardiovascular </text>
<text top="728" left="184" width="136" height="20" font="0">risk reduction employing </text>
<text top="745" left="184" width="114" height="20" font="0">statin and non-statin </text>
<text top="763" left="184" width="54" height="20" font="0">therapies </text>
<text top="780" left="184" width="3" height="20" font="0"> </text>
<text top="659" left="339" width="106" height="20" font="7"><b>Inclusion criteria: </b></text>
<text top="677" left="339" width="126" height="20" font="0">49 RCT’s of 9 different </text>
<text top="694" left="339" width="120" height="20" font="0">approaches to LDL-C </text>
<text top="711" left="339" width="129" height="20" font="0">reduction with reported </text>
<text top="728" left="339" width="126" height="20" font="0">ASCVD outcomes that </text>
<text top="745" left="339" width="112" height="20" font="0">included myocardial </text>
<text top="763" left="339" width="53" height="20" font="0">infarction </text>
<text top="780" left="339" width="3" height="20" font="0"> </text>
<text top="659" left="514" width="107" height="20" font="7"><b>Intervention/comp</b></text>
<text top="677" left="514" width="42" height="20" font="7"><b>arator: </b></text>
<text top="694" left="514" width="96" height="20" font="0">Drug vs. placebo </text>
<text top="659" left="643" width="72" height="22" font="7"><b>1</b>⁰<b>endpoint: </b></text>
<text top="677" left="643" width="167" height="20" font="0">Relative risk of major vascular </text>
<text top="694" left="643" width="127" height="20" font="0">events (a composite of </text>
<text top="711" left="643" width="185" height="20" font="0">cardiovascular death, acute MI or </text>
<text top="729" left="643" width="177" height="20" font="0">other acute coronary syndrome, </text>
<text top="746" left="643" width="165" height="20" font="0">coronary revascularization, or </text>
<text top="763" left="643" width="199" height="20" font="0">stroke) associated with the absolute </text>
<text top="780" left="643" width="197" height="20" font="0">reduction in LDL-C level; 5-y rate of </text>
<text top="659" left="859" width="76" height="20" font="7"><b>Limitations:  </b></text>
<text top="677" left="859" width="234" height="20" font="0">PCSK9 inhibitor outcome trial results were </text>
<text top="694" left="859" width="239" height="20" font="0">not available to be included in the results of </text>
<text top="711" left="859" width="55" height="20" font="0">this study </text>
</page>
<page number="41" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">41 </text>
<text top="107" left="184" width="101" height="20" font="7"><b>Study type</b>: Meta-</text>
<text top="124" left="184" width="99" height="20" font="0">analysis of RCT’s </text>
<text top="141" left="184" width="3" height="20" font="0"> </text>
<text top="159" left="184" width="96" height="20" font="7"><b>Size:</b> N=312,175 </text>
<text top="107" left="339" width="110" height="20" font="7"><b>Exclusion criteria: </b></text>
<text top="124" left="339" width="151" height="20" font="0">RCT’s of &lt;6 mo duration or </text>
<text top="141" left="339" width="143" height="20" font="0">with fewer than 50 clinical </text>
<text top="159" left="339" width="40" height="20" font="0">events </text>
<text top="107" left="643" width="181" height="20" font="0">major coronary events (coronary </text>
<text top="124" left="643" width="157" height="20" font="0">death or MI) associated with </text>
<text top="141" left="643" width="124" height="20" font="0">achieved LDL-C level. </text>
<text top="159" left="643" width="185" height="20" font="0">1. Relative risk for major vascular </text>
<text top="176" left="643" width="193" height="20" font="0">events per 38.7 mg/dL reduction in </text>
<text top="193" left="643" width="171" height="20" font="0">LDL-C was 0.77 (95% CI: 0.71-</text>
<text top="210" left="643" width="182" height="20" font="0">0.84), p&lt;0.001) and was 0.75 for </text>
<text top="228" left="643" width="184" height="20" font="0">non-statin interventions that work </text>
<text top="245" left="643" width="182" height="20" font="0">primarily by up-regulation of LDL-</text>
<text top="262" left="643" width="194" height="20" font="0">receptor expression, including diet, </text>
<text top="279" left="643" width="194" height="20" font="0">bile acid sequestrants, ileal bypass </text>
<text top="296" left="643" width="170" height="20" font="0">and ezetimibe (between-group </text>
<text top="314" left="643" width="179" height="20" font="0">significance, p=0.72). Combined </text>
<text top="331" left="643" width="182" height="20" font="0">therapies were associated with a </text>
<text top="348" left="643" width="193" height="20" font="0">relative risk reduction of 0.77 (95% </text>
<text top="365" left="643" width="134" height="20" font="0">CI: 0.75-0.79, p&lt;0.001). </text>
<text top="383" left="643" width="185" height="20" font="0">2. Achieved absolute LDL-C level </text>
<text top="400" left="643" width="183" height="20" font="0">was associated with the absolute </text>
<text top="417" left="643" width="163" height="20" font="0">rate of major coronary events </text>
<text top="434" left="643" width="151" height="20" font="0">(11,301 coronary deaths or </text>
<text top="451" left="643" width="185" height="20" font="0">myocardial infarctions for primary </text>
<text top="469" left="643" width="192" height="20" font="0">prevention trials (1.5% lower event </text>
<text top="486" left="643" width="182" height="20" font="0">rate [95% CI: 0.5-2.6%] per each </text>
<text top="503" left="643" width="169" height="20" font="0">38.7 mg/dL lower LDL-C level; </text>
<text top="520" left="643" width="197" height="20" font="0">p=0.008) and secondary prevention </text>
<text top="537" left="643" width="187" height="20" font="0">trials (4.6% lower event rate [95% </text>
<text top="555" left="643" width="188" height="20" font="0">CI: 2.9-6.4%] for each 38.7 mg/dL </text>
<text top="572" left="643" width="131" height="20" font="0">lower LDL-C; p&lt;0.001). </text>
<text top="589" left="643" width="192" height="20" font="0">3. Interventions (in aggregate) that </text>
<text top="606" left="643" width="195" height="20" font="0">lower LDL-C via other mechanisms </text>
<text top="623" left="643" width="180" height="20" font="0">did not demonstrate ASCVD risk </text>
<text top="641" left="643" width="61" height="20" font="0">reduction.  </text>
<text top="659" left="89" width="70" height="20" font="0">Shepherd J, </text>
<text top="676" left="89" width="64" height="20" font="0">et al., 1995 </text>
<text top="693" left="89" width="25" height="20" font="0"><a href="data supplement.html#237">(34)</a> </text>
<text top="710" left="89" width="48" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7566020">7566020</a></text>
<text top="710" left="137" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=7566020"> </a></text>
<text top="659" left="184" width="111" height="20" font="7"><b>Aim:</b> To assess the </text>
<text top="676" left="184" width="111" height="20" font="0">effect of pravastatin </text>
<text top="693" left="184" width="137" height="20" font="0">therapy on the incidence </text>
<text top="710" left="184" width="106" height="20" font="0">of non-fatal MI and </text>
<text top="727" left="184" width="129" height="20" font="0">coronary heart disease </text>
<text top="745" left="184" width="47" height="20" font="0">death in </text>
<text top="762" left="184" width="120" height="20" font="0">hypercholesterolemic </text>
<text top="779" left="184" width="75" height="20" font="0">Scottish men </text>
<text top="659" left="339" width="106" height="20" font="7"><b>Inclusion criteria: </b></text>
<text top="676" left="339" width="152" height="20" font="0">Men 45-64 y of age with no </text>
<text top="693" left="339" width="146" height="20" font="0">history of MI with LDL-C ≥ </text>
<text top="710" left="339" width="137" height="20" font="0">155 mg/dL during and at </text>
<text top="727" left="339" width="135" height="20" font="0">least one value 174-232 </text>
<text top="745" left="339" width="97" height="20" font="0">mg/dL during pre-</text>
<text top="762" left="339" width="115" height="20" font="0">randomization visits. </text>
<text top="779" left="339" width="137" height="20" font="0">Patients with a history of </text>
<text top="659" left="514" width="107" height="20" font="7"><b>Intervention/comp</b></text>
<text top="676" left="514" width="42" height="20" font="7"><b>arator: </b></text>
<text top="693" left="514" width="102" height="20" font="0">Pravastatin 40 mg </text>
<text top="710" left="514" width="94" height="20" font="0">daily vs. placebo </text>
<text top="727" left="514" width="107" height="20" font="0">over a mean follow-</text>
<text top="745" left="514" width="98" height="20" font="0">up period of 4.9 y </text>
<text top="659" left="643" width="79" height="22" font="7"><b>1</b>⁰<b> endpoint:  </b></text>
<text top="676" left="643" width="198" height="20" font="0">1. Combined occurrence of nonfatal </text>
<text top="693" left="643" width="177" height="20" font="0">MI or death from coronary heart </text>
<text top="711" left="643" width="136" height="20" font="0">disease as a first event.  </text>
<text top="728" left="643" width="157" height="20" font="0">2. Occurrence of death from </text>
<text top="745" left="643" width="200" height="20" font="0">coronary heart disease and nonfatal </text>
<text top="762" left="643" width="21" height="20" font="0">MI. </text>
<text top="779" left="643" width="3" height="20" font="0"> </text>
<text top="659" left="859" width="76" height="22" font="7"><b>2</b>⁰<b> endpoint: </b></text>
<text top="676" left="859" width="147" height="20" font="0">Death from cardiovascular </text>
<text top="693" left="859" width="215" height="20" font="0">causes, death from any cause, and the </text>
<text top="711" left="859" width="218" height="20" font="0">frequency of coronary revascularization </text>
<text top="728" left="859" width="68" height="20" font="0">procedures. </text>
<text top="745" left="859" width="237" height="20" font="0">Results: In the pravastatin group there was </text>
<text top="762" left="859" width="241" height="20" font="0">a 32% relative risk reduction in risk of death </text>
<text top="779" left="859" width="231" height="20" font="0">from all cardiovascular causes (95% CI: 3-</text>
</page>
<page number="42" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">42 </text>
<text top="107" left="184" width="3" height="20" font="0"> </text>
<text top="124" left="184" width="128" height="20" font="7"><b>Study Design:</b> Double </text>
<text top="141" left="184" width="132" height="20" font="0">blind placebo controlled </text>
<text top="159" left="184" width="29" height="20" font="0">RCT </text>
<text top="176" left="184" width="3" height="20" font="0"> </text>
<text top="193" left="184" width="82" height="20" font="7"><b>Size:</b> N= 6595 </text>
<text top="107" left="339" width="126" height="20" font="0">stable angina could be </text>
<text top="124" left="339" width="155" height="20" font="0">enrolled if no hospitalization </text>
<text top="141" left="339" width="129" height="20" font="0">in the preceding 12 mo </text>
<text top="159" left="339" width="110" height="20" font="7"><b>Exclusion criteria: </b></text>
<text top="176" left="339" width="117" height="20" font="0">1. No history or ECG </text>
<text top="193" left="339" width="83" height="20" font="0">evidence of MI </text>
<text top="210" left="339" width="159" height="20" font="0">2. No atrial fibrillation, flutter, </text>
<text top="228" left="339" width="108" height="20" font="0">frequent premature </text>
<text top="245" left="339" width="159" height="20" font="0">ventricular beats, high grade </text>
<text top="262" left="339" width="116" height="20" font="0">atrioventricular block </text>
<text top="279" left="339" width="155" height="20" font="0">3. Blood pressure &gt;180/110 </text>
<text top="296" left="339" width="43" height="20" font="0">mm Hg </text>
<text top="314" left="339" width="130" height="20" font="0">4. History of rheumatic, </text>
<text top="331" left="339" width="135" height="20" font="0">congenital or pulmonary </text>
<text top="348" left="339" width="77" height="20" font="0">heart disease </text>
<text top="365" left="339" width="158" height="20" font="0">5. Cardiomegaly, congestive </text>
<text top="383" left="339" width="141" height="20" font="0">heart failure or significant </text>
<text top="400" left="339" width="123" height="20" font="0">valvular heart disease </text>
<text top="417" left="339" width="114" height="20" font="0">6. Psychiatric illness </text>
<text top="434" left="339" width="132" height="20" font="0">7. Current lipid lowering </text>
<text top="451" left="339" width="44" height="20" font="0">therapy </text>
<text top="469" left="339" width="129" height="20" font="0">8. Excluding laboratory </text>
<text top="486" left="339" width="94" height="20" font="0">values, including </text>
<text top="503" left="339" width="138" height="20" font="0">triglycerides &gt;534 mg/dL </text>
<text top="107" left="643" width="52" height="20" font="7"><b>Results: </b></text>
<text top="124" left="643" width="203" height="20" font="0">1. In the pravastatin group there was </text>
<text top="141" left="643" width="190" height="20" font="0">a 31% relative risk reduction (95% </text>
<text top="159" left="643" width="154" height="20" font="0">CI: 17-43%, p&lt;0.001) in the </text>
<text top="176" left="643" width="189" height="20" font="0">combined endpoint of definite non-</text>
<text top="193" left="643" width="196" height="20" font="0">fatal MI and coronary heart disease </text>
<text top="210" left="643" width="201" height="20" font="0">death (absolute risk reduction 2.4%) </text>
<text top="107" left="859" width="220" height="20" font="0">53%, p=0.0333) and a 37% reduction in </text>
<text top="124" left="859" width="229" height="20" font="0">revascularization procedures (95% CI: 11-</text>
<text top="141" left="859" width="84" height="20" font="0">56%; p=0.009) </text>
<text top="159" left="859" width="234" height="20" font="0">Adverse events were similar in pravastatin </text>
<text top="176" left="859" width="115" height="20" font="0">and placebo groups. </text>
<text top="193" left="859" width="3" height="20" font="0"> </text>
<text top="210" left="859" width="127" height="20" font="7"><b>Limitations:</b> Men only </text>
<text top="521" left="89" width="55" height="20" font="7"><b>RUTHER-</b></text>
<text top="538" left="89" width="38" height="20" font="7"><b>FORD </b></text>
<text top="555" left="89" width="63" height="20" font="0">Raal FJ, et </text>
<text top="573" left="89" width="76" height="20" font="0">al., 2015 <a href="data supplement.html#237">(35)</a> </text>
<text top="590" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25282519">25282519</a></text>
<text top="590" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25282519"> </a></text>
<text top="521" left="184" width="131" height="20" font="7"><b>Aim:</b> To investigate the </text>
<text top="538" left="184" width="91" height="20" font="0">effect of PCSK9 </text>
<text top="555" left="184" width="77" height="20" font="0">inhibition with </text>
<text top="573" left="184" width="139" height="20" font="0">evolocumab on LDL-C in </text>
<text top="590" left="184" width="72" height="20" font="0">patients with </text>
<text top="607" left="184" width="97" height="20" font="0">heterozygous FH </text>
<text top="624" left="184" width="3" height="20" font="0"> </text>
<text top="641" left="184" width="73" height="20" font="7"><b>Study Type</b>: </text>
<text top="659" left="184" width="113" height="20" font="0">Randomized double-</text>
<text top="676" left="184" width="133" height="20" font="0">blind placebo-controlled </text>
<text top="693" left="184" width="87" height="20" font="0">multicenter trial </text>
<text top="710" left="184" width="3" height="20" font="0"> </text>
<text top="727" left="184" width="118" height="20" font="7"><b>Size</b>: N=331 patients </text>
<text top="521" left="339" width="157" height="20" font="7"><b>Inclusion criteria:</b> Men and </text>
<text top="538" left="339" width="127" height="20" font="0">women age 18-80 with </text>
<text top="555" left="339" width="132" height="20" font="0">clinical FH using Simon-</text>
<text top="573" left="339" width="140" height="20" font="0">Broome criteria on stable </text>
<text top="590" left="339" width="148" height="20" font="0">dose of statin ± ezetimibe, </text>
<text top="607" left="339" width="135" height="20" font="0">resins, stanols or niacin; </text>
<text top="624" left="339" width="116" height="20" font="0">LDL-C ≥ 100 mg/dL; </text>
<text top="641" left="339" width="145" height="20" font="0">mutations causative of FH </text>
<text top="659" left="339" width="157" height="20" font="0">were recorded in 211 of 264 </text>
<text top="676" left="339" width="109" height="20" font="0">patients (80%) who </text>
<text top="693" left="339" width="117" height="20" font="0">consented to genetic </text>
<text top="710" left="339" width="51" height="20" font="0">analysis. </text>
<text top="727" left="339" width="3" height="20" font="0"> </text>
<text top="745" left="339" width="151" height="20" font="7"><b>Exclusion criteria</b>: Fibrate </text>
<text top="762" left="339" width="161" height="20" font="0">therapy. Apheresis within the </text>
<text top="779" left="339" width="100" height="20" font="0">past 4 mo. HoFH. </text>
<text top="521" left="514" width="107" height="20" font="7"><b>Intervention/comp</b></text>
<text top="538" left="514" width="90" height="20" font="7"><b>arator:</b> Patients </text>
<text top="555" left="514" width="107" height="20" font="0">randomly allocated </text>
<text top="573" left="514" width="105" height="20" font="0">in a 2:2:1:1 ratio to </text>
<text top="590" left="514" width="64" height="20" font="0">receive SQ </text>
<text top="607" left="514" width="114" height="20" font="0">evolocumab 140 mg </text>
<text top="624" left="514" width="114" height="20" font="0">Q2 wk (N=111), 420 </text>
<text top="641" left="514" width="71" height="20" font="0">mg Q month </text>
<text top="659" left="514" width="98" height="20" font="0">(N=110), placebo </text>
<text top="676" left="514" width="92" height="20" font="0">Q2 wk (n=55) or </text>
<text top="693" left="514" width="97" height="20" font="0">placebo Q month </text>
<text top="710" left="514" width="93" height="20" font="0">(n=55) for 12 wk </text>
<text top="727" left="514" width="3" height="20" font="0"> </text>
<text top="745" left="514" width="3" height="20" font="0"> </text>
<text top="521" left="643" width="158" height="22" font="7"><b>1</b>⁰<b>endpoint</b>: Compared with </text>
<text top="539" left="643" width="166" height="20" font="0">placebo: Evolocumab Q 2 wk: </text>
<text top="556" left="643" width="193" height="20" font="0">reduced LDL-C by 59% (95% CI: 4-</text>
<text top="573" left="643" width="90" height="20" font="0">65.1, p&lt;0.0001) </text>
<text top="590" left="643" width="203" height="20" font="0">Q 4 wk: reduced LDL-C 61.3% (95% </text>
<text top="607" left="643" width="130" height="20" font="0">CI: 53.6-69, p&lt;0.0001). </text>
<text top="625" left="643" width="173" height="20" font="0">&gt;60% treated with evo at either </text>
<text top="642" left="643" width="187" height="20" font="0">dose achieved LDL-C &lt; 70 mg/dL </text>
<text top="659" left="643" width="192" height="20" font="0">Reduction in Lp(a) ranged from 19-</text>
<text top="676" left="643" width="31" height="20" font="0">45%. </text>
<text top="693" left="643" width="184" height="20" font="0">Post hoc analysis showed LDL-C </text>
<text top="711" left="643" width="143" height="20" font="0">reduction in those with no </text>
<text top="728" left="643" width="181" height="20" font="0">genetically defined mutation was </text>
<text top="745" left="643" width="148" height="20" font="0">similar to that in those with </text>
<text top="762" left="643" width="139" height="20" font="0">genetically confirmed FH </text>
<text top="779" left="643" width="3" height="20" font="0"> </text>
<text top="521" left="859" width="234" height="20" font="7"><b>Adverse events</b>: Rates of adverse events </text>
<text top="538" left="859" width="201" height="20" font="0">with evolocumab similar to placebo.  </text>
<text top="555" left="859" width="79" height="20" font="0">Limitations:     </text>
<text top="573" left="859" width="239" height="20" font="0">1. Analysis of response based on genotype </text>
<text top="590" left="859" width="79" height="20" font="0">was post hoc. </text>
<text top="607" left="859" width="171" height="20" font="0">2. Short study duration (12 wk) </text>
</page>
<page number="43" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">43 </text>
<text top="107" left="89" width="63" height="20" font="7"><b>ODYSSEY </b></text>
<text top="124" left="89" width="66" height="20" font="7"><b>FH 1 and 2 </b></text>
<text top="141" left="89" width="54" height="20" font="0">Kastelein </text>
<text top="159" left="89" width="61" height="20" font="0">JJP, et al., </text>
<text top="176" left="89" width="56" height="20" font="0">2015 <a href="data supplement.html#238">(36)</a> </text>
<text top="193" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26330422">26330422</a></text>
<text top="193" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26330422"> </a></text>
<text top="107" left="184" width="129" height="20" font="7"><b>Aim:</b> To assess LDL-C </text>
<text top="124" left="184" width="118" height="20" font="0">lowering efficacy and </text>
<text top="141" left="184" width="127" height="20" font="0">safety of long-term (78 </text>
<text top="159" left="184" width="141" height="20" font="0">wk) alirocumab treatment </text>
<text top="176" left="184" width="120" height="20" font="0">in patients with HeFH </text>
<text top="193" left="184" width="3" height="20" font="0"> </text>
<text top="210" left="184" width="129" height="20" font="7"><b>Study type</b>: Combined </text>
<text top="227" left="184" width="76" height="20" font="0">results of two </text>
<text top="245" left="184" width="138" height="20" font="0">randomized double-blind </text>
<text top="262" left="184" width="104" height="20" font="0">placebo-controlled </text>
<text top="279" left="184" width="93" height="20" font="0">multicenter trials </text>
<text top="296" left="184" width="3" height="20" font="7"><b> </b></text>
<text top="314" left="184" width="119" height="20" font="7"><b>Size:</b> N=735 patients </text>
<text top="107" left="339" width="157" height="20" font="7"><b>Inclusion criteria:</b> Men and </text>
<text top="124" left="339" width="127" height="20" font="0">women age ≥18 y with </text>
<text top="141" left="339" width="152" height="20" font="0">HeFH with no history of CV </text>
<text top="159" left="339" width="161" height="20" font="0">events; and those who had a </text>
<text top="176" left="339" width="126" height="20" font="0">history of a myocardial </text>
<text top="193" left="339" width="159" height="20" font="0">infarction or ischemic stroke, </text>
<text top="210" left="339" width="152" height="20" font="0">if their LDL-C levels were ≥ </text>
<text top="228" left="339" width="150" height="20" font="0">100 mg/dL for primary or ≥ </text>
<text top="245" left="339" width="133" height="20" font="0">70 mg/dL for secondary </text>
<text top="262" left="339" width="136" height="20" font="0">prevention, respectively. </text>
<text top="279" left="339" width="156" height="20" font="0">HeFH was diagnosed with a </text>
<text top="296" left="339" width="162" height="20" font="0">score &gt;8 points. Patients had </text>
<text top="314" left="339" width="161" height="20" font="0">to be on stable dose of statin </text>
<text top="331" left="339" width="155" height="20" font="0">for ≥4 wk and/or fenofibrate </text>
<text top="348" left="339" width="160" height="20" font="0">≥6 wk prior to screening visit </text>
<text top="365" left="339" width="147" height="20" font="0">and from screening visit to </text>
<text top="383" left="339" width="84" height="20" font="0">randomization. </text>
<text top="400" left="339" width="3" height="20" font="0"> </text>
<text top="417" left="339" width="151" height="20" font="7"><b>Exclusion criteria:</b> Known </text>
<text top="434" left="339" width="141" height="20" font="0">HoFH or fasting TG &gt;400 </text>
<text top="451" left="339" width="38" height="20" font="0">mg/dL </text>
<text top="107" left="514" width="107" height="20" font="7"><b>Intervention/comp</b></text>
<text top="124" left="514" width="90" height="20" font="7"><b>arator:</b> Patients </text>
<text top="141" left="514" width="111" height="20" font="0">were randomized 2: </text>
<text top="159" left="514" width="101" height="20" font="0">1 to receive either </text>
<text top="176" left="514" width="101" height="20" font="0">alirocumab 75 mg </text>
<text top="193" left="514" width="76" height="20" font="0">every 2 wk or </text>
<text top="210" left="514" width="50" height="20" font="0">placebo. </text>
<text top="228" left="514" width="85" height="20" font="0">Randomization </text>
<text top="245" left="514" width="106" height="20" font="0">stratified by history </text>
<text top="262" left="514" width="96" height="20" font="0">of MI or ischemic </text>
<text top="279" left="514" width="73" height="20" font="0">stroke, statin </text>
<text top="296" left="514" width="55" height="20" font="0">treatment </text>
<text top="314" left="514" width="109" height="20" font="0">(atorvastatin 40–80 </text>
<text top="331" left="514" width="105" height="20" font="0">mg or rosuvastatin </text>
<text top="348" left="514" width="106" height="20" font="0">20–40 mg daily vs. </text>
<text top="365" left="514" width="101" height="20" font="0">simvastatin in any </text>
<text top="383" left="514" width="100" height="20" font="0">dose, atorvastatin </text>
<text top="400" left="514" width="91" height="20" font="0">&lt;40 mg daily, or </text>
<text top="417" left="514" width="114" height="20" font="0">rosuvastatin &lt;20 mg </text>
<text top="434" left="514" width="60" height="20" font="0">daily), and </text>
<text top="451" left="514" width="102" height="20" font="0">geographic region </text>
<text top="469" left="514" width="110" height="20" font="0">(FH I only). Dose of </text>
<text top="486" left="514" width="89" height="20" font="0">alirocumab was </text>
<text top="503" left="514" width="80" height="20" font="0">increased in a </text>
<text top="520" left="514" width="100" height="20" font="0">blinded fashion to </text>
<text top="537" left="514" width="111" height="20" font="0">150 mg Q2W at Wk </text>
<text top="555" left="514" width="96" height="20" font="0">12 if the patient’s </text>
<text top="572" left="514" width="110" height="20" font="0">LDL-C level at wk 8 </text>
<text top="589" left="514" width="87" height="20" font="0">was 70 mg/dL.  </text>
<text top="606" left="514" width="3" height="20" font="0"> </text>
<text top="623" left="514" width="72" height="20" font="0">Comparator: </text>
<text top="641" left="514" width="48" height="20" font="0">Placebo </text>
<text top="107" left="643" width="147" height="22" font="7"><b>1</b>⁰<b> endpoint:</b> % change in </text>
<text top="125" left="643" width="189" height="20" font="0">calculated LDL-C from baseline to </text>
<text top="142" left="643" width="185" height="20" font="0">Wk 24. using an intention-to-treat </text>
<text top="159" left="643" width="176" height="20" font="0">(ITT)approach, including values </text>
<text top="176" left="643" width="197" height="20" font="0">obtained after stopping treatment in </text>
<text top="193" left="643" width="193" height="20" font="0">patients who discontinued therapy: </text>
<text top="211" left="643" width="3" height="20" font="0"> </text>
<text top="228" left="643" width="52" height="20" font="7"><b>Results: </b></text>
<text top="245" left="643" width="186" height="20" font="0">Mean LDL-C decreased from 145 </text>
<text top="262" left="643" width="177" height="20" font="0">mg/dL at baseline to 71 mg/dL (-</text>
<text top="280" left="643" width="170" height="20" font="0">57.9% vs. placebo) at wk 24 in </text>
<text top="297" left="643" width="192" height="20" font="0">patients randomized to alirocumab </text>
<text top="314" left="643" width="187" height="20" font="0">in FH 1 and from 135 mg/dL to 68 </text>
<text top="331" left="643" width="151" height="20" font="0">mg/dL in FH 2 (p&lt;0.0001).  </text>
<text top="348" left="643" width="3" height="20" font="0"> </text>
<text top="366" left="643" width="3" height="20" font="0"> </text>
<text top="383" left="643" width="48" height="20" font="0">              </text>
<text top="107" left="859" width="243" height="20" font="7"><b>Secondary endpoints:</b> % change in LDL-C </text>
<text top="124" left="859" width="196" height="20" font="0">in an on-treatment analysis and the </text>
<text top="141" left="859" width="240" height="20" font="0">proportion of patients reaching LDL-C &lt;100 </text>
<text top="159" left="859" width="228" height="20" font="0">mg/dL (for those without prior CV events) </text>
<text top="176" left="859" width="209" height="20" font="0">and &lt;70 mg/dL regardless of prior CV </text>
<text top="193" left="859" width="241" height="20" font="0">events; the proportion achieving LDL-C &lt;70 </text>
<text top="210" left="859" width="208" height="20" font="0">regardless of CV events. All achieved </text>
<text top="228" left="859" width="125" height="20" font="0">significant reductions.  </text>
<text top="245" left="859" width="242" height="20" font="0">The reductions were maintained through wk </text>
<text top="262" left="859" width="242" height="20" font="0">78. LDL-C &lt;70 mg/dL, regardless of CV risk </text>
<text top="279" left="859" width="237" height="20" font="0">was achieved at wk 24 by 59.8 and 68% of </text>
<text top="296" left="859" width="236" height="20" font="0">alirocumb-treated patients in FH1 and FH2 </text>
<text top="314" left="859" width="72" height="20" font="0">respectively. </text>
<text top="331" left="859" width="3" height="20" font="0"> </text>
<text top="348" left="859" width="110" height="20" font="7"><b>Safety endpoints:  </b></text>
<text top="365" left="859" width="223" height="20" font="0">The percentage of patients experiencing </text>
<text top="382" left="859" width="228" height="20" font="0">treatment-emergent adverse events were </text>
<text top="400" left="859" width="219" height="20" font="0">similar between treatment groups in the </text>
<text top="417" left="859" width="101" height="20" font="0">individual studies. </text>
<text top="434" left="859" width="227" height="20" font="0">Anti-drug antibodies were observed in 17 </text>
<text top="451" left="859" width="53" height="20" font="0">(5.5%) of </text>
<text top="469" left="859" width="240" height="20" font="0">alirocumab and one (0.6%) placebo-treated </text>
<text top="486" left="859" width="224" height="20" font="0">patient in FH I and 14 (8.6%) alirocumab </text>
<text top="503" left="859" width="138" height="20" font="0">and one (1.3%) placebo  </text>
<text top="520" left="859" width="3" height="20" font="0"> </text>
<text top="659" left="89" width="80" height="20" font="0">Ross S, et al., </text>
<text top="676" left="89" width="56" height="20" font="0">2015 <a href="data supplement.html#238">(37)</a> </text>
<text top="693" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26043746">26043746</a></text>
<text top="693" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26043746"> </a></text>
<text top="659" left="184" width="111" height="20" font="7"><b>Aim:</b> To assess the </text>
<text top="676" left="184" width="96" height="20" font="0">effect of bile acid </text>
<text top="693" left="184" width="111" height="20" font="0">sequestrants on the </text>
<text top="710" left="184" width="120" height="20" font="0">incidence of coronary </text>
<text top="727" left="184" width="120" height="20" font="0">artery disease events </text>
<text top="745" left="184" width="101" height="20" font="7"><b>Study type</b>: Meta-</text>
<text top="762" left="184" width="90" height="20" font="0">analysis of RCT </text>
<text top="779" left="184" width="50" height="20" font="0">N=7,021 </text>
<text top="659" left="339" width="106" height="20" font="7"><b>Inclusion criteria: </b></text>
<text top="676" left="339" width="158" height="20" font="0">19 RCT’s employing therapy </text>
<text top="693" left="339" width="126" height="20" font="0">with cholestyramine or </text>
<text top="710" left="339" width="163" height="20" font="0">coselsevelam was performed </text>
<text top="727" left="339" width="130" height="20" font="0">as part of a study using </text>
<text top="745" left="339" width="154" height="20" font="0">Mendelian randomization to </text>
<text top="762" left="339" width="158" height="20" font="0">assess the effect of bile acid </text>
<text top="779" left="339" width="148" height="20" font="0">sequestrants on CAD: 6 of </text>
<text top="659" left="514" width="107" height="20" font="7"><b>Intervention/comp</b></text>
<text top="676" left="514" width="42" height="20" font="7"><b>arator: </b></text>
<text top="693" left="514" width="50" height="20" font="0">Bile acid </text>
<text top="710" left="514" width="87" height="20" font="0">sequestrant vs. </text>
<text top="727" left="514" width="113" height="20" font="0">placebo, or bile acid </text>
<text top="745" left="514" width="87" height="20" font="0">sequestrant vs. </text>
<text top="762" left="514" width="81" height="20" font="0">additional lipid </text>
<text top="779" left="514" width="114" height="20" font="0">lowering drug or bile </text>
<text top="659" left="643" width="76" height="22" font="7"><b>1</b>⁰<b>endpoint:  </b></text>
<text top="676" left="643" width="107" height="20" font="0">Studies evaluating: </text>
<text top="693" left="643" width="149" height="20" font="0">1. Cardiovascular mortality </text>
<text top="711" left="643" width="200" height="20" font="0">2. Incidence of myocardial infarction </text>
<text top="728" left="643" width="173" height="20" font="0">3. Baseline and mean endpoint </text>
<text top="745" left="643" width="194" height="20" font="0">values or the absolute difference in </text>
<text top="762" left="643" width="189" height="20" font="0">the intervention and placebo arms </text>
<text top="779" left="643" width="114" height="20" font="0">for change in LDL-C </text>
<text top="659" left="859" width="79" height="22" font="7"><b>2</b>⁰<b>endpoints: </b></text>
<text top="676" left="859" width="233" height="20" font="0">Baseline and endpoint mean values or the </text>
<text top="693" left="859" width="196" height="20" font="0">absolute treatment difference in the </text>
<text top="711" left="859" width="206" height="20" font="0">intervention and placebo arms for the </text>
<text top="728" left="859" width="194" height="20" font="0">change in HDL-C, total cholesterol, </text>
<text top="745" left="859" width="196" height="20" font="0">triglycerides, apolipoprotein A1 and </text>
<text top="762" left="859" width="96" height="20" font="0">apolipoprotein B  </text>
</page>
<page number="44" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">44 </text>
<text top="107" left="339" width="113" height="20" font="0">cholestyramine, 3 of </text>
<text top="124" left="339" width="109" height="20" font="0">colestipol and 10 of </text>
<text top="141" left="339" width="75" height="20" font="0">colesevelam. </text>
<text top="159" left="339" width="3" height="20" font="0"> </text>
<text top="176" left="339" width="110" height="20" font="7"><b>Exclusion criteria: </b></text>
<text top="193" left="339" width="159" height="20" font="0">1.The 3 studies on colestipol </text>
<text top="210" left="339" width="146" height="20" font="0">were excluded because of </text>
<text top="228" left="339" width="140" height="20" font="0">lack of reported data and </text>
<text top="245" left="339" width="160" height="20" font="0">differences in the study dose </text>
<text top="262" left="339" width="148" height="20" font="0">2. Only the Lipid Research </text>
<text top="279" left="339" width="139" height="20" font="0">Clinics Coronary Primary </text>
<text top="296" left="339" width="145" height="20" font="0">Prevention Trial was used </text>
<text top="314" left="339" width="154" height="20" font="0">for cholestyramine because </text>
<text top="331" left="339" width="146" height="20" font="0">of the heterogeneity in the </text>
<text top="348" left="339" width="156" height="20" font="0">pooled estimates of the lipid </text>
<text top="365" left="339" width="88" height="20" font="0">results from the </text>
<text top="382" left="339" width="129" height="20" font="0">cholestyramine studies </text>
<text top="107" left="514" width="104" height="20" font="0">acid sequestrant + </text>
<text top="124" left="514" width="82" height="20" font="0">additional lipid-</text>
<text top="141" left="514" width="77" height="20" font="0">lowering drug </text>
<text top="107" left="643" width="3" height="20" font="0"> </text>
<text top="124" left="643" width="52" height="20" font="7"><b>Results: </b></text>
<text top="141" left="643" width="202" height="20" font="0">1. Cholestyramine therapy 24 grams </text>
<text top="159" left="643" width="197" height="20" font="0">daily reduced LDL-C by 23.5 mg/dL </text>
<text top="176" left="643" width="181" height="20" font="0">(95% CI: -26.8 to -20.2; N=3,806 </text>
<text top="193" left="643" width="159" height="20" font="0">and exhibited a trend toward </text>
<text top="210" left="643" width="202" height="20" font="0">reduced coronary artery disease risk </text>
<text top="228" left="643" width="202" height="20" font="0">(odds ratio: 0.81; 95% CI: 0.70-1.02; </text>
<text top="245" left="643" width="96" height="20" font="0">p=0.07; N=3806) </text>
<text top="262" left="643" width="182" height="20" font="0">2. Colesevelam 3.75 grams daily </text>
<text top="279" left="643" width="200" height="20" font="0">reduced LDL-C by 22.7 mg/dL (95% </text>
<text top="296" left="643" width="133" height="20" font="0">CI: -28.3, -17.2; N=759) </text>
<text top="314" left="643" width="198" height="20" font="0">3. There ae no adequately powered </text>
<text top="331" left="643" width="179" height="20" font="0">trials of bile acid sequestrants to </text>
<text top="348" left="643" width="187" height="20" font="0">determine their effect on coronary </text>
<text top="365" left="643" width="141" height="20" font="0">artery disease endpoints. </text>
<text top="400" left="89" width="61" height="20" font="0">Huijgen R, </text>
<text top="418" left="89" width="56" height="20" font="0">2010 <a href="data supplement.html#238">(38)</a> </text>
<text top="435" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20435231">20435231</a></text>
<text top="435" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20435231"> </a></text>
<text top="400" left="184" width="136" height="20" font="7"><b>Aim:</b> Assess efficacy ad </text>
<text top="418" left="184" width="72" height="20" font="0">tolerability of </text>
<text top="435" left="184" width="123" height="20" font="0">colesevelam added to </text>
<text top="452" left="184" width="113" height="20" font="0">maximally tolerated, </text>
<text top="469" left="184" width="136" height="20" font="0">stable dose combination </text>
<text top="487" left="184" width="124" height="20" font="0">treatment with a statin </text>
<text top="504" left="184" width="141" height="20" font="0">plus ezetimibe in patients </text>
<text top="521" left="184" width="126" height="20" font="0">with heterozygous FH. </text>
<text top="538" left="184" width="3" height="20" font="0"> </text>
<text top="555" left="184" width="142" height="20" font="7"><b>Study type</b>: Randomized </text>
<text top="573" left="184" width="117" height="20" font="0">double-blind placebo </text>
<text top="590" left="184" width="120" height="20" font="0">controlled multicenter </text>
<text top="607" left="184" width="23" height="20" font="0">trial </text>
<text top="624" left="184" width="3" height="20" font="0"> </text>
<text top="641" left="184" width="101" height="20" font="7"><b>Study size:</b> N=86 </text>
<text top="659" left="184" width="139" height="20" font="0">patients (45 colesevelam </text>
<text top="676" left="184" width="92" height="20" font="0">and 41 placebo) </text>
<text top="400" left="339" width="157" height="20" font="7"><b>Inclusion criteria</b>: Men and </text>
<text top="418" left="339" width="137" height="20" font="0">women age 18-75 y with </text>
<text top="435" left="339" width="161" height="20" font="0">history of a documented LDL </text>
<text top="452" left="339" width="131" height="20" font="0">receptor mutation or an </text>
<text top="469" left="339" width="115" height="20" font="0">untreated LDL-C &gt;95</text>
<text top="471" left="454" width="7" height="13" font="9">th</text>
<text top="469" left="461" width="3" height="20" font="0"> </text>
<text top="487" left="339" width="158" height="20" font="0">percentile for sex and age in </text>
<text top="504" left="339" width="162" height="20" font="0">combination with at least one </text>
<text top="521" left="339" width="145" height="20" font="0">of the following: (1) typical </text>
<text top="538" left="339" width="138" height="20" font="0">tendon xanthomas in the </text>
<text top="555" left="339" width="144" height="20" font="0">patient or in a first-degree </text>
<text top="573" left="339" width="159" height="20" font="0">relative; (2) an LDL-C &gt; 95th </text>
<text top="590" left="339" width="146" height="20" font="0">percentile in a first-degree </text>
<text top="607" left="339" width="140" height="20" font="0">relative; and (3) coronary </text>
<text top="624" left="339" width="154" height="20" font="0">artery disease in the patient </text>
<text top="641" left="339" width="146" height="20" font="0">or in a first-degree relative </text>
<text top="659" left="339" width="68" height="20" font="0">aged &lt;60 y. </text>
<text top="676" left="339" width="148" height="20" font="0">Additional eligibility criteria </text>
<text top="693" left="339" width="152" height="20" font="0">were refractory FH, defined </text>
<text top="710" left="339" width="150" height="20" font="0">as an LDL-C concentration </text>
<text top="727" left="339" width="105" height="20" font="0">&gt;95 mg/dL despite </text>
<text top="745" left="339" width="161" height="20" font="0">combination treatment with a </text>
<text top="762" left="339" width="133" height="20" font="0">maximally tolerated and </text>
<text top="779" left="339" width="108" height="20" font="0">stable regimen of a </text>
<text top="400" left="514" width="78" height="20" font="7"><b>Intervention:</b> </text>
<text top="418" left="514" width="98" height="20" font="0">Colesevelam 625 </text>
<text top="435" left="514" width="99" height="20" font="0">mg 6 tablets daily </text>
<text top="452" left="514" width="80" height="20" font="0">with a meal or </text>
<text top="469" left="514" width="88" height="20" font="0">beverage taken </text>
<text top="487" left="514" width="100" height="20" font="0">either as 6 tablets </text>
<text top="504" left="514" width="77" height="20" font="0">one daily or 3 </text>
<text top="521" left="514" width="100" height="20" font="0">tablets twice daily </text>
<text top="538" left="514" width="3" height="20" font="0"> </text>
<text top="555" left="514" width="77" height="20" font="7"><b>Comparator:</b> </text>
<text top="573" left="514" width="48" height="20" font="0">Placebo </text>
<text top="401" left="643" width="167" height="22" font="7"><b>1</b>⁰<b> endpoint:</b> difference in the </text>
<text top="418" left="643" width="200" height="20" font="0">percentage change from baseline to </text>
<text top="435" left="643" width="202" height="20" font="0">wk 6 in LDL-C between colesevelam </text>
<text top="452" left="643" width="162" height="20" font="0">and placebo. Tolerability was </text>
<text top="470" left="643" width="197" height="20" font="0">assessed based on prevalence and </text>
<text top="487" left="643" width="178" height="20" font="0">severity of adverse events or on </text>
<text top="504" left="643" width="187" height="20" font="0">laboratory analysis of hematology </text>
<text top="521" left="643" width="193" height="20" font="0">and blood chemistry, including CK, </text>
<text top="539" left="643" width="192" height="20" font="0">liver and kidney function tests, and </text>
<text top="556" left="643" width="183" height="20" font="0">discontinuation due to AEs at the </text>
<text top="573" left="643" width="77" height="20" font="0">end of 12 wk. </text>
<text top="590" left="643" width="3" height="20" font="0"> </text>
<text top="607" left="643" width="162" height="20" font="7"><b>Results:</b> The between-group </text>
<text top="625" left="643" width="192" height="20" font="0">difference in change from baseline </text>
<text top="642" left="643" width="194" height="20" font="0">LDL-C was significant at wk 6, with </text>
<text top="659" left="643" width="148" height="20" font="0">an LSM change of –18.5% </text>
<text top="676" left="643" width="189" height="20" font="0"> (95% CI: –25.3 to –11.8) p&lt;0.001 </text>
<text top="693" left="643" width="170" height="20" font="0">Apo A1/apo B ratio fell by 14% </text>
<text top="711" left="643" width="182" height="20" font="0">(p=0.003). No change in hs-CRP </text>
<text top="728" left="643" width="3" height="20" font="0"> </text>
<text top="401" left="859" width="215" height="22" font="7"><b>2</b>⁰<b> endpoint:</b> Various lipid parameters, </text>
<text top="418" left="859" width="120" height="20" font="0">HgbA1C and hs-CRP </text>
<text top="435" left="859" width="223" height="20" font="0">Adverse events: Frequency of treatment-</text>
<text top="452" left="859" width="226" height="20" font="0">emergent adverse events over the 12-wk </text>
<text top="470" left="859" width="231" height="20" font="0">study period was not significantly different </text>
<text top="487" left="859" width="213" height="20" font="0">between the colesevelam and placebo </text>
<text top="504" left="859" width="44" height="20" font="0">groups. </text>
<text top="521" left="859" width="235" height="20" font="0">The most commonly reported TEAEs were </text>
<text top="539" left="859" width="211" height="20" font="0">gastrointestinal (12/45 [27%] and 7/40 </text>
<text top="556" left="859" width="156" height="20" font="0">[18%], respectively; p=NS).  </text>
<text top="573" left="859" width="3" height="20" font="0"> </text>
<text top="590" left="859" width="76" height="20" font="7"><b>Limitations:  </b></text>
<text top="607" left="859" width="153" height="20" font="0">1. Small number of patients </text>
<text top="625" left="859" width="94" height="20" font="0">2. Short duration </text>
<text top="642" left="859" width="232" height="20" font="0">3. DM and high TG were exclusion criteria </text>
</page>
<page number="45" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">45 </text>
<text top="107" left="339" width="137" height="20" font="0">combination of a statin + </text>
<text top="124" left="339" width="99" height="20" font="0">ezetimibe for ≥12 </text>
<text top="141" left="339" width="150" height="20" font="0">consecutive wks preceding </text>
<text top="159" left="339" width="105" height="20" font="0">the screening visit. </text>
<text top="177" left="89" width="65" height="20" font="0">Cholesterol </text>
<text top="194" left="89" width="60" height="20" font="0">Treatment </text>
<text top="211" left="89" width="46" height="20" font="0">Trialists </text>
<text top="228" left="89" width="80" height="20" font="0">Collaborators, </text>
<text top="245" left="89" width="56" height="20" font="0">2010 <a href="data supplement.html#236">(13)</a> </text>
<text top="263" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21067804">21067804</a></text>
<text top="263" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21067804"> </a></text>
<text top="177" left="184" width="131" height="20" font="7"><b>Aim:</b> Assess the safety </text>
<text top="194" left="184" width="114" height="20" font="0">and efficacy of more </text>
<text top="211" left="184" width="129" height="20" font="0">intensive statin therapy </text>
<text top="228" left="184" width="93" height="20" font="0">Meta-analysis of </text>
<text top="245" left="184" width="142" height="20" font="0">individual participant data </text>
<text top="263" left="184" width="115" height="20" font="0">from statin RCT with </text>
<text top="280" left="184" width="106" height="20" font="0">ASCVD outcomes  </text>
<text top="297" left="184" width="3" height="20" font="0"> </text>
<text top="314" left="184" width="96" height="20" font="7"><b>Size:</b> N=169,138 </text>
<text top="177" left="339" width="135" height="20" font="0">Major statin primary and </text>
<text top="194" left="339" width="150" height="20" font="0">secondary prevention trials </text>
<text top="211" left="339" width="99" height="20" font="0">with at least 1000 </text>
<text top="228" left="339" width="155" height="20" font="0">participants with a minimum </text>
<text top="246" left="339" width="141" height="20" font="0">follow-up of 2 y, including </text>
<text top="263" left="339" width="139" height="20" font="0">trials of more versus less </text>
<text top="280" left="339" width="139" height="20" font="0">intensive statin regimens </text>
<text top="297" left="339" width="156" height="20" font="0">(five trials; 39, 612 subjects; </text>
<text top="314" left="339" width="154" height="20" font="0">median follow-up 5.1 y) and </text>
<text top="332" left="339" width="134" height="20" font="0">statin versus control (21 </text>
<text top="349" left="339" width="132" height="20" font="0">trials; 129 526 subjects; </text>
<text top="366" left="339" width="134" height="20" font="0">median follow-up 4.8 y). </text>
<text top="383" left="339" width="3" height="20" font="0"> </text>
<text top="400" left="339" width="132" height="20" font="7"><b>Exclusion criteria:</b> For </text>
<text top="418" left="339" width="142" height="20" font="0">acute coronary syndrome </text>
<text top="435" left="339" width="148" height="20" font="0">subjects, revascularization </text>
<text top="452" left="339" width="128" height="20" font="0">not related to recurrent </text>
<text top="469" left="339" width="155" height="20" font="0">ischemia or occurring &lt;30 d </text>
<text top="487" left="339" width="89" height="20" font="0">from the time of </text>
<text top="504" left="339" width="81" height="20" font="0">randomization </text>
<text top="177" left="514" width="109" height="20" font="7"><b>Intervention/Comp</b></text>
<text top="194" left="514" width="42" height="20" font="7"><b>arator: </b></text>
<text top="211" left="514" width="115" height="20" font="0">Statin versus control </text>
<text top="228" left="514" width="114" height="20" font="0">More intense versus </text>
<text top="246" left="514" width="101" height="20" font="0">less intense statin </text>
<text top="177" left="643" width="160" height="22" font="7"><b>1</b>⁰<b> endpoint:</b> Cause-specific </text>
<text top="194" left="643" width="172" height="20" font="0">mortality, major coronary event </text>
<text top="211" left="643" width="185" height="20" font="0">defined as coronary death or non-</text>
<text top="229" left="643" width="173" height="20" font="0">fatal MI percutaneous coronary </text>
<text top="246" left="643" width="176" height="20" font="0">intervention or bypass grafting), </text>
<text top="263" left="643" width="178" height="20" font="0">stroke (subdivided by type), and </text>
<text top="280" left="643" width="188" height="20" font="0">new cancer diagnosis (subdivided </text>
<text top="298" left="643" width="46" height="20" font="0">by site). </text>
<text top="315" left="643" width="3" height="20" font="0"> </text>
<text top="332" left="643" width="52" height="20" font="7"><b>Results: </b></text>
<text top="349" left="643" width="162" height="20" font="0">1. More intensive versus less </text>
<text top="366" left="643" width="199" height="20" font="0">intensive regimens produced a 15% </text>
<text top="384" left="643" width="188" height="20" font="0">(95% CI: 11-18; p&lt;0.0001) further </text>
<text top="401" left="643" width="194" height="20" font="0">reduction in major vascular events, </text>
<text top="418" left="643" width="173" height="20" font="0">including a 13% (95% CI: 7-19; </text>
<text top="435" left="643" width="165" height="20" font="0">p&lt;0.0001) further reduction in </text>
<text top="452" left="643" width="182" height="20" font="0">coronary death or non-fatal MI, a </text>
<text top="470" left="643" width="177" height="20" font="0">19% (95% CI: 15-24; p&lt;0.0001) </text>
<text top="487" left="643" width="118" height="20" font="0">reduction in coronary </text>
<text top="504" left="643" width="193" height="20" font="0">revascularization, and a 16% (95% </text>
<text top="521" left="643" width="167" height="20" font="0">CI: 5-26, p=0.005) in ischemic </text>
<text top="539" left="643" width="44" height="20" font="0">stroke.  </text>
<text top="556" left="643" width="191" height="20" font="0">2. For every 39 mg/dL reduction in </text>
<text top="573" left="643" width="194" height="20" font="0">LDL-C, there was a 22% (rate ratio </text>
<text top="590" left="643" width="196" height="20" font="0">0.78; 95% CI: 0.76-0.80; p&lt;0.0001) </text>
<text top="607" left="643" width="201" height="20" font="0">reduction in the relative risk of major </text>
<text top="625" left="643" width="92" height="20" font="0">vascular events. </text>
<text top="642" left="643" width="191" height="20" font="0">3. All-cause mortality was reduced </text>
<text top="659" left="643" width="189" height="20" font="0">by 10% for every 39 mg/dL LDL-C </text>
<text top="676" left="643" width="181" height="20" font="0">reduction (rate ratio 0.9; 95% CI: </text>
<text top="693" left="643" width="192" height="20" font="0">0.87-0.93; p&lt;0.0001) primarily due </text>
<text top="711" left="643" width="163" height="20" font="0">to reduction in coronary heart </text>
<text top="728" left="643" width="189" height="20" font="0">disease death (risk ratio: 0.8; 99% </text>
<text top="745" left="643" width="193" height="20" font="0">CI: 0.74-0.87; p&lt;0.0001) and other </text>
<text top="762" left="643" width="202" height="20" font="0">cardiac causes (risk ratio: 0.89: 99% </text>
<text top="779" left="643" width="137" height="20" font="0">CI: 0.89-0.98; p=0.002).  </text>
<text top="177" left="859" width="24" height="20" font="0">N/A </text>
</page>
<page number="46" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">46 </text>
<text top="107" left="643" width="192" height="20" font="0">3. No effect on death due to stroke </text>
<text top="124" left="643" width="178" height="20" font="0">or other vascular causes and no </text>
<text top="141" left="643" width="200" height="20" font="0">effect on death due to cancer, death </text>
<text top="159" left="643" width="176" height="20" font="0">from non-vascular causes or on </text>
<text top="176" left="643" width="99" height="20" font="0">cancer incidence. </text>
<text top="194" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="212" left="81" width="929" height="24" font="4"><b>Data Supplement 10. Non-randomized Trials, Observational Studies and/or Registries for Severe Hypercholesterolemia (Section 4.2) </b></text>
<text top="234" left="103" width="98" height="20" font="7"><b>Study Acronym: </b></text>
<text top="251" left="128" width="48" height="20" font="7"><b>Author; </b></text>
<text top="269" left="106" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="234" left="236" width="118" height="20" font="7"><b>Study Type/Design; </b></text>
<text top="251" left="262" width="66" height="20" font="7"><b>Study Size </b></text>
<text top="234" left="431" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="234" left="625" width="195" height="20" font="7"><b>Primary Endpoint and Results (P </b></text>
<text top="251" left="638" width="169" height="20" font="7"><b>values; OR or RR; &amp; 95% CI) </b></text>
<text top="234" left="872" width="205" height="20" font="7"><b>Summary/Conclusion Comment(s) </b></text>
<text top="287" left="89" width="134" height="20" font="0">Perak, AM, et al., </text>
<text top="304" left="89" width="56" height="20" font="0">2016 <a href="data supplement.html#238">(39)</a> </text>
<text top="321" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27358432">27358432</a></text>
<text top="321" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27358432"> </a></text>
<text top="287" left="227" width="136" height="20" font="7"><b>Study Type:</b>  Pooled </text>
<text top="304" left="227" width="140" height="20" font="0">cohort analysis from 6 </text>
<text top="321" left="227" width="221" height="20" font="0">large US </text>
<text top="338" left="227" width="132" height="20" font="0">epidemiological cohorts </text>
<text top="355" left="227" width="3" height="20" font="0"> </text>
<text top="373" left="227" width="145" height="20" font="7"><b>Size:</b>  68565 baseline </text>
<text top="390" left="227" width="111" height="20" font="0">person-examination </text>
<text top="287" left="376" width="226" height="20" font="7"><b>Inclusion criteria:</b>  Men and women </text>
<text top="304" left="376" width="221" height="20" font="0">stratified by LDL-C at ages 20-79 y with </text>
<text top="321" left="376" width="226" height="20" font="0">at least 1 baseline examination with </text>
<text top="338" left="376" width="227" height="20" font="0">direct measurement of serum lipids, </text>
<text top="355" left="376" width="240" height="20" font="0">physiological and anthropometric </text>
<text top="373" left="376" width="223" height="20" font="0">variables. Primary analysis defined FH </text>
<text top="390" left="376" width="221" height="20" font="0">phenotype as LDL-C ≥ 190 mg/dL and </text>
<text top="407" left="376" width="114" height="20" font="0">referent &lt;130 mg/dL </text>
<text top="424" left="376" width="3" height="20" font="0"> </text>
<text top="442" left="376" width="134" height="20" font="7"><b>Exclusion criteria:</b> N/A </text>
<text top="287" left="610" width="228" height="22" font="7"><b>1</b>⁰<b>endpoint:</b>  long term CHD and total </text>
<text top="304" left="610" width="228" height="20" font="0">ASCVD risks in UD adults with an FH </text>
<text top="321" left="610" width="64" height="20" font="0">phenotype. </text>
<text top="339" left="610" width="7" height="20" font="0">  </text>
<text top="356" left="610" width="52" height="20" font="7"><b>Results: </b></text>
<text top="373" left="610" width="242" height="20" font="0">After co-variate adjustment, FH </text>
<text top="390" left="610" width="225" height="20" font="0">phenotype was associated with HR: up to </text>
<text top="407" left="610" width="228" height="20" font="0">5.0 (95% CI: 1.1-21.7). CHD risk was </text>
<text top="425" left="610" width="225" height="20" font="0">accelerated by 10-20 y in men and 20-30 </text>
<text top="442" left="610" width="230" height="20" font="0">y in women. Total ASCVD risk was </text>
<text top="459" left="610" width="226" height="20" font="0">associated with HR: up to 4.1 (95% CI: </text>
<text top="476" left="610" width="53" height="20" font="0">1.2-13.4) </text>
<text top="287" left="848" width="64" height="20" font="7"><b>Summary: </b></text>
<text top="304" left="848" width="258" height="20" font="0">FH phenotype is associated with increased </text>
<text top="321" left="848" width="256" height="20" font="0">risk for ASCVD and accelerates risk in both </text>
<text top="338" left="848" width="98" height="20" font="0">men and women. </text>
<text top="355" left="848" width="3" height="20" font="0"> </text>
<text top="373" left="848" width="262" height="20" font="7"><b>Limitations:</b>  1. Phenotypic rather than </text>
<text top="390" left="848" width="148" height="20" font="0">genotypic diagnosis of FH. </text>
<text top="407" left="848" width="252" height="20" font="0">2. Single measurement of LDL-C for inclusion </text>
<text top="424" left="848" width="257" height="20" font="0">3. Secondary hypercholesterolemia was not </text>
<text top="442" left="848" width="56" height="20" font="0">excluded. </text>
<text top="459" left="848" width="172" height="20" font="0">4. Limited family data available </text>
<text top="494" left="89" width="125" height="20" font="0"> Khera AV, et al., 2016 </text>
<text top="512" left="89" width="25" height="20" font="0"><a href="data supplement.html#238">(40)</a> </text>
<text top="529" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27050191">27050191</a></text>
<text top="529" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27050191"> </a></text>
<text top="494" left="227" width="136" height="20" font="7"><b>Study Type</b>:  Pooled </text>
<text top="512" left="227" width="135" height="20" font="0">cohort analysis of 7 CAD </text>
<text top="529" left="227" width="136" height="20" font="0">case control cohorts and </text>
<text top="546" left="227" width="147" height="20" font="0">5 prospective cohort </text>
<text top="563" left="227" width="42" height="20" font="0">studies </text>
<text top="580" left="227" width="3" height="20" font="0"> </text>
<text top="598" left="227" width="122" height="20" font="7"><b>Size:</b> 20,485 subjects </text>
<text top="494" left="376" width="106" height="20" font="7"><b>Inclusion criteria: </b></text>
<text top="512" left="376" width="218" height="20" font="0">1386 subjects were identified with LDL-</text>
<text top="529" left="376" width="225" height="20" font="0">C  ≥  190  mg/dL. Whole exome gene </text>
<text top="546" left="376" width="226" height="20" font="0">sequencing was done on those with </text>
<text top="563" left="376" width="221" height="20" font="0">LDL-C ≥ 190 mg/dL comparing risk for </text>
<text top="580" left="376" width="218" height="20" font="0">CAD in those with vs. without FH-</text>
<text top="598" left="376" width="106" height="20" font="0">causing mutations. </text>
<text top="615" left="376" width="3" height="20" font="0"> </text>
<text top="632" left="376" width="134" height="20" font="7"><b>Exclusion criteria:</b> N/A </text>
<text top="494" left="610" width="234" height="22" font="7"><b>1</b>⁰<b>endpoint:</b>  Prevalence of an FH </text>
<text top="512" left="610" width="233" height="20" font="0">mutation among those with severe </text>
<text top="529" left="610" width="226" height="20" font="0">hypercholesterolemia and determination </text>
<text top="546" left="610" width="226" height="20" font="0">of whether CAD risk varies according to </text>
<text top="563" left="610" width="230" height="20" font="0">mutation status beyond the observed </text>
<text top="581" left="610" width="71" height="20" font="0">LDL-C level. </text>
<text top="598" left="610" width="3" height="20" font="0"> </text>
<text top="615" left="610" width="3" height="20" font="0"> </text>
<text top="632" left="610" width="52" height="20" font="7"><b>Results: </b></text>
<text top="650" left="610" width="225" height="20" font="0">1. Those with LDL-C ≥190 mg/dL and no </text>
<text top="667" left="610" width="226" height="20" font="0">FH mutation had a 6-fold higher risk for </text>
<text top="684" left="610" width="225" height="20" font="0">CAD (odds ratio: 6.0; 95% CI: 5.2-6.9) </text>
<text top="701" left="610" width="224" height="20" font="0">than those with LDL-C &lt;130 mg/dl and no </text>
<text top="718" left="610" width="225" height="20" font="0">mutation. Those with both LDL-C ≥190 </text>
<text top="736" left="610" width="225" height="20" font="0">mg/dl and an FH mutation had a 22-fold </text>
<text top="753" left="610" width="226" height="20" font="0">increased risk (odds ratio: 22.3; 95% CI: </text>
<text top="770" left="610" width="63" height="20" font="0">10.7-53.2). </text>
<text top="494" left="848" width="67" height="20" font="7"><b>Summary:  </b></text>
<text top="512" left="848" width="254" height="20" font="0">CAD risk is higher in those with LDL-C ≥ 190 </text>
<text top="529" left="848" width="255" height="20" font="0">mg/dL than in those with LDL-C &lt;130 mg/dL </text>
<text top="546" left="848" width="255" height="20" font="0">and the risk is more than tripled in those with </text>
<text top="563" left="848" width="254" height="20" font="0">LDL-C  ≥190  mg/dL  and  a  concomitant  FH </text>
<text top="580" left="848" width="96" height="20" font="0">causing mutation </text>
<text top="598" left="848" width="254" height="20" font="0">3. These findings may be mediated via  a </text>
<text top="615" left="848" width="210" height="20" font="0">higher cumulative exposure to LDL-C. </text>
<text top="632" left="848" width="107" height="20" font="7"><b>Study limitations: </b></text>
<text top="649" left="848" width="255" height="20" font="0">1. Study participants could not be stratified by </text>
<text top="666" left="848" width="207" height="20" font="0">family history or physical examination </text>
<text top="684" left="848" width="254" height="20" font="0">2. Assumption of 30% LDL-C lowering in those </text>
<text top="701" left="848" width="254" height="20" font="0">treated with statin therapy may not be accurate </text>
<text top="718" left="848" width="256" height="20" font="0">3. Those with LDL mutations may have had </text>
<text top="735" left="848" width="95" height="20" font="0">survivorship bias </text>
</page>
<page number="47" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">47 </text>
<text top="107" left="610" width="225" height="20" font="0">2. Cumulative exposure to high LDL-C </text>
<text top="124" left="610" width="229" height="20" font="0">was assessed using a cohort from of </text>
<text top="141" left="610" width="246" height="20" font="0">5,727 Atherosclerosis Risk in </text>
<text top="159" left="610" width="229" height="20" font="0">Communities Study cohort participants </text>
<text top="176" left="610" width="232" height="20" font="0">and 2,714 Framingham Heart Study </text>
<text top="193" left="610" width="226" height="20" font="0">participants and in those with serial lipid </text>
<text top="210" left="610" width="231" height="20" font="0">measurements over many y. Among </text>
<text top="227" left="610" width="224" height="20" font="0">these subjects 25 participants with an FH </text>
<text top="245" left="610" width="225" height="20" font="0">mutation  and  LDL  cholesterol  ≥130 </text>
<text top="262" left="610" width="230" height="20" font="0">mg/dL were identified Compared with </text>
<text top="279" left="610" width="225" height="20" font="0">matched non-carriers with similar LDL-C </text>
<text top="296" left="610" width="227" height="20" font="0">levels participants with an FH mutation </text>
<text top="314" left="610" width="228" height="20" font="0">had a 17 mg/dl (95% CI: 5-29 mg/dl; </text>
<text top="331" left="610" width="225" height="20" font="0">p=0.007) higher average LDL cholesterol </text>
<text top="348" left="610" width="225" height="20" font="0">exposure in the y preceding the last visit. </text>
<text top="366" left="89" width="125" height="20" font="0">Nanchen D, et al., <a href="data supplement.html#238">(41)</a> </text>
<text top="383" left="89" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27462068"> </a></text>
<text top="383" left="93" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27462068">27462068</a></text>
<text top="383" left="148" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27462068"> </a></text>
<text top="366" left="227" width="136" height="20" font="7"><b>Study type:</b> Multicenter </text>
<text top="383" left="227" width="140" height="20" font="0">prospective cohort study  </text>
<text top="400" left="227" width="109" height="20" font="7"><b>Size:</b> 4534 patients </text>
<text top="418" left="227" width="3" height="20" font="0"> </text>
<text top="366" left="376" width="109" height="20" font="7"><b>Inclusion criteria:  </b></text>
<text top="383" left="376" width="221" height="20" font="0">1.  Patients  ≥  age  18  y  with  a  primary </text>
<text top="400" left="376" width="221" height="20" font="0">diagnosis of ST elevation MI, non-ST </text>
<text top="418" left="376" width="232" height="20" font="0">elevation MI or unstable angina, </text>
<text top="435" left="376" width="235" height="20" font="0">hospitalized with acute coronary </text>
<text top="452" left="376" width="222" height="20" font="0">syndrome in Switzerland between 2009 </text>
<text top="469" left="376" width="226" height="20" font="0">and 2013 and who were individually </text>
<text top="487" left="376" width="228" height="20" font="0">screened for clinical FH using the </text>
<text top="504" left="376" width="231" height="20" font="0">definitions of the American Heart </text>
<text top="521" left="376" width="226" height="20" font="0">Association, Simon Broome, and the </text>
<text top="538" left="376" width="146" height="20" font="0">Dutch Lipid Clinic criteria.  </text>
<text top="555" left="376" width="223" height="20" font="0">2. Patients with complete baseline and </text>
<text top="573" left="376" width="221" height="20" font="0">follow-up lipid measurements and family </text>
<text top="590" left="376" width="107" height="20" font="0">history information. </text>
<text top="607" left="376" width="7" height="20" font="0">  </text>
<text top="624" left="376" width="222" height="20" font="7"><b>Exclusion criteria:</b> Those with missing </text>
<text top="641" left="376" width="183" height="20" font="0">lipid or family history information. </text>
<text top="659" left="376" width="3" height="20" font="0"> </text>
<text top="676" left="376" width="3" height="20" font="0"> </text>
<text top="366" left="610" width="227" height="22" font="0"> <b>1</b>⁰<b>  endpoint:</b>  1-y risk of first recurrent </text>
<text top="384" left="610" width="227" height="20" font="0">coronary death or myocardial infarction </text>
<text top="401" left="610" width="226" height="20" font="0">after multivariable adjustment, assessed </text>
<text top="418" left="610" width="222" height="20" font="0">by telephone monitoring and by a follow-</text>
<text top="435" left="610" width="211" height="20" font="0">up clinic visit 1 y after the acute event. </text>
<text top="452" left="610" width="225" height="20" font="7"><b>Results:</b> The risk of recurrent coronary </text>
<text top="470" left="610" width="227" height="20" font="0">events was greater in patients with FH </text>
<text top="487" left="610" width="227" height="20" font="0">than in those without, with an adjusted </text>
<text top="504" left="610" width="229" height="20" font="0">hazard ratio of 2.46 (95% confidence </text>
<text top="521" left="610" width="232" height="20" font="0">interval: 1.07–5.65; p=0.034) for the </text>
<text top="539" left="610" width="229" height="20" font="0">American Heart Association definition, </text>
<text top="556" left="610" width="222" height="20" font="0">2.73 (95% confidence interval: 1.46–</text>
<text top="573" left="610" width="229" height="20" font="0">5.11; p=0.002) for the  Simon Broome </text>
<text top="590" left="610" width="231" height="20" font="0">definition, and 3.53 (95% confidence </text>
<text top="607" left="610" width="232" height="20" font="0">interval: 1.26–9.94;  p=0.017) for the </text>
<text top="625" left="610" width="227" height="20" font="0">Dutch Lipid Clinic definition. Depending </text>
<text top="642" left="610" width="229" height="20" font="0">on which clinical definition of FH was </text>
<text top="659" left="610" width="230" height="20" font="0">used, between 94.5% and 99.1% of </text>
<text top="676" left="610" width="229" height="20" font="0">patients with FH were discharged on </text>
<text top="693" left="610" width="227" height="20" font="0">statins and between 74.0% and 82.3% </text>
<text top="711" left="610" width="132" height="20" font="0">on high-intensity statins </text>
<text top="366" left="848" width="259" height="20" font="7"><b>Summary:</b>  Recurrent coronary events are </text>
<text top="383" left="848" width="257" height="20" font="0">more likely in those with FH than in those </text>
<text top="400" left="848" width="182" height="20" font="0">without despite high-dose statins </text>
<text top="418" left="848" width="73" height="20" font="7"><b>Limitations: </b></text>
<text top="435" left="848" width="256" height="20" font="0">1. Possible selection bias of MI patients with </text>
<text top="452" left="848" width="252" height="20" font="0">vs. without FH presenting with recurrent ACS  </text>
<text top="469" left="848" width="256" height="20" font="0">2. No genetic testing was performed, so the </text>
<text top="487" left="848" width="258" height="20" font="0">presence of polygenic hypercholesterolemia </text>
<text top="504" left="848" width="127" height="20" font="0">could not be excluded. </text>
<text top="521" left="848" width="255" height="20" font="0">3. No data were collected on family history or </text>
<text top="538" left="848" width="217" height="20" font="0">physical findings related to possible FH </text>
<text top="555" left="848" width="251" height="20" font="0">4. Lower LDL-C values on blood collected 12-</text>
<text top="573" left="848" width="262" height="20" font="0">24 H  after ACS may have resulted in </text>
<text top="590" left="848" width="205" height="20" font="0">underestimation of prevalence of FH. </text>
<text top="729" left="89" width="129" height="20" font="0">Versmissen J, et al., </text>
<text top="746" left="89" width="56" height="20" font="0">2008 <a href="data supplement.html#238">(42)</a><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19001495"> </a></text>
<text top="746" left="146" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19001495">19001495</a></text>
<text top="746" left="200" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19001495"> </a></text>
<text top="729" left="227" width="136" height="20" font="7"><b>Study Type:</b> </text>
<text top="746" left="227" width="156" height="20" font="0">Retrospective cohort </text>
<text top="763" left="227" width="141" height="20" font="0">study of 27 outpatient </text>
<text top="729" left="376" width="106" height="20" font="7"><b>Inclusion criteria: </b></text>
<text top="746" left="376" width="235" height="20" font="0">Patients with phenotypic familial </text>
<text top="763" left="376" width="229" height="20" font="0">hypercholesterolemia identified in a </text>
<text top="780" left="376" width="228" height="20" font="0">Dutch cohort from 1/1/90 to 2002. </text>
<text top="729" left="610" width="227" height="22" font="7"><b>1</b>⁰<b>endpoint</b>: Relative risk of myocardial </text>
<text top="746" left="610" width="225" height="20" font="0">infarction in statin treated patients and in </text>
<text top="763" left="610" width="225" height="20" font="0">those who were delayed in starting statin </text>
<text top="781" left="610" width="238" height="20" font="0">treatment compared with a Cox </text>
<text top="729" left="848" width="259" height="20" font="7"><b>Summary:</b>  Statin therapy reduces incident </text>
<text top="746" left="848" width="260" height="20" font="0">myocardial infarction risk in subjects with </text>
<text top="763" left="848" width="165" height="20" font="0">familial hypercholesterolemia  </text>
<text top="780" left="848" width="3" height="20" font="0"> </text>
</page>
<page number="48" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">48 </text>
<text top="107" left="227" width="150" height="20" font="0">lipid clinics in the </text>
<text top="124" left="227" width="73" height="20" font="0">Netherlands. </text>
<text top="141" left="227" width="3" height="20" font="0"> </text>
<text top="159" left="227" width="109" height="20" font="7"><b>Size:</b> 2146 patients </text>
<text top="107" left="376" width="223" height="20" font="0">Enrollees had to have no documented </text>
<text top="124" left="376" width="211" height="20" font="0">coronary heart disease prior to 1/1/90. </text>
<text top="141" left="376" width="3" height="20" font="0"> </text>
<text top="159" left="376" width="110" height="20" font="7"><b>Exclusion criteria: </b></text>
<text top="176" left="376" width="224" height="20" font="0">Those with established coronary heart </text>
<text top="193" left="376" width="128" height="20" font="0">disease prior to 1/1/90. </text>
<text top="107" left="610" width="225" height="20" font="0">regression model in which statin use was </text>
<text top="124" left="610" width="148" height="20" font="0">a time dependent variable. </text>
<text top="141" left="610" width="226" height="20" font="0">Results: In January 1990, 413 (21%) of </text>
<text top="159" left="610" width="225" height="20" font="0">the patients had been started on a statin, </text>
<text top="176" left="610" width="224" height="20" font="0">and during follow-up 1294 patients (66%) </text>
<text top="193" left="610" width="226" height="20" font="0">started after a mean delay of 4.3 y (SD </text>
<text top="210" left="610" width="226" height="20" font="0">3.3 y). During a mean follow-up of 8.5 y </text>
<text top="227" left="610" width="230" height="20" font="0">(SD 3.1 y) there was a reduction in </text>
<text top="245" left="610" width="230" height="20" font="0">myocardial infarction risk reduction of </text>
<text top="262" left="610" width="225" height="20" font="0">76% (hazard ratio: 0.24; CI: 0.18-0.30), </text>
<text top="279" left="610" width="228" height="20" font="0">p&lt;0.001) in those initially started on a </text>
<text top="296" left="610" width="229" height="20" font="0">statin as compared to those in whom </text>
<text top="314" left="610" width="227" height="20" font="0">statin administration had been delayed. </text>
<text top="331" left="610" width="230" height="20" font="0">After additional reduction for baseline </text>
<text top="348" left="610" width="228" height="20" font="0">characteristics, there was an 82% risk </text>
<text top="365" left="610" width="225" height="20" font="0">reduction (HR: 0.18; 95% CI: 0.13-0.25; </text>
<text top="382" left="610" width="56" height="20" font="0">p&lt;0.001). </text>
<text top="107" left="848" width="76" height="20" font="7"><b>Limitations</b>:  </text>
<text top="124" left="848" width="260" height="20" font="0">1. Possible selection bias favoring earlier </text>
<text top="141" left="848" width="258" height="20" font="0">treatment of patients with perceived higher </text>
<text top="159" left="848" width="26" height="20" font="0">risk. </text>
<text top="176" left="848" width="144" height="20" font="0">2. Lack of placebo control </text>
<text top="193" left="848" width="254" height="20" font="0">3. Intention to treat analysis was not employed </text>
<text top="400" left="89" width="132" height="20" font="0">Besseling J, et al., </text>
<text top="418" left="89" width="56" height="20" font="0">2016 <a href="data supplement.html#238">(43)</a> </text>
<text top="435" left="89" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27417002"> </a></text>
<text top="435" left="93" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27417002">27417002</a></text>
<text top="435" left="148" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27417002"> </a></text>
<text top="452" left="89" width="3" height="20" font="0"> </text>
<text top="400" left="227" width="70" height="20" font="7"><b>Study Type </b></text>
<text top="418" left="227" width="156" height="20" font="0">Retrospective cohort </text>
<text top="435" left="227" width="135" height="20" font="0">study of the database of </text>
<text top="452" left="227" width="136" height="20" font="0">the national FH cascade </text>
<text top="469" left="227" width="145" height="20" font="0">screening program in </text>
<text top="487" left="227" width="140" height="20" font="0">the  Netherlands and a </text>
<text top="504" left="227" width="164" height="20" font="0">patient-centric data </text>
<text top="521" left="227" width="46" height="20" font="0">network </text>
<text top="538" left="227" width="140" height="20" font="0">of multiple health care </text>
<text top="555" left="227" width="60" height="20" font="0">databases </text>
<text top="573" left="227" width="109" height="20" font="7"><b>Size:</b> 1559 patients </text>
<text top="400" left="376" width="105" height="20" font="7"><b>Inclusion criteria</b>: </text>
<text top="418" left="376" width="221" height="20" font="0">Patients’  age  ≥18  y  with  genetically </text>
<text top="435" left="376" width="239" height="20" font="0">determined deleterious mutations </text>
<text top="452" left="376" width="223" height="20" font="0">associated with FH and free of clinical </text>
<text top="469" left="376" width="154" height="20" font="0">CAD at entry into the study. </text>
<text top="487" left="376" width="3" height="20" font="0"> </text>
<text top="504" left="376" width="110" height="20" font="7"><b>Exclusion criteria: </b></text>
<text top="521" left="376" width="221" height="20" font="0">Patients with homozygous,  compound </text>
<text top="538" left="376" width="225" height="20" font="0">heterozygous or double heterozygous </text>
<text top="555" left="376" width="221" height="20" font="0">FH or carriers of a non-deleterious </text>
<text top="573" left="376" width="54" height="20" font="0">mutation. </text>
<text top="401" left="610" width="228" height="22" font="7"><b>1</b>⁰<b>endpoint:</b>  Relative risk reduction for </text>
<text top="418" left="610" width="235" height="20" font="0">CAD (myocardial infarction, angina </text>
<text top="435" left="610" width="225" height="20" font="0">pectoris, or other forms of atherosclerotic </text>
<text top="452" left="610" width="228" height="20" font="0">or ischemic heart disease or coronary </text>
<text top="470" left="610" width="225" height="20" font="0">artery bypass graft or PCI), and all-cause </text>
<text top="487" left="610" width="227" height="20" font="0">mortality by statins in heterozygous FH </text>
<text top="504" left="610" width="50" height="20" font="0">patients. </text>
<text top="521" left="610" width="3" height="20" font="0"> </text>
<text top="539" left="610" width="3" height="20" font="0"> </text>
<text top="556" left="610" width="52" height="20" font="7"><b>Results: </b></text>
<text top="573" left="610" width="226" height="20" font="0">Patients treated with statins (n = 1,041) </text>
<text top="590" left="610" width="225" height="20" font="0">(most often simvastatin 40 mg daily] </text>
<text top="607" left="610" width="232" height="20" font="0">[23.1%] or atorvastatin 40 mg daily </text>
<text top="625" left="610" width="229" height="20" font="0">[22.8%])  had 89 CAD events and 17 </text>
<text top="642" left="610" width="221" height="20" font="0">deaths during 11,674 person-y of follow-</text>
<text top="659" left="610" width="232" height="20" font="0">up versus those never treated with </text>
<text top="676" left="610" width="224" height="20" font="0">statins (n = 518), who had 22 CAD events </text>
<text top="693" left="610" width="225" height="20" font="0">and 9 deaths during 4,892 person-y </text>
<text top="711" left="610" width="228" height="20" font="0">(combined rates 8.8 vs. 5.3 per 1,000 </text>
<text top="728" left="610" width="229" height="20" font="0">person-y, respectively; p&lt;0.001). After </text>
<text top="745" left="610" width="228" height="20" font="0">applying IPTW and adjusting for other </text>
<text top="762" left="610" width="228" height="20" font="0">medications, the hazard ratio of statin </text>
<text top="779" left="610" width="226" height="20" font="0">use for CAD and all-cause mortality was </text>
<text top="400" left="848" width="64" height="20" font="7"><b>Summary: </b></text>
<text top="418" left="848" width="254" height="20" font="0">In patients with heterozygous FH, moderate- to </text>
<text top="435" left="848" width="257" height="20" font="0">high-intensity statin therapy lowered the risk </text>
<text top="452" left="848" width="222" height="20" font="0">for CAD and all-cause mortality by 44%. </text>
<text top="469" left="848" width="3" height="20" font="0"> </text>
<text top="487" left="848" width="73" height="20" font="7"><b>Limitations: </b></text>
<text top="504" left="848" width="255" height="20" font="0">1. Because of the observational nature of the </text>
<text top="521" left="848" width="254" height="20" font="0">study, indication bias could have been present. </text>
<text top="538" left="848" width="254" height="20" font="0">2. Time lag between the first observation in the </text>
<text top="555" left="848" width="257" height="20" font="0">database and the first visit in the screening </text>
<text top="573" left="848" width="193" height="20" font="0">program may have affected results </text>
<text top="590" left="848" width="202" height="20" font="0">3. Cause of death was not specified. </text>
</page>
<page number="49" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">49 </text>
<text top="107" left="610" width="228" height="20" font="0">0.56 (95% confidence interval: 0.33 to </text>
<text top="124" left="610" width="35" height="20" font="0">0.96). </text>
<text top="142" left="89" width="129" height="20" font="0"> Perez de Isla, 2017 </text>
<text top="159" left="89" width="25" height="20" font="0"><a href="data supplement.html#238">(44)</a> </text>
<text top="177" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28275165">28275165</a></text>
<text top="177" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28275165"> </a></text>
<text top="194" left="89" width="3" height="20" font="0"> </text>
<text top="211" left="89" width="3" height="20" font="0"> </text>
<text top="142" left="227" width="136" height="20" font="7"><b>Study Type:</b> </text>
<text top="159" left="227" width="167" height="20" font="0">Prospective cohort </text>
<text top="177" left="227" width="151" height="20" font="0">study from multiple </text>
<text top="194" left="227" width="136" height="20" font="0">medical centers in Spain </text>
<text top="211" left="227" width="192" height="20" font="0">employing the </text>
<text top="228" left="227" width="121" height="20" font="0">SAFEHEART registry </text>
<text top="245" left="227" width="109" height="20" font="7"><b>Size</b>: 2404 patients </text>
<text top="142" left="376" width="109" height="20" font="7"><b>Inclusion criteria:  </b></text>
<text top="159" left="376" width="221" height="20" font="0">Age  ≥  18  y  with  molecularly  defined </text>
<text top="177" left="376" width="231" height="20" font="0">heterozygous FH, with or without </text>
<text top="194" left="376" width="103" height="20" font="0">previous ASCVD   </text>
<text top="211" left="376" width="228" height="20" font="0">Assessment of fasting lipids; Lp(a); </text>
<text top="228" left="376" width="231" height="20" font="0">ASCVD risk factors; whole blood </text>
<text top="245" left="376" width="221" height="20" font="0">molecular analysis of DNA;  assessment </text>
<text top="263" left="376" width="186" height="20" font="0">of   previous and incident ASCVD </text>
<text top="280" left="376" width="3" height="20" font="0"> </text>
<text top="297" left="376" width="135" height="20" font="7"><b>Exclusion criteria: N/A </b></text>
<text top="142" left="610" width="229" height="22" font="7"><b>1</b>⁰<b>  endpoint:</b>  Identification of key risk </text>
<text top="160" left="610" width="233" height="20" font="0">factors for prediction of ASCVD in </text>
<text top="177" left="610" width="281" height="20" font="0">patients with familial </text>
<text top="194" left="610" width="251" height="20" font="0">hypercholesterolemia using the </text>
<text top="211" left="610" width="128" height="20" font="0">SAFEHEART registry.  </text>
<text top="229" left="610" width="3" height="20" font="0"> </text>
<text top="246" left="610" width="55" height="20" font="7"><b>Results:  </b></text>
<text top="263" left="610" width="225" height="20" font="0">1. Over a mean period of 5.5 y, 12 (0.5%) </text>
<text top="280" left="610" width="225" height="20" font="0">had fatal and 122 (5.1%) non-fatal </text>
<text top="298" left="610" width="105" height="20" font="0">ASCVD incidents.  </text>
<text top="315" left="610" width="226" height="20" font="0">2. Age male gender, history of pervious </text>
<text top="332" left="610" width="226" height="20" font="0">ASCVD, high blood pressure, increased </text>
<text top="349" left="610" width="232" height="20" font="0">waist circumference, active smoking, </text>
<text top="366" left="610" width="232" height="20" font="0">LDL-C and Lp(a) were independent </text>
<text top="384" left="610" width="163" height="20" font="0">predictors of incident ASCVD </text>
<text top="401" left="610" width="165" height="20" font="0">See table 3 from article below </text>
<text top="418" left="610" width="224" height="20" font="0">3. Molecular diagnosis: Two hundred and </text>
<text top="435" left="610" width="225" height="20" font="0">nine different functional mutations in LDL </text>
<text top="452" left="610" width="225" height="20" font="0">receptor (LDLR) (97.0%) and APO-B </text>
<text top="470" left="610" width="231" height="20" font="0">(3.0%) genes were identified. In the </text>
<text top="487" left="610" width="227" height="20" font="0">cohort 856 (35.6%) patients had LDLR </text>
<text top="504" left="610" width="222" height="20" font="0">null mutations, 1092 (45.4%) defective-</text>
<text top="521" left="610" width="227" height="20" font="0">mutations and 384 (16.0%) unclassified </text>
<text top="539" left="610" width="60" height="20" font="0">mutations. </text>
<text top="556" left="610" width="225" height="20" font="0">4. A risk equation was derived from these </text>
<text top="573" left="610" width="200" height="20" font="0">results with Harrell’s C index of 0.85 </text>
<text top="590" left="610" width="226" height="20" font="0">5. Individual risk was estimated for each </text>
<text top="607" left="610" width="235" height="20" font="0">person without established ASCVD </text>
<text top="625" left="610" width="225" height="20" font="0">before enrollment using SAFEHEART </text>
<text top="642" left="610" width="226" height="20" font="0">risk equation, modified Framingham risk </text>
<text top="659" left="610" width="230" height="20" font="0">Scoring and ACC/AHA Pooled cohort </text>
<text top="676" left="610" width="225" height="20" font="0">Risk Equations. SAFEHEART-RE </text>
<text top="693" left="610" width="198" height="20" font="0">outperformed the other two models. </text>
<text top="142" left="848" width="64" height="20" font="7"><b>Summary: </b></text>
<text top="159" left="848" width="263" height="20" font="0">1. Several easily obtained clinical and </text>
<text top="177" left="848" width="272" height="20" font="0">laboratory studies were independent </text>
<text top="194" left="848" width="170" height="20" font="0">predictors of incident ASCVD.  </text>
<text top="211" left="848" width="255" height="20" font="0">2. A SAFEHEART risk equation, derived from </text>
<text top="228" left="848" width="259" height="20" font="0">the ASCVD outcomes of this cohort, was </text>
<text top="245" left="848" width="256" height="20" font="0">shown to be a useful tool to predict ASCVD </text>
<text top="263" left="848" width="255" height="20" font="0">risk in these patients with molecularly defined </text>
<text top="280" left="848" width="23" height="20" font="0">FH. </text>
<text top="297" left="848" width="3" height="20" font="0"> </text>
<text top="314" left="848" width="73" height="20" font="7"><b>Limitations</b>: </text>
<text top="332" left="848" width="218" height="20" font="0">1. No data from children or adolescents </text>
<text top="349" left="848" width="259" height="20" font="0">2. Not all patients had pre-treatment lipid </text>
<text top="366" left="848" width="39" height="20" font="0">values </text>
<text top="383" left="848" width="225" height="20" font="0">3. No external validation cohort available </text>
<text top="400" left="848" width="253" height="20" font="0">4. Relatively short mean follow-up period of 5.5 </text>
<text top="418" left="848" width="10" height="20" font="0">y </text>
<text top="711" left="89" width="129" height="20" font="0">Perez de Isla et al., </text>
<text top="729" left="89" width="56" height="20" font="0">2017<a href="data supplement.html#238"> (44)</a> </text>
<text top="746" left="89" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28275165"> </a></text>
<text top="746" left="93" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28275165">28275165</a></text>
<text top="746" left="148" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28275165"> </a></text>
<text top="763" left="89" width="3" height="20" font="0"> </text>
<text top="780" left="89" width="3" height="20" font="0"> </text>
<text top="711" left="227" width="136" height="20" font="7"><b>Study Type:</b> </text>
<text top="729" left="227" width="167" height="20" font="0">Prospective cohort </text>
<text top="746" left="227" width="151" height="20" font="0">study from multiple </text>
<text top="763" left="227" width="136" height="20" font="0">medical centers in Spain </text>
<text top="711" left="376" width="109" height="20" font="7"><b>Inclusion criteria:  </b></text>
<text top="729" left="376" width="221" height="20" font="0">Age  ≥  18  y  with  molecularly  defined </text>
<text top="746" left="376" width="231" height="20" font="0">heterozygous FH, with or without </text>
<text top="763" left="376" width="103" height="20" font="0">previous ASCVD   </text>
<text top="712" left="610" width="229" height="22" font="7"><b>1</b>⁰<b>  endpoint</b>: Identification of key risk </text>
<text top="729" left="610" width="233" height="20" font="0">factors for prediction of ASCVD in </text>
<text top="746" left="610" width="281" height="20" font="0">patients with familial </text>
<text top="763" left="610" width="251" height="20" font="0">hypercholesterolemia using the </text>
<text top="781" left="610" width="128" height="20" font="0">SAFEHEART registry.  </text>
<text top="711" left="848" width="64" height="20" font="7"><b>Summary: </b></text>
<text top="729" left="848" width="263" height="20" font="0">1. Several easily obtained clinical and </text>
<text top="746" left="848" width="272" height="20" font="0">laboratory studies were independent </text>
<text top="763" left="848" width="170" height="20" font="0">predictors of incident ASCVD.  </text>
</page>
<page number="50" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">50 </text>
<text top="107" left="227" width="192" height="20" font="0">employing the </text>
<text top="124" left="227" width="121" height="20" font="0">SAFEHEART registry </text>
<text top="141" left="227" width="109" height="20" font="7"><b>Size:</b> 2404 patients </text>
<text top="107" left="376" width="228" height="20" font="0">Assessment of fasting lipids; Lp(a); </text>
<text top="124" left="376" width="231" height="20" font="0">ASCVD risk factors; whole blood </text>
<text top="141" left="376" width="221" height="20" font="0">molecular analysis of DNA;  assessment </text>
<text top="159" left="376" width="186" height="20" font="0">of   previous and incident ASCVD </text>
<text top="176" left="376" width="3" height="20" font="0"> </text>
<text top="193" left="376" width="138" height="20" font="7"><b>Exclusion criteria : N/A </b></text>
<text top="107" left="610" width="229" height="20" font="0"> 1. Over a mean period of 5.5 y, 12 </text>
<text top="124" left="610" width="225" height="20" font="0">(0.5%) had fatal and 122 (5.1%) non-fatal </text>
<text top="141" left="610" width="105" height="20" font="0">ASCVD incidents.  </text>
<text top="159" left="610" width="226" height="20" font="0">2. Age male gender, history of pervious </text>
<text top="176" left="610" width="226" height="20" font="0">ASCVD, high blood pressure, increased </text>
<text top="193" left="610" width="232" height="20" font="0">waist circumference, active smoking, </text>
<text top="210" left="610" width="232" height="20" font="0">LDL-C and Lp(a) were independent </text>
<text top="227" left="610" width="163" height="20" font="0">predictors of incident ASCVD </text>
<text top="245" left="610" width="165" height="20" font="0">See table 3 from article below </text>
<text top="262" left="610" width="224" height="20" font="0">3. Molecular diagnosis: Two hundred and </text>
<text top="279" left="610" width="225" height="20" font="0">nine different functional mutations in LDL </text>
<text top="296" left="610" width="225" height="20" font="0">receptor (LDLR) (97.0%) and APO-B </text>
<text top="314" left="610" width="231" height="20" font="0">(3.0%) genes were identified. In the </text>
<text top="331" left="610" width="227" height="20" font="0">cohort 856 (35.6%) patients had LDLR </text>
<text top="348" left="610" width="222" height="20" font="0">null mutations, 1092 (45.4%) defective-</text>
<text top="365" left="610" width="227" height="20" font="0">mutations and 384 (16.0%) unclassified </text>
<text top="382" left="610" width="60" height="20" font="0">mutations. </text>
<text top="400" left="610" width="225" height="20" font="0">4. A risk equation was derived from these </text>
<text top="417" left="610" width="200" height="20" font="0">results with Harrell’s C index of 0.85 </text>
<text top="434" left="610" width="226" height="20" font="0">5. Individual risk was estimated for each </text>
<text top="451" left="610" width="235" height="20" font="0">person without established ASCVD </text>
<text top="469" left="610" width="225" height="20" font="0">before enrollment using SAFEHEART </text>
<text top="486" left="610" width="226" height="20" font="0">risk equation, modified Framingham risk </text>
<text top="503" left="610" width="230" height="20" font="0">Scoring and ACC/AHA Pooled cohort </text>
<text top="520" left="610" width="225" height="20" font="0">Risk Equations. SAFEHEART-RE </text>
<text top="537" left="610" width="198" height="20" font="0">outperformed the other two models. </text>
<text top="107" left="848" width="255" height="20" font="0">2. A SAFEHEART risk equation, derived from </text>
<text top="124" left="848" width="259" height="20" font="0">the ASCVD outcomes of this cohort, was </text>
<text top="141" left="848" width="256" height="20" font="0">shown to be a useful tool to predict ASCVD </text>
<text top="159" left="848" width="255" height="20" font="0">risk in these patients with molecularly defined </text>
<text top="176" left="848" width="23" height="20" font="0">FH. </text>
<text top="193" left="848" width="3" height="20" font="0"> </text>
<text top="210" left="848" width="73" height="20" font="7"><b>Limitations: </b></text>
<text top="227" left="848" width="218" height="20" font="0">1. No data from children or adolescents </text>
<text top="245" left="848" width="259" height="20" font="0">2. Not all patients had pre-treatment lipid </text>
<text top="262" left="848" width="39" height="20" font="0">values </text>
<text top="279" left="848" width="225" height="20" font="0">3. No external validation cohort available </text>
<text top="296" left="848" width="253" height="20" font="0">4. Relatively short mean follow-up period of 5.5 </text>
<text top="314" left="848" width="10" height="20" font="0">y </text>
<text top="555" left="81" width="4" height="22" font="1"> </text>
<text top="574" left="81" width="4" height="22" font="1"> </text>
</page>
<page number="51" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">51 </text>
<text top="106" left="81" width="922" height="24" font="4"><b>Data Supplement 11. Nonrandomized Trials, Observational Studies, and/or Registries of Diabetes Mellitus 40-75 Years (Section 4.3) </b></text>
<text top="108" left="1003" width="4" height="22" font="5"><b> </b></text>
<text top="128" left="105" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="145" left="131" width="48" height="20" font="7"><b>Author; </b></text>
<text top="162" left="108" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="136" left="246" width="118" height="20" font="7"><b>Study Type/Design; </b></text>
<text top="154" left="273" width="66" height="20" font="7"><b>Study Size </b></text>
<text top="145" left="418" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="136" left="617" width="179" height="20" font="7"><b>Primary Endpoint and Results </b></text>
<text top="154" left="615" width="184" height="20" font="7"><b>(P values; OR or RR; &amp; 95% CI) </b></text>
<text top="136" left="923" width="130" height="20" font="7"><b>Summary/Conclusion </b></text>
<text top="154" left="950" width="75" height="20" font="7"><b>Comment(s) </b></text>
<text top="180" left="91" width="124" height="20" font="0">Wong ND, et al., 2012 </text>
<text top="197" left="91" width="25" height="20" font="0"><a href="data supplement.html#238">(45)</a> </text>
<text top="215" left="91" width="55" height="20" font="16"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22377485">22377485</a></text>
<text top="215" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22377485"> </a></text>
<text top="180" left="231" width="105" height="20" font="7"><b>Study type</b>: Cross </text>
<text top="197" left="231" width="138" height="20" font="0">sectional cohort analysis </text>
<text top="215" left="231" width="3" height="20" font="0"> </text>
<text top="232" left="231" width="132" height="20" font="7"><b>Design</b>: Assessment of </text>
<text top="249" left="231" width="132" height="20" font="0">distribution of 10 y CVD </text>
<text top="266" left="231" width="147" height="20" font="0">risk in a representative US </text>
<text top="283" left="231" width="130" height="20" font="0">sample of subjects with </text>
<text top="301" left="231" width="140" height="20" font="0">diabetes (NHANES 2003-</text>
<text top="318" left="231" width="140" height="20" font="0">6) using the Framingham </text>
<text top="335" left="231" width="137" height="20" font="0">score which divides 10 y </text>
<text top="352" left="231" width="144" height="20" font="0">CVD risk into low (&lt;10%), </text>
<text top="369" left="231" width="149" height="20" font="0">intermediate (10-20%) and </text>
<text top="387" left="231" width="93" height="20" font="0">high risk (&gt;20%) </text>
<text top="404" left="231" width="64" height="20" font="0">categories. </text>
<text top="421" left="231" width="3" height="20" font="0"> </text>
<text top="438" left="231" width="83" height="20" font="7"><b>Size</b>: n=1,114, </text>
<text top="456" left="231" width="138" height="20" font="0">representing 18.2 million </text>
<text top="180" left="393" width="141" height="20" font="7"><b>Inclusion criteria</b>: adults </text>
<text top="197" left="393" width="92" height="20" font="0">30-74 y with DM </text>
<text top="215" left="393" width="3" height="20" font="0"> </text>
<text top="232" left="393" width="133" height="20" font="7"><b>Exclusion criteria</b>: N/A </text>
<text top="181" left="568" width="271" height="20" font="7"><b>1</b>°<b> endpoint</b>: 10 y total CVD events estimated by </text>
<text top="199" left="568" width="154" height="20" font="0">the Framingham algorithm.  </text>
<text top="216" left="568" width="3" height="20" font="0"> </text>
<text top="233" left="568" width="52" height="20" font="7"><b>Results: </b></text>
<text top="250" left="568" width="254" height="20" font="0">r• Among those without pre-existing CVD 27% </text>
<text top="267" left="568" width="271" height="20" font="0">had &lt;10%, 23% had 10-20% and 50% had &gt;20% </text>
<text top="285" left="568" width="53" height="20" font="0">10 y risk. </text>
<text top="304" left="568" width="7" height="18" font="0">•</text>
<text top="303" left="575" width="93" height="20" font="0"> Age subgroups: </text>
<text top="326" left="576" width="9" height="12" font="0">o</text>
<text top="325" left="585" width="4" height="14" font="0"> </text>
<text top="320" left="590" width="201" height="20" font="0">40-49 y, low risk 47%; high risk 15% </text>
<text top="344" left="576" width="9" height="12" font="0">o</text>
<text top="342" left="585" width="4" height="14" font="0"> </text>
<text top="337" left="590" width="201" height="20" font="0">50-59 y, low risk 17%; high risk 33% </text>
<text top="361" left="576" width="9" height="12" font="0">o</text>
<text top="360" left="585" width="4" height="14" font="0"> </text>
<text top="355" left="590" width="194" height="20" font="0">60-69 y, low risk 6%, high risk 42% </text>
<text top="374" left="568" width="7" height="18" font="0">•</text>
<text top="373" left="575" width="270" height="20" font="0"> 49.3% of subjects with T1DM, 10.3% with type 2 </text>
<text top="390" left="568" width="273" height="20" font="0">and 17.5% with previously undiagnosed DM were </text>
<text top="407" left="568" width="65" height="20" font="0">at low risk.  </text>
<text top="426" left="568" width="7" height="18" font="0">•</text>
<text top="426" left="575" width="183" height="20" font="0"> Low risk subgroups (% low risk): </text>
<text top="443" left="568" width="183" height="20" font="0">Sex; Female/Male: 26.8%/18.6% </text>
<text top="460" left="568" width="234" height="20" font="0">Race/Ethnicity; Black/Hispanic/Caucasian: </text>
<text top="477" left="568" width="115" height="20" font="0">30.6%/32.4%/16.8% </text>
<text top="496" left="568" width="7" height="18" font="0">•</text>
<text top="496" left="575" width="218" height="20" font="0"> 59% of low risk subjects had metabolic </text>
<text top="513" left="568" width="159" height="20" font="0">syndrome and 7% had CKD. </text>
<text top="180" left="859" width="67" height="20" font="7"><b>Summary:  </b></text>
<text top="199" left="859" width="7" height="18" font="0">•</text>
<text top="199" left="865" width="209" height="20" font="0"> 75% of subjects without CVD were at </text>
<text top="216" left="859" width="138" height="20" font="0">intermediate or high risk. </text>
<text top="235" left="856" width="11" height="18" font="0">• </text>
<text top="234" left="869" width="228" height="20" font="0">A minority of adults with T2DM and about </text>
<text top="251" left="869" width="226" height="20" font="0">half of those with T1DM are at &lt;10% 10y </text>
<text top="268" left="869" width="215" height="20" font="0">CVD risk using the Framingham score, </text>
<text top="285" left="869" width="218" height="20" font="0">especially those &lt;50 y, females&gt;males, </text>
<text top="303" left="869" width="131" height="20" font="0">minorities&gt;Caucasians. </text>
<text top="322" left="859" width="7" height="18" font="0">•</text>
<text top="321" left="865" width="246" height="20" font="0"> Half the cohort were at high risk (&gt;20% 10 y </text>
<text top="338" left="859" width="59" height="20" font="0">CVD risk). </text>
<text top="357" left="859" width="7" height="18" font="0">•</text>
<text top="357" left="865" width="188" height="20" font="0"> Low risk subjects frequently have </text>
<text top="374" left="859" width="236" height="20" font="0">comorbidities that increase their long-term. </text>
<text top="391" left="859" width="3" height="20" font="0"> </text>
<text top="408" left="859" width="73" height="20" font="7"><b>Limitations: </b></text>
<text top="427" left="859" width="7" height="18" font="0">•</text>
<text top="427" left="865" width="248" height="20" font="0"> Though representative of the US population, </text>
<text top="444" left="859" width="188" height="20" font="0">the study group is relatively small. </text>
<text top="463" left="859" width="7" height="18" font="0">•</text>
<text top="462" left="865" width="242" height="20" font="0"> The Framingham score may underestimate </text>
<text top="480" left="859" width="240" height="20" font="0">risk and its validity in subjects with diabetes </text>
<text top="497" left="859" width="121" height="20" font="0">has been questioned. </text>
<text top="531" left="91" width="118" height="20" font="0">Rana JS, et al., 2016 </text>
<text top="548" left="91" width="25" height="20" font="0"><a href="data supplement.html#238">(46)</a> </text>
<text top="565" left="91" width="58" height="20" font="16"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26666660">26666660 </a></text>
<text top="582" left="91" width="3" height="20" font="0"> </text>
<text top="531" left="231" width="137" height="20" font="7"><b>Study type</b>: Prospective </text>
<text top="548" left="231" width="135" height="20" font="0">population-based cohort </text>
<text top="565" left="231" width="103" height="20" font="0">case-control study </text>
<text top="582" left="231" width="3" height="20" font="0"> </text>
<text top="600" left="231" width="132" height="20" font="7"><b>Design:</b> Comparison of </text>
<text top="617" left="231" width="112" height="20" font="0">risk of incident CHD </text>
<text top="634" left="231" width="129" height="20" font="0">events over 10 y (2002-</text>
<text top="651" left="231" width="144" height="20" font="0">2011) among members of </text>
<text top="669" left="231" width="148" height="20" font="0">Kaiser Permanente with or </text>
<text top="686" left="231" width="137" height="20" font="0">without diabetes or CHD </text>
<text top="703" left="231" width="3" height="20" font="0"> </text>
<text top="720" left="231" width="139" height="20" font="7"><b>Size</b>: 1,586,061 adults of </text>
<text top="737" left="231" width="108" height="20" font="0">whom 138,507 had </text>
<text top="755" left="231" width="109" height="20" font="0">diabetes (ICD code </text>
<text top="772" left="231" width="60" height="20" font="0">diagnosis) </text>
<text top="531" left="393" width="109" height="20" font="7"><b>Inclusion criteria</b>:  </text>
<text top="550" left="393" width="7" height="18" font="0">•</text>
<text top="549" left="400" width="122" height="20" font="0"> continuously enrolled </text>
<text top="568" left="393" width="7" height="18" font="0">•</text>
<text top="568" left="400" width="48" height="20" font="0"> 30-90 y </text>
<text top="585" left="393" width="3" height="20" font="0"> </text>
<text top="602" left="393" width="133" height="20" font="7"><b>Exclusion criteria</b>: N/A </text>
<text top="532" left="568" width="256" height="20" font="7"><b>1</b>°<b> endpoint</b>: Age-adjusted rate of new fatal or </text>
<text top="549" left="568" width="267" height="20" font="0">non-fatal CHD or revascularization; n/1,000 pt.-y </text>
<text top="566" left="568" width="49" height="20" font="0">(95%CI) </text>
<text top="584" left="568" width="3" height="20" font="0"> </text>
<text top="601" left="568" width="55" height="20" font="7"><b>Results:  </b></text>
<text top="620" left="568" width="7" height="18" font="0">•</text>
<text top="619" left="575" width="91" height="20" font="0"> With CHD only; </text>
<text top="636" left="568" width="146" height="20" font="0">Overall; 22.5 (22.0–22.98) </text>
<text top="655" left="568" width="7" height="18" font="0">•</text>
<text top="655" left="575" width="157" height="20" font="0"> With DM only (n=118,952);  </text>
<text top="672" left="568" width="200" height="20" font="0">Overall; 12.2 (95% CI: 12.02–12.49) </text>
<text top="689" left="568" width="234" height="20" font="0">HR: 3.7 (95% CI: 3.6–3.8) vs. no DM/CHD </text>
<text top="706" left="568" width="179" height="20" font="0">men; 15.2 (95% CI: 14.8–15.53) </text>
<text top="724" left="568" width="177" height="20" font="0">women 8.8 (95% CI: 8.58–9.14) </text>
<text top="743" left="568" width="7" height="18" font="0">•</text>
<text top="742" left="575" width="109" height="20" font="0"> By age subgroups; </text>
<text top="759" left="568" width="119" height="20" font="0">- 40-49 y (n=19,746); </text>
<text top="776" left="568" width="55" height="20" font="0"> men 9.0, </text>
<text top="531" left="859" width="67" height="20" font="7"><b>Summary:  </b></text>
<text top="550" left="859" width="7" height="18" font="0">•</text>
<text top="549" left="865" width="234" height="20" font="0"> Overall incident CHD rates were 15.2% in </text>
<text top="566" left="859" width="239" height="20" font="0">men and 8.8% in women. By age subgroup </text>
<text top="584" left="859" width="243" height="20" font="0">rates rose from 5% or less for those 30-39 y </text>
<text top="601" left="859" width="247" height="20" font="0">old and rose incrementally with age reaching </text>
<text top="618" left="859" width="139" height="20" font="0">15-25% for age 60-69 y.  </text>
<text top="635" left="859" width="258" height="20" font="0">-There was a modest increase of incident CHD </text>
<text top="653" left="859" width="210" height="20" font="0">in those with duration of diabetes &lt;5 y </text>
<text top="670" left="859" width="236" height="20" font="0">(compared to those without DM) and event </text>
<text top="687" left="859" width="242" height="20" font="0">rates increased with duration until it was not </text>
<text top="704" left="859" width="233" height="20" font="0">different from those with prior CVD and no </text>
<text top="721" left="859" width="207" height="20" font="0">diabetes in those with duration &gt;10 y. </text>
<text top="741" left="859" width="7" height="18" font="0">•</text>
<text top="740" left="865" width="235" height="20" font="0"> Overall the risk for a CHD event in a large </text>
<text top="757" left="859" width="250" height="20" font="0">cohort with diabetes but no CVD is about half </text>
<text top="774" left="859" width="254" height="20" font="0">that in subjects without diabetes but with CHD </text>
</page>
<page number="52" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">52 </text>
<text top="107" left="568" width="67" height="20" font="0"> women 6.6 </text>
<text top="126" left="568" width="7" height="18" font="0">•</text>
<text top="125" left="575" width="242" height="20" font="0"> Rates for other subgroups are taken from a </text>
<text top="143" left="568" width="259" height="20" font="0">figure and are therefore not exact, but because </text>
<text top="160" left="568" width="152" height="20" font="0">their importance are shown </text>
<text top="179" left="568" width="7" height="18" font="0">•</text>
<text top="178" left="575" width="172" height="20" font="0"> 30-39y; men~5%; women&lt;5% </text>
<text top="197" left="568" width="7" height="18" font="0">•</text>
<text top="197" left="575" width="189" height="20" font="0"> 50-59 y; men~18%; women~10% </text>
<text top="216" left="568" width="7" height="18" font="0">•</text>
<text top="215" left="575" width="189" height="20" font="0"> 60-69 y; men~25%; women~15% </text>
<text top="234" left="568" width="7" height="18" font="0">•</text>
<text top="233" left="575" width="264" height="20" font="0"> By DM duration: risk increased by duration with </text>
<text top="251" left="568" width="270" height="20" font="0">no tabulated data provided but data from a figure </text>
<text top="268" left="568" width="264" height="20" font="0">were taken because of their importance and are </text>
<text top="285" left="568" width="274" height="20" font="0">shown as HRs by duration compared to the group </text>
<text top="302" left="568" width="146" height="20" font="0">without diabetes and CVD </text>
<text top="321" left="568" width="7" height="18" font="0">•</text>
<text top="321" left="575" width="58" height="20" font="0"> &lt;5 y ~1.4 </text>
<text top="340" left="568" width="7" height="18" font="0">•</text>
<text top="339" left="575" width="58" height="20" font="0"> 5-9 y~1.8 </text>
<text top="358" left="568" width="7" height="18" font="0">•</text>
<text top="357" left="575" width="243" height="20" font="0"> &gt;10 y~2.5 (not different from the group with </text>
<text top="375" left="568" width="122" height="20" font="0">prior CHD but no DM) </text>
<text top="107" left="859" width="3" height="20" font="0"> </text>
<text top="124" left="859" width="73" height="20" font="7"><b>Limitations: </b></text>
<text top="143" left="859" width="7" height="18" font="0">•</text>
<text top="143" left="865" width="220" height="20" font="0"> All diagnoses were based on electronic </text>
<text top="160" left="859" width="237" height="20" font="0">records only, including CHD ascertainment </text>
<text top="179" left="859" width="7" height="18" font="0">•</text>
<text top="178" left="865" width="220" height="20" font="0"> All subjects were insured and therefore </text>
<text top="195" left="859" width="226" height="20" font="0">results may not be generalizable to other </text>
<text top="213" left="859" width="151" height="20" font="0">segments of the population </text>
<text top="230" left="859" width="3" height="20" font="0"> </text>
<text top="393" left="91" width="39" height="20" font="7"><b>MESA </b></text>
<text top="410" left="91" width="111" height="20" font="0">Malik S, et al., 2011 </text>
<text top="427" left="91" width="25" height="20" font="0"><a href="data supplement.html#238">(47)</a> </text>
<text top="444" left="91" width="55" height="20" font="16"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21844289">21844289</a></text>
<text top="444" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21844289"> </a></text>
<text top="393" left="231" width="137" height="20" font="7"><b>Study type</b>: Prospective </text>
<text top="410" left="231" width="139" height="20" font="0">observational multiethnic </text>
<text top="427" left="231" width="70" height="20" font="0">cohort study </text>
<text top="444" left="231" width="3" height="20" font="0"> </text>
<text top="461" left="231" width="137" height="20" font="7"><b>Design</b>: Comparisons of </text>
<text top="479" left="231" width="148" height="20" font="0">CAC and CIMT in subjects </text>
<text top="496" left="231" width="149" height="20" font="0">free of CVD with metabolic </text>
<text top="513" left="231" width="139" height="20" font="0">syndrome, DM or neither </text>
<text top="530" left="231" width="129" height="20" font="0">in prediction of incident </text>
<text top="547" left="231" width="33" height="20" font="0">CVD. </text>
<text top="565" left="231" width="3" height="20" font="0"> </text>
<text top="582" left="231" width="139" height="20" font="7"><b>Size</b>: 6,603 people in the </text>
<text top="599" left="231" width="114" height="20" font="0">MESA including 881 </text>
<text top="616" left="231" width="134" height="20" font="0">subjects with T2DM and </text>
<text top="633" left="231" width="115" height="20" font="0">1,686 with metabolic </text>
<text top="651" left="231" width="61" height="20" font="0">syndrome. </text>
<text top="393" left="393" width="154" height="20" font="7"><b>Inclusion criteria</b>: Persons </text>
<text top="410" left="393" width="120" height="20" font="0">living within 6 defined </text>
<text top="427" left="393" width="129" height="20" font="0">geographic boundaries </text>
<text top="444" left="393" width="143" height="20" font="0">between 45 and 84 y who </text>
<text top="461" left="393" width="122" height="20" font="0">are African-American, </text>
<text top="479" left="393" width="108" height="20" font="0">Chinese-American, </text>
<text top="496" left="393" width="127" height="20" font="0">Caucasian or Hispanic </text>
<text top="513" left="393" width="3" height="20" font="0"> </text>
<text top="530" left="393" width="114" height="20" font="7"><b>Exclusion criteria:  </b></text>
<text top="547" left="393" width="148" height="20" font="0">• People with clinical CVD  </text>
<text top="565" left="393" width="153" height="20" font="0">• 6,603 had CAC and CIMT </text>
<text top="582" left="393" width="139" height="20" font="0">measurements and were </text>
<text top="599" left="393" width="154" height="20" font="0">followed for a median of 6.4 </text>
<text top="616" left="393" width="103" height="20" font="0">y for incident CVD </text>
<text top="633" left="393" width="117" height="20" font="0">Mean (SD) age (DM, </text>
<text top="651" left="393" width="134" height="20" font="0">metabolic syndrome, no </text>
<text top="668" left="393" width="157" height="20" font="0">DM/metabolic syndrome) y;  </text>
<text top="685" left="393" width="134" height="20" font="0">65 (9.6), 64 (10), 62(10) </text>
<text top="394" left="568" width="144" height="20" font="7"><b>1</b>°<b> endpoint</b>: CVD events </text>
<text top="411" left="568" width="3" height="20" font="0"> </text>
<text top="428" left="568" width="55" height="20" font="7"><b>Results</b>:  </text>
<text top="447" left="568" width="11" height="18" font="0">• </text>
<text top="446" left="576" width="212" height="20" font="0">Mean (SD) CAC score (DM, metabolic </text>
<text top="463" left="576" width="221" height="20" font="0">syndrome, no DM/metabolic syndrome): </text>
<text top="487" left="583" width="9" height="12" font="0">o</text>
<text top="486" left="592" width="4" height="14" font="0"> </text>
<text top="481" left="596" width="175" height="20" font="0">255 (596), 157 (417), 119 (365) </text>
<text top="504" left="583" width="9" height="12" font="0">o</text>
<text top="503" left="592" width="4" height="14" font="0"> </text>
<text top="498" left="596" width="112" height="20" font="0">CAC 0%; 38, 45, 55 </text>
<text top="517" left="568" width="11" height="18" font="0">• </text>
<text top="516" left="576" width="133" height="20" font="0">Annual CVD events (%) </text>
<text top="540" left="583" width="9" height="12" font="0">o</text>
<text top="538" left="592" width="4" height="14" font="0"> </text>
<text top="533" left="596" width="111" height="20" font="0">CAC 0; 0.8, 0.4, 0.2 </text>
<text top="557" left="583" width="9" height="12" font="0">o</text>
<text top="556" left="592" width="4" height="14" font="0"> </text>
<text top="551" left="596" width="129" height="20" font="0">CAC 1-99; 2.2, 1.2, 0.7 </text>
<text top="574" left="583" width="9" height="12" font="0">o</text>
<text top="573" left="592" width="4" height="14" font="0"> </text>
<text top="568" left="596" width="150" height="20" font="0">CAC 100-399; 2.9, 2.4, 1.7 </text>
<text top="591" left="583" width="9" height="12" font="0">o</text>
<text top="590" left="592" width="4" height="14" font="0"> </text>
<text top="585" left="596" width="132" height="20" font="0">CAC 400+; 5.1, 4.6, 2.6 </text>
<text top="609" left="583" width="9" height="12" font="0">o</text>
<text top="607" left="592" width="4" height="14" font="0"> </text>
<text top="602" left="596" width="198" height="20" font="0">CVD events in CAC 1-99 vs. CAC 0 </text>
<text top="626" left="583" width="9" height="12" font="0">o</text>
<text top="625" left="592" width="4" height="14" font="0"> </text>
<text top="620" left="596" width="185" height="20" font="0">HR: 2.0; 95% CI: 1.1–3.7; p&lt;0.05 </text>
<text top="643" left="583" width="9" height="12" font="0">o</text>
<text top="642" left="592" width="4" height="14" font="0"> </text>
<text top="637" left="596" width="244" height="20" font="0">In a model adjusted for the Framingham risk </text>
<text top="654" left="596" width="236" height="20" font="0">score CAC still predicted CVD events in D; </text>
<text top="671" left="596" width="144" height="20" font="0">HR: 2.0; 95% CI: 1.5–2.6. </text>
<text top="393" left="859" width="241" height="20" font="0">• Although mean CAC was higher in DM vs. </text>
<text top="410" left="859" width="228" height="20" font="0">metabolic syndrome vs. no DM/metabolic </text>
<text top="427" left="859" width="195" height="20" font="0">syndrome, 38% of DM had CAC 0.  </text>
<text top="444" left="859" width="237" height="20" font="0">• CAC 0 in DM was associated with a 0.8% </text>
<text top="461" left="859" width="138" height="20" font="0">annual rate risk of CVD.  </text>
<text top="479" left="859" width="157" height="20" font="0">• CAC 1-99 doubled the rate </text>
<text top="496" left="859" width="209" height="20" font="0">• CAC &gt;100 more than tripled the rate </text>
<text top="513" left="859" width="226" height="20" font="0">• CAC screening in diabetes predicts risk </text>
<text top="530" left="859" width="234" height="20" font="0">independent of the Framingham risk score </text>
<text top="547" left="859" width="245" height="20" font="0">• CIMT showed the same trends as CAC but </text>
<text top="565" left="859" width="201" height="20" font="0">was not as good a predictor of CVD. </text>
<text top="703" left="91" width="101" height="20" font="0">Mulnier HE, et al., </text>
<text top="720" left="91" width="56" height="20" font="0">2008 <a href="data supplement.html#238">(48)</a> </text>
<text top="737" left="91" width="55" height="20" font="16"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18581091">18581091</a></text>
<text top="737" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18581091"> </a></text>
<text top="703" left="231" width="137" height="20" font="7"><b>Study type</b>: Prospective </text>
<text top="720" left="231" width="74" height="20" font="0">case- control </text>
<text top="737" left="231" width="147" height="20" font="0">observational cohort study </text>
<text top="755" left="231" width="3" height="20" font="7"><b> </b></text>
<text top="772" left="231" width="51" height="20" font="7"><b>Design</b>:  </text>
<text top="703" left="393" width="99" height="20" font="0">Inclusion criteria:  </text>
<text top="720" left="393" width="151" height="20" font="0">• Men and women aged 35-</text>
<text top="737" left="393" width="27" height="20" font="0">89 y </text>
<text top="755" left="393" width="84" height="20" font="0">• Free of CHD  </text>
<text top="772" left="393" width="3" height="20" font="7"><b> </b></text>
<text top="789" left="393" width="148" height="20" font="7"><b>Baseline characteristics: </b></text>
<text top="704" left="568" width="159" height="20" font="7"><b>1</b>°<b> endpoint: </b>7 y Incident MI </text>
<text top="721" left="568" width="3" height="20" font="0"> </text>
<text top="739" left="568" width="55" height="20" font="7"><b>Results:  </b></text>
<text top="756" left="568" width="263" height="20" font="0">Incident MI: rate/1000 pt. y (95% CI) over mean </text>
<text top="773" left="568" width="86" height="20" font="0">follow-up of 7 y </text>
<text top="705" left="859" width="11" height="18" font="0">• </text>
<text top="704" left="869" width="207" height="20" font="0">The primary objective of this study, to </text>
<text top="721" left="869" width="237" height="20" font="0">compare incident MI rates in DM versus no </text>
<text top="739" left="869" width="247" height="20" font="0">DM, demonstrated overall more than a 2-fold </text>
<text top="756" left="869" width="64" height="20" font="0">excess risk </text>
</page>
<page number="53" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">53 </text>
<text top="109" left="231" width="11" height="18" font="0">• </text>
<text top="108" left="244" width="83" height="20" font="0">Comparison of </text>
<text top="125" left="244" width="111" height="20" font="0">adjudicated MI over </text>
<text top="143" left="244" width="135" height="20" font="0">time in patients with and </text>
<text top="160" left="244" width="134" height="20" font="0">without DM and no prior </text>
<text top="177" left="244" width="108" height="20" font="0">MI in the very large </text>
<text top="194" left="244" width="95" height="20" font="0">General Practice </text>
<text top="211" left="244" width="112" height="20" font="0">Research Database </text>
<text top="229" left="244" width="134" height="20" font="0">representing ~5% of the </text>
<text top="246" left="244" width="81" height="20" font="0">UK population </text>
<text top="265" left="231" width="11" height="18" font="0">• </text>
<text top="264" left="244" width="81" height="20" font="0">This permitted </text>
<text top="281" left="244" width="132" height="20" font="0">estimates of incident MI </text>
<text top="298" left="244" width="107" height="20" font="0">by age, specifically </text>
<text top="316" left="244" width="67" height="20" font="0">those &gt;75 y </text>
<text top="333" left="231" width="3" height="20" font="0"> </text>
<text top="350" left="231" width="146" height="20" font="7"><b>Size</b>: 40,727 subjects with </text>
<text top="367" left="231" width="137" height="20" font="0">and 194,913 without DM </text>
<text top="109" left="393" width="11" height="18" font="0">• </text>
<text top="108" left="403" width="135" height="20" font="0">Average baseline age in </text>
<text top="125" left="403" width="118" height="20" font="0">DM group; men 65 y, </text>
<text top="143" left="403" width="80" height="20" font="0">women 68.5 y </text>
<text top="162" left="393" width="11" height="18" font="0">• </text>
<text top="161" left="403" width="147" height="20" font="0">n&gt;75 y of age; men 4,952, </text>
<text top="178" left="403" width="77" height="20" font="0">women 6,746 </text>
<text top="197" left="393" width="11" height="18" font="0">• </text>
<text top="196" left="403" width="152" height="20" font="0">MI diagnosed by diagnostic </text>
<text top="213" left="403" width="36" height="20" font="0">codes </text>
<text top="231" left="393" width="3" height="20" font="0"> </text>
<text top="248" left="393" width="133" height="20" font="7"><b>Exclusion criteria</b>: N/A </text>
<text top="109" left="568" width="11" height="18" font="0">• </text>
<text top="108" left="583" width="184" height="20" font="0">DM 18.03 (95% CI: 17.41–18.69) </text>
<text top="127" left="568" width="11" height="18" font="0">• </text>
<text top="126" left="583" width="183" height="20" font="0">No DM 7.00 (95% CI: 6.82–7.18) </text>
<text top="145" left="568" width="11" height="18" font="0">• </text>
<text top="145" left="583" width="220" height="20" font="0">RR (adjusted) 2.47 (95% CI: 2.36–2.59) </text>
<text top="164" left="568" width="11" height="18" font="0">• </text>
<text top="163" left="583" width="259" height="20" font="0">MI events (n) and rates/1,000 pt. y (95% CI) by </text>
<text top="180" left="583" width="170" height="20" font="0">attained age in group with DM; </text>
<text top="199" left="568" width="11" height="18" font="0">• </text>
<text top="198" left="583" width="27" height="20" font="0">Men </text>
<text top="222" left="583" width="9" height="12" font="0">o</text>
<text top="220" left="592" width="4" height="14" font="0"> </text>
<text top="215" left="597" width="223" height="20" font="0">35-54 y: 119, 8.64 (95% CI: 7.22–10.34) </text>
<text top="239" left="583" width="9" height="12" font="0">o</text>
<text top="238" left="592" width="4" height="14" font="0"> </text>
<text top="233" left="597" width="237" height="20" font="0">55-64 y: 328, 14.03 (95% CI: 12.59–15.64) </text>
<text top="256" left="583" width="9" height="12" font="0">o</text>
<text top="255" left="592" width="4" height="14" font="0"> </text>
<text top="250" left="597" width="230" height="20" font="0">65-74 y: 655, 19.40 (95% CI: 18.27–20.6) </text>
<text top="273" left="583" width="9" height="12" font="0">o</text>
<text top="272" left="592" width="4" height="14" font="0"> </text>
<text top="267" left="597" width="183" height="20" font="0">75-84 y: 517, 25.61 (24.1–27.22) </text>
<text top="291" left="583" width="9" height="12" font="0">o</text>
<text top="289" left="592" width="4" height="14" font="0"> </text>
<text top="284" left="597" width="182" height="20" font="0">&gt;85 y:  120, 27.91 (24.88–31.32) </text>
<text top="303" left="568" width="11" height="18" font="0">• </text>
<text top="303" left="583" width="46" height="20" font="0">Women </text>
<text top="326" left="583" width="9" height="12" font="0">o</text>
<text top="325" left="592" width="4" height="14" font="0"> </text>
<text top="320" left="595" width="162" height="20" font="0">35-54 y: 40, 4.32 (3.17–5.88) </text>
<text top="343" left="583" width="9" height="12" font="0">o</text>
<text top="342" left="592" width="4" height="14" font="0"> </text>
<text top="337" left="595" width="183" height="20" font="0">55-64 y: 177, 10.30 (8.89–11.94) </text>
<text top="361" left="583" width="9" height="12" font="0">o</text>
<text top="359" left="592" width="4" height="14" font="0"> </text>
<text top="354" left="595" width="190" height="20" font="0">65-74 y: 405, 15.88 (14.41–17.51) </text>
<text top="378" left="583" width="9" height="12" font="0">o</text>
<text top="376" left="592" width="4" height="14" font="0"> </text>
<text top="371" left="595" width="190" height="20" font="0">75-84 y: 517, 23.24 (21.32–25.34) </text>
<text top="395" left="583" width="9" height="12" font="0">o</text>
<text top="394" left="592" width="4" height="14" font="0"> </text>
<text top="389" left="595" width="182" height="20" font="0">&gt;85 y:  170, 25.32 (21.78–29.42) </text>
<text top="109" left="859" width="11" height="18" font="0">• </text>
<text top="108" left="869" width="247" height="20" font="0">The study also demonstrated that MI rates in </text>
<text top="125" left="869" width="225" height="20" font="0">the DM cohort increase with age and are </text>
<text top="143" left="869" width="230" height="20" font="0">greater in those &gt;75 y than those &lt;75 y in </text>
<text top="160" left="869" width="122" height="20" font="0">both men and women </text>
<text top="179" left="859" width="11" height="18" font="0">• </text>
<text top="178" left="869" width="230" height="20" font="0">The excess risk for MI in subjects with vs. </text>
<text top="195" left="869" width="236" height="20" font="0">without DM persisted in those &gt;75 y of age </text>
<text top="212" left="869" width="49" height="20" font="0">(~2-fold) </text>
<text top="231" left="859" width="11" height="18" font="0">• </text>
<text top="231" left="869" width="201" height="20" font="0">The limitation is that incident MI was </text>
<text top="248" left="869" width="172" height="20" font="0">diagnosed by diagnostic codes </text>
<text top="265" left="859" width="3" height="20" font="0"> </text>
<text top="407" left="91" width="124" height="20" font="0">Soedamah-Muthu SS, </text>
<text top="424" left="91" width="90" height="20" font="0">et al., 2006 <a href="data supplement.html#238">(49)</a><i> </i></text>
<text top="441" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16567818">16567818</a></text>
<text top="441" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16567818"> </a></text>
<text top="458" left="91" width="3" height="20" font="0"> </text>
<text top="407" left="231" width="137" height="20" font="7"><b>Study type</b>: Prospective </text>
<text top="424" left="231" width="74" height="20" font="0">case- control </text>
<text top="441" left="231" width="147" height="20" font="0">observational cohort study </text>
<text top="458" left="231" width="3" height="20" font="7"><b> </b></text>
<text top="475" left="231" width="51" height="20" font="7"><b>Design</b>:  </text>
<text top="494" left="231" width="11" height="18" font="0">• </text>
<text top="494" left="243" width="118" height="20" font="0">To estimate absolute </text>
<text top="511" left="243" width="132" height="20" font="0">and relative CVD risk in </text>
<text top="528" left="243" width="133" height="20" font="0">subjects with type 1 DM </text>
<text top="545" left="243" width="91" height="20" font="0">in the very large </text>
<text top="562" left="243" width="95" height="20" font="0">General Practice </text>
<text top="580" left="243" width="112" height="20" font="0">Research Database </text>
<text top="597" left="243" width="134" height="20" font="0">representing ~6% of the </text>
<text top="614" left="243" width="84" height="20" font="0">UK population  </text>
<text top="633" left="231" width="11" height="18" font="0">• </text>
<text top="633" left="244" width="110" height="20" font="0">Incident major CVD </text>
<text top="650" left="244" width="121" height="20" font="0">events between 1992-</text>
<text top="667" left="244" width="59" height="20" font="0">1999 from </text>
<text top="684" left="244" width="131" height="20" font="0">computerized database </text>
<text top="701" left="244" width="94" height="20" font="0">records checked </text>
<text top="718" left="244" width="129" height="20" font="0">against medical charts  </text>
<text top="736" left="244" width="3" height="20" font="0"> </text>
<text top="753" left="231" width="139" height="20" font="7"><b>Size</b>: 7,479 subjects with </text>
<text top="770" left="231" width="148" height="20" font="0">and 38,116 without Type 1 </text>
<text top="787" left="231" width="22" height="20" font="0">DM </text>
<text top="407" left="393" width="109" height="20" font="7"><b>Inclusion criteria:  </b></text>
<text top="426" left="393" width="11" height="18" font="0">• </text>
<text top="425" left="405" width="149" height="20" font="0">Men and women aged &lt;35 </text>
<text top="442" left="405" width="126" height="20" font="0">- &gt;75 y with type 1 DM </text>
<text top="459" left="405" width="140" height="20" font="0">(defined as being treated </text>
<text top="476" left="405" width="134" height="20" font="0">with insulin + diagnosed </text>
<text top="494" left="405" width="100" height="20" font="0">&lt;35 years of age) </text>
<text top="513" left="393" width="11" height="18" font="0">• </text>
<text top="512" left="405" width="137" height="20" font="0">5 randomly selected age </text>
<text top="529" left="405" width="144" height="20" font="0">and sex-matched controls </text>
<text top="546" left="405" width="126" height="20" font="0">for each 1 subject with </text>
<text top="564" left="405" width="63" height="20" font="0">type 1 DM  </text>
<text top="581" left="393" width="3" height="20" font="7"><b> </b></text>
<text top="598" left="393" width="148" height="20" font="7"><b>Baseline characteristics: </b></text>
<text top="617" left="393" width="11" height="18" font="0">• </text>
<text top="616" left="403" width="142" height="20" font="0">Baseline age (mean±SD) </text>
<text top="633" left="403" width="148" height="20" font="0">33±14.5 y; 55% men, type </text>
<text top="651" left="403" width="96" height="20" font="0">1 DM prevalence </text>
<text top="668" left="403" width="132" height="20" font="0">2.15/1000; average DM </text>
<text top="685" left="403" width="78" height="20" font="0">duration 15 y  </text>
<text top="704" left="393" width="11" height="18" font="0">• </text>
<text top="703" left="405" width="147" height="20" font="0">Baseline CVD prevalence; </text>
<text top="721" left="405" width="131" height="20" font="0">3% in type 1 DM, 1% in </text>
<text top="738" left="405" width="139" height="20" font="0">controls, RR 3.0 [95% CI </text>
<text top="755" left="405" width="51" height="20" font="0">2.5–3.5]  </text>
<text top="772" left="393" width="3" height="20" font="0"> </text>
<text top="789" left="393" width="133" height="20" font="7"><b>Exclusion criteria</b>: N/A </text>
<text top="407" left="568" width="52" height="20" font="7"><b>Results: </b></text>
<text top="424" left="568" width="3" height="20" font="0"> </text>
<text top="441" left="568" width="135" height="20" font="7"><b>First major CVD event</b>  </text>
<text top="460" left="568" width="11" height="18" font="0">• </text>
<text top="459" left="583" width="258" height="20" font="0">DM vs non-DM: 219 vs 289 events (cumulative </text>
<text top="476" left="583" width="135" height="20" font="0">incidence 3% vs 0.76%) </text>
<text top="495" left="568" width="11" height="18" font="0">• </text>
<text top="495" left="580" width="232" height="20" font="0">DM vs non-DM HR (95% CI); 4.5 (3.8-5.4) </text>
<text top="514" left="568" width="11" height="18" font="0">• </text>
<text top="513" left="581" width="258" height="20" font="0">Men [absolute risk/1000 person-y (95%CI); HR </text>
<text top="530" left="581" width="52" height="20" font="0">(95%CI); </text>
<text top="554" left="581" width="9" height="12" font="0">o</text>
<text top="552" left="589" width="4" height="14" font="0"> </text>
<text top="547" left="594" width="119" height="20" font="0">Overall: 7.3 (6.1–8.6);</text>
<text top="551" left="713" width="5" height="16" font="15"> </text>
<text top="547" left="717" width="73" height="20" font="0">5.5 (4.4–6.8) </text>
<text top="571" left="581" width="9" height="12" font="0">o</text>
<text top="569" left="589" width="4" height="14" font="0"> </text>
<text top="564" left="594" width="201" height="20" font="0">&lt;35 y: 0.8 (0.4–1.6); 11.3 (2.9–43.8) </text>
<text top="588" left="581" width="9" height="12" font="0">o</text>
<text top="587" left="590" width="4" height="14" font="0"> </text>
<text top="582" left="594" width="41" height="20" font="0">35-44y:</text>
<text top="585" left="635" width="5" height="16" font="15"> </text>
<text top="582" left="640" width="153" height="20" font="0">4.8 (3.2–7.1); 4.4 (2.5–7.6)  </text>
<text top="605" left="581" width="9" height="12" font="0">o</text>
<text top="604" left="590" width="4" height="14" font="0"> </text>
<text top="599" left="594" width="211" height="20" font="0">45-54 y: 10.6 (7.3–15.2); 3.0 (1.9–4.8) </text>
<text top="622" left="581" width="9" height="12" font="0">o</text>
<text top="621" left="590" width="4" height="14" font="0"> </text>
<text top="616" left="594" width="218" height="20" font="0">55-64 y: 39.4 (29.5–52.6); 4.1 (2.8–6.0) </text>
<text top="640" left="581" width="9" height="12" font="0">o</text>
<text top="638" left="590" width="4" height="14" font="0"> </text>
<text top="633" left="594" width="222" height="20" font="0">65-74 y: 35.2 (21.6–57.5);  2.3 (1.3–4.1) </text>
<text top="657" left="579" width="9" height="12" font="0">o</text>
<text top="655" left="588" width="4" height="14" font="0"> </text>
<text top="651" left="594" width="221" height="20" font="0">&gt;75 y: 122.2 (69.4–215.2); 3.5 (1.6–7.3) </text>
<text top="670" left="568" width="11" height="18" font="0">• </text>
<text top="669" left="583" width="46" height="20" font="0">Women </text>
<text top="692" left="581" width="9" height="12" font="0">o</text>
<text top="691" left="589" width="4" height="14" font="0"> </text>
<text top="686" left="594" width="202" height="20" font="0">Overall: 5.5 (4.4–6.8); 7.7 (5.5–10.7) </text>
<text top="710" left="581" width="9" height="12" font="0">o</text>
<text top="708" left="589" width="4" height="14" font="0"> </text>
<text top="703" left="595" width="194" height="20" font="0">&lt;35 y: 0.5 (0.2–1.3); 9.8 (1.8–53.6) </text>
<text top="727" left="581" width="9" height="12" font="0">o</text>
<text top="725" left="590" width="4" height="14" font="0"> </text>
<text top="721" left="595" width="44" height="20" font="0">35-44 y:</text>
<text top="724" left="640" width="5" height="16" font="15"> </text>
<text top="721" left="644" width="163" height="20" font="0">3.5 (2.1–6.1); 15.4 (5.0–47.3) </text>
<text top="744" left="581" width="9" height="12" font="0">o</text>
<text top="743" left="590" width="4" height="14" font="0"> </text>
<text top="738" left="595" width="225" height="20" font="0">45-54 y: 10.2 (6.7–15.5); 10.1 (5.0–20.4) </text>
<text top="761" left="581" width="9" height="12" font="0">o</text>
<text top="760" left="590" width="4" height="14" font="0"> </text>
<text top="755" left="595" width="225" height="20" font="0">55-64 y: 22.8 (15.0–34.7); 5.7 (3.2–10.4) </text>
<text top="778" left="581" width="9" height="12" font="0">o</text>
<text top="777" left="590" width="4" height="14" font="0"> </text>
<text top="772" left="595" width="225" height="20" font="0">65-74 y: 38.7 (24.1–62.3); 8.3 (4.0–17.2) </text>
<text top="796" left="581" width="9" height="12" font="0">o</text>
<text top="794" left="590" width="4" height="14" font="0"> </text>
<text top="789" left="595" width="225" height="20" font="0">&gt;75 y:  87.3 (39.2–194.3); 4.0 (1.4–11.2) </text>
<text top="408" left="859" width="11" height="18" font="0">• </text>
<text top="408" left="869" width="239" height="20" font="0">The study demonstrated an age-dependent </text>
<text top="425" left="869" width="227" height="20" font="0">increase in absolute event rates in type 1 </text>
<text top="442" left="869" width="247" height="20" font="0">DM; rates increasing by each decade in both </text>
<text top="459" left="869" width="247" height="20" font="0">men and women beginning at age &lt;35 y and </text>
<text top="476" left="869" width="159" height="20" font="0">increasing through age&gt;75 y </text>
<text top="495" left="859" width="11" height="18" font="0">• </text>
<text top="495" left="869" width="234" height="20" font="0">The HR for fatal CVD was much greater in </text>
<text top="512" left="869" width="247" height="20" font="0">type 1 DM than controls especially in women </text>
<text top="529" left="869" width="133" height="20" font="0">(men 5.8, women 11.6). </text>
<text top="548" left="859" width="11" height="18" font="0">• </text>
<text top="547" left="869" width="217" height="20" font="0">The HR for each secondary endpoint in </text>
<text top="564" left="869" width="224" height="20" font="0">those with type 1 DM was increased and </text>
<text top="582" left="869" width="233" height="20" font="0">varied from 3.0-5.8 in men and 4.8-16.8 in </text>
<text top="599" left="869" width="46" height="20" font="0">women  </text>
<text top="618" left="859" width="11" height="18" font="0">• </text>
<text top="617" left="869" width="241" height="20" font="0">The absolute risk of a first major CVD event </text>
<text top="635" left="869" width="226" height="20" font="0">in men with type 1 DM aged 45-55 y was </text>
<text top="652" left="869" width="244" height="20" font="0">equivalent to men 10-15 y older without DM; </text>
<text top="669" left="869" width="233" height="20" font="0">the risk in women with type 1 DM aged 45-</text>
<text top="686" left="869" width="233" height="20" font="0">55 y was equivalent to women &gt;20 y older </text>
<text top="703" left="869" width="68" height="20" font="0">without DM  </text>
<text top="721" left="869" width="3" height="20" font="0"> </text>
<text top="738" left="869" width="76" height="20" font="7"><b>Limitations:  </b></text>
<text top="757" left="859" width="11" height="18" font="0">• </text>
<text top="756" left="871" width="199" height="20" font="0">The diagnosis of type 1 DM was not </text>
<text top="773" left="871" width="238" height="20" font="0">confirmed by antibody testing so the cohort </text>
</page>
<page number="54" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">54 </text>
<text top="107" left="393" width="3" height="20" font="0"> </text>
<text top="125" left="393" width="137" height="20" font="7"><b>1</b>°<b> endpoint: </b>First major </text>
<text top="143" left="393" width="150" height="20" font="0">CVD event defined as fatal </text>
<text top="160" left="393" width="137" height="20" font="0">or non-fatal MI or stroke, </text>
<text top="177" left="393" width="122" height="20" font="0">fatal CHD or coronary </text>
<text top="194" left="393" width="96" height="20" font="0">revascularization </text>
<text top="211" left="393" width="3" height="20" font="0"> </text>
<text top="230" left="393" width="118" height="20" font="7"><b>2</b>°<b> endpoints: </b>Acute </text>
<text top="247" left="393" width="140" height="20" font="0">coronary event, coronary </text>
<text top="264" left="393" width="139" height="20" font="0">revascularization, stroke, </text>
<text top="282" left="393" width="161" height="20" font="0">major CHD, fatal CVD, major </text>
<text top="299" left="393" width="29" height="20" font="0">CVD </text>
<text top="316" left="393" width="3" height="20" font="0"> </text>
<text top="107" left="595" width="3" height="20" font="0"> </text>
<text top="124" left="568" width="257" height="20" font="7"><b>Fatal CVD: </b>fatal MI, stroke and CHD [absolute </text>
<text top="141" left="568" width="233" height="20" font="0">risk/1000 person-y (95%CI); HR (95%CI);  </text>
<text top="160" left="568" width="11" height="18" font="0">• </text>
<text top="160" left="580" width="181" height="20" font="0">Men: 2.8 (2.1–3.7); 5.8 (3.9–8.6) </text>
<text top="179" left="568" width="11" height="18" font="0">• </text>
<text top="178" left="580" width="213" height="20" font="0">Women: 2.5 (1.9–3.5); 11.6 (6.7–20.1) </text>
<text top="107" left="871" width="239" height="20" font="0">may have included subjects with type 2 DM </text>
<text top="124" left="871" width="231" height="20" font="0">diagnosed &lt;35 years and requiring insulin </text>
<text top="143" left="859" width="11" height="18" font="0">• </text>
<text top="143" left="871" width="236" height="20" font="0">The data were collected over 20 years ago </text>
<text top="334" left="91" width="105" height="20" font="0">Huo X, et al., 2016 </text>
<text top="351" left="91" width="25" height="20" font="0"><a href="data supplement.html#238">(50)</a> </text>
<text top="368" left="91" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26704379"> </a></text>
<text top="368" left="94" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26704379">26704379</a></text>
<text top="368" left="149" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26704379"> </a></text>
<text top="334" left="231" width="148" height="20" font="7"><b>Study type</b>: Retrospective </text>
<text top="351" left="231" width="85" height="20" font="0">cohort analysis </text>
<text top="368" left="231" width="3" height="20" font="0"> </text>
<text top="386" left="231" width="51" height="20" font="7"><b>Design</b>:  </text>
<text top="405" left="231" width="11" height="18" font="0">• </text>
<text top="404" left="244" width="128" height="20" font="0">Comparison of rates of </text>
<text top="421" left="244" width="133" height="20" font="0">non-fatal CVD identified </text>
<text top="438" left="244" width="133" height="20" font="0">from records of patients </text>
<text top="455" left="244" width="124" height="20" font="0">attending 603 medical </text>
<text top="473" left="244" width="132" height="20" font="0">centers with early onset </text>
<text top="490" left="244" width="105" height="20" font="0">(&lt;40 y) versus late </text>
<text top="507" left="244" width="132" height="20" font="0">onset T2DM taken from </text>
<text top="524" left="244" width="104" height="20" font="0">the China National </text>
<text top="541" left="244" width="111" height="20" font="0">HbA1c Surveillance </text>
<text top="559" left="244" width="48" height="20" font="0">System. </text>
<text top="578" left="231" width="11" height="18" font="0">• </text>
<text top="577" left="244" width="76" height="20" font="0">This provides </text>
<text top="594" left="244" width="107" height="20" font="0">information of CVD </text>
<text top="611" left="244" width="123" height="20" font="0">prevalence in patients </text>
<text top="629" left="244" width="130" height="20" font="0">with DM who are 40-50 </text>
<text top="646" left="244" width="107" height="20" font="0">y of age and by 5 y </text>
<text top="663" left="244" width="111" height="20" font="0">increments to &gt;70 y </text>
<text top="680" left="231" width="3" height="20" font="0"> </text>
<text top="697" left="231" width="128" height="20" font="7"><b>Size</b>: 222,773 subjects </text>
<text top="334" left="393" width="157" height="20" font="7"><b>Inclusion criteria</b>: Being an </text>
<text top="351" left="393" width="161" height="20" font="0">outpatient with T2DM 18 y or </text>
<text top="368" left="393" width="31" height="20" font="0">older </text>
<text top="386" left="393" width="3" height="20" font="0"> </text>
<text top="403" left="393" width="114" height="20" font="7"><b>Exclusion criteria:  </b></text>
<text top="422" left="393" width="11" height="18" font="0">• </text>
<text top="421" left="403" width="37" height="20" font="0">T1DM </text>
<text top="440" left="393" width="11" height="18" font="0">• </text>
<text top="439" left="403" width="110" height="20" font="0">secondary diabetes </text>
<text top="335" left="568" width="158" height="20" font="7"><b>1</b>°<b> endpoint:</b> Non-fatal CVD </text>
<text top="352" left="568" width="3" height="20" font="0"> </text>
<text top="370" left="568" width="55" height="20" font="7"><b>Results</b>:  </text>
<text top="389" left="568" width="11" height="18" font="0">• </text>
<text top="388" left="583" width="176" height="20" font="0">Mean (SD) age at assessment;  </text>
<text top="411" left="583" width="9" height="12" font="0">o</text>
<text top="410" left="592" width="4" height="14" font="0"> </text>
<text top="405" left="603" width="134" height="20" font="0">Early onset; 40.9 (7.9) y </text>
<text top="428" left="583" width="9" height="12" font="0">o</text>
<text top="427" left="592" width="4" height="14" font="0"> </text>
<text top="422" left="603" width="130" height="20" font="0">Late onset; 60.7 (9.6) y </text>
<text top="441" left="568" width="11" height="18" font="0">• </text>
<text top="440" left="583" width="131" height="20" font="0">Mean age at diagnosis; </text>
<text top="464" left="583" width="9" height="12" font="0">o</text>
<text top="463" left="592" width="4" height="14" font="0"> </text>
<text top="458" left="603" width="135" height="20" font="0">Early onset; 34·5 (5·0) y </text>
<text top="481" left="583" width="9" height="12" font="0">o</text>
<text top="480" left="592" width="4" height="14" font="0"> </text>
<text top="475" left="603" width="131" height="20" font="0">Late onset; 55·3 (8·9) y </text>
<text top="494" left="568" width="11" height="18" font="0">• </text>
<text top="493" left="583" width="246" height="20" font="0">Risk of non-fatal CVD in Early onset vs. Late </text>
<text top="510" left="583" width="83" height="20" font="0">onset diabetes </text>
<text top="534" left="583" width="9" height="12" font="0">o</text>
<text top="532" left="592" width="4" height="14" font="0"> </text>
<text top="527" left="603" width="161" height="20" font="0">OR: 1.91; 95% CI: 1.81–2.02 </text>
<text top="551" left="583" width="9" height="12" font="0">o</text>
<text top="550" left="592" width="4" height="14" font="0"> </text>
<text top="545" left="603" width="218" height="20" font="0">(p&lt;0.0001) which was attenuated when </text>
<text top="562" left="603" width="226" height="20" font="0">adjusted for diabetes duration (OR: 1.13; </text>
<text top="579" left="603" width="109" height="20" font="0">95% CI: 1.06–1.20. </text>
<text top="598" left="568" width="11" height="18" font="0">• </text>
<text top="597" left="583" width="230" height="20" font="0">Prevalence of CVD by age in Early onset: </text>
<text top="621" left="583" width="9" height="12" font="0">o</text>
<text top="620" left="592" width="4" height="14" font="0"> </text>
<text top="615" left="603" width="79" height="20" font="0">30-34 y; 1.9% </text>
<text top="638" left="583" width="9" height="12" font="0">o</text>
<text top="637" left="592" width="4" height="14" font="0"> </text>
<text top="632" left="603" width="79" height="20" font="0">35-39 y; 3.3% </text>
<text top="655" left="583" width="9" height="12" font="0">o</text>
<text top="654" left="592" width="4" height="14" font="0"> </text>
<text top="649" left="603" width="79" height="20" font="0">40-44 y; 5.8% </text>
<text top="673" left="583" width="9" height="12" font="0">o</text>
<text top="671" left="592" width="4" height="14" font="0"> </text>
<text top="666" left="603" width="79" height="20" font="0">45-49 y; 8.8% </text>
<text top="690" left="583" width="9" height="12" font="0">o</text>
<text top="688" left="592" width="4" height="14" font="0"> </text>
<text top="684" left="603" width="86" height="20" font="0">50-54 y; 13.9% </text>
<text top="707" left="583" width="9" height="12" font="0">o</text>
<text top="706" left="592" width="4" height="14" font="0"> </text>
<text top="701" left="603" width="86" height="20" font="0">55-59 y; 21.3% </text>
<text top="724" left="583" width="9" height="12" font="0">o</text>
<text top="723" left="592" width="4" height="14" font="0"> </text>
<text top="718" left="603" width="86" height="20" font="0">60-64 y; 29.6% </text>
<text top="741" left="583" width="9" height="12" font="0">o</text>
<text top="740" left="592" width="4" height="14" font="0"> </text>
<text top="735" left="603" width="86" height="20" font="0">65-69 y; 28.4% </text>
<text top="759" left="583" width="9" height="12" font="0">o</text>
<text top="757" left="592" width="4" height="14" font="0"> </text>
<text top="752" left="603" width="76" height="20" font="0">&gt;70 y; 42.7% </text>
<text top="769" left="568" width="3" height="20" font="0"> </text>
<text top="334" left="859" width="223" height="20" font="0">• This is one of two studies that provides </text>
<text top="351" left="859" width="241" height="20" font="0">information on rates of CVD in a cohort with </text>
<text top="368" left="859" width="172" height="20" font="0">T2DM diagnosed &lt;40 y of age. </text>
<text top="386" left="859" width="252" height="20" font="0">• Although prevalence of CVD is relatively low </text>
<text top="403" left="859" width="247" height="20" font="0">in 30-44 y old subjects (1.9-5.8%) diagnosed </text>
<text top="420" left="859" width="232" height="20" font="0">&lt;40 y, it increases rapidly with age in both </text>
<text top="437" left="859" width="101" height="20" font="0">men and women.  </text>
<text top="454" left="859" width="235" height="20" font="0">• The principal finding was that Early onset </text>
<text top="472" left="859" width="247" height="20" font="0">T2DM has a higher lifetime risk for CVD than </text>
<text top="489" left="859" width="254" height="20" font="0">Late onset, which occurs at an earlier stage of </text>
<text top="506" left="859" width="243" height="20" font="0">life in Early onset, but in regression analysis </text>
<text top="523" left="859" width="219" height="20" font="0">was more strongly related to duration of </text>
<text top="540" left="859" width="243" height="20" font="0">diabetes rather than lower age of DM onset. </text>
<text top="558" left="859" width="3" height="20" font="0"> </text>
</page>
<page number="55" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">55 </text>
<text top="107" left="91" width="123" height="20" font="0">Constantino MI, et al., </text>
<text top="124" left="91" width="56" height="20" font="0">2013 <a href="data supplement.html#238">(51)</a> </text>
<text top="141" left="91" width="55" height="20" font="16"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23846814">23846814</a></text>
<text top="141" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23846814"> </a></text>
<text top="107" left="231" width="97" height="20" font="7"><b>Study type</b>: 25-y </text>
<text top="124" left="231" width="126" height="20" font="0">retrospective review of </text>
<text top="141" left="231" width="90" height="20" font="0">hospital records </text>
<text top="159" left="231" width="3" height="20" font="0"> </text>
<text top="176" left="231" width="132" height="20" font="7"><b>Design:</b> Comparison of </text>
<text top="193" left="231" width="148" height="20" font="0">diabetic complications and </text>
<text top="210" left="231" width="124" height="20" font="0">mortality in T1DM and </text>
<text top="228" left="231" width="143" height="20" font="0">T2DM cohorts with age of </text>
<text top="245" left="231" width="141" height="20" font="0">onset between 15 and 30 </text>
<text top="262" left="231" width="47" height="20" font="0">y of age </text>
<text top="279" left="231" width="3" height="20" font="0"> </text>
<text top="296" left="231" width="126" height="20" font="0">Size: 354 patients with </text>
<text top="314" left="231" width="131" height="20" font="0">T2DM and 470 patients </text>
<text top="331" left="231" width="62" height="20" font="0">with T1DM </text>
<text top="107" left="393" width="109" height="20" font="7"><b>Inclusion criteria</b>:  </text>
<text top="126" left="390" width="11" height="18" font="0">• </text>
<text top="125" left="403" width="150" height="20" font="0">Records of all patients with </text>
<text top="143" left="403" width="138" height="20" font="0">diabetes aged 15-30 y in </text>
<text top="160" left="403" width="129" height="20" font="0">the Royal Prince Alfred </text>
<text top="177" left="403" width="152" height="20" font="0">Hospital diabetes database </text>
<text top="194" left="403" width="146" height="20" font="0">in Sydney Australia during </text>
<text top="211" left="403" width="124" height="20" font="0">the period 1986-2011. </text>
<text top="229" left="393" width="3" height="20" font="0"> </text>
<text top="246" left="393" width="148" height="20" font="7"><b>Baseline characteristics: </b></text>
<text top="265" left="393" width="11" height="18" font="0">• </text>
<text top="264" left="410" width="141" height="20" font="0">Mean current age (SD) y; </text>
<text top="283" left="393" width="11" height="18" font="0">• </text>
<text top="282" left="410" width="103" height="20" font="0">T2DM: 40.4 (12.5) </text>
<text top="301" left="393" width="11" height="18" font="0">• </text>
<text top="301" left="410" width="103" height="20" font="0">T1DM: 38.9 (10.9) </text>
<text top="319" left="393" width="11" height="18" font="0">• </text>
<text top="319" left="410" width="141" height="20" font="0">Median diabetes duration </text>
<text top="336" left="410" width="43" height="20" font="0">(IQR) y </text>
<text top="355" left="393" width="11" height="18" font="0">• </text>
<text top="354" left="410" width="127" height="20" font="0">T2DM: 11.6 (4.5–22.6) </text>
<text top="373" left="393" width="11" height="18" font="0">• </text>
<text top="373" left="410" width="127" height="20" font="0">T1DM: 14.7 (8.2–23.6) </text>
<text top="390" left="393" width="3" height="20" font="0"> </text>
<text top="407" left="393" width="134" height="20" font="7"><b>Exclusion criteria:</b> N/A </text>
<text top="108" left="568" width="125" height="20" font="7"><b>1</b>°<b> endpoint</b>: Mortality </text>
<text top="125" left="568" width="3" height="20" font="0"> </text>
<text top="143" left="568" width="55" height="20" font="7"><b>Results:  </b></text>
<text top="160" left="568" width="231" height="20" font="0">• Other outcomes: Macrovascular disease </text>
<text top="179" left="568" width="11" height="18" font="0">• </text>
<text top="178" left="583" width="165" height="20" font="0">Mortality T2DM vs. T1DM (%) </text>
<text top="197" left="568" width="11" height="18" font="0">• </text>
<text top="196" left="583" width="113" height="20" font="0">Total: 11% vs. 6.8% </text>
<text top="215" left="568" width="11" height="18" font="0">• </text>
<text top="215" left="583" width="235" height="20" font="0">Median duration of DM until death (IQR) y: </text>
<text top="234" left="568" width="11" height="18" font="0">• </text>
<text top="233" left="583" width="136" height="20" font="0">T2DM; 26.9 [18.1–36.0]  </text>
<text top="252" left="568" width="11" height="18" font="0">• </text>
<text top="251" left="583" width="181" height="20" font="0">T1DM; 36.5 [24.4– 45.4], p=0.01 </text>
<text top="270" left="568" width="11" height="18" font="0">• </text>
<text top="269" left="583" width="151" height="20" font="0">Mean age at death (SD) y:  </text>
<text top="288" left="568" width="11" height="18" font="0">• </text>
<text top="288" left="583" width="107" height="20" font="0">T2DM; 52.9 (14.7)  </text>
<text top="306" left="568" width="11" height="18" font="0">• </text>
<text top="306" left="583" width="93" height="20" font="0">T1DM; 57.4 (12) </text>
<text top="325" left="568" width="11" height="18" font="0">• </text>
<text top="324" left="583" width="67" height="20" font="0">CVD death; </text>
<text top="343" left="568" width="11" height="18" font="0">• </text>
<text top="342" left="583" width="79" height="20" font="0">T2DM; 50.0% </text>
<text top="361" left="568" width="11" height="18" font="0">• </text>
<text top="361" left="583" width="130" height="20" font="0">T1DM; 30.3%, p=0.053 </text>
<text top="380" left="568" width="11" height="18" font="0">• </text>
<text top="379" left="583" width="250" height="20" font="0">Cumulative macrovascular disease T2DM vs. </text>
<text top="396" left="583" width="59" height="20" font="0">T1DM (%) </text>
<text top="415" left="568" width="11" height="18" font="0">• </text>
<text top="414" left="583" width="175" height="20" font="0">IHD: 12.6% vs. 2.5%, p&lt;0.0001 </text>
<text top="433" left="568" width="11" height="18" font="0">• </text>
<text top="433" left="583" width="186" height="20" font="0">Stroke: 4.3% vs. 0.7%, p&lt;0.0001  </text>
<text top="451" left="568" width="11" height="18" font="0">• </text>
<text top="451" left="583" width="179" height="20" font="0"> Any: 14.4% vs. 5.7%, p&lt;0.0001 </text>
<text top="107" left="859" width="246" height="20" font="0">• This study provides comparative, long-term </text>
<text top="124" left="859" width="258" height="20" font="0">data on complications and mortality in subjects </text>
<text top="141" left="859" width="251" height="20" font="0">with T1DM or T2DM, diagnosed between age </text>
<text top="159" left="859" width="112" height="20" font="0">15 and 30 y of age.  </text>
<text top="176" left="859" width="253" height="20" font="0">• The principal finding is that those with T2DM </text>
<text top="193" left="859" width="248" height="20" font="0">have a greater risk of macrovascular disease </text>
<text top="210" left="859" width="200" height="20" font="0">and mortality than those with T1DM. </text>
<text top="228" left="859" width="227" height="20" font="0">•The study also demonstrates that over a </text>
<text top="245" left="859" width="228" height="20" font="0">mean duration of diabetes of 11.6-14.7 y, </text>
<text top="262" left="859" width="245" height="20" font="0">14.4% of T2DM and 5.7% of T1D diagnosed </text>
<text top="279" left="859" width="197" height="20" font="0">between 15 and 30 y develop CVD. </text>
<text top="469" left="91" width="116" height="20" font="0">Svensson MK, et al., </text>
<text top="486" left="91" width="56" height="20" font="0">2013 <a href="data supplement.html#239">(52)</a> </text>
<text top="503" left="91" width="55" height="20" font="16"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24002670">24002670</a></text>
<text top="503" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24002670"> </a></text>
<text top="469" left="231" width="71" height="20" font="7"><b>Study type:</b> </text>
<text top="486" left="231" width="117" height="20" font="0">Observational cohort </text>
<text top="503" left="231" width="33" height="20" font="0">study </text>
<text top="520" left="231" width="3" height="20" font="0"> </text>
<text top="537" left="231" width="137" height="20" font="7"><b>Design:</b> To evaluate the </text>
<text top="555" left="231" width="102" height="20" font="0">predictive value of </text>
<text top="572" left="231" width="149" height="20" font="0">reduced renal function and </text>
<text top="589" left="231" width="113" height="20" font="0">albuminuria on CVD </text>
<text top="606" left="231" width="119" height="20" font="0">events and all- cause </text>
<text top="624" left="231" width="113" height="20" font="0">mortality in diabetes </text>
<text top="641" left="231" width="3" height="20" font="0"> </text>
<text top="658" left="231" width="73" height="20" font="7"><b>Size</b>: 66,065 </text>
<text top="469" left="393" width="109" height="20" font="7"><b>Inclusion criteria:  </b></text>
<text top="486" left="393" width="143" height="20" font="0">Subjects with T2DM aged </text>
<text top="503" left="393" width="138" height="20" font="0">30-79 y (mean age 64 y) </text>
<text top="520" left="393" width="154" height="20" font="0">registered with the Swedish </text>
<text top="537" left="393" width="150" height="20" font="0">National Diabetes Register </text>
<text top="555" left="393" width="155" height="20" font="0">and followed for an average </text>
<text top="572" left="393" width="44" height="20" font="0">of 5.7 y </text>
<text top="589" left="393" width="156" height="20" font="0">17% of the cohort had RRF, </text>
<text top="606" left="393" width="153" height="20" font="0">(eGFR&lt;60 ml/min/1.73m2); </text>
<text top="624" left="393" width="119" height="20" font="0">24% had albuminuria </text>
<text top="641" left="393" width="136" height="20" font="0">(&gt;30mcg/mg creatinine). </text>
<text top="658" left="393" width="3" height="20" font="0"> </text>
<text top="675" left="393" width="133" height="20" font="7"><b>Exclusion criteria</b>: N/A </text>
<text top="470" left="568" width="79" height="20" font="7"><b>1</b>°<b> endpoint:  </b></text>
<text top="489" left="568" width="11" height="18" font="0">• </text>
<text top="488" left="583" width="112" height="20" font="0">Fatal/non-fatal CHD </text>
<text top="507" left="568" width="11" height="18" font="0">• </text>
<text top="506" left="583" width="111" height="20" font="0">Fatal/non-fatal CVD </text>
<text top="525" left="568" width="11" height="18" font="0">• </text>
<text top="524" left="583" width="104" height="20" font="0">All-cause mortality </text>
<text top="542" left="568" width="3" height="20" font="0"> </text>
<text top="559" left="568" width="55" height="20" font="7"><b>Results:  </b></text>
<text top="578" left="568" width="11" height="18" font="0">• </text>
<text top="577" left="583" width="215" height="20" font="0">Fatal/non-fatal CVD events (n [%], fully </text>
<text top="594" left="583" width="248" height="20" font="0">adjusted HR [95%CI] vs. those without either </text>
<text top="612" left="583" width="110" height="20" font="0">albuminuria or RRF </text>
<text top="629" left="583" width="220" height="20" font="0">- No albuminuria/RRF: 3306 (7.7%), 1.0 </text>
<text top="646" left="583" width="233" height="20" font="0">-albuminuria: 1484 (12.5%), 1.27; 95% CI: </text>
<text top="663" left="583" width="62" height="20" font="0">1.20–1.36. </text>
<text top="680" left="583" width="250" height="20" font="0">-RRF: 951 (12.7%), 1.21; 95% CI: 1.12–1.30. </text>
<text top="698" left="583" width="262" height="20" font="0">-albuminuria +RRF: 749 (19.3%), 1.41; 95% CI: </text>
<text top="715" left="583" width="62" height="20" font="0">1.30–1.53. </text>
<text top="734" left="568" width="11" height="18" font="0">• </text>
<text top="733" left="583" width="104" height="20" font="0">All-cause mortality </text>
<text top="750" left="583" width="217" height="20" font="0">-No albuminuria /RRF: 2713 (6.3%) 1.0 </text>
<text top="767" left="583" width="233" height="20" font="0">-albuminuria: 1378 (11.6%), 1.43; 95% CI: </text>
<text top="785" left="583" width="62" height="20" font="0">1.34–1.53. </text>
<text top="469" left="859" width="243" height="20" font="0">•Albuminuria and reduced renal function are </text>
<text top="486" left="859" width="235" height="20" font="0">each independent risk factors for CVD and </text>
<text top="503" left="859" width="153" height="20" font="0">mortality in type 2 diabetes. </text>
<text top="520" left="859" width="232" height="20" font="0">•Albuminuria was predictive at all levels of </text>
<text top="537" left="859" width="235" height="20" font="0">renal function and additive to the effects of </text>
<text top="555" left="859" width="32" height="20" font="0">RRF. </text>
<text top="572" left="859" width="248" height="20" font="0">•In normoalbuminuric patients, reduced renal </text>
<text top="589" left="859" width="225" height="20" font="0">function is an important predictor of CVD </text>
<text top="606" left="859" width="117" height="20" font="0">events and mortality. </text>
<text top="624" left="859" width="250" height="20" font="0">•Limitations include the fact that subjects with </text>
<text top="641" left="859" width="213" height="20" font="0">more severe degrees of RRF were not </text>
<text top="658" left="859" width="258" height="20" font="0">included, that only 1 baseline measure of renal </text>
<text top="675" left="859" width="211" height="20" font="0">function was used, and effects of RAS </text>
<text top="692" left="859" width="162" height="20" font="0">inhibitors were not assessed. </text>
</page>
<page number="56" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">56 </text>
<text top="107" left="583" width="250" height="20" font="0">-RRF: 965 (12.9%), 1.30; 95% CI: 1.20–1.40. </text>
<text top="124" left="583" width="262" height="20" font="0">-albuminuria +RRF: 907 (23.4%), 1.82; 95% CI: </text>
<text top="141" left="583" width="62" height="20" font="0">1.67–1.97. </text>
<text top="159" left="91" width="114" height="20" font="0">Guo VY, et al., 2016 </text>
<text top="177" left="91" width="29" height="20" font="0"><a href="data supplement.html#239">(53)</a>  </text>
<text top="194" left="91" width="55" height="20" font="16"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27068777">27068777</a></text>
<text top="194" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27068777"> </a></text>
<text top="159" left="231" width="102" height="20" font="7"><b>Study type:</b> Meta-</text>
<text top="177" left="231" width="141" height="20" font="0">analysis of cohort studies </text>
<text top="194" left="231" width="3" height="20" font="7"><b> </b></text>
<text top="211" left="231" width="137" height="20" font="7"><b>Design:</b> To evaluate the </text>
<text top="228" left="231" width="138" height="20" font="0">association between any </text>
<text top="245" left="231" width="139" height="20" font="0">diabetic retinopathy (DR) </text>
<text top="263" left="231" width="133" height="20" font="0">and CVD in T1DM AND </text>
<text top="280" left="231" width="137" height="20" font="0">T2DM without prior CVD </text>
<text top="297" left="231" width="3" height="20" font="0"> </text>
<text top="314" left="231" width="147" height="20" font="7"><b>Size</b>: 17,611 patients from </text>
<text top="332" left="231" width="129" height="20" font="0">13 studies; 10,200 with </text>
<text top="349" left="231" width="122" height="20" font="0">T2DM (8 studies) and </text>
<text top="366" left="231" width="107" height="20" font="0">7411 with T1DM (5 </text>
<text top="383" left="231" width="46" height="20" font="0">studies) </text>
<text top="159" left="393" width="109" height="20" font="7"><b>Inclusion criteria:  </b></text>
<text top="178" left="393" width="11" height="18" font="0">• </text>
<text top="178" left="406" width="141" height="20" font="0">presented original data in </text>
<text top="195" left="406" width="146" height="20" font="0">prospective, observational </text>
<text top="212" left="406" width="46" height="20" font="0">studies; </text>
<text top="231" left="393" width="11" height="18" font="0">• </text>
<text top="230" left="406" width="145" height="20" font="0">evaluated the presence of </text>
<text top="247" left="406" width="130" height="20" font="0">DR in pts T2DM or with </text>
<text top="265" left="406" width="37" height="20" font="0">T1DM </text>
<text top="284" left="393" width="11" height="18" font="0">• </text>
<text top="283" left="406" width="102" height="20" font="0">reported all-cause </text>
<text top="300" left="406" width="129" height="20" font="0">mortality and/or fatal or </text>
<text top="318" left="406" width="107" height="20" font="0">nonfatal CV events </text>
<text top="337" left="393" width="11" height="18" font="0">• </text>
<text top="336" left="406" width="76" height="20" font="0">No prior CVD </text>
<text top="354" left="393" width="145" height="19" font="0">• T1DM studies (showing </text>
<text top="370" left="406" width="144" height="20" font="0">range of findings between </text>
<text top="388" left="406" width="105" height="20" font="0">individual studies). </text>
<text top="405" left="406" width="3" height="20" font="0"> </text>
<text top="422" left="390" width="161" height="20" font="7"><b>Population characteristics</b>  </text>
<text top="439" left="390" width="86" height="20" font="0">  T1DM studies </text>
<text top="456" left="406" width="116" height="20" font="0">-Mean ages; 28-37 y </text>
<text top="474" left="406" width="106" height="20" font="0">-Mean durations of </text>
<text top="491" left="406" width="98" height="20" font="0">diabetes; 10-22 y </text>
<text top="508" left="406" width="103" height="20" font="0">-Mean f/us; 6-12 y </text>
<text top="525" left="406" width="107" height="20" font="0">-Prevalence of DR; </text>
<text top="543" left="403" width="79" height="20" font="0">T2DM studies </text>
<text top="560" left="406" width="116" height="20" font="0">-Mean ages; 53-62 y </text>
<text top="577" left="406" width="135" height="20" font="0">-Mean durations; mostly </text>
<text top="594" left="406" width="24" height="20" font="0">N/A </text>
<text top="611" left="406" width="113" height="20" font="0">-Mean f/us; 4.7-18 y </text>
<text top="629" left="406" width="131" height="20" font="0">-Prevalence of DR; N/A </text>
<text top="646" left="393" width="3" height="20" font="0"> </text>
<text top="663" left="393" width="133" height="20" font="7"><b>Exclusion criteria</b>: N/A </text>
<text top="161" left="568" width="268" height="20" font="7"><b>1</b>°<b> endpoint:</b> Risk ratio for first CVD event in DR </text>
<text top="178" left="568" width="57" height="20" font="0">vs. no DR </text>
<text top="195" left="568" width="3" height="20" font="7"><b> </b></text>
<text top="212" left="568" width="52" height="20" font="7"><b>Results: </b></text>
<text top="231" left="570" width="11" height="18" font="0">• </text>
<text top="231" left="583" width="193" height="20" font="0">Risk ratio (RR) range from studies  </text>
<text top="248" left="583" width="107" height="20" font="0">- All T1D 1.63-6.66 </text>
<text top="265" left="583" width="107" height="20" font="0">- All T2D 1.30-2.55 </text>
<text top="284" left="570" width="11" height="18" font="0">• </text>
<text top="283" left="583" width="104" height="20" font="0">Mean RR (95%CI) </text>
<text top="300" left="583" width="148" height="20" font="0">- Overall; 2.42, (1.77-3.31) </text>
<text top="319" left="570" width="11" height="18" font="0">• </text>
<text top="319" left="583" width="236" height="20" font="0">Overall adjusted for risk factors; 2.01 (1.65-</text>
<text top="336" left="583" width="31" height="20" font="0">2.45) </text>
<text top="353" left="583" width="139" height="20" font="0">- T2DM; 1.81 (1.47-2.23) </text>
<text top="370" left="583" width="139" height="20" font="0">- T1DM; 3.59 (1.79-7.20) </text>
<text top="389" left="570" width="11" height="18" font="0">• </text>
<text top="389" left="583" width="69" height="20" font="0">RR for CHD </text>
<text top="406" left="583" width="144" height="20" font="0">-Overall, 1.83, (1.52-2.19) </text>
<text top="159" left="859" width="245" height="20" font="0">• Overall DR is associated with an increased </text>
<text top="177" left="859" width="172" height="20" font="0">risk of CVD events in diabetes. </text>
<text top="194" left="859" width="231" height="20" font="0">• The risk associated with DR is greater in </text>
<text top="211" left="859" width="222" height="20" font="0">those with T1DM than those with T2DM, </text>
<text top="228" left="859" width="215" height="20" font="0">although the T1DM data were strongly. </text>
<text top="246" left="859" width="235" height="20" font="0">influenced by a single large study that only </text>
<text top="263" left="859" width="213" height="20" font="0">studied pts with advanced retinopathy. </text>
<text top="280" left="859" width="251" height="20" font="0">• The DR associated CVD risk is independent </text>
<text top="297" left="859" width="111" height="20" font="0">of other risk factors. </text>
<text top="314" left="859" width="241" height="20" font="0">• It was not possible in this meta-analysis to </text>
<text top="332" left="859" width="252" height="20" font="0">determine whether severity of DR was related </text>
<text top="349" left="859" width="249" height="20" font="0">to CVD risk, although the ACCORD study did </text>
<text top="366" left="859" width="58" height="20" font="0">show this. </text>
<text top="681" left="91" width="114" height="20" font="0">Brownrigg JR, et al., </text>
<text top="698" left="91" width="56" height="20" font="0">2014 <a href="data supplement.html#239">(54)</a> </text>
<text top="715" left="91" width="55" height="20" font="16"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25095826">25095826</a></text>
<text top="715" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25095826"> </a></text>
<text top="681" left="231" width="149" height="20" font="7"><b>Study type</b>: Observational </text>
<text top="698" left="231" width="144" height="20" font="0">case- control cohort study </text>
<text top="715" left="231" width="3" height="20" font="7"><b> </b></text>
<text top="733" left="231" width="118" height="20" font="7"><b>Design:</b> To compare </text>
<text top="750" left="231" width="138" height="20" font="0">incident first CVD events </text>
<text top="767" left="231" width="149" height="20" font="0">in a large group of patients </text>
<text top="784" left="231" width="142" height="20" font="0">with type 2 diabetes seen </text>
<text top="681" left="393" width="109" height="20" font="7"><b>Inclusion criteria:  </b></text>
<text top="700" left="393" width="11" height="18" font="0">• </text>
<text top="699" left="403" width="71" height="20" font="0">&gt;18 y of age </text>
<text top="718" left="393" width="11" height="18" font="0">• </text>
<text top="717" left="403" width="75" height="20" font="0">no prior CVD </text>
<text top="736" left="393" width="11" height="18" font="0">• </text>
<text top="736" left="403" width="87" height="20" font="0">type 2 diabetes </text>
<text top="755" left="393" width="11" height="18" font="0">• </text>
<text top="754" left="403" width="100" height="20" font="0">foot exam using a </text>
<text top="771" left="403" width="77" height="20" font="0">monofilament </text>
<text top="788" left="393" width="3" height="20" font="0"> </text>
<text top="682" left="568" width="204" height="20" font="7"><b>1</b>°<b> endpoint:</b> First CVD event, death </text>
<text top="699" left="568" width="3" height="20" font="0"> </text>
<text top="716" left="568" width="55" height="20" font="7"><b>Results:  </b></text>
<text top="735" left="595" width="11" height="18" font="0">• </text>
<text top="735" left="622" width="105" height="20" font="0">CVD events, n (%) </text>
<text top="758" left="597" width="9" height="12" font="0">o</text>
<text top="757" left="606" width="4" height="14" font="0"> </text>
<text top="752" left="617" width="81" height="20" font="0">PN; 65 (5.0%) </text>
<text top="775" left="597" width="9" height="12" font="0">o</text>
<text top="774" left="606" width="4" height="14" font="0"> </text>
<text top="769" left="617" width="107" height="20" font="0">No PN; 334 (2.8%) </text>
<text top="788" left="595" width="11" height="18" font="0">• </text>
<text top="787" left="622" width="179" height="20" font="0">Crude mortality, n per 1000 pt. y </text>
<text top="681" left="859" width="259" height="20" font="0">• PN is associated with increased risk for a first </text>
<text top="698" left="859" width="220" height="20" font="0">CVD event in people with diabetes after </text>
<text top="715" left="859" width="220" height="20" font="0">adjustment for conventional risk factors. </text>
<text top="733" left="859" width="198" height="20" font="0">• The presence of PN led to modest </text>
<text top="750" left="859" width="252" height="20" font="0">reclassification of individuals into different risk </text>
<text top="767" left="859" width="64" height="20" font="0">categories. </text>
<text top="784" left="859" width="225" height="20" font="0">• A limitation is the short follow-up period </text>
</page>
<page number="57" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">57 </text>
<text top="107" left="231" width="144" height="20" font="0">in primary care practice in </text>
<text top="124" left="231" width="123" height="20" font="0">the UK with or without </text>
<text top="141" left="231" width="148" height="20" font="0">peripheral neuropathy <a href="data supplement.html#239">(55)</a> </text>
<text top="159" left="231" width="3" height="20" font="0"> </text>
<text top="176" left="231" width="118" height="20" font="0">Size: Data on 13,043 </text>
<text top="193" left="231" width="113" height="20" font="0">individuals from 122 </text>
<text top="210" left="231" width="124" height="20" font="0">primary care practices </text>
<text top="228" left="231" width="143" height="20" font="0">extracted using a national </text>
<text top="245" left="231" width="99" height="20" font="0">software program </text>
<text top="107" left="393" width="148" height="20" font="7"><b>Baseline characteristics: </b></text>
<text top="126" left="393" width="11" height="18" font="0">• </text>
<text top="125" left="410" width="127" height="20" font="0">mean age (SD); 63.8 y </text>
<text top="143" left="410" width="36" height="20" font="0">(12.8) </text>
<text top="162" left="393" width="11" height="18" font="0">• </text>
<text top="161" left="410" width="115" height="20" font="0">PN prevalence 9.9% </text>
<text top="178" left="410" width="80" height="20" font="0">(1296/13,043) </text>
<text top="197" left="393" width="11" height="18" font="0">• </text>
<text top="196" left="410" width="129" height="20" font="0">Mean follow-up was 30 </text>
<text top="213" left="410" width="21" height="20" font="0">mo </text>
<text top="231" left="393" width="3" height="20" font="0"> </text>
<text top="248" left="393" width="133" height="20" font="7"><b>Exclusion criteria</b>: N/A </text>
<text top="113" left="597" width="9" height="12" font="0">o</text>
<text top="112" left="606" width="4" height="14" font="0"> </text>
<text top="107" left="617" width="51" height="20" font="0">PN; 22.8 </text>
<text top="130" left="597" width="9" height="12" font="0">o</text>
<text top="129" left="606" width="4" height="14" font="0"> </text>
<text top="124" left="617" width="122" height="20" font="0">No PN; 11.3, p&lt;0.001 </text>
<text top="143" left="595" width="11" height="18" font="0">• </text>
<text top="143" left="622" width="176" height="20" font="0">Effect of PN vs. no PN on CVD; </text>
<text top="166" left="597" width="9" height="12" font="0">o</text>
<text top="165" left="605" width="4" height="14" font="0"> </text>
<text top="160" left="617" width="203" height="20" font="0">Unadjusted HR: 1.78; (95% CI: 1.37–</text>
<text top="177" left="617" width="83" height="20" font="0">2.32); p&lt;0.001 </text>
<text top="201" left="597" width="9" height="12" font="0">o</text>
<text top="199" left="605" width="4" height="14" font="0"> </text>
<text top="194" left="617" width="219" height="20" font="0">Adjusted for risk factors; HR: 1.38; 95% </text>
<text top="211" left="617" width="129" height="20" font="0">CI: 1.05 to1.80; p=0.02 </text>
<text top="230" left="595" width="11" height="18" font="0">• </text>
<text top="230" left="622" width="222" height="20" font="0">Reclassification of risk categories based </text>
<text top="247" left="622" width="155" height="20" font="0">on the Framingham score: - </text>
<text top="266" left="595" width="11" height="18" font="0">• </text>
<text top="265" left="622" width="203" height="20" font="0">PN reclassified 6.9% into a higher or </text>
<text top="282" left="622" width="109" height="20" font="0">lower risk category. </text>
<text top="107" left="859" width="251" height="20" font="0">• The diagnosis of PN is imprecise, which is a </text>
<text top="124" left="859" width="109" height="20" font="0">potential limitation.  </text>
<text top="300" left="91" width="120" height="20" font="0">Pang XH, et al., 2017 </text>
<text top="317" left="91" width="25" height="20" font="0"><a href="data supplement.html#239">(56)</a> </text>
<text top="335" left="91" width="55" height="20" font="16"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28607554">28607554</a></text>
<text top="335" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28607554"> </a></text>
<text top="300" left="231" width="106" height="20" font="7"><b>Study type</b>: Cross-</text>
<text top="317" left="231" width="122" height="20" font="0">sectional case-control </text>
<text top="335" left="231" width="70" height="20" font="0">cohort study </text>
<text top="352" left="231" width="3" height="20" font="0"> </text>
<text top="369" left="231" width="132" height="20" font="7"><b>Design:</b> Comparison of </text>
<text top="386" left="231" width="145" height="20" font="0">CVD risk estimated by the </text>
<text top="404" left="231" width="91" height="20" font="0">United Kingdom </text>
<text top="421" left="231" width="120" height="20" font="0">Prospective Diabetes </text>
<text top="438" left="231" width="111" height="20" font="0">Study risk engine in </text>
<text top="455" left="231" width="122" height="20" font="0">Chinese subjects with </text>
<text top="472" left="231" width="113" height="20" font="0">diabetes and with or </text>
<text top="490" left="231" width="133" height="20" font="0">without PAD and free of </text>
<text top="507" left="231" width="33" height="20" font="0">CVD. </text>
<text top="524" left="231" width="3" height="20" font="0"> </text>
<text top="541" left="231" width="140" height="20" font="7"><b>Size:</b> 1,178 subjects with </text>
<text top="558" left="231" width="50" height="20" font="0">diabetes </text>
<text top="300" left="393" width="109" height="20" font="7"><b>Inclusion criteria:  </b></text>
<text top="317" left="393" width="154" height="20" font="0">•All 1,178 patients with type </text>
<text top="335" left="393" width="124" height="20" font="0">2 diabetes admitted to </text>
<text top="352" left="393" width="154" height="20" font="0">Zhejiang University Medical </text>
<text top="369" left="393" width="143" height="20" font="0">College Hospital between </text>
<text top="386" left="393" width="86" height="20" font="0">2008 and 2013 </text>
<text top="404" left="393" width="153" height="20" font="0">•88 had asymptomatic PAD </text>
<text top="421" left="393" width="143" height="20" font="0">defined as an ABI &lt;0.9 or </text>
<text top="438" left="393" width="28" height="20" font="0">&gt;1.4 </text>
<text top="455" left="393" width="101" height="20" font="0">•Mean (SD) age y </text>
<text top="472" left="393" width="122" height="20" font="0">•No PAD; 57.2 (12.3)  </text>
<text top="490" left="393" width="99" height="20" font="0">•PAD; 69.8 (11.8) </text>
<text top="507" left="393" width="3" height="20" font="7"><b> </b></text>
<text top="524" left="393" width="133" height="20" font="7"><b>Exclusion criteria</b>: N/A </text>
<text top="301" left="568" width="247" height="20" font="7"><b>1</b>°<b> endpoint:</b> 10 y % fatal/non-fatal CVD risk </text>
<text top="319" left="568" width="184" height="20" font="0">assessed by UKPDS risk engine. </text>
<text top="336" left="568" width="3" height="20" font="0"> </text>
<text top="353" left="568" width="55" height="20" font="7"><b>Results:  </b></text>
<text top="370" left="568" width="100" height="20" font="0">• Mean [95%CI]% </text>
<text top="387" left="568" width="155" height="20" font="0"> - No PAD; 20.5 [19.6–21.4] </text>
<text top="405" left="568" width="184" height="20" font="0"> - PAD; 35.1 [30.7–39.5] p&lt;0.001 </text>
<text top="424" left="570" width="11" height="18" font="0">• </text>
<text top="423" left="583" width="259" height="20" font="0">Multivariate logistic regression (OR [95%CI]) of </text>
<text top="440" left="583" width="243" height="20" font="0">PAD vs. non-PVD on CVD risk that included </text>
<text top="457" left="583" width="169" height="20" font="0">age and standard risk factors,  </text>
<text top="474" left="583" width="169" height="20" font="0">- CHD: 3.6, (2.2–6.0); p&lt;0.001 </text>
<text top="492" left="568" width="188" height="20" font="0"> - Stroke: 6.9, (4.0–11.8); p&lt;0.001 </text>
<text top="300" left="859" width="235" height="20" font="0">•An ABI&lt;0.9&gt;1.4 in a large Chinese cohort </text>
<text top="317" left="859" width="205" height="20" font="0">with type 2 diabetes free of CVD was </text>
<text top="335" left="859" width="249" height="20" font="0">associated with increased risk for future CVD </text>
<text top="352" left="859" width="221" height="20" font="0">as assessed by the UKPDS risk engine. </text>
<text top="369" left="859" width="201" height="20" font="0">•This increased risk was found to be </text>
<text top="386" left="859" width="220" height="20" font="0">independent of age and of standard risk </text>
<text top="404" left="859" width="44" height="20" font="0">factors. </text>
<text top="421" left="859" width="224" height="20" font="0">•A limitation is the use of a risk engine to </text>
<text top="438" left="859" width="217" height="20" font="0">assess CVD instead of incident events. </text>
<text top="576" left="81" width="4" height="22" font="1"> </text>
<text top="609" left="81" width="4" height="22" font="1"> </text>
<text top="641" left="81" width="4" height="22" font="1"> </text>
<text top="673" left="81" width="4" height="22" font="1"> </text>
<text top="706" left="81" width="4" height="22" font="1"> </text>
<text top="738" left="81" width="4" height="22" font="1"> </text>
</page>
<page number="58" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">58 </text>
<text top="106" left="81" width="581" height="24" font="4"><b>Data Supplement 12. RCTs Comparing Diabetes Mellitus 40-75 Years (Section 4.3)  </b></text>
<text top="136" left="97" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="154" left="123" width="48" height="20" font="7"><b>Author; </b></text>
<text top="171" left="100" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="136" left="244" width="83" height="20" font="7"><b>Aim of Study; </b></text>
<text top="154" left="249" width="74" height="20" font="7"><b>Study Type; </b></text>
<text top="171" left="243" width="86" height="20" font="7"><b>Study Size (N) </b></text>
<text top="154" left="391" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="128" left="557" width="111" height="20" font="7"><b>Study Intervention </b></text>
<text top="145" left="574" width="76" height="20" font="7"><b>(# patients) / </b></text>
<text top="162" left="557" width="111" height="20" font="7"><b>Study Comparator </b></text>
<text top="179" left="578" width="69" height="20" font="7"><b>(# patients) </b></text>
<text top="136" left="751" width="105" height="20" font="7"><b>Endpoint Results </b></text>
<text top="154" left="735" width="137" height="20" font="7"><b>(Absolute Event Rates, </b></text>
<text top="171" left="713" width="181" height="20" font="7"><b>P values; OR or RR; &amp; 95% CI) </b></text>
<text top="137" left="932" width="175" height="20" font="7"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="154" left="964" width="111" height="20" font="7"><b>Study Limitations; </b></text>
<text top="171" left="971" width="96" height="20" font="7"><b>Adverse Events </b></text>
<text top="197" left="89" width="29" height="20" font="7"><b>HPS </b></text>
<text top="215" left="89" width="89" height="20" font="0">Collins R, et al., </text>
<text top="232" left="89" width="56" height="20" font="0">2003 <a href="data supplement.html#239">(57)</a> </text>
<text top="249" left="89" width="55" height="20" font="16"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12814710">12814710</a></text>
<text top="249" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12814710"> </a></text>
<text top="197" left="217" width="34" height="20" font="7"><b>Aim:</b>  </text>
<text top="216" left="217" width="7" height="18" font="0">•</text>
<text top="216" left="224" width="118" height="20" font="0"> To evaluate whether </text>
<text top="233" left="217" width="112" height="20" font="0">(moderate intensity) </text>
<text top="250" left="217" width="124" height="20" font="0">statin therapy reduces </text>
<text top="267" left="217" width="106" height="20" font="0">CVD morbidity and </text>
<text top="285" left="217" width="137" height="20" font="0">mortality in subjects with </text>
<text top="302" left="217" width="113" height="20" font="0">diabetes and with or </text>
<text top="319" left="217" width="130" height="20" font="0">without CVD compared </text>
<text top="336" left="217" width="64" height="20" font="0">to placebo. </text>
<text top="355" left="217" width="7" height="18" font="0">•</text>
<text top="355" left="224" width="66" height="20" font="0"> This report </text>
<text top="372" left="217" width="128" height="20" font="0">summarizes findings in </text>
<text top="389" left="217" width="98" height="20" font="0">the pre- specified </text>
<text top="406" left="217" width="135" height="20" font="0">subgroup of participants </text>
<text top="423" left="217" width="118" height="20" font="0">without ASCVD only. </text>
<text top="441" left="217" width="3" height="20" font="0"> </text>
<text top="458" left="217" width="71" height="20" font="7"><b>Study type:</b> </text>
<text top="475" left="217" width="113" height="20" font="0">Randomized double-</text>
<text top="492" left="217" width="137" height="20" font="0">blind placebo- controlled </text>
<text top="509" left="217" width="64" height="20" font="0">clinical trial </text>
<text top="527" left="217" width="3" height="20" font="0"> </text>
<text top="544" left="217" width="115" height="20" font="7"><b>Size:</b> 5,963 subjects </text>
<text top="561" left="217" width="113" height="20" font="0">with diabetes 615 of </text>
<text top="578" left="217" width="135" height="20" font="0">whom had T1DM; 3,051 </text>
<text top="595" left="217" width="118" height="20" font="0">subjects had ASCVD </text>
<text top="613" left="217" width="119" height="20" font="0">and 2,912 individuals </text>
<text top="630" left="217" width="47" height="20" font="0">did not.  </text>
<text top="197" left="368" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="216" left="368" width="7" height="18" font="0">•</text>
<text top="216" left="375" width="73" height="20" font="0"> Age 40-80 y </text>
<text top="235" left="368" width="7" height="18" font="0">•</text>
<text top="234" left="375" width="92" height="20" font="0"> T1DM or T2DM </text>
<text top="253" left="368" width="7" height="18" font="0">•</text>
<text top="252" left="375" width="132" height="20" font="0"> Non-fasting cholesterol </text>
<text top="270" left="368" width="133" height="20" font="0">&gt;3.5 mmol/l (135 mg/dl) </text>
<text top="289" left="368" width="7" height="18" font="0">•</text>
<text top="288" left="375" width="133" height="20" font="0"> treated hypertension (if </text>
<text top="305" left="368" width="154" height="20" font="0">also male and aged at least </text>
<text top="322" left="368" width="31" height="20" font="0">65 y) </text>
<text top="340" left="368" width="3" height="20" font="0"> </text>
<text top="357" left="368" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="376" left="368" width="7" height="18" font="0">•</text>
<text top="375" left="375" width="112" height="20" font="0"> No CVD for the pre-</text>
<text top="392" left="368" width="157" height="20" font="0">specified primary prevention </text>
<text top="410" left="368" width="55" height="20" font="0">subgroup </text>
<text top="429" left="368" width="7" height="18" font="0">•</text>
<text top="428" left="375" width="111" height="20" font="0"> Subject’s physician </text>
<text top="445" left="368" width="132" height="20" font="0">assessment that statins </text>
<text top="462" left="368" width="106" height="20" font="0">clearly indicated or </text>
<text top="480" left="368" width="87" height="20" font="0">contraindicated </text>
<text top="499" left="368" width="7" height="18" font="0">•</text>
<text top="498" left="375" width="75" height="20" font="0"> liver disease </text>
<text top="517" left="368" width="7" height="18" font="0">•</text>
<text top="516" left="375" width="120" height="20" font="0"> severe renal disease </text>
<text top="535" left="368" width="7" height="18" font="0">•</text>
<text top="535" left="375" width="126" height="20" font="0"> cyclosporine, fibrates, </text>
<text top="552" left="368" width="36" height="20" font="0">niacin </text>
<text top="571" left="368" width="7" height="18" font="0">•</text>
<text top="570" left="375" width="130" height="20" font="0"> Baseline LDL-C; mean </text>
<text top="588" left="368" width="126" height="20" font="0">(SD) 3·2 (0·82) mmol/l </text>
<text top="605" left="368" width="90" height="20" font="0">[125 (32) mg/dl] </text>
<text top="622" left="368" width="3" height="20" font="0"> </text>
<text top="197" left="539" width="81" height="20" font="7"><b>Intervention:</b>  </text>
<text top="215" left="539" width="104" height="20" font="0">Simva 40 mg daily </text>
<text top="232" left="539" width="53" height="20" font="0">(n=1455) </text>
<text top="249" left="539" width="125" height="20" font="0"> -average statin usage </text>
<text top="266" left="539" width="31" height="20" font="0">83%, </text>
<text top="283" left="539" width="115" height="20" font="0"> -average LDL-C 2.2 </text>
<text top="301" left="539" width="98" height="20" font="0">mmol/l (86 mg/dl) </text>
<text top="318" left="539" width="81" height="20" font="7"><b>Comparator:</b>  </text>
<text top="335" left="539" width="101" height="20" font="0">Placebo (n=1457) </text>
<text top="352" left="539" width="125" height="20" font="0"> -average statin usage </text>
<text top="369" left="539" width="28" height="20" font="0">11% </text>
<text top="387" left="539" width="115" height="20" font="0"> -average LDL-C 3.1 </text>
<text top="404" left="539" width="109" height="20" font="0">mmol/L (121 mg/dl) </text>
<text top="421" left="539" width="3" height="20" font="0"> </text>
<text top="440" left="539" width="7" height="18" font="0">•</text>
<text top="439" left="546" width="100" height="20" font="0"> LDL-C difference </text>
<text top="457" left="539" width="109" height="20" font="0">between simva and </text>
<text top="474" left="539" width="122" height="20" font="0">placebo 0.9 mmol (35 </text>
<text top="491" left="539" width="38" height="20" font="0">mg/dl) </text>
<text top="510" left="539" width="7" height="18" font="0">•</text>
<text top="509" left="546" width="116" height="20" font="0"> Mean duration 4.8 y </text>
<text top="527" left="539" width="3" height="20" font="7"><b> </b></text>
<text top="199" left="698" width="79" height="20" font="7"><b>1</b>°<b> endpoint:</b>  </text>
<text top="218" left="698" width="7" height="18" font="0">•</text>
<text top="217" left="705" width="163" height="20" font="0"> Non-fatal MI, death from any </text>
<text top="234" left="698" width="97" height="20" font="0">coronary disease </text>
<text top="251" left="698" width="3" height="20" font="0"> </text>
<text top="269" left="698" width="52" height="20" font="7"><b>Results:</b> </text>
<text top="288" left="698" width="7" height="18" font="0">•</text>
<text top="287" left="705" width="88" height="20" font="0"> n (rate ratio %) </text>
<text top="304" left="698" width="105" height="20" font="0">Simva; 135 (9.3%) </text>
<text top="321" left="698" width="122" height="20" font="0">Placebo; 196 (13.5%) </text>
<text top="339" left="698" width="150" height="20" font="0">RRR 33% (95% CI: 17–46; </text>
<text top="356" left="698" width="60" height="20" font="0">p=0·0003) </text>
<text top="375" left="698" width="7" height="18" font="0">•</text>
<text top="374" left="705" width="195" height="20" font="0"> Men: RRR [SE] 33% [10], p=0·002 </text>
<text top="393" left="698" width="7" height="18" font="0">•</text>
<text top="392" left="705" width="170" height="20" font="0"> Women RRR 30% [19], p=0·1 </text>
<text top="411" left="698" width="7" height="18" font="0">•</text>
<text top="411" left="705" width="174" height="20" font="0"> 40-64 y of age: RRR 33% [12], </text>
<text top="428" left="698" width="49" height="20" font="0">p=0·006 </text>
<text top="447" left="698" width="7" height="18" font="0">•</text>
<text top="446" left="705" width="174" height="20" font="0"> 65-80 y of age: RRR 31% [14], </text>
<text top="464" left="698" width="41" height="20" font="0">p=0.03 </text>
<text top="199" left="921" width="7" height="18" font="0">•</text>
<text top="199" left="928" width="179" height="20" font="0"> Adverse events: (full group with </text>
<text top="216" left="921" width="54" height="20" font="0">diabetes) </text>
<text top="235" left="921" width="7" height="18" font="0">•</text>
<text top="234" left="928" width="134" height="20" font="0"> Liver enzymes &gt;4X UL  </text>
<text top="251" left="921" width="170" height="20" font="0">Simvastatin: n (%) 14 [0·47%]  </text>
<text top="269" left="921" width="118" height="20" font="0">Placebo: 11 [0·37%]) </text>
<text top="288" left="921" width="7" height="18" font="0">•</text>
<text top="287" left="928" width="76" height="20" font="0"> CK &gt;10X UL </text>
<text top="304" left="921" width="97" height="20" font="0">Simva: 4 [0·13%] </text>
<text top="321" left="921" width="107" height="20" font="0">Placebo: 2 [0·07%] </text>
<text top="339" left="921" width="3" height="20" font="0"> </text>
<text top="648" left="89" width="47" height="20" font="7"><b>CARDS </b></text>
<text top="665" left="89" width="109" height="20" font="0">Colhoun HM, et al., </text>
<text top="682" left="89" width="56" height="20" font="0">2004 <a href="data supplement.html#239">(58)</a> </text>
<text top="699" left="89" width="55" height="20" font="16"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15325833">15325833</a></text>
<text top="699" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15325833"> </a></text>
<text top="648" left="217" width="92" height="20" font="7"><b>Aim:</b> To test the </text>
<text top="665" left="217" width="89" height="20" font="0">effectiveness of </text>
<text top="682" left="217" width="122" height="20" font="0">atorvastatin 10 mg for </text>
<text top="699" left="217" width="119" height="20" font="0">primary prevention of </text>
<text top="717" left="217" width="116" height="20" font="0">major CVD events in </text>
<text top="734" left="217" width="109" height="20" font="0">patients with T2DM </text>
<text top="751" left="217" width="108" height="20" font="0">without high LDL-C </text>
<text top="768" left="217" width="3" height="20" font="0"> </text>
<text top="648" left="368" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="667" left="368" width="7" height="18" font="0">•</text>
<text top="666" left="375" width="146" height="20" font="0"> Men and women aged 40-</text>
<text top="683" left="368" width="17" height="20" font="0">75 </text>
<text top="702" left="368" width="7" height="18" font="0">•</text>
<text top="702" left="375" width="40" height="20" font="0"> T2DM </text>
<text top="721" left="368" width="7" height="18" font="0">•</text>
<text top="720" left="375" width="85" height="20" font="0"> At least one of </text>
<text top="737" left="368" width="145" height="20" font="0">hypertension, retinopathy, </text>
<text top="755" left="368" width="121" height="20" font="0">microalbuminuria and </text>
<text top="772" left="368" width="49" height="20" font="0">smoking </text>
<text top="789" left="368" width="3" height="20" font="0"> </text>
<text top="648" left="539" width="134" height="20" font="7"><b>Intervention:</b> Atorva 10 </text>
<text top="665" left="539" width="53" height="20" font="0">mg daily  </text>
<text top="682" left="539" width="53" height="20" font="0">(n=1428) </text>
<text top="699" left="539" width="7" height="20" font="0">  </text>
<text top="717" left="539" width="81" height="20" font="7"><b>Comparator:</b>  </text>
<text top="736" left="539" width="7" height="18" font="0">•</text>
<text top="735" left="546" width="104" height="20" font="0"> Placebo (n=1410) </text>
<text top="754" left="539" width="7" height="18" font="0">•</text>
<text top="753" left="546" width="66" height="20" font="0"> 1 y LDL -C </text>
<text top="772" left="539" width="7" height="18" font="0">•</text>
<text top="772" left="546" width="113" height="20" font="0"> Mean (SD) mmol/l/  </text>
<text top="789" left="539" width="33" height="20" font="0">mg/dl </text>
<text top="649" left="698" width="200" height="20" font="7"><b>1</b>°<b> endpoint:</b> (first acute CHD event </text>
<text top="666" left="698" width="175" height="20" font="0">[MI including silent MI, unstable </text>
<text top="683" left="698" width="181" height="20" font="0">angina, CHD death, resuscitated </text>
<text top="701" left="698" width="136" height="20" font="0">cardiac arrest], coronary </text>
<text top="718" left="698" width="154" height="20" font="0">revascularization, or stroke) </text>
<text top="735" left="698" width="3" height="20" font="0"> </text>
<text top="752" left="698" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="649" left="921" width="76" height="20" font="7"><b>2</b>°<b> Endpoint</b>: </text>
<text top="668" left="921" width="7" height="18" font="0">•</text>
<text top="667" left="928" width="166" height="20" font="0"> Acute coronary events, n (%) </text>
<text top="685" left="921" width="95" height="20" font="0">  Atorva: 51 (3.6) </text>
<text top="702" left="921" width="104" height="20" font="0">  Placebo: 77 (5.5) </text>
<text top="721" left="921" width="7" height="18" font="0">•</text>
<text top="720" left="928" width="179" height="20" font="0"> Acute coronary events, rate per </text>
<text top="737" left="921" width="55" height="20" font="0">100 per y </text>
<text top="755" left="921" width="80" height="20" font="0">   Atorva: 0.94 </text>
<text top="772" left="921" width="89" height="20" font="0">   Placebo: 1.47 </text>
<text top="789" left="921" width="179" height="20" font="0">   HR: 0.64; 95% CI: 0.45 - 0.91; </text>
</page>
<page number="59" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">59 </text>
<text top="107" left="217" width="71" height="20" font="7"><b>Study type:</b> </text>
<text top="124" left="217" width="113" height="20" font="0">Randomized double-</text>
<text top="141" left="217" width="137" height="20" font="0">blind placebo- controlled </text>
<text top="159" left="217" width="64" height="20" font="0">clinical trial </text>
<text top="176" left="217" width="3" height="20" font="0"> </text>
<text top="193" left="217" width="66" height="20" font="7"><b>Size:</b> 2,838 </text>
<text top="107" left="368" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="126" left="368" width="7" height="18" font="0">•</text>
<text top="125" left="375" width="57" height="20" font="0"> Any CVD </text>
<text top="144" left="368" width="7" height="18" font="0">•</text>
<text top="144" left="375" width="107" height="20" font="0"> LDL-C &gt;160 mg/dl </text>
<text top="163" left="368" width="7" height="18" font="0">•</text>
<text top="162" left="375" width="131" height="20" font="0"> triglyceride &gt;160 mg/dl </text>
<text top="181" left="368" width="7" height="18" font="0">•</text>
<text top="181" left="375" width="134" height="20" font="0"> plasma creatinine &gt;150 </text>
<text top="198" left="368" width="33" height="20" font="0">mol/L </text>
<text top="217" left="368" width="7" height="18" font="0">•</text>
<text top="216" left="375" width="79" height="20" font="0"> HbA1c &gt;12% </text>
<text top="235" left="368" width="7" height="18" font="0">•</text>
<text top="235" left="375" width="104" height="20" font="0"> &lt;80% compliance </text>
<text top="254" left="368" width="7" height="18" font="0">•</text>
<text top="253" left="375" width="133" height="20" font="0"> with placebo during the </text>
<text top="270" left="368" width="86" height="20" font="0">baseline phase </text>
<text top="289" left="368" width="7" height="18" font="0">•</text>
<text top="289" left="375" width="130" height="20" font="0"> Baseline LDL-C: mean </text>
<text top="306" left="368" width="105" height="20" font="0">(SD) mmol/l/mg/dl  </text>
<text top="323" left="368" width="155" height="20" font="0">Atorva: 3.04 (0.72)/118 (28) </text>
<text top="340" left="368" width="138" height="20" font="0">Placebo: 3.02 (0.70)/118 </text>
<text top="357" left="368" width="25" height="20" font="0">(27) </text>
<text top="107" left="539" width="122" height="20" font="0">Atorva:1.86 (0.69)/ 70 </text>
<text top="124" left="539" width="29" height="20" font="0">(39)  </text>
<text top="141" left="539" width="141" height="20" font="0">Placebo: 3.10 (0.80)/ 121 </text>
<text top="159" left="539" width="25" height="20" font="0">(31) </text>
<text top="178" left="539" width="7" height="18" font="0">•</text>
<text top="177" left="546" width="96" height="20" font="0"> Mean change % </text>
<text top="194" left="539" width="70" height="20" font="0">Atorva: 38.8 </text>
<text top="211" left="539" width="79" height="20" font="0">Placebo; 2.65 </text>
<text top="229" left="539" width="116" height="20" font="0">Absolute change %,  </text>
<text top="246" left="539" width="84" height="20" font="0">Atorva: -1.1/46 </text>
<text top="263" left="539" width="89" height="20" font="0">Placebo: 0.08/3 </text>
<text top="282" left="539" width="7" height="18" font="0">•</text>
<text top="282" left="546" width="94" height="20" font="0"> Between-group  </text>
<text top="299" left="539" width="91" height="20" font="0">Difference, 40% </text>
<text top="316" left="539" width="3" height="20" font="7"><b> </b></text>
<text top="109" left="698" width="7" height="18" font="0">•</text>
<text top="108" left="705" width="196" height="20" font="0"> The trial was terminated 2 y earlier </text>
<text top="125" left="698" width="197" height="20" font="0">than expected (median duration 3.9 </text>
<text top="143" left="698" width="187" height="20" font="0">y) because efficacy had been met </text>
<text top="162" left="698" width="7" height="18" font="0">•</text>
<text top="161" left="705" width="77" height="20" font="0"> Events n (%) </text>
<text top="178" left="698" width="102" height="20" font="0">    Atorva: 83 (5.8) </text>
<text top="195" left="698" width="118" height="20" font="0">    Placebo: 127 (9.0) </text>
<text top="214" left="698" width="7" height="18" font="0">•</text>
<text top="214" left="705" width="102" height="20" font="0"> Rate per 100 pt-y </text>
<text top="231" left="698" width="83" height="20" font="0">    Atorva: 1.54 </text>
<text top="248" left="698" width="92" height="20" font="0">    Placebo: 2.46 </text>
<text top="266" left="698" width="182" height="20" font="0">    HR: 0.63; 95% CI: 0.48 - 0.83; </text>
<text top="283" left="698" width="59" height="20" font="0">   p=0.001 </text>
<text top="302" left="698" width="7" height="18" font="0">•</text>
<text top="301" left="705" width="131" height="20" font="0"> Death from any cause  </text>
<text top="318" left="698" width="140" height="20" font="0">   HR: 0.73; 95% CI: 0.52 </text>
<text top="336" left="698" width="90" height="20" font="0">  -1.01; p=0.059 </text>
<text top="355" left="698" width="7" height="18" font="0">•</text>
<text top="354" left="705" width="185" height="20" font="0"> NNT is 37 major vascular events </text>
<text top="371" left="698" width="109" height="20" font="0">   per 1000 over 4 y<b> </b></text>
<text top="107" left="921" width="39" height="20" font="0"> p=NR </text>
<text top="126" left="921" width="7" height="18" font="0">•</text>
<text top="125" left="928" width="161" height="20" font="0"> Any acute CVD event, n (%) </text>
<text top="143" left="921" width="105" height="20" font="0">   Atorva: 134 (9.4) </text>
<text top="160" left="921" width="121" height="20" font="0">   Placebo: 189 (13.4) </text>
<text top="177" left="921" width="181" height="20" font="0">   HR: 0.68; 95% CI: 0.55 – 0.85; </text>
<text top="194" left="921" width="52" height="20" font="0"> p=0.001 </text>
<text top="213" left="921" width="7" height="18" font="0">•</text>
<text top="213" left="928" width="79" height="20" font="0"> Stroke, n (%) </text>
<text top="230" left="921" width="98" height="20" font="0">   Atorva: 21 (1.7) </text>
<text top="247" left="921" width="107" height="20" font="0">   Placebo: 39 (2.8) </text>
<text top="264" left="921" width="185" height="20" font="0">   HR: 0.52; 95% CI: 0.31 – 0.89;  </text>
<text top="282" left="921" width="39" height="20" font="0"> p=NR </text>
<text top="301" left="921" width="7" height="18" font="0">•</text>
<text top="300" left="928" width="190" height="20" font="0"> Coronary revascularization, n (%) </text>
<text top="317" left="921" width="92" height="20" font="0"> Atorva: 24 (1.7) </text>
<text top="334" left="921" width="101" height="20" font="0"> Placebo: 34 (2.4) </text>
<text top="352" left="921" width="174" height="20" font="0"> HR: 0.69; 95% CI: 0.41 – 1.16; </text>
<text top="369" left="921" width="35" height="20" font="0">p=NR </text>
<text top="386" left="921" width="3" height="20" font="0"> </text>
<text top="403" left="921" width="173" height="20" font="7"><b>Adverse events: </b>No excess of </text>
<text top="420" left="921" width="180" height="20" font="0">adverse events was noted in the </text>
<text top="438" left="921" width="102" height="20" font="0">atorvastatin group<b> </b></text>
<text top="455" left="921" width="3" height="20" font="0"> </text>
<text top="472" left="921" width="168" height="20" font="7"><b>Limitations: </b>15% drop-in lipid </text>
<text top="489" left="921" width="142" height="20" font="0">lowering meds in placebo<b> </b></text>
<text top="507" left="89" width="75" height="20" font="7"><b>ASCOT-LLA </b></text>
<text top="524" left="89" width="92" height="20" font="0">Sever PS, et al., </text>
<text top="542" left="89" width="56" height="20" font="0">2005 <a href="data supplement.html#239">(59)</a> </text>
<text top="559" left="89" width="55" height="20" font="16"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15855581">15855581</a></text>
<text top="559" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15855581"> </a></text>
<text top="507" left="217" width="34" height="20" font="7"><b>Aim:</b>  </text>
<text top="526" left="217" width="7" height="18" font="0">•</text>
<text top="526" left="224" width="94" height="20" font="0"> To establish the </text>
<text top="543" left="217" width="109" height="20" font="0">benefits of lowering </text>
<text top="560" left="217" width="122" height="20" font="0">cholesterol in patients </text>
<text top="577" left="217" width="107" height="20" font="0">with well-controlled </text>
<text top="594" left="217" width="98" height="20" font="0">hypertension and </text>
<text top="612" left="217" width="132" height="20" font="0">average/below-average </text>
<text top="629" left="217" width="63" height="20" font="0">cholesterol </text>
<text top="646" left="217" width="107" height="20" font="0">concentrations, but </text>
<text top="663" left="217" width="108" height="20" font="0">without established </text>
<text top="680" left="217" width="100" height="20" font="0">coronary disease. </text>
<text top="699" left="217" width="7" height="18" font="0">•</text>
<text top="699" left="224" width="129" height="20" font="0"> This report focuses on </text>
<text top="716" left="217" width="131" height="20" font="0">the group with diabetes </text>
<text top="733" left="217" width="137" height="20" font="0">which was analyzed and </text>
<text top="750" left="217" width="109" height="20" font="0">reported separately </text>
<text top="768" left="217" width="3" height="20" font="0"> </text>
<text top="507" left="368" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="526" left="368" width="7" height="18" font="0">•</text>
<text top="526" left="375" width="142" height="20" font="0"> Men and women 40-80 y </text>
<text top="545" left="368" width="7" height="18" font="0">•</text>
<text top="544" left="375" width="79" height="20" font="0"> Hypertension </text>
<text top="563" left="368" width="7" height="18" font="0">•</text>
<text top="562" left="375" width="124" height="20" font="0"> Total chol &lt;6.5mmol/l </text>
<text top="580" left="368" width="66" height="20" font="0">(253 mg/dl) </text>
<text top="599" left="368" width="7" height="18" font="0">•</text>
<text top="598" left="375" width="151" height="20" font="0"> 3 of; T2DM, male sex, age </text>
<text top="615" left="368" width="149" height="20" font="0">&gt;55 y, microalbuminuria or </text>
<text top="632" left="368" width="118" height="20" font="0">proteinuria, smoking, </text>
<text top="650" left="368" width="148" height="20" font="0">total/HDL-C &gt;6, premature </text>
<text top="667" left="368" width="150" height="20" font="0">FH of CHD, LVH, specified </text>
<text top="684" left="368" width="142" height="20" font="0">ECG abnormalities, PAD, </text>
<text top="701" left="368" width="74" height="20" font="0">stroke or TIA </text>
<text top="718" left="368" width="3" height="20" font="0"> </text>
<text top="736" left="368" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="755" left="368" width="7" height="18" font="0">•</text>
<text top="754" left="375" width="106" height="20" font="0"> MI current angina, </text>
<text top="771" left="368" width="137" height="20" font="0">cerebrovascular event in </text>
<text top="788" left="368" width="57" height="20" font="0">past 3 mo </text>
<text top="507" left="539" width="81" height="20" font="7"><b>Intervention:</b>  </text>
<text top="526" left="539" width="7" height="18" font="0">•</text>
<text top="526" left="546" width="109" height="20" font="0"> Atorva 10 mg daily </text>
<text top="543" left="539" width="53" height="20" font="0">(n=1258) </text>
<text top="560" left="539" width="134" height="20" font="0"> - Baseline LDL-C mean </text>
<text top="577" left="539" width="109" height="20" font="0">(SD) mmol.l/ mg/dl; </text>
<text top="594" left="539" width="102" height="20" font="0">3.3 (0.7)/ 128 (27) </text>
<text top="612" left="539" width="70" height="20" font="0"> -1 y LDL-C; </text>
<text top="629" left="539" width="98" height="20" font="0">2.1 (0.66)/82 (26) </text>
<text top="646" left="539" width="3" height="20" font="0"> </text>
<text top="663" left="539" width="73" height="20" font="7"><b>Comparator</b> </text>
<text top="682" left="539" width="7" height="18" font="0">•</text>
<text top="682" left="546" width="104" height="20" font="0"> Placebo (n=1274) </text>
<text top="699" left="539" width="124" height="20" font="0"> - Baseline LDL-C; 3.3 </text>
<text top="716" left="539" width="78" height="20" font="0">(0.8)/128 (31) </text>
<text top="733" left="539" width="70" height="20" font="0"> -1 y LDL-C; </text>
<text top="750" left="539" width="98" height="20" font="0">3.3 (0.8)/128 (31) </text>
<text top="768" left="539" width="3" height="20" font="0"> </text>
<text top="508" left="698" width="79" height="20" font="7"><b>1</b>°<b> endpoint:</b>  </text>
<text top="527" left="698" width="7" height="18" font="0">•</text>
<text top="527" left="705" width="203" height="20" font="0"> The trial was terminated earlier than </text>
<text top="544" left="698" width="183" height="20" font="0">expected (median duration 3.3 y) </text>
<text top="561" left="698" width="178" height="20" font="0">because efficacy for the primary </text>
<text top="578" left="698" width="198" height="20" font="0">endpoint for the full group had been </text>
<text top="596" left="698" width="200" height="20" font="0">met. However, this meant there was </text>
<text top="613" left="698" width="187" height="20" font="0">insufficient power in the subgroup </text>
<text top="630" left="698" width="158" height="20" font="0">with diabetes for the primary </text>
<text top="647" left="698" width="193" height="20" font="0">outcome, which was non-fatal MI + </text>
<text top="664" left="698" width="57" height="20" font="0">fatal CHD </text>
<text top="683" left="698" width="7" height="18" font="0">•</text>
<text top="683" left="705" width="187" height="20" font="0"> Diabetes group results: n(%) [per </text>
<text top="700" left="698" width="61" height="20" font="0">1000 pt. y] </text>
<text top="717" left="698" width="112" height="20" font="0">Atorva: 38(3.0) [9.6] </text>
<text top="734" left="698" width="139" height="20" font="0">Placebo: 46(3.6%) [11.4] </text>
<text top="752" left="698" width="201" height="20" font="0">HR: 0.84 (95% CI: 0.55-1.29); p=NR </text>
<text top="771" left="698" width="7" height="18" font="0">•</text>
<text top="770" left="705" width="174" height="20" font="0"> Accordingly, the subgroup with </text>
<text top="787" left="698" width="203" height="20" font="0">diabetes was analyzed based on the </text>
<text top="509" left="921" width="7" height="18" font="0">•</text>
<text top="508" left="928" width="171" height="20" font="0"> 2° endpoint for the main study </text>
<text top="526" left="921" width="147" height="20" font="0">which became the primary </text>
<text top="543" left="921" width="180" height="20" font="0">endpoint for the diabetes cohort: </text>
<text top="566" left="931" width="9" height="12" font="0">o</text>
<text top="565" left="940" width="4" height="14" font="0"> </text>
<text top="560" left="951" width="133" height="20" font="0">Total CVD events; CVD </text>
<text top="577" left="951" width="121" height="20" font="0">mortality, nonfatal MI, </text>
<text top="594" left="951" width="137" height="20" font="0">unstable angina, chronic </text>
<text top="612" left="951" width="165" height="20" font="0">stable angina, life-threatening </text>
<text top="629" left="951" width="154" height="20" font="0">arrhythmias, non-fatal heart </text>
<text top="646" left="951" width="164" height="20" font="0">failure, non-fatal stroke, PAD, </text>
<text top="663" left="951" width="104" height="20" font="0">retinal thrombosis, </text>
<text top="680" left="951" width="149" height="20" font="0">revascularization, TIA, and </text>
<text top="698" left="951" width="108" height="20" font="0">reversible ischemic </text>
<text top="715" left="951" width="115" height="20" font="0">neurological deficits. </text>
<text top="734" left="921" width="7" height="18" font="0">•</text>
<text top="733" left="928" width="133" height="20" font="0"> Diabetes group results: </text>
<text top="757" left="931" width="9" height="12" font="0">o</text>
<text top="755" left="940" width="4" height="14" font="0"> </text>
<text top="750" left="951" width="154" height="20" font="0">Total CVD events n(%) [per </text>
<text top="768" left="951" width="61" height="20" font="0">1000 pt. y] </text>
<text top="791" left="931" width="9" height="12" font="0">o</text>
<text top="790" left="940" width="4" height="14" font="0"> </text>
<text top="785" left="951" width="137" height="20" font="0">Atorva: 116(9.2%) [30.2] </text>
</page>
<page number="60" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">60 </text>
<text top="107" left="217" width="71" height="20" font="7"><b>Study type:</b> </text>
<text top="124" left="217" width="113" height="20" font="0">Randomized double-</text>
<text top="141" left="217" width="132" height="20" font="0">blind placebo controlled </text>
<text top="159" left="217" width="64" height="20" font="0">clinical trial </text>
<text top="176" left="217" width="3" height="20" font="0"> </text>
<text top="193" left="217" width="135" height="20" font="7"><b>Size:</b> 10,305 subjects of </text>
<text top="210" left="217" width="128" height="20" font="0">whom 2532 had T2DM </text>
<text top="109" left="368" width="7" height="18" font="0">•</text>
<text top="108" left="375" width="129" height="20" font="0"> uncontrolled arrythmia </text>
<text top="127" left="368" width="7" height="18" font="0">•</text>
<text top="127" left="375" width="131" height="20" font="0"> fasting trig &gt;4.5 mmol/l </text>
<text top="144" left="368" width="66" height="20" font="0">(400 mg/dl) </text>
<text top="163" left="368" width="7" height="18" font="0">•</text>
<text top="162" left="375" width="107" height="20" font="0"> clinically important </text>
<text top="179" left="368" width="135" height="20" font="0">laboratory abnormalities </text>
<text top="198" left="368" width="7" height="18" font="0">•</text>
<text top="198" left="375" width="136" height="20" font="0"> no current statin/ fibrate </text>
<text top="215" left="368" width="3" height="20" font="0"> </text>
<text top="232" left="368" width="152" height="20" font="7"><b>Baseline characteristics:</b>  </text>
<text top="251" left="368" width="7" height="18" font="0">•</text>
<text top="251" left="375" width="149" height="20" font="0"> Mean age 64 &gt;60 y (66%) </text>
<text top="270" left="368" width="7" height="18" font="0">•</text>
<text top="269" left="375" width="105" height="20" font="0"> 16% had previous </text>
<text top="286" left="368" width="151" height="20" font="0">cerebrovascular disease or </text>
<text top="303" left="368" width="29" height="20" font="0">PAD </text>
<text top="322" left="368" width="7" height="18" font="0">•</text>
<text top="322" left="375" width="135" height="20" font="0"> Mean no. of risk factors </text>
<text top="339" left="368" width="123" height="20" font="0">including diabetes = 4 </text>
<text top="109" left="539" width="7" height="18" font="0">•</text>
<text top="108" left="546" width="121" height="20" font="0"> Differences in LDL-C </text>
<text top="125" left="539" width="105" height="20" font="0">between treatment </text>
<text top="143" left="539" width="130" height="20" font="0">groups not provided for </text>
<text top="160" left="539" width="105" height="20" font="0">diabetes subgroup </text>
<text top="177" left="539" width="3" height="20" font="7"><b> </b></text>
<text top="107" left="698" width="170" height="20" font="0">study trial secondary outcome, </text>
<text top="124" left="698" width="139" height="20" font="0">namely total CVD events </text>
<text top="113" left="931" width="9" height="12" font="0">o</text>
<text top="112" left="940" width="4" height="14" font="0"> </text>
<text top="107" left="951" width="152" height="20" font="0">Placebo: 151(11.9%) [39.1] </text>
<text top="130" left="931" width="9" height="12" font="0">o</text>
<text top="129" left="940" width="4" height="14" font="0"> </text>
<text top="124" left="951" width="161" height="20" font="0">HR: 0.77; 95% CI: 0.61-0.98; </text>
<text top="141" left="951" width="48" height="20" font="0">p=0.036 </text>
<text top="165" left="931" width="9" height="12" font="0">o</text>
<text top="164" left="940" width="4" height="14" font="0"> </text>
<text top="159" left="951" width="165" height="20" font="0">Excluding those with baseline </text>
<text top="176" left="951" width="152" height="20" font="0">CVD (12%); HR: 0.75; 95% </text>
<text top="193" left="951" width="130" height="20" font="0">CI: 0.57-0.99; p=0.038. </text>
<text top="217" left="931" width="9" height="12" font="0">o</text>
<text top="215" left="940" width="4" height="14" font="0"> </text>
<text top="210" left="951" width="162" height="20" font="0">No difference in liver enzyme </text>
<text top="228" left="951" width="133" height="20" font="0">or other adverse events </text>
<text top="245" left="951" width="158" height="20" font="0">between atorva and placebo </text>
<text top="262" left="951" width="41" height="20" font="0">groups </text>
<text top="279" left="921" width="3" height="20" font="0"> </text>
<text top="296" left="921" width="189" height="20" font="7"><b>Limitation:</b> There was insufficient </text>
<text top="314" left="921" width="186" height="20" font="0">power to test the efficacy of statin </text>
<text top="331" left="921" width="190" height="20" font="0">therapy on the primary outcome in </text>
<text top="348" left="921" width="105" height="20" font="0">the diabetes group </text>
<text top="365" left="921" width="3" height="20" font="0"> </text>
<text top="383" left="89" width="46" height="20" font="7"><b>ASPEN </b></text>
<text top="400" left="89" width="97" height="20" font="0">Knopp RH, et al., </text>
<text top="418" left="89" width="56" height="20" font="0">2006 <a href="data supplement.html#239">(60)</a> </text>
<text top="435" left="89" width="55" height="20" font="16"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16801565">16801565</a></text>
<text top="435" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16801565"> </a></text>
<text top="383" left="217" width="34" height="20" font="7"><b>Aim:</b>  </text>
<text top="402" left="217" width="7" height="18" font="0">•</text>
<text top="402" left="224" width="118" height="20" font="0"> To evaluate whether </text>
<text top="419" left="217" width="112" height="20" font="0">(moderate intensity) </text>
<text top="436" left="217" width="77" height="20" font="0">statin therapy </text>
<text top="453" left="217" width="109" height="20" font="0">(atorvastatin 10 mg </text>
<text top="470" left="217" width="109" height="20" font="0">daily) reduces CVD </text>
<text top="488" left="217" width="127" height="20" font="0">morbidity and mortality </text>
<text top="505" left="217" width="109" height="20" font="0">in subjects with DM </text>
<text top="522" left="217" width="118" height="20" font="0">compared to placebo </text>
<text top="541" left="217" width="7" height="18" font="0">•</text>
<text top="540" left="224" width="88" height="20" font="0"> This study was </text>
<text top="558" left="217" width="132" height="20" font="0">originally designed as a </text>
<text top="575" left="217" width="81" height="20" font="0">4-y secondary </text>
<text top="592" left="217" width="133" height="20" font="0">prevention trial but after </text>
<text top="609" left="217" width="131" height="20" font="0">2 y it became a primary </text>
<text top="627" left="217" width="114" height="20" font="0">prevention trial. This </text>
<text top="644" left="217" width="119" height="20" font="0">report focuses on the </text>
<text top="661" left="217" width="126" height="20" font="0">group without baseline </text>
<text top="678" left="217" width="46" height="20" font="0">ASCVD </text>
<text top="695" left="217" width="3" height="20" font="7"><b> </b></text>
<text top="713" left="217" width="71" height="20" font="7"><b>Study type:</b> </text>
<text top="730" left="217" width="113" height="20" font="0">Randomized double-</text>
<text top="747" left="217" width="132" height="20" font="0">blind placebo controlled </text>
<text top="764" left="217" width="64" height="20" font="0">clinical trial </text>
<text top="781" left="217" width="3" height="20" font="0"> </text>
<text top="383" left="368" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="402" left="368" width="7" height="18" font="0">•</text>
<text top="402" left="375" width="142" height="20" font="0"> Men and women 40-75 y </text>
<text top="421" left="368" width="7" height="18" font="0">•</text>
<text top="420" left="375" width="40" height="20" font="0"> T2DM </text>
<text top="439" left="368" width="7" height="18" font="0">•</text>
<text top="438" left="375" width="92" height="20" font="0"> LDL cholesterol </text>
<text top="456" left="368" width="61" height="20" font="0">&lt;160mg/dl </text>
<text top="475" left="368" width="7" height="18" font="0">•</text>
<text top="474" left="375" width="135" height="20" font="0"> Triglyceride &lt;600 mg/dl </text>
<text top="491" left="368" width="3" height="20" font="0"> </text>
<text top="508" left="368" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="527" left="368" width="11" height="18" font="0">• </text>
<text top="527" left="378" width="37" height="20" font="0">T1DM </text>
<text top="546" left="368" width="11" height="18" font="0">• </text>
<text top="545" left="378" width="29" height="20" font="0">CVD </text>
<text top="564" left="368" width="11" height="18" font="0">• </text>
<text top="563" left="378" width="72" height="20" font="0">HbA1c&gt;10% </text>
<text top="582" left="368" width="11" height="18" font="0">• </text>
<text top="581" left="378" width="109" height="20" font="0">hepatic dysfunction </text>
<text top="600" left="368" width="11" height="18" font="0">• </text>
<text top="600" left="378" width="117" height="20" font="0">severe renal disease </text>
<text top="619" left="368" width="11" height="18" font="0">• </text>
<text top="618" left="378" width="75" height="20" font="0">BP &gt;160/100 </text>
<text top="637" left="368" width="11" height="18" font="0">• </text>
<text top="636" left="378" width="49" height="20" font="0">BMI &gt;35 </text>
<text top="655" left="368" width="11" height="18" font="0">• </text>
<text top="654" left="378" width="79" height="20" font="0">alcohol abuse </text>
<text top="673" left="368" width="11" height="18" font="0">• </text>
<text top="673" left="378" width="116" height="20" font="0">&lt;80% placebo run-in </text>
<text top="690" left="378" width="66" height="20" font="0">compliance </text>
<text top="709" left="368" width="11" height="18" font="0">• </text>
<text top="708" left="378" width="123" height="20" font="0">Excluded medications </text>
<text top="725" left="368" width="3" height="20" font="0"> </text>
<text top="742" left="368" width="90" height="20" font="7"><b>Baseline data:</b>  </text>
<text top="761" left="368" width="11" height="18" font="0">• </text>
<text top="761" left="378" width="42" height="20" font="0">Atorva: </text>
<text top="784" left="378" width="9" height="12" font="0">o</text>
<text top="783" left="387" width="4" height="14" font="0"> </text>
<text top="778" left="391" width="95" height="20" font="0">mean age 60.5 y </text>
<text top="383" left="539" width="81" height="20" font="7"><b>Intervention:</b>  </text>
<text top="402" left="539" width="11" height="18" font="0">• </text>
<text top="402" left="550" width="105" height="20" font="0">Atorva 10 mg daily </text>
<text top="419" left="550" width="111" height="20" font="0">(Primary prevention </text>
<text top="436" left="550" width="42" height="20" font="0">n=959) </text>
<text top="459" left="561" width="9" height="12" font="0">o</text>
<text top="458" left="570" width="4" height="14" font="0"> </text>
<text top="453" left="574" width="89" height="20" font="0">Baseline LDL-C </text>
<text top="470" left="574" width="86" height="20" font="0">mg/dl; 114 (26) </text>
<text top="494" left="561" width="9" height="12" font="0">o</text>
<text top="492" left="570" width="4" height="14" font="0"> </text>
<text top="487" left="574" width="109" height="20" font="0">End of treatment % </text>
<text top="505" left="574" width="72" height="20" font="0">change from </text>
<text top="522" left="574" width="88" height="20" font="0">baseline LDL-C </text>
<text top="541" left="539" width="11" height="18" font="0">• </text>
<text top="540" left="550" width="42" height="20" font="0">-30.5% </text>
<text top="557" left="539" width="3" height="20" font="0"> </text>
<text top="575" left="539" width="81" height="20" font="7"><b>Comparator:</b>  </text>
<text top="594" left="539" width="11" height="18" font="0">• </text>
<text top="593" left="566" width="98" height="20" font="0">Placebo (Primary </text>
<text top="610" left="566" width="103" height="20" font="0">prevention n=946) </text>
<text top="634" left="561" width="9" height="12" font="0">o</text>
<text top="632" left="570" width="4" height="14" font="0"> </text>
<text top="627" left="574" width="89" height="20" font="0">Baseline LDL-C </text>
<text top="644" left="574" width="49" height="20" font="0">114 (26) </text>
<text top="668" left="561" width="9" height="12" font="0">o</text>
<text top="667" left="570" width="4" height="14" font="0"> </text>
<text top="662" left="574" width="109" height="20" font="0">End of treatment % </text>
<text top="679" left="574" width="72" height="20" font="0">change from </text>
<text top="696" left="574" width="88" height="20" font="0">baseline LDL-C </text>
<text top="715" left="539" width="11" height="18" font="0">• </text>
<text top="714" left="566" width="36" height="20" font="0">-0.5%<b> </b></text>
<text top="384" left="698" width="79" height="20" font="7"><b>1</b>°<b> endpoint:</b>  </text>
<text top="403" left="695" width="11" height="18" font="0">• </text>
<text top="403" left="708" width="192" height="20" font="0">time to first CVD death, nonfatal or </text>
<text top="420" left="708" width="140" height="20" font="0">silent MI, nonfatal stroke, </text>
<text top="437" left="708" width="169" height="20" font="0">revascularization, resuscitated </text>
<text top="454" left="708" width="172" height="20" font="0">cardiac arrest, unstable angina </text>
<text top="473" left="695" width="11" height="18" font="0">• </text>
<text top="473" left="708" width="190" height="20" font="0">Duration; median duration was 4 y </text>
<text top="490" left="708" width="187" height="20" font="0">overall; mean duration for primary </text>
<text top="507" left="708" width="151" height="20" font="0">prevention group was 2.4 y </text>
<text top="524" left="708" width="165" height="20" font="0">(reflecting change in protocol) </text>
<text top="541" left="698" width="3" height="20" font="0"> </text>
<text top="560" left="698" width="174" height="20" font="7"><b>1</b>°<b> endpoint results:</b> n (rate%) </text>
<text top="577" left="698" width="113" height="20" font="0">Atorva: 100 (10.4%) </text>
<text top="594" left="698" width="122" height="20" font="0">Placebo: 102 (10.8%) </text>
<text top="611" left="698" width="169" height="20" font="0">HR: (0.97; 95% CI: 0.74–1.28) </text>
<text top="629" left="698" width="3" height="20" font="7"><b> </b></text>
<text top="383" left="921" width="177" height="20" font="7"><b>Reasons proposed for lack of </b></text>
<text top="400" left="921" width="113" height="20" font="7"><b>significant benefit: </b></text>
<text top="420" left="921" width="11" height="18" font="0">• </text>
<text top="419" left="931" width="167" height="20" font="0">26.9% drop-in lipid lowering in </text>
<text top="436" left="931" width="81" height="20" font="0">placebo group </text>
<text top="455" left="921" width="11" height="18" font="0">• </text>
<text top="454" left="931" width="168" height="20" font="0">relatively short duration of trial </text>
<text top="473" left="921" width="11" height="18" font="0">• </text>
<text top="472" left="931" width="154" height="20" font="0">lower number of risk factors </text>
<text top="491" left="921" width="11" height="18" font="0">• </text>
<text top="491" left="931" width="174" height="20" font="0">younger cohort than other trials </text>
<text top="510" left="921" width="11" height="18" font="0">• </text>
<text top="509" left="931" width="126" height="20" font="0">requirement that study </text>
<text top="526" left="931" width="180" height="20" font="0">medication be discontinued after </text>
<text top="543" left="931" width="102" height="20" font="0">end point reached </text>
<text top="562" left="921" width="11" height="18" font="0">• </text>
<text top="562" left="931" width="164" height="20" font="0">inclusion of hospitalization for </text>
<text top="579" left="931" width="161" height="20" font="0">angina in endpoint may have </text>
<text top="596" left="931" width="106" height="20" font="0">diluted statin effect </text>
<text top="613" left="921" width="3" height="20" font="7"><b> </b></text>
<text top="630" left="921" width="98" height="20" font="7"><b>Adverse events: </b></text>
<text top="649" left="921" width="11" height="18" font="0">• </text>
<text top="649" left="938" width="86" height="20" font="0">abnormal LFTs </text>
<text top="668" left="921" width="11" height="18" font="0">• </text>
<text top="667" left="938" width="70" height="20" font="0">Atorva 1.4% </text>
<text top="686" left="921" width="11" height="18" font="0">• </text>
<text top="685" left="938" width="79" height="20" font="0">Placebo 1.2% </text>
<text top="704" left="921" width="11" height="18" font="0">• </text>
<text top="703" left="938" width="46" height="20" font="0">myalgia </text>
<text top="722" left="921" width="11" height="18" font="0">• </text>
<text top="722" left="938" width="60" height="20" font="0">Atorva 3% </text>
<text top="740" left="921" width="11" height="18" font="0">• </text>
<text top="740" left="938" width="79" height="20" font="0">Placebo 1.6% </text>
<text top="759" left="921" width="11" height="18" font="0">• </text>
<text top="758" left="938" width="42" height="20" font="0">rhabdo </text>
<text top="777" left="921" width="11" height="18" font="0">• </text>
<text top="776" left="938" width="49" height="20" font="0">Atorva 1 </text>
</page>
<page number="61" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">61 </text>
<text top="107" left="217" width="115" height="20" font="7"><b>Size:</b> 2,410 subjects </text>
<text top="124" left="217" width="113" height="20" font="0">with T2DM. 505 had </text>
<text top="141" left="217" width="128" height="20" font="0">CVD and 1,905 did not </text>
<text top="113" left="378" width="9" height="12" font="0">o</text>
<text top="112" left="387" width="4" height="14" font="0"> </text>
<text top="107" left="392" width="108" height="20" font="0">&gt;65 y n=332 (35%) </text>
<text top="130" left="378" width="9" height="12" font="0">o</text>
<text top="129" left="387" width="4" height="14" font="0"> </text>
<text top="124" left="391" width="118" height="20" font="0">diabetes duration 8 y </text>
<text top="148" left="378" width="9" height="12" font="0">o</text>
<text top="146" left="387" width="4" height="14" font="0"> </text>
<text top="141" left="391" width="105" height="20" font="0">hypertension; 55% </text>
<text top="160" left="368" width="11" height="18" font="0">• </text>
<text top="160" left="378" width="51" height="20" font="0">Placebo: </text>
<text top="179" left="378" width="11" height="18" font="0">• </text>
<text top="178" left="391" width="95" height="20" font="0">mean age 60.4 y </text>
<text top="197" left="378" width="11" height="18" font="0">• </text>
<text top="196" left="392" width="108" height="20" font="0">&gt;65 y n=305 (32%) </text>
<text top="215" left="378" width="11" height="18" font="0">• </text>
<text top="215" left="392" width="90" height="20" font="0">DM duration 8 y </text>
<text top="233" left="378" width="11" height="18" font="0">• </text>
<text top="233" left="392" width="105" height="20" font="0">hypertension; 53% </text>
<text top="109" left="921" width="11" height="18" font="0">• </text>
<text top="108" left="938" width="58" height="20" font="0">Placebo 1 </text>
<text top="251" left="89" width="107" height="20" font="0">de Vries FM, et al., </text>
<text top="268" left="89" width="56" height="20" font="0">2012 <a href="data supplement.html#239">(61)</a> </text>
<text top="285" left="89" width="55" height="20" font="16"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23186103">23186103</a></text>
<text top="285" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23186103"> </a></text>
<text top="251" left="217" width="111" height="20" font="7"><b>Aim:</b> To assess the </text>
<text top="268" left="217" width="131" height="20" font="0">efficacy of statins in the </text>
<text top="285" left="217" width="119" height="20" font="0">primary prevention of </text>
<text top="302" left="217" width="126" height="20" font="0">major ASCVD event in </text>
<text top="319" left="217" width="122" height="20" font="0">patients with diabetes </text>
<text top="337" left="217" width="3" height="20" font="0"> </text>
<text top="354" left="217" width="104" height="20" font="7"><b>Study type:</b> Fixed </text>
<text top="371" left="217" width="136" height="20" font="0">effects meta- analysis of </text>
<text top="388" left="217" width="116" height="20" font="0">4 high quality clinical </text>
<text top="406" left="217" width="90" height="20" font="0">trials comparing </text>
<text top="423" left="217" width="102" height="20" font="0">moderate statin to </text>
<text top="440" left="217" width="118" height="20" font="0">therapy to placebo in </text>
<text top="457" left="217" width="121" height="20" font="0">patients with diabetes </text>
<text top="474" left="217" width="83" height="20" font="0">for the primary </text>
<text top="492" left="217" width="109" height="20" font="0">prevention of major </text>
<text top="509" left="217" width="46" height="20" font="0">ASCVD </text>
<text top="526" left="217" width="3" height="20" font="0"> </text>
<text top="543" left="217" width="125" height="20" font="7"><b>Size:</b> 10,187 subjects, </text>
<text top="560" left="217" width="111" height="20" font="0">5100 on statins and </text>
<text top="578" left="217" width="94" height="20" font="0">5087 on placebo </text>
<text top="251" left="368" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="270" left="368" width="11" height="18" font="0">• </text>
<text top="269" left="385" width="87" height="20" font="0">double-blinded, </text>
<text top="286" left="385" width="100" height="20" font="0">randomized study </text>
<text top="305" left="368" width="11" height="18" font="0">• </text>
<text top="304" left="385" width="140" height="20" font="0">separate data on primary </text>
<text top="321" left="385" width="109" height="20" font="0">prevention subjects </text>
<text top="341" left="368" width="11" height="18" font="0">• </text>
<text top="340" left="385" width="91" height="20" font="0">minimum of 500 </text>
<text top="357" left="385" width="66" height="20" font="0">participants </text>
<text top="376" left="368" width="11" height="18" font="0">• </text>
<text top="375" left="385" width="128" height="20" font="0">mean follow-up of &gt;2 y </text>
<text top="394" left="368" width="11" height="18" font="0">• </text>
<text top="394" left="385" width="113" height="20" font="0">high quality – Jadad </text>
<text top="411" left="385" width="51" height="20" font="0">score &gt;4 </text>
<text top="428" left="368" width="3" height="20" font="0"> </text>
<text top="445" left="368" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="462" left="368" width="145" height="20" font="0">•11 reports were retrieved </text>
<text top="479" left="368" width="158" height="20" font="0">for detailed evaluation and 7 </text>
<text top="497" left="368" width="117" height="20" font="0">were excluded; 2 not </text>
<text top="514" left="368" width="141" height="20" font="0">double-blinded, 2 too few </text>
<text top="531" left="368" width="148" height="20" font="0">subjects, 1 used surrogate </text>
<text top="548" left="368" width="111" height="20" font="0">endpoints, 1 had no </text>
<text top="566" left="368" width="150" height="20" font="0">separate results and 1 was </text>
<text top="583" left="368" width="128" height="20" font="0">in a specific population </text>
<text top="600" left="368" width="149" height="20" font="0">•Trials included were HPS, </text>
<text top="617" left="368" width="145" height="20" font="0">CARDS, ASPEN, ASCOT-</text>
<text top="635" left="368" width="25" height="20" font="0">LLA </text>
<text top="652" left="368" width="126" height="20" font="0">•Baseline data in the 4 </text>
<text top="669" left="368" width="33" height="20" font="0">trials: </text>
<text top="688" left="368" width="11" height="18" font="0">• </text>
<text top="687" left="378" width="146" height="20" font="0">Men; 77%, 62%, 68%, NR </text>
<text top="706" left="368" width="11" height="18" font="0">• </text>
<text top="705" left="378" width="144" height="20" font="0">Mean age; 60, 62, 64, NR </text>
<text top="724" left="368" width="11" height="18" font="0">• </text>
<text top="724" left="378" width="133" height="20" font="0">HTN%; 52, 84, 100, NR </text>
<text top="743" left="368" width="11" height="18" font="0">• </text>
<text top="742" left="378" width="145" height="20" font="0">Smokers; 20.4, 12, 23 NR </text>
<text top="761" left="368" width="11" height="18" font="0">• </text>
<text top="760" left="378" width="137" height="20" font="0">Mean LDL-C mmol/l 3.3, </text>
<text top="777" left="378" width="69" height="20" font="0">2.9, 3.0, NR </text>
<text top="251" left="539" width="81" height="20" font="7"><b>Intervention:</b>  </text>
<text top="268" left="539" width="126" height="20" font="0"> Statin; n=5100 (simva </text>
<text top="285" left="539" width="122" height="20" font="0">40mg daily in 1 study, </text>
<text top="302" left="539" width="138" height="20" font="0">atorva 10mg in 3 studies </text>
<text top="319" left="539" width="3" height="20" font="0"> </text>
<text top="337" left="539" width="81" height="20" font="7"><b>Comparator:</b>  </text>
<text top="354" left="539" width="96" height="20" font="0">Placebo; n=5087 </text>
<text top="371" left="539" width="130" height="20" font="0">Mean(range) follow-up; </text>
<text top="388" left="539" width="80" height="20" font="0">3.8 (2.4-4.8) y<b> </b></text>
<text top="252" left="698" width="79" height="20" font="7"><b>1</b>°<b> endpoint:</b>  </text>
<text top="269" left="698" width="145" height="20" font="0">•Major cardiovascular and </text>
<text top="286" left="698" width="138" height="20" font="0">cerebrovascular events;  </text>
<text top="303" left="698" width="85" height="20" font="0">•Results: n (%) </text>
<text top="321" left="698" width="98" height="20" font="0">Statin 434 (8.5%) </text>
<text top="338" left="698" width="118" height="20" font="0">Placebo 576 (11.3%) </text>
<text top="355" left="698" width="185" height="20" font="0">RR: 0.75; 95% CI: 0.67–0.85; 3/4 </text>
<text top="372" left="698" width="131" height="20" font="0">studies were significant </text>
<text top="390" left="698" width="180" height="20" font="0">•NNT/3.8 y; 35; (95% CI: 25–58) </text>
<text top="407" left="698" width="3" height="20" font="7"><b> </b></text>
<text top="251" left="921" width="86" height="20" font="7"><b>2° endpoints:  </b></text>
<text top="270" left="921" width="11" height="18" font="0">• </text>
<text top="269" left="948" width="163" height="20" font="0">-Fatal/non-fatal stroke events </text>
<text top="286" left="948" width="83" height="20" font="0">(n) (3 studies)  </text>
<text top="305" left="921" width="11" height="18" font="0">• </text>
<text top="304" left="948" width="52" height="20" font="0">Statin 75 </text>
<text top="323" left="921" width="11" height="18" font="0">• </text>
<text top="323" left="948" width="72" height="20" font="0">Placebo 109 </text>
<text top="342" left="921" width="11" height="18" font="0">• </text>
<text top="341" left="948" width="118" height="20" font="0">RR 0.69 (0.51–0.92)  </text>
<text top="360" left="921" width="11" height="18" font="0">• </text>
<text top="359" left="948" width="122" height="20" font="0">NNT 0.69 (0.51–0.92) </text>
<text top="378" left="921" width="11" height="18" font="0">• </text>
<text top="377" left="948" width="157" height="20" font="0">Fatal/non-fatal MI events (n) </text>
<text top="395" left="948" width="64" height="20" font="0">(3 studies)  </text>
<text top="414" left="921" width="11" height="18" font="0">• </text>
<text top="413" left="948" width="52" height="20" font="0">Statin 99 </text>
<text top="432" left="921" width="11" height="18" font="0">• </text>
<text top="431" left="948" width="72" height="20" font="0">Placebo 141 </text>
<text top="450" left="921" width="11" height="18" font="0">• </text>
<text top="449" left="948" width="115" height="20" font="0">RR 0.70 (0.54–0.90) </text>
<text top="468" left="921" width="11" height="18" font="0">• </text>
<text top="468" left="948" width="98" height="20" font="0">NNT 86 (50–290) </text>
<text top="486" left="921" width="11" height="18" font="0">• </text>
<text top="486" left="948" width="162" height="20" font="0">All-cause mortality events (n) </text>
<text top="503" left="948" width="64" height="20" font="0">(2 studies)  </text>
<text top="522" left="921" width="11" height="18" font="0">• </text>
<text top="521" left="948" width="59" height="20" font="0">Statin 105 </text>
<text top="540" left="921" width="11" height="18" font="0">• </text>
<text top="539" left="948" width="72" height="20" font="0">Placebo 123 </text>
<text top="558" left="921" width="11" height="18" font="0">• </text>
<text top="558" left="948" width="115" height="20" font="0">RR 0.84 (0.65–1.09) </text>
<text top="577" left="921" width="11" height="18" font="0">• </text>
<text top="576" left="948" width="53" height="20" font="0">NNT 130 </text>
<text top="593" left="921" width="3" height="20" font="0"> </text>
<text top="610" left="921" width="73" height="20" font="7"><b>Limitations: </b></text>
<text top="629" left="921" width="11" height="18" font="0">• </text>
<text top="629" left="931" width="169" height="20" font="0">differences between studies in </text>
<text top="646" left="931" width="171" height="20" font="0">endpoints although these were </text>
<text top="663" left="931" width="34" height="20" font="0">minor </text>
<text top="682" left="921" width="11" height="18" font="0">• </text>
<text top="681" left="931" width="186" height="20" font="0">included some subjects with CVD </text>
<text top="698" left="931" width="128" height="20" font="0">(~12% in ASCOT-LLA) </text>
<text top="717" left="921" width="11" height="18" font="0">• </text>
<text top="717" left="931" width="163" height="20" font="0">diagnostic criteria of diabetes </text>
<text top="734" left="931" width="44" height="20" font="0">differed </text>
<text top="753" left="921" width="11" height="18" font="0">• </text>
<text top="752" left="931" width="148" height="20" font="0">differences in baseline risk </text>
<text top="771" left="921" width="11" height="18" font="0">• </text>
<text top="770" left="931" width="180" height="20" font="0">in HPS and ASCOT-LLA subject </text>
<text top="787" left="931" width="170" height="20" font="0">with diabetes were a subgroup </text>
</page>
<page number="62" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">62 </text>
<text top="109" left="921" width="11" height="18" font="0">• </text>
<text top="108" left="931" width="166" height="20" font="0">Drop-in statin used in placebo </text>
<text top="125" left="931" width="44" height="20" font="0">groups. </text>
<text top="150" left="89" width="55" height="20" font="7"><b>JUPITER </b></text>
<text top="167" left="89" width="98" height="20" font="0">Ridker PM, et al., </text>
<text top="184" left="89" width="56" height="20" font="0">2008 <a href="data supplement.html#236">(11)</a> </text>
<text top="201" left="89" width="55" height="20" font="16"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18997196">18997196</a></text>
<text top="201" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18997196"> </a></text>
<text top="150" left="217" width="111" height="20" font="7"><b>Aim: </b>To investigate </text>
<text top="167" left="217" width="128" height="20" font="0">whether treatment with </text>
<text top="184" left="217" width="111" height="20" font="0">rosuvastatin, 20 mg </text>
<text top="201" left="217" width="133" height="20" font="0">daily vs. placebo, would </text>
<text top="219" left="217" width="106" height="20" font="0">decrease MACE in </text>
<text top="236" left="217" width="104" height="20" font="0">apparently healthy </text>
<text top="253" left="217" width="121" height="20" font="0">persons with levels of </text>
<text top="270" left="217" width="116" height="20" font="0">LDL-C below current </text>
<text top="287" left="217" width="136" height="20" font="0">treatment thresholds but </text>
<text top="305" left="217" width="102" height="20" font="0">with elevated high-</text>
<text top="322" left="217" width="111" height="20" font="0">sensitivity (hs) CRP<b> </b></text>
<text top="339" left="217" width="3" height="20" font="7"><b> </b></text>
<text top="356" left="217" width="70" height="20" font="7"><b>Study type: </b></text>
<text top="373" left="217" width="113" height="20" font="0">Randomized double-</text>
<text top="391" left="217" width="132" height="20" font="0">blind placebo controlled </text>
<text top="408" left="217" width="64" height="20" font="0">clinical trial<b> </b></text>
<text top="425" left="217" width="3" height="20" font="7"><b> </b></text>
<text top="442" left="217" width="122" height="20" font="7"><b>Size: </b>17,802 subjects<b> </b></text>
<text top="150" left="368" width="109" height="20" font="7"><b>Inclusion criteria:  </b></text>
<text top="169" left="368" width="11" height="18" font="0">• </text>
<text top="168" left="385" width="104" height="20" font="0">Age: men &gt;50 and </text>
<text top="185" left="385" width="77" height="20" font="0">women &gt;60 y </text>
<text top="204" left="368" width="11" height="18" font="0">• </text>
<text top="203" left="385" width="100" height="20" font="0">LDL-C&lt;130 mg/dl </text>
<text top="222" left="368" width="11" height="18" font="0">• </text>
<text top="222" left="385" width="86" height="20" font="0">hsCRP &gt;2 mg/l </text>
<text top="241" left="368" width="11" height="18" font="0">• </text>
<text top="240" left="385" width="124" height="20" font="0">triglyceride&lt;500 mg/dl </text>
<text top="257" left="368" width="3" height="20" font="7"><b> </b></text>
<text top="274" left="368" width="114" height="20" font="7"><b>Exclusion criteria:  </b></text>
<text top="293" left="368" width="11" height="18" font="0">• </text>
<text top="293" left="385" width="86" height="20" font="0">history of CVD  </text>
<text top="312" left="368" width="11" height="18" font="0">• </text>
<text top="311" left="385" width="50" height="20" font="0">diabetes </text>
<text top="330" left="368" width="11" height="18" font="0">• </text>
<text top="329" left="385" width="109" height="20" font="0">past or current lipid-</text>
<text top="346" left="385" width="94" height="20" font="0">lowering therapy </text>
<text top="365" left="368" width="11" height="18" font="0">• </text>
<text top="364" left="385" width="127" height="20" font="0">PMP hormone therapy </text>
<text top="383" left="368" width="11" height="18" font="0">• </text>
<text top="383" left="385" width="76" height="20" font="0">ALT&gt;2X ULN </text>
<text top="402" left="368" width="11" height="18" font="0">• </text>
<text top="401" left="385" width="79" height="20" font="0">CPK&gt;3X ULN </text>
<text top="420" left="368" width="11" height="18" font="0">• </text>
<text top="419" left="385" width="87" height="20" font="0">SCr ±2.0 mg/dl </text>
<text top="438" left="368" width="11" height="18" font="0">• </text>
<text top="437" left="385" width="99" height="20" font="0">uncontrolled HTN </text>
<text top="456" left="368" width="11" height="18" font="0">• </text>
<text top="456" left="385" width="40" height="20" font="0">cancer </text>
<text top="475" left="368" width="11" height="18" font="0">• </text>
<text top="474" left="385" width="104" height="20" font="0">inflammatory state </text>
<text top="493" left="368" width="11" height="18" font="0">• </text>
<text top="492" left="385" width="86" height="20" font="0">hypothyroidism </text>
<text top="511" left="368" width="11" height="18" font="0">• </text>
<text top="510" left="385" width="96" height="20" font="0">substance abuse </text>
<text top="528" left="368" width="3" height="20" font="0"> </text>
<text top="545" left="368" width="148" height="20" font="7"><b>Baseline characteristics: </b></text>
<text top="564" left="368" width="11" height="18" font="0">• </text>
<text top="563" left="385" width="94" height="20" font="0">mean [IQR] age; </text>
<text top="582" left="368" width="11" height="18" font="0">• </text>
<text top="581" left="385" width="68" height="20" font="0">66 [60-71] y </text>
<text top="600" left="368" width="11" height="18" font="0">• </text>
<text top="600" left="385" width="92" height="20" font="0">females 38-39% </text>
<text top="618" left="368" width="11" height="18" font="0">• </text>
<text top="618" left="385" width="135" height="20" font="0">Metabolic syndrome (41-</text>
<text top="635" left="385" width="32" height="20" font="0">42%) </text>
<text top="654" left="368" width="11" height="18" font="0">• </text>
<text top="653" left="385" width="131" height="20" font="0">mean LDL-C 108 mg/dl </text>
<text top="150" left="539" width="81" height="20" font="7"><b>Intervention:  </b></text>
<text top="167" left="539" width="144" height="20" font="0"> Rosuvastatin 20 mg daily </text>
<text top="184" left="539" width="49" height="20" font="0">-n=8901 </text>
<text top="201" left="539" width="142" height="20" font="0">-median [IQR] 1 y LDL-C; </text>
<text top="219" left="539" width="92" height="20" font="0">55 [44-72] mg/dl </text>
<text top="236" left="539" width="109" height="20" font="0">- 50% reduction vs. </text>
<text top="253" left="539" width="46" height="20" font="0">placebo </text>
<text top="270" left="539" width="3" height="20" font="7"><b> </b></text>
<text top="287" left="539" width="130" height="20" font="7"><b>Comparator: </b>Matching </text>
<text top="305" left="539" width="46" height="20" font="0">placebo </text>
<text top="322" left="539" width="48" height="20" font="0">n=8901  </text>
<text top="339" left="539" width="142" height="20" font="0">-median [IQR] 1 y LDL-C; </text>
<text top="356" left="539" width="106" height="20" font="0">110 [94-125] mg/dl </text>
<text top="151" left="698" width="79" height="20" font="7"><b>1</b>°<b> endpoint: </b> </text>
<text top="168" left="698" width="188" height="20" font="0">•Median follow-up 1.9 y; the study </text>
<text top="185" left="698" width="187" height="20" font="0">ended early because efficacy had </text>
<text top="202" left="698" width="55" height="20" font="0">been met </text>
<text top="220" left="698" width="195" height="20" font="0">•Primary endpoint: first nonfatal MI, </text>
<text top="237" left="698" width="191" height="20" font="0">non-fatal stroke, hospitalization for </text>
<text top="254" left="698" width="207" height="20" font="0">unstable angina, revascularization, or </text>
<text top="271" left="698" width="67" height="20" font="0">CVD death. </text>
<text top="289" left="698" width="48" height="20" font="0">Results: </text>
<text top="308" left="698" width="11" height="18" font="0">• </text>
<text top="307" left="708" width="97" height="20" font="0">n (rate/100pt.yrs) </text>
<text top="324" left="698" width="105" height="20" font="0">Rosuva 142 (0.77) </text>
<text top="341" left="698" width="107" height="20" font="0">Placebo 251 (1.36) </text>
<text top="358" left="698" width="167" height="20" font="0">HR: 0.56 ; 95% CI: 0.46–0.69; </text>
<text top="376" left="698" width="55" height="20" font="0">p&lt;0.0001 </text>
<text top="393" left="698" width="3" height="20" font="7"><b> </b></text>
<text top="150" left="921" width="173" height="20" font="7"><b>2° Endpoint n (rate/100pt.yr): </b></text>
<text top="169" left="921" width="11" height="18" font="0">• </text>
<text top="168" left="938" width="17" height="20" font="0">MI </text>
<text top="191" left="938" width="9" height="12" font="0">o</text>
<text top="190" left="947" width="4" height="14" font="0"> </text>
<text top="185" left="958" width="98" height="20" font="0">Rosuva 31 (0.17) </text>
<text top="209" left="938" width="9" height="12" font="0">o</text>
<text top="207" left="947" width="4" height="14" font="0"> </text>
<text top="202" left="958" width="101" height="20" font="0">Placebo 68 (0.37) </text>
<text top="226" left="938" width="9" height="12" font="0">o</text>
<text top="225" left="947" width="4" height="14" font="0"> </text>
<text top="220" left="958" width="113" height="20" font="0">HR: 0.46;0.30–0.70; </text>
<text top="237" left="958" width="55" height="20" font="0">p=0.0002 </text>
<text top="256" left="921" width="11" height="18" font="0">• </text>
<text top="255" left="938" width="39" height="20" font="0">Stroke </text>
<text top="278" left="938" width="9" height="12" font="0">o</text>
<text top="277" left="947" width="4" height="14" font="0"> </text>
<text top="272" left="958" width="98" height="20" font="0">Rosuva 33 (0.18) </text>
<text top="296" left="938" width="9" height="12" font="0">o</text>
<text top="294" left="947" width="4" height="14" font="0"> </text>
<text top="289" left="958" width="101" height="20" font="0">Placebo 64 (0.34) </text>
<text top="313" left="938" width="9" height="12" font="0">o</text>
<text top="312" left="947" width="4" height="14" font="0"> </text>
<text top="307" left="958" width="133" height="20" font="0">HR: 0.52; 95% CI: 0.34–</text>
<text top="324" left="958" width="79" height="20" font="0">0.79; p=0.002 </text>
<text top="343" left="921" width="11" height="18" font="0">• </text>
<text top="342" left="938" width="100" height="20" font="0">Revascularization </text>
<text top="366" left="938" width="9" height="12" font="0">o</text>
<text top="364" left="947" width="4" height="14" font="0"> </text>
<text top="359" left="958" width="98" height="20" font="0">Rosuva 71 (0.38) </text>
<text top="383" left="938" width="9" height="12" font="0">o</text>
<text top="382" left="947" width="4" height="14" font="0"> </text>
<text top="377" left="958" width="107" height="20" font="0">Placebo 131 (0.71) </text>
<text top="400" left="938" width="9" height="12" font="0">o</text>
<text top="399" left="947" width="4" height="14" font="0"> </text>
<text top="394" left="958" width="133" height="20" font="0">HR: 0.54; 95% CI: 0.41–</text>
<text top="411" left="958" width="86" height="20" font="0">0.72; p&lt;0.0001 </text>
<text top="430" left="921" width="11" height="18" font="0">• </text>
<text top="429" left="938" width="36" height="20" font="0">Death </text>
<text top="453" left="938" width="9" height="12" font="0">o</text>
<text top="451" left="947" width="4" height="14" font="0"> </text>
<text top="446" left="958" width="105" height="20" font="0">Rosuva 198 (1.00) </text>
<text top="470" left="938" width="9" height="12" font="0">o</text>
<text top="469" left="947" width="4" height="14" font="0"> </text>
<text top="464" left="958" width="107" height="20" font="0">Placebo 247 (1.25) </text>
<text top="487" left="938" width="9" height="12" font="0">o</text>
<text top="486" left="947" width="4" height="14" font="0"> </text>
<text top="481" left="958" width="130" height="20" font="0">HR: 0.80; 95% CI: 0.67-</text>
<text top="498" left="958" width="72" height="20" font="0">0.97; p&lt;0.02 </text>
<text top="515" left="921" width="3" height="20" font="0"> </text>
<text top="532" left="921" width="128" height="20" font="7"><b>Adverse events n(%): </b></text>
<text top="551" left="921" width="11" height="18" font="0">• </text>
<text top="551" left="938" width="102" height="20" font="0">Muscle symptoms </text>
<text top="570" left="921" width="11" height="18" font="0">• </text>
<text top="569" left="938" width="111" height="20" font="0">Rosuva 1421 (16.0) </text>
<text top="588" left="921" width="11" height="18" font="0">• </text>
<text top="587" left="938" width="156" height="20" font="0">Placebo 1375 (15.4) p=0.34 </text>
<text top="606" left="921" width="11" height="18" font="0">• </text>
<text top="605" left="938" width="76" height="20" font="0">ALT &gt;3XULN </text>
<text top="624" left="921" width="11" height="18" font="0">• </text>
<text top="624" left="938" width="111" height="20" font="0">Rosuva 23 (0.3) 17  </text>
<text top="643" left="921" width="11" height="18" font="0">• </text>
<text top="642" left="938" width="135" height="20" font="0">Placebo 17 (0.2) p=0.34 </text>
<text top="661" left="921" width="11" height="18" font="0">• </text>
<text top="660" left="938" width="78" height="20" font="0">New diabetes </text>
<text top="679" left="921" width="11" height="18" font="0">• </text>
<text top="678" left="938" width="101" height="20" font="0">Rosuva 270 (3.0)  </text>
<text top="697" left="921" width="11" height="18" font="0">• </text>
<text top="697" left="938" width="142" height="20" font="0">Placebo 216 (2.4) p&lt;0.01 </text>
<text top="714" left="921" width="3" height="20" font="0"> </text>
<text top="731" left="921" width="73" height="20" font="7"><b>Limitations: </b></text>
<text top="750" left="921" width="11" height="18" font="0">• </text>
<text top="749" left="938" width="139" height="20" font="0">Non-diabetic participants </text>
<text top="768" left="921" width="11" height="18" font="0">• </text>
<text top="767" left="938" width="167" height="20" font="0">age restricted to men &gt;50 and </text>
<text top="785" left="938" width="77" height="20" font="0">women &gt;60 y </text>
</page>
<page number="63" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">63 </text>
<text top="112" left="81" width="5" height="15" font="5"><b> </b></text>
<text top="106" left="297" width="4" height="22" font="5"><b> </b></text>
</page>
<page number="64" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">64 </text>
<text top="106" left="81" width="1002" height="24" font="4"><b>Data Supplement 13. Nonrandomized Trials, Observational Studies, and/or Registries of ASCVD Risk Associated with the Metabolic Syndrome </b></text>
<text top="127" left="81" width="104" height="24" font="4"><b>(Section 4.4.1) </b></text>
<text top="148" left="121" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="166" left="147" width="48" height="20" font="7"><b>Author; </b></text>
<text top="183" left="124" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="157" left="280" width="118" height="20" font="7"><b>Study Type/Design; </b></text>
<text top="174" left="306" width="66" height="20" font="7"><b>Study Size </b></text>
<text top="166" left="458" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="157" left="647" width="179" height="20" font="7"><b>Primary Endpoint and Results </b></text>
<text top="174" left="644" width="184" height="20" font="7"><b>(P values; OR or RR; &amp; 95% CI) </b></text>
<text top="157" left="931" width="130" height="20" font="7"><b>Summary/Conclusion </b></text>
<text top="174" left="958" width="75" height="20" font="7"><b>Comment(s) </b></text>
<text top="201" left="91" width="149" height="20" font="0">Gami AS, et al., 2007 <a href="data supplement.html#239">(62)</a>  </text>
<text top="218" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17258085">17258085</a></text>
<text top="218" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17258085"> </a></text>
<text top="201" left="263" width="134" height="20" font="7"><b>Study type:</b> Systematic </text>
<text top="218" left="263" width="148" height="20" font="0">Review and Meta-Analysis </text>
<text top="235" left="263" width="3" height="20" font="0"> </text>
<text top="252" left="263" width="117" height="20" font="7"><b>Size:</b> 43 cohorts and </text>
<text top="270" left="263" width="68" height="20" font="0">172,573 pts </text>
<text top="201" left="428" width="156" height="20" font="7"><b>Inclusion criteria:</b> Included </text>
<text top="218" left="428" width="163" height="20" font="0">only prospective studies, with </text>
<text top="235" left="428" width="139" height="20" font="0">assessment of metabolic </text>
<text top="252" left="428" width="152" height="20" font="0">syndrome and follow-up for </text>
<text top="270" left="428" width="112" height="20" font="0">CV events or death  </text>
<text top="287" left="428" width="3" height="20" font="0"> </text>
<text top="304" left="428" width="170" height="20" font="7"><b>Exclusion criteria:</b> see above </text>
<text top="202" left="613" width="234" height="20" font="7"><b>1</b>°<b> endpoint:</b> Composite of cardiovascular </text>
<text top="219" left="613" width="242" height="20" font="0">events and death; also, individual endpoints </text>
<text top="236" left="613" width="174" height="20" font="0">of CV events and total mortality </text>
<text top="254" left="613" width="3" height="20" font="0"> </text>
<text top="271" left="613" width="228" height="20" font="7"><b>Results:</b> Metabolic syndrome associated </text>
<text top="288" left="613" width="237" height="20" font="0">with RR of 1.78 (95% CI: 1.58-2.00) for the </text>
<text top="305" left="613" width="230" height="20" font="0">primary outcome; RR: 2.18 (95% CI: 1.63-</text>
<text top="322" left="613" width="240" height="20" font="0">2.93) for CV events; and RR: 1.60 (95% CI: </text>
<text top="340" left="613" width="157" height="20" font="0">1.37-1.92) for total mortality  </text>
<text top="357" left="613" width="3" height="20" font="0"> </text>
<text top="203" left="874" width="7" height="18" font="0">•</text>
<text top="202" left="881" width="228" height="20" font="0"> Demonstrates clear association between </text>
<text top="219" left="874" width="230" height="20" font="0">metabolic syndrome and increased risk of </text>
<text top="236" left="874" width="143" height="20" font="0">CVD events and mortality </text>
<text top="254" left="874" width="3" height="20" font="0"> </text>
<text top="273" left="874" width="7" height="18" font="0">•</text>
<text top="272" left="881" width="205" height="20" font="0"> Trend towards stronger associations </text>
<text top="289" left="874" width="214" height="20" font="0">among women than men (RR: 2.63 vs. </text>
<text top="306" left="874" width="76" height="20" font="0">1.98; p=0.09) </text>
<text top="324" left="874" width="3" height="20" font="0"> </text>
<text top="341" left="874" width="3" height="20" font="0"> </text>
<text top="360" left="874" width="7" height="18" font="0">•</text>
<text top="359" left="881" width="231" height="20" font="0"> Stronger associations in lower (&lt;10% ten </text>
<text top="376" left="874" width="219" height="20" font="0">y risk) than higher risk populations (RR: </text>
<text top="394" left="874" width="123" height="20" font="0">1.96 vs. 1.43; p=0.04) </text>
<text top="411" left="874" width="3" height="20" font="0"> </text>
<text top="430" left="874" width="7" height="18" font="0">•</text>
<text top="429" left="881" width="225" height="20" font="0"> Persistent association after adjusting for </text>
<text top="446" left="874" width="231" height="20" font="0">traditional cardiovascular risk factors (RR: </text>
<text top="464" left="874" width="141" height="20" font="0">1.54; 95% CI: 1.32-1.79)  </text>
<text top="481" left="874" width="3" height="20" font="0"> </text>
<text top="499" left="91" width="118" height="20" font="0">Galassi A et al., <a href="data supplement.html#239">(63)</a>  </text>
<text top="516" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17000207">17000207</a></text>
<text top="516" left="146" width="3" height="20" font="11"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17000207"> </a></text>
<text top="533" left="91" width="3" height="20" font="0"> </text>
<text top="499" left="263" width="150" height="20" font="7"><b>Study type:</b> Meta-analysis </text>
<text top="516" left="263" width="3" height="20" font="0"> </text>
<text top="533" left="263" width="95" height="20" font="7"><b>Size:</b> 21 studies  </text>
<text top="499" left="428" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="516" left="428" width="3" height="20" font="0"> </text>
<text top="533" left="428" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="500" left="613" width="238" height="20" font="7"><b>1</b>°<b> endpoint:</b> CVD mortality, total mortality, </text>
<text top="517" left="613" width="224" height="20" font="0">incident CVD, incident CHD and incident </text>
<text top="534" left="613" width="40" height="20" font="0">stroke  </text>
<text top="551" left="613" width="3" height="20" font="0"> </text>
<text top="569" left="613" width="228" height="20" font="7"><b>Results:</b> Metabolic syndrome associated </text>
<text top="586" left="613" width="223" height="20" font="0">with increased risk for all outcomes: RR: </text>
<text top="603" left="613" width="239" height="20" font="0">1.74 for CVD mortality (95% CI: 1.29-2.35); </text>
<text top="620" left="613" width="222" height="20" font="0">RR 1.35 for total mortality (95% CI: 1.17-</text>
<text top="638" left="613" width="231" height="20" font="0">1.56); RR: 1.53 for incident CVD (95% CI: </text>
<text top="655" left="613" width="240" height="20" font="0">1.26-1.87); RR: 1.52 for incident CHD (95% </text>
<text top="672" left="613" width="222" height="20" font="0">CI: 1.37-1.69); and RR: 1.76 for incident </text>
<text top="689" left="613" width="148" height="20" font="0">stroke (95% CI: 1.37-2.25) </text>
<text top="501" left="874" width="7" height="18" font="0">•</text>
<text top="500" left="881" width="226" height="20" font="0"> Metabolic syndrome strongly associated </text>
<text top="517" left="874" width="224" height="20" font="0">with incident CVD, CVD mortality and all-</text>
<text top="534" left="874" width="86" height="20" font="0">cause mortality </text>
<text top="551" left="874" width="3" height="20" font="0"> </text>
<text top="571" left="874" width="7" height="18" font="0">•</text>
<text top="570" left="881" width="219" height="20" font="0"> Stronger risk associations seen among </text>
<text top="587" left="874" width="237" height="20" font="0">women (RR: 2.10; 95% CI: 1.79-2.45) than </text>
<text top="604" left="874" width="242" height="20" font="0">men (RR: 1.57; 95% CI: 1.41-1.75); no p for </text>
<text top="622" left="874" width="109" height="20" font="0">interaction reported </text>
<text top="639" left="874" width="3" height="20" font="0"> </text>
<text top="713" left="81" width="5" height="16" font="15"> </text>
<text top="734" left="81" width="5" height="16" font="15"> </text>
</page>
<page number="65" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="17" size="12" family="Times" color="#1a1919"/>
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">65 </text>
<text top="106" left="81" width="1012" height="24" font="4"><b>Data Supplement 14. Nonrandomized Trials, Observational Studies, and/or Registries of Q1: Performance of the Pooled Cohort Equations (PCE) </b></text>
<text top="127" left="81" width="991" height="24" font="4"><b>when used for the prediction of first incident atherosclerotic cardiovascular disease (ASCVD) events in diverse populations (Section 4.4.1.2)  </b></text>
<text top="148" left="102" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="166" left="128" width="48" height="20" font="7"><b>Author; </b></text>
<text top="183" left="105" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="148" left="234" width="118" height="20" font="7"><b>Study Type/Design; </b></text>
<text top="166" left="261" width="66" height="20" font="7"><b>Study Size </b></text>
<text top="148" left="400" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="148" left="612" width="179" height="20" font="7"><b>Primary Endpoint and Results </b></text>
<text top="166" left="609" width="184" height="20" font="7"><b>(P values; OR or RR; &amp; 95% CI) </b></text>
<text top="148" left="919" width="130" height="20" font="7"><b>Summary/Conclusion </b></text>
<text top="166" left="947" width="75" height="20" font="7"><b>Comment(s) </b></text>
<text top="201" left="91" width="112" height="20" font="7"><b>Framingham Heart </b></text>
<text top="218" left="91" width="115" height="20" font="7"><b>Study </b>Andersson C, </text>
<text top="235" left="91" width="90" height="20" font="0">et al., 2015<a href="data supplement.html#239"> (64)</a> </text>
<text top="253" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25888372">25888372</a></text>
<text top="253" left="145" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25888372"> </a></text>
<text top="201" left="225" width="71" height="20" font="7"><b>Study type:</b> </text>
<text top="218" left="225" width="67" height="20" font="0">Prospective </text>
<text top="235" left="225" width="120" height="20" font="0">Observational Cohort </text>
<text top="253" left="225" width="33" height="20" font="0">study </text>
<text top="270" left="225" width="3" height="20" font="0"> </text>
<text top="287" left="225" width="129" height="20" font="7"><b>Size:</b> 7234 participants </text>
<text top="304" left="225" width="133" height="20" font="0">in the U.S. Framingham </text>
<text top="321" left="225" width="121" height="20" font="0">Heart Study Offspring </text>
<text top="339" left="225" width="40" height="20" font="0">Cohort </text>
<text top="201" left="375" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="220" left="375" width="7" height="18" font="0">•</text>
<text top="219" left="381" width="149" height="20" font="0"> Age 40 to 75 y at baseline </text>
<text top="238" left="375" width="7" height="18" font="0">•</text>
<text top="238" left="381" width="155" height="20" font="0"> Absence of clinical ASCVD </text>
<text top="257" left="375" width="7" height="18" font="0">•</text>
<text top="256" left="381" width="85" height="20" font="0"> Participants of </text>
<text top="273" left="375" width="141" height="20" font="0">Framingham Heart Study </text>
<text top="290" left="375" width="135" height="20" font="0">Offspring Cohort cycle 1 </text>
<text top="308" left="375" width="132" height="20" font="0">(1971– 1975), 3 (1983– </text>
<text top="325" left="375" width="129" height="20" font="0">1987), and/or 6 (1995– </text>
<text top="342" left="375" width="35" height="20" font="0">1998) </text>
<text top="359" left="375" width="3" height="20" font="0"> </text>
<text top="376" left="375" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="395" left="375" width="7" height="18" font="0">•</text>
<text top="395" left="381" width="127" height="20" font="0"> Prevalent MI or stroke </text>
<text top="412" left="375" width="122" height="20" font="0">(recognized or silent)  </text>
<text top="431" left="375" width="7" height="18" font="0">•</text>
<text top="430" left="381" width="135" height="20" font="0"> Missing values of blood </text>
<text top="448" left="375" width="128" height="20" font="0">pressure, treatment for </text>
<text top="465" left="375" width="140" height="20" font="0">hypertension, cholesterol </text>
<text top="482" left="375" width="120" height="20" font="0">values, diabetes, and </text>
<text top="499" left="375" width="53" height="20" font="0">smoking  </text>
<text top="518" left="375" width="7" height="18" font="0">•</text>
<text top="518" left="381" width="145" height="20" font="0"> Lipid-lowering medication </text>
<text top="535" left="375" width="86" height="20" font="0">use at baseline<b> </b></text>
<text top="202" left="550" width="296" height="20" font="7"><b>1</b>°<b> endpoint:</b>  New-onset ASCVD, defined as incident </text>
<text top="219" left="550" width="256" height="20" font="0">MI, nonfatal or fatal ischemic stroke (excluding </text>
<text top="236" left="550" width="283" height="20" font="0">transient ischemic attack), or death due to coronary </text>
<text top="254" left="550" width="84" height="20" font="0">artery disease; </text>
<text top="271" left="550" width="171" height="20" font="0">Median duration follow-up 10 y </text>
<text top="288" left="550" width="3" height="20" font="0"> </text>
<text top="305" left="550" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="324" left="549" width="11" height="18" font="0">• </text>
<text top="324" left="563" width="283" height="20" font="0">284 incident ASCVD events (8.4%) in men and 112 </text>
<text top="341" left="563" width="129" height="20" font="0">events (3%) in women. </text>
<text top="360" left="549" width="11" height="18" font="0">• </text>
<text top="359" left="563" width="282" height="20" font="0">Hosmer–Lemeshow chi-square statistics were 16.3 </text>
<text top="376" left="563" width="284" height="20" font="0">in men (340 predicted versus 285 observed events) </text>
<text top="393" left="563" width="253" height="20" font="0">and 29.1 in women (166 predicted versus 112 </text>
<text top="411" left="563" width="101" height="20" font="0">observed events). </text>
<text top="430" left="549" width="11" height="18" font="0">• </text>
<text top="429" left="563" width="257" height="20" font="0">Overprediction predominantly occurred among </text>
<text top="446" left="563" width="283" height="20" font="0">women in the highest risk decile and among men in </text>
<text top="463" left="563" width="273" height="20" font="0">the ≥ 7th risk deciles, for which observed ASCVD </text>
<text top="480" left="563" width="141" height="20" font="0">event rates were ≥ 7.5%. </text>
<text top="499" left="549" width="11" height="18" font="0">• </text>
<text top="499" left="563" width="288" height="20" font="17">Assessed by PCE, 36% had estimated ASCVD risks </text>
<text top="516" left="563" width="289" height="20" font="17">≥7.5% (or diabetes) and LDL-C ≥70 mg/dL and thus </text>
<text top="533" left="563" width="280" height="20" font="17">were eligible for statins. In contrast, only 24% were </text>
<text top="550" left="563" width="275" height="20" font="17">eligible according to ATP III guidelines, translating </text>
<text top="568" left="563" width="266" height="20" font="17">into a net overall 51% increase (59% increase in </text>
<text top="585" left="563" width="236" height="20" font="0">women and 47% increase in men for statin </text>
<text top="602" left="563" width="57" height="20" font="0">eligibility). </text>
<text top="621" left="549" width="11" height="18" font="0">• </text>
<text top="620" left="563" width="285" height="20" font="0">The discrepancy between statin-eligible participants </text>
<text top="637" left="563" width="268" height="20" font="0">in the new versus old guidelines increased in the </text>
<text top="655" left="563" width="289" height="20" font="0">higher age groups, exceeding 10% in men aged &gt;50 </text>
<text top="672" left="563" width="275" height="20" font="0">y and in women aged &gt;60 y. Discordance in statin </text>
<text top="689" left="563" width="275" height="20" font="0">eligibility between the 2 guidelines was greatest in </text>
<text top="706" left="563" width="108" height="20" font="0">women aged &gt;65 y </text>
<text top="725" left="549" width="11" height="18" font="0">• </text>
<text top="725" left="563" width="271" height="20" font="0">Censored for initiation of lipid-lowering treatment, </text>
<text top="742" left="563" width="267" height="20" font="0">the calibration of the PCE was slightly improved, </text>
<text top="759" left="563" width="288" height="20" font="0">with chi-square values of 13.1 (340 predicted versus </text>
<text top="203" left="865" width="7" height="18" font="0">•</text>
<text top="202" left="872" width="224" height="20" font="0"> The PCE overpredicted ASCVD risk but </text>
<text top="219" left="865" width="232" height="20" font="0">did so mainly among high-risk participants </text>
<text top="236" left="865" width="235" height="20" font="0">who would be considered eligible for statin </text>
<text top="254" left="865" width="72" height="20" font="0">use anyway. </text>
<text top="273" left="865" width="7" height="18" font="0">•</text>
<text top="272" left="872" width="230" height="20" font="0"> Limitations: sample was not a completely </text>
<text top="289" left="865" width="230" height="20" font="0">independent external validation sample of </text>
<text top="306" left="865" width="202" height="20" font="0">PCE because data from some of the </text>
<text top="324" left="865" width="208" height="20" font="0">participants were included in the PCE </text>
<text top="341" left="865" width="178" height="20" font="0">derivation (i.e., Offspring Cohort </text>
<text top="358" left="865" width="209" height="20" font="0">examination cycles 1 and 3); included </text>
<text top="375" left="865" width="228" height="20" font="0">whites only; somewhat low ASCVD event </text>
<text top="393" left="865" width="28" height="20" font="0">rate. </text>
<text top="410" left="865" width="3" height="20" font="0"> </text>
<text top="427" left="865" width="175" height="20" font="0">OVERALL QUALITY: Moderate </text>
</page>
<page number="66" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">66 </text>
<text top="107" left="563" width="284" height="20" font="0">301 observed) among men and 22.8 (166 predicted </text>
<text top="124" left="563" width="209" height="20" font="0">versus 126 observed) among women. </text>
<text top="141" left="563" width="3" height="20" font="0"> </text>
<text top="159" left="563" width="3" height="20" font="0"> </text>
<text top="177" left="91" width="117" height="20" font="0">Chia YC, et al., 2014 </text>
<text top="194" left="91" width="25" height="20" font="0"><a href="data supplement.html#239">(65)</a> </text>
<text top="211" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25410585">25410585</a></text>
<text top="211" left="145" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25410585"> </a></text>
<text top="228" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="245" left="91" width="7" height="20" font="7"><b>  </b></text>
<text top="177" left="225" width="71" height="20" font="7"><b>Study type:</b> </text>
<text top="194" left="225" width="119" height="20" font="0">Retrospective Cohort </text>
<text top="211" left="225" width="36" height="20" font="0">study  </text>
<text top="228" left="225" width="3" height="20" font="0"> </text>
<text top="245" left="225" width="115" height="20" font="7"><b>Size:</b> 922 patients in </text>
<text top="263" left="225" width="120" height="20" font="0">Asia (Malay, Chinese </text>
<text top="280" left="225" width="92" height="20" font="0">and Indian race) </text>
<text top="177" left="375" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="196" left="375" width="7" height="18" font="0">•</text>
<text top="195" left="381" width="90" height="20" font="0"> Age 40 to 79 y  </text>
<text top="214" left="375" width="7" height="18" font="0">•</text>
<text top="213" left="381" width="155" height="20" font="0"> Absence of clinical ASCVD </text>
<text top="232" left="375" width="7" height="18" font="0">•</text>
<text top="232" left="381" width="139" height="20" font="0"> Enrolled in an outpatient </text>
<text top="249" left="375" width="150" height="20" font="0">primary care clinic in Kuala </text>
<text top="266" left="375" width="100" height="20" font="0">Lumpur, Malaysia </text>
<text top="283" left="375" width="3" height="20" font="0"> </text>
<text top="301" left="375" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="320" left="375" width="7" height="18" font="0">•</text>
<text top="319" left="381" width="101" height="20" font="0"> Age &lt;40 or &gt;79 y </text>
<text top="338" left="375" width="7" height="18" font="0">•</text>
<text top="337" left="381" width="155" height="20" font="0"> Clinical ASCVD at baseline </text>
<text top="356" left="375" width="7" height="18" font="0">•</text>
<text top="356" left="381" width="155" height="20" font="0"> Missing data for calculation </text>
<text top="373" left="375" width="149" height="20" font="0">of risk score (PCE or FRS) </text>
<text top="390" left="375" width="148" height="20" font="0">or data on ASCVD events  </text>
<text top="178" left="550" width="274" height="20" font="7"><b>1</b>°<b> endpoint:</b> Nonfatal MI, coronary heart disease </text>
<text top="195" left="550" width="176" height="20" font="0">death, and fatal/nonfatal stroke; </text>
<text top="212" left="550" width="79" height="20" font="0">10 y follow up </text>
<text top="229" left="550" width="3" height="20" font="0"> </text>
<text top="247" left="550" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="266" left="550" width="7" height="18" font="0">•</text>
<text top="265" left="557" width="290" height="20" font="0"> Mean age 57.5 ± 8.8 y; 66.7% female; 47% diabetic </text>
<text top="284" left="550" width="7" height="18" font="0">•</text>
<text top="283" left="557" width="283" height="20" font="0"> Overall AUC=0.632 (95% CI: 0.557-0.70), p=0.003 </text>
<text top="306" left="554" width="9" height="13" font="0">- </text>
<text top="301" left="567" width="277" height="20" font="0">Malay race: 0.737 (95% CI: 0.641-0.834), p=0.011 </text>
<text top="323" left="553" width="9" height="13" font="0">- </text>
<text top="318" left="567" width="242" height="20" font="0">Chinese race: 0.625 (95% CI: 0.512-0.737), </text>
<text top="335" left="567" width="48" height="20" font="0">p=0.054 </text>
<text top="358" left="553" width="9" height="13" font="0">- </text>
<text top="352" left="567" width="278" height="20" font="0">Indian race: 0.576 (95% CI: 0.417-0.736), p=0.335 </text>
<text top="371" left="550" width="7" height="18" font="0">•</text>
<text top="371" left="557" width="289" height="20" font="0"> Good calibration (Hosmer-Lemeshow test χ2 =12.6, </text>
<text top="388" left="550" width="46" height="20" font="0">p=0.12) </text>
<text top="406" left="550" width="271" height="20" font="0"> • Net Reclassification Improvement (NRI) 0.031, </text>
<text top="423" left="550" width="148" height="20" font="0">p=0.001 compared to FRS </text>
<text top="442" left="550" width="273" height="20" font="0"> • Notably, the number of patients receiving statin </text>
<text top="459" left="550" width="284" height="20" font="0">therapy increased from 9.7% (n = 90) to 63.7% (n = </text>
<text top="476" left="550" width="301" height="20" font="0">587) over the 10-y period of follow up (1998-2007) and </text>
<text top="493" left="550" width="276" height="20" font="0">mean blood pressure, total cholesterol and HbA1c </text>
<text top="511" left="550" width="129" height="20" font="0">were lower at follow up </text>
<text top="530" left="550" width="7" height="18" font="0">•</text>
<text top="529" left="557" width="256" height="20" font="0"> Observed/predicted events: 45 actual ASCVD </text>
<text top="546" left="550" width="275" height="20" font="0">events (4.9%) over 10-y: 22 (7.2%) in men and 23 </text>
<text top="563" left="550" width="278" height="20" font="0">(3.7%) in women vs. predicted 93 (10.1%) ASCVD </text>
<text top="581" left="550" width="240" height="20" font="0">events: 21.1% in men and 6.7% in women.  </text>
<text top="598" left="550" width="3" height="20" font="0"> </text>
<text top="615" left="550" width="148" height="20" font="0">Observed v. Predicted (%) </text>
<text top="632" left="550" width="234" height="20" font="0">                        All Adults    Men     Women </text>
<text top="650" left="550" width="238" height="20" font="0">&lt; 7.5%        2.2 v. 3.8    0 v. 4.5    2.4 v. 3.6 </text>
<text top="667" left="550" width="239" height="20" font="0">7.5%-9.9% 7.0 v. 8.4   5.3 v. 8.2   7.5 v. 8.4 </text>
<text top="684" left="550" width="242" height="20" font="0">10-19.9%   5.3 v.13.9  6.5 v.14.3  4.4 v.13.5 </text>
<text top="701" left="550" width="242" height="20" font="0">&gt;=20%      7.9 v.30.5   9.1 v.31.1  5.3 v.28.2 </text>
<text top="718" left="550" width="3" height="20" font="0"> </text>
<text top="178" left="865" width="7" height="18" font="0">•</text>
<text top="178" left="872" width="211" height="20" font="0"> The PCE had poor discrimination and </text>
<text top="195" left="865" width="205" height="20" font="0">fair calibration in an Asian population </text>
<text top="212" left="865" width="206" height="20" font="0">overall, with reasonable calibration at </text>
<text top="229" left="865" width="208" height="20" font="0">lower risk levels and more substantial </text>
<text top="247" left="865" width="208" height="20" font="0">overprediction at higher predicted risk </text>
<text top="264" left="865" width="213" height="20" font="0">levels (≥10%, and especially ≥20%) in </text>
<text top="281" left="865" width="94" height="20" font="0">men and women </text>
<text top="300" left="865" width="7" height="18" font="0">•</text>
<text top="299" left="872" width="213" height="20" font="0"> Lower observed vs. predicted ASCVD </text>
<text top="317" left="865" width="222" height="20" font="0">events may be partially explained by the </text>
<text top="334" left="865" width="198" height="20" font="0">very high proportion of patients who </text>
<text top="351" left="865" width="205" height="20" font="0">initiated statin therapy, and observed </text>
<text top="368" left="865" width="222" height="20" font="0">improvements in risk factor control (e.g., </text>
<text top="386" left="865" width="219" height="20" font="0">lower blood pressure and lower HbA1c) </text>
<text top="403" left="865" width="215" height="20" font="0">over the 10-y study period, which likely </text>
<text top="420" left="865" width="237" height="20" font="0">resulted in a reduction in observed ASCVD </text>
<text top="437" left="865" width="43" height="20" font="0">events. </text>
<text top="456" left="865" width="7" height="18" font="0">•</text>
<text top="456" left="872" width="225" height="20" font="0"> Limitations: recall bias potential, unclear </text>
<text top="473" left="865" width="237" height="20" font="0">if chart abstractors were blinded to ASCVD </text>
<text top="490" left="865" width="213" height="20" font="0">event outcome prior to calculating risk; </text>
<text top="507" left="865" width="200" height="20" font="0">significant missing data (36%) led to </text>
<text top="524" left="865" width="226" height="20" font="0">participant exclusion; very high predicted </text>
<text top="542" left="865" width="228" height="20" font="0">risk population overall with fewer persons </text>
<text top="559" left="865" width="185" height="20" font="0">in low-risk category and intensive </text>
<text top="576" left="865" width="152" height="20" font="0">treatment after assessment </text>
<text top="593" left="865" width="3" height="20" font="0"> </text>
<text top="610" left="865" width="3" height="20" font="0"> </text>
<text top="628" left="865" width="175" height="20" font="0">OVERALL QUALITY: Moderate </text>
<text top="645" left="865" width="3" height="20" font="0"> </text>
<text top="736" left="91" width="65" height="20" font="7"><b>REGARDS </b></text>
<text top="753" left="91" width="113" height="20" font="0">Colantonio L, et al.,  </text>
<text top="771" left="91" width="56" height="20" font="0">2017<a href="data supplement.html#239"> (66)</a> </text>
<text top="788" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28314800">28314800</a></text>
<text top="788" left="145" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28314800"> </a></text>
<text top="736" left="225" width="71" height="20" font="7"><b>Study type:</b> </text>
<text top="753" left="225" width="67" height="20" font="0">Prospective </text>
<text top="771" left="225" width="120" height="20" font="0">Observational Cohort </text>
<text top="788" left="225" width="35" height="20" font="0">Study </text>
<text top="736" left="375" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="755" left="375" width="7" height="18" font="0">•</text>
<text top="755" left="381" width="86" height="20" font="0"> Age 45 to 70 y </text>
<text top="774" left="375" width="7" height="18" font="0">•</text>
<text top="773" left="381" width="136" height="20" font="0"> No history of ASCVD or </text>
<text top="790" left="375" width="22" height="20" font="0">DM </text>
<text top="737" left="550" width="278" height="20" font="7"><b>1</b>°<b> endpoint:</b> Nonfatal/fatal stroke, MI, or coronary </text>
<text top="755" left="550" width="266" height="20" font="0">heart disease death, stratified by socioeconomic </text>
<text top="772" left="550" width="40" height="20" font="0">status; </text>
<text top="789" left="550" width="123" height="20" font="0">Median ~7 y follow-up </text>
<text top="738" left="865" width="7" height="18" font="0">•</text>
<text top="737" left="872" width="214" height="20" font="0"> The PCE had good discrimination and </text>
<text top="755" left="865" width="208" height="20" font="0">calibration overall, with overprediction </text>
<text top="772" left="865" width="206" height="20" font="0">among individuals at higher SES with </text>
<text top="789" left="865" width="200" height="20" font="0">higher risk, fairly accurate prediction </text>
</page>
<page number="67" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="18" size="12" family="Times" color="#1a1919"/>
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">67 </text>
<text top="107" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="107" left="225" width="3" height="20" font="0"> </text>
<text top="124" left="225" width="119" height="20" font="7"><b>Size:</b> 9066 black and </text>
<text top="141" left="225" width="126" height="20" font="0">white participants from </text>
<text top="159" left="225" width="112" height="20" font="0">the U.S. REGARDS </text>
<text top="176" left="225" width="75" height="20" font="0">(REasons for </text>
<text top="193" left="225" width="130" height="20" font="0">Geographic And Racial </text>
<text top="210" left="225" width="121" height="20" font="0">Differences in Stroke) </text>
<text top="228" left="225" width="33" height="20" font="0">study </text>
<text top="109" left="375" width="7" height="18" font="0">•</text>
<text top="108" left="381" width="109" height="20" font="0"> Not taking statin at </text>
<text top="125" left="375" width="53" height="20" font="0">baseline  </text>
<text top="144" left="375" width="7" height="18" font="0">•</text>
<text top="144" left="381" width="128" height="20" font="0"> Fasting LDL-C 70-189 </text>
<text top="161" left="375" width="150" height="20" font="0">mg/dL or NHDL-C 100-219 </text>
<text top="178" left="375" width="38" height="20" font="0">mg/dL<b> </b></text>
<text top="197" left="375" width="7" height="18" font="0">•</text>
<text top="197" left="381" width="120" height="20" font="0"> Participants from the </text>
<text top="214" left="375" width="139" height="20" font="0">REGARDS (REasons for </text>
<text top="231" left="375" width="130" height="20" font="0">Geographic And Racial </text>
<text top="248" left="375" width="155" height="20" font="0">Differences in Stroke) study </text>
<text top="266" left="375" width="3" height="20" font="0"> </text>
<text top="283" left="375" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="302" left="375" width="7" height="18" font="0">•</text>
<text top="301" left="381" width="108" height="20" font="0"> Prevalent ASCVD, </text>
<text top="318" left="375" width="130" height="20" font="0">diabetes mellitus, heart </text>
<text top="336" left="375" width="76" height="20" font="0">failure or Afib </text>
<text top="355" left="375" width="7" height="18" font="0">•</text>
<text top="354" left="381" width="132" height="20" font="0"> Low-density lipoprotein </text>
<text top="371" left="375" width="161" height="20" font="0">cholesterol level &lt;70 or &gt;189 </text>
<text top="388" left="375" width="158" height="20" font="0">mg/dL or NHDL-C &lt;100 or &gt; </text>
<text top="406" left="375" width="62" height="20" font="0">219 mg/dL<b> </b></text>
<text top="425" left="375" width="7" height="18" font="0">•</text>
<text top="424" left="381" width="125" height="20" font="0"> Statin use<b> </b>at baseline </text>
<text top="107" left="550" width="3" height="20" font="0"> </text>
<text top="124" left="550" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="143" left="550" width="7" height="18" font="0">•</text>
<text top="143" left="557" width="3" height="20" font="0"> </text>
<text top="143" left="561" width="285" height="20" font="17">457 incident ASCVD events occurred during 59,648 </text>
<text top="160" left="550" width="118" height="20" font="17">person-y of follow-up </text>
<text top="179" left="550" width="7" height="18" font="0">•</text>
<text top="178" left="557" width="247" height="20" font="0"> Social deprivation was defined as any of the </text>
<text top="195" left="550" width="69" height="20" font="0">following: 1) </text>
<text top="195" left="619" width="216" height="20" font="17">self-reported annual household income </text>
<text top="213" left="550" width="266" height="20" font="17">&lt;$35,000, 2) &lt; high school education or 3) living </text>
<text top="230" left="550" width="98" height="20" font="17">without a partner. </text>
<text top="249" left="550" width="11" height="18" font="17">• </text>
<text top="248" left="560" width="275" height="20" font="17">C statistics generally &gt;0.70 and H-L X2 ≤15 for all </text>
<text top="265" left="550" width="48" height="20" font="17">groups.  </text>
<text top="284" left="550" width="11" height="18" font="17">• </text>
<text top="284" left="560" width="250" height="20" font="17">Predicted and observed rates similar at lower </text>
<text top="301" left="550" width="291" height="20" font="17">predicted risks, with overprediction observed more in </text>
<text top="318" left="550" width="299" height="20" font="17">higher risk individuals and higher SES individuals, and </text>
<text top="335" left="550" width="247" height="20" font="17">modest underprediction in lower SES groups </text>
<text top="354" left="550" width="7" height="18" font="0">•</text>
<text top="353" left="557" width="220" height="20" font="0"> Predicted and observed per 1000 per-y </text>
<text top="371" left="550" width="217" height="20" font="13"><i>By number of indicators of deprivation:  </i></text>
<text top="388" left="550" width="282" height="20" font="0">0 indicators: 8.02 and 6.23 (95% CI: 5.31– 7.31), H-</text>
<text top="405" left="550" width="86" height="20" font="0">L12.43, p=0.01 </text>
<text top="422" left="550" width="286" height="20" font="0">1 indicator: 8.05 and 6.61 (95% CI: 5.29– 8.24), H-L </text>
<text top="440" left="550" width="65" height="20" font="0">6.6, p=0.09 </text>
<text top="457" left="550" width="262" height="20" font="0">2 or 3 indicators: 9.83 and 11.40 (95% CI: 9.23–</text>
<text top="474" left="550" width="137" height="20" font="0">14.05), H-L 5.77, p=0.12 </text>
<text top="491" left="550" width="3" height="20" font="0"> </text>
<text top="509" left="550" width="145" height="20" font="13"><i>Annual household income</i> </text>
<text top="526" left="550" width="292" height="20" font="17">≥$50 000: 6.91 and 5.15 (95% CI?!: 4.21–6.29), H-L: </text>
<text top="543" left="550" width="79" height="20" font="17">10.91, p=0.01 </text>
<text top="560" left="550" width="291" height="20" font="17">$25 000 to &lt;$50 000: 9.16 and 7.48 (95% CI?!: 6.22–</text>
<text top="577" left="550" width="127" height="20" font="17">9.00), H-L8.09, p=0.04 </text>
<text top="595" left="550" width="295" height="20" font="17">&lt;$25 000: 9.72 and 10.73 (95% CI?!: 8.88–12.95), h-l </text>
<text top="612" left="550" width="72" height="20" font="17">4.74, p=0.19 </text>
<text top="629" left="550" width="3" height="20" font="17"> </text>
<text top="646" left="550" width="58" height="20" font="18"><i>Education </i></text>
<text top="663" left="550" width="275" height="20" font="17">College graduate+: 7.74 and 6.03 (95% CI?!:5.01–</text>
<text top="681" left="550" width="124" height="20" font="17">7.26), h-l 9.01, p=0.03 </text>
<text top="698" left="550" width="287" height="20" font="17">High school/some college: 8.33 and 7.18 (95% CI?!: </text>
<text top="715" left="550" width="161" height="20" font="17">6.15–8.39), H-L 8.62, p=0.03 </text>
<text top="732" left="550" width="280" height="20" font="17">Less than high school: 11.87 and 14.56 (95% CI?!: </text>
<text top="750" left="550" width="175" height="20" font="17">10.92–19.35), H-L 8.92, p=0.03 </text>
<text top="767" left="550" width="3" height="20" font="17"> </text>
<text top="784" left="550" width="107" height="20" font="18"><i>Relationship status </i></text>
<text top="107" left="865" width="218" height="20" font="0">among individuals at intermediate SES, </text>
<text top="124" left="865" width="197" height="20" font="0">and modest underprediction among </text>
<text top="141" left="865" width="142" height="20" font="0">individuals at lower SES.  </text>
<text top="160" left="865" width="7" height="18" font="0">•</text>
<text top="160" left="872" width="225" height="20" font="0"> Adding information on social deprivation </text>
<text top="177" left="865" width="202" height="20" font="0">added a modest improvement in risk </text>
<text top="194" left="865" width="139" height="20" font="0">classification of the PCE. </text>
<text top="213" left="865" width="11" height="18" font="0">• </text>
<text top="213" left="876" width="166" height="20" font="0">Large, representative sample. </text>
<text top="232" left="865" width="7" height="18" font="0">•</text>
<text top="231" left="872" width="212" height="20" font="0"> Limitations: 7-y observation period for </text>
<text top="248" left="865" width="89" height="20" font="0">ASCVD events  </text>
<text top="265" left="865" width="3" height="20" font="0"> </text>
<text top="283" left="865" width="147" height="20" font="0">OVERAL QUALITY: HIGH </text>
<text top="300" left="865" width="3" height="20" font="0"> </text>
</page>
<page number="68" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="19" size="12" family="Times" color="#1a171c"/>
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">68 </text>
<text top="107" left="550" width="289" height="20" font="17">Living with a partner: 8.42 and 6.92 (6.02–7.96), H-L </text>
<text top="124" left="550" width="79" height="20" font="17">11.45, p=0.01 </text>
<text top="141" left="550" width="274" height="20" font="17">Living without a partner: 8.23 and 7.79 (95% CI?!: </text>
<text top="159" left="550" width="161" height="20" font="17">6.50–9.32, H-L 7.49, p=0.06) </text>
<text top="176" left="550" width="3" height="20" font="18"><i> </i></text>
<text top="195" left="550" width="7" height="18" font="0">•</text>
<text top="194" left="557" width="234" height="20" font="0"> Discrimination Harrell’s C-index (95% CI)  </text>
<text top="212" left="550" width="140" height="20" font="13"><i>indicators of deprivation:  </i></text>
<text top="229" left="550" width="111" height="20" font="0">0: 0.72 (0.69– 0.75) </text>
<text top="246" left="550" width="114" height="20" font="0">1:  0.73 (0.69– 0.78) </text>
<text top="263" left="550" width="139" height="20" font="0">2 or 3: 0.70 (0.65– 0.75)  </text>
<text top="280" left="550" width="3" height="20" font="0"> </text>
<text top="298" left="550" width="145" height="20" font="13"><i>Annual household income</i> </text>
<text top="315" left="550" width="174" height="20" font="17">≥$50 000: 0.724 (0.683–0.765) </text>
<text top="332" left="550" width="234" height="20" font="17">$25 000 to &lt;$50 000: 0.711 (0.671–0.751) </text>
<text top="349" left="550" width="173" height="20" font="17">&lt;$25 000: 0.703 (0.660–0.746) </text>
<text top="367" left="550" width="3" height="20" font="17"> </text>
<text top="384" left="550" width="58" height="20" font="18"><i>Education </i></text>
<text top="401" left="550" width="215" height="20" font="17">College graduate: 0.724 (0.685–0.763) </text>
<text top="418" left="550" width="261" height="20" font="17">High school/some college: 0.704 (0.671–0.737) </text>
<text top="435" left="550" width="240" height="20" font="17">Less than high school: 0.742 (0.676–0.808) </text>
<text top="453" left="550" width="3" height="20" font="17"> </text>
<text top="470" left="550" width="107" height="20" font="18"><i>Relationship status </i></text>
<text top="487" left="550" width="231" height="20" font="17">Living with a partner: 0.720 (0.692–0.749) </text>
<text top="504" left="550" width="244" height="20" font="17">Living without a partner: 0.722 (0.680–0.763 </text>
<text top="521" left="550" width="3" height="20" font="7"><b> </b></text>
<text top="540" left="550" width="7" height="18" font="0">•</text>
<text top="540" left="557" width="275" height="20" font="0"> The NRI after adding deprivation data to the PCE </text>
<text top="557" left="550" width="278" height="20" font="0">was modest (0.12; 95% CI: 0.03– 0.21); for annual </text>
<text top="574" left="550" width="107" height="20" font="0">household income: </text>
<text top="574" left="657" width="185" height="20" font="17">0.16 (0.06–0.25); education: 0.07 </text>
<text top="591" left="550" width="271" height="20" font="17">(95% CI?!: 0.02 to 0.15), relationship status: 0.02 </text>
<text top="609" left="550" width="134" height="20" font="17">(95% CI?!: 0.07 to 0.11) </text>
<text top="626" left="550" width="3" height="20" font="0"> </text>
<text top="644" left="91" width="85" height="20" font="0">Cook N, et al.,  </text>
<text top="661" left="91" width="56" height="20" font="0">2014<a href="data supplement.html#239"> (67)</a> </text>
<text top="678" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25285455">25285455</a></text>
<text top="678" left="145" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25285455"> </a></text>
<text top="695" left="91" width="3" height="20" font="0"> </text>
<text top="713" left="91" width="7" height="20" font="7"><b>  </b></text>
<text top="644" left="225" width="70" height="20" font="7"><b>Study type: </b></text>
<text top="661" left="225" width="67" height="20" font="0">Prospective </text>
<text top="678" left="225" width="120" height="20" font="0">Observational Cohort </text>
<text top="695" left="225" width="35" height="20" font="0">Study </text>
<text top="713" left="225" width="3" height="20" font="0"> </text>
<text top="730" left="225" width="73" height="20" font="7"><b>Size:</b> 27,542 </text>
<text top="747" left="225" width="135" height="20" font="0">participants from the US </text>
<text top="764" left="225" width="132" height="20" font="0">Women’s Health Study  </text>
<text top="644" left="375" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="663" left="375" width="7" height="18" font="0">•</text>
<text top="662" left="381" width="140" height="20" font="0"> Participants from the US </text>
<text top="679" left="375" width="128" height="20" font="0">Women’s Health Study<b> </b></text>
<text top="698" left="375" width="7" height="18" font="0">•</text>
<text top="698" left="381" width="137" height="20" font="0"> Women ages 45 to 70 y </text>
<text top="717" left="375" width="7" height="18" font="0">•</text>
<text top="716" left="381" width="122" height="20" font="0"> No clinical ASCVD at </text>
<text top="733" left="375" width="49" height="20" font="0">baseline </text>
<text top="752" left="375" width="7" height="18" font="0">•</text>
<text top="752" left="381" width="3" height="20" font="0"> </text>
<text top="752" left="385" width="150" height="20" font="19">Complete ascertainment of </text>
<text top="769" left="375" width="163" height="20" font="19">plasma lipids and information </text>
<text top="786" left="375" width="115" height="20" font="19">on other risk factors  </text>
<text top="645" left="550" width="76" height="20" font="7"><b>1</b>°<b> endpoint:</b> </text>
<text top="645" left="626" width="195" height="20" font="19">ASCVD, defined as any myocardial </text>
<text top="662" left="550" width="289" height="20" font="19">infarction, any stroke, or death due to cardiovascular </text>
<text top="679" left="550" width="40" height="20" font="19">cause. </text>
<text top="697" left="550" width="3" height="20" font="0"> </text>
<text top="714" left="550" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="733" left="550" width="7" height="18" font="0">•</text>
<text top="732" left="557" width="28" height="20" font="0"> The </text>
<text top="732" left="585" width="264" height="20" font="19">PCE average predicted risk was 3.6% over 10 y </text>
<text top="749" left="550" width="246" height="20" font="19">vs. actual observed risk in the WHS of 2.2%. </text>
<text top="768" left="550" width="7" height="18" font="0">•</text>
<text top="768" left="557" width="3" height="20" font="0"> </text>
<text top="768" left="561" width="276" height="20" font="19">Ratios of predicted to observed rates were 1.90 or </text>
<text top="785" left="550" width="301" height="20" font="19">higher in the groups with 0 to less than 5.0% and 5.0% </text>
<text top="646" left="865" width="7" height="18" font="0">•</text>
<text top="645" left="872" width="226" height="20" font="0"> The PCE overpredicted risk in this study </text>
<text top="662" left="865" width="182" height="20" font="0">sample, with the largest absolute </text>
<text top="679" left="865" width="210" height="20" font="0">discrepancies at the highest predicted </text>
<text top="697" left="865" width="195" height="20" font="0">risks (&gt;10%). Ratios of predicted to </text>
<text top="714" left="865" width="207" height="20" font="0">observed risks were greatest at lower </text>
<text top="731" left="865" width="211" height="20" font="0">predicted risk but absolute differences </text>
<text top="748" left="865" width="213" height="20" font="0">between predicted and observed rates </text>
<text top="765" left="865" width="196" height="20" font="0">were highest at high predicted risks </text>
<text top="783" left="865" width="47" height="20" font="0">(&gt;10%). </text>
</page>
<page number="69" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">69 </text>
<text top="107" left="375" width="3" height="20" font="0"> </text>
<text top="124" left="375" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="143" left="375" width="7" height="18" font="0">•</text>
<text top="143" left="381" width="156" height="20" font="0"> The WHS excluded women </text>
<text top="160" left="375" width="132" height="20" font="0">with angina at baseline <b> </b></text>
<text top="177" left="375" width="3" height="20" font="0"> </text>
<text top="107" left="550" width="263" height="20" font="19">to less than 7.5% risk and were over 1.40 in the </text>
<text top="124" left="550" width="279" height="20" font="19">groups with 7.5% to less than 10.0% and 10.0% or </text>
<text top="141" left="550" width="60" height="20" font="19">higher risk </text>
<text top="160" left="550" width="7" height="18" font="0">•</text>
<text top="160" left="557" width="293" height="20" font="0"> The ratios of predicted to observed remained 1.80 or </text>
<text top="177" left="550" width="290" height="20" font="0">higher in the lower 2 risk groups and over 1.30 in the </text>
<text top="194" left="550" width="280" height="20" font="0">higher risk groups after adjustment for hypothetical </text>
<text top="211" left="550" width="244" height="20" font="0">statin use, revascularization procedures and </text>
<text top="229" left="550" width="142" height="20" font="0">confounding by indication </text>
<text top="246" left="550" width="3" height="20" font="0"> </text>
<text top="263" left="550" width="3" height="20" font="0"> </text>
<text top="280" left="550" width="242" height="20" font="0">           Observed vs. Predicted, % E/O.         </text>
<text top="298" left="550" width="203" height="20" font="0">&lt;5%             1.01      1.92           1.90 </text>
<text top="315" left="550" width="203" height="20" font="0">5-7.5%         3.20      6.13           1.91 </text>
<text top="332" left="550" width="204" height="20" font="0">7.5%-9.9%   6.04      8.62           1.43 </text>
<text top="349" left="550" width="203" height="20" font="0">&gt;10%           10.79    15.60         1.45 </text>
<text top="367" left="550" width="3" height="20" font="0"> </text>
<text top="384" left="550" width="3" height="20" font="0"> </text>
<text top="109" left="864" width="11" height="18" font="19">• </text>
<text top="108" left="878" width="215" height="20" font="19">Statin use and revascularization during </text>
<text top="125" left="865" width="193" height="20" font="19">follow up explained only part of the </text>
<text top="143" left="865" width="217" height="20" font="19">discrepancy between observed rates of </text>
<text top="160" left="865" width="223" height="20" font="19">ASCVD in the WHS and those predicted </text>
<text top="177" left="865" width="211" height="20" font="19">by PCE. Other assumptions regarding </text>
<text top="194" left="865" width="220" height="20" font="19">effects of statin use might explain more, </text>
<text top="211" left="865" width="167" height="20" font="19">but not all, of the discrepancy. </text>
<text top="230" left="864" width="11" height="18" font="19">• </text>
<text top="230" left="878" width="206" height="20" font="19">Large, lower risk sample of women in </text>
<text top="247" left="864" width="200" height="20" font="19">clinical trial (half receiving aspirin by </text>
<text top="264" left="864" width="136" height="20" font="19">design) and at high SES </text>
<text top="283" left="865" width="7" height="18" font="0">•</text>
<text top="282" left="872" width="69" height="20" font="0"> Limitations: </text>
<text top="282" left="941" width="131" height="20" font="19">cumulative incidence of </text>
<text top="300" left="865" width="228" height="20" font="19">ASCVD was estimated as of 8 y because </text>
<text top="317" left="865" width="214" height="20" font="19">women were followed for 8 y, and then </text>
<text top="334" left="865" width="215" height="20" font="19">extrapolated to 10 y using a converting </text>
<text top="351" left="865" width="227" height="20" font="19">equation. Statin use was not assessed at </text>
<text top="368" left="865" width="207" height="20" font="19">every exam in the WHS. Estimates of </text>
<text top="386" left="865" width="172" height="20" font="19">confounding by indication were </text>
<text top="403" left="865" width="208" height="20" font="19">hypothetical and not data-derived. No </text>
<text top="420" left="865" width="187" height="20" font="19">report of discrimination/calibration </text>
<text top="437" left="865" width="57" height="20" font="19">statistics.  </text>
<text top="455" left="865" width="3" height="20" font="0"> </text>
<text top="472" left="865" width="175" height="20" font="0">OVERALL QUALITY: Moderate </text>
<text top="489" left="865" width="3" height="20" font="0"> </text>
<text top="507" left="91" width="116" height="20" font="0">Crowson et al., 2017 </text>
<text top="524" left="91" width="25" height="20" font="0"><a href="data supplement.html#240">(68)</a> </text>
<text top="541" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28339992">28339992</a></text>
<text top="541" left="145" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28339992"> </a></text>
<text top="507" left="225" width="130" height="20" font="7"><b>Study type:</b> Combined </text>
<text top="524" left="225" width="120" height="20" font="0">Observational Cohort </text>
<text top="541" left="225" width="122" height="20" font="0">(both prospective and </text>
<text top="559" left="225" width="78" height="20" font="0">retrospective) </text>
<text top="576" left="225" width="3" height="20" font="0"> </text>
<text top="593" left="225" width="134" height="20" font="7"><b>Size:</b> 1796 patients with </text>
<text top="610" left="225" width="109" height="20" font="0">rheumatoid arthritis </text>
<text top="627" left="225" width="129" height="20" font="0">(RA) from UK, Norway, </text>
<text top="645" left="225" width="105" height="20" font="0">Netherlands, USA, </text>
<text top="662" left="225" width="124" height="20" font="0">South Africa, Canada, </text>
<text top="679" left="225" width="70" height="20" font="0">and Mexico  </text>
<text top="507" left="375" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="526" left="375" width="7" height="18" font="0">•</text>
<text top="525" left="381" width="3" height="20" font="0"> </text>
<text top="525" left="385" width="130" height="20" font="17">Seven RA cohorts from </text>
<text top="542" left="375" width="146" height="20" font="17">UK, Norway, Netherlands, </text>
<text top="560" left="375" width="152" height="20" font="17">USA, South Africa, Canada </text>
<text top="577" left="375" width="157" height="20" font="17">and Mexico were combined. </text>
<text top="596" left="375" width="7" height="18" font="0">•</text>
<text top="595" left="381" width="80" height="20" font="0"> No prior CVD<b> </b></text>
<text top="614" left="375" width="7" height="18" font="0">•</text>
<text top="614" left="381" width="149" height="20" font="0"> Physician diagnosis of RA </text>
<text top="631" left="375" width="150" height="20" font="0">and/or fulfilment of 1987 or </text>
<text top="648" left="375" width="145" height="20" font="0">2010 American College of </text>
<text top="665" left="375" width="161" height="20" font="0">Rheumatology criteria for RA </text>
<text top="683" left="375" width="3" height="20" font="0"> </text>
<text top="700" left="375" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="719" left="375" width="7" height="18" font="0">•</text>
<text top="718" left="381" width="144" height="20" font="0"> Other RA cohorts without </text>
<text top="735" left="375" width="127" height="20" font="0">information on disease </text>
<text top="753" left="375" width="119" height="20" font="0">activity or CVD death<b> </b></text>
<text top="772" left="375" width="7" height="18" font="0">•</text>
<text top="771" left="381" width="124" height="20" font="0"> CVD prior to baseline<b> </b></text>
<text top="788" left="375" width="3" height="20" font="0"> </text>
<text top="508" left="550" width="274" height="20" font="7"><b>1</b>°<b> endpoint:</b> CVD event, defined as MI, ischemic </text>
<text top="525" left="550" width="115" height="20" font="0">stroke or CVD death </text>
<text top="542" left="550" width="3" height="20" font="0"> </text>
<text top="560" left="550" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="579" left="550" width="7" height="18" font="0">•</text>
<text top="578" left="557" width="271" height="20" font="0"> The Standardized Incidence Ratio (SIR) for PCE </text>
<text top="595" left="550" width="161" height="20" font="0">was 0.73, 95% CI: 0.60, 0.89<b> </b></text>
<text top="614" left="550" width="7" height="18" font="0">•</text>
<text top="614" left="557" width="258" height="20" font="0"> There were no significant differences between </text>
<text top="631" left="550" width="280" height="20" font="0">predicted and observed risks by decile for the PCE<b> </b></text>
<text top="650" left="550" width="7" height="18" font="0">•</text>
<text top="649" left="557" width="262" height="20" font="0"> Discrimination was moderate (c-statistic: 0.72)  </text>
<text top="668" left="550" width="7" height="18" font="0">•</text>
<text top="668" left="557" width="74" height="20" font="0"> In sensitivity </text>
<text top="668" left="631" width="203" height="20" font="17">analysis including only patients aged </text>
<text top="685" left="550" width="287" height="20" font="17">40-74 y at baseline, calibration of the PCE improved </text>
<text top="702" left="550" width="269" height="20" font="17">(SIR: 0.73-0.93), but discrimination decreased (c-</text>
<text top="719" left="550" width="79" height="20" font="17">statistic: 0.70) </text>
<text top="738" left="550" width="7" height="18" font="0">•</text>
<text top="738" left="557" width="277" height="20" font="0"> Other risk calculators that include RA-specific risk </text>
<text top="755" left="550" width="262" height="20" font="0">factors (e.g., ERS-RA, QRISK2 and EULAR 1.5 </text>
<text top="772" left="550" width="288" height="20" font="0">multiplier) did not improve risk prediction for patients </text>
<text top="789" left="550" width="175" height="20" font="0">with RA compared with the PCE</text>
<text top="789" left="725" width="3" height="20" font="17"> </text>
<text top="509" left="865" width="7" height="18" font="0">•</text>
<text top="508" left="872" width="214" height="20" font="0"> PCE had moderate discrimination and </text>
<text top="525" left="865" width="232" height="20" font="0">fair overall calibration among patients with </text>
<text top="542" left="865" width="234" height="20" font="0">RA, with modest underestimation of risk at </text>
<text top="560" left="865" width="177" height="20" font="0">lower predicted risk and modest </text>
<text top="577" left="865" width="196" height="20" font="0">overprediction at very high levels of </text>
<text top="594" left="865" width="123" height="20" font="0">predicted risk (&gt;20%). </text>
<text top="613" left="865" width="7" height="18" font="0">•</text>
<text top="613" left="872" width="3" height="20" font="0"> </text>
<text top="613" left="876" width="188" height="20" font="17">RA-specific risk calculators do not </text>
<text top="630" left="865" width="229" height="20" font="17">predict CVD risk in patients with RA more </text>
<text top="647" left="865" width="235" height="20" font="17">accurately than the general population risk </text>
<text top="664" left="865" width="69" height="20" font="17">calculators.  </text>
<text top="683" left="864" width="11" height="18" font="0">• </text>
<text top="683" left="878" width="208" height="20" font="0">Limitations: lower than expected CVD </text>
<text top="700" left="864" width="203" height="20" font="0">event rate for RA patients, who were </text>
<text top="717" left="864" width="211" height="20" font="0">treated at specialty centers; combined </text>
<text top="734" left="864" width="223" height="20" font="0">prospective and retrospective studies so </text>
<text top="751" left="864" width="215" height="20" font="0">risk of ascertainment bias; CVD events </text>
<text top="768" left="864" width="117" height="20" font="0">were not adjudicated </text>
<text top="786" left="865" width="3" height="20" font="0"> </text>
</page>
<page number="70" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">70 </text>
<text top="107" left="865" width="175" height="20" font="0">OVERALL QUALITY: Moderate </text>
<text top="124" left="865" width="3" height="20" font="0"> </text>
<text top="407" left="91" width="94" height="20" font="0">Dalton JE, et al., </text>
<text top="424" left="91" width="56" height="20" font="0">2017<a href="data supplement.html#240"> (69)</a> </text>
<text top="441" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28847012">28847012</a></text>
<text top="441" left="145" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28847012"> </a></text>
<text top="407" left="225" width="71" height="20" font="7"><b>Study type:</b> </text>
<text top="424" left="225" width="119" height="20" font="0">Retrospective Cohort </text>
<text top="441" left="225" width="33" height="20" font="0">study </text>
<text top="458" left="225" width="3" height="20" font="0"> </text>
<text top="476" left="225" width="133" height="20" font="7"><b>Size:</b> 109,793 patients  <b> </b></text>
<text top="407" left="375" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="426" left="375" width="7" height="18" font="0">•</text>
<text top="425" left="381" width="100" height="20" font="0"> Patients from the </text>
<text top="442" left="375" width="130" height="20" font="0">Cleveland Clinic Health </text>
<text top="460" left="375" width="111" height="20" font="0">System who had an </text>
<text top="477" left="375" width="153" height="20" font="0">outpatient lipid panel drawn </text>
<text top="494" left="375" width="135" height="20" font="0">between 2007 and 2010<b> </b></text>
<text top="513" left="375" width="7" height="18" font="0">•</text>
<text top="512" left="381" width="150" height="20" font="0"> White or African-American<b> </b></text>
<text top="531" left="375" width="7" height="18" font="0">•</text>
<text top="531" left="381" width="66" height="20" font="0"> Age &gt; 35 y </text>
<text top="550" left="375" width="7" height="18" font="0">•</text>
<text top="549" left="381" width="106" height="20" font="0"> Resided in 1 of 21 </text>
<text top="566" left="375" width="151" height="20" font="0">northeastern Ohio counties </text>
<text top="584" left="375" width="3" height="20" font="0"> </text>
<text top="601" left="375" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="620" left="375" width="7" height="18" font="0">•</text>
<text top="619" left="381" width="151" height="20" font="0"> History of MI, stroke, heart </text>
<text top="636" left="375" width="98" height="20" font="0">valve disorder, or </text>
<text top="654" left="375" width="139" height="20" font="0">pericarditis, endocarditis, </text>
<text top="671" left="375" width="83" height="20" font="0">myocarditis, or </text>
<text top="688" left="375" width="90" height="20" font="0">cardiomyopathy </text>
<text top="707" left="372" width="11" height="18" font="0">• </text>
<text top="706" left="386" width="73" height="20" font="0">Missing data<b> </b></text>
<text top="408" left="550" width="299" height="20" font="7"><b>1</b>°<b> endpoint:</b> Incident major ASCVD event, defined as </text>
<text top="425" left="550" width="240" height="20" font="0">first occurrence of MI, stroke or CVD death; </text>
<text top="442" left="550" width="129" height="20" font="0">Median follow up of 5 y </text>
<text top="460" left="550" width="3" height="20" font="0"> </text>
<text top="477" left="550" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="496" left="550" width="7" height="18" font="0">•</text>
<text top="495" left="557" width="276" height="20" font="0"> 4933 incident events (1676 MI, 2605 strokes, 652 </text>
<text top="512" left="550" width="74" height="20" font="0">CVD deaths) </text>
<text top="531" left="546" width="11" height="18" font="0">• </text>
<text top="531" left="560" width="250" height="20" font="0">PCE model discrimination was poorer among </text>
<text top="548" left="546" width="291" height="20" font="0">patients from disadvantaged communities (C statistic </text>
<text top="565" left="546" width="279" height="20" font="0">0.70; [95% CI: 0.67 to 0.74]) than the most affluent </text>
<text top="582" left="546" width="231" height="20" font="0">communities (0.80 [95% CI: 0.78 to 0.81]) </text>
<text top="601" left="546" width="11" height="18" font="0">• </text>
<text top="601" left="560" width="272" height="20" font="0">PCE systematically underpredicted risk across all </text>
<text top="618" left="546" width="230" height="20" font="0">predicted risk levels in individuals living in </text>
<text top="635" left="546" width="304" height="20" font="0">disadvantaged neighborhoods, who were more likely to </text>
<text top="652" left="546" width="286" height="20" font="0">be black and female. Underprediction was observed </text>
<text top="669" left="546" width="250" height="20" font="0">especially in the top quartile (least affluent) of </text>
<text top="687" left="546" width="192" height="20" font="0">neighborhood disadvantage index. </text>
<text top="706" left="546" width="11" height="18" font="0">• </text>
<text top="705" left="560" width="283" height="20" font="0">PCE had near perfect calibration among individuals </text>
<text top="722" left="546" width="275" height="20" font="0">living in more affluent communities (neighborhood </text>
<text top="739" left="546" width="217" height="20" font="0">disadvantage index below the median). </text>
<text top="756" left="550" width="3" height="20" font="7"><b> </b></text>
<text top="409" left="865" width="7" height="18" font="0">•</text>
<text top="408" left="872" width="167" height="20" font="0"> PCE were well calibrated and </text>
<text top="425" left="865" width="182" height="20" font="0">discriminate well in more affluent </text>
<text top="442" left="865" width="73" height="20" font="0">communities </text>
<text top="461" left="864" width="11" height="18" font="0">• </text>
<text top="461" left="877" width="182" height="20" font="0">PCE underpredicted ASCVD risk </text>
<text top="478" left="864" width="187" height="20" font="0">substantially among patients from </text>
<text top="495" left="864" width="156" height="20" font="0">disadvantaged communities </text>
<text top="514" left="865" width="7" height="18" font="0">•</text>
<text top="513" left="872" width="189" height="20" font="0"> Limitations: Patients from affluent </text>
<text top="531" left="865" width="199" height="20" font="0">communities were overrepresented. </text>
<text top="548" left="865" width="213" height="20" font="0">Socioeconomic position was assessed </text>
<text top="565" left="865" width="226" height="20" font="0">using a composite index and thus cannot </text>
<text top="582" left="865" width="164" height="20" font="0">determine which measures of </text>
<text top="599" left="865" width="213" height="20" font="0">neighborhood characteristics and SES </text>
<text top="617" left="865" width="219" height="20" font="0">actually contribute to the disparity; used </text>
<text top="634" left="865" width="163" height="20" font="0">EHR data and thus subject to </text>
<text top="651" left="865" width="237" height="20" font="0">ascertainment bias, particularly with regard </text>
<text top="668" left="865" width="234" height="20" font="0">to event outcomes, since persons with low </text>
<text top="685" left="865" width="237" height="20" font="0">SES were more likely to not follow up; may </text>
<text top="703" left="865" width="213" height="20" font="0">have missed some events occurring at </text>
<text top="720" left="865" width="225" height="20" font="0">facilities outside of CCHS system; use of </text>
<text top="737" left="865" width="197" height="20" font="0">administrative data may have led to </text>
<text top="754" left="865" width="235" height="20" font="0">overdiagnosis of some ASCVD events; 5 y </text>
<text top="772" left="865" width="55" height="20" font="0">follow up. </text>
<text top="789" left="865" width="3" height="20" font="0"> </text>
</page>
<page number="71" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">71 </text>
<text top="107" left="865" width="175" height="20" font="0">OVERALL QUALITY: Moderate </text>
<text top="124" left="865" width="3" height="20" font="0"> </text>
<text top="142" left="91" width="39" height="20" font="7"><b>MESA </b></text>
<text top="159" left="91" width="118" height="20" font="0">DeFilippis AP, et al.,  </text>
<text top="177" left="91" width="56" height="20" font="0">2015<a href="data supplement.html#240"> (70)</a> </text>
<text top="194" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25686167">25686167</a></text>
<text top="194" left="145" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25686167"> </a></text>
<text top="142" left="225" width="74" height="20" font="7"><b>Study type:</b>  </text>
<text top="159" left="225" width="105" height="20" font="0">Prospective cohort </text>
<text top="177" left="225" width="3" height="20" font="0"> </text>
<text top="194" left="225" width="129" height="20" font="7"><b>Size:</b> 4227 participants </text>
<text top="211" left="225" width="106" height="20" font="0">from the U.S. Multi-</text>
<text top="228" left="225" width="86" height="20" font="0">Ethnic Study of </text>
<text top="246" left="225" width="134" height="20" font="0">Atherosclerosis (MESA) </text>
<text top="263" left="225" width="47" height="20" font="0">Cohort   </text>
<text top="142" left="375" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="161" left="375" width="7" height="18" font="0">•</text>
<text top="161" left="381" width="86" height="20" font="0"> Age 50 to 74 y<b> </b></text>
<text top="180" left="375" width="7" height="18" font="0">•</text>
<text top="179" left="381" width="146" height="20" font="0"> Free of clinical ASCVD or </text>
<text top="196" left="375" width="113" height="20" font="0">diabetes at baseline<b> </b></text>
<text top="215" left="375" width="7" height="18" font="0">•</text>
<text top="215" left="381" width="134" height="20" font="0"> MESA participants who </text>
<text top="232" left="375" width="149" height="20" font="0">identified as White, African </text>
<text top="249" left="375" width="127" height="20" font="0">American, Hispanic, or </text>
<text top="266" left="375" width="52" height="20" font="0">Chinese  </text>
<text top="284" left="375" width="3" height="20" font="0"> </text>
<text top="301" left="375" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="320" left="375" width="7" height="18" font="0">•</text>
<text top="319" left="381" width="118" height="20" font="0"> Diabetes at baseline<b> </b></text>
<text top="338" left="375" width="7" height="18" font="0">•</text>
<text top="337" left="381" width="116" height="20" font="0"> Missing data (2.7%)<b> </b></text>
<text top="355" left="375" width="3" height="20" font="0"> </text>
<text top="143" left="550" width="76" height="20" font="7"><b>1</b>°<b> endpoint:</b> </text>
<text top="143" left="626" width="177" height="20" font="17">MI, death from CHD, and stroke </text>
<text top="161" left="550" width="3" height="20" font="0"> </text>
<text top="178" left="550" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="197" left="550" width="7" height="18" font="0">•</text>
<text top="196" left="557" width="239" height="20" font="0"> Five prediction scores were calculated and </text>
<text top="213" left="550" width="287" height="20" font="0">compared: PCE, FRS-CHD, FRS-CVD, ATPIII-FRS, </text>
<text top="231" left="550" width="87" height="20" font="0">CHD, and RRS </text>
<text top="248" left="550" width="3" height="20" font="0"> </text>
<text top="265" left="550" width="177" height="20" font="0">    ALL           P    O     C    slope </text>
<text top="282" left="550" width="176" height="20" font="0">FRS-HD        9.42 6.22 .68 0.05 </text>
<text top="299" left="550" width="188" height="20" font="0">FRS-CVD     13.28 10.60 .71 0.09 </text>
<text top="317" left="550" width="200" height="20" font="0">ATPIII-FRS-CHD 6.83 3.17 .71 0.06 </text>
<text top="334" left="550" width="170" height="20" font="0">RRS            7.43 7.64 .72 0.07 </text>
<text top="351" left="550" width="169" height="20" font="0">PCE            9.16 5.16 .71 0.06 </text>
<text top="368" left="550" width="3" height="20" font="0"> </text>
<text top="386" left="550" width="206" height="20" font="0">    MEN            P         O     C     slope </text>
<text top="403" left="550" width="207" height="20" font="0">FRS-HD        12.8     8.36   .69    0.05 </text>
<text top="420" left="550" width="205" height="20" font="0">FRS-CVD      18.29  13.31  .71   0.09 </text>
<text top="437" left="550" width="206" height="20" font="0">ATPIII-FRS-CHD 11.15 4.39 .71 0.05 </text>
<text top="454" left="550" width="207" height="20" font="0">RRS              10.89   9.99    .70   0.06 </text>
<text top="472" left="550" width="207" height="20" font="0">PCE              11.84   6.37    .71   0.06 </text>
<text top="489" left="550" width="3" height="20" font="0"> </text>
<text top="506" left="550" width="214" height="20" font="0">  WOMEN        P        O       C      slope </text>
<text top="523" left="550" width="207" height="20" font="0">FRS-HD          6.47   4.37   .60    0.01 </text>
<text top="540" left="550" width="209" height="20" font="0">FRS-CVD       8.94    8.25   .70    0.05 </text>
<text top="558" left="550" width="206" height="20" font="0">ATPIII-FRS-CHD 3.10 2.12 .67   0.02 </text>
<text top="575" left="550" width="207" height="20" font="0">RRS               4.44    5.60    .72   0.05 </text>
<text top="592" left="550" width="207" height="20" font="0">PCE               6.84    4.10     .70. 0.05 </text>
<text top="609" left="550" width="3" height="20" font="0"> </text>
<text top="628" left="550" width="7" height="18" font="0">•</text>
<text top="628" left="557" width="84" height="20" font="0"> For those with </text>
<text top="628" left="641" width="195" height="20" font="17">PCE risk score of 7.5% to 10%, the </text>
<text top="645" left="550" width="300" height="20" font="17">actual event rate was 3% in men and 5.1% in women.  </text>
<text top="664" left="550" width="7" height="18" font="0">•</text>
<text top="663" left="557" width="289" height="20" font="0"> C-statistic for PCE: overall, 0.71; men, 0.71; women </text>
<text top="680" left="550" width="27" height="20" font="0">0.70 </text>
<text top="699" left="550" width="7" height="18" font="0">•</text>
<text top="699" left="557" width="291" height="20" font="0"> Calibration results in clinically relevant predicted risk </text>
<text top="716" left="550" width="64" height="20" font="0">categories: </text>
<text top="733" left="550" width="63" height="20" font="17">PCE: MEN </text>
<text top="750" left="550" width="202" height="20" font="0">                         P      O        H-L         </text>
<text top="768" left="550" width="179" height="20" font="0">&lt;5%               3.4     1.3       4.94 </text>
<text top="785" left="550" width="179" height="20" font="0">5-7.5%           6.2     2.5       7.45 </text>
<text top="144" left="865" width="7" height="18" font="0">•</text>
<text top="143" left="872" width="215" height="20" font="17"> Four of the 5 risk scores, including the </text>
<text top="161" left="865" width="204" height="20" font="17">PCE, overestimated risk in a modern </text>
<text top="178" left="865" width="100" height="20" font="17">multiethnic cohort </text>
<text top="197" left="865" width="7" height="18" font="0">•</text>
<text top="196" left="872" width="204" height="20" font="17"> Absolute differences in predicted vs. </text>
<text top="213" left="865" width="232" height="20" font="17">observed risk were most notable at higher </text>
<text top="231" left="865" width="125" height="20" font="17">levels of predicted risk </text>
<text top="250" left="864" width="11" height="18" font="17">• </text>
<text top="249" left="876" width="225" height="20" font="17">Women experienced less overestimation </text>
<text top="266" left="864" width="238" height="20" font="17">than men in all models, including PCE, and </text>
<text top="283" left="864" width="181" height="20" font="17">had underestimation by the RRS </text>
<text top="302" left="865" width="7" height="18" font="0">•</text>
<text top="302" left="872" width="192" height="20" font="0"> Attempts to adjust for aspirin, lipid-</text>
<text top="319" left="865" width="201" height="20" font="0">lowering or antihypertensive therapy </text>
<text top="336" left="865" width="154" height="20" font="0">during follow up and interim </text>
<text top="353" left="865" width="234" height="20" font="0">revascularization did not appear to explain </text>
<text top="370" left="865" width="104" height="20" font="0">the overestimation </text>
<text top="389" left="864" width="11" height="18" font="0">• </text>
<text top="389" left="879" width="197" height="20" font="0">Limitations: multi-ethnic cohort, and </text>
<text top="406" left="865" width="204" height="20" font="0">PCE were derived only in whites and </text>
<text top="423" left="865" width="183" height="20" font="0">blacks; participants with diabetes </text>
<text top="441" left="865" width="228" height="20" font="0">excluded; participants received intensive, </text>
<text top="458" left="865" width="236" height="20" font="0">repeated screenings for subclinical CVD at </text>
<text top="475" left="865" width="228" height="20" font="0">baseline and during follow up, which may </text>
<text top="492" left="865" width="221" height="20" font="0">have influenced preventive approaches; </text>
<text top="509" left="865" width="217" height="20" font="0">may represent a healthier subset of the </text>
<text top="527" left="865" width="237" height="20" font="0">U.S. population; inadequate adjustment for </text>
<text top="544" left="865" width="96" height="20" font="0">follow up therapy </text>
<text top="561" left="865" width="3" height="20" font="0"> </text>
<text top="578" left="865" width="3" height="20" font="0"> </text>
<text top="595" left="865" width="175" height="20" font="0">OVERALL QUALITY: Moderate </text>
</page>
<page number="72" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">72 </text>
<text top="107" left="550" width="183" height="20" font="0">7.5%-9.9%     8.7     3.0      10.56 </text>
<text top="124" left="550" width="186" height="20" font="0">&gt;10%             17.6   10.3     36.32 </text>
<text top="141" left="550" width="3" height="20" font="17"> </text>
<text top="159" left="550" width="84" height="20" font="17">PCE: WOMEN </text>
<text top="176" left="550" width="198" height="20" font="0">                       P       O        H-L         </text>
<text top="193" left="550" width="176" height="20" font="0">&lt;5%               2.4    1.7       2.64 </text>
<text top="210" left="550" width="176" height="20" font="0">5-7.5%           6.1    4.5       1.65 </text>
<text top="228" left="550" width="176" height="20" font="0">7.5%-9.9%     8.7    5.1       3.86 </text>
<text top="245" left="550" width="179" height="20" font="0">&gt;10%            15.9   8.6      21.60 </text>
<text top="262" left="550" width="3" height="20" font="0"> </text>
<text top="280" left="91" width="39" height="20" font="7"><b>MESA </b></text>
<text top="297" left="91" width="118" height="20" font="0">DeFilippis AP, et al.,  </text>
<text top="314" left="91" width="60" height="20" font="0">2017<a href="data supplement.html#240"> (71)</a>  </text>
<text top="332" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27436865">27436865</a></text>
<text top="332" left="145" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27436865"> </a></text>
<text top="280" left="225" width="77" height="20" font="7"><b>Study type:</b>   </text>
<text top="297" left="225" width="3" height="20" font="0"> </text>
<text top="314" left="225" width="129" height="20" font="7"><b>Size:</b> 6441 participants </text>
<text top="332" left="225" width="106" height="20" font="0">from the U.S. Multi-</text>
<text top="349" left="225" width="86" height="20" font="0">Ethnic Study of </text>
<text top="366" left="225" width="134" height="20" font="0">Atherosclerosis (MESA) </text>
<text top="383" left="225" width="47" height="20" font="0">Cohort   </text>
<text top="280" left="375" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="299" left="375" width="7" height="18" font="0">•</text>
<text top="298" left="381" width="73" height="20" font="0"> Age 45-79 y<b> </b></text>
<text top="317" left="375" width="7" height="18" font="0">•</text>
<text top="317" left="381" width="144" height="20" font="0"> Free of known ASCVD at </text>
<text top="334" left="375" width="49" height="20" font="0">baseline<b> </b></text>
<text top="351" left="375" width="3" height="20" font="0"> </text>
<text top="368" left="375" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="387" left="375" width="7" height="18" font="0">•</text>
<text top="387" left="381" width="150" height="20" font="0"> Missing data for risk score </text>
<text top="404" left="375" width="129" height="20" font="0">calculation (&lt;1%) or no </text>
<text top="421" left="375" width="157" height="20" font="0">follow-up data after baseline </text>
<text top="438" left="375" width="37" height="20" font="0">(&lt;1%) </text>
<text top="281" left="550" width="122" height="20" font="7"><b>1</b>°<b> endpoint:</b> Incident </text>
<text top="281" left="673" width="173" height="20" font="17">MI, death from CHD, and stroke</text>
<text top="281" left="846" width="3" height="20" font="0"> </text>
<text top="298" left="550" width="3" height="20" font="0"> </text>
<text top="316" left="550" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="335" left="550" width="7" height="18" font="0">•</text>
<text top="334" left="557" width="282" height="20" font="0"> Risk overestimation was similar for women (100%) </text>
<text top="351" left="550" width="297" height="20" font="0">and men (93%) as was discrimination: c-statistic: 0.74 </text>
<text top="368" left="550" width="157" height="20" font="0">for women and 0.71 for men </text>
<text top="387" left="550" width="7" height="18" font="0">•</text>
<text top="387" left="557" width="273" height="20" font="0"> Overestimation was observed in all race/ethnicity </text>
<text top="404" left="550" width="280" height="20" font="0">groups and was highest among Chinese (252% for </text>
<text top="421" left="550" width="264" height="20" font="0">women and 314% for men), and lowest in White </text>
<text top="438" left="550" width="224" height="20" font="0">women (72%) and Hispanic men (67%).  </text>
<text top="456" left="550" width="268" height="20" font="0">Modelling of the AHA-ACC- ASCVD risk score in </text>
<text top="473" left="550" width="233" height="20" font="0">MESA demonstrates a mean absolute risk </text>
<text top="490" left="550" width="185" height="20" font="0">overestimation of 5.5% (p=0.001) </text>
<text top="509" left="550" width="7" height="18" font="0">•</text>
<text top="508" left="557" width="263" height="20" font="0"> C-statistics in women: overall, 0.74; white 0.70; </text>
<text top="526" left="550" width="230" height="20" font="0">black, 0.75; Hispanic, 0.79; Chinese, 0.83 </text>
<text top="544" left="550" width="290" height="20" font="0"> • C-statistics in men: overall, 0.71; white 0.71, black </text>
<text top="561" left="550" width="195" height="20" font="0">0.68; Hispanic, 0.75; Chinese, 0.63 </text>
<text top="580" left="550" width="7" height="18" font="0">•</text>
<text top="579" left="557" width="236" height="20" font="0"> C-statistics in women not on lipid-lowering </text>
<text top="597" left="550" width="297" height="20" font="0">medications with baseline LDLC 70-189: overall, 0.77; </text>
<text top="614" left="550" width="287" height="20" font="0">white 0.70; black, 0.77; Hispanic, 0.84; Chinese (too </text>
<text top="631" left="550" width="66" height="20" font="0">few events) </text>
<text top="649" left="550" width="299" height="20" font="0"> • C-statistics in men not on lipid-lowering medications </text>
<text top="667" left="550" width="291" height="20" font="0">with baseline LDLC 70-189: overall, 0.71; white 0.72, </text>
<text top="684" left="550" width="287" height="20" font="0">black 0.70; Hispanic, 0.74; Chinese (too few events) </text>
<text top="703" left="549" width="11" height="18" font="0">• </text>
<text top="702" left="558" width="293" height="20" font="0">Predicted risks were higher, and absolute differences </text>
<text top="719" left="550" width="276" height="20" font="0">between predicted and observed event rates were </text>
<text top="737" left="550" width="297" height="20" font="0">greater, for those who initiated preventive therapies or </text>
<text top="754" left="550" width="213" height="20" font="0">had revascularization during follow up. </text>
<text top="282" left="865" width="7" height="18" font="0">•</text>
<text top="281" left="872" width="222" height="20" font="0"> PCE overestimated ASCVD risk among </text>
<text top="298" left="865" width="205" height="20" font="0">men, women, and all four race/ethnic </text>
<text top="316" left="865" width="209" height="20" font="0">groups in a modern American primary </text>
<text top="333" left="865" width="98" height="20" font="0">prevention cohort </text>
<text top="352" left="865" width="7" height="18" font="0">•</text>
<text top="351" left="872" width="199" height="20" font="0"> Overestimation was highest among </text>
<text top="368" left="865" width="236" height="20" font="0">Chinese men and lowest in Hispanic Men.  </text>
<text top="387" left="865" width="7" height="18" font="0">•</text>
<text top="387" left="872" width="226" height="20" font="0"> Suggested that overestimation could not </text>
<text top="404" left="865" width="203" height="20" font="0">be fully attributed to treatment effect, </text>
<text top="421" left="865" width="159" height="20" font="0">although it did explain some  </text>
<text top="440" left="865" width="7" height="18" font="0">•</text>
<text top="440" left="872" width="219" height="20" font="0"> Limitations: very few events in Chinese </text>
<text top="457" left="865" width="55" height="20" font="0">subgroup </text>
<text top="474" left="865" width="3" height="20" font="0"> </text>
<text top="491" left="865" width="175" height="20" font="0">OVERALL QUALITY: Moderate </text>
<text top="508" left="865" width="3" height="20" font="0"> </text>
<text top="526" left="865" width="3" height="20" font="0"> </text>
</page>
<page number="73" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">73 </text>
<text top="107" left="91" width="118" height="20" font="0">Feinstein et al., 2017 </text>
<text top="124" left="91" width="25" height="20" font="0"><a href="data supplement.html#240">(72)</a> </text>
<text top="141" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27436865">28002550</a></text>
<text top="141" left="145" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27436865"> </a></text>
<text top="159" left="91" width="3" height="20" font="0"> </text>
<text top="107" left="225" width="71" height="20" font="7"><b>Study type:</b> </text>
<text top="124" left="225" width="126" height="20" font="0">Retrospective analysis </text>
<text top="141" left="225" width="124" height="20" font="0">of previously collected </text>
<text top="159" left="225" width="104" height="20" font="0">multicenter clinical </text>
<text top="176" left="225" width="104" height="20" font="0">prospective cohort </text>
<text top="193" left="225" width="64" height="20" font="0">study data  </text>
<text top="210" left="225" width="3" height="20" font="0"> </text>
<text top="227" left="225" width="97" height="20" font="7"><b>Size:</b> 11,288 HIV-</text>
<text top="245" left="225" width="131" height="20" font="0">infected adults from the </text>
<text top="262" left="225" width="96" height="20" font="0">Centers for AIDS </text>
<text top="279" left="225" width="118" height="20" font="0">Research Network of </text>
<text top="296" left="225" width="102" height="20" font="0">Integrated Clinical </text>
<text top="314" left="225" width="100" height="20" font="0">Systems (CNICS) </text>
<text top="331" left="225" width="38" height="20" font="0">cohort </text>
<text top="107" left="375" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="126" left="375" width="7" height="18" font="0">•</text>
<text top="125" left="381" width="92" height="20" font="0"> Adults age 18 y </text>
<text top="143" left="375" width="163" height="20" font="0">or older receiving HIV care at </text>
<text top="160" left="375" width="128" height="20" font="0">1 of 5 centers for AIDS </text>
<text top="177" left="375" width="142" height="20" font="0">research clinics in the US </text>
<text top="194" left="375" width="125" height="20" font="0">with adjudicated MI as </text>
<text top="212" left="375" width="51" height="20" font="0">outcome<b> </b></text>
<text top="231" left="375" width="7" height="18" font="0">•</text>
<text top="230" left="381" width="126" height="20" font="0"> Free of MI at baseline<b> </b></text>
<text top="247" left="375" width="3" height="20" font="0"> </text>
<text top="264" left="375" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="283" left="375" width="7" height="18" font="0">•</text>
<text top="283" left="381" width="112" height="20" font="0"> MI prior to baseline<b> </b></text>
<text top="300" left="375" width="3" height="20" font="0"> </text>
<text top="108" left="550" width="169" height="20" font="7"><b>1</b>°<b> endpoint:</b> Incident MI only; </text>
<text top="125" left="550" width="139" height="20" font="0">Median follow up of 4.1 y </text>
<text top="143" left="550" width="3" height="20" font="0"> </text>
<text top="160" left="550" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="179" left="550" width="7" height="18" font="0">•</text>
<text top="178" left="557" width="284" height="20" font="0"> PCE adequately discriminated MI risk in the overall </text>
<text top="195" left="550" width="279" height="20" font="0">cohort (Harrell C statistic=0.75, 95% CI: 0.71-0.78)<b> </b></text>
<text top="214" left="550" width="7" height="18" font="0">•</text>
<text top="214" left="557" width="280" height="20" font="0"> Among those with baseline age &gt;=40 y, C-statistic </text>
<text top="231" left="550" width="300" height="20" font="0">0.70 (95% CI: 0.66,0.74) overall; white men 0.69 (95% </text>
<text top="248" left="550" width="286" height="20" font="0">CI: 0.64-0.75); black men 0.69 (95% CI: 0.63, 0.76); </text>
<text top="265" left="550" width="295" height="20" font="0">white women 0.65 (95% CI: 0.48, 0.82); black women </text>
<text top="283" left="550" width="141" height="20" font="0">0.74 (95% CI: 0.66, 0.83) </text>
<text top="302" left="550" width="7" height="18" font="0">•</text>
<text top="301" left="557" width="183" height="20" font="0"> PCE were moderately calibrated </text>
<text top="301" left="740" width="111" height="20" font="17">in the overall cohort </text>
<text top="318" left="550" width="300" height="20" font="17">(slope = 0.815; intercept = 0.0015; GND test statistic = </text>
<text top="336" left="550" width="267" height="20" font="17">13.1; p=0.16), particularly for white men (slope = </text>
<text top="353" left="550" width="269" height="20" font="17">0.857; intercept = 0.009; GND test statistic = 6.4; </text>
<text top="370" left="550" width="49" height="20" font="17">p=0.50)  </text>
<text top="109" left="865" width="7" height="18" font="0">•</text>
<text top="108" left="872" width="183" height="20" font="0"> PCE, which predict ASCVD risk, </text>
<text top="125" left="865" width="219" height="20" font="0">adequately discriminated MI risk overall </text>
<text top="143" left="865" width="220" height="20" font="0">and in most race and sex combinations, </text>
<text top="160" left="865" width="198" height="20" font="0">and were moderately calibrated in a </text>
<text top="177" left="865" width="198" height="20" font="0">multicenter HIV cohort, with modest </text>
<text top="194" left="865" width="217" height="20" font="0">underestimation of MI risk at lower risk. </text>
<text top="212" left="865" width="232" height="20" font="0">This indicates substantial underestimation </text>
<text top="229" left="865" width="208" height="20" font="0">of risk for ASCVD since stroke events </text>
<text top="246" left="865" width="176" height="20" font="0">were not captured in the cohort. </text>
<text top="265" left="865" width="7" height="18" font="0">•</text>
<text top="264" left="872" width="204" height="20" font="0"> PCE were not as well fitted for black </text>
<text top="281" left="865" width="202" height="20" font="0">men, black women or white women.  </text>
<text top="301" left="865" width="7" height="18" font="0">•</text>
<text top="300" left="872" width="216" height="20" font="0"> HIV-related factors did not appreciably </text>
<text top="317" left="865" width="218" height="20" font="0">increase the discrimination and actually </text>
<text top="334" left="865" width="228" height="20" font="0">worsened model fit compared to the PCE </text>
<text top="352" left="865" width="3" height="20" font="0"> </text>
<text top="369" left="865" width="148" height="20" font="0">OVERALL QUALITY: High </text>
<text top="409" left="91" width="39" height="20" font="7"><b>MESA </b></text>
<text top="427" left="91" width="109" height="20" font="0">Flueckiger P, et al., </text>
<text top="444" left="91" width="56" height="20" font="0">2017<a href="data supplement.html#240"> (73)</a> </text>
<text top="461" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27859433">27859433</a></text>
<text top="461" left="145" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27859433"> </a></text>
<text top="409" left="225" width="71" height="20" font="7"><b>Study type:</b> </text>
<text top="427" left="225" width="67" height="20" font="0">Prospective </text>
<text top="444" left="225" width="120" height="20" font="0">Observational Cohort </text>
<text top="461" left="225" width="36" height="20" font="0">study  </text>
<text top="478" left="225" width="3" height="20" font="0"> </text>
<text top="496" left="225" width="132" height="20" font="7"><b>Size:</b> 5,002 participants </text>
<text top="513" left="225" width="106" height="20" font="0">from the U.S. Multi-</text>
<text top="530" left="225" width="86" height="20" font="0">Ethnic Study of </text>
<text top="547" left="225" width="134" height="20" font="0">Atherosclerosis (MESA) </text>
<text top="564" left="225" width="47" height="20" font="0">Cohort   </text>
<text top="409" left="375" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="429" left="375" width="7" height="18" font="0">•</text>
<text top="428" left="381" width="123" height="20" font="0"> Adults age 45 to 75 y<b> </b></text>
<text top="447" left="375" width="7" height="18" font="0">•</text>
<text top="446" left="381" width="75" height="20" font="0"> Free of CVD<b> </b></text>
<text top="463" left="375" width="3" height="20" font="0"> </text>
<text top="481" left="375" width="3" height="20" font="0"> </text>
<text top="498" left="375" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="517" left="375" width="7" height="18" font="0">•</text>
<text top="516" left="381" width="126" height="20" font="0"> missing covariates for </text>
<text top="533" left="375" width="125" height="20" font="0">ASCVD risk prediction<b> </b></text>
<text top="553" left="375" width="7" height="18" font="0">•</text>
<text top="552" left="381" width="142" height="20" font="0"> taking statins at baseline<b> </b></text>
<text top="571" left="375" width="7" height="18" font="0">•</text>
<text top="570" left="381" width="68" height="20" font="0"> age &gt; 75 y  </text>
<text top="411" left="550" width="283" height="20" font="7"><b>1</b>°<b> endpoint:</b> 10-y CVD events defined as fatal and </text>
<text top="428" left="550" width="294" height="20" font="0">nonfatal MI, CHD death, fatal and nonfatal stroke and </text>
<text top="445" left="550" width="301" height="20" font="0">sudden cardiac death and CAC categories (&gt;0, &gt;=100, </text>
<text top="462" left="550" width="42" height="20" font="0">&gt;=300) </text>
<text top="479" left="550" width="3" height="20" font="0"> </text>
<text top="497" left="550" width="112" height="20" font="7"><b>Results (for PCE):</b>  </text>
<text top="516" left="550" width="7" height="18" font="0">•</text>
<text top="515" left="557" width="244" height="20" font="0"> For incident ASCVD, sensitivity was 79.6%, </text>
<text top="532" left="550" width="273" height="20" font="0">specificity was 50.7%, NPV was 98.0%, PPV was </text>
<text top="550" left="550" width="294" height="20" font="0">7.7%, Negative LR 1.61 (95% CI: 1.50-1.73), Positive </text>
<text top="567" left="550" width="157" height="20" font="0">LR 0.40 (95% CI: 0.31-0.52) </text>
<text top="586" left="550" width="7" height="18" font="0">•</text>
<text top="585" left="557" width="269" height="20" font="0"> Overall, the PCE had higher sensitivity and NPV </text>
<text top="602" left="550" width="272" height="20" font="0">than the 2004 NCEP ATP III and 2016 ESC/EAS  </text>
<text top="621" left="550" width="7" height="18" font="0">•</text>
<text top="621" left="557" width="277" height="20" font="0"> For CAC &gt;=300, sensitivity was 87.2%, specificity </text>
<text top="638" left="550" width="258" height="20" font="0">was 52.6%, NPV was 97.8%, PPV was 14.5%, </text>
<text top="655" left="550" width="277" height="20" font="0">Negative LR 0.24 (95% CI: 0.19-0.31), positive LR </text>
<text top="672" left="550" width="138" height="20" font="0">1.84 (95% CI: 1.76-1.93) </text>
<text top="691" left="550" width="7" height="18" font="0">•</text>
<text top="691" left="557" width="277" height="20" font="0"> For CAC &gt;=100, sensitivity was 83.1%, specificity </text>
<text top="708" left="550" width="258" height="20" font="0">was 56.1%, NPV was 97.8%, PPV was 14.5%, </text>
<text top="725" left="550" width="278" height="20" font="0">Negative LR 0.30 (95% CI: 0.26-0.35), Positive LR </text>
<text top="742" left="550" width="138" height="20" font="0">1.89 (95% CI: 1.81-1.98)<b> </b></text>
<text top="761" left="550" width="7" height="18" font="0">•</text>
<text top="761" left="557" width="281" height="20" font="0"> For CAC &gt;0, sensitivity was 69.8%, specificity was </text>
<text top="778" left="550" width="284" height="20" font="0">63.2%, NPV was 97.8%, PPV was 14.5%, Negative </text>
<text top="411" left="865" width="7" height="18" font="0">•</text>
<text top="411" left="872" width="209" height="20" font="0"> ACC/AHA approach (including use of </text>
<text top="428" left="865" width="182" height="20" font="0">PCE) appears to be an improved </text>
<text top="445" left="865" width="204" height="20" font="0">screening tool for the identification of </text>
<text top="462" left="865" width="200" height="20" font="0">asymptomatic individuals with future </text>
<text top="480" left="865" width="211" height="20" font="0">ASCVD events and current subclinical </text>
<text top="497" left="865" width="229" height="20" font="0">CAC compared with the 2004 NCEP ATP </text>
<text top="514" left="865" width="225" height="20" font="0">III and 2016 ESC/EAS class I indications </text>
<text top="531" left="865" width="176" height="20" font="0">for statins/lipid-lowering therapy </text>
<text top="550" left="865" width="7" height="18" font="0">•</text>
<text top="550" left="872" width="218" height="20" font="0"> Limitations: overall low event rates, did </text>
<text top="567" left="865" width="227" height="20" font="0">not account for statin use over time (25% </text>
<text top="584" left="865" width="230" height="20" font="0">of population taking statins after baseline) </text>
<text top="601" left="865" width="3" height="20" font="0"> </text>
<text top="618" left="865" width="175" height="20" font="0">OVERALL QUALITY: Moderate </text>
</page>
<page number="74" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">74 </text>
<text top="107" left="550" width="286" height="20" font="0">LR 0.47 (95% CI: 0.44-0.51), Positive LR 1.90 (95% </text>
<text top="124" left="550" width="79" height="20" font="0">CI: 1.80-2.01)<b> </b></text>
<text top="141" left="550" width="3" height="20" font="7"><b> </b></text>
<text top="159" left="91" width="118" height="20" font="7"><b>Korean Heart Study </b></text>
<text top="177" left="91" width="115" height="20" font="0">Jung KJ, et al., 2015 </text>
<text top="194" left="91" width="25" height="20" font="0"><a href="data supplement.html#240">(74)</a> </text>
<text top="211" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26255683">26255683</a></text>
<text top="211" left="145" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26255683"> </a></text>
<text top="159" left="225" width="71" height="20" font="7"><b>Study type:</b> </text>
<text top="177" left="225" width="67" height="20" font="0">Prospective </text>
<text top="194" left="225" width="120" height="20" font="0">Observational Cohort </text>
<text top="211" left="225" width="3" height="20" font="0"> </text>
<text top="228" left="225" width="80" height="20" font="7"><b>Size:</b> 192,605 </text>
<text top="245" left="225" width="66" height="20" font="0">participants </text>
<text top="159" left="375" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="178" left="375" width="7" height="18" font="0">•</text>
<text top="178" left="381" width="73" height="20" font="0"> Age 40-79 y </text>
<text top="197" left="375" width="7" height="18" font="0">•</text>
<text top="196" left="381" width="116" height="20" font="0"> Korean adults in the </text>
<text top="213" left="375" width="161" height="20" font="0">Korean Heart Study who had </text>
<text top="231" left="375" width="159" height="20" font="0">a minimum 10 y follow-up by </text>
<text top="248" left="375" width="31" height="20" font="0">2012 </text>
<text top="265" left="375" width="3" height="20" font="0"> </text>
<text top="282" left="375" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="301" left="375" width="7" height="18" font="0">•</text>
<text top="301" left="381" width="149" height="20" font="0"> Stroke or CVD at baseline </text>
<text top="320" left="375" width="7" height="18" font="0">•</text>
<text top="319" left="381" width="149" height="20" font="0"> use of lipid-lowering meds </text>
<text top="336" left="375" width="63" height="20" font="0">at baseline </text>
<text top="355" left="375" width="7" height="18" font="0">•</text>
<text top="355" left="381" width="122" height="20" font="0"> Persons with missing </text>
<text top="372" left="375" width="141" height="20" font="0">values of blood pressure, </text>
<text top="389" left="375" width="121" height="20" font="0">total cholesterol, HDL </text>
<text top="406" left="375" width="155" height="20" font="0">cholesterol, fasting glucose, </text>
<text top="423" left="375" width="128" height="20" font="0">smoking status, or BMI </text>
<text top="161" left="550" width="180" height="20" font="7"><b>1</b>°<b> endpoint:</b> ASCVD incidence; </text>
<text top="178" left="550" width="234" height="20" font="0">Minimum of 10 y of follow up; mean 12.8 y<b> </b></text>
<text top="195" left="550" width="3" height="20" font="0"> </text>
<text top="212" left="550" width="52" height="20" font="7"><b>Results: </b></text>
<text top="231" left="550" width="7" height="18" font="0">•</text>
<text top="231" left="557" width="293" height="20" font="0"> 12,237 ASCVD events overall (10,049 of which were </text>
<text top="248" left="550" width="88" height="20" font="0">nonfatal stroke) </text>
<text top="267" left="550" width="7" height="18" font="0">•</text>
<text top="266" left="557" width="271" height="20" font="0"> Discrimination: ACC/AHA PCE for white or black </text>
<text top="283" left="550" width="300" height="20" font="0">men exhibited moderate discrimination (AUROC 0.727 </text>
<text top="301" left="550" width="291" height="20" font="0">and 0.725 respectively), and similarly for the white or </text>
<text top="318" left="550" width="252" height="20" font="0">black women PCE (AUROC 0.738 and 0.739, </text>
<text top="335" left="550" width="73" height="20" font="0">respectively) </text>
<text top="354" left="550" width="7" height="18" font="0">•</text>
<text top="353" left="557" width="276" height="20" font="0"> Calibration: ACC/AHA PCEs overestimated event </text>
<text top="371" left="550" width="256" height="20" font="0">rates in KHS cohort for men. Absolute 10y risk </text>
<text top="388" left="550" width="280" height="20" font="0">overestimated by 56.5% from the white men model </text>
<text top="405" left="550" width="302" height="20" font="0">and 74.1% from the black men model. For women, risk </text>
<text top="422" left="550" width="291" height="20" font="0">was underestimated by 27.9% in the white model but </text>
<text top="440" left="550" width="279" height="20" font="0">overestimated by 29.1% in the black model. These </text>
<text top="457" left="550" width="274" height="20" font="0">patterns of inadequate calibration were consistent </text>
<text top="474" left="550" width="104" height="20" font="0">across risk deciles </text>
<text top="493" left="550" width="7" height="18" font="0">•</text>
<text top="492" left="557" width="289" height="20" font="0"> A recalibrated model exhibited improved calibration; </text>
<text top="510" left="550" width="289" height="20" font="0">the largest differences between actual and predicted </text>
<text top="527" left="550" width="297" height="20" font="0">rates within a risk decile were 1.7% in the recalibrated </text>
<text top="544" left="550" width="297" height="20" font="0">model (compared with 8.75% in the original ACC/AHA </text>
<text top="561" left="550" width="47" height="20" font="0">models) </text>
<text top="580" left="550" width="7" height="18" font="0">•</text>
<text top="579" left="557" width="293" height="20" font="0"> The Korean Risk Prediction Model (KRPM) exhibited </text>
<text top="597" left="550" width="294" height="20" font="0">somewhat better calibration than the PCEs; of note, it </text>
<text top="614" left="550" width="282" height="20" font="0">appears that the KRPM was derived from the same </text>
<text top="631" left="550" width="194" height="20" font="0">KHS cohort it was then validated in </text>
<text top="161" left="865" width="7" height="18" font="0">•</text>
<text top="161" left="872" width="219" height="20" font="0"> PCE exhibited moderate discrimination </text>
<text top="178" left="865" width="234" height="20" font="0">but inadequate calibration when applied to </text>
<text top="195" left="865" width="188" height="20" font="0">a large Korean prospective cohort </text>
<text top="214" left="865" width="7" height="18" font="0">•</text>
<text top="213" left="872" width="219" height="20" font="0"> PCE had systematic mismatch for men </text>
<text top="231" left="865" width="200" height="20" font="0">whereby predicted risks consistently </text>
<text top="248" left="865" width="182" height="20" font="0">exceeded observed; this was not </text>
<text top="265" left="865" width="179" height="20" font="0">consistently the case for women </text>
<text top="284" left="865" width="7" height="18" font="0">•</text>
<text top="283" left="872" width="217" height="20" font="0"> A simple recalibrated ACC/AHA model </text>
<text top="301" left="865" width="120" height="20" font="0">was better calibrated  </text>
<text top="320" left="865" width="7" height="18" font="0">•</text>
<text top="319" left="872" width="192" height="20" font="0"> A Korean-specific model was best </text>
<text top="336" left="865" width="222" height="20" font="0">calibrated, though this is expected given </text>
<text top="354" left="865" width="200" height="20" font="0">the derivation and validation cohorts </text>
<text top="371" left="865" width="127" height="20" font="0">appear to be the same </text>
<text top="388" left="865" width="3" height="20" font="0"> </text>
<text top="407" left="864" width="11" height="18" font="0">• </text>
<text top="406" left="874" width="220" height="20" font="0">Limitations: The better calibrated nature </text>
<text top="423" left="864" width="189" height="20" font="0">of the KRPM is expected as these </text>
<text top="440" left="864" width="215" height="20" font="0">analyses were biased toward optimism </text>
<text top="458" left="864" width="206" height="20" font="0">because the derivation and validation </text>
<text top="475" left="864" width="238" height="20" font="0">cohort appear to have been the same; very </text>
<text top="492" left="864" width="221" height="20" font="0">different population than PCE derivation </text>
<text top="509" left="864" width="204" height="20" font="0">cohorts – far more strokes than CHD </text>
<text top="527" left="865" width="3" height="20" font="0"> </text>
<text top="544" left="865" width="175" height="20" font="0">OVERALL QUALITY: Moderate </text>
<text top="561" left="865" width="3" height="20" font="0"> </text>
<text top="649" left="91" width="101" height="20" font="0">Kavousi M, et al.,  </text>
<text top="666" left="91" width="56" height="20" font="0">2014<a href="data supplement.html#240"> (75)</a> </text>
<text top="683" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24681960">24681960</a></text>
<text top="683" left="145" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24681960"> </a></text>
<text top="649" left="225" width="71" height="20" font="7"><b>Study type:</b> </text>
<text top="666" left="225" width="67" height="20" font="0">Prospective </text>
<text top="683" left="225" width="120" height="20" font="0">Observational Cohort </text>
<text top="701" left="225" width="33" height="20" font="0">study </text>
<text top="718" left="225" width="3" height="20" font="0"> </text>
<text top="735" left="225" width="129" height="20" font="7"><b>Size:</b> 4854 participants </text>
<text top="649" left="375" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="668" left="375" width="7" height="18" font="0">•</text>
<text top="667" left="381" width="150" height="20" font="0"> Age 55-75 y in Rotterdam, </text>
<text top="685" left="375" width="70" height="20" font="0">Netherlands </text>
<text top="702" left="375" width="3" height="20" font="0"> </text>
<text top="719" left="375" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="738" left="375" width="7" height="18" font="0">•</text>
<text top="737" left="381" width="145" height="20" font="0"> Lipid-lowering medication </text>
<text top="755" left="375" width="23" height="20" font="0">use </text>
<text top="774" left="375" width="7" height="18" font="0">•</text>
<text top="773" left="381" width="139" height="20" font="0"> Prevalent CVD or LDL-c </text>
<text top="790" left="375" width="31" height="20" font="0">&gt;190 </text>
<text top="650" left="550" width="290" height="20" font="7"><b>1</b>°<b> endpoint:</b> Hard ASCVD: stroke, nonfatal MI, fatal </text>
<text top="667" left="550" width="81" height="20" font="0">CHD, fatal MI; </text>
<text top="685" left="550" width="130" height="20" font="0">Median follow up &gt;10 y<b> </b></text>
<text top="702" left="550" width="3" height="20" font="0"> </text>
<text top="719" left="550" width="52" height="20" font="7"><b>Results: </b></text>
<text top="738" left="546" width="11" height="18" font="0">• </text>
<text top="737" left="560" width="109" height="20" font="0">343 ASCVD events<b> </b></text>
<text top="756" left="546" width="11" height="18" font="0">• </text>
<text top="756" left="560" width="292" height="20" font="0">PCE: Predicted vs. observed ASCVD risk was 21.5% </text>
<text top="773" left="546" width="301" height="20" font="0">(95% CI: 20.9-22.1%) vs. 12.7% (95% CI: 11.1-14.5%) </text>
<text top="790" left="546" width="283" height="20" font="0">for men; and 11.6% (95% CI: 11.2-12.0%) vs. 7.9% </text>
<text top="651" left="865" width="7" height="18" font="0">•</text>
<text top="650" left="872" width="204" height="20" font="0"> All 3 risk models exhibited moderate </text>
<text top="667" left="865" width="215" height="20" font="0">discrimination and poor calibration with </text>
<text top="685" left="865" width="233" height="20" font="0">overestimation of risk in an older (55-75 y) </text>
<text top="702" left="865" width="179" height="20" font="0">population from the Netherlands </text>
<text top="721" left="865" width="7" height="18" font="0">•</text>
<text top="720" left="872" width="215" height="20" font="0"> Calibration of PCE was better at lower </text>
<text top="737" left="865" width="209" height="20" font="0">(&lt;10%) compared with higher (≥10%) </text>
<text top="755" left="865" width="227" height="20" font="0">predicted risks, especially in women, and </text>
<text top="772" left="865" width="210" height="20" font="0">overall in women compared with men. </text>
<text top="789" left="865" width="3" height="20" font="0"> </text>
</page>
<page number="75" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">75 </text>
<text top="107" left="546" width="290" height="20" font="0">(95% CI: 6.7-9.2%) for women. The C-statistic of this </text>
<text top="124" left="546" width="297" height="20" font="0">model was 0.67 (95% CI: 0.63-0.71) for men and 0.68 </text>
<text top="141" left="546" width="293" height="20" font="0">(95% CI: 0.64-0.73) for women. Across predicted risk </text>
<text top="159" left="546" width="300" height="20" font="0">strata, absolute mismatch between PCE predicted and </text>
<text top="176" left="546" width="283" height="20" font="0">observed rates was moderate for men at &lt;10% and </text>
<text top="193" left="546" width="306" height="20" font="0">substantial at ≥10% predicted risk; for women, absolute </text>
<text top="210" left="546" width="291" height="20" font="0">mismatch was small at &lt;10% and moderate at ≥10% </text>
<text top="228" left="546" width="80" height="20" font="0">predicted risk. </text>
<text top="247" left="550" width="7" height="18" font="0">•</text>
<text top="246" left="557" width="282" height="20" font="0"> ATP3: C-statistic 0.67 (95% CI: 0.62-0.72) for men </text>
<text top="263" left="550" width="226" height="20" font="0">and 0.69 (95% CI: 0.63-0.75) for women  </text>
<text top="282" left="550" width="7" height="18" font="0">•</text>
<text top="281" left="557" width="278" height="20" font="0"> ESC SCORE: C-statistic 0.76 (95% CI: 0.70-0.82) </text>
<text top="299" left="550" width="248" height="20" font="0">for men, 0.77 (95% CI: 0.71-0.83) for women </text>
<text top="316" left="550" width="3" height="20" font="0"> </text>
<text top="107" left="865" width="206" height="20" font="7"><b>Limitations:</b> Older age of the cohort, </text>
<text top="124" left="865" width="222" height="20" font="0">which included only persons age 55 and </text>
<text top="141" left="865" width="183" height="20" font="0">over at baseline; all white cohort. </text>
<text top="159" left="865" width="3" height="20" font="0"> </text>
<text top="176" left="865" width="178" height="20" font="0">OVERALL QUALITY: Moderate  </text>
<text top="193" left="865" width="3" height="20" font="0"> </text>
<text top="210" left="865" width="3" height="20" font="0"> </text>
<text top="334" left="91" width="116" height="20" font="0">Khalili D, et al., 2015 </text>
<text top="351" left="91" width="25" height="20" font="0"><a href="data supplement.html#240">(76)</a> </text>
<text top="368" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25769004">25769004</a></text>
<text top="368" left="145" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25769004"> </a></text>
<text top="334" left="225" width="71" height="20" font="7"><b>Study type:</b> </text>
<text top="351" left="225" width="67" height="20" font="0">Prospective </text>
<text top="368" left="225" width="120" height="20" font="0">Observational Cohort </text>
<text top="386" left="225" width="33" height="20" font="0">study </text>
<text top="403" left="225" width="3" height="20" font="0"> </text>
<text top="420" left="225" width="129" height="20" font="7"><b>Size:</b> 6275 participants </text>
<text top="334" left="375" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="353" left="375" width="7" height="18" font="0">•</text>
<text top="352" left="381" width="73" height="20" font="0"> Age 40-75 y </text>
<text top="371" left="375" width="7" height="18" font="0">•</text>
<text top="371" left="381" width="152" height="20" font="0"> Iranian urban population in </text>
<text top="388" left="375" width="46" height="20" font="0">Tehran  </text>
<text top="405" left="375" width="3" height="20" font="0"> </text>
<text top="422" left="375" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="441" left="375" width="7" height="18" font="0">•</text>
<text top="441" left="381" width="145" height="20" font="0"> Lipid-lowering medication </text>
<text top="458" left="375" width="23" height="20" font="0">use </text>
<text top="477" left="375" width="7" height="18" font="0">•</text>
<text top="476" left="381" width="80" height="20" font="0"> Hemodialysis </text>
<text top="495" left="375" width="7" height="18" font="0">•</text>
<text top="495" left="381" width="132" height="20" font="0"> Missing data on LDL-c, </text>
<text top="512" left="375" width="163" height="20" font="0">DM, SBP, or current smoking </text>
<text top="529" left="375" width="63" height="20" font="0">at baseline </text>
<text top="548" left="375" width="7" height="18" font="0">•</text>
<text top="547" left="381" width="129" height="20" font="0"> Missing follow-up data </text>
<text top="335" left="550" width="269" height="20" font="7"><b>1</b>°<b> endpoint:</b> Incident CVD, defined as CHD and </text>
<text top="352" left="550" width="131" height="20" font="0">cerebrovascular events<b> </b></text>
<text top="370" left="550" width="3" height="20" font="0"> </text>
<text top="387" left="550" width="52" height="20" font="7"><b>Results: </b></text>
<text top="406" left="550" width="7" height="18" font="0">•</text>
<text top="405" left="557" width="292" height="20" font="0"> Among pts without prevalent CVD at baseline, mean </text>
<text top="422" left="550" width="269" height="20" font="0">calculated and observed 10-y ASCVD risks were </text>
<text top="440" left="550" width="293" height="20" font="0">12.4% and 7.9% for men, respectively, and 4.9% and </text>
<text top="457" left="550" width="92" height="20" font="0">3.3% for women </text>
<text top="476" left="550" width="7" height="18" font="0">•</text>
<text top="475" left="557" width="270" height="20" font="0"> Discrimination was better for men (C-index 0.82; </text>
<text top="492" left="550" width="287" height="20" font="0">95% CI: 0.78-0.86) than women (0.74; 95% CI: 0.71-</text>
<text top="510" left="550" width="269" height="20" font="0">0.78). This corresponded to consistent mismatch </text>
<text top="527" left="550" width="297" height="20" font="0">whereby ASCVD risks were 57% lower than predicted </text>
<text top="544" left="550" width="299" height="20" font="0">for men and 48% lower than predicted for women. H-L </text>
<text top="561" left="550" width="271" height="20" font="0">chi-square was 23.5 for men and 56.7 for women </text>
<text top="580" left="550" width="7" height="18" font="0">•</text>
<text top="579" left="557" width="284" height="20" font="0"> Simple recalibrations improved the calibration, with </text>
<text top="597" left="550" width="272" height="20" font="0">H-L chi-square down to 14.7 for men and 12.9 for </text>
<text top="614" left="550" width="46" height="20" font="0">women  </text>
<text top="633" left="550" width="7" height="18" font="0">•</text>
<text top="632" left="557" width="269" height="20" font="0"> Moderate statin therapy: Net Benefit Fraction for </text>
<text top="650" left="550" width="299" height="20" font="0">non-diabetic Men with LDL-c 70-189 and no prior CVD </text>
<text top="667" left="550" width="294" height="20" font="0">with predicted 10y ASCVD risk of 5% to 7.4% is 0.46. </text>
<text top="684" left="550" width="276" height="20" font="0">For women, this was 0.11 (not significant). Among </text>
<text top="701" left="550" width="296" height="20" font="0">those with DM, these numbers were 0.72 for men and </text>
<text top="718" left="550" width="92" height="20" font="0">0.39 for women. </text>
<text top="737" left="550" width="7" height="18" font="0">•</text>
<text top="737" left="557" width="291" height="20" font="0"> Intensive statin therapy: Net Benefit Fraction for non-</text>
<text top="754" left="550" width="300" height="20" font="0">diabetic Men with LDL-c 70-189 and no prior CVD with </text>
<text top="771" left="550" width="264" height="20" font="0">predicted 10y ASCVD risk of ≥7.5% is 0.71. For </text>
<text top="336" left="865" width="7" height="18" font="0">•</text>
<text top="335" left="872" width="227" height="20" font="0"> Although there was consistent mismatch </text>
<text top="352" left="865" width="235" height="20" font="0">whereby risk predicted by PCEs exceeded </text>
<text top="370" left="865" width="221" height="20" font="0">observed ASCVD risk in this population, </text>
<text top="387" left="865" width="236" height="20" font="0">this overestimation had negligible effect on </text>
<text top="404" left="865" width="222" height="20" font="0">the validity and clinical usefulness of the </text>
<text top="421" left="865" width="213" height="20" font="0">PCEs and related guideline, as the net </text>
<text top="438" left="865" width="225" height="20" font="0">benefit fraction was positive for men with </text>
<text top="456" left="865" width="222" height="20" font="0">5% or greater predicted risk and women </text>
<text top="473" left="865" width="190" height="20" font="0">with 7.5% or greater predicted risk </text>
<text top="492" left="865" width="7" height="18" font="0">•</text>
<text top="491" left="872" width="214" height="20" font="0"> Limitations: Some of the analyses use </text>
<text top="508" left="865" width="219" height="20" font="0">the PCE inappropriately to estimate risk </text>
<text top="526" left="865" width="234" height="20" font="0">among persons with pre-existing CVD; the </text>
<text top="543" left="865" width="232" height="20" font="0">results included in this evidence synthesis </text>
<text top="560" left="865" width="230" height="20" font="0">thus focus on the analyses that evaluated </text>
<text top="577" left="865" width="222" height="20" font="0">the PCEs in persons with no prior CVD.  </text>
<text top="594" left="865" width="3" height="20" font="0"> </text>
<text top="612" left="865" width="3" height="20" font="0"> </text>
<text top="629" left="865" width="175" height="20" font="0">OVERALL QUALITY: Moderate </text>
<text top="646" left="865" width="3" height="20" font="0"> </text>
<text top="663" left="865" width="3" height="20" font="0"> </text>
</page>
<page number="76" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">76 </text>
<text top="107" left="550" width="286" height="20" font="0">women, this was 0.96. Among those with DM, these </text>
<text top="124" left="550" width="269" height="20" font="0">numbers were 0.12 for men and 0.55 for women. </text>
<text top="142" left="91" width="113" height="20" font="0">Lee CH, et al., 2015 </text>
<text top="159" left="91" width="25" height="20" font="0"><a href="data supplement.html#240">(77)</a> </text>
<text top="177" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26350809">26350809</a></text>
<text top="177" left="145" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26350809"> </a></text>
<text top="142" left="225" width="71" height="20" font="7"><b>Study type:</b> </text>
<text top="159" left="225" width="67" height="20" font="0">Prospective </text>
<text top="177" left="225" width="110" height="20" font="0">Observation Cohort </text>
<text top="194" left="225" width="33" height="20" font="0">study </text>
<text top="211" left="225" width="3" height="20" font="0"> </text>
<text top="228" left="225" width="129" height="20" font="7"><b>Size:</b> 1753 participants<b> </b></text>
<text top="142" left="375" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="161" left="375" width="7" height="18" font="0">•</text>
<text top="161" left="381" width="146" height="20" font="0"> Chinese men and women </text>
<text top="178" left="375" width="153" height="20" font="0">in Hong Kong aged 25-75 y </text>
<text top="195" left="375" width="3" height="20" font="0"> </text>
<text top="212" left="375" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="231" left="375" width="7" height="18" font="0">•</text>
<text top="231" left="381" width="133" height="20" font="0"> Lipid-lowering med use </text>
<text top="250" left="375" width="7" height="18" font="0">•</text>
<text top="249" left="381" width="139" height="20" font="0"> Prevalent CVD or LDL-c </text>
<text top="266" left="375" width="31" height="20" font="0">&gt;190<b> </b></text>
<text top="143" left="550" width="269" height="20" font="7"><b>1</b>°<b> endpoint:</b> Incident CVD event: First-recorded </text>
<text top="161" left="550" width="293" height="20" font="0">diagnosis of CV event based on administrative codes </text>
<text top="178" left="550" width="290" height="20" font="0">(ICD-9); hard ASCVD defined as MI, stroke, CHD, or </text>
<text top="195" left="550" width="273" height="20" font="0">stroke-related mortality; Total CVD defined as MI, </text>
<text top="212" left="550" width="290" height="20" font="0">coronary insufficiency, angina, stroke, TIA, PVD, HF, </text>
<text top="229" left="550" width="200" height="20" font="0">and CHD or stroke-related mortality; </text>
<text top="247" left="550" width="136" height="20" font="0">Median follow up of 10 y<b> </b></text>
<text top="264" left="550" width="3" height="20" font="0"> </text>
<text top="281" left="550" width="52" height="20" font="7"><b>Results: </b></text>
<text top="300" left="550" width="7" height="18" font="0">•</text>
<text top="299" left="557" width="269" height="20" font="0"> 122 persons had incident ASCVD, 138 with total </text>
<text top="317" left="550" width="295" height="20" font="0">CVD; 45 CHD events and 41 strokes in men, 32 CHD </text>
<text top="334" left="550" width="180" height="20" font="0">events and 20 strokes in women </text>
<text top="353" left="550" width="7" height="18" font="0">•</text>
<text top="352" left="557" width="127" height="20" font="0"> PCE C statistic 0.714 (</text>
<text top="352" left="684" width="47" height="20" font="17">95% CI: </text>
<text top="352" left="732" width="91" height="20" font="0">0.567-0.770) for </text>
<text top="370" left="550" width="69" height="20" font="0">men, 0.765 (</text>
<text top="370" left="619" width="47" height="20" font="17">95% CI: </text>
<text top="370" left="666" width="186" height="20" font="0">0.69-0.84) for women. Calibration </text>
<text top="387" left="550" width="278" height="20" font="0">chi-square was 24.1 for men and 10.1 for women.  </text>
<text top="406" left="550" width="7" height="18" font="0">•</text>
<text top="405" left="557" width="256" height="20" font="0"> Framingham CV risk equation AUROC 0.773 (</text>
<text top="405" left="813" width="28" height="20" font="17">95% </text>
<text top="422" left="550" width="19" height="20" font="17">CI: </text>
<text top="422" left="569" width="160" height="20" font="0">0.742-0.802) for men, 0.788 (</text>
<text top="422" left="729" width="47" height="20" font="17">95% CI: </text>
<text top="422" left="776" width="73" height="20" font="0">0.724-0.852) </text>
<text top="440" left="550" width="295" height="20" font="0">for women. Chi-square was 20.1 for men and 12.1 for </text>
<text top="457" left="550" width="43" height="20" font="0">women </text>
<text top="476" left="550" width="7" height="18" font="0">•</text>
<text top="475" left="557" width="278" height="20" font="0"> Recalibration not possible for PCE due to variable </text>
<text top="492" left="550" width="272" height="20" font="0">misclassification across predicted risk categories.<b> </b></text>
<text top="144" left="865" width="7" height="18" font="0">•</text>
<text top="143" left="872" width="202" height="20" font="0"> PCE were poorly calibrated in Hong </text>
<text top="161" left="865" width="215" height="20" font="0">Kong Chinese population, especially in </text>
<text top="178" left="865" width="27" height="20" font="0">men </text>
<text top="197" left="865" width="7" height="18" font="0">•</text>
<text top="196" left="872" width="185" height="20" font="0"> PCE and Framingham total CVD </text>
<text top="213" left="865" width="215" height="20" font="0">equations had moderate discrimination </text>
<text top="231" left="865" width="3" height="20" font="0"> </text>
<text top="250" left="865" width="7" height="18" font="0">•</text>
<text top="249" left="872" width="230" height="20" font="0"> Limitations: Events were not adjudicated; </text>
<text top="266" left="865" width="215" height="20" font="0">potential for misclassification; relatively </text>
<text top="283" left="865" width="66" height="20" font="0">few events. </text>
<text top="301" left="865" width="3" height="20" font="0"> </text>
<text top="318" left="865" width="149" height="20" font="0">OVERALL QUALITY: Poor </text>
<text top="510" left="91" width="55" height="20" font="7"><b>NHANES </b></text>
<text top="527" left="91" width="107" height="20" font="0">Loprinzi PD, et al.,  </text>
<text top="545" left="91" width="56" height="20" font="0">2016<a href="data supplement.html#240"> (78)</a> </text>
<text top="562" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27180122">27180122</a></text>
<text top="562" left="145" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27180122"> </a></text>
<text top="510" left="225" width="71" height="20" font="7"><b>Study type:</b> </text>
<text top="527" left="225" width="105" height="20" font="0">Prospective cohort </text>
<text top="545" left="225" width="3" height="20" font="0"> </text>
<text top="562" left="225" width="73" height="20" font="7"><b>Size:</b> 11,171<b> </b></text>
<text top="510" left="375" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="529" left="375" width="7" height="18" font="0">•</text>
<text top="529" left="381" width="134" height="20" font="0"> Noninstitutionalized US </text>
<text top="546" left="375" width="147" height="20" font="0">adults age 40-79 y without </text>
<text top="563" left="375" width="162" height="20" font="0">CVD, non-pregnant, and with </text>
<text top="580" left="375" width="106" height="20" font="0">complete BMI data </text>
<text top="599" left="372" width="11" height="18" font="0">• </text>
<text top="599" left="386" width="117" height="20" font="0">NHANES 1999-2010 </text>
<text top="616" left="372" width="49" height="20" font="0">samples </text>
<text top="633" left="375" width="3" height="20" font="0"> </text>
<text top="650" left="375" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="669" left="375" width="7" height="18" font="0">•</text>
<text top="668" left="381" width="57" height="20" font="0"> Pregnant </text>
<text top="688" left="375" width="7" height="18" font="0">•</text>
<text top="687" left="381" width="88" height="20" font="0"> Prevalent CVD </text>
<text top="706" left="375" width="7" height="18" font="0">•</text>
<text top="705" left="381" width="133" height="20" font="0"> Lipid-lowering med use<b> </b></text>
<text top="511" left="550" width="278" height="20" font="7"><b>1</b>°<b> endpoint:</b> All-cause and CVD-specific mortality </text>
<text top="529" left="550" width="262" height="20" font="0">across different levels of predicted ASCVD risk; </text>
<text top="546" left="550" width="151" height="20" font="0">Median follow-up of 72 mo.<b> </b></text>
<text top="563" left="550" width="3" height="20" font="0"> </text>
<text top="580" left="550" width="52" height="20" font="7"><b>Results: </b></text>
<text top="599" left="550" width="7" height="18" font="0">•</text>
<text top="599" left="557" width="192" height="20" font="0"> 851 total deaths; 124 CVD deaths </text>
<text top="618" left="550" width="11" height="18" font="0">• </text>
<text top="617" left="560" width="239" height="20" font="0">Predicted 10y ASCVD risk was significantly </text>
<text top="634" left="550" width="295" height="20" font="0">associated with all-cause and CVD-specific mortality.  </text>
<text top="653" left="550" width="7" height="18" font="0">•</text>
<text top="652" left="557" width="264" height="20" font="0"> Each 1% higher predicted 10y ASCVD risk was </text>
<text top="670" left="550" width="278" height="20" font="0">associated with a 6% greater risk for all-cause and </text>
<text top="687" left="550" width="287" height="20" font="0">CVD mortality (HR: 1.06; 95% CI: 1.05-1.07 for both </text>
<text top="704" left="550" width="277" height="20" font="0">per 1% higher predicted risk by PCEs). Harrell’s C-</text>
<text top="721" left="550" width="282" height="20" font="0">statistic for this was 0.74 for all-cause mortality and </text>
<text top="739" left="550" width="128" height="20" font="0">0.79 for CVD mortality. </text>
<text top="758" left="546" width="11" height="18" font="0">• </text>
<text top="757" left="561" width="276" height="20" font="0">After adjustment for physical activity, obesity, age, </text>
<text top="774" left="546" width="303" height="20" font="0">sex and race/ethnicity, HR per 1% higher predicted risk </text>
<text top="512" left="865" width="7" height="18" font="0">•</text>
<text top="511" left="872" width="215" height="20" font="0"> Predicted 10y ASCVD risk levels were </text>
<text top="529" left="865" width="231" height="20" font="0">significantly associated with all-cause and </text>
<text top="546" left="865" width="237" height="20" font="0">CVD-specific mortality among those free of </text>
<text top="563" left="865" width="29" height="20" font="0">CVD </text>
<text top="582" left="864" width="11" height="18" font="0">• </text>
<text top="581" left="877" width="218" height="20" font="0">PCE can rank-order all-cause and CVD </text>
<text top="598" left="864" width="73" height="20" font="0">mortality risk </text>
<text top="618" left="865" width="7" height="18" font="0">•</text>
<text top="617" left="872" width="214" height="20" font="0"> Strength of association was similar for </text>
<text top="634" left="865" width="204" height="20" font="0">all-cause and CVD-specific mortality. </text>
<text top="651" left="865" width="3" height="20" font="0"> </text>
<text top="669" left="865" width="218" height="20" font="0">Limitations: Outcomes assessed do not </text>
<text top="686" left="865" width="179" height="20" font="0">include nonfatal ASCVD events  </text>
<text top="703" left="865" width="3" height="20" font="0"> </text>
<text top="720" left="865" width="225" height="20" font="0">OVERALL QUALITY: Moderate-to-poor.  </text>
</page>
<page number="77" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">77 </text>
<text top="107" left="546" width="284" height="20" font="0">was 1.03 (95% CI: 1.02-1.04) for all-cause mortality </text>
<text top="124" left="546" width="55" height="20" font="0">and 1.03 (</text>
<text top="124" left="602" width="47" height="20" font="17">95% CI: </text>
<text top="124" left="649" width="163" height="20" font="0">1.01-1.05) for CVD mortality.  </text>
<text top="143" left="550" width="7" height="18" font="0">•</text>
<text top="143" left="557" width="268" height="20" font="0"> Hazard ratios for total mortality by predicted 10y </text>
<text top="160" left="550" width="72" height="20" font="0">ASCVD risk: </text>
<text top="179" left="566" width="11" height="18" font="0">• </text>
<text top="178" left="581" width="269" height="20" font="0">≥7.5% vs. &lt;7.5%: Unadjusted HR: 5.44; 95% CI: </text>
<text top="195" left="566" width="286" height="20" font="0">4.34-6.77; HR adjusted for physical activity, obesity, </text>
<text top="213" left="566" width="259" height="20" font="0">age, sex and race/ethnicity: 1.77; 95% CI: 1.27-</text>
<text top="230" left="566" width="27" height="20" font="0">2.48<b> </b></text>
<text top="249" left="566" width="11" height="18" font="0">• </text>
<text top="248" left="581" width="255" height="20" font="0">≥20% vs. &lt;20%: HR: 5.57; 95% CI: 4.73-6.56; </text>
<text top="265" left="566" width="277" height="20" font="0">HR adjusted for physical activity, obesity, age, sex </text>
<text top="282" left="566" width="233" height="20" font="0">and race/ethnicity 1.47; 95% CI: 1.10-1.97<b> </b></text>
<text top="301" left="550" width="7" height="18" font="0">•</text>
<text top="301" left="557" width="292" height="20" font="0"> Hazard ratios for CVD-specific mortality by predicted </text>
<text top="318" left="550" width="92" height="20" font="0">10y ASCVD risk </text>
<text top="337" left="566" width="11" height="18" font="0">• </text>
<text top="336" left="583" width="269" height="20" font="0">≥7.5% vs. &lt;7.5%: HR: 7.21; 95% CI: 3.70-14.05; </text>
<text top="354" left="567" width="277" height="20" font="0">HR adjusted for physical activity, obesity, age, sex </text>
<text top="371" left="567" width="237" height="20" font="0">and race/ethnicity 3.16; 95% CI: 1.16-8.58 <b> </b></text>
<text top="390" left="566" width="11" height="18" font="0">• </text>
<text top="389" left="583" width="255" height="20" font="0">≥20% vs. &lt;20%: HR: 5.24; 95% CI: 3.43-7.99; </text>
<text top="406" left="566" width="277" height="20" font="0">HR adjusted for physical activity, obesity, age, sex </text>
<text top="423" left="566" width="237" height="20" font="0">and race/ethnicity 1.36; 95% CI: 0.71-2.60.<b> </b></text>
<text top="441" left="91" width="124" height="20" font="0">Mortensen MB, et al.,  </text>
<text top="458" left="91" width="56" height="20" font="0">2015<a href="data supplement.html#240"> (79)</a> </text>
<text top="476" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26700832">26700832</a></text>
<text top="476" left="145" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26700832"> </a></text>
<text top="441" left="225" width="71" height="20" font="7"><b>Study type:</b> </text>
<text top="458" left="225" width="67" height="20" font="0">Prospective </text>
<text top="476" left="225" width="110" height="20" font="0">Observation Cohort </text>
<text top="493" left="225" width="111" height="20" font="0">study (Copenhagen </text>
<text top="510" left="225" width="109" height="20" font="0">General Population </text>
<text top="527" left="225" width="105" height="20" font="0">Study, 2003-2008) </text>
<text top="544" left="225" width="3" height="20" font="0"> </text>
<text top="562" left="225" width="73" height="20" font="7"><b>Size:</b> 37,892 </text>
<text top="579" left="225" width="66" height="20" font="0">participants<b> </b></text>
<text top="441" left="375" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="460" left="375" width="7" height="18" font="0">•</text>
<text top="460" left="381" width="122" height="20" font="0"> Adults age 40-75 y in </text>
<text top="477" left="375" width="131" height="20" font="0">Copenhagen, Denmark </text>
<text top="494" left="375" width="3" height="20" font="0"> </text>
<text top="511" left="375" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="530" left="375" width="7" height="18" font="0">•</text>
<text top="530" left="381" width="55" height="20" font="0"> Diabetes </text>
<text top="549" left="375" width="7" height="18" font="0">•</text>
<text top="548" left="381" width="145" height="20" font="0"> Lipid-lowering medication </text>
<text top="565" left="375" width="23" height="20" font="0">use </text>
<text top="584" left="375" width="7" height="18" font="0">•</text>
<text top="584" left="381" width="108" height="20" font="0"> Prevalent ASCVD <b> </b></text>
<text top="442" left="550" width="175" height="20" font="7"><b>1</b>°<b> endpoint:</b> Incident ASCVD;  </text>
<text top="460" left="550" width="72" height="20" font="0">5 y follow up<b> </b></text>
<text top="477" left="550" width="3" height="20" font="0"> </text>
<text top="494" left="550" width="52" height="20" font="7"><b>Results: </b></text>
<text top="513" left="548" width="11" height="18" font="0">• </text>
<text top="512" left="562" width="275" height="20" font="0">Compared statin eligibility of sample by ACC/AHA </text>
<text top="530" left="548" width="301" height="20" font="0">approach using PCE (42% eligible) vs. approach using </text>
<text top="547" left="548" width="297" height="20" font="0">trial eligibility criteria (56%) vs. hybrid approach (21%) </text>
<text top="566" left="548" width="11" height="18" font="0">• </text>
<text top="565" left="562" width="264" height="20" font="0">834 ASCVD events (323 myocardial infarctions)<b> </b></text>
<text top="584" left="548" width="11" height="18" font="0">• </text>
<text top="583" left="562" width="280" height="20" font="0">PCE well calibrated below 10% predicted 10 y risk, </text>
<text top="600" left="548" width="284" height="20" font="0">with predicted and observed event rates statistically </text>
<text top="618" left="548" width="230" height="20" font="0">similar for predicted risk strata &lt;10%, and </text>
<text top="635" left="548" width="298" height="20" font="0">overprediction of observed risk at predicted risk ≥10% </text>
<text top="654" left="548" width="11" height="18" font="0">• </text>
<text top="653" left="562" width="262" height="20" font="0">Events (K-M adjusted) over 5 y stratified by 10y </text>
<text top="670" left="548" width="174" height="20" font="0">ASCVD predicted risk by PCE:  </text>
<text top="687" left="562" width="282" height="20" font="0">-  &lt;5% predicted risk: 1.0% observed events, 0.8% </text>
<text top="705" left="575" width="130" height="20" font="0">predicted, ratio P/O 0.8 </text>
<text top="722" left="562" width="276" height="20" font="0">-  5 to &lt;7.5% predicted risk: 2.1% observed, 2.3% </text>
<text top="739" left="575" width="130" height="20" font="0">predicted, ratio P/O 1.1 </text>
<text top="756" left="562" width="283" height="20" font="0">-  7.5 to &lt;10% predicted risk: 2.7% observed, 3.4% </text>
<text top="774" left="575" width="130" height="20" font="0">predicted, ratio P/O 1.2 </text>
<text top="443" left="864" width="11" height="18" font="0">• </text>
<text top="442" left="875" width="226" height="20" font="0">In a contemporary Danish cohort, clinical </text>
<text top="460" left="864" width="204" height="20" font="0">performance of ACC/AHA risk-based </text>
<text top="477" left="864" width="233" height="20" font="0">approach (based on PCE) was superior to </text>
<text top="494" left="864" width="188" height="20" font="0">other approaches, suggesting this </text>
<text top="511" left="864" width="212" height="20" font="0">approach would prevent more ASCVD </text>
<text top="528" left="864" width="214" height="20" font="0">events and treat fewer people than the </text>
<text top="546" left="864" width="116" height="20" font="0">trial-based approach </text>
<text top="565" left="864" width="11" height="18" font="0">• </text>
<text top="564" left="875" width="208" height="20" font="0">PCE were well calibrated at predicted </text>
<text top="581" left="864" width="64" height="20" font="0">risks &lt;10% </text>
<text top="598" left="865" width="3" height="20" font="0"> </text>
<text top="615" left="865" width="182" height="20" font="0">Limitations: No formal calibration </text>
<text top="633" left="865" width="195" height="20" font="0">calculation used; white-only cohort; </text>
<text top="650" left="865" width="199" height="20" font="0">persons with diabetes excluded; 5-y </text>
<text top="667" left="865" width="226" height="20" font="0">predicted and observed event rates used </text>
<text top="684" left="865" width="168" height="20" font="0">given lack of 10 y of follow up  </text>
<text top="701" left="865" width="3" height="20" font="0"> </text>
<text top="719" left="865" width="175" height="20" font="0">OVERALL QUALITY: Moderate </text>
</page>
<page number="78" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">78 </text>
<text top="107" left="562" width="249" height="20" font="0">-  10%+ predicted risk: 5.7% observed, 8.2% </text>
<text top="124" left="575" width="130" height="20" font="0">predicted, ratio P/O 1.4 </text>
<text top="143" left="548" width="11" height="18" font="0">• </text>
<text top="143" left="560" width="286" height="20" font="0">C statistics: 0.676 for ACC/AHA PCEs (vs. 0.572 for </text>
<text top="160" left="548" width="287" height="20" font="0">trial-based approach and 0.613 for hybrid approach, </text>
<text top="177" left="548" width="277" height="20" font="0">p&lt;0.0001 for both); for men this was 0.647 and for </text>
<text top="194" left="548" width="262" height="20" font="0">women this was 0.669 for the PCEs with poorer </text>
<text top="211" left="548" width="284" height="20" font="0">discrimination by trial-based and hybrid approaches<b> </b></text>
<text top="230" left="548" width="11" height="18" font="0">• </text>
<text top="230" left="560" width="256" height="20" font="0">Net reclassification improvement for improving </text>
<text top="247" left="548" width="302" height="20" font="0">decision making for statin therapy compared with PCE: </text>
<text top="264" left="548" width="254" height="20" font="0">-0.21 for trial-based approach, -0.13 for hybrid </text>
<text top="281" left="548" width="296" height="20" font="0">approach (p&lt;0.0001 for both), with similar NRI among </text>
<text top="298" left="548" width="98" height="20" font="0">men and women <b> </b></text>
<text top="316" left="548" width="3" height="20" font="7"><b> </b></text>
<text top="334" left="91" width="124" height="20" font="0">Mortensen MB, et al.,  </text>
<text top="351" left="91" width="56" height="20" font="0">2017<a href="data supplement.html#240"> (80)</a> </text>
<text top="368" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28363217">28363217</a></text>
<text top="368" left="145" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28363217"> </a></text>
<text top="334" left="225" width="71" height="20" font="7"><b>Study type:</b> </text>
<text top="351" left="225" width="67" height="20" font="0">Prospective </text>
<text top="368" left="225" width="119" height="20" font="0">Observational Cohort </text>
<text top="385" left="225" width="111" height="20" font="0">study (Copenhagen </text>
<text top="402" left="225" width="109" height="20" font="0">General Population </text>
<text top="420" left="225" width="105" height="20" font="0">Study, 2003-2009) </text>
<text top="437" left="225" width="3" height="20" font="0"> </text>
<text top="454" left="225" width="73" height="20" font="7"><b>Size:</b> 44,889 </text>
<text top="471" left="225" width="66" height="20" font="0">participants<b> </b></text>
<text top="334" left="375" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="353" left="375" width="7" height="18" font="0">•</text>
<text top="352" left="381" width="122" height="20" font="0"> Adults age 40-75 y in </text>
<text top="369" left="375" width="131" height="20" font="0">Copenhagen, Denmark </text>
<text top="386" left="375" width="3" height="20" font="0"> </text>
<text top="404" left="375" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="423" left="375" width="7" height="18" font="0">•</text>
<text top="422" left="381" width="55" height="20" font="0"> Diabetes </text>
<text top="441" left="375" width="7" height="18" font="0">•</text>
<text top="440" left="381" width="145" height="20" font="0"> Lipid-lowering medication </text>
<text top="458" left="375" width="23" height="20" font="0">use </text>
<text top="477" left="375" width="7" height="18" font="0">•</text>
<text top="476" left="381" width="108" height="20" font="0"> Prevalent ASCVD <b> </b></text>
<text top="335" left="550" width="283" height="20" font="7"><b>1</b>°<b> endpoint:</b> Incident ASCVD (for PCE) or incident </text>
<text top="352" left="550" width="254" height="20" font="0">CVD death (for European-SCORE equations); </text>
<text top="369" left="550" width="73" height="20" font="0">5 y follow-up<b> </b></text>
<text top="386" left="550" width="3" height="20" font="0"> </text>
<text top="404" left="550" width="52" height="20" font="7"><b>Results: </b></text>
<text top="423" left="548" width="11" height="18" font="0">• </text>
<text top="422" left="562" width="275" height="20" font="0">Compared statin eligibility of sample by ACC/AHA </text>
<text top="439" left="548" width="301" height="20" font="0">approach using PCE (42% eligible) vs. approach using </text>
<text top="456" left="548" width="253" height="20" font="0">ESC/EAS guidelines using European-SCORE </text>
<text top="474" left="548" width="84" height="20" font="0">approach (6%) </text>
<text top="493" left="548" width="11" height="18" font="0">• </text>
<text top="492" left="562" width="116" height="20" font="0">1265 ASCVD events<b> </b></text>
<text top="511" left="548" width="11" height="18" font="0">• </text>
<text top="510" left="562" width="278" height="20" font="0">PCE were well calibrated overall (overall predicted </text>
<text top="527" left="548" width="298" height="20" font="0">to observed ratio 1.2), especially below 10% predicted </text>
<text top="544" left="548" width="274" height="20" font="0">10 y risk, with predicted and observed event rates </text>
<text top="562" left="548" width="269" height="20" font="0">statistically similar for predicted risk strata &lt;10%. </text>
<text top="579" left="548" width="300" height="20" font="0">Overprediction of observed risk at predicted risk ≥10% </text>
<text top="596" left="548" width="62" height="20" font="0">was seen.  </text>
<text top="615" left="548" width="11" height="18" font="0">• </text>
<text top="614" left="562" width="269" height="20" font="0">European-SCORE was not well calibrated at any </text>
<text top="631" left="548" width="298" height="20" font="0">level of predicted risk for CVD death (overall predicted </text>
<text top="649" left="548" width="286" height="20" font="0">to observed ratio 5.0, range 3.6 to 5.4 across all risk </text>
<text top="666" left="548" width="42" height="20" font="0">strata). </text>
<text top="685" left="548" width="11" height="18" font="0">• </text>
<text top="684" left="562" width="262" height="20" font="0">Events (K-M adjusted) over 5 y stratified by 10y </text>
<text top="701" left="548" width="174" height="20" font="0">ASCVD predicted risk by PCE:  </text>
<text top="719" left="562" width="267" height="20" font="0">-  &lt;5% predicted risk: 235 observed events, 164 </text>
<text top="736" left="575" width="130" height="20" font="0">predicted, ratio P/O 0.7 </text>
<text top="753" left="562" width="277" height="20" font="0">-  5 to &lt;7.5% predicted risk: 123 observed events, </text>
<text top="770" left="575" width="154" height="20" font="0">125 predicted, ratio P/O 1.0 </text>
<text top="335" left="864" width="11" height="18" font="0">• </text>
<text top="335" left="875" width="226" height="20" font="0">In a contemporary Danish cohort, clinical </text>
<text top="352" left="864" width="204" height="20" font="0">performance of ACC/AHA risk-based </text>
<text top="369" left="864" width="233" height="20" font="0">approach (based on PCE) was superior to </text>
<text top="386" left="864" width="159" height="20" font="0">European-SCORE approach </text>
<text top="405" left="864" width="11" height="18" font="0">• </text>
<text top="405" left="875" width="208" height="20" font="0">PCE were well calibrated at predicted </text>
<text top="422" left="864" width="64" height="20" font="0">risks &lt;10% </text>
<text top="439" left="865" width="3" height="20" font="0"> </text>
<text top="456" left="865" width="182" height="20" font="0">Limitations: No formal calibration </text>
<text top="473" left="865" width="195" height="20" font="0">calculation used; white-only cohort; </text>
<text top="491" left="865" width="199" height="20" font="0">persons with diabetes excluded; 5-y </text>
<text top="508" left="865" width="226" height="20" font="0">predicted and observed event rates used </text>
<text top="525" left="865" width="168" height="20" font="0">given lack of 10 y of follow up  </text>
<text top="542" left="865" width="3" height="20" font="0"> </text>
<text top="559" left="865" width="175" height="20" font="0">OVERALL QUALITY: Moderate </text>
<text top="577" left="865" width="3" height="20" font="0"> </text>
<text top="594" left="865" width="3" height="20" font="0"> </text>
</page>
<page number="79" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">79 </text>
<text top="107" left="562" width="284" height="20" font="0">-  7.5 to &lt;10% predicted risk: 115 observed events, </text>
<text top="124" left="575" width="154" height="20" font="0">130 predicted, ratio P/O 1.1 </text>
<text top="141" left="562" width="282" height="20" font="0">-  ≥10% predicted risk: 792 observed events, 1144 </text>
<text top="159" left="575" width="130" height="20" font="0">predicted, ratio P/O 1.4 </text>
<text top="178" left="548" width="11" height="18" font="0">• </text>
<text top="177" left="562" width="283" height="20" font="0">Overall C-statistic for PCEs 0.72 for ASCVD overall </text>
<text top="194" left="548" width="275" height="20" font="0">and 0.82 for fatal ASCVD; for men these numbers </text>
<text top="211" left="548" width="281" height="20" font="0">were 0.71 and 0.77, and for women they were 0.71 </text>
<text top="229" left="548" width="272" height="20" font="0">and 0.85. These were consistently superior to the </text>
<text top="246" left="548" width="144" height="20" font="0">European SCORE model.<b> </b></text>
<text top="265" left="548" width="11" height="18" font="0">• </text>
<text top="264" left="562" width="256" height="20" font="0">Net reclassification improvement for improving </text>
<text top="281" left="548" width="270" height="20" font="0">decision making for statin therapy compared with </text>
<text top="298" left="548" width="292" height="20" font="0">European-SCORE: +0.27 for PCE for ASCVD overall </text>
<text top="316" left="548" width="284" height="20" font="0">(+0.21 in men, +0.28 in women, p&lt;0.0001 for both).<b> </b></text>
<text top="334" left="91" width="65" height="20" font="7"><b>REGARDS </b></text>
<text top="351" left="91" width="101" height="20" font="0">Muntner P, et al.,  </text>
<text top="368" left="91" width="56" height="20" font="0">2014<a href="data supplement.html#240"> (81)</a> </text>
<text top="385" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24682252">24682252</a></text>
<text top="385" left="145" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24682252"> </a></text>
<text top="402" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="334" left="225" width="71" height="20" font="7"><b>Study type:</b> </text>
<text top="351" left="225" width="67" height="20" font="0">Prospective </text>
<text top="368" left="225" width="120" height="20" font="0">Observational Cohort </text>
<text top="385" left="225" width="33" height="20" font="0">study </text>
<text top="402" left="225" width="75" height="20" font="0">(REasons for </text>
<text top="420" left="225" width="130" height="20" font="0">Geographic And Racial </text>
<text top="437" left="225" width="117" height="20" font="0">Differences in Stroke </text>
<text top="454" left="225" width="109" height="20" font="0">[REGARDS] Study, </text>
<text top="471" left="225" width="66" height="20" font="0">2003-2007) </text>
<text top="489" left="225" width="3" height="20" font="0"> </text>
<text top="506" left="225" width="73" height="20" font="7"><b>Size:</b> 10,997 </text>
<text top="523" left="225" width="125" height="20" font="0">participants (subgroup </text>
<text top="540" left="225" width="91" height="20" font="0">analysis in 3333 </text>
<text top="557" left="225" width="131" height="20" font="0">Medicare beneficiaries)<b> </b></text>
<text top="334" left="375" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="353" left="375" width="7" height="18" font="0">•</text>
<text top="352" left="381" width="122" height="20" font="0"> Adults age 45-79 y in </text>
<text top="369" left="375" width="145" height="20" font="0">nationwide US cohort with </text>
<text top="386" left="375" width="127" height="20" font="0">LDL-C 70 to 189 mg/dl </text>
<text top="404" left="375" width="3" height="20" font="0"> </text>
<text top="421" left="375" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="440" left="375" width="7" height="18" font="0">•</text>
<text top="439" left="381" width="145" height="20" font="0"> Lipid-lowering medication </text>
<text top="456" left="375" width="23" height="20" font="0">use </text>
<text top="475" left="375" width="7" height="18" font="0">•</text>
<text top="475" left="381" width="108" height="20" font="0"> Prevalent ASCVD  </text>
<text top="494" left="375" width="7" height="18" font="0">•</text>
<text top="493" left="381" width="55" height="20" font="0"> Diabetes<b> </b></text>
<text top="335" left="550" width="287" height="20" font="7"><b>1</b>°<b> endpoint:</b> Incident ASCVD (CHD death, nonfatal </text>
<text top="352" left="550" width="153" height="20" font="0">MI, fatal or nonfatal stroke); </text>
<text top="369" left="550" width="90" height="20" font="0">Follow-up of 5 y<b> </b></text>
<text top="386" left="550" width="3" height="20" font="0"> </text>
<text top="404" left="550" width="52" height="20" font="7"><b>Results: </b></text>
<text top="423" left="548" width="11" height="18" font="0">• </text>
<text top="422" left="562" width="282" height="20" font="0">338 ASCVD events (192 CHD events, 146 strokes) </text>
<text top="441" left="548" width="11" height="18" font="0">• </text>
<text top="440" left="562" width="289" height="20" font="0">PCE were very well calibrated in lower predicted risk </text>
<text top="457" left="550" width="287" height="20" font="0">strata (&lt;10% predicted 10-y risk), and overpredicted </text>
<text top="474" left="550" width="295" height="20" font="0">events in higher predicted risk strata (≥10% predicted </text>
<text top="492" left="550" width="58" height="20" font="0">10-yr risk) </text>
<text top="511" left="549" width="11" height="18" font="0">• </text>
<text top="510" left="562" width="257" height="20" font="0">In the group for whom the PCE were intended, </text>
<text top="527" left="550" width="272" height="20" font="0">events over 5 y across 10y ASCVD predicted risk </text>
<text top="544" left="550" width="71" height="20" font="0">strata were:  </text>
<text top="562" left="562" width="282" height="20" font="0">-  &lt;5% predicted risk: 1.9% observed events, 1.9% </text>
<text top="579" left="576" width="54" height="20" font="0">predicted </text>
<text top="596" left="562" width="276" height="20" font="0">-  5 to &lt;7.5% predicted risk: 4.8% observed, 4.8% </text>
<text top="613" left="575" width="54" height="20" font="0">predicted </text>
<text top="631" left="562" width="283" height="20" font="0">-  7.5 to &lt;10% predicted risk: 6.1% observed, 6.9% </text>
<text top="648" left="575" width="54" height="20" font="0">predicted </text>
<text top="665" left="562" width="264" height="20" font="0">-  ≥10% predicted risk: 12.0% observed, 15.1% </text>
<text top="682" left="575" width="54" height="20" font="0">predicted </text>
<text top="699" left="562" width="127" height="20" font="0">-  C-statistics for PCE: </text>
<text top="718" left="575" width="11" height="18" font="0">• </text>
<text top="718" left="589" width="179" height="20" font="0">Overall: 0.72, 95% CI: 0.70-0.75 </text>
<text top="737" left="575" width="11" height="18" font="0">• </text>
<text top="736" left="589" width="183" height="20" font="0">Women: 0.75, 95% CI: 0.71-0.79 </text>
<text top="755" left="575" width="11" height="18" font="0">• </text>
<text top="754" left="589" width="164" height="20" font="0">Men: 0.66, 95% CI: 0.62-0.70 </text>
<text top="773" left="575" width="11" height="18" font="0">• </text>
<text top="772" left="589" width="176" height="20" font="0">Blacks: 0.69, 95% CI: 0.65-0.74 </text>
<text top="335" left="865" width="7" height="18" font="0">•</text>
<text top="335" left="872" width="185" height="20" font="0"> PCE exhibited moderate to good </text>
<text top="352" left="865" width="221" height="20" font="0">discrimination and were moderately well </text>
<text top="369" left="865" width="208" height="20" font="0">calibrated, especially at predicted risk </text>
<text top="386" left="865" width="210" height="20" font="0">levels &lt;10%, in a large geographically </text>
<text top="404" left="865" width="224" height="20" font="0">diverse US cohort, and particularly when </text>
<text top="421" left="865" width="198" height="20" font="0">the cohort was restricted to persons </text>
<text top="438" left="865" width="235" height="20" font="0">without DM, not taking statins, LDL 70-189 </text>
<text top="455" left="865" width="237" height="20" font="0">mg/dl, and without pre-existing ASCVD, for </text>
<text top="473" left="865" width="198" height="20" font="0">whom the PCE were intended. PCE </text>
<text top="490" left="865" width="227" height="20" font="0">overpredicted risk somewhat at very high </text>
<text top="507" left="865" width="61" height="20" font="0">risk levels. </text>
<text top="526" left="864" width="11" height="18" font="0">• </text>
<text top="525" left="878" width="221" height="20" font="0">PCE were well calibrated across deciles </text>
<text top="542" left="864" width="163" height="20" font="0">of risk in Medicare population </text>
<text top="561" left="864" width="11" height="18" font="0">• </text>
<text top="561" left="878" width="215" height="20" font="0">Broad-based representative population </text>
<text top="578" left="865" width="43" height="20" font="0">sample </text>
<text top="595" left="865" width="3" height="20" font="0"> </text>
<text top="614" left="865" width="7" height="18" font="0">•</text>
<text top="613" left="872" width="196" height="20" font="0"> Limitations: 5 y of follow-up; use of </text>
<text top="631" left="865" width="229" height="20" font="0">administrative codes for additional events </text>
<text top="648" left="865" width="230" height="20" font="0">in Medicare subset may have led to some </text>
<text top="665" left="865" width="231" height="20" font="0">misclassification of events; did not assess </text>
<text top="682" left="865" width="237" height="20" font="0">effects of statin or other preventive therapy </text>
<text top="700" left="865" width="81" height="20" font="0">after baseline. </text>
<text top="717" left="865" width="3" height="20" font="0"> </text>
<text top="734" left="865" width="133" height="20" font="0">QUALITY: MODERATE </text>
<text top="751" left="865" width="3" height="20" font="0"> </text>
<text top="768" left="865" width="3" height="20" font="0"> </text>
</page>
<page number="80" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">80 </text>
<text top="109" left="575" width="11" height="18" font="0">• </text>
<text top="108" left="589" width="178" height="20" font="0">Whites: 0.74, 95% CI: 0.71-0.77 </text>
<text top="127" left="562" width="11" height="18" font="0">• </text>
<text top="126" left="575" width="217" height="20" font="0">Discrimination (Hosmer-Lemeshow X2: </text>
<text top="145" left="577" width="11" height="18" font="0">• </text>
<text top="145" left="589" width="118" height="20" font="0">Overall: 19.9; p=0.01 </text>
<text top="164" left="577" width="11" height="18" font="0">• </text>
<text top="163" left="589" width="114" height="20" font="0">Women: 8.3; p=0.41 </text>
<text top="182" left="577" width="11" height="18" font="0">• </text>
<text top="181" left="589" width="103" height="20" font="0">Men: 16.5; p=0.04 </text>
<text top="200" left="577" width="11" height="18" font="0">• </text>
<text top="199" left="589" width="115" height="20" font="0">Blacks: 11.8; p=0.16 </text>
<text top="218" left="577" width="11" height="18" font="0">• </text>
<text top="218" left="589" width="117" height="20" font="0">Whites: 14.0; p=0.08 </text>
<text top="236" left="548" width="11" height="18" font="0">• </text>
<text top="236" left="561" width="266" height="20" font="0">PCE performed similarly in the stroke belt states </text>
<text top="253" left="550" width="251" height="20" font="0">(NC, SC, GA, AL, MS, LA, TN, AK) and in the </text>
<text top="270" left="550" width="176" height="20" font="0">remainder of the continental US </text>
<text top="289" left="548" width="11" height="18" font="0">• </text>
<text top="289" left="561" width="284" height="20" font="0">In the subgroup of Medicare beneficiaries (N=3333) </text>
<text top="306" left="550" width="297" height="20" font="0">without diabetes and not taking statins, with LDL-C 70-</text>
<text top="323" left="550" width="284" height="20" font="0">189 mg/dL, PCE tended to underpredict event rates </text>
<text top="340" left="550" width="260" height="20" font="0">somewhat. Events over 5 y across 10y ASCVD </text>
<text top="357" left="550" width="144" height="20" font="0">predicted risk strata were: </text>
<text top="374" left="562" width="252" height="20" font="0">-  &lt;7.5% predicted risk: 5.3% observed, 4.0% </text>
<text top="392" left="575" width="54" height="20" font="0">predicted </text>
<text top="409" left="562" width="283" height="20" font="0">-  7.5 to &lt;10% predicted risk: 7.9% observed, 6.4% </text>
<text top="426" left="575" width="54" height="20" font="0">predicted </text>
<text top="443" left="562" width="264" height="20" font="0">-  ≥10% predicted risk: 17.4% observed, 16.4% </text>
<text top="460" left="575" width="54" height="20" font="0">predicted </text>
<text top="478" left="562" width="246" height="20" font="0">-  Overall C statistic 0.67, 95% CI: 0.64-0.71 </text>
<text top="495" left="562" width="132" height="20" font="0">-  Hosmer-Lemeshow X</text>
<text top="497" left="694" width="4" height="13" font="9">2</text>
<text top="495" left="698" width="72" height="20" font="0"> 5.4, p=0.71. </text>
<text top="512" left="550" width="3" height="20" font="0"> </text>
<text top="530" left="91" width="39" height="20" font="7"><b>MESA </b></text>
<text top="547" left="91" width="84" height="20" font="0">Nasir K, et al.,  </text>
<text top="564" left="91" width="56" height="20" font="0">2015<a href="data supplement.html#240"> (82)</a> </text>
<text top="582" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26449135">26449135</a></text>
<text top="582" left="145" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/26449135"> </a></text>
<text top="530" left="225" width="71" height="20" font="7"><b>Study type:</b> </text>
<text top="547" left="225" width="67" height="20" font="0">Prospective </text>
<text top="564" left="225" width="120" height="20" font="0">Observational Cohort </text>
<text top="582" left="225" width="79" height="20" font="0">study (MESA) </text>
<text top="599" left="225" width="3" height="20" font="0"> </text>
<text top="616" left="225" width="63" height="20" font="7"><b>Size:</b> 4758<b> </b></text>
<text top="530" left="375" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="549" left="375" width="7" height="18" font="0">•</text>
<text top="548" left="381" width="135" height="20" font="0"> Adults age 45-75 y with </text>
<text top="566" left="375" width="161" height="20" font="0">complete data for risk factors </text>
<text top="583" left="375" width="72" height="20" font="0">used in PCE </text>
<text top="600" left="375" width="3" height="20" font="0"> </text>
<text top="617" left="375" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="636" left="375" width="7" height="18" font="0">•</text>
<text top="636" left="381" width="145" height="20" font="0"> Lipid-lowering medication </text>
<text top="653" left="375" width="23" height="20" font="0">use </text>
<text top="672" left="375" width="7" height="18" font="0">•</text>
<text top="671" left="381" width="108" height="20" font="0"> Prevalent ASCVD  </text>
<text top="690" left="375" width="7" height="18" font="0">•</text>
<text top="690" left="381" width="87" height="20" font="0"> LDL &lt;70 mg/dl<b> </b></text>
<text top="531" left="550" width="240" height="20" font="7"><b>1</b>°<b> endpoint:</b> Incident ASCVD (CHD death, </text>
<text top="548" left="550" width="295" height="20" font="0">resuscitated cardiac arrest, myocardial infarction, and </text>
<text top="566" left="550" width="44" height="20" font="0">stroke); </text>
<text top="583" left="550" width="146" height="20" font="0">Median follow up of 10.3 y<b> </b></text>
<text top="600" left="550" width="3" height="20" font="0"> </text>
<text top="617" left="550" width="52" height="20" font="7"><b>Results: </b></text>
<text top="636" left="548" width="11" height="18" font="0">• </text>
<text top="636" left="562" width="235" height="20" font="0">247 ASCVD events; 155 hard CHD events </text>
<text top="655" left="548" width="11" height="18" font="0">• </text>
<text top="654" left="562" width="269" height="20" font="0">Event rates based on recommendation status for </text>
<text top="671" left="548" width="211" height="20" font="0">statins per 2013 ACC/AHA guidelines: </text>
<text top="688" left="562" width="271" height="20" font="0">-  Recommended for statins based on PCE (10-y </text>
<text top="705" left="562" width="246" height="20" font="0">predicted risk ≥7.5% or LDL-C 190 mg/dL or </text>
<text top="723" left="562" width="267" height="20" font="0">diabetes): 9.1/1000 person-y, 95% CI: 7.9-10.5); </text>
<text top="740" left="562" width="273" height="20" font="0">-  Considered for statins (10-y predicted risk 5% - </text>
<text top="757" left="562" width="251" height="20" font="0">&lt;7.5%): 4.00/1000 person-y, 95% CI: 2.6-6.0; </text>
<text top="532" left="865" width="7" height="18" font="0">•</text>
<text top="531" left="872" width="174" height="20" font="0"> PCE rank-ordered ASCVD risk </text>
<text top="548" left="865" width="226" height="20" font="0">appropriately, but there was evidence for </text>
<text top="566" left="865" width="202" height="20" font="0">mis-calibration with overprediction of </text>
<text top="583" left="865" width="192" height="20" font="0">observed event rates in this cohort </text>
<text top="600" left="865" width="3" height="20" font="0"> </text>
<text top="619" left="865" width="7" height="18" font="0">•</text>
<text top="618" left="872" width="204" height="20" font="0"> Limitations: No formal discrimination </text>
<text top="636" left="865" width="234" height="20" font="0">/calibration assessment, as the purpose of </text>
<text top="653" left="865" width="235" height="20" font="0">this study was not as much to evaluate the </text>
<text top="670" left="865" width="210" height="20" font="0">PCE as it was to evaluate the additive </text>
<text top="687" left="865" width="139" height="20" font="0">value of CAC to the PCE </text>
<text top="705" left="865" width="3" height="20" font="0"> </text>
<text top="722" left="865" width="175" height="20" font="0">OVERALL QUALITY: Moderate </text>
</page>
<page number="81" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">81 </text>
<text top="107" left="562" width="276" height="20" font="0">-  Not statin candidates (10-y predicted risk &lt;5%): </text>
<text top="124" left="562" width="209" height="20" font="0">1.62/1000 person-y, 95% CI: 1.2-2.3.  </text>
<text top="142" left="91" width="87" height="20" font="0">Rana JS, et al., </text>
<text top="159" left="91" width="56" height="20" font="0">2016<a href="data supplement.html#241"> (83)</a> </text>
<text top="177" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27151343">27151343</a></text>
<text top="177" left="145" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27151343"> </a></text>
<text top="142" left="225" width="71" height="20" font="7"><b>Study type:</b> </text>
<text top="159" left="225" width="78" height="20" font="0">Retrospective </text>
<text top="177" left="225" width="117" height="20" font="0">administrative cohort </text>
<text top="194" left="225" width="123" height="20" font="0">(integrated healthcare </text>
<text top="211" left="225" width="130" height="20" font="0">system, baseline 2008) </text>
<text top="228" left="225" width="3" height="20" font="0"> </text>
<text top="245" left="225" width="80" height="20" font="7"><b>Size:</b> 307,591<b> </b></text>
<text top="142" left="375" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="161" left="375" width="7" height="18" font="0">•</text>
<text top="161" left="381" width="141" height="20" font="0"> Adults aged 40-75 y with </text>
<text top="178" left="375" width="111" height="20" font="0">LDL-c 70-189 mg/dl </text>
<text top="195" left="375" width="132" height="20" font="0">receiving care at Kaiser </text>
<text top="212" left="375" width="122" height="20" font="0">Permanente Northern </text>
<text top="229" left="375" width="114" height="20" font="0">California with blood </text>
<text top="247" left="375" width="138" height="20" font="0">pressure and cholesterol </text>
<text top="264" left="375" width="27" height="20" font="0">data </text>
<text top="281" left="375" width="3" height="20" font="0"> </text>
<text top="298" left="375" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="317" left="375" width="7" height="18" font="0">•</text>
<text top="317" left="381" width="145" height="20" font="0"> Lipid-lowering medication </text>
<text top="334" left="375" width="149" height="20" font="0">use within 5 y before index </text>
<text top="351" left="375" width="27" height="20" font="0">date </text>
<text top="370" left="375" width="7" height="18" font="0">•</text>
<text top="370" left="381" width="134" height="20" font="0"> Unknown race/ethnicity </text>
<text top="389" left="375" width="7" height="18" font="0">•</text>
<text top="388" left="381" width="152" height="20" font="0"> Prior hospitalization for MI, </text>
<text top="405" left="375" width="106" height="20" font="0">stroke, CABG, PCI<b> </b></text>
<text top="143" left="550" width="283" height="20" font="7"><b>1</b>°<b> endpoint:</b> Incidence of ASCVD (MI, CHD death, </text>
<text top="161" left="550" width="280" height="20" font="0">stroke) based on administrative codes and hospital </text>
<text top="178" left="550" width="93" height="20" font="0">discharge plans; </text>
<text top="195" left="550" width="90" height="20" font="0">Follow-up of 5 y<b> </b></text>
<text top="212" left="550" width="3" height="20" font="0"> </text>
<text top="229" left="550" width="52" height="20" font="7"><b>Results: </b></text>
<text top="249" left="550" width="7" height="18" font="0">•</text>
<text top="248" left="557" width="269" height="20" font="0"> 2061 ASCVD events observed during 1,515,142 </text>
<text top="265" left="550" width="51" height="20" font="0">person-y </text>
<text top="284" left="550" width="7" height="18" font="0">•</text>
<text top="283" left="557" width="249" height="20" font="0"> Consistent mismatch between predicted and </text>
<text top="301" left="550" width="299" height="20" font="0">observed event rates; PCE substantially overpredicted </text>
<text top="318" left="550" width="295" height="20" font="0">event rates in this sample and in all subgroups by sex </text>
<text top="335" left="550" width="161" height="20" font="0">and race and diabetes status </text>
<text top="354" left="548" width="11" height="18" font="0">• </text>
<text top="353" left="562" width="273" height="20" font="0">Event rates over 5 y by 5-y predicted risk strata in </text>
<text top="370" left="550" width="214" height="20" font="0">patients without diabetes (N=307,591): </text>
<text top="388" left="564" width="253" height="20" font="0">-  &lt;2.5%: observed rate 0.20%, predicted rate </text>
<text top="405" left="575" width="38" height="20" font="0">1.04% </text>
<text top="422" left="564" width="280" height="20" font="0">-  2.5% to &lt;3.75%: observed rate 0.65%, predicted </text>
<text top="439" left="575" width="63" height="20" font="0">rate 3.08% </text>
<text top="457" left="564" width="273" height="20" font="0">-  3.75% to &lt;5.0%: observed rate 0.9%, predicted </text>
<text top="474" left="575" width="63" height="20" font="0">rate 4.34% </text>
<text top="491" left="564" width="254" height="20" font="0">-  ≥5.0%: observed rate 1.85%, predicted rate </text>
<text top="508" left="575" width="38" height="20" font="0">8.72% </text>
<text top="527" left="548" width="11" height="18" font="0">• </text>
<text top="527" left="562" width="273" height="20" font="0">Event rates over 5 y by 5-y predicted risk strata in </text>
<text top="544" left="550" width="180" height="20" font="0">patients with diabetes (N=4242): </text>
<text top="561" left="564" width="253" height="20" font="0">-  &lt;2.5%: observed rate 0.10%, predicted rate </text>
<text top="578" left="575" width="38" height="20" font="0">1.36% </text>
<text top="595" left="564" width="280" height="20" font="0">-  2.5% to &lt;3.75%: observed rate 2.55%, predicted </text>
<text top="613" left="575" width="63" height="20" font="0">rate 3.11% </text>
<text top="630" left="564" width="280" height="20" font="0">-  3.75% to &lt;5.0%: observed rate 2.65%, predicted </text>
<text top="647" left="575" width="63" height="20" font="0">rate 4.37% </text>
<text top="664" left="564" width="254" height="20" font="0">-  ≥5.0%: observed rate 5.50%, predicted rate </text>
<text top="681" left="575" width="45" height="20" font="0">13.38% </text>
<text top="700" left="548" width="11" height="18" font="0">• </text>
<text top="700" left="562" width="290" height="20" font="0">Mis-calibration similar with substantial overprediction </text>
<text top="717" left="550" width="259" height="20" font="0">by PCE across all subgroups by sex, race, and </text>
<text top="734" left="550" width="86" height="20" font="0">diabetes status </text>
<text top="753" left="548" width="11" height="18" font="0">• </text>
<text top="753" left="562" width="247" height="20" font="0">Discrimination C statistics moderate to good: </text>
<text top="770" left="562" width="178" height="20" font="0">-  Overall without diabetes: 0.74 </text>
<text top="787" left="577" width="88" height="20" font="0">-  Women: 0.72 </text>
<text top="144" left="864" width="11" height="18" font="0">• </text>
<text top="143" left="874" width="215" height="20" font="0">Authors concluded that PCE should be </text>
<text top="161" left="864" width="212" height="20" font="0">recalibrated due to the substantial and </text>
<text top="178" left="864" width="237" height="20" font="0">consistent overestimation of ASCVD risk in </text>
<text top="195" left="864" width="70" height="20" font="0">their sample </text>
<text top="212" left="865" width="3" height="20" font="0"> </text>
<text top="231" left="864" width="11" height="18" font="0">• </text>
<text top="230" left="874" width="204" height="20" font="0">Limitations: Approximately 90% of all </text>
<text top="247" left="865" width="216" height="20" font="0">covered individuals and &gt;2/3 of original </text>
<text top="265" left="865" width="210" height="20" font="0">eligible population excluded, including </text>
<text top="282" left="865" width="220" height="20" font="0">those treated after baseline; as a result, </text>
<text top="299" left="865" width="215" height="20" font="0">very low prevalence of diabetes (1.4%) </text>
<text top="316" left="865" width="223" height="20" font="0">and other high-risk conditions, and there </text>
<text top="334" left="865" width="226" height="20" font="0">were very low event rates compared with </text>
<text top="351" left="865" width="226" height="20" font="0">other samples from the same population. </text>
<text top="368" left="865" width="205" height="20" font="0">Administrative data used to ascertain </text>
<text top="385" left="865" width="219" height="20" font="0">endpoints, which may have led to some </text>
<text top="403" left="865" width="231" height="20" font="0">misclassification; uncertain how scaling of </text>
<text top="420" left="865" width="236" height="20" font="0">10-y to 5-y predicted risks was performed.  </text>
<text top="437" left="865" width="3" height="20" font="0"> </text>
<text top="454" left="865" width="89" height="20" font="0">QUALITY: Low  </text>
</page>
<page number="82" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">82 </text>
<text top="107" left="577" width="70" height="20" font="0">-  Men: 0.68 </text>
<text top="124" left="577" width="155" height="20" font="0">-  Non-Hispanic White: 0.74 </text>
<text top="141" left="577" width="139" height="20" font="0">-  African American: 0.70 </text>
<text top="159" left="577" width="164" height="20" font="0">-  Asian-Pacific Islander: 0.72 </text>
<text top="176" left="577" width="93" height="20" font="0">-  Hispanic: 0.74 </text>
<text top="193" left="562" width="162" height="20" font="0">-  Overall with diabetes: 0.64 </text>
<text top="213" left="91" width="101" height="20" font="0">Ungprasert et al.,  </text>
<text top="231" left="91" width="56" height="20" font="0">2017<a href="data supplement.html#241"> (84)</a> </text>
<text top="248" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28705378">28705378</a></text>
<text top="248" left="145" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28705378"> </a></text>
<text top="213" left="225" width="71" height="20" font="7"><b>Study type:</b> </text>
<text top="231" left="225" width="111" height="20" font="0">Retrospective Case-</text>
<text top="248" left="225" width="101" height="20" font="0">Cohort study from </text>
<text top="265" left="225" width="121" height="20" font="0">Olmsted County, MN, </text>
<text top="282" left="225" width="62" height="20" font="0">1989-2013 </text>
<text top="299" left="225" width="3" height="20" font="0"> </text>
<text top="317" left="225" width="128" height="20" font="7"><b>Size:</b> 358 patients with </text>
<text top="334" left="225" width="89" height="20" font="0">sarcoidosis and </text>
<text top="351" left="225" width="97" height="20" font="0">matched controls </text>
<text top="368" left="225" width="136" height="20" font="0">(N=203 total for persons </text>
<text top="386" left="225" width="113" height="20" font="0">for whom PCE were </text>
<text top="403" left="225" width="47" height="20" font="0">applied)<b> </b></text>
<text top="213" left="375" width="126" height="20" font="7"><b>Inclusion criteria (for </b></text>
<text top="231" left="375" width="107" height="20" font="7"><b>analysis of PCE):</b>  </text>
<text top="250" left="375" width="7" height="18" font="0">•</text>
<text top="249" left="381" width="139" height="20" font="0"> Patients aged 40 to 74 y </text>
<text top="266" left="375" width="160" height="20" font="0">with incident sarcoidosis and </text>
<text top="283" left="375" width="103" height="20" font="0">randomly selected </text>
<text top="301" left="375" width="160" height="20" font="0">comparators from underlying </text>
<text top="318" left="375" width="155" height="20" font="0">population matched on age, </text>
<text top="335" left="375" width="156" height="20" font="0">sex and date of diagnosis of </text>
<text top="352" left="375" width="107" height="20" font="0">sarcoidosis in case </text>
<text top="370" left="375" width="3" height="20" font="0"> </text>
<text top="387" left="375" width="130" height="20" font="7"><b>Exclusion criteria (for </b></text>
<text top="404" left="375" width="114" height="20" font="7"><b>analysis of PCEs):</b>  </text>
<text top="423" left="375" width="7" height="18" font="0">•</text>
<text top="422" left="381" width="143" height="20" font="0"> Incomplete data on lipids </text>
<text top="440" left="375" width="152" height="20" font="0">and other variables needed </text>
<text top="457" left="375" width="46" height="20" font="0">for PCE </text>
<text top="476" left="375" width="7" height="18" font="0">•</text>
<text top="475" left="381" width="88" height="20" font="0"> Prevalent CVD </text>
<text top="494" left="375" width="7" height="18" font="0">•</text>
<text top="493" left="381" width="115" height="20" font="0"> Prevalent statin use<b> </b></text>
<text top="215" left="550" width="291" height="20" font="7"><b>1</b>°<b> endpoint:</b> Incident CHD or stroke (for analyses of </text>
<text top="232" left="550" width="36" height="20" font="0">PCE); </text>
<text top="249" left="550" width="120" height="20" font="0">Median follow up N/A </text>
<text top="266" left="550" width="3" height="20" font="0"> </text>
<text top="283" left="550" width="3" height="20" font="0"> </text>
<text top="301" left="550" width="55" height="20" font="7"><b>Results: </b> </text>
<text top="320" left="548" width="11" height="18" font="0">• </text>
<text top="319" left="561" width="261" height="20" font="0">In analysis of the PCE, the predicted number of </text>
<text top="336" left="550" width="299" height="20" font="0">ASCVD events among those with sarcoidosis was 4.6, </text>
<text top="353" left="550" width="243" height="20" font="0">and the observed number of events was 16, </text>
<text top="370" left="550" width="294" height="20" font="0">corresponding to a standardized incidence ratio (SIR) </text>
<text top="388" left="550" width="289" height="20" font="0">of 4.11, 95% CI: 2.62-6.44. Among comparators, the </text>
<text top="405" left="550" width="297" height="20" font="0">predicted number of events was 5.4 and the observed </text>
<text top="422" left="550" width="297" height="20" font="0">number was 6, for an SIR of 1.12, 95% CI: 0.50-2.49.  </text>
<text top="441" left="548" width="11" height="18" font="0">• </text>
<text top="440" left="561" width="282" height="20" font="0">In analysis of Framingham general CVD equations, </text>
<text top="458" left="550" width="302" height="20" font="0">the predicted number of CVD events among those with </text>
<text top="475" left="550" width="278" height="20" font="0">sarcoidosis was 11.8, and the observed number of </text>
<text top="492" left="550" width="288" height="20" font="0">CVD events was 34, corresponding to a SIR of 2.88, </text>
<text top="509" left="550" width="298" height="20" font="0">95% CI: 2.06-4.04. Among comparators, the predicted </text>
<text top="527" left="550" width="295" height="20" font="0">number of events was 11.0 and the observed number </text>
<text top="544" left="550" width="283" height="20" font="0">was 11, for an SIR of 1.00, 95% CI: 0.56-1.81. FRS </text>
<text top="561" left="550" width="290" height="20" font="0">consistently underpredicted risk across subgroups of </text>
<text top="578" left="550" width="205" height="20" font="0">age, sex and severity of sarcoidosis.  </text>
<text top="595" left="550" width="3" height="20" font="7"><b> </b></text>
<text top="215" left="864" width="11" height="18" font="0">• </text>
<text top="215" left="873" width="209" height="20" font="0">PCE substantially underestimated the </text>
<text top="232" left="865" width="178" height="20" font="0">risk of CVD among patients with </text>
<text top="249" left="865" width="65" height="20" font="0">sarcoidosis </text>
<text top="266" left="865" width="3" height="20" font="0"> </text>
<text top="285" left="864" width="11" height="18" font="0">• </text>
<text top="284" left="873" width="171" height="20" font="0">Limitations: Small sample size, </text>
<text top="301" left="865" width="228" height="20" font="0">retrospective study; unclear what the role </text>
<text top="319" left="865" width="224" height="20" font="0">of controls is here; non-parallel nature of </text>
<text top="336" left="865" width="221" height="20" font="0">ASCVD PCE and overall CVD endpoint  </text>
<text top="353" left="865" width="3" height="20" font="0"> </text>
<text top="370" left="865" width="89" height="20" font="0">QUALITY: Poor </text>
<text top="613" left="91" width="98" height="20" font="0">Wolfson J, et al.,  </text>
<text top="631" left="91" width="56" height="20" font="0">2017<a href="data supplement.html#241"> (85)</a> </text>
<text top="648" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28438733">28438733</a></text>
<text top="648" left="145" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28438733"> </a></text>
<text top="613" left="225" width="71" height="20" font="7"><b>Study type:</b> </text>
<text top="631" left="225" width="78" height="20" font="0">Retrospective </text>
<text top="648" left="225" width="117" height="20" font="0">administrative cohort </text>
<text top="665" left="225" width="98" height="20" font="0">study, 2001-2011 </text>
<text top="682" left="225" width="3" height="20" font="0"> </text>
<text top="699" left="225" width="120" height="20" font="7"><b>Size:</b> 84,116 patients<b> </b></text>
<text top="613" left="375" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="632" left="375" width="7" height="18" font="0">•</text>
<text top="632" left="381" width="116" height="20" font="0"> Adults aged 40-79 y </text>
<text top="649" left="375" width="129" height="20" font="0">without CVD, in a large </text>
<text top="666" left="375" width="130" height="20" font="0">combined medical care </text>
<text top="683" left="375" width="141" height="20" font="0">network and/or insurance </text>
<text top="701" left="375" width="103" height="20" font="0">plan in Minnesota  </text>
<text top="720" left="375" width="11" height="18" font="0">• </text>
<text top="719" left="386" width="118" height="20" font="0">Two or more medical </text>
<text top="736" left="375" width="123" height="20" font="0">encounters with blood </text>
<text top="753" left="375" width="154" height="20" font="0">pressure measurement &gt;30 </text>
<text top="770" left="375" width="106" height="20" font="0">ds but &lt;1.5 y apart </text>
<text top="614" left="550" width="258" height="20" font="7"><b>1</b>°<b> endpoint:</b> Incident CHD or stroke based on </text>
<text top="632" left="550" width="119" height="20" font="0">administrative codes; </text>
<text top="649" left="550" width="140" height="20" font="0">Median follow-up of 4.5 y<b> </b></text>
<text top="666" left="550" width="3" height="20" font="7"><b> </b></text>
<text top="683" left="550" width="55" height="20" font="7"><b>Results: </b> </text>
<text top="702" left="548" width="11" height="18" font="0">• </text>
<text top="702" left="564" width="267" height="20" font="0">PCE were well calibrated in lower-risk strata and </text>
<text top="719" left="548" width="297" height="20" font="0">overpredicted risk notably in higher risk strata (~&gt;10% </text>
<text top="736" left="548" width="54" height="20" font="0">10-y risk) </text>
<text top="755" left="548" width="11" height="18" font="0">• </text>
<text top="754" left="564" width="281" height="20" font="0">Kaplan-Meier event rates for strata of predicted 5-y </text>
<text top="771" left="548" width="101" height="20" font="0">risk by PCE were: </text>
<text top="615" left="864" width="11" height="18" font="0">• </text>
<text top="614" left="874" width="228" height="20" font="0">PCE exhibited good calibration, except at </text>
<text top="631" left="864" width="223" height="20" font="0">higher risk levels (~&gt;10% predicted 10-y </text>
<text top="649" left="864" width="224" height="20" font="0">risk), and moderate discrimination in this </text>
<text top="666" left="864" width="232" height="20" font="0">EHR-based cohort. Recalibrating the PCE </text>
<text top="683" left="864" width="225" height="20" font="0">did not improve calibration substantially.  </text>
<text top="702" left="864" width="11" height="18" font="0">• </text>
<text top="701" left="874" width="218" height="20" font="0">Limitations: Retrospective cohort study; </text>
<text top="719" left="864" width="222" height="20" font="0">administrative data and non-adjudicated </text>
<text top="736" left="864" width="232" height="20" font="0">endpoints; 4.5 y of follow up; missing data </text>
<text top="753" left="864" width="187" height="20" font="0">handled by imputation rather than </text>
<text top="770" left="864" width="206" height="20" font="0">restricting analyses; no accounting of </text>
<text top="787" left="864" width="182" height="20" font="0">preventive therapy after baseline </text>
</page>
<page number="83" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">83 </text>
<text top="109" left="375" width="11" height="18" font="0">• </text>
<text top="108" left="386" width="137" height="20" font="0">Prescription drug benefit </text>
<text top="125" left="375" width="129" height="20" font="0">during the same period </text>
<text top="143" left="375" width="3" height="20" font="0"> </text>
<text top="160" left="375" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="179" left="375" width="7" height="18" font="0">•</text>
<text top="178" left="381" width="142" height="20" font="0"> Prevalent CVD based on </text>
<text top="195" left="375" width="61" height="20" font="0">ICD codes<b> </b></text>
<text top="109" left="562" width="11" height="18" font="0">• </text>
<text top="108" left="575" width="252" height="20" font="0">0%-2.5%: observed rate of 13/1000 person-y, </text>
<text top="125" left="562" width="185" height="20" font="0">predicted rate of 9/1000 person-y </text>
<text top="144" left="562" width="11" height="18" font="0">• </text>
<text top="144" left="575" width="252" height="20" font="0">2.5%-5%: observed rate of 41/1000 person-y, </text>
<text top="161" left="562" width="192" height="20" font="0">predicted rate of 35/1000 person-y </text>
<text top="180" left="562" width="11" height="18" font="0">• </text>
<text top="179" left="575" width="265" height="20" font="0">5% to 7.5%: observed rate of 56/1000 person-y, </text>
<text top="196" left="562" width="192" height="20" font="0">predicted rate of 61/1000 person-y </text>
<text top="215" left="562" width="11" height="18" font="0">• </text>
<text top="215" left="575" width="258" height="20" font="0">7.5%-10%: observed rate of 74/1000 person-y, </text>
<text top="232" left="562" width="192" height="20" font="0">predicted rate of 86/1000 person-y </text>
<text top="251" left="562" width="11" height="18" font="0">• </text>
<text top="250" left="575" width="240" height="20" font="0">&gt;10%: observed rate of 117/1000 person-y, </text>
<text top="267" left="562" width="198" height="20" font="0">predicted rate of 148/1000 person-y </text>
<text top="286" left="548" width="11" height="18" font="0">• </text>
<text top="285" left="563" width="279" height="20" font="0">Hosmer-Lemeshow-like calibration statistic of PCE </text>
<text top="303" left="548" width="149" height="20" font="0">overall was 43.7 (p&lt;0.001) </text>
<text top="322" left="548" width="11" height="18" font="0">• </text>
<text top="321" left="563" width="272" height="20" font="0">Discrimination C-statistic of PCE was 0.747; 95% </text>
<text top="338" left="548" width="88" height="20" font="0">CI: 0.727-0.768 </text>
<text top="357" left="548" width="11" height="18" font="0">• </text>
<text top="356" left="563" width="271" height="20" font="0">Results were similar when restricted to non-statin </text>
<text top="374" left="548" width="245" height="20" font="0">users only, and whites and blacks only. PCE </text>
<text top="391" left="548" width="289" height="20" font="0">calibration was excellent for blacks when considered </text>
<text top="408" left="548" width="233" height="20" font="0">separately; calibration statistic 2.8, p=0.42 </text>
<text top="427" left="548" width="11" height="18" font="0">• </text>
<text top="426" left="563" width="281" height="20" font="0">PCE were well calibrated across all 5-y age groups </text>
<text top="443" left="548" width="288" height="20" font="0">from 40 to 75 y, and overpredicted risk among those </text>
<text top="460" left="548" width="77" height="20" font="0">75 to 80 y old </text>
<text top="480" left="548" width="11" height="18" font="0">• </text>
<text top="479" left="563" width="232" height="20" font="0">Recalibration of PCE using locally derived </text>
<text top="496" left="550" width="269" height="20" font="0">coefficients and hazards only modestly improved </text>
<text top="513" left="550" width="60" height="20" font="0">calibration </text>
<text top="532" left="548" width="11" height="18" font="0">• </text>
<text top="532" left="563" width="282" height="20" font="0">Framingham risk score performed slightly better for </text>
<text top="549" left="548" width="136" height="20" font="0">its endpoint of total CVD </text>
<text top="107" left="865" width="3" height="20" font="0"> </text>
<text top="124" left="865" width="157" height="20" font="0">QUALITY: Moderate to poor </text>
<text top="141" left="865" width="3" height="20" font="0"> </text>
<text top="159" left="865" width="3" height="20" font="0"> </text>
<text top="567" left="91" width="84" height="20" font="0">Yang X, et al.,  </text>
<text top="584" left="91" width="56" height="20" font="0">2016<a href="data supplement.html#241"> (86)</a> </text>
<text top="601" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27682885">27682885</a></text>
<text top="601" left="145" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27682885"> </a></text>
<text top="567" left="225" width="71" height="20" font="7"><b>Study type:</b> </text>
<text top="584" left="225" width="67" height="20" font="0">Prospective </text>
<text top="601" left="225" width="120" height="20" font="0">Observational Cohort </text>
<text top="618" left="225" width="33" height="20" font="0">study </text>
<text top="635" left="225" width="3" height="20" font="0"> </text>
<text top="653" left="225" width="73" height="20" font="7"><b>Size:</b> 84,961 </text>
<text top="670" left="225" width="66" height="20" font="0">participants </text>
<text top="687" left="225" width="110" height="20" font="0">(combination of two </text>
<text top="704" left="225" width="102" height="20" font="0">external validation </text>
<text top="721" left="225" width="48" height="20" font="0">cohorts)<b> </b></text>
<text top="567" left="375" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="586" left="375" width="7" height="18" font="0">•</text>
<text top="585" left="381" width="130" height="20" font="0"> Adults aged 35-74 y at </text>
<text top="602" left="375" width="53" height="20" font="0">baseline  </text>
<text top="619" left="375" width="3" height="20" font="0"> </text>
<text top="637" left="375" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="656" left="375" width="7" height="18" font="0">•</text>
<text top="655" left="381" width="127" height="20" font="0"> Prevalent MI or stroke </text>
<text top="674" left="372" width="11" height="18" font="0">• </text>
<text top="673" left="386" width="73" height="20" font="0">Missing data </text>
<text top="690" left="375" width="3" height="20" font="7"><b> </b></text>
<text top="568" left="550" width="281" height="20" font="7"><b>1</b>°<b> endpoint:</b> Incident ASCVD (nonfatal MI or CHD </text>
<text top="585" left="550" width="82" height="20" font="0">death, stroke); </text>
<text top="602" left="550" width="136" height="20" font="0">Median follow up of 12 y<b> </b></text>
<text top="619" left="550" width="3" height="20" font="7"><b> </b></text>
<text top="637" left="550" width="55" height="20" font="7"><b>Results: </b> </text>
<text top="656" left="548" width="11" height="18" font="0">• </text>
<text top="655" left="564" width="268" height="20" font="0">PCE for white individuals tended to overestimate </text>
<text top="672" left="548" width="247" height="20" font="0">risk in men and underestimate risk in women </text>
<text top="691" left="548" width="11" height="18" font="0">• </text>
<text top="690" left="564" width="286" height="20" font="0">Using PCE for white participants, measures of utility </text>
<text top="708" left="548" width="37" height="20" font="0">were:  </text>
<text top="725" left="562" width="272" height="20" font="0">-  Kaplan-Meier-adjusted observed events 218.7, </text>
<text top="742" left="562" width="273" height="20" font="0">predicted events 336.9; C-statistic 0.768; 95% CI: </text>
<text top="759" left="562" width="290" height="20" font="0">0.733-0.803; calibration X2 118.8 (p&lt;0.001) in China </text>
<text top="776" left="562" width="67" height="20" font="0">MUCA men </text>
<text top="568" left="865" width="11" height="18" font="0">• </text>
<text top="568" left="874" width="215" height="20" font="0">PCE exhibited good discrimination and </text>
<text top="585" left="865" width="202" height="20" font="0">poor calibration in two large Chinese </text>
<text top="602" left="865" width="197" height="20" font="0">cohorts, in both men and women. A </text>
<text top="619" left="865" width="224" height="20" font="0">separate Chinese-specific risk prediction </text>
<text top="636" left="865" width="237" height="20" font="0">model demonstrated better calibration than </text>
<text top="654" left="865" width="205" height="20" font="0">the PCE when applied in this cohort.  </text>
<text top="671" left="865" width="3" height="20" font="0"> </text>
<text top="690" left="865" width="11" height="18" font="0">• </text>
<text top="689" left="874" width="214" height="20" font="0">Limitations: PCE applied in race/ethnic </text>
<text top="706" left="865" width="234" height="20" font="0">population not included in the derivation of </text>
<text top="724" left="865" width="56" height="20" font="0">the PCE.  </text>
<text top="741" left="865" width="3" height="20" font="0"> </text>
<text top="758" left="865" width="175" height="20" font="0">OVERALL QUALITY: Moderate </text>
<text top="775" left="865" width="3" height="20" font="0"> </text>
</page>
<page number="84" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">84 </text>
<text top="350" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="369" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="387" left="81" width="620" height="24" font="4"><b>Data Supplement 15. Nonrandomized Trials, Observational Studies, and/or Registries of </b></text>
<text top="387" left="701" width="29" height="24" font="6"><b>Q2: </b></text>
<text top="387" left="729" width="376" height="24" font="4"><b>Performance of coronary artery calcium screening to </b></text>
<text top="408" left="81" width="989" height="24" font="4"><b>reclassify risk appropriately for atherosclerotic cardiovascular disease (ASCVD) events when used for the prediction of first incident ASCVD </b></text>
<text top="429" left="81" width="737" height="24" font="4"><b>events in diverse populations, especially in the context of the Pooled Cohort Equations (Section 4.4.1.2)  </b></text>
<text top="450" left="116" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="468" left="141" width="48" height="20" font="7"><b>Author; </b></text>
<text top="485" left="119" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="450" left="266" width="118" height="20" font="7"><b>Study Type/Design; </b></text>
<text top="468" left="292" width="66" height="20" font="7"><b>Study Size </b></text>
<text top="450" left="435" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="450" left="618" width="179" height="20" font="7"><b>Primary Endpoint and Results </b></text>
<text top="468" left="615" width="184" height="20" font="7"><b>(P values; OR or RR; &amp; 95% CI) </b></text>
<text top="450" left="908" width="130" height="20" font="7"><b>Summary/Conclusion </b></text>
<text top="468" left="935" width="75" height="20" font="7"><b>Comment(s) </b></text>
<text top="503" left="91" width="51" height="20" font="7"><b>CARDIA </b></text>
<text top="520" left="91" width="92" height="20" font="0">Carr J, et al.<a href="data supplement.html#241">(87)</a> </text>
<text top="537" left="91" width="31" height="20" font="0">2017 </text>
<text top="554" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28196265">28196265</a></text>
<text top="554" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28196265"> </a></text>
<text top="503" left="253" width="138" height="20" font="7"><b>Study type:</b> Prospective </text>
<text top="520" left="253" width="128" height="20" font="0">cohort (CARDIA study, </text>
<text top="537" left="253" width="129" height="20" font="0">exam years 15, 20 and </text>
<text top="554" left="253" width="21" height="20" font="0">25) </text>
<text top="572" left="253" width="3" height="20" font="0"> </text>
<text top="589" left="253" width="129" height="20" font="7"><b>Size:</b> 3036 participants </text>
<text top="503" left="410" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="522" left="410" width="7" height="18" font="0">•</text>
<text top="521" left="417" width="144" height="20" font="0"> Black and white men and </text>
<text top="538" left="410" width="143" height="20" font="0">women attending Year 15 </text>
<text top="555" left="410" width="154" height="20" font="0">examination of the CARDIA </text>
<text top="573" left="410" width="153" height="20" font="0">Study and undergoing CAC </text>
<text top="590" left="410" width="79" height="20" font="0">measurement </text>
<text top="609" left="407" width="11" height="18" font="0">• </text>
<text top="608" left="418" width="130" height="20" font="0">Adults age 32-46 years </text>
<text top="625" left="410" width="3" height="20" font="0"> </text>
<text top="643" left="410" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="662" left="407" width="11" height="18" font="0">• </text>
<text top="661" left="421" width="73" height="20" font="0">Missing data </text>
<text top="680" left="407" width="11" height="18" font="0">• </text>
<text top="679" left="421" width="53" height="20" font="0">Pregnant </text>
<text top="698" left="407" width="11" height="18" font="0">• </text>
<text top="697" left="421" width="85" height="20" font="0">Prevalent CHD </text>
<text top="504" left="584" width="243" height="20" font="7"><b>1</b>°<b> endpoint:</b> Incident clinical CHD, CVD, or </text>
<text top="521" left="584" width="233" height="20" font="0">all-cause mortality, considered separately; </text>
<text top="538" left="584" width="170" height="20" font="0">Median follow up of 12.5 years<b> </b></text>
<text top="555" left="584" width="3" height="20" font="0"> </text>
<text top="573" left="584" width="52" height="20" font="7"><b>Results: </b></text>
<text top="592" left="584" width="7" height="18" font="0">•</text>
<text top="591" left="591" width="147" height="20" font="0"> <b>Any CAC versus CAC=0</b> </text>
<text top="610" left="586" width="11" height="18" font="0">• </text>
<text top="609" left="597" width="174" height="20" font="0">All CHD (57 events/38,056 p-y) </text>
<text top="627" left="586" width="165" height="20" font="0">Any CAC: 30 events/3644 p-y </text>
<text top="646" left="586" width="165" height="20" font="0">CAC=0: 27 events/34,413 p-y </text>
<text top="666" left="586" width="185" height="20" font="0">Adjusted HR 5.0, 95% CI: 2.8-8.7 </text>
<text top="688" left="586" width="11" height="18" font="0">• </text>
<text top="687" left="600" width="137" height="20" font="0">CHD excluding coronary </text>
<text top="704" left="586" width="233" height="20" font="0">revascularization without acute events (46 </text>
<text top="721" left="586" width="105" height="20" font="0">events/38,125 p-y) </text>
<text top="739" left="584" width="165" height="20" font="0">Any CAC: 23 events/3693 p-y </text>
<text top="756" left="584" width="165" height="20" font="0">CAC=0: 23 events/34,432 p-y </text>
<text top="773" left="584" width="185" height="20" font="0">Adjusted HR 4.1, 95% CI: 2.2-7.7 </text>
<text top="505" left="842" width="11" height="18" font="0">• </text>
<text top="504" left="858" width="238" height="20" font="0">CAC&gt;0 among adults age 32-46 years was </text>
<text top="521" left="842" width="259" height="20" font="0">associated with higher risk of fatal and nonfatal </text>
<text top="538" left="842" width="240" height="20" font="0">CHD; CAC&gt;100 was associated with nearly </text>
<text top="555" left="842" width="235" height="20" font="0">four-fold risk of all-cause mortality, most of </text>
<text top="573" left="842" width="128" height="20" font="0">which was due to CHD </text>
<text top="592" left="843" width="7" height="18" font="0">•</text>
<text top="591" left="850" width="247" height="20" font="0"> There is a dose-response gradient for future </text>
<text top="608" left="843" width="230" height="20" font="0">CHD events evident for CAC scores even </text>
<text top="625" left="843" width="252" height="20" font="0">among younger adults aged 32-46 years over </text>
<text top="643" left="843" width="133" height="20" font="0">12.5 years of follow up.  </text>
<text top="662" left="843" width="7" height="18" font="0">•</text>
<text top="661" left="850" width="226" height="20" font="0"> Presence of risk factors for CVD in early </text>
<text top="678" left="843" width="237" height="20" font="0">adult life identified those above the median </text>
<text top="695" left="843" width="239" height="20" font="0">risk for developing CAC and, if applied, in a </text>
<text top="713" left="843" width="259" height="20" font="0">selective CAC screening strategy could reduce </text>
<text top="730" left="843" width="237" height="20" font="0">the number of people screened for CAC by </text>
<text top="747" left="843" width="253" height="20" font="0">50% and the number imaged needed to find 1 </text>
<text top="764" left="843" width="182" height="20" font="0">person with CAC from 3.5 to 2.2. </text>
<text top="107" left="562" width="272" height="20" font="0">-  Kaplan-Meier-adjusted observed events 166.4, </text>
<text top="124" left="562" width="273" height="20" font="0">predicted events 121.6; C-statistic 0.786; 95% CI: </text>
<text top="141" left="562" width="256" height="20" font="0">0.752-0.820; X2 18.7 (p=0.03) in China MUCA </text>
<text top="159" left="562" width="43" height="20" font="0">women </text>
<text top="176" left="562" width="272" height="20" font="0">-  Kaplan-Meier-adjusted observed events 746.7, </text>
<text top="193" left="562" width="280" height="20" font="0">predicted events 1249.3; C-statistic 0.793; 95% CI: </text>
<text top="210" left="562" width="253" height="20" font="0">0.778-0.808; X2 81.3 (p&lt;0.001) in CIMIC men </text>
<text top="228" left="562" width="272" height="20" font="0">-  Kaplan-Meier-adjusted observed events 716.0, </text>
<text top="245" left="562" width="274" height="20" font="0">predicted events 646.3; C-statistic 0.785 (95% CI: </text>
<text top="262" left="562" width="273" height="20" font="0">0.771-0.800); X2 65.9 (p&lt;0.001) in CIMIC women </text>
<text top="279" left="550" width="3" height="20" font="0"> </text>
<text top="298" left="548" width="11" height="18" font="0">• </text>
<text top="298" left="564" width="232" height="20" font="0">Recalibration improved discrimination and </text>
<text top="315" left="548" width="102" height="20" font="0">calibration of PCE </text>
<text top="332" left="548" width="3" height="20" font="0"> </text>
</page>
<page number="85" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">85 </text>
<text top="109" left="586" width="11" height="18" font="0">• </text>
<text top="108" left="597" width="221" height="20" font="0">Any CVD event (108 events/37,599 p-y) </text>
<text top="125" left="586" width="165" height="20" font="0">Any CAC: 38 events/3555 p-y </text>
<text top="145" left="586" width="122" height="20" font="0">CAC=0: 70/34,045p-y </text>
<text top="165" left="586" width="185" height="20" font="0">Adjusted HR 3.0, 95% CI, 1.9-4.7 </text>
<text top="186" left="586" width="11" height="18" font="0">• </text>
<text top="186" left="600" width="220" height="20" font="0">All-cause mortality (107 events/38330 p-</text>
<text top="203" left="586" width="14" height="20" font="0">y) </text>
<text top="220" left="586" width="165" height="20" font="0">Any CAC: 25 events/3847 p-y </text>
<text top="240" left="586" width="165" height="20" font="0">CAC=0: 82 events/34,847 p-y </text>
<text top="260" left="586" width="182" height="20" font="0">Adjusted HR 1.6, 95% CI 1.0-2.6 </text>
<text top="294" left="584" width="3" height="20" font="0"> </text>
<text top="313" left="584" width="11" height="18" font="0">• </text>
<text top="313" left="594" width="175" height="20" font="7"><b>CAC score ranges vs. CAC=0 </b></text>
<text top="332" left="586" width="11" height="18" font="0">• </text>
<text top="331" left="596" width="47" height="20" font="0">All CHD </text>
<text top="348" left="586" width="162" height="20" font="0">CAC 1-19: 7 events/1844 p-y </text>
<text top="368" left="586" width="188" height="20" font="0">Adjusted HR 2.6, 95% CI: 1.0, 5.7 </text>
<text top="403" left="586" width="179" height="20" font="0">CAC 20-99: 10 events/1177 p-y  </text>
<text top="420" left="586" width="189" height="20" font="0">Adjusted HR 5.8, 95% CI 2.6-12.1 </text>
<text top="437" left="586" width="166" height="20" font="0">CAC ≥100: 13 events/623-py  </text>
<text top="454" left="586" width="189" height="20" font="0">Adjusted HR 9.8, 95% CI 4.5-20.5 </text>
<text top="474" left="584" width="11" height="18" font="0">• </text>
<text top="473" left="594" width="87" height="20" font="0">Any CVD event </text>
<text top="490" left="586" width="172" height="20" font="0">CAC 1-19: 11 events/1814 p-y  </text>
<text top="507" left="586" width="182" height="20" font="0">Adjusted HR 1.8, 95% CI 0.9-3.4 </text>
<text top="524" left="586" width="179" height="20" font="0">CAC 20-99: 13 events/1150 p-y  </text>
<text top="541" left="586" width="182" height="20" font="0">Adjusted HR 3.6, 95% CI 1.8-6.5 </text>
<text top="559" left="586" width="169" height="20" font="0">CAC &gt;100: 14 events/591 p-y  </text>
<text top="576" left="586" width="189" height="20" font="0">Adjusted HR 5.7, 95% CI 2.8-10.9 </text>
<text top="595" left="586" width="11" height="18" font="0">• </text>
<text top="594" left="597" width="104" height="20" font="0">All-cause mortality </text>
<text top="611" left="584" width="165" height="20" font="0">CAC 1-19: 8 events/1897 p-y  </text>
<text top="629" left="584" width="182" height="20" font="0">Adjusted HR 1.1, 95% CI 0.5-2.1 </text>
<text top="646" left="584" width="172" height="20" font="0">CAC 20-99: 4 events/1243 p-y  </text>
<text top="663" left="584" width="182" height="20" font="0">Adjusted HR 0.9, 95% CI 0.3-2.7 </text>
<text top="680" left="584" width="162" height="20" font="0">CAC&gt;100: 13 events/706 p-y </text>
<text top="697" left="584" width="189" height="20" font="0">Adjusted HR 3.7, 95% CI 1.5-10.0 </text>
<text top="715" left="584" width="3" height="20" font="0"> </text>
<text top="734" left="584" width="11" height="18" font="0">• </text>
<text top="733" left="596" width="215" height="20" font="0">When participants were stratified into 3 </text>
<text top="750" left="584" width="236" height="20" font="0">tiers of Framingham CHD risk score (≤4%, </text>
<text top="767" left="584" width="223" height="20" font="0">5%-11%, and ≥12%), CAC score further </text>
<text top="784" left="584" width="240" height="20" font="0">stratified CHD incidence density, with those </text>
<text top="109" left="842" width="11" height="18" font="0">• </text>
<text top="108" left="858" width="243" height="20" font="0">Selective use of screening for CAC in adults </text>
<text top="125" left="842" width="259" height="20" font="0">before the age of 50, based on the presence of </text>
<text top="143" left="842" width="224" height="20" font="0">risk factors in young adulthood, might be </text>
<text top="160" left="842" width="244" height="20" font="0">considered to inform discussions on primary </text>
<text top="177" left="842" width="68" height="20" font="0">prevention.  </text>
<text top="194" left="843" width="3" height="20" font="0"> </text>
<text top="213" left="842" width="11" height="18" font="0">• </text>
<text top="213" left="856" width="231" height="20" font="0">Limitations: Small number of events given </text>
<text top="230" left="843" width="123" height="20" font="0">younger age of cohort </text>
<text top="247" left="843" width="3" height="20" font="0"> </text>
</page>
<page number="86" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">86 </text>
<text top="107" left="584" width="200" height="20" font="0">with lower CAC scores experiencing </text>
<text top="124" left="584" width="229" height="20" font="0">substantially lower event rates than those </text>
<text top="141" left="584" width="226" height="20" font="0">with higher CAC scores, especially when </text>
<text top="159" left="584" width="241" height="20" font="0">CAC score ≥100 at 10-year CHD risk levels </text>
<text top="176" left="584" width="232" height="20" font="0">&gt;5% and when CAC score ≥20 at 10-year </text>
<text top="193" left="584" width="124" height="20" font="0">CHD risk levels ≥12% </text>
<text top="210" left="584" width="3" height="20" font="0"> </text>
<text top="232" left="584" width="11" height="18" font="0">• </text>
<text top="231" left="596" width="207" height="20" font="0">Among participants predicted to be at </text>
<text top="248" left="584" width="234" height="20" font="0">lower risk for CAC&gt;0 in middle age (based </text>
<text top="265" left="584" width="217" height="20" font="0">on being below the median in predicted </text>
<text top="283" left="584" width="215" height="20" font="0">CAC risk from risk factor levels in early </text>
<text top="300" left="584" width="239" height="20" font="0">adulthood), CAC prevalence was 13.2% for </text>
<text top="317" left="584" width="241" height="20" font="0">number needed to screen  to find CAC&gt;0 of </text>
<text top="334" left="584" width="21" height="20" font="0">7.7 </text>
<text top="353" left="584" width="11" height="18" font="0">• </text>
<text top="353" left="596" width="207" height="20" font="0">Among participants predicted to be at </text>
<text top="370" left="584" width="239" height="20" font="0">higher risk for CAC&gt;0 in middle age (above </text>
<text top="387" left="584" width="220" height="20" font="0">the median in predicted CAC risk), CAC </text>
<text top="404" left="584" width="235" height="20" font="0">prevalence was 44.7% for number needed </text>
<text top="422" left="584" width="169" height="20" font="0">to screen to find CAC&gt;0 of 2.2 </text>
<text top="439" left="584" width="3" height="20" font="0"> </text>
<text top="457" left="91" width="39" height="20" font="7"><b>MESA </b></text>
<text top="474" left="91" width="102" height="20" font="0">Flueckiger P, et al.</text>
<text top="477" left="193" width="5" height="16" font="15"> </text>
<text top="474" left="197" width="26" height="20" font="0"><a href="data supplement.html#240">(73)</a> </text>
<text top="491" left="91" width="38" height="20" font="0">2017   </text>
<text top="508" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27859433">27859433</a></text>
<text top="508" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27859433"> </a></text>
<text top="457" left="253" width="138" height="20" font="7"><b>Study type:</b> Prospective </text>
<text top="474" left="253" width="38" height="20" font="0">cohort </text>
<text top="491" left="253" width="3" height="20" font="0"> </text>
<text top="508" left="253" width="129" height="20" font="7"><b>Size:</b> 5002 participants </text>
<text top="457" left="410" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="476" left="410" width="7" height="18" font="0">•</text>
<text top="475" left="417" width="99" height="20" font="0"> Untreated MESA </text>
<text top="492" left="410" width="148" height="20" font="0">participants (adults age 45-</text>
<text top="509" left="410" width="141" height="20" font="0">84 years) who underwent </text>
<text top="527" left="410" width="149" height="20" font="0">CAC screening at baseline </text>
<text top="544" left="410" width="3" height="20" font="0"> </text>
<text top="561" left="410" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="580" left="407" width="11" height="18" font="0">• </text>
<text top="579" left="417" width="142" height="20" font="0">Lipid-lowering medication </text>
<text top="596" left="407" width="23" height="20" font="0">use </text>
<text top="616" left="407" width="11" height="18" font="0">• </text>
<text top="615" left="417" width="76" height="20" font="0">Missing data  </text>
<text top="634" left="407" width="11" height="18" font="0">• </text>
<text top="633" left="417" width="87" height="20" font="0">Age &gt;75 years  </text>
<text top="458" left="584" width="83" height="20" font="7"><b>1</b>°<b> endpoints:</b> </text>
<text top="475" left="584" width="229" height="20" font="0">Sensitivity/specificity/NPV/PPV of several </text>
<text top="492" left="584" width="234" height="20" font="0">risk scores/guideline recommendations for </text>
<text top="509" left="584" width="149" height="20" font="0">detecting CAC at baseline; </text>
<text top="527" left="584" width="210" height="20" font="0">Incident CHD (for ATP III – defined as </text>
<text top="544" left="584" width="166" height="20" font="0">fatal/nonfatal MI or fatal CHD) </text>
<text top="561" left="584" width="243" height="20" font="0">Incident ASCVD (for ACC/AHA – defined as </text>
<text top="578" left="584" width="242" height="20" font="0">including fatal/nonfatal myocardial infarction </text>
<text top="596" left="584" width="233" height="20" font="0">(MI), coronary heart disease (CHD) death, </text>
<text top="613" left="584" width="118" height="20" font="0">fatal/nonfatal stroke); </text>
<text top="630" left="584" width="245" height="20" font="0">ASCVD death (for ESC/EAS – defined as all </text>
<text top="647" left="584" width="228" height="20" font="0">fatal ASCVD events, including MI, stroke, </text>
<text top="664" left="584" width="211" height="20" font="0">occlusive atherosclerotic disease, and </text>
<text top="682" left="584" width="165" height="20" font="0">sudden cardiovascular death) </text>
<text top="699" left="584" width="120" height="20" font="0">Follow up of 10 years </text>
<text top="716" left="584" width="3" height="20" font="0"> </text>
<text top="733" left="584" width="52" height="20" font="7"><b>Results: </b></text>
<text top="750" left="584" width="239" height="20" font="7"><b>Using Class I recommendations for lipid-</b></text>
<text top="768" left="584" width="237" height="20" font="7"><b>lowering therapy by different guidelines </b></text>
<text top="785" left="584" width="194" height="20" font="7"><b>for detection of CAC at baseline: </b></text>
<text top="457" left="843" width="24" height="20" font="0">       </text>
<text top="476" left="842" width="11" height="18" font="0">• </text>
<text top="475" left="858" width="236" height="20" font="0">ACC/AHA approach using PCE appears to </text>
<text top="492" left="843" width="254" height="20" font="0">have the best balance between sensitivity and </text>
<text top="509" left="843" width="256" height="20" font="0">specificity for detecting CAC and for predicting </text>
<text top="526" left="843" width="239" height="20" font="0">incident CVD events compared with ATP III </text>
<text top="544" left="843" width="84" height="20" font="0">and ESC/EAS. </text>
<text top="561" left="842" width="3" height="20" font="0"> </text>
<text top="580" left="842" width="11" height="18" font="0">• </text>
<text top="579" left="858" width="212" height="20" font="0">There were modest differences by sex </text>
<text top="596" left="843" width="258" height="20" font="0">(more sensitive in men), age (more sensitive in </text>
<text top="614" left="843" width="247" height="20" font="0">older adults), and race (minimal differences), </text>
<text top="631" left="843" width="252" height="20" font="0">but these differences appear largely driven by </text>
<text top="648" left="843" width="26" height="20" font="0">risk. </text>
<text top="665" left="842" width="3" height="20" font="0"> </text>
<text top="684" left="842" width="11" height="18" font="0">• </text>
<text top="684" left="858" width="227" height="20" font="0">The proportion with baseline CAC=0 was </text>
<text top="701" left="843" width="241" height="20" font="0">high for all Class I recommendation groups, </text>
<text top="718" left="843" width="253" height="20" font="0">but similar across groups: ATP III (57%), PCE </text>
<text top="735" left="843" width="150" height="20" font="0">(58%), and SCORE (60%). </text>
<text top="752" left="843" width="3" height="20" font="0"> </text>
</page>
<page number="87" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">87 </text>
<text top="109" left="586" width="11" height="18" font="0">• </text>
<text top="108" left="600" width="192" height="20" font="0">Sensitivity/Specificity/NPV/PPV for </text>
<text top="125" left="586" width="43" height="20" font="0">CAC&gt;0 </text>
<text top="143" left="584" width="229" height="20" font="0">2004 ATP III: 35.0%/80.7%/62.9%/57.0% </text>
<text top="160" left="584" width="246" height="20" font="0">2013 ACC/AHA: 69.8%/63.2%/74.2%/58.1% </text>
<text top="177" left="584" width="244" height="20" font="0">2016 ESC/EAS: 39.1%/80.8%/64.5%/59.7% </text>
<text top="196" left="584" width="11" height="18" font="0">• </text>
<text top="195" left="596" width="192" height="20" font="0">Sensitivity/Specificity/NPV/PPV for </text>
<text top="212" left="584" width="58" height="20" font="0">CAC≥100 </text>
<text top="230" left="584" width="198" height="20" font="0">ATP III: 40.2%/77.1%/85.9%/27.1% </text>
<text top="247" left="584" width="215" height="20" font="0">ACC/AHA: 83.1%/56.1%/94.0%/28.6% </text>
<text top="264" left="584" width="213" height="20" font="0">ESC/EAS: 48.5%/76.8%/87.5%/30.7% </text>
<text top="283" left="584" width="11" height="18" font="0">• </text>
<text top="282" left="594" width="192" height="20" font="0">Sensitivity/Specificity/NPV/PPV for </text>
<text top="300" left="584" width="58" height="20" font="0">CAC≥300 </text>
<text top="317" left="584" width="198" height="20" font="0">ATP III: 41.1%/75.5%/93.3%/13.4% </text>
<text top="334" left="584" width="215" height="20" font="0">ACC/AHA: 87.2%/52.6%/97.8%/14.5% </text>
<text top="351" left="584" width="210" height="20" font="0">ESC/EAS: 54.1%/74.8%/94.6%16.6% </text>
<text top="370" left="584" width="11" height="18" font="0">• </text>
<text top="370" left="594" width="192" height="20" font="0">Sensitivity/Specificity/NPV/PPV for </text>
<text top="387" left="584" width="82" height="20" font="0">CAC≥300 + 75</text>
<text top="388" left="666" width="7" height="13" font="9">th</text>
<text top="387" left="673" width="122" height="20" font="0"> %ile for age/sex/race </text>
<text top="404" left="584" width="194" height="20" font="0">ATP III: 36.3%/77.2%/80.1%32.4% </text>
<text top="421" left="584" width="215" height="20" font="0">ACC/AHA: 66.3%/53.9%/84.2%/30.2% </text>
<text top="438" left="584" width="213" height="20" font="0">ESC/EAS: 39.4%/75.9%/80.6%/33.0% </text>
<text top="455" left="584" width="3" height="20" font="0"> </text>
<text top="473" left="584" width="239" height="20" font="7"><b>Using Class I recommendations for lipid-</b></text>
<text top="490" left="584" width="237" height="20" font="7"><b>lowering therapy by different guidelines </b></text>
<text top="507" left="584" width="220" height="20" font="7"><b>for prediction of incident events (risk </b></text>
<text top="524" left="584" width="152" height="20" font="7"><b>score-specific outcomes) </b></text>
<text top="543" left="586" width="11" height="18" font="0">• </text>
<text top="543" left="598" width="230" height="20" font="0">HR (95% CI) for incident events (absolute </text>
<text top="560" left="586" width="212" height="20" font="0">event rates not reported) among statin </text>
<text top="577" left="586" width="224" height="20" font="0">eligible compared with statin not eligible: </text>
<text top="594" left="584" width="195" height="20" font="0">ATP III: HR 2.24, 95% CI 1.74-2.88 </text>
<text top="611" left="584" width="213" height="20" font="0">ACC/AHA: HR 4.10, 95% CI 3.01-5.60 </text>
<text top="629" left="584" width="211" height="20" font="0">ESC/EAS: HR 2.41, 95% CI 1.87-3.10 </text>
<text top="646" left="584" width="3" height="20" font="0"> </text>
<text top="665" left="584" width="11" height="18" font="0">• </text>
<text top="664" left="593" width="192" height="20" font="0">Sensitivity/Specificity/NPV/PPV for </text>
<text top="681" left="584" width="85" height="20" font="0">incident events </text>
<text top="698" left="584" width="191" height="20" font="0">ATP III: 45.8%/75.1%/96.3%/8.9% </text>
<text top="716" left="584" width="208" height="20" font="0">ACC/AHA: 79.6%/50.7%/98.0%/7.7% </text>
<text top="733" left="584" width="207" height="20" font="0">ESC/EAS: 50.5%/72.9%/98.7%/3.6% </text>
<text top="750" left="584" width="3" height="20" font="0"> </text>
<text top="767" left="584" width="206" height="20" font="0">AUC (95% CI) for statin eligibility and </text>
<text top="784" left="584" width="85" height="20" font="0">incident events </text>
</page>
<page number="88" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">88 </text>
<text top="107" left="584" width="177" height="20" font="0">ATP III: 0.59, 95% CI 0.56, 0.62 </text>
<text top="124" left="584" width="191" height="20" font="0">ACC/AHA: 0.66, 95% CI 0.63-0.68 </text>
<text top="141" left="584" width="190" height="20" font="0">ESC/EAS: 0.63, 95% CI 0.60-0.66 </text>
<text top="159" left="584" width="3" height="20" font="0"> </text>
<text top="177" left="91" width="39" height="20" font="7"><b>MESA </b></text>
<text top="194" left="91" width="81" height="20" font="0">Fudim M, et al.</text>
<text top="197" left="172" width="5" height="16" font="15"> </text>
<text top="194" left="177" width="25" height="20" font="0"><a href="data supplement.html#241">(88)</a> </text>
<text top="211" left="91" width="31" height="20" font="0">2016 </text>
<text top="228" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26909370">26909370</a></text>
<text top="228" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26909370"> </a></text>
<text top="177" left="253" width="138" height="20" font="7"><b>Study type:</b> Prospective </text>
<text top="194" left="253" width="84" height="20" font="0">cohort (MESA) </text>
<text top="211" left="253" width="3" height="20" font="0"> </text>
<text top="228" left="253" width="129" height="20" font="7"><b>Size:</b> 6742 participants </text>
<text top="177" left="410" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="196" left="410" width="7" height="18" font="0">•</text>
<text top="195" left="417" width="122" height="20" font="0"> MESA participants at </text>
<text top="212" left="410" width="83" height="20" font="0">baseline exam </text>
<text top="229" left="410" width="3" height="20" font="0"> </text>
<text top="247" left="410" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="266" left="407" width="11" height="18" font="0">• </text>
<text top="265" left="421" width="73" height="20" font="0">Missing data </text>
<text top="178" left="584" width="213" height="20" font="7"><b>1</b>°<b> endpoint:</b> Hard CVD events, which </text>
<text top="195" left="584" width="241" height="20" font="0">included myocardial infarction, death due to </text>
<text top="212" left="584" width="232" height="20" font="0">myocardial infarction, resuscitated cardiac </text>
<text top="229" left="584" width="202" height="20" font="0">arrest, stroke and death from stroke; </text>
<text top="247" left="584" width="163" height="20" font="0">Median follow up of 7.5 years </text>
<text top="264" left="584" width="3" height="20" font="0"> </text>
<text top="281" left="584" width="52" height="20" font="7"><b>Results: </b></text>
<text top="298" left="584" width="214" height="20" font="7"><b>Metrics for utility of addition of CAC </b></text>
<text top="316" left="584" width="221" height="20" font="7"><b>score to PCE for prediction of CVD in </b></text>
<text top="333" left="584" width="71" height="20" font="7"><b>subgroups: </b></text>
<text top="352" left="584" width="11" height="18" font="0">• </text>
<text top="351" left="594" width="124" height="20" font="0">Men: 6.1 per 1000 p-y </text>
<text top="368" left="584" width="212" height="20" font="0">Increase in C-statistic: 0.025, P=0.047 </text>
<text top="385" left="584" width="212" height="20" font="0">Hosmer-Lemeshow X2: 8.587, P=0.38 </text>
<text top="403" left="584" width="181" height="20" font="0">Categorical NRI: 0.080, P=0.037 </text>
<text top="420" left="584" width="117" height="20" font="0">IDI: 0.0117, P=0.001 </text>
<text top="439" left="584" width="11" height="18" font="0">• </text>
<text top="438" left="593" width="139" height="20" font="0">Women 3.7 per 1000 p-y </text>
<text top="455" left="584" width="212" height="20" font="0">Increase in C-statistic: 0.018, P=0.019 </text>
<text top="473" left="584" width="232" height="20" font="0">Hosmer –Lemeshow X2: 16.715, P=0.033 </text>
<text top="490" left="584" width="181" height="20" font="0">Categorical NRI: 0.095, P=0.039 </text>
<text top="507" left="584" width="117" height="20" font="0">IDI: 0.0069, P=0.032 </text>
<text top="526" left="584" width="11" height="18" font="0">• </text>
<text top="525" left="595" width="158" height="20" font="0">Caucasian: 5.4 per 1000 p-y </text>
<text top="542" left="584" width="205" height="20" font="0">Increase in C-statistic: 0.019, P=0.18 </text>
<text top="560" left="584" width="209" height="20" font="0">Hosmer -Lemeshow X2: 11.9, P=0.16 </text>
<text top="577" left="584" width="174" height="20" font="0">Categorical NRI: 0.111, P=0.02 </text>
<text top="594" left="584" width="110" height="20" font="0">IDI: 0.012, P=0.001 </text>
<text top="613" left="584" width="11" height="18" font="0">• </text>
<text top="612" left="593" width="127" height="20" font="0">Black 5.0 per 1000 p-y </text>
<text top="630" left="584" width="205" height="20" font="0">Increase in C-statistic: 0.033, P=0.11 </text>
<text top="647" left="584" width="206" height="20" font="0">Hosmer-Lemeshow X2: 12.3, P=0.14 </text>
<text top="664" left="584" width="174" height="20" font="0">Categorical NRI: 0.024, P=0.61 </text>
<text top="681" left="584" width="103" height="20" font="0">IDI: 0.006, P=0.23 </text>
<text top="700" left="584" width="11" height="18" font="0">• </text>
<text top="700" left="595" width="201" height="20" font="0">Chinese-American: 2.5 per 1000 p-y </text>
<text top="717" left="584" width="205" height="20" font="0">Increase in C-statistic: 0.013, P=0.66 </text>
<text top="734" left="584" width="199" height="20" font="0">Hosmer-Lemeshow X2: 4.9, P=0.77 </text>
<text top="751" left="584" width="178" height="20" font="0">Categorical NRI: -0.121, P=0.11 </text>
<text top="768" left="584" width="103" height="20" font="0">IDI: 0.005, P=0.27 </text>
<text top="787" left="584" width="11" height="18" font="0">• </text>
<text top="787" left="594" width="144" height="20" font="0">Hispanic 5.0 per 1000 p-y </text>
<text top="178" left="843" width="7" height="18" font="0">•</text>
<text top="178" left="850" width="243" height="20" font="0"> Addition of CAC to PCE modestly improved </text>
<text top="195" left="843" width="232" height="20" font="0">discrimination, calibration, categorical and </text>
<text top="212" left="843" width="253" height="20" font="0">continuous net reclassification, and integrated </text>
<text top="229" left="843" width="216" height="20" font="0">discrimination, similarly across sex and </text>
<text top="247" left="843" width="137" height="20" font="0">race/ethnicity subgroups </text>
</page>
<page number="89" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">89 </text>
<text top="107" left="584" width="205" height="20" font="0">Increase in C-statistic: 0.009, P=0.45 </text>
<text top="142" left="584" width="209" height="20" font="0">Hosmer-Lemeshow X2: 12.3, P=0.14  </text>
<text top="159" left="584" width="174" height="20" font="0">Categorical NRI: 0.024, P=0.61 </text>
<text top="176" left="584" width="103" height="20" font="0">IDI: 0.006, P=0.23 </text>
<text top="193" left="584" width="3" height="20" font="0"> </text>
<text top="211" left="584" width="3" height="20" font="0"> </text>
<text top="229" left="91" width="83" height="20" font="7"><b>Gupta A, et al.</b></text>
<text top="232" left="174" width="5" height="16" font="15"> </text>
<text top="229" left="178" width="25" height="20" font="7"><a href="data supplement.html#241"><b>(89)</b></a><b> </b></text>
<text top="246" left="91" width="31" height="20" font="7"><b>2017 </b></text>
<text top="263" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28797402">28797402</a></text>
<text top="263" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28797402"> </a></text>
<text top="229" left="253" width="134" height="20" font="7"><b>Study type:</b> Systematic </text>
<text top="246" left="253" width="39" height="20" font="0">review </text>
<text top="263" left="253" width="3" height="20" font="0"> </text>
<text top="280" left="253" width="137" height="20" font="7"><b>Size:</b> 8 studies identified </text>
<text top="298" left="253" width="137" height="20" font="0">(7 observational, 1 RCT) </text>
<text top="315" left="253" width="144" height="20" font="0">but only 6 studies (11,256 </text>
<text top="332" left="253" width="143" height="20" font="0">participants) included due </text>
<text top="349" left="253" width="105" height="20" font="0">to data availability. </text>
<text top="366" left="253" width="3" height="20" font="0"> </text>
<text top="384" left="253" width="96" height="20" font="0">Single arm (CAC </text>
<text top="401" left="253" width="96" height="20" font="0">measurement) of </text>
<text top="418" left="253" width="135" height="20" font="0">EISNER study included. </text>
<text top="435" left="253" width="3" height="20" font="0"> </text>
<text top="452" left="253" width="120" height="20" font="0">Note 2 reports from 1 </text>
<text top="470" left="253" width="106" height="20" font="0">study with different </text>
<text top="487" left="253" width="57" height="20" font="0">outcomes </text>
<text top="504" left="253" width="3" height="20" font="0"> </text>
<text top="229" left="410" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="248" left="410" width="7" height="18" font="0">•</text>
<text top="247" left="417" width="149" height="20" font="0"> Studies that evaluated the </text>
<text top="264" left="410" width="152" height="20" font="0">influence of CAC scores on </text>
<text top="282" left="410" width="111" height="20" font="0">subsequent lifestyle </text>
<text top="299" left="410" width="152" height="20" font="0">modifications or medication </text>
<text top="316" left="410" width="160" height="20" font="0">usage for primary prevention </text>
<text top="333" left="410" width="46" height="20" font="0">of CVD  </text>
<text top="350" left="410" width="3" height="20" font="0"> </text>
<text top="368" left="410" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="387" left="410" width="11" height="18" font="0">• </text>
<text top="386" left="423" width="24" height="20" font="0">N/A </text>
<text top="230" left="584" width="175" height="20" font="7"><b>1</b>°<b> endpoint:</b> Use of preventive </text>
<text top="247" left="584" width="177" height="20" font="0">interventions (both initiation and </text>
<text top="264" left="584" width="206" height="20" font="0">continuation), including aspirin, blood </text>
<text top="282" left="584" width="206" height="20" font="0">pressure lowering, lipid lowering, and </text>
<text top="299" left="584" width="110" height="20" font="0">behavioral changes<b> </b></text>
<text top="316" left="584" width="3" height="20" font="0"> </text>
<text top="333" left="584" width="52" height="20" font="7"><b>Results: </b></text>
<text top="352" left="584" width="7" height="18" font="0">•</text>
<text top="352" left="591" width="222" height="20" font="0"> Compared with individuals with CAC=0, </text>
<text top="369" left="584" width="160" height="20" font="0">individuals with CAC&gt;0 had:  </text>
<text top="388" left="593" width="11" height="18" font="0">• </text>
<text top="387" left="607" width="221" height="20" font="0">Aspirin initiation OR 2.6, 95% CI 1.8-3.8 </text>
<text top="404" left="607" width="205" height="20" font="0">(30% vs. 15%, 4 studies with 1.6 to 6 </text>
<text top="421" left="607" width="106" height="20" font="0">years of follow up, I</text>
<text top="423" left="713" width="4" height="13" font="9">2</text>
<text top="421" left="717" width="39" height="20" font="0">=86%) </text>
<text top="440" left="593" width="11" height="18" font="0">• </text>
<text top="440" left="607" width="212" height="20" font="0">Lipid lowering medication initiation OR </text>
<text top="457" left="607" width="202" height="20" font="0">2.9, 95% CI 1.9-4.4 (20% vs. 10%, 3 </text>
<text top="474" left="607" width="215" height="20" font="0">studies with 1.6 to 6 years of follow up, </text>
<text top="491" left="607" width="3" height="20" font="0">I</text>
<text top="493" left="610" width="4" height="13" font="9">2</text>
<text top="491" left="615" width="43" height="20" font="0">=89%); </text>
<text top="510" left="593" width="11" height="18" font="0">• </text>
<text top="510" left="607" width="198" height="20" font="0">Blood pressure lowering medication </text>
<text top="527" left="607" width="212" height="20" font="0">initiation OR 1.9, 95% CI 1.6-2.3 (19% </text>
<text top="544" left="607" width="220" height="20" font="0">vs. 11%, 2 studies with 1.6 to 4 years of </text>
<text top="561" left="607" width="59" height="20" font="0">follow up, I</text>
<text top="563" left="665" width="4" height="13" font="9">2</text>
<text top="561" left="670" width="43" height="20" font="0">=15%). </text>
<text top="580" left="593" width="11" height="18" font="0">• </text>
<text top="579" left="607" width="200" height="20" font="0">Aspirin continuation OR 1.3, 95% CI </text>
<text top="597" left="607" width="223" height="20" font="0">0.8-2.2 (66% vs. 65%, 3 studies with 3.2 </text>
<text top="614" left="607" width="130" height="20" font="0">to 6 years of follow up, I</text>
<text top="615" left="737" width="4" height="13" font="9">2</text>
<text top="614" left="741" width="43" height="20" font="0">=75%); </text>
<text top="633" left="593" width="11" height="18" font="0">• </text>
<text top="632" left="607" width="211" height="20" font="0">Lipid lowering medication continuation </text>
<text top="649" left="607" width="214" height="20" font="0">OR 2.3, 95% CI 1.6-3.3 (75% vs. 69%, </text>
<text top="666" left="607" width="215" height="20" font="0">4 studies with 3 to 6 years of follow up, </text>
<text top="684" left="607" width="3" height="20" font="0">I</text>
<text top="685" left="610" width="4" height="13" font="9">2</text>
<text top="684" left="615" width="46" height="20" font="0">=52%);  </text>
<text top="703" left="593" width="11" height="18" font="0">• </text>
<text top="702" left="607" width="198" height="20" font="0">Blood pressure lowering medication </text>
<text top="719" left="607" width="214" height="20" font="0">continuation OR 1.4, 95% CI 0.9 to 2.2 </text>
<text top="736" left="607" width="205" height="20" font="0">(73% vs. 64%, 2 studies with 3.2 to 4 </text>
<text top="753" left="607" width="106" height="20" font="0">years of follow up, I</text>
<text top="755" left="713" width="4" height="13" font="9">2</text>
<text top="753" left="717" width="43" height="20" font="0">=34%). </text>
<text top="231" left="843" width="7" height="18" font="0">•</text>
<text top="230" left="850" width="243" height="20" font="0"> Identification of coronary atherosclerosis by </text>
<text top="247" left="843" width="228" height="20" font="0">coronary calcium scanning is significantly </text>
<text top="264" left="843" width="239" height="20" font="0">associated with the likelihood of initiation or </text>
<text top="282" left="843" width="245" height="20" font="0">continuation of pharmacological and lifestyle </text>
<text top="299" left="843" width="254" height="20" font="0">therapies for prevention of CVD in follow up of </text>
<text top="316" left="843" width="78" height="20" font="0">up to 6 years. </text>
<text top="333" left="843" width="3" height="20" font="0"> </text>
<text top="350" left="843" width="246" height="20" font="0">Limitations: Self-reported use of medications </text>
<text top="368" left="843" width="243" height="20" font="0">in at least half of studies; degree of exercise </text>
<text top="385" left="843" width="217" height="20" font="0">increase and dietary change ill-defined; </text>
<text top="402" left="843" width="258" height="20" font="0">predominantly Caucasian participants; variable </text>
<text top="419" left="843" width="221" height="20" font="0">means for informing participants of CAC </text>
<text top="436" left="843" width="111" height="20" font="0">presence and score </text>
<text top="454" left="843" width="3" height="20" font="0"> </text>
</page>
<page number="90" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">90 </text>
<text top="109" left="593" width="11" height="18" font="0">• </text>
<text top="108" left="607" width="202" height="20" font="0">Increase in exercise OR 1.8, 95% CI </text>
<text top="125" left="607" width="213" height="20" font="0">1.4-2.4 (51% vs. 32%; 3 studies with 3 </text>
<text top="143" left="607" width="130" height="20" font="0">to 6 years of follow up, I</text>
<text top="144" left="737" width="4" height="13" font="9">2</text>
<text top="143" left="741" width="43" height="20" font="0">=43%); </text>
<text top="162" left="593" width="11" height="18" font="0">• </text>
<text top="161" left="607" width="217" height="20" font="0">Dietary change OR 1.9, 95% CI 1.5-2.5 </text>
<text top="178" left="607" width="195" height="20" font="0">(45% vs. 27%, 2 studies with 3 to 6 </text>
<text top="195" left="607" width="106" height="20" font="0">years of follow up, I</text>
<text top="197" left="713" width="4" height="13" font="9">2</text>
<text top="195" left="717" width="33" height="20" font="0">=0%) </text>
<text top="212" left="584" width="3" height="20" font="0"> </text>
<text top="230" left="584" width="3" height="20" font="0"> </text>
<text top="247" left="584" width="3" height="20" font="0"> </text>
<text top="265" left="91" width="70" height="20" font="7"><b>Han D, et al.</b></text>
<text top="268" left="161" width="5" height="16" font="15"> </text>
<text top="265" left="166" width="25" height="20" font="7"><a href="data supplement.html#241"><b>(90)</b></a><b> </b></text>
<text top="282" left="91" width="31" height="20" font="7"><b>2017 </b></text>
<text top="299" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28531241">28531241</a></text>
<text top="299" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28531241"> </a></text>
<text top="265" left="253" width="71" height="20" font="7"><b>Study type:</b> </text>
<text top="282" left="253" width="122" height="20" font="0">Retrospective registry </text>
<text top="299" left="253" width="120" height="20" font="0">(KOICA, Korea, 2002-</text>
<text top="316" left="253" width="35" height="20" font="0">2014) </text>
<text top="334" left="253" width="3" height="20" font="0"> </text>
<text top="351" left="253" width="120" height="20" font="7"><b>Size:</b> 31,375 patients </text>
<text top="265" left="410" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="284" left="410" width="7" height="18" font="0">•</text>
<text top="283" left="417" width="133" height="20" font="0"> Adults age 40-75 years </text>
<text top="300" left="410" width="3" height="20" font="0"> </text>
<text top="317" left="410" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="337" left="410" width="11" height="18" font="0">• </text>
<text top="336" left="421" width="85" height="20" font="0">Prevalent CVD </text>
<text top="355" left="410" width="11" height="18" font="0">• </text>
<text top="354" left="421" width="84" height="20" font="0">LDL&lt;70 mg/dL </text>
<text top="373" left="410" width="11" height="18" font="0">• </text>
<text top="372" left="421" width="141" height="20" font="0">Lipid lowering medication </text>
<text top="390" left="410" width="23" height="20" font="0">use </text>
<text top="409" left="410" width="11" height="18" font="0">• </text>
<text top="408" left="421" width="145" height="20" font="0">Missing risk factor or CAC </text>
<text top="425" left="410" width="27" height="20" font="0">data </text>
<text top="266" left="584" width="183" height="20" font="7"><b>1</b>°<b> endpoint:</b> All-cause mortality; </text>
<text top="283" left="584" width="242" height="20" font="0">Median follow-up of 5 years (IQR 3-7 years) </text>
<text top="300" left="584" width="3" height="20" font="7"><b> </b></text>
<text top="317" left="584" width="52" height="20" font="7"><b>Results: </b></text>
<text top="335" left="584" width="113" height="20" font="7"><b>All-cause mortality </b></text>
<text top="354" left="584" width="11" height="18" font="0">• </text>
<text top="353" left="596" width="214" height="20" font="0">Statin recommended group (n=13,888; </text>
<text top="370" left="584" width="238" height="20" font="0">10-year predicted risk ≥7.5% or LDL-C 190 </text>
<text top="387" left="584" width="106" height="20" font="0">mg/dL or diabetes) </text>
<text top="406" left="593" width="11" height="18" font="0">• </text>
<text top="406" left="607" width="107" height="20" font="0">CAC=0 (reference) </text>
<text top="423" left="593" width="154" height="20" font="0">68 events/7083 participants </text>
<text top="442" left="593" width="11" height="18" font="0">• </text>
<text top="441" left="607" width="57" height="20" font="0">Any CAC  </text>
<text top="458" left="593" width="161" height="20" font="0">110 events/6805 participants </text>
<text top="476" left="593" width="202" height="20" font="0">Adjusted HR 1.29, 95% CI 0.93-1.77 </text>
<text top="495" left="593" width="11" height="18" font="0">• </text>
<text top="494" left="607" width="64" height="20" font="0">CAC 1-100 </text>
<text top="511" left="593" width="154" height="20" font="0">63 events/4583 participants </text>
<text top="528" left="593" width="202" height="20" font="0">Adjusted HR 1.14, 95% CI 0.80-1.63 </text>
<text top="547" left="593" width="11" height="18" font="0">• </text>
<text top="547" left="607" width="60" height="20" font="0">CAC&gt;100  </text>
<text top="564" left="593" width="154" height="20" font="0">47 events/2222 participants </text>
<text top="581" left="593" width="202" height="20" font="0">Adjusted HR 1.60, 95% CI 1.07-2.38 </text>
<text top="598" left="584" width="3" height="20" font="7"><b> </b></text>
<text top="617" left="584" width="11" height="18" font="0">• </text>
<text top="617" left="593" width="231" height="20" font="0">Statin considered group (n=4046; 10-year </text>
<text top="634" left="584" width="151" height="20" font="0">predicted risk 5.0%-&lt;7.5%) </text>
<text top="653" left="593" width="11" height="18" font="0">• </text>
<text top="652" left="607" width="107" height="20" font="0">CAC=0 (reference) </text>
<text top="669" left="593" width="154" height="20" font="0">13 events/2428 participants </text>
<text top="688" left="593" width="11" height="18" font="0">• </text>
<text top="687" left="607" width="57" height="20" font="0">Any CAC  </text>
<text top="705" left="593" width="154" height="20" font="0">12 events/1618 participants </text>
<text top="722" left="593" width="202" height="20" font="0">Adjusted HR 1.19, 95% CI 0.53-2.66 </text>
<text top="741" left="593" width="11" height="18" font="0">• </text>
<text top="740" left="607" width="64" height="20" font="0">CAC 1-100 </text>
<text top="757" left="593" width="147" height="20" font="0">6 events/1214 participants </text>
<text top="774" left="593" width="202" height="20" font="0">Adjusted HR 0.76, 95% CI 0.28-2.02 </text>
<text top="267" left="843" width="7" height="18" font="0">•</text>
<text top="266" left="850" width="239" height="20" font="0"> Presence of CAC and CAC score stratified </text>
<text top="283" left="843" width="237" height="20" font="0">risk for all-cause mortality in different statin-</text>
<text top="300" left="843" width="234" height="20" font="0">eligibility groups as assigned by ACC/AHA </text>
<text top="318" left="843" width="216" height="20" font="0">2013 guidelines in a Korean population </text>
<text top="337" left="843" width="11" height="18" font="0">• </text>
<text top="336" left="856" width="227" height="20" font="0">Limitations: Retrospective study; patients </text>
<text top="353" left="843" width="251" height="20" font="0">self-referred for CAC; predominantly male; no </text>
<text top="370" left="843" width="230" height="20" font="0">data on ASCVD events; use of preventive </text>
<text top="387" left="843" width="190" height="20" font="0">therapy during follow up unknown; </text>
<text top="405" left="843" width="3" height="20" font="0"> </text>
</page>
<page number="91" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">91 </text>
<text top="109" left="593" width="11" height="18" font="0">• </text>
<text top="108" left="607" width="60" height="20" font="0">CAC&gt;100  </text>
<text top="125" left="593" width="140" height="20" font="0">6 events/404 participants </text>
<text top="143" left="593" width="202" height="20" font="0">Adjusted HR 2.98, 95% CI 1.09-8.13 </text>
<text top="160" left="584" width="3" height="20" font="7"><b> </b></text>
<text top="179" left="584" width="11" height="18" font="0">• </text>
<text top="178" left="594" width="235" height="20" font="0">Statin not recommended group (n=13,441; </text>
<text top="195" left="584" width="154" height="20" font="0">10-year predicted risk &lt;5%) </text>
<text top="214" left="593" width="11" height="18" font="0">• </text>
<text top="213" left="609" width="107" height="20" font="0">CAC=0 (reference) </text>
<text top="231" left="593" width="164" height="20" font="0">36 events/10,484 participants </text>
<text top="250" left="593" width="11" height="18" font="0">• </text>
<text top="249" left="609" width="57" height="20" font="0">Any CAC  </text>
<text top="266" left="593" width="154" height="20" font="0">12 events/3091 participants </text>
<text top="283" left="593" width="202" height="20" font="0">Adjusted HR 1.21, 95% CI 0.61-2.39 </text>
<text top="302" left="593" width="11" height="18" font="0">• </text>
<text top="302" left="609" width="68" height="20" font="0">CAC=1-100 </text>
<text top="319" left="593" width="147" height="20" font="0">8 events/2554 participants </text>
<text top="336" left="593" width="202" height="20" font="0">Adjusted HR 0.93, 95% CI 0.43-2.06 </text>
<text top="355" left="593" width="11" height="18" font="0">• </text>
<text top="354" left="609" width="60" height="20" font="0">CAC&gt;100  </text>
<text top="371" left="593" width="140" height="20" font="0">4 events/537 participants </text>
<text top="389" left="593" width="202" height="20" font="0">Adjusted HR 3.14, 95% CI 1.08-9.17 </text>
<text top="406" left="584" width="3" height="20" font="0"> </text>
<text top="423" left="584" width="3" height="20" font="0"> </text>
<text top="441" left="91" width="85" height="20" font="7"><b>Hong JC, et al.</b></text>
<text top="444" left="176" width="5" height="16" font="15"> </text>
<text top="441" left="181" width="25" height="20" font="7"><a href="data supplement.html#241"><b>(91)</b></a><b> </b></text>
<text top="458" left="91" width="31" height="20" font="7"><b>2017 </b></text>
<text top="475" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28797417">28797417</a></text>
<text top="475" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28797417"> </a></text>
<text top="441" left="253" width="71" height="20" font="7"><b>Study type:</b> </text>
<text top="458" left="253" width="126" height="20" font="0">Microsimulation model </text>
<text top="475" left="253" width="96" height="20" font="0">(based on MESA </text>
<text top="493" left="253" width="70" height="20" font="0">participants) </text>
<text top="510" left="253" width="3" height="20" font="0"> </text>
<text top="527" left="253" width="56" height="20" font="7"><b>Size:</b> N/A </text>
<text top="441" left="410" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="460" left="410" width="7" height="18" font="0">•</text>
<text top="459" left="417" width="146" height="20" font="0"> Individuals were modeled </text>
<text top="477" left="410" width="112" height="20" font="0">based on AHA/ACC </text>
<text top="494" left="410" width="118" height="20" font="0">cholesterol treatment </text>
<text top="511" left="410" width="141" height="20" font="0">guideline using data from </text>
<text top="528" left="410" width="38" height="20" font="0">MESA </text>
<text top="545" left="410" width="3" height="20" font="0"> </text>
<text top="563" left="410" width="134" height="20" font="7"><b>Exclusion criteria:</b> N/A </text>
<text top="442" left="584" width="223" height="20" font="7"><b>1</b>°<b> endpoint:</b> Lifetime direct and indirect </text>
<text top="459" left="584" width="242" height="20" font="0">costs (societal perspective; 1 year intervals) </text>
<text top="477" left="584" width="215" height="20" font="0">comparing 2 strategies: 1) CAC testing </text>
<text top="494" left="584" width="217" height="20" font="0">among statin eligible individuals, where </text>
<text top="511" left="584" width="222" height="20" font="0">long-term statin therapy is guided by the </text>
<text top="528" left="584" width="238" height="20" font="0">reclassification of risk; versus 2) treating all </text>
<text top="545" left="584" width="227" height="20" font="0">statin-eligible individuals according to the </text>
<text top="563" left="584" width="212" height="20" font="0">ACC/AHA guideline recommendations </text>
<text top="580" left="584" width="3" height="20" font="0"> </text>
<text top="597" left="584" width="52" height="20" font="7"><b>Results: </b></text>
<text top="616" left="584" width="11" height="18" font="0">• </text>
<text top="615" left="596" width="154" height="20" font="0">CAC testing-based strategy </text>
<text top="632" left="584" width="223" height="20" font="0">Costs: $11,579, 95% CI $5,417-$19,183 </text>
<text top="650" left="584" width="220" height="20" font="0">QALYs: 11.859, 95% CI: 10.859-12,838 </text>
<text top="667" left="584" width="3" height="20" font="0"> </text>
<text top="686" left="584" width="11" height="18" font="0">• </text>
<text top="685" left="595" width="191" height="20" font="0">Treat per guideline-based strategy </text>
<text top="702" left="584" width="223" height="20" font="0">Costs: $11,498, 95% CI $2,048-$19,135 </text>
<text top="720" left="584" width="230" height="20" font="0">QALYs: 11.849, 95% CI $10.834-$12,829 </text>
<text top="737" left="584" width="3" height="20" font="0"> </text>
<text top="756" left="584" width="11" height="18" font="0">• </text>
<text top="755" left="593" width="204" height="20" font="0">Both strategies had similar costs and </text>
<text top="772" left="584" width="224" height="20" font="0">QALYs. CAC resulted in increased costs </text>
<text top="789" left="584" width="239" height="20" font="0">(+$81) and near-equal QALY (+0.01) for an </text>
<text top="443" left="843" width="7" height="18" font="0">•</text>
<text top="442" left="850" width="239" height="20" font="0"> Modeling suggests “both approaches have </text>
<text top="459" left="843" width="213" height="20" font="0">generally similar clinical and economic </text>
<text top="477" left="843" width="90" height="20" font="0">consequences.” </text>
<text top="496" left="843" width="11" height="18" font="0">• </text>
<text top="495" left="858" width="219" height="20" font="0">“Clinicians should account for individual </text>
<text top="512" left="843" width="228" height="20" font="0">preferences in context of shared decision </text>
<text top="529" left="843" width="245" height="20" font="0">making when choosing the most appropriate </text>
<text top="546" left="843" width="190" height="20" font="0">strategy to guide statin decisions.” </text>
<text top="566" left="843" width="11" height="18" font="0">• </text>
<text top="565" left="858" width="225" height="20" font="0">“CAC testing can supplement the shared </text>
<text top="582" left="843" width="215" height="20" font="0">decision-making process through more </text>
<text top="599" left="843" width="236" height="20" font="0">accurate risk prediction and help avoid low-</text>
<text top="616" left="843" width="178" height="20" font="0">value pharmacological therapy.” </text>
<text top="634" left="843" width="3" height="20" font="0"> </text>
<text top="651" left="843" width="237" height="20" font="0">Limitations: Microsimulation study; Multiple </text>
<text top="668" left="843" width="234" height="20" font="0">assumptions regarding costs, benefits and </text>
<text top="685" left="843" width="38" height="20" font="0">utility;  </text>
<text top="702" left="843" width="3" height="20" font="0"> </text>
<text top="720" left="843" width="3" height="20" font="0"> </text>
</page>
<page number="92" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">92 </text>
<text top="107" left="584" width="210" height="20" font="0">incremental cost-effectiveness ratio of </text>
<text top="124" left="584" width="234" height="20" font="0">$8,100/QALY compared with the guideline </text>
<text top="141" left="584" width="51" height="20" font="0">strategy. </text>
<text top="159" left="584" width="3" height="20" font="0"> </text>
<text top="180" left="584" width="11" height="18" font="0">• </text>
<text top="180" left="593" width="203" height="20" font="0">For 10,000 patients, guideline-based </text>
<text top="197" left="584" width="216" height="20" font="0">strategy would avert 21 ASCVD events </text>
<text top="214" left="584" width="224" height="20" font="0">prevented and would add 47,294 person-</text>
<text top="231" left="584" width="86" height="20" font="0">years of statins </text>
<text top="248" left="584" width="3" height="20" font="0"> </text>
<text top="284" left="91" width="125" height="20" font="7"><b>Kavousi M, et al. <a href="data supplement.html#241">(92)</a></b><b> </b></text>
<text top="301" left="91" width="31" height="20" font="7"><b>2016 </b></text>
<text top="318" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27846641">27846641</a></text>
<text top="318" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27846641"> </a></text>
<text top="284" left="253" width="126" height="20" font="7"><b>Study type:</b> Individual </text>
<text top="301" left="253" width="119" height="20" font="0">participant data meta-</text>
<text top="318" left="253" width="48" height="20" font="0">analysis </text>
<text top="335" left="253" width="3" height="20" font="0"> </text>
<text top="353" left="253" width="135" height="20" font="7"><b>Size:</b> Meta-analysis of 5 </text>
<text top="370" left="253" width="133" height="20" font="0">prospective, community-</text>
<text top="387" left="253" width="122" height="20" font="0">based cohorts (Dallas </text>
<text top="404" left="253" width="103" height="20" font="0">Heart Study, FHS, </text>
<text top="422" left="253" width="122" height="20" font="0">MESA, Heinz Nixdorf, </text>
<text top="439" left="253" width="99" height="20" font="0">Rotterdam), 6739 </text>
<text top="456" left="253" width="70" height="20" font="0">participants<b>  </b></text>
<text top="473" left="253" width="3" height="20" font="0"> </text>
<text top="284" left="410" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="303" left="410" width="7" height="18" font="0">•</text>
<text top="302" left="417" width="150" height="20" font="0"> Women with low predicted </text>
<text top="319" left="410" width="130" height="20" font="0">ASCVD risk using PCE </text>
<text top="337" left="410" width="153" height="20" font="0">variables (&lt; 7.5% predicted </text>
<text top="354" left="410" width="144" height="20" font="0">event rate over 10 years)  </text>
<text top="371" left="410" width="3" height="20" font="0"> </text>
<text top="388" left="410" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="407" left="410" width="11" height="18" font="0">• </text>
<text top="407" left="421" width="126" height="20" font="0">In all cohorts, previous </text>
<text top="424" left="410" width="139" height="20" font="0">history of coronary artery </text>
<text top="441" left="410" width="132" height="20" font="0">disease, stroke, chronic </text>
<text top="458" left="410" width="110" height="20" font="0">kidney disease with </text>
<text top="475" left="410" width="158" height="20" font="0">glomerular filtration rate less </text>
<text top="493" left="410" width="136" height="20" font="0">than 30 mL/min/1.73m2, </text>
<text top="510" left="410" width="156" height="20" font="0">treatment with statin, LDL-C </text>
<text top="527" left="410" width="155" height="20" font="0">≥190 mg/dL , and age older </text>
<text top="544" left="410" width="78" height="20" font="0">than 79 years </text>
<text top="285" left="584" width="223" height="20" font="7"><b>1</b>°<b> endpoint:</b> Incident ASCVD, including </text>
<text top="302" left="584" width="218" height="20" font="0">nonfatal myocardial infarction, coronary </text>
<text top="319" left="584" width="217" height="20" font="0">heart disease (CHD) death, and stroke; </text>
<text top="337" left="584" width="195" height="20" font="0">Median follow-up of 7 to 11.6 years </text>
<text top="354" left="584" width="3" height="20" font="0"> </text>
<text top="371" left="584" width="52" height="20" font="7"><b>Results: </b></text>
<text top="390" left="584" width="7" height="18" font="0">•</text>
<text top="389" left="591" width="114" height="20" font="0"> <b>Primary event rate </b></text>
<text top="407" left="593" width="120" height="20" font="0">-  CAC=0 (reference) </text>
<text top="424" left="593" width="215" height="20" font="0">62 events/4304 participants/44,043 p-y </text>
<text top="441" left="593" width="57" height="20" font="0">-  CAC&gt;0 </text>
<text top="458" left="593" width="222" height="20" font="0">103 events/2435 participants/23,785 p-y </text>
<text top="476" left="593" width="213" height="20" font="0">Incidence rate difference 2.92, 95% CI </text>
<text top="493" left="593" width="59" height="20" font="0">2.02- 3.83 </text>
<text top="510" left="593" width="202" height="20" font="0">Adjusted HR 2.04, 95% CI 1.44-2.90 </text>
<text top="527" left="593" width="77" height="20" font="0">-  CAC 1-100 </text>
<text top="545" left="593" width="212" height="20" font="0">59 events/1951 participants/19,238p-y </text>
<text top="562" left="593" width="213" height="20" font="0">Incidence rate difference 1.66, 95% CI </text>
<text top="579" left="593" width="55" height="20" font="0">0.80-2.52 </text>
<text top="596" left="593" width="202" height="20" font="0">Adjusted HR 1.53, 95% CI 1.02-2.29 </text>
<text top="613" left="593" width="70" height="20" font="0">-  CAC&gt;100 </text>
<text top="631" left="593" width="198" height="20" font="0">44 events/484 participants/4546 p-y </text>
<text top="648" left="593" width="213" height="20" font="0">Incidence rate difference 8.27, 95% CI </text>
<text top="665" left="593" width="66" height="20" font="0">5.39- 11.15 </text>
<text top="682" left="593" width="202" height="20" font="0">Adjusted HR 4.02, 95% CI 2.61-6.19 </text>
<text top="699" left="584" width="3" height="20" font="0"> </text>
<text top="718" left="584" width="11" height="18" font="0">• </text>
<text top="718" left="594" width="234" height="20" font="0">C-statistic with CAC added to base model: </text>
<text top="735" left="584" width="130" height="20" font="0">0.77, 95% CI 0.74-0.81 </text>
<text top="754" left="584" width="11" height="18" font="0">• </text>
<text top="753" left="594" width="227" height="20" font="0">Increase in C-statistic with CAC added to </text>
<text top="770" left="584" width="200" height="20" font="0">base model: 0.02, 95% CI 0.00-0.05 </text>
<text top="286" left="843" width="11" height="18" font="0">• </text>
<text top="285" left="858" width="211" height="20" font="0">In women from 5 cohort studies at low </text>
<text top="302" left="843" width="247" height="20" font="0">predicted 10-year ASCVD risk (&lt;7.5%), CAC </text>
<text top="319" left="843" width="239" height="20" font="0">was present in approximately one-third and </text>
<text top="337" left="843" width="251" height="20" font="0">was associated with increased risk of ASCVD </text>
<text top="354" left="843" width="215" height="20" font="0">and modest improvement in prognostic </text>
<text top="371" left="843" width="215" height="20" font="0">accuracy compared with traditional risk </text>
<text top="388" left="843" width="44" height="20" font="0">factors. </text>
<text top="406" left="843" width="3" height="20" font="0"> </text>
<text top="427" left="843" width="11" height="18" font="0">• </text>
<text top="426" left="858" width="188" height="20" font="0">Limitations: Relatively few events; </text>
<text top="444" left="843" width="215" height="20" font="0">predominantly Caucasian; women only </text>
<text top="461" left="843" width="3" height="20" font="0"> </text>
</page>
<page number="93" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">93 </text>
<text top="109" left="584" width="11" height="18" font="0">• </text>
<text top="108" left="594" width="223" height="20" font="0">Continuous NRI with CAC: 0.20 (95% CI </text>
<text top="125" left="584" width="62" height="20" font="0">0.09, 0.31) </text>
<text top="144" left="584" width="11" height="18" font="0">• </text>
<text top="144" left="594" width="201" height="20" font="0">Results evaluating CHD as outcome </text>
<text top="161" left="584" width="182" height="20" font="0">similar but generally more robust </text>
<text top="178" left="584" width="3" height="20" font="0"> </text>
<text top="196" left="91" width="144" height="20" font="7"><b>Mahabadi AA, et al. 2017</b></text>
<text top="199" left="235" width="5" height="16" font="15"> </text>
<text top="213" left="91" width="25" height="20" font="7"><a href="data supplement.html#241"><b>(93)</b></a><b> </b></text>
<text top="230" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27665163">27665163</a></text>
<text top="230" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27665163"> </a></text>
<text top="196" left="253" width="138" height="20" font="7"><b>Study type:</b> Prospective </text>
<text top="213" left="253" width="123" height="20" font="0">cohort (Heinz-Nixdorf, </text>
<text top="230" left="253" width="66" height="20" font="0">2000-2003) </text>
<text top="247" left="253" width="3" height="20" font="0"> </text>
<text top="265" left="253" width="129" height="20" font="7"><b>Size:</b> 3745 participants </text>
<text top="196" left="410" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="215" left="410" width="7" height="18" font="0">•</text>
<text top="214" left="417" width="144" height="20" font="0"> Asymptomatic adults age </text>
<text top="231" left="410" width="155" height="20" font="0">45-75 years from 3 German </text>
<text top="249" left="410" width="31" height="20" font="0">cities </text>
<text top="266" left="410" width="3" height="20" font="0"> </text>
<text top="283" left="410" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="302" left="407" width="11" height="18" font="0">• </text>
<text top="301" left="416" width="130" height="20" font="0">Prevalent ASCVD, lipid </text>
<text top="319" left="407" width="156" height="20" font="0">lowering therapy, or missing </text>
<text top="336" left="407" width="128" height="20" font="0">risk factor or CAC data </text>
<text top="197" left="584" width="217" height="20" font="7"><b>1</b>°<b> endpoint:</b> Incident coronary events, </text>
<text top="214" left="584" width="233" height="20" font="0">stroke, or cardiovascular death comparing </text>
<text top="231" left="584" width="243" height="20" font="0">strategies of 2012 ESC and 2013 ACC/AHA </text>
<text top="249" left="584" width="163" height="20" font="0">guidelines for statin eligibility; </text>
<text top="266" left="584" width="170" height="20" font="0">Median follow up of 10.4 years </text>
<text top="283" left="584" width="3" height="20" font="0"> </text>
<text top="300" left="584" width="52" height="20" font="7"><b>Results: </b></text>
<text top="319" left="584" width="7" height="18" font="0">•</text>
<text top="319" left="591" width="208" height="20" font="0"> Low CAC score (&lt;100) was common </text>
<text top="336" left="584" width="243" height="20" font="0">(60%) among those recommended for statin </text>
<text top="353" left="584" width="147" height="20" font="0">therapy by both guidelines </text>
<text top="372" left="584" width="11" height="18" font="0">• </text>
<text top="372" left="593" width="119" height="20" font="7"><b>Events by guideline</b> </text>
<text top="389" left="593" width="235" height="20" font="0">-  2012 ESC guideline statin not indicated, </text>
<text top="406" left="593" width="45" height="20" font="0">n=2457 </text>
<text top="423" left="593" width="163" height="20" font="0">CAC, median (IQR): 2 (0, 43) </text>
<text top="440" left="593" width="169" height="20" font="0">CVD events: 97 events (4.0%) </text>
<text top="457" left="593" width="194" height="20" font="0">Coronary events: 60 events (2.4%) </text>
<text top="475" left="593" width="215" height="20" font="0">-  2012 ESC guideline statin indicated, </text>
<text top="492" left="593" width="45" height="20" font="0">n=1288 </text>
<text top="509" left="593" width="176" height="20" font="0">CAC, median (IQR): 59 (5, 244) </text>
<text top="526" left="593" width="183" height="20" font="0">CVD events: 144 events (11.2%) </text>
<text top="544" left="593" width="194" height="20" font="0">Coronary events: 71 events (5.5%) </text>
<text top="561" left="593" width="227" height="20" font="0">-  2013 PCE statin not indicated, n=1254 </text>
<text top="578" left="593" width="206" height="20" font="0">(plus 396 with predicted risk=5-7.5%) </text>
<text top="595" left="593" width="163" height="20" font="0">CAC, median (IQR): 0 (0, 15) </text>
<text top="612" left="593" width="169" height="20" font="0">CVD events: 35 events (2.1%) </text>
<text top="630" left="593" width="194" height="20" font="0">Coronary events: 19 events (1.2%) </text>
<text top="647" left="593" width="207" height="20" font="0">-  2013 PCE statin indicated, n=2095 </text>
<text top="664" left="593" width="176" height="20" font="0">CAC, median (IQR): 46 (3, 200) </text>
<text top="681" left="593" width="172" height="20" font="0">CVD events 206 events (9.8%) </text>
<text top="698" left="593" width="197" height="20" font="0">Coronary events 112 events (5.3%) </text>
<text top="716" left="593" width="3" height="20" font="0"> </text>
<text top="735" left="584" width="11" height="18" font="0">• </text>
<text top="734" left="593" width="49" height="20" font="7"><b>By CAC </b></text>
<text top="751" left="593" width="106" height="20" font="0">-  CAC=0, n=1272 </text>
<text top="768" left="593" width="129" height="20" font="0">CVD events: 30 (2.4%) </text>
<text top="785" left="593" width="154" height="20" font="0">Coronary events: 17 (1.3%) </text>
<text top="196" left="843" width="3" height="20" font="0"> </text>
<text top="215" left="842" width="11" height="18" font="0">• </text>
<text top="214" left="855" width="232" height="20" font="0">“Quantification of CAC score in addition to </text>
<text top="231" left="842" width="252" height="20" font="0">the guidelines improves stratification between </text>
<text top="249" left="842" width="242" height="20" font="0">subjects at high versus low risk for coronary </text>
<text top="266" left="842" width="248" height="20" font="0">events, indicating that CAC scoring may help </text>
<text top="283" left="842" width="249" height="20" font="0">to match intensified risk factor modification to </text>
<text top="300" left="842" width="259" height="20" font="0">atherosclerotic plaque burden as well as actual </text>
<text top="318" left="842" width="256" height="20" font="0">risk while avoiding therapy in subjects with low </text>
<text top="335" left="842" width="258" height="20" font="0">coronary atherosclerosis that have low 10-year </text>
<text top="352" left="842" width="66" height="20" font="0">event rate.” </text>
<text top="371" left="842" width="11" height="18" font="0">• </text>
<text top="370" left="855" width="226" height="20" font="0">Limitations: Limited racial/ethnic diversity </text>
</page>
<page number="94" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">94 </text>
<text top="107" left="593" width="120" height="20" font="0">-  CAC 1-100, n=555 </text>
<text top="124" left="593" width="129" height="20" font="0">CVD events: 88 (5.7%) </text>
<text top="141" left="593" width="147" height="20" font="0">Coronary events: 8 (2.4%) </text>
<text top="159" left="593" width="126" height="20" font="0">-  CAC 100-399, n601 </text>
<text top="176" left="593" width="129" height="20" font="0">CVD events: 58 (9.7%) </text>
<text top="193" left="593" width="154" height="20" font="0">Coronary events: 36 (6.0%) </text>
<text top="210" left="593" width="107" height="20" font="0">-  CAC≥400, n=17 </text>
<text top="228" left="593" width="136" height="20" font="0">CVD events: 65 (20.5%) </text>
<text top="245" left="593" width="161" height="20" font="0">Coronary events: 40 (12.6%) </text>
<text top="262" left="584" width="3" height="20" font="0"> </text>
<text top="281" left="584" width="11" height="18" font="0">• </text>
<text top="280" left="595" width="117" height="20" font="7"><b>By guideline + CAC </b></text>
<text top="297" left="584" width="155" height="20" font="0">- 2012 ESC statin indicated </text>
<text top="315" left="584" width="232" height="20" font="0">CAC=0: 5.7 per 1,000 p-y, 95% CI 2.7-8.7 </text>
<text top="332" left="584" width="225" height="20" font="0">CAC 1-99: 7.8 per 1,000 p-y, 95% CI 5.5-</text>
<text top="349" left="584" width="27" height="20" font="0">10.0 </text>
<text top="366" left="584" width="240" height="20" font="0">CAC≥100: 17.4 per 1,000 p-y, 95% CI 14.1-</text>
<text top="383" left="584" width="27" height="20" font="0">20.7 </text>
<text top="401" left="584" width="176" height="20" font="0">- 2012 ESC statin not indicated </text>
<text top="418" left="584" width="232" height="20" font="0">CAC=0: 1.5 per 1,000 p-y, 95% CI 0.8-2.2 </text>
<text top="435" left="584" width="246" height="20" font="0">CAC 1-99: 4.3 per 1,000 p-y, 95% CI 3.1-5.5 </text>
<text top="452" left="584" width="226" height="20" font="0">CAC≥100: 8.7 per 1,000 p-y, 95% CI 6.0-</text>
<text top="470" left="584" width="27" height="20" font="0">11.5 </text>
<text top="487" left="584" width="155" height="20" font="0">- 2013 PCE statin indicated </text>
<text top="504" left="584" width="232" height="20" font="0">CAC=0: 5.4 per 1,000 p-y, 95% CI 3.2-7.5 </text>
<text top="521" left="584" width="222" height="20" font="0">CAC1-99: 7.5 per 1,000 p-y, 95% CI 5.8-</text>
<text top="538" left="584" width="27" height="20" font="0">10.9 </text>
<text top="556" left="584" width="240" height="20" font="0">CAC≥100: 14.6 per 1,000 p-y, 95% CI 12.2-</text>
<text top="573" left="584" width="27" height="20" font="0">17.1 </text>
<text top="590" left="584" width="176" height="20" font="0">- 2013 PCE statin not indicated </text>
<text top="607" left="584" width="232" height="20" font="0">CAC=0: 0.8 per 1,000 p-y, 95% CI 0.3-1.2 </text>
<text top="625" left="584" width="246" height="20" font="0">CAC 1-99: 2.8 per 1,000 p-y, 95% CI 1.5-4.0 </text>
<text top="642" left="584" width="226" height="20" font="0">CAC≥100: 6.5 per 1,000 p-y, 95% CI 2.2-</text>
<text top="659" left="584" width="31" height="20" font="0">11.8) </text>
<text top="676" left="584" width="3" height="20" font="0"> </text>
<text top="698" left="584" width="11" height="18" font="0">• </text>
<text top="697" left="594" width="206" height="20" font="0">Number needed to screen to detect 1 </text>
<text top="714" left="584" width="137" height="20" font="0">individual with CAC&gt;100 </text>
<text top="732" left="584" width="138" height="20" font="0">ESC statin indicated: 2.4 </text>
<text top="766" left="584" width="162" height="20" font="0">ESC statin not indicated: 6.3  </text>
<text top="783" left="584" width="168" height="20" font="0">ACC/AHA statin indicated: 2.6 </text>
</page>
<page number="95" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">95 </text>
<text top="107" left="584" width="195" height="20" font="0">ACC/AHA statin not indicated: 13.9 </text>
<text top="124" left="584" width="3" height="20" font="0"> </text>
<text top="142" left="91" width="123" height="20" font="7"><b>McClelland RL, et al. </b></text>
<text top="159" left="91" width="27" height="20" font="7"><b>2015</b></text>
<text top="163" left="118" width="5" height="16" font="15"> </text>
<text top="159" left="123" width="25" height="20" font="7"><a href="data supplement.html#241"><b>(94)</b></a><b> </b></text>
<text top="177" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26449133">26449133</a></text>
<text top="177" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26449133"> </a></text>
<text top="142" left="253" width="138" height="20" font="7"><b>Study type:</b> Prospective </text>
<text top="159" left="253" width="126" height="20" font="0">cohort studies (MESA, </text>
<text top="177" left="253" width="110" height="20" font="0">Dallas Heart, Heinz-</text>
<text top="194" left="253" width="132" height="20" font="0">Nixdorf Recall Studies), </text>
<text top="211" left="253" width="137" height="20" font="0">risk score derivation and </text>
<text top="228" left="253" width="55" height="20" font="0">validation </text>
<text top="245" left="253" width="3" height="20" font="0"> </text>
<text top="263" left="253" width="142" height="20" font="7"><b>Size:</b> 6727 participants in </text>
<text top="280" left="253" width="129" height="20" font="0">derivation cohort; 3692 </text>
<text top="297" left="253" width="123" height="20" font="0">and 1080 in validation </text>
<text top="314" left="253" width="44" height="20" font="0">cohorts </text>
<text top="142" left="410" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="161" left="410" width="7" height="18" font="0">•</text>
<text top="161" left="417" width="146" height="20" font="0"> Adults age 45-84 years in </text>
<text top="178" left="410" width="146" height="20" font="0">derivation cohort; 45 to 75 </text>
<text top="195" left="410" width="148" height="20" font="0">years in HNR; 45-65 years </text>
<text top="212" left="410" width="42" height="20" font="0">in DHS </text>
<text top="229" left="410" width="3" height="20" font="0"> </text>
<text top="247" left="410" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="266" left="410" width="11" height="18" font="0">• </text>
<text top="265" left="421" width="85" height="20" font="0">Prevalent CVD </text>
<text top="284" left="410" width="11" height="18" font="0">• </text>
<text top="283" left="421" width="73" height="20" font="0">Missing data </text>
<text top="143" left="584" width="236" height="20" font="7"><b>1</b>°<b> endpoint:</b> Incident hard CHD, including </text>
<text top="161" left="584" width="231" height="20" font="0">MI, resuscitated cardiac arrest, fatal CHD, </text>
<text top="178" left="584" width="230" height="20" font="0">and revascularization in setting of angina; </text>
<text top="195" left="584" width="226" height="20" font="0">Median follow up 10.2 years in derivation </text>
<text top="212" left="584" width="38" height="20" font="0">cohort<b> </b></text>
<text top="229" left="584" width="3" height="20" font="0"> </text>
<text top="247" left="584" width="52" height="20" font="7"><b>Results: </b></text>
<text top="266" left="586" width="11" height="18" font="0">• </text>
<text top="265" left="600" width="201" height="20" font="0">422 CHD events in derivation cohort </text>
<text top="284" left="586" width="11" height="18" font="0">• </text>
<text top="283" left="600" width="215" height="20" font="0">Compared MESA score with traditional </text>
<text top="300" left="586" width="220" height="20" font="0">risk factors to MESA score + ln(CAC+1) </text>
<text top="319" left="586" width="11" height="18" font="0">• </text>
<text top="319" left="600" width="164" height="20" font="0">In MESA, MESA score model </text>
<text top="336" left="586" width="207" height="20" font="0">performance vs. MESA score + CAC: </text>
<text top="353" left="584" width="142" height="20" font="0">C-statistics 0.75 and 0.80 </text>
<text top="370" left="584" width="212" height="20" font="0">Discrimination slopes 0.052 and 0.086 </text>
<text top="387" left="584" width="194" height="20" font="0">Calibration slopes 0.834 and 0.857 </text>
<text top="405" left="584" width="205" height="20" font="0">Hosmer-Lemeshow P &gt; 0.22 for both </text>
<text top="422" left="584" width="43" height="20" font="0">models </text>
<text top="441" left="584" width="11" height="18" font="0">• </text>
<text top="440" left="600" width="212" height="20" font="0">In HNR and DHS, MESA score + CAC </text>
<text top="457" left="584" width="206" height="20" font="0">performed well with good to excellent </text>
<text top="475" left="584" width="214" height="20" font="0">discrimination and excellent calibration </text>
<text top="492" left="584" width="136" height="20" font="0">C-statistic 0.78 and 0.82 </text>
<text top="509" left="584" width="212" height="20" font="0">Discrimination slopes 0.095 and 0.078 </text>
<text top="526" left="584" width="187" height="20" font="0">Calibration slopes 0.899 and 1.19 </text>
<text top="543" left="584" width="205" height="20" font="0">Hosmer-Lemeshow P &gt; 0.22 for both </text>
<text top="561" left="584" width="43" height="20" font="0">models </text>
<text top="578" left="584" width="3" height="20" font="0"> </text>
<text top="595" left="584" width="3" height="20" font="0"> </text>
<text top="144" left="843" width="11" height="18" font="0">• </text>
<text top="143" left="859" width="239" height="20" font="0">Routine addition of CAC score to traditional </text>
<text top="161" left="843" width="235" height="20" font="0">risk scores in contemporary cohorts added </text>
<text top="178" left="843" width="183" height="20" font="0">significant utility to risk prediction </text>
<text top="197" left="843" width="11" height="18" font="0">• </text>
<text top="196" left="859" width="190" height="20" font="0">Limitations: Implies universal CAC </text>
<text top="213" left="843" width="219" height="20" font="0">screening; targeted usage of preventive </text>
<text top="230" left="843" width="250" height="20" font="0">therapies for higher risk individuals may have </text>
<text top="247" left="843" width="244" height="20" font="0">resulted from intensive screening for CAC in </text>
<text top="265" left="843" width="81" height="20" font="0">these cohorts  </text>
<text top="613" left="91" width="123" height="20" font="7"><b>Mortensen MB, et al. </b></text>
<text top="630" left="91" width="27" height="20" font="7"><b>2016</b></text>
<text top="634" left="118" width="5" height="16" font="15"> </text>
<text top="630" left="123" width="25" height="20" font="7"><a href="data supplement.html#241"><b>(95)</b></a><b> </b></text>
<text top="647" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27561760">27561760</a></text>
<text top="647" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27561760"> </a></text>
<text top="665" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="613" left="253" width="138" height="20" font="7"><b>Study type:</b> Prospective </text>
<text top="630" left="253" width="119" height="20" font="0">Observational Cohort </text>
<text top="647" left="253" width="130" height="20" font="0">study (BioImage Study, </text>
<text top="665" left="253" width="66" height="20" font="0">2008-2009) </text>
<text top="682" left="253" width="3" height="20" font="0"> </text>
<text top="699" left="253" width="129" height="20" font="7"><b>Size:</b> 5805 participants </text>
<text top="613" left="410" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="632" left="410" width="7" height="18" font="0">•</text>
<text top="631" left="417" width="123" height="20" font="0"> Men 55-80 years and </text>
<text top="649" left="410" width="111" height="20" font="0">women 60-80 years </text>
<text top="666" left="410" width="3" height="20" font="0"> </text>
<text top="683" left="410" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="702" left="410" width="11" height="18" font="0">• </text>
<text top="701" left="423" width="101" height="20" font="0">Prevalent ASCVD </text>
<text top="614" left="584" width="235" height="20" font="7"><b>1</b>°<b> endpoints:</b> Incident CHD, including MI, </text>
<text top="631" left="584" width="169" height="20" font="0">unstable angina, and coronary </text>
<text top="649" left="584" width="99" height="20" font="0">revascularization; </text>
<text top="666" left="584" width="245" height="20" font="0">Incident ASCVD, including CVD death, CHD </text>
<text top="683" left="584" width="106" height="20" font="0">or ischemic stroke; </text>
<text top="700" left="584" width="163" height="20" font="0">Median follow up of 2.7 years<b> </b></text>
<text top="717" left="584" width="3" height="20" font="0"> </text>
<text top="735" left="584" width="52" height="20" font="7"><b>Results: </b></text>
<text top="754" left="584" width="7" height="18" font="0">•</text>
<text top="753" left="591" width="212" height="20" font="0"> Assessed strategy of using ACC/AHA </text>
<text top="770" left="584" width="238" height="20" font="0">statin eligibility recommendations based on </text>
<text top="787" left="584" width="239" height="20" font="0">PCE, and added reclassification strategy of </text>
<text top="615" left="843" width="7" height="18" font="0">•</text>
<text top="614" left="850" width="246" height="20" font="0"> A simple theoretical reclassification strategy </text>
<text top="631" left="843" width="234" height="20" font="0">using CAC ≥100 to up-risk intermediate or </text>
<text top="649" left="843" width="251" height="20" font="0">CAC=0 to de-risk individuals with 10-year risk </text>
<text top="666" left="843" width="235" height="20" font="0">≥7.5% and &lt;15% by PCE led to significant </text>
<text top="683" left="843" width="243" height="20" font="0">improvements in reclassification and correct </text>
<text top="700" left="843" width="124" height="20" font="0">assignment of therapy </text>
<text top="717" left="843" width="3" height="20" font="0"> </text>
</page>
<page number="96" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">96 </text>
<text top="107" left="584" width="215" height="20" font="0">down-classifying (to non-statin eligible) </text>
<text top="124" left="584" width="241" height="20" font="0">those with 10-year predicted risk ≥7.5% but </text>
<text top="141" left="584" width="225" height="20" font="0">with CAC=0, and up-classifying (to statin </text>
<text top="159" left="584" width="226" height="20" font="0">eligible) those with 10-year predicted risk </text>
<text top="176" left="584" width="196" height="20" font="0">5% to &lt;7.5% and CAC score ≥100. </text>
<text top="195" left="593" width="11" height="18" font="0">• </text>
<text top="194" left="607" width="200" height="20" font="0">91 CHD events; 138 ASCVD events </text>
<text top="213" left="593" width="11" height="18" font="0">• </text>
<text top="213" left="607" width="204" height="20" font="0">Among these older participants, 86% </text>
<text top="230" left="607" width="208" height="20" font="0">were eligible for statins per ACC/AHA </text>
<text top="247" left="607" width="154" height="20" font="0">guideline recommendations </text>
<text top="266" left="593" width="11" height="18" font="0">• </text>
<text top="265" left="607" width="221" height="20" font="0">After reclassification by CAC, 64% were </text>
<text top="282" left="607" width="98" height="20" font="0">eligible for statins </text>
<text top="301" left="593" width="11" height="18" font="0">• </text>
<text top="301" left="607" width="222" height="20" font="0">NRI of reclassification strategy was 0.20 </text>
<text top="318" left="607" width="202" height="20" font="0">for CHD and 0.14 for ASCVD overall </text>
<text top="335" left="607" width="92" height="20" font="0">(both P&lt;0.0001) </text>
<text top="354" left="593" width="11" height="18" font="0">• </text>
<text top="353" left="607" width="206" height="20" font="0">Among participants with predicted 10-</text>
<text top="370" left="607" width="159" height="20" font="0">year risk &lt;15%, CAC-guided </text>
<text top="388" left="607" width="205" height="20" font="0">reclassification strategy led to gain of </text>
<text top="405" left="607" width="206" height="20" font="0">1% in sensitivity (P=0.56) and gain of </text>
<text top="422" left="607" width="221" height="20" font="0">10% in specificity (P&lt;0.0001) for correct </text>
<text top="439" left="607" width="170" height="20" font="0">prediction of CHD (NRI = 0.11, </text>
<text top="457" left="607" width="65" height="20" font="0">P&lt;0.0001)) </text>
<text top="476" left="593" width="11" height="18" font="0">• </text>
<text top="475" left="607" width="206" height="20" font="0">Among participants with predicted 10-</text>
<text top="492" left="607" width="159" height="20" font="0">year risk &lt;15%, CAC-guided </text>
<text top="509" left="607" width="204" height="20" font="0">reclassification strategy led to loss of </text>
<text top="526" left="607" width="206" height="20" font="0">2% in sensitivity (P=0.26) and gain of </text>
<text top="544" left="607" width="221" height="20" font="0">10% in specificity (P&lt;0.0001) for correct </text>
<text top="561" left="607" width="186" height="20" font="0">prediction of ASCVD (NRI = 0.08, </text>
<text top="578" left="607" width="60" height="20" font="0">P&lt;0.0001) </text>
<text top="595" left="642" width="3" height="20" font="0"> </text>
<text top="631" left="91" width="39" height="20" font="7"><b>MESA </b></text>
<text top="648" left="91" width="109" height="20" font="7"><b>Nasir K, et al. 2015</b></text>
<text top="651" left="199" width="5" height="16" font="15"> </text>
<text top="648" left="204" width="26" height="20" font="7"><a href="data supplement.html#240"><b>(82)</b></a><b> </b></text>
<text top="665" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26449135">26449135</a></text>
<text top="665" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26449135"> </a></text>
<text top="631" left="253" width="138" height="20" font="7"><b>Study type:</b> Prospective </text>
<text top="648" left="253" width="120" height="20" font="0">Observational Cohort </text>
<text top="665" left="253" width="79" height="20" font="0">study (MESA) </text>
<text top="682" left="253" width="3" height="20" font="0"> </text>
<text top="699" left="253" width="79" height="20" font="7"><b>Size:</b> N=4758 </text>
<text top="717" left="253" width="70" height="20" font="0">participants, </text>
<text top="734" left="253" width="3" height="20" font="0"> </text>
<text top="631" left="410" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="650" left="410" width="7" height="18" font="0">•</text>
<text top="649" left="417" width="132" height="20" font="0"> All MESA participants,  </text>
<text top="666" left="410" width="3" height="20" font="0"> </text>
<text top="683" left="410" width="3" height="20" font="0"> </text>
<text top="701" left="410" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="720" left="407" width="11" height="18" font="0">• </text>
<text top="719" left="421" width="111" height="20" font="0">Participants on lipid-</text>
<text top="736" left="421" width="121" height="20" font="0">lowering medications, </text>
<text top="753" left="421" width="108" height="20" font="0">&gt;75yo, missing key </text>
<text top="771" left="421" width="126" height="20" font="0">covariates, LDL-C &lt;70 </text>
<text top="788" left="421" width="41" height="20" font="0">mg/dL  </text>
<text top="632" left="584" width="246" height="20" font="7"><b>1</b>°<b> endpoint:</b> Incident CHD: MI, resuscitated </text>
<text top="649" left="584" width="167" height="20" font="0">cardiac arrest, or CHD death;  </text>
<text top="666" left="584" width="218" height="20" font="0">Incident ASCVD: CHD or fatal/non-fatal </text>
<text top="683" left="584" width="37" height="20" font="0">stroke </text>
<text top="701" left="584" width="157" height="20" font="0">Median follow up 10.3 years </text>
<text top="718" left="584" width="3" height="20" font="0"> </text>
<text top="735" left="584" width="52" height="20" font="7"><b>Results: </b></text>
<text top="754" left="584" width="7" height="18" font="0">•</text>
<text top="753" left="591" width="243" height="20" font="0"> 247 ASCVD Events; 155 hard CHD events  </text>
<text top="771" left="584" width="3" height="20" font="0"> </text>
<text top="632" left="843" width="7" height="18" font="0">•</text>
<text top="632" left="850" width="188" height="20" font="0"> CAC =0 is prevalent (≥35%), and </text>
<text top="649" left="843" width="221" height="20" font="0">reclassifies risk to &lt;7.5% for all strata of </text>
<text top="666" left="843" width="200" height="20" font="0">predicted risk &lt;20% and for patients </text>
<text top="683" left="843" width="235" height="20" font="0">recommended for or considered for statins </text>
<text top="701" left="843" width="176" height="20" font="0">under ACC/AHA 2013 guideline </text>
<text top="718" left="843" width="105" height="20" font="0">recommendations. </text>
<text top="737" left="842" width="11" height="18" font="0">• </text>
<text top="736" left="855" width="244" height="20" font="0">CAC &gt;100 identifies individuals with 10-year </text>
<text top="753" left="843" width="233" height="20" font="0">event rates ≥7.5%, even among those not </text>
<text top="771" left="843" width="181" height="20" font="0">recommended for statin therapy. </text>
</page>
<page number="97" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">97 </text>
<text top="109" left="580" width="11" height="18" font="0">• </text>
<text top="108" left="593" width="233" height="20" font="0">Prevalence of CAC =0 among participants </text>
<text top="125" left="593" width="230" height="20" font="0">stratified by statin recommendation status </text>
<text top="143" left="593" width="223" height="20" font="0">using 2013 ACC/AHA recommendations </text>
<text top="160" left="593" width="91" height="20" font="0">(based on PCE) </text>
<text top="179" left="593" width="11" height="18" font="0">• </text>
<text top="178" left="607" width="224" height="20" font="0">41% of ppts recommended for moderate </text>
<text top="195" left="607" width="219" height="20" font="0">to high-intensity statin Rx had CAC = 0; </text>
<text top="212" left="607" width="123" height="20" font="0">29% had CAC &gt;100.   </text>
<text top="231" left="593" width="11" height="18" font="0">• </text>
<text top="231" left="607" width="206" height="20" font="0">57% of ppts considered for moderate-</text>
<text top="248" left="607" width="211" height="20" font="0">intensity statin had CAC = 0; 12% had </text>
<text top="265" left="607" width="67" height="20" font="0">CAC &gt;100.  </text>
<text top="284" left="593" width="11" height="18" font="0">• </text>
<text top="283" left="607" width="222" height="20" font="0">79% of ppts not recommended for statin </text>
<text top="300" left="607" width="187" height="20" font="0">had CAC = 0; 4% had CAC &gt;100. </text>
<text top="318" left="580" width="3" height="20" font="0"> </text>
<text top="337" left="580" width="11" height="18" font="0">• </text>
<text top="336" left="593" width="233" height="20" font="0">Prevalence of CAC =0 among participants </text>
<text top="353" left="593" width="234" height="20" font="0">stratified by predicted 10-year ASCVD risk </text>
<text top="370" left="593" width="91" height="20" font="0">(based on PCE) </text>
<text top="389" left="593" width="11" height="18" font="0">• </text>
<text top="389" left="607" width="220" height="20" font="0">7.5% - 9.9%: 55% of ppts had CAC = 0; </text>
<text top="406" left="607" width="123" height="20" font="0">17% had CAC &gt;100.   </text>
<text top="425" left="593" width="11" height="18" font="0">• </text>
<text top="424" left="607" width="220" height="20" font="0">10.0% - 14.9%: 43% of ppts had CAC = </text>
<text top="441" left="607" width="133" height="20" font="0">0; 24% had CAC &gt;100.  </text>
<text top="460" left="593" width="11" height="18" font="0">• </text>
<text top="460" left="607" width="220" height="20" font="0">15.0% - 19.9%: 35% of ppts had CAC = </text>
<text top="477" left="607" width="130" height="20" font="0">0; 33% had CAC &gt;100. </text>
<text top="496" left="593" width="11" height="18" font="0">• </text>
<text top="495" left="607" width="214" height="20" font="0">≥20%: 26% of ppts had CAC = 0; 46% </text>
<text top="512" left="607" width="88" height="20" font="0">had CAC &gt;100. </text>
<text top="529" left="580" width="3" height="20" font="0"> </text>
<text top="548" left="580" width="11" height="18" font="0">• </text>
<text top="548" left="593" width="234" height="20" font="0">Observed 10-year ASCVD Event Rates by </text>
<text top="565" left="593" width="185" height="20" font="0">Statin Recommendation Groups:  </text>
<text top="584" left="593" width="11" height="18" font="0">• </text>
<text top="583" left="607" width="195" height="20" font="0">Statin recommended: 8.2% overall; </text>
<text top="600" left="607" width="196" height="20" font="0">4.9% with CAC=0; 13.3% with CAC </text>
<text top="617" left="607" width="35" height="20" font="0">&gt;100. </text>
<text top="637" left="593" width="11" height="18" font="0">• </text>
<text top="636" left="607" width="208" height="20" font="0">Statin considered: 3.9% overall; 1.5% </text>
<text top="653" left="607" width="193" height="20" font="0">with CAC=0; 6.0% with CAC &gt;100. </text>
<text top="672" left="593" width="11" height="18" font="0">• </text>
<text top="671" left="607" width="215" height="20" font="0">Statin not recommended: 1.6% overall; </text>
<text top="688" left="607" width="190" height="20" font="0">1.3% with CAC=0; 9.6% with CAC </text>
<text top="706" left="607" width="35" height="20" font="0">&gt;100. </text>
<text top="723" left="584" width="3" height="20" font="0"> </text>
<text top="742" left="580" width="11" height="18" font="0">• </text>
<text top="741" left="593" width="234" height="20" font="0">Observed 10-year ASCVD Event Rates by </text>
<text top="758" left="593" width="183" height="20" font="0">Predicted 10-Year Risk Stratum:  </text>
<text top="109" left="842" width="11" height="18" font="0">• </text>
<text top="108" left="855" width="242" height="20" font="0">In middle-aged people who are statin naïve, </text>
<text top="125" left="843" width="243" height="20" font="0">the addition of CAC scoring can help stratify </text>
<text top="143" left="843" width="247" height="20" font="0">risk and appropriately reclassify intermediate </text>
<text top="160" left="843" width="253" height="20" font="0">risk into lower risk categories and low risk into </text>
<text top="177" left="843" width="131" height="20" font="0">higher risk categories.   </text>
<text top="196" left="842" width="11" height="18" font="0">• </text>
<text top="195" left="855" width="231" height="20" font="0">Limitations: Overprediction of ASCVD risk </text>
<text top="212" left="843" width="243" height="20" font="0">by PCE in MESA has been described and is </text>
<text top="230" left="843" width="220" height="20" font="0">present in this analysis. This might over-</text>
<text top="247" left="843" width="255" height="20" font="0">estimate the reclassification benefits of CAC = </text>
<text top="264" left="843" width="17" height="20" font="0">0.  </text>
<text top="281" left="843" width="3" height="20" font="0"> </text>
<text top="298" left="843" width="3" height="20" font="0"> </text>
</page>
<page number="98" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">98 </text>
<text top="109" left="593" width="11" height="18" font="0">• </text>
<text top="108" left="607" width="209" height="20" font="0">7.5% - 9.9%: 2.7% with CAC=0; 7.3% </text>
<text top="125" left="607" width="89" height="20" font="0">with CAC &gt;100. </text>
<text top="144" left="593" width="11" height="18" font="0">• </text>
<text top="144" left="607" width="191" height="20" font="0">10.0% - 14.9%: 6.4% with CAC=0; </text>
<text top="161" left="607" width="127" height="20" font="0">11.1% with CAC &gt;100. </text>
<text top="180" left="593" width="11" height="18" font="0">• </text>
<text top="179" left="607" width="191" height="20" font="0">15.0% - 19.9%: 4.4% with CAC=0; </text>
<text top="196" left="607" width="127" height="20" font="0">20.5% with CAC &gt;100. </text>
<text top="215" left="593" width="11" height="18" font="0">• </text>
<text top="215" left="607" width="203" height="20" font="0">≥20%: 11.7% with CAC=0; 19% with </text>
<text top="232" left="607" width="64" height="20" font="0">CAC &gt;100. </text>
<text top="249" left="584" width="3" height="20" font="0"> </text>
<text top="266" left="584" width="3" height="20" font="0"> </text>
<text top="284" left="91" width="77" height="20" font="7"><b>Framingham </b></text>
<text top="301" left="91" width="130" height="20" font="7"><b>Pursnani A, et al. 2015</b></text>
<text top="305" left="221" width="5" height="16" font="15"> </text>
<text top="318" left="91" width="25" height="20" font="7"><a href="data supplement.html#241"><b>(96)</b></a><b> </b></text>
<text top="336" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26172893">26172893</a></text>
<text top="336" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26172893"> </a></text>
<text top="284" left="253" width="138" height="20" font="7"><b>Study type:</b> Prospective </text>
<text top="301" left="253" width="120" height="20" font="0">Observational Cohort </text>
<text top="318" left="253" width="33" height="20" font="0">study </text>
<text top="336" left="253" width="3" height="20" font="0"> </text>
<text top="353" left="253" width="79" height="20" font="7"><b>Size:</b> N=2435 </text>
<text top="370" left="253" width="66" height="20" font="0">participants </text>
<text top="284" left="410" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="303" left="410" width="7" height="18" font="0">•</text>
<text top="302" left="417" width="144" height="20" font="0"> Framingham Offspring or </text>
<text top="320" left="410" width="148" height="20" font="0">Gen3 participants; men 35 </text>
<text top="337" left="410" width="142" height="20" font="0">and older, women 40 and </text>
<text top="354" left="410" width="133" height="20" font="0">older, weighted towards </text>
<text top="371" left="410" width="156" height="20" font="0">families with larger numbers </text>
<text top="388" left="410" width="51" height="20" font="0">in cohort </text>
<text top="406" left="410" width="3" height="20" font="0"> </text>
<text top="423" left="410" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="442" left="410" width="11" height="18" font="0">• </text>
<text top="441" left="421" width="147" height="20" font="0">Participants with prevalent </text>
<text top="458" left="421" width="136" height="20" font="0">CVD or on lipid-lowering </text>
<text top="476" left="421" width="44" height="20" font="0">therapy </text>
<text top="285" left="584" width="168" height="20" font="7"><b>1</b>°<b> endpoint:</b> Incident ASCVD </text>
<text top="302" left="584" width="150" height="20" font="0">Median follow up 9.4 years<b> </b></text>
<text top="320" left="584" width="3" height="20" font="0"> </text>
<text top="337" left="584" width="52" height="20" font="7"><b>Results: </b></text>
<text top="356" left="584" width="7" height="18" font="0">•</text>
<text top="355" left="591" width="212" height="20" font="0"> Among participants recommended for </text>
<text top="372" left="584" width="236" height="20" font="0">statin therapy by 2013 AC/AHA guidelines, </text>
<text top="390" left="584" width="203" height="20" font="0">33% had CAC=0, with an associated </text>
<text top="407" left="584" width="230" height="20" font="0">ASCVD event rate of 1.6% over 9.4 years </text>
<text top="424" left="584" width="3" height="20" font="0"> </text>
<text top="286" left="843" width="7" height="18" font="0">•</text>
<text top="285" left="850" width="249" height="20" font="0"> CAC = 0 identified individuals recommended </text>
<text top="302" left="843" width="239" height="20" font="0">for statin therapy who had very low ASCVD </text>
<text top="320" left="843" width="71" height="20" font="0">event rates.  </text>
<text top="337" left="843" width="3" height="20" font="0"> </text>
<text top="494" left="91" width="138" height="20" font="7"><b>Qureshi W.T. et al. 2015</b></text>
<text top="497" left="229" width="5" height="16" font="15"> </text>
<text top="511" left="91" width="25" height="20" font="7"><a href="data supplement.html#241"><b>(97)</b></a><b> </b></text>
<text top="528" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26482753">26482753</a></text>
<text top="528" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26482753"> </a></text>
<text top="494" left="253" width="134" height="20" font="7"><b>Study type:</b> Systematic </text>
<text top="511" left="253" width="142" height="20" font="0">review and meta-analysis </text>
<text top="528" left="253" width="112" height="20" font="0">of published studies </text>
<text top="545" left="253" width="3" height="20" font="0"> </text>
<text top="562" left="253" width="144" height="20" font="7"><b>Size:</b> N=8 studies of CAC </text>
<text top="580" left="253" width="113" height="20" font="0">and N=22 studies of </text>
<text top="597" left="253" width="42" height="20" font="0">hsCRP </text>
<text top="494" left="410" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="513" left="410" width="7" height="18" font="0">•</text>
<text top="512" left="417" width="151" height="20" font="0"> Studies examining change </text>
<text top="529" left="410" width="139" height="20" font="0">in discrimination for CVD </text>
<text top="546" left="410" width="154" height="20" font="0">events with addition of CAC </text>
<text top="564" left="410" width="139" height="20" font="0">or hsCRP to models with </text>
<text top="581" left="410" width="149" height="20" font="0">traditional CVD risk factors </text>
<text top="598" left="410" width="3" height="20" font="0"> </text>
<text top="615" left="410" width="134" height="20" font="7"><b>Exclusion criteria:</b> N/A </text>
<text top="495" left="584" width="152" height="20" font="7"><b>1</b>°<b> endpoint:</b> Incident CVD<b> </b></text>
<text top="512" left="584" width="3" height="20" font="0"> </text>
<text top="529" left="584" width="52" height="20" font="7"><b>Results: </b></text>
<text top="548" left="584" width="7" height="18" font="0">•</text>
<text top="547" left="591" width="237" height="20" font="0"> Meta-analysis of change in area under the </text>
<text top="565" left="584" width="68" height="20" font="0">ROC curve: </text>
<text top="582" left="584" width="219" height="20" font="0">With addition of hsCRP: 0.012, 95% CI, </text>
<text top="599" left="584" width="122" height="20" font="0">0.008-0.017, P&lt;0.001 </text>
<text top="616" left="584" width="241" height="20" font="0">With addition of CAC: 0.063, 95% CI, 0,042-</text>
<text top="634" left="584" width="34" height="20" font="0">0.084 </text>
<text top="495" left="843" width="7" height="18" font="0">•</text>
<text top="495" left="850" width="244" height="20" font="0"> Addition of CAC score to models containing </text>
<text top="512" left="843" width="253" height="20" font="0">traditional risk factors changes the area under </text>
<text top="529" left="843" width="242" height="20" font="0">the ROC curve for prediction of CVD events </text>
<text top="546" left="843" width="237" height="20" font="0">significantly and substantially, and by more </text>
<text top="564" left="843" width="133" height="20" font="0">than addition of hsCRP. </text>
<text top="581" left="843" width="3" height="20" font="0"> </text>
<text top="651" left="91" width="125" height="20" font="7"><b>Jackson Heart Study </b></text>
<text top="669" left="91" width="123" height="20" font="7"><b>Shah R.V., et al. 2017</b></text>
<text top="672" left="214" width="5" height="16" font="15"> </text>
<text top="686" left="91" width="25" height="20" font="7"><a href="data supplement.html#241"><b>(98)</b></a><b> </b></text>
<text top="703" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28315622">28315622</a></text>
<text top="703" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28315622"> </a></text>
<text top="651" left="253" width="138" height="20" font="7"><b>Study type:</b> Prospective </text>
<text top="669" left="253" width="120" height="20" font="0">Observational Cohort </text>
<text top="686" left="253" width="33" height="20" font="0">study </text>
<text top="703" left="253" width="3" height="20" font="0"> </text>
<text top="720" left="253" width="130" height="20" font="7"><b>Size:</b> N=2812 (N=1743 </text>
<text top="738" left="253" width="92" height="20" font="0">with CAC score) </text>
<text top="755" left="253" width="66" height="20" font="0">participants </text>
<text top="651" left="410" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="670" left="410" width="7" height="18" font="0">•</text>
<text top="670" left="417" width="152" height="20" font="0"> African American men and </text>
<text top="687" left="410" width="135" height="20" font="0">women age 40-75 years </text>
<text top="704" left="410" width="3" height="20" font="0"> </text>
<text top="721" left="410" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="740" left="407" width="11" height="18" font="0">• </text>
<text top="740" left="421" width="138" height="20" font="0">Prevalent CVD, on statin </text>
<text top="757" left="407" width="120" height="20" font="0">therapy, missing data </text>
<text top="653" left="584" width="168" height="20" font="7"><b>1</b>°<b> endpoint:</b> Incident ASCVD </text>
<text top="670" left="584" width="146" height="20" font="0">Median follow up 10 years<b> </b></text>
<text top="687" left="584" width="3" height="20" font="0"> </text>
<text top="704" left="584" width="52" height="20" font="7"><b>Results: </b></text>
<text top="723" left="584" width="7" height="18" font="0">•</text>
<text top="723" left="591" width="226" height="20" font="0"> 55 incident ASCVD events among those </text>
<text top="740" left="584" width="88" height="20" font="0">with CAC score </text>
<text top="757" left="584" width="3" height="20" font="0"> </text>
<text top="653" left="843" width="7" height="18" font="0">•</text>
<text top="653" left="850" width="235" height="20" font="0"> Among those who were recommended for </text>
<text top="670" left="843" width="215" height="20" font="0">statin by the ACC/AHA 2013 guideline, </text>
<text top="687" left="843" width="254" height="20" font="0">presence of CAC identified those with 10-year </text>
<text top="704" left="843" width="249" height="20" font="0">event rates &gt;7.5%, whereas absence of CAC </text>
<text top="721" left="843" width="219" height="20" font="0">was associated with event rates &lt;7.5%. </text>
<text top="739" left="843" width="250" height="20" font="0">Among those not recommended for statin, 10-</text>
<text top="756" left="843" width="164" height="20" font="0">year event rates were &lt;1.0%. </text>
<text top="773" left="843" width="3" height="20" font="0"> </text>
</page>
<page number="99" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="20" height="21" font="1">99 </text>
<text top="109" left="586" width="11" height="18" font="0">• </text>
<text top="108" left="600" width="220" height="20" font="0">CAC &gt;0 prevalence increased in a dose </text>
<text top="125" left="586" width="240" height="20" font="0">dependent fashion from ~13% in those with </text>
<text top="143" left="586" width="234" height="20" font="0">10-year predicted risk (by PCE) of 2.5% to </text>
<text top="160" left="586" width="220" height="20" font="0">~75% in those with predicted risk ≥15% </text>
<text top="179" left="586" width="11" height="18" font="0">• </text>
<text top="178" left="600" width="188" height="20" font="0">ASCVD event rate for participants </text>
<text top="195" left="586" width="238" height="20" font="0">recommended for statin by ACC/AHA 2013 </text>
<text top="212" left="586" width="56" height="20" font="0">guideline: </text>
<text top="230" left="586" width="133" height="20" font="0">With CAC: 8.1/1000 p-y </text>
<text top="249" left="586" width="196" height="20" font="0">Without CAC: 3.1/1000 p-y; P=0.02 </text>
<text top="271" left="586" width="11" height="18" font="0">• </text>
<text top="270" left="600" width="208" height="20" font="0">ASCVD event rate for participants not </text>
<text top="287" left="586" width="238" height="20" font="0">recommended for statin by ACC/AHA 2013 </text>
<text top="305" left="586" width="56" height="20" font="0">guideline: </text>
<text top="322" left="584" width="133" height="20" font="0">With CAC: 0.9/1000 p-y </text>
<text top="339" left="584" width="196" height="20" font="0">Without CAC: 0.8/1000 p-y; P&gt;0.99 </text>
<text top="356" left="584" width="3" height="20" font="0"> </text>
<text top="374" left="91" width="139" height="20" font="7"><b>St. Francis Heart Study </b></text>
<text top="391" left="91" width="128" height="20" font="7"><b>Waheed S., et al. 2016</b></text>
<text top="395" left="219" width="5" height="16" font="15"> </text>
<text top="409" left="91" width="25" height="20" font="7"><a href="data supplement.html#242"><b>(99)</b></a><b> </b></text>
<text top="426" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27693004">27693004</a></text>
<text top="426" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/27693004"> </a></text>
<text top="374" left="253" width="122" height="20" font="7"><b>Study type:</b> Post hoc </text>
<text top="391" left="253" width="90" height="20" font="0">analysis of RCT </text>
<text top="409" left="253" width="3" height="20" font="0"> </text>
<text top="426" left="253" width="138" height="20" font="7"><b>Size:</b> N=990 participants </text>
<text top="374" left="410" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="393" left="410" width="7" height="18" font="0">•</text>
<text top="393" left="417" width="130" height="20" font="0"> Individuals aged 50-70 </text>
<text top="410" left="410" width="143" height="20" font="0">years with CAC score ≥80</text>
<text top="412" left="553" width="7" height="13" font="9">th</text>
<text top="410" left="560" width="3" height="20" font="0"> </text>
<text top="427" left="410" width="145" height="20" font="0">percentile for age and sex </text>
<text top="444" left="410" width="102" height="20" font="0">enrolled in RCT of </text>
<text top="462" left="410" width="152" height="20" font="0">atorvastatin, vitamin C, and </text>
<text top="479" left="410" width="122" height="20" font="0">vitamin E vs placebos </text>
<text top="496" left="410" width="3" height="20" font="0"> </text>
<text top="513" left="410" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="532" left="407" width="11" height="18" font="0">• </text>
<text top="532" left="420" width="104" height="20" font="0">Prevalent ASCVD, </text>
<text top="548" left="407" width="154" height="20" font="0">diabetes, extreme values of </text>
<text top="566" left="407" width="165" height="20" font="0">cholesterol or blood pressure  </text>
<text top="375" left="584" width="207" height="20" font="7"><b>1</b>°<b> endpoint:</b> Incident CVD (non-fatal </text>
<text top="393" left="584" width="219" height="20" font="0">myocardial infarction or coronary death, </text>
<text top="410" left="584" width="215" height="20" font="0">coronary revascularization, stroke, and </text>
<text top="427" left="584" width="199" height="20" font="0">peripheral arterial revascularization)<b> </b></text>
<text top="444" left="584" width="150" height="20" font="0">Median follow up 4.8 years </text>
<text top="462" left="584" width="3" height="20" font="0"> </text>
<text top="479" left="584" width="52" height="20" font="7"><b>Results: </b></text>
<text top="498" left="584" width="11" height="18" font="0">• </text>
<text top="497" left="593" width="206" height="20" font="0">CVD incidence rates (per 100 p-y) by </text>
<text top="514" left="584" width="227" height="20" font="0">statin eligibility, randomization status and </text>
<text top="531" left="584" width="66" height="20" font="0">CAC score: </text>
<text top="549" left="584" width="244" height="20" font="0">Statin ineligible by ACC/AHA 2013 guideline </text>
<text top="568" left="584" width="140" height="20" font="0">CAC &lt;100 and treated: 0 </text>
<text top="588" left="584" width="154" height="20" font="0">CAC &lt;100 and untreated: 0 </text>
<text top="608" left="584" width="157" height="20" font="0">CAC 100-300 and treated: 5 </text>
<text top="628" left="584" width="171" height="20" font="0">CAC 100-300 and untreated: 5 </text>
<text top="648" left="584" width="147" height="20" font="0">CAC &gt;300 and treated: 17 </text>
<text top="667" left="584" width="160" height="20" font="0">CAC &gt;300 and untreated: 23 </text>
<text top="687" left="584" width="3" height="20" font="0"> </text>
<text top="707" left="584" width="235" height="20" font="0">Statin eligible by ACC/AHA 2013 guideline </text>
<text top="727" left="584" width="140" height="20" font="0">CAC &lt;100 and treated: 0 </text>
<text top="746" left="584" width="154" height="20" font="0">CAC &lt;100 and untreated: 0 </text>
<text top="766" left="584" width="164" height="20" font="0">CAC 100-300 and treated: 20 </text>
<text top="786" left="584" width="178" height="20" font="0">CAC 100-300 and untreated: 26 </text>
<text top="376" left="843" width="7" height="18" font="0">•</text>
<text top="375" left="850" width="250" height="20" font="0"> No CVD events were observed among those </text>
<text top="393" left="843" width="250" height="20" font="0">with CAC &lt;100, regardless of statin eligibility. </text>
<text top="410" left="843" width="255" height="20" font="0">CAC scores &gt;100 were associated with higher </text>
<text top="427" left="843" width="256" height="20" font="0">event rates, especially among those who were </text>
<text top="444" left="843" width="126" height="20" font="0">deemed statin eligible. </text>
<text top="461" left="843" width="3" height="20" font="0"> </text>
<text top="479" left="843" width="3" height="20" font="0"> </text>
<text top="496" left="843" width="223" height="20" font="0">Limitations: Post-hoc analysis, restricted </text>
<text top="513" left="843" width="230" height="20" font="0">population with high CAC for age and sex </text>
<text top="530" left="843" width="3" height="20" font="0"> </text>
</page>
<page number="100" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">100 </text>
<text top="107" left="584" width="147" height="20" font="0">CAC &gt;300 and treated: 22 </text>
<text top="127" left="584" width="160" height="20" font="0">CAC &gt;300 and untreated: 34 </text>
<text top="162" left="584" width="3" height="20" font="0"> </text>
<text top="180" left="91" width="39" height="20" font="7"><b>MESA </b></text>
<text top="197" left="91" width="127" height="20" font="7"><b>Yeboah J., et al.</b> 2015 </text>
<text top="214" left="91" width="32" height="20" font="0"><a href="data supplement.html#242">(100)</a><b> </b></text>
<text top="231" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="180" left="253" width="138" height="20" font="7"><b>Study type:</b> Prospective </text>
<text top="197" left="253" width="120" height="20" font="0">Observational Cohort </text>
<text top="214" left="253" width="79" height="20" font="0">study (MESA) </text>
<text top="231" left="253" width="3" height="20" font="0"> </text>
<text top="248" left="253" width="79" height="20" font="7"><b>Size:</b> N=4185 </text>
<text top="266" left="253" width="91" height="20" font="0">participants with </text>
<text top="283" left="253" width="124" height="20" font="0">recalibrated (to MESA </text>
<text top="300" left="253" width="143" height="20" font="0">sample) PCE 10-year risk </text>
<text top="317" left="253" width="72" height="20" font="0">score &lt;7.5% </text>
<text top="180" left="410" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="199" left="410" width="7" height="18" font="0">•</text>
<text top="198" left="417" width="150" height="20" font="0"> MESA participants age 45-</text>
<text top="215" left="410" width="51" height="20" font="0">84 years </text>
<text top="232" left="410" width="3" height="20" font="0"> </text>
<text top="250" left="410" width="110" height="20" font="7"><b>Exclusion criteria: </b></text>
<text top="269" left="407" width="11" height="18" font="0">• </text>
<text top="268" left="421" width="142" height="20" font="0">Missing data, participants </text>
<text top="285" left="410" width="148" height="20" font="0">receiving statin at baseline </text>
<text top="181" left="584" width="168" height="20" font="7"><b>1</b>°<b> endpoint:</b> Incident ASCVD </text>
<text top="198" left="584" width="146" height="20" font="0">Median follow up 10 years </text>
<text top="215" left="584" width="3" height="20" font="0"> </text>
<text top="232" left="584" width="52" height="20" font="7"><b>Results: </b></text>
<text top="251" left="584" width="7" height="18" font="0">•</text>
<text top="251" left="591" width="101" height="20" font="0"> CAC ≥300 or ≥75</text>
<text top="252" left="692" width="7" height="13" font="9">th</text>
<text top="251" left="699" width="128" height="20" font="0"> percentile for age, sex </text>
<text top="268" left="584" width="217" height="20" font="0">and race, hsCRP ≥2 mg/dl, AMBI &lt;0.9, </text>
<text top="285" left="584" width="207" height="20" font="0">LDL-C ≥160 mg/dL, or positive family </text>
<text top="302" left="584" width="214" height="20" font="0">history of ASCVD each identified small </text>
<text top="320" left="584" width="213" height="20" font="0">proportions (&lt;10%) of participants with </text>
<text top="337" left="584" width="210" height="20" font="0">predicted 10-year risk &lt;7.5% who had </text>
<text top="354" left="584" width="222" height="20" font="0">observed 10-year event rates &gt;7.5%. Of </text>
<text top="371" left="584" width="225" height="20" font="0">these additional tests, CAC identified the </text>
<text top="388" left="584" width="103" height="20" font="0">largest proportion. </text>
<text top="406" left="584" width="3" height="20" font="0"> </text>
<text top="181" left="843" width="7" height="18" font="0">•</text>
<text top="181" left="850" width="226" height="20" font="0"> Among individuals with low predicted 10-</text>
<text top="198" left="843" width="251" height="20" font="0">year risk not expected to be in a statin benefit </text>
<text top="215" left="843" width="136" height="20" font="0">group, CAC ≥300 or ≥75</text>
<text top="217" left="979" width="7" height="13" font="9">th</text>
<text top="215" left="986" width="105" height="20" font="0"> percentile for age, </text>
<text top="232" left="843" width="217" height="20" font="0">sex and race identified a subgroup with </text>
<text top="250" left="843" width="238" height="20" font="0">observed event rate &gt;7.5%, and performed </text>
<text top="267" left="843" width="194" height="20" font="0">better than other additional tests or </text>
<text top="284" left="843" width="71" height="20" font="0">biomarkers.  </text>
<text top="301" left="843" width="3" height="20" font="0"> </text>
<text top="424" left="91" width="39" height="20" font="7"><b>MESA </b></text>
<text top="441" left="91" width="129" height="20" font="7"><b>Yeboah J., et al.</b> <a href="data supplement.html#242">(101)</a> </text>
<text top="458" left="91" width="31" height="20" font="0">2016<b> </b></text>
<text top="424" left="253" width="138" height="20" font="7"><b>Study type:</b> Prospective </text>
<text top="441" left="253" width="120" height="20" font="0">Observational Cohort </text>
<text top="458" left="253" width="79" height="20" font="0">study (MESA) </text>
<text top="475" left="253" width="3" height="20" font="0"> </text>
<text top="492" left="253" width="79" height="20" font="7"><b>Size:</b> N=5185 </text>
<text top="510" left="253" width="91" height="20" font="0">participants with </text>
<text top="527" left="253" width="124" height="20" font="0">recalibrated (to MESA </text>
<text top="544" left="253" width="109" height="20" font="0">sample) PCE score </text>
<text top="424" left="410" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="443" left="410" width="7" height="18" font="0">•</text>
<text top="442" left="417" width="150" height="20" font="0"> MESA participants age 45-</text>
<text top="459" left="410" width="51" height="20" font="0">84 years </text>
<text top="476" left="410" width="3" height="20" font="0"> </text>
<text top="494" left="410" width="110" height="20" font="7"><b>Exclusion criteria: </b></text>
<text top="511" left="410" width="142" height="20" font="0">Missing data, participants </text>
<text top="528" left="410" width="148" height="20" font="0">receiving statin at baseline </text>
<text top="425" left="584" width="168" height="20" font="7"><b>1</b>°<b> endpoint:</b> Incident ASCVD </text>
<text top="442" left="584" width="146" height="20" font="0">Median follow up 10 years<b> </b></text>
<text top="459" left="584" width="3" height="20" font="0"> </text>
<text top="476" left="584" width="52" height="20" font="7"><b>Results: </b></text>
<text top="495" left="584" width="7" height="18" font="0">•</text>
<text top="495" left="591" width="196" height="20" font="0"> CAC, ABI,  and family history were </text>
<text top="512" left="584" width="244" height="20" font="0">associated with ASCVD events independent </text>
<text top="529" left="584" width="114" height="20" font="0">of recalibrated PCE. </text>
<text top="546" left="584" width="3" height="20" font="0"> </text>
<text top="566" left="584" width="11" height="18" font="0">• </text>
<text top="565" left="593" width="191" height="20" font="0">Harrell’s C statistic with addition to </text>
<text top="582" left="584" width="100" height="20" font="0">recalibrated PCE: </text>
<text top="599" left="584" width="165" height="20" font="0">Recalibrated PCE alone: 0.74 </text>
<text top="619" left="584" width="155" height="20" font="0">+ CAC score: 0.76 (P=0.04) </text>
<text top="639" left="584" width="116" height="20" font="0">+ ABI: 0.75 (P=0.55) </text>
<text top="659" left="584" width="135" height="20" font="0">+ hsCRP: 0.74 (P=0.25) </text>
<text top="678" left="584" width="172" height="20" font="0">+ Family history: 0.74 (P=0.98) </text>
<text top="698" left="584" width="3" height="20" font="0"> </text>
<text top="720" left="584" width="11" height="18" font="0">• </text>
<text top="719" left="593" width="234" height="20" font="0">NRI for threshold of 7.5% 10-year risk with </text>
<text top="736" left="584" width="160" height="20" font="0">addition to recalibrated PCE: </text>
<text top="753" left="584" width="227" height="20" font="0">+ CAC score: 0.119, 95% CI 0.080-0.256 </text>
<text top="773" left="584" width="192" height="20" font="0">+ ABI: 0.017, 95% CI -0.031-0.058 </text>
<text top="425" left="843" width="7" height="18" font="0">•</text>
<text top="425" left="850" width="214" height="20" font="0"> CAC improved discrimination and NRI </text>
<text top="442" left="843" width="246" height="20" font="0">beyond recalibrated PCE whereas other non-</text>
<text top="459" left="843" width="174" height="20" font="0">traditional risk markers did not.  </text>
<text top="476" left="843" width="3" height="20" font="0"> </text>
</page>
<page number="101" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">101 </text>
<text top="107" left="584" width="211" height="20" font="0">+ hsCRP: 0.025, 95% CI -0.015-0.067 </text>
<text top="127" left="584" width="244" height="20" font="0">+ Family history: 0.051, 95% CI 0.000-0.109 </text>
<text top="162" left="584" width="3" height="20" font="0"> </text>
<text top="179" left="584" width="3" height="20" font="0"> </text>
<text top="203" left="81" width="5" height="16" font="15"> </text>
<text top="217" left="81" width="836" height="24" font="4"><b>Data Supplement 16. Evidence Tables for Borderline and Intermediate Risk Group (5-&lt;7.5%; 7.5 to 20%) (Section 4.4.2)  </b></text>
<text top="240" left="90" width="98" height="20" font="7"><b>Acronym; Study </b></text>
<text top="257" left="101" width="78" height="20" font="7"><b>Author; Year </b></text>
<text top="274" left="109" width="62" height="20" font="7"><b>Published </b></text>
<text top="240" left="216" width="83" height="20" font="7"><b>Aim of Study; </b></text>
<text top="257" left="221" width="77" height="20" font="7"><b>Study Type;  </b></text>
<text top="274" left="215" width="86" height="20" font="7"><b>Study Size (N) </b></text>
<text top="291" left="231" width="54" height="20" font="7"><b>Duration </b></text>
<text top="240" left="368" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="257" left="325" width="3" height="20" font="0"> </text>
<text top="240" left="572" width="118" height="20" font="7"><b>Study Intervention/  </b></text>
<text top="257" left="575" width="114" height="20" font="7"><b>Study Comparator  </b></text>
<text top="274" left="561" width="139" height="20" font="7"><b>Definition of Outcomes </b></text>
<text top="291" left="572" width="116" height="20" font="7"><b>Primary/Secondary </b></text>
<text top="240" left="766" width="105" height="20" font="7"><b>Endpoint Results </b></text>
<text top="257" left="744" width="149" height="20" font="7"><b>(Absolute Event Rates, P </b></text>
<text top="274" left="747" width="142" height="20" font="7"><b>value; OR or RR; &amp; 95% </b></text>
<text top="291" left="808" width="20" height="20" font="7"><b>CI) </b></text>
<text top="240" left="941" width="131" height="22" font="7"><b>Relevant 2</b>⁰<b>Endpoints </b></text>
<text top="257" left="982" width="51" height="20" font="7"><b>(if any);  </b></text>
<text top="274" left="951" width="114" height="20" font="7"><b>Study Limitations;  </b></text>
<text top="292" left="959" width="96" height="20" font="7"><b>Adverse Events </b></text>
<text top="330" left="90" width="49" height="20" font="7"><b>HOPE 3 </b></text>
<text top="347" left="90" width="83" height="20" font="0">Yusuf S, et al., </text>
<text top="365" left="90" width="56" height="20" font="0">2016 <a href="data supplement.html#236">(12)</a> </text>
<text top="382" left="90" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27040132"> </a></text>
<text top="382" left="93" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27040132">27040132</a></text>
<text top="382" left="148" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27040132"> </a></text>
<text top="399" left="90" width="3" height="20" font="0"> </text>
<text top="416" left="90" width="7" height="20" font="0">  </text>
<text top="433" left="90" width="3" height="20" font="0"> </text>
<text top="451" left="90" width="3" height="20" font="0"> </text>
<text top="468" left="90" width="3" height="20" font="0"> </text>
<text top="485" left="90" width="3" height="20" font="0"> </text>
<text top="330" left="203" width="81" height="20" font="0">Determine net </text>
<text top="347" left="203" width="109" height="20" font="0">benefit of moderate </text>
<text top="365" left="203" width="81" height="20" font="0">intensity statin </text>
<text top="382" left="203" width="57" height="20" font="0">therapy in </text>
<text top="399" left="203" width="71" height="20" font="0">intermediate </text>
<text top="416" left="203" width="107" height="20" font="0">ASCVD risk group; </text>
<text top="433" left="203" width="102" height="20" font="7"><b>Study type</b>: RCT  </text>
<text top="451" left="203" width="76" height="20" font="7"><b>Size:</b>  12,705 </text>
<text top="468" left="203" width="70" height="20" font="0">participants  </text>
<text top="485" left="203" width="83" height="20" font="0">Duration: 5.6 y </text>
<text top="502" left="203" width="3" height="20" font="0"> </text>
<text top="519" left="203" width="3" height="20" font="0"> </text>
<text top="537" left="203" width="3" height="20" font="0"> </text>
<text top="554" left="203" width="7" height="20" font="0">  </text>
<text top="330" left="325" width="108" height="20" font="7"><b>Inclusion Criteria:</b> </text>
<text top="347" left="325" width="73" height="20" font="0">Men: ≥ 55 y  </text>
<text top="365" left="325" width="87" height="20" font="0">Women ≥ 65 y  </text>
<text top="382" left="325" width="182" height="20" font="0">with one of the following CV Risk </text>
<text top="399" left="325" width="47" height="20" font="0">factors:  </text>
<text top="416" left="325" width="117" height="20" font="0">-Elev. waist/hip ratio, </text>
<text top="433" left="325" width="129" height="20" font="0">-History of low HDL-C;  </text>
<text top="451" left="325" width="170" height="20" font="0">-Current or recent tobacco use </text>
<text top="468" left="325" width="81" height="20" font="0">-Dysglycemia, </text>
<text top="485" left="325" width="173" height="20" font="0">-Family Hx premature coronary </text>
<text top="502" left="325" width="53" height="20" font="0">disease,  </text>
<text top="520" left="325" width="184" height="20" font="0">-Mild renal dysfunction Women ≥ </text>
<text top="537" left="325" width="198" height="20" font="0">60 with 2 or more such risk factors.  </text>
<text top="554" left="325" width="116" height="20" font="7"><b>Exclusion Criteria:</b>  </text>
<text top="571" left="325" width="173" height="20" font="0">•Cardiovascular disease (CVD) </text>
<text top="588" left="325" width="191" height="20" font="0">• Indication for CVD drugs such as </text>
<text top="606" left="325" width="158" height="20" font="0">statins, angiotensin-receptor </text>
<text top="623" left="325" width="183" height="20" font="0">blockers, angiotensin-converting–</text>
<text top="640" left="325" width="163" height="20" font="0">enzyme inhibitors, or thiazide </text>
<text top="657" left="325" width="53" height="20" font="0">diuretics  </text>
<text top="674" left="325" width="3" height="20" font="0"> </text>
<text top="692" left="325" width="10" height="20" font="0">   </text>
<text top="330" left="535" width="81" height="20" font="7"><b>Intervention:</b>  </text>
<text top="347" left="535" width="101" height="20" font="0">G1: Rosuvastatin  </text>
<text top="365" left="535" width="87" height="20" font="0">10 mg/d (6361) </text>
<text top="382" left="535" width="182" height="20" font="0">G2: Comparator: Placebo (6364) </text>
<text top="399" left="535" width="112" height="20" font="0">46.4% Female in GI </text>
<text top="416" left="535" width="116" height="20" font="0">46.1% Female in G2 </text>
<text top="433" left="535" width="134" height="20" font="0">Definitions of Outcomes </text>
<text top="451" left="535" width="147" height="20" font="0">-First co-primary outcome  </text>
<text top="468" left="535" width="96" height="20" font="0">or “hard ASCVD” </text>
<text top="485" left="535" width="168" height="20" font="0">-Second co-primary outcome:  </text>
<text top="502" left="535" width="120" height="20" font="0">-Secondary outcome  </text>
<text top="519" left="535" width="185" height="20" font="0">First primary outcome: composite </text>
<text top="537" left="535" width="151" height="20" font="0">of death from CVD causes, </text>
<text top="554" left="535" width="173" height="20" font="0">nonfatal MI, or nonfatal stroke,  </text>
<text top="571" left="535" width="143" height="20" font="0">Second primary outcome: </text>
<text top="588" left="535" width="180" height="20" font="0">included revascularization, heart </text>
<text top="606" left="535" width="177" height="20" font="0">failure, and resuscitated cardiac </text>
<text top="623" left="535" width="42" height="20" font="0">arrest.  </text>
<text top="640" left="535" width="158" height="20" font="0">Secondary outcome –Above </text>
<text top="657" left="535" width="181" height="20" font="0">second co-primary outcome plus </text>
<text top="675" left="535" width="187" height="20" font="0">angina with evidence of ischemia  </text>
<text top="692" left="535" width="3" height="20" font="0"> </text>
<text top="709" left="535" width="7" height="20" font="0">  </text>
<text top="330" left="738" width="141" height="20" font="7"><b>Frist primary outcome:  </b></text>
<text top="347" left="738" width="55" height="20" font="0">G1: 3.7% </text>
<text top="365" left="738" width="58" height="20" font="0">G2: 4.8%  </text>
<text top="382" left="738" width="135" height="20" font="0">0.76 (0.64-0.91) p 0.002 </text>
<text top="399" left="738" width="155" height="20" font="7"><b>Second primary outcome: </b></text>
<text top="416" left="738" width="55" height="20" font="0">G1: 4.4% </text>
<text top="433" left="738" width="55" height="20" font="0">G2: 5.7% </text>
<text top="451" left="738" width="143" height="20" font="0">0.75 (0.66-0.88); p&lt;0.001 </text>
<text top="468" left="738" width="3" height="20" font="0"> </text>
<text top="485" left="738" width="120" height="20" font="0">LDL-C Changes with  </text>
<text top="502" left="738" width="114" height="20" font="0">G1 lower than G2 at </text>
<text top="519" left="738" width="121" height="20" font="0">1-y 39.6 mg/dL (1.02) </text>
<text top="537" left="738" width="120" height="20" font="0">3 y: 34.7 mg/dl ((0.90 </text>
<text top="554" left="738" width="100" height="20" font="0">Overall mean diff: </text>
<text top="571" left="738" width="137" height="20" font="0">34.6 mg/dl [0.90) 26.5%; </text>
<text top="588" left="738" width="52" height="20" font="0">p&lt;0.001) </text>
<text top="606" left="738" width="3" height="20" font="0"> </text>
<text top="623" left="738" width="159" height="20" font="0">ASCVD Risk Placebo Group </text>
<text top="640" left="738" width="32" height="20" font="0">(%/y) </text>
<text top="657" left="738" width="133" height="20" font="0">First primary outcome = </text>
<text top="675" left="738" width="89" height="20" font="0">4.8%/5.6 y =8.6 </text>
<text top="692" left="738" width="151" height="20" font="0">Second primary outcome = </text>
<text top="709" left="738" width="96" height="20" font="0">5.7%/5.6 y =10.1 </text>
<text top="726" left="738" width="3" height="20" font="0"> </text>
<text top="743" left="738" width="3" height="20" font="0"> </text>
<text top="330" left="911" width="129" height="20" font="7"><b>Secondary outcome:  </b></text>
<text top="347" left="911" width="55" height="20" font="0">G1: 4.8% </text>
<text top="365" left="911" width="55" height="20" font="0">G2: 6.2% </text>
<text top="382" left="911" width="149" height="20" font="0">0.77 (0.66-0.89); p&lt; 0.001  </text>
<text top="399" left="911" width="171" height="20" font="0">Hospitalized for cardiovascular </text>
<text top="416" left="911" width="46" height="20" font="0">causes  </text>
<text top="433" left="911" width="89" height="20" font="0">G1: 281 [4.4%]  </text>
<text top="451" left="911" width="145" height="20" font="0">G2: 369 [5.8%], p&lt;0.001)  </text>
<text top="468" left="911" width="119" height="20" font="0">Total number of CVD </text>
<text top="485" left="911" width="91" height="20" font="0">hospitalizations  </text>
<text top="502" left="911" width="51" height="20" font="0">G1: 444  </text>
<text top="520" left="911" width="47" height="20" font="0">G2: 596 </text>
<text top="537" left="911" width="187" height="20" font="7"><b>Study limitations:</b> Short duration </text>
<text top="554" left="911" width="140" height="20" font="0">of treatment and time to 1</text>
<text top="556" left="1052" width="6" height="13" font="9">st</text>
<text top="554" left="1058" width="37" height="20" font="0"> event </text>
<text top="571" left="911" width="148" height="20" font="0">may underestimate events </text>
<text top="588" left="911" width="167" height="20" font="0">Despite decreased adherence </text>
<text top="606" left="911" width="180" height="20" font="0">with time, the reduction of risk of </text>
<text top="623" left="911" width="138" height="20" font="0">CVD increased with time </text>
<text top="640" left="911" width="94" height="20" font="7"><b>Adverse events </b></text>
<text top="657" left="911" width="145" height="20" font="0">Muscle pain or weakness  </text>
<text top="674" left="911" width="90" height="20" font="0">G1 (367 [5.8%]  </text>
<text top="692" left="911" width="145" height="20" font="0">G2: 296 [4.7%], p=0.005)  </text>
<text top="709" left="911" width="105" height="20" font="0">Muscle symptoms  </text>
<text top="726" left="911" width="83" height="20" font="0">G1 (83 [1.3%]  </text>
<text top="743" left="911" width="124" height="20" font="0">G2 76 [1.2%] p=0.63)  </text>
<text top="760" left="911" width="98" height="20" font="0">Cataract surgery  </text>
<text top="778" left="911" width="187" height="20" font="0">G1 241 [3.8%] vs. G2 194 [3.1%]; </text>
</page>
<page number="102" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">102 </text>
<text top="108" left="911" width="45" height="20" font="0">p=0.02  </text>
<text top="125" left="911" width="137" height="20" font="0">Deep-vein thrombosis or </text>
<text top="142" left="911" width="120" height="20" font="0">pulmonary embolism  </text>
<text top="159" left="911" width="180" height="20" font="0">G1 14 vs. G2 31; HR: 0.45; 95% </text>
<text top="177" left="911" width="139" height="20" font="0">CI: 0.24 to 0.84; p=0.01.  </text>
<text top="194" left="911" width="78" height="20" font="0">No excess of: </text>
<text top="211" left="911" width="131" height="20" font="0">DM: G1: 3.9% vs. 3.8% </text>
<text top="228" left="911" width="172" height="20" font="0">Rhabdomyolysis or myopathy;  </text>
<text top="246" left="911" width="112" height="20" font="0">G1 2 vs. G2: 1 case </text>
<text top="263" left="911" width="46" height="20" font="0">Cancer  </text>
<text top="280" left="911" width="110" height="20" font="0">G1 267 vs. G2 286  </text>
<text top="299" left="90" width="54" height="20" font="7"><b>AFCAPS-</b></text>
<text top="316" left="90" width="65" height="20" font="7"><b>TEXCAPS  </b></text>
<text top="333" left="90" width="96" height="20" font="0">Downs JR, et al., </text>
<text top="350" left="90" width="63" height="20" font="0">1998 <a href="data supplement.html#242">(102)</a> </text>
<text top="368" left="90" width="48" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9613910">9613910</a></text>
<text top="368" left="138" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9613910"> </a></text>
<text top="385" left="90" width="3" height="20" font="0"> </text>
<text top="299" left="203" width="95" height="20" font="0">Does lowering of </text>
<text top="316" left="203" width="103" height="20" font="0">LDL-C with statins </text>
<text top="333" left="203" width="71" height="20" font="0">benefit men, </text>
<text top="350" left="203" width="86" height="20" font="0">women, elderly </text>
<text top="368" left="203" width="86" height="20" font="0">with normal TC </text>
<text top="385" left="203" width="42" height="20" font="0">levels.  </text>
<text top="402" left="203" width="3" height="20" font="0"> </text>
<text top="419" left="203" width="103" height="20" font="7"><b>Study Type:</b> RCT </text>
<text top="436" left="203" width="98" height="20" font="0">6805 Participants </text>
<text top="454" left="203" width="89" height="20" font="0">Size: 5608 men </text>
<text top="471" left="203" width="94" height="20" font="0">and 997 women. </text>
<text top="488" left="203" width="7" height="20" font="0">  </text>
<text top="505" left="203" width="92" height="20" font="7"><b>Duration:</b> 5.2 y  </text>
<text top="522" left="203" width="110" height="20" font="0">Included Hispanics, </text>
<text top="540" left="203" width="81" height="20" font="0">African Ameri- </text>
<text top="557" left="203" width="87" height="20" font="0">cans, and older </text>
<text top="574" left="203" width="100" height="20" font="0">persons (baseline </text>
<text top="591" left="203" width="102" height="20" font="0">mean age, 58.2 y; </text>
<text top="608" left="203" width="94" height="20" font="0">upper limit, 73 y; </text>
<text top="626" left="203" width="103" height="20" font="0">21% older than 65 </text>
<text top="643" left="203" width="17" height="20" font="0">y). </text>
<text top="660" left="203" width="3" height="20" font="0"> </text>
<text top="677" left="203" width="3" height="20" font="0"> </text>
<text top="694" left="203" width="3" height="20" font="0"> </text>
<text top="712" left="203" width="3" height="20" font="0"> </text>
<text top="299" left="325" width="111" height="20" font="7"><b>Inclusion Criteria:  </b></text>
<text top="316" left="325" width="109" height="20" font="0">Men aged 45-73 y;  </text>
<text top="333" left="325" width="190" height="20" font="0">Postmenopausal Women aged 55-</text>
<text top="350" left="325" width="173" height="20" font="0">73 y; Men: 85%; Women 15%.  </text>
<text top="368" left="325" width="3" height="20" font="0"> </text>
<text top="385" left="325" width="185" height="20" font="7"><b>Exclusion Criteria:</b> Uncontrolled </text>
<text top="402" left="325" width="137" height="20" font="0">hypertension, secondary </text>
<text top="419" left="325" width="174" height="20" font="0">hyperlipidemia, type 1 or type 2 </text>
<text top="436" left="325" width="175" height="20" font="0">diabetes mellitus managed with </text>
<text top="454" left="325" width="195" height="20" font="0">insulin, a glycol-hemoglobin level ≥ </text>
<text top="471" left="325" width="154" height="20" font="0">10%, or body weight ≥ 50% </text>
<text top="488" left="325" width="187" height="20" font="0">greater than the desirable limit for </text>
<text top="505" left="325" width="40" height="20" font="0">height. </text>
<text top="522" left="325" width="3" height="20" font="0"> </text>
<text top="540" left="325" width="111" height="20" font="7"><b>Lipid entry criteria</b> </text>
<text top="557" left="325" width="146" height="20" font="0">TC 180-264; (4.65 - 6.82)  </text>
<text top="574" left="325" width="161" height="20" font="0">LDL-C, 130-190 (3.36- 4.91)  </text>
<text top="591" left="325" width="172" height="20" font="0">HDL-C: men: &lt;45 mg/dl (1.16)  </text>
<text top="608" left="325" width="188" height="20" font="0">HDL-C:  women &lt;47 mg/dl (1.22)  </text>
<text top="626" left="325" width="196" height="20" font="0">TG&lt;400 mg/dl; (4.52) at both 4 and </text>
<text top="643" left="325" width="176" height="20" font="0">2 wk before randomization, with </text>
<text top="660" left="325" width="187" height="20" font="0">&lt;15% change in LDL-C values. In </text>
<text top="677" left="325" width="148" height="20" font="0">addition, those with LDL-C </text>
<text top="694" left="325" width="187" height="20" font="0">between 125-129 mg/dl (3.23 and </text>
<text top="712" left="325" width="182" height="20" font="0">3.34) were included if the ratio of </text>
<text top="729" left="325" width="109" height="20" font="0">TC to HDL-C &gt; 6.0. </text>
<text top="299" left="535" width="162" height="20" font="0">G1: Lovastatin 20 or 40 mg/d </text>
<text top="316" left="535" width="50" height="20" font="0">N=3304  </text>
<text top="333" left="535" width="121" height="20" font="0">G2: Placebo N=3301  </text>
<text top="350" left="535" width="3" height="20" font="0"> </text>
<text top="368" left="535" width="143" height="20" font="7"><b>Definition of Outcomes: </b></text>
<text top="385" left="535" width="187" height="20" font="0">Primary outcome (PO) First acute </text>
<text top="402" left="535" width="179" height="20" font="0">major coronary event defined as </text>
<text top="419" left="535" width="151" height="20" font="0">fatal or nonfatal myocardial </text>
<text top="436" left="535" width="165" height="20" font="0">infarction, unstable angina, or </text>
<text top="454" left="535" width="128" height="20" font="0">sudden cardiac death.  </text>
<text top="471" left="535" width="111" height="20" font="0">AFCAPS found that </text>
<text top="488" left="535" width="165" height="20" font="0">approximately equal numbers </text>
<text top="505" left="535" width="174" height="20" font="0">present with unstable angina or </text>
<text top="522" left="535" width="21" height="20" font="0">MI. </text>
<text top="540" left="535" width="3" height="20" font="0"> </text>
<text top="557" left="535" width="3" height="20" font="0"> </text>
<text top="574" left="535" width="3" height="20" font="0"> </text>
<text top="591" left="535" width="3" height="20" font="0"> </text>
<text top="608" left="535" width="3" height="20" font="0"> </text>
<text top="299" left="738" width="109" height="20" font="7"><b>Primary Outcome</b>  </text>
<text top="316" left="738" width="109" height="20" font="0">G1 116/3301; 3.5% </text>
<text top="333" left="738" width="113" height="20" font="0">G2: 183/3304; 5.5% </text>
<text top="350" left="738" width="146" height="20" font="0">0.63; (0.50-0.70) p&lt;0.001  </text>
<text top="368" left="738" width="138" height="20" font="0">Rates per 1000 patient y </text>
<text top="385" left="738" width="128" height="20" font="0">G1 6.8% vs. G2 10.9% </text>
<text top="402" left="738" width="3" height="20" font="0"> </text>
<text top="419" left="738" width="159" height="20" font="0">The differences between the </text>
<text top="436" left="738" width="107" height="20" font="0">2 treatment groups </text>
<text top="454" left="738" width="159" height="20" font="0">appeared as early as 1 y (40 </text>
<text top="471" left="738" width="154" height="20" font="0">w/events in G2 vs.23 in G1  </text>
<text top="488" left="738" width="144" height="20" font="0">For the primary end point, </text>
<text top="505" left="738" width="143" height="20" font="0">these rates correspond to </text>
<text top="522" left="738" width="137" height="20" font="0">cumulative incidences of </text>
<text top="540" left="738" width="125" height="20" font="0">4.0% and 6.8% for the </text>
<text top="557" left="738" width="126" height="20" font="0">lovastatin and placebo </text>
<text top="574" left="738" width="154" height="20" font="0">groups, respectively, during </text>
<text top="591" left="738" width="150" height="20" font="0">the study period (p 0.001).  </text>
<text top="608" left="738" width="89" height="20" font="0">LDL-C changes </text>
<text top="626" left="738" width="159" height="20" font="0">G1: LDL-C 151 (3.89) (lower </text>
<text top="643" left="738" width="130" height="20" font="0">by 25% reduced to 115 </text>
<text top="660" left="738" width="36" height="20" font="0">(2.96) </text>
<text top="677" left="738" width="3" height="20" font="0"> </text>
<text top="299" left="911" width="176" height="20" font="0">Primary end point risk reduction </text>
<text top="316" left="911" width="158" height="20" font="0">with lovastatin was apparent </text>
<text top="333" left="911" width="187" height="20" font="0">across all baseline LDL-C tertiles  </text>
<text top="350" left="911" width="150" height="20" font="0">with no threshold to benefit </text>
<text top="368" left="911" width="182" height="20" font="0">observed across baseline LDL-C </text>
<text top="385" left="911" width="170" height="20" font="0">levels LDL-C ≤142 (3.67); 143-</text>
<text top="402" left="911" width="163" height="20" font="0">156 (3.67-4.05) ≥157 (&gt;4.05) </text>
<text top="419" left="911" width="179" height="20" font="0">There were no clinically relevant </text>
<text top="436" left="911" width="178" height="20" font="0">differences in safety parameters </text>
<text top="454" left="911" width="153" height="20" font="0">between treatment groups.  </text>
<text top="471" left="911" width="3" height="20" font="0"> </text>
<text top="488" left="911" width="176" height="20" font="7"><b>Study Limitations</b>: Inclusion of </text>
<text top="505" left="911" width="168" height="20" font="0">unstable angina in the primary </text>
<text top="522" left="911" width="167" height="20" font="0">endpoint; but in this trial equal </text>
<text top="540" left="911" width="185" height="20" font="0">numbers presented with unstable </text>
<text top="557" left="911" width="127" height="20" font="0">angina or non-fatal MI. </text>
<text top="574" left="911" width="133" height="20" font="0">New Onset of Diabetes  </text>
<text top="591" left="911" width="40" height="20" font="0">G1: 74 </text>
<text top="608" left="911" width="40" height="20" font="0">G2: 72 </text>
<text top="626" left="911" width="3" height="20" font="0"> </text>
</page>
<page number="103" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">103 </text>
<text top="108" left="90" width="89" height="20" font="0">Nakamura H, et </text>
<text top="125" left="90" width="83" height="20" font="0">al., 2006 <a href="data supplement.html#242">(103)</a> </text>
<text top="142" left="90" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17011942">17011942</a></text>
<text top="142" left="145" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17011942"> </a></text>
<text top="108" left="203" width="93" height="20" font="0">Effect of primary </text>
<text top="125" left="203" width="86" height="20" font="0">prevention with </text>
<text top="142" left="203" width="86" height="20" font="0">statin in clinical </text>
<text top="159" left="203" width="96" height="20" font="0">practice in Japan </text>
<text top="177" left="203" width="73" height="20" font="7"><b>Study Type</b>: </text>
<text top="194" left="203" width="71" height="20" font="0">Prospective, </text>
<text top="211" left="203" width="103" height="20" font="0">randomized, open-</text>
<text top="228" left="203" width="76" height="20" font="0">label, blinded </text>
<text top="246" left="203" width="83" height="20" font="0">endpoint study </text>
<text top="263" left="203" width="87" height="20" font="7"><b>Duration</b>: 5.3 y </text>
<text top="280" left="203" width="3" height="20" font="0"> </text>
<text top="108" left="325" width="108" height="20" font="7"><b>Inclusion Criteria: </b></text>
<text top="125" left="325" width="169" height="20" font="0">Men, Postmenopausal women </text>
<text top="142" left="325" width="77" height="20" font="0">AGE: 40-70 y </text>
<text top="159" left="325" width="67" height="20" font="0">Men: (31%) </text>
<text top="177" left="325" width="85" height="20" font="0">Women: (69%) </text>
<text top="194" left="325" width="95" height="20" font="0">Body wt &gt;40 kg;  </text>
<text top="211" left="325" width="187" height="20" font="0">Total cholesterol levels measured </text>
<text top="228" left="325" width="188" height="20" font="0">on 2 or 3 occasions during ≥ 4 wk </text>
<text top="246" left="325" width="178" height="20" font="0">washout period on a low fat, low </text>
<text top="263" left="325" width="90" height="20" font="0">cholesterol diet  </text>
<text top="280" left="325" width="191" height="20" font="0">Baseline cholesterol level required </text>
<text top="297" left="325" width="113" height="20" font="0">to be 220-270 mg/dl </text>
<text top="314" left="325" width="57" height="20" font="0">(5.7-6.96) </text>
<text top="332" left="325" width="3" height="20" font="0"> </text>
<text top="349" left="325" width="144" height="20" font="7"><b>Major exclusion criteria</b>  </text>
<text top="366" left="325" width="135" height="20" font="0">those with familial hyper-</text>
<text top="383" left="325" width="153" height="20" font="0">cholesterolaemia; history of </text>
<text top="400" left="325" width="183" height="20" font="0">coronary heart disease or stroke; </text>
<text top="418" left="325" width="143" height="20" font="0">diagnosis of congenital or </text>
<text top="435" left="325" width="181" height="20" font="0">rheumatic heart disease; chronic </text>
<text top="452" left="325" width="186" height="20" font="0">atrial fibrillation; current diagnosis </text>
<text top="469" left="325" width="196" height="20" font="0">of malignancy; severe liver (chronic </text>
<text top="487" left="325" width="176" height="20" font="0">active hepatitis and cirrhosis) or </text>
<text top="504" left="325" width="148" height="20" font="0">renal (creatinine ≥4 mg/dl) </text>
<text top="521" left="325" width="143" height="20" font="0">disease; poorly controlled </text>
<text top="538" left="325" width="187" height="20" font="0">hypertension or diabetes mellitus; </text>
<text top="555" left="325" width="188" height="20" font="0">secondary hyperlipidemia; current </text>
<text top="573" left="325" width="134" height="20" font="0">use of oral or parenteral </text>
<text top="590" left="325" width="90" height="20" font="0">corticosteroids.  </text>
<text top="108" left="535" width="154" height="20" font="0">G1 Diet + pravastatin (3866 </text>
<text top="125" left="535" width="182" height="20" font="0">participants) Initial 10 mg/d or 20 </text>
<text top="142" left="535" width="114" height="20" font="0">mg if TC &gt;221 mg/dl </text>
<text top="159" left="535" width="3" height="20" font="0"> </text>
<text top="177" left="535" width="154" height="20" font="0">G2: Diet (3966 participants) </text>
<text top="194" left="535" width="3" height="20" font="0"> </text>
<text top="211" left="535" width="177" height="20" font="7"><b>Primary composite endpoint: </b> </text>
<text top="228" left="535" width="188" height="20" font="0">First occurrence of coronary heart </text>
<text top="245" left="535" width="184" height="20" font="0">disease, which included fatal and </text>
<text top="263" left="535" width="171" height="20" font="0">non-fatal myocardial infarction, </text>
<text top="280" left="535" width="154" height="20" font="0">angina, cardiac and sudden </text>
<text top="297" left="535" width="123" height="20" font="0">death, and a coronary </text>
<text top="314" left="535" width="158" height="20" font="0">revascularization procedure. </text>
<text top="332" left="535" width="168" height="20" font="0">Secondary endpoints included </text>
<text top="349" left="535" width="169" height="20" font="0">stroke, coronary heart disease </text>
<text top="366" left="535" width="146" height="20" font="0">plus cerebral infarction, all </text>
<text top="383" left="535" width="176" height="20" font="0">cardiovascular events, and total </text>
<text top="401" left="535" width="57" height="20" font="0">mortality.  </text>
<text top="418" left="535" width="3" height="20" font="0"> </text>
<text top="108" left="738" width="131" height="20" font="0">Coronary heart disease </text>
<text top="125" left="738" width="130" height="20" font="0">(CHD) was significantly </text>
<text top="142" left="738" width="146" height="20" font="0">lower in G1 than in the G2 </text>
<text top="159" left="738" width="48" height="20" font="0">groups.  </text>
<text top="177" left="738" width="77" height="20" font="0">G1 66 events </text>
<text top="194" left="738" width="83" height="20" font="0">G2 101 events </text>
<text top="211" left="738" width="134" height="20" font="0">HR: 0·67; 95% CI: 0·49–</text>
<text top="228" left="738" width="84" height="20" font="0">0·91; p=0·01).  </text>
<text top="246" left="738" width="3" height="20" font="0"> </text>
<text top="263" left="738" width="67" height="20" font="7"><b>Adherence</b> </text>
<text top="280" left="738" width="51" height="20" font="0">1 y: 95% </text>
<text top="297" left="738" width="48" height="20" font="0">5 y 90% </text>
<text top="314" left="738" width="55" height="20" font="0">9 y: 89%  </text>
<text top="332" left="738" width="141" height="20" font="0">Mean dose of pravastatin </text>
<text top="349" left="738" width="74" height="20" font="0">was 8·3 mg.  </text>
<text top="366" left="738" width="140" height="20" font="0">Mean LDL-C reductions:  </text>
<text top="383" left="738" width="148" height="20" font="0">G1: 18%; 157 to 128 (4.05-</text>
<text top="400" left="738" width="35" height="20" font="0">3.31)  </text>
<text top="418" left="738" width="152" height="20" font="0">G2: 3.2%; 157 to 151 (4.05-</text>
<text top="435" left="738" width="28" height="20" font="0">3.9). </text>
<text top="108" left="911" width="136" height="20" font="7"><b>Secondary end-points  </b></text>
<text top="125" left="911" width="165" height="20" font="0">Included: stroke and transient </text>
<text top="142" left="911" width="189" height="20" font="0">ischemic attack, all cardiovascular </text>
<text top="159" left="911" width="147" height="20" font="0">events and total mortality.  </text>
<text top="177" left="911" width="39" height="20" font="0">Stroke </text>
<text top="194" left="911" width="158" height="20" font="0">HR: 0.83; 95% CI: 0.57-121; </text>
<text top="211" left="911" width="41" height="20" font="0">p=0.33 </text>
<text top="228" left="911" width="3" height="20" font="0"> </text>
<text top="246" left="911" width="141" height="20" font="0">Incidence CHD +cerebral </text>
<text top="263" left="911" width="53" height="20" font="0">infarction </text>
<text top="280" left="911" width="163" height="20" font="0">HR: 0.70; 95%CI: (0.54-0.90) </text>
<text top="297" left="911" width="91" height="20" font="0">p=0.05; NNT 91 </text>
<text top="314" left="911" width="81" height="20" font="0">Total mortality </text>
<text top="332" left="911" width="165" height="20" font="0">HR: 0.72; 95% CI: (0.72; 0.51-</text>
<text top="349" left="911" width="83" height="20" font="0">1.01; p=0.055) </text>
<text top="366" left="911" width="3" height="20" font="0"> </text>
<text top="383" left="911" width="169" height="20" font="7"><b>Study limitations</b>: Open label </text>
<text top="400" left="911" width="152" height="20" font="0">No significant safety issues </text>
<text top="418" left="911" width="185" height="20" font="0">No significant difference between </text>
<text top="435" left="911" width="187" height="20" font="0">the two groups in the incidence or </text>
<text top="452" left="911" width="182" height="20" font="0">primary site of malignancy, or for </text>
<text top="469" left="911" width="183" height="20" font="0">the site of malignant neoplasms.  </text>
<text top="608" left="90" width="59" height="20" font="7"><b>JUPITER  </b></text>
<text top="626" left="90" width="98" height="20" font="0">Ridker PM, et al., </text>
<text top="643" left="90" width="56" height="20" font="0">2008 <a href="data supplement.html#236">(11)</a> </text>
<text top="660" left="90" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18997196">18997196</a></text>
<text top="660" left="145" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18997196"> </a></text>
<text top="677" left="90" width="3" height="20" font="0"> </text>
<text top="608" left="203" width="104" height="20" font="0">Would people with </text>
<text top="626" left="203" width="77" height="20" font="0">elevated high-</text>
<text top="643" left="203" width="70" height="20" font="0">sensitivity C-</text>
<text top="660" left="203" width="87" height="20" font="0">reactive protein </text>
<text top="677" left="203" width="98" height="20" font="0">levels but without </text>
<text top="694" left="203" width="83" height="20" font="0">hyperlipidemia </text>
<text top="712" left="203" width="83" height="20" font="0">(LDL-C ≥ 130) </text>
<text top="729" left="203" width="101" height="20" font="0">benefit from statin </text>
<text top="746" left="203" width="62" height="20" font="0">treatment.  </text>
<text top="763" left="203" width="106" height="20" font="7"><b>Study Type:</b> RCT  </text>
<text top="781" left="203" width="3" height="20" font="0"> </text>
<text top="608" left="325" width="111" height="20" font="7"><b>Inclusion Criteria:</b>  </text>
<text top="626" left="325" width="56" height="20" font="0">Men ≥ 50 </text>
<text top="643" left="325" width="71" height="20" font="0">Women ≥60 </text>
<text top="660" left="325" width="178" height="20" font="0">with no history of cardiovascular </text>
<text top="677" left="325" width="196" height="20" font="0">disease and at initial screening visit </text>
<text top="694" left="325" width="180" height="20" font="0">LDL-C &lt;130 mg/dl (3.4 mm) and </text>
<text top="712" left="325" width="92" height="20" font="0">CRP ≥ 2.0 mg/L </text>
<text top="729" left="325" width="66" height="20" font="0">Men ≥ 50 y </text>
<text top="746" left="325" width="7" height="20" font="0">  </text>
<text top="763" left="325" width="106" height="20" font="7"><b>Exclusion criteria </b></text>
<text top="781" left="325" width="195" height="20" font="0">Those with  previous or current use </text>
<text top="608" left="535" width="172" height="20" font="0">G1: rosuvastatin 20 mg/d (high </text>
<text top="626" left="535" width="56" height="20" font="0">intensity)  </text>
<text top="643" left="535" width="121" height="20" font="0">G2: Placebo N=8901  </text>
<text top="660" left="535" width="85" height="20" font="0">37.9% women  </text>
<text top="677" left="535" width="131" height="20" font="0">Definition of Outcomes  </text>
<text top="694" left="535" width="188" height="20" font="7"><b>Primary Outcome:</b> occurrence of </text>
<text top="712" left="535" width="189" height="20" font="0">the combined primary end point of </text>
<text top="729" left="535" width="102" height="20" font="0">MI, stroke, arterial </text>
<text top="746" left="535" width="180" height="20" font="0">revascularization, hospitalization </text>
<text top="763" left="535" width="188" height="20" font="0">for unstable angina, or death from </text>
<text top="781" left="535" width="69" height="20" font="0">CVD cause  </text>
<text top="608" left="738" width="95" height="20" font="0">LDL-C At 12 mo  </text>
<text top="626" left="738" width="98" height="20" font="0">G1; LDL-C -50%  </text>
<text top="643" left="738" width="3" height="20" font="0"> </text>
<text top="660" left="738" width="131" height="20" font="7"><b>Primary outcome:</b> G1: </text>
<text top="677" left="738" width="127" height="20" font="0">0.77, G2: 1.36 per 100 </text>
<text top="694" left="738" width="146" height="20" font="0">person-y of follow-up (HR: </text>
<text top="712" left="738" width="137" height="20" font="0">0.56; 95% CI: 0.46-0.69; </text>
<text top="729" left="738" width="73" height="20" font="0">p&lt;0.00001),  </text>
<text top="746" left="738" width="3" height="20" font="0"> </text>
<text top="763" left="738" width="60" height="20" font="0">Hard CHD </text>
<text top="781" left="738" width="113" height="20" font="0">G1: 108/8901; 1.2% </text>
<text top="612" left="911" width="127" height="20" font="0">Death from any cause  </text>
<text top="633" left="911" width="101" height="20" font="0">G1 1.00; G2 1.25  </text>
<text top="654" left="911" width="178" height="20" font="0">(HR: 0.80; 95% CI: 0.67 to 0.97; </text>
<text top="675" left="911" width="52" height="20" font="0">p=0.02).  </text>
<text top="692" left="911" width="3" height="20" font="0"> </text>
<text top="713" left="911" width="114" height="20" font="7"><b>Study Limitations:</b>  </text>
<text top="734" left="911" width="159" height="20" font="0">Independent data and safety </text>
<text top="755" left="911" width="189" height="20" font="0">monitoring<b> </b>committee stopped the </text>
<text top="776" left="911" width="178" height="20" font="0">Trial early (median follow-up 1.9 </text>
</page>
<page number="104" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">104 </text>
<text top="718" left="81" width="5" height="16" font="15"> </text>
<text top="732" left="81" width="751" height="24" font="4"><b>Data Supplement 17. Evidence Tables Monitoring in Response to LDL-C–Lowering Therapy (Section 4.4.3)  </b></text>
<text top="754" left="121" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="771" left="147" width="48" height="20" font="7"><b>Author; </b></text>
<text top="788" left="124" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="762" left="280" width="118" height="20" font="7"><b>Study Type/Design; </b></text>
<text top="780" left="306" width="66" height="20" font="7"><b>Study Size </b></text>
<text top="764" left="458" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="762" left="617" width="237" height="20" font="7"><b>Primary Endpoint and Results(P values; </b></text>
<text top="780" left="674" width="123" height="20" font="7"><b>OR or RR; &amp; 95% CI) </b></text>
<text top="762" left="930" width="130" height="20" font="7"><b>Summary/Conclusion </b></text>
<text top="780" left="957" width="75" height="20" font="7"><b>Comment(s) </b></text>
<text top="108" left="203" width="66" height="20" font="7"><b>Study Size</b> </text>
<text top="125" left="203" width="108" height="20" font="7"><b>Participants</b>:1782  </text>
<text top="142" left="203" width="3" height="20" font="0"> </text>
<text top="159" left="203" width="101" height="20" font="7"><b>Duration</b>: median </text>
<text top="177" left="203" width="96" height="20" font="0">follow-up of 1.9 y </text>
<text top="194" left="203" width="96" height="20" font="0">(maximum, 5.0).  </text>
<text top="108" left="325" width="178" height="20" font="0">of lipid-lowering therapy, current </text>
<text top="125" left="325" width="191" height="20" font="0">use of post- menopausal hormone-</text>
<text top="142" left="325" width="185" height="20" font="0">replacement therapy, evidence of </text>
<text top="159" left="325" width="173" height="20" font="0">hepatic dysfunction (an alanine </text>
<text top="177" left="325" width="193" height="20" font="0">amino transferase level &gt; twice the </text>
<text top="194" left="325" width="168" height="20" font="0">upper limit of normal range), a </text>
<text top="211" left="325" width="190" height="20" font="0">creatine kinase level &gt; three times </text>
<text top="228" left="325" width="194" height="20" font="0">the upper limit of the normal range, </text>
<text top="246" left="325" width="193" height="20" font="0">a creatinine level &gt; 2.0 mg/deciliter </text>
<text top="263" left="325" width="152" height="20" font="0">(176.8 μmol/liter), diabetes, </text>
<text top="280" left="325" width="192" height="20" font="0">uncontrolled hypertension (systolic </text>
<text top="297" left="325" width="173" height="20" font="0">blood pressure &gt;190 mm Hg or </text>
<text top="314" left="325" width="188" height="20" font="0">diastolic blood pressure &gt;100 mm </text>
<text top="332" left="325" width="184" height="20" font="0">Hg), cancer within 5 years before </text>
<text top="349" left="325" width="180" height="20" font="0">enrollment (with the exception of </text>
<text top="366" left="325" width="152" height="20" font="0">basal-cell or squamous-cell </text>
<text top="383" left="325" width="127" height="20" font="0">carcinoma of the skin), </text>
<text top="401" left="325" width="171" height="20" font="0">uncontrolled hypothyroidism (a </text>
<text top="418" left="325" width="184" height="20" font="0">thyroid-stimulating hormone level </text>
<text top="435" left="325" width="175" height="20" font="0">&gt;1.5 times the upper limit of the </text>
<text top="452" left="325" width="195" height="20" font="0">normal range), and a recent history </text>
<text top="469" left="325" width="195" height="20" font="0">of alcohol or drug abuse or another </text>
<text top="487" left="325" width="156" height="20" font="0">medical condition that might </text>
<text top="504" left="325" width="141" height="20" font="0">compromise safety or the </text>
<text top="521" left="325" width="158" height="20" font="0">successful completion of the </text>
<text top="538" left="325" width="183" height="20" font="0">study.  Also excluded were those </text>
<text top="555" left="325" width="187" height="20" font="0">with inflammatory conditions such </text>
<text top="573" left="325" width="154" height="20" font="0">as severe arthritis, lupus, or </text>
<text top="590" left="325" width="179" height="20" font="0">inflammatory bowel disease and </text>
<text top="607" left="325" width="184" height="20" font="0">those taking immunosuppressant </text>
<text top="624" left="325" width="161" height="20" font="0">agents such as cyclosporine, </text>
<text top="641" left="325" width="182" height="20" font="0">tacrolimus, azathioprine, or long- </text>
<text top="659" left="325" width="140" height="20" font="0">term oral glucocorticoids. </text>
<text top="676" left="325" width="3" height="20" font="0"> </text>
<text top="693" left="325" width="3" height="20" font="0"> </text>
<text top="108" left="738" width="116" height="20" font="0">G2:  189/8901; 2.1% </text>
<text top="125" left="738" width="137" height="20" font="0">HR: 0.57; 95% CI: [0.45, </text>
<text top="142" left="738" width="34" height="20" font="0">0.72]  </text>
<text top="159" left="738" width="3" height="20" font="0"> </text>
<text top="177" left="738" width="79" height="20" font="0">MI: G1 vs. G2 </text>
<text top="194" left="738" width="79" height="20" font="0">0.17 and 0.37 </text>
<text top="211" left="738" width="148" height="20" font="0">(HR: 0.46; 95% CI: 0.30 to </text>
<text top="228" left="738" width="97" height="20" font="0">0.70; p=0.0002),  </text>
<text top="246" left="738" width="105" height="20" font="0">Stroke: G1 vs. G2  </text>
<text top="263" left="738" width="138" height="20" font="0">0.18 and 0.34 (HR: 0.52; </text>
<text top="280" left="738" width="119" height="20" font="0">95% CI: 0.34 to 0.79; </text>
<text top="297" left="738" width="59" height="20" font="0">p=0.002),  </text>
<text top="314" left="738" width="72" height="20" font="0">Revasc/UA:  </text>
<text top="332" left="738" width="132" height="20" font="0">G1 vs. G2 0.41 vs. 0.77 </text>
<text top="349" left="738" width="148" height="20" font="0">(HR: 0.53; 95% CI: 0.40 to </text>
<text top="366" left="738" width="104" height="20" font="0">0.70; p&lt;0.00001).  </text>
<text top="383" left="738" width="3" height="20" font="0"> </text>
<text top="401" left="738" width="127" height="20" font="0">Combined end point of </text>
<text top="418" left="738" width="160" height="20" font="0">myocardial infarction, stroke, </text>
<text top="435" left="738" width="159" height="20" font="0">or death from cardiovascular </text>
<text top="452" left="738" width="144" height="20" font="0">causes G1 0.45; G2 0.85  </text>
<text top="469" left="738" width="110" height="20" font="0">(HR: 0.53; 95% CI:  </text>
<text top="487" left="738" width="128" height="20" font="0">0.40-0.69; p&lt;0.00001). </text>
<text top="504" left="738" width="3" height="20" font="0"> </text>
<text top="112" left="911" width="166" height="20" font="0">y) due to persistent significant </text>
<text top="133" left="911" width="169" height="20" font="0">difference in primary endpoint. </text>
<text top="154" left="911" width="174" height="20" font="0">Longer duration of the trial may </text>
<text top="175" left="911" width="163" height="20" font="0">have provided a more refined </text>
<text top="196" left="911" width="176" height="20" font="0">estimate of efficacy and safety.  </text>
<text top="217" left="911" width="187" height="20" font="0">(The magnitude of benefit may be </text>
<text top="238" left="911" width="148" height="20" font="0">overestimated if an RCT is </text>
<text top="259" left="911" width="99" height="20" font="0">terminated early.) </text>
<text top="280" left="911" width="3" height="20" font="0"> </text>
<text top="301" left="911" width="98" height="20" font="7"><b>Adverse events: </b></text>
<text top="322" left="911" width="164" height="20" font="0">Physician Reported DM more </text>
<text top="343" left="911" width="187" height="20" font="0">frequent in the rosuvastatin group </text>
<text top="364" left="911" width="76" height="20" font="0">G1: 270 (3%) </text>
<text top="385" left="911" width="87" height="20" font="0">G2: 216 (2.4%) </text>
<text top="406" left="911" width="41" height="20" font="0">p=0.01 </text>
<text top="427" left="911" width="3" height="20" font="0"> </text>
<text top="448" left="911" width="159" height="20" font="0">G1 did not have a significant </text>
<text top="469" left="911" width="178" height="20" font="0">increase in myopathy or cancer  </text>
<text top="490" left="911" width="138" height="20" font="0">Non-significant increase  </text>
<text top="511" left="911" width="103" height="20" font="0">In rhabdomyolysis </text>
<text top="532" left="911" width="141" height="20" font="0">G1: one non-fatal case of </text>
<text top="553" left="911" width="144" height="20" font="0">rhabdomyolysis occurred  </text>
<text top="574" left="911" width="81" height="20" font="0">G2: No cases  </text>
<text top="595" left="911" width="3" height="20" font="0"> </text>
<text top="616" left="911" width="148" height="20" font="0">Can’t rule out that adverse </text>
<text top="637" left="911" width="167" height="20" font="0">events would have been more </text>
<text top="658" left="911" width="130" height="20" font="0">with longer exposure to </text>
<text top="679" left="911" width="70" height="20" font="0">intervention<b>. </b></text>
</page>
<page number="105" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">105 </text>
<text top="107" left="91" width="123" height="20" font="0">Benner JS, et al.<a href="data supplement.html#242">(104)</a> </text>
<text top="124" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15669150">15669150</a></text>
<text top="124" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15669150"> </a></text>
<text top="141" left="91" width="3" height="20" font="0"> </text>
<text top="107" left="263" width="77" height="20" font="7"><b>Study type:</b>   </text>
<text top="124" left="263" width="3" height="20" font="0"> </text>
<text top="141" left="263" width="139" height="20" font="0">Retrospective cohort trial </text>
<text top="159" left="263" width="3" height="20" font="0"> </text>
<text top="176" left="263" width="140" height="20" font="7"><b>Size:</b>  19 422 men (50%) </text>
<text top="193" left="263" width="103" height="20" font="0">and women (50%) </text>
<text top="210" left="263" width="63" height="20" font="0">Ages      % </text>
<text top="227" left="263" width="76" height="20" font="0">45-54.   22. 9 </text>
<text top="245" left="263" width="73" height="20" font="0">55-64.   21.8 </text>
<text top="262" left="263" width="69" height="20" font="0">65-74.  25.4 </text>
<text top="279" left="263" width="73" height="20" font="0">≥. 75.    16.5 </text>
<text top="296" left="263" width="3" height="20" font="0"> </text>
<text top="314" left="263" width="129" height="20" font="0">Clinical Diagnosis.    % </text>
<text top="331" left="263" width="122" height="20" font="0">1) Angina or coronary </text>
<text top="348" left="263" width="103" height="20" font="0">angiography 4.9% </text>
<text top="365" left="263" width="139" height="20" font="0">2) PTCA, CABG, chronic </text>
<text top="383" left="263" width="33" height="20" font="0">CHD  </text>
<text top="400" left="263" width="140" height="20" font="0">3) Acute MI in past year.  </text>
<text top="417" left="263" width="31" height="20" font="0">1.8% </text>
<text top="434" left="263" width="109" height="20" font="0">4) HTN:        34.1% </text>
<text top="451" left="263" width="102" height="20" font="0">5) CHF.        3.8% </text>
<text top="469" left="263" width="103" height="20" font="0">6) DM:        19.9% </text>
<text top="486" left="263" width="92" height="20" font="0">7) Stroke.  3.9% </text>
<text top="503" left="263" width="3" height="20" font="0"> </text>
<text top="107" left="428" width="113" height="20" font="7"><b>Inclusion criteria:</b>   </text>
<text top="139" left="428" width="153" height="20" font="0">Enrollees in a US managed </text>
<text top="156" left="428" width="158" height="20" font="0">care plan who initiated statin </text>
<text top="174" left="428" width="152" height="20" font="0">treatment between October </text>
<text top="191" left="428" width="118" height="20" font="0">1999 &amp; August 2001. </text>
<text top="208" left="428" width="141" height="20" font="0">Computerised pharmacy, </text>
<text top="225" left="428" width="128" height="20" font="0">medical and laboratory </text>
<text top="242" left="428" width="124" height="20" font="0">records  used to study </text>
<text top="260" left="428" width="143" height="20" font="0">patterns and predictors of </text>
<text top="277" left="428" width="156" height="20" font="0">adherence with lipid therapy </text>
<text top="294" left="428" width="92" height="20" font="0">for up to 3 years </text>
<text top="311" left="428" width="3" height="20" font="0"> </text>
<text top="108" left="612" width="219" height="20" font="7"><b>1</b>°<b> endpoint:</b>  Adherence checked at  3-</text>
<text top="125" left="612" width="99" height="20" font="0">monthly intervals. </text>
<text top="143" left="612" width="3" height="20" font="0"> </text>
<text top="160" left="612" width="190" height="20" font="0">Patients  considered '’adherent'’ if  </text>
<text top="177" left="612" width="206" height="20" font="0">≥  80% of days were covered by lipid-</text>
<text top="194" left="612" width="97" height="20" font="0">lowering therapy. </text>
<text top="211" left="612" width="3" height="20" font="0"> </text>
<text top="229" left="612" width="66" height="20" font="7"><b>Results:</b>     </text>
<text top="261" left="612" width="85" height="20" font="0">First 3 months: </text>
<text top="278" left="612" width="78" height="20" font="0">% of patients  </text>
<text top="295" left="612" width="166" height="20" font="0">40% had follow-up lipid tests;  </text>
<text top="312" left="612" width="171" height="20" font="0">21% had follow-up lipid visits ;  </text>
<text top="330" left="612" width="86" height="20" font="0">14% had both.  </text>
<text top="362" left="612" width="223" height="20" font="0">Those who received followup care  were </text>
<text top="379" left="612" width="229" height="20" font="0">substantially more likely to be adherent in </text>
<text top="396" left="612" width="123" height="20" font="0">subsequent intervals.  </text>
<text top="414" left="612" width="3" height="20" font="0"> </text>
<text top="431" left="612" width="229" height="20" font="0">Relative odds of adherence  of those with </text>
<text top="448" left="612" width="144" height="20" font="0">vs. those without followup </text>
<text top="465" left="612" width="198" height="20" font="0">Odds 1.42  if one or more lipid tests </text>
<text top="482" left="612" width="245" height="20" font="0">Odds  1.27  if  one or more lipid visits,  (95% </text>
<text top="500" left="612" width="248" height="20" font="0">confidence intervals [CI] 1.33, 1.50 and 1.16, </text>
<text top="517" left="612" width="46" height="20" font="0">1.39). P </text>
<text top="534" left="612" width="3" height="20" font="0"> </text>
<text top="551" left="612" width="217" height="20" font="0">In other words, patients who received a </text>
<text top="569" left="612" width="239" height="20" font="0">follow-up visit and lipid test were 45% more </text>
<text top="586" left="612" width="227" height="20" font="0">likely to be adherent (95% CI 1.34, 1.55). </text>
<text top="603" left="612" width="229" height="20" font="0">Similar associations were observed when </text>
<text top="620" left="612" width="239" height="20" font="0">lipid tests and dyslipidaemia visits occurred </text>
<text top="637" left="612" width="88" height="20" font="0">later in therapy. </text>
<text top="655" left="612" width="3" height="20" font="0"> </text>
<text top="107" left="873" width="85" height="20" font="7"><b>Conclusions:  </b></text>
<text top="124" left="873" width="3" height="20" font="7"><b> </b></text>
<text top="141" left="873" width="241" height="20" font="0">Early and frequent follow-up  and especially </text>
<text top="159" left="873" width="194" height="20" font="0">if associated with  lipid testing, was </text>
<text top="176" left="873" width="242" height="20" font="0">associated with improved adherence to lipid </text>
<text top="193" left="873" width="51" height="20" font="0">therapy.  </text>
<text top="210" left="873" width="7" height="20" font="7"><b>  </b></text>
<text top="227" left="873" width="83" height="20" font="7"><b>Limitations: </b>   </text>
<text top="245" left="873" width="190" height="20" font="0">Not a randomized prospective trial </text>
<text top="262" left="873" width="7" height="20" font="0">  </text>
<text top="294" left="873" width="3" height="20" font="0"> </text>
<text top="694" left="81" width="5" height="16" font="15"> </text>
<text top="714" left="81" width="5" height="16" font="15"> </text>
<text top="730" left="99" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="748" left="109" width="78" height="20" font="7"><b>Author; Year </b></text>
<text top="765" left="117" width="62" height="20" font="7"><b>Published </b></text>
<text top="739" left="227" width="121" height="20" font="7"><b>Aim of Study; Study </b></text>
<text top="756" left="226" width="122" height="20" font="7"><b>Type; Study Size (N) </b></text>
<text top="748" left="393" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="730" left="552" width="123" height="20" font="7"><b>Study Intervention(# </b></text>
<text top="748" left="565" width="96" height="20" font="7"><b>patients) /Study </b></text>
<text top="765" left="544" width="139" height="20" font="7"><b>Comparator(# patients) </b></text>
<text top="730" left="705" width="198" height="20" font="7"><b>Endpoint Results(Absolute Event </b></text>
<text top="748" left="703" width="201" height="20" font="7"><b>Rates, P values; OR or RR; &amp; 95% </b></text>
<text top="765" left="794" width="20" height="20" font="7"><b>CI) </b></text>
<text top="731" left="946" width="146" height="20" font="7"><b>Relevant  2</b>°<b> Endpoint (if </b></text>
<text top="748" left="923" width="192" height="20" font="7"><b>any);Study Limitations; Adverse </b></text>
<text top="765" left="998" width="44" height="20" font="7"><b>Events </b></text>
</page>
<page number="106" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">106 </text>
<text top="107" left="91" width="95" height="20" font="0">Chiavaroli L et al </text>
<text top="124" left="91" width="32" height="20" font="0"><a href="data supplement.html#242">(105)</a> </text>
<text top="141" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29807048">29807048</a></text>
<text top="141" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/29807048"> </a></text>
<text top="107" left="218" width="128" height="20" font="0">Aim:  To determine the </text>
<text top="124" left="218" width="99" height="20" font="0">effectiveness of a </text>
<text top="141" left="218" width="128" height="20" font="0">Portfolio Dietary added </text>
<text top="159" left="218" width="99" height="20" font="0">to a Step II diet in </text>
<text top="176" left="218" width="93" height="20" font="0">reducing LDL-C  </text>
<text top="208" left="218" width="3" height="20" font="0"> </text>
<text top="240" left="218" width="128" height="20" font="0">Study type: Systematic </text>
<text top="258" left="218" width="94" height="20" font="0">review and meta-</text>
<text top="275" left="218" width="118" height="20" font="0">analysis of controlled </text>
<text top="292" left="218" width="29" height="20" font="0">trials </text>
<text top="324" left="218" width="3" height="20" font="0"> </text>
<text top="356" left="218" width="3" height="20" font="0"> </text>
<text top="389" left="218" width="34" height="20" font="0">Size:  </text>
<text top="421" left="218" width="125" height="20" font="0"> Eligibility criteria were </text>
<text top="438" left="218" width="74" height="20" font="0">met by 7 trial </text>
<text top="455" left="218" width="110" height="20" font="0">comparisons in 439 </text>
<text top="473" left="218" width="91" height="20" font="0">participants with </text>
<text top="490" left="218" width="86" height="20" font="0">hyperlipidemia, </text>
<text top="522" left="218" width="3" height="20" font="0"> </text>
<text top="554" left="218" width="7" height="20" font="0">  </text>
<text top="586" left="218" width="3" height="20" font="0"> </text>
<text top="107" left="369" width="103" height="20" font="0">Inclusion criteria:   </text>
<text top="139" left="369" width="121" height="20" font="0">Randomized and non-</text>
<text top="157" left="369" width="154" height="20" font="0">randomized controlled trials </text>
<text top="189" left="369" width="3" height="20" font="0"> </text>
<text top="221" left="369" width="107" height="20" font="0">Exclusion criteria:   </text>
<text top="253" left="369" width="140" height="20" font="0">Limited to human studies </text>
<text top="270" left="369" width="153" height="20" font="0">with no language restriction </text>
<text top="303" left="369" width="7" height="20" font="0">  </text>
<text top="335" left="369" width="7" height="20" font="0">  </text>
<text top="367" left="369" width="7" height="20" font="0">  </text>
<text top="107" left="540" width="75" height="20" font="0">Intervention:  </text>
<text top="139" left="540" width="118" height="20" font="0">The combination of a </text>
<text top="156" left="540" width="129" height="20" font="0">portfolio dietary pattern </text>
<text top="174" left="540" width="127" height="20" font="0">and NCEP Step II diet  </text>
<text top="206" left="540" width="121" height="20" font="0">• The Portfolio dietary </text>
<text top="223" left="540" width="122" height="20" font="0">pattern had to include </text>
<text top="240" left="540" width="141" height="20" font="0">these components as the </text>
<text top="258" left="540" width="125" height="20" font="0">intended intervention:  </text>
<text top="290" left="540" width="141" height="20" font="0">1) 1–3 g/day plant sterols </text>
<text top="307" left="540" width="128" height="20" font="0">(plant-sterol containing </text>
<text top="324" left="540" width="68" height="20" font="0">margarines, </text>
<text top="341" left="540" width="133" height="20" font="0">supplements), 2) 15–25 </text>
<text top="359" left="540" width="136" height="20" font="0">g/day viscous fibres (gel-</text>
<text top="376" left="540" width="127" height="20" font="0">forming fibres, such as </text>
<text top="393" left="540" width="98" height="20" font="0">from oats, barley, </text>
<text top="410" left="540" width="104" height="20" font="0">psyllium, legumes, </text>
<text top="428" left="540" width="98" height="20" font="0">eggplants, okra),  </text>
<text top="460" left="540" width="116" height="20" font="0">3) 35–50 g/day plant </text>
<text top="477" left="540" width="141" height="20" font="0">protein (such as from soy </text>
<text top="494" left="540" width="94" height="20" font="0">and pulses) and  </text>
<text top="526" left="540" width="112" height="20" font="0">4) 25–50 g/day nuts </text>
<text top="544" left="540" width="131" height="20" font="0">(including tree nuts and </text>
<text top="561" left="540" width="55" height="20" font="0">peanuts). </text>
<text top="593" left="540" width="86" height="20" font="0">Comparator:     </text>
<text top="625" left="540" width="110" height="20" font="0">• NCEP Step II Diet </text>
<text top="107" left="699" width="22" height="20" font="0">1</text>
<text top="107" left="709" width="153" height="20" font="0"> endpoint:  LDL-Cholesterol </text>
<text top="124" left="699" width="3" height="20" font="0"> </text>
<text top="141" left="699" width="51" height="20" font="0">Results:  </text>
<text top="159" left="699" width="202" height="20" font="0">The Portfolio dietary pattern lowered </text>
<text top="176" left="699" width="198" height="20" font="0">LDL-C by 17% (7 trial comparisons, </text>
<text top="193" left="699" width="197" height="20" font="0">MD = −0.73 mmol/L [95% CI: −0.89 </text>
<text top="210" left="699" width="168" height="20" font="0">to −0.56 mmol/L], p b 0.0001)  </text>
<text top="228" left="699" width="3" height="20" font="0"> </text>
<text top="245" left="699" width="189" height="20" font="0">There was evidence of substantial </text>
<text top="262" left="699" width="78" height="20" font="0">heterogeneity </text>
<text top="279" left="699" width="206" height="20" font="0"> (I2 = 67%, P-heterogeneity = 0.006). </text>
<text top="296" left="699" width="3" height="20" font="0"> </text>
<text top="314" left="699" width="164" height="20" font="0">Saw reduction in high-density </text>
<text top="331" left="699" width="207" height="20" font="0">lipoprotein cholesterol, apolipoprotein </text>
<text top="348" left="699" width="180" height="20" font="0">B, total cholesterol, triglycerides, </text>
<text top="365" left="699" width="204" height="20" font="0">systolic and diastolic blood pressure, </text>
<text top="383" left="699" width="202" height="20" font="0">C-reactive protein, and estimated 10-</text>
<text top="400" left="699" width="194" height="20" font="0">year coronary heart disease (CHD) </text>
<text top="417" left="699" width="203" height="20" font="0">risk, compared with an NCEP Step 2 </text>
<text top="434" left="699" width="119" height="21" font="0">diet alone (p &lt; 0.05).  </text>
<text top="451" left="699" width="3" height="20" font="0"> </text>
<text top="469" left="699" width="204" height="20" font="0">No effect on HDL-C or body weight.   </text>
<text top="107" left="921" width="83" height="20" font="0">Study strength </text>
<text top="124" left="921" width="167" height="20" font="0">Using the GRADE criteria, the </text>
<text top="141" left="921" width="188" height="20" font="0">certainty in the evidence was high </text>
<text top="159" left="921" width="176" height="20" font="0">for LDL-C, TC, TG, non-HDL-C, </text>
<text top="176" left="921" width="125" height="20" font="0">apoB and body weight </text>
<text top="193" left="921" width="3" height="20" font="0"> </text>
<text top="210" left="921" width="114" height="20" font="0">Study limitations:      </text>
<text top="228" left="921" width="3" height="20" font="0"> </text>
<text top="245" left="921" width="194" height="20" font="0">Using the Grade criteria it was only </text>
<text top="262" left="921" width="181" height="20" font="0">moderate for HDL-C, SBP, DBP, </text>
<text top="279" left="921" width="181" height="20" font="0">CRP and 10-year CHD risk. This </text>
<text top="296" left="921" width="146" height="20" font="0">was due to downgrades in </text>
<text top="314" left="921" width="180" height="20" font="0">certainty for serious imprecision. </text>
<text top="658" left="91" width="113" height="20" font="0">Stone NJ et al <a href="data supplement.html#242">(106)</a> </text>
<text top="675" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24239923">24239923</a></text>
<text top="675" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24239923"> </a></text>
<text top="708" left="91" width="3" height="20" font="0"> </text>
<text top="725" left="91" width="3" height="20" font="0"> </text>
<text top="742" left="91" width="3" height="20" font="0"> </text>
<text top="658" left="218" width="100" height="20" font="0"> 2013 Cholesterol </text>
<text top="675" left="218" width="119" height="20" font="0">Guideline Systematic </text>
<text top="692" left="218" width="99" height="20" font="0">Review and Meta-</text>
<text top="710" left="218" width="48" height="20" font="0">analysis </text>
<text top="742" left="218" width="134" height="20" font="0">Evidence Statement 45  </text>
<text top="658" left="369" width="138" height="20" font="0">In randomized controlled </text>
<text top="675" left="369" width="117" height="20" font="0">trials (RCTs)  of high-</text>
<text top="692" left="369" width="132" height="20" font="0">intensity compared with </text>
<text top="710" left="369" width="143" height="20" font="0">moderate-intensity statins </text>
<text top="727" left="369" width="137" height="20" font="0">(clinical CVD), moderate-</text>
<text top="744" left="369" width="139" height="20" font="0">intensity statin compared </text>
<text top="761" left="369" width="129" height="20" font="0">with placebo (diabetes, </text>
<text top="779" left="369" width="140" height="20" font="0">primary prevention), high-</text>
<text top="658" left="540" width="145" height="20" font="0">Participants were seen  at </text>
<text top="675" left="540" width="137" height="20" font="0">visits that occurred at 4 –</text>
<text top="692" left="540" width="83" height="20" font="0">13 weeks after </text>
<text top="710" left="540" width="135" height="20" font="0">randomization, and then </text>
<text top="727" left="540" width="101" height="20" font="0">every 3–6 months </text>
<text top="744" left="540" width="60" height="20" font="0">thereafter. </text>
<text top="658" left="699" width="58" height="20" font="0">Endpoints </text>
<text top="690" left="699" width="196" height="20" font="0">1. Assessed for adherence to study </text>
<text top="708" left="699" width="138" height="20" font="0">medication at every visit. </text>
<text top="740" left="699" width="192" height="20" font="0">2. Assessed for adverse effects by </text>
<text top="757" left="699" width="206" height="20" font="0">history and laboratory measurements </text>
<text top="774" left="699" width="176" height="20" font="0">at every visit or every other visit </text>
<text top="658" left="921" width="88" height="20" font="0">Study Strength: </text>
<text top="690" left="921" width="153" height="20" font="0">Evidence Statement 45 is a </text>
<text top="708" left="921" width="189" height="20" font="0">complete analysis of the effects of </text>
<text top="725" left="921" width="185" height="20" font="0">follow-up visits and lipid testing in </text>
<text top="742" left="921" width="178" height="20" font="0">the RCTS reviewed by the 2013 </text>
<text top="759" left="921" width="173" height="20" font="0">ACC-AHA Guideline Panel that </text>
<text top="776" left="921" width="184" height="20" font="0">were selected by an independent </text>
</page>
<page number="107" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">107 </text>
<text top="107" left="369" width="139" height="20" font="0">intensity statin compared </text>
<text top="124" left="369" width="136" height="20" font="0">with placebo (secondary </text>
<text top="141" left="369" width="151" height="20" font="0">and primary prevention), or </text>
<text top="159" left="369" width="109" height="20" font="0">statin-niacin versus </text>
<text top="176" left="369" width="50" height="20" font="0">placebo, </text>
<text top="107" left="921" width="187" height="20" font="0">contractor chosen by the National </text>
<text top="124" left="921" width="117" height="20" font="0">Heart Lung Institutes </text>
<text top="157" left="921" width="96" height="20" font="0">Study limitations: </text>
<text top="189" left="921" width="148" height="20" font="0"> Included only those RCTs </text>
<text top="206" left="921" width="189" height="20" font="0">available to the panel for the 2013 </text>
<text top="223" left="921" width="111" height="20" font="0">ACC-AHA guideline </text>
<text top="262" left="81" width="5" height="16" font="15"> </text>
<text top="276" left="81" width="540" height="24" font="4"><b>Data Supplement 18. Evidence Table to discontinue therapy (Section 4.4.4.1) </b></text>
<text top="298" left="107" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="315" left="132" width="48" height="20" font="7"><b>Author; </b></text>
<text top="333" left="110" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="298" left="286" width="83" height="20" font="7"><b>Aim of Study; </b></text>
<text top="315" left="291" width="74" height="20" font="7"><b>Study Type; </b></text>
<text top="333" left="284" width="86" height="20" font="7"><b>Study Size (N) </b></text>
<text top="298" left="499" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="298" left="695" width="112" height="20" font="7"><b>Study Intervention </b></text>
<text top="315" left="694" width="114" height="20" font="7"><b>(# patients) / Study </b></text>
<text top="333" left="715" width="71" height="20" font="7"><b>comparator </b></text>
<text top="298" left="910" width="108" height="20" font="7"><b>Endpoint Results  </b></text>
<text top="315" left="835" width="256" height="20" font="7"><b>(Absolute Event Rates, p values, OR or RR, </b></text>
<text top="333" left="926" width="73" height="20" font="7"><b>and 95% CI) </b></text>
<text top="351" left="89" width="127" height="20" font="0">Qi K, et al., 2015 <a href="data supplement.html#242">(107)</a> </text>
<text top="368" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26047944">26047944</a></text>
<text top="368" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26047944"> </a></text>
<text top="351" left="236" width="169" height="20" font="7"><b>Aim: </b>To study the feasibility of </text>
<text top="368" left="236" width="165" height="20" font="0">deprescribing statins in adults </text>
<text top="385" left="236" width="60" height="20" font="0">aged ≥65  </text>
<text top="402" left="236" width="3" height="20" font="0"> </text>
<text top="419" left="236" width="162" height="20" font="7"><b>Study Type: </b>Cross-sectional </text>
<text top="437" left="236" width="109" height="20" font="0">observational study </text>
<text top="454" left="236" width="3" height="20" font="0"> </text>
<text top="471" left="236" width="76" height="20" font="7"><b>Size: </b>N=180  </text>
<text top="488" left="236" width="111" height="20" font="0">median age of 78 y, </text>
<text top="505" left="236" width="158" height="20" font="0">(interquartile range 71–85 y) </text>
<text top="351" left="432" width="211" height="20" font="7"><b>Inclusion criteria:</b> adults aged ≥65 y, </text>
<text top="368" left="432" width="228" height="20" font="0">admitted to hospital (cardiology, geriatric, </text>
<text top="385" left="432" width="126" height="20" font="0">orthopedics, gen med) </text>
<text top="402" left="432" width="3" height="20" font="0"> </text>
<text top="419" left="432" width="110" height="20" font="7"><b>Exclusion criteria: </b></text>
<text top="437" left="432" width="210" height="20" font="0">Cognitively or functionally impaired as </text>
<text top="454" left="432" width="242" height="20" font="0">judged by the nurses on each study ward or </text>
<text top="471" left="432" width="122" height="20" font="0">refused to participate. </text>
<text top="351" left="690" width="78" height="20" font="7"><b>Intervention: </b></text>
<text top="368" left="690" width="53" height="20" font="0">Interview </text>
<text top="351" left="823" width="260" height="20" font="7"><b>1° Endpoint:</b> qualitative assessment regarding </text>
<text top="368" left="823" width="206" height="20" font="0">their willingness to discontinue statin  </text>
<text top="385" left="823" width="3" height="20" font="0"> </text>
<text top="523" left="89" width="132" height="20" font="0">Garfinkel D, et al., 2010 </text>
<text top="541" left="89" width="32" height="20" font="0"><a href="data supplement.html#242">(108)</a> </text>
<text top="558" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20937924">20937924</a></text>
<text top="558" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20937924"> </a></text>
<text top="523" left="236" width="151" height="20" font="7"><b>Aim:</b> to study the impact of </text>
<text top="541" left="236" width="161" height="20" font="0">medication de-prescription in </text>
<text top="558" left="236" width="70" height="20" font="0">older adults  </text>
<text top="575" left="236" width="3" height="20" font="0"> </text>
<text top="592" left="236" width="178" height="20" font="7"><b>Study Type:</b> prospective cohort </text>
<text top="609" left="236" width="3" height="20" font="0"> </text>
<text top="627" left="236" width="68" height="20" font="7"><b>Size</b>: N=70  </text>
<text top="644" left="236" width="180" height="20" font="0">43 patients (61%) had 3 or more </text>
<text top="661" left="236" width="132" height="20" font="0">and 26% had 5 or more </text>
<text top="678" left="236" width="83" height="20" font="0">comorbidities.  </text>
<text top="523" left="432" width="106" height="20" font="7"><b>Inclusion criteria: </b></text>
<text top="541" left="432" width="243" height="20" font="0">Patients referred by their family physician or </text>
<text top="558" left="432" width="187" height="20" font="0">family for comprehensive geriatric </text>
<text top="575" left="432" width="79" height="20" font="0">assessments  </text>
<text top="592" left="432" width="3" height="20" font="0"> </text>
<text top="609" left="432" width="3" height="20" font="0"> </text>
<text top="627" left="432" width="110" height="20" font="7"><b>Exclusion criteria: </b></text>
<text top="644" left="432" width="233" height="20" font="0">patients with advanced disease (cancer or </text>
<text top="661" left="432" width="230" height="20" font="0">noncancer) in whom the initial estimate of </text>
<text top="678" left="432" width="231" height="20" font="0">life expectancy was &lt;3 mo and patients in </text>
<text top="696" left="432" width="216" height="20" font="0">whom follow-up availability was &lt;4 mo. </text>
<text top="523" left="690" width="78" height="20" font="7"><b>Intervention: </b></text>
<text top="541" left="690" width="117" height="20" font="0">removing medication </text>
<text top="558" left="690" width="3" height="20" font="0"> </text>
<text top="575" left="690" width="3" height="20" font="0"> </text>
<text top="523" left="823" width="77" height="20" font="7"><b>1° Endpoint: </b></text>
<text top="542" left="823" width="11" height="18" font="0">• </text>
<text top="542" left="836" width="237" height="20" font="0">Successful discontinuation of all meds was </text>
<text top="559" left="836" width="248" height="20" font="0">achieved in 81%; discontinuation of statins in </text>
<text top="576" left="836" width="28" height="20" font="0">72% </text>
<text top="593" left="823" width="3" height="20" font="0"> </text>
<text top="612" left="823" width="11" height="18" font="0">• </text>
<text top="612" left="836" width="249" height="20" font="0">No significant adverse events or deaths were </text>
<text top="629" left="836" width="163" height="20" font="0">attributable to discontinuation </text>
<text top="646" left="823" width="3" height="20" font="0"> </text>
<text top="665" left="823" width="11" height="18" font="0">• </text>
<text top="664" left="836" width="261" height="20" font="0">88% of patients reported global improvement in </text>
<text top="681" left="836" width="40" height="20" font="0">health. </text>
<text top="699" left="823" width="3" height="20" font="0"> </text>
<text top="716" left="823" width="3" height="20" font="0"> </text>
<text top="733" left="823" width="3" height="20" font="0"> </text>
<text top="751" left="89" width="111" height="20" font="0">Todd A, et al., 2016 </text>
<text top="768" left="89" width="32" height="20" font="0"><a href="data supplement.html#242">(109)</a> </text>
<text top="785" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26822776">26822776</a></text>
<text top="785" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26822776"> </a></text>
<text top="751" left="236" width="137" height="20" font="7"><b>Aim:</b> to explore the lived </text>
<text top="768" left="236" width="127" height="20" font="0">experience of patients, </text>
<text top="785" left="236" width="145" height="20" font="0">caregivers and healthcare </text>
<text top="751" left="432" width="106" height="20" font="7"><b>Inclusion criteria: </b></text>
<text top="768" left="432" width="224" height="20" font="0">Patients attending a day care center at a </text>
<text top="785" left="432" width="159" height="20" font="0">specialist palliative care unit  </text>
<text top="751" left="690" width="94" height="20" font="0">Patient interview </text>
<text top="753" left="822" width="11" height="18" font="0">• </text>
<text top="752" left="836" width="222" height="20" font="0">Medication formed a significant part of a </text>
<text top="769" left="836" width="229" height="20" font="0">patient’s day-to-day routine; this was also </text>
<text top="786" left="836" width="244" height="20" font="0">apparent for their caregivers who took on an </text>
</page>
<page number="108" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">108 </text>
<text top="107" left="236" width="166" height="20" font="0">professionals in the context of </text>
<text top="124" left="236" width="161" height="20" font="0">medication use in life-limiting </text>
<text top="141" left="236" width="41" height="20" font="0">illness. </text>
<text top="159" left="236" width="3" height="20" font="0"> </text>
<text top="176" left="236" width="161" height="20" font="7"><b>Size:</b> N=12, 50% aged &gt;70 y </text>
<text top="193" left="236" width="102" height="20" font="0">and 2 aged &gt;80 y. </text>
<text top="107" left="432" width="3" height="20" font="0"> </text>
<text top="124" left="432" width="224" height="20" font="0">To be included in the study, patients and </text>
<text top="141" left="432" width="241" height="20" font="0">caregivers had to be aged &gt;18 y of age and </text>
<text top="159" left="432" width="192" height="20" font="0">healthcare professionals had to be </text>
<text top="176" left="432" width="224" height="20" font="0">responsible for prescribing medication to </text>
<text top="193" left="432" width="149" height="20" font="0">this general patient group.  </text>
<text top="107" left="836" width="264" height="20" font="0">active role-as a gatekeeper of care-in managing </text>
<text top="124" left="836" width="70" height="20" font="0">medication.  </text>
<text top="143" left="822" width="11" height="18" font="0">• </text>
<text top="143" left="836" width="256" height="20" font="0">Patients described the experience of a point in </text>
<text top="160" left="836" width="263" height="20" font="0">which, in their disease journey, they placed less </text>
<text top="177" left="836" width="230" height="20" font="0">importance on taking certain medications; </text>
<text top="194" left="836" width="266" height="20" font="0">healthcare professionals also recognize this and </text>
<text top="211" left="836" width="131" height="20" font="0">refer it as a ‘transition’.  </text>
<text top="229" left="89" width="125" height="20" font="0">Kutner JS, et al., 2015 </text>
<text top="247" left="89" width="32" height="20" font="0"><a href="data supplement.html#242">(110)</a> </text>
<text top="264" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25798575">25798575</a></text>
<text top="264" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25798575"> </a></text>
<text top="281" left="103" width="3" height="20" font="0"> </text>
<text top="229" left="236" width="159" height="20" font="7"><b>Aim: </b>To evaluate the safety, </text>
<text top="247" left="236" width="143" height="20" font="0">clinical and cost impact of </text>
<text top="264" left="236" width="177" height="20" font="0">discontinuing statin medications </text>
<text top="281" left="236" width="176" height="20" font="0">for patients in the palliative care </text>
<text top="298" left="236" width="43" height="20" font="0">setting  </text>
<text top="315" left="236" width="3" height="20" font="0"> </text>
<text top="333" left="236" width="141" height="20" font="7"><b>Study Type:</b> Multicenter, </text>
<text top="350" left="236" width="139" height="20" font="0">parallel-group, unblinded </text>
<text top="367" left="236" width="121" height="20" font="0">pragmatic clinical trial </text>
<text top="384" left="236" width="3" height="20" font="0"> </text>
<text top="401" left="236" width="131" height="20" font="7"><b>Size: </b>381<b> </b>enrolled (189 </text>
<text top="419" left="236" width="153" height="20" font="0">discontinued statin and 192 </text>
<text top="436" left="236" width="183" height="20" font="0">continued statin). Mean age 74.1 </text>
<text top="453" left="236" width="66" height="20" font="0">y (SD 11.6)<b> </b></text>
<text top="229" left="432" width="206" height="20" font="7"><b>Inclusion criteria:</b> English-speaking, </text>
<text top="247" left="432" width="207" height="20" font="0">receiving statin for ≥3 mo for 1° or 2° </text>
<text top="264" left="432" width="204" height="20" font="0">prevention, documented diagnosis of </text>
<text top="281" left="432" width="182" height="20" font="0">advanced, life-limiting illness (life </text>
<text top="298" left="432" width="193" height="20" font="0">expectancy 1-12 mo), and reduced </text>
<text top="315" left="432" width="105" height="20" font="0">functional capacity </text>
<text top="333" left="432" width="233" height="20" font="7"><b>Exclusion criteria:</b> Physician opinion that </text>
<text top="350" left="432" width="245" height="20" font="0">the patient had active CVD or sufficient CVD </text>
<text top="367" left="432" width="220" height="20" font="0">risk to require ongoing statin therapy, or </text>
<text top="384" left="432" width="220" height="20" font="0">symptoms of myositis, liver function test </text>
<text top="401" left="432" width="204" height="20" font="0">(aspartate aminotransferase, alanine </text>
<text top="419" left="432" width="239" height="20" font="0">aminotransferase, or alkaline phosphatase) </text>
<text top="436" left="432" width="230" height="20" font="0">or creatine kinase levels of &gt;2.5 times the </text>
<text top="453" left="432" width="170" height="20" font="0">upper limits of normal, or other </text>
<text top="470" left="432" width="215" height="20" font="0">contraindications to continuing statins.  </text>
<text top="229" left="690" width="78" height="20" font="7"><b>Intervention: </b></text>
<text top="247" left="690" width="114" height="20" font="0">Statin removed from </text>
<text top="264" left="690" width="114" height="20" font="0">patients randomized </text>
<text top="281" left="690" width="120" height="20" font="0">to the discontinuation </text>
<text top="298" left="690" width="111" height="20" font="0">group vs. continued </text>
<text top="315" left="690" width="103" height="20" font="0">in the continuation </text>
<text top="333" left="690" width="35" height="20" font="0">group </text>
<text top="231" left="822" width="11" height="18" font="0">• </text>
<text top="230" left="836" width="223" height="20" font="0">Discontinuing statin was associated with </text>
<text top="247" left="836" width="265" height="20" font="0">improved QOL, reduced non-statin medications, </text>
<text top="265" left="836" width="170" height="20" font="0">and reduced medication costs. </text>
<text top="488" left="89" width="133" height="20" font="0">Tjia J, et al., 2017 <a href="data supplement.html#242">(111)</a> </text>
<text top="505" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28520522">28520522</a></text>
<text top="505" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28520522"> </a></text>
<text top="488" left="236" width="173" height="20" font="7"><b>Aim:</b> The aim of this study was </text>
<text top="505" left="236" width="137" height="20" font="0">to quantify the perceived </text>
<text top="523" left="236" width="170" height="20" font="0">benefits and concerns of statin </text>
<text top="540" left="236" width="173" height="20" font="0">discontinuation among patients </text>
<text top="557" left="236" width="128" height="20" font="0">with life-limiting illness. </text>
<text top="574" left="236" width="3" height="20" font="0"> </text>
<text top="591" left="236" width="160" height="20" font="7"><b>Size:</b> 297 participants, Mean </text>
<text top="609" left="236" width="96" height="20" font="0">age 72 y (SD 11)<b> </b></text>
<text top="488" left="432" width="206" height="20" font="7"><b>Inclusion criteria:</b> English-speaking, </text>
<text top="505" left="432" width="207" height="20" font="0">receiving statin for ≥3 mo for 1° or 2° </text>
<text top="523" left="432" width="230" height="20" font="0">prevention, with documented diagnosis of </text>
<text top="540" left="432" width="182" height="20" font="0">advanced, life-limiting illness (life </text>
<text top="557" left="432" width="226" height="20" font="0">expectancy 1-12 mo), reduced functional </text>
<text top="574" left="432" width="224" height="20" font="0">capacity, cognitively intact. (defined as a </text>
<text top="591" left="432" width="241" height="20" font="0">Short Portable Mental Status Questionnaire </text>
<text top="609" left="432" width="56" height="20" font="0">score ≥6) </text>
<text top="626" left="432" width="233" height="20" font="7"><b>Exclusion criteria:</b> Physician opinion that </text>
<text top="643" left="432" width="245" height="20" font="0">the patient had active CVD or sufficient CVD </text>
<text top="660" left="432" width="220" height="20" font="0">risk to require ongoing statin therapy, or </text>
<text top="678" left="432" width="220" height="20" font="0">symptoms of myositis, liver function test </text>
<text top="695" left="432" width="204" height="20" font="0">(aspartate aminotransferase, alanine </text>
<text top="712" left="432" width="239" height="20" font="0">aminotransferase, or alkaline phosphatase) </text>
<text top="729" left="432" width="230" height="20" font="0">or creatine kinase levels of &gt;2.5 times the </text>
<text top="746" left="432" width="170" height="20" font="0">upper limits of normal, or other </text>
<text top="764" left="432" width="215" height="20" font="0">contraindications to continuing statins.  </text>
<text top="488" left="690" width="78" height="20" font="7"><b>Intervention: </b></text>
<text top="505" left="689" width="100" height="20" font="0">Responses to a 9-</text>
<text top="523" left="689" width="104" height="20" font="0">item questionnaire </text>
<text top="540" left="689" width="104" height="20" font="0">addressing patient </text>
<text top="557" left="689" width="87" height="20" font="0">concerns about </text>
<text top="574" left="689" width="114" height="20" font="0">discontinuing statins </text>
<text top="591" left="689" width="85" height="20" font="0">were collected. </text>
<text top="490" left="822" width="11" height="18" font="0">• </text>
<text top="489" left="836" width="241" height="20" font="0">Few participants expressed concerns about </text>
<text top="506" left="836" width="258" height="20" font="0">discontinuing statins; many perceived potential </text>
<text top="524" left="836" width="228" height="20" font="0">benefits. Cardiovascular disease patients </text>
<text top="541" left="836" width="262" height="20" font="0">perceived greater potential positive impact from </text>
<text top="558" left="836" width="122" height="20" font="0">statin discontinuation. </text>
<text top="781" left="81" width="4" height="22" font="5"><b> </b></text>
</page>
<page number="109" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">109 </text>
<text top="106" left="81" width="647" height="24" font="4"><b>Data Supplement 19. Evidence Table for Statin therapy for adults &gt;75 years (Section 4.4.4.1) </b></text>
<text top="150" left="105" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="168" left="130" width="48" height="20" font="7"><b>Author; </b></text>
<text top="185" left="108" width="92" height="20" font="7"><b>Year Published</b> </text>
<text top="150" left="254" width="83" height="20" font="7"><b>Aim of Study; </b></text>
<text top="168" left="258" width="74" height="20" font="7"><b>Study Type; </b></text>
<text top="185" left="252" width="86" height="20" font="7"><b>Study Size (N) </b></text>
<text top="150" left="411" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="150" left="604" width="38" height="20" font="7"><b>Study </b></text>
<text top="168" left="586" width="74" height="20" font="7"><b>Intervention </b></text>
<text top="185" left="621" width="3" height="20" font="7"><b> </b></text>
<text top="150" left="696" width="253" height="20" font="7"><b>Endpoint Results (Absolute Event Rates, p </b></text>
<text top="168" left="734" width="176" height="20" font="7"><b>values, OR or RR, and 95% CI </b></text>
<text top="150" left="1003" width="71" height="20" font="7"><b>Relevant 2° </b></text>
<text top="168" left="983" width="110" height="20" font="7"><b>endpoints (if any); </b></text>
<text top="185" left="985" width="107" height="20" font="7"><b>Study limitations; </b></text>
<text top="202" left="991" width="94" height="20" font="7"><b>Adverse events </b></text>
<text top="220" left="89" width="55" height="20" font="7"><b>JUPITER </b></text>
<text top="237" left="89" width="119" height="20" font="0">Ridker D, et al., 2008 </text>
<text top="254" left="89" width="25" height="20" font="0"><a href="data supplement.html#236">(11)</a> </text>
<text top="272" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18997196">18997196</a></text>
<text top="272" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18997196"> </a></text>
<text top="289" left="89" width="3" height="20" font="0"> </text>
<text top="306" left="89" width="122" height="20" font="0">Glynn RJ, et al., 2010 </text>
<text top="323" left="89" width="32" height="20" font="0"><a href="data supplement.html#242">(112)</a> </text>
<text top="340" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20404379">20404379</a></text>
<text top="340" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20404379"> </a></text>
<text top="220" left="231" width="124" height="20" font="7"><b>Aim: </b>Study of primary </text>
<text top="237" left="231" width="86" height="20" font="0">prevention with </text>
<text top="254" left="231" width="70" height="20" font="0">rosuvastatin </text>
<text top="272" left="231" width="3" height="20" font="0"> </text>
<text top="289" left="231" width="102" height="20" font="7"><b>Study Type:</b> RCT </text>
<text top="306" left="231" width="3" height="20" font="0"> </text>
<text top="323" left="231" width="124" height="20" font="7"><b>Size:</b> 17,802 men and </text>
<text top="340" left="231" width="46" height="20" font="0">women  </text>
<text top="358" left="231" width="115" height="20" font="0">5695 (32%) ≥70 y of </text>
<text top="375" left="231" width="117" height="20" font="0">age (mean age 74 y) </text>
<text top="220" left="372" width="174" height="20" font="7"><b>Inclusion criteria: </b>free of CVD </text>
<text top="237" left="372" width="180" height="20" font="0">with LDL cholesterol levels &lt;130 </text>
<text top="254" left="372" width="159" height="20" font="0">mg/dL and high-sensitivity C-</text>
<text top="272" left="372" width="174" height="20" font="0">reactive protein levels &gt;2 mg/L. </text>
<text top="289" left="372" width="103" height="20" font="0">(Intermediate risk) </text>
<text top="306" left="372" width="3" height="20" font="0"> </text>
<text top="323" left="372" width="178" height="20" font="7"><b>Exclusion criteria: </b>intolerant to </text>
<text top="340" left="372" width="70" height="20" font="0">rosuvastatin </text>
<text top="220" left="575" width="78" height="20" font="7"><b>Intervention: </b></text>
<text top="237" left="575" width="87" height="20" font="0">rosuvastatin 20 </text>
<text top="254" left="575" width="21" height="20" font="0">mg </text>
<text top="272" left="575" width="3" height="20" font="0"> </text>
<text top="289" left="575" width="81" height="20" font="7"><b>Comparator:  </b></text>
<text top="306" left="575" width="46" height="20" font="0">placebo </text>
<text top="220" left="683" width="79" height="20" font="7"><b>1° endpoint:  </b></text>
<text top="239" left="683" width="11" height="18" font="0">• </text>
<text top="238" left="697" width="257" height="20" font="0">Overall trial: the JUPITER trial overall reported </text>
<text top="255" left="697" width="249" height="20" font="0">a 47% reduction in atherosclerotic CV events </text>
<text top="273" left="697" width="261" height="20" font="0">(nonfatal MI, nonfatal stroke, or CV death) (HR: </text>
<text top="290" left="697" width="259" height="20" font="0">0.53; 95% CI: 0.40–0.69; p&lt;0.0001), as well as </text>
<text top="307" left="697" width="236" height="20" font="0">a 20% reduction in all-cause mortality (HR: </text>
<text top="324" left="697" width="188" height="20" font="0">0.80; 95% CI: 0.67–0.97; p=0.02). </text>
<text top="343" left="683" width="11" height="18" font="0">• </text>
<text top="343" left="697" width="257" height="20" font="0">Participants ≥70 y (mean age 74 y): amounted </text>
<text top="360" left="697" width="241" height="20" font="0">to 32% of the total JUPITER population, but </text>
<text top="377" left="697" width="237" height="20" font="0">suffered 55% of all the hard atherosclerotic </text>
<text top="394" left="697" width="233" height="20" font="0">cardiovascular events occurring in the trial </text>
<text top="413" left="683" width="11" height="18" font="0">• </text>
<text top="412" left="697" width="195" height="20" font="0">In adults &gt;70: 39% reduction in risk </text>
<text top="430" left="697" width="250" height="20" font="0">atherosclerotic CV events (HR: 0.61; 95% CI: </text>
<text top="447" left="697" width="114" height="20" font="0">0.43–0.86; p=0.004) </text>
<text top="466" left="683" width="11" height="18" font="0">• </text>
<text top="465" left="697" width="228" height="20" font="0">Nonsignificant 20% reduction in all-cause </text>
<text top="482" left="697" width="260" height="20" font="0">mortality in the older age strata (HR: 0.80; 95% </text>
<text top="499" left="697" width="119" height="20" font="0">CI: 0.62–1.0; p=0.09) </text>
<text top="222" left="973" width="11" height="18" font="0">• </text>
<text top="221" left="987" width="73" height="20" font="7"><b>Limitations: </b></text>
<text top="240" left="973" width="11" height="18" font="0">• </text>
<text top="239" left="987" width="110" height="20" font="0">median follow-up of </text>
<text top="256" left="987" width="56" height="20" font="0">only 1.9 y </text>
<text top="275" left="973" width="11" height="18" font="0">• </text>
<text top="275" left="987" width="104" height="20" font="0">Relatively younger </text>
<text top="292" left="987" width="105" height="20" font="0">older adult cohort.  </text>
<text top="309" left="975" width="3" height="20" font="0"> </text>
<text top="326" left="975" width="3" height="20" font="0"> </text>
<text top="517" left="89" width="49" height="20" font="7"><b>HOPE-3 </b></text>
<text top="535" left="89" width="118" height="20" font="0">Yusuf, S, et al., 2016 </text>
<text top="552" left="89" width="25" height="20" font="0"><a href="data supplement.html#236">(12)</a> </text>
<text top="569" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27040132">27040132</a></text>
<text top="569" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27040132"> </a></text>
<text top="517" left="231" width="98" height="20" font="7"><b>Aim:</b> To evaluate </text>
<text top="535" left="231" width="112" height="20" font="0">benefits of statins in </text>
<text top="552" left="231" width="115" height="20" font="0">an intermediate-risk, </text>
<text top="569" left="231" width="98" height="20" font="0">ethnically diverse </text>
<text top="586" left="231" width="102" height="20" font="0">population without </text>
<text top="603" left="231" width="83" height="20" font="0">cardiovascular </text>
<text top="621" left="231" width="46" height="20" font="0">disease<b> </b></text>
<text top="638" left="231" width="3" height="20" font="0"> </text>
<text top="655" left="231" width="102" height="20" font="7"><b>Study Type:</b> RCT </text>
<text top="672" left="231" width="3" height="20" font="0"> </text>
<text top="690" left="231" width="126" height="20" font="7"><b>Size: </b>12,705 men ≥55 </text>
<text top="707" left="231" width="128" height="20" font="0">and women ≥65 with 1 </text>
<text top="724" left="231" width="103" height="20" font="0">or more risk factor </text>
<text top="741" left="231" width="123" height="20" font="0">~50% ≥65 (mean age </text>
<text top="758" left="231" width="31" height="20" font="0">71 y) </text>
<text top="776" left="231" width="103" height="20" font="0">3086 ≥70 y of age </text>
<text top="517" left="372" width="106" height="20" font="7"><b>Inclusion criteria: </b></text>
<text top="535" left="372" width="189" height="20" font="0">Free of CVD but with intermediate </text>
<text top="552" left="372" width="26" height="20" font="0">risk  </text>
<text top="569" left="372" width="3" height="20" font="0"> </text>
<text top="586" left="372" width="178" height="20" font="7"><b>Exclusion criteria: </b>intolerant to </text>
<text top="603" left="372" width="39" height="20" font="0">statins </text>
<text top="517" left="575" width="78" height="20" font="7"><b>Intervention: </b></text>
<text top="535" left="575" width="87" height="20" font="0">rosuvastatin 10 </text>
<text top="552" left="575" width="21" height="20" font="0">mg </text>
<text top="569" left="575" width="3" height="20" font="0"> </text>
<text top="586" left="575" width="76" height="20" font="7"><b>Comparator</b>: </text>
<text top="603" left="575" width="46" height="20" font="0">placebo </text>
<text top="517" left="683" width="77" height="20" font="7"><b>1° Endpoint: </b></text>
<text top="536" left="683" width="11" height="18" font="0">• </text>
<text top="536" left="696" width="263" height="20" font="0">Overall trial: hard atherosclerotic cardiovascular </text>
<text top="553" left="696" width="248" height="20" font="0">events: 24% reduction in risk (HR: 0.76; 95% </text>
<text top="570" left="696" width="188" height="20" font="0">CI: 0.64–0.91; p=0.002) and a 7% </text>
<text top="587" left="696" width="248" height="20" font="0">nonsignificant reduction in all-cause mortality </text>
<text top="604" left="696" width="262" height="20" font="0">(HR: 0.93; 95% CI: 0.80–1.08; p=0.32) over 5.6 </text>
<text top="622" left="696" width="13" height="20" font="0">y. </text>
<text top="641" left="683" width="11" height="18" font="0">• </text>
<text top="640" left="696" width="254" height="20" font="0">Subjects ≥70 y of age represented 24% of the </text>
<text top="657" left="696" width="256" height="20" font="0">total trial population yet suffered 43% of all the </text>
<text top="674" left="696" width="234" height="20" font="0">hard atherosclerotic cardiovascular events </text>
<text top="693" left="683" width="11" height="18" font="0">• </text>
<text top="693" left="696" width="192" height="20" font="0">Among those ≥70 ye: Comparable </text>
<text top="710" left="696" width="256" height="20" font="0">nonsignificant 17% reduction in risk was found </text>
<text top="727" left="696" width="260" height="20" font="0">for the combined cardiovascular end point (HR: </text>
<text top="744" left="696" width="192" height="20" font="0">0.83; 95% CI: 0.64–1.07; p=0.16),  </text>
<text top="517" left="975" width="3" height="20" font="0"> </text>
<text top="535" left="975" width="24" height="20" font="0">N/A </text>
</page>
<page number="110" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">110 </text>
<text top="107" left="231" width="3" height="20" font="0"> </text>
<text top="109" left="683" width="11" height="18" font="0">• </text>
<text top="108" left="696" width="254" height="20" font="0">Comparable nonsignificant 9% reduction in all-</text>
<text top="125" left="696" width="254" height="20" font="0">cause mortality (HR: 0.91; 95% CI: 0.73–1.13; </text>
<text top="143" left="696" width="49" height="20" font="0">p=0.38). </text>
<text top="160" left="683" width="101" height="20" font="7"><b>Safety Endpoint: </b></text>
<text top="177" left="683" width="242" height="20" font="0">Rates of drug withdrawal in the rosuvastatin </text>
<text top="194" left="683" width="258" height="20" font="0">groups were 21.4%, 23.1%, and 29.1% among </text>
<text top="211" left="683" width="219" height="20" font="0">those &lt;65, 65 to &lt;70, and &gt;70 y of age, </text>
<text top="229" left="683" width="68" height="20" font="0">respectively </text>
<text top="247" left="89" width="64" height="20" font="7"><b>PROSPER </b></text>
<text top="264" left="89" width="100" height="20" font="0">Shepherd J, 2002 </text>
<text top="281" left="89" width="32" height="20" font="0"><a href="data supplement.html#242">(113)</a> </text>
<text top="298" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12457784">12457784</a></text>
<text top="298" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12457784"> </a></text>
<text top="247" left="231" width="111" height="20" font="7"><b>Aim:</b> risk factors for </text>
<text top="264" left="231" width="120" height="20" font="0">CVD or Hx CHD or to </text>
<text top="281" left="231" width="101" height="20" font="0">pravastatin 40 mg </text>
<text top="298" left="231" width="90" height="20" font="0">daily or placebo </text>
<text top="315" left="231" width="3" height="20" font="0"> </text>
<text top="333" left="231" width="102" height="20" font="7"><b>Study Type:</b> RCT </text>
<text top="350" left="231" width="3" height="20" font="0"> </text>
<text top="367" left="231" width="114" height="20" font="7"><b>Size: </b>5804 men and </text>
<text top="384" left="231" width="109" height="20" font="0">women aged 70-82 </text>
<text top="401" left="231" width="125" height="20" font="0">--subgroup with ASCV </text>
<text top="419" left="231" width="110" height="20" font="0">risk elevated due to </text>
<text top="436" left="231" width="127" height="20" font="0">tobacco, hypertension, </text>
<text top="453" left="231" width="22" height="20" font="0">DM </text>
<text top="247" left="372" width="155" height="20" font="7"><b>Inclusion criteria:</b> high risk<b> </b></text>
<text top="264" left="372" width="3" height="20" font="7"><b> </b></text>
<text top="281" left="372" width="110" height="20" font="7"><b>Exclusion criteria:</b> </text>
<text top="247" left="575" width="78" height="20" font="7"><b>Intervention: </b></text>
<text top="264" left="575" width="82" height="20" font="0">Pravastatin 40 </text>
<text top="281" left="575" width="24" height="20" font="0">mg  </text>
<text top="298" left="575" width="3" height="20" font="0"> </text>
<text top="315" left="575" width="81" height="20" font="7"><b>Comparator:  </b></text>
<text top="333" left="575" width="46" height="20" font="0">placebo </text>
<text top="247" left="683" width="80" height="20" font="7"><b>1° Endpoint:  </b></text>
<text top="266" left="682" width="11" height="18" font="0">• </text>
<text top="265" left="696" width="222" height="20" font="0">Pravastatin therapy reduced the primary </text>
<text top="282" left="696" width="265" height="20" font="0">endpoint of CHD death, non-fatal MI and fatal or </text>
<text top="299" left="696" width="256" height="20" font="0">non-fatal stroke (HR: 0.85; 95% CI: 0.74–0.97, </text>
<text top="316" left="696" width="59" height="20" font="0">p=0.014).  </text>
<text top="335" left="682" width="11" height="18" font="0">• </text>
<text top="335" left="696" width="148" height="20" font="0">3.2 y of average follow-up, </text>
<text top="352" left="683" width="3" height="20" font="0"> </text>
<text top="369" left="683" width="3" height="20" font="0"> </text>
<text top="247" left="975" width="24" height="20" font="0">N/A </text>
<text top="264" left="975" width="3" height="20" font="0"> </text>
<text top="471" left="89" width="109" height="20" font="7"><b>Physicians Health </b></text>
<text top="488" left="89" width="38" height="20" font="7"><b>Study </b></text>
<text top="505" left="89" width="126" height="20" font="0">Orkaby, J, 2017 <a href="data supplement.html#242">(114)</a>  </text>
<text top="523" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28892121">28892121</a></text>
<text top="523" left="144" width="3" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28892121"><b> </b></a></text>
<text top="471" left="231" width="103" height="20" font="7"><b>Aim: </b>to determine<b> </b></text>
<text top="488" left="231" width="121" height="20" font="0">whether statin use for </text>
<text top="505" left="231" width="118" height="20" font="0">primary prevention is </text>
<text top="523" left="231" width="62" height="20" font="0">associated </text>
<text top="540" left="231" width="104" height="20" font="0">with a lower risk of </text>
<text top="557" left="231" width="122" height="20" font="0">cardiovascular events </text>
<text top="574" left="231" width="68" height="20" font="0">or mortality  </text>
<text top="591" left="231" width="74" height="20" font="7"><b>Study Type: </b></text>
<text top="609" left="231" width="105" height="20" font="0">Prospective cohort </text>
<text top="626" left="231" width="33" height="20" font="0">study<b> </b></text>
<text top="643" left="231" width="96" height="20" font="7"><b>Size: </b>7,213 male </text>
<text top="660" left="231" width="104" height="20" font="0">physicians Median </text>
<text top="677" left="231" width="91" height="20" font="0">age 77 (77-102) </text>
<text top="471" left="372" width="106" height="20" font="7"><b>Inclusion criteria: </b></text>
<text top="488" left="372" width="141" height="20" font="0">≥70 y without a history of </text>
<text top="505" left="372" width="166" height="20" font="0">cardiovascular disease (CVD) </text>
<text top="523" left="372" width="3" height="20" font="7"><b> </b></text>
<text top="540" left="372" width="110" height="20" font="7"><b>Exclusion criteria: </b></text>
<text top="557" left="372" width="183" height="20" font="0">2,670 participants were excluded </text>
<text top="574" left="372" width="172" height="20" font="0">because of prevalent CVD (MI, </text>
<text top="591" left="372" width="162" height="20" font="0">stroke, or peripheral vascular </text>
<text top="609" left="372" width="171" height="20" font="0">disease) and an additional 105 </text>
<text top="626" left="372" width="165" height="20" font="0">were excluded due to missing </text>
<text top="643" left="372" width="151" height="20" font="0">information on statin use at </text>
<text top="660" left="372" width="53" height="20" font="0">baseline. </text>
<text top="471" left="575" width="78" height="20" font="7"><b>Intervention: </b></text>
<text top="488" left="575" width="63" height="20" font="0">Completed </text>
<text top="505" left="575" width="40" height="20" font="0">annual </text>
<text top="523" left="575" width="83" height="20" font="0">questionnaires </text>
<text top="540" left="575" width="83" height="20" font="0">from 1999, the </text>
<text top="557" left="575" width="82" height="20" font="0">year a specific </text>
<text top="574" left="575" width="50" height="20" font="0">question </text>
<text top="591" left="575" width="88" height="20" font="0">regarding statin </text>
<text top="609" left="575" width="90" height="20" font="0">use was added.<b> </b></text>
<text top="626" left="575" width="3" height="20" font="7"><b> </b></text>
<text top="643" left="575" width="81" height="20" font="7"><b>Comparator:  </b></text>
<text top="660" left="575" width="90" height="20" font="0">Non-users were </text>
<text top="677" left="575" width="64" height="20" font="0">matched to </text>
<text top="695" left="575" width="67" height="20" font="0">1,130 statin </text>
<text top="712" left="575" width="37" height="20" font="0">users.<b> </b></text>
<text top="471" left="683" width="80" height="20" font="7"><b>1° Endpoint:  </b></text>
<text top="488" left="683" width="272" height="20" font="0">Statin use was associated with a significant lower </text>
<text top="505" left="683" width="270" height="20" font="0">risk of mortality in older male physicians ≥70 and </text>
<text top="523" left="683" width="275" height="20" font="0">a nonsignificant lower risk of CVD events. Results </text>
<text top="540" left="683" width="234" height="20" font="0">did not change in those who were &gt;76 y at </text>
<text top="557" left="683" width="265" height="20" font="0">baseline or according to functional status. There </text>
<text top="574" left="683" width="258" height="20" font="0">was a suggestion that those with elevated total </text>
<text top="591" left="683" width="137" height="20" font="0">cholesterol may benefit.  </text>
<text top="609" left="683" width="3" height="20" font="7"><b> </b></text>
<text top="626" left="683" width="145" height="20" font="0">Median follow-up was 7 y. </text>
<text top="643" left="683" width="3" height="20" font="7"><b> </b></text>
<text top="471" left="975" width="24" height="20" font="0">N/A </text>
<text top="730" left="89" width="105" height="20" font="7"><b>Health Protection </b></text>
<text top="747" left="89" width="104" height="20" font="7"><b>Study</b> 2002<a href="data supplement.html#242"> (115)</a>  </text>
<text top="764" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19442259">19442259</a></text>
<text top="764" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19442259"> </a></text>
<text top="730" left="231" width="113" height="20" font="0">Aim: CHD or at high </text>
<text top="747" left="231" width="96" height="20" font="0">risk for CHD with </text>
<text top="764" left="231" width="53" height="20" font="0">diabetes, </text>
<text top="730" left="372" width="109" height="20" font="7"><b>Inclusion criteria:  </b></text>
<text top="747" left="372" width="3" height="20" font="7"><b> </b></text>
<text top="764" left="372" width="109" height="20" font="7"><b>Exclusion criteria</b>: </text>
<text top="730" left="575" width="78" height="20" font="7"><b>Intervention: </b></text>
<text top="747" left="575" width="67" height="20" font="0">Simvastatin </text>
<text top="764" left="575" width="3" height="20" font="0"> </text>
<text top="782" left="575" width="81" height="20" font="7"><b>Comparator:  </b></text>
<text top="730" left="683" width="80" height="20" font="7"><b>1° Endpoint:</b>  </text>
<text top="749" left="682" width="11" height="18" font="0">• </text>
<text top="748" left="696" width="264" height="20" font="0">reduced all-cause mortality and CHD death with </text>
<text top="765" left="696" width="228" height="20" font="0">treatment with simvastatin 40 mg daily as </text>
<text top="730" left="975" width="3" height="20" font="0"> </text>
</page>
<page number="111" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">111 </text>
<text top="107" left="231" width="3" height="20" font="0"> </text>
<text top="124" left="231" width="98" height="20" font="0">Study Type: RCT </text>
<text top="141" left="231" width="3" height="20" font="0"> </text>
<text top="159" left="231" width="89" height="20" font="7"><b>Size:</b> N=20,536 </text>
<text top="176" left="231" width="128" height="20" font="0">patients aged 40–80 y. </text>
<text top="193" left="231" width="112" height="20" font="0">N=5806 aged ≥65 y </text>
<text top="107" left="696" width="221" height="20" font="0">compared to placebo (12.9% vs. 14.7%, </text>
<text top="124" left="696" width="249" height="20" font="0">p=0.0003) and (5.7% vs. 6.9%), respectively. </text>
<text top="143" left="682" width="11" height="18" font="0">• </text>
<text top="143" left="696" width="245" height="20" font="0">In 5806 patients aged ≥65, major CV events </text>
<text top="160" left="696" width="233" height="20" font="0">were reduced by absolute rates of 6.3% in </text>
<text top="177" left="696" width="250" height="20" font="0">patients aged 65–69 and 5.1% in patients 70–</text>
<text top="194" left="696" width="21" height="20" font="0">80. </text>
<text top="212" left="89" width="51" height="20" font="7"><b>CARDS  </b></text>
<text top="229" left="89" width="111" height="20" font="0">Neil HA, 2006 <a href="data supplement.html#243">(116)</a> </text>
<text top="247" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17065671">17065671</a></text>
<text top="247" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17065671"> </a></text>
<text top="212" left="231" width="75" height="20" font="7"><b>Aim: </b>primary </text>
<text top="229" left="231" width="124" height="20" font="0">prevention in older pts </text>
<text top="247" left="231" width="48" height="20" font="0">with DM </text>
<text top="264" left="231" width="3" height="20" font="0"> </text>
<text top="281" left="231" width="74" height="20" font="7"><b>Study Type: </b></text>
<text top="298" left="231" width="3" height="20" font="0"> </text>
<text top="315" left="231" width="109" height="20" font="7"><b>Size:</b> 1129 diabetic </text>
<text top="333" left="231" width="112" height="20" font="0">patients aged 65-75 </text>
<text top="212" left="372" width="106" height="20" font="7"><b>Inclusion criteria: </b></text>
<text top="229" left="372" width="170" height="20" font="0">DM and at least one risk factor </text>
<text top="247" left="372" width="3" height="20" font="0"> </text>
<text top="264" left="372" width="110" height="20" font="7"><b>Exclusion criteria: </b></text>
<text top="212" left="575" width="78" height="20" font="7"><b>Intervention: </b></text>
<text top="229" left="575" width="84" height="20" font="0">atorvastatin 10 </text>
<text top="247" left="575" width="21" height="20" font="0">mg </text>
<text top="264" left="575" width="3" height="20" font="0"> </text>
<text top="281" left="575" width="81" height="20" font="7"><b>Comparator:  </b></text>
<text top="298" left="575" width="46" height="20" font="0">placebo </text>
<text top="212" left="683" width="77" height="20" font="7"><b>1° Endpoint: </b></text>
<text top="231" left="682" width="11" height="18" font="0">• </text>
<text top="230" left="696" width="181" height="20" font="0">Overall 37% CHD risk reduction  </text>
<text top="249" left="682" width="11" height="18" font="0">• </text>
<text top="249" left="696" width="254" height="20" font="0">In, the older group, treatment with atorvastatin </text>
<text top="266" left="696" width="248" height="20" font="0">reduced the risk of first major CHD events by </text>
<text top="283" left="696" width="161" height="20" font="0">38%; 95% CI: 58–8, p&lt;0.017 </text>
<text top="212" left="975" width="121" height="20" font="0">No significant change </text>
<text top="229" left="975" width="111" height="20" font="0">in all cause morality </text>
<text top="247" left="975" width="3" height="20" font="0"> </text>
<text top="351" left="89" width="44" height="20" font="7"><b>MEGA  </b></text>
<text top="368" left="89" width="110" height="20" font="0">Nakaya N, 2011 <a href="data supplement.html#236">(8)</a> </text>
<text top="385" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21815708">21815708</a></text>
<text top="385" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21815708"> </a></text>
<text top="402" left="89" width="3" height="20" font="0"> </text>
<text top="351" left="231" width="115" height="20" font="7"><b>Aim: </b>to evaluate the </text>
<text top="368" left="231" width="122" height="20" font="0">relationships between </text>
<text top="385" left="231" width="117" height="20" font="0">age, baseline patient </text>
<text top="402" left="231" width="109" height="20" font="0">characteristics, and </text>
<text top="419" left="231" width="119" height="20" font="0">pravastatin treatment </text>
<text top="437" left="231" width="103" height="20" font="0">with respect to the </text>
<text top="454" left="231" width="87" height="20" font="0">development of </text>
<text top="471" left="231" width="83" height="20" font="0">cardiovascular </text>
<text top="488" left="231" width="117" height="20" font="0">disease (CVD) in the </text>
<text top="505" left="231" width="73" height="20" font="0">MEGA study </text>
<text top="523" left="231" width="3" height="20" font="0"> </text>
<text top="540" left="231" width="102" height="20" font="7"><b>Study Type: </b>RCT </text>
<text top="557" left="231" width="3" height="20" font="0"> </text>
<text top="574" left="231" width="109" height="20" font="7"><b>Size: </b>7832 patients </text>
<text top="591" left="231" width="108" height="20" font="0">(ages women up to </text>
<text top="609" left="231" width="127" height="20" font="0">80, men 40–70); 6 age </text>
<text top="626" left="231" width="113" height="20" font="0">groups: &lt;45, 45–49, </text>
<text top="643" left="231" width="120" height="20" font="0">50–54, 55–59, 60–64 </text>
<text top="660" left="231" width="66" height="20" font="0">and ≥65 y.  </text>
<text top="351" left="372" width="157" height="20" font="7"><b>Inclusion criteria:</b> men and </text>
<text top="368" left="372" width="168" height="20" font="0">postmenopausal women aged </text>
<text top="385" left="372" width="72" height="20" font="0">40–70 y with </text>
<text top="402" left="372" width="186" height="20" font="0">hypercholesterolaemia (TC levels </text>
<text top="419" left="372" width="180" height="20" font="0">of 5.7–7.0 mmol/L), no history of </text>
<text top="437" left="372" width="54" height="20" font="0">CHD and </text>
<text top="454" left="372" width="40" height="20" font="0">stroke, </text>
<text top="471" left="372" width="3" height="20" font="0"> </text>
<text top="488" left="372" width="110" height="20" font="7"><b>Exclusion criteria: </b></text>
<text top="351" left="575" width="78" height="20" font="7"><b>Intervention: </b></text>
<text top="368" left="575" width="84" height="20" font="0">pravastatin 10–</text>
<text top="385" left="575" width="66" height="20" font="0">20 mg daily </text>
<text top="402" left="575" width="3" height="20" font="0"> </text>
<text top="419" left="575" width="76" height="20" font="7"><b>Comparator</b>: </text>
<text top="437" left="575" width="46" height="20" font="0">placebo </text>
<text top="351" left="683" width="80" height="20" font="7"><b>1° Endpoint:  </b></text>
<text top="370" left="682" width="11" height="18" font="0">• </text>
<text top="369" left="696" width="235" height="20" font="0">30–40% reduction in clinical events across </text>
<text top="386" left="696" width="265" height="20" font="0">multiple age ranges including in patients greater </text>
<text top="403" left="696" width="54" height="20" font="0">than 65 y </text>
<text top="422" left="682" width="11" height="18" font="0">• </text>
<text top="422" left="696" width="246" height="20" font="0">Pravastatin (10–20 mg/d) reduced the risk of </text>
<text top="439" left="696" width="249" height="20" font="0">CVD by about 30–40% across all age groups </text>
<text top="456" left="696" width="219" height="20" font="0">(including those &gt;65), and there was no </text>
<text top="473" left="696" width="209" height="20" font="0">difference between men and women.  </text>
<text top="492" left="682" width="11" height="18" font="0">• </text>
<text top="491" left="696" width="237" height="20" font="0">Of particular note in this analysis, CVD risk </text>
<text top="509" left="696" width="262" height="20" font="0">lowering benefits (old vs. young) similar in men, </text>
<text top="526" left="696" width="262" height="20" font="0">but CVD risk lowering older women significantly </text>
<text top="543" left="696" width="200" height="20" font="0">greater in older vs. younger women. </text>
<text top="351" left="975" width="24" height="20" font="0">N/A </text>
</page>
<page number="112" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">112 </text>
<text top="107" left="89" width="79" height="20" font="7"><b>ALLHAT-LLT </b></text>
<text top="124" left="89" width="106" height="20" font="0">Han BH, 2017 <a href="data supplement.html#241">(90)</a> </text>
<text top="141" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28531241">28531241</a></text>
<text top="141" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28531241"> </a></text>
<text top="107" left="231" width="124" height="20" font="7"><b>Aim:</b> to study benefits </text>
<text top="124" left="231" width="94" height="20" font="0">of statins among </text>
<text top="141" left="231" width="105" height="20" font="0">adults aged 65–74 </text>
<text top="159" left="231" width="113" height="20" font="0">and ≥75 in ALLHAT-</text>
<text top="176" left="231" width="25" height="20" font="0">LLT </text>
<text top="193" left="231" width="3" height="20" font="0"> </text>
<text top="210" left="231" width="124" height="20" font="7"><b>Study Type: </b>post hoc </text>
<text top="227" left="231" width="121" height="20" font="0">secondary analysis of </text>
<text top="245" left="231" width="80" height="20" font="0">older adults in </text>
<text top="262" left="231" width="104" height="20" font="0">ALLHAAT-LLT, an </text>
<text top="279" left="231" width="29" height="20" font="0">RCT </text>
<text top="296" left="231" width="3" height="20" font="0"> </text>
<text top="314" left="231" width="125" height="20" font="7"><b>Size:</b> 2867 (mean age </text>
<text top="331" left="231" width="41" height="20" font="0">71.3 y) </text>
<text top="107" left="372" width="161" height="20" font="7"><b>Inclusion criteria: </b>Moderate </text>
<text top="124" left="372" width="185" height="20" font="0">hyperlipidemia and HTN in adults </text>
<text top="141" left="372" width="109" height="20" font="0">without evidence of </text>
<text top="159" left="372" width="166" height="20" font="0">atherosclerotic cardiovascular </text>
<text top="176" left="372" width="46" height="20" font="0">disease </text>
<text top="193" left="372" width="3" height="20" font="0"> </text>
<text top="210" left="372" width="3" height="20" font="0"> </text>
<text top="107" left="575" width="78" height="20" font="7"><b>Intervention: </b></text>
<text top="124" left="575" width="82" height="20" font="0">Pravastatin 40 </text>
<text top="141" left="575" width="3" height="20" font="0"> </text>
<text top="159" left="575" width="81" height="20" font="7"><b>Comparator:  </b></text>
<text top="107" left="683" width="80" height="20" font="7"><b>1° Endpoint:  </b></text>
<text top="126" left="682" width="11" height="18" font="0">• </text>
<text top="125" left="696" width="262" height="20" font="0">All-cause mortality: HR for all-cause mortality in </text>
<text top="143" left="696" width="245" height="20" font="0">the pravastatin group vs. the UC group were </text>
<text top="160" left="696" width="260" height="20" font="0">1.18; 95% CI: 0.97–1.42; p=0.09 for adults ≥65 </text>
<text top="177" left="696" width="10" height="20" font="0">y </text>
<text top="196" left="682" width="11" height="18" font="0">• </text>
<text top="195" left="696" width="260" height="20" font="0">HR: 1.08; 95% CI: 0.85–1.37; p=0.55 for adults </text>
<text top="212" left="696" width="82" height="20" font="0">aged 65-74 y,  </text>
<text top="231" left="682" width="11" height="18" font="0">• </text>
<text top="231" left="696" width="260" height="20" font="0">HR: 1.34; 95% CI: 0.98–1.84; p=0.07 for adults </text>
<text top="248" left="696" width="42" height="20" font="0">≥75 y.  </text>
<text top="107" left="975" width="102" height="20" font="7"><b>Major limitation:  </b></text>
<text top="124" left="975" width="69" height="20" font="0">Significantly </text>
<text top="141" left="975" width="84" height="20" font="0">confounded by </text>
<text top="159" left="975" width="105" height="20" font="0">contamination with </text>
<text top="176" left="975" width="92" height="20" font="0">newer and more </text>
<text top="193" left="975" width="110" height="20" font="0">potent statins in the </text>
<text top="210" left="975" width="124" height="20" font="0">control group, with the </text>
<text top="228" left="975" width="121" height="20" font="0">effect that CHD event </text>
<text top="245" left="975" width="81" height="20" font="0">rates were not </text>
<text top="262" left="975" width="115" height="20" font="0">significantly different </text>
<text top="279" left="975" width="109" height="20" font="0">among the groups.  </text>
<text top="349" left="89" width="92" height="20" font="7"><b>Cardiovascular </b></text>
<text top="366" left="89" width="79" height="20" font="7"><b>Health Study </b></text>
<text top="383" left="89" width="107" height="20" font="0">Lemaitre RN, 2002 </text>
<text top="400" left="89" width="32" height="20" font="0"><a href="data supplement.html#243">(117)</a> </text>
<text top="418" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12076239">12076239</a></text>
<text top="418" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=12076239"> </a></text>
<text top="349" left="231" width="90" height="20" font="7"><b>Aim:</b> To assess </text>
<text top="366" left="231" width="109" height="20" font="0">effects of statins on </text>
<text top="383" left="231" width="100" height="20" font="0">CV events and all-</text>
<text top="400" left="231" width="86" height="20" font="0">cause mortality </text>
<text top="418" left="231" width="3" height="20" font="0"> </text>
<text top="435" left="231" width="74" height="20" font="7"><b>Study Type: </b></text>
<text top="452" left="231" width="79" height="20" font="0">Observational </text>
<text top="469" left="231" width="3" height="20" font="0"> </text>
<text top="487" left="231" width="102" height="20" font="7"><b>Size:</b> 1914 elderly </text>
<text top="504" left="231" width="125" height="20" font="0">men and women older </text>
<text top="521" left="231" width="127" height="20" font="0">than 65 y (average 72) </text>
<text top="349" left="372" width="182" height="20" font="7"><b>Inclusion criteria: </b>Subjects with </text>
<text top="366" left="372" width="46" height="20" font="0">no CVD </text>
<text top="383" left="372" width="3" height="20" font="0"> </text>
<text top="400" left="372" width="110" height="20" font="7"><b>Exclusion criteria: </b></text>
<text top="349" left="575" width="78" height="20" font="7"><b>Intervention: </b></text>
<text top="366" left="575" width="79" height="20" font="0">Statin therapy </text>
<text top="383" left="575" width="3" height="20" font="0"> </text>
<text top="400" left="575" width="77" height="20" font="7"><b>Comparator:</b> </text>
<text top="418" left="575" width="52" height="20" font="0">No statin </text>
<text top="349" left="683" width="77" height="20" font="7"><b>1° Endpoint: </b></text>
<text top="366" left="683" width="271" height="20" font="0">56% lower risk of incident CVD events (HR: 0.44, </text>
<text top="383" left="683" width="273" height="20" font="0">95% CI: 0.27–0.71) and 44% lower mortality (HR: </text>
<text top="400" left="683" width="147" height="20" font="0">0.56, 95% CI: 0.36–0.88).  </text>
<text top="418" left="683" width="3" height="20" font="0"> </text>
<text top="435" left="683" width="236" height="20" font="0">A subgroup aged &gt;75 y had same benefit.  </text>
<text top="452" left="683" width="3" height="20" font="0"> </text>
<text top="349" left="975" width="24" height="20" font="0">N/A </text>
<text top="539" left="89" width="98" height="20" font="7"><b>Jupiter—Hope-3 </b></text>
<text top="556" left="89" width="127" height="20" font="0">Ridker PM, 2017 <a href="data supplement.html#243">(118)</a> </text>
<text top="573" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28385949">28385949</a></text>
<text top="573" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28385949"> </a></text>
<text top="539" left="231" width="84" height="20" font="7"><b>Aim: </b>To clarify </text>
<text top="556" left="231" width="103" height="20" font="0">efficacy of primary </text>
<text top="573" left="231" width="107" height="20" font="0">statin prevention in </text>
<text top="591" left="231" width="67" height="20" font="0">older adults </text>
<text top="608" left="231" width="3" height="20" font="0"> </text>
<text top="625" left="231" width="105" height="20" font="7"><b>Study Type: </b>Meta-</text>
<text top="642" left="231" width="112" height="20" font="0">analysis Jupiter and </text>
<text top="659" left="231" width="44" height="20" font="0">Hope-3 </text>
<text top="677" left="231" width="3" height="20" font="0"> </text>
<text top="694" left="231" width="125" height="20" font="7"><b>Size:</b> 30,507 subjects; </text>
<text top="711" left="231" width="96" height="20" font="0">8781 aged ≥70 y </text>
<text top="539" left="372" width="106" height="20" font="7"><b>Inclusion criteria: </b></text>
<text top="556" left="372" width="169" height="20" font="0">Low risk subjects with no CVD </text>
<text top="573" left="372" width="3" height="20" font="0"> </text>
<text top="591" left="372" width="110" height="20" font="7"><b>Exclusion criteria: </b></text>
<text top="539" left="575" width="78" height="20" font="7"><b>Intervention: </b></text>
<text top="556" left="575" width="74" height="20" font="0">Rosuvastatin </text>
<text top="573" left="575" width="85" height="20" font="0">(20 mg, Jupiter </text>
<text top="591" left="575" width="65" height="20" font="0">and 10 mg, </text>
<text top="608" left="575" width="48" height="20" font="0">Hope-3) </text>
<text top="625" left="575" width="3" height="20" font="0"> </text>
<text top="642" left="575" width="81" height="20" font="7"><b>Comparator:  </b></text>
<text top="659" left="575" width="48" height="20" font="0">Placebo </text>
<text top="539" left="683" width="80" height="20" font="7"><b>1° Endpoint:</b>  </text>
<text top="558" left="682" width="11" height="18" font="0">• </text>
<text top="557" left="696" width="253" height="20" font="0">26% relative risk reduction observed for those </text>
<text top="574" left="696" width="250" height="20" font="0">&gt;70 y for the end point of nonfatal myocardial </text>
<text top="591" left="696" width="241" height="20" font="0">infarction, nonfatal stroke, or cardiovascular </text>
<text top="609" left="696" width="258" height="20" font="0">death (HR: 0.74; 95% CI: 0.61–0.91; p=0.0048 </text>
<text top="628" left="682" width="11" height="18" font="0">• </text>
<text top="627" left="696" width="255" height="20" font="0">The much higher event rates in those ≥70 y of </text>
<text top="644" left="696" width="242" height="20" font="0">age, along with the comparable relative rate </text>
<text top="661" left="696" width="256" height="20" font="0">reductions, i.e., larger absolute rate reductions </text>
<text top="679" left="696" width="237" height="20" font="0">associated with statin treatment and hence </text>
<text top="696" left="696" width="256" height="20" font="0">smaller numbers needed to treat to prevent an </text>
<text top="713" left="696" width="252" height="20" font="0">event in older compared with younger people. </text>
<text top="732" left="682" width="11" height="18" font="0">• </text>
<text top="731" left="696" width="245" height="20" font="0">In neither of these analyses was evidence of </text>
<text top="748" left="696" width="172" height="20" font="0">heterogeneity by age observed </text>
<text top="767" left="682" width="11" height="18" font="0">• </text>
<text top="767" left="696" width="242" height="20" font="0">Rates of drug withdrawal in the rosuvastatin </text>
<text top="784" left="696" width="258" height="20" font="0">groups were 14.3%, 17.0%, and 21.6% among </text>
<text top="539" left="975" width="96" height="20" font="0">For an expanded </text>
<text top="556" left="975" width="123" height="20" font="0">endpoint that includes </text>
<text top="573" left="975" width="99" height="20" font="0">revascularization, </text>
<text top="591" left="975" width="115" height="20" font="0">effects were virtually </text>
<text top="608" left="975" width="119" height="20" font="0">identical in those &gt;70 </text>
<text top="625" left="975" width="107" height="20" font="0">y of age (HR: 0.74; </text>
<text top="642" left="975" width="109" height="20" font="0">95% CI: 0.61–0.89; </text>
<text top="659" left="975" width="66" height="20" font="0">p=0.0016).  </text>
<text top="677" left="975" width="3" height="20" font="0"> </text>
<text top="694" left="975" width="3" height="20" font="0"> </text>
</page>
<page number="113" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">113 </text>
<text top="107" left="696" width="239" height="20" font="0">those &lt;65 y, 65 to &lt;70 y, and ≥70 y of age, </text>
<text top="124" left="696" width="72" height="20" font="0">respectively. </text>
<text top="141" left="682" width="101" height="20" font="7"><b>Safety Endpoint: </b></text>
<text top="160" left="682" width="11" height="18" font="0">• </text>
<text top="160" left="696" width="242" height="20" font="0">Effects consistent across age groups, and a </text>
<text top="177" left="696" width="264" height="20" font="0">formal test for heterogeneity was nonsignificant. </text>
<text top="196" left="682" width="11" height="18" font="0">• </text>
<text top="195" left="696" width="266" height="20" font="0">Uncertainties remain with regard to hemorrhagic </text>
<text top="212" left="696" width="240" height="20" font="0">stroke, cognitive function, drug interactions, </text>
<text top="230" left="696" width="191" height="20" font="0">adherence, quality of life, and cost-</text>
<text top="247" left="696" width="82" height="20" font="0">effectiveness.  </text>
<text top="266" left="682" width="11" height="18" font="0">• </text>
<text top="265" left="696" width="131" height="20" font="0">concerns regarding DM </text>
<text top="283" left="89" width="112" height="20" font="0">Savarese GJ, 2013  </text>
<text top="300" left="89" width="32" height="20" font="0"><a href="data supplement.html#243">(119)</a> </text>
<text top="317" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23954343">23954343</a></text>
<text top="317" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23954343"> </a></text>
<text top="283" left="231" width="100" height="20" font="7"><b>Aim: </b>Study of CV </text>
<text top="300" left="231" width="81" height="20" font="0">endpoints and </text>
<text top="317" left="231" width="121" height="20" font="0">mortality using statins </text>
<text top="335" left="231" width="80" height="20" font="0">in older adults </text>
<text top="352" left="231" width="3" height="20" font="0"> </text>
<text top="369" left="231" width="105" height="20" font="7"><b>Study Type: </b>Meta-</text>
<text top="386" left="231" width="90" height="20" font="0">analysis of RCT </text>
<text top="404" left="231" width="3" height="20" font="0"> </text>
<text top="421" left="231" width="121" height="20" font="7"><b>Size:</b> 24,674 subjects </text>
<text top="438" left="231" width="91" height="20" font="0">age ≥65. 42.7% </text>
<text top="455" left="231" width="108" height="20" font="0">females; mean age </text>
<text top="472" left="231" width="31" height="20" font="0">73.0  </text>
<text top="283" left="372" width="106" height="20" font="7"><b>Inclusion criteria: </b></text>
<text top="300" left="372" width="168" height="20" font="0">RTC comparing statins versus </text>
<text top="317" left="372" width="75" height="20" font="0">placebo with  </text>
<text top="335" left="372" width="179" height="20" font="0">--all-cause and CV mortality, MI, </text>
<text top="352" left="372" width="177" height="20" font="0">stroke, and new cancer onset in </text>
<text top="369" left="372" width="92" height="20" font="0">elderly subjects  </text>
<text top="386" left="372" width="3" height="20" font="0"> </text>
<text top="404" left="372" width="110" height="20" font="7"><b>Exclusion criteria: </b></text>
<text top="421" left="372" width="60" height="20" font="0">38 studies </text>
<text top="438" left="372" width="150" height="20" font="0">excluded: 25 trials enrolled </text>
<text top="455" left="372" width="180" height="20" font="0">patients with established CVD; 7 </text>
<text top="472" left="372" width="172" height="20" font="0">trials reported duplicate data; 2 </text>
<text top="490" left="372" width="136" height="20" font="0">trials reported no clinical </text>
<text top="507" left="372" width="187" height="20" font="0">endpoint; 1 trial excluded patients </text>
<text top="524" left="372" width="179" height="20" font="0">age &gt;70 y; 1 randomized clinical </text>
<text top="541" left="372" width="182" height="20" font="0">study having missing information </text>
<text top="558" left="372" width="147" height="20" font="0">that we could not obtained </text>
<text top="283" left="575" width="78" height="20" font="7"><b>Intervention: </b></text>
<text top="300" left="575" width="35" height="20" font="0">Statin </text>
<text top="317" left="575" width="3" height="20" font="0"> </text>
<text top="335" left="575" width="81" height="20" font="7"><b>Comparator:  </b></text>
<text top="352" left="575" width="48" height="20" font="0">Placebo </text>
<text top="283" left="683" width="77" height="20" font="7"><b>1° Endpoint: </b></text>
<text top="302" left="682" width="11" height="18" font="0">• </text>
<text top="301" left="696" width="246" height="20" font="0">Statins significantly reduced the risk of MI by </text>
<text top="318" left="696" width="244" height="20" font="0">39.4% (RR: 0.606; 95% CI: 0.434–0.847; p= </text>
<text top="336" left="696" width="239" height="20" font="0">0.003) and the risk of stroke by 23.8% (RR: </text>
<text top="353" left="696" width="219" height="20" font="0">0.762; 95% CI: 0.626–0.926; p=0.006).  </text>
<text top="372" left="682" width="11" height="18" font="0">• </text>
<text top="371" left="696" width="234" height="20" font="0">Risk of all-cause death (RR: 0.94; 95% CI: </text>
<text top="388" left="696" width="249" height="20" font="0">0.856–1.035; p=0.210) and of CV death (RR: </text>
<text top="406" left="696" width="263" height="20" font="0">0.907; 95% CI: 0.686–1.199; p=0.493) were not </text>
<text top="423" left="696" width="118" height="20" font="0">significantly reduced. </text>
<text top="440" left="682" width="167" height="20" font="7"><b>Safety Endpoint (if relevant) </b></text>
<text top="459" left="682" width="11" height="18" font="0">• </text>
<text top="458" left="696" width="260" height="20" font="0">New cancer onset did not differ between statin- </text>
<text top="475" left="696" width="256" height="20" font="0">and placebo-treated subjects (RR: 0.989; 95% </text>
<text top="493" left="696" width="150" height="20" font="0">CI: 0.851–1.151; p=0.890). </text>
<text top="283" left="975" width="73" height="20" font="7"><b>Limitations: </b></text>
<text top="300" left="975" width="120" height="20" font="0">2.9 y; mean follow up </text>
<text top="317" left="975" width="60" height="20" font="0">3.5±1.5 y) </text>
<text top="576" left="89" width="119" height="20" font="0">TENG M, et al., 2015 </text>
<text top="594" left="89" width="32" height="20" font="0"><a href="data supplement.html#243">(120)</a> </text>
<text top="611" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26245770">26245770</a></text>
<text top="611" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26245770"> </a></text>
<text top="576" left="231" width="105" height="20" font="7"><b>Study Type:</b> Meta-</text>
<text top="594" left="231" width="76" height="20" font="0">analysis RCT </text>
<text top="611" left="231" width="3" height="20" font="0"> </text>
<text top="628" left="231" width="129" height="20" font="7"><b>Size:</b> 8 studies 25,952  </text>
<text top="645" left="231" width="3" height="20" font="0"> </text>
<text top="662" left="231" width="3" height="20" font="0"> </text>
<text top="680" left="231" width="127" height="20" font="7"><b>Subjects</b>: aged ≥65 y. </text>
<text top="697" left="231" width="95" height="20" font="0">Mean age 72.7 y </text>
<text top="714" left="231" width="101" height="20" font="0">(range 69–75.5 y) </text>
<text top="731" left="231" width="3" height="20" font="0"> </text>
<text top="576" left="372" width="106" height="20" font="7"><b>Inclusion criteria: </b></text>
<text top="594" left="372" width="156" height="20" font="0">participants aged ≥65 y and </text>
<text top="611" left="372" width="138" height="20" font="0">without established CVD </text>
<text top="628" left="372" width="3" height="20" font="0"> </text>
<text top="645" left="372" width="169" height="20" font="0">The proportion of patients with </text>
<text top="662" left="372" width="173" height="20" font="0">diabetes and hypertension was </text>
<text top="680" left="372" width="168" height="20" font="0">51.2 and 56.8 %, respectively. </text>
<text top="697" left="372" width="128" height="20" font="0">--22% current smokers </text>
<text top="714" left="372" width="3" height="20" font="0"> </text>
<text top="731" left="372" width="158" height="20" font="7"><b>Exclusion criteria: </b>younger </text>
<text top="748" left="372" width="46" height="20" font="0">patients </text>
<text top="576" left="575" width="78" height="20" font="7"><b>Intervention: </b></text>
<text top="594" left="575" width="77" height="20" font="0">statin therapy<b> </b></text>
<text top="611" left="575" width="3" height="20" font="7"><b> </b></text>
<text top="628" left="575" width="77" height="20" font="7"><b>Comparator: </b></text>
<text top="645" left="575" width="94" height="20" font="0">placebo or usual </text>
<text top="662" left="575" width="27" height="20" font="0">care </text>
<text top="576" left="683" width="77" height="20" font="7"><b>1° Endpoint: </b></text>
<text top="595" left="682" width="11" height="18" font="0">• </text>
<text top="595" left="696" width="219" height="20" font="0">Statins significantly reduced the risks of </text>
<text top="612" left="696" width="260" height="20" font="0">composite major adverse CV events (RR: 0.82, </text>
<text top="629" left="696" width="243" height="20" font="0">95% CI: 0.74–0.92), nonfatal MI (0.75, 0.59–</text>
<text top="646" left="696" width="203" height="20" font="0">0.94) and total MI (0.74, 0.61–0.90).  </text>
<text top="665" left="682" width="11" height="18" font="0">• </text>
<text top="665" left="696" width="245" height="20" font="0">Treatment effects of statins were statistically </text>
<text top="682" left="696" width="262" height="20" font="0">insignificant in fatal MI (0.43, 0.09–2.01), stroke </text>
<text top="699" left="696" width="239" height="20" font="0">(fatal: 0.76, 0.24–2.45; nonfatal: 0.76, 0.53–</text>
<text top="716" left="696" width="230" height="20" font="0">1.11; total: 0.85, 0.68–1.06) and all-cause </text>
<text top="733" left="696" width="150" height="20" font="0">mortality (0.96, 0.88–1.04). </text>
<text top="751" left="683" width="105" height="20" font="7"><b>Safety Endpoint:  </b></text>
<text top="768" left="683" width="265" height="20" font="0">No significant differences in myalgia (0.88, 0.69–</text>
<text top="785" left="683" width="263" height="20" font="0">1.13), elevation of hepatic transaminases (0.98, </text>
<text top="576" left="975" width="70" height="20" font="7"><b>Limitation:</b>  </text>
<text top="594" left="975" width="103" height="20" font="0">The occurrence of </text>
<text top="611" left="975" width="60" height="20" font="0">myopathy, </text>
<text top="628" left="975" width="113" height="20" font="0">rhabdomyolysis and </text>
<text top="645" left="975" width="116" height="20" font="0">cognitive impairment </text>
<text top="662" left="975" width="65" height="20" font="0">was largely </text>
<text top="680" left="975" width="96" height="20" font="0">unreported in the </text>
<text top="697" left="975" width="82" height="20" font="0">included trials. </text>
</page>
<page number="114" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">114 </text>
<text top="107" left="683" width="244" height="20" font="0">0.71–1.34), new–onset diabetes (1.07, 0.77–</text>
<text top="124" left="683" width="262" height="20" font="0">1.48), serious adverse events (1.00, 0.97–1.04) </text>
<text top="141" left="683" width="269" height="20" font="0">and discontinuation due to adverse events (1.10, </text>
<text top="159" left="683" width="69" height="20" font="0">0.85–1.42).  </text>
<text top="177" left="89" width="27" height="20" font="7"><b>CTT </b></text>
<text top="194" left="89" width="125" height="20" font="0">Cholesterol Treatment </text>
<text top="211" left="89" width="128" height="20" font="0">Trialists’ Collaborators, </text>
<text top="228" left="89" width="63" height="20" font="0">2012 <a href="data supplement.html#243">(121)</a> </text>
<text top="246" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22607822">22607822</a></text>
<text top="245" left="144" width="7" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22607822">  </a></text>
<text top="263" left="89" width="75" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=PMC3437972">PMC3437972</a></text>
<text top="263" left="165" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=PMC3437972"> </a></text>
<text top="177" left="231" width="105" height="20" font="7"><b>Study Type:</b> Meta-</text>
<text top="194" left="231" width="90" height="20" font="0">analysis of RCT </text>
<text top="211" left="231" width="3" height="20" font="0"> </text>
<text top="228" left="231" width="32" height="20" font="7"><b>Size:</b> </text>
<text top="228" left="287" width="96" height="20" font="0">22 RCT. </text>
<text top="245" left="231" width="64" height="20" font="0">N=134,537 </text>
<text top="177" left="372" width="166" height="20" font="7"><b>Inclusion criteria:</b> A trial was </text>
<text top="194" left="372" width="64" height="20" font="0">eligible if it  </text>
<text top="211" left="371" width="139" height="20" font="0">1. it included at least one </text>
<text top="228" left="385" width="169" height="20" font="0">intervention whose main effect </text>
<text top="246" left="385" width="161" height="20" font="0">was to lower LDL cholesterol </text>
<text top="263" left="385" width="77" height="20" font="0">concentration </text>
<text top="280" left="371" width="155" height="20" font="0">2. it was unconfounded with </text>
<text top="297" left="385" width="174" height="20" font="0">respect to this intervention (i.e., </text>
<text top="314" left="385" width="148" height="20" font="0">no other differences in risk </text>
<text top="332" left="385" width="174" height="20" font="0">factor modification between the </text>
<text top="349" left="385" width="127" height="20" font="0">treatment groups were </text>
<text top="366" left="385" width="55" height="20" font="0">intended) </text>
<text top="383" left="371" width="148" height="20" font="0">3. it recruited at least 1000 </text>
<text top="400" left="385" width="151" height="20" font="0">participants with scheduled </text>
<text top="418" left="385" width="170" height="20" font="0">treatment duration of at least 2 </text>
<text top="435" left="385" width="13" height="20" font="0">y. </text>
<text top="177" left="575" width="78" height="20" font="7"><b>Intervention: </b></text>
<text top="194" left="575" width="77" height="20" font="0">statin therapy </text>
<text top="211" left="575" width="3" height="20" font="0"> </text>
<text top="228" left="575" width="77" height="20" font="7"><b>Comparator:</b> </text>
<text top="245" left="575" width="44" height="20" font="0">control  </text>
<text top="263" left="575" width="3" height="20" font="0"> </text>
<text top="177" left="683" width="53" height="20" font="7"><b>Overall:  </b></text>
<text top="196" left="682" width="11" height="18" font="0">• </text>
<text top="195" left="737" width="197" height="20" font="0">Reduction of LDL cholesterol with a </text>
<text top="212" left="689" width="260" height="20" font="0">statin reduced the risk of major vascular events </text>
<text top="229" left="689" width="256" height="20" font="0">(RR: 0·79, 95% CI: 0·77–0·81, per 1·0 mmol/L </text>
<text top="247" left="689" width="58" height="20" font="0">reduction) </text>
<text top="266" left="682" width="11" height="18" font="0">• </text>
<text top="265" left="737" width="198" height="20" font="0">Among adults ≥70, effects on major </text>
<text top="282" left="689" width="267" height="20" font="0">vascular events per 1.0 mmol/L reduction in LDL </text>
<text top="299" left="689" width="238" height="20" font="0">cholesterol (RR: 0.83; 95% CI: 0.78 − 0.87; </text>
<text top="316" left="689" width="59" height="20" font="0">p&lt;0.0001) </text>
<text top="177" left="975" width="21" height="20" font="0">NA </text>
<text top="453" left="89" width="98" height="20" font="0">Ridker PM, et al., </text>
<text top="470" left="89" width="63" height="20" font="0">2017 <a href="data supplement.html#243">(118)</a> </text>
<text top="487" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28385949">28385949</a></text>
<text top="487" left="144" width="3" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28385949"><b> </b></a></text>
<text top="453" left="231" width="119" height="20" font="7"><b>Aim:</b> To describe the </text>
<text top="470" left="231" width="128" height="20" font="0">role of statin therapy in </text>
<text top="487" left="231" width="60" height="20" font="0">the elderly<b> </b></text>
<text top="504" left="231" width="3" height="20" font="7"><b> </b></text>
<text top="522" left="231" width="105" height="20" font="7"><b>Study type: </b>Fixed-</text>
<text top="539" left="231" width="119" height="20" font="0">effects meta-analysis </text>
<text top="556" left="231" width="110" height="20" font="0">of age-specific data </text>
<text top="573" left="231" width="106" height="20" font="0">from JUPITER and </text>
<text top="591" left="231" width="49" height="20" font="0">HOPE-3<b> </b></text>
<text top="608" left="231" width="3" height="20" font="7"><b> </b></text>
<text top="625" left="231" width="73" height="20" font="7"><b>Size: </b>30,507<b> </b></text>
<text top="453" left="372" width="109" height="20" font="7"><b>Inclusion criteria:  </b></text>
<text top="470" left="372" width="187" height="20" font="7"><b>•</b> Participants in the JUPITER trial </text>
<text top="487" left="372" width="159" height="20" font="0">(rosuvastatin 20 mg daily vs. </text>
<text top="504" left="372" width="184" height="20" font="0">placebo) and H trial (rosuvastatin </text>
<text top="522" left="372" width="139" height="20" font="0">10 mg daily vs. placebo)  </text>
<text top="539" left="372" width="167" height="20" font="0">-All subjects were free of CVD </text>
<text top="556" left="372" width="185" height="20" font="0">and were divided into age groups </text>
<text top="573" left="372" width="156" height="20" font="0">&lt;65 y (n=13, 517), 65-&lt;70 y </text>
<text top="591" left="372" width="174" height="20" font="0">(n=8,218) and &gt;70 y (n=8,781). </text>
<text top="610" left="372" width="11" height="18" font="0">• </text>
<text top="609" left="383" width="159" height="20" font="0">Those &gt;70 y comprised 32% </text>
<text top="626" left="383" width="165" height="20" font="0">and 24% of the J and H study </text>
<text top="643" left="383" width="158" height="20" font="0">populations respectively and </text>
<text top="660" left="383" width="162" height="20" font="0">suffered 55% and 43% of the </text>
<text top="678" left="383" width="69" height="20" font="0">CVD events </text>
<text top="695" left="372" width="3" height="20" font="7"><b> </b></text>
<text top="712" left="372" width="134" height="20" font="7"><b>Exclusion criteria: </b>N/A<b> </b></text>
<text top="453" left="575" width="78" height="20" font="7"><b>Intervention: </b></text>
<text top="470" left="575" width="91" height="20" font="0">Rosuvastatin 20 </text>
<text top="487" left="575" width="73" height="20" font="0">mg or 10 mg<b> </b></text>
<text top="504" left="575" width="7" height="20" font="7"><b>  </b></text>
<text top="522" left="575" width="77" height="20" font="7"><b>Comparator: </b></text>
<text top="539" left="575" width="48" height="20" font="0">Placebo<b> </b></text>
<text top="454" left="683" width="260" height="20" font="7"><b>1</b>°<b> endpoint: </b>non-fatal MI. non-fatal stroke and </text>
<text top="471" left="683" width="64" height="20" font="0">CVD death </text>
<text top="488" left="683" width="3" height="20" font="7"><b> </b></text>
<text top="506" left="683" width="55" height="20" font="7"><b>Results: </b> </text>
<text top="525" left="683" width="11" height="18" font="0">• </text>
<text top="524" left="710" width="213" height="20" font="0">Rates of primary outcome/100 pt.-y for </text>
<text top="541" left="710" width="231" height="20" font="0">rosuva/placebo and pooled HR: (95% CI): </text>
<text top="560" left="683" width="11" height="18" font="0">• </text>
<text top="559" left="710" width="41" height="20" font="0">&lt;65 y;  </text>
<text top="578" left="683" width="11" height="18" font="0">• </text>
<text top="578" left="710" width="113" height="20" font="0">JUPITER: 0.27/0.59 </text>
<text top="596" left="683" width="11" height="18" font="0">• </text>
<text top="596" left="710" width="107" height="20" font="0">HOPE-3: 0.46/0.53 </text>
<text top="615" left="683" width="11" height="18" font="0">• </text>
<text top="614" left="710" width="87" height="20" font="0">0.75 (0.5; 0.97) </text>
<text top="633" left="683" width="11" height="18" font="0">• </text>
<text top="632" left="710" width="55" height="20" font="0">65-&lt;70 y: </text>
<text top="651" left="683" width="11" height="18" font="0">• </text>
<text top="651" left="710" width="113" height="20" font="0">JUPITER: 0.24/0.61 </text>
<text top="670" left="683" width="11" height="18" font="0">• </text>
<text top="669" left="710" width="107" height="20" font="0">HOPE-3: 0.50/0.91 </text>
<text top="688" left="683" width="11" height="18" font="0">• </text>
<text top="687" left="710" width="94" height="20" font="0">0.51 (0.38; 0.69) </text>
<text top="706" left="683" width="11" height="18" font="0">• </text>
<text top="705" left="710" width="37" height="20" font="0">&gt;70 y; </text>
<text top="724" left="683" width="11" height="18" font="0">• </text>
<text top="724" left="710" width="113" height="20" font="0">JUPITER: 0.82/1.36 </text>
<text top="742" left="683" width="11" height="18" font="0">• </text>
<text top="742" left="710" width="107" height="20" font="0">HOPE-3: 1.25/1.50 </text>
<text top="761" left="683" width="11" height="18" font="0">• </text>
<text top="760" left="710" width="94" height="20" font="0">0.74 (0.61; 0.91) </text>
<text top="453" left="975" width="114" height="20" font="0">•In subjects &gt;70 y of </text>
<text top="470" left="975" width="119" height="20" font="0">age there was a 26% </text>
<text top="487" left="975" width="108" height="20" font="0">RRR in the primary </text>
<text top="504" left="975" width="115" height="20" font="0">and in the expanded </text>
<text top="522" left="975" width="104" height="20" font="0">endpoint (included </text>
<text top="539" left="975" width="106" height="20" font="0">revascularizations) </text>
<text top="556" left="975" width="82" height="20" font="0">•There was no </text>
<text top="573" left="975" width="118" height="20" font="0">heterogeneity by age </text>
<text top="591" left="975" width="100" height="20" font="0">•The higher event </text>
<text top="608" left="975" width="125" height="20" font="0">rates in those &gt;70 y of </text>
<text top="625" left="975" width="100" height="20" font="0">age implies larger </text>
<text top="642" left="975" width="75" height="20" font="0">absolute rate </text>
<text top="659" left="975" width="84" height="20" font="0">reductions and </text>
<text top="677" left="975" width="120" height="20" font="0">therefore lower NNTs </text>
<text top="694" left="975" width="3" height="20" font="0"> </text>
<text top="711" left="975" width="73" height="20" font="7"><b>Limitations: </b></text>
<text top="730" left="975" width="11" height="18" font="0">• </text>
<text top="729" left="1002" width="84" height="20" font="0">The upper age </text>
<text top="746" left="1002" width="89" height="20" font="0">cut-off was 70 y </text>
<text top="764" left="1002" width="47" height="20" font="0">not 75 y </text>
</page>
<page number="115" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">115 </text>
<text top="264" left="81" width="4" height="22" font="1"> </text>
<text top="303" left="81" width="5" height="16" font="15"> </text>
<text top="318" left="81" width="1026" height="22" font="5"><b>Data Supplement 20. Nonrandomized Trials, Observational Studies, and/or Registries of Q4: Evidence regarding the cost-effectiveness of screening for familial </b></text>
<text top="337" left="81" width="254" height="22" font="5"><b>hypercholesterolemia (Section 4.4.4.3)  </b></text>
<text top="357" left="116" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="374" left="142" width="48" height="20" font="7"><b>Author; </b></text>
<text top="391" left="120" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="357" left="267" width="118" height="20" font="7"><b>Study Type/Design; </b></text>
<text top="374" left="293" width="66" height="20" font="7"><b>Study Size </b></text>
<text top="357" left="437" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="357" left="617" width="179" height="20" font="7"><b>Primary Endpoint and Results </b></text>
<text top="374" left="614" width="184" height="20" font="7"><b>(P values; OR or RR; &amp; 95% CI) </b></text>
<text top="357" left="906" width="130" height="20" font="7"><b>Summary/Conclusion </b></text>
<text top="374" left="933" width="75" height="20" font="7"><b>Comment(s) </b></text>
<text top="409" left="91" width="149" height="20" font="0">Ademi Z, et al., 2013 <a href="data supplement.html#243">(122)</a> </text>
<text top="426" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23490080">23490080</a></text>
<text top="426" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23490080"> </a></text>
<text top="443" left="91" width="3" height="20" font="0"> </text>
<text top="409" left="253" width="134" height="20" font="7"><b>Study type:</b> Systematic </text>
<text top="426" left="253" width="42" height="20" font="0">review  </text>
<text top="443" left="253" width="3" height="20" font="0"> </text>
<text top="461" left="253" width="151" height="20" font="7"><b>Size: </b>6 published studies    </text>
<text top="409" left="412" width="150" height="20" font="7"><b>Inclusion criteria:</b> English </text>
<text top="426" left="412" width="156" height="20" font="0">literature studies performing </text>
<text top="443" left="412" width="135" height="20" font="0">economic evaluations of </text>
<text top="461" left="412" width="159" height="20" font="0">screening for FH (defined by </text>
<text top="478" left="412" width="147" height="20" font="0">Dutch Lipid Clinic Network </text>
<text top="495" left="412" width="123" height="20" font="0">or modified UK Simon </text>
<text top="512" left="412" width="98" height="20" font="0">Broome criteria).  </text>
<text top="529" left="412" width="3" height="20" font="0"> </text>
<text top="547" left="412" width="154" height="20" font="7"><b>Exclusion criteria:</b> Studies </text>
<text top="564" left="412" width="116" height="20" font="0">with duplicated data. </text>
<text top="410" left="586" width="231" height="20" font="7"><b>1</b>°<b> endpoint:</b> Cost estimates of screening </text>
<text top="427" left="586" width="60" height="20" font="0">strategies. </text>
<text top="444" left="586" width="3" height="20" font="0"> </text>
<text top="462" left="586" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="481" left="582" width="11" height="18" font="0">• </text>
<text top="480" left="595" width="217" height="20" font="0">When compared with no screening, the </text>
<text top="497" left="595" width="228" height="20" font="0">incremental cost-effectiveness ratio <a href="data supplement.html#243">(123)</a> </text>
<text top="514" left="595" width="229" height="20" font="0">of screening ranged from €3177–€29,554 </text>
<text top="532" left="595" width="115" height="20" font="0">per life year gained.  </text>
<text top="411" left="838" width="11" height="18" font="0">• </text>
<text top="410" left="852" width="194" height="20" font="0">Screening of relatives of those with </text>
<text top="427" left="852" width="226" height="20" font="0">diagnosed FH is cost effective compared </text>
<text top="444" left="852" width="198" height="20" font="0">with no screening across a range of </text>
<text top="462" left="852" width="219" height="20" font="0">assumptions and geographic locations.  </text>
<text top="481" left="838" width="11" height="18" font="0">• </text>
<text top="480" left="852" width="242" height="20" font="0">Across studies, results were sensitive to the </text>
<text top="497" left="852" width="237" height="20" font="0">prevalence of FH, the utility (sensitivity and </text>
<text top="514" left="852" width="250" height="20" font="0">specificity) of the screening test used and the </text>
<text top="532" left="852" width="241" height="20" font="0">assumed price and efficacy of lipid-lowering </text>
<text top="549" left="852" width="48" height="20" font="0">therapy. </text>
<text top="568" left="838" width="11" height="18" font="0">• </text>
<text top="567" left="852" width="235" height="20" font="0">Specific studies included in this systematic </text>
<text top="584" left="852" width="234" height="20" font="0">review are also included in the table below </text>
<text top="601" left="852" width="218" height="20" font="0">(and indicate by an asterisk) for greater </text>
<text top="618" left="852" width="128" height="20" font="0">clarification of findings. </text>
<text top="636" left="852" width="3" height="20" font="0"> </text>
<text top="653" left="840" width="259" height="20" font="0">Limitations: Numerous assumptions inherent in </text>
<text top="670" left="840" width="153" height="20" font="0">cost-effectiveness analysis. </text>
<text top="687" left="840" width="3" height="20" font="0"> </text>
<text top="705" left="91" width="149" height="20" font="0">Ademi Z, et al., 2014 <a href="data supplement.html#243">(124)</a> </text>
<text top="722" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25110220">25110220</a></text>
<text top="722" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25110220"> </a></text>
<text top="740" left="91" width="3" height="20" font="0"> </text>
<text top="705" left="253" width="124" height="20" font="7"><b>Study type:</b>  Decision </text>
<text top="722" left="253" width="126" height="20" font="0">and cost-effectiveness </text>
<text top="740" left="253" width="48" height="20" font="0">analysis </text>
<text top="757" left="253" width="3" height="20" font="0"> </text>
<text top="705" left="412" width="106" height="20" font="7"><b>Inclusion criteria:</b> </text>
<text top="722" left="412" width="139" height="20" font="0">Consecutive index cases </text>
<text top="740" left="412" width="113" height="20" font="0">and newly screened </text>
<text top="757" left="412" width="122" height="20" font="0">relatives, 2008 - 2013 </text>
<text top="774" left="412" width="3" height="20" font="0"> </text>
<text top="706" left="586" width="238" height="20" font="7"><b>1</b>°<b> endpoint:</b> ICER per quality-adjusted life </text>
<text top="724" left="586" width="217" height="20" font="0">year (QALY) gained and per year of life </text>
<text top="741" left="586" width="189" height="20" font="0">saved (YoLS) for screening vs. no </text>
<text top="758" left="586" width="227" height="20" font="0">screening of relatives of index cases with </text>
<text top="775" left="586" width="23" height="20" font="0">FH. </text>
<text top="707" left="838" width="11" height="18" font="0">• </text>
<text top="706" left="852" width="189" height="20" font="0">Cascade screening for FH using a </text>
<text top="724" left="852" width="213" height="20" font="0">combination of genetic and phenotypic </text>
<text top="741" left="852" width="241" height="20" font="0">testing represents a cost-effective means of </text>
<text top="758" left="852" width="189" height="20" font="0">preventing CHD in at-risk families. </text>
<text top="109" left="683" width="11" height="18" font="0">• </text>
<text top="108" left="710" width="231" height="20" font="0">Rates of drug withdrawal in those &lt;65, 65-</text>
<text top="125" left="710" width="123" height="20" font="0">&lt;70 and &gt;70 y of age: </text>
<text top="144" left="683" width="11" height="18" font="0">• </text>
<text top="144" left="710" width="157" height="20" font="0">JUPITER: 14.3, 17.0, 21.6 y </text>
<text top="161" left="683" width="114" height="20" font="0">H: 21.4, 23.1, 29.1 y<b> </b></text>
<text top="107" left="975" width="113" height="20" font="0">Adverse event rates </text>
<text top="124" left="975" width="117" height="20" font="0">by age group are not </text>
<text top="141" left="975" width="108" height="20" font="0">provided, but &gt;70 y </text>
<text top="159" left="975" width="109" height="20" font="0">old had higher drug </text>
<text top="176" left="975" width="89" height="20" font="0">withdrawal than </text>
<text top="193" left="975" width="89" height="20" font="0">younger groups </text>
</page>
<page number="116" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">116 </text>
<text top="107" left="253" width="117" height="20" font="7"><b>Size:</b> 81 consecutive </text>
<text top="124" left="253" width="126" height="20" font="0">index cases of FH and </text>
<text top="141" left="253" width="31" height="20" font="0">175 1</text>
<text top="143" left="284" width="6" height="13" font="9">st</text>
<text top="141" left="290" width="34" height="20" font="0"> and 2</text>
<text top="143" left="324" width="9" height="13" font="9">nd</text>
<text top="141" left="333" width="45" height="20" font="0"> degree </text>
<text top="159" left="253" width="120" height="20" font="0">relatives, Royal Perth </text>
<text top="176" left="253" width="132" height="20" font="0">Hospital, used to model </text>
<text top="193" left="253" width="115" height="20" font="0">cost-effectiveness in </text>
<text top="210" left="253" width="102" height="20" font="0">Australian general </text>
<text top="228" left="253" width="60" height="20" font="0">population </text>
<text top="107" left="412" width="134" height="20" font="7"><b>Exclusion criteria:</b> N/A </text>
<text top="107" left="586" width="3" height="20" font="0"> </text>
<text top="124" left="586" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="143" left="582" width="11" height="18" font="0">• </text>
<text top="143" left="595" width="226" height="20" font="0">Cascade screening for FH would prevent </text>
<text top="160" left="595" width="200" height="20" font="0">1 CHD event over 10 y for every 7.4 </text>
<text top="177" left="595" width="226" height="20" font="0">people screened. The number needed to </text>
<text top="194" left="595" width="226" height="20" font="0">screen <a href="data supplement.html#243">(125)</a> to prevent one CHD-related </text>
<text top="211" left="595" width="226" height="20" font="0">death would be 18.3. In the population of </text>
<text top="229" left="595" width="194" height="20" font="0">relatives identified as having FH by </text>
<text top="246" left="595" width="217" height="20" font="0">cascade screening, the NNS to prevent </text>
<text top="263" left="595" width="164" height="20" font="0">one CHD event would be 4.0. </text>
<text top="282" left="582" width="11" height="18" font="0">• </text>
<text top="281" left="595" width="225" height="20" font="0">The authors estimated that for every 100 </text>
<text top="298" left="595" width="224" height="20" font="0">people undergoing cascade screening in </text>
<text top="316" left="595" width="213" height="20" font="0">Australia (including the 45.7% of those </text>
<text top="333" left="595" width="231" height="20" font="0">without underlying FH), there would be an </text>
<text top="350" left="595" width="230" height="20" font="0">overall gain of 24.9 life y and 29.1 QALYs </text>
<text top="367" left="595" width="177" height="20" font="0">(discounted) over a 10-y period. </text>
<text top="386" left="582" width="11" height="18" font="0">• </text>
<text top="386" left="595" width="201" height="20" font="0">ICERs over a 10-y period were AUD </text>
<text top="403" left="595" width="212" height="20" font="0">(Australian) $4154 per YoLS and AUD </text>
<text top="420" left="595" width="139" height="20" font="0">$3565 per QALY gained. </text>
<text top="439" left="582" width="11" height="18" font="0">• </text>
<text top="438" left="595" width="211" height="20" font="0">In sensitivity analyses, using age- and </text>
<text top="455" left="595" width="229" height="20" font="0">gender- adjusted LDL-C thresholds (only) </text>
<text top="473" left="595" width="231" height="20" font="0">for diagnosis of close relatives with FH for </text>
<text top="490" left="595" width="220" height="20" font="0">cascade screening was deemed to be a </text>
<text top="507" left="595" width="224" height="20" font="0">cost-effective strategy compared with no </text>
<text top="524" left="595" width="230" height="20" font="0">screening. In this strategy, the yield of FH </text>
<text top="541" left="595" width="208" height="20" font="0">relatives detected per index case was </text>
<text top="559" left="595" width="215" height="20" font="0">comparable to genetic testing (1.09 vs. </text>
<text top="576" left="595" width="201" height="20" font="0">1.17), with incrementally lower costs </text>
<text top="593" left="595" width="220" height="20" font="0">(because no DNA tests would be used). </text>
<text top="610" left="595" width="190" height="20" font="0">There was an 86.9% concordance </text>
<text top="628" left="595" width="214" height="20" font="0">between genetic testing and using age-</text>
<text top="645" left="595" width="209" height="20" font="0">gender adjusted LDL-C cutoffs for the </text>
<text top="662" left="595" width="152" height="20" font="0">detection of FH in relatives. </text>
<text top="113" left="832" width="4" height="14" font="0"> </text>
<text top="108" left="838" width="257" height="20" font="0">Analysis using only plasma LDL-C for cascade </text>
<text top="125" left="838" width="238" height="20" font="0">screening found cascade screening to be a </text>
<text top="143" left="838" width="247" height="20" font="0">cost-effective approach when compared with </text>
<text top="160" left="838" width="77" height="20" font="0">no screening. </text>
<text top="179" left="838" width="7" height="18" font="0">•</text>
<text top="178" left="845" width="235" height="20" font="0"> ICERs were sensitive to the prevalence of </text>
<text top="195" left="852" width="234" height="20" font="0">FH, assumptions regarding annual risks of </text>
<text top="213" left="852" width="241" height="20" font="0">CHD and relative benefits of statins, but still </text>
<text top="230" left="852" width="227" height="20" font="0">led to favorable ICERs compared with no </text>
<text top="247" left="852" width="60" height="20" font="0">screening. </text>
<text top="266" left="838" width="7" height="18" font="0">•</text>
<text top="265" left="845" width="248" height="20" font="0"> Extending the time frame of this model to 20 </text>
<text top="283" left="852" width="246" height="20" font="0">or 30 y (compared with the 10-y examined in </text>
<text top="300" left="852" width="223" height="20" font="0">this analysis) would lead to even greater </text>
<text top="317" left="852" width="175" height="20" font="0">estimates of cost-effectiveness. </text>
<text top="334" left="840" width="3" height="20" font="0"> </text>
<text top="351" left="840" width="262" height="20" font="0">Limitations: Did not consider children; uncertain </text>
<text top="369" left="840" width="250" height="20" font="0">generalizability beyond Australian population; </text>
<text top="386" left="840" width="234" height="20" font="0">sensitivity and specificity of genetic testing </text>
<text top="403" left="840" width="253" height="20" font="0">assumed to be 100%; numerous assumptions </text>
<text top="420" left="840" width="214" height="20" font="0">inherent in cost-effectiveness analysis. </text>
<text top="437" left="840" width="3" height="20" font="0"> </text>
<text top="680" left="91" width="121" height="20" font="0">Chen CX, et al., 2015 </text>
<text top="697" left="91" width="36" height="20" font="0"><a href="data supplement.html#243">(126)</a>  </text>
<text top="714" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25569270">25569270</a></text>
<text top="714" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25569270"> </a></text>
<text top="680" left="253" width="145" height="20" font="7"><b>Study type:</b> Decision and </text>
<text top="697" left="253" width="102" height="20" font="0">cost-effectiveness </text>
<text top="714" left="253" width="48" height="20" font="0">analysis </text>
<text top="731" left="253" width="3" height="20" font="0"> </text>
<text top="749" left="253" width="133" height="20" font="7"><b>Size:</b>  Analysis from US </text>
<text top="766" left="253" width="90" height="20" font="0">male population </text>
<text top="680" left="412" width="130" height="20" font="7"><b>Inclusion criteria:</b> N/A </text>
<text top="697" left="412" width="3" height="20" font="0"> </text>
<text top="714" left="412" width="134" height="20" font="7"><b>Exclusion criteria:</b> N/A </text>
<text top="681" left="586" width="237" height="20" font="7"><b>1</b>°<b> endpoint:</b> Cost-effectiveness of genetic </text>
<text top="698" left="586" width="226" height="20" font="0">screening and lipid-based screening with </text>
<text top="715" left="586" width="224" height="20" font="0">statin adherence measures compared to </text>
<text top="733" left="586" width="211" height="20" font="0">lipid-based screening alone in the US. </text>
<text top="750" left="586" width="3" height="20" font="0"> </text>
<text top="767" left="586" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="786" left="582" width="11" height="18" font="0">• </text>
<text top="785" left="595" width="227" height="20" font="0">For each man with a family history of FH: </text>
<text top="682" left="838" width="11" height="18" font="0">• </text>
<text top="681" left="852" width="247" height="20" font="0">Results support implementation of enhanced </text>
<text top="698" left="852" width="219" height="20" font="0">lipid cascade screening, potentially with </text>
<text top="715" left="852" width="243" height="20" font="0">additional statin adherence measures, while </text>
<text top="733" left="852" width="234" height="20" font="0">showing that genetic cascade screening is </text>
<text top="750" left="852" width="220" height="20" font="0">currently not cost-effective in US males. </text>
<text top="769" left="836" width="11" height="18" font="0">• </text>
<text top="768" left="849" width="215" height="20" font="0">At a US willingness-to-pay threshold of </text>
<text top="785" left="849" width="228" height="20" font="0">$150,000/QALY Genetic Screening is not </text>
</page>
<page number="117" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">117 </text>
<text top="107" left="253" width="134" height="20" font="0">perspective with lifetime </text>
<text top="124" left="253" width="47" height="20" font="0">horizon. </text>
<text top="141" left="253" width="113" height="20" font="0">initial cohort of 1000 </text>
<text top="159" left="253" width="128" height="20" font="0">Caucasian male adults </text>
<text top="176" left="253" width="148" height="20" font="0">with a family history of FH  </text>
<text top="193" left="253" width="115" height="20" font="0">followed in a Markov </text>
<text top="210" left="253" width="96" height="20" font="0">model simulation </text>
<text top="107" left="595" width="210" height="20" font="0">-  Genetic Screening cost $15,594 for </text>
<text top="124" left="609" width="77" height="20" font="0">18.29 QALYs </text>
<text top="141" left="595" width="188" height="20" font="0">-  Lipid Screening with adherence </text>
<text top="159" left="609" width="183" height="20" font="0">measures cost $16,385 for 18.77 </text>
<text top="176" left="609" width="46" height="20" font="0">QALYs  </text>
<text top="193" left="595" width="227" height="20" font="0">-  Lipid Screening alone cost $10,396 for </text>
<text top="210" left="609" width="80" height="20" font="0">18.28 QALYs  </text>
<text top="228" left="640" width="3" height="20" font="0"> </text>
<text top="247" left="582" width="11" height="18" font="0">• </text>
<text top="246" left="595" width="219" height="20" font="0">The ICER for Genetic Screening versus </text>
<text top="263" left="595" width="147" height="20" font="0">Lipid Screening alone was </text>
<text top="280" left="595" width="94" height="20" font="0">$519,813/QALY. </text>
<text top="299" left="582" width="11" height="18" font="0">• </text>
<text top="299" left="595" width="189" height="20" font="0">The ICER for Lipid Screening with </text>
<text top="316" left="595" width="188" height="20" font="0">adherence measures versus Lipid </text>
<text top="333" left="595" width="205" height="20" font="0">Screening alone was $12,223/QALY, </text>
<text top="350" left="595" width="230" height="20" font="0">which would generally be considered cost </text>
<text top="367" left="595" width="53" height="20" font="0">effective. </text>
<text top="107" left="849" width="247" height="20" font="0">cost-effective compared with Lipid Screening </text>
<text top="124" left="849" width="37" height="20" font="0">alone. </text>
<text top="143" left="836" width="11" height="18" font="0">• </text>
<text top="143" left="849" width="251" height="20" font="0">Lipid screening alone and lipid screening with </text>
<text top="160" left="849" width="237" height="20" font="0">enhanced adherence measures dominated </text>
<text top="177" left="849" width="234" height="20" font="0">genetic screening for men with a history of </text>
<text top="194" left="849" width="99" height="20" font="0">FH in this model.  </text>
<text top="213" left="836" width="11" height="18" font="0">• </text>
<text top="213" left="849" width="250" height="20" font="0">Sensitivity analyses showed that results were </text>
<text top="230" left="849" width="222" height="20" font="0">robust to reasonable variations in model </text>
<text top="247" left="849" width="231" height="20" font="0">parameters. Costs of DNA testing had the </text>
<text top="264" left="849" width="158" height="20" font="0">largest effects on the model. </text>
<text top="281" left="836" width="3" height="20" font="0"> </text>
<text top="298" left="836" width="243" height="20" font="0">Limitations: Study performed at a time when </text>
<text top="316" left="836" width="261" height="20" font="0">there were limited data on CHD incidence rates </text>
<text top="333" left="836" width="257" height="20" font="0">in US population with FH; men only; numerous </text>
<text top="350" left="836" width="235" height="20" font="0">assumptions inherent in cost-effectiveness </text>
<text top="367" left="836" width="51" height="20" font="0">analysis. </text>
<text top="385" left="91" width="127" height="20" font="0">Marang-van de Mheen </text>
<text top="402" left="91" width="121" height="20" font="0">PJ., et al., 2002<a href="data supplement.html#243"> (127)</a> </text>
<text top="420" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12473254">12473254</a></text>
<text top="420" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12473254"> </a></text>
<text top="437" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="385" left="253" width="103" height="20" font="7"><b>Study type:</b>  Cost-</text>
<text top="402" left="253" width="123" height="20" font="0">effectiveness analysis </text>
<text top="420" left="253" width="3" height="20" font="0"> </text>
<text top="437" left="253" width="129" height="20" font="7"><b>Size:</b>  2229 relatives of </text>
<text top="454" left="253" width="102" height="20" font="0">137 FH probands. </text>
<text top="471" left="253" width="3" height="20" font="0"> </text>
<text top="385" left="412" width="106" height="20" font="7"><b>Inclusion criteria:</b> </text>
<text top="402" left="412" width="153" height="20" font="0">Individuals aged ≥16 y who </text>
<text top="420" left="412" width="146" height="20" font="0">were related to genetically </text>
<text top="437" left="412" width="155" height="20" font="0">identified FH probands from </text>
<text top="454" left="412" width="120" height="20" font="0">a closed cohort in the </text>
<text top="471" left="412" width="135" height="20" font="0">Netherlands, 1994-1997 </text>
<text top="488" left="412" width="3" height="20" font="0"> </text>
<text top="506" left="412" width="134" height="20" font="7"><b>Exclusion criteria:</b> N/A </text>
<text top="523" left="412" width="3" height="20" font="0"> </text>
<text top="386" left="586" width="216" height="20" font="7"><b>1</b>°<b> endpoint:</b> Life years gained and life </text>
<text top="404" left="586" width="198" height="20" font="0">time costs of the screened cohort of </text>
<text top="421" left="586" width="235" height="20" font="0">relatives, theoretically subjected to various </text>
<text top="438" left="586" width="219" height="20" font="0">strategies of treatment compared with a </text>
<text top="455" left="586" width="138" height="20" font="0">strategy of no screening. </text>
<text top="472" left="586" width="3" height="20" font="0"> </text>
<text top="490" left="586" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="509" left="582" width="11" height="18" font="0">• </text>
<text top="508" left="595" width="203" height="20" font="0">Depending on the treatment strategy </text>
<text top="525" left="595" width="231" height="20" font="0">implemented, costs per year of life gained </text>
<text top="542" left="595" width="229" height="20" font="0">varied between 25,600 and 32,200 Euros </text>
<text top="560" left="586" width="3" height="20" font="0"> </text>
<text top="387" left="840" width="7" height="18" font="0">•</text>
<text top="386" left="847" width="252" height="20" font="0"> At the time of the study, statin costs were the </text>
<text top="404" left="840" width="199" height="20" font="0">major determinant of costs and cost-</text>
<text top="421" left="840" width="254" height="20" font="0">effectiveness. The ICER for genetic screening </text>
<text top="438" left="840" width="209" height="20" font="0">and treatment therefore exceeded the </text>
<text top="455" left="840" width="256" height="20" font="0">recommended threshold for cost-effectiveness </text>
<text top="472" left="840" width="246" height="20" font="0">for Dutch guidelines at the time. The authors </text>
<text top="490" left="840" width="228" height="20" font="0">recommended a screening and treatment </text>
<text top="507" left="840" width="244" height="20" font="0">approach based solely on LDL-C levels as a </text>
<text top="524" left="840" width="238" height="20" font="0">result. Statin costs have declined since this </text>
<text top="541" left="840" width="145" height="20" font="0">analysis was undertaken.  </text>
<text top="559" left="840" width="3" height="20" font="0"> </text>
<text top="576" left="840" width="255" height="20" font="0">Limitations: Generalizability beyond this Dutch </text>
<text top="593" left="840" width="260" height="20" font="0">population; time effects of costs given this is an </text>
<text top="610" left="840" width="260" height="20" font="0">older analysis; numerous assumptions inherent </text>
<text top="627" left="840" width="166" height="20" font="0">in cost-effectiveness analysis. </text>
<text top="645" left="840" width="3" height="20" font="0"> </text>
<text top="663" left="91" width="86" height="20" font="0">Marks D, et al., </text>
<text top="680" left="91" width="63" height="20" font="0">2002 <a href="data supplement.html#243">(128)</a> </text>
<text top="697" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12039822">12039822</a></text>
<text top="697" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12039822"> </a></text>
<text top="663" left="253" width="103" height="20" font="7"><b>Study type:</b>  Cost-</text>
<text top="680" left="253" width="123" height="20" font="0">effectiveness analysis </text>
<text top="697" left="253" width="3" height="20" font="0"> </text>
<text top="714" left="253" width="93" height="20" font="7"><b>Size:</b>  Simulated </text>
<text top="731" left="253" width="135" height="20" font="0">population aged 16-54 y </text>
<text top="749" left="253" width="127" height="20" font="0">in England and Wales. </text>
<text top="663" left="412" width="106" height="20" font="7"><b>Inclusion criteria:</b> </text>
<text top="680" left="412" width="149" height="20" font="0">Simulated population aged </text>
<text top="697" left="412" width="130" height="20" font="0">16-54 y in England and </text>
<text top="714" left="412" width="160" height="20" font="0">Wales, using a lifetime event </text>
<text top="731" left="412" width="47" height="20" font="0">horizon. </text>
<text top="749" left="412" width="3" height="20" font="0"> </text>
<text top="766" left="412" width="134" height="20" font="7"><b>Exclusion criteria:</b> N/A </text>
<text top="664" left="586" width="212" height="20" font="7"><b>1</b>°<b> endpoint:</b> Cost per life year gained </text>
<text top="681" left="586" width="238" height="20" font="0">using a lifetime horizon comparing different </text>
<text top="698" left="586" width="226" height="20" font="0">screening strategies: universal screening </text>
<text top="715" left="586" width="194" height="20" font="0">(all in the population), opportunistic </text>
<text top="733" left="586" width="210" height="20" font="0">screening in primary care (fasting lipid </text>
<text top="750" left="586" width="196" height="20" font="0">panel in those with non-fasting total </text>
<text top="767" left="586" width="84" height="20" font="0">cholesterol &gt;95</text>
<text top="769" left="669" width="7" height="13" font="9">th</text>
<text top="767" left="676" width="138" height="20" font="0"> percentile), screening of </text>
<text top="784" left="586" width="235" height="20" font="0">people admitted to hospital with premature </text>
<text top="664" left="840" width="7" height="18" font="0">•</text>
<text top="664" left="847" width="226" height="20" font="0"> Family tracing of FH-affected individuals </text>
<text top="681" left="840" width="219" height="20" font="0">followed by lipid screening and possible </text>
<text top="698" left="840" width="216" height="20" font="0">genetic confirmation was the most cost-</text>
<text top="715" left="840" width="213" height="20" font="0">effective strategy when compared with </text>
<text top="733" left="840" width="243" height="20" font="0">universal screening, screening of premature </text>
<text top="750" left="840" width="248" height="20" font="0">CHD patients, and opportunistic screening of </text>
<text top="767" left="840" width="235" height="20" font="0">those identified through routine lab testing. </text>
<text top="784" left="840" width="3" height="20" font="0"> </text>
</page>
<page number="118" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">118 </text>
<text top="107" left="586" width="210" height="20" font="0">myocardial infarction, or tracing family </text>
<text top="124" left="586" width="221" height="20" font="0">members of known FH-affected patients </text>
<text top="141" left="586" width="174" height="20" font="0">and inviting them for screening. </text>
<text top="159" left="586" width="3" height="20" font="0"> </text>
<text top="176" left="586" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="195" left="582" width="11" height="18" font="0">• </text>
<text top="194" left="595" width="198" height="20" font="0">Tracing of family members and lipid </text>
<text top="211" left="595" width="208" height="20" font="0">screening was the most cost-effective </text>
<text top="229" left="595" width="218" height="20" font="0">strategy (at £3097/€5066/$4479 per life </text>
<text top="246" left="595" width="227" height="20" font="0">year gained) with a NNS of 2.6 to identify </text>
<text top="263" left="595" width="206" height="20" font="0">one case. If the genetic mutation was </text>
<text top="280" left="595" width="225" height="20" font="0">known within the family then the cost per </text>
<text top="297" left="595" width="225" height="20" font="0">life year gained (£4914) was only slightly </text>
<text top="315" left="595" width="221" height="20" font="0">increased by genetic confirmation of the </text>
<text top="332" left="595" width="230" height="20" font="0">diagnosis. Universal population screening </text>
<text top="349" left="595" width="222" height="20" font="0">was least cost effective (£13 029 per life </text>
<text top="366" left="595" width="195" height="20" font="0">year gained) with a NNS of 1365 to </text>
<text top="383" left="595" width="103" height="20" font="0">identify one case.  </text>
<text top="402" left="582" width="11" height="18" font="0">• </text>
<text top="402" left="595" width="191" height="20" font="0">For each strategy it was more cost </text>
<text top="419" left="595" width="215" height="20" font="0">effective to screen younger people and </text>
<text top="436" left="595" width="46" height="20" font="0">women. </text>
<text top="455" left="582" width="11" height="18" font="0">• </text>
<text top="455" left="595" width="206" height="20" font="0">Universal lipid screening of 16-y old’s </text>
<text top="472" left="595" width="223" height="20" font="0">(only) in this hypothetical population had </text>
<text top="489" left="595" width="190" height="20" font="0">similar cost-effectiveness to family </text>
<text top="506" left="595" width="44" height="20" font="0">tracing. </text>
<text top="523" left="586" width="3" height="20" font="0"> </text>
<text top="107" left="840" width="217" height="20" font="0">Limitations: Generalizability beyond UK </text>
<text top="124" left="840" width="260" height="20" font="0">population; older study with high assumed drug </text>
<text top="141" left="840" width="254" height="20" font="0">costs; numerous assumptions inherent in cost-</text>
<text top="159" left="840" width="127" height="20" font="0">effectiveness analysis. </text>
<text top="176" left="840" width="3" height="20" font="0"> </text>
<text top="541" left="91" width="86" height="20" font="0">Marks D, et al., </text>
<text top="558" left="91" width="63" height="20" font="0">2003 <a href="data supplement.html#243">(129)</a> </text>
<text top="576" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12669918">12669918</a></text>
<text top="576" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/12669918"> </a></text>
<text top="593" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="541" left="253" width="103" height="20" font="7"><b>Study type:</b>  Cost-</text>
<text top="558" left="253" width="123" height="20" font="0">effectiveness analysis </text>
<text top="576" left="253" width="3" height="20" font="0"> </text>
<text top="593" left="253" width="93" height="20" font="7"><b>Size:</b>  Simulated </text>
<text top="610" left="253" width="135" height="20" font="0">population aged 16-54 y </text>
<text top="627" left="253" width="123" height="20" font="0">in England and Wales </text>
<text top="541" left="412" width="106" height="20" font="7"><b>Inclusion criteria:</b> </text>
<text top="558" left="412" width="149" height="20" font="0">Simulated population aged </text>
<text top="576" left="412" width="130" height="20" font="0">16-54 y in England and </text>
<text top="593" left="412" width="145" height="20" font="0">Wales, using a 10-y event </text>
<text top="610" left="412" width="44" height="20" font="0">horizon </text>
<text top="627" left="412" width="3" height="20" font="0"> </text>
<text top="644" left="412" width="134" height="20" font="7"><b>Exclusion criteria:</b> N/A </text>
<text top="542" left="586" width="212" height="20" font="7"><b>1</b>°<b> endpoint:</b> Cost per life year gained </text>
<text top="560" left="586" width="198" height="20" font="0">using a 10-y horizon comparing two </text>
<text top="577" left="586" width="217" height="20" font="0">different screening strategies: universal </text>
<text top="594" left="586" width="228" height="20" font="0">screening of all 16-y-old individuals in the </text>
<text top="611" left="586" width="224" height="20" font="0">population vs. tracing family members of </text>
<text top="628" left="586" width="219" height="20" font="0">known FH-affected patients and inviting </text>
<text top="646" left="586" width="109" height="20" font="0">them for screening. </text>
<text top="663" left="586" width="3" height="20" font="0"> </text>
<text top="680" left="586" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="699" left="582" width="11" height="18" font="0">• </text>
<text top="698" left="595" width="224" height="20" font="0">Screening all 16-y-olds in this population </text>
<text top="715" left="595" width="206" height="20" font="0">would result in an estimated 470 new </text>
<text top="733" left="595" width="211" height="20" font="0">diagnoses of FH and would avert 11.7 </text>
<text top="750" left="595" width="223" height="20" font="0">deaths over 10 y at a cost of £6,176,649 </text>
<text top="767" left="595" width="226" height="20" font="0">(including 10-y drug costs of £1,584,918. </text>
<text top="543" left="840" width="7" height="18" font="0">•</text>
<text top="542" left="847" width="237" height="20" font="0"> Although the two approaches compared in </text>
<text top="560" left="840" width="189" height="20" font="0">this study appeared similar in cost-</text>
<text top="577" left="840" width="250" height="20" font="0">effectiveness over a lifetime (see Marks 2002 </text>
<text top="594" left="840" width="256" height="20" font="0">analysis, above), results from this shorter-term </text>
<text top="611" left="840" width="241" height="20" font="0">(10-y) cost-effectiveness clearly favored the </text>
<text top="628" left="840" width="127" height="20" font="0">family tracing strategy. </text>
<text top="646" left="840" width="3" height="20" font="0"> </text>
<text top="663" left="840" width="3" height="20" font="0"> </text>
<text top="680" left="840" width="217" height="20" font="0">Limitations: Generalizability beyond UK </text>
<text top="697" left="840" width="260" height="20" font="0">population; older study with high assumed drug </text>
<text top="714" left="840" width="247" height="20" font="0">cost; numerous assumptions inherent in cost-</text>
<text top="732" left="840" width="127" height="20" font="0">effectiveness analysis. </text>
<text top="749" left="840" width="3" height="20" font="0"> </text>
</page>
<page number="119" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">119 </text>
<text top="107" left="595" width="220" height="20" font="0">The cost per case identified and treated </text>
<text top="124" left="595" width="104" height="20" font="0">would be £13141.  </text>
<text top="143" left="582" width="11" height="18" font="0">• </text>
<text top="143" left="595" width="226" height="20" font="0">Screening first-degree relatives of known </text>
<text top="160" left="595" width="201" height="20" font="0">FH cases would result in 13248 new </text>
<text top="177" left="595" width="229" height="20" font="0">diagnoses, 560 deaths averted over 10 y, </text>
<text top="194" left="595" width="211" height="20" font="0">at a cost of £46 430 681. The cost per </text>
<text top="211" left="595" width="217" height="20" font="0">case identified and treated would be £3 </text>
<text top="229" left="595" width="229" height="20" font="0">505 (including 10-y drug costs of £44 645 </text>
<text top="246" left="595" width="31" height="20" font="0">760). </text>
<text top="264" left="91" width="126" height="20" font="0">Nherera L, et al., 2011 </text>
<text top="281" left="91" width="32" height="20" font="0"><a href="data supplement.html#243">(130)</a> </text>
<text top="298" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21685482">21685482</a></text>
<text top="298" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21685482"> </a></text>
<text top="264" left="253" width="103" height="20" font="7"><b>Study type:</b>  Cost-</text>
<text top="281" left="253" width="123" height="20" font="0">effectiveness analysis </text>
<text top="298" left="253" width="3" height="20" font="0"> </text>
<text top="315" left="253" width="145" height="20" font="7"><b>Size:</b>  Simulated cohort of </text>
<text top="333" left="253" width="125" height="20" font="0">1000 people in the UK </text>
<text top="350" left="253" width="132" height="20" font="0">suspected of having FH </text>
<text top="367" left="253" width="143" height="20" font="0">aged 50 y for index cases </text>
<text top="384" left="253" width="121" height="20" font="0">and 30 y for relatives, </text>
<text top="401" left="253" width="122" height="20" font="0">followed for a lifetime. </text>
<text top="264" left="412" width="130" height="20" font="7"><b>Inclusion criteria:</b> N/A </text>
<text top="281" left="412" width="3" height="20" font="0"> </text>
<text top="298" left="412" width="134" height="20" font="7"><b>Exclusion criteria:</b> N/A </text>
<text top="265" left="586" width="219" height="20" font="7"><b>1</b>°<b> endpoint:</b> Costs, QALYs and ICERs </text>
<text top="282" left="586" width="215" height="20" font="0">comparing different cascade screening </text>
<text top="299" left="586" width="193" height="20" font="0">strategies: using LDL-C levels only </text>
<text top="317" left="586" width="217" height="20" font="0">(cholesterol method); cascading only in </text>
<text top="334" left="586" width="241" height="20" font="0">patients with a causative mutation identified </text>
<text top="351" left="586" width="232" height="20" font="0">and using DNA tests to diagnose relatives </text>
<text top="368" left="586" width="211" height="20" font="0">(DNA method); DNA testing combined </text>
<text top="385" left="586" width="238" height="20" font="0">with LDL-cholesterol testing in families with </text>
<text top="403" left="586" width="235" height="20" font="0">no mutation identified, only in patients with </text>
<text top="420" left="586" width="227" height="20" font="0">clinically defined ‘definite’ FH (DNA+DFH </text>
<text top="437" left="586" width="227" height="20" font="0">method); and DNA testing combined with </text>
<text top="454" left="586" width="211" height="20" font="0">LDL-cholesterol testing in no-mutation </text>
<text top="471" left="586" width="235" height="20" font="0">families of both ‘definite’ and ‘probable’ FH </text>
<text top="489" left="586" width="152" height="20" font="0">patients (DNA+DFH+PFH). </text>
<text top="506" left="586" width="3" height="20" font="0"> </text>
<text top="523" left="586" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="542" left="582" width="11" height="18" font="0">• </text>
<text top="541" left="595" width="228" height="20" font="0">All DNA-based methods were considered </text>
<text top="559" left="595" width="218" height="20" font="0">more cost-effective than the cholesterol </text>
<text top="576" left="595" width="77" height="20" font="0">only method.  </text>
<text top="595" left="582" width="11" height="18" font="0">• </text>
<text top="594" left="595" width="204" height="20" font="0">The DNA+DFH+PFH method had an </text>
<text top="611" left="595" width="204" height="20" font="0">ICER of £3666/QALY compared with </text>
<text top="628" left="595" width="174" height="20" font="0">DNA alone and of £4145/QALY </text>
<text top="646" left="595" width="215" height="20" font="0">compared with the cholesterol method. </text>
<text top="663" left="586" width="3" height="20" font="0"> </text>
<text top="266" left="840" width="7" height="18" font="0">•</text>
<text top="265" left="847" width="235" height="20" font="0"> In this study, the DNA+DFH+PFH method </text>
<text top="282" left="840" width="258" height="20" font="0">was the most cost-effective cascade screening </text>
<text top="299" left="840" width="240" height="20" font="0">strategy as a result of lower DNA screening </text>
<text top="317" left="840" width="236" height="20" font="0">costs compared with the higher number of  </text>
<text top="334" left="840" width="3" height="20" font="0"> </text>
<text top="351" left="840" width="241" height="20" font="0">Limitations: Assumptions based on 50-y old </text>
<text top="368" left="840" width="178" height="20" font="0">probands and 30-y old relatives; </text>
<text top="385" left="840" width="213" height="20" font="0">generalizability beyond UK population; </text>
<text top="403" left="840" width="218" height="20" font="0">numerous assumptions inherent in cost-</text>
<text top="420" left="840" width="127" height="20" font="0">effectiveness analysis. </text>
<text top="681" left="91" width="141" height="20" font="0">Oliva J, et al., 2009 <a href="data supplement.html#243">(131)</a> </text>
<text top="698" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19150015">19150015</a></text>
<text top="698" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19150015"> </a></text>
<text top="681" left="253" width="103" height="20" font="7"><b>Study type:</b>  Cost-</text>
<text top="698" left="253" width="123" height="20" font="0">effectiveness analysis </text>
<text top="715" left="253" width="3" height="20" font="0"> </text>
<text top="732" left="253" width="121" height="20" font="7"><b>Size:</b>  Representative </text>
<text top="750" left="253" width="140" height="20" font="0">data from 503 individuals </text>
<text top="767" left="253" width="143" height="20" font="0">with FH and national data </text>
<text top="784" left="253" width="63" height="20" font="0">from Spain </text>
<text top="681" left="412" width="130" height="20" font="7"><b>Inclusion criteria:</b> N/A </text>
<text top="698" left="412" width="3" height="20" font="0"> </text>
<text top="715" left="412" width="134" height="20" font="7"><b>Exclusion criteria:</b> N/A </text>
<text top="682" left="586" width="241" height="20" font="7"><b>1</b>°<b> endpoint:</b> Costs and ICER per Life Year </text>
<text top="699" left="586" width="240" height="20" font="0">Gained (LYG) comparing genetic screening </text>
<text top="716" left="586" width="100" height="20" font="0">and treatment of 1</text>
<text top="718" left="686" width="6" height="13" font="9">st</text>
<text top="716" left="692" width="108" height="20" font="0"> degree relatives of </text>
<text top="734" left="586" width="222" height="20" font="0">probands with genetically diagnosed FH </text>
<text top="751" left="586" width="161" height="20" font="0">compared with no screening. </text>
<text top="768" left="586" width="3" height="20" font="0"> </text>
<text top="785" left="586" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="683" left="838" width="11" height="18" font="0">• </text>
<text top="682" left="852" width="123" height="20" font="0">Genetic screening of 1</text>
<text top="684" left="975" width="6" height="13" font="9">st</text>
<text top="682" left="981" width="108" height="20" font="0"> degree relatives of </text>
<text top="699" left="852" width="232" height="20" font="0">those with FH appeared to be favorable in </text>
<text top="716" left="852" width="233" height="20" font="0">terms of cost-effectiveness compared with </text>
<text top="733" left="852" width="144" height="20" font="0">no screening of relatives.  </text>
<text top="751" left="852" width="3" height="20" font="0"> </text>
<text top="770" left="838" width="11" height="18" font="0">• </text>
<text top="769" left="852" width="241" height="20" font="0">In sensitivity analyses, cost-effectiveness of </text>
<text top="786" left="852" width="229" height="20" font="0">genetic screening was favorable across a </text>
</page>
<page number="120" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">120 </text>
<text top="109" left="582" width="11" height="18" font="0">• </text>
<text top="108" left="595" width="199" height="20" font="0">For the base case, the results were: </text>
<text top="125" left="595" width="159" height="20" font="0">Group       Cost     Life Years </text>
<text top="143" left="595" width="145" height="20" font="0">Screened     €8891    56.7 </text>
<text top="160" left="595" width="152" height="20" font="0">Not screened €4298    55.4 </text>
<text top="177" left="595" width="147" height="20" font="0">Increment     €4593    1.34 </text>
<text top="194" left="595" width="3" height="20" font="0"> </text>
<text top="211" left="595" width="130" height="20" font="0">ICER = €3423 per LYG </text>
<text top="107" left="852" width="199" height="20" font="0">wide range of assumptions and was </text>
<text top="124" left="852" width="168" height="20" font="0">sensitive to the cost of statins. </text>
<text top="141" left="894" width="3" height="20" font="0"> </text>
<text top="159" left="840" width="245" height="20" font="0">Limitations: Generalizability beyond Spanish </text>
<text top="176" left="840" width="261" height="20" font="0">populations; numerous assumptions inherent in </text>
<text top="193" left="840" width="153" height="20" font="0">cost-effectiveness analysis. </text>
<text top="229" left="91" width="145" height="20" font="0">Wonderling D, et al., 2004 </text>
<text top="247" left="91" width="32" height="20" font="0"><a href="data supplement.html#243">(132)</a> </text>
<text top="264" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15199439">15199439</a></text>
<text top="264" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/15199439"> </a></text>
<text top="281" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="229" left="253" width="103" height="20" font="7"><b>Study type:</b>  Cost-</text>
<text top="247" left="253" width="123" height="20" font="0">effectiveness analysis </text>
<text top="264" left="253" width="3" height="20" font="0"> </text>
<text top="281" left="253" width="93" height="20" font="7"><b>Size:</b>  Data from </text>
<text top="298" left="253" width="119" height="20" font="0">nationwide screening </text>
<text top="315" left="253" width="120" height="20" font="0">program for FH in the </text>
<text top="333" left="253" width="132" height="20" font="0">Netherlands 1994-2002 </text>
<text top="229" left="412" width="130" height="20" font="7"><b>Inclusion criteria:</b> N/A </text>
<text top="247" left="412" width="3" height="20" font="0"> </text>
<text top="264" left="412" width="134" height="20" font="7"><b>Exclusion criteria:</b> N/A </text>
<text top="230" left="586" width="228" height="20" font="7"><b>1</b>°<b> endpoint:</b> Costs per Life Year Gained </text>
<text top="248" left="586" width="221" height="20" font="0">(LYG) comparing genetic screening and </text>
<text top="265" left="586" width="212" height="20" font="0">treatment of relatives of probands with </text>
<text top="282" left="586" width="213" height="20" font="0">genetically diagnosed FH compared to </text>
<text top="299" left="586" width="225" height="20" font="0">national data, with a lifetime perspective. </text>
<text top="317" left="586" width="3" height="20" font="0"> </text>
<text top="334" left="586" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="353" left="582" width="11" height="18" font="0">• </text>
<text top="352" left="595" width="193" height="20" font="0">Compared with no screening, DNA </text>
<text top="369" left="595" width="216" height="20" font="0">testing of families with a known genetic </text>
<text top="386" left="595" width="141" height="20" font="0">defect was cost effective. </text>
<text top="405" left="582" width="11" height="18" font="0">• </text>
<text top="405" left="595" width="229" height="20" font="0">Individuals with newly-diagnosed FH as a </text>
<text top="422" left="595" width="229" height="20" font="0">result of the screening program appeared </text>
<text top="439" left="595" width="219" height="20" font="0">to gain, on average, 3.3 y of life each at </text>
<text top="456" left="595" width="210" height="20" font="0">an average cost of US $7500 per new </text>
<text top="474" left="595" width="89" height="20" font="0">case identified.  </text>
<text top="493" left="582" width="11" height="18" font="0">• </text>
<text top="492" left="595" width="185" height="20" font="0">The cost per life-year gained was </text>
<text top="509" left="595" width="58" height="20" font="0">US$8700. </text>
<text top="231" left="838" width="11" height="18" font="0">• </text>
<text top="230" left="852" width="234" height="20" font="0">Genetic screening of families of those with </text>
<text top="247" left="852" width="221" height="20" font="0">FH appeared to be favorable in terms of </text>
<text top="265" left="852" width="202" height="20" font="0">cost-effectiveness compared with no </text>
<text top="282" left="852" width="127" height="20" font="0">screening of relatives.  </text>
<text top="299" left="852" width="3" height="20" font="0"> </text>
<text top="318" left="838" width="11" height="18" font="0">• </text>
<text top="317" left="852" width="241" height="20" font="0">In sensitivity analyses, cost-effectiveness of </text>
<text top="335" left="852" width="229" height="20" font="0">genetic screening was favorable across a </text>
<text top="352" left="852" width="199" height="20" font="0">wide range of assumptions and was </text>
<text top="369" left="852" width="168" height="20" font="0">sensitive to the cost of statins. </text>
<text top="386" left="894" width="3" height="20" font="0"> </text>
<text top="404" left="840" width="259" height="20" font="0">Limitations: Numerous assumptions inherent in </text>
<text top="421" left="840" width="153" height="20" font="0">cost-effectiveness analysis. </text>
<text top="527" left="88" width="93" height="20" font="7"><b>Abbreviations:</b>  </text>
<text top="544" left="88" width="300" height="20" font="7"><b>Search Terms and Date of Search</b>: Author to provide </text>
<text top="561" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="580" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="599" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="618" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="637" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="656" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="675" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="694" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="712" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="732" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="750" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="769" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="788" left="81" width="4" height="22" font="5"><b> </b></text>
</page>
<page number="121" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">121 </text>
<text top="106" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="125" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="144" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="163" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="182" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="201" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="220" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="239" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="257" left="81" width="4" height="22" font="5"><b> </b></text>
<text top="276" left="81" width="674" height="24" font="4"><b>Data Supplement 21. RCTs Comparing Screening of Children and Adolescents (Section 4.4.4.3)  </b></text>
<text top="298" left="98" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="315" left="123" width="51" height="20" font="7"><b>Author;  </b></text>
<text top="332" left="99" width="96" height="20" font="7"><b>Year Published; </b></text>
<text top="350" left="130" width="34" height="20" font="7"><b>PMID </b></text>
<text top="298" left="243" width="83" height="20" font="7"><b>Aim of Study; </b></text>
<text top="315" left="248" width="74" height="20" font="7"><b>Study Type; </b></text>
<text top="332" left="242" width="86" height="20" font="7"><b>Study Size (N) </b></text>
<text top="298" left="386" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="298" left="544" width="115" height="20" font="7"><b>Study Intervention  </b></text>
<text top="315" left="562" width="79" height="20" font="7"><b>(# patients) /  </b></text>
<text top="332" left="545" width="114" height="20" font="7"><b>Study Comparator  </b></text>
<text top="350" left="565" width="69" height="20" font="7"><b>(# patients) </b></text>
<text top="298" left="729" width="105" height="20" font="7"><b>Endpoint Results </b></text>
<text top="315" left="713" width="141" height="20" font="7"><b>(Absolute Event Rates,  </b></text>
<text top="332" left="691" width="181" height="20" font="7"><b>P values; OR or RR; &amp; 95% CI) </b></text>
<text top="299" left="923" width="175" height="20" font="7"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="316" left="955" width="111" height="20" font="7"><b>Study Limitations; </b></text>
<text top="334" left="962" width="96" height="20" font="7"><b>Adverse Events </b></text>
<text top="368" left="89" width="104" height="20" font="0">Kusters DM, et al., </text>
<text top="385" left="89" width="63" height="20" font="0">2015 <a href="data supplement.html#244">(133)</a> </text>
<text top="402" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25841542">25841542</a></text>
<text top="402" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25841542"> </a></text>
<text top="368" left="218" width="119" height="20" font="7"><b>Aim:</b> To evaluate the </text>
<text top="385" left="218" width="119" height="20" font="0">safety and efficacy of </text>
<text top="402" left="218" width="131" height="20" font="0">ezetimibe monotherapy </text>
<text top="419" left="218" width="121" height="20" font="0">in young children with </text>
<text top="436" left="218" width="99" height="20" font="0">Heterozygous FH </text>
<text top="454" left="218" width="3" height="20" font="0"> </text>
<text top="471" left="218" width="134" height="20" font="7"><b>Study type:</b> multicenter </text>
<text top="488" left="218" width="117" height="20" font="0">double-blind placebo </text>
<text top="505" left="218" width="121" height="20" font="0">controlled 12 wk RCT </text>
<text top="523" left="218" width="3" height="20" font="0"> </text>
<text top="540" left="218" width="83" height="20" font="7"><b>Size:</b>  138, 2:1 </text>
<text top="557" left="218" width="128" height="20" font="0">randomization strategy </text>
<text top="574" left="218" width="119" height="20" font="0">ezetimibe 10 mg (n = </text>
<text top="591" left="218" width="128" height="20" font="0">93) or placebo (n = 45) </text>
<text top="368" left="365" width="141" height="20" font="7"><b>Inclusion criteria:</b> age 6-</text>
<text top="385" left="365" width="87" height="20" font="0">10 y diagnosed </text>
<text top="402" left="365" width="111" height="20" font="0">heterozygous FH or </text>
<text top="419" left="365" width="148" height="20" font="0">clinically important non-FH </text>
<text top="436" left="365" width="104" height="20" font="0">(LDL ≥160 mg/dL) </text>
<text top="454" left="365" width="3" height="20" font="0"> </text>
<text top="471" left="365" width="130" height="20" font="7"><b>Exclusion criteria:</b> TG </text>
<text top="488" left="365" width="138" height="20" font="0">&gt;300 mg/dL, evidence of </text>
<text top="505" left="365" width="116" height="20" font="0">secondary causes of </text>
<text top="523" left="365" width="136" height="20" font="0">hyperlipidemia, elevated </text>
<text top="540" left="365" width="137" height="20" font="0">LFTs, hypersensitivity or </text>
<text top="557" left="365" width="103" height="20" font="0">contraindication to </text>
<text top="574" left="365" width="136" height="20" font="0">ezetimibe or other major </text>
<text top="591" left="365" width="63" height="20" font="0">diagnoses  </text>
<text top="368" left="530" width="135" height="20" font="7"><b>Intervention:</b> Ezetimibe </text>
<text top="385" left="530" width="82" height="20" font="0">10 mg per day </text>
<text top="402" left="530" width="7" height="20" font="0">  </text>
<text top="419" left="530" width="132" height="20" font="7"><b>Comparator:</b> Placebo <b>  </b></text>
<text top="369" left="682" width="150" height="20" font="7"><b>1</b>°<b> endpoint:</b> Compared to </text>
<text top="386" left="682" width="196" height="20" font="0">placebo, Ezetimibe lowered LDL by </text>
<text top="403" left="682" width="168" height="20" font="0">27%, TC by 21%, non-HDL by </text>
<text top="420" left="682" width="192" height="20" font="0">26%, and apolipoprotein B by 20% </text>
<text top="438" left="682" width="72" height="20" font="0">(all p&lt;0.001) </text>
<text top="455" left="682" width="3" height="20" font="0"> </text>
<text top="472" left="682" width="193" height="20" font="7"><b>Safety endpoint (if relevant):</b> N/A<b> </b></text>
<text top="369" left="894" width="7" height="18" font="0">•</text>
<text top="369" left="901" width="170" height="20" font="0"> Ezetimibe reduced markers of </text>
<text top="386" left="894" width="224" height="20" font="0">cholesterol absorption (placebo adjusted </text>
<text top="403" left="894" width="194" height="20" font="0">changes at wk 12: sitosterol, -63%; </text>
<text top="420" left="894" width="214" height="20" font="0">campesterol, -65%; cholestanol, -32%; </text>
<text top="438" left="894" width="199" height="20" font="0">p&lt;0.001) and increased a marker of </text>
<text top="455" left="894" width="224" height="20" font="0">cholesterol synthesis (lathosterol, +24%; </text>
<text top="472" left="894" width="52" height="20" font="0">p&lt;0.001) </text>
<text top="491" left="894" width="7" height="18" font="0">•</text>
<text top="490" left="901" width="219" height="20" font="0"> Well tolerated without significant safety </text>
<text top="508" left="894" width="217" height="20" font="0">effects. One girl experienced persistent </text>
<text top="525" left="894" width="231" height="20" font="0">elevated mild elevations in ALT that led to </text>
<text top="542" left="894" width="148" height="20" font="0">ezetimibe discontinuation.  </text>
<text top="609" left="89" width="48" height="20" font="7"><b>APPLE  </b></text>
<text top="627" left="89" width="98" height="20" font="0">Schanberg LE, et </text>
<text top="644" left="89" width="86" height="20" font="0">al., 2012 <a href="data supplement.html#244">(134)</a>  </text>
<text top="661" left="89" width="58" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22031171">22031171 </a></text>
<text top="678" left="89" width="3" height="20" font="0"> </text>
<text top="695" left="89" width="96" height="20" font="0">Ardion SP, et al., </text>
<text top="713" left="89" width="63" height="20" font="0">2014 <a href="data supplement.html#244">(135)</a> </text>
<text top="730" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23436914">23436914</a></text>
<text top="730" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23436914"> </a></text>
<text top="609" left="218" width="120" height="20" font="7"><b>Aim:</b> determine the 3-</text>
<text top="627" left="218" width="132" height="20" font="0">year efficacy and safety </text>
<text top="644" left="218" width="94" height="20" font="0">of atorvastatin in </text>
<text top="661" left="218" width="121" height="20" font="0">preventing subclinical </text>
<text top="678" left="218" width="86" height="20" font="0">atherosclerosis </text>
<text top="696" left="218" width="126" height="20" font="0">progression measured </text>
<text top="713" left="218" width="85" height="20" font="0">by mean-mean </text>
<text top="730" left="218" width="128" height="20" font="0">common carotid intima-</text>
<text top="747" left="218" width="96" height="20" font="0">media thickening </text>
<text top="764" left="218" width="105" height="20" font="0">(CIMT) in pediatric-</text>
<text top="782" left="218" width="60" height="20" font="0">onset SLE </text>
<text top="609" left="365" width="136" height="20" font="7"><b>Inclusion criteria:</b> SLE, </text>
<text top="627" left="365" width="142" height="20" font="0">weight ≥25 kg, English or </text>
<text top="644" left="365" width="102" height="20" font="0">Spanish language </text>
<text top="661" left="365" width="3" height="20" font="0"> </text>
<text top="678" left="365" width="145" height="20" font="7"><b>Exclusion criteria:</b> active </text>
<text top="695" left="365" width="115" height="20" font="0">nephrotic syndrome, </text>
<text top="713" left="365" width="126" height="20" font="0">myositis, liver disease, </text>
<text top="730" left="365" width="119" height="20" font="0">renal insufficiency, or </text>
<text top="747" left="365" width="120" height="20" font="0">hypercholesterolemia </text>
<text top="764" left="365" width="125" height="20" font="0">(total cholesterol &gt;350 </text>
<text top="782" left="365" width="116" height="20" font="0">mg/dl) or were being </text>
<text top="609" left="530" width="78" height="20" font="7"><b>Intervention:</b> </text>
<text top="627" left="530" width="136" height="20" font="0">atorvastatin 10 or 20 mg </text>
<text top="644" left="530" width="44" height="20" font="0">per day </text>
<text top="661" left="530" width="7" height="20" font="0">  </text>
<text top="678" left="530" width="130" height="20" font="7"><b>Comparator:</b> <b> placebo </b></text>
<text top="611" left="682" width="186" height="20" font="7"><b>1</b>°<b> endpoint:</b> No difference in the </text>
<text top="628" left="682" width="189" height="20" font="0">rate of progression of mean-mean </text>
<text top="645" left="682" width="189" height="20" font="0">common CIMT between treatment </text>
<text top="662" left="682" width="138" height="20" font="0">groups (0.0010 mm/y for </text>
<text top="679" left="682" width="181" height="20" font="0">atorvastatin versus 0.0024 mm/y </text>
<text top="697" left="682" width="120" height="20" font="0">for placebo; p=0.24).  </text>
<text top="714" left="682" width="3" height="20" font="0"> </text>
<text top="731" left="682" width="124" height="20" font="7"><b>Safety endpoint:</b> N/A<b> </b></text>
<text top="611" left="894" width="7" height="18" font="0">•</text>
<text top="611" left="901" width="215" height="20" font="0"> The atorvastatin group achieved lower </text>
<text top="628" left="894" width="226" height="20" font="0">hsCRP (p=0.04), TC (p&lt;0.001), and LDL-</text>
<text top="645" left="894" width="187" height="20" font="0">C (p&lt;0.001) levels compared with </text>
<text top="662" left="894" width="53" height="20" font="0">placebo.  </text>
<text top="681" left="894" width="7" height="18" font="0">•</text>
<text top="681" left="901" width="215" height="20" font="0"> Post-pubertal patients with high hCRP </text>
<text top="698" left="894" width="215" height="20" font="0">seemed to benefit the most in post-hoc </text>
<text top="715" left="894" width="52" height="20" font="0">analyses </text>
<text top="734" left="894" width="7" height="18" font="0">•</text>
<text top="733" left="901" width="217" height="20" font="0"> CIMT progressed in the placebo group </text>
<text top="751" left="894" width="227" height="20" font="0">over time (0.0023-0.0144 mm/y; p&lt;0.05). </text>
<text top="770" left="894" width="7" height="18" font="0">•</text>
<text top="769" left="901" width="177" height="20" font="0"> No significant safety concerns.  </text>
</page>
<page number="122" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">122 </text>
<text top="107" left="218" width="3" height="20" font="0"> </text>
<text top="124" left="218" width="114" height="20" font="7"><b>Study type:</b>  double </text>
<text top="141" left="218" width="58" height="20" font="0">blind RCT </text>
<text top="159" left="218" width="3" height="20" font="0"> </text>
<text top="176" left="218" width="118" height="20" font="7"><b>Size:</b>  221 youth with </text>
<text top="193" left="218" width="113" height="20" font="0">SLE (ages 10-21 y), </text>
<text top="210" left="218" width="128" height="20" font="0">182 completed the trial </text>
<text top="107" left="365" width="139" height="20" font="0">treated with cyclosporine </text>
<text top="124" left="365" width="141" height="20" font="0">or tacrolimus, unwilling to </text>
<text top="141" left="365" width="128" height="20" font="0">follow AHA therapeutic </text>
<text top="159" left="365" width="132" height="20" font="0">lifestyle changes diet or </text>
<text top="176" left="365" width="146" height="20" font="0">use approved birth control </text>
<text top="193" left="365" width="51" height="20" font="0">methods </text>
<text top="109" left="894" width="7" height="18" font="0">•</text>
<text top="108" left="901" width="220" height="20" font="0"> Patients ineligible for participation were </text>
<text top="125" left="894" width="209" height="20" font="0">at the highest risk of progression, and </text>
<text top="143" left="894" width="210" height="20" font="0">possibly could have demonstrated the </text>
<text top="160" left="894" width="70" height="20" font="0">most benefit </text>
<text top="228" left="89" width="40" height="20" font="7"><b>STRIP </b></text>
<text top="245" left="89" width="104" height="20" font="0">Niinikoski H, et al., </text>
<text top="263" left="89" width="63" height="20" font="0">2007<b> </b><a href="data supplement.html#244">(136)</a><b> </b></text>
<text top="280" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17698729">17698729</a></text>
<text top="280" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/17698729"> </a></text>
<text top="228" left="218" width="129" height="20" font="7"><b>Aim:</b> effect of a dietary </text>
<text top="245" left="218" width="109" height="20" font="0">intervention on lipid </text>
<text top="263" left="218" width="35" height="20" font="0">levels </text>
<text top="280" left="218" width="3" height="20" font="0"> </text>
<text top="297" left="218" width="74" height="20" font="7"><b>Study type:</b>  </text>
<text top="314" left="218" width="128" height="20" font="0">randomized, controlled </text>
<text top="332" left="218" width="87" height="20" font="0">atherosclerosis-</text>
<text top="349" left="218" width="94" height="20" font="0">prevention study </text>
<text top="366" left="218" width="3" height="20" font="0"> </text>
<text top="383" left="218" width="113" height="20" font="7"><b>Size:</b> complete data </text>
<text top="400" left="218" width="120" height="20" font="0">were available at age </text>
<text top="418" left="218" width="134" height="20" font="0">15 (n=394), 17 (n=376), </text>
<text top="435" left="218" width="97" height="20" font="0">and 19 (n=298) y<b> </b></text>
<text top="228" left="365" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="245" left="365" width="3" height="20" font="0"> </text>
<text top="263" left="365" width="114" height="20" font="7"><b>Exclusion criteria:</b> <b> </b></text>
<text top="228" left="530" width="130" height="20" font="7"><b>Intervention:</b> repeated </text>
<text top="245" left="530" width="126" height="20" font="0">dietary counseling and </text>
<text top="263" left="530" width="112" height="20" font="0">anti-smoking advice </text>
<text top="280" left="530" width="117" height="20" font="0">starting infancy up to </text>
<text top="297" left="530" width="51" height="20" font="0">age 14 y </text>
<text top="314" left="530" width="7" height="20" font="0">  </text>
<text top="332" left="530" width="127" height="20" font="7"><b>Comparator: </b>biannual </text>
<text top="349" left="530" width="137" height="20" font="0">clinical visits without diet </text>
<text top="366" left="530" width="133" height="20" font="0">or smoking counseling <b>  </b></text>
<text top="229" left="682" width="195" height="20" font="7"><b>1</b>°<b> endpoint:</b> Saturated fat intakes, </text>
<text top="247" left="682" width="188" height="20" font="0">TC, and LDL-C values were lower </text>
<text top="264" left="682" width="197" height="20" font="0">(p&lt;0.001) in the intervention than in </text>
<text top="281" left="682" width="190" height="20" font="0">control children over 14 y of follow-</text>
<text top="298" left="682" width="21" height="20" font="0">up. </text>
<text top="317" left="682" width="7" height="18" font="0">•</text>
<text top="317" left="689" width="150" height="20" font="0"> HDL-C levels did not differ </text>
<text top="334" left="682" width="129" height="20" font="0">between the 2 groups.  </text>
<text top="353" left="682" width="7" height="18" font="0">•</text>
<text top="352" left="689" width="174" height="20" font="0"> Boys had lower TC and LDL-C </text>
<text top="370" left="682" width="172" height="20" font="0">than girls throughout childhood </text>
<text top="387" left="682" width="63" height="20" font="0">(p&lt;0.001),  </text>
<text top="406" left="682" width="7" height="18" font="0">•</text>
<text top="405" left="689" width="183" height="20" font="0"> The intervention effect on serum </text>
<text top="422" left="682" width="165" height="20" font="0">cholesterol concentration was </text>
<text top="440" left="682" width="138" height="20" font="0">larger in boys than girls.  </text>
<text top="459" left="682" width="7" height="18" font="0">•</text>
<text top="458" left="689" width="177" height="20" font="0"> TC and HDL-C decreased from </text>
<text top="475" left="682" width="194" height="20" font="0">4.5 and 1.4 mmol/L, respectively in </text>
<text top="492" left="682" width="189" height="20" font="0">Tanner stage 1 (prepubertal) boys </text>
<text top="510" left="682" width="138" height="20" font="0">to approximately 3.9 and </text>
<text top="527" left="682" width="157" height="20" font="0">approximately 1.1 mmol/L in </text>
<text top="544" left="682" width="198" height="20" font="0">Tanner stage 4 (late pubertal) boys. </text>
<text top="561" left="682" width="3" height="20" font="0"> </text>
<text top="578" left="682" width="168" height="20" font="7"><b>Safety endpoint:</b> The 2 study </text>
<text top="596" left="682" width="174" height="20" font="0">groups showed no difference in </text>
<text top="613" left="682" width="191" height="20" font="0">growth, body mass index, pubertal </text>
<text top="630" left="682" width="187" height="20" font="0">development, or age at menarche </text>
<text top="647" left="682" width="173" height="20" font="0">(median, 13.0 and 12.8 y in the </text>
<text top="664" left="682" width="161" height="20" font="0">intervention and control girls, </text>
<text top="682" left="682" width="121" height="20" font="0">respectively; p=0.52). </text>
<text top="699" left="682" width="3" height="20" font="7"><b> </b></text>
<text top="228" left="894" width="24" height="20" font="0">N/A </text>
<text top="717" left="89" width="43" height="20" font="7"><b>STRIP</b>  </text>
<text top="734" left="89" width="96" height="20" font="0">Pahkala K, et al., </text>
<text top="751" left="89" width="63" height="20" font="0">2013 <a href="data supplement.html#244">(137)</a> </text>
<text top="768" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23613255">23613255</a></text>
<text top="768" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23613255"> </a></text>
<text top="717" left="218" width="128" height="20" font="7"><b>Aim:</b> post hoc analysis </text>
<text top="734" left="218" width="132" height="20" font="0">of the effect of a dietary </text>
<text top="751" left="218" width="113" height="20" font="0">intervention on ideal </text>
<text top="768" left="218" width="123" height="20" font="0">cardiovascular health; </text>
<text top="786" left="218" width="128" height="20" font="0">relationship with intima-</text>
<text top="717" left="365" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="734" left="365" width="3" height="20" font="0"> </text>
<text top="751" left="365" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="717" left="530" width="130" height="20" font="7"><b>Intervention:</b> repeated </text>
<text top="734" left="530" width="126" height="20" font="0">dietary counseling and </text>
<text top="751" left="530" width="112" height="20" font="0">anti-smoking advice </text>
<text top="768" left="530" width="117" height="20" font="0">starting infancy up to </text>
<text top="786" left="530" width="51" height="20" font="0">age 20 y </text>
<text top="718" left="682" width="180" height="20" font="7"><b>1</b>°<b> endpoint:</b> Adolescents in the </text>
<text top="735" left="682" width="196" height="20" font="0">control group had an increased risk </text>
<text top="752" left="682" width="185" height="20" font="0">of low ideal cardiovascular health </text>
<text top="770" left="682" width="174" height="20" font="0">(≤3 metrics) compared with the </text>
<text top="787" left="682" width="163" height="20" font="0">intervention adolescents (risk </text>
<text top="719" left="894" width="7" height="18" font="0">•</text>
<text top="718" left="901" width="168" height="20" font="0"> No participants had all 7 ideal </text>
<text top="735" left="894" width="176" height="20" font="0">cardiovascular health metrics in </text>
<text top="752" left="894" width="79" height="20" font="0">adolescence.  </text>
<text top="771" left="894" width="7" height="18" font="0">•</text>
<text top="771" left="901" width="208" height="20" font="0"> At least 5 ideal metrics were found in </text>
<text top="788" left="894" width="180" height="20" font="0">60.2%, 45.5%, and 34.2% of the </text>
</page>
<page number="123" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">123 </text>
<text top="107" left="218" width="115" height="20" font="0">media thickness and </text>
<text top="124" left="218" width="54" height="20" font="0">elasticity  </text>
<text top="141" left="218" width="3" height="20" font="0"> </text>
<text top="159" left="218" width="74" height="20" font="7"><b>Study type:</b>  </text>
<text top="176" left="218" width="69" height="20" font="0">longitudinal, </text>
<text top="193" left="218" width="128" height="20" font="0">randomized, controlled </text>
<text top="210" left="218" width="87" height="20" font="0">atherosclerosis-</text>
<text top="228" left="218" width="133" height="20" font="0">prevention STRIP study </text>
<text top="245" left="218" width="3" height="20" font="0"> </text>
<text top="262" left="218" width="113" height="20" font="7"><b>Size:</b> complete data </text>
<text top="279" left="218" width="120" height="20" font="0">were available at age </text>
<text top="296" left="218" width="134" height="20" font="0">15 (n=394), 17 (n=376), </text>
<text top="314" left="218" width="100" height="20" font="0">and 19 (n=298) y  </text>
<text top="107" left="530" width="7" height="20" font="0">  </text>
<text top="124" left="530" width="127" height="20" font="7"><b>Comparator: </b>biannual </text>
<text top="141" left="530" width="137" height="20" font="0">clinical visits without diet </text>
<text top="159" left="530" width="133" height="20" font="0">or smoking counseling <b>  </b></text>
<text top="107" left="682" width="153" height="20" font="0">ratio=1.35; 95% confidence </text>
<text top="124" left="682" width="113" height="20" font="0">interval=1.04-1.77).  </text>
<text top="141" left="682" width="3" height="20" font="0"> </text>
<text top="159" left="682" width="124" height="20" font="7"><b>Safety endpoint:</b> N/A </text>
<text top="176" left="682" width="3" height="20" font="7"><b> </b></text>
<text top="107" left="894" width="215" height="20" font="0">adolescents at 15, 17, and 19 y of age, </text>
<text top="124" left="894" width="75" height="20" font="0">respectively.  </text>
<text top="143" left="894" width="7" height="18" font="0">•</text>
<text top="143" left="901" width="213" height="20" font="0"> Number of ideal cardiovascular health </text>
<text top="160" left="894" width="208" height="20" font="0">metrics was inversely associated with </text>
<text top="177" left="894" width="188" height="20" font="0">aortic IMT (p&lt;0.0001) and directly </text>
<text top="194" left="894" width="201" height="20" font="0">associated with elasticity (p=0.045).  </text>
<text top="213" left="894" width="7" height="18" font="0">•</text>
<text top="213" left="901" width="190" height="20" font="0"> Adolescents with a low number of </text>
<text top="230" left="894" width="228" height="20" font="0">metrics (≤3) had nearly double the risk of </text>
<text top="247" left="894" width="195" height="20" font="0">having high intima-media thickness </text>
<text top="264" left="894" width="216" height="20" font="0">(&gt;85th percentile) compared with those </text>
<text top="282" left="894" width="223" height="20" font="0">with a higher score (risk ratio: 1.78; 95% </text>
<text top="299" left="894" width="172" height="20" font="0">confidence interval: 1.31-2.43). </text>
<text top="332" left="89" width="98" height="20" font="0">Iannuzzi A, et al., </text>
<text top="349" left="89" width="66" height="20" font="0">2009 <a href="data supplement.html#244">(138)</a>  </text>
<text top="366" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20108073">20108073</a></text>
<text top="366" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20108073"> </a></text>
<text top="332" left="218" width="122" height="20" font="7"><b>Aim:</b> to test the effect </text>
<text top="349" left="218" width="134" height="20" font="0">of hypocaloric diets with </text>
<text top="366" left="218" width="127" height="20" font="0">varying glycemic index </text>
<text top="383" left="218" width="105" height="20" font="0">on weight loss and </text>
<text top="400" left="218" width="60" height="20" font="0">subclinical </text>
<text top="418" left="218" width="124" height="20" font="0">atherosclerosis (aortic </text>
<text top="435" left="218" width="125" height="20" font="0">IMT) in obese children </text>
<text top="452" left="218" width="3" height="20" font="0"> </text>
<text top="469" left="218" width="134" height="20" font="7"><b>Study type:</b> 6-mo RCT  </text>
<text top="487" left="218" width="3" height="20" font="0"> </text>
<text top="504" left="218" width="95" height="20" font="7"><b>Size:</b>  26 divided </text>
<text top="521" left="218" width="122" height="20" font="0">between the 2 groups </text>
<text top="332" left="365" width="143" height="20" font="7"><b>Inclusion criteria:</b> obese </text>
<text top="349" left="365" width="124" height="20" font="0">children enrolled in an </text>
<text top="366" left="365" width="96" height="20" font="0">outpatient weight </text>
<text top="383" left="365" width="109" height="20" font="0">management clinic  </text>
<text top="400" left="365" width="3" height="20" font="0"> </text>
<text top="418" left="365" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="332" left="530" width="78" height="20" font="7"><b>Intervention:</b> </text>
<text top="349" left="530" width="88" height="20" font="0">hypocaloric low-</text>
<text top="366" left="530" width="111" height="20" font="0">glycemic index diet  </text>
<text top="383" left="530" width="77" height="20" font="7"><b>Comparator:</b> </text>
<text top="400" left="530" width="93" height="20" font="0">hypocaloric high-</text>
<text top="418" left="530" width="114" height="20" font="0">glycemic index diet <b>  </b></text>
<text top="333" left="682" width="188" height="20" font="7"><b>1</b>°<b> endpoint:</b> No differences were </text>
<text top="350" left="682" width="184" height="20" font="0">detectable in fasting TG, TC, and </text>
<text top="367" left="682" width="41" height="20" font="0">HDL-C </text>
<text top="384" left="682" width="3" height="20" font="0"> </text>
<text top="402" left="682" width="127" height="20" font="7"><b>Safety endpoint:</b> N/A  </text>
<text top="419" left="682" width="3" height="20" font="7"><b> </b></text>
<text top="333" left="894" width="7" height="18" font="0">•</text>
<text top="333" left="901" width="204" height="20" font="0"> All participants: BMI decreased from </text>
<text top="350" left="894" width="222" height="20" font="0">28.3 +/- 3.1 to 25.8 +/- 3.3 kg/m(2), SBP </text>
<text top="367" left="894" width="200" height="20" font="0">from 119 +/- 12 to 110 +/- 11 mmHg </text>
<text top="384" left="894" width="221" height="20" font="0">(p&lt;0.001), DBP from 78 +/- 8 to 74 +/- 7 </text>
<text top="402" left="894" width="225" height="20" font="0">mmHg (p&lt;0.001), IMT from 0.48 +/- 0.05 </text>
<text top="419" left="894" width="219" height="20" font="0">to 0.43 +/- 0.07 mm (p&lt;0.001), stiffness </text>
<text top="436" left="894" width="233" height="20" font="0">from 3.57 +/- 1.04 to 2.98 +/- 0.94 mm (p= </text>
<text top="453" left="894" width="225" height="20" font="0">0.002), and CRP from 1.5 +/- 0.9 (values </text>
<text top="470" left="894" width="226" height="20" font="0">log transformed) to 0.4 +/- 1.1 (p&lt;0.001). </text>
<text top="489" left="894" width="7" height="18" font="0">•</text>
<text top="489" left="901" width="226" height="20" font="0"> Insulin resistance (calculated by HOMA) </text>
<text top="506" left="894" width="207" height="20" font="0">was reduced only in the low-glycemic-</text>
<text top="523" left="894" width="144" height="20" font="0">index diet group (p&lt;0.04). </text>
<text top="541" left="89" width="102" height="20" font="0">Murphy EC, et al., </text>
<text top="558" left="89" width="63" height="20" font="0">2009 <a href="data supplement.html#244">(139)</a> </text>
<text top="576" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19922034">19922034</a></text>
<text top="576" left="144" width="3" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19922034"><b> </b></a></text>
<text top="541" left="218" width="107" height="20" font="7"><b>Aim:</b> To determine </text>
<text top="558" left="218" width="113" height="20" font="0">whether an exercise </text>
<text top="576" left="218" width="117" height="20" font="0">intervention using an </text>
<text top="593" left="218" width="102" height="20" font="0">active video game </text>
<text top="610" left="218" width="82" height="20" font="0">(Dance Dance </text>
<text top="627" left="218" width="119" height="20" font="0">Revolution) improves </text>
<text top="644" left="218" width="128" height="20" font="0">endothelial dysfunction </text>
<text top="662" left="218" width="131" height="20" font="0">and other risk factors in </text>
<text top="679" left="218" width="109" height="20" font="0">overweight children </text>
<text top="696" left="218" width="3" height="20" font="0"> </text>
<text top="713" left="218" width="102" height="20" font="7"><b>Study type:</b>  RCT </text>
<text top="730" left="218" width="3" height="20" font="0"> </text>
<text top="748" left="218" width="126" height="20" font="7"><b>Size:</b>  35 children total </text>
<text top="541" left="365" width="131" height="20" font="7"><b>Inclusion criteria:</b> BMI </text>
<text top="558" left="365" width="22" height="20" font="0">≥85</text>
<text top="560" left="387" width="7" height="13" font="9">th</text>
<text top="558" left="393" width="85" height="20" font="0"> percentile with </text>
<text top="576" left="365" width="128" height="20" font="0">endothelial dysfunction </text>
<text top="593" left="365" width="3" height="20" font="0"> </text>
<text top="610" left="365" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="541" left="530" width="128" height="20" font="7"><b>Intervention:</b> 12-wk of </text>
<text top="558" left="530" width="126" height="20" font="0">aerobic exercise using </text>
<text top="576" left="530" width="134" height="20" font="0">dance dance revolution  </text>
<text top="593" left="530" width="7" height="20" font="0">  </text>
<text top="610" left="530" width="102" height="20" font="7"><b>Comparator:</b> non-</text>
<text top="627" left="530" width="106" height="20" font="0">exercising delayed-</text>
<text top="644" left="530" width="59" height="20" font="0">treatment <b> </b></text>
<text top="542" left="682" width="161" height="20" font="7"><b>1</b>°<b> endpoint:</b> Exercise group </text>
<text top="560" left="682" width="128" height="20" font="0">experienced significant </text>
<text top="577" left="682" width="170" height="20" font="0">improvements in FMD ( 5.56+/-</text>
<text top="594" left="682" width="167" height="20" font="0">5.04% compared with 0.263+/-</text>
<text top="611" left="682" width="94" height="20" font="0">4.54%, p=0.008) </text>
<text top="628" left="682" width="3" height="20" font="0"> </text>
<text top="646" left="682" width="124" height="20" font="7"><b>Safety endpoint:</b> N/A </text>
<text top="543" left="894" width="7" height="18" font="0">•</text>
<text top="542" left="901" width="197" height="20" font="0"> Intervention group had an increase </text>
<text top="560" left="894" width="228" height="20" font="0">exercise time on the graded exercise test </text>
<text top="577" left="894" width="217" height="20" font="0">(53.59+/-91.54 compared with -12.83+/-</text>
<text top="594" left="894" width="218" height="20" font="0">68.10 seconds, p=0.025), mean arterial </text>
<text top="611" left="894" width="222" height="20" font="0">pressure (MAP) (-5.62+/-7.03 compared </text>
<text top="628" left="894" width="226" height="20" font="0">with -1.44+/-2.16 mmHg, p=0.05), weight </text>
<text top="646" left="894" width="220" height="20" font="0">(0.91+/-1.53 compared with 2.43+/-1.80 </text>
<text top="663" left="894" width="233" height="20" font="0">kg, p=0.017) and peak VO(2) (2.38+/-3.91 </text>
<text top="680" left="894" width="217" height="20" font="0">compared with -1.23+/-3.18 mg/kg/min, </text>
<text top="697" left="894" width="183" height="20" font="0">p=0.005) compared with control.  </text>
</page>
<page number="124" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">124 </text>
<text top="107" left="89" width="96" height="20" font="0">Farpour-Lambert </text>
<text top="124" left="89" width="88" height="20" font="0">NJ, 2009 <a href="data supplement.html#244">(140)</a>  </text>
<text top="141" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20082930">20082930</a></text>
<text top="141" left="144" width="3" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20082930"><b> </b></a></text>
<text top="107" left="218" width="123" height="20" font="7"><b>Aim: </b>to determine the </text>
<text top="124" left="218" width="101" height="20" font="0">effects of physical </text>
<text top="141" left="218" width="110" height="20" font="0">activity on SBP and </text>
<text top="159" left="218" width="60" height="20" font="0">subclinical </text>
<text top="176" left="218" width="121" height="20" font="0">atherosclerosis in pre-</text>
<text top="193" left="218" width="131" height="20" font="0">pubertal obese children<b> </b></text>
<text top="210" left="218" width="3" height="20" font="7"><b> </b></text>
<text top="227" left="218" width="119" height="20" font="7"><b>Study type: </b>3-month </text>
<text top="245" left="218" width="114" height="20" font="0">RCT with a modified </text>
<text top="262" left="218" width="96" height="20" font="0">crossover design<b> </b></text>
<text top="279" left="218" width="3" height="20" font="7"><b> </b></text>
<text top="296" left="218" width="126" height="20" font="7"><b>Size: </b>44 overweight or </text>
<text top="314" left="218" width="83" height="20" font="0">obese children </text>
<text top="331" left="218" width="124" height="20" font="0">(exercise (n = 22) or a </text>
<text top="348" left="218" width="128" height="20" font="0">control group (n = 22).  </text>
<text top="365" left="218" width="108" height="20" font="0">22 lean children for </text>
<text top="382" left="218" width="116" height="20" font="0">baseline comparison </text>
<text top="107" left="365" width="128" height="20" font="7"><b>Inclusion criteria:</b> pre-</text>
<text top="124" left="365" width="131" height="20" font="0">pubertal obese children </text>
<text top="141" left="365" width="50" height="20" font="0">(BMI &gt;97</text>
<text top="143" left="415" width="7" height="13" font="9">th</text>
<text top="141" left="422" width="68" height="20" font="0"> percentile)  </text>
<text top="159" left="365" width="3" height="20" font="7"><b> </b></text>
<text top="176" left="365" width="110" height="20" font="7"><b>Exclusion criteria: </b></text>
<text top="193" left="365" width="148" height="20" font="0">pubertal stage &gt; Tanner 1, </text>
<text top="210" left="365" width="124" height="20" font="0">involved in any weight </text>
<text top="228" left="365" width="150" height="20" font="0">control, physical activity, or </text>
<text top="245" left="365" width="142" height="20" font="0">behavioral therapy, had a </text>
<text top="262" left="365" width="95" height="20" font="0">familial history of </text>
<text top="279" left="365" width="137" height="20" font="0">dyslipidemia or essential </text>
<text top="296" left="365" width="127" height="20" font="0">hypertension, took any </text>
<text top="314" left="365" width="141" height="20" font="0">medications or hormones </text>
<text top="331" left="365" width="110" height="20" font="0">that might influence </text>
<text top="348" left="365" width="132" height="20" font="0">cardiovascular function, </text>
<text top="365" left="365" width="142" height="20" font="0">body composition, or lipid </text>
<text top="383" left="365" width="130" height="20" font="0">or glucose metabolism, </text>
<text top="400" left="365" width="152" height="20" font="0">had an orthopedic affection </text>
<text top="417" left="365" width="134" height="20" font="0">limiting physical activity, </text>
<text top="434" left="365" width="150" height="20" font="0">had a genetic disorder or a </text>
<text top="451" left="365" width="137" height="20" font="0">chronic disease, or were </text>
<text top="469" left="365" width="121" height="20" font="0">followed a therapy for </text>
<text top="486" left="365" width="119" height="20" font="0">psychiatric problems.<b> </b></text>
<text top="107" left="530" width="136" height="20" font="7"><b>Intervention: </b>trained 60 </text>
<text top="124" left="530" width="132" height="20" font="0">min 3 times/wk during 3 </text>
<text top="141" left="530" width="21" height="20" font="0">mo </text>
<text top="159" left="530" width="7" height="20" font="7"><b>  </b></text>
<text top="176" left="530" width="141" height="20" font="7"><b>Comparator: </b>no training  </text>
<text top="193" left="530" width="3" height="20" font="0"> </text>
<text top="210" left="530" width="103" height="20" font="0">Then, both groups </text>
<text top="228" left="530" width="139" height="20" font="0">trained twice/wk during 3 </text>
<text top="245" left="530" width="24" height="20" font="0">mo.<b> </b></text>
<text top="108" left="682" width="185" height="20" font="7"><b>1</b>°<b> endpoint: </b>Exercise group at 3 </text>
<text top="125" left="682" width="192" height="20" font="0">months experienced a decrease in </text>
<text top="143" left="682" width="190" height="20" font="0">BMI z-score (-5.5%), whole body (-</text>
<text top="160" left="682" width="184" height="20" font="0">3.6%) and abdominal fat (-4.2%), </text>
<text top="177" left="682" width="194" height="20" font="0">TC (-3.7%), LDL-C (-4.2%), HDL-C </text>
<text top="194" left="682" width="175" height="20" font="0">(-5.3%), office SBP (-2.0%) and </text>
<text top="212" left="682" width="164" height="20" font="0">DBP (-4.1%), and 24-h SBP (-</text>
<text top="229" left="682" width="182" height="20" font="0">4.9%) and DBP (-3.2%). Fat-free </text>
<text top="246" left="682" width="155" height="20" font="0">mass (+4.6%) and VO2max </text>
<text top="263" left="682" width="162" height="20" font="0">(+6.0%) increased during the </text>
<text top="280" left="682" width="123" height="20" font="0">intervention (p &lt;0.05). </text>
<text top="299" left="682" width="7" height="18" font="0">•</text>
<text top="299" left="689" width="173" height="20" font="0"> At 6 mo, change differences in </text>
<text top="316" left="682" width="168" height="20" font="0">arterial stiffness and IMT were </text>
<text top="333" left="682" width="62" height="20" font="0">significant.<b> </b></text>
<text top="350" left="682" width="3" height="20" font="7"><b> </b></text>
<text top="368" left="682" width="124" height="20" font="7"><b>Safety endpoint: </b>N/A<b> </b></text>
<text top="385" left="682" width="3" height="20" font="7"><b> </b></text>
<text top="109" left="894" width="7" height="18" font="0">•</text>
<text top="108" left="901" width="215" height="20" font="0"> Obese children had higher BP, arterial </text>
<text top="125" left="894" width="213" height="20" font="0">stiffness, body weight, BMI, abdominal </text>
<text top="143" left="894" width="204" height="20" font="0">fat, insulin resistance indexes, and C-</text>
<text top="160" left="894" width="208" height="20" font="0">reactive protein levels, and lower flow-</text>
<text top="177" left="894" width="210" height="20" font="0">mediated dilation, VO(2)max, physical </text>
<text top="194" left="894" width="199" height="20" font="0">activity, and high-density lipoprotein </text>
<text top="212" left="894" width="207" height="20" font="0">cholesterol levels than lean subjects.  </text>
<text top="229" left="894" width="3" height="20" font="7"><b> </b></text>
<text top="246" left="894" width="3" height="20" font="7"><b> </b></text>
<text top="504" left="89" width="112" height="20" font="0">Velázquez-López L, </text>
<text top="521" left="89" width="96" height="20" font="0">et al., 2014 <a href="data supplement.html#244">(141)</a> </text>
<text top="538" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24997634">24997634</a></text>
<text top="538" left="144" width="3" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24997634"><b> </b></a></text>
<text top="504" left="218" width="107" height="20" font="7"><b>Aim: </b>to assess the </text>
<text top="521" left="218" width="79" height="20" font="0">efficacy of the </text>
<text top="538" left="218" width="111" height="20" font="0">Mediterranean style </text>
<text top="555" left="218" width="91" height="20" font="0">diet to decrease </text>
<text top="573" left="218" width="105" height="20" font="0">cardiovascular risk </text>
<text top="590" left="218" width="124" height="20" font="0">factors in children and </text>
<text top="607" left="218" width="94" height="20" font="0">adolescents with </text>
<text top="624" left="218" width="42" height="20" font="0">obesity </text>
<text top="641" left="218" width="3" height="20" font="7"><b> </b></text>
<text top="659" left="218" width="130" height="20" font="7"><b>Study type:  </b>RCT – 16 </text>
<text top="676" left="218" width="98" height="20" font="0">wk dietary advice<b> </b></text>
<text top="693" left="218" width="3" height="20" font="7"><b> </b></text>
<text top="710" left="218" width="115" height="20" font="7"><b>Size: </b>24 assigned to </text>
<text top="727" left="218" width="101" height="20" font="0">intervention, 25 to </text>
<text top="745" left="218" width="40" height="20" font="0">control<b> </b></text>
<text top="504" left="365" width="131" height="20" font="7"><b>Inclusion criteria:</b> BMI </text>
<text top="521" left="365" width="140" height="20" font="0">≥95th percentile and any </text>
<text top="538" left="365" width="113" height="20" font="0">metabolic syndrome </text>
<text top="555" left="365" width="138" height="20" font="0">component, according to </text>
<text top="573" left="365" width="121" height="20" font="0">modified International </text>
<text top="590" left="365" width="146" height="20" font="0">Diabetes Federation (IDF) </text>
<text top="607" left="365" width="129" height="20" font="0">criteria for children and </text>
<text top="624" left="365" width="69" height="20" font="0">adolescents </text>
<text top="641" left="365" width="3" height="20" font="7"><b> </b></text>
<text top="659" left="365" width="110" height="20" font="7"><b>Exclusion criteria: </b></text>
<text top="676" left="365" width="84" height="20" font="0">chronic illness, </text>
<text top="693" left="365" width="148" height="20" font="0">pharmacological treatment </text>
<text top="710" left="365" width="154" height="20" font="0">for obesity or comorbidities<b>  </b></text>
<text top="504" left="530" width="114" height="20" font="7"><b>Intervention: </b>16 wk </text>
<text top="521" left="530" width="96" height="20" font="0">dietary advice on </text>
<text top="538" left="530" width="61" height="20" font="0">following a </text>
<text top="555" left="530" width="135" height="20" font="0">Mediterranean style diet </text>
<text top="573" left="530" width="127" height="20" font="0">rich in polyunsaturated </text>
<text top="590" left="530" width="93" height="20" font="0">fatty acids, fiber, </text>
<text top="607" left="530" width="83" height="20" font="0">flavonoids and </text>
<text top="624" left="530" width="115" height="20" font="0">antioxidants (60% of </text>
<text top="641" left="530" width="69" height="20" font="0">energy from </text>
<text top="659" left="530" width="135" height="20" font="0">carbohydrate, 25% from </text>
<text top="676" left="530" width="100" height="20" font="0">fat, and 15% from </text>
<text top="693" left="530" width="93" height="21" font="0">protein, (n = 24); </text>
<text top="710" left="530" width="7" height="20" font="7"><b>  </b></text>
<text top="728" left="530" width="128" height="20" font="7"><b>Comparator: </b>standard </text>
<text top="745" left="530" width="69" height="20" font="0">diet (55% of </text>
<text top="762" left="530" width="135" height="20" font="0">carbohydrate, 30% from </text>
<text top="505" left="682" width="182" height="20" font="7"><b>1</b>°<b> endpoint: </b>Mediterranean diet </text>
<text top="522" left="682" width="190" height="20" font="0">group had a significantly decrease </text>
<text top="539" left="682" width="158" height="20" font="0">in BMI, lean mass, fat mass, </text>
<text top="557" left="682" width="188" height="20" font="0">glucose, TC, TG, HDL-C and LDL-</text>
<text top="574" left="682" width="78" height="21" font="0">C. (p &lt; 0.05);  </text>
<text top="591" left="682" width="3" height="20" font="7"><b> </b></text>
<text top="608" left="682" width="124" height="20" font="7"><b>Safety endpoint: </b>N/A<b> </b></text>
<text top="625" left="682" width="3" height="20" font="7"><b> </b></text>
<text top="506" left="894" width="7" height="18" font="0">•</text>
<text top="505" left="901" width="204" height="20" font="7"><b> </b>The standard diet group decrease in </text>
<text top="522" left="894" width="222" height="20" font="0">glucose levels and frequency of glucose </text>
<text top="539" left="894" width="128" height="21" font="0">&gt;100 mg/dL (p &lt; 0.05).<b> </b></text>
<text top="558" left="894" width="7" height="18" font="0">•</text>
<text top="558" left="901" width="166" height="20" font="7"><b> </b>dietary compliance increased </text>
<text top="575" left="894" width="229" height="20" font="0">consumption of omega 9 fatty acids, zinc, </text>
<text top="592" left="894" width="198" height="20" font="0">vitamin E, selenium, and decreased </text>
<text top="609" left="894" width="200" height="20" font="0">consumption of saturated fatty acids </text>
<text top="627" left="894" width="56" height="21" font="0">(p &lt; 0.05) </text>
<text top="646" left="894" width="7" height="18" font="0">•</text>
<text top="645" left="901" width="200" height="20" font="7"><b> </b>Excluded non-adherent participants </text>
<text top="662" left="894" width="96" height="20" font="0">from the analysis<b> </b></text>
</page>
<page number="125" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">125 </text>
<text top="107" left="530" width="97" height="20" font="0">fat and 15% from </text>
<text top="124" left="530" width="97" height="21" font="0">protein, (n = 25),  </text>
<text top="141" left="530" width="3" height="20" font="0"> </text>
<text top="159" left="530" width="117" height="20" font="0">Individualized caloric </text>
<text top="176" left="530" width="69" height="20" font="0">intake goals<b> </b></text>
<text top="193" left="530" width="3" height="20" font="7"><b> </b></text>
<text top="211" left="89" width="96" height="20" font="0">Singhal A, et al.,  </text>
<text top="228" left="89" width="66" height="20" font="0">2013 <a href="data supplement.html#244">(142)</a>  </text>
<text top="245" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23817470">23817470</a></text>
<text top="245" left="144" width="3" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23817470"><b> </b></a></text>
<text top="211" left="218" width="75" height="20" font="7"><b>Aim: </b>test the </text>
<text top="228" left="218" width="115" height="20" font="0">hypothesis that DHA </text>
<text top="245" left="218" width="94" height="20" font="0">supplementation </text>
<text top="263" left="218" width="116" height="20" font="0">improves endothelial </text>
<text top="280" left="218" width="122" height="20" font="0">function and CVD risk </text>
<text top="297" left="218" width="44" height="20" font="0">factors  </text>
<text top="314" left="218" width="3" height="20" font="7"><b> </b></text>
<text top="332" left="218" width="120" height="20" font="7"><b>Study type:  </b>RCT 16 </text>
<text top="349" left="218" width="19" height="20" font="0">wk </text>
<text top="366" left="218" width="3" height="20" font="7"><b> </b></text>
<text top="383" left="218" width="123" height="20" font="7"><b>Size: </b>n=328, vascular </text>
<text top="400" left="218" width="96" height="20" font="0">data available on </text>
<text top="418" left="218" width="38" height="20" font="0">n=268<b> </b></text>
<text top="211" left="365" width="151" height="20" font="7"><b>Inclusion criteria: </b>Healthy </text>
<text top="228" left="365" width="152" height="20" font="0">volunteers, aged 18 to 37 y </text>
<text top="245" left="365" width="3" height="20" font="7"><b> </b></text>
<text top="263" left="365" width="110" height="20" font="7"><b>Exclusion criteria: </b></text>
<text top="280" left="365" width="133" height="20" font="0">chronic disease likely to </text>
<text top="297" left="365" width="143" height="20" font="0">affect endothelial function </text>
<text top="314" left="365" width="132" height="20" font="0">(e.g., insulin-dependent </text>
<text top="332" left="365" width="139" height="20" font="0">diabetes), pregnancy, on </text>
<text top="349" left="365" width="130" height="20" font="0">unusual diets, or taking </text>
<text top="366" left="365" width="140" height="20" font="0">regular medication or n-3 </text>
<text top="383" left="365" width="133" height="20" font="0">LC-PUFA supplements<b>  </b></text>
<text top="211" left="530" width="109" height="20" font="7"><b>Intervention: </b>1.6 g </text>
<text top="228" left="530" width="82" height="20" font="0">DHA/d (from a </text>
<text top="245" left="530" width="108" height="20" font="0">microalgae source) </text>
<text top="263" left="530" width="115" height="20" font="0">together with 2.4 g/d </text>
<text top="280" left="530" width="57" height="20" font="0">carrier oil  </text>
<text top="297" left="530" width="7" height="20" font="7"><b>  </b></text>
<text top="314" left="530" width="118" height="20" font="7"><b>Comparator: </b>4.0 g/d </text>
<text top="332" left="530" width="48" height="20" font="0">olive oil <b> </b></text>
<text top="349" left="530" width="3" height="20" font="7"><b> </b></text>
<text top="212" left="682" width="154" height="20" font="7"><b>1</b>°<b> endpoint: </b>Brachial Flow-</text>
<text top="229" left="682" width="187" height="20" font="0">mediated endothelium-dependent </text>
<text top="247" left="682" width="186" height="20" font="0">vasodilation (FMD) was the same </text>
<text top="264" left="682" width="191" height="20" font="0">at randomization (mean, SD; 0.27, </text>
<text top="281" left="682" width="184" height="20" font="0">0.1 mm), but was higher after the </text>
<text top="298" left="682" width="176" height="20" font="0">intervention in the control group </text>
<text top="316" left="682" width="167" height="20" font="0">(0.29, 0.1 mm) compared with </text>
<text top="333" left="682" width="184" height="20" font="0">intervention (0.26, 0.1 mm; mean </text>
<text top="350" left="682" width="167" height="20" font="0">difference -0.03 mm; 95% CI: -</text>
<text top="367" left="682" width="152" height="20" font="0">0.005 to -0.06 mm; p=0.02) </text>
<text top="384" left="682" width="3" height="20" font="7"><b> </b></text>
<text top="402" left="682" width="124" height="20" font="7"><b>Safety endpoint: </b>N/A<b> </b></text>
<text top="419" left="682" width="3" height="20" font="7"><b> </b></text>
<text top="213" left="894" width="7" height="18" font="0">•</text>
<text top="212" left="901" width="196" height="20" font="7"><b> </b>Of other outcomes, only TG (mean </text>
<text top="229" left="894" width="222" height="20" font="0">difference -28%, 95% CI: -40% to -15%; </text>
<text top="247" left="894" width="201" height="20" font="0">p&lt;0.0001) and VLDL concentrations </text>
<text top="264" left="894" width="54" height="20" font="0">improved </text>
<text top="281" left="894" width="3" height="20" font="7"><b> </b></text>
<text top="437" left="89" width="87" height="20" font="0">Vuorio A, et al., </text>
<text top="454" left="89" width="63" height="20" font="0">2017 <a href="data supplement.html#244">(143)</a> </text>
<text top="471" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28685504">28685504</a></text>
<text top="471" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28685504"> </a></text>
<text top="488" left="89" width="3" height="20" font="11"> </text>
<text top="506" left="89" width="3" height="20" font="7"><b> </b></text>
<text top="437" left="218" width="115" height="20" font="7"><b>Aim: </b>to describe the </text>
<text top="454" left="218" width="99" height="20" font="0">effectiveness and </text>
<text top="471" left="218" width="102" height="20" font="0">safety of statins in </text>
<text top="488" left="218" width="122" height="20" font="0">children with inherited </text>
<text top="506" left="218" width="102" height="20" font="0">high cholesterol in </text>
<text top="523" left="218" width="70" height="20" font="0">children and </text>
<text top="540" left="218" width="94" height="20" font="0">adolescents with </text>
<text top="557" left="218" width="97" height="20" font="0">heterozygous FH </text>
<text top="575" left="218" width="3" height="20" font="7"><b> </b></text>
<text top="592" left="218" width="105" height="20" font="7"><b>Study type:  </b>meta-</text>
<text top="609" left="218" width="96" height="20" font="0">analysis of RCTs </text>
<text top="626" left="218" width="84" height="20" font="0">through Feb 20</text>
<text top="628" left="301" width="7" height="13" font="9">th</text>
<text top="626" left="308" width="38" height="20" font="0">, 2017 </text>
<text top="643" left="218" width="3" height="20" font="0"> </text>
<text top="661" left="218" width="129" height="20" font="7"><b>Size: </b>9 RCTs including </text>
<text top="678" left="218" width="97" height="20" font="0">1177 participants<b> </b></text>
<text top="437" left="365" width="141" height="20" font="7"><b>Inclusion criteria: </b>RCTs </text>
<text top="454" left="365" width="145" height="20" font="0">of children up to age 18 y  </text>
<text top="471" left="365" width="3" height="20" font="7"><b> </b></text>
<text top="488" left="365" width="138" height="20" font="7"><b>Exclusion criteria: </b>poor </text>
<text top="506" left="365" width="130" height="20" font="0">quality studies and non-</text>
<text top="523" left="365" width="35" height="20" font="0">RCTs<b> </b></text>
<text top="437" left="530" width="129" height="20" font="7"><b>Intervention: </b>statin<b>,</b>12-</text>
<text top="454" left="530" width="116" height="20" font="0">104 wk interventions </text>
<text top="471" left="530" width="7" height="20" font="7"><b>  </b></text>
<text top="488" left="530" width="138" height="20" font="7"><b>Comparator: </b>placebo or </text>
<text top="506" left="530" width="57" height="20" font="0">diet alone<b> </b></text>
<text top="438" left="682" width="191" height="20" font="7"><b>1</b>°<b> endpoint: </b>The mean change in </text>
<text top="455" left="682" width="180" height="20" font="0">serum LDL-C was 32.15% lower </text>
<text top="472" left="682" width="188" height="20" font="0">(95% CI: 34.90% lower to 29.40% </text>
<text top="490" left="682" width="141" height="20" font="0">lower) in the stains group </text>
<text top="507" left="682" width="155" height="20" font="0">(moderate quality evidence) </text>
<text top="524" left="682" width="3" height="20" font="7"><b> </b></text>
<text top="541" left="682" width="103" height="20" font="7"><b>Safety endpoint:  </b></text>
<text top="560" left="682" width="7" height="18" font="0">•</text>
<text top="560" left="689" width="190" height="20" font="0"> AST, ALT, CK levels did not differ </text>
<text top="577" left="682" width="162" height="20" font="0">between treated and placebo </text>
<text top="594" left="682" width="167" height="20" font="0">groups at any time points (low </text>
<text top="611" left="682" width="96" height="20" font="0">quality evidence) </text>
<text top="630" left="682" width="7" height="18" font="0">•</text>
<text top="630" left="689" width="172" height="20" font="0"> Risks of myopathy (low quality </text>
<text top="647" left="682" width="159" height="20" font="0">evidence) and other adverse </text>
<text top="664" left="682" width="195" height="20" font="0">effects (moderate quality evidence) </text>
<text top="681" left="682" width="52" height="20" font="0">were low </text>
<text top="700" left="682" width="7" height="18" font="0">•</text>
<text top="700" left="689" width="142" height="20" font="0"> no significant differences </text>
<text top="717" left="682" width="185" height="20" font="0">between statins and placebo with </text>
<text top="734" left="682" width="168" height="20" font="0">regard to pubertal progression </text>
<text top="439" left="894" width="7" height="18" font="0">•</text>
<text top="438" left="901" width="209" height="20" font="0"> The mean change in carotid IMT was </text>
<text top="455" left="894" width="230" height="20" font="0">0.01 mm lower (0.03mm lower to 0.00mm </text>
<text top="472" left="894" width="206" height="20" font="0">lower) in the stains group (low quality </text>
<text top="490" left="894" width="57" height="20" font="0">evidence) </text>
<text top="509" left="894" width="7" height="18" font="0">•</text>
<text top="508" left="901" width="191" height="20" font="0"> The mean change in brachial flow-</text>
<text top="525" left="894" width="208" height="20" font="0">mediated dilatation was 2.70% higher </text>
<text top="542" left="894" width="208" height="20" font="0">(0.42% to 4.98% higher) in the statins </text>
<text top="560" left="894" width="157" height="20" font="0">group (low quality evidence) </text>
</page>
<page number="126" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">126 </text>
<text top="107" left="89" width="92" height="20" font="0">Lozano P, et al., </text>
<text top="124" left="89" width="66" height="20" font="0">2016  <a href="data supplement.html#244">(144)</a> </text>
<text top="141" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27559556">27559556</a></text>
<text top="141" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27559556"> </a></text>
<text top="107" left="218" width="128" height="20" font="7"><b>Aim: </b>To systematically </text>
<text top="124" left="218" width="129" height="20" font="0">review the evidence on </text>
<text top="141" left="218" width="122" height="20" font="0">benefits and harms of </text>
<text top="159" left="218" width="113" height="20" font="0">treating adolescents </text>
<text top="176" left="218" width="126" height="20" font="0">and children who have </text>
<text top="193" left="218" width="132" height="20" font="0">heterozygous FH with a </text>
<text top="210" left="218" width="93" height="20" font="0">statin (USPSTF) </text>
<text top="227" left="218" width="3" height="20" font="7"><b> </b></text>
<text top="245" left="218" width="74" height="20" font="7"><b>Study type:  </b></text>
<text top="262" left="218" width="100" height="20" font="0">systematic review </text>
<text top="279" left="218" width="118" height="20" font="0">through April 8, 2016<b> </b></text>
<text top="296" left="218" width="3" height="20" font="7"><b> </b></text>
<text top="314" left="218" width="115" height="20" font="7"><b>Size: </b>2 to 18 studies </text>
<text top="331" left="218" width="98" height="20" font="0">depending on the </text>
<text top="348" left="218" width="114" height="20" font="0">question addressed<b>  </b></text>
<text top="107" left="365" width="131" height="20" font="7"><b>Inclusion criteria: </b>Fair </text>
<text top="124" left="365" width="149" height="20" font="0">and good quality studies in </text>
<text top="141" left="365" width="135" height="20" font="0">English with participants </text>
<text top="159" left="365" width="81" height="20" font="0">ages 0 to 20 y </text>
<text top="176" left="365" width="3" height="20" font="0"> </text>
<text top="193" left="365" width="138" height="20" font="7"><b>Exclusion criteria: </b>poor </text>
<text top="210" left="365" width="130" height="20" font="0">quality studies and non-</text>
<text top="227" left="365" width="35" height="20" font="0">RCTs<b> </b></text>
<text top="107" left="530" width="122" height="20" font="7"><b>Intervention: </b>Statins, </text>
<text top="124" left="530" width="128" height="20" font="0">ezetimibe and bile acid </text>
<text top="141" left="530" width="79" height="20" font="0">binding resins </text>
<text top="159" left="530" width="7" height="20" font="7"><b>  </b></text>
<text top="176" left="530" width="125" height="20" font="7"><b>Comparator: </b>Placebo<b> </b></text>
<text top="193" left="530" width="3" height="20" font="7"><b> </b></text>
<text top="108" left="682" width="179" height="20" font="7"><b>1</b>°<b> endpoint: </b>meta-analysis of<b> </b>8 </text>
<text top="125" left="682" width="181" height="20" font="0">placebo trials of statin drugs (n = </text>
<text top="143" left="682" width="165" height="20" font="0">1071, 6-104 wk) found LDL-C </text>
<text top="160" left="682" width="147" height="20" font="0">decreases of 20% to 40%  </text>
<text top="177" left="682" width="3" height="20" font="7"><b> </b></text>
<text top="194" left="682" width="103" height="20" font="7"><b>Safety endpoint:  </b></text>
<text top="213" left="682" width="7" height="18" font="0">•</text>
<text top="213" left="689" width="163" height="20" font="0"> Statins are well tolerated (18 </text>
<text top="230" left="682" width="46" height="20" font="0">studies) </text>
<text top="249" left="682" width="7" height="18" font="0">•</text>
<text top="248" left="689" width="167" height="20" font="0"> Adverse effects were minimal </text>
<text top="265" left="682" width="181" height="20" font="0">aside from those experienced by </text>
<text top="283" left="682" width="179" height="20" font="0">individuals in studies of bile acid-</text>
<text top="300" left="682" width="118" height="20" font="0">sequestering agents. </text>
<text top="109" left="894" width="7" height="18" font="0">•</text>
<text top="108" left="901" width="207" height="20" font="0"> statins decrease cIMT 1% more than </text>
<text top="125" left="894" width="96" height="20" font="0">placebo (p=0.02) </text>
<text top="144" left="894" width="7" height="18" font="0">•</text>
<text top="144" left="901" width="3" height="20" font="0"> </text>
<text top="144" left="904" width="152" height="20" font="19">3 placebo trials of bile acid–</text>
<text top="161" left="894" width="217" height="20" font="19">sequestering agents (n = 332, 8-52 wk) </text>
<text top="178" left="894" width="225" height="20" font="19">showed LDL-C reductions of 10%to 20%.</text>
<text top="178" left="1119" width="7" height="20" font="0">  </text>
<text top="197" left="894" width="7" height="18" font="0">•</text>
<text top="197" left="901" width="220" height="20" font="0"> bile-acid binding resins decreased LDL-</text>
<text top="214" left="894" width="55" height="20" font="0">C 10-20%</text>
<text top="214" left="948" width="3" height="20" font="19"> </text>
<text top="233" left="894" width="7" height="18" font="0">•</text>
<text top="232" left="901" width="187" height="20" font="0"> ezetimibe decreased LDL-C 28% </text>
<text top="249" left="894" width="226" height="20" font="0">(monotherapy) or an additional 14% over </text>
<text top="267" left="894" width="126" height="20" font="0">and above simvastatin </text>
<text top="366" left="89" width="36" height="20" font="7"><b>DISC</b>  </text>
<text top="383" left="89" width="112" height="20" font="0">Obarzanek E, et al., </text>
<text top="400" left="89" width="63" height="20" font="0">2001 <a href="data supplement.html#244">(145)</a> </text>
<text top="418" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11158455">11158455</a></text>
<text top="418" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11158455"> </a></text>
<text top="435" left="89" width="3" height="20" font="0"> </text>
<text top="452" left="89" width="96" height="20" font="7"><b>DISC 1995</b><a href="data supplement.html#244"> (146)</a> </text>
<text top="469" left="89" width="48" height="20" font="8"><a href="">7723156</a></text>
<text top="469" left="137" width="3" height="20" font="0"><a href=""> </a></text>
<text top="487" left="89" width="3" height="20" font="0"> </text>
<text top="504" left="89" width="115" height="20" font="0">Obarzanek E, et al.,  </text>
<text top="521" left="89" width="63" height="20" font="0">1997 <a href="data supplement.html#244">(147)</a> </text>
<text top="538" left="89" width="3" height="20" font="0"> </text>
<text top="555" left="89" width="98" height="20" font="7"><b>Disc 3 y Results</b> </text>
<text top="573" left="89" width="104" height="20" font="0">Lavigne JV, et al.,  </text>
<text top="590" left="89" width="66" height="20" font="0">1999 <a href="data supplement.html#244">(148)</a>  </text>
<text top="607" left="89" width="55" height="20" font="8"><a href="">10619534</a></text>
<text top="607" left="144" width="3" height="20" font="0"><a href=""> </a></text>
<text top="624" left="89" width="3" height="20" font="0"> </text>
<text top="641" left="89" width="94" height="20" font="7"><b>DISC Follow-up </b></text>
<text top="659" left="89" width="38" height="20" font="7"><b>Study </b></text>
<text top="676" left="89" width="98" height="20" font="0">Dorgan JE, et al., </text>
<text top="693" left="89" width="63" height="20" font="0">2011 <a href="data supplement.html#244">(149)</a> </text>
<text top="710" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21994964">21994964</a></text>
<text top="710" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21994964"> </a></text>
<text top="727" left="89" width="3" height="20" font="0"> </text>
<text top="745" left="89" width="3" height="20" font="0"> </text>
<text top="762" left="89" width="3" height="20" font="7"><b> </b></text>
<text top="366" left="218" width="115" height="20" font="7"><b>Aim: </b>to evaluate the </text>
<text top="383" left="218" width="107" height="20" font="0">effect of a modified </text>
<text top="400" left="218" width="76" height="20" font="0">Step II diet of </text>
<text top="418" left="218" width="132" height="20" font="0">cholesterol in childhood </text>
<text top="435" left="218" width="3" height="20" font="7"><b> </b></text>
<text top="452" left="218" width="102" height="20" font="7"><b>Study type: </b>RCT<b>  </b></text>
<text top="469" left="218" width="3" height="20" font="7"><b> </b></text>
<text top="487" left="218" width="84" height="20" font="7"><b>Size: </b>663 (334 </text>
<text top="504" left="218" width="94" height="20" font="0">intervention, 329 </text>
<text top="521" left="218" width="44" height="20" font="0">control)<b> </b></text>
<text top="366" left="365" width="106" height="20" font="7"><b>Inclusion criteria: </b></text>
<text top="383" left="365" width="137" height="20" font="0">Prepubertal (age 8-10 y) </text>
<text top="400" left="365" width="73" height="20" font="0">with LDL ≥80</text>
<text top="402" left="438" width="7" height="13" font="9">th</text>
<text top="400" left="445" width="27" height="20" font="0"> and </text>
<text top="418" left="365" width="21" height="20" font="0">&lt;98</text>
<text top="419" left="386" width="7" height="13" font="9">th</text>
<text top="418" left="392" width="121" height="20" font="0"> %tile for age and sex </text>
<text top="435" left="365" width="139" height="20" font="0">recruited from public and </text>
<text top="452" left="365" width="150" height="20" font="0">private elementary schools </text>
<text top="469" left="365" width="128" height="20" font="0">with TC level was ≥4.5 </text>
<text top="487" left="365" width="128" height="20" font="0">mmol/L (175 mg/dL) or </text>
<text top="504" left="365" width="147" height="20" font="0">greater (approximately the </text>
<text top="521" left="365" width="147" height="20" font="0">75th age- and sex-specific </text>
<text top="538" left="365" width="86" height="20" font="0">percentile) with </text>
<text top="555" left="365" width="114" height="20" font="0">fasting LDL-C≥ 70th </text>
<text top="573" left="365" width="107" height="20" font="0">and ≤99th age and </text>
<text top="590" left="365" width="131" height="20" font="0">sex-specific percentiles </text>
<text top="607" left="365" width="3" height="20" font="0"> </text>
<text top="624" left="365" width="152" height="20" font="0">Final lipid eligibility criterion </text>
<text top="641" left="365" width="138" height="20" font="0">was the average of the 2 </text>
<text top="659" left="365" width="134" height="20" font="0">screening LDL-C values </text>
<text top="676" left="365" width="95" height="20" font="0">≥80th and ≤98th </text>
<text top="693" left="365" width="129" height="20" font="0">percentiles for age and </text>
<text top="710" left="365" width="26" height="20" font="0">sex. </text>
<text top="727" left="365" width="3" height="20" font="0"> </text>
<text top="745" left="365" width="110" height="20" font="7"><b>Exclusion criteria: </b></text>
<text top="762" left="365" width="113" height="20" font="0">medical condition or </text>
<text top="779" left="365" width="120" height="20" font="0">medication that might </text>
<text top="366" left="530" width="128" height="20" font="7"><b>Intervention: </b>modified </text>
<text top="383" left="530" width="130" height="20" font="0">NCEP Step II delivered </text>
<text top="400" left="530" width="92" height="20" font="0">via family-based </text>
<text top="418" left="530" width="111" height="20" font="0">counseling for 0-3 y </text>
<text top="435" left="530" width="134" height="20" font="0">old’s and lower intensity </text>
<text top="452" left="530" width="134" height="20" font="0">counseling age 4-8 yrs.  </text>
<text top="469" left="530" width="7" height="20" font="0">  </text>
<text top="487" left="530" width="130" height="20" font="7"><b>Comparator: </b>feedback </text>
<text top="504" left="530" width="124" height="20" font="0">to parent about child’s </text>
<text top="521" left="530" width="136" height="20" font="0">baseline cholesterol and </text>
<text top="538" left="530" width="137" height="20" font="0">written heart healthy diet </text>
<text top="555" left="530" width="57" height="20" font="0">materials<b>  </b></text>
<text top="367" left="682" width="79" height="20" font="7"><b>1</b>°<b> endpoint: </b> </text>
<text top="386" left="682" width="7" height="18" font="0">•</text>
<text top="386" left="689" width="178" height="20" font="7"><b> </b>At 7 y of follow-up reductions in </text>
<text top="403" left="682" width="187" height="20" font="0">dietary total fat, saturated fat, and </text>
<text top="420" left="682" width="169" height="20" font="0">cholesterol were greater in the </text>
<text top="437" left="682" width="188" height="20" font="0">intervention than in the usual care </text>
<text top="454" left="682" width="42" height="20" font="0">group.  </text>
<text top="473" left="682" width="7" height="18" font="0">•</text>
<text top="473" left="689" width="129" height="20" font="0">At 1 y, 3 y, and 7 y, the </text>
<text top="490" left="682" width="171" height="20" font="0">intervention compared with the </text>
<text top="507" left="682" width="177" height="20" font="0">usual care group had 4.8 mg/dL </text>
<text top="524" left="682" width="159" height="20" font="0">(.13 mmol/L), 3.3 mg/dL (.09 </text>
<text top="542" left="682" width="158" height="20" font="0">mmol/L), and 2.0 mg/dL (.05 </text>
<text top="559" left="682" width="198" height="20" font="0">mmol/L) lower LDL-C, respectively.  </text>
<text top="578" left="682" width="7" height="18" font="0">•</text>
<text top="577" left="689" width="180" height="20" font="0"> Follow-up of female participants </text>
<text top="594" left="682" width="162" height="20" font="0">at age ~18 y found Metabolic </text>
<text top="612" left="682" width="190" height="20" font="0">syndrome was uncommon, and its </text>
<text top="629" left="682" width="151" height="20" font="0">prevalence did not differ by </text>
<text top="646" left="682" width="97" height="20" font="0">treatment group.  </text>
<text top="665" left="682" width="7" height="18" font="0">•</text>
<text top="664" left="689" width="175" height="20" font="0"> After adjustment for nondietary </text>
<text top="682" left="682" width="132" height="20" font="0">variables, mean ABP of </text>
<text top="699" left="682" width="166" height="20" font="0">intervention and control group </text>
<text top="716" left="682" width="193" height="20" font="0">participants were 107.7- and 110.0-</text>
<text top="733" left="682" width="168" height="20" font="0">mm Hg, respectively (p=0.03), </text>
<text top="750" left="682" width="167" height="20" font="0">whereas mean fasting plasma </text>
<text top="768" left="682" width="189" height="20" font="0">glucose levels were 87.0 and 89.1 </text>
<text top="785" left="682" width="162" height="20" font="0">mg/dl, respectively (p=0.01).  </text>
<text top="368" left="894" width="7" height="18" font="0">•</text>
<text top="367" left="901" width="225" height="20" font="0"> At 3 y dietary total fat, saturated fat, and </text>
<text top="384" left="894" width="226" height="20" font="0">cholesterol levels decreased significantly </text>
<text top="402" left="894" width="219" height="20" font="0">in the intervention group compared with </text>
<text top="419" left="894" width="195" height="20" font="0">the usual care group (all p&lt;0.001).<b>  </b></text>
<text top="438" left="894" width="7" height="18" font="0">•</text>
<text top="437" left="901" width="176" height="20" font="0"> Both groups experienced small </text>
<text top="454" left="894" width="203" height="20" font="0">increases in TG levels ~1 mg/dl) that </text>
<text top="472" left="894" width="225" height="20" font="0">were not statistically different or clinically </text>
<text top="489" left="894" width="62" height="20" font="0">important.  </text>
</page>
<page number="127" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">127 </text>
<text top="107" left="365" width="122" height="20" font="0">affect growth or blood </text>
<text top="124" left="365" width="117" height="20" font="0">cholesterol, behavior </text>
<text top="141" left="365" width="131" height="20" font="0">problems in the child or </text>
<text top="159" left="365" width="121" height="20" font="0">family likely to reduce </text>
<text top="176" left="365" width="112" height="20" font="0">adherence, onset of </text>
<text top="193" left="365" width="142" height="20" font="0">puberty, or plans to move </text>
<text top="210" left="365" width="132" height="20" font="0">within the 3 study years </text>
<text top="109" left="682" width="7" height="18" font="0">•</text>
<text top="108" left="689" width="172" height="20" font="0"> Intervention group participants </text>
<text top="125" left="682" width="180" height="20" font="0">also had lower concentrations of </text>
<text top="143" left="682" width="198" height="20" font="0">large VLDL particles compared with </text>
<text top="160" left="682" width="145" height="20" font="0">control group participants. </text>
<text top="177" left="682" width="3" height="20" font="0"> </text>
<text top="194" left="682" width="183" height="20" font="7"><b>Safety endpoint: </b>There were no </text>
<text top="211" left="682" width="183" height="20" font="0">differences at any data collection </text>
<text top="229" left="682" width="184" height="20" font="0">point in height or serum ferritin or </text>
<text top="246" left="682" width="164" height="20" font="0">any differences in an adverse </text>
<text top="263" left="682" width="176" height="20" font="0">direction in red blood cell folate, </text>
<text top="280" left="682" width="166" height="20" font="0">serum retinol and zinc, sexual </text>
<text top="298" left="682" width="179" height="20" font="0">maturation, or body mass index. </text>
<text top="317" left="682" width="7" height="18" font="0">•</text>
<text top="316" left="689" width="144" height="20" font="0"> No significant differences </text>
<text top="333" left="682" width="174" height="20" font="0">between the groups in adjusted </text>
<text top="350" left="682" width="195" height="20" font="0">mean height or serum ferritin levels </text>
<text top="368" left="682" width="190" height="20" font="0">(P &gt; .05) or other safety outcomes </text>
<text top="385" left="682" width="170" height="20" font="0">up to 18 y after randomization  </text>
<text top="403" left="89" width="87" height="20" font="0">Shivakumar S,  </text>
<text top="420" left="89" width="63" height="20" font="0">2015 <a href="data supplement.html#245">(150)</a> </text>
<text top="437" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25847553">25847553</a></text>
<text top="437" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25847553"> </a></text>
<text top="403" left="218" width="109" height="20" font="7"><b>Aim: </b>to explore the </text>
<text top="420" left="218" width="126" height="20" font="0">efficacy of plant-based </text>
<text top="437" left="218" width="98" height="20" font="0">formulation in the </text>
<text top="454" left="218" width="89" height="20" font="0">management of </text>
<text top="472" left="218" width="129" height="20" font="0">adolescent obesity and </text>
<text top="489" left="218" width="78" height="20" font="0">its associated </text>
<text top="506" left="218" width="64" height="20" font="0">biomarkers </text>
<text top="523" left="218" width="3" height="20" font="0"> </text>
<text top="540" left="218" width="102" height="20" font="7"><b>Study type: </b>RCT<b>  </b></text>
<text top="558" left="218" width="3" height="20" font="7"><b> </b></text>
<text top="575" left="218" width="93" height="20" font="7"><b>Size: </b>130 obese </text>
<text top="592" left="218" width="110" height="20" font="0">adolescents of both </text>
<text top="609" left="218" width="68" height="20" font="0">sexes, with <b> </b></text>
<text top="403" left="365" width="106" height="20" font="7"><b>Inclusion criteria: </b></text>
<text top="420" left="365" width="135" height="20" font="0">adolescents, BMI above </text>
<text top="437" left="365" width="40" height="20" font="0">25kg/m</text>
<text top="439" left="405" width="4" height="13" font="9">2</text>
<text top="437" left="410" width="3" height="20" font="0"> </text>
<text top="454" left="365" width="3" height="20" font="0"> </text>
<text top="472" left="365" width="114" height="20" font="7"><b>Exclusion criteria:  </b></text>
<text top="403" left="530" width="109" height="20" font="7"><b>Intervention: </b>plant-</text>
<text top="420" left="530" width="124" height="20" font="0">based formulation two </text>
<text top="437" left="530" width="87" height="20" font="0">500mg capsule </text>
<text top="454" left="530" width="83" height="20" font="0">containing test </text>
<text top="472" left="530" width="64" height="20" font="0">formulation </text>
<text top="489" left="530" width="7" height="20" font="7"><b>  </b></text>
<text top="506" left="530" width="81" height="20" font="7"><b>Comparator:  </b></text>
<text top="523" left="530" width="128" height="20" font="0">two 500mg of cellulose </text>
<text top="540" left="530" width="103" height="20" font="0">powder containing </text>
<text top="558" left="530" width="123" height="20" font="0">capsule daily for 3 mo<b> </b></text>
<text top="404" left="682" width="197" height="20" font="7"><b>1</b>°<b> endpoint: </b>statistically significant<b> </b></text>
<text top="421" left="682" width="187" height="20" font="0">differences mean ( 95% CI:) were </text>
<text top="438" left="682" width="187" height="20" font="0">seen in the treatment group in TC </text>
<text top="456" left="682" width="183" height="20" font="0">mg/dl (-20.9±5.0 (-30.8 to -11.0), </text>
<text top="473" left="682" width="196" height="20" font="0">TG mg/dl (-12.9±5.7 (-23.9 to -1.2), </text>
<text top="490" left="682" width="178" height="20" font="0">HDL-C mg/dl (7.2±0.8 (5.6-8.8)) </text>
<text top="507" left="682" width="3" height="20" font="7"><b> </b></text>
<text top="524" left="682" width="175" height="20" font="7"><b>Safety endpoint: </b>no significant </text>
<text top="542" left="682" width="188" height="20" font="0">differences between the groups in </text>
<text top="559" left="682" width="173" height="20" font="0">adjusted mean height or serum </text>
<text top="576" left="682" width="169" height="20" font="0">ferritin levels (P &gt; .05) or other </text>
<text top="593" left="682" width="93" height="20" font="0">safety outcomes </text>
<text top="405" left="894" width="7" height="18" font="0">•</text>
<text top="404" left="901" width="186" height="20" font="0"> Plant-based test formulation may </text>
<text top="421" left="894" width="208" height="20" font="0">prevent the future cardio vascular risk </text>
<text top="438" left="894" width="191" height="20" font="0">incidence in obese adolescents by </text>
<text top="456" left="894" width="219" height="20" font="0">reducing inflammation, overweight, lipid </text>
<text top="473" left="894" width="200" height="20" font="0">profile and by regulating adipokines. </text>
<text top="492" left="894" width="7" height="18" font="0">•</text>
<text top="491" left="901" width="210" height="20" font="0"> Other differences in favor of the plant-</text>
<text top="508" left="894" width="184" height="20" font="0">based extract include CRP mg/l (-</text>
<text top="526" left="894" width="233" height="20" font="0">1.0±0.01 (-1.2 to -0.8)), adiponectin µg/ml </text>
<text top="543" left="894" width="228" height="20" font="0">(4.9±0.4 (4.2-5.7)), leptin ng/ml (-8.0±1.4 </text>
<text top="560" left="894" width="223" height="20" font="0">(-10.7 to -5.3)), DBP mmHg (-10.4±0.8 (-</text>
<text top="577" left="894" width="228" height="20" font="0">12.0 to -8.7)) and SBP mmHg (-6.7±0.7 (-</text>
<text top="594" left="894" width="70" height="20" font="0">8.1 to -5.3)). </text>
<text top="627" left="89" width="102" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Kelishadi%20R%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21028969">Kelishadi R, e</a>t al.,<b> </b></text>
<text top="644" left="89" width="63" height="20" font="0">2010 <a href="data supplement.html#245">(151)</a> </text>
<text top="662" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=%3A+21028969">21028969</a></text>
<text top="663" left="144" width="2" height="13" font="9"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=%3A+21028969"> </a></text>
<text top="627" left="218" width="115" height="20" font="7"><b>Aim: </b>to evaluate the </text>
<text top="644" left="218" width="131" height="20" font="0">effects of zinc sulfate in </text>
<text top="662" left="218" width="92" height="20" font="0">comparison with </text>
<text top="679" left="218" width="125" height="20" font="0">placebo on markers of </text>
<text top="696" left="218" width="101" height="20" font="0">insulin resistance, </text>
<text top="713" left="218" width="115" height="20" font="0">oxidative stress, and </text>
<text top="730" left="218" width="96" height="20" font="0">inflammation in a </text>
<text top="748" left="218" width="94" height="20" font="0">sample of obese </text>
<text top="765" left="218" width="128" height="20" font="0">prepubescent children.<b> </b></text>
<text top="782" left="218" width="3" height="20" font="7"><b> </b></text>
<text top="627" left="365" width="152" height="20" font="7"><b>Inclusion criteria: </b>children </text>
<text top="644" left="365" width="98" height="20" font="0">with<b> </b>BMI &gt;25kg/m</text>
<text top="646" left="463" width="4" height="13" font="9">2</text>
<text top="644" left="467" width="3" height="20" font="0"> </text>
<text top="662" left="365" width="3" height="20" font="0"> </text>
<text top="679" left="365" width="114" height="20" font="7"><b>Exclusion criteria:  </b></text>
<text top="627" left="530" width="132" height="20" font="7"><b>Intervention:</b> 8 wk zinc </text>
<text top="644" left="530" width="67" height="20" font="0">supplement </text>
<text top="662" left="530" width="7" height="20" font="0">  </text>
<text top="679" left="530" width="127" height="20" font="7"><b>Comparator: </b>placebo<b>  </b></text>
<text top="696" left="530" width="3" height="20" font="7"><b> </b></text>
<text top="628" left="682" width="168" height="20" font="7"><b>1</b>°<b> endpoint: </b>decrease in Apo </text>
<text top="646" left="682" width="187" height="20" font="0">B/ApoA-I ratio, ox-LDL, leptin and </text>
<text top="663" left="682" width="177" height="20" font="0">malondialdehyde, total and LDL-</text>
<text top="680" left="682" width="172" height="20" font="0">cholesterol after receiving zinc, </text>
<text top="697" left="682" width="172" height="20" font="0">without significant change after </text>
<text top="714" left="682" width="103" height="20" font="0">receiving placebo. </text>
<text top="732" left="682" width="3" height="20" font="7"><b> </b></text>
<text top="749" left="682" width="124" height="20" font="7"><b>Safety endpoint: </b>N/A<b> </b></text>
<text top="766" left="682" width="3" height="20" font="7"><b> </b></text>
<text top="629" left="894" width="7" height="18" font="0">•</text>
<text top="628" left="901" width="171" height="20" font="0"> hs-CRP and insulin resistance </text>
<text top="646" left="894" width="194" height="20" font="0">significantly after receiving zinc but </text>
<text top="663" left="894" width="191" height="20" font="0">increased after receiving placebo.  </text>
<text top="682" left="894" width="7" height="18" font="0">•</text>
<text top="681" left="901" width="206" height="20" font="0"> In both groups, the mean body mass </text>
<text top="698" left="894" width="200" height="20" font="0">index (BMI) Z-score remained high,  </text>
<text top="717" left="894" width="7" height="18" font="0">•</text>
<text top="717" left="901" width="211" height="20" font="7"><b> </b>After receiving zinc, the mean weight, </text>
<text top="734" left="894" width="230" height="20" font="0">BMI, BMI Z-score decreased significantly, </text>
<text top="751" left="894" width="207" height="20" font="0">whereas these values increased after </text>
<text top="768" left="894" width="103" height="20" font="0">receiving placebo. </text>
</page>
<page number="128" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">128 </text>
<text top="107" left="218" width="99" height="20" font="7"><b>Study type: </b>RCT </text>
<text top="124" left="218" width="70" height="20" font="0">double blind </text>
<text top="141" left="218" width="111" height="20" font="7"><b>Size: </b>60 youth from </text>
<text top="159" left="218" width="25" height="20" font="0">Iran<b> </b></text>
<text top="193" left="89" width="87" height="20" font="0">Horner K, 2015 </text>
<text top="211" left="89" width="32" height="20" font="0"><a href="data supplement.html#245">(152)</a> </text>
<text top="228" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26181766">26181766</a></text>
<text top="228" left="144" width="7" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26181766">  </a></text>
<text top="193" left="218" width="120" height="20" font="7"><b>Aim:</b> To compare the </text>
<text top="211" left="218" width="100" height="20" font="0">effects of aerobic, </text>
<text top="228" left="218" width="104" height="20" font="0">resistance, and no </text>
<text top="245" left="218" width="132" height="20" font="0">exercise on Pulse wave </text>
<text top="262" left="218" width="116" height="20" font="0">velocity, carotid IMT, </text>
<text top="279" left="218" width="122" height="20" font="0">LV mass indexed and </text>
<text top="297" left="218" width="112" height="20" font="0">cardiometabolic risk </text>
<text top="314" left="218" width="40" height="20" font="0">factors </text>
<text top="331" left="218" width="3" height="20" font="0"> </text>
<text top="348" left="218" width="102" height="20" font="7"><b>Study type:</b>  RCT </text>
<text top="365" left="218" width="3" height="20" font="0"> </text>
<text top="383" left="218" width="117" height="20" font="7"><b>Size:</b> 81 pts, 3 mo of </text>
<text top="400" left="218" width="93" height="20" font="0">aerobic (n = 30), </text>
<text top="417" left="218" width="130" height="20" font="0">resistance (n = 27) or a </text>
<text top="434" left="218" width="121" height="20" font="0">control group (n = 24) </text>
<text top="193" left="365" width="150" height="20" font="7"><b>Inclusion criteria:</b> 12-18 y </text>
<text top="211" left="365" width="110" height="20" font="0">old, obese (BMI &gt;95</text>
<text top="212" left="475" width="7" height="13" font="9">th</text>
<text top="211" left="482" width="34" height="20" font="0">%tile) </text>
<text top="228" left="365" width="3" height="20" font="0"> </text>
<text top="245" left="365" width="114" height="20" font="7"><b>Exclusion criteria:</b> <b> </b></text>
<text top="193" left="530" width="122" height="20" font="7"><b>Intervention:</b> aerobic </text>
<text top="211" left="530" width="112" height="20" font="0">exercise, resistance </text>
<text top="228" left="530" width="49" height="20" font="0">exercise </text>
<text top="245" left="530" width="7" height="20" font="0">  </text>
<text top="262" left="530" width="94" height="20" font="7"><b>Comparator:</b> no </text>
<text top="279" left="530" width="49" height="20" font="0">exercise<b> </b></text>
<text top="194" left="682" width="79" height="20" font="7"><b>1</b>°<b> endpoint:</b>  </text>
<text top="213" left="682" width="7" height="18" font="0">•</text>
<text top="213" left="689" width="179" height="20" font="0"> significant reductions in total fat </text>
<text top="230" left="682" width="118" height="20" font="0">and improvements in </text>
<text top="247" left="682" width="187" height="20" font="0">cardiorespiratory fitness in the AE </text>
<text top="264" left="682" width="85" height="20" font="0">and RE groups </text>
<text top="283" left="682" width="7" height="18" font="0">•</text>
<text top="283" left="689" width="169" height="20" font="0"> aPWV, cIMT, LVMI, BP, lipids </text>
<text top="300" left="682" width="177" height="20" font="0">and body weight did not change </text>
<text top="317" left="682" width="182" height="20" font="0">compared to controls (p&gt;0.05 for </text>
<text top="334" left="682" width="20" height="20" font="0">all) </text>
<text top="352" left="682" width="3" height="20" font="0"> </text>
<text top="369" left="682" width="193" height="20" font="7"><b>Safety endpoint (if relevant):</b> N/A </text>
<text top="386" left="682" width="3" height="20" font="7"><b> </b></text>
<text top="195" left="894" width="7" height="18" font="0">•</text>
<text top="194" left="901" width="200" height="20" font="0"> Baseline the strongest correlates of </text>
<text top="212" left="894" width="208" height="20" font="0">aPWV were body weight (r = .31) and </text>
<text top="229" left="894" width="222" height="20" font="0">diastolic BP (r = .28); of cIMT were body </text>
<text top="246" left="894" width="230" height="20" font="0">weight (r=0.26) and CRF (r=-0.25); and of </text>
<text top="263" left="894" width="216" height="20" font="0">LVMI was CRF (r=0.32) (p&lt;0.05 for all) </text>
<text top="452" left="89" width="87" height="20" font="0">de Ferranti SD, </text>
<text top="469" left="89" width="63" height="20" font="0">2015 <a href="data supplement.html#245">(153)</a> </text>
<text top="487" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26337820">26337820</a></text>
<text top="487" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26337820"> </a></text>
<text top="452" left="218" width="116" height="20" font="7"><b>Aim:</b> to compare the </text>
<text top="469" left="218" width="112" height="20" font="0">effects of a reduced-</text>
<text top="487" left="218" width="113" height="20" font="0">calorie low glycemic </text>
<text top="504" left="218" width="124" height="20" font="0">diet to a low saturated </text>
<text top="521" left="218" width="112" height="20" font="0">fat diet in youth with </text>
<text top="538" left="218" width="129" height="20" font="0">overweight/obesity and </text>
<text top="555" left="218" width="112" height="20" font="0">cardiometabolic risk </text>
<text top="573" left="218" width="40" height="20" font="0">factors </text>
<text top="590" left="218" width="3" height="20" font="0"> </text>
<text top="607" left="218" width="113" height="20" font="7"><b>Study type:</b> RCT of </text>
<text top="624" left="218" width="115" height="20" font="0">home delivered food </text>
<text top="641" left="218" width="81" height="20" font="0">and nutritional </text>
<text top="659" left="218" width="66" height="20" font="0">counseling  </text>
<text top="676" left="218" width="3" height="20" font="0"> </text>
<text top="693" left="218" width="125" height="20" font="7"><b>Size: </b>27 adolescents;<b> </b> </text>
<text top="710" left="218" width="3" height="20" font="7"><b> </b></text>
<text top="452" left="365" width="150" height="20" font="7"><b>Inclusion criteria:</b> 12-17 y </text>
<text top="469" left="365" width="110" height="20" font="0">old, obese (BMI &gt;95</text>
<text top="471" left="475" width="7" height="13" font="9">th</text>
<text top="469" left="482" width="34" height="20" font="0">%tile) </text>
<text top="487" left="365" width="3" height="20" font="0"> </text>
<text top="504" left="365" width="148" height="20" font="7"><b>Exclusion criteria</b>: known </text>
<text top="521" left="365" width="131" height="20" font="0">endocrine diagnoses or </text>
<text top="538" left="365" width="152" height="20" font="0">other conditions associated </text>
<text top="555" left="365" width="141" height="20" font="0">with lipid abnormalities or </text>
<text top="573" left="365" width="98" height="20" font="0">insulin resistance<b> </b></text>
<text top="452" left="530" width="118" height="20" font="7"><b>Intervention: </b>calorie </text>
<text top="469" left="530" width="127" height="20" font="0">restricted low glycemic </text>
<text top="487" left="530" width="27" height="20" font="0">diet  </text>
<text top="504" left="530" width="3" height="20" font="7"><b> </b></text>
<text top="521" left="530" width="117" height="20" font="7"><b>Comparator: </b>calorie </text>
<text top="538" left="530" width="130" height="20" font="0">restricted low saturated </text>
<text top="555" left="530" width="44" height="20" font="0">fat diet <b> </b></text>
<text top="453" left="682" width="188" height="20" font="7"><b>1</b>°<b> endpoint:</b> Overall, participants </text>
<text top="471" left="682" width="154" height="20" font="0">(n = 27) showed substantial </text>
<text top="488" left="682" width="185" height="20" font="0">improvement during the Intensive </text>
<text top="505" left="682" width="176" height="20" font="0">Phase, including InsAUC (-59 ± </text>
<text top="522" left="682" width="182" height="20" font="0">18.2 µU/ml × 120 min, p=0.004), </text>
<text top="539" left="682" width="187" height="20" font="0">total cholesterol (-9.9 ± 3.6 mg/dl, </text>
<text top="557" left="682" width="169" height="20" font="0">p=0.01), weight (-2.7 ± 0.5 kg, </text>
<text top="574" left="682" width="197" height="20" font="0">p&lt;0.001), waist circumference (-3.1 </text>
<text top="591" left="682" width="197" height="20" font="0">± 0.8 cm, p&lt;0.001), HOMA-IR (-1.7 </text>
<text top="608" left="682" width="194" height="20" font="0">± 0.4, p&lt;0.001), SBP (-5 ± 1.4 mm </text>
<text top="626" left="682" width="193" height="20" font="0">Hg, p=0.002), and CRP (-0.1 ± 0.1 </text>
<text top="643" left="682" width="89" height="20" font="0">mg/dl, p=0.04).  </text>
<text top="662" left="682" width="7" height="18" font="0">•</text>
<text top="661" left="689" width="165" height="20" font="0"> There were minimal between-</text>
<text top="678" left="682" width="175" height="20" font="0">group differences; the LF group </text>
<text top="696" left="682" width="178" height="20" font="0">showed greater declines in HDL </text>
<text top="713" left="682" width="187" height="20" font="0">(p=0.005) and fasting glucose (p= </text>
<text top="730" left="682" width="192" height="20" font="0">0.01) compared to the LGL group.  </text>
<text top="749" left="682" width="7" height="18" font="0">•</text>
<text top="748" left="689" width="173" height="20" font="0"> Improvements waned during 4-</text>
<text top="766" left="682" width="135" height="20" font="0">mo maintenance period. </text>
<text top="783" left="682" width="3" height="20" font="7"><b> </b></text>
<text top="454" left="894" width="7" height="18" font="0">•</text>
<text top="453" left="901" width="187" height="20" font="0"> Home delivery of LF or LGL diets </text>
<text top="471" left="894" width="197" height="20" font="0">resulted in improvements in CV risk </text>
<text top="488" left="894" width="196" height="20" font="0">factors that diminished without food </text>
<text top="505" left="894" width="195" height="20" font="0">delivery and did not differ based on </text>
<text top="522" left="894" width="111" height="20" font="0">dietary intervention. </text>
</page>
<page number="129" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">129 </text>
<text top="107" left="682" width="193" height="20" font="7"><b>Safety endpoint (if relevant):</b> N/A </text>
<text top="124" left="682" width="3" height="20" font="7"><b> </b></text>
<text top="193" left="89" width="100" height="20" font="0">Gidding SS, 2014 </text>
<text top="211" left="89" width="32" height="20" font="0"><a href="data supplement.html#245">(154)</a> </text>
<text top="228" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25008950">25008950</a></text>
<text top="228" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25008950"> </a></text>
<text top="193" left="218" width="119" height="20" font="7"><b>Aim:</b> To evaluate the </text>
<text top="211" left="218" width="126" height="20" font="0">effect of omega-3 fatty </text>
<text top="228" left="218" width="122" height="20" font="0">acids supplements on </text>
<text top="245" left="218" width="68" height="20" font="0">TG levels in </text>
<text top="262" left="218" width="113" height="20" font="0">hypertriglyceridemic </text>
<text top="279" left="218" width="73" height="20" font="0">adolescents. </text>
<text top="297" left="218" width="3" height="20" font="0"> </text>
<text top="314" left="218" width="99" height="20" font="7"><b>Study type:</b> 8 wk </text>
<text top="331" left="218" width="130" height="20" font="0">double-blind, crossover </text>
<text top="348" left="218" width="29" height="20" font="0">RCT </text>
<text top="365" left="218" width="3" height="20" font="0"> </text>
<text top="383" left="218" width="115" height="20" font="7"><b>Size:</b>42 adolescents<b> </b></text>
<text top="193" left="365" width="106" height="20" font="7"><b>Inclusion criteria:</b> </text>
<text top="211" left="365" width="137" height="20" font="0">hypertriglyceridemia and </text>
<text top="228" left="365" width="125" height="20" font="0">low-density lipoprotein </text>
<text top="245" left="365" width="128" height="20" font="0">(LDL) cholesterol &lt;160 </text>
<text top="262" left="365" width="38" height="20" font="0">mg/dL </text>
<text top="279" left="365" width="3" height="20" font="0"> </text>
<text top="297" left="365" width="113" height="20" font="7"><b>Exclusion criteria</b>: <b> </b></text>
<text top="193" left="530" width="129" height="20" font="7"><b>Intervention: </b>8 wk fish </text>
<text top="211" left="530" width="16" height="20" font="0">oil </text>
<text top="228" left="530" width="3" height="20" font="7"><b> </b></text>
<text top="245" left="530" width="105" height="20" font="7"><b>Comparator</b>: 8 wk </text>
<text top="262" left="530" width="46" height="20" font="0">placebo<b> </b></text>
<text top="194" left="682" width="192" height="20" font="7"><b>1</b>°<b> endpoint:</b> TG levels decreased </text>
<text top="212" left="682" width="194" height="20" font="0">on fish oil treatment compared with </text>
<text top="229" left="682" width="196" height="20" font="0">placebo but did not reach statistical </text>
<text top="246" left="682" width="182" height="20" font="0">significance (-52 ± 16 mg/dL vs. -</text>
<text top="263" left="682" width="94" height="20" font="0">16 ± 16 mg/dL).  </text>
<text top="282" left="682" width="7" height="18" font="0">•</text>
<text top="282" left="689" width="161" height="20" font="0"> Large VLDL particle number </text>
<text top="299" left="682" width="195" height="20" font="0">decreased (-5.83 ± 1.29 nmol/L vs. </text>
<text top="316" left="682" width="177" height="20" font="0">-0.96 ± 1.31 nmol/L; p&lt;0.0001). </text>
<text top="335" left="682" width="7" height="18" font="0">•</text>
<text top="334" left="689" width="148" height="20" font="0"> No change in LDL particle </text>
<text top="352" left="682" width="92" height="20" font="0">number or size.  </text>
<text top="371" left="682" width="7" height="18" font="0">•</text>
<text top="370" left="689" width="129" height="20" font="0"> Trend towards a lower </text>
<text top="387" left="682" width="146" height="20" font="0">prothrombotic state (lower </text>
<text top="404" left="682" width="154" height="20" font="0">fibrinogen and plasminogen </text>
<text top="422" left="682" width="191" height="20" font="0">activator inhibitor-1; 10 &gt; p&gt;0.05);  </text>
<text top="439" left="682" width="3" height="20" font="0"> </text>
<text top="456" left="682" width="193" height="20" font="7"><b>Safety endpoint (if relevant):</b> N/A </text>
<text top="473" left="682" width="3" height="20" font="7"><b> </b></text>
<text top="195" left="894" width="7" height="18" font="0">•</text>
<text top="194" left="901" width="206" height="20" font="0"> Fish oil (4 g/d) may lower TG slightly </text>
<text top="212" left="894" width="212" height="20" font="0">and may have an antithrombotic effect </text>
<text top="229" left="894" width="189" height="20" font="0">without an effect on LDL particles. </text>
<text top="248" left="894" width="7" height="18" font="0">•</text>
<text top="247" left="901" width="120" height="20" font="0"> Likely underpowered </text>
<text top="491" left="89" width="87" height="20" font="0">de Ferranti SD, </text>
<text top="508" left="89" width="63" height="20" font="0">2014 <a href="data supplement.html#245">(155)</a> </text>
<text top="526" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24707021">24707021</a></text>
<text top="526" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24707021"> </a></text>
<text top="491" left="218" width="119" height="20" font="7"><b>Aim:</b> To evaluate the </text>
<text top="508" left="218" width="126" height="20" font="0">effect of omega-3 fatty </text>
<text top="526" left="218" width="122" height="20" font="0">acids supplements on </text>
<text top="543" left="218" width="68" height="20" font="0">TG levels in </text>
<text top="560" left="218" width="113" height="20" font="0">hypertriglyceridemic </text>
<text top="577" left="218" width="73" height="20" font="0">adolescents. </text>
<text top="595" left="218" width="3" height="20" font="0"> </text>
<text top="612" left="218" width="101" height="20" font="7"><b>Study type:</b> 6 mo </text>
<text top="629" left="218" width="103" height="20" font="0">double-blind RCT  </text>
<text top="646" left="218" width="3" height="20" font="0"> </text>
<text top="663" left="218" width="118" height="20" font="7"><b>Size: </b>25 adolescents<b> </b></text>
<text top="491" left="365" width="141" height="20" font="7"><b>Inclusion criteria:</b> 10-19 </text>
<text top="508" left="365" width="137" height="20" font="0">y, TG levels 150 to 1000 </text>
<text top="526" left="365" width="38" height="20" font="0">mg/dL </text>
<text top="543" left="365" width="3" height="20" font="0"> </text>
<text top="560" left="365" width="113" height="20" font="7"><b>Exclusion criteria</b>: <b> </b></text>
<text top="491" left="530" width="121" height="20" font="7"><b>Intervention: </b>Lovaza </text>
<text top="508" left="530" width="63" height="20" font="0">(~3360 mg </text>
<text top="526" left="530" width="136" height="20" font="0">docosahexaenoic acid + </text>
<text top="543" left="530" width="125" height="20" font="0">eicosapentaenoic acid </text>
<text top="560" left="530" width="49" height="20" font="0">per day) </text>
<text top="577" left="530" width="3" height="20" font="7"><b> </b></text>
<text top="595" left="530" width="124" height="20" font="7"><b>Comparator: </b>placebo </text>
<text top="612" left="530" width="51" height="20" font="0">(corn oil)<b> </b></text>
<text top="492" left="682" width="194" height="20" font="7"><b>1</b>°<b> endpoint:</b> TG levels declined at </text>
<text top="510" left="682" width="187" height="20" font="0">3 mo in the Lovaza group by 54 ± </text>
<text top="527" left="682" width="189" height="20" font="0">27 mg/dL (mean ± standard error; </text>
<text top="544" left="682" width="169" height="20" font="0">p=0.02) and by 34 ± 26 mg/dL </text>
<text top="561" left="682" width="193" height="20" font="0">(p=0.16) in the placebo group. The </text>
<text top="579" left="682" width="190" height="20" font="0">difference in TG lowering between </text>
<text top="596" left="682" width="198" height="20" font="0">groups was not significant (p=0.52). </text>
<text top="613" left="682" width="168" height="20" font="0">There were no between-group </text>
<text top="630" left="682" width="190" height="20" font="0">differences in endothelial function, </text>
<text top="647" left="682" width="187" height="20" font="0">blood pressure, body mass index, </text>
<text top="665" left="682" width="187" height="20" font="0">C-reactive protein, or side effects. </text>
<text top="682" left="682" width="3" height="20" font="0"> </text>
<text top="699" left="682" width="173" height="20" font="7"><b>Safety endpoint (if relevant):</b> <b> </b></text>
<text top="493" left="894" width="7" height="18" font="0">•</text>
<text top="492" left="901" width="167" height="20" font="0"> High-dose omega-3 fatty acid </text>
<text top="510" left="894" width="183" height="20" font="0">supplements are well tolerated in </text>
<text top="527" left="894" width="210" height="20" font="0">adolescents. However, declines in TG </text>
<text top="544" left="894" width="201" height="20" font="0">levels did not differ significantly from </text>
<text top="561" left="894" width="50" height="20" font="0">placebo  </text>
<text top="580" left="894" width="7" height="18" font="0">•</text>
<text top="580" left="901" width="124" height="20" font="0"> Likely underpowered  </text>
<text top="718" left="88" width="994" height="20" font="7"><b>Abbreviations: </b>1° indicated primary; CI, confidence interval; HR, hazard ratio; N/A, not available; OR, odds ratio; RCT, randomized controlled trial; and RR, relative risk. ICVH – Ideal </text>
<text top="735" left="88" width="120" height="20" font="0">cardiovascular health<b> </b></text>
<text top="753" left="88" width="256" height="20" font="7"><b>HOMA </b>HOmeostatic Model Assessment index </text>
<text top="770" left="88" width="300" height="20" font="7"><b>Search Terms and Date of Search</b>: Author to provide </text>
<text top="787" left="81" width="4" height="22" font="5"><b> </b></text>
</page>
<page number="130" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">130 </text>
<text top="106" left="81" width="4" height="22" font="5"><b> </b></text>
</page>
<page number="131" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">131 </text>
<text top="106" left="81" width="972" height="24" font="4"><b>Data Supplement 22. Nonrandomized Trials, Observational Studies, and/or Registries of Metabolic Syndrome of Children and Adolescents </b></text>
<text top="127" left="81" width="116" height="24" font="4"><b>(Section 4.4.4.3) </b></text>
<text top="148" left="115" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="166" left="140" width="48" height="20" font="7"><b>Author; </b></text>
<text top="183" left="116" width="96" height="20" font="7"><b>Year Published’ </b></text>
<text top="200" left="147" width="34" height="20" font="7"><b>PMID </b></text>
<text top="148" left="267" width="118" height="20" font="7"><b>Study Type/Design; </b></text>
<text top="166" left="293" width="66" height="20" font="7"><b>Study Size </b></text>
<text top="148" left="440" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="148" left="620" width="179" height="20" font="7"><b>Primary Endpoint and Results </b></text>
<text top="166" left="618" width="184" height="20" font="7"><b>(P values; OR or RR; &amp; 95% CI) </b></text>
<text top="148" left="907" width="130" height="20" font="7"><b>Summary/Conclusion </b></text>
<text top="166" left="935" width="75" height="20" font="7"><b>Comment(s) </b></text>
<text top="218" left="89" width="123" height="20" font="0">Gunnarsdottir T, 2014 </text>
<text top="235" left="89" width="32" height="20" font="0"><a href="data supplement.html#245">(156)</a> </text>
<text top="252" left="89" width="58" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24636901">24636901 </a></text>
<text top="252" left="148" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24636901"> </a></text>
<text top="218" left="252" width="77" height="20" font="7"><b>Study type:</b>   </text>
<text top="235" left="252" width="94" height="20" font="0">Weight loss obs. </text>
<text top="252" left="252" width="3" height="20" font="0"> </text>
<text top="270" left="252" width="132" height="20" font="7"><b>Size:</b> 84 obese children </text>
<text top="287" left="252" width="143" height="20" font="0">(age-range: 8-13 y) and a </text>
<text top="304" left="252" width="108" height="20" font="0">participating parent </text>
<text top="218" left="413" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="235" left="413" width="3" height="20" font="0"> </text>
<text top="252" left="413" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="219" left="591" width="223" height="20" font="7"><b>1</b>°<b> endpoint:</b> body-mass index standard </text>
<text top="236" left="591" width="86" height="20" font="0">deviation score </text>
<text top="254" left="591" width="231" height="20" font="0">- Laeknabladid. 2014 Mar; 100(3):139-45. </text>
<text top="271" left="591" width="125" height="20" font="0">– Article in Icelandic… </text>
<text top="288" left="591" width="3" height="20" font="0"> </text>
<text top="305" left="591" width="213" height="20" font="7"><b>Results:</b> Among treatment completers </text>
<text top="322" left="591" width="206" height="20" font="0">BMI-SDS (body-mass index standard </text>
<text top="340" left="591" width="218" height="20" font="0">deviation score) decreased significantly </text>
<text top="357" left="591" width="204" height="20" font="0">from pre- to post- treatment (F (2.60) </text>
<text top="374" left="591" width="228" height="20" font="0">=110.31, p&lt;0.001) which was maintained </text>
<text top="391" left="591" width="213" height="20" font="0">at one-y (F (2.60) =1.33; p=0.253) and </text>
<text top="408" left="591" width="207" height="20" font="0">two-y (F (2.60) = 3, 19; p=0.079) post </text>
<text top="426" left="591" width="62" height="20" font="0">treatment.  </text>
<text top="443" left="591" width="3" height="20" font="0"> </text>
<text top="220" left="842" width="7" height="18" font="0">•</text>
<text top="219" left="849" width="242" height="20" font="0"> Among a subsample (n=23) of participants, </text>
<text top="236" left="842" width="255" height="20" font="0">significant reductions were observed in fasting </text>
<text top="254" left="842" width="193" height="20" font="0">insulin levels, (t (22) =6.1, p&lt;0.05), </text>
<text top="271" left="842" width="239" height="20" font="0">triglycerides (t (22) =0.31, p&lt;0.05) and total </text>
<text top="288" left="842" width="186" height="20" font="0">cholesterol (t (22) =0.35, p&lt;0.05). </text>
<text top="307" left="842" width="7" height="18" font="0">•</text>
<text top="306" left="849" width="205" height="20" font="0">Analysis was done only among study </text>
<text top="324" left="842" width="67" height="20" font="0">completers. </text>
<text top="343" left="842" width="7" height="18" font="0">•</text>
<text top="342" left="849" width="111" height="20" font="0"> Written in Icelandic </text>
<text top="461" left="89" width="129" height="20" font="0">Viitasalo A, et al., 2014 </text>
<text top="478" left="89" width="32" height="20" font="0"><a href="data supplement.html#245">(157)</a> </text>
<text top="495" left="89" width="58" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24463933"> 24463933</a></text>
<text top="495" left="148" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24463933"> </a></text>
<text top="461" left="252" width="112" height="20" font="7"><b>Study type:</b>  Factor </text>
<text top="478" left="252" width="121" height="20" font="0">analyses of metabolic </text>
<text top="495" left="252" width="110" height="20" font="0">syndrome definition </text>
<text top="512" left="252" width="3" height="20" font="0"> </text>
<text top="530" left="252" width="140" height="20" font="7"><b>Size:</b> 491 children, 1,900 </text>
<text top="547" left="252" width="126" height="20" font="0">middle-aged men, 614 </text>
<text top="564" left="252" width="122" height="20" font="0">older women and 555 </text>
<text top="581" left="252" width="130" height="20" font="0">older men from Finland </text>
<text top="461" left="413" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="478" left="413" width="3" height="20" font="0"> </text>
<text top="495" left="413" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="462" left="591" width="212" height="20" font="7"><b>1</b>°<b> endpoint:</b> incident type 2 diabetes, </text>
<text top="479" left="591" width="226" height="20" font="0">myocardial infarction, and cardiovascular </text>
<text top="496" left="591" width="209" height="20" font="0">and overall death in middle-aged men </text>
<text top="514" left="591" width="3" height="20" font="0"> </text>
<text top="531" left="591" width="203" height="20" font="7"><b>Results:</b> The risk of type 2 diabetes, </text>
<text top="548" left="591" width="237" height="20" font="0">myocardial infarction, cardiovascular death </text>
<text top="565" left="591" width="224" height="20" font="0">and overall death increased 3.67-, 1.38-, </text>
<text top="582" left="591" width="220" height="20" font="0">1.56- and 1.44-fold, respectively, for a 1 </text>
<text top="600" left="591" width="173" height="20" font="0">SD increase in the MetS score. </text>
<text top="463" left="842" width="7" height="18" font="0">•</text>
<text top="462" left="849" width="215" height="20" font="0"> Factor analysis was used to develop a </text>
<text top="479" left="842" width="248" height="20" font="0">metabolic syndrome score which was related </text>
<text top="496" left="842" width="105" height="20" font="0">to hard outcomes.  </text>
<text top="514" left="842" width="3" height="20" font="0"> </text>
<text top="618" left="89" width="130" height="20" font="0">Benson M, et al.,  2012 </text>
<text top="635" left="89" width="32" height="20" font="0"><a href="data supplement.html#245">(158)</a> </text>
<text top="652" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22819275">22819275</a></text>
<text top="652" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22819275"> </a></text>
<text top="618" left="252" width="107" height="20" font="7"><b>Study type:</b>  cross </text>
<text top="635" left="252" width="128" height="20" font="0">sectional description of </text>
<text top="652" left="252" width="126" height="20" font="0">lipoprotein subtypes in </text>
<text top="669" left="252" width="134" height="20" font="0">lean and obese children </text>
<text top="686" left="252" width="3" height="20" font="0"> </text>
<text top="704" left="252" width="106" height="20" font="7"><b>Size:</b> 162 pediatric </text>
<text top="721" left="252" width="131" height="20" font="0">subjects—75 were lean </text>
<text top="738" left="252" width="128" height="20" font="0">(41 prepubertal and 34 </text>
<text top="755" left="252" width="139" height="20" font="0">pubertal, 43 boys and 32 </text>
<text top="773" left="252" width="129" height="20" font="0">girls) and 87 obese (39 </text>
<text top="790" left="252" width="107" height="20" font="0">prepubertal and 48 </text>
<text top="618" left="413" width="146" height="20" font="7"><b>Inclusion criteria:</b> Obese </text>
<text top="635" left="413" width="140" height="20" font="0">children (BMI &gt;95%) with </text>
<text top="652" left="413" width="153" height="20" font="0">normal BP, fasting glucose, </text>
<text top="669" left="413" width="141" height="20" font="0">TC (&lt;200 mg/dL) and TG </text>
<text top="687" left="413" width="156" height="20" font="0">(&lt;130 mg/dL) and normal or </text>
<text top="704" left="413" width="140" height="20" font="0">mildly decreased HDL-C. </text>
<text top="721" left="413" width="155" height="20" font="0">Lean children were age and </text>
<text top="738" left="413" width="149" height="20" font="0">puberty matched and were </text>
<text top="755" left="413" width="164" height="20" font="0">healthy, on no medications or </text>
<text top="773" left="413" width="158" height="20" font="0">herbal remedies and without </text>
<text top="790" left="413" width="7" height="20" font="0">1</text>
<text top="792" left="420" width="6" height="13" font="9">st</text>
<text top="790" left="426" width="120" height="20" font="0"> degree relatives with </text>
<text top="619" left="591" width="210" height="20" font="7"><b>1</b>°<b> endpoint:</b> lipoprotein sub-fractions </text>
<text top="636" left="591" width="176" height="20" font="0">using a novel ion mobility assay </text>
<text top="653" left="591" width="3" height="20" font="0"> </text>
<text top="670" left="591" width="219" height="20" font="7"><b>Results:</b> Lean children had higher HDL-</text>
<text top="688" left="591" width="223" height="20" font="0">large (76%), HDL-small (13%), and HDL-</text>
<text top="705" left="591" width="236" height="20" font="0">total (27%) compared with obese (p&lt;0.01), </text>
<text top="722" left="591" width="216" height="20" font="0">and lower LDL-medium (-30%, p&lt;0.01) </text>
<text top="739" left="591" width="215" height="20" font="0">and medium + small (-21%, p=0.02) as </text>
<text top="757" left="591" width="193" height="20" font="0">well as LDL-total (-13%, p=0.035).  </text>
<text top="619" left="842" width="7" height="18" font="0">•</text>
<text top="619" left="849" width="225" height="20" font="0"> In both groups, the LDL component was </text>
<text top="636" left="842" width="262" height="20" font="0">higher in males and pubertal children (p&lt;0.01).  </text>
<text top="655" left="842" width="7" height="18" font="0">•</text>
<text top="654" left="849" width="217" height="20" font="0"> Prepubertal children had a higher HDL </text>
<text top="672" left="842" width="233" height="20" font="0">component than pubertal ones (p&lt;0.004).  </text>
<text top="691" left="842" width="7" height="18" font="0">•</text>
<text top="690" left="849" width="232" height="20" font="0"> Adjusting for sex and pubertal status LDL </text>
<text top="707" left="842" width="199" height="20" font="0">component was positively, and HDL </text>
<text top="724" left="842" width="252" height="20" font="0">component negatively, correlated with obesity </text>
<text top="742" left="842" width="60" height="20" font="0">(p&lt;0.004). </text>
<text top="761" left="842" width="7" height="18" font="0">•</text>
<text top="760" left="849" width="235" height="20" font="0"> Despite relatively normal triglycerides and </text>
<text top="777" left="842" width="253" height="20" font="0">cholesterol measured with standard assays at </text>
</page>
<page number="132" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">132 </text>
<text top="107" left="252" width="139" height="20" font="0">pubertal, 58 boys and 29 </text>
<text top="124" left="252" width="30" height="20" font="0">girls) </text>
<text top="107" left="413" width="136" height="20" font="0">obesity, type 2 diabetes, </text>
<text top="124" left="413" width="92" height="20" font="0">hypertension, or </text>
<text top="141" left="413" width="75" height="20" font="0">dyslipidemia. </text>
<text top="159" left="413" width="156" height="20" font="7"><b>Exclusion criteria:</b> Genetic </text>
<text top="176" left="413" width="137" height="20" font="0">and endocrine causes of </text>
<text top="193" left="413" width="42" height="20" font="0">obesity </text>
<text top="107" left="842" width="219" height="20" font="0">screening, ion mobility analysis showed </text>
<text top="124" left="842" width="184" height="20" font="0">significant differences in lipid and </text>
<text top="141" left="842" width="255" height="20" font="0">apolipoprotein sub-fractions between lean and </text>
<text top="159" left="842" width="203" height="20" font="0">obese children, even before puberty. </text>
<text top="211" left="89" width="125" height="20" font="0">Elkiran O, et al., 2013  </text>
<text top="228" left="89" width="63" height="20" font="0"><a href="data supplement.html#245">(159)</a>          </text>
<text top="245" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22014414">22014414</a></text>
<text top="245" left="144" width="3" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22014414"><b> </b></a></text>
<text top="211" left="252" width="139" height="20" font="7"><b>Study type:</b> Substudy of </text>
<text top="228" left="252" width="135" height="20" font="0">a cross sectional school-</text>
<text top="245" left="252" width="134" height="20" font="0">based survey of Turkish </text>
<text top="263" left="252" width="82" height="20" font="0">schoolchildren </text>
<text top="280" left="252" width="3" height="20" font="0"> </text>
<text top="297" left="252" width="123" height="20" font="7"><b>Size:</b> 123 children; 67 </text>
<text top="314" left="252" width="141" height="20" font="0">obese and 24 overweight </text>
<text top="332" left="252" width="127" height="20" font="0">and 32 healthy weight  </text>
<text top="211" left="413" width="113" height="20" font="7"><b>Inclusion criteria:</b> 6</text>
<text top="213" left="526" width="7" height="13" font="9">th</text>
<text top="211" left="533" width="14" height="20" font="0">, 7</text>
<text top="213" left="547" width="7" height="13" font="9">th</text>
<text top="211" left="553" width="3" height="20" font="0"> </text>
<text top="228" left="413" width="31" height="20" font="0">and 8</text>
<text top="230" left="444" width="7" height="13" font="9">th</text>
<text top="228" left="451" width="94" height="20" font="0"> graders from 18 </text>
<text top="245" left="413" width="143" height="20" font="0">schools in eastern Turkey </text>
<text top="263" left="413" width="152" height="20" font="0">with available clinical data.  </text>
<text top="280" left="413" width="3" height="20" font="0"> </text>
<text top="297" left="413" width="127" height="20" font="7"><b>Exclusion criteria:</b> no </text>
<text top="314" left="413" width="151" height="20" font="0">subject or parental consent </text>
<text top="212" left="591" width="190" height="20" font="7"><b>1</b>°<b> endpoint:</b> carotid intima-media </text>
<text top="229" left="591" width="91" height="20" font="0">thickness (IMT)  </text>
<text top="268" left="591" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="287" left="591" width="7" height="18" font="0">•</text>
<text top="286" left="597" width="214" height="20" font="0"> Carotid IMT was significantly higher in </text>
<text top="303" left="591" width="222" height="20" font="0">overweight (0.52±0.008 mm) and obese </text>
<text top="320" left="591" width="225" height="20" font="0">(0.53±0.008 mm) groups compare to the </text>
<text top="338" left="591" width="205" height="20" font="0">controls (0.36±0.009 mm) (p=0.001). </text>
<text top="357" left="591" width="7" height="18" font="0">•</text>
<text top="356" left="597" width="222" height="20" font="0"> Carotid IMT was significantly correlated </text>
<text top="373" left="591" width="239" height="20" font="0">to the body mass index (r=0.396, p=0.001), </text>
<text top="390" left="591" width="224" height="20" font="0">fat mass percentage (r=0.257, p=0.036), </text>
<text top="408" left="591" width="221" height="20" font="0">waist circumference (r=0.390, p=0.001), </text>
<text top="425" left="591" width="222" height="20" font="0">diastolic BP (r=0.266, p=0.030), glucose </text>
<text top="442" left="591" width="229" height="20" font="0">(r=0.250, p=0.042), and high-sensitivity C-</text>
<text top="459" left="591" width="228" height="20" font="0">reactive protein levels (r=0.269, p=0.001) </text>
<text top="476" left="591" width="224" height="20" font="0">in the obese group. Waist circumference </text>
<text top="494" left="591" width="208" height="20" font="0">(p=0.045), and diastolic BP (p=0.031) </text>
<text top="511" left="591" width="194" height="20" font="0">persisted in multivariable analyses. </text>
<text top="213" left="842" width="7" height="18" font="0">•</text>
<text top="212" left="849" width="221" height="20" font="0"> Obesity is related to cardiovascular risk </text>
<text top="229" left="842" width="228" height="20" font="0">factors leading to subclinical measures of </text>
<text top="247" left="842" width="185" height="20" font="0">atherosclerosis in schoolchildren. </text>
<text top="266" left="842" width="7" height="18" font="0">•</text>
<text top="265" left="849" width="195" height="20" font="0"> Central obesity measured by waist </text>
<text top="282" left="842" width="203" height="20" font="0">circumference and diastolic BP were </text>
<text top="300" left="842" width="136" height="20" font="0">significant determinants. </text>
<text top="529" left="89" width="111" height="20" font="0">Dalili S, et al., <a href="data supplement.html#245">(160)</a> </text>
<text top="546" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25249405">25249405</a></text>
<text top="546" left="144" width="7" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25249405">  </a></text>
<text top="529" left="252" width="109" height="20" font="7"><b>Study type:</b>  Cross </text>
<text top="546" left="252" width="52" height="20" font="0">sectional </text>
<text top="563" left="252" width="3" height="20" font="0"> </text>
<text top="580" left="252" width="147" height="20" font="7"><b>Size:</b>  859 children age 12 </text>
<text top="598" left="252" width="140" height="20" font="0">y; 550 boys and 309 girls </text>
<text top="529" left="413" width="154" height="20" font="7"><b>Inclusion criteria:</b> 12-y-old </text>
<text top="546" left="413" width="161" height="20" font="0">junior students referred to 15 </text>
<text top="563" left="413" width="129" height="20" font="0">urban health centers of </text>
<text top="580" left="413" width="64" height="20" font="0">Rasht, Iran </text>
<text top="598" left="413" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="530" left="591" width="234" height="20" font="7"><b>1</b>°<b> endpoint:</b> correlates of hypertension in </text>
<text top="547" left="591" width="56" height="20" font="0">childhood </text>
<text top="564" left="591" width="3" height="20" font="0"> </text>
<text top="582" left="591" width="169" height="20" font="7"><b>Results:</b> weight, waist and hip </text>
<text top="599" left="591" width="238" height="20" font="0">circumferences, insulin levels, high TG and </text>
<text top="616" left="591" width="224" height="20" font="0">low HDL were correlated with high blood </text>
<text top="633" left="591" width="55" height="20" font="0">pressure. </text>
<text top="531" left="842" width="7" height="18" font="0">•</text>
<text top="530" left="849" width="241" height="20" font="0"> Children with one cardiovascular risk factor </text>
<text top="547" left="842" width="207" height="20" font="0">(elevated BP) should be screened for </text>
<text top="564" left="842" width="119" height="20" font="0">additional risk factors </text>
<text top="651" left="89" width="130" height="20" font="0">de Jong M, et al., <a href="data supplement.html#245">(161)</a> </text>
<text top="668" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26086641">26086641</a></text>
<text top="668" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26086641"> </a></text>
<text top="686" left="89" width="3" height="20" font="0"> </text>
<text top="651" left="252" width="74" height="20" font="7"><b>Study type:</b>  </text>
<text top="668" left="252" width="142" height="20" font="0">observational longitudinal </text>
<text top="686" left="252" width="38" height="20" font="0">cohort </text>
<text top="703" left="252" width="3" height="20" font="0"> </text>
<text top="720" left="252" width="125" height="20" font="7"><b>Size:</b> 38 very low birth </text>
<text top="737" left="252" width="132" height="20" font="0">weight (VLBW) children </text>
<text top="755" left="252" width="147" height="20" font="0">and 82 term born children, </text>
<text top="772" left="252" width="146" height="20" font="0">64 average for gestational </text>
<text top="652" left="413" width="132" height="20" font="7"><b>1</b>°<b> endpoint:</b> Metabolic </text>
<text top="670" left="413" width="141" height="20" font="0">syndrome components in </text>
<text top="687" left="413" width="145" height="20" font="0">early childhood in children </text>
<text top="704" left="413" width="137" height="20" font="0">born at VLBW, SGA and </text>
<text top="721" left="413" width="33" height="20" font="0">AGA. </text>
<text top="739" left="413" width="3" height="20" font="0"> </text>
<text top="756" left="413" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="652" left="591" width="189" height="20" font="7"><b>1</b>°<b> endpoint:</b> Metabolic syndrome </text>
<text top="670" left="591" width="229" height="20" font="0">components in early childhood in children </text>
<text top="687" left="591" width="170" height="20" font="0">born at VLBW, SGA and AGA. </text>
<text top="704" left="591" width="3" height="20" font="0"> </text>
<text top="721" left="591" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="740" left="591" width="7" height="18" font="0">•</text>
<text top="740" left="597" width="229" height="20" font="0"> At age 2 y corrected, VLBW children had </text>
<text top="757" left="591" width="194" height="20" font="0">lower BMI and higher glucose level </text>
<text top="774" left="591" width="155" height="20" font="0">compared to AGA children.  </text>
<text top="653" left="842" width="7" height="18" font="0">•</text>
<text top="652" left="849" width="226" height="20" font="0"> In early childhood, VLBW and term SGA </text>
<text top="670" left="842" width="235" height="20" font="0">children already have a high prevalence of </text>
<text top="687" left="842" width="217" height="20" font="0">some metabolic syndrome components </text>
<text top="704" left="842" width="179" height="20" font="0">compared to term AGA children. </text>
<text top="723" left="842" width="7" height="18" font="0">•</text>
<text top="722" left="849" width="211" height="20" font="0"> Body fat was a significant correlate of </text>
<text top="740" left="842" width="247" height="20" font="0">cardiovascular risk factors in children born at </text>
<text top="757" left="842" width="92" height="20" font="0">low birth weight. </text>
</page>
<page number="133" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">133 </text>
<text top="107" left="252" width="128" height="20" font="0">age (AGA)/18 small for </text>
<text top="124" left="252" width="143" height="20" font="0">gestational a birth weight<b>  </b></text>
<text top="141" left="252" width="3" height="20" font="7"><b> </b></text>
<text top="159" left="252" width="133" height="20" font="7"><b>Inclusion criteria:</b> very </text>
<text top="176" left="252" width="138" height="20" font="0">low birth weight (VLBW), </text>
<text top="193" left="252" width="137" height="20" font="0">small for gestational age </text>
<text top="210" left="252" width="127" height="20" font="0">(SGA) and average for </text>
<text top="228" left="252" width="124" height="20" font="0">gestational age (AGA) </text>
<text top="245" left="252" width="3" height="20" font="0"> </text>
<text top="262" left="252" width="134" height="20" font="7"><b>Exclusion criteria:</b> N/A<b> </b></text>
<text top="109" left="413" width="7" height="18" font="0">•</text>
<text top="108" left="420" width="120" height="20" font="0"> At age 2 y corrected, </text>
<text top="125" left="413" width="141" height="20" font="0">VLBW children had lower </text>
<text top="143" left="413" width="161" height="20" font="0">BMI and higher glucose level </text>
<text top="160" left="413" width="155" height="20" font="0">compared to AGA children.  </text>
<text top="179" left="413" width="7" height="18" font="0">•</text>
<text top="178" left="420" width="136" height="20" font="0"> SGA children had lower </text>
<text top="195" left="413" width="154" height="20" font="0">BMI at 1 and 2 y of age and </text>
<text top="213" left="413" width="161" height="20" font="0">a high prevalence of high TG </text>
<text top="230" left="413" width="164" height="20" font="0">levels at 1 y of age compared </text>
<text top="247" left="413" width="96" height="20" font="0">to AGA children.  </text>
<text top="266" left="413" width="7" height="18" font="0">•</text>
<text top="265" left="420" width="117" height="20" font="0"> Total body fat was a </text>
<text top="283" left="413" width="140" height="20" font="0">significant determinant of </text>
<text top="300" left="413" width="159" height="20" font="0">HDL cholesterol and TG and </text>
<text top="317" left="413" width="160" height="20" font="0">birth weight was a significant </text>
<text top="334" left="413" width="161" height="20" font="0">determinant of glucose at 2 y </text>
<text top="352" left="413" width="82" height="20" font="0">corrected age.<b> </b></text>
<text top="109" left="591" width="7" height="18" font="0">•</text>
<text top="108" left="597" width="229" height="20" font="0"> SGA children had lower BMI at 1 and 2 y </text>
<text top="125" left="591" width="223" height="20" font="0">of age and a high prevalence of high TG </text>
<text top="143" left="591" width="207" height="20" font="0">levels at 1 y of age compared to AGA </text>
<text top="160" left="591" width="53" height="20" font="0">children.  </text>
<text top="179" left="591" width="7" height="18" font="0">•</text>
<text top="178" left="597" width="175" height="20" font="0"> Total body fat was a significant </text>
<text top="195" left="591" width="217" height="20" font="0">determinant of HDL cholesterol and TG </text>
<text top="213" left="591" width="184" height="20" font="0">and birth weight was a significant </text>
<text top="230" left="591" width="216" height="20" font="0">determinant of glucose at 2 y corrected </text>
<text top="247" left="591" width="24" height="20" font="0">age<b> </b></text>
<text top="370" left="89" width="143" height="20" font="0">Ma CM, et al., 2015 <a href="data supplement.html#245">(162)</a> </text>
<text top="387" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25809784">25809784</a></text>
<text top="387" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25809784"> </a></text>
<text top="370" left="252" width="107" height="20" font="7"><b>Study type:</b>  cross-</text>
<text top="387" left="252" width="113" height="20" font="0">sectional population-</text>
<text top="404" left="252" width="70" height="20" font="0">based study </text>
<text top="421" left="252" width="3" height="20" font="0"> </text>
<text top="438" left="252" width="89" height="20" font="7"><b>Size:</b> 3136 Han </text>
<text top="456" left="252" width="138" height="20" font="0">adolescents age 13-17 y<b> </b></text>
<text top="370" left="413" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="387" left="413" width="3" height="20" font="0"> </text>
<text top="404" left="413" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="371" left="591" width="238" height="20" font="7"><b>1</b>°<b> endpoint:</b> Elevated TC (≥5.18 mmol/L), </text>
<text top="388" left="591" width="219" height="20" font="0">high LDL-C (≥3.37 mmol/L), low HDL-C </text>
<text top="405" left="591" width="206" height="20" font="0">(&lt;1.03 mmol/L), and high non-HDL-C </text>
<text top="422" left="591" width="184" height="20" font="0">(≥3.76 mmol/L) could be used as </text>
<text top="440" left="591" width="210" height="20" font="0">screening tools for the identification of </text>
<text top="457" left="591" width="230" height="20" font="0">adolescents characterized by atherogenic </text>
<text top="474" left="591" width="66" height="20" font="0">lipid profile. </text>
<text top="491" left="591" width="3" height="20" font="0"> </text>
<text top="508" left="591" width="230" height="20" font="7"><b>Results:</b> adolescents with waist-to-height </text>
<text top="526" left="591" width="232" height="20" font="0">ratio (WHtR) ≥0.48 for boys and ≥0.46 for </text>
<text top="543" left="591" width="215" height="20" font="0">girls and TG levels ≥1.47 mmol/L were </text>
<text top="560" left="591" width="226" height="20" font="0">more likely to have hypercholesterolemia </text>
<text top="577" left="591" width="220" height="21" font="0">(odds ratio (OR) = 7.8, 95 % confidence </text>
<text top="595" left="591" width="222" height="21" font="0">interval (CI:) = 3.5-17.3, P &lt; 0.001), high </text>
<text top="612" left="591" width="211" height="21" font="0">LDL-C (OR = 9.4, 95 % CI: = 2.8-31.2, </text>
<text top="629" left="591" width="224" height="21" font="0">P &lt; 0.001), low HDL-C (OR = 10.8, 95 % </text>
<text top="646" left="591" width="219" height="21" font="0">CI: = 6.9-17.0, P &lt; 0.001), and high non-</text>
<text top="663" left="591" width="227" height="21" font="0">HDL-C (OR = 22.9, 95 % CI: = 10.0-52.2, </text>
<text top="681" left="591" width="215" height="21" font="0">P &lt; 0.001) than those adolescents with </text>
<text top="698" left="591" width="200" height="20" font="0">normal WHtR and normal serum TG </text>
<text top="371" left="842" width="7" height="18" font="0">•</text>
<text top="371" left="849" width="227" height="20" font="0"> hypertriglyceridemic waist-to-height ratio </text>
<text top="388" left="842" width="234" height="20" font="0">phenotype identified Han adolescents with </text>
<text top="405" left="842" width="202" height="20" font="0">atherogenic lipid profile in a non-age </text>
<text top="422" left="842" width="105" height="20" font="0">dependent fashion </text>
<text top="716" left="89" width="150" height="20" font="0">de Lima Sanches P, et al.,<b> </b> </text>
<text top="733" left="89" width="63" height="20" font="0">2011 <a href="data supplement.html#245">(163)</a><b> </b></text>
<text top="750" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21124323">21124323</a></text>
<text top="750" left="144" width="7" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21124323">  </a></text>
<text top="767" left="89" width="3" height="20" font="0"> </text>
<text top="716" left="252" width="95" height="20" font="7"><b>Study type:</b> non-</text>
<text top="733" left="252" width="126" height="20" font="0">randomized 1 y weight </text>
<text top="750" left="252" width="92" height="20" font="0">loss intervention </text>
<text top="767" left="252" width="3" height="20" font="0"> </text>
<text top="716" left="413" width="133" height="20" font="7"><b>Inclusion criteria:</b> post-</text>
<text top="733" left="413" width="146" height="20" font="0">pubertal (Tanner 5) obese </text>
<text top="750" left="413" width="69" height="20" font="0">adolescents </text>
<text top="767" left="413" width="3" height="20" font="0"> </text>
<text top="717" left="591" width="202" height="20" font="7"><b>1</b>°<b> endpoint:</b> common carotid artery </text>
<text top="734" left="591" width="165" height="20" font="0">intima-media thickness (IMT)  </text>
<text top="751" left="591" width="3" height="20" font="0"> </text>
<text top="769" left="591" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="718" left="842" width="7" height="18" font="0">•</text>
<text top="717" left="849" width="208" height="20" font="0"> The weight-loss program promoted a </text>
<text top="734" left="842" width="248" height="20" font="0">significant improvement in body composition, </text>
<text top="751" left="842" width="245" height="20" font="0">insulin concentration, HOMA-IR, lipid profile, </text>
<text top="769" left="842" width="224" height="20" font="0">BP and inflammatory state, in addition to </text>
</page>
<page number="134" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">134 </text>
<text top="107" left="252" width="124" height="20" font="7"><b>Size:</b> 29 post pubertal </text>
<text top="124" left="252" width="69" height="20" font="0">adolescents<b> </b></text>
<text top="107" left="413" width="141" height="20" font="7"><b>Exclusion criteria:</b> other </text>
<text top="124" left="413" width="128" height="20" font="0">metabolic or endocrine </text>
<text top="141" left="413" width="141" height="20" font="0">diseases; chronic alcohol </text>
<text top="159" left="413" width="163" height="20" font="0">consumption; previous use of </text>
<text top="176" left="413" width="132" height="20" font="0">drugs, such as anabolic </text>
<text top="193" left="413" width="125" height="20" font="0">androgenic steroids or </text>
<text top="210" left="413" width="163" height="20" font="0">psychotropics that may affect </text>
<text top="228" left="413" width="111" height="20" font="0">appetite regulation;  </text>
<text top="245" left="413" width="61" height="20" font="0">pregnancy<b> </b></text>
<text top="109" left="591" width="7" height="18" font="0">•</text>
<text top="108" left="597" width="227" height="20" font="0"> 1-y interdisciplinary weight-loss program </text>
<text top="125" left="591" width="191" height="20" font="0">including nutrition and aerobic and </text>
<text top="143" left="591" width="239" height="20" font="0">resistance exercise programming improved </text>
<text top="160" left="591" width="141" height="20" font="0">cIMT (-0.06 mm, P≤0.01) </text>
<text top="179" left="591" width="7" height="18" font="0">•</text>
<text top="178" left="597" width="218" height="20" font="0"> Change in HOMA-IR (ΔHOMA-IR) was </text>
<text top="195" left="591" width="212" height="20" font="0">negatively correlated with concomitant </text>
<text top="213" left="591" width="227" height="20" font="0">changes in the adiponectin concentration </text>
<text top="230" left="591" width="198" height="20" font="0">(Δadiponectin; r=-0.42; p=0.02) and </text>
<text top="247" left="591" width="200" height="20" font="0">positively correlated with changes in </text>
<text top="264" left="591" width="231" height="20" font="0">common carotid artery IMT (Δcarotid IMT; </text>
<text top="281" left="591" width="91" height="20" font="0">r=0.41; p=0.03). </text>
<text top="107" left="842" width="242" height="20" font="0">significantly decreasing the common carotid </text>
<text top="124" left="842" width="63" height="20" font="0">artery IMT. </text>
<text top="143" left="842" width="7" height="18" font="0">•</text>
<text top="143" left="849" width="204" height="20" font="0"> Only reported results on participants </text>
<text top="160" left="842" width="233" height="20" font="0">completing &gt;75% of the exercise sessions </text>
<text top="299" left="89" width="98" height="20" font="7"><b>HEALTHY study </b></text>
<text top="317" left="89" width="127" height="20" font="0">Bauer KW, et al., 2015 </text>
<text top="334" left="89" width="32" height="20" font="0"><a href="data supplement.html#245">(164)</a> </text>
<text top="351" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25515620">25515620</a></text>
<text top="351" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25515620"> </a></text>
<text top="299" left="252" width="107" height="20" font="7"><b>Study type:</b> Cross-</text>
<text top="317" left="252" width="129" height="20" font="0">sectional 42 US middle </text>
<text top="334" left="252" width="114" height="20" font="0">schools with student </text>
<text top="351" left="252" width="137" height="20" font="0">populations at increased </text>
<text top="368" left="252" width="131" height="20" font="0">risk for type 2 diabetes, </text>
<text top="386" left="252" width="133" height="20" font="0">i.e., with at least 50% of </text>
<text top="403" left="252" width="148" height="20" font="0">students eligible for free or </text>
<text top="420" left="252" width="126" height="20" font="0">reduced-price lunch or </text>
<text top="437" left="252" width="128" height="20" font="0">belonging to a racial or </text>
<text top="454" left="252" width="124" height="20" font="0">ethnic minority group.  </text>
<text top="472" left="252" width="3" height="20" font="0"> </text>
<text top="489" left="252" width="132" height="20" font="7"><b>Size:</b> 6097 adolescents<b> </b></text>
<text top="299" left="413" width="151" height="20" font="7"><b>Inclusion criteria: </b>10-13 y-</text>
<text top="317" left="413" width="124" height="20" font="0">old with available data </text>
<text top="334" left="413" width="3" height="20" font="0"> </text>
<text top="351" left="413" width="114" height="20" font="7"><b>Exclusion criteria:</b> <b> </b></text>
<text top="301" left="591" width="233" height="20" font="7"><b>1</b>°<b> endpoint:</b> cardio-metabolic risk among </text>
<text top="318" left="591" width="216" height="20" font="0">youth defined as glucose ≥ 100 mg/dL, </text>
<text top="335" left="591" width="221" height="20" font="0">fasting insulin ≥ 30 μU/mL, SBP or DBP </text>
<text top="352" left="591" width="215" height="20" font="0">≥95th percentile, TC ≥200 mg/dL, LDL </text>
<text top="370" left="591" width="219" height="20" font="0">≥130 mg/dL, triglycerides ≥ 130 mg/dL, </text>
<text top="387" left="591" width="115" height="20" font="0">and HDL ≤40 mg/dL </text>
<text top="404" left="591" width="3" height="20" font="0"> </text>
<text top="421" left="591" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="440" left="591" width="7" height="18" font="0">•</text>
<text top="440" left="597" width="215" height="20" font="0"> Discriminatory ability of BMI percentile </text>
<text top="457" left="591" width="177" height="20" font="0">was good (area under the curve </text>
<text top="474" left="591" width="208" height="21" font="0">[AUC] ≥ 0.80) for elevated insulin and </text>
<text top="491" left="591" width="223" height="20" font="0">clustering of ≥3 risk factors, with optimal </text>
<text top="508" left="591" width="204" height="20" font="0">cut-points of 96 and 95, respectively. </text>
<text top="527" left="591" width="7" height="18" font="0">•</text>
<text top="527" left="597" width="207" height="20" font="0"> BMI percentile performed poor to fair </text>
<text top="544" left="591" width="233" height="21" font="0">(AUC = 0.57-0.75) in identifying youth with </text>
<text top="561" left="591" width="219" height="20" font="0">elevated glucose, TC, LDL, BP, TG and </text>
<text top="578" left="591" width="35" height="20" font="0">HDL.  </text>
<text top="597" left="591" width="7" height="18" font="0">•</text>
<text top="597" left="597" width="204" height="20" font="0"> WC percentile and WtHR performed </text>
<text top="614" left="591" width="147" height="20" font="0">similarly to BMI percentile. </text>
<text top="301" left="842" width="7" height="18" font="0">•</text>
<text top="301" left="849" width="156" height="20" font="0"> Obesity defined by BMI ≥95</text>
<text top="302" left="1005" width="7" height="13" font="9">th</text>
<text top="301" left="1012" width="82" height="20" font="0">%tile identifies </text>
<text top="318" left="842" width="248" height="20" font="0">elevated insulin and a clustering of ≥3 cardio-</text>
<text top="335" left="842" width="126" height="20" font="0">metabolic risk factors.  </text>
<text top="375" left="842" width="7" height="18" font="0">•</text>
<text top="374" left="849" width="248" height="20" font="0"> Evidence does not support WC percentile or </text>
<text top="392" left="842" width="245" height="20" font="0">WtHR as superior screening tools compared </text>
<text top="409" left="842" width="222" height="20" font="0">with BMI percentile for identifying cardio-</text>
<text top="426" left="842" width="79" height="20" font="0">metabolic risk </text>
<text top="633" left="88" width="921" height="20" font="7"><b>Abbreviations:</b> 1° indicated primary; CI, confidence interval; HR, hazard ratio; N/A, not available; OR, odds ratio; RCT, randomized controlled trial; and RR, relative risk. </text>
<text top="650" left="88" width="300" height="20" font="7"><b>Search Terms and Date of Search</b>: Author to provide </text>
<text top="667" left="81" width="4" height="22" font="1"> </text>
<text top="686" left="81" width="811" height="24" font="4"><b>Data Supplement 23. Nonrandomized Trials, Observational Studies, and/or Registries of Treatment (Section 4.4.4.3) </b></text>
<text top="708" left="117" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="725" left="143" width="48" height="20" font="7"><b>Author; </b></text>
<text top="742" left="119" width="96" height="20" font="7"><b>Year Published’ </b></text>
<text top="760" left="149" width="34" height="20" font="7"><b>PMID </b></text>
<text top="708" left="269" width="118" height="20" font="7"><b>Study Type/Design; </b></text>
<text top="725" left="295" width="66" height="20" font="7"><b>Study Size </b></text>
<text top="708" left="439" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="708" left="617" width="179" height="20" font="7"><b>Primary Endpoint and Results </b></text>
<text top="725" left="615" width="184" height="20" font="7"><b>(P values; OR or RR; &amp; 95% CI) </b></text>
<text top="708" left="905" width="130" height="20" font="7"><b>Summary/Conclusion </b></text>
<text top="725" left="933" width="75" height="20" font="7"><b>Comment(s) </b></text>
</page>
<page number="135" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">135 </text>
<text top="107" left="91" width="132" height="20" font="0">Braamskamp MJ, et al., </text>
<text top="124" left="91" width="63" height="20" font="0">2015 <a href="data supplement.html#246">(165)</a> </text>
<text top="141" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26079405">26079405</a></text>
<text top="141" left="146" width="3" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26079405"><b> </b></a></text>
<text top="159" left="91" width="3" height="20" font="0"> </text>
<text top="107" left="255" width="74" height="20" font="7"><b>Study type:</b>  </text>
<text top="124" left="255" width="77" height="20" font="0">observational </text>
<text top="141" left="255" width="3" height="20" font="0"> </text>
<text top="159" left="255" width="109" height="20" font="7"><b>Size:</b>  88 cases, 62 </text>
<text top="176" left="255" width="109" height="20" font="0">unaffected siblings  </text>
<text top="107" left="413" width="155" height="20" font="7"><b>Inclusion criteria:</b> Children </text>
<text top="124" left="413" width="111" height="20" font="0">age 8-18 previously </text>
<text top="141" left="413" width="145" height="20" font="0">randomized to pravastatin </text>
<text top="159" left="413" width="157" height="20" font="0">and their unaffected siblings </text>
<text top="176" left="413" width="3" height="20" font="0"> </text>
<text top="193" left="413" width="154" height="20" font="7"><b>Exclusion criteria:</b> Current </text>
<text top="210" left="413" width="53" height="20" font="0">OCP use </text>
<text top="108" left="588" width="226" height="20" font="7"><b>1</b>°<b> endpoint:</b> testosterone, estradiol, LH, </text>
<text top="125" left="588" width="119" height="20" font="0">FSH, DHEAS levels,  </text>
<text top="143" left="588" width="3" height="20" font="0"> </text>
<text top="160" left="588" width="228" height="20" font="7"><b>Results:</b> No difference in hormone levels </text>
<text top="177" left="588" width="183" height="20" font="0">between FH patients treated with </text>
<text top="194" left="588" width="227" height="20" font="0">pravastatin and their unaffected siblings.  </text>
<text top="211" left="588" width="3" height="20" font="0"> </text>
<text top="109" left="839" width="7" height="18" font="0">•</text>
<text top="108" left="845" width="241" height="20" font="0">Statin use in children and adolescents does </text>
<text top="125" left="839" width="241" height="20" font="0">not affect gonadal steroid and gonadotropin </text>
<text top="143" left="839" width="35" height="20" font="0">levels </text>
<text top="160" left="839" width="3" height="20" font="0"> </text>
<text top="229" left="91" width="150" height="20" font="0">Pratt RE, et al., 2014 <a href="data supplement.html#246">(166)</a><b> </b></text>
<text top="247" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24636177">24636177</a></text>
<text top="247" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24636177"> </a></text>
<text top="229" left="255" width="144" height="20" font="7"><b>Study type:</b> retrospective </text>
<text top="247" left="255" width="146" height="20" font="0">review of clinical practice   </text>
<text top="264" left="255" width="3" height="20" font="0"> </text>
<text top="281" left="255" width="96" height="20" font="7"><b>Size:</b> 53 patients </text>
<text top="229" left="413" width="157" height="20" font="7"><b>Inclusion criteria: </b>6 to 18 y </text>
<text top="247" left="413" width="132" height="20" font="0">of age with diagnosis of </text>
<text top="264" left="413" width="128" height="20" font="0">combined dyslipidemia </text>
<text top="281" left="413" width="150" height="20" font="0">cared for in a pediatric lipid </text>
<text top="298" left="413" width="144" height="20" font="0">clinic with at least 2 visits, </text>
<text top="316" left="413" width="142" height="20" font="0">≥2 lipid values exceeding </text>
<text top="333" left="413" width="153" height="20" font="0">the upper limit of normal for </text>
<text top="350" left="413" width="157" height="20" font="0">TC, TG, non-HDL-C, or LDL-</text>
<text top="367" left="413" width="154" height="20" font="0">C ± HDL-C below the lower </text>
<text top="384" left="413" width="87" height="20" font="0">limit of normal.  </text>
<text top="402" left="413" width="3" height="20" font="0"> </text>
<text top="419" left="413" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="231" left="588" width="165" height="20" font="7"><b>1</b>°<b> endpoint:</b> lipid levels, BMI </text>
<text top="248" left="588" width="3" height="20" font="0"> </text>
<text top="265" left="588" width="213" height="20" font="7"><b>Results:</b> mean follow-up 9.2 mo. Lipid </text>
<text top="282" left="588" width="235" height="20" font="0">parameters (mean ± SD, mg/dL) improved </text>
<text top="299" left="588" width="237" height="20" font="0">significantly (p&lt;0.001): TC 209 ± 39 to 181 </text>
<text top="317" left="588" width="232" height="20" font="0">± 32; TG 255 ± 119 to168 ± 99; non-HDL-</text>
<text top="334" left="588" width="230" height="20" font="0">C 167 ± 35 to 138 ± 30 and LDL-C 121 ± </text>
<text top="351" left="588" width="224" height="20" font="0">43 to 106 ± 30. HDL-C was unchanged.  </text>
<text top="370" left="588" width="7" height="18" font="0">•</text>
<text top="370" left="595" width="214" height="20" font="0"> BMI decreased in 58% and mean BMI </text>
<text top="387" left="588" width="190" height="20" font="0">decreased 0.67 kg/m (2) (p&lt;0.05). </text>
<text top="404" left="588" width="3" height="20" font="0"> </text>
<text top="231" left="839" width="7" height="18" font="0">•</text>
<text top="231" left="845" width="215" height="20" font="0"> Focused lifestyle changes significantly </text>
<text top="248" left="839" width="232" height="20" font="0">improved combined dyslipidemia in obese </text>
<text top="265" left="839" width="46" height="20" font="0">children </text>
<text top="284" left="839" width="7" height="18" font="0">•</text>
<text top="283" left="845" width="241" height="20" font="0"> . With no direct weight loss approach, body </text>
<text top="301" left="839" width="171" height="20" font="0">mass index decreased in 58%. </text>
<text top="318" left="839" width="3" height="20" font="0"> </text>
<text top="437" left="91" width="143" height="20" font="0">Zachariah JP, et al., 2016 </text>
<text top="454" left="91" width="32" height="20" font="0"><a href="data supplement.html#246">(167)</a><b> </b></text>
<text top="471" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27810053">27810053</a></text>
<text top="471" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27810053"> </a></text>
<text top="437" left="255" width="144" height="20" font="7"><b>Study type:</b> retrospective </text>
<text top="454" left="255" width="139" height="20" font="0">review of clinical practice </text>
<text top="471" left="255" width="3" height="20" font="0"> </text>
<text top="488" left="255" width="140" height="20" font="7"><b>Size:</b> 501 youth with lipid </text>
<text top="506" left="255" width="61" height="20" font="0">disorders   </text>
<text top="437" left="413" width="146" height="20" font="7"><b>Inclusion criteria;</b> seen a </text>
<text top="454" left="413" width="150" height="20" font="0">preventive cardiology clinic </text>
<text top="471" left="413" width="159" height="20" font="0">for lipid disorder with at least </text>
<text top="488" left="413" width="101" height="20" font="0">one follow-up visit </text>
<text top="506" left="413" width="3" height="20" font="0"> </text>
<text top="523" left="413" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="438" left="588" width="221" height="20" font="7"><b>1</b>°<b> endpoint:</b> change in lipid levels from </text>
<text top="455" left="588" width="129" height="20" font="0">first to most recent visit </text>
<text top="472" left="588" width="3" height="20" font="0"> </text>
<text top="490" left="588" width="240" height="20" font="7"><b>Results:</b> Over a median follow-up of 231 d  </text>
<text top="507" left="588" width="196" height="20" font="0">Depending on baseline lipid levels:  </text>
<text top="524" left="588" width="153" height="20" font="0">LDL decreased 3% to 15%  </text>
<text top="541" left="588" width="144" height="20" font="0">TG decreased 2% to 27% </text>
<text top="558" left="588" width="202" height="20" font="0">HDL increased 9% to decreased 2% </text>
<text top="576" left="588" width="221" height="20" font="0">BMI z-score= -0.05; interquartile range: -</text>
<text top="593" left="588" width="226" height="20" font="0">0.22 to 0.05; p&lt;0.0001; proportion obese </text>
<text top="610" left="588" width="123" height="20" font="0">39% vs. 36%, p=0.03. </text>
<text top="439" left="839" width="7" height="18" font="0">•</text>
<text top="438" left="845" width="252" height="20" font="0"> Lifestyle interventions delivered in a pediatric </text>
<text top="455" left="839" width="258" height="20" font="0">subspecialty lipid clinic can improve lipid levels </text>
<text top="474" left="839" width="7" height="18" font="0">•</text>
<text top="473" left="845" width="248" height="20" font="0"> Change in BMI explained some but not all of </text>
<text top="491" left="839" width="245" height="20" font="0">the improvements (moderately elevated LDL </text>
<text top="508" left="839" width="145" height="20" font="0">and elevated TG patients) </text>
<text top="629" left="88" width="921" height="20" font="7"><b>Abbreviations:</b> 1° indicated primary; CI, confidence interval; HR, hazard ratio; N/A, not available; OR, odds ratio; RCT, randomized controlled trial; and RR, relative risk. </text>
<text top="646" left="88" width="300" height="20" font="7"><b>Search Terms and Date of Search</b>: Author to provide </text>
<text top="663" left="81" width="4" height="22" font="1"> </text>
<text top="682" left="81" width="853" height="24" font="4"><b>Data Supplement 24. Nonrandomized Trials, observational studies and / Registries for African Americans. (Section 4.5.1)  </b></text>
<text top="704" left="94" width="176" height="20" font="7"><b>Study Acronym; Author; Year </b></text>
<text top="721" left="151" width="62" height="20" font="7"><b>Published </b></text>
<text top="704" left="300" width="159" height="20" font="7"><b>Study Type /Design; Study </b></text>
<text top="721" left="365" width="28" height="20" font="7"><b>Size </b></text>
<text top="704" left="521" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="704" left="686" width="230" height="20" font="7"><b>Primary Endpoint and Results (include </b></text>
<text top="721" left="714" width="174" height="20" font="7"><b>P value; OR or RR; &amp; 95% CI) </b></text>
<text top="704" left="959" width="133" height="20" font="7"><b>Summary /Conclusion </b></text>
<text top="721" left="988" width="75" height="20" font="7"><b>Comment(s) </b></text>
<text top="739" left="89" width="153" height="20" font="0">Muntner P, et al., 2014 <a href="data supplement.html#240">(81)</a> </text>
<text top="756" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24682252">24682252</a></text>
<text top="756" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24682252"> </a></text>
<text top="773" left="89" width="3" height="20" font="0"> </text>
<text top="739" left="287" width="177" height="20" font="7"><b>AIM:</b> Assess the calibration and </text>
<text top="756" left="287" width="165" height="20" font="0">discrimination of the PCE in a </text>
<text top="773" left="287" width="140" height="20" font="0">contemporary US cohort.<b> </b></text>
<text top="739" left="485" width="172" height="20" font="0">REGARDS study: 45-79 y old.  </text>
<text top="756" left="485" width="177" height="20" font="7"><b>Inclusion</b>: Regards participants </text>
<text top="773" left="485" width="154" height="20" font="0">with characteristic similar to </text>
<text top="739" left="682" width="176" height="20" font="7"><b>Primary Outcome: </b>adjudicated </text>
<text top="756" left="682" width="219" height="20" font="0">atherosclerotic CVD incidence (nonfatal </text>
<text top="773" left="682" width="203" height="20" font="0">myocardial infarction, coronary heart </text>
<text top="739" left="933" width="171" height="20" font="0">The Pooled Cohort Equation is </text>
<text top="756" left="933" width="136" height="20" font="0">well calibrated in African </text>
<text top="773" left="933" width="150" height="20" font="0">Americans and Whites and </text>
</page>
<page number="136" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">136 </text>
<text top="107" left="287" width="3" height="20" font="7"><b> </b></text>
<text top="124" left="287" width="181" height="20" font="7"><b>Study Type</b>: Prospective study   </text>
<text top="141" left="287" width="3" height="20" font="0"> </text>
<text top="159" left="287" width="179" height="20" font="7"><b>Study Size:</b> N= 10,997 ( African </text>
<text top="176" left="287" width="111" height="20" font="0">Americans = 7,705) </text>
<text top="107" left="485" width="177" height="20" font="0">participants used to develop the </text>
<text top="124" left="485" width="134" height="20" font="0">Pooled Cohort Equation </text>
<text top="141" left="485" width="3" height="20" font="0"> </text>
<text top="159" left="485" width="117" height="20" font="0"> <b>Exclusion</b>: h/o prior </text>
<text top="176" left="485" width="166" height="20" font="0">atherosclerotic cardiovascular </text>
<text top="193" left="485" width="175" height="20" font="0">disease (ASCVD) or DM, LDLC </text>
<text top="210" left="485" width="170" height="20" font="0">≥190mg/dl and not on statin at </text>
<text top="228" left="485" width="49" height="20" font="0">baseline </text>
<text top="245" left="485" width="3" height="20" font="0"> </text>
<text top="262" left="485" width="3" height="20" font="0"> </text>
<text top="107" left="682" width="209" height="20" font="0">disease [CHD] death, nonfatal or fatal </text>
<text top="124" left="682" width="75" height="20" font="0">stroke) at 5 y<b> </b></text>
<text top="141" left="682" width="209" height="20" font="7"><b>Results:</b> Observed and Predicted 5-y </text>
<text top="159" left="682" width="200" height="20" font="0">ASCVD incidence /1000-person y of </text>
<text top="176" left="682" width="222" height="20" font="0">persons with 10y predicted ASCVD risk: </text>
<text top="193" left="682" width="150" height="20" font="0">&lt;5% = 1.9(1.3-2.7) and 1.9 </text>
<text top="210" left="682" width="165" height="20" font="0">5-7.5% = 4.8(3.4-6.7) and 4.8 </text>
<text top="228" left="682" width="171" height="20" font="0">7.5-10% = 6.1(4.4-8.6) and 6.9 </text>
<text top="245" left="682" width="185" height="20" font="0">&gt;10% = 12.0(10.6-13.6) and 15.1 </text>
<text top="262" left="682" width="234" height="20" font="0">(Hosmer-Lemeshow χ2 = 19.9, p=0.01). C-</text>
<text top="279" left="682" width="195" height="20" font="0">statistics =0.72; 95% CI: 0.70-0.75. </text>
<text top="296" left="682" width="233" height="20" font="0">Medicare Linked: Observed and Predicted </text>
<text top="314" left="682" width="221" height="20" font="0">5-y ASCVD incidence /1000-person y of </text>
<text top="331" left="682" width="222" height="20" font="0">persons with 10y predicted ASCVD risk: </text>
<text top="348" left="682" width="164" height="20" font="0">&lt;7.5%= 5.3(2.8-10.1) and 4.0 </text>
<text top="365" left="682" width="175" height="20" font="0">7.5-10% = 7.9(4.6-13.5)and 6.4 </text>
<text top="383" left="682" width="202" height="20" font="0">≥10% = 17.4(15.3-19.8) and 16.4. C-</text>
<text top="400" left="682" width="155" height="20" font="0">statistics of 0.67(0.64-0.71). </text>
<text top="417" left="682" width="207" height="20" font="0">(Hosmer-Lemeshow χ2 = 5.4, p=0.71 </text>
<text top="434" left="682" width="3" height="20" font="0"> </text>
<text top="107" left="933" width="172" height="20" font="0">demonstrate moderate to good </text>
<text top="124" left="933" width="82" height="20" font="0">discrimination. </text>
<text top="452" left="89" width="141" height="20" font="0">Fox ER, et al., 2016<a href="data supplement.html#246">(168)</a> </text>
<text top="469" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27437649">27437649</a></text>
<text top="469" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27437649"> </a></text>
<text top="487" left="89" width="3" height="20" font="0"> </text>
<text top="452" left="287" width="169" height="20" font="7"><b>Aim: </b>develop and validate risk </text>
<text top="469" left="287" width="147" height="20" font="0">prediction models for CVD </text>
<text top="487" left="287" width="140" height="20" font="0">incidence in black adults, </text>
<text top="504" left="287" width="148" height="20" font="0">incorporating standard risk </text>
<text top="521" left="287" width="135" height="20" font="0">factors, biomarkers, and </text>
<text top="538" left="287" width="109" height="20" font="0">subclinical disease.<b> </b></text>
<text top="555" left="287" width="3" height="20" font="7"><b> </b></text>
<text top="573" left="287" width="174" height="20" font="7"><b>Study Type: </b>Prospective study </text>
<text top="590" left="287" width="3" height="20" font="0"> </text>
<text top="607" left="287" width="161" height="20" font="7"><b>Study Size:</b> N= 3689 African </text>
<text top="624" left="287" width="62" height="20" font="0">Americans<b> </b></text>
<text top="641" left="287" width="3" height="20" font="7"><b> </b></text>
<text top="452" left="485" width="120" height="20" font="0">Jackson Heart Study. </text>
<text top="469" left="485" width="3" height="20" font="0"> </text>
<text top="487" left="485" width="182" height="20" font="7"><b>Inclusion:</b> Participants who JHS </text>
<text top="504" left="485" width="138" height="20" font="0">examination # 1 and had </text>
<text top="521" left="485" width="178" height="20" font="0">available data on key covariates </text>
<text top="538" left="485" width="181" height="20" font="0">considered for prediction models </text>
<text top="452" left="682" width="235" height="20" font="7"><b>Primary Endpoint</b>: First occurrence of MI, </text>
<text top="469" left="682" width="230" height="20" font="0">CHD death, CHF, stroke, incident angina, </text>
<text top="487" left="682" width="150" height="20" font="0">or intermittent claudication. </text>
<text top="504" left="682" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="521" left="682" width="237" height="20" font="0">C- Statistics of the Pooled Cohort Equation </text>
<text top="538" left="682" width="210" height="20" font="0">= 0.75(0.71-0.79). The event and Non-</text>
<text top="555" left="682" width="76" height="20" font="0">Event NRI of: </text>
<text top="573" left="682" width="224" height="20" font="0"> PCE vs. Model 1: were 0.016 and 0.007 </text>
<text top="590" left="682" width="214" height="20" font="0">PCE vs. Model 6: were 0.00 and 0.024 </text>
<text top="452" left="933" width="158" height="20" font="0">The Pooled Cohort Equation </text>
<text top="469" left="933" width="182" height="20" font="0">(PCE) has good discrimination in </text>
<text top="487" left="933" width="131" height="20" font="0">African Americans. The </text>
<text top="504" left="933" width="176" height="20" font="0">discriminative ability of the PCE </text>
<text top="521" left="933" width="162" height="20" font="0">in African Americans was not </text>
<text top="538" left="933" width="170" height="20" font="0">improved by the 6 models built </text>
<text top="555" left="933" width="178" height="20" font="0">and validated in this study using </text>
<text top="573" left="933" width="139" height="20" font="0">other subclinical markers </text>
<text top="659" left="89" width="167" height="20" font="0">George MD, et al., 2016 <a href="data supplement.html#246">(169)</a> </text>
<text top="677" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27537560">27537560</a></text>
<text top="677" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27537560"> </a></text>
<text top="694" left="89" width="7" height="20" font="0">  </text>
<text top="659" left="287" width="163" height="20" font="7"><b>Aim: </b>Evaluate clinical factors </text>
<text top="677" left="287" width="149" height="20" font="0">associated with CK among </text>
<text top="694" left="287" width="141" height="20" font="0">healthy individuals and to </text>
<text top="711" left="287" width="151" height="20" font="0">develop practical reference </text>
<text top="728" left="287" width="174" height="20" font="0">ranges for important subgroups </text>
<text top="745" left="287" width="159" height="20" font="0">to improve test interpretation </text>
<text top="763" left="287" width="3" height="20" font="0"> </text>
<text top="780" left="287" width="165" height="20" font="7"><b>Study Type</b>: Cross-sectional  </text>
<text top="659" left="485" width="161" height="20" font="0">National Health and Nutrition </text>
<text top="677" left="485" width="175" height="20" font="0">Examination Survey (NHANES) </text>
<text top="694" left="485" width="72" height="20" font="0">2011–2014.  </text>
<text top="711" left="485" width="3" height="20" font="0"> </text>
<text top="728" left="485" width="175" height="20" font="7"><b>Exclusion</b>: Pregnant, &lt;20y old, </text>
<text top="745" left="485" width="173" height="20" font="0">strenuous exercise in the last 3 </text>
<text top="763" left="485" width="14" height="20" font="0">d. </text>
<text top="780" left="485" width="3" height="20" font="0"> </text>
<text top="659" left="682" width="143" height="20" font="7"><b>Primary Outcome:</b> None<b> </b></text>
<text top="677" left="682" width="3" height="20" font="7"><b> </b></text>
<text top="694" left="682" width="232" height="20" font="7"><b>Results:</b> Provided data on 90%, 95% and </text>
<text top="711" left="682" width="228" height="20" font="0">97.5% percentile and their corresponding </text>
<text top="728" left="682" width="116" height="20" font="0">confidence intervals. </text>
<text top="745" left="682" width="81" height="20" font="0">             Males </text>
<text top="763" left="682" width="70" height="20" font="0">Race        95</text>
<text top="764" left="752" width="11" height="13" font="9">TH</text>
<text top="763" left="763" width="34" height="20" font="0"> %tile </text>
<text top="780" left="682" width="129" height="20" font="0">White      312(268,356) </text>
<text top="659" left="933" width="170" height="20" font="0">African Americans have a high </text>
<text top="677" left="933" width="170" height="20" font="0">CK levels compared with other </text>
<text top="694" left="933" width="160" height="20" font="0">race/ethnic groups. The 95th </text>
<text top="711" left="933" width="116" height="20" font="0">percentile or the 97.5</text>
<text top="713" left="1049" width="7" height="13" font="9">th</text>
<text top="711" left="1055" width="39" height="20" font="0"> in sex </text>
<text top="728" left="933" width="156" height="20" font="0">and race specific subgroups </text>
<text top="745" left="933" width="161" height="20" font="0">provides a practical guide for </text>
<text top="763" left="933" width="174" height="20" font="0">clinicians interpreting CK levels </text>
</page>
<page number="137" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">137 </text>
<text top="107" left="287" width="3" height="20" font="0"> </text>
<text top="124" left="287" width="164" height="20" font="0">Study Size: N = 10,096 (3156 </text>
<text top="141" left="287" width="177" height="20" font="0">used to derive the race/ethnicity </text>
<text top="159" left="287" width="152" height="20" font="0">and sex specific normal CK </text>
<text top="176" left="287" width="39" height="20" font="0">levels)<b> </b></text>
<text top="107" left="485" width="124" height="20" font="7"><b>Note:</b> thyroid disease, </text>
<text top="124" left="485" width="172" height="20" font="0">cholesterol medications, heavy </text>
<text top="141" left="485" width="139" height="20" font="0">alcohol use not excluded </text>
<text top="159" left="485" width="127" height="20" font="0">because they were not </text>
<text top="176" left="485" width="173" height="20" font="0">associated with higher levels in </text>
<text top="193" left="485" width="170" height="20" font="0">their models. Exclusion did not </text>
<text top="210" left="485" width="135" height="20" font="0">substantially change the </text>
<text top="228" left="485" width="116" height="20" font="0">percentile estimates. </text>
<text top="107" left="682" width="131" height="20" font="0">Black       712(530,894) </text>
<text top="124" left="682" width="141" height="20" font="0">Hispanic    394(258, 530) </text>
<text top="141" left="682" width="128" height="20" font="0">Asian      378(185,571) </text>
<text top="159" left="682" width="3" height="20" font="0"> </text>
<text top="176" left="682" width="95" height="20" font="0">             Females </text>
<text top="193" left="682" width="92" height="20" font="0">              95%tile </text>
<text top="210" left="682" width="129" height="20" font="0">White      188(122,254) </text>
<text top="228" left="682" width="127" height="20" font="0">Black      323(218,428) </text>
<text top="245" left="682" width="134" height="20" font="0">Hispanic   207(176,238) </text>
<text top="262" left="682" width="128" height="20" font="0">Asian      162(139,185) </text>
<text top="279" left="682" width="3" height="20" font="0"> </text>
<text top="297" left="89" width="155" height="20" font="0">Yeboah J, et al., 2016 <a href="data supplement.html#242">(100)</a> </text>
<text top="314" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26791059">26791059</a></text>
<text top="314" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26791059"> </a></text>
<text top="297" left="287" width="167" height="20" font="7"><b>Aim: </b>To assess the predictive </text>
<text top="314" left="287" width="164" height="20" font="0">accuracy and improvement in </text>
<text top="332" left="287" width="161" height="20" font="0">reclassification gained by the </text>
<text top="349" left="287" width="167" height="20" font="0">addition of the coronary artery </text>
<text top="366" left="287" width="145" height="20" font="0">calcium <a href="data supplement.html#244">(133)</a> score to the </text>
<text top="383" left="287" width="167" height="20" font="0">Pooled Cohort Equation in the </text>
<text top="400" left="287" width="115" height="20" font="0">Multi Ethnic Study of </text>
<text top="418" left="287" width="137" height="20" font="0">Atherosclerosis (MESA).<b> </b></text>
<text top="435" left="287" width="3" height="20" font="7"><b> </b></text>
<text top="452" left="287" width="179" height="20" font="7"><b>Study Type: </b>Prospective cohort </text>
<text top="469" left="287" width="35" height="20" font="0">Study </text>
<text top="487" left="287" width="3" height="20" font="0"> </text>
<text top="504" left="287" width="155" height="20" font="7"><b>Study Size:</b> N=5,185( 1402 </text>
<text top="521" left="287" width="137" height="20" font="0">were African Americans)<b> </b></text>
<text top="297" left="485" width="173" height="20" font="0">MESA participants were free of </text>
<text top="314" left="485" width="182" height="20" font="0">clinical cardiovascular disease at </text>
<text top="332" left="485" width="49" height="20" font="0">baseline </text>
<text top="349" left="485" width="3" height="20" font="0"> </text>
<text top="366" left="485" width="183" height="20" font="7"><b>Inclusion:</b> All MESA participants </text>
<text top="383" left="485" width="152" height="20" font="0">age 40-75y during baseline </text>
<text top="400" left="485" width="161" height="20" font="0">exam and has complete data </text>
<text top="418" left="485" width="3" height="20" font="0"> </text>
<text top="435" left="485" width="157" height="20" font="7"><b>Exclusion: </b>Older than 75 y, </text>
<text top="452" left="485" width="185" height="20" font="0">missing data, those taking statins </text>
<text top="469" left="485" width="181" height="20" font="0">during the baseline examination. </text>
<text top="297" left="682" width="186" height="20" font="7"><b>Primary Outcome: </b>Composite of </text>
<text top="314" left="682" width="203" height="20" font="0">myocardial infarction, coronary heart </text>
<text top="332" left="682" width="230" height="20" font="0">disease–related death, or fatal or nonfatal </text>
<text top="349" left="682" width="37" height="20" font="0">stroke<b> </b></text>
<text top="366" left="682" width="195" height="20" font="7"><b>Results: </b>CAC was an independent </text>
<text top="383" left="682" width="231" height="20" font="0">predictor of atherosclerotic cardiovascular </text>
<text top="400" left="682" width="97" height="20" font="0">(ASCVD) events. </text>
<text top="418" left="682" width="209" height="20" font="0">HR(95%CI): 1.58(1.40-1.79), p&lt;0.001 </text>
<text top="435" left="682" width="201" height="20" font="0">CAC improved the C statistics of the </text>
<text top="452" left="682" width="211" height="20" font="0">calibrated PCE: 0.74 vs. 0.76, p=0.04. </text>
<text top="469" left="682" width="228" height="20" font="0">CAC improved Net<b> </b>Reclassification Index </text>
<text top="487" left="682" width="40" height="20" font="0">(NRI):  </text>
<text top="504" left="682" width="222" height="20" font="0">Event NRI: 0.178(0.080-0.256) and Non-</text>
<text top="521" left="682" width="183" height="20" font="0">Event NRI: -0.059(-0.075-0.030).<b> </b></text>
<text top="297" left="933" width="172" height="20" font="0">In this Multi-Ethic Cohort which </text>
<text top="314" left="933" width="156" height="20" font="0">included African Americans, </text>
<text top="332" left="933" width="152" height="20" font="0">CAC improved ASCVD risk </text>
<text top="349" left="933" width="73" height="20" font="0">assessment. </text>
<text top="539" left="89" width="172" height="20" font="0">Paixao ARM, et al., 2015 <a href="data supplement.html#246">(170)</a> </text>
<text top="556" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26476504">26476504</a></text>
<text top="556" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26476504"> </a></text>
<text top="573" left="89" width="3" height="20" font="11"> </text>
<text top="573" left="93" width="3" height="20" font="0"> </text>
<text top="539" left="287" width="161" height="20" font="7"><b>Aim : </b>To assess the effect of </text>
<text top="556" left="287" width="181" height="20" font="0">coronary artery calcium <a href="data supplement.html#244">(133)</a> on </text>
<text top="573" left="287" width="151" height="20" font="0">coronary heart disease risk </text>
<text top="591" left="287" width="128" height="20" font="0">prediction in a younger </text>
<text top="608" left="287" width="60" height="20" font="0">population<b> </b></text>
<text top="625" left="287" width="3" height="20" font="7"><b> </b></text>
<text top="642" left="287" width="176" height="20" font="7"><b>Study type: </b>Prospective cohort </text>
<text top="659" left="287" width="33" height="20" font="0">study<b> </b></text>
<text top="677" left="287" width="3" height="20" font="7"><b> </b></text>
<text top="694" left="287" width="175" height="20" font="7"><b>Study Size:</b> N=2084( 956 were </text>
<text top="711" left="287" width="107" height="20" font="0">African Americans)<b> </b></text>
<text top="539" left="485" width="157" height="20" font="0">DHS (Dallas Heart Study), a </text>
<text top="556" left="485" width="159" height="20" font="0">multiethnic probability-based </text>
<text top="573" left="485" width="154" height="20" font="0">population sample of Dallas </text>
<text top="591" left="485" width="163" height="20" font="0">County Adults with deliberate </text>
<text top="608" left="485" width="132" height="20" font="0">oversampling of African </text>
<text top="625" left="485" width="65" height="20" font="0">Americans. </text>
<text top="642" left="485" width="3" height="20" font="0"> </text>
<text top="659" left="485" width="183" height="20" font="7"><b>Inclusion:</b> All participants free of </text>
<text top="677" left="485" width="152" height="20" font="0">cardiovascular disease and </text>
<text top="694" left="485" width="95" height="20" font="0">diabetes mellitus </text>
<text top="711" left="485" width="3" height="20" font="0"> </text>
<text top="728" left="485" width="173" height="20" font="7"><b>Exclusion:</b> Uninterpretable CT </text>
<text top="745" left="485" width="159" height="20" font="0">scans, prior CHD, End stage </text>
<text top="763" left="485" width="156" height="20" font="0">renal disease, missing data, </text>
<text top="539" left="682" width="211" height="20" font="7"><b>Primary outcome: </b>composite of CHD </text>
<text top="556" left="682" width="209" height="20" font="0">death, myocardial infarction, coronary </text>
<text top="573" left="682" width="223" height="20" font="0">revascularization after 9.2 y of follow up. </text>
<text top="591" left="682" width="3" height="20" font="0"> </text>
<text top="608" left="682" width="140" height="20" font="7"><b>Results:</b> Mean age 44 y. </text>
<text top="625" left="682" width="238" height="20" font="0">CAC was an independent predictor of CHD </text>
<text top="642" left="682" width="43" height="20" font="0">events: </text>
<text top="659" left="682" width="217" height="20" font="0">HR: 1.90; 95%CI: 1.51-2.38; p&lt;0.0001. </text>
<text top="677" left="682" width="231" height="20" font="0">CAC improved the C statistics of the base </text>
<text top="694" left="682" width="231" height="20" font="0">traditional risk factor model: 0.86(0.83-91) </text>
<text top="711" left="682" width="158" height="20" font="0">vs. 0.89(0.86-0.93), p=0.03.  </text>
<text top="728" left="682" width="236" height="20" font="0">CAC also improved the Net reclassification </text>
<text top="745" left="682" width="210" height="20" font="0">index of the base model. NRI = 0.216, </text>
<text top="763" left="682" width="48" height="20" font="0">p=0.012 </text>
<text top="780" left="682" width="3" height="20" font="7"><b> </b></text>
<text top="539" left="933" width="166" height="20" font="0">CAC improved coronary heart </text>
<text top="556" left="933" width="177" height="20" font="0">disease risk classification in this </text>
<text top="573" left="933" width="152" height="20" font="0">multi-ethnic younger cohort </text>
<text top="591" left="933" width="134" height="20" font="0">( included ~46% African </text>
<text top="608" left="933" width="66" height="20" font="0">Americans) </text>
</page>
<page number="138" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">138 </text>
<text top="107" left="485" width="166" height="20" font="0">incomplete follow up data and </text>
<text top="124" left="485" width="98" height="20" font="0">diabetes mellitus. </text>
<text top="142" left="89" width="136" height="20" font="0">Carr JJ, et al., 2017 <a href="data supplement.html#241">(87)</a> </text>
<text top="159" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28196265">28196265</a></text>
<text top="159" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28196265"> </a></text>
<text top="142" left="287" width="158" height="20" font="7"><b>Aim: </b>To determine if CAC in </text>
<text top="159" left="287" width="137" height="20" font="0">adults aged 32 to 46 y is </text>
<text top="177" left="287" width="174" height="20" font="0">associated with incident clinical </text>
<text top="194" left="287" width="143" height="20" font="0">CHD, CVD, and all-cause </text>
<text top="211" left="287" width="173" height="20" font="0">mortality during 12.5 y of follow-</text>
<text top="228" left="287" width="17" height="20" font="0">up<b> </b></text>
<text top="245" left="287" width="3" height="20" font="7"><b> </b></text>
<text top="263" left="287" width="176" height="20" font="7"><b>Study type: </b>Prospective cohort </text>
<text top="280" left="287" width="33" height="20" font="0">study </text>
<text top="297" left="287" width="3" height="20" font="0"> </text>
<text top="314" left="287" width="172" height="20" font="7"><b>Study Size</b>: N= 3980 had CAC </text>
<text top="332" left="287" width="150" height="20" font="0">ever measured (1918 were </text>
<text top="349" left="287" width="105" height="20" font="0">African American).<b> </b></text>
<text top="142" left="485" width="142" height="20" font="0">The Coronary Artery Risk </text>
<text top="159" left="485" width="165" height="20" font="0">Development in Young Adults </text>
<text top="177" left="485" width="168" height="20" font="0"><a href="data supplement.html#246">(171)</a> study enrolled black and </text>
<text top="194" left="485" width="175" height="20" font="0">white men and women aged 18-</text>
<text top="211" left="485" width="141" height="20" font="0">30 y from 3/1985-6/1986. </text>
<text top="228" left="485" width="3" height="20" font="0"> </text>
<text top="246" left="485" width="170" height="20" font="7"><b>Inclusion</b>: All participants who </text>
<text top="263" left="485" width="180" height="20" font="0">had CT scanning in the CARDIA </text>
<text top="280" left="485" width="33" height="20" font="0">study </text>
<text top="297" left="485" width="3" height="20" font="0"> </text>
<text top="314" left="485" width="159" height="20" font="7"><b>Exclusion:</b> Participants who </text>
<text top="332" left="485" width="106" height="20" font="0">died before their 15</text>
<text top="333" left="591" width="7" height="13" font="9">th</text>
<text top="332" left="597" width="68" height="20" font="0"> recruitment </text>
<text top="349" left="485" width="141" height="20" font="0">anniversary, unable to be </text>
<text top="366" left="485" width="178" height="20" font="0">contacted, never had a CT scan </text>
<text top="383" left="485" width="146" height="20" font="0">and those ineligible for CT </text>
<text top="400" left="485" width="170" height="20" font="0">scanning: i.e. pregnant, weight </text>
<text top="418" left="485" width="170" height="20" font="0">above the limit for the CT scan </text>
<text top="435" left="485" width="33" height="20" font="0">table. </text>
<text top="142" left="682" width="234" height="20" font="7"><b>Primary outcome:</b> Incident CHD included </text>
<text top="159" left="682" width="208" height="20" font="0">fatal or nonfatal myocardial infarction, </text>
<text top="177" left="682" width="185" height="20" font="0">acute coronary syndrome without </text>
<text top="194" left="682" width="171" height="20" font="0">myocardial infarction, coronary </text>
<text top="211" left="682" width="228" height="20" font="0">revascularization, or CHD death. Incident </text>
<text top="228" left="682" width="224" height="20" font="0">CVD included CHD, stroke, heart failure, </text>
<text top="246" left="682" width="209" height="20" font="0">and peripheral arterial disease. Death </text>
<text top="263" left="682" width="111" height="20" font="0">included all causes. </text>
<text top="280" left="682" width="3" height="20" font="0"> </text>
<text top="297" left="682" width="195" height="20" font="7"><b>Results:</b> 57 CHD, 108 CVD events </text>
<text top="314" left="682" width="51" height="20" font="0">occurred </text>
<text top="332" left="682" width="95" height="20" font="0">CAC vs. CAC=0: </text>
<text top="349" left="682" width="196" height="20" font="0">For CHD: HR: 5.0; 95% CI: 2.8-8.7; </text>
<text top="366" left="682" width="48" height="20" font="0">p&lt;0.001 </text>
<text top="383" left="682" width="153" height="20" font="0">Similar association for CVD </text>
<text top="401" left="682" width="227" height="20" font="0">For all- cause mortality: HR: 1.6; 95% CI: </text>
<text top="418" left="682" width="87" height="20" font="0">1.0-2.6; p=0.05 </text>
<text top="435" left="682" width="3" height="20" font="7"><b> </b></text>
<text top="142" left="933" width="163" height="20" font="0">The presence of CAC among </text>
<text top="159" left="933" width="152" height="20" font="0">individuals aged 32-46 was </text>
<text top="177" left="933" width="168" height="20" font="0">independently associated with </text>
<text top="194" left="933" width="180" height="20" font="0">incident CHD, CVD and death in </text>
<text top="211" left="933" width="144" height="20" font="0">this cohort which included </text>
<text top="228" left="933" width="107" height="20" font="0">African Americans. </text>
<text top="459" left="81" width="5" height="16" font="15"> </text>
<text top="480" left="81" width="5" height="16" font="15"> </text>
<text top="494" left="81" width="1001" height="24" font="4"><b>Data Supplement 25. Nonrandomized Trials, Observational Studies, and/or Registries of Pooled Cohorts Equation Risk Estimation in Adults of </b></text>
<text top="515" left="81" width="210" height="24" font="4"><b>Asian Descent (Section 4.5.1) </b></text>
<text top="545" left="133" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="562" left="158" width="48" height="20" font="7"><b>Author; </b></text>
<text top="580" left="136" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="545" left="318" width="38" height="20" font="7"><b>Study </b></text>
<text top="562" left="296" width="81" height="20" font="7"><b>Type/Design; </b></text>
<text top="580" left="304" width="66" height="20" font="7"><b>Study Size </b></text>
<text top="562" left="456" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="554" left="705" width="179" height="20" font="7"><b>Primary Endpoint and Results </b></text>
<text top="571" left="702" width="184" height="20" font="7"><b>(P values; OR or RR; &amp; 95% CI) </b></text>
<text top="554" left="977" width="130" height="20" font="7"><b>Summary/Conclusion </b></text>
<text top="571" left="1004" width="75" height="20" font="7"><b>Comment(s) </b></text>
<text top="598" left="91" width="146" height="20" font="0">Cho YK, et al., 2016 <a href="data supplement.html#246">(172)</a> </text>
<text top="615" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27543305">27543305</a></text>
<text top="615" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27543305"> </a></text>
<text top="632" left="91" width="3" height="20" font="0"> </text>
<text top="598" left="286" width="74" height="20" font="7"><b>Study type:</b>  </text>
<text top="615" left="286" width="78" height="20" font="0">Retrospective </text>
<text top="632" left="286" width="70" height="20" font="0">cohort study </text>
<text top="649" left="286" width="3" height="20" font="0"> </text>
<text top="667" left="286" width="70" height="20" font="7"><b>Size:</b>  1,246 </text>
<text top="684" left="286" width="97" height="20" font="0">1019 male (82%)<b> </b></text>
<text top="598" left="400" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="615" left="400" width="113" height="20" font="0">Adults aged 20-79 y </text>
<text top="632" left="400" width="3" height="20" font="0"> </text>
<text top="649" left="400" width="3" height="20" font="0"> </text>
<text top="667" left="400" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="684" left="400" width="137" height="20" font="0">CVD; Prescribed statins  </text>
<text top="701" left="400" width="3" height="20" font="0"> </text>
<text top="718" left="400" width="7" height="20" font="0"> <b> </b></text>
<text top="599" left="636" width="294" height="20" font="7"><b>1</b>°<b> endpoint:</b> Risk Assessment and CAC progression </text>
<text top="616" left="636" width="3" height="20" font="0"> </text>
<text top="633" left="636" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="650" left="636" width="290" height="20" font="0">The 10-y FRS and 10-y PCE score were significantly </text>
<text top="668" left="636" width="265" height="20" font="0">higher in CAC progressors than nonprogressors </text>
<text top="685" left="636" width="3" height="20" font="7"><b> </b></text>
<text top="702" left="636" width="295" height="20" font="0">Individuals with PCE score ≥7.5% were more likely to </text>
<text top="719" left="636" width="144" height="20" font="0">have progression of CAC  </text>
<text top="737" left="636" width="3" height="20" font="0"> </text>
<text top="754" left="636" width="306" height="20" font="0">When compared to those recommended to take a statin </text>
<text top="771" left="636" width="277" height="20" font="0">under ATP III guideline, subjects considered statin </text>
<text top="788" left="636" width="299" height="20" font="0">eligible by PCE had a higher OR for CAC progression: </text>
<text top="598" left="967" width="129" height="20" font="0">The PCE predicts CAC </text>
<text top="615" left="967" width="124" height="20" font="0">score progression in a </text>
<text top="632" left="967" width="110" height="20" font="0">Korean population.  </text>
</page>
<page number="139" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">139 </text>
<text top="107" left="636" width="297" height="20" font="0">2.73 (95% CI: 2.07– 3.61) versus 2.00 (95% CI: 1.49– </text>
<text top="124" left="636" width="38" height="20" font="0">2.68).  </text>
<text top="141" left="636" width="3" height="20" font="0"> </text>
<text top="159" left="636" width="295" height="20" font="0">The PCE predicted CAC progression more accurately </text>
<text top="176" left="636" width="198" height="20" font="0">than the ATP III guideline (p=0.006) </text>
<text top="194" left="91" width="144" height="20" font="0">Rana JS, et al., 2016 <a href="data supplement.html#241">(83)</a> </text>
<text top="211" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27151343">27151343</a></text>
<text top="211" left="146" width="3" height="20" font="11"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27151343"> </a></text>
<text top="228" left="91" width="3" height="20" font="0"> </text>
<text top="194" left="286" width="74" height="20" font="7"><b>Study type:</b>  </text>
<text top="211" left="286" width="78" height="20" font="0">Retrospective </text>
<text top="228" left="286" width="70" height="20" font="0">cohort study </text>
<text top="245" left="286" width="3" height="20" font="0"> </text>
<text top="263" left="286" width="84" height="20" font="7"><b>Size:</b>  307,591 </text>
<text top="280" left="286" width="41" height="20" font="0">52,917 </text>
<text top="297" left="286" width="74" height="20" font="0">Asian/Pacific </text>
<text top="314" left="286" width="47" height="20" font="0">Islander<b> </b></text>
<text top="194" left="400" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="211" left="400" width="212" height="20" font="0">Adults aged ≥21 y; LDL 70-189 mg/dL </text>
<text top="228" left="400" width="3" height="20" font="0"> </text>
<text top="245" left="400" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="263" left="400" width="171" height="20" font="0">Unknown sex or race/ethnicity; </text>
<text top="280" left="400" width="222" height="20" font="0">Prescribed statins or other lipid-lowering </text>
<text top="297" left="400" width="200" height="20" font="0">therapies within 5 y before the index </text>
<text top="314" left="400" width="27" height="20" font="0">date </text>
<text top="332" left="400" width="162" height="20" font="0">Prior hospitalization for acute </text>
<text top="349" left="400" width="211" height="20" font="0">myocardial infarction, ischemic stroke, </text>
<text top="366" left="400" width="207" height="20" font="0">or receipt of CABG or PCI; &lt;12 mo of </text>
<text top="383" left="400" width="215" height="20" font="0">continuous membership and pharmacy </text>
<text top="400" left="400" width="218" height="20" font="0">benefit before the index date (to ensure </text>
<text top="418" left="400" width="206" height="20" font="0">more complete information on clinical </text>
<text top="435" left="400" width="200" height="20" font="0">characteristics; &lt;5 y of complete f/u, </text>
<text top="452" left="400" width="201" height="20" font="0">except if due to death; Missing SBP, </text>
<text top="469" left="400" width="220" height="20" font="0">TC, or HDL data; Patients who received </text>
<text top="487" left="400" width="187" height="20" font="0">statins during follow-up if used for </text>
<text top="504" left="400" width="192" height="20" font="0">primary prevention of ASCVD (i.e., </text>
<text top="521" left="400" width="198" height="20" font="0">statin initiated before a documented </text>
<text top="538" left="400" width="87" height="20" font="0">ASCVD event) <b> </b></text>
<text top="195" left="636" width="177" height="20" font="7"><b>1</b>°<b> endpoint:</b> Risk Assessment  </text>
<text top="212" left="636" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="229" left="636" width="314" height="20" font="0">Overall observed 5-y ASCVD risk was substantially lower </text>
<text top="247" left="636" width="201" height="20" font="0">than predicted in each risk category: </text>
<text top="264" left="636" width="188" height="20" font="0">   0.20% for predicted risk &lt;2.50% </text>
<text top="281" left="636" width="222" height="20" font="0">   0.65% for predicted risk 2.50 to 3.74% </text>
<text top="298" left="636" width="222" height="20" font="0">   0.90% for predicted risk 3.75 to 4.99% </text>
<text top="316" left="636" width="190" height="20" font="0">   1.85% for predicted risk ≥5.00% </text>
<text top="333" left="636" width="279" height="20" font="0">The observed 5-y ASCVD risk was also lower than </text>
<text top="350" left="636" width="198" height="20" font="0">predicted in Asian/Pacific Islanders: </text>
<text top="367" left="636" width="188" height="20" font="0">   0.20% for predicted risk &lt;2.50% </text>
<text top="384" left="636" width="222" height="20" font="0">   0.75% for predicted risk 2.50 to 3.74% </text>
<text top="402" left="636" width="222" height="20" font="0">   0.75% for predicted risk 3.75 to 4.99% </text>
<text top="419" left="636" width="190" height="20" font="0">   1.65% for predicted risk ≥5.00%<b> </b></text>
<text top="194" left="967" width="124" height="20" font="0">The PCE substantially </text>
<text top="211" left="967" width="137" height="20" font="0">overestimated actual 5-y </text>
<text top="228" left="967" width="123" height="20" font="0">ASCVD risk in eligible </text>
<text top="246" left="967" width="132" height="20" font="0">adults without diabetes, </text>
<text top="263" left="967" width="134" height="20" font="0">known ASCVD and with </text>
<text top="280" left="967" width="122" height="20" font="0">LDL 70 to 189 mg/dL  </text>
<text top="297" left="967" width="3" height="20" font="0"> </text>
<text top="314" left="967" width="100" height="20" font="0">c-statistic 0.72 for </text>
<text top="332" left="967" width="121" height="20" font="0">Asian/Pacific Islander </text>
<text top="349" left="967" width="3" height="20" font="0"> </text>
<text top="556" left="91" width="141" height="20" font="0">Jung KJ, et al., 2015 <a href="data supplement.html#240">(74)</a> </text>
<text top="573" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26255683">26255683</a></text>
<text top="573" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26255683"> </a></text>
<text top="591" left="91" width="3" height="20" font="0"> </text>
<text top="556" left="286" width="74" height="20" font="7"><b>Study type:</b>  </text>
<text top="573" left="286" width="78" height="20" font="0">Retrospective </text>
<text top="591" left="286" width="70" height="20" font="0">cohort study </text>
<text top="608" left="286" width="3" height="20" font="0"> </text>
<text top="625" left="286" width="84" height="20" font="7"><b>Size:</b>  192,605 </text>
<text top="642" left="286" width="81" height="20" font="0">114622 males </text>
<text top="659" left="286" width="36" height="20" font="0">(60%) </text>
<text top="556" left="400" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="573" left="400" width="195" height="20" font="0">Adults aged 40-79 y without clinical </text>
<text top="591" left="400" width="194" height="20" font="0">ASCVD who were registered in the </text>
<text top="608" left="400" width="101" height="20" font="0">Republic of Korea </text>
<text top="625" left="400" width="3" height="20" font="0"> </text>
<text top="642" left="400" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="659" left="400" width="189" height="20" font="0">Age &lt;40 ; Receiving lipid-lowering </text>
<text top="677" left="400" width="213" height="20" font="0">medication at baseline; CVD or stroke; </text>
<text top="694" left="400" width="219" height="20" font="0">Missing values of variables such as BP, </text>
<text top="711" left="400" width="204" height="20" font="0">TC, HDL, glucose, smoking status or </text>
<text top="728" left="400" width="25" height="20" font="0">BMI<b> </b></text>
<text top="557" left="636" width="177" height="20" font="7"><b>1</b>°<b> endpoint:</b> Risk Assessment  </text>
<text top="574" left="636" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="592" left="636" width="259" height="20" font="0"> The PCE distinguished cases from non-cases. </text>
<text top="609" left="636" width="3" height="20" font="0"> </text>
<text top="626" left="636" width="306" height="20" font="0">In men, the AUROCs were 0.727; 95% CI: 0.721-0.734; </text>
<text top="643" left="636" width="300" height="20" font="0">using the white model and 0.725; 95% CI: 0.718-0.731 </text>
<text top="660" left="636" width="117" height="20" font="0">using the AA model.  </text>
<text top="678" left="636" width="3" height="20" font="0"> </text>
<text top="695" left="636" width="284" height="20" font="0">In women, the AUROCs were 0.738; 95% CI: 0.729-</text>
<text top="712" left="636" width="303" height="20" font="0">0.746, using the white model and 0.739; 95% CI: 0.731-</text>
<text top="729" left="636" width="144" height="20" font="0">0.747 using the AA model </text>
<text top="747" left="636" width="3" height="20" font="0"> </text>
<text top="764" left="636" width="314" height="20" font="0">10-y ASCVD risk for men was overestimated by 56.5% in </text>
<text top="781" left="636" width="249" height="20" font="0">the white model and 74.1% in the AA model,  </text>
<text top="556" left="967" width="116" height="20" font="0">The PCE statistically </text>
<text top="573" left="967" width="147" height="20" font="0">overestimated the ASCVD </text>
<text top="591" left="967" width="141" height="20" font="0">event rates observed in a </text>
<text top="608" left="967" width="81" height="20" font="0">Korean cohort </text>
<text top="625" left="967" width="3" height="20" font="0"> </text>
<text top="642" left="967" width="3" height="20" font="0"> </text>
<text top="659" left="967" width="3" height="20" font="0"> </text>
<text top="677" left="967" width="3" height="20" font="0"> </text>
<text top="694" left="967" width="3" height="20" font="0"> </text>
</page>
<page number="140" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">140 </text>
<text top="107" left="636" width="3" height="20" font="0"> </text>
<text top="124" left="636" width="286" height="20" font="0">10-y ASCVD risk for women was underestimated by </text>
<text top="141" left="636" width="313" height="20" font="0">27.9% in the white model and overestimated by 29.1% in </text>
<text top="159" left="636" width="77" height="20" font="0">the AA model </text>
<text top="177" left="91" width="138" height="20" font="0">Lee CH, et al., 2015 <a href="data supplement.html#240">(77)</a> </text>
<text top="194" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26350809">26350809</a></text>
<text top="194" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26350809"> </a></text>
<text top="177" left="286" width="74" height="20" font="7"><b>Study type:</b>  </text>
<text top="194" left="286" width="99" height="20" font="0">Population-based </text>
<text top="211" left="286" width="66" height="20" font="0">prospective </text>
<text top="228" left="286" width="70" height="20" font="0">cohort study </text>
<text top="245" left="286" width="3" height="20" font="0"> </text>
<text top="263" left="286" width="66" height="20" font="7"><b>Size:</b>  1753 </text>
<text top="280" left="286" width="90" height="20" font="0">Male 804 (46%) </text>
<text top="177" left="400" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="194" left="400" width="222" height="20" font="0">Chinese men and women aged 25-74 y  </text>
<text top="211" left="400" width="3" height="20" font="0"> </text>
<text top="228" left="400" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="245" left="400" width="194" height="20" font="0">Age&lt;40 y or &gt;79 y; CVD; LDL&gt;190 </text>
<text top="263" left="400" width="33" height="20" font="0">mg/dl </text>
<text top="280" left="400" width="3" height="20" font="7"><b> </b></text>
<text top="297" left="400" width="3" height="20" font="7"><b> </b></text>
<text top="178" left="636" width="177" height="20" font="7"><b>1</b>°<b> endpoint:</b> Risk Assessment  </text>
<text top="195" left="636" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="212" left="636" width="3" height="20" font="0"> </text>
<text top="229" left="636" width="317" height="20" font="0">The AUROC of the PCE was 0.714; 95% CI: 0.657–0.770 </text>
<text top="247" left="636" width="280" height="20" font="0">in men and 0.765; 95% CI: 0.690–0.840 in women, </text>
<text top="264" left="636" width="3" height="20" font="0"> </text>
<text top="281" left="636" width="298" height="20" font="0">The AUROC of the Framingham CV risk equation was </text>
<text top="298" left="636" width="309" height="20" font="0">0.773, 95% CI: 0.742–0.802, in men and 0.788, 95% CI: </text>
<text top="316" left="636" width="138" height="20" font="0">0.724–0.852, in women.  </text>
<text top="333" left="636" width="3" height="20" font="0"> </text>
<text top="350" left="636" width="304" height="20" font="0">The calibration scores of both models were suboptimal  </text>
<text top="177" left="967" width="131" height="20" font="0">The predictive power of </text>
<text top="194" left="967" width="135" height="20" font="0">the PCE was poor when </text>
<text top="211" left="967" width="126" height="20" font="0">applied to the Chinese </text>
<text top="228" left="967" width="138" height="20" font="0">population in Hong Kong </text>
<text top="245" left="967" width="3" height="20" font="0"> </text>
<text top="263" left="967" width="7" height="20" font="0">  </text>
<text top="280" left="967" width="3" height="20" font="0"> </text>
<text top="297" left="967" width="3" height="20" font="0"> </text>
<text top="314" left="967" width="3" height="20" font="0"> </text>
<text top="368" left="91" width="56" height="20" font="7"><b>MASALA </b></text>
<text top="385" left="91" width="170" height="20" font="0">Kandula NR, et al., 2014 <a href="data supplement.html#246">(173)</a> </text>
<text top="402" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25277669">25277669</a></text>
<text top="402" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25277669"> </a></text>
<text top="420" left="91" width="3" height="20" font="0"> </text>
<text top="368" left="286" width="74" height="20" font="7"><b>Study type:</b>  </text>
<text top="385" left="286" width="70" height="20" font="0">Longitudinal </text>
<text top="402" left="286" width="70" height="20" font="0">cohort study </text>
<text top="420" left="286" width="3" height="20" font="0"> </text>
<text top="437" left="286" width="60" height="20" font="7"><b>Size:</b>  906 </text>
<text top="454" left="286" width="90" height="20" font="0">Male 486 (54%) </text>
<text top="368" left="400" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="385" left="400" width="206" height="20" font="0">Self-identify as South Asian ethnicity; </text>
<text top="402" left="400" width="213" height="20" font="0">Speak English, Hindi, or Urdu; 40-84 y </text>
<text top="420" left="400" width="3" height="20" font="0"> </text>
<text top="437" left="400" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="454" left="400" width="183" height="20" font="0">Clinical ASCVD, HF, pacemaker, </text>
<text top="471" left="400" width="222" height="20" font="0">current atrial fibrillation, active treatment </text>
<text top="488" left="400" width="205" height="20" font="0">for cancer; Live in nursing home; Life </text>
<text top="506" left="400" width="199" height="20" font="0">expectancy &lt; 5y; Impaired cognitive </text>
<text top="523" left="400" width="187" height="20" font="0">ability; Plans to move out of study </text>
<text top="540" left="400" width="196" height="20" font="0">region in next 5 y; Weight &gt;300 lbs. </text>
<text top="369" left="636" width="177" height="20" font="7"><b>1</b>°<b> endpoint:</b> Risk Assessment  </text>
<text top="386" left="636" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="404" left="636" width="308" height="20" font="0">Using the PCE for risk stratification, 49% of South Asian </text>
<text top="421" left="636" width="304" height="20" font="0">men and 13% of women had a high 10-y predicted risk. </text>
<text top="438" left="636" width="3" height="20" font="0"> </text>
<text top="455" left="636" width="285" height="20" font="0">The majority of South Asian men (79%) and women </text>
<text top="472" left="636" width="279" height="20" font="0">(70%) had a high lifetime predicted risk of ASCVD. </text>
<text top="490" left="636" width="3" height="20" font="0"> </text>
<text top="507" left="636" width="312" height="20" font="0">High 10-y predicted risk was associated with higher CAC </text>
<text top="524" left="636" width="316" height="20" font="0">prevalence (68%) and greater adjusted odds ratio of CAC </text>
<text top="541" left="636" width="318" height="20" font="0">(OR: 1.81; 95%CI: 1.0-3.3) compared with low 10-y risk in </text>
<text top="558" left="636" width="303" height="20" font="0">men. In women, the high 10-y predicted risk group also </text>
<text top="576" left="636" width="301" height="20" font="0">had a greater CAC burden than women in the low 10-y </text>
<text top="593" left="636" width="300" height="20" font="0">risk group, but this did not meet statistical significance. </text>
<text top="368" left="967" width="121" height="20" font="0">South Asian men and </text>
<text top="385" left="967" width="122" height="20" font="0">women with high 10-y </text>
<text top="402" left="967" width="130" height="20" font="0">predicted risk using the </text>
<text top="420" left="967" width="134" height="20" font="0">PCE had a greater CAC </text>
<text top="437" left="967" width="150" height="20" font="0">burden than those with low </text>
<text top="454" left="967" width="61" height="20" font="0">10-yr risk.  </text>
<text top="471" left="967" width="3" height="20" font="0"> </text>
<text top="488" left="967" width="128" height="20" font="0">South Asians with high </text>
<text top="506" left="967" width="143" height="20" font="0">lifetime predicted risk had </text>
<text top="523" left="967" width="134" height="20" font="0">increased odds for CAC </text>
<text top="540" left="967" width="132" height="20" font="0">higher than 0 (OR: men </text>
<text top="557" left="967" width="136" height="20" font="0">1.97; 95% CI: 1.2 to 3.2; </text>
<text top="574" left="967" width="145" height="20" font="0">women 3.14; 95% CI: 1.5, </text>
<text top="592" left="967" width="28" height="20" font="0">6.6). </text>
<text top="609" left="967" width="3" height="20" font="0"> </text>
<text top="626" left="967" width="3" height="20" font="0"> </text>
<text top="644" left="91" width="142" height="20" font="0">Chia YC, et al., 2014 <a href="data supplement.html#239">(65)</a> </text>
<text top="661" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25410585">25410585</a></text>
<text top="661" left="146" width="3" height="20" font="11"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25410585"> </a></text>
<text top="678" left="91" width="3" height="20" font="0"> </text>
<text top="644" left="286" width="74" height="20" font="7"><b>Study type:</b>  </text>
<text top="661" left="286" width="78" height="20" font="0">Retrospective </text>
<text top="678" left="286" width="70" height="20" font="0">cohort study </text>
<text top="696" left="286" width="3" height="20" font="0"> </text>
<text top="713" left="286" width="60" height="20" font="7"><b>Size:</b>  922 </text>
<text top="730" left="286" width="90" height="20" font="0">Male 307 (33%) </text>
<text top="644" left="400" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="661" left="400" width="195" height="20" font="0">Adults aged 40-79 y without clinical </text>
<text top="678" left="400" width="194" height="20" font="0">ASCVD who were registered in the </text>
<text top="696" left="400" width="174" height="20" font="0">outpatient primary care clinic of </text>
<text top="713" left="400" width="187" height="20" font="0">University Malaya Medical Centre </text>
<text top="730" left="400" width="3" height="20" font="0"> </text>
<text top="747" left="400" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="764" left="400" width="197" height="20" font="0">Age&lt;40 or &gt;79 y; Lack of all clinical </text>
<text top="782" left="400" width="217" height="20" font="0">variables to calculate the pooled cohort </text>
<text top="645" left="636" width="177" height="20" font="7"><b>1</b>°<b> endpoint:</b> Risk Assessment  </text>
<text top="662" left="636" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="680" left="636" width="299" height="20" font="0"> High 10-y risk (≥7.5%) with the PCE agreed with FRS </text>
<text top="697" left="636" width="159" height="20" font="0">&gt;10% in 98% of the subjects </text>
<text top="714" left="636" width="7" height="20" font="0">  </text>
<text top="731" left="636" width="316" height="20" font="0">The PCE does not appear to overestimate cardiovascular </text>
<text top="748" left="636" width="139" height="20" font="0">risk as compared to FRS </text>
<text top="766" left="636" width="3" height="20" font="0"> </text>
<text top="783" left="636" width="177" height="20" font="0">The AUC for the PCE was 0.63. </text>
<text top="644" left="967" width="147" height="20" font="0">Overall cardiovascular risk </text>
<text top="661" left="967" width="143" height="20" font="0">was overestimated as the </text>
<text top="678" left="967" width="137" height="20" font="0">observed event rate was </text>
<text top="696" left="967" width="140" height="20" font="0">significantly less than the </text>
<text top="713" left="967" width="136" height="20" font="0">predicted event rate, but </text>
<text top="730" left="967" width="132" height="20" font="0">this may be a treatment </text>
<text top="747" left="967" width="33" height="20" font="0">effect </text>
<text top="764" left="967" width="3" height="20" font="0"> </text>
<text top="782" left="967" width="3" height="20" font="0"> </text>
</page>
<page number="141" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="20" size="7" family="Times" color="#000000"/>
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">141 </text>
<text top="107" left="400" width="215" height="20" font="0">risk score; Missing data on the ASCVD </text>
<text top="124" left="400" width="33" height="20" font="0">event<b> </b></text>
<text top="107" left="636" width="3" height="20" font="0"> </text>
<text top="143" left="88" width="1035" height="20" font="7"><b>Abbreviations:</b> 1° indicated primary; AA African American; ASCVD atherosclerotic cardiovascular disease; ATP, Adult Treatment Panel; AUC area under curve; AUROC area under receiver </text>
<text top="161" left="88" width="1048" height="20" font="0">operating curve; BMI body mass index; CABG coronary artery bypass grafting; CAC coronary artery calcium; CI, confidence interval; CVD, cardiovascular disease; FRS Framingham risk score; </text>
<text top="178" left="88" width="1036" height="20" font="0">HF heart failure; HR, hazard ratio; N/A, not available; OR, odds ratio; PCE pooled cohort equation; PCI percutaneous coronary intervention; RCT, randomized controlled trial; and RR, relative </text>
<text top="195" left="88" width="299" height="20" font="0">risk; SBP systolic blood pressure; TC total cholesterol. </text>
<text top="212" left="88" width="391" height="20" font="7"><b>Search Terms and Date of Search</b>: Risk Calculator, Asians 5/20/2017 </text>
<text top="236" left="81" width="5" height="16" font="15"> </text>
<text top="250" left="81" width="789" height="24" font="4"><b>Data Supplement 26. Nonrandomized Trials, Observational Studies, and/or Registries of Hispanic (Section 4.5.1) </b></text>
<text top="272" left="94" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="289" left="120" width="48" height="20" font="7"><b>Author; </b></text>
<text top="306" left="97" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="280" left="226" width="118" height="20" font="7"><b>Study Type/Design; </b></text>
<text top="297" left="252" width="66" height="20" font="7"><b>Study Size </b></text>
<text top="289" left="408" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="280" left="624" width="179" height="20" font="7"><b>Primary Endpoint and Results </b></text>
<text top="297" left="622" width="184" height="20" font="7"><b>(P values; OR or RR; &amp; 95% CI) </b></text>
<text top="280" left="922" width="130" height="20" font="7"><b>Summary/Conclusion </b></text>
<text top="297" left="950" width="75" height="20" font="7"><b>Comment(s) </b></text>
<text top="324" left="82" width="42" height="20" font="7"><b>MESA  </b></text>
<text top="341" left="82" width="106" height="20" font="0">Qureshi WT, et al., </text>
<text top="358" left="82" width="63" height="20" font="0">2016 <a href="data supplement.html#246">(174)</a> </text>
<text top="376" left="82" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27445216">27445216</a></text>
<text top="376" left="137" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27445216"> </a></text>
<text top="324" left="217" width="85" height="20" font="7"><b>Aim:</b> Compare </text>
<text top="341" left="217" width="119" height="20" font="0">accuracy of the PCE, </text>
<text top="358" left="217" width="122" height="20" font="0">modified FRS and the </text>
<text top="376" left="217" width="102" height="20" font="0">SCORE, and their </text>
<text top="393" left="217" width="89" height="20" font="0">impact on statin </text>
<text top="410" left="217" width="103" height="20" font="0">eligibility using the </text>
<text top="427" left="217" width="89" height="20" font="0">≥7.5% 10-y risk </text>
<text top="444" left="217" width="54" height="20" font="0">threshold </text>
<text top="462" left="217" width="116" height="20" font="0">recommended in the </text>
<text top="479" left="217" width="84" height="20" font="0">new ACC/AHA </text>
<text top="496" left="217" width="125" height="20" font="0">cholesterol guidelines. </text>
<text top="513" left="217" width="3" height="20" font="0"> </text>
<text top="530" left="217" width="74" height="20" font="7"><b>Study type:</b>  </text>
<text top="548" left="217" width="105" height="20" font="0">Prospective cohort </text>
<text top="565" left="217" width="33" height="20" font="0">study </text>
<text top="582" left="217" width="3" height="20" font="0"> </text>
<text top="599" left="217" width="110" height="20" font="7"><b>Size:</b>  6,814 initially </text>
<text top="616" left="217" width="117" height="20" font="0">5,654 after exclusion </text>
<text top="634" left="217" width="44" height="20" font="0">criteria. </text>
<text top="324" left="366" width="193" height="20" font="7"><b>Inclusion criteria:</b> Adults between </text>
<text top="341" left="366" width="193" height="20" font="0">45 and 84 y with no cardiovascular </text>
<text top="358" left="366" width="49" height="20" font="0">disease. </text>
<text top="376" left="366" width="3" height="20" font="0"> </text>
<text top="393" left="366" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="410" left="366" width="165" height="20" font="0">Being on cholesterol reducing </text>
<text top="427" left="366" width="66" height="20" font="0">medication. </text>
<text top="444" left="366" width="190" height="20" font="0">Missing characteristics (n = 1,160) </text>
<text top="462" left="366" width="187" height="20" font="0">Characteristics were age, gender, </text>
<text top="479" left="366" width="115" height="20" font="0">race/ethnicity, family </text>
<text top="496" left="366" width="3" height="20" font="0"> </text>
<text top="513" left="366" width="176" height="20" font="7"><b>Intervention:</b> Calculation of the </text>
<text top="530" left="366" width="173" height="20" font="0">10-y risk of incident ASCVD for </text>
<text top="548" left="366" width="196" height="20" font="0">each individual using FRS, SCORE </text>
<text top="565" left="366" width="194" height="20" font="0">and PCE. For Hispanics white race </text>
<text top="582" left="366" width="120" height="20" font="0">estimates were used. </text>
<text top="599" left="366" width="3" height="20" font="0"> </text>
<text top="616" left="366" width="174" height="20" font="0">Participants were followed from </text>
<text top="634" left="366" width="175" height="20" font="0">baseline through December 31, </text>
<text top="651" left="366" width="174" height="20" font="0">2012. Median follow up of 8.5 y </text>
<text top="668" left="366" width="7" height="20" font="0">  </text>
<text top="685" left="366" width="184" height="20" font="0">FRS, SCORE and PCE history of </text>
<text top="703" left="366" width="188" height="20" font="0">coronary artery disease, smoking, </text>
<text top="720" left="366" width="188" height="20" font="0">measurements of total cholesterol </text>
<text top="737" left="366" width="154" height="20" font="0">and high-density lipoprotein </text>
<text top="754" left="366" width="175" height="20" font="0">cholesterol and blood pressure. </text>
<text top="324" left="575" width="22" height="20" font="7"><b>1</b></text>
<text top="324" left="585" width="264" height="20" font="7"><b> endpoint:</b> Incident of ASCV, composed of fatal </text>
<text top="341" left="575" width="273" height="20" font="0">and nonfatal myocardial infarction, other fatal and </text>
<text top="358" left="575" width="277" height="20" font="0">nonfatal coronary heart disease, fatal and nonfatal </text>
<text top="376" left="575" width="269" height="20" font="0">cerebrovascular disease, and fatal/nonfatal other </text>
<text top="393" left="575" width="136" height="20" font="0">atherosclerotic disease.  </text>
<text top="410" left="575" width="217" height="20" font="0">342 (6%) of which 22 % were Hispanic. </text>
<text top="427" left="575" width="3" height="20" font="0"> </text>
<text top="444" left="575" width="3" height="20" font="0"> </text>
<text top="324" left="865" width="243" height="20" font="0">∙ Impact of replacing the PCE with either the </text>
<text top="341" left="865" width="163" height="20" font="0">modified FRS or the SCORE. </text>
<text top="358" left="865" width="193" height="20" font="0">Study shows PCE to have the best </text>
<text top="376" left="865" width="82" height="20" font="0">discrimination. </text>
<text top="393" left="865" width="3" height="20" font="0"> </text>
<text top="410" left="865" width="69" height="20" font="7"><b>Limitations </b></text>
<text top="427" left="865" width="199" height="20" font="0">∙ Not relevant in determining special </text>
<text top="444" left="865" width="217" height="20" font="0">considerations for Hispanics. Hispanics </text>
<text top="462" left="865" width="230" height="20" font="0">were not classified by their race and were </text>
<text top="479" left="865" width="183" height="20" font="0">applied the white race estimates. </text>
<text top="772" left="82" width="39" height="20" font="7"><b>MESA </b></text>
<text top="772" left="217" width="109" height="20" font="7"><b>Aim:</b> Evaluated the </text>
<text top="789" left="217" width="102" height="20" font="0">ASCVD risk score </text>
<text top="772" left="366" width="193" height="20" font="7"><b>Inclusion criteria:</b> Adults between </text>
<text top="789" left="366" width="135" height="20" font="0">the ages of 45 and 79 y. </text>
<text top="772" left="575" width="7" height="20" font="7"><b>1</b></text>
<text top="774" left="582" width="4" height="13" font="20"><b>0</b></text>
<text top="772" left="586" width="70" height="20" font="7"><b> endpoint:</b>   </text>
<text top="772" left="865" width="201" height="20" font="0">∙ Overestimation was observed in all </text>
<text top="789" left="865" width="202" height="20" font="0">race/ethnic groups, men and women </text>
</page>
<page number="142" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">142 </text>
<text top="107" left="82" width="114" height="20" font="0">DeFilippis AP, et al., </text>
<text top="124" left="82" width="56" height="20" font="0">2017 <a href="data supplement.html#240">(71)</a> </text>
<text top="141" left="82" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27436865">27436865</a></text>
<text top="141" left="137" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27436865"> </a></text>
<text top="107" left="217" width="114" height="20" font="0">among four different </text>
<text top="124" left="217" width="129" height="20" font="0">race/ethnic groups and </text>
<text top="141" left="217" width="102" height="20" font="0">to ascertain which </text>
<text top="159" left="217" width="92" height="20" font="0">factors are most </text>
<text top="176" left="217" width="110" height="20" font="0">associated with risk </text>
<text top="193" left="217" width="120" height="20" font="0">overestimation by the </text>
<text top="210" left="217" width="105" height="20" font="0">AHA-ACC-ASCVD </text>
<text top="228" left="217" width="37" height="20" font="0">score. </text>
<text top="245" left="217" width="3" height="20" font="0"> </text>
<text top="262" left="217" width="74" height="20" font="7"><b>Study type:</b>  </text>
<text top="279" left="217" width="105" height="20" font="0">Prospective cohort </text>
<text top="296" left="217" width="33" height="20" font="0">study </text>
<text top="314" left="217" width="3" height="20" font="0"> </text>
<text top="331" left="217" width="66" height="20" font="7"><b>Size:</b>  6441 </text>
<text top="107" left="366" width="3" height="20" font="0"> </text>
<text top="124" left="366" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="141" left="366" width="133" height="20" font="0">Adults age 80 and over. </text>
<text top="159" left="366" width="165" height="20" font="0">Participants with missing data </text>
<text top="176" left="366" width="184" height="20" font="0">required for risk score calculation </text>
<text top="193" left="366" width="175" height="20" font="0">(n=53, 1%) or no follow up after </text>
<text top="210" left="366" width="114" height="20" font="0">baseline (n=3, &lt;1%) </text>
<text top="228" left="366" width="3" height="20" font="0"> </text>
<text top="245" left="366" width="176" height="20" font="7"><b>Intervention:</b> Calculation of the </text>
<text top="262" left="366" width="152" height="20" font="0">predicted 10 y ASCVD risk. </text>
<text top="279" left="366" width="180" height="20" font="0">Observation of the 10 y ASCVD. </text>
<text top="296" left="366" width="7" height="20" font="0">  </text>
<text top="314" left="366" width="152" height="20" font="7"><b>Comparator:</b> <b> </b>Discordance </text>
<text top="331" left="366" width="182" height="20" font="0">between predicted and observed </text>
<text top="348" left="366" width="53" height="20" font="0">10 y risk. </text>
<text top="365" left="366" width="3" height="20" font="0"> </text>
<text top="382" left="366" width="189" height="20" font="0">Impact of individual risk factors on </text>
<text top="400" left="366" width="94" height="20" font="0">the discordance. </text>
<text top="107" left="575" width="277" height="20" font="0">Risk discrimination was similar for women (100%0 </text>
<text top="124" left="575" width="91" height="20" font="0">and men (93%). </text>
<text top="141" left="575" width="276" height="20" font="0">Observed rates were roughly half of that predicted </text>
<text top="159" left="575" width="96" height="20" font="0">by the risk score. </text>
<text top="176" left="575" width="3" height="20" font="0"> </text>
<text top="193" left="575" width="244" height="20" font="0">Overestimation was highest among Chinese </text>
<text top="210" left="575" width="270" height="20" font="0">(252% for women and 314% for men) and lowest </text>
<text top="228" left="575" width="269" height="20" font="0">in White women (72%) and Hispanic men (67%). </text>
<text top="245" left="575" width="260" height="20" font="0">The lowest discordance between observed and </text>
<text top="262" left="575" width="230" height="20" font="0">calculated ASCVD event rats was seen in </text>
<text top="279" left="575" width="217" height="20" font="0">Hispanic men (71%) and women (49%) </text>
<text top="296" left="575" width="3" height="20" font="0"> </text>
<text top="314" left="575" width="3" height="20" font="0"> </text>
<text top="107" left="865" width="3" height="20" font="0"> </text>
<text top="124" left="865" width="69" height="20" font="7"><b>Limitations </b></text>
<text top="141" left="865" width="230" height="20" font="0">∙ Risk score specifically recommended for </text>
<text top="159" left="865" width="225" height="20" font="0">White Americans used for Hispanics, not </text>
<text top="176" left="865" width="235" height="20" font="0">considering that there are White and Black </text>
<text top="193" left="865" width="60" height="20" font="0">Hispanics. </text>
<text top="210" left="865" width="3" height="20" font="0"> </text>
<text top="418" left="82" width="118" height="20" font="0">Rana JS, et al., 2016 </text>
<text top="435" left="82" width="25" height="20" font="0"><a href="data supplement.html#241">(83)</a> </text>
<text top="452" left="82" width="55" height="20" font="8"><a href="">27151343</a></text>
<text top="452" left="137" width="3" height="20" font="0"><a href=""> </a></text>
<text top="418" left="217" width="109" height="20" font="7"><b>Aim:</b> Evaluated the </text>
<text top="435" left="217" width="118" height="20" font="0">accuracy of the 2013 </text>
<text top="452" left="217" width="131" height="20" font="0">ACC/AHA risk equation </text>
<text top="469" left="217" width="79" height="20" font="0">within a large, </text>
<text top="487" left="217" width="135" height="20" font="0">multiethnic population in </text>
<text top="504" left="217" width="71" height="20" font="0">clinical care. </text>
<text top="521" left="217" width="3" height="20" font="0"> </text>
<text top="538" left="217" width="74" height="20" font="7"><b>Study type:</b>  </text>
<text top="555" left="217" width="70" height="20" font="0">prospective  </text>
<text top="573" left="217" width="3" height="20" font="0"> </text>
<text top="590" left="217" width="84" height="20" font="7"><b>Size:</b>  307,591 </text>
<text top="607" left="217" width="114" height="20" font="0">Also identified 4,242 </text>
<text top="624" left="217" width="100" height="20" font="0">patients that were </text>
<text top="641" left="217" width="110" height="20" font="0">diabetic and did not </text>
<text top="659" left="217" width="133" height="20" font="0">have prior lipid-lowering </text>
<text top="676" left="217" width="132" height="20" font="0">therapy, known ASCVD </text>
<text top="693" left="217" width="124" height="20" font="0">or any other exclusion </text>
<text top="710" left="217" width="44" height="20" font="0">criteria. </text>
<text top="727" left="217" width="3" height="20" font="0"> </text>
<text top="745" left="217" width="120" height="20" font="7"><b>Duration:</b> 2008-2013 </text>
<text top="418" left="366" width="193" height="20" font="7"><b>Inclusion criteria:</b> Adults between </text>
<text top="435" left="366" width="109" height="20" font="0">40 and 75 y of age. </text>
<text top="452" left="366" width="174" height="20" font="0">LDL between 70 and 189 mg/dl </text>
<text top="469" left="366" width="3" height="20" font="0"> </text>
<text top="487" left="366" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="504" left="366" width="185" height="20" font="0">Unidentified sex or race/ethnicity. </text>
<text top="521" left="366" width="194" height="20" font="0">Having known ASCVD or diabetes. </text>
<text top="538" left="366" width="62" height="20" font="0">Statin use. </text>
<text top="555" left="366" width="177" height="20" font="0">Missing systolic blood pressure, </text>
<text top="573" left="366" width="173" height="20" font="0">total cholesterol or high-density </text>
<text top="590" left="366" width="194" height="20" font="0">lipoprotein cholesterol information.  </text>
<text top="607" left="366" width="3" height="20" font="0"> </text>
<text top="624" left="366" width="3" height="20" font="0"> </text>
<text top="641" left="366" width="154" height="20" font="0">Compared predicted versus </text>
<text top="659" left="366" width="162" height="20" font="0">observed 5-y risks of ASCVS </text>
<text top="676" left="366" width="188" height="20" font="0">events, overall and within sex and </text>
<text top="693" left="366" width="104" height="20" font="0">ethnic subgroups   </text>
<text top="418" left="575" width="22" height="20" font="7"><b>1</b></text>
<text top="418" left="585" width="262" height="20" font="7"><b> endpoint:</b> Among the patient without diabetes, </text>
<text top="435" left="575" width="273" height="20" font="0">2,061 events were observed. Observed incidence </text>
<text top="452" left="575" width="276" height="20" font="0">was lower that the predicted risk in each category: </text>
<text top="469" left="575" width="259" height="20" font="0"> 0.20% (95% CI: 0.20% to 0.25%) for predicted </text>
<text top="487" left="575" width="226" height="20" font="0">risk &lt;2.50%; 0.65% (0.55% to 0.70%) for </text>
<text top="504" left="575" width="272" height="20" font="0">predicted risk 2.50% to &lt;3.75%; 0.90% (0.75% to </text>
<text top="521" left="575" width="262" height="20" font="0">1.00%) for predicted risk 3.75% to &lt;5.00%: and </text>
<text top="538" left="575" width="231" height="20" font="0">1.85% (1.75% to 1.95%) for predicted risk </text>
<text top="555" left="575" width="50" height="20" font="0">≥5.00%  </text>
<text top="573" left="575" width="3" height="20" font="0"> </text>
<text top="590" left="575" width="242" height="20" font="0">Overestimation was similar in both men and </text>
<text top="607" left="575" width="252" height="20" font="0">women and across the 4 major ethnic groups. </text>
<text top="624" left="575" width="239" height="20" font="0">Poor calibration reported in each subgroup. </text>
<text top="641" left="575" width="3" height="20" font="0"> </text>
<text top="418" left="865" width="242" height="20" font="0">Overestimation was similar in both men and </text>
<text top="435" left="865" width="208" height="20" font="0">women and across the 4 major ethnic </text>
<text top="452" left="865" width="226" height="20" font="0">groups. Poor calibration reported in each </text>
<text top="469" left="865" width="58" height="20" font="0">subgroup. </text>
<text top="487" left="865" width="3" height="20" font="0"> </text>
<text top="504" left="865" width="69" height="20" font="7"><b>Limitations </b></text>
<text top="521" left="865" width="123" height="20" font="0">5 y instead of 10 y FU </text>
<text top="538" left="865" width="89" height="20" font="0">Poor calibration </text>
<text top="555" left="865" width="233" height="20" font="0">Hispanics were not classified by their race </text>
<text top="573" left="865" width="237" height="20" font="0">and were applied the white race estimates. </text>
</page>
<page number="143" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">143 </text>
<text top="107" left="82" width="55" height="20" font="7"><b>NHANES </b></text>
<text top="124" left="82" width="100" height="20" font="0">Mercado C, et al., </text>
<text top="141" left="82" width="63" height="20" font="0">2015 <a href="data supplement.html#246">(175)</a><b> </b></text>
<text top="159" left="82" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26633047">26633047</a></text>
<text top="159" left="137" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26633047"> </a></text>
<text top="176" left="82" width="3" height="20" font="0"> </text>
<text top="193" left="82" width="110" height="20" font="0">Data analyzed from </text>
<text top="210" left="82" width="83" height="20" font="0">the 2005-2012 </text>
<text top="227" left="82" width="46" height="20" font="0">surveys </text>
<text top="107" left="217" width="109" height="20" font="7"><b>Study type:</b>  Cross </text>
<text top="124" left="217" width="52" height="20" font="0">sectional </text>
<text top="141" left="217" width="3" height="20" font="0"> </text>
<text top="159" left="217" width="66" height="20" font="7"><b>Size:</b>  8644 </text>
<text top="176" left="217" width="3" height="20" font="0"> </text>
<text top="193" left="217" width="106" height="20" font="0">Identify sexual and </text>
<text top="210" left="217" width="112" height="20" font="0">ethnic disparities on </text>
<text top="228" left="217" width="118" height="20" font="0">cholesterol treatment </text>
<text top="245" left="217" width="109" height="20" font="0">for patients that are </text>
<text top="262" left="217" width="97" height="20" font="0">treatment eligible </text>
<text top="107" left="366" width="185" height="20" font="7"><b>Inclusion criteria:</b> Adults age 21 </text>
<text top="124" left="366" width="55" height="20" font="0">and older </text>
<text top="141" left="366" width="3" height="20" font="0"> </text>
<text top="159" left="366" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="176" left="366" width="96" height="20" font="0">Pregnant women </text>
<text top="193" left="366" width="143" height="20" font="0">Missing fasting laboratory </text>
<text top="210" left="366" width="60" height="20" font="0">specimen. </text>
<text top="228" left="366" width="176" height="20" font="0">Not able to determine treatment </text>
<text top="245" left="366" width="53" height="20" font="0">eligibility. </text>
<text top="107" left="575" width="272" height="20" font="7"><b>1 endpoint:</b> Half of treatment eligible adults were </text>
<text top="124" left="575" width="231" height="20" font="0">receiving cholesterol lowering medication. </text>
<text top="141" left="575" width="260" height="20" font="0">There were significant differences on treatment </text>
<text top="159" left="575" width="265" height="20" font="0">eligibility between racial/ethnic groups in (24.2% </text>
<text top="176" left="575" width="254" height="20" font="0">for Mexican-Americans, 38.4% for whites, and </text>
<text top="193" left="575" width="154" height="20" font="0">39.5% for blacks; p&lt;0.001). </text>
<text top="210" left="575" width="251" height="20" font="0">There were also significant differences on the </text>
<text top="227" left="575" width="251" height="20" font="0">proportion of adult taking cholesterol lowering </text>
<text top="245" left="575" width="226" height="20" font="0">medication between racial/ethnic groups. </text>
<text top="262" left="575" width="273" height="20" font="0">(58.0% for whites, 47.1% for Mexican-Americans, </text>
<text top="279" left="575" width="174" height="20" font="0">and 46.0% for blacks; p&lt;0.001) </text>
<text top="296" left="575" width="255" height="20" font="0">Significant differences were also found among </text>
<text top="314" left="575" width="265" height="20" font="0">men and women and subgroups of age, poverty-</text>
<text top="331" left="575" width="276" height="20" font="0">to-income ratio, body mass index and presence of </text>
<text top="348" left="575" width="142" height="20" font="0">diabetes or hypertension. </text>
<text top="365" left="575" width="243" height="20" font="7"><b>Results:</b> Prevalence of cholesterol-lowering </text>
<text top="382" left="575" width="223" height="20" font="0">medication use among adults eligible for </text>
<text top="400" left="575" width="260" height="20" font="0">treatment varied within racial/ethnic subgroups, </text>
<text top="417" left="575" width="267" height="20" font="0">with the lowest prevalence (5.7%) among blacks </text>
<text top="434" left="575" width="277" height="20" font="0">without health care access and the highest among </text>
<text top="451" left="575" width="210" height="20" font="0">persons who reported making lifestyle </text>
<text top="469" left="575" width="79" height="20" font="0">modifications. </text>
<text top="486" left="575" width="3" height="20" font="0"> </text>
<text top="107" left="865" width="203" height="20" font="0">Cholesterol use medication lower for </text>
<text top="124" left="865" width="206" height="20" font="0">Mexican Americans than no Hispanic </text>
<text top="141" left="865" width="42" height="20" font="0">whites. </text>
<text top="159" left="865" width="215" height="20" font="0">Cholesterol use medication was lowest </text>
<text top="176" left="865" width="83" height="20" font="0">among blacks. </text>
<text top="193" left="865" width="3" height="20" font="7"><b> </b></text>
<text top="210" left="865" width="3" height="20" font="7"><b> </b></text>
<text top="227" left="865" width="69" height="20" font="7"><b>Limitations </b></text>
<text top="245" left="865" width="205" height="20" font="0">Adults in nursing homes not included </text>
<text top="262" left="865" width="205" height="20" font="0">Limited data on estimation of lifestyle </text>
<text top="279" left="865" width="79" height="20" font="0">modifications. </text>
<text top="296" left="865" width="67" height="20" font="0">Recall bias. </text>
<text top="314" left="865" width="229" height="20" font="0">Potential for overestimation of eligibility in </text>
<text top="331" left="865" width="223" height="20" font="0">following the 2013 ACC/AHA guidelines. </text>
<text top="348" left="865" width="190" height="20" font="0">Patient taking cholesterol lowering </text>
<text top="365" left="865" width="242" height="20" font="0">medication included any type of medication. </text>
<text top="383" left="865" width="3" height="20" font="0"> </text>
<text top="400" left="865" width="215" height="20" font="0">∙More studies are needed to determine </text>
<text top="417" left="865" width="217" height="20" font="0">disparities and programs are needed to </text>
<text top="434" left="865" width="220" height="20" font="0">increase screening and management of </text>
<text top="451" left="865" width="86" height="20" font="0">hyperlipidemia. </text>
<text top="469" left="865" width="3" height="20" font="0"> </text>
<text top="504" left="88" width="111" height="20" font="7"><b>Abbreviations:</b> 1</text>
<text top="504" left="188" width="936" height="20" font="0"> indicated primary; CI, confidence interval; HR, hazard ratio; N/A, not available; OR, odds ratio; RCT, randomized controlled trial; and RR, relative risk; HCHS/SOL Hispanic </text>
<text top="521" left="88" width="1040" height="20" font="0">Community Health Study. /Study of Latinos; ACC/AHA American College of Cardiology/ American Heart Association; ATP Adult Treatment Panel; MESA Multi-Ethnic Study of Atherosclerosis; </text>
<text top="538" left="88" width="579" height="20" font="0">PCE Poole Cohort Equation; FRS Framingham Risk Score; SCORE Systematic Coronary Risk Evaluation </text>
<text top="555" left="88" width="3" height="20" font="0"> </text>
<text top="573" left="88" width="394" height="20" font="0">Search Terms and Date of Search: ASCVD RISK and Hispanic, 6/28/17 </text>
<text top="590" left="81" width="4" height="22" font="1"> </text>
<text top="608" left="88" width="4" height="22" font="1"> </text>
<text top="627" left="81" width="789" height="24" font="4"><b>Data Supplement 27. Nonrandomized Trials, Observational Studies, and/or Registries of Hispanic (Section 4.5.1) </b></text>
<text top="649" left="102" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="666" left="127" width="48" height="20" font="7"><b>Author; </b></text>
<text top="683" left="105" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="658" left="267" width="118" height="20" font="7"><b>Study Type/Design; </b></text>
<text top="675" left="293" width="66" height="20" font="7"><b>Study Size </b></text>
<text top="666" left="469" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="658" left="641" width="179" height="20" font="7"><b>Primary Endpoint and Results </b></text>
<text top="675" left="638" width="184" height="20" font="7"><b>(P values; OR or RR; &amp; 95% CI) </b></text>
<text top="658" left="920" width="130" height="20" font="7"><b>Summary/Conclusion </b></text>
<text top="675" left="947" width="75" height="20" font="7"><b>Comment(s) </b></text>
<text top="701" left="91" width="70" height="20" font="7"><b>HCHS/SOL  </b></text>
<text top="719" left="91" width="109" height="20" font="0">Qureshi, WT, et al., </text>
<text top="736" left="91" width="63" height="20" font="0">2017 <a href="data supplement.html#246">(176)</a> </text>
<text top="753" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28495699">28495699</a></text>
<text top="753" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28495699"> </a></text>
<text top="770" left="91" width="3" height="20" font="0"> </text>
<text top="701" left="224" width="3" height="20" font="0"> </text>
<text top="719" left="224" width="161" height="20" font="7"><b>Study type:</b>  Cross sectional </text>
<text top="736" left="224" width="3" height="20" font="0"> </text>
<text top="753" left="224" width="73" height="20" font="7"><b>Size:</b>  16415 </text>
<text top="770" left="224" width="3" height="20" font="0"> </text>
<text top="701" left="440" width="106" height="20" font="7"><b>Inclusion criteria:</b> </text>
<text top="719" left="440" width="154" height="20" font="0">Hispanic/Latino adults aged </text>
<text top="736" left="440" width="140" height="20" font="0">18 to 74 y at recruitment, </text>
<text top="753" left="440" width="110" height="20" font="0">recruited from 4 US </text>
<text top="770" left="440" width="109" height="20" font="0">metropolitan areas. </text>
<text top="787" left="440" width="3" height="20" font="0"> </text>
<text top="703" left="622" width="150" height="20" font="7"><b>1</b>°<b> endpoint:</b> Out of 16415 </text>
<text top="720" left="622" width="194" height="20" font="0">participants. 4160 (26.9%; 95% CI: </text>
<text top="737" left="622" width="210" height="20" font="0">25.7-28.0%) were statin eligible under </text>
<text top="754" left="622" width="168" height="20" font="0">the 2013 ACC/AHA guidelines </text>
<text top="771" left="622" width="213" height="20" font="0">compared to 2609 (15.9%; 95 CI: 15.0-</text>
<text top="789" left="622" width="180" height="20" font="0">16.7 %) under the NCEP/ATP III </text>
<text top="703" left="852" width="7" height="18" font="0">•</text>
<text top="703" left="859" width="228" height="20" font="0"> Among participants that were eligible the </text>
<text top="720" left="852" width="262" height="20" font="0">prevalence of statin use was 7.9%; 95% CI: 7.2-</text>
<text top="737" left="852" width="245" height="20" font="0">8.6%. That is only about one third for ATP III </text>
<text top="754" left="852" width="246" height="20" font="0">guidelines (28.2%; 95% CI: 26.3-30.0%) and </text>
<text top="771" left="852" width="247" height="20" font="0">about one fifth for 2013 ACC/AHA guidelines </text>
<text top="789" left="852" width="163" height="20" font="0">(20.6%; 95% CI: 19.4-21.9%) </text>
</page>
<page number="144" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">144 </text>
<text top="107" left="224" width="178" height="20" font="0">Determine statin eligibility under </text>
<text top="124" left="224" width="153" height="20" font="0">2013 ACC/AHA criteria and </text>
<text top="141" left="224" width="82" height="20" font="0">NCEP/ATP III. </text>
<text top="159" left="224" width="192" height="20" font="0">Characteristics of Hispanic/Latinos </text>
<text top="176" left="224" width="135" height="20" font="0">treated and non-treated. </text>
<text top="193" left="224" width="171" height="20" font="0">Predetermined using black risk </text>
<text top="210" left="224" width="185" height="20" font="0">estimates for Dominicans, Puerto </text>
<text top="228" left="224" width="148" height="20" font="0">Ricans, Cuban and central </text>
<text top="245" left="224" width="65" height="20" font="0">Americans. </text>
<text top="262" left="224" width="3" height="20" font="0"> </text>
<text top="107" left="440" width="143" height="20" font="7"><b>Exclusion criteria:</b> None </text>
<text top="124" left="440" width="3" height="20" font="0"> </text>
<text top="141" left="440" width="142" height="20" font="7"><b>Aim:</b> Prevalence of statin </text>
<text top="159" left="440" width="91" height="20" font="0">eligibility among </text>
<text top="176" left="440" width="158" height="20" font="0">Hispanic/Latinos living in the </text>
<text top="193" left="440" width="132" height="20" font="0">US under the new 2013 </text>
<text top="210" left="440" width="120" height="20" font="0">ACC/AHA guidelines. </text>
<text top="228" left="440" width="160" height="20" font="0">Comparison with NCEP/ATP </text>
<text top="245" left="440" width="76" height="20" font="0">III guidelines. </text>
<text top="262" left="440" width="3" height="20" font="0"> </text>
<text top="107" left="622" width="3" height="20" font="0"> </text>
<text top="107" left="852" width="3" height="20" font="0"> </text>
<text top="124" left="852" width="249" height="20" font="0">It was noticed too that using the 10 y ASCVD </text>
<text top="141" left="852" width="249" height="20" font="0">risk for White non-Hispanics, one fourth were </text>
<text top="159" left="852" width="258" height="20" font="0">statin eligible (26.9%; 95% CI: 5.8-28.0%); and </text>
<text top="176" left="852" width="233" height="20" font="0">using the black coefficient for Dominicans, </text>
<text top="193" left="852" width="254" height="20" font="0">Puerto Ricans and Central Americans, 28.2%; </text>
<text top="210" left="852" width="260" height="20" font="0">95% CI: 27.0-29.4%; were statin eligible, which </text>
<text top="228" left="852" width="256" height="20" font="0">is a 1.3 % absolute increase in statin eligibility. </text>
<text top="245" left="852" width="3" height="20" font="0"> </text>
<text top="262" left="852" width="82" height="20" font="7"><b>LIMITATIONS</b> </text>
<text top="279" left="852" width="143" height="20" font="0">Hispanic not well defined. </text>
<text top="296" left="852" width="249" height="20" font="0">Hispanic is not a race and the study does not </text>
<text top="314" left="852" width="256" height="20" font="0">take into consideration the race. Hispanics are </text>
<text top="331" left="852" width="213" height="20" font="0">classified by geographical area, not by </text>
<text top="348" left="852" width="53" height="20" font="0">ancestry. </text>
<text top="365" left="852" width="3" height="20" font="0"> </text>
<text top="383" left="91" width="67" height="20" font="7"><b>HCHS/SOL </b></text>
<text top="400" left="91" width="113" height="20" font="0">Mattei J, WT, et al.,  </text>
<text top="418" left="91" width="63" height="20" font="0">2016 <a href="data supplement.html#246">(177)</a> </text>
<text top="435" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27605403">27605403</a></text>
<text top="435" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27605403"> </a></text>
<text top="452" left="91" width="3" height="20" font="11"> </text>
<text top="452" left="94" width="3" height="20" font="0"> </text>
<text top="469" left="91" width="3" height="20" font="0"> </text>
<text top="383" left="224" width="161" height="20" font="7"><b>Study type:</b>  Cross sectional </text>
<text top="400" left="224" width="3" height="20" font="0"> </text>
<text top="418" left="224" width="77" height="20" font="7"><b>Size:</b>  12,406 </text>
<text top="435" left="224" width="3" height="20" font="0"> </text>
<text top="452" left="224" width="3" height="20" font="0"> </text>
<text top="383" left="440" width="106" height="20" font="7"><b>Inclusion criteria:</b> </text>
<text top="400" left="440" width="160" height="20" font="0">Hispanic/Latino, aged 18 -74 </text>
<text top="418" left="440" width="92" height="20" font="0">free of diabetes. </text>
<text top="435" left="440" width="128" height="20" font="0">(Multicenter population-</text>
<text top="452" left="440" width="44" height="20" font="0">based)  </text>
<text top="469" left="440" width="3" height="20" font="0"> </text>
<text top="487" left="440" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="504" left="440" width="162" height="20" font="0">Diabetes, self-report or in the </text>
<text top="521" left="440" width="100" height="20" font="0">laboratory values. </text>
<text top="538" left="440" width="3" height="20" font="0"> </text>
<text top="555" left="440" width="169" height="20" font="0">Aimed to compare diet quality, </text>
<text top="573" left="440" width="143" height="20" font="0">using AHEI, Range 0-110 </text>
<text top="590" left="440" width="138" height="20" font="0">lowest to highest quality. </text>
<text top="607" left="440" width="163" height="20" font="0"> With the association of MetS </text>
<text top="624" left="440" width="129" height="20" font="0">and its cardiometabolic </text>
<text top="641" left="440" width="161" height="20" font="0">components across 6 groups </text>
<text top="659" left="440" width="111" height="20" font="0">of Hispanic/Latinos. </text>
<text top="676" left="440" width="55" height="20" font="0">Mexicans </text>
<text top="693" left="440" width="81" height="20" font="0">Puerto Ricans </text>
<text top="710" left="440" width="40" height="20" font="0">Cuban </text>
<text top="727" left="440" width="68" height="20" font="0">Dominicans </text>
<text top="745" left="440" width="105" height="20" font="0">Central Americans </text>
<text top="762" left="440" width="97" height="20" font="0">South Americans </text>
<text top="779" left="440" width="3" height="20" font="0"> </text>
<text top="384" left="622" width="178" height="20" font="7"><b>1</b>°<b> endpoint:</b> The prevalence of </text>
<text top="402" left="622" width="179" height="20" font="0">Metabolic Syndrome was 23.2% </text>
<text top="419" left="622" width="43" height="20" font="0">overall. </text>
<text top="436" left="622" width="3" height="20" font="0"> </text>
<text top="453" left="622" width="187" height="20" font="0">Adjusted odds (95% CI) of having </text>
<text top="470" left="622" width="199" height="20" font="0">MetS were 22% (9%-33%) lower for </text>
<text top="488" left="622" width="179" height="20" font="0">each 10 – unit increase in AHEI. </text>
<text top="505" left="622" width="3" height="20" font="0"> </text>
<text top="522" left="622" width="214" height="20" font="7"><b>Results:</b> Adjusted mean AHEI differed </text>
<text top="539" left="622" width="180" height="20" font="0">by ethnic background (p&lt;0.001), </text>
<text top="557" left="622" width="212" height="20" font="0">ranging from 43.0 for Puerto Ricans to </text>
<text top="574" left="622" width="104" height="20" font="0">52.6 for Mexicans. </text>
<text top="591" left="622" width="3" height="20" font="0"> </text>
<text top="608" left="622" width="165" height="20" font="0">Lower odds observed only for </text>
<text top="625" left="622" width="198" height="20" font="0">Mexicans (30%; 95%CI: 13%, 44%) </text>
<text top="643" left="622" width="211" height="20" font="0">and Central Americans (42%; 95% CI: </text>
<text top="660" left="622" width="60" height="20" font="0">9%, 64%). </text>
<text top="677" left="622" width="203" height="20" font="0">AHEI inversely associated with waist </text>
<text top="694" left="622" width="193" height="20" font="0">circumference, blood pressure and </text>
<text top="711" left="622" width="206" height="20" font="0">glucose among Mexicans and Puerto </text>
<text top="729" left="622" width="200" height="20" font="0">Ricans and with triglycerides among </text>
<text top="746" left="622" width="85" height="20" font="0">Mexicans only. </text>
<text top="385" left="852" width="7" height="18" font="0">•</text>
<text top="384" left="859" width="249" height="20" font="0"> Diet varies with Hispanic/Latino background. </text>
<text top="402" left="852" width="240" height="20" font="0">This is important because a healthier diet is </text>
<text top="419" left="852" width="200" height="20" font="0">associated with lower odds of MetS. </text>
<text top="436" left="852" width="251" height="20" font="0">Association of AHEI and cardio metabolic risk </text>
<text top="453" left="852" width="204" height="20" font="0">factors, varies by ethnic background. </text>
<text top="472" left="852" width="7" height="18" font="0">•</text>
<text top="472" left="859" width="254" height="20" font="0"> The conclusion of the studies is that research </text>
<text top="489" left="852" width="243" height="20" font="0">and interventions should be different among </text>
<text top="506" left="852" width="142" height="20" font="0">ethnically diverse groups. </text>
<text top="523" left="852" width="243" height="20" font="0">There is a need to consider individual ethnic </text>
<text top="540" left="852" width="187" height="20" font="0">backgrounds to optimized results. </text>
<text top="559" left="852" width="7" height="18" font="0">•</text>
<text top="559" left="859" width="258" height="20" font="0"> CVD prevention strategies should address the </text>
<text top="576" left="852" width="251" height="20" font="0">fact that Hispanics have high rates of multiple </text>
<text top="593" left="852" width="254" height="20" font="0">risk factors and that interventions should differ </text>
<text top="610" left="852" width="179" height="20" font="0">by individual ethnic background. </text>
<text top="629" left="852" width="7" height="18" font="0">•</text>
<text top="629" left="859" width="215" height="20" font="0"> Ethnicity-specific analysis helps clarify </text>
<text top="646" left="852" width="256" height="20" font="0">inconsistent results of diet-disease association </text>
<text top="663" left="852" width="242" height="20" font="0">in Hispanics as a group and it will help tailor </text>
<text top="680" left="852" width="110" height="20" font="0">disease prevention. </text>
<text top="698" left="852" width="3" height="20" font="0"> </text>
<text top="715" left="852" width="252" height="20" font="0">Suggest types of foods and nutrients targeted </text>
<text top="732" left="852" width="143" height="20" font="0">for specific ethnic groups. </text>
<text top="749" left="852" width="3" height="20" font="0"> </text>
</page>
<page number="145" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">145 </text>
<text top="107" left="440" width="167" height="20" font="0">Previous studies reported one </text>
<text top="124" left="440" width="130" height="20" font="0">ethnicity or put them all </text>
<text top="141" left="440" width="49" height="20" font="0">together </text>
<text top="107" left="622" width="176" height="20" font="0">AHEI positively associated HDL </text>
<text top="124" left="622" width="209" height="20" font="0">cholesterol among Puerto Ricans and </text>
<text top="141" left="622" width="170" height="20" font="0">Central Americans (all p&lt;0.05) </text>
<text top="159" left="622" width="3" height="20" font="0"> </text>
<text top="176" left="622" width="205" height="20" font="0">Most ethnicities had unhealthy intake </text>
<text top="193" left="622" width="200" height="20" font="0">of sugar-sweetened beverages, and </text>
<text top="210" left="622" width="194" height="20" font="0">fruit juices, whole grains and whole </text>
<text top="228" left="622" width="212" height="20" font="0">fruit and favorable intakes of trans fats </text>
<text top="245" left="622" width="128" height="20" font="0">and nuts and legumes. </text>
<text top="262" left="622" width="3" height="20" font="0"> </text>
<text top="279" left="622" width="183" height="20" font="0">It helps understand why previous </text>
<text top="296" left="622" width="184" height="20" font="0">studies have inconsistent results. </text>
<text top="314" left="622" width="3" height="20" font="0"> </text>
<text top="331" left="622" width="203" height="20" font="0">Understand ethnic differences in diet </text>
<text top="348" left="622" width="170" height="20" font="0">and health and direct culturally </text>
<text top="365" left="622" width="198" height="20" font="0">appropriate diet quality components </text>
<text top="383" left="622" width="3" height="20" font="0"> </text>
<text top="107" left="852" width="241" height="20" font="0">Overall reinforce reducing sugar sweetened </text>
<text top="124" left="852" width="241" height="20" font="0">beverages and increasing whole grains and </text>
<text top="141" left="852" width="33" height="20" font="0">fruits. </text>
<text top="159" left="852" width="3" height="20" font="0"> </text>
<text top="176" left="852" width="215" height="20" font="0">Reduce sodium intake among Cubans, </text>
<text top="193" left="852" width="265" height="20" font="0">Increase vegetable intake among Puerto Ricans </text>
<text top="210" left="852" width="3" height="20" font="0"> </text>
<text top="228" left="852" width="225" height="20" font="0">AVOID GENERALIZATIONS on diet and </text>
<text top="245" left="852" width="204" height="20" font="0">cardiometabolic health for Hispanics. </text>
<text top="262" left="852" width="3" height="20" font="0"> </text>
<text top="279" left="852" width="259" height="20" font="0">Variation of diet among geographical areas but </text>
<text top="296" left="852" width="254" height="20" font="0">it was consistently best for Mexicans and poor </text>
<text top="314" left="852" width="102" height="20" font="0">for Puerto Ricans. </text>
<text top="331" left="852" width="3" height="20" font="0"> </text>
<text top="348" left="852" width="81" height="20" font="0">LIMITATIONS </text>
<text top="365" left="852" width="87" height="20" font="0">Cross sectional </text>
<text top="383" left="852" width="64" height="20" font="0">Recall bias </text>
<text top="400" left="852" width="252" height="20" font="0">AHEI is a measurement that is not specific for </text>
<text top="417" left="852" width="111" height="20" font="0">Hispanic population </text>
<text top="435" left="91" width="67" height="20" font="7"><b>HCHS/SOL </b></text>
<text top="452" left="91" width="108" height="20" font="0">Daviglus ML, et al., </text>
<text top="469" left="91" width="63" height="20" font="0">2016 <a href="data supplement.html#246">(178)</a> </text>
<text top="487" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27543802">27543802</a></text>
<text top="487" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27543802"> </a></text>
<text top="504" left="91" width="3" height="20" font="0"> </text>
<text top="521" left="91" width="107" height="20" font="0">HCHS data allow a </text>
<text top="538" left="91" width="116" height="20" font="0">level of granularity in </text>
<text top="555" left="91" width="100" height="20" font="0">examining the US </text>
<text top="573" left="91" width="87" height="20" font="0">Hispanic/Latino </text>
<text top="590" left="91" width="113" height="20" font="0">population by ethnic </text>
<text top="607" left="91" width="92" height="20" font="0">background and </text>
<text top="624" left="91" width="113" height="20" font="0">other characteristics </text>
<text top="641" left="91" width="70" height="20" font="0">that was not </text>
<text top="659" left="91" width="114" height="20" font="0">available previously. </text>
<text top="435" left="224" width="159" height="20" font="7"><b>Study type:</b>  cross sectional </text>
<text top="452" left="224" width="3" height="20" font="0"> </text>
<text top="469" left="224" width="77" height="20" font="7"><b>Size:</b>  14,757 </text>
<text top="487" left="224" width="3" height="20" font="0"> </text>
<text top="504" left="224" width="200" height="20" font="0">Aims to determine the prevalence of </text>
<text top="521" left="224" width="168" height="20" font="0">Low cardiovascular risk profile </text>
<text top="538" left="224" width="202" height="20" font="0">among Hispanics and its association </text>
<text top="555" left="224" width="105" height="20" font="0">with acculturation.  </text>
<text top="573" left="224" width="197" height="20" font="0">(SASH short acculturation Scale for </text>
<text top="590" left="224" width="61" height="20" font="0">Hispanics) </text>
<text top="607" left="224" width="3" height="20" font="0"> </text>
<text top="624" left="224" width="200" height="20" font="0">Low cardiovascular risk was defined </text>
<text top="641" left="224" width="156" height="20" font="0">by favorable levels of serum </text>
<text top="659" left="224" width="200" height="20" font="0">cholesterol, blood pressure and BMI </text>
<text top="676" left="224" width="195" height="20" font="0">and by not having diabetes and not </text>
<text top="693" left="224" width="103" height="20" font="0">currently smoking. </text>
<text top="435" left="440" width="142" height="20" font="7"><b>Inclusion criteria:</b> adults </text>
<text top="452" left="440" width="75" height="20" font="0">aged 18 to74 </text>
<text top="469" left="440" width="155" height="20" font="0">Hispanic/Latino background </text>
<text top="487" left="440" width="92" height="20" font="0">and free of CVD </text>
<text top="504" left="440" width="3" height="20" font="0"> </text>
<text top="521" left="440" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="538" left="440" width="94" height="20" font="0">CVD or diabetes </text>
<text top="555" left="440" width="109" height="20" font="0">Missing data for LR </text>
<text top="573" left="440" width="154" height="20" font="0">Lack of self-identification as </text>
<text top="590" left="440" width="118" height="20" font="0">any of the 6 Hispanic </text>
<text top="607" left="440" width="77" height="20" font="0">backgrounds. </text>
<text top="436" left="622" width="210" height="20" font="7"><b>1</b>°<b> endpoint:</b> Prevalence of LR profile </text>
<text top="453" left="622" width="214" height="20" font="0">among Hispanics is low, (8.4% overall; </text>
<text top="470" left="622" width="211" height="20" font="0">5.1% for men, 11.2% for women), and </text>
<text top="488" left="622" width="178" height="20" font="0">varied by background, (4.2% for </text>
<text top="505" left="622" width="211" height="20" font="0">Mexican men versus 15.0% in women </text>
<text top="522" left="622" width="109" height="20" font="0">of Cuban heritage). </text>
<text top="539" left="622" width="212" height="20" font="0">Acculturation is associated with higher </text>
<text top="557" left="622" width="187" height="20" font="0">odds of a LR only among women. </text>
<text top="574" left="622" width="3" height="20" font="0"> </text>
<text top="591" left="622" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="608" left="622" width="214" height="20" font="0">OR of having LR were 1.64% (95% CI: </text>
<text top="625" left="622" width="207" height="20" font="0">1.24-2.17) for foreign born versus US-</text>
<text top="643" left="622" width="202" height="20" font="0">born women and 1.96 (95% CI: 1.49-</text>
<text top="660" left="622" width="193" height="20" font="0">2.58) for women residing in the US </text>
<text top="677" left="622" width="182" height="20" font="0">less than 10 y versus 10 or more </text>
<text top="694" left="622" width="37" height="20" font="0">years. </text>
<text top="711" left="622" width="3" height="20" font="0"> </text>
<text top="729" left="622" width="185" height="20" font="0">Lack of current smoking the most </text>
<text top="746" left="622" width="186" height="20" font="0">predominant favorable risk factor. </text>
<text top="763" left="622" width="166" height="20" font="0">LR was higher among women </text>
<text top="437" left="852" width="7" height="18" font="0">•</text>
<text top="436" left="859" width="135" height="20" font="0"> Prevalence of LR is low </text>
<text top="455" left="852" width="7" height="18" font="0">•</text>
<text top="454" left="859" width="251" height="20" font="0"> Lower acculturation is associated with higher </text>
<text top="472" left="852" width="263" height="20" font="0">odds of a LR profile among women but no men. </text>
<text top="491" left="852" width="7" height="18" font="0">•</text>
<text top="490" left="859" width="254" height="20" font="0"> In general, LR adults were younger and more </text>
<text top="507" left="852" width="57" height="20" font="0">educated. </text>
<text top="526" left="852" width="7" height="18" font="0">•</text>
<text top="526" left="859" width="229" height="20" font="0"> Variations across Hispanic backgrounds. </text>
<text top="543" left="852" width="255" height="20" font="0">Men with Dominican and Mexican background </text>
<text top="560" left="852" width="169" height="20" font="0">had the lowest LR prevalence. </text>
<text top="577" left="852" width="258" height="20" font="0">Women with Puerto Rican background had the </text>
<text top="594" left="852" width="197" height="20" font="0">lowest rate of favorable risk factors. </text>
<text top="612" left="852" width="3" height="20" font="0"> </text>
<text top="629" left="852" width="250" height="20" font="0">Almost 1 in 4 Hispanic adult men and women </text>
<text top="646" left="852" width="264" height="20" font="0">(ranging from 15% Puerto Rican women to 36% </text>
<text top="663" left="852" width="235" height="20" font="0">South American men) have unfavorable or </text>
<text top="680" left="852" width="265" height="20" font="0">borderline risk status. This together with the fact </text>
<text top="698" left="852" width="248" height="20" font="0">that almost half of men and more than half of </text>
<text top="715" left="852" width="258" height="20" font="0">women have no health insurance, points to the </text>
<text top="732" left="852" width="248" height="20" font="0">need of developing public health initiatives to </text>
<text top="749" left="852" width="230" height="20" font="0">lower CVD risk in this growing population. </text>
<text top="766" left="852" width="3" height="20" font="0"> </text>
</page>
<page number="146" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">146 </text>
<text top="107" left="852" width="204" height="20" font="0">Further research need to understand </text>
<text top="124" left="852" width="77" height="20" font="0">acculturation. </text>
<text top="142" left="91" width="67" height="20" font="7"><b>HCHS/SOL </b></text>
<text top="159" left="91" width="100" height="20" font="0">Qi, Q, et al., 2015 </text>
<text top="177" left="91" width="32" height="20" font="0"><a href="data supplement.html#242">(107)</a><b> </b></text>
<text top="194" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26416808">26416808</a></text>
<text top="194" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26416808"> </a></text>
<text top="211" left="91" width="3" height="20" font="0"> </text>
<text top="142" left="224" width="161" height="20" font="7"><b>Study type:</b>  Cross sectional </text>
<text top="159" left="224" width="3" height="20" font="0"> </text>
<text top="177" left="224" width="77" height="20" font="7"><b>Size:</b>  12,083 </text>
<text top="142" left="440" width="142" height="20" font="7"><b>Inclusion criteria:</b> adults </text>
<text top="159" left="440" width="75" height="20" font="0">aged 18 to74 </text>
<text top="177" left="440" width="155" height="20" font="0">Hispanic/Latino background </text>
<text top="194" left="440" width="100" height="20" font="0">Complete data on </text>
<text top="211" left="440" width="154" height="20" font="0">cardiometabolic biomarkers </text>
<text top="228" left="440" width="3" height="20" font="0"> </text>
<text top="245" left="440" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="263" left="440" width="88" height="20" font="0">Not adherent to </text>
<text top="280" left="440" width="128" height="20" font="0">accelerometer protocol </text>
<text top="297" left="440" width="3" height="20" font="0"> </text>
<text top="314" left="440" width="3" height="20" font="0"> </text>
<text top="332" left="440" width="165" height="20" font="7"><b>UNIQUE CONTTRIBUTIONS </b></text>
<text top="349" left="440" width="150" height="20" font="0">-Objectively measured, not </text>
<text top="366" left="440" width="73" height="20" font="0">self-reported </text>
<text top="383" left="440" width="120" height="20" font="0">-Differences between </text>
<text top="401" left="440" width="155" height="20" font="0">Hispanic/Latino background </text>
<text top="418" left="440" width="44" height="20" font="0">groups. </text>
<text top="435" left="440" width="167" height="20" font="0">-Analysis stratified by physical </text>
<text top="452" left="440" width="44" height="20" font="0">activity. </text>
<text top="143" left="622" width="178" height="20" font="7"><b>1</b>°<b> endpoint:</b> sedentary lifestyle </text>
<text top="161" left="622" width="176" height="20" font="0">associated with decreased HDL </text>
<text top="178" left="622" width="210" height="20" font="0">cholesterol, cholesterol and increased </text>
<text top="195" left="622" width="185" height="20" font="0">blood pressure, elevated TG, 2-H </text>
<text top="212" left="622" width="211" height="20" font="0">glucose, fasting insulin, HOMA-IR and </text>
<text top="229" left="622" width="171" height="20" font="0">CRP (all p for trend p&lt;0.0001)  </text>
<text top="247" left="622" width="152" height="20" font="0">After adjustment for MVPA, </text>
<text top="264" left="622" width="168" height="20" font="0">association attenuated but still </text>
<text top="281" left="622" width="167" height="20" font="0">significant for HDL cholesterol </text>
<text top="298" left="622" width="212" height="20" font="0">(p=0.04), triglycerides (p&lt;0.0001), 2-H </text>
<text top="316" left="622" width="190" height="20" font="0">glucose (p&lt;0.0001), fasting insulin </text>
<text top="333" left="622" width="214" height="20" font="0">(p&lt;0.0001), and HOMA-IR (p&lt;0.0001). </text>
<text top="350" left="622" width="199" height="20" font="0">After further adjustment for BMI and </text>
<text top="367" left="622" width="207" height="20" font="0">waist to hip ratio, only the association </text>
<text top="384" left="622" width="211" height="20" font="0">with elevated TG, 2-H glucose, fasting </text>
<text top="402" left="622" width="186" height="20" font="0">insulin, and HOMA-IR (p&lt;0.0001) </text>
<text top="419" left="622" width="103" height="20" font="0">remain significant. </text>
<text top="436" left="622" width="3" height="20" font="0"> </text>
<text top="453" left="622" width="204" height="20" font="0">Even among those who met physical </text>
<text top="470" left="622" width="205" height="20" font="0">activity guidelines, sedentary lifestyle </text>
<text top="488" left="622" width="186" height="20" font="0">was detrimentally associated with </text>
<text top="505" left="622" width="197" height="20" font="0">several cardiometabolic biomarkers </text>
<text top="522" left="622" width="210" height="20" font="0">(diastolic blood pressure, high-density </text>
<text top="539" left="622" width="213" height="20" font="0">lipoprotein cholesterol, fasting and 2-H </text>
<text top="557" left="622" width="151" height="20" font="0">glucose, fasting insulin and </text>
<text top="574" left="622" width="189" height="20" font="0">homeostatic model assessment of </text>
<text top="591" left="622" width="166" height="20" font="0">insulin resistance; all p&lt;0.05). </text>
<text top="608" left="622" width="3" height="20" font="0"> </text>
<text top="625" left="622" width="206" height="20" font="7"><b>Results:</b> Strong association between </text>
<text top="643" left="622" width="132" height="20" font="0">sedentary behavior and </text>
<text top="660" left="622" width="116" height="20" font="0">cardiometabolic risk. </text>
<text top="677" left="622" width="196" height="20" font="0">Across Hispanic/Latino background </text>
<text top="694" left="622" width="44" height="20" font="0">groups. </text>
<text top="144" left="852" width="7" height="18" font="0">•</text>
<text top="143" left="859" width="220" height="20" font="0"> Association between sedentary life and </text>
<text top="161" left="852" width="215" height="20" font="0">elevated TG and insulin resistance. No </text>
<text top="178" left="852" width="252" height="20" font="0">association with blood pressure or cholesterol </text>
<text top="195" left="852" width="38" height="20" font="0">levels. </text>
<text top="212" left="852" width="3" height="20" font="0"> </text>
<text top="231" left="852" width="7" height="18" font="0">•</text>
<text top="231" left="859" width="244" height="20" font="0"> Need to reduce sedentary behaviors for the </text>
<text top="248" left="852" width="243" height="20" font="0">prevention of cardiometabolic disease, even </text>
<text top="265" left="852" width="220" height="20" font="0">among those who meet physical activity </text>
<text top="282" left="852" width="62" height="20" font="0">guidelines. </text>
<text top="300" left="852" width="3" height="20" font="0"> </text>
<text top="317" left="852" width="3" height="20" font="0"> </text>
<text top="334" left="852" width="82" height="20" font="7"><b>LIMITATIONS</b> </text>
<text top="351" left="852" width="264" height="20" font="0">Accelerometers placement and not discernment </text>
<text top="368" left="852" width="255" height="20" font="0">between sitting and standing up. Epoch length </text>
<text top="386" left="852" width="230" height="20" font="0">Self-reporting of some cardiovascular risk </text>
<text top="403" left="852" width="40" height="20" font="0">factors </text>
<text top="420" left="852" width="128" height="20" font="0">Cross sectional………. </text>
<text top="712" left="91" width="100" height="20" font="0">Kershaw K, et al., </text>
<text top="729" left="91" width="63" height="20" font="0">2012 <a href="data supplement.html#246">(179)</a> </text>
<text top="747" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23036519">23036519</a></text>
<text top="747" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23036519"> </a></text>
<text top="764" left="91" width="3" height="20" font="0"> </text>
<text top="781" left="91" width="3" height="20" font="11"> </text>
<text top="781" left="94" width="3" height="20" font="0"> </text>
<text top="712" left="224" width="158" height="20" font="7"><b>Study type:</b> Cross sectional </text>
<text top="729" left="224" width="3" height="20" font="0"> </text>
<text top="747" left="224" width="66" height="20" font="7"><b>Size:</b>  8693 </text>
<text top="764" left="224" width="3" height="20" font="0"> </text>
<text top="712" left="440" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="729" left="440" width="3" height="20" font="0"> </text>
<text top="747" left="440" width="155" height="20" font="7"><b>Exclusion criteria:</b> missing </text>
<text top="764" left="440" width="140" height="20" font="0">data on study covariates, </text>
<text top="781" left="440" width="98" height="20" font="0">pregnant women. </text>
<text top="713" left="622" width="216" height="20" font="7"><b>1</b>°<b> endpoint:</b> No differences in low risk </text>
<text top="730" left="622" width="160" height="20" font="0">among foreign born Mexican-</text>
<text top="748" left="622" width="211" height="20" font="0">Americans versus non-Hispanic White </text>
<text top="765" left="622" width="209" height="20" font="0">Americans when adjusted for sex and </text>
<text top="782" left="622" width="194" height="20" font="0">age (OR: 0.90; 95% CI: 0.62-1.33). </text>
<text top="714" left="852" width="7" height="18" font="0">•</text>
<text top="713" left="859" width="203" height="20" font="0">HEALTHY MIGRANT HYPOTHESIS </text>
<text top="730" left="852" width="260" height="20" font="0">Foreign born Mexican-Americans more likely to </text>
<text top="748" left="852" width="233" height="20" font="0">be low risk than Whites when adjusting for </text>
<text top="765" left="852" width="254" height="20" font="0">education and insurance status. Healthier, but </text>
<text top="782" left="852" width="254" height="20" font="0">education and insurance suppresses this, and </text>
</page>
<page number="147" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">147 </text>
<text top="107" left="224" width="144" height="20" font="0">Ethnic and nativity related </text>
<text top="124" left="224" width="196" height="20" font="0">differences in the prevalence of low </text>
<text top="141" left="224" width="145" height="20" font="0">cardiovascular risk and its </text>
<text top="159" left="224" width="168" height="20" font="0">relationship with acculturation, </text>
<text top="176" left="224" width="202" height="20" font="0">socioeconomic position and lifestyle. </text>
<text top="193" left="224" width="3" height="20" font="0"> </text>
<text top="107" left="440" width="3" height="20" font="0"> </text>
<text top="124" left="440" width="169" height="20" font="0">HEI Healthy Eating Index form </text>
<text top="141" left="440" width="132" height="20" font="0">2005 US Department of </text>
<text top="159" left="440" width="66" height="20" font="0">Agriculture. </text>
<text top="176" left="440" width="35" height="20" font="0">0-100 </text>
<text top="193" left="440" width="56" height="20" font="0">0-50 poor </text>
<text top="210" left="440" width="146" height="20" font="0">51-80 needs improvement </text>
<text top="228" left="440" width="55" height="20" font="0">&gt;80 good </text>
<text top="245" left="440" width="3" height="20" font="0"> </text>
<text top="262" left="440" width="165" height="20" font="0">Only 1% good poor vs. needs </text>
<text top="279" left="440" width="75" height="20" font="0">improvement </text>
<text top="296" left="440" width="3" height="20" font="0"> </text>
<text top="107" left="622" width="204" height="20" font="0">When adjusted for education odds of </text>
<text top="124" left="622" width="213" height="20" font="0">being low risk was 1.40 (95% CI: 0.92, </text>
<text top="141" left="622" width="206" height="20" font="0">2.12) higher for foreign born Mexican-</text>
<text top="159" left="622" width="176" height="20" font="0">Americans versus non-Hispanic </text>
<text top="176" left="622" width="209" height="20" font="0">Whites. Unchanged after adjusting for </text>
<text top="193" left="622" width="139" height="20" font="0">diet and physical activity. </text>
<text top="210" left="622" width="3" height="20" font="0"> </text>
<text top="227" left="622" width="3" height="20" font="0"> </text>
<text top="245" left="622" width="211" height="20" font="0">When adjusted for sex and age, being </text>
<text top="262" left="622" width="210" height="20" font="0">low risk was lower (OR: 0.49; 95% CI: </text>
<text top="279" left="622" width="202" height="20" font="0">0.34, 0.71) among US-born Mexican-</text>
<text top="296" left="622" width="202" height="20" font="0">American compared to non-Hispanic </text>
<text top="314" left="622" width="184" height="20" font="0">Whites. Adjustment for education </text>
<text top="331" left="622" width="206" height="20" font="0">attenuates the difference but remains </text>
<text top="348" left="622" width="196" height="20" font="0">significant (OR: 0.59; 95% CI: 0.41, </text>
<text top="365" left="622" width="38" height="20" font="0">0.84).  </text>
<text top="383" left="622" width="3" height="20" font="0"> </text>
<text top="400" left="622" width="190" height="20" font="0">Language of the questionnaire not </text>
<text top="417" left="622" width="210" height="20" font="0">associated with low risk, but language </text>
<text top="434" left="622" width="191" height="20" font="0">spoken at home is Spanish versus </text>
<text top="451" left="622" width="198" height="20" font="0">English or a mixture of Spanish and </text>
<text top="469" left="622" width="211" height="20" font="0">English (OR: 2.25; 95% CI: 1.20-4.23) </text>
<text top="486" left="622" width="170" height="20" font="0">The language spoken at home </text>
<text top="503" left="622" width="197" height="20" font="0">attenuated the association between </text>
<text top="520" left="622" width="114" height="20" font="0">low risk and nativity  </text>
<text top="537" left="622" width="3" height="20" font="0"> </text>
<text top="555" left="622" width="3" height="20" font="0"> </text>
<text top="572" left="622" width="184" height="20" font="0">Living less than 10 y foreign born </text>
<text top="589" left="622" width="208" height="20" font="0">Mexican-Americans are more likely to </text>
<text top="606" left="622" width="187" height="20" font="0">be low risk than US born Mexican-</text>
<text top="623" left="622" width="203" height="20" font="0">Americans 4.30 (95% CI: 2.61-7.10). </text>
<text top="641" left="622" width="203" height="20" font="0">Living more than 10 y decreased the </text>
<text top="658" left="622" width="183" height="20" font="0">ratio to 1.61 (95% CI: 0.99-2.61)  </text>
<text top="675" left="622" width="3" height="20" font="0"> </text>
<text top="692" left="622" width="3" height="20" font="0"> </text>
<text top="710" left="622" width="3" height="20" font="0"> </text>
<text top="727" left="622" width="184" height="20" font="7"><b>Results:</b> Low CV risk prevalence </text>
<text top="744" left="622" width="208" height="20" font="0">among men was less common for US </text>
<text top="761" left="622" width="188" height="20" font="0">born Mexican-Americans and non-</text>
<text top="778" left="622" width="164" height="20" font="0">Hispanic Whites. Low CV risk </text>
<text top="107" left="852" width="219" height="20" font="0">makes that without adjusting there is no </text>
<text top="124" left="852" width="215" height="20" font="0">difference in low risk between Mexican-</text>
<text top="141" left="852" width="127" height="20" font="0">Americans and Whites </text>
<text top="160" left="852" width="7" height="18" font="0">•</text>
<text top="160" left="859" width="222" height="20" font="0"> In contrast disparities between US born </text>
<text top="177" left="852" width="243" height="20" font="0">Mexican Americans and Whites persist after </text>
<text top="194" left="852" width="227" height="20" font="0">adjusting, suggesting that there are other </text>
<text top="211" left="852" width="225" height="20" font="0">factors, like discrimination and the stress </text>
<text top="229" left="852" width="168" height="20" font="0">associated with acculturation.  </text>
<text top="246" left="852" width="254" height="20" font="0">Language associated with close communities, </text>
<text top="263" left="852" width="247" height="20" font="0">where there might be less discrimination and </text>
<text top="280" left="852" width="79" height="20" font="0">more support. </text>
<text top="299" left="852" width="7" height="18" font="0">•</text>
<text top="299" left="859" width="163" height="20" font="0"> Ethnic and nativity variations </text>
<text top="318" left="852" width="7" height="18" font="0">•</text>
<text top="317" left="859" width="125" height="20" font="0"> Effect of acculturation </text>
<text top="334" left="852" width="3" height="20" font="0"> </text>
<text top="352" left="852" width="82" height="20" font="7"><b>LIMITATIONS </b></text>
<text top="369" left="852" width="262" height="20" font="0">Cross sectional, so it does not capture changes </text>
<text top="386" left="852" width="57" height="20" font="0">over time. </text>
<text top="403" left="852" width="141" height="20" font="0">Measure of acculturation. </text>
<text top="420" left="852" width="228" height="20" font="0">Influence of discrimination not measured. </text>
</page>
<page number="148" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">148 </text>
<text top="107" left="622" width="198" height="20" font="0">prevalence among women was less </text>
<text top="124" left="622" width="210" height="20" font="0">common for foreign born and US born </text>
<text top="141" left="622" width="169" height="20" font="0">Mexican-American versus non-</text>
<text top="159" left="622" width="95" height="20" font="0">Hispanic Whites. </text>
<text top="176" left="622" width="3" height="20" font="0"> </text>
<text top="193" left="622" width="203" height="20" font="0">Acculturation attenuates the effect of </text>
<text top="210" left="622" width="45" height="20" font="0">nativity. </text>
<text top="227" left="622" width="3" height="20" font="0"> </text>
<text top="247" left="88" width="921" height="20" font="7"><b>Abbreviations:</b> 1° indicated primary; CI, confidence interval; HR, hazard ratio; N/A, not available; OR, odds ratio; RCT, randomized controlled trial; and RR, relative risk. </text>
<text top="264" left="88" width="831" height="20" font="0">HCHS/SOL, Hispanic Community Health Study/Study of Latinos; ACC/AHA, American college of cardiology/American Heart Association; NCEP/ATP III 3</text>
<text top="266" left="919" width="7" height="13" font="9">rd</text>
<text top="264" left="926" width="173" height="20" font="0"> National cholesterol Education </text>
<text top="281" left="88" width="1048" height="20" font="0">Program Adult Treatment Panel; MetS M, metabolic syndrome; AHEI, Alternate Healthy Eating Index; LR, low risk; CVD, cardiovascular disease; LDL low density lipoprotein; HDL, High Density </text>
<text top="298" left="88" width="1029" height="20" font="0">Lipoprotein; BMI, Body Mass Index, HOMA – IR Homeostatic Model Assessment of Insulin Resistance; CRP, C-reactive protein; CV, cardiovascular; NHANES, National Health and Nutrition </text>
<text top="316" left="88" width="113" height="20" font="0">Examination Survey </text>
<text top="333" left="88" width="450" height="20" font="7"><b>Search Terms and Date of Search</b>: Cholesterol guidelines and Hispanic, 6/28/17 </text>
<text top="350" left="81" width="4" height="22" font="1"> </text>
<text top="368" left="81" width="789" height="24" font="4"><b>Data Supplement 28. Nonrandomized Trials, Observational Studies, and/or Registries of Hispanic (Section 4.5.1) </b></text>
<text top="390" left="111" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="407" left="136" width="48" height="20" font="7"><b>Author; </b></text>
<text top="425" left="114" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="399" left="263" width="118" height="20" font="7"><b>Study Type/Design; </b></text>
<text top="416" left="289" width="66" height="20" font="7"><b>Study Size </b></text>
<text top="407" left="439" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="399" left="634" width="179" height="20" font="7"><b>Primary Endpoint and Results </b></text>
<text top="416" left="632" width="184" height="20" font="7"><b>(P values; OR or RR; &amp; 95% CI) </b></text>
<text top="399" left="929" width="130" height="20" font="7"><b>Summary/Conclusion </b></text>
<text top="416" left="956" width="75" height="20" font="7"><b>Comment(s) </b></text>
<text top="443" left="96" width="104" height="20" font="0">Yoshida YX, et al., </text>
<text top="460" left="96" width="63" height="20" font="0">2016 <a href="data supplement.html#246">(180)</a> </text>
<text top="477" left="96" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27524787">27524787</a></text>
<text top="477" left="150" width="7" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27524787">  </a></text>
<text top="443" left="238" width="161" height="20" font="7"><b>Study type:</b>  Cross sectional </text>
<text top="460" left="238" width="3" height="20" font="0"> </text>
<text top="477" left="238" width="60" height="20" font="7"><b>Size:</b>  622 </text>
<text top="494" left="238" width="3" height="20" font="0"> </text>
<text top="512" left="238" width="127" height="20" font="0">Association of nutrition </text>
<text top="529" left="238" width="146" height="20" font="0">recommendations by ADA </text>
<text top="546" left="238" width="169" height="20" font="0">with sociodemographic factors </text>
<text top="563" left="238" width="161" height="20" font="0">and acculturation in Hispanic </text>
<text top="580" left="238" width="46" height="20" font="0">patients </text>
<text top="598" left="238" width="3" height="20" font="0"> </text>
<text top="615" left="238" width="167" height="20" font="0">Nutrition is an important factor </text>
<text top="632" left="238" width="118" height="20" font="0">in cardiovascular risk </text>
<text top="649" left="238" width="61" height="20" font="0">prevention </text>
<text top="443" left="420" width="106" height="20" font="7"><b>Inclusion criteria:</b> </text>
<text top="460" left="420" width="129" height="20" font="0">Hispanic, 20 y or older, </text>
<text top="477" left="420" width="141" height="20" font="0">with a previous diagnosis </text>
<text top="494" left="420" width="67" height="20" font="0">of diabetes. </text>
<text top="512" left="420" width="3" height="20" font="0"> </text>
<text top="529" left="420" width="131" height="20" font="7"><b>Exclusion criteria:</b> NA </text>
<text top="546" left="420" width="3" height="20" font="0"> </text>
<text top="563" left="420" width="120" height="20" font="0">Diet recommendation </text>
<text top="580" left="420" width="132" height="20" font="0">based on daily intake of </text>
<text top="598" left="420" width="138" height="20" font="0">saturated fat, cholesterol </text>
<text top="615" left="420" width="140" height="20" font="0">sodium, fiber and alcohol </text>
<text top="632" left="420" width="36" height="20" font="0">intake </text>
<text top="649" left="420" width="3" height="20" font="0"> </text>
<text top="666" left="420" width="132" height="20" font="0">Acculturation measured </text>
<text top="684" left="420" width="97" height="20" font="0">based on spoken </text>
<text top="701" left="420" width="142" height="20" font="0">language, country of birth </text>
<text top="718" left="420" width="129" height="20" font="0">and number of years in </text>
<text top="735" left="420" width="41" height="20" font="0">the US </text>
<text top="443" left="582" width="275" height="20" font="7"><b>1° endpoint:</b> Only 51%, 18% and 38% of HA with </text>
<text top="460" left="582" width="280" height="20" font="0">diabetes met saturated fat, fiber and sodium intake </text>
<text top="477" left="582" width="105" height="20" font="0">recommendations. </text>
<text top="494" left="582" width="205" height="20" font="0">Female HA were more likely to reach </text>
<text top="512" left="582" width="249" height="20" font="0">recommendations for cholesterol and sodium </text>
<text top="529" left="582" width="40" height="20" font="0">intake. </text>
<text top="546" left="582" width="263" height="20" font="0">The lowest achievement was among individuals </text>
<text top="563" left="582" width="175" height="20" font="0">between the ages of 20 to 45 y. </text>
<text top="580" left="582" width="3" height="20" font="0"> </text>
<text top="598" left="582" width="148" height="20" font="7"><b>UNEXPECTED RESULTS </b></text>
<text top="615" left="582" width="276" height="20" font="0">Low education had higher frequencies of meeting, </text>
<text top="632" left="582" width="237" height="20" font="0">fat, fiber , sodium, and three or more target </text>
<text top="649" left="582" width="101" height="20" font="0">recommendations </text>
<text top="666" left="582" width="3" height="20" font="0"> </text>
<text top="684" left="582" width="254" height="20" font="0">No insurance and public insurance had higher </text>
<text top="701" left="582" width="271" height="20" font="0">frequencies of meeting fiber, sodium, and alcohol </text>
<text top="718" left="582" width="176" height="20" font="0">intake target recommendations. </text>
<text top="735" left="582" width="3" height="20" font="0"> </text>
<text top="752" left="582" width="256" height="20" font="0">Poverty had higher frequency of meeting fiber, </text>
<text top="770" left="582" width="192" height="20" font="0">sodium, and three or more criteria. </text>
<text top="787" left="582" width="3" height="20" font="0"> </text>
<text top="445" left="879" width="7" height="18" font="0">•</text>
<text top="444" left="886" width="155" height="20" font="0">Only 49% of Hispanic met 3 </text>
<text top="461" left="879" width="139" height="20" font="0">recommendation criteria. </text>
<text top="478" left="879" width="186" height="20" font="0">Poor recommendation adherence </text>
<text top="496" left="879" width="183" height="20" font="0">associated with male gender and </text>
<text top="513" left="879" width="201" height="20" font="0">younger age (equal or less than 45). </text>
<text top="532" left="879" width="7" height="18" font="0">•</text>
<text top="531" left="886" width="219" height="20" font="0"> Female HA with diabetes more likely to </text>
<text top="548" left="879" width="222" height="20" font="0">achieve recommendation for cholesterol </text>
<text top="566" left="879" width="149" height="20" font="0">sodium and alcohol intake. </text>
<text top="585" left="879" width="7" height="18" font="0">•</text>
<text top="584" left="886" width="209" height="20" font="0"> Older HA with diabetes more likely to </text>
<text top="601" left="879" width="189" height="20" font="0">achieve recommendation for fiber, </text>
<text top="618" left="879" width="144" height="20" font="0">sodium and three or more </text>
<text top="636" left="879" width="105" height="20" font="0">recommendations. </text>
<text top="653" left="879" width="3" height="20" font="0"> </text>
<text top="670" left="879" width="218" height="20" font="0">Interesting positive association with low </text>
<text top="687" left="879" width="220" height="20" font="0">socioeconomic status, lack of insurance </text>
<text top="704" left="879" width="117" height="20" font="0">and lower education. </text>
<text top="722" left="879" width="3" height="20" font="0"> </text>
<text top="739" left="879" width="82" height="20" font="7"><b>LIMITATIONS </b></text>
<text top="756" left="879" width="172" height="20" font="0">-Cross sectional (not causality) </text>
</page>
<page number="149" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">149 </text>
<text top="107" left="582" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="124" left="582" width="268" height="20" font="0">Male lower odds to achieve daily cholesterol and </text>
<text top="141" left="582" width="272" height="20" font="0">sodium reductions recommendations than female </text>
<text top="159" left="582" width="260" height="20" font="0">(OR: 0.3; CI: 0.1– 0.5 and OR: 0.4; CI: 0.2–0.6, </text>
<text top="176" left="582" width="76" height="20" font="0">respectively). </text>
<text top="193" left="582" width="3" height="20" font="0"> </text>
<text top="210" left="582" width="260" height="20" font="0">Age between 45-60 and over 60 higher odds of </text>
<text top="228" left="582" width="190" height="20" font="0">achieving dietary fiber and sodium </text>
<text top="245" left="582" width="221" height="20" font="0">recommendations than younger than 45 </text>
<text top="262" left="582" width="264" height="20" font="0">(OR 4.0; CI: 2.0–7.9 and OR: 6.2; CI: 3.2– 11.9, </text>
<text top="279" left="582" width="73" height="20" font="0">respectively) </text>
<text top="296" left="582" width="3" height="20" font="0"> </text>
<text top="314" left="582" width="280" height="20" font="0">Highest income 50% lower odds of meeting dietary </text>
<text top="331" left="582" width="266" height="20" font="0">fiber recommendation than individuals under the </text>
<text top="348" left="582" width="192" height="20" font="0">poverty line (OR1: 0.5; CI: 0.2-0.9) </text>
<text top="365" left="582" width="3" height="20" font="0"> </text>
<text top="383" left="582" width="275" height="20" font="0">Lower odds for acculturated individuals to achieve </text>
<text top="400" left="582" width="277" height="20" font="0">saturated fat (OR: 0.5; CI: 0.2–0.7), fiber (OR: 0.5; </text>
<text top="417" left="582" width="259" height="20" font="0">CI: 0.2– 0.9), sodium (OR 0.5; CI: 0.3–0.9) and </text>
<text top="434" left="582" width="217" height="20" font="0">cholesterol intake (OR 0.5; CI: 0.3–0.8) </text>
<text top="451" left="582" width="224" height="20" font="0">recommendations than less acculturated </text>
<text top="469" left="582" width="61" height="20" font="0">individuals </text>
<text top="486" left="582" width="3" height="20" font="0"> </text>
<text top="503" left="582" width="3" height="20" font="0"> </text>
<text top="107" left="879" width="184" height="20" font="0">-Self reported, so individuals with </text>
<text top="124" left="879" width="197" height="20" font="0">undiagnosed diabetes not included. </text>
<text top="141" left="879" width="196" height="20" font="0">Not motivated for diet if not diabetic </text>
<text top="159" left="879" width="75" height="20" font="0">∙Type I and II </text>
<text top="176" left="879" width="217" height="20" font="0">-Study does not include undocumented </text>
<text top="193" left="879" width="67" height="20" font="0">immigrants. </text>
<text top="210" left="879" width="3" height="20" font="0"> </text>
<text top="228" left="879" width="3" height="20" font="0"> </text>
<text top="245" left="879" width="99" height="20" font="0">Female and older </text>
<text top="262" left="879" width="182" height="20" font="0">ROLE OF FAMILY IN HISPANIC </text>
<text top="279" left="879" width="176" height="20" font="0">CULTURE important to develop </text>
<text top="296" left="879" width="55" height="20" font="0">programs </text>
<text top="314" left="879" width="3" height="20" font="0"> </text>
<text top="521" left="96" width="115" height="20" font="0">Rana JS, et al.,2016 </text>
<text top="538" left="96" width="25" height="20" font="0"><a href="data supplement.html#241">(83)</a> </text>
<text top="555" left="96" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27151343">27151343</a></text>
<text top="555" left="150" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27151343"> </a></text>
<text top="521" left="238" width="141" height="20" font="7"><b>Study type:</b>  Prospective </text>
<text top="538" left="238" width="38" height="20" font="0">cohort </text>
<text top="555" left="238" width="3" height="20" font="0"> </text>
<text top="573" left="238" width="137" height="20" font="7"><b>Size:</b>  307,591 subset of </text>
<text top="590" left="238" width="109" height="20" font="0">4/242 with diabetes </text>
<text top="521" left="420" width="143" height="20" font="7"><b>Inclusion criteria:</b> Adults </text>
<text top="538" left="420" width="35" height="20" font="0">40-75 </text>
<text top="555" left="420" width="3" height="20" font="0"> </text>
<text top="573" left="420" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="590" left="420" width="140" height="20" font="0">Known ASCVD, diabetes </text>
<text top="607" left="420" width="144" height="20" font="0">mellitus, LDL less than 70 </text>
<text top="624" left="420" width="129" height="20" font="0">or more than 190, prior </text>
<text top="641" left="420" width="111" height="20" font="0">use of lipid lowering </text>
<text top="659" left="420" width="141" height="20" font="0">therapy or incomplete 5 y </text>
<text top="676" left="420" width="55" height="20" font="0">follow up. </text>
<text top="693" left="420" width="120" height="20" font="0">Sex or race. Ethnicity </text>
<text top="710" left="420" width="53" height="20" font="0">unknown </text>
<text top="727" left="420" width="85" height="20" font="0">missing criteria </text>
<text top="521" left="582" width="79" height="20" font="7"><b>1° endpoint:</b>  </text>
<text top="538" left="582" width="3" height="20" font="0"> </text>
<text top="555" left="582" width="264" height="20" font="0">Observed 5-y ASCVD incidence was lower than </text>
<text top="573" left="582" width="251" height="20" font="0">the predicted risk in each category: 0.20% vs. </text>
<text top="590" left="582" width="256" height="20" font="0">1.04% (95% CI: 0.20 to 0.25) for predicted risk </text>
<text top="607" left="582" width="268" height="20" font="0">&lt;2.50%; 0.65% vs. 3.08% (95% CI: 0.55 to 0.70) </text>
<text top="624" left="582" width="253" height="20" font="0">for predicted risk 2.50% to &lt;3.75%; 0.90% vs. </text>
<text top="641" left="582" width="256" height="20" font="0">4.34% (95% CI: 0.75 to 1.00) for predicted risk </text>
<text top="659" left="582" width="272" height="20" font="0">3.75% to &lt;5.00%; and 1.85% vs. 8.72% (95% CI: </text>
<text top="676" left="582" width="213" height="20" font="0">1.75 to 1.95) for predicted risk ≥5.00% </text>
<text top="693" left="582" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="710" left="582" width="3" height="20" font="0"> </text>
<text top="727" left="582" width="278" height="20" font="0">Overestimation and poor calibration with moderate </text>
<text top="745" left="582" width="268" height="20" font="0">discrimination observed in sex, racial/ethnic, and </text>
<text top="762" left="582" width="182" height="20" font="0">socioeconomic status subgroups </text>
<text top="779" left="582" width="140" height="20" font="0">(C statistic: 0.68 to 0.74)  </text>
<text top="523" left="879" width="7" height="18" font="0">•</text>
<text top="522" left="886" width="171" height="20" font="0">Overestimation across gender, </text>
<text top="539" left="879" width="213" height="20" font="0">ethnic/race groups and socioeconomic </text>
<text top="557" left="879" width="36" height="20" font="0">status </text>
<text top="574" left="879" width="3" height="20" font="0"> </text>
<text top="591" left="879" width="82" height="20" font="7"><b>LIMITATIONS </b></text>
<text top="608" left="879" width="20" height="20" font="0">5 y </text>
</page>
<page number="150" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">150 </text>
<text top="107" left="582" width="3" height="20" font="0"> </text>
<text top="124" left="582" width="3" height="20" font="0"> </text>
<text top="141" left="582" width="282" height="20" font="0">Better calibration for adults with diabetes but worse </text>
<text top="159" left="582" width="79" height="20" font="0">discrimination </text>
<text top="177" left="96" width="120" height="20" font="0">Rivera-Hernandez M, </text>
<text top="194" left="96" width="96" height="20" font="0">et al., 2016 <a href="data supplement.html#246">(181)</a> </text>
<text top="211" left="96" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27111865">27111865</a></text>
<text top="211" left="150" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27111865"> </a></text>
<text top="228" left="96" width="3" height="20" font="11"> </text>
<text top="228" left="99" width="3" height="20" font="0"> </text>
<text top="245" left="96" width="3" height="20" font="0"> </text>
<text top="177" left="238" width="165" height="20" font="7"><b>Study type:</b>  Cross sectional  </text>
<text top="194" left="238" width="3" height="20" font="0"> </text>
<text top="211" left="238" width="123" height="20" font="7"><b>Size:</b>  7.35 million MA </text>
<text top="228" left="238" width="53" height="20" font="0">enrollees </text>
<text top="245" left="238" width="118" height="20" font="0">Of those 14/4% were </text>
<text top="263" left="238" width="54" height="20" font="0">Hispanic. </text>
<text top="280" left="238" width="168" height="20" font="0">25.1% of all Hispanic reside in </text>
<text top="297" left="238" width="166" height="20" font="0">Puerto Rico, more than in any </text>
<text top="314" left="238" width="33" height="20" font="0">state. </text>
<text top="332" left="238" width="150" height="20" font="0">(99% of Puerto Ricans self-</text>
<text top="349" left="238" width="117" height="20" font="0">identify as Hispanic.) </text>
<text top="366" left="238" width="3" height="20" font="0"> </text>
<text top="177" left="420" width="128" height="20" font="7"><b>Inclusion criteria:</b> MA </text>
<text top="194" left="420" width="57" height="20" font="0">enrollees. </text>
<text top="211" left="420" width="3" height="20" font="0"> </text>
<text top="228" left="420" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="245" left="420" width="98" height="20" font="0">-Younger than 65 </text>
<text top="263" left="420" width="133" height="20" font="0">-Enrollees that were not </text>
<text top="280" left="420" width="140" height="20" font="0">Hispanic or non-Hispanic </text>
<text top="297" left="420" width="35" height="20" font="0">White </text>
<text top="314" left="420" width="132" height="20" font="0">-Not residents in Puerto </text>
<text top="332" left="420" width="140" height="20" font="0">Rico or the United States </text>
<text top="349" left="420" width="145" height="20" font="0">-Puerto Ricans enrolled in </text>
<text top="366" left="420" width="122" height="20" font="0">an MA plan outside of </text>
<text top="383" left="420" width="68" height="20" font="0">Puerto Rico </text>
<text top="401" left="420" width="132" height="20" font="0">-Puerto Rican residents </text>
<text top="418" left="420" width="127" height="20" font="0">who were not Hispanic </text>
<text top="178" left="582" width="249" height="20" font="7"><b>1</b>°<b> endpoint:</b> For 15 of the 17 measures, MA </text>
<text top="195" left="582" width="278" height="20" font="0">enrollees in Puerto Rico, received worse care than </text>
<text top="212" left="582" width="171" height="20" font="0">Hispanics in the United States. </text>
<text top="229" left="582" width="3" height="20" font="0"> </text>
<text top="247" left="582" width="277" height="20" font="0">BP control was worse for Hispanics in Puerto Rico </text>
<text top="264" left="582" width="255" height="20" font="0">versus Hispanics in the United States by 5.3% </text>
<text top="281" left="582" width="213" height="20" font="0">percentage points (95%CI: -9.7to -0.8) </text>
<text top="298" left="582" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="316" left="582" width="3" height="20" font="0"> </text>
<text top="333" left="582" width="3" height="20" font="0"> </text>
<text top="350" left="582" width="244" height="20" font="0">Measures related to cardiovascular disease. </text>
<text top="367" left="609" width="223" height="20" font="0">1.  LDL screening among persons with </text>
<text top="384" left="636" width="128" height="20" font="0">ischemic heart disease </text>
<text top="402" left="609" width="253" height="20" font="0">2.  LDL levels less than 100 among persons </text>
<text top="419" left="636" width="154" height="20" font="0">with ischemic heart disease </text>
<text top="436" left="609" width="221" height="20" font="0">3.  Beta blocker use 6 mo following MI </text>
<text top="453" left="609" width="248" height="20" font="0">4.  Blood pressure less than 140/90 among </text>
<text top="470" left="636" width="148" height="20" font="0">persons with Hypertension </text>
<text top="178" left="879" width="7" height="18" font="0">•</text>
<text top="178" left="886" width="207" height="20" font="0"> Slight differences between white and </text>
<text top="195" left="879" width="198" height="20" font="0">Hispanic MA enrollees in the United </text>
<text top="212" left="879" width="219" height="20" font="0">States but it was substantially worse for </text>
<text top="229" left="879" width="138" height="20" font="0">enrollees in Puerto Rico. </text>
<text top="247" left="879" width="3" height="20" font="0"> </text>
<text top="488" left="96" width="120" height="20" font="0">Adedinsewo D, et al., </text>
<text top="506" left="96" width="63" height="20" font="0">2016 <a href="data supplement.html#247">(182)</a> </text>
<text top="523" left="96" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27505443">27505443</a></text>
<text top="523" left="150" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27505443"> </a></text>
<text top="540" left="96" width="3" height="20" font="0"> </text>
<text top="488" left="238" width="159" height="20" font="7"><b>Study type:</b>  cross sectional </text>
<text top="506" left="238" width="3" height="20" font="0"> </text>
<text top="523" left="238" width="66" height="20" font="7"><b>Size:</b>  5319 </text>
<text top="540" left="238" width="3" height="20" font="0"> </text>
<text top="557" left="238" width="152" height="20" font="0">Prevalence of statin use for </text>
<text top="574" left="238" width="156" height="20" font="0">adults with diabetes mellitus </text>
<text top="592" left="238" width="163" height="20" font="0">and dyslipidemia. (defined as </text>
<text top="609" left="238" width="158" height="20" font="0">low density lipoprotein equal </text>
<text top="626" left="238" width="159" height="20" font="0">or over 70); defined as statin </text>
<text top="643" left="238" width="154" height="20" font="0">benefit group 1 (SBG1) and </text>
<text top="660" left="238" width="145" height="20" font="0">adults with atherosclerotic </text>
<text top="678" left="238" width="132" height="20" font="0">cardiovascular disease, </text>
<text top="695" left="238" width="168" height="20" font="0">defined as statin benefit group </text>
<text top="712" left="238" width="55" height="20" font="0">2 (SBG2) </text>
<text top="488" left="420" width="143" height="20" font="7"><b>Inclusion criteria:</b> Adults </text>
<text top="506" left="420" width="107" height="20" font="0">20 y and older who </text>
<text top="523" left="420" width="133" height="20" font="0">completed the interview </text>
<text top="540" left="420" width="3" height="20" font="0"> </text>
<text top="557" left="420" width="131" height="20" font="7"><b>Exclusion criteria:</b> NA </text>
<text top="490" left="582" width="257" height="20" font="7"><b>1</b>°<b> endpoint:</b> Uninsured and Hispanic persons </text>
<text top="507" left="582" width="263" height="20" font="0">were less likely to be on statin compared to non-</text>
<text top="524" left="582" width="272" height="20" font="0">Hispanic whites (ORs 0.33 and 0.70 respectively) </text>
<text top="541" left="582" width="96" height="20" font="0">(no CIs reported) </text>
<text top="558" left="582" width="3" height="20" font="0"> </text>
<text top="576" left="582" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="593" left="582" width="265" height="20" font="0">Persons in SBG1 and persons in SBG2 were as </text>
<text top="610" left="582" width="122" height="20" font="0">likely to be on a statin </text>
<text top="627" left="582" width="283" height="20" font="0">(ORs 4.15 and 4.96, respectively) (no CIs reported) </text>
<text top="644" left="582" width="281" height="20" font="0">Uninsured and Hispanic persons were less likely to </text>
<text top="662" left="582" width="252" height="20" font="0">be on statin compared to non-Hispanic whites </text>
<text top="679" left="582" width="280" height="20" font="0">(ORs 0.33 and 0.70 respectively) (no CIs reported) </text>
<text top="696" left="582" width="268" height="20" font="0">There was no significant difference between non-</text>
<text top="713" left="582" width="230" height="20" font="0">Hispanic whites and non-Hispanic blacks. </text>
<text top="490" left="879" width="7" height="18" font="0">•</text>
<text top="490" left="886" width="222" height="20" font="0"> Hispanic ethnicity and lack of insurance </text>
<text top="507" left="879" width="159" height="20" font="0">remain barriers to statin use. </text>
<text top="731" left="88" width="921" height="20" font="7"><b>Abbreviations:</b> 1° indicated primary; CI, confidence interval; HR, hazard ratio; N/A, not available; OR, odds ratio; RCT, randomized controlled trial; and RR, relative risk. </text>
<text top="748" left="88" width="1045" height="20" font="0">NHANES, National Health and Nutrition Examination Survey; ADA&lt; American Diabetes Association; US, United States; HA Hispanic American; ASCVD Atherosclerotic cardiovascular disease; </text>
<text top="766" left="88" width="772" height="20" font="0">LDL, Low density lipoprotein; MA, Medicare Advantage; HEDIS Healthcare Effectiveness Data and Information set; MI, myocardial infarction;  </text>
<text top="783" left="88" width="446" height="20" font="7"><b>Search Terms and Date of Search</b>: Cholesterol treatment and Hispanic, 6/28/17 </text>
</page>
<page number="151" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">151 </text>
<text top="106" left="88" width="944" height="20" font="0">Prevalence and Factors Associated With Statin Use Among a Nationally Representative Sample of US Adults: National Health and Nutrition Examination Survey, 2011-2012. </text>
<text top="123" left="81" width="1025" height="20" font="0">Another major knowledge gap is the lack of accurate ASCVD risk estimation specific to persons of Asian/Pacific Islander and Hispanic ethnicities, who are currently combined with the white </text>
<text top="141" left="81" width="259" height="20" font="0">population in the Pooled Cohort Risk Equation  </text>
<text top="158" left="81" width="4" height="22" font="1"> </text>
<text top="177" left="81" width="4" height="22" font="1"> </text>
<text top="195" left="81" width="797" height="24" font="4"><b>Data Supplement 29. Nonrandomized Trials, Observational Studies, and/or Registries of Hispanics (Section 4.5.1) </b></text>
<text top="217" left="105" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="234" left="131" width="48" height="20" font="7"><b>Author; </b></text>
<text top="252" left="108" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="217" left="270" width="38" height="20" font="7"><b>Study </b></text>
<text top="234" left="248" width="81" height="20" font="7"><b>Type/Design; </b></text>
<text top="252" left="256" width="66" height="20" font="7"><b>Study Size </b></text>
<text top="234" left="361" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="226" left="573" width="179" height="20" font="7"><b>Primary Endpoint and Results </b></text>
<text top="243" left="571" width="184" height="20" font="7"><b>(P values; OR or RR; &amp; 95% CI) </b></text>
<text top="226" left="920" width="130" height="20" font="7"><b>Summary/Conclusion </b></text>
<text top="243" left="947" width="75" height="20" font="7"><b>Comment(s) </b></text>
<text top="270" left="91" width="67" height="20" font="7"><b>HCHS/SOL </b></text>
<text top="287" left="91" width="101" height="20" font="0">Daviglus M, et al., </text>
<text top="304" left="91" width="31" height="20" font="0">2014 </text>
<text top="321" left="91" width="55" height="20" font="8"><a href="">25242694</a></text>
<text top="321" left="146" width="7" height="20" font="0"><a href=""> </a> </text>
<text top="270" left="231" width="107" height="20" font="7"><b>Study type:</b>  cross </text>
<text top="287" left="231" width="52" height="20" font="0">sectional </text>
<text top="304" left="231" width="3" height="20" font="0"> </text>
<text top="321" left="231" width="70" height="20" font="7"><b>Size:</b>  5079  </text>
<text top="338" left="231" width="3" height="20" font="0"> </text>
<text top="356" left="231" width="111" height="20" font="0">Study the burden of </text>
<text top="373" left="231" width="83" height="20" font="0">CV risk factors </text>
<text top="390" left="231" width="60" height="20" font="0">among HL </text>
<text top="407" left="231" width="3" height="20" font="0"> </text>
<text top="424" left="231" width="79" height="20" font="0">Compare with </text>
<text top="442" left="231" width="92" height="20" font="0">previous studies </text>
<text top="459" left="231" width="66" height="20" font="0">done in MA </text>
<text top="270" left="359" width="102" height="20" font="0">Participants of the </text>
<text top="287" left="359" width="70" height="20" font="0">HCHS/SOL  </text>
<text top="270" left="487" width="3" height="20" font="7"><b> </b></text>
<text top="287" left="487" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="304" left="487" width="3" height="20" font="7"><b> </b></text>
<text top="321" left="487" width="32" height="20" font="0">HTN  </text>
<text top="338" left="487" width="263" height="20" font="0">NHANES data MA lower prevalence among MA </text>
<text top="356" left="487" width="70" height="20" font="0">HCHS/SOL  </text>
<text top="373" left="487" width="342" height="20" font="0">Dominican men highest prevalence of HTN followed by Puerto </text>
<text top="390" left="487" width="78" height="20" font="0">Rican women </text>
<text top="407" left="487" width="265" height="20" font="0">SA, both men and women, had the lowest rates. </text>
<text top="424" left="487" width="345" height="20" font="0">Awareness, rate of treatment and control vary by group, lowest </text>
<text top="442" left="487" width="122" height="20" font="0">for Central Americans </text>
<text top="459" left="487" width="3" height="20" font="0"> </text>
<text top="476" left="487" width="122" height="20" font="0">Hypercholesterolemia </text>
<text top="493" left="487" width="66" height="20" font="0">HCHS/SOL </text>
<text top="511" left="487" width="350" height="20" font="0">Mean levels higher for HL than non-Hispanic whites and blacks. </text>
<text top="528" left="487" width="252" height="20" font="0">Highest for CA men and Puerto Rican women </text>
<text top="545" left="487" width="3" height="20" font="0"> </text>
<text top="562" left="487" width="52" height="20" font="0">Diabetes </text>
<text top="579" left="487" width="196" height="20" font="0">Higher rates for HL in the NHANES </text>
<text top="597" left="487" width="66" height="20" font="0">HCHS/SOL </text>
<text top="614" left="487" width="208" height="20" font="0">Similar rates for all groups as a whole </text>
<text top="631" left="487" width="333" height="20" font="0">Highest for MA men and Puerto Rican women, lowest for SA </text>
<text top="648" left="487" width="94" height="20" font="0">men and women </text>
<text top="665" left="487" width="3" height="20" font="0"> </text>
<text top="683" left="487" width="45" height="20" font="0">Obesity </text>
<text top="700" left="487" width="66" height="20" font="0">HCHS/SOL </text>
<text top="717" left="487" width="323" height="20" font="0">Highest for Puerto Rican women and lowest for SA women </text>
<text top="734" left="487" width="3" height="20" font="0"> </text>
<text top="751" left="487" width="51" height="20" font="0">Smoking </text>
<text top="769" left="487" width="66" height="20" font="0">HCHS/SOL </text>
<text top="786" left="487" width="257" height="20" font="0">Higher rates of smoking than National average </text>
<text top="271" left="852" width="7" height="18" font="0">•</text>
<text top="271" left="859" width="240" height="20" font="0"> Large proportion of men and women ( 80% </text>
<text top="288" left="852" width="256" height="20" font="0">and 71% respectively) have at least one major </text>
<text top="305" left="852" width="86" height="20" font="0">CVD risk factor </text>
<text top="324" left="852" width="7" height="18" font="0">•</text>
<text top="324" left="859" width="250" height="20" font="0"> Prevalence of 3 or more CV disease RF was </text>
<text top="341" left="852" width="172" height="20" font="0">highest among Puerto Ricans.  </text>
<text top="360" left="852" width="7" height="18" font="0">•</text>
<text top="359" left="859" width="224" height="20" font="0"> Prevalence of 3 or more CV disease RF </text>
<text top="376" left="852" width="263" height="20" font="0">higher among participants with lower education. </text>
<text top="395" left="852" width="7" height="18" font="0">•</text>
<text top="395" left="859" width="240" height="20" font="0"> Acculturation associated to higher levels of </text>
<text top="412" left="852" width="40" height="20" font="0">CV RF </text>
<text top="429" left="852" width="191" height="20" font="0">BURDEN OF CV RISK FACTORS </text>
<text top="446" left="852" width="100" height="20" font="0">Marked variations </text>
<text top="464" left="852" width="260" height="20" font="0">HETEROGENEICITY OF HISPANIC GROUPS </text>
<text top="481" left="852" width="226" height="20" font="0">IS THE CONCLUSION OF THIS STUDY </text>
<text top="498" left="852" width="3" height="20" font="0"> </text>
<text top="515" left="852" width="232" height="20" font="0">Previous studies underestimated the CVD </text>
<text top="532" left="852" width="190" height="20" font="0">burden and masked heterogeneity </text>
<text top="550" left="852" width="3" height="20" font="0"> </text>
<text top="567" left="852" width="131" height="20" font="0">Rates in general higher </text>
<text top="584" left="852" width="259" height="20" font="0">The risk factors highly prevalent among HL are </text>
<text top="601" left="852" width="68" height="20" font="0">in this order </text>
<text top="619" left="852" width="31" height="20" font="0">MEN </text>
<text top="636" left="852" width="122" height="20" font="0">Hypercholesterolemia </text>
<text top="653" left="852" width="45" height="20" font="0">Obesity </text>
<text top="670" left="852" width="29" height="20" font="0">HTN </text>
<text top="688" left="852" width="51" height="20" font="0">Smoking </text>
<text top="705" left="852" width="52" height="20" font="0">WOMEN </text>
<text top="722" left="852" width="45" height="20" font="0">Obesity </text>
<text top="739" left="852" width="122" height="20" font="0">Hypercholesterolemia </text>
<text top="756" left="852" width="29" height="20" font="0">HTN </text>
</page>
<page number="152" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">152 </text>
<text top="107" left="487" width="310" height="20" font="0">Highest for men of Puerto Rican and Cuban background </text>
<text top="125" left="91" width="67" height="20" font="7"><b>HCHS/SOL </b></text>
<text top="142" left="91" width="101" height="20" font="0">Daviglus M, et al., </text>
<text top="159" left="91" width="63" height="20" font="0">2012 <a href="data supplement.html#247">(183)</a> </text>
<text top="177" left="91" width="55" height="20" font="8"><a href="">23117778</a></text>
<text top="177" left="146" width="3" height="20" font="0"><a href=""> </a></text>
<text top="125" left="231" width="109" height="20" font="7"><b>Study type:</b>  Cross </text>
<text top="142" left="231" width="52" height="20" font="0">sectional </text>
<text top="159" left="231" width="3" height="20" font="0"> </text>
<text top="177" left="231" width="73" height="20" font="7"><b>Size:</b>  15079 </text>
<text top="194" left="231" width="3" height="20" font="0"> </text>
<text top="211" left="231" width="110" height="20" font="0">RF association with </text>
<text top="228" left="231" width="91" height="20" font="0">CHD and stroke </text>
<text top="125" left="359" width="102" height="20" font="0">Participants of the </text>
<text top="142" left="359" width="70" height="20" font="0">HCHS/SOL  </text>
<text top="125" left="487" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="142" left="487" width="3" height="20" font="0"> </text>
<text top="159" left="487" width="185" height="20" font="0">Same as above in RF distribution </text>
<text top="177" left="487" width="3" height="20" font="7"><b> </b></text>
<text top="194" left="487" width="219" height="20" font="0">HTN and smoking associated with CHD </text>
<text top="211" left="487" width="312" height="20" font="0">In both sexes , hyperlipidemia and obesity in women and </text>
<text top="228" left="487" width="168" height="20" font="0">diabetes in men (ORs 1.5-2.2) </text>
<text top="246" left="487" width="3" height="20" font="0"> </text>
<text top="263" left="487" width="338" height="20" font="0">HTN associated with stroke in both sexes, smoking in women </text>
<text top="280" left="487" width="192" height="20" font="0">and diabetes in men (ORs 1.7-2.6) </text>
<text top="127" left="852" width="7" height="18" font="0">•</text>
<text top="126" left="859" width="245" height="20" font="0"> Adverse CVD risk profile was higher among </text>
<text top="143" left="852" width="237" height="20" font="0">participants with Puerto Rican background, </text>
<text top="161" left="852" width="244" height="20" font="0">lower SES and higher levels of acculturation </text>
<text top="178" left="852" width="3" height="20" font="0"> </text>
<text top="298" left="91" width="67" height="20" font="7"><b>HCHS/SOL</b> </text>
<text top="315" left="91" width="112" height="20" font="0">Schneiderman N, et </text>
<text top="332" left="91" width="83" height="20" font="0">al., 2014 <a href="data supplement.html#247">(184)</a><b> </b></text>
<text top="350" left="91" width="55" height="20" font="8"><a href="">25212986</a></text>
<text top="350" left="146" width="3" height="20" font="0"><a href=""> </a></text>
<text top="298" left="231" width="77" height="20" font="7"><b>Study type:</b>   </text>
<text top="315" left="231" width="3" height="20" font="0"> </text>
<text top="332" left="231" width="73" height="20" font="7"><b>Size:</b>  16415 </text>
<text top="298" left="359" width="102" height="20" font="0">Participants of the </text>
<text top="315" left="359" width="66" height="20" font="0">HCHS/SOL </text>
<text top="298" left="487" width="3" height="20" font="0"> </text>
<text top="315" left="487" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="332" left="487" width="230" height="20" font="0">Diabetes associated with CHD and stroke </text>
<text top="350" left="487" width="204" height="20" font="0">Diabetes prevalence varied by group </text>
<text top="367" left="487" width="182" height="20" font="0">Less awareness and less control </text>
<text top="384" left="487" width="342" height="20" font="0">MetS significant variability in prevalence among participants of </text>
<text top="401" left="487" width="299" height="20" font="0">different HL background. Puerto Rican women highest </text>
<text top="418" left="487" width="213" height="20" font="0">prevalence and SA women the lowest. </text>
<text top="436" left="487" width="171" height="20" font="0">Prevalence increased with age </text>
<text top="453" left="487" width="336" height="20" font="0">Obesity, among HL women more likely to be obese than men </text>
<text top="470" left="487" width="311" height="20" font="0">HTN significant variability among groups, highest among </text>
<text top="487" left="487" width="258" height="20" font="0">Dominican men and lowest among SA women. </text>
<text top="504" left="487" width="222" height="20" font="0">Difference across geographical location. </text>
<text top="522" left="487" width="241" height="20" font="0">No variation with education level or income. </text>
<text top="539" left="487" width="160" height="20" font="0">Less awareness and control. </text>
<text top="556" left="487" width="300" height="20" font="0">Sleep disorders, unawareness and lack of treatment in </text>
<text top="573" left="487" width="77" height="20" font="0">consequence </text>
<text top="591" left="487" width="282" height="20" font="0">Smoking Highest among Puerto Ricans and Cuban </text>
<text top="608" left="487" width="49" height="20" font="0">Nutrition </text>
<text top="625" left="487" width="349" height="20" font="0">Puerto Ricans and Dominicans reported higher intakes of foods </text>
<text top="642" left="487" width="257" height="20" font="0">that are a risk for CVD and the opposite for SA </text>
<text top="298" left="852" width="259" height="20" font="0">To be successful in preventing CVD among HL </text>
<text top="315" left="852" width="255" height="20" font="0">we need to understand the diversity within this </text>
<text top="332" left="852" width="64" height="20" font="0">population. </text>
<text top="350" left="852" width="138" height="20" font="0">Target of specific groups </text>
<text top="367" left="852" width="3" height="20" font="0"> </text>
<text top="384" left="852" width="259" height="20" font="0">Attention to Access to health care and Lifestyle </text>
<text top="401" left="852" width="255" height="20" font="0">variables to lighten the burden of CVD RF and </text>
<text top="418" left="852" width="154" height="20" font="0">disease burdens among HL </text>
<text top="660" left="81" width="3" height="20" font="7"><b> </b></text>
<text top="678" left="81" width="991" height="20" font="7"><b>Abbreviations:</b> 1° indicated primary; CI, confidence interval; HR, hazard ratio; N/A, not available; OR, odds ratio; RCT, randomized controlled trial; and RR, relative risk; HCHS/SOL<b>, </b></text>
<text top="696" left="81" width="996" height="20" font="0">Hispanic Community Health Study/Study of Latinos; NHANES, Hispanic Health and Nutrition Examination;<b> </b>CV, cardiovascular; CVD, cardiovascular Disease; HL, Hispanic/Latino; MA, </text>
<text top="713" left="81" width="706" height="20" font="0">Mexican-American; SA, South American; CA, Central American; RF Risk factors; HTN, Hypertension; MetS, Metabolic Syndrome<b> </b></text>
<text top="730" left="81" width="472" height="20" font="7"><b>Search Terms and Date of Search</b>: Cardiovascular disease risk factors and Hispanic </text>
<text top="747" left="81" width="4" height="22" font="1"> </text>
<text top="766" left="81" width="4" height="22" font="1"> </text>
<text top="785" left="81" width="4" height="22" font="1"> </text>
</page>
<page number="153" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">153 </text>
<text top="106" left="81" width="785" height="24" font="4"><b>Data Supplement 30 Nonrandomized Trials, Observational Studies, and/or Registries of Hispanic (Section 4.5.1) </b></text>
<text top="128" left="95" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="145" left="120" width="48" height="20" font="7"><b>Author; </b></text>
<text top="162" left="98" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="136" left="226" width="118" height="20" font="7"><b>Study Type/Design; </b></text>
<text top="154" left="252" width="66" height="20" font="7"><b>Study Size </b></text>
<text top="145" left="381" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="136" left="577" width="179" height="20" font="7"><b>Primary Endpoint and Results </b></text>
<text top="154" left="574" width="184" height="20" font="7"><b>(P values; OR or RR; &amp; 95% CI) </b></text>
<text top="136" left="910" width="130" height="20" font="7"><b>Summary/Conclusion </b></text>
<text top="154" left="937" width="75" height="20" font="7"><b>Comment(s) </b></text>
<text top="180" left="91" width="67" height="20" font="7"><b>HCHS/SOL</b> </text>
<text top="197" left="91" width="107" height="20" font="0">Arguelles W, et al<b>., </b></text>
<text top="215" left="91" width="63" height="20" font="0">2015 <a href="data supplement.html#247">(185)</a><b> </b></text>
<text top="232" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25745986">25745986</a></text>
<text top="232" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25745986"> </a></text>
<text top="180" left="211" width="107" height="20" font="7"><b>Study type:</b>  cross </text>
<text top="197" left="211" width="52" height="20" font="0">sectional </text>
<text top="215" left="211" width="3" height="20" font="0"> </text>
<text top="232" left="211" width="77" height="20" font="7"><b>Size:</b>  15,825 </text>
<text top="249" left="211" width="3" height="20" font="0"> </text>
<text top="266" left="211" width="3" height="20" font="0"> </text>
<text top="283" left="211" width="145" height="20" font="0">To see if distinct subtypes </text>
<text top="301" left="211" width="148" height="20" font="0">of MetS could be identified </text>
<text top="318" left="211" width="136" height="20" font="0">and how these subtypes </text>
<text top="335" left="211" width="141" height="20" font="0">relate to CVD prevalence </text>
<text top="180" left="373" width="66" height="20" font="0">HCHS/SOL </text>
<text top="197" left="373" width="70" height="20" font="0">participants  </text>
<text top="215" left="373" width="3" height="20" font="0"> </text>
<text top="232" left="373" width="120" height="20" font="0">Excluded participants </text>
<text top="249" left="373" width="122" height="20" font="0">who had missing data </text>
<text top="266" left="373" width="118" height="20" font="0">on HL background or </text>
<text top="283" left="373" width="120" height="20" font="0">self-reported as more </text>
<text top="301" left="373" width="99" height="20" font="0">than one heritage </text>
<text top="318" left="373" width="3" height="20" font="0"> </text>
<text top="335" left="373" width="119" height="20" font="0">Covariates: age, sex, </text>
<text top="352" left="373" width="90" height="20" font="0">HL background, </text>
<text top="369" left="373" width="88" height="20" font="0">smoking, family </text>
<text top="387" left="373" width="109" height="20" font="0">History of CHD and </text>
<text top="404" left="373" width="121" height="20" font="0">stroke, education and </text>
<text top="421" left="373" width="79" height="20" font="0">family income </text>
<text top="180" left="514" width="3" height="20" font="0"> </text>
<text top="197" left="514" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="215" left="514" width="274" height="20" font="0">Including covariates, changed classification, more </text>
<text top="232" left="514" width="167" height="20" font="0">individuals classified as MetS. </text>
<text top="249" left="541" width="271" height="20" font="0">1.  Being older (OR: 1.32 for men and OR: 1.29 </text>
<text top="269" left="568" width="247" height="20" font="0">for women) and having family history of CHD </text>
<text top="289" left="568" width="244" height="20" font="0">(OR: 1.12 for men and OR: 1.16 for women) </text>
<text top="308" left="568" width="243" height="20" font="0">increases the odds of belonging to the MetS </text>
<text top="328" left="568" width="43" height="20" font="0">cluster. </text>
<text top="348" left="541" width="263" height="20" font="0">2.  Being of SA compared to Mexican descent </text>
<text top="368" left="568" width="232" height="20" font="0">associated with lower odds (OR = 0.46 for </text>
<text top="388" left="568" width="248" height="20" font="0">men and 0.61 for women) of belonging to the </text>
<text top="407" left="568" width="72" height="20" font="0">MetS cluster </text>
<text top="427" left="541" width="275" height="20" font="0">3.  In women, Lower education (OR:0.77), lower </text>
<text top="447" left="568" width="248" height="20" font="0">income (OR:0.87), never smoking (OR: 0.72) </text>
<text top="467" left="568" width="204" height="20" font="0">and being Puerto Rican compared to </text>
<text top="486" left="568" width="221" height="20" font="0">Mexican descent associated with higher </text>
<text top="506" left="568" width="236" height="20" font="0">odds of belonging to the MetS cluster (OR: </text>
<text top="526" left="568" width="31" height="20" font="0">2.01) </text>
<text top="561" left="514" width="297" height="20" font="0">This is consistent with previous studies, except for the </text>
<text top="578" left="514" width="77" height="20" font="0">non-smoking. </text>
<text top="595" left="514" width="302" height="20" font="0">Family History of stroke and other backgrounds did not </text>
<text top="612" left="514" width="107" height="20" font="0">affect classification </text>
<text top="630" left="514" width="265" height="20" font="0">Mexicans had the highest prevalence of MetS in </text>
<text top="647" left="514" width="191" height="20" font="0">MESA&lt; followed by Puerto Ricans </text>
<text top="182" left="832" width="7" height="18" font="0">•</text>
<text top="181" left="838" width="255" height="20" font="0"> Unable to distinguish subtypes of MetS in HL. </text>
<text top="200" left="832" width="7" height="18" font="0">•</text>
<text top="200" left="838" width="249" height="20" font="0"> waist circumference cut off may not optimize </text>
<text top="217" left="832" width="275" height="20" font="0">diagnosis for HL women (Elevated WC among HL </text>
<text top="234" left="832" width="245" height="20" font="0">women with an otherwise healthy CV profile, </text>
<text top="251" left="832" width="147" height="20" font="0">clustered in the non-MetS  </text>
<text top="269" left="832" width="274" height="20" font="0">Ethnic specific cut offs? Aschner et al. (reference) </text>
<text top="286" left="832" width="271" height="20" font="0">suggest 90 cm instead of 88 cm, but this reduces </text>
<text top="303" left="832" width="159" height="20" font="0">de prevalence by only 1-2%) </text>
<text top="322" left="832" width="7" height="18" font="0">•</text>
<text top="321" left="838" width="257" height="20" font="0"> HDL differentiates poorly between US HL with </text>
<text top="339" left="832" width="273" height="20" font="0">and without MetS (mean= 45.4 vs. 44.6 mg/dL for </text>
<text top="356" left="832" width="228" height="20" font="0">men and 51.3 vs. 52.0 mg/dL for women) </text>
<text top="373" left="832" width="245" height="20" font="0">CURRENT CRITERIA MAY NOT OPTIMIZE </text>
<text top="390" left="832" width="238" height="20" font="0">DIAGNOSIS OFMETABOLIC SYNDROME </text>
<text top="407" left="832" width="69" height="20" font="0">AMONG HL </text>
<text top="425" left="832" width="3" height="20" font="0"> </text>
<text top="442" left="832" width="271" height="20" font="0">NOT CONSENSUS in the role of MetS as screen </text>
<text top="459" left="832" width="124" height="20" font="0">for risk of CV disease. </text>
<text top="476" left="832" width="276" height="20" font="0">Use individual cardiovascular risk factors, whether </text>
<text top="493" left="832" width="170" height="20" font="0">they occur alone or in clusters. </text>
<text top="665" left="91" width="67" height="20" font="7"><b>HCHS/SOL </b></text>
<text top="682" left="91" width="84" height="20" font="0">Heiss G, et al., </text>
<text top="699" left="91" width="63" height="20" font="0">2014 <a href="data supplement.html#247">(184)</a> </text>
<text top="717" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25061141">25061141</a></text>
<text top="717" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25061141"> </a></text>
<text top="665" left="211" width="107" height="20" font="7"><b>Study type:</b>  cross </text>
<text top="682" left="211" width="52" height="20" font="0">sectional </text>
<text top="699" left="211" width="3" height="20" font="0"> </text>
<text top="717" left="211" width="77" height="20" font="7"><b>Size:</b>  16,319 </text>
<text top="734" left="211" width="3" height="20" font="0"> </text>
<text top="751" left="211" width="148" height="20" font="0">Prevalence of MetS higher </text>
<text top="768" left="211" width="137" height="20" font="0">among HL, but unknown </text>
<text top="665" left="373" width="66" height="20" font="0">HCHS/SOL </text>
<text top="682" left="373" width="70" height="20" font="0">participants  </text>
<text top="699" left="373" width="3" height="20" font="0"> </text>
<text top="717" left="373" width="120" height="20" font="0">Excluded participants </text>
<text top="734" left="373" width="122" height="20" font="0">who had missing data </text>
<text top="751" left="373" width="118" height="20" font="0">on HL background or </text>
<text top="768" left="373" width="120" height="20" font="0">self-reported as more </text>
<text top="785" left="373" width="99" height="20" font="0">than one heritage </text>
<text top="665" left="514" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="682" left="514" width="291" height="20" font="0">Different prevalence by age, sex and HL background </text>
<text top="699" left="514" width="92" height="20" font="0">Worse with age. </text>
<text top="717" left="514" width="199" height="20" font="0">Increased more with age for women </text>
<text top="734" left="514" width="266" height="20" font="0">Highest among Puerto Rican women and lowest </text>
<text top="751" left="514" width="159" height="20" font="0">among women and men SA. </text>
<text top="768" left="514" width="3" height="20" font="0"> </text>
<text top="667" left="832" width="7" height="18" font="0">•</text>
<text top="666" left="838" width="274" height="20" font="0"> Prevalence of MEtS higher for HL than non-white </text>
<text top="683" left="832" width="243" height="20" font="0">but varies with age, sex and HL background </text>
<text top="702" left="832" width="7" height="18" font="0">•</text>
<text top="702" left="838" width="259" height="20" font="0"> Abdominal adiposity is the main contributor for </text>
<text top="719" left="832" width="46" height="20" font="0">women. </text>
<text top="736" left="832" width="277" height="20" font="0">WC cutoff discussion need for sex race and ethnic </text>
<text top="753" left="832" width="108" height="20" font="0">specific thresholds. </text>
<text top="770" left="832" width="3" height="20" font="0"> </text>
</page>
<page number="154" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">154 </text>
<text top="107" left="211" width="85" height="20" font="0">variation by HL </text>
<text top="124" left="211" width="68" height="20" font="0">background </text>
<text top="141" left="211" width="3" height="20" font="0"> </text>
<text top="159" left="211" width="133" height="20" font="0">34% in men and 36% in </text>
<text top="176" left="211" width="43" height="20" font="0">women </text>
<text top="107" left="373" width="3" height="20" font="0"> </text>
<text top="107" left="514" width="278" height="20" font="0">Abdominal obesity was higher in women than men </text>
<text top="124" left="514" width="87" height="20" font="0">(96% vs. 73%). </text>
<text top="141" left="514" width="285" height="20" font="0">Hyperglycemia was worse among men than women </text>
<text top="159" left="514" width="83" height="20" font="0">(73% vs. 62%) </text>
<text top="176" left="514" width="3" height="20" font="0"> </text>
<text top="193" left="514" width="3" height="20" font="0"> </text>
<text top="109" left="832" width="7" height="18" font="0">•</text>
<text top="108" left="838" width="266" height="20" font="0"> Not consensus in the role of MetS as screen for </text>
<text top="125" left="832" width="106" height="20" font="0">risk of CV disease. </text>
<text top="143" left="832" width="276" height="20" font="0">Use individual cardiovascular risk factors, whether </text>
<text top="160" left="832" width="170" height="20" font="0">they occur alone or in clusters. </text>
<text top="177" left="832" width="3" height="20" font="0"> </text>
<text top="211" left="91" width="67" height="20" font="7"><b>HCHS/SOL </b></text>
<text top="228" left="91" width="98" height="20" font="0">Llabre MM, et al., </text>
<text top="245" left="91" width="63" height="20" font="0">2015 <a href="data supplement.html#247">(185)</a> </text>
<text top="263" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25818844">25818844</a></text>
<text top="263" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25818844"> </a></text>
<text top="211" left="211" width="109" height="20" font="7"><b>Study type:</b>  Cross </text>
<text top="228" left="211" width="52" height="20" font="0">sectional </text>
<text top="245" left="211" width="3" height="20" font="0"> </text>
<text top="263" left="211" width="80" height="20" font="7"><b>Size:</b>  15.823  </text>
<text top="280" left="211" width="3" height="20" font="0"> </text>
<text top="297" left="211" width="3" height="20" font="0"> </text>
<text top="314" left="211" width="124" height="20" font="0">PREVIOUS STUDIES </text>
<text top="332" left="211" width="128" height="20" font="0">Most studies before on </text>
<text top="349" left="211" width="109" height="20" font="0">Mexican-American. </text>
<text top="366" left="211" width="108" height="20" font="0">MESA showed that </text>
<text top="383" left="211" width="139" height="20" font="0">Mexican-American had a </text>
<text top="401" left="211" width="147" height="20" font="0">higher prevalence of MetS </text>
<text top="418" left="211" width="111" height="20" font="0">compared to Puerto </text>
<text top="435" left="211" width="44" height="20" font="0">Ricans. </text>
<text top="452" left="211" width="143" height="20" font="0">Hispanic higher incidence </text>
<text top="469" left="211" width="133" height="20" font="0">of obesity, diabetes and </text>
<text top="487" left="211" width="148" height="20" font="0">elevated TG and low HDL, </text>
<text top="504" left="211" width="139" height="20" font="0">but HDL does not predict </text>
<text top="521" left="211" width="129" height="20" font="0">myocardial infarction in </text>
<text top="538" left="211" width="22" height="20" font="0">HL. </text>
<text top="555" left="211" width="65" height="20" font="0">HTN lower. </text>
<text top="573" left="211" width="103" height="20" font="0">CVD lower among </text>
<text top="590" left="211" width="118" height="20" font="0">Mexican- Americans, </text>
<text top="607" left="211" width="3" height="20" font="0"> </text>
<text top="624" left="211" width="139" height="20" font="0">Do RF and cut off values </text>
<text top="641" left="211" width="73" height="20" font="0">apply to HL? </text>
<text top="211" left="373" width="66" height="20" font="0">HCHS/SOL </text>
<text top="228" left="373" width="70" height="20" font="0">participants  </text>
<text top="245" left="373" width="3" height="20" font="0"> </text>
<text top="263" left="373" width="120" height="20" font="0">Excluded participants </text>
<text top="280" left="373" width="122" height="20" font="0">who had missing data </text>
<text top="297" left="373" width="118" height="20" font="0">on HL background or </text>
<text top="314" left="373" width="120" height="20" font="0">self-reported as more </text>
<text top="332" left="373" width="99" height="20" font="0">than one heritage </text>
<text top="349" left="373" width="3" height="20" font="0"> </text>
<text top="211" left="514" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="228" left="514" width="3" height="20" font="0"> </text>
<text top="245" left="514" width="294" height="20" font="0">Of all the indicators HDL has the weakest association </text>
<text top="263" left="514" width="83" height="20" font="0">with the others </text>
<text top="280" left="514" width="3" height="20" font="0"> </text>
<text top="297" left="514" width="240" height="20" font="0">No variation in clustering among subgroups </text>
<text top="314" left="514" width="3" height="20" font="0"> </text>
<text top="332" left="514" width="273" height="20" font="0">Association with diabetes OR: 2.39 (95% CI: 2.25-</text>
<text top="349" left="514" width="282" height="20" font="0">2.55) for men and OR: 2.78 (95% CI: 2.60-2.97) for </text>
<text top="366" left="514" width="50" height="20" font="0">women.  </text>
<text top="383" left="514" width="282" height="20" font="0">The odds of having diabetes with MetS increase by </text>
<text top="401" left="514" width="181" height="20" font="0">130 % both for men and women. </text>
<text top="418" left="514" width="3" height="20" font="0"> </text>
<text top="435" left="514" width="301" height="20" font="0">Association with CHD OR: 1.18 [95% CI: 1.08-1.29] for </text>
<text top="452" left="514" width="279" height="20" font="0">men and OR: 1.22 (95% CI: 1.11-1.35) for women. </text>
<text top="469" left="514" width="290" height="20" font="0">The odds of having CHD with MetS increase by 20% </text>
<text top="487" left="514" width="143" height="20" font="0">for both men and women. </text>
<text top="504" left="514" width="3" height="20" font="0"> </text>
<text top="213" left="832" width="7" height="18" font="0">•</text>
<text top="212" left="838" width="277" height="20" font="0"> Current indicators of MetS cluster together in HL.  </text>
<text top="229" left="832" width="249" height="20" font="0">Similarity for men and women, except for BP, </text>
<text top="247" left="832" width="163" height="20" font="0">stronger indicator for women. </text>
<text top="264" left="832" width="3" height="20" font="0"> </text>
<text top="283" left="832" width="7" height="18" font="0">•</text>
<text top="282" left="838" width="261" height="20" font="0"> HDL does not cluster together as strong as the </text>
<text top="300" left="832" width="273" height="20" font="0">other risk factors that define MetS. HDL is a weak </text>
<text top="317" left="832" width="149" height="20" font="0">indicator. (UNEXPECTED) </text>
<text top="334" left="832" width="269" height="20" font="0">Correlation with cardio protection not seen in HL. </text>
<text top="351" left="832" width="243" height="20" font="0">Not all components equally important for HL </text>
<text top="368" left="832" width="3" height="20" font="0"> </text>
<text top="387" left="832" width="7" height="18" font="0">•</text>
<text top="387" left="838" width="272" height="20" font="0"> Not difference across HL ancestry groups for the </text>
<text top="404" left="832" width="273" height="20" font="0">components of MetS. The cluster of risk factors is </text>
<text top="421" left="832" width="172" height="20" font="0">comparable across subgroups. </text>
<text top="438" left="832" width="276" height="20" font="0">DESPITE what it was shown in the study by Heiss </text>
<text top="456" left="832" width="284" height="20" font="0">et al prevalence of MetS different for groups but the </text>
<text top="473" left="832" width="133" height="20" font="0">clustering does not vary </text>
<text top="490" left="832" width="3" height="20" font="0"> </text>
<text top="509" left="832" width="7" height="18" font="0">•</text>
<text top="508" left="838" width="233" height="20" font="0"> MetS associated with CHD and Diabetes. </text>
<text top="526" left="832" width="3" height="20" font="0"> </text>
<text top="543" left="832" width="3" height="20" font="0"> </text>
<text top="560" left="832" width="234" height="20" font="0">Needs studies to determine sensitivity and </text>
<text top="577" left="832" width="164" height="20" font="0">specificity of cut-points for HL </text>
<text top="660" left="88" width="1042" height="20" font="7"><b>Abbreviations:</b> 1° indicated primary; CI, confidence interval; HR, hazard ratio; N/A, not available; OR, odds ratio; RCT, randomized controlled trial; and RR, relative risk. HCHS/SOL, Hispanic </text>
<text top="678" left="88" width="1054" height="20" font="0">Community Health Study/Study of Latinos; HL, Hispanic/Latinos; US, United States; MetS, Metabolic Syndrome; SA, South American; WC&lt; waist circumference; HDL, High Density Lipoprotein;  </text>
<text top="695" left="88" width="840" height="20" font="0">NCEP ATP, National Cholesterol Education Program Adult Treatment Panel; CHD, Coronary Heart Disease; MESA, Multi-ethnic Study of Atherosclerosis; </text>
<text top="712" left="88" width="391" height="20" font="7"><b>Search Terms and Date of Search</b>: Metabolic syndrome and Hispanic </text>
<text top="729" left="81" width="3" height="20" font="0"> </text>
<text top="752" left="81" width="5" height="15" font="5"><b> </b></text>
<text top="746" left="297" width="4" height="22" font="5"><b> </b></text>
</page>
<page number="155" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">155 </text>
<text top="106" left="81" width="501" height="24" font="4"><b>Data Supplement 31. Hypertriglyceridemia: RCT, Meta Analyses (4.5.2)  </b></text>
<text top="128" left="101" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="145" left="127" width="48" height="20" font="7"><b>Author;</b> </text>
<text top="162" left="104" width="92" height="20" font="7"><b>Year Published</b> </text>
<text top="128" left="246" width="83" height="20" font="7"><b>Aim of Study;</b> </text>
<text top="145" left="251" width="74" height="20" font="7"><b>Study Type;</b> </text>
<text top="162" left="244" width="86" height="20" font="7"><b>Study Size (N)</b> </text>
<text top="128" left="406" width="111" height="20" font="7"><b>Patient population</b> </text>
<text top="128" left="572" width="187" height="20" font="7"><b>Study Intervention (# patients) /</b> </text>
<text top="145" left="576" width="180" height="20" font="7"><b>Study Comparator (# patients)</b> </text>
<text top="128" left="832" width="105" height="20" font="7"><b>Endpoint Results</b> </text>
<text top="145" left="779" width="210" height="20" font="7"><b>(Absolute Event Rates, P value; OR </b></text>
<text top="162" left="833" width="101" height="20" font="7"><b>or RR; &amp; 95% CI)</b> </text>
<text top="128" left="1019" width="71" height="20" font="7"><b>Relevant 2</b>° </text>
<text top="145" left="1019" width="72" height="20" font="7"><b>Endpoint (if </b></text>
<text top="162" left="1038" width="33" height="20" font="7"><b>any);</b> </text>
<text top="179" left="1036" width="38" height="20" font="7"><b>Study </b></text>
<text top="197" left="1018" width="73" height="20" font="7"><b>Limitations;</b> </text>
<text top="214" left="1029" width="52" height="20" font="7"><b>Adverse </b></text>
<text top="231" left="1033" width="44" height="20" font="7"><b>Events</b> </text>
<text top="249" left="89" width="49" height="20" font="7"><b>HOPE-3 </b></text>
<text top="266" left="89" width="114" height="20" font="0">Yusuf S, et al., 2016 </text>
<text top="283" left="89" width="25" height="20" font="0"><a href="data supplement.html#236">(12)</a> </text>
<text top="301" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27040132">27040132</a></text>
<text top="301" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27040132"> </a></text>
<text top="249" left="224" width="113" height="20" font="7"><b>Aim</b>: Assess impact </text>
<text top="266" left="224" width="118" height="20" font="0">of moderate intensity </text>
<text top="283" left="224" width="118" height="20" font="0">statin on ASCVD risk </text>
<text top="301" left="224" width="124" height="20" font="0">in an intermediate risk </text>
<text top="318" left="224" width="60" height="20" font="0">population </text>
<text top="335" left="224" width="100" height="20" font="0">Double blind RCT </text>
<text top="352" left="224" width="57" height="20" font="0">N=12,705 </text>
<text top="249" left="364" width="105" height="20" font="7"><b>Inclusion criteria</b>: </text>
<text top="266" left="364" width="192" height="20" font="0">Men age ≥55 y and women ≥ 65 y </text>
<text top="283" left="364" width="178" height="20" font="0">with at least one of the following </text>
<text top="301" left="364" width="149" height="20" font="0">cardiovascular risk factors: </text>
<text top="318" left="364" width="187" height="20" font="0">elevated waist-to-hip ratio, history </text>
<text top="335" left="364" width="189" height="20" font="0">of a low level of HDL-C, current or </text>
<text top="352" left="364" width="185" height="20" font="0">recent tobacco use, dysglycemia, </text>
<text top="369" left="364" width="148" height="20" font="0">family history of premature </text>
<text top="387" left="364" width="181" height="20" font="0">coronary disease, and mild renal </text>
<text top="404" left="364" width="69" height="20" font="0">dysfunction. </text>
<text top="421" left="364" width="182" height="20" font="0">Also enrolled women age 60 y or </text>
<text top="438" left="364" width="193" height="20" font="0">older with at least two of the above </text>
<text top="456" left="364" width="70" height="20" font="0">risk factors.  </text>
<text top="473" left="364" width="3" height="20" font="0"> </text>
<text top="490" left="364" width="109" height="20" font="7"><b>Exclusion criteria</b>: </text>
<text top="507" left="364" width="185" height="20" font="0">1. Clinical atherothrombotic CVD  </text>
<text top="524" left="364" width="158" height="20" font="0">2. Symptomatic hypotension </text>
<text top="542" left="364" width="135" height="20" font="0">3. Chronic liver disease  </text>
<text top="559" left="364" width="176" height="20" font="0">4. Inflammatory muscle disease </text>
<text top="576" left="364" width="173" height="20" font="0">creatine kinase (CK &gt; 3 x ULN) </text>
<text top="593" left="364" width="165" height="20" font="0">5. Moderate renal dysfunction </text>
<text top="610" left="364" width="186" height="20" font="0">defined as serum creatinine &gt; 2.0 </text>
<text top="628" left="364" width="157" height="20" font="0">mg/dL (180μmol/L) or eGFR </text>
<text top="645" left="364" width="102" height="20" font="0">&lt;45ml/min/1.73m² </text>
<text top="662" left="364" width="185" height="20" font="0">6. Treatment with cyclosporine or </text>
<text top="679" left="364" width="44" height="20" font="0">fibrates </text>
<text top="696" left="364" width="3" height="20" font="0"> </text>
<text top="714" left="364" width="3" height="20" font="0"> </text>
<text top="249" left="571" width="176" height="20" font="0">Rosuvastatin 10 mg daily (6361 </text>
<text top="266" left="571" width="154" height="20" font="0">subjects) vs. Placebo (6344 </text>
<text top="283" left="571" width="182" height="20" font="0">subjects) followed over a median </text>
<text top="301" left="571" width="44" height="20" font="0">of 5.6 y </text>
<text top="249" left="773" width="135" height="20" font="7"><b>Co-primary endpoints</b>: </text>
<text top="266" left="773" width="152" height="20" font="0">1. Composite of death from </text>
<text top="283" left="773" width="175" height="20" font="0">cardiovascular causes, nonfatal </text>
<text top="301" left="773" width="225" height="20" font="0">myocardial infarction, or nonfatal stroke.  </text>
<text top="318" left="773" width="213" height="20" font="0">2. Revascularization, heart failure, and </text>
<text top="335" left="773" width="155" height="20" font="0">resuscitated cardiac arrest.  </text>
<text top="352" left="773" width="55" height="20" font="7"><b>Results</b>:  </text>
<text top="369" left="773" width="152" height="20" font="0">1. Composite of death from </text>
<text top="387" left="773" width="176" height="20" font="0">cardiovascular causes, nonfatal </text>
<text top="404" left="773" width="218" height="20" font="0">myocardial infarction, or nonfatal stroke </text>
<text top="421" left="773" width="210" height="20" font="0">occurred in 235 subjects (3.7%) in the </text>
<text top="438" left="773" width="214" height="20" font="0">rosuvastatin group and in 304 subjects </text>
<text top="456" left="773" width="200" height="20" font="0">(4.8%) in the placebo group (hazard </text>
<text top="473" left="773" width="180" height="20" font="0">ratio, 0.76; 95% CI: 0.64 to 0.91; </text>
<text top="490" left="773" width="101" height="20" font="0">p=0.002; NNT 91) </text>
<text top="507" left="773" width="213" height="20" font="0">2. Revascularization, heart failure, and </text>
<text top="524" left="773" width="212" height="20" font="0">resuscitated cardiac arrest occurred in </text>
<text top="542" left="773" width="215" height="20" font="0">277 subjects (4.4%) in the rosuvastatin </text>
<text top="559" left="773" width="217" height="20" font="0">group and in 363 subjects (5.7%) in the </text>
<text top="576" left="773" width="215" height="20" font="0">placebo group (HR: 0.75; 95% CI: 0.64 </text>
<text top="593" left="773" width="146" height="20" font="0">to 0.88; p&lt;0.001; NNT 73) </text>
<text top="610" left="773" width="215" height="20" font="0">3. Median predicted 5-y major vascular </text>
<text top="628" left="773" width="211" height="20" font="0">event rate in placebo group for first co-</text>
<text top="645" left="773" width="218" height="20" font="0">primary endpoint: 4.28%; for secondary </text>
<text top="662" left="773" width="154" height="20" font="0">co-primary endpoint: 5.09% </text>
<text top="249" left="1008" width="21" height="20" font="0">NA </text>
<text top="732" left="89" width="120" height="20" font="0">Frick MH, et al., 1987 </text>
<text top="749" left="89" width="110" height="20" font="0">(Frick, 1987 #3268) </text>
<text top="766" left="89" width="48" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3313401">3313401</a></text>
<text top="766" left="137" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=3313401"> </a></text>
<text top="732" left="224" width="111" height="20" font="7"><b>Aim: </b>To assess the </text>
<text top="749" left="224" width="110" height="20" font="0">effect of gemfibrozil </text>
<text top="766" left="224" width="107" height="20" font="0">therapy on incident </text>
<text top="783" left="224" width="86" height="20" font="0">cardiac events. </text>
<text top="732" left="364" width="106" height="20" font="7"><b>Inclusion criteria: </b></text>
<text top="749" left="364" width="178" height="20" font="0">Finnish men age 40-55y with no </text>
<text top="766" left="364" width="193" height="20" font="0">clinical cardiovascular disease and </text>
<text top="732" left="571" width="147" height="20" font="7"><b>Intervention/Comparator </b></text>
<text top="749" left="571" width="170" height="20" font="0">Gemfibrozil 600 mg twice daily </text>
<text top="766" left="571" width="188" height="20" font="0">(2051 subjects) vs. placebo (2030 </text>
<text top="732" left="773" width="178" height="22" font="7"><b>1</b>⁰<b>endpoint: </b>Fatal and non-fatal </text>
<text top="749" left="773" width="221" height="20" font="0">myocardial infarction and cardiac death. </text>
<text top="766" left="773" width="3" height="20" font="7"><b> </b></text>
<text top="784" left="773" width="52" height="20" font="7"><b>Results: </b></text>
<text top="732" left="1008" width="82" height="20" font="0">No increase in </text>
<text top="749" left="1008" width="69" height="20" font="0">incidence of </text>
<text top="766" left="1008" width="81" height="20" font="0">cancer or total </text>
<text top="783" left="1008" width="50" height="20" font="0">mortality </text>
</page>
<page number="156" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">156 </text>
<text top="107" left="224" width="3" height="20" font="0"> </text>
<text top="124" left="224" width="74" height="20" font="7"><b>Study Type: </b></text>
<text top="141" left="224" width="108" height="20" font="0">Placebo controlled, </text>
<text top="159" left="224" width="98" height="20" font="0">double blind RCT </text>
<text top="176" left="224" width="47" height="20" font="0">N=4081 </text>
<text top="107" left="364" width="163" height="20" font="0">non-HDL-C ≥200 mg/dL on 2 </text>
<text top="124" left="364" width="152" height="20" font="0">successive measurements. </text>
<text top="141" left="364" width="3" height="20" font="0"> </text>
<text top="159" left="364" width="114" height="20" font="7"><b>Exclusion criteria:  </b></text>
<text top="176" left="364" width="175" height="20" font="0">Clinical coronary heart disease, </text>
<text top="193" left="364" width="191" height="20" font="0">electrocardiographic abnormalities </text>
<text top="210" left="364" width="157" height="20" font="0">or other diseases that would </text>
<text top="228" left="364" width="133" height="20" font="0">impact study outcomes. </text>
<text top="107" left="571" width="177" height="20" font="0">subjects) over a mean follow-up </text>
<text top="124" left="571" width="103" height="20" font="0">period of 60.4 mo. </text>
<text top="107" left="773" width="196" height="20" font="0">1. Incidence of cardiac endpoints in </text>
<text top="124" left="773" width="181" height="20" font="0">gemfibrozil group was 27.3/1000 </text>
<text top="141" left="773" width="213" height="20" font="0">person-y vs. 41.4/1000-person y in the </text>
<text top="159" left="773" width="134" height="20" font="0">placebo group (p&lt;0.02). </text>
<text top="176" left="773" width="179" height="20" font="0">2. 10% reduction in LDL-C, 14% </text>
<text top="193" left="773" width="218" height="20" font="0">reduction in non-HDL-C; 43% reduction </text>
<text top="210" left="773" width="85" height="20" font="0">in triglycerides. </text>
<text top="227" left="773" width="198" height="20" font="0">3.Median predicted 5-y incidence of </text>
<text top="245" left="773" width="220" height="20" font="0">fatal and non-fatal MI and cardiac death </text>
<text top="262" left="773" width="150" height="20" font="0">4.1% in the placebo group. </text>
<text top="280" left="89" width="65" height="20" font="7"><b>VOYAGER </b></text>
<text top="297" left="89" width="101" height="20" font="0">Nicholls SJ, et al., </text>
<text top="314" left="89" width="115" height="20" font="0">2010 (Nicholls, 2010 </text>
<text top="332" left="89" width="42" height="20" font="0">#3272) </text>
<text top="349" left="89" width="55" height="20" font="8"><a href="">20102893</a></text>
<text top="349" left="144" width="3" height="20" font="0"><a href=""> </a></text>
<text top="366" left="89" width="3" height="20" font="0"> </text>
<text top="280" left="224" width="120" height="20" font="7"><b>Aim</b>: To assess dose-</text>
<text top="297" left="224" width="122" height="20" font="0">dependent reductions </text>
<text top="314" left="224" width="61" height="20" font="0">in levels of </text>
<text top="332" left="224" width="99" height="20" font="0">atherogenic lipids </text>
<text top="349" left="224" width="120" height="20" font="0">/lipoproteins in statin- </text>
<text top="366" left="224" width="92" height="20" font="0">treated patients. </text>
<text top="383" left="224" width="3" height="20" font="0"> </text>
<text top="400" left="224" width="73" height="20" font="7"><b>Study Type</b>: </text>
<text top="418" left="224" width="123" height="20" font="0">Individual patient data </text>
<text top="435" left="224" width="88" height="20" font="0">pooled analysis </text>
<text top="452" left="224" width="60" height="20" font="0">N= 32,258 </text>
<text top="280" left="364" width="165" height="20" font="7"><b>Inclusion criteria</b>: 37 studies </text>
<text top="297" left="364" width="165" height="20" font="0">assessing fasting atherogenic </text>
<text top="314" left="364" width="153" height="20" font="0">lipids/lipoproteins in studies </text>
<text top="332" left="364" width="185" height="20" font="0">involving fixed-dose comparisons </text>
<text top="349" left="364" width="143" height="20" font="0">of rosuvastatin with either </text>
<text top="366" left="364" width="172" height="20" font="0">atorvastatin or atorvastatin and </text>
<text top="383" left="364" width="186" height="20" font="0">recording data at baseline and on </text>
<text top="401" left="364" width="192" height="20" font="0">therapy for which individual patient </text>
<text top="418" left="364" width="113" height="20" font="0">data were available. </text>
<text top="435" left="364" width="3" height="20" font="0"> </text>
<text top="452" left="364" width="133" height="20" font="7"><b>Exclusion criteria</b>: N/A </text>
<text top="280" left="571" width="150" height="20" font="7"><b>Intervention/Comparator</b>: </text>
<text top="297" left="571" width="163" height="20" font="0">Lipids/lipoproteins in subjects </text>
<text top="314" left="571" width="125" height="20" font="0">taking rosuvastatin vs. </text>
<text top="332" left="571" width="145" height="20" font="0">atorvastatin v. simvastatin </text>
<text top="280" left="773" width="55" height="20" font="7"><b>Results</b>:  </text>
<text top="297" left="773" width="193" height="20" font="0">1. Doubling the dose of each statin </text>
<text top="314" left="773" width="212" height="20" font="0">resulted in a 4-7% greater reduction in </text>
<text top="332" left="773" width="181" height="20" font="0">all atherogenic lipids/lipoproteins </text>
<text top="349" left="773" width="206" height="20" font="0">2. Mean reduction in non-HDL-C with </text>
<text top="366" left="773" width="172" height="20" font="0">moderate intensity simvastatin, </text>
<text top="383" left="773" width="217" height="20" font="0">atorvastatin or rouvastatin was ≥30.1% </text>
<text top="280" left="1008" width="24" height="20" font="0">N/A </text>
<text top="470" left="89" width="65" height="20" font="0">Cholesterol </text>
<text top="487" left="89" width="105" height="20" font="0">Treatment Trialists </text>
<text top="504" left="89" width="107" height="20" font="0">Collaborators 2012 </text>
<text top="522" left="89" width="70" height="20" font="0">(Cholesterol </text>
<text top="539" left="89" width="109" height="20" font="0">Treatment Trialists, </text>
<text top="556" left="89" width="73" height="20" font="0">2012 #3245) </text>
<text top="573" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22607822">22607822</a></text>
<text top="573" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22607822"> </a></text>
<text top="470" left="224" width="110" height="20" font="7"><b>Aim</b>: To assess the </text>
<text top="487" left="224" width="124" height="20" font="0">effect of statin therapy </text>
<text top="504" left="224" width="122" height="20" font="0">on incident ASCVD in </text>
<text top="522" left="224" width="117" height="20" font="0">“low risk” individuals. </text>
<text top="539" left="224" width="3" height="20" font="0"> </text>
<text top="556" left="224" width="105" height="20" font="7"><b>Study Type</b>: Meta-</text>
<text top="573" left="224" width="116" height="20" font="0">analysis of individual </text>
<text top="591" left="224" width="116" height="20" font="0">participant data from </text>
<text top="608" left="224" width="107" height="20" font="0">statin RCT ASCVD </text>
<text top="625" left="224" width="86" height="20" font="0">outcomes trials </text>
<text top="642" left="224" width="64" height="20" font="0">N=174,179 </text>
<text top="470" left="364" width="172" height="20" font="7"><b>Inclusion criteria</b>: Major statin </text>
<text top="487" left="364" width="174" height="20" font="0">primary prevention trials with at </text>
<text top="504" left="364" width="175" height="20" font="0">least 1,000 participants with 5-y </text>
<text top="522" left="364" width="173" height="20" font="0">risk of major vascular events of </text>
<text top="539" left="364" width="194" height="20" font="0">&lt;10%, with a minimum follow-up of </text>
<text top="556" left="364" width="23" height="20" font="0">2 y. </text>
<text top="573" left="364" width="133" height="20" font="7"><b>Exclusion criteria</b>: N/A </text>
<text top="470" left="571" width="150" height="20" font="7"><b>Intervention/Comparator</b>: </text>
<text top="487" left="571" width="167" height="20" font="0">22 RCT’s statin versus control </text>
<text top="504" left="571" width="188" height="20" font="0">(N=134,537, median follow-up 4.8 </text>
<text top="522" left="571" width="170" height="20" font="0">y) and 5 RCT’s of more versus </text>
<text top="539" left="571" width="166" height="20" font="0">less statin (N=39,612, median </text>
<text top="556" left="571" width="87" height="20" font="0">follow-up 5.1 y) </text>
<text top="470" left="773" width="219" height="22" font="7"><b>1</b>⁰<b> endpoint</b>: Effect of statin therapy on </text>
<text top="488" left="773" width="215" height="20" font="0">non-fatal MI or coronary death, strokes </text>
<text top="505" left="773" width="205" height="20" font="0">or coronary revascularization, cancer </text>
<text top="522" left="773" width="214" height="20" font="0">incidence and cause-specific mortality. </text>
<text top="539" left="773" width="3" height="20" font="0"> </text>
<text top="556" left="773" width="55" height="20" font="7"><b>Results</b>:  </text>
<text top="574" left="773" width="202" height="20" font="0">1. Statins reduce the risk of vascular </text>
<text top="591" left="773" width="215" height="20" font="0">events (relative risk 0.79, 95% CI: 0.77-</text>
<text top="608" left="773" width="184" height="20" font="0">0.81) irrespective of age, gender, </text>
<text top="625" left="773" width="202" height="20" font="0">baseline LDL-C or previous vascular </text>
<text top="642" left="773" width="209" height="20" font="0">disease and of vascular and all-cause </text>
<text top="660" left="773" width="50" height="20" font="0">mortality </text>
<text top="677" left="773" width="206" height="20" font="0">2. Specifically in the intermediate risk </text>
<text top="694" left="773" width="216" height="20" font="0">group (5- to &lt;10 % 5 y risk) the relative </text>
<text top="711" left="773" width="193" height="20" font="0">risk reduction with statins was 0.69 </text>
<text top="729" left="773" width="111" height="20" font="0">(99% CI: 0.60-0.79) </text>
<text top="746" left="773" width="204" height="20" font="0">3. Reported 5 y major vascular event </text>
<text top="763" left="773" width="118" height="20" font="0">rates in statin RCT’s: </text>
<text top="470" left="1008" width="24" height="20" font="0">N/A </text>
</page>
<page number="157" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">157 </text>
<text top="107" left="773" width="210" height="20" font="0">JUPITER: 4.4%; AFCAPS/TEXCAPS: </text>
<text top="124" left="773" width="141" height="20" font="0">5.2%; ASCOT-LLA: 8.1% </text>
<text top="141" left="773" width="185" height="20" font="0">4. Statin therapy had no effect on </text>
<text top="159" left="773" width="204" height="20" font="0">cancer incidence, cancer mortality or </text>
<text top="176" left="773" width="155" height="20" font="0">other non-vascular mortality </text>
<text top="200" left="81" width="5" height="16" font="15"> </text>
<text top="221" left="81" width="5" height="16" font="15"> </text>
<text top="241" left="81" width="5" height="16" font="15"> </text>
<text top="262" left="81" width="5" height="16" font="15"> </text>
<text top="277" left="103" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="295" left="128" width="48" height="20" font="7"><b>Author;</b> </text>
<text top="312" left="106" width="92" height="20" font="7"><b>Year Published</b> </text>
<text top="277" left="248" width="83" height="20" font="7"><b>Aim of Study;</b> </text>
<text top="295" left="253" width="74" height="20" font="7"><b>Study Type;</b> </text>
<text top="312" left="247" width="86" height="20" font="7"><b>Study Size (N)</b> </text>
<text top="277" left="405" width="111" height="20" font="7"><b>Patient population</b> </text>
<text top="277" left="568" width="187" height="20" font="7"><b>Study Intervention (# patients) /</b> </text>
<text top="295" left="572" width="180" height="20" font="7"><b>Study Comparator (# patients)</b> </text>
<text top="277" left="828" width="105" height="20" font="7"><b>Endpoint Results</b> </text>
<text top="295" left="775" width="210" height="20" font="7"><b>(Absolute Event Rates, P value; OR </b></text>
<text top="312" left="829" width="101" height="20" font="7"><b>or RR; &amp; 95% CI)</b> </text>
<text top="277" left="1017" width="71" height="20" font="7"><b>Relevant 2</b>° </text>
<text top="295" left="1017" width="72" height="20" font="7"><b>Endpoint (if </b></text>
<text top="312" left="1036" width="33" height="20" font="7"><b>any);</b> </text>
<text top="329" left="1034" width="38" height="20" font="7"><b>Study </b></text>
<text top="346" left="1016" width="73" height="20" font="7"><b>Limitations;</b> </text>
<text top="363" left="1005" width="96" height="20" font="7"><b>Adverse Events</b> </text>
<text top="381" left="89" width="65" height="20" font="7"><b>VOYAGER </b></text>
<text top="399" left="89" width="125" height="20" font="0">Nicholls SJ,  et al., </text>
<text top="416" left="89" width="63" height="20" font="0">2010<a href="data supplement.html#247"> (186)</a> </text>
<text top="433" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20102893">20102893</a></text>
<text top="433" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20102893"> </a></text>
<text top="450" left="89" width="3" height="20" font="0"> </text>
<text top="467" left="89" width="3" height="20" font="0"> </text>
<text top="381" left="227" width="122" height="20" font="7"><b>Aim</b>: To assess dose-</text>
<text top="399" left="227" width="129" height="20" font="0">dependent reductions </text>
<text top="416" left="227" width="158" height="20" font="0">in levels of </text>
<text top="433" left="227" width="68" height="20" font="0">atherogenic </text>
<text top="450" left="227" width="140" height="20" font="0">lipids/lipoproteins in </text>
<text top="467" left="227" width="37" height="20" font="0">statin- </text>
<text top="467" left="311" width="42" height="20" font="0">treated </text>
<text top="485" left="227" width="50" height="20" font="0">patients. </text>
<text top="502" left="227" width="3" height="20" font="0"> </text>
<text top="519" left="227" width="73" height="20" font="7"><b>Study Type</b>: </text>
<text top="536" left="227" width="127" height="20" font="0">Individual patient data </text>
<text top="553" left="227" width="88" height="20" font="0">pooled analysis </text>
<text top="571" left="227" width="60" height="20" font="0">N= 32,258 </text>
<text top="381" left="366" width="197" height="20" font="7"><b>Inclusion criteria</b>: 37 studies </text>
<text top="399" left="366" width="201" height="20" font="0">assessing fasting atherogenic </text>
<text top="416" left="366" width="207" height="20" font="0">lipids/lipoproteins  in studies </text>
<text top="433" left="366" width="192" height="20" font="0">involving fixed-dose comparisons </text>
<text top="450" left="366" width="205" height="20" font="0">of rosuvastatin with either </text>
<text top="467" left="366" width="195" height="20" font="0">atorvastatin or atorvastatin and </text>
<text top="485" left="366" width="190" height="20" font="0">recording data at baseline and on </text>
<text top="502" left="366" width="188" height="20" font="0">therapy for which individual patient </text>
<text top="519" left="366" width="113" height="20" font="0">data were available. </text>
<text top="536" left="366" width="3" height="20" font="0"> </text>
<text top="553" left="366" width="133" height="20" font="7"><b>Exclusion criteria</b>: N/A </text>
<text top="381" left="568" width="150" height="20" font="7"><b>Intervention/Comparator</b>: </text>
<text top="399" left="568" width="202" height="20" font="0">Lipids/lipoproteins in subjects </text>
<text top="416" left="568" width="221" height="20" font="0">taking rosuvastatin vs. </text>
<text top="433" left="568" width="145" height="20" font="0">atorvastatin v. simvastatin </text>
<text top="381" left="770" width="55" height="20" font="7"><b>Results</b>:  </text>
<text top="399" left="770" width="226" height="20" font="0">1. Doubling the dose of each statin </text>
<text top="416" left="770" width="223" height="20" font="0">resulted in a 4-7% greater reduction in </text>
<text top="433" left="770" width="181" height="20" font="0">all atherogenic lipids/lipoproteins </text>
<text top="450" left="770" width="224" height="20" font="0">2. Mean reduction in non-HDL-C with </text>
<text top="467" left="770" width="221" height="20" font="0">moderate intensity simvastatin, </text>
<text top="485" left="770" width="217" height="20" font="0">atorvastatin or rouvastatin was ≥30.1% </text>
<text top="381" left="1004" width="24" height="20" font="0">N/A </text>
<text top="589" left="89" width="125" height="20" font="0">Cholesterol Treatment </text>
<text top="606" left="89" width="128" height="20" font="0">Trialists Collaborators </text>
<text top="623" left="89" width="63" height="20" font="0">2012<a href="data supplement.html#243"> (121)</a> </text>
<text top="640" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22607822">22607822</a></text>
<text top="640" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22607822"> </a></text>
<text top="589" left="227" width="130" height="20" font="7"><b>Aim</b>:  To assess the </text>
<text top="606" left="227" width="126" height="20" font="0">effect of statin therapy </text>
<text top="623" left="227" width="127" height="20" font="0">on incident ASCVD in </text>
<text top="640" left="227" width="117" height="20" font="0">“low risk” individuals. </text>
<text top="658" left="227" width="3" height="20" font="0"> </text>
<text top="675" left="227" width="122" height="20" font="7"><b>Study Type</b>:  Meta-</text>
<text top="692" left="227" width="130" height="20" font="0">analysis of individual </text>
<text top="709" left="227" width="130" height="20" font="0">participant data from </text>
<text top="726" left="227" width="134" height="20" font="0">statin RCT ASCVD </text>
<text top="744" left="227" width="86" height="20" font="0">outcomes trials </text>
<text top="761" left="227" width="64" height="20" font="0">N=174,179 </text>
<text top="589" left="366" width="195" height="20" font="7"><b>Inclusion criteria</b>: Major statin </text>
<text top="606" left="366" width="189" height="20" font="0">primary prevention trials with at </text>
<text top="623" left="366" width="189" height="20" font="0">least 1,000 participants with 5-y </text>
<text top="640" left="366" width="192" height="20" font="0">risk of major vascular events of </text>
<text top="658" left="366" width="189" height="20" font="0">&lt;10%, with a minimum follow-up </text>
<text top="675" left="366" width="37" height="20" font="0">of 2 y. </text>
<text top="692" left="366" width="3" height="20" font="0"> </text>
<text top="709" left="366" width="133" height="20" font="7"><b>Exclusion criteria</b>: N/A </text>
<text top="589" left="568" width="150" height="20" font="7"><b>Intervention/Comparator</b>: </text>
<text top="606" left="568" width="195" height="20" font="0">22 RCT’s statin versus control </text>
<text top="623" left="568" width="189" height="20" font="0">(N=134,537, median follow-up 4.8 </text>
<text top="640" left="568" width="192" height="20" font="0">y) and 5 RCT’s of more versus </text>
<text top="658" left="568" width="197" height="20" font="0">less statin (N=39,612, median </text>
<text top="675" left="568" width="87" height="20" font="0">follow-up 5.1 y) </text>
<text top="589" left="770" width="222" height="22" font="7"><b>1</b>⁰<b> endpoint</b>: Effect of statin therapy on </text>
<text top="606" left="770" width="222" height="20" font="0">non-fatal MI or coronary death, strokes </text>
<text top="623" left="770" width="227" height="20" font="0">or coronary revascularization, cancer </text>
<text top="641" left="770" width="211" height="20" font="0">incidence and cause-specific mortality </text>
<text top="658" left="770" width="55" height="20" font="7"><b>Results</b>:  </text>
<text top="675" left="770" width="224" height="20" font="0">1. Statins reduce the risk of vascular </text>
<text top="692" left="770" width="218" height="20" font="0">events (relative risk 0.79; 95% CI: 0.77-</text>
<text top="710" left="770" width="231" height="20" font="0">0.81) irrespective of age, gender, </text>
<text top="727" left="770" width="226" height="20" font="0">baseline LDL-C or previous vascular </text>
<text top="744" left="770" width="221" height="20" font="0">disease and of vascular and all-cause </text>
<text top="761" left="770" width="50" height="20" font="0">mortality </text>
<text top="589" left="1004" width="24" height="20" font="0">N/A </text>
</page>
<page number="158" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">158 </text>
<text top="107" left="770" width="224" height="20" font="0">2. Specifically in the intermediate risk </text>
<text top="124" left="770" width="222" height="20" font="0">group (5- to &lt;10 % 5 y risk) the relative </text>
<text top="141" left="770" width="221" height="20" font="0">risk reduction with statins was 0.69 (99% </text>
<text top="159" left="770" width="79" height="20" font="0">CI: 0.60-0.79) </text>
<text top="176" left="770" width="224" height="20" font="0">3. Reported 5 y  major vascular event </text>
<text top="193" left="770" width="118" height="20" font="0">rates in statin RCT’s: </text>
<text top="210" left="770" width="227" height="20" font="0">JUPITER: 4.4%; AFCAPS/TEXCAPS: </text>
<text top="227" left="770" width="141" height="20" font="0">5.2%; ASCOT-LLA: 8.1% </text>
<text top="245" left="770" width="221" height="20" font="0">4. Statin therapy had no effect on cancer </text>
<text top="262" left="770" width="218" height="20" font="0">incidence, cancer mortality or other non-</text>
<text top="279" left="770" width="99" height="20" font="0">vascular mortality </text>
<text top="297" left="89" width="125" height="20" font="0">Cholesterol Treatment </text>
<text top="314" left="89" width="122" height="20" font="0">Trialists Collaborators </text>
<text top="332" left="89" width="31" height="20" font="0">2010 </text>
<text top="332" left="145" width="70" height="20" font="0">(Cholesterol </text>
<text top="349" left="89" width="141" height="20" font="0">Treatment Trialists, </text>
<text top="366" left="89" width="73" height="20" font="0">2010 #3244) </text>
<text top="383" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21067804">21067804</a></text>
<text top="383" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21067804"> </a></text>
<text top="297" left="227" width="141" height="20" font="7"><b>Aim</b>:  Assess the </text>
<text top="314" left="227" width="128" height="20" font="0">safety and efficacy of </text>
<text top="332" left="227" width="130" height="20" font="0">more intensive statin </text>
<text top="349" left="227" width="48" height="20" font="0">therapy. </text>
<text top="366" left="227" width="3" height="20" font="0"> </text>
<text top="383" left="227" width="122" height="20" font="7"><b>Study Type</b>:  Meta-</text>
<text top="400" left="227" width="130" height="20" font="0">analysis of individual </text>
<text top="418" left="227" width="130" height="20" font="0">participant data from </text>
<text top="435" left="227" width="145" height="20" font="0">statin RCT with </text>
<text top="452" left="227" width="106" height="20" font="0">ASCVD outcomes  </text>
<text top="469" left="227" width="64" height="20" font="7"><b>N</b>=169,138 </text>
<text top="297" left="366" width="195" height="20" font="7"><b>Inclusion criteria</b>:  Major statin </text>
<text top="314" left="366" width="189" height="20" font="0">primary and secondary prevention </text>
<text top="332" left="366" width="204" height="20" font="0">trials with at least 1000 </text>
<text top="349" left="366" width="201" height="20" font="0">participants with a minimum </text>
<text top="366" left="366" width="190" height="20" font="0">follow-up of 2 y, including trials of </text>
<text top="383" left="366" width="191" height="20" font="0">more versus less intensive statin </text>
<text top="400" left="366" width="113" height="20" font="0">regimens<b> </b>(five trials; </text>
<text top="418" left="366" width="186" height="20" font="0">39, 612 subjects; median follow-</text>
<text top="435" left="366" width="189" height="20" font="0">up 5.1 y) and statin versus control </text>
<text top="452" left="366" width="198" height="20" font="0">(21 trials; 129 526 subjects; </text>
<text top="469" left="366" width="134" height="20" font="0">median follow-up 4.8 y). </text>
<text top="487" left="366" width="3" height="20" font="7"><b> </b></text>
<text top="504" left="366" width="197" height="20" font="7"><b>Exclusion criteria:  </b>For acute </text>
<text top="521" left="366" width="203" height="20" font="0">coronary syndrome subjects, </text>
<text top="538" left="366" width="195" height="20" font="0">revascularization not related to </text>
<text top="555" left="366" width="195" height="20" font="0">recurrent ischemia or occurring </text>
<text top="573" left="366" width="202" height="20" font="0">&lt;30  d  from the time of </text>
<text top="590" left="366" width="81" height="20" font="0">randomization<b> </b></text>
<text top="297" left="568" width="150" height="20" font="7"><b>Intervention/Comparator</b>: </text>
<text top="314" left="568" width="115" height="20" font="0">Statin versus control </text>
<text top="332" left="568" width="191" height="20" font="0">More intense versus less intense </text>
<text top="349" left="568" width="33" height="20" font="0">statin </text>
<text top="297" left="770" width="221" height="22" font="7"><b>1</b>⁰<b>  endpoint</b>: Cause-specific  mortality, </text>
<text top="315" left="770" width="232" height="20" font="0">major coronary event  defined as </text>
<text top="332" left="770" width="221" height="20" font="0">coronary death or non-fatal MI </text>
<text top="349" left="770" width="225" height="20" font="0">percutaneous  coronary intervention or </text>
<text top="366" left="770" width="223" height="20" font="0">bypass grafting), stroke (subdivided by </text>
<text top="384" left="770" width="232" height="20" font="0">type), and new cancer diagnosis </text>
<text top="401" left="770" width="113" height="20" font="0">(subdivided by site). </text>
<text top="418" left="770" width="3" height="20" font="0"> </text>
<text top="435" left="770" width="51" height="20" font="7"><b>Results</b>: </text>
<text top="452" left="770" width="223" height="20" font="0">1. More intensive versus less intensive </text>
<text top="470" left="770" width="218" height="20" font="0">regimens produced a 15% (95% CI: 11-</text>
<text top="487" left="770" width="221" height="20" font="0">18; p&lt;0.0001) further reduction in major </text>
<text top="504" left="770" width="222" height="20" font="0">vascular events, including a 13% (95% </text>
<text top="521" left="770" width="222" height="20" font="0">CI: 7-19; p&lt;0.0001) further reduction in </text>
<text top="539" left="770" width="223" height="20" font="0">coronary death or non-fatal MI, a 19% </text>
<text top="556" left="770" width="222" height="20" font="0">(95% CI: 15-24; p&lt;0.0001) reduction in </text>
<text top="573" left="770" width="223" height="20" font="0">coronary  revascularization, and a 16% </text>
<text top="590" left="770" width="228" height="20" font="0">(95%CI:  5-26;  p=0.005) in ischemic </text>
<text top="607" left="770" width="40" height="20" font="0">stroke  </text>
<text top="625" left="770" width="218" height="20" font="0">2. For every 39 mg/dL reduction in LDL-</text>
<text top="642" left="770" width="221" height="20" font="0">C, there was a 22% (rate ratio 0.78; 95% </text>
<text top="659" left="770" width="221" height="20" font="0">CI: 0.76-0.80; p&lt;0.0001) reduction in the </text>
<text top="676" left="770" width="206" height="20" font="0">relative risk of major vascular events. </text>
<text top="693" left="770" width="224" height="20" font="0">3. All-cause mortality  was  reduced by </text>
<text top="711" left="770" width="221" height="20" font="0">10% for every 39 mg/dL LDL-C </text>
<text top="728" left="770" width="218" height="20" font="0">reduction (rate ratio 0.9; 95% CI: 0.87-</text>
<text top="745" left="770" width="232" height="20" font="0">0.93;  p&lt;0.0001) primarily due to </text>
<text top="762" left="770" width="228" height="20" font="0">reduction in coronary heart disease </text>
<text top="779" left="770" width="221" height="20" font="0">death (risk ratio 0.8, 99% CI: 0.74-0.87; </text>
<text top="297" left="1004" width="24" height="20" font="0">N/A </text>
</page>
<page number="159" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">159 </text>
<text top="107" left="770" width="226" height="20" font="0">p&lt;0.0001) and other cardiac causes </text>
<text top="124" left="770" width="221" height="20" font="0">(risk ratio 0.89;  99%  CI:  0.89-0.98; </text>
<text top="141" left="770" width="59" height="20" font="0">p=0.002).  </text>
<text top="159" left="770" width="223" height="20" font="0">3. No effect on death due to stroke or </text>
<text top="176" left="770" width="222" height="20" font="0">other vascular causes and no effect on </text>
<text top="193" left="770" width="218" height="20" font="0">death due to cancer, death from non-</text>
<text top="210" left="770" width="219" height="20" font="0">vascular causes or on cancer incidence </text>
<text top="228" left="89" width="85" height="20" font="7"><b>MARINE Trial  </b></text>
<text top="245" left="89" width="120" height="20" font="0">Bays HE, et al., <a href="data supplement.html#247">(187)</a> </text>
<text top="263" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21683321">21683321</a></text>
<text top="263" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21683321"> </a></text>
<text top="228" left="227" width="107" height="20" font="7"><b>Aim:</b> to investigate </text>
<text top="245" left="227" width="125" height="20" font="0">the efficacy and safety </text>
<text top="263" left="227" width="126" height="20" font="0">of omega-3 EPA ethyl </text>
<text top="280" left="227" width="141" height="20" font="0">ester in reducing </text>
<text top="297" left="227" width="127" height="20" font="0">triglyceride levels and </text>
<text top="314" left="227" width="122" height="20" font="0">other lipid parameters </text>
<text top="332" left="227" width="126" height="20" font="0">in patients with fasting </text>
<text top="349" left="227" width="125" height="20" font="0">triglycerides  ≥  500  in </text>
<text top="366" left="227" width="140" height="20" font="0">mg/dL in patients </text>
<text top="383" left="227" width="128" height="20" font="0">treated with omega 3 </text>
<text top="400" left="227" width="133" height="20" font="0">EPA ethyl ester or </text>
<text top="418" left="227" width="46" height="20" font="0">placebo </text>
<text top="435" left="227" width="3" height="20" font="0"> </text>
<text top="452" left="227" width="73" height="20" font="7"><b>Study Type</b>: </text>
<text top="469" left="227" width="122" height="20" font="0">Multi-center, placebo-</text>
<text top="487" left="227" width="60" height="20" font="0">controlled, </text>
<text top="504" left="227" width="71" height="20" font="0">randomized, </text>
<text top="521" left="227" width="125" height="20" font="0">double-blind, 12-wk </text>
<text top="538" left="227" width="122" height="20" font="0">study with an open-</text>
<text top="555" left="227" width="85" height="20" font="0">label extension </text>
<text top="573" left="227" width="47" height="20" font="7"><b>N</b>= 229  </text>
<text top="590" left="227" width="3" height="20" font="0"> </text>
<text top="228" left="366" width="189" height="20" font="7"><b>Inclusion criteria</b>: Men or women </text>
<text top="245" left="366" width="189" height="20" font="0">&gt;18  y  of age with diet-stable </text>
<text top="263" left="366" width="189" height="20" font="0">patients with triglycerides  &gt;500 </text>
<text top="280" left="366" width="192" height="20" font="0">mg/dl and &lt;2,000 mg/dl (with or </text>
<text top="297" left="366" width="189" height="20" font="0">without background statin therapy) </text>
<text top="314" left="366" width="188" height="20" font="0">willing to maintain a stable diet and </text>
<text top="332" left="366" width="196" height="20" font="0">not alter their normal physical </text>
<text top="349" left="366" width="189" height="20" font="0">activity level throughout the study. </text>
<text top="366" left="366" width="7" height="20" font="0">  </text>
<text top="383" left="366" width="182" height="20" font="7"><b>Exclusion criteria: </b>Women who </text>
<text top="400" left="366" width="203" height="20" font="0">were pregnant, planning to </text>
<text top="418" left="366" width="225" height="20" font="0">become pregnant, or </text>
<text top="435" left="366" width="135" height="20" font="0">breastfeeding; history of </text>
<text top="452" left="366" width="189" height="20" font="0">pancreatitis; body mass index &gt;45 </text>
<text top="469" left="366" width="123" height="20" font="0">kg/m2; weight change </text>
<text top="487" left="366" width="192" height="20" font="0">&gt;3 kg during the lead-in period; </text>
<text top="504" left="366" width="130" height="20" font="0">hemoglobin A1c &gt;9.5% </text>
<text top="521" left="366" width="195" height="20" font="0">(patients with diabetes mellitus </text>
<text top="538" left="366" width="189" height="20" font="0">were required to be receiving </text>
<text top="555" left="366" width="191" height="20" font="0">stable therapy); history of stroke, </text>
<text top="573" left="366" width="120" height="20" font="0">myocardial infarction, </text>
<text top="590" left="366" width="202" height="20" font="0">life-threatening arrhythmia, or </text>
<text top="607" left="366" width="136" height="20" font="0">coronary vascularization </text>
<text top="624" left="366" width="189" height="20" font="0">within 6 mo before screening; TSH </text>
<text top="641" left="366" width="198" height="20" font="0">&gt;1.5X upper limit of normal; </text>
<text top="659" left="366" width="192" height="20" font="0">clinical hypothyroidism or thyroid </text>
<text top="676" left="366" width="117" height="20" font="0">hormone therapy not </text>
<text top="693" left="366" width="189" height="20" font="0">been stable for &gt;6 wk  before </text>
<text top="710" left="366" width="190" height="20" font="0">screening; ALT or AST &gt; 3 times </text>
<text top="727" left="366" width="203" height="20" font="0">upper limit of normal; an </text>
<text top="745" left="366" width="206" height="20" font="0">unexplained creatine kinase </text>
<text top="762" left="366" width="128" height="20" font="0">concentration &gt;3 times </text>
<text top="228" left="568" width="148" height="20" font="7"><b>Intervention/comparator</b>: </text>
<text top="245" left="568" width="189" height="20" font="0">Omega 3 EPA ethyl ester 4 g/d, or </text>
<text top="263" left="568" width="98" height="20" font="0">2 g/d, or placebo. </text>
<text top="280" left="568" width="3" height="20" font="0"> </text>
<text top="228" left="770" width="221" height="22" font="7"><b>1</b>⁰<b> endpoint:</b> placebo-corrected median </text>
<text top="246" left="770" width="229" height="20" font="0">percentage of change in TG from </text>
<text top="263" left="770" width="227" height="20" font="0">baseline to wk  12 in the 2 active </text>
<text top="280" left="770" width="222" height="20" font="0">treatment groups compared to placebo.<b>  </b></text>
<text top="298" left="770" width="3" height="20" font="7"><b> </b></text>
<text top="315" left="770" width="221" height="20" font="7"><b>Results:  </b>In the setting of baseline<b> </b></text>
<text top="332" left="770" width="222" height="20" font="0">triglycerides of 680, 657, and 703 mg/dl </text>
<text top="349" left="770" width="223" height="20" font="0">for omega 3 EPA ethyl esters 4 g/d, 2 </text>
<text top="366" left="770" width="221" height="20" font="0">g/d, and placebo,  placebo-corrected </text>
<text top="384" left="770" width="228" height="20" font="0">triglyceride levels  were reduced by </text>
<text top="401" left="770" width="221" height="20" font="0">33.1% (n =76, p &lt;0.0001) and 19.7% (n </text>
<text top="418" left="770" width="221" height="20" font="0">=73, p=0.0051). For a baseline TG level </text>
<text top="435" left="770" width="221" height="20" font="0">&gt;750 mg/dl, omega 3 EPA ethyl esters 4 </text>
<text top="452" left="770" width="231" height="20" font="0">g/d  reduced placebo-corrected TG </text>
<text top="470" left="770" width="221" height="20" font="0">levels by 45.4% (n = 28, p&lt;0.0001) and </text>
<text top="487" left="770" width="221" height="20" font="0">2 g/d  by 32.9% (n =28, p&lt;0.0016). </text>
<text top="504" left="770" width="55" height="20" font="0">AMR101. </text>
<text top="521" left="770" width="3" height="20" font="0"> </text>
<text top="228" left="1004" width="110" height="20" font="7"><b>Other relevant </b></text>
<text top="245" left="1004" width="67" height="20" font="7"><b>Endpoints</b>: </text>
<text top="263" left="1004" width="108" height="20" font="0">LDL-C did not </text>
<text top="280" left="1004" width="44" height="20" font="0">change </text>
<text top="297" left="1004" width="70" height="20" font="0">significantly. </text>
<text top="314" left="1004" width="98" height="20" font="0">Side effect profile </text>
<text top="332" left="1004" width="144" height="20" font="0">similar to </text>
<text top="349" left="1004" width="50" height="20" font="0">placebo. </text>
<text top="366" left="1004" width="3" height="20" font="0"> </text>
<text top="383" left="1004" width="38" height="20" font="7"><b>Study </b></text>
<text top="400" left="1004" width="68" height="20" font="7"><b>limitation</b>s: </text>
<text top="418" left="1004" width="84" height="20" font="0">Short duration; </text>
<text top="435" left="1004" width="134" height="20" font="0">Open label </text>
<text top="452" left="1004" width="89" height="20" font="0">extension study </text>
</page>
<page number="160" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">160 </text>
<text top="107" left="366" width="192" height="20" font="0">upper limit of normal or creatine </text>
<text top="124" left="366" width="194" height="20" font="0">kinase elevation due to known </text>
<text top="141" left="366" width="190" height="20" font="0">muscle disease; the consumption </text>
<text top="159" left="366" width="143" height="20" font="0">of &gt;2 alcoholic beverages </text>
<text top="176" left="366" width="190" height="20" font="0">per day after screening; a history </text>
<text top="193" left="366" width="189" height="20" font="0">of illicit drug use within 1 y before </text>
<text top="210" left="366" width="211" height="20" font="0">screening; a history of </text>
<text top="227" left="366" width="198" height="20" font="0">symptomatic gallstone disease </text>
<text top="245" left="366" width="231" height="20" font="0">unless treated with </text>
<text top="262" left="366" width="188" height="20" font="0">cholecystectomy; known nephrotic </text>
<text top="279" left="366" width="189" height="20" font="0">syndrome or &gt;3 g/d  proteinuria; </text>
<text top="296" left="366" width="189" height="20" font="0">and use of a variety of weight loss </text>
<text top="314" left="366" width="155" height="20" font="0">or triglyceride- raising drugs </text>
<text top="331" left="366" width="3" height="20" font="7"><b> </b></text>
<text top="349" left="81" width="4" height="22" font="1"> </text>
<text top="373" left="81" width="5" height="15" font="1"> </text>
<text top="367" left="297" width="4" height="22" font="1"> </text>
</page>
<page number="161" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">161 </text>
<text top="106" left="81" width="569" height="24" font="4"><b>Data Supplement 32. Hypertriglyceridemia: Observational Studies (Section 4.5.2) </b></text>
<text top="128" left="107" width="94" height="20" font="7"><b>Study Acronym </b></text>
<text top="145" left="115" width="78" height="20" font="7"><b>Author; Year </b></text>
<text top="162" left="123" width="62" height="20" font="7"><b>Published </b></text>
<text top="128" left="246" width="118" height="20" font="7"><b>Study Type/Design; </b></text>
<text top="145" left="273" width="66" height="20" font="7"><b>Study Size </b></text>
<text top="128" left="418" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="128" left="576" width="262" height="20" font="7"><b>Primary Endpoint and Results (P values; OR </b></text>
<text top="145" left="656" width="101" height="20" font="7"><b>or RR; &amp; 95% CI) </b></text>
<text top="128" left="886" width="205" height="20" font="7"><b>Summary/Conclusion Comment(s) </b></text>
<text top="180" left="89" width="101" height="20" font="0">Hokanson JE and </text>
<text top="197" left="89" width="126" height="20" font="0">Austin MA, 1996 <a href="data supplement.html#247">(188)</a> </text>
<text top="215" left="89" width="48" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8836866">8836866</a></text>
<text top="215" left="137" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=8836866"> </a></text>
<text top="180" left="231" width="105" height="20" font="7"><b>Study Type</b>: meta-</text>
<text top="197" left="231" width="145" height="20" font="0">analysis of 17 prospective </text>
<text top="215" left="231" width="140" height="20" font="0">population-based studies </text>
<text top="232" left="231" width="64" height="20" font="0">N=57,277.  </text>
<text top="180" left="393" width="109" height="20" font="7"><b>Inclusion criteria</b>:  </text>
<text top="197" left="393" width="72" height="20" font="0">46,413 men; </text>
<text top="215" left="393" width="87" height="20" font="0">10,864 women; </text>
<text top="232" left="393" width="73" height="20" font="0">Age 15-81 y; </text>
<text top="249" left="393" width="97" height="20" font="0">Caucasians only; </text>
<text top="266" left="393" width="73" height="20" font="0">multinational </text>
<text top="284" left="393" width="3" height="20" font="0"> </text>
<text top="180" left="568" width="108" height="20" font="7"><b>Primary endpoint</b>: </text>
<text top="197" left="568" width="231" height="20" font="0">Incident fatal and non-fatal cardiovascular </text>
<text top="215" left="568" width="254" height="20" font="0">endpoints relative to fasting triglycerides (TG); </text>
<text top="232" left="568" width="271" height="20" font="0">average follow-up in men 8.4 y; in women 11.4 y. </text>
<text top="249" left="568" width="51" height="20" font="7"><b>Results</b>: </text>
<text top="266" left="568" width="259" height="20" font="0">Men: Univariate RR for TG: 1.32 (95% CI: 1.26-</text>
<text top="283" left="568" width="76" height="20" font="0">1.39; p&lt;0.05) </text>
<text top="301" left="568" width="249" height="20" font="0">Women: Univariate RR for TG: 1.76 (95% CI: </text>
<text top="318" left="568" width="104" height="20" font="0">1.50-2.07; p&lt;0.05) </text>
<text top="335" left="568" width="154" height="20" font="0">With adjustment for HDL-C: </text>
<text top="352" left="568" width="259" height="20" font="0">Men: Univariate RR for TG: 1.14 (95% CI: 1.05-</text>
<text top="370" left="568" width="76" height="20" font="0">1.28; p&lt;0.05) </text>
<text top="387" left="568" width="273" height="20" font="0">Women: Univariate RR for TG 1.37 (95% CI: 1.13 </text>
<text top="404" left="568" width="84" height="20" font="0">-1.66; p &lt;0.05) </text>
<text top="180" left="859" width="81" height="20" font="7"><b>Conclusions</b>: </text>
<text top="197" left="859" width="249" height="20" font="0">Suggest TG is a risk factor for cardiovascular </text>
<text top="215" left="859" width="216" height="20" font="0">disease events for Caucasian men and </text>
<text top="232" left="859" width="172" height="20" font="0">women, independent of HDL-C </text>
<text top="249" left="859" width="3" height="20" font="0"> </text>
<text top="266" left="859" width="228" height="20" font="7"><b>Limitations:</b> Study limited to Caucasians </text>
<text top="422" left="89" width="108" height="20" font="0">The Emerging Risk </text>
<text top="439" left="89" width="120" height="20" font="0">Factors Collaboration </text>
<text top="456" left="89" width="63" height="20" font="0">2009<a href="data supplement.html#247"> (189)</a> </text>
<text top="474" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19903920">19903920</a></text>
<text top="474" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19903920"> </a></text>
<text top="422" left="231" width="102" height="20" font="0">Patient level meta-</text>
<text top="439" left="231" width="134" height="20" font="0">analysis of 68 long-term </text>
<text top="456" left="231" width="112" height="20" font="0">prospective studies, </text>
<text top="474" left="231" width="134" height="20" font="0">mostly in North America </text>
<text top="491" left="231" width="74" height="20" font="0">and Europe.  </text>
<text top="508" left="231" width="71" height="20" font="0">N=302,430.  </text>
<text top="422" left="393" width="120" height="20" font="7"><b>Inclusion criteria</b>: At </text>
<text top="439" left="393" width="147" height="20" font="0">baseline: Men and women </text>
<text top="456" left="393" width="156" height="20" font="0">with no history of MI, angina </text>
<text top="474" left="393" width="154" height="20" font="0">or stroke who had complete </text>
<text top="491" left="393" width="108" height="20" font="0">information on total </text>
<text top="508" left="393" width="111" height="20" font="0">cholesterol, HDL-C, </text>
<text top="525" left="393" width="156" height="20" font="0">triglycerides and risk factors </text>
<text top="542" left="393" width="154" height="20" font="0">including age, sex, smoking </text>
<text top="560" left="393" width="143" height="20" font="0">status, history of diabetes </text>
<text top="577" left="393" width="126" height="20" font="0">mellitus, systolic blood </text>
<text top="594" left="393" width="138" height="20" font="0">pressure and body mass </text>
<text top="611" left="393" width="150" height="20" font="0">index. Outcomes based on </text>
<text top="628" left="393" width="145" height="20" font="0">death certificates, medical </text>
<text top="646" left="393" width="143" height="20" font="0">records, autopsy findings, </text>
<text top="663" left="393" width="143" height="20" font="0">and “other supplementary </text>
<text top="680" left="393" width="152" height="20" font="0">sources to classify deaths.” </text>
<text top="697" left="393" width="148" height="20" font="0">Stroke diagnosis based on </text>
<text top="714" left="393" width="112" height="20" font="0">clinical features and </text>
<text top="732" left="393" width="139" height="20" font="0">characteristic findings on </text>
<text top="749" left="393" width="120" height="20" font="0">brain imaging, and all </text>
<text top="766" left="393" width="158" height="20" font="0">studies attempted to classify </text>
<text top="783" left="393" width="87" height="20" font="0">stroke subtype. </text>
<text top="422" left="568" width="262" height="22" font="7"><b>1</b>⁰<b> outcome (regarding triglycerides)</b>: Hazard </text>
<text top="440" left="568" width="243" height="20" font="0">ratios, adjusted for conventional risk factors, </text>
<text top="457" left="568" width="268" height="20" font="0">calculated for 1-standard deviation higher values </text>
<text top="474" left="568" width="57" height="20" font="0">of 0.52 log</text>
<text top="480" left="626" width="4" height="13" font="9">e</text>
<text top="474" left="630" width="172" height="20" font="0"> triglyceride. Within-study meta </text>
<text top="491" left="568" width="252" height="20" font="0">regression analysis adjusted for within person </text>
<text top="508" left="568" width="246" height="20" font="0">variation and combined using meta-analysis. </text>
<text top="526" left="568" width="3" height="20" font="0"> </text>
<text top="543" left="568" width="265" height="20" font="7"><b>Results: </b>Mean age 59 ± 8 y. 43% women. 60% </text>
<text top="560" left="568" width="260" height="20" font="0">Western European, 32% North American. CHD </text>
<text top="577" left="568" width="257" height="20" font="0">rates per 1,000 person-y in the bottom and top </text>
<text top="594" left="568" width="254" height="20" font="0">thirds of baseline lipids, respectively, were 2.6 </text>
<text top="612" left="568" width="258" height="20" font="0">and 6.2. Highest usual mean TG level was 250 </text>
<text top="629" left="568" width="240" height="20" font="0">mg/dL.  Unadjusted hazard ratio for CHD of </text>
<text top="646" left="568" width="260" height="20" font="0">fasting or non-fasting triglycerides for CHD was </text>
<text top="663" left="568" width="272" height="20" font="0">1.37 (95% CI: 1.31-1.42) after adjustment for non-</text>
<text top="680" left="568" width="260" height="20" font="0">lipid risk factors, but after additional adjustment </text>
<text top="698" left="568" width="256" height="20" font="0">for HDL-C and non- HDL-C was 0.99 (95% CI: </text>
<text top="715" left="568" width="268" height="20" font="0">0.94-1.05) for CHD, and for ischemic stroke 1.02 </text>
<text top="732" left="568" width="114" height="20" font="0">(95% CI: 0.94-1.11).<b> </b></text>
<text top="422" left="859" width="209" height="20" font="0">Population-wide fasting or non-fasting </text>
<text top="439" left="859" width="188" height="20" font="0">triglyceride concentrations are not </text>
<text top="456" left="859" width="230" height="20" font="0">independently related to CHD or ischemic </text>
<text top="474" left="859" width="243" height="20" font="0">stroke risk when controlling for standard risk </text>
<text top="491" left="859" width="198" height="20" font="0">factors and HDL-C and non-HDL-C. </text>
<text top="508" left="859" width="3" height="20" font="0"> </text>
<text top="525" left="859" width="3" height="20" font="0"> </text>
<text top="542" left="859" width="3" height="20" font="0"> </text>
<text top="560" left="859" width="3" height="20" font="0"> </text>
<text top="577" left="859" width="3" height="20" font="0"> </text>
<text top="594" left="859" width="3" height="20" font="0"> </text>
<text top="611" left="859" width="3" height="20" font="0"> </text>
<text top="628" left="913" width="3" height="20" font="0"> </text>
</page>
<page number="162" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">162 </text>
<text top="107" left="393" width="133" height="20" font="7"><b>Exclusion criteria</b>: N/A </text>
<text top="125" left="89" width="119" height="20" font="0">Nordestgaard, BG, et </text>
<text top="142" left="89" width="83" height="20" font="0">al., 2007 <a href="data supplement.html#247">(190)</a> </text>
<text top="159" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17635890">17635890</a></text>
<text top="159" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17635890"> </a></text>
<text top="125" left="231" width="141" height="20" font="0">Prospective cohort study  </text>
<text top="142" left="231" width="57" height="20" font="0">N=13,981 </text>
<text top="125" left="393" width="136" height="20" font="7"><b>Inclusion criteria</b>: 7587 </text>
<text top="142" left="393" width="153" height="20" font="0">men and 6394 women from </text>
<text top="159" left="393" width="139" height="20" font="0">the general population of </text>
<text top="177" left="393" width="158" height="20" font="0">Copenhagen, Denmark; age </text>
<text top="194" left="393" width="124" height="20" font="0">20-93 y; followed from </text>
<text top="211" left="393" width="146" height="20" font="0">baseline (1976-1978) until </text>
<text top="228" left="393" width="38" height="20" font="0">2004.  </text>
<text top="245" left="393" width="3" height="20" font="0"> </text>
<text top="263" left="393" width="133" height="20" font="7"><b>Exclusion criteria</b>: N/A </text>
<text top="125" left="568" width="236" height="22" font="7"><b>1</b>⁰<b> endpoint</b>: Hazard ratios for incident MI, </text>
<text top="143" left="568" width="273" height="20" font="0">ischemic heart disease (IHD) and total death over </text>
<text top="160" left="568" width="246" height="20" font="0">a mean follow-up of 28 y, according the 88.5 </text>
<text top="177" left="568" width="265" height="20" font="0">mg/dL quintiles of non-fasting triglycerides (TG), </text>
<text top="194" left="568" width="243" height="20" font="0">as compared to those with TG &lt;88.5 mg/dL. </text>
<text top="211" left="568" width="7" height="20" font="0">  </text>
<text top="229" left="568" width="55" height="20" font="7"><b>Results</b>:  </text>
<text top="246" left="568" width="257" height="20" font="7"><b>MI</b>: Women: age (and multifactorially adjusted) </text>
<text top="263" left="568" width="250" height="20" font="0">HR’s for each quintile: 2.2 (1.7); 4.4 (2.5), 3.9 </text>
<text top="280" left="568" width="258" height="20" font="0">(2.1); 5.1 (2.4); 16.8 (5.4). For both, P for trend </text>
<text top="298" left="568" width="38" height="20" font="0">&lt;.001. </text>
<text top="315" left="568" width="262" height="20" font="0">Men: 1.6 (1.4), 2.3 (1.6), 3.6 (2.3), 3.3 (1.9) and </text>
<text top="332" left="568" width="204" height="20" font="0">4.6 (2.4). For both, P for trend &lt;.001. </text>
<text top="349" left="568" width="257" height="20" font="7"><b>IHD: </b>Women:<b> </b>1.7 (1.4),<b> </b>2.8 (1.8), 3.0 (1.8), 2.1 </text>
<text top="366" left="568" width="268" height="20" font="0">(1.2), 5.9 (2.6). For both trend, P for trend &lt;.001. </text>
<text top="384" left="568" width="262" height="20" font="0">Men: 1.3 (1.1), 1.7 (1.3), 2.1 (1.3), 2.0 (1.2), 2.9 </text>
<text top="401" left="568" width="243" height="20" font="0">(1.5). P for trend &lt;.001 for age adjusted and </text>
<text top="418" left="568" width="194" height="20" font="0">p=0.03 for multifactorially adjusted. </text>
<text top="435" left="568" width="7" height="20" font="0">  </text>
<text top="452" left="568" width="248" height="20" font="7"><b>Total death</b>: Women: 1.3 (1.3), 1.7 (1.6), 2.2 </text>
<text top="470" left="568" width="232" height="20" font="0">(2.2), 2.2 (1.9) and 4.3 (3.3), for both P for </text>
<text top="487" left="568" width="63" height="20" font="0">trend&lt;.001 </text>
<text top="504" left="568" width="262" height="20" font="0">Men: 1.3 (1.2), 1.4 (1.4), 1.7 (1.5), 1.8 (1.6) and </text>
<text top="521" left="568" width="175" height="20" font="0">2.0 (1.8); for both, trend &lt;.001). </text>
<text top="539" left="568" width="3" height="20" font="0"> </text>
<text top="125" left="859" width="256" height="20" font="0">Elevated age and multifactorially-adjusted non-</text>
<text top="142" left="859" width="237" height="20" font="0">fasting TG concentration is associated with </text>
<text top="159" left="859" width="237" height="20" font="0">increased risk of MI, IHD and death in men </text>
<text top="177" left="859" width="226" height="20" font="0">and women in a large Danish population. </text>
<text top="194" left="859" width="3" height="20" font="0"> </text>
<text top="211" left="859" width="253" height="20" font="7"><b>Limitations</b>: White population only. Relatively </text>
<text top="228" left="859" width="254" height="20" font="0">small sample size and wide CI’s in the quintile </text>
<text top="245" left="859" width="148" height="20" font="0">with the highest TG levels. </text>
<text top="556" left="89" width="102" height="20" font="0">Freiberg JJ, et al., </text>
<text top="574" left="89" width="63" height="20" font="0">2008<a href="data supplement.html#247"> (191)</a> </text>
<text top="591" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19001625">19001625</a></text>
<text top="591" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19001625"> </a></text>
<text top="556" left="231" width="138" height="20" font="0">Prospective cohort study </text>
<text top="574" left="231" width="91" height="20" font="0">N=13,956 in the </text>
<text top="591" left="231" width="102" height="20" font="0">prospective study; </text>
<text top="608" left="231" width="117" height="20" font="0">N=9,367 in the cross-</text>
<text top="625" left="231" width="85" height="20" font="0">sectional study </text>
<text top="556" left="393" width="157" height="20" font="7"><b>Inclusion criteria</b>: Men and </text>
<text top="574" left="393" width="162" height="20" font="0">women age 20-93 y of age in </text>
<text top="591" left="393" width="152" height="20" font="0">the Copenhagen City Heart </text>
<text top="608" left="393" width="124" height="20" font="0">Study, with enrollment </text>
<text top="625" left="393" width="141" height="20" font="0">initiating in 1976 and with </text>
<text top="642" left="393" width="157" height="20" font="0">follow-up through July 2007. </text>
<text top="660" left="393" width="161" height="20" font="0">Cross sectional study of men </text>
<text top="677" left="393" width="141" height="20" font="0">and women attending the </text>
<text top="694" left="393" width="146" height="20" font="0">1991-1994 examination of </text>
<text top="711" left="393" width="127" height="20" font="0">the prospective study.  </text>
<text top="729" left="393" width="134" height="20" font="7"><b>Exclusion criteria: </b>NA <b> </b></text>
<text top="556" left="568" width="111" height="20" font="7"><b>Primary endpoint</b>:  </text>
<text top="574" left="568" width="239" height="20" font="0">Prospective study: Baseline non-fasting TG </text>
<text top="591" left="568" width="243" height="20" font="0">(NFTG), other risk factors at baseline and at </text>
<text top="608" left="568" width="267" height="20" font="0">follow-up examination and incidence of ischemic </text>
<text top="625" left="568" width="40" height="20" font="0">stroke. </text>
<text top="642" left="568" width="261" height="20" font="0">Cross sectional study: NFTG, levels of remnant </text>
<text top="660" left="568" width="256" height="20" font="0">cholesterol and prevalence of ischemic stroke. </text>
<text top="677" left="568" width="52" height="20" font="7"><b>Results: </b></text>
<text top="694" left="568" width="104" height="20" font="0">Prospective study: </text>
<text top="711" left="568" width="256" height="20" font="0">Incidence of ischemic stroke versus those with </text>
<text top="729" left="568" width="98" height="20" font="0">NFTG &lt;89 mg/dl: </text>
<text top="746" left="568" width="245" height="20" font="0">Men with NFTG 89-176 mg/dL: multivariable-</text>
<text top="763" left="568" width="250" height="20" font="0">adjusted HR: (MAHR) 1.3 (95% CI: 0.8-1.91); </text>
<text top="780" left="568" width="254" height="20" font="0">177-265 mg/dL: MAHR: 1.6 (95% CI: 1.0-2.5); </text>
<text top="556" left="859" width="255" height="20" font="0">In this Danish population in both a prospective </text>
<text top="574" left="859" width="243" height="20" font="0">cohort study and in a cross- sectional study, </text>
<text top="591" left="859" width="240" height="20" font="0">NFTG levels predicted ischemic stroke risk. </text>
</page>
<page number="163" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">163 </text>
<text top="107" left="568" width="250" height="20" font="0">266-353 mg/dL: MAHR 1.5 (95% CI: 0.9-2.7); </text>
<text top="124" left="568" width="262" height="20" font="0">354-442 mg/dL: MAHR 2.2 (95% CI: 1.3-4.8); ≥ </text>
<text top="141" left="568" width="274" height="20" font="0">443 mg/dL: MAHR 2.5 (95% CI: 1.3-4.8). p&lt;0.001 </text>
<text top="159" left="568" width="53" height="20" font="0">for trend. </text>
<text top="176" left="568" width="251" height="20" font="0">Women with NFTG 89-176 mg/dL: MAHR 1.3 </text>
<text top="193" left="568" width="250" height="20" font="0">(95% CI: 0.9-1.7); 177-265 mg/dL: MAHR 2.0 </text>
<text top="210" left="568" width="262" height="20" font="0">(95% CI: 1.3-2.9); 266-353 mg/dL: 1.4 (95% CI: </text>
<text top="228" left="568" width="271" height="20" font="0">0.7-2.9); 354-442 mg/dL: MAHR 2.5 (95% CI: 1.0-</text>
<text top="245" left="568" width="267" height="20" font="0">6.4); ≥443 mg/dL: 3.8 (95% CI: 1.3-11); p&lt;0.001 </text>
<text top="262" left="568" width="56" height="20" font="0">for trend.  </text>
<text top="279" left="568" width="216" height="20" font="0">Absolute 10-y risk of ischemic stroke in </text>
<text top="296" left="568" width="254" height="20" font="0">men/women &lt;age 55 y and NFTG &lt;89 mg/dL: </text>
<text top="314" left="568" width="270" height="20" font="0">2.6%/1.9%; in men/women &gt;age 55 y with NFTG </text>
<text top="331" left="568" width="160" height="20" font="0">≥ 443 mg/dL: 16.7%/12.2%.  </text>
<text top="348" left="568" width="226" height="20" font="0">Cross sectional study: Men with previous </text>
<text top="365" left="568" width="259" height="20" font="0">ischemic stroke versus controls had NFTG 191 </text>
<text top="382" left="568" width="255" height="20" font="0">(IQR, 131-259/) mg/dL vs. 148 (IQR: 104-214) </text>
<text top="400" left="568" width="270" height="20" font="0">mg/dL (p&lt;0.01). For women: NFTG 167(IQR 121-</text>
<text top="417" left="568" width="274" height="20" font="0">229) mg/dL vs. 127 (IQR 91-181) mg/dL (p&lt;0.05). </text>
<text top="435" left="89" width="109" height="20" font="0">Karlson, BW, et al., </text>
<text top="452" left="89" width="63" height="20" font="0">2016 <a href="data supplement.html#247">(192)</a> </text>
<text top="469" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26969416">26969416</a></text>
<text top="469" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26969416"> </a></text>
<text top="435" left="231" width="142" height="20" font="0">Cohort study of Individual </text>
<text top="452" left="231" width="122" height="20" font="0">patient data extracted </text>
<text top="469" left="231" width="139" height="20" font="0">from a patient level meta-</text>
<text top="487" left="231" width="111" height="20" font="0">analysis examining  </text>
<text top="504" left="231" width="126" height="20" font="0">LDL-C and triglyceride </text>
<text top="521" left="231" width="120" height="20" font="0">reductions in patients </text>
<text top="538" left="231" width="133" height="20" font="0">receiving treatment with </text>
<text top="555" left="231" width="147" height="20" font="0">different statins and doses </text>
<text top="573" left="231" width="60" height="20" font="0">N=15,800  </text>
<text top="435" left="393" width="105" height="20" font="7"><b>Inclusion criteria</b>: </text>
<text top="452" left="393" width="125" height="20" font="0">Subjects with baseline </text>
<text top="469" left="393" width="154" height="20" font="0">fasting triglycerides of ≥177 </text>
<text top="487" left="393" width="134" height="20" font="0">mg/dL derived from The </text>
<text top="504" left="393" width="120" height="20" font="0">VOYAGER (Of Statin </text>
<text top="521" left="393" width="152" height="20" font="0">Therapy in At-Risk Groups: </text>
<text top="538" left="393" width="132" height="20" font="0">Effects of Rosuvastatin, </text>
<text top="555" left="393" width="92" height="20" font="0">Atorvastatin and </text>
<text top="573" left="393" width="151" height="20" font="0">Simvastatin) database who </text>
<text top="590" left="393" width="162" height="20" font="0">were treated with daily doses </text>
<text top="607" left="393" width="159" height="20" font="0">of rosuvastatin 5, 10, 20 and </text>
<text top="624" left="393" width="149" height="20" font="0">40 mg; atorvastatin 10, 20, </text>
<text top="641" left="393" width="106" height="20" font="0">40 and 80 mg; and </text>
<text top="659" left="393" width="147" height="20" font="0">simvastatin 10, 20, 40 and </text>
<text top="676" left="393" width="41" height="20" font="0">80 mg  </text>
<text top="435" left="568" width="111" height="20" font="7"><b>Primary endpoint</b>:  </text>
<text top="452" left="568" width="249" height="20" font="0">Percent changes from baseline in LDL-C and </text>
<text top="469" left="568" width="266" height="20" font="0">triglycerides and least square means calculated. </text>
<text top="487" left="568" width="250" height="20" font="0">Percentage of patients reaching on treatment </text>
<text top="504" left="568" width="264" height="20" font="0">triglycerides of &lt;150 mg/dL was calculated after </text>
<text top="521" left="568" width="268" height="20" font="0">adjusting for study and baseline triglyceride level </text>
<text top="538" left="568" width="55" height="20" font="7"><b>Results:  </b></text>
<text top="555" left="568" width="265" height="20" font="0">1. The mean percent reduction in triglycerides ± </text>
<text top="573" left="568" width="273" height="20" font="0">standard error of the means across all statins and </text>
<text top="590" left="568" width="260" height="20" font="0">all doses ranged from -15.1% (3.2%) to -31.3% </text>
<text top="607" left="568" width="40" height="20" font="0">(1.4%) </text>
<text top="624" left="568" width="217" height="20" font="0">2. Atorvastatin 80 mg produced greater </text>
<text top="641" left="568" width="252" height="20" font="0">triglyceride reduction than rosuvastatin 10 mg </text>
<text top="659" left="568" width="60" height="20" font="0">(p=0.003)  </text>
<text top="676" left="568" width="268" height="20" font="0">2. Triglyceride reduction with atorvastatin 20 and </text>
<text top="693" left="568" width="269" height="20" font="0">40 mg were similar to that seen with rosuvastatin </text>
<text top="710" left="568" width="185" height="20" font="0">20 and 40 mg (P non-significant). </text>
<text top="727" left="568" width="265" height="20" font="0">3. Triglyceride reduction with atorvastatin 80 mg </text>
<text top="745" left="568" width="265" height="20" font="0">was similar to that seen with rosuvastatin 40 mg </text>
<text top="762" left="568" width="106" height="20" font="0">(P non-significant)  </text>
<text top="779" left="568" width="3" height="20" font="0"> </text>
<text top="435" left="859" width="243" height="20" font="0">1. High-intensity statin therapy is associated </text>
<text top="452" left="859" width="234" height="20" font="0">with triglyceride reductions of up to 31% in </text>
<text top="469" left="859" width="190" height="20" font="0">patients with baseline triglycerides </text>
<text top="487" left="859" width="229" height="20" font="0">2. High-intensity statins therapy produces </text>
<text top="504" left="859" width="242" height="20" font="0">greater triglyceride reduction than moderate </text>
<text top="521" left="859" width="91" height="20" font="0">intensity statins  </text>
<text top="538" left="859" width="3" height="20" font="0"> </text>
<text top="555" left="859" width="76" height="20" font="7"><b>Limitations:  </b></text>
<text top="573" left="859" width="255" height="20" font="0">1. No cardiovascular outcomes data available  </text>
<text top="590" left="859" width="226" height="20" font="0">2. Short duration of the individual studies </text>
<text top="607" left="859" width="98" height="20" font="0">(typically 4-6 wk)  </text>
</page>
<page number="164" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">164 </text>
<text top="107" left="568" width="3" height="20" font="7"><b> </b></text>
<text top="125" left="89" width="113" height="20" font="0">Pederson SB, et al., </text>
<text top="142" left="89" width="63" height="20" font="0">2016<a href="data supplement.html#247"> (193)</a> </text>
<text top="159" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27820614">27820614</a></text>
<text top="159" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27820614"> </a></text>
<text top="177" left="89" width="7" height="20" font="0">  </text>
<text top="125" left="231" width="138" height="20" font="0">Prospective cohort study </text>
<text top="142" left="231" width="64" height="20" font="0">N=116,550 </text>
<text top="125" left="393" width="146" height="20" font="7"><b>Inclusion criteria</b>: 98,649 </text>
<text top="142" left="393" width="97" height="20" font="0">subjects from the </text>
<text top="159" left="393" width="121" height="20" font="0">Copenhagen General </text>
<text top="177" left="393" width="154" height="20" font="0">Population Study in 2003 to </text>
<text top="194" left="393" width="144" height="20" font="0">2015 and 17,901 from the </text>
<text top="211" left="393" width="132" height="20" font="0">Copenhagen City Heart </text>
<text top="228" left="393" width="130" height="20" font="0">Study from 1976-8 with </text>
<text top="246" left="393" width="141" height="20" font="0">follow-up examinations in </text>
<text top="263" left="393" width="156" height="20" font="0">1981-3, 1991-4 and 2001-3. </text>
<text top="280" left="393" width="156" height="20" font="0">All followed until occurrence </text>
<text top="297" left="393" width="105" height="20" font="0">of an event, death, </text>
<text top="314" left="393" width="148" height="20" font="0">emigration or end of follow-</text>
<text top="332" left="393" width="124" height="20" font="0">up in November 2014. </text>
<text top="349" left="393" width="130" height="20" font="0">Median follow-up 6.7 y. </text>
<text top="366" left="393" width="3" height="20" font="0"> </text>
<text top="383" left="393" width="130" height="20" font="7"><b>Exclusion criteria</b>: NA </text>
<text top="125" left="568" width="226" height="22" font="7"><b>1</b>⁰<b> endpoint</b>: Hazard ratio (HR) for acute </text>
<text top="143" left="568" width="255" height="20" font="0">pancreatitis (N=434) and myocardial infarction </text>
<text top="160" left="568" width="58" height="20" font="0">(N=3,942) </text>
<text top="177" left="568" width="3" height="20" font="0"> </text>
<text top="194" left="568" width="264" height="20" font="7"><b>Results</b>: As compared to those with non-fasting </text>
<text top="211" left="568" width="268" height="20" font="0">TG &lt;89 mg/dL, the multivariable adjusted HR for </text>
<text top="229" left="568" width="223" height="20" font="0">acute pancreatitis/myocardial infarction:  </text>
<text top="246" left="568" width="241" height="20" font="0">TG 89-176 mg/dL: 1.6 (95% CI: 1.0-2.6; 4.3 </text>
<text top="263" left="568" width="271" height="20" font="0">events/10,000-person y). For MI:1.6 (95% CI: 1.4-</text>
<text top="280" left="568" width="177" height="20" font="0">1.9; 41 events/10,000 person-y) </text>
<text top="298" left="568" width="248" height="20" font="0">TG 177-265 mg/dL: 2.3 (95% CI: 1.3-4.0; 5.5 </text>
<text top="315" left="568" width="254" height="20" font="0">events/10,000-person y). For MI: 2.2 (95% CI: </text>
<text top="332" left="568" width="202" height="20" font="0">1.9-2.7; 57 events /10,000-person y) </text>
<text top="349" left="568" width="248" height="20" font="0">TG 266-353 mg/dL: 2.9 (95% CI: 1.4-5.9; 6.3 </text>
<text top="366" left="568" width="254" height="20" font="0">events/10,000-person y). For MI: 3.2 (95% CI: </text>
<text top="384" left="568" width="202" height="20" font="0">2.6-4.1; 72 events /10,000-person y) </text>
<text top="401" left="568" width="234" height="20" font="0">TG 354-442 mg/dL: 3.9 (95% CI: 1.5-10.0; </text>
<text top="418" left="568" width="271" height="20" font="0">7.5 events/10,000-person y). For MI:2.8 (95% CI: </text>
<text top="435" left="568" width="198" height="20" font="0">2.0-3.9; 68 events/10,000-person y) </text>
<text top="452" left="568" width="221" height="20" font="0">TG ≥ 443 mg/dL: 8.7 (95% CI: 3.7-20.0; </text>
<text top="470" left="568" width="259" height="20" font="0">12 events per 10,000-person y) (trend P=6 x 10</text>
<text top="471" left="827" width="7" height="13" font="9">-8</text>
<text top="470" left="834" width="11" height="20" font="0">). </text>
<text top="487" left="568" width="237" height="20" font="0">For MI: 3.4 (95% CI: 2.4-4.7; 78 events per </text>
<text top="504" left="568" width="96" height="20" font="0">10,000-person y) </text>
<text top="521" left="568" width="261" height="20" font="0">Multivariable adjusted HR for acute pancreatitis </text>
<text top="539" left="568" width="277" height="20" font="0">was 1.17 (95% CI: 1.10-1.24) per 89 mg/dL higher </text>
<text top="556" left="568" width="73" height="20" font="0">triglycerides. </text>
<text top="125" left="859" width="256" height="20" font="0">Non-fasting TG above 177 mg/dL predicts and </text>
<text top="142" left="859" width="221" height="20" font="0">increased risk of acute pancreatitis, with </text>
<text top="159" left="859" width="248" height="20" font="0">incremental risk proportionate to NFTG level. </text>
<text top="177" left="859" width="3" height="20" font="0"> </text>
<text top="194" left="859" width="3" height="20" font="0"> </text>
<text top="574" left="89" width="102" height="20" font="0">Rhodes KS, et al., </text>
<text top="591" left="89" width="63" height="20" font="0">2015 <a href="data supplement.html#247">(194)</a> </text>
<text top="608" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26228674">26228674</a></text>
<text top="608" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26228674"> </a></text>
<text top="574" left="231" width="124" height="20" font="0">Prospective outcomes </text>
<text top="591" left="231" width="33" height="20" font="0">study </text>
<text top="608" left="231" width="40" height="20" font="0">N=168 </text>
<text top="574" left="393" width="109" height="20" font="7"><b>Inclusion criteria</b>:  </text>
<text top="591" left="393" width="145" height="20" font="0">New patients referred to a </text>
<text top="608" left="393" width="143" height="20" font="0">University Medical Center </text>
<text top="625" left="393" width="150" height="20" font="0">lipid management program </text>
<text top="642" left="393" width="134" height="20" font="0">with fasting triglycerides </text>
<text top="660" left="393" width="120" height="20" font="0">≥500 mg/dL between </text>
<text top="677" left="393" width="139" height="20" font="0">September 10, 2001 and </text>
<text top="694" left="393" width="140" height="20" font="0">October 5, 2007. Patents </text>
<text top="711" left="393" width="139" height="20" font="0">received fasting baseline </text>
<text top="729" left="393" width="92" height="20" font="0">lipid, lipoprotein, </text>
<text top="746" left="393" width="108" height="20" font="0">apolipoprotein, and </text>
<text top="763" left="393" width="146" height="20" font="0">additional screening blood </text>
<text top="780" left="393" width="158" height="20" font="0">testing followed by a 75 min. </text>
<text top="574" left="568" width="74" height="22" font="7"><b>1</b>⁰<b>outcome</b>:  </text>
<text top="591" left="568" width="274" height="20" font="0">Triglyceride level achieved at the second visit and </text>
<text top="608" left="568" width="257" height="20" font="0">the median percent change in triglyceride level </text>
<text top="626" left="568" width="177" height="20" font="0">from the first to the second visit. </text>
<text top="643" left="568" width="3" height="20" font="7"><b> </b></text>
<text top="660" left="568" width="3" height="20" font="7"><b> </b></text>
<text top="677" left="568" width="51" height="20" font="7"><b>Results</b>: </text>
<text top="694" left="568" width="221" height="20" font="0">1. Outside physicians initiated fibric acid </text>
<text top="712" left="568" width="268" height="20" font="0">derivatives for 15 patient and other lipid-lowering </text>
<text top="729" left="568" width="239" height="20" font="0">medications for 8 patients during the period </text>
<text top="746" left="568" width="195" height="20" font="0">between the first and second visits. </text>
<text top="574" left="859" width="237" height="20" font="0">A lifestyle intervention comprised of dietary </text>
<text top="591" left="859" width="236" height="20" font="0">change focusing on low simple and refined </text>
<text top="608" left="859" width="260" height="20" font="0">carbohydrates, high soluble fiber (&gt;10 g/d), low </text>
<text top="625" left="859" width="247" height="20" font="0">saturated and minimal trans-fat, limited or no </text>
<text top="642" left="859" width="238" height="20" font="0">alcohol, and aerobic exercise of 30-60 min. </text>
<text top="660" left="859" width="226" height="20" font="0">most days of the week is associated with </text>
<text top="677" left="859" width="225" height="20" font="0">significant short-term reduction of fasting </text>
<text top="694" left="859" width="194" height="20" font="0">triglycerides in patients with severe </text>
<text top="711" left="859" width="212" height="20" font="0">hypertriglyceridemia, regardless of the </text>
<text top="729" left="859" width="227" height="20" font="0">absence or presence of concomitant lipid </text>
<text top="746" left="859" width="94" height="20" font="0">lowering therapy </text>
<text top="763" left="859" width="3" height="20" font="0"> </text>
</page>
<page number="165" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">165 </text>
<text top="107" left="393" width="140" height="20" font="0">nutrition assessment and </text>
<text top="124" left="393" width="156" height="20" font="0">initiation of an individualized </text>
<text top="141" left="393" width="113" height="20" font="0">dietary and exercise </text>
<text top="159" left="393" width="125" height="20" font="0">intervention. A second </text>
<text top="176" left="393" width="141" height="20" font="0">nutrition consultation was </text>
<text top="193" left="393" width="143" height="20" font="0">provided one month later, </text>
<text top="210" left="393" width="129" height="20" font="0">with repeat lipid profile  </text>
<text top="227" left="393" width="159" height="20" font="7"><b>Exclusion criteria</b>: Age &lt;20 </text>
<text top="245" left="393" width="132" height="20" font="0">y, pregnant or lactating, </text>
<text top="262" left="393" width="149" height="20" font="0">history of organ transplant, </text>
<text top="279" left="393" width="122" height="20" font="0">creatinine &gt;1.5 mg/dL </text>
<text top="107" left="568" width="252" height="20" font="0">2. With median baseline triglycerides of 961.5 </text>
<text top="124" left="568" width="258" height="20" font="0">mg/dL at first visit, 123 (78%) achieved greater </text>
<text top="141" left="568" width="224" height="20" font="0">than 20% reduction in triglyceride levels. </text>
<text top="159" left="568" width="252" height="20" font="0">3. The reduction in median fasting triglyceride </text>
<text top="176" left="568" width="262" height="20" font="0">level from the first to the second visit was 468.5 </text>
<text top="193" left="568" width="272" height="20" font="0">mg/dL, representing a 48.8% (IQR -73.3 to -23.2) </text>
<text top="210" left="568" width="113" height="20" font="0">Wilcoxon P &lt;0.0001 </text>
<text top="227" left="568" width="267" height="20" font="0">4. Among those whose lipid-lowering medication </text>
<text top="245" left="568" width="257" height="20" font="0">regimen remained stable between the first and </text>
<text top="262" left="568" width="242" height="20" font="0">second visits, there was no difference in the </text>
<text top="279" left="568" width="273" height="20" font="0">median percentage reduction in triglycerides after </text>
<text top="296" left="568" width="277" height="20" font="0">lifestyle intervention between those not taking lipid </text>
<text top="314" left="568" width="257" height="20" font="0">medication, those taking a fibrate, those taking </text>
<text top="331" left="568" width="238" height="20" font="0">other lipid-lowering medication, or those on </text>
<text top="348" left="568" width="246" height="20" font="0">combination lipid-lowering therapy (p=0.376) </text>
<text top="107" left="859" width="246" height="20" font="7"><b>Limitations</b>: Short follow-up period does not </text>
<text top="124" left="859" width="254" height="20" font="0">assure maintained long term adherence to the </text>
<text top="141" left="859" width="138" height="20" font="0">lifestyle change program </text>
<text top="159" left="859" width="3" height="20" font="0"> </text>
<text top="366" left="89" width="107" height="20" font="0">Christian JB, et al., </text>
<text top="383" left="89" width="63" height="20" font="0">2012<a href="data supplement.html#247"> (195)</a> </text>
<text top="400" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23009781">23009781</a></text>
<text top="400" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23009781"> </a></text>
<text top="366" left="231" width="149" height="20" font="0">Retrospective cohort study </text>
<text top="383" left="231" width="57" height="20" font="0">N=41,210 </text>
<text top="366" left="393" width="107" height="20" font="7"><b>Inclusion Criteria</b>: </text>
<text top="383" left="393" width="148" height="20" font="0">Patients ≥ age 18 y of age </text>
<text top="400" left="393" width="153" height="20" font="0">enrolled from January 2001 </text>
<text top="418" left="393" width="149" height="20" font="0">through December 2010 in </text>
<text top="435" left="393" width="136" height="20" font="0">&gt;46 different health care </text>
<text top="452" left="393" width="134" height="20" font="0">plans with full insurance </text>
<text top="469" left="393" width="145" height="20" font="0">coverage for professional, </text>
<text top="487" left="393" width="127" height="20" font="0">hospital and outpatient </text>
<text top="504" left="393" width="130" height="20" font="0">prescription medication </text>
<text top="521" left="393" width="137" height="20" font="0">services with continuous </text>
<text top="538" left="393" width="156" height="20" font="0">enrollment with medical and </text>
<text top="555" left="393" width="144" height="20" font="0">pharmacy claims for 6 mo </text>
<text top="573" left="393" width="157" height="20" font="0">before the index date and at </text>
<text top="590" left="393" width="138" height="20" font="0">least 90 d after the index </text>
<text top="607" left="393" width="31" height="20" font="0">date. </text>
<text top="624" left="393" width="119" height="20" font="0">Had to have baseline </text>
<text top="641" left="393" width="156" height="20" font="0">triglyceride result and follow-</text>
<text top="659" left="393" width="113" height="20" font="0">up triglyceride result </text>
<text top="676" left="393" width="155" height="20" font="0">between 6 and &lt;24 wk after </text>
<text top="693" left="393" width="84" height="20" font="0">the index date. </text>
<text top="710" left="393" width="3" height="20" font="0"> </text>
<text top="727" left="393" width="113" height="20" font="7"><b>Exclusion criteria</b>:  </text>
<text top="745" left="393" width="139" height="20" font="0">Medical claims indicating </text>
<text top="762" left="393" width="152" height="20" font="0">pregnancy during the study </text>
<text top="779" left="393" width="41" height="20" font="0">period. </text>
<text top="366" left="568" width="114" height="20" font="7"><b>Primary outcomes</b>: </text>
<text top="383" left="568" width="73" height="20" font="0">Incidence of: </text>
<text top="400" left="568" width="125" height="20" font="0">Cardiovascular events </text>
<text top="418" left="568" width="120" height="20" font="0">Pancreatitis episodes </text>
<text top="435" left="568" width="133" height="20" font="0">Diabetes-related events </text>
<text top="452" left="568" width="269" height="20" font="0">Combined chronic kidney disease and end-stage </text>
<text top="469" left="568" width="77" height="20" font="0">renal disease </text>
<text top="487" left="568" width="186" height="20" font="0">Disease-related health care costs </text>
<text top="504" left="568" width="275" height="20" font="0">among those patients whose follow-up triglyceride </text>
<text top="521" left="568" width="38" height="20" font="0">levels: </text>
<text top="538" left="568" width="254" height="20" font="0">1) remained ≥ 500 mg/dL (8,493 patients) vs.  </text>
<text top="555" left="568" width="212" height="20" font="0">2) fell to &lt;500 mg/dL (32,217 patients) </text>
<text top="573" left="568" width="3" height="20" font="0"> </text>
<text top="590" left="568" width="51" height="20" font="7"><b>Results</b>: </text>
<text top="607" left="568" width="239" height="20" font="0">Those with triglycerides ≥ 500 mg/dL had a </text>
<text top="624" left="568" width="81" height="20" font="0">greater rate of </text>
<text top="641" left="568" width="265" height="20" font="0">1. Pancreatitis episodes (hazard ratio [HR:]1.79; </text>
<text top="659" left="568" width="220" height="20" font="0">95% confidence interval [CI:] 1.47-2.18) </text>
<text top="676" left="568" width="273" height="20" font="0">2. Cardiovascular events (HR: 1.19; 95% CI: 1.10-</text>
<text top="693" left="568" width="31" height="20" font="0">1.28) </text>
<text top="710" left="568" width="253" height="20" font="0">3. Diabetes-related events (HR: 1.42; 95% CI: </text>
<text top="727" left="568" width="60" height="20" font="0">1.27-1.59) </text>
<text top="745" left="568" width="267" height="20" font="0">4. Kidney disease (HR: 1.13; 95% CI: 1.04-1.22) </text>
<text top="366" left="859" width="81" height="20" font="7"><b>Conclusions</b>: </text>
<text top="383" left="859" width="257" height="20" font="0">The group with triglycerides &lt;500 mg/dL had a </text>
<text top="400" left="859" width="239" height="20" font="0">lower rate of clinical events as compared to </text>
<text top="418" left="859" width="242" height="20" font="0">those with triglycerides that remained ≥ 500 </text>
<text top="435" left="859" width="38" height="20" font="0">mg/dL </text>
<text top="452" left="859" width="73" height="20" font="7"><b>Limitations</b>: </text>
<text top="469" left="859" width="224" height="20" font="0">1. Retrospective design and potential for </text>
<text top="487" left="859" width="200" height="20" font="0">measured and unmeasured residual </text>
<text top="504" left="859" width="70" height="20" font="0">confounding </text>
<text top="521" left="859" width="252" height="20" font="0">2. Etiology of high triglyceride levels could not </text>
<text top="538" left="859" width="82" height="20" font="0">be determined </text>
<text top="555" left="859" width="249" height="20" font="0">3. Smoking and body mass index information </text>
<text top="573" left="859" width="73" height="20" font="0">not available </text>
<text top="590" left="859" width="7" height="20" font="0">  </text>
<text top="607" left="859" width="3" height="20" font="0"> </text>
</page>
<page number="166" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">166 </text>
<text top="194" left="81" width="4" height="22" font="1"> </text>
<text top="213" left="81" width="4" height="22" font="1"> </text>
<text top="245" left="81" width="4" height="22" font="1"> </text>
<text top="277" left="81" width="4" height="22" font="1"> </text>
<text top="310" left="81" width="4" height="22" font="1"> </text>
<text top="342" left="81" width="4" height="22" font="1"> </text>
<text top="375" left="81" width="4" height="22" font="1"> </text>
<text top="407" left="81" width="4" height="22" font="1"> </text>
<text top="440" left="81" width="4" height="22" font="1"> </text>
<text top="472" left="81" width="759" height="24" font="4"><b>Data Supplement 33. Randomized Trials of Statins in Women for Primary Prevention of CVD (Section 4.5.3.)  </b></text>
<text top="107" left="393" width="3" height="20" font="0"> </text>
<text top="107" left="568" width="257" height="20" font="0">Those with triglycerides &lt;500 mg/dL had lower </text>
<text top="124" left="568" width="250" height="20" font="0">adjusted all-cause and cardiovascular related </text>
<text top="141" left="568" width="220" height="20" font="0">costs in the first three years of follow-up </text>
<text top="159" left="568" width="3" height="20" font="0"> </text>
<text top="176" left="568" width="3" height="20" font="0"> </text>
<text top="494" left="99" width="94" height="20" font="7"><b>Study Acronym </b></text>
<text top="511" left="124" width="44" height="20" font="7"><b>Author </b></text>
<text top="528" left="131" width="30" height="20" font="7"><b>Year </b></text>
<text top="545" left="144" width="3" height="20" font="7"><b> </b></text>
<text top="494" left="241" width="79" height="20" font="7"><b>Aim of Study </b></text>
<text top="511" left="246" width="70" height="20" font="7"><b>Study Type </b></text>
<text top="528" left="238" width="86" height="20" font="7"><b>Study Size (N) </b></text>
<text top="494" left="395" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="494" left="564" width="111" height="20" font="7"><b>Study Intervention </b></text>
<text top="511" left="562" width="116" height="20" font="7"><b>(include # patients) </b></text>
<text top="528" left="564" width="111" height="20" font="7"><b>Study Comparator </b></text>
<text top="545" left="562" width="116" height="20" font="7"><b>(include # patients) </b></text>
<text top="494" left="729" width="105" height="20" font="7"><b>Endpoint Results </b></text>
<text top="511" left="710" width="144" height="20" font="7"><b>(include Absolute Event </b></text>
<text top="528" left="705" width="154" height="20" font="7"><b>Rates, P value; OR or RR; </b></text>
<text top="545" left="745" width="73" height="20" font="7"><b>and 95% CI) </b></text>
<text top="494" left="892" width="213" height="20" font="7"><b>Relevant 2° Endpoint (if any); Study </b></text>
<text top="511" left="914" width="169" height="20" font="7"><b>Limitations; Adverse Events </b></text>
<text top="563" left="89" width="113" height="20" font="7"><b>AFCAPS/TexCAPS </b></text>
<text top="580" left="89" width="96" height="20" font="0">Downs JR, et al., </text>
<text top="598" left="89" width="63" height="20" font="0">1998 <a href="data supplement.html#242">(102)</a> </text>
<text top="615" left="89" width="48" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9613910">9613910</a></text>
<text top="615" left="137" width="3" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=9613910"><b> </b></a></text>
<text top="563" left="215" width="100" height="20" font="7"><b>Aim:</b> To compare </text>
<text top="580" left="215" width="127" height="20" font="0">lovastatin with placebo </text>
<text top="598" left="215" width="116" height="20" font="0">for prevention of first </text>
<text top="615" left="215" width="119" height="20" font="0">acute major coronary </text>
<text top="632" left="215" width="98" height="20" font="0">event in men and </text>
<text top="649" left="215" width="85" height="20" font="0">women without </text>
<text top="667" left="215" width="92" height="20" font="0">clinically evident </text>
<text top="684" left="215" width="83" height="20" font="0">atherosclerotic </text>
<text top="701" left="215" width="128" height="20" font="0">cardiovascular disease </text>
<text top="718" left="215" width="100" height="20" font="0">with average total </text>
<text top="736" left="215" width="126" height="20" font="0">cholesterol and LDL-C </text>
<text top="753" left="215" width="94" height="20" font="0">levels and below </text>
<text top="770" left="215" width="127" height="20" font="0">average HDL-C levels. </text>
<text top="787" left="215" width="3" height="20" font="0"> </text>
<text top="563" left="360" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="582" left="360" width="11" height="18" font="0">• </text>
<text top="582" left="387" width="138" height="20" font="0">Men 45-73 y old, women </text>
<text top="599" left="387" width="68" height="20" font="0">55-73 y old  </text>
<text top="618" left="360" width="11" height="18" font="0">• </text>
<text top="617" left="387" width="148" height="20" font="0">TC 180-264 mg/dL, LDL-C </text>
<text top="634" left="387" width="142" height="20" font="0">130-190 mg/dL, HDL-C ≤ </text>
<text top="651" left="387" width="153" height="20" font="0">45 mg/dL for men and ≤ 47 </text>
<text top="669" left="387" width="119" height="20" font="0">for women, TG &lt; 400 </text>
<text top="686" left="387" width="44" height="20" font="0">mg/dL.  </text>
<text top="705" left="360" width="11" height="18" font="0">• </text>
<text top="704" left="387" width="123" height="20" font="0">When LDL-C 125-129 </text>
<text top="721" left="387" width="149" height="20" font="0">mg/dL, if TC/HDL-C ratio &gt; </text>
<text top="739" left="387" width="159" height="20" font="0">6.0, subjects were included.  </text>
<text top="756" left="360" width="3" height="20" font="0"> </text>
<text top="773" left="360" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="563" left="555" width="107" height="20" font="7"><b>Intervention:</b> AHA </text>
<text top="580" left="555" width="125" height="20" font="0">Step I diet + lovastatin </text>
<text top="598" left="555" width="119" height="20" font="0">20-40 mg daily (2805 </text>
<text top="615" left="555" width="102" height="20" font="0">men, 499 women) </text>
<text top="632" left="555" width="7" height="20" font="0">  </text>
<text top="649" left="555" width="106" height="20" font="7"><b>Comparator:</b> AHA </text>
<text top="667" left="555" width="103" height="20" font="0">Step I diet alone + </text>
<text top="684" left="555" width="112" height="20" font="0">placebo (2803 men, </text>
<text top="701" left="555" width="75" height="20" font="0">498 women)  </text>
<text top="718" left="555" width="3" height="20" font="0"> </text>
<text top="735" left="555" width="3" height="20" font="0"> </text>
<text top="754" left="555" width="11" height="18" font="0">• </text>
<text top="754" left="582" width="96" height="20" font="0">Consecutive LFT </text>
<text top="771" left="582" width="82" height="20" font="0">&gt; 3 times ULN </text>
<text top="564" left="697" width="137" height="20" font="7"><b>1</b>°<b> endpoint:</b> First acute </text>
<text top="582" left="697" width="164" height="20" font="0">major coronary event (fatal or </text>
<text top="599" left="697" width="161" height="20" font="0">nonfatal MI, unstable angina, </text>
<text top="616" left="697" width="125" height="20" font="0">sudden cardiac death) </text>
<text top="635" left="697" width="11" height="18" font="0">• </text>
<text top="634" left="724" width="140" height="20" font="0">Lova 116 events (6.8 per </text>
<text top="652" left="724" width="135" height="20" font="0">1000 patient-y), placebo </text>
<text top="669" left="724" width="116" height="20" font="0">183 events (10.9 per </text>
<text top="686" left="724" width="85" height="20" font="0">1000 patient-y) </text>
<text top="705" left="697" width="11" height="18" font="0">• </text>
<text top="704" left="724" width="124" height="20" font="0">RR for lova 0.63; 95% </text>
<text top="721" left="724" width="95" height="20" font="0">CI: 0.50 to 0.79), </text>
<text top="739" left="724" width="48" height="20" font="0">p&lt;0.001 </text>
<text top="758" left="697" width="11" height="18" font="0">• </text>
<text top="757" left="724" width="118" height="20" font="0">No sex differences in </text>
<text top="774" left="724" width="98" height="20" font="0">treatment effects  </text>
<text top="563" left="879" width="130" height="20" font="7"><b>Secondary Endpoints </b></text>
<text top="580" left="879" width="3" height="20" font="0"> </text>
<text top="598" left="879" width="156" height="20" font="0">Coronary revascularizations </text>
<text top="617" left="879" width="11" height="18" font="0">• </text>
<text top="616" left="906" width="170" height="20" font="0">Lova 106 events (6.2 per 1000 </text>
<text top="633" left="906" width="193" height="20" font="0">patient-y), placebo 157 events (9.3 </text>
<text top="650" left="906" width="107" height="20" font="0">per 1000 patient-y) </text>
<text top="669" left="879" width="11" height="18" font="0">• </text>
<text top="669" left="906" width="184" height="20" font="0">RR for lova 0.67; 95% CI: 0.52 to </text>
<text top="686" left="906" width="83" height="20" font="0">0.85), p=0.001 </text>
<text top="703" left="879" width="92" height="20" font="0">Unstable angina </text>
<text top="722" left="879" width="11" height="18" font="0">• </text>
<text top="721" left="906" width="204" height="20" font="0">Lova 60 events (3.5 per 1000 patient-</text>
<text top="739" left="906" width="197" height="20" font="0">y), placebo 87 events (5.1 per 1000 </text>
<text top="756" left="906" width="55" height="20" font="0">patient-y) </text>
</page>
<page number="167" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">167 </text>
<text top="107" left="215" width="102" height="20" font="7"><b>Study type:</b>  RCT </text>
<text top="124" left="215" width="3" height="20" font="0"> </text>
<text top="141" left="215" width="118" height="20" font="7"><b>Size:</b>  5608 men and </text>
<text top="159" left="215" width="67" height="20" font="0">997 women<b> </b></text>
<text top="109" left="360" width="11" height="18" font="0">• </text>
<text top="108" left="387" width="139" height="20" font="0">Clinical evidence of CVD<b> </b></text>
<text top="127" left="360" width="11" height="18" font="0">• </text>
<text top="126" left="387" width="145" height="20" font="0">Secondary hyperlipidemia<b> </b></text>
<text top="145" left="360" width="11" height="18" font="0">• </text>
<text top="145" left="387" width="38" height="20" font="0">IDDM <b> </b></text>
<text top="164" left="360" width="11" height="18" font="0">• </text>
<text top="163" left="387" width="105" height="20" font="0">Uncontrolled HTN <b> </b></text>
<text top="182" left="360" width="11" height="18" font="0">• </text>
<text top="181" left="387" width="153" height="20" font="0">Ventricular ectopy requiring </text>
<text top="198" left="387" width="66" height="20" font="0">medication <b> </b></text>
<text top="217" left="360" width="11" height="18" font="0">• </text>
<text top="217" left="387" width="94" height="20" font="0">Impaired hepatic </text>
<text top="234" left="387" width="153" height="20" font="0">transaminase &gt; 20% above </text>
<text top="251" left="387" width="44" height="20" font="0">normal <b> </b></text>
<text top="270" left="360" width="11" height="18" font="0">• </text>
<text top="269" left="387" width="136" height="20" font="0">Body weight &gt; 50% over </text>
<text top="286" left="387" width="87" height="20" font="0">ideal for height <b> </b></text>
<text top="304" left="360" width="160" height="20" font="0">Use of other lipid-lowering or </text>
<text top="321" left="360" width="125" height="20" font="0">investigational agents.<b> </b></text>
<text top="107" left="582" width="101" height="20" font="0">rare (&lt; 1% in both </text>
<text top="124" left="582" width="45" height="20" font="0">groups) </text>
<text top="143" left="555" width="11" height="18" font="0">• </text>
<text top="143" left="582" width="89" height="20" font="0">Myalgia leading </text>
<text top="160" left="582" width="99" height="20" font="0">to discontinuation </text>
<text top="177" left="582" width="76" height="20" font="0">0.3% for both </text>
<text top="194" left="582" width="41" height="20" font="0">groups </text>
<text top="213" left="555" width="11" height="18" font="0">• </text>
<text top="213" left="582" width="81" height="20" font="0">CK &gt; 10 times </text>
<text top="230" left="582" width="101" height="20" font="0">ULN rate (&lt; 1% in </text>
<text top="247" left="582" width="73" height="20" font="0">both groups) </text>
<text top="264" left="555" width="129" height="20" font="0">3 cases of rhabdo (2 in </text>
<text top="281" left="555" width="108" height="20" font="0">placebo group, 1 in </text>
<text top="298" left="555" width="75" height="20" font="0">lova group).  <b> </b></text>
<text top="107" left="697" width="3" height="20" font="0"> </text>
<text top="124" left="697" width="100" height="20" font="7"><b>Safety endpoint: </b></text>
<text top="143" left="697" width="11" height="18" font="0">• </text>
<text top="143" left="724" width="127" height="20" font="0">Total mortality: 80 lova </text>
<text top="160" left="724" width="136" height="20" font="0">(4.6 per 1000 person-y), </text>
<text top="177" left="724" width="136" height="20" font="0">77 placebo 4.4 per 1000 </text>
<text top="194" left="724" width="51" height="20" font="0">person-y </text>
<text top="213" left="697" width="11" height="18" font="0">• </text>
<text top="213" left="724" width="139" height="20" font="0">Cardiovascular mortality: </text>
<text top="230" left="724" width="120" height="20" font="0">17 lova (1.0 per 1000 </text>
<text top="247" left="724" width="122" height="20" font="0">person-y), 25 placebo </text>
<text top="264" left="724" width="124" height="20" font="0">1.4 per 1000 person-y </text>
<text top="283" left="697" width="11" height="18" font="0">• </text>
<text top="282" left="724" width="105" height="20" font="0">Noncardiovascular </text>
<text top="300" left="724" width="128" height="20" font="0">mortality: : 63 lova (3.6 </text>
<text top="317" left="724" width="128" height="20" font="0">per 1000 person-y), 52 </text>
<text top="334" left="724" width="119" height="20" font="0">placebo 3.0 per 1000 </text>
<text top="351" left="724" width="51" height="20" font="0">person-y </text>
<text top="370" left="697" width="11" height="18" font="0">• </text>
<text top="370" left="724" width="102" height="20" font="0">Fatal and nonfatal </text>
<text top="387" left="724" width="123" height="20" font="0">cancer: 252 lovastatin </text>
<text top="404" left="724" width="142" height="20" font="0">(15.1 per 1000 person-y), </text>
<text top="421" left="724" width="123" height="20" font="0">259 placebo (15.6 per </text>
<text top="438" left="724" width="134" height="20" font="0">1000 person-y); p=0.75  </text>
<text top="455" left="697" width="3" height="20" font="7"><b> </b></text>
<text top="109" left="879" width="11" height="18" font="0">• </text>
<text top="108" left="906" width="184" height="20" font="0">RR for lova 0.68; 95% CI: 0.49 to </text>
<text top="125" left="906" width="76" height="20" font="0">0.95), p=0.02 </text>
<text top="143" left="879" width="119" height="20" font="0">Fatal and nonfatal MI </text>
<text top="162" left="879" width="11" height="18" font="0">• </text>
<text top="161" left="906" width="204" height="20" font="0">Lova 57 events (3.3 per 1000 patient-</text>
<text top="178" left="906" width="197" height="20" font="0">y), placebo 95 events (5.6 per 1000 </text>
<text top="195" left="906" width="55" height="20" font="0">patient-y) </text>
<text top="214" left="879" width="11" height="18" font="0">• </text>
<text top="213" left="906" width="184" height="20" font="0">RR for lova 0.60; 95% CI: 0.43 to </text>
<text top="231" left="906" width="83" height="20" font="0">0.83), p=0.002 </text>
<text top="248" left="879" width="139" height="20" font="0">All cardiovascular events </text>
<text top="267" left="879" width="11" height="18" font="0">• </text>
<text top="266" left="906" width="177" height="20" font="0">Lova 194 events (11.5 per 1000 </text>
<text top="283" left="906" width="200" height="20" font="0">patient-y), placebo 255 events (15.3 </text>
<text top="300" left="906" width="107" height="20" font="0">per 1000 patient-y) </text>
<text top="319" left="879" width="11" height="18" font="0">• </text>
<text top="319" left="906" width="184" height="20" font="0">RR for lova 0.75; 95% CI: 0.62 to </text>
<text top="336" left="906" width="83" height="20" font="0">0.91), p=0.003 </text>
<text top="353" left="879" width="108" height="20" font="0">All coronary events </text>
<text top="372" left="879" width="11" height="18" font="0">• </text>
<text top="371" left="906" width="170" height="20" font="0">Lova 163 events (9.6 per 1000 </text>
<text top="389" left="906" width="200" height="20" font="0">patient-y), placebo 215 events (12.8 </text>
<text top="406" left="906" width="107" height="20" font="0">per 1000 patient-y) </text>
<text top="425" left="879" width="11" height="18" font="0">• </text>
<text top="424" left="906" width="184" height="20" font="0">RR for lova 0.75; 95% CI: 0.61 to </text>
<text top="441" left="906" width="83" height="20" font="0">0.92), p=0.006 </text>
<text top="458" left="879" width="3" height="20" font="0"> </text>
<text top="476" left="879" width="94" height="20" font="7"><b>Adverse events </b></text>
<text top="495" left="879" width="11" height="18" font="0">• </text>
<text top="494" left="906" width="162" height="20" font="0">Any adverse event leading to </text>
<text top="511" left="906" width="206" height="20" font="0">discontinuation similar in both groups </text>
<text top="528" left="906" width="168" height="20" font="0">(Lova 13.6%, placebo 13.8%). </text>
<text top="547" left="879" width="11" height="18" font="0">• </text>
<text top="547" left="906" width="203" height="20" font="0">Consecutive LFT &gt; 3 times ULN rare </text>
<text top="564" left="906" width="121" height="20" font="0">(&lt; 1% in both groups) </text>
<text top="583" left="879" width="11" height="18" font="0">• </text>
<text top="582" left="906" width="188" height="20" font="0">Myalgia leading to discontinuation </text>
<text top="599" left="906" width="118" height="20" font="0">0.3% for both groups </text>
<text top="618" left="879" width="11" height="18" font="0">• </text>
<text top="618" left="906" width="210" height="20" font="0">CK &gt; 10 times ULN rate (&lt; 1% in both </text>
<text top="635" left="906" width="45" height="20" font="0">groups) </text>
<text top="652" left="879" width="237" height="20" font="0">3 cases of rhabdo (2 in placebo group, 1 in </text>
<text top="669" left="879" width="75" height="20" font="0">lova group).  <b> </b></text>
<text top="687" left="89" width="113" height="20" font="7"><b>AFCAPS/TexCAPS </b></text>
<text top="704" left="89" width="106" height="20" font="0">Clearfield M, et al., </text>
<text top="721" left="89" width="63" height="20" font="0">2001 <a href="data supplement.html#247">(196)</a> </text>
<text top="739" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11788107">11788107</a></text>
<text top="739" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11788107"> </a></text>
<text top="756" left="89" width="3" height="20" font="7"><b> </b></text>
<text top="687" left="215" width="119" height="20" font="7"><b>Aim:</b> To examine the </text>
<text top="704" left="215" width="119" height="20" font="0">efficacy and safety of </text>
<text top="721" left="215" width="111" height="20" font="0">long-term lovastatin </text>
<text top="739" left="215" width="113" height="20" font="0">treatment in the 997 </text>
<text top="756" left="215" width="103" height="20" font="0">women enrolled in </text>
<text top="773" left="215" width="110" height="20" font="0">AFCAPS/TexCAPS </text>
<text top="687" left="360" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="706" left="360" width="11" height="18" font="0">• </text>
<text top="705" left="387" width="138" height="20" font="0">Men 45-73 y old, women </text>
<text top="722" left="387" width="68" height="20" font="0">55-73 y old  </text>
<text top="742" left="360" width="11" height="18" font="0">• </text>
<text top="741" left="387" width="135" height="20" font="0">TC 180-264 mg/dL, LDL </text>
<text top="758" left="387" width="146" height="20" font="0">130-190 mg/dL, HDL ≤ 45 </text>
<text top="687" left="555" width="107" height="20" font="7"><b>Intervention:</b> AHA </text>
<text top="704" left="555" width="125" height="20" font="0">Step I diet + lovastatin </text>
<text top="721" left="555" width="119" height="20" font="0">20-40 mg daily (2805 </text>
<text top="739" left="555" width="102" height="20" font="0">men, 499 women) </text>
<text top="756" left="555" width="7" height="20" font="0">  </text>
<text top="688" left="697" width="137" height="20" font="7"><b>1</b>°<b> endpoint:</b> First acute </text>
<text top="705" left="697" width="164" height="20" font="0">major coronary event (fatal or </text>
<text top="723" left="697" width="161" height="20" font="0">nonfatal MI, unstable angina, </text>
<text top="740" left="697" width="125" height="20" font="0">sudden cardiac death) </text>
<text top="687" left="879" width="192" height="20" font="7"><b>Secondary Endpoints in Women </b></text>
<text top="704" left="879" width="3" height="20" font="7"><b> </b></text>
<text top="721" left="879" width="156" height="20" font="0">Coronary revascularizations </text>
<text top="740" left="879" width="11" height="18" font="0">• </text>
<text top="740" left="906" width="202" height="20" font="0">RR for lova 0.89; 95% CI: 0.32-2.44; </text>
<text top="757" left="906" width="48" height="20" font="0">p=0.814 </text>
<text top="774" left="879" width="92" height="20" font="0">Unstable angina </text>
</page>
<page number="168" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">168 </text>
<text top="107" left="215" width="3" height="20" font="7"><b> </b></text>
<text top="124" left="215" width="102" height="20" font="7"><b>Study type:</b>  RCT </text>
<text top="141" left="215" width="3" height="20" font="0"> </text>
<text top="159" left="215" width="118" height="20" font="7"><b>Size:</b>  5608 men and </text>
<text top="176" left="215" width="67" height="20" font="0">997 women<b> </b></text>
<text top="107" left="387" width="153" height="20" font="0">mg/dL for men and ≤ 47 for </text>
<text top="124" left="387" width="146" height="20" font="0">women, TG &lt; 400 mg/dL.  </text>
<text top="143" left="360" width="11" height="18" font="0">• </text>
<text top="143" left="387" width="123" height="20" font="0">When LDL-C 125-129 </text>
<text top="160" left="387" width="149" height="20" font="0">mg/dL, if TC/HDL-C ratio &gt; </text>
<text top="177" left="387" width="159" height="20" font="0">6.0, subjects were included.  </text>
<text top="194" left="360" width="3" height="20" font="0"> </text>
<text top="211" left="360" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="230" left="360" width="11" height="18" font="0">• </text>
<text top="230" left="387" width="139" height="20" font="0">Clinical evidence of CVD<b> </b></text>
<text top="249" left="360" width="11" height="18" font="0">• </text>
<text top="248" left="387" width="145" height="20" font="0">Secondary hyperlipidemia<b> </b></text>
<text top="267" left="360" width="11" height="18" font="0">• </text>
<text top="266" left="387" width="38" height="20" font="0">IDDM <b> </b></text>
<text top="285" left="360" width="11" height="18" font="0">• </text>
<text top="284" left="387" width="105" height="20" font="0">Uncontrolled HTN <b> </b></text>
<text top="303" left="360" width="11" height="18" font="0">• </text>
<text top="303" left="387" width="153" height="20" font="0">Ventricular ectopy requiring </text>
<text top="320" left="387" width="66" height="20" font="0">medication <b> </b></text>
<text top="339" left="360" width="11" height="18" font="0">• </text>
<text top="338" left="387" width="94" height="20" font="0">Impaired hepatic </text>
<text top="355" left="387" width="153" height="20" font="0">transaminase &gt; 20% above </text>
<text top="372" left="387" width="44" height="20" font="0">normal <b> </b></text>
<text top="391" left="360" width="11" height="18" font="0">• </text>
<text top="391" left="387" width="136" height="20" font="0">Body weight &gt; 50% over </text>
<text top="408" left="387" width="87" height="20" font="0">ideal for height <b> </b></text>
<text top="425" left="360" width="160" height="20" font="0">Use of other lipid-lowering or </text>
<text top="442" left="360" width="125" height="20" font="0">investigational agents.<b> </b></text>
<text top="107" left="555" width="106" height="20" font="7"><b>Comparator:</b> AHA </text>
<text top="124" left="555" width="103" height="20" font="0">Step I diet alone + </text>
<text top="141" left="555" width="112" height="20" font="0">placebo (2803 men, </text>
<text top="159" left="555" width="71" height="20" font="0">498 women)<b> </b></text>
<text top="109" left="697" width="11" height="18" font="0">• </text>
<text top="108" left="724" width="129" height="20" font="0">Women<b>: </b>2.65 per 1000 </text>
<text top="125" left="724" width="141" height="20" font="0">person-y for lova vs. 4.92 </text>
<text top="143" left="724" width="64" height="20" font="0">for placebo </text>
<text top="162" left="697" width="11" height="18" font="0">• </text>
<text top="161" left="724" width="110" height="20" font="0">Men: 7.57 per 1000 </text>
<text top="178" left="724" width="114" height="20" font="0">person-y for lova vs. </text>
<text top="195" left="724" width="98" height="20" font="0">11.95 for placebo </text>
<text top="214" left="697" width="11" height="18" font="0">• </text>
<text top="213" left="724" width="132" height="20" font="0">Risk of first acute major </text>
<text top="231" left="724" width="130" height="20" font="0">coronary event was 3.4 </text>
<text top="248" left="724" width="116" height="20" font="0">times greater in men </text>
<text top="265" left="724" width="83" height="20" font="0">than in women </text>
<text top="284" left="697" width="11" height="18" font="0">• </text>
<text top="283" left="724" width="129" height="20" font="0">Women:<b> </b>RR 0.54; 95% </text>
<text top="300" left="724" width="139" height="20" font="0">CI: 0.22 to 1.35; p=0.183 </text>
<text top="319" left="697" width="11" height="18" font="0">• </text>
<text top="319" left="724" width="133" height="20" font="0">Men: RR: 0.63; 95% CI: </text>
<text top="336" left="724" width="120" height="20" font="0">0.50 to 0.81; p&lt;0.001 </text>
<text top="355" left="697" width="11" height="18" font="0">• </text>
<text top="354" left="724" width="132" height="20" font="0">Heterogeneity, p=0.859 </text>
<text top="371" left="697" width="3" height="20" font="0"> </text>
<text top="389" left="697" width="163" height="20" font="7"><b>Safety endpoint in women:</b>  </text>
<text top="408" left="697" width="11" height="18" font="0">• </text>
<text top="407" left="724" width="127" height="20" font="0">Total mortality: 11 lova </text>
<text top="424" left="724" width="142" height="20" font="0">(4.11 per 1000 person-y), </text>
<text top="441" left="724" width="140" height="20" font="0">7 placebo (2.61 per 1000 </text>
<text top="458" left="724" width="55" height="20" font="0">person-y) </text>
<text top="477" left="697" width="11" height="18" font="0">• </text>
<text top="477" left="724" width="105" height="20" font="0">Noncardiovascular </text>
<text top="494" left="724" width="140" height="20" font="0">mortality: all of the above </text>
<text top="511" left="724" width="141" height="20" font="0">except for 1 death in lova </text>
<text top="528" left="724" width="38" height="20" font="0">group  </text>
<text top="547" left="697" width="11" height="18" font="0">• </text>
<text top="547" left="724" width="102" height="20" font="0">Fatal and nonfatal </text>
<text top="564" left="724" width="125" height="20" font="0">cancer: 32 lova (12.38 </text>
<text top="581" left="724" width="128" height="20" font="0">per 1000 person-y), 28 </text>
<text top="598" left="724" width="137" height="20" font="0">placebo (10.71 per 1000 </text>
<text top="615" left="724" width="126" height="20" font="0">person-y); p=0.69 (pre-</text>
<text top="633" left="724" width="131" height="20" font="0">existing cancer was not </text>
<text top="650" left="724" width="76" height="20" font="0">an exclusion) </text>
<text top="667" left="697" width="3" height="20" font="0"> </text>
<text top="684" left="697" width="3" height="20" font="7"><b> </b></text>
<text top="109" left="879" width="11" height="18" font="0">• </text>
<text top="108" left="906" width="184" height="20" font="0">RR for lova 0.34; 95% CI: 0.09 to </text>
<text top="125" left="906" width="79" height="20" font="0">2.14; p=0.085 </text>
<text top="143" left="879" width="119" height="20" font="0">Fatal and nonfatal MI </text>
<text top="162" left="879" width="11" height="18" font="0">• </text>
<text top="161" left="906" width="184" height="20" font="0">RR for lova 0.67; 95% CI: 0.19 to </text>
<text top="178" left="906" width="79" height="20" font="0">2.37; p=0.532 </text>
<text top="195" left="879" width="143" height="20" font="0">All cardiovascular events  </text>
<text top="214" left="879" width="11" height="18" font="0">• </text>
<text top="213" left="906" width="184" height="20" font="0">RR for lova 0.67; 95% CI: 0.34 to </text>
<text top="231" left="906" width="79" height="20" font="0">1.31; p=0.236 </text>
<text top="248" left="879" width="108" height="20" font="0">All coronary events </text>
<text top="267" left="879" width="11" height="18" font="0">• </text>
<text top="266" left="906" width="202" height="20" font="0">RR for lova 0.56; 95% CI: 0.25-1.28; </text>
<text top="283" left="906" width="48" height="20" font="0">p=0.164 </text>
<text top="300" left="879" width="3" height="20" font="0"> </text>
<text top="318" left="879" width="107" height="20" font="7"><b>Study Limitations </b></text>
<text top="337" left="879" width="11" height="18" font="0">• </text>
<text top="336" left="906" width="194" height="20" font="0">Women comprised only 15% of the </text>
<text top="353" left="906" width="64" height="20" font="0">total cohort </text>
<text top="372" left="879" width="11" height="18" font="0">• </text>
<text top="372" left="906" width="160" height="20" font="0">Insufficient power to detect a </text>
<text top="389" left="906" width="181" height="20" font="0">treatment group difference in the </text>
<text top="406" left="906" width="151" height="20" font="0">primary endpoint in women </text>
<text top="425" left="879" width="11" height="18" font="0">• </text>
<text top="424" left="906" width="189" height="20" font="0">Small number of events in women </text>
<text top="443" left="879" width="11" height="18" font="0">• </text>
<text top="442" left="906" width="198" height="20" font="0">54% of women took HRT during the </text>
<text top="460" left="906" width="83" height="20" font="0">trial (?? Effect) </text>
<text top="477" left="879" width="3" height="20" font="0"> </text>
<text top="494" left="879" width="94" height="20" font="7"><b>Adverse events </b></text>
<text top="513" left="879" width="11" height="18" font="0">• </text>
<text top="512" left="906" width="170" height="20" font="0">Fewer women taking lova than </text>
<text top="529" left="906" width="196" height="20" font="0">placebo had serious cardiovascular </text>
<text top="547" left="906" width="176" height="20" font="0">adverse events (5.2% vs. 8.6%; </text>
<text top="564" left="906" width="52" height="20" font="0">p=0.034)<b> </b></text>
<text top="583" left="879" width="11" height="18" font="0">• </text>
<text top="582" left="906" width="203" height="20" font="0">Consecutive LFT &gt; 3 times ULN rare </text>
<text top="599" left="906" width="121" height="20" font="0">(&lt; 1% in both groups) </text>
<text top="618" left="879" width="11" height="18" font="0">• </text>
<text top="618" left="906" width="205" height="20" font="0">CK &gt; 10 times ULN rare (1 woman in </text>
<text top="635" left="906" width="69" height="20" font="0">each group) </text>
<text top="654" left="879" width="11" height="18" font="0">• </text>
<text top="653" left="906" width="181" height="20" font="0">No cases of myopathy or rhabdo </text>
<text top="670" left="879" width="3" height="20" font="0"> </text>
<text top="702" left="89" width="40" height="20" font="7"><b>MEGA </b></text>
<text top="719" left="89" width="109" height="20" font="0">Nakamura H, et al., </text>
<text top="737" left="89" width="63" height="20" font="0">2006 <a href="data supplement.html#242">(103)</a> </text>
<text top="754" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17011942">17011942</a></text>
<text top="754" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17011942"> </a></text>
<text top="702" left="215" width="118" height="20" font="7"><b>AIM</b>: To evaluate the </text>
<text top="719" left="215" width="76" height="20" font="0">usefulness of </text>
<text top="737" left="215" width="97" height="20" font="0">pravastatin in the </text>
<text top="754" left="215" width="119" height="20" font="0">primary prevention of </text>
<text top="771" left="215" width="111" height="20" font="0">CVD in daily clinical </text>
<text top="788" left="215" width="100" height="20" font="0">practice in Japan. </text>
<text top="702" left="360" width="106" height="20" font="7"><b>Inclusion criteria: </b></text>
<text top="721" left="360" width="11" height="18" font="0">• </text>
<text top="721" left="387" width="145" height="20" font="0">Men and postmenopausal </text>
<text top="738" left="387" width="118" height="20" font="0">women aged 40-70 y </text>
<text top="755" left="387" width="140" height="20" font="0">(mean age: 59.7 women, </text>
<text top="772" left="387" width="59" height="20" font="0">55.2 men)<b> </b></text>
<text top="702" left="555" width="115" height="20" font="7"><b>Intervention:</b> NCEP </text>
<text top="719" left="555" width="83" height="20" font="0">step I diet plus </text>
<text top="737" left="555" width="119" height="20" font="0">pravastatin 10-20 mg </text>
<text top="754" left="555" width="29" height="20" font="0">daily </text>
<text top="771" left="555" width="112" height="20" font="0">(2638 women, 1228 </text>
<text top="788" left="555" width="31" height="20" font="0">men) </text>
<text top="703" left="697" width="152" height="20" font="7"><b>1</b>°<b> endpoint:</b> Composite of </text>
<text top="721" left="697" width="162" height="20" font="0">first occurrence of CHD (fatal </text>
<text top="738" left="697" width="159" height="20" font="0">and nonfatal MI, cardiac and </text>
<text top="755" left="697" width="133" height="20" font="0">sudden death, coronary </text>
<text top="772" left="697" width="158" height="20" font="0">revascularization procedure, </text>
<text top="789" left="697" width="68" height="20" font="0">and angina) </text>
<text top="702" left="879" width="130" height="20" font="7"><b>Secondary Endpoints </b></text>
<text top="721" left="879" width="11" height="18" font="0">• </text>
<text top="721" left="906" width="182" height="20" font="0">Stroke: 50 events in the diet plus </text>
<text top="738" left="906" width="202" height="20" font="0">prava group vs. 62 events in the diet </text>
<text top="755" left="906" width="208" height="20" font="0">alone group (HR: for prava 0.83; 95% </text>
<text top="772" left="906" width="136" height="20" font="0">CI: 0.57 to 1.21; p=0.33) </text>
</page>
<page number="169" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">169 </text>
<text top="107" left="215" width="3" height="20" font="0"> </text>
<text top="124" left="215" width="99" height="20" font="7"><b>Study type:</b> RCT </text>
<text top="141" left="215" width="3" height="20" font="0"> </text>
<text top="159" left="215" width="114" height="20" font="7"><b>Size:</b> 7832 men and </text>
<text top="176" left="215" width="43" height="20" font="0">women </text>
<text top="193" left="215" width="3" height="20" font="0"> </text>
<text top="109" left="360" width="11" height="18" font="0">• </text>
<text top="108" left="387" width="132" height="20" font="0">Body weight of 40 kg or </text>
<text top="125" left="387" width="31" height="20" font="0">more<b> </b></text>
<text top="144" left="360" width="11" height="18" font="0">• </text>
<text top="144" left="387" width="153" height="20" font="0">Hypercholesterolemia (total </text>
<text top="161" left="387" width="138" height="20" font="0">cholesterol 220 mg/dL to </text>
<text top="178" left="387" width="66" height="20" font="0">270 mg/dL)<b> </b></text>
<text top="195" left="360" width="3" height="20" font="7"><b> </b></text>
<text top="212" left="360" width="110" height="20" font="7"><b>Exclusion criteria: </b></text>
<text top="231" left="360" width="11" height="18" font="0">• </text>
<text top="231" left="387" width="99" height="20" font="0">History of CVD or </text>
<text top="248" left="387" width="140" height="20" font="0">cerebrovascular disease <b> </b></text>
<text top="267" left="360" width="11" height="18" font="0">• </text>
<text top="266" left="387" width="46" height="20" font="0">Familial </text>
<text top="283" left="387" width="120" height="20" font="0">hypercholesterolemia<b> </b></text>
<text top="302" left="360" width="11" height="18" font="0">• </text>
<text top="302" left="387" width="113" height="20" font="0">Current diagnosis of </text>
<text top="319" left="387" width="66" height="20" font="0">malignancy<b> </b></text>
<text top="338" left="360" width="11" height="18" font="0">• </text>
<text top="337" left="387" width="145" height="20" font="0">Secondary hyperlipidemia<b> </b></text>
<text top="107" left="555" width="7" height="20" font="0">  </text>
<text top="124" left="555" width="115" height="20" font="7"><b>Comparator:</b> NCEP </text>
<text top="141" left="555" width="94" height="20" font="0">step I diet alone  </text>
<text top="159" left="555" width="112" height="20" font="0">(2718 women, 1248 </text>
<text top="176" left="555" width="31" height="20" font="0">men)<b> </b></text>
<text top="109" left="697" width="11" height="18" font="0">• </text>
<text top="108" left="724" width="133" height="20" font="0">Follow-up of 5 y plus an </text>
<text top="125" left="724" width="139" height="20" font="0">additional 5 y to increase </text>
<text top="143" left="724" width="44" height="20" font="0">events) </text>
<text top="162" left="697" width="11" height="18" font="0">• </text>
<text top="161" left="724" width="102" height="20" font="0">Diet plus prava 66 </text>
<text top="178" left="724" width="124" height="20" font="0">events, diet alone 101 </text>
<text top="195" left="724" width="40" height="20" font="0">events </text>
<text top="214" left="697" width="11" height="18" font="0">• </text>
<text top="213" left="724" width="135" height="20" font="0">HR: for prava 0.67; 95% </text>
<text top="231" left="724" width="139" height="20" font="0">CI: 0.49 to 0.91; p=0.011 </text>
<text top="250" left="697" width="11" height="18" font="0">• </text>
<text top="249" left="724" width="100" height="20" font="0">Treatment-by-sex </text>
<text top="266" left="724" width="126" height="20" font="0">interaction using a sex-</text>
<text top="283" left="724" width="75" height="20" font="0">stratified Cox </text>
<text top="300" left="724" width="116" height="20" font="0">proportional-hazards </text>
<text top="318" left="724" width="141" height="20" font="0">model was nonsignificant </text>
<text top="335" left="724" width="53" height="20" font="0">(p=0.71). </text>
<text top="352" left="697" width="3" height="20" font="0"> </text>
<text top="369" left="697" width="3" height="20" font="7"><b> </b></text>
<text top="387" left="697" width="3" height="20" font="0"> </text>
<text top="404" left="697" width="3" height="20" font="7"><b> </b></text>
<text top="109" left="879" width="11" height="18" font="0">• </text>
<text top="108" left="906" width="178" height="20" font="0">CHD plus cerebral infarction: 98 </text>
<text top="125" left="906" width="211" height="20" font="0">events in the diet plus prava group vs. </text>
<text top="143" left="906" width="196" height="20" font="0">144 in the diet alone group (HR: for </text>
<text top="160" left="906" width="184" height="20" font="0">prava 0.70; 95% CI: 0.54 to 0.90; </text>
<text top="177" left="906" width="52" height="20" font="0">p=0.005) </text>
<text top="196" left="879" width="11" height="18" font="0">• </text>
<text top="195" left="906" width="184" height="20" font="0">Total mortality: 55 in the diet plus </text>
<text top="212" left="906" width="196" height="20" font="0">prava group vs. 79 in the diet alone </text>
<text top="230" left="906" width="194" height="20" font="0">group (HR: for prava 0.72; 95% CI: </text>
<text top="247" left="906" width="120" height="20" font="0">0.51 to 1.01; p=0.055 </text>
<text top="264" left="879" width="96" height="20" font="7"><b>Adverse Events </b></text>
<text top="283" left="879" width="11" height="18" font="0">• </text>
<text top="282" left="906" width="177" height="20" font="0">No difference in severe adverse </text>
<text top="299" left="906" width="131" height="20" font="0">events between groups </text>
<text top="319" left="879" width="11" height="18" font="0">• </text>
<text top="318" left="906" width="209" height="20" font="0">Incidence rate of cancer: 119 in diet + </text>
<text top="335" left="906" width="184" height="20" font="0">prava vs. 126 in diet only; p=0.81 </text>
<text top="354" left="879" width="11" height="18" font="0">• </text>
<text top="353" left="906" width="175" height="20" font="0">ALT &gt; 100 IU/L occurred in 107 </text>
<text top="370" left="906" width="203" height="20" font="0">(2.8%) patients in the diet plus prava </text>
<text top="388" left="906" width="198" height="20" font="0">group vs. 104 (2.8%) patients in the </text>
<text top="405" left="906" width="84" height="20" font="0">diet only group </text>
<text top="424" left="879" width="11" height="18" font="0">• </text>
<text top="423" left="906" width="209" height="20" font="0">CK &gt; 500 IU/L occurred in 111 (3.1%) </text>
<text top="440" left="906" width="188" height="20" font="0">in the diet plus prava group vs. 98 </text>
<text top="457" left="906" width="157" height="20" font="0">(2.6%) in the diet only group </text>
<text top="475" left="89" width="40" height="20" font="7"><b>MEGA </b></text>
<text top="493" left="89" width="92" height="20" font="0">Mizuno K, et al., </text>
<text top="510" left="89" width="63" height="20" font="0">2008 <a href="data supplement.html#247">(197)</a> </text>
<text top="527" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18172039">18172039</a></text>
<text top="527" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18172039"> </a></text>
<text top="475" left="215" width="131" height="20" font="7"><b>AIM</b>: To summarize the </text>
<text top="493" left="215" width="101" height="20" font="0">comparison of the </text>
<text top="510" left="215" width="113" height="20" font="0">results of the MEGA </text>
<text top="527" left="215" width="110" height="20" font="0">study between men </text>
<text top="544" left="215" width="70" height="20" font="0">and women. </text>
<text top="561" left="215" width="3" height="20" font="0"> </text>
<text top="579" left="215" width="99" height="20" font="7"><b>Study type:</b> RCT </text>
<text top="596" left="215" width="3" height="20" font="0"> </text>
<text top="613" left="215" width="109" height="20" font="7"><b>Size:</b> 5356 women, </text>
<text top="630" left="215" width="58" height="20" font="0">2476 men </text>
<text top="647" left="215" width="3" height="20" font="7"><b> </b></text>
<text top="475" left="360" width="106" height="20" font="7"><b>Inclusion criteria: </b></text>
<text top="494" left="360" width="11" height="18" font="0">• </text>
<text top="494" left="387" width="145" height="20" font="0">Men and postmenopausal </text>
<text top="511" left="387" width="118" height="20" font="0">women aged 40-70 y </text>
<text top="528" left="387" width="140" height="20" font="0">(mean age: 59.7 women, </text>
<text top="545" left="387" width="59" height="20" font="0">55.2 men)<b> </b></text>
<text top="564" left="360" width="11" height="18" font="0">• </text>
<text top="564" left="387" width="132" height="20" font="0">Body weight of 40 kg or </text>
<text top="581" left="387" width="31" height="20" font="0">more<b> </b></text>
<text top="600" left="360" width="11" height="18" font="0">• </text>
<text top="599" left="387" width="153" height="20" font="0">Hypercholesterolemia (total </text>
<text top="616" left="387" width="138" height="20" font="0">cholesterol 220 mg/dL to </text>
<text top="633" left="387" width="66" height="20" font="0">270 mg/dL)<b> </b></text>
<text top="651" left="360" width="3" height="20" font="7"><b> </b></text>
<text top="668" left="360" width="110" height="20" font="7"><b>Exclusion criteria: </b></text>
<text top="687" left="360" width="11" height="18" font="0">• </text>
<text top="686" left="387" width="99" height="20" font="0">History of CVD or </text>
<text top="703" left="387" width="140" height="20" font="0">cerebrovascular disease <b> </b></text>
<text top="722" left="360" width="11" height="18" font="0">• </text>
<text top="722" left="387" width="46" height="20" font="0">Familial </text>
<text top="739" left="387" width="120" height="20" font="0">hypercholesterolemia<b> </b></text>
<text top="758" left="360" width="11" height="18" font="0">• </text>
<text top="757" left="387" width="113" height="20" font="0">Current diagnosis of </text>
<text top="774" left="387" width="66" height="20" font="0">malignancy<b> </b></text>
<text top="475" left="555" width="115" height="20" font="7"><b>Intervention:</b> NCEP </text>
<text top="493" left="555" width="83" height="20" font="0">step I diet plus </text>
<text top="510" left="555" width="119" height="20" font="0">pravastatin 10-20 mg </text>
<text top="527" left="555" width="29" height="20" font="0">daily </text>
<text top="544" left="555" width="112" height="20" font="0">(2638 women, 1228 </text>
<text top="561" left="555" width="31" height="20" font="0">men) </text>
<text top="579" left="555" width="7" height="20" font="0">  </text>
<text top="596" left="555" width="115" height="20" font="7"><b>Comparator:</b> NCEP </text>
<text top="613" left="555" width="90" height="20" font="0">step I diet alone </text>
<text top="630" left="555" width="112" height="20" font="0">(2718 women, 1248 </text>
<text top="647" left="555" width="31" height="20" font="0">men)<b> </b></text>
<text top="477" left="697" width="152" height="20" font="7"><b>1</b>°<b> endpoint:</b> Composite of </text>
<text top="494" left="697" width="162" height="20" font="0">first occurrence of CHD (fatal </text>
<text top="511" left="697" width="159" height="20" font="0">and nonfatal MI, cardiac and </text>
<text top="528" left="697" width="133" height="20" font="0">sudden death, coronary </text>
<text top="545" left="697" width="158" height="20" font="0">revascularization procedure, </text>
<text top="563" left="697" width="68" height="20" font="0">and angina) </text>
<text top="582" left="697" width="11" height="18" font="0">• </text>
<text top="581" left="724" width="122" height="20" font="0">Women<b>: </b>2.2 per 1000 </text>
<text top="598" left="724" width="137" height="20" font="0">person-y for diet + prava </text>
<text top="615" left="724" width="107" height="20" font="0">vs. 2.9 for diet only </text>
<text top="634" left="697" width="11" height="18" font="0">• </text>
<text top="634" left="724" width="103" height="20" font="0">Men: 5.7 per 1000 </text>
<text top="651" left="724" width="137" height="20" font="0">person-y for diet + prava </text>
<text top="668" left="724" width="107" height="20" font="0">vs. 8.9 for diet only </text>
<text top="687" left="697" width="11" height="18" font="0">• </text>
<text top="686" left="724" width="132" height="20" font="0">Women:<b> </b>HR: 0.75; 95% </text>
<text top="703" left="724" width="119" height="20" font="0">CI: 0.45-1.25; p=0.27 </text>
<text top="722" left="697" width="11" height="18" font="0">• </text>
<text top="722" left="724" width="133" height="20" font="0">Men: HR: 0.65; 95% CI: </text>
<text top="739" left="724" width="100" height="20" font="0">0.41-1.02; p=0.06 </text>
<text top="758" left="697" width="11" height="18" font="0">• </text>
<text top="757" left="724" width="135" height="20" font="0">P for heterogeneity 0.67 </text>
<text top="475" left="879" width="130" height="20" font="7"><b>Secondary Endpoints </b></text>
<text top="493" left="879" width="3" height="20" font="0"> </text>
<text top="510" left="879" width="39" height="20" font="0">Stroke </text>
<text top="529" left="879" width="11" height="18" font="0">• </text>
<text top="528" left="906" width="193" height="20" font="0">Women:<b> </b>HR: 0.63; 95% CI: 0.67 to </text>
<text top="545" left="906" width="72" height="20" font="0">1.10; p=0.10 </text>
<text top="564" left="879" width="11" height="18" font="0">• </text>
<text top="564" left="906" width="205" height="20" font="0">Men: HR: 0.66; 95% CI: 0.37 to 1.20; </text>
<text top="581" left="906" width="41" height="20" font="0">p=0.17 </text>
<text top="600" left="879" width="11" height="18" font="0">• </text>
<text top="599" left="906" width="128" height="20" font="0">Heterogeneity,  p=0.90 </text>
<text top="618" left="879" width="11" height="18" font="0">• </text>
<text top="617" left="906" width="190" height="20" font="0">Women ≥ 60 y:<b> </b>HR: 0.36; 95% CI: </text>
<text top="634" left="906" width="120" height="20" font="0">0.17 to 0.77; p=0.008 </text>
<text top="652" left="879" width="193" height="20" font="0">CHD plus cerebrovascular disease </text>
<text top="671" left="879" width="11" height="18" font="0">• </text>
<text top="670" left="906" width="193" height="20" font="0">Women:<b> </b>HR: 0.74; 95% CI: 0.50 to </text>
<text top="687" left="906" width="76" height="20" font="0">1.12; p=0.15. </text>
<text top="706" left="879" width="11" height="18" font="0">• </text>
<text top="705" left="906" width="205" height="20" font="0">Men: HR: 0.59; 95% CI: 0.40 to 0.87; </text>
<text top="723" left="906" width="52" height="20" font="0">p=0.007. </text>
<text top="742" left="879" width="11" height="18" font="0">• </text>
<text top="741" left="906" width="121" height="20" font="0">Heterogeneity p=0.42 </text>
<text top="760" left="879" width="11" height="18" font="0">• </text>
<text top="759" left="906" width="190" height="20" font="0">Women ≥ 60 y;<b> </b>HR: 0.50; 95% CI: </text>
<text top="776" left="906" width="111" height="20" font="0">0.31-0.83; p=0.007. </text>
</page>
<page number="170" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">170 </text>
<text top="109" left="360" width="11" height="18" font="0">• </text>
<text top="108" left="387" width="145" height="20" font="0">Secondary hyperlipidemia<b> </b></text>
<text top="109" left="697" width="11" height="18" font="0">• </text>
<text top="108" left="724" width="112" height="20" font="0">Women ≥ 60 y:<b> </b>HR: </text>
<text top="125" left="724" width="137" height="20" font="0">0.55; 95% CI: 0.30-1.01; </text>
<text top="143" left="724" width="48" height="20" font="0">p=0.054 </text>
<text top="160" left="697" width="3" height="20" font="0"> </text>
<text top="177" left="697" width="3" height="20" font="0"> </text>
<text top="194" left="697" width="3" height="20" font="7"><b> </b></text>
<text top="107" left="879" width="81" height="20" font="0">Total mortality </text>
<text top="126" left="879" width="11" height="18" font="0">• </text>
<text top="125" left="906" width="193" height="20" font="0">Women:<b> </b>HR: 0.59; 95% CI: 0.35 to </text>
<text top="143" left="906" width="82" height="20" font="0">1.00; p=0.046. </text>
<text top="162" left="879" width="11" height="18" font="0">• </text>
<text top="161" left="906" width="205" height="20" font="0">Men: HR: 0.81; 95% CI: 0.46 to 1.43; </text>
<text top="178" left="906" width="45" height="20" font="0">p=0.46. </text>
<text top="197" left="879" width="11" height="18" font="0">• </text>
<text top="196" left="906" width="119" height="20" font="0">heterogeneity p=0.43 </text>
<text top="215" left="879" width="11" height="18" font="0">• </text>
<text top="215" left="906" width="190" height="20" font="0">Women ≥ 60 y;<b> </b>HR: 0.52; 95% CI: </text>
<text top="232" left="906" width="100" height="20" font="0">0.28-0.97; p=0.04 </text>
<text top="249" left="879" width="3" height="20" font="0"> </text>
<text top="266" left="879" width="107" height="20" font="7"><b>Study Limitations </b></text>
<text top="285" left="879" width="11" height="18" font="0">• </text>
<text top="284" left="906" width="206" height="20" font="0">Lower percentage of women with risk </text>
<text top="301" left="906" width="191" height="20" font="0">factors is probably associated with </text>
<text top="319" left="906" width="190" height="20" font="0">less incidence of events in women </text>
<text top="336" left="906" width="114" height="20" font="0">compared with men. </text>
<text top="355" left="879" width="11" height="18" font="0">• </text>
<text top="354" left="906" width="212" height="20" font="0">Insufficient number of younger women </text>
<text top="371" left="906" width="81" height="20" font="0">were enrolled. </text>
<text top="390" left="879" width="11" height="18" font="0">• </text>
<text top="390" left="906" width="200" height="20" font="0">Analyses in subgroups of women by </text>
<text top="407" left="906" width="205" height="20" font="0">age are exploratory because of small </text>
<text top="424" left="906" width="108" height="20" font="0">numbers of events. </text>
<text top="443" left="879" width="11" height="18" font="0">• </text>
<text top="442" left="906" width="199" height="20" font="0">Japanese people have a lower CVD </text>
<text top="460" left="906" width="194" height="20" font="0">risk compared with other countries. </text>
<text top="477" left="879" width="3" height="20" font="0"> </text>
<text top="494" left="879" width="96" height="20" font="7"><b>Adverse Events </b></text>
<text top="513" left="879" width="11" height="18" font="0">• </text>
<text top="512" left="906" width="179" height="20" font="0">No difference in the incidence of </text>
<text top="529" left="906" width="196" height="20" font="0">severe adverse events in women in </text>
<text top="547" left="906" width="206" height="20" font="0">the diet plus prava group (252; 9.6%) </text>
<text top="564" left="906" width="170" height="20" font="0">vs. diet only group (242; 8.9%) </text>
<text top="583" left="879" width="11" height="18" font="0">• </text>
<text top="582" left="906" width="211" height="20" font="0">Total incidence of cancer did not differ </text>
<text top="599" left="906" width="189" height="20" font="0">between the diet plus prava group </text>
<text top="617" left="906" width="202" height="20" font="0">(74; 5.46 per 1000 person-y) vs. diet </text>
<text top="634" left="906" width="207" height="20" font="0">only group (78; 5.55 per 1000 person-</text>
<text top="651" left="906" width="14" height="20" font="0">y) </text>
<text top="668" left="879" width="3" height="20" font="0"> </text>
<text top="685" left="879" width="3" height="20" font="0"> </text>
<text top="703" left="89" width="55" height="20" font="7"><b>JUPITER </b></text>
<text top="721" left="89" width="98" height="20" font="0">Ridker PM, et al., </text>
<text top="738" left="89" width="63" height="20" font="0">2008 <a href="data supplement.html#248">(198)</a> </text>
<text top="755" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18997196">18997196</a></text>
<text top="755" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18997196"> </a></text>
<text top="772" left="89" width="3" height="20" font="0"> </text>
<text top="703" left="215" width="111" height="20" font="7"><b>Aim: </b>To investigate </text>
<text top="721" left="215" width="128" height="20" font="0">whether treatment with </text>
<text top="738" left="215" width="111" height="20" font="0">rosuvastatin, 20 mg </text>
<text top="755" left="215" width="132" height="20" font="0">daily, as compared with </text>
<text top="772" left="215" width="85" height="20" font="0">placebo, would </text>
<text top="789" left="215" width="113" height="20" font="0">decrease the rate of </text>
<text top="703" left="360" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="722" left="360" width="11" height="18" font="0">• </text>
<text top="722" left="387" width="125" height="20" font="0">Women ≥ 60 y of age  </text>
<text top="740" left="360" width="11" height="18" font="0">• </text>
<text top="740" left="387" width="69" height="20" font="0">Men ≥ 50 y  </text>
<text top="759" left="360" width="11" height="18" font="0">• </text>
<text top="758" left="387" width="114" height="20" font="0">LDL-C &lt; 130 mg/dL  </text>
<text top="777" left="360" width="11" height="18" font="0">• </text>
<text top="776" left="387" width="109" height="20" font="0">hsCRP ≥ 2.0 mg/L  </text>
<text top="703" left="555" width="78" height="20" font="7"><b>Intervention:</b> </text>
<text top="721" left="555" width="112" height="20" font="0">Rosuvastatin 20 mg </text>
<text top="738" left="555" width="110" height="20" font="0">daily (3426 women; </text>
<text top="755" left="555" width="62" height="20" font="0">5475 men) </text>
<text top="772" left="555" width="3" height="20" font="7"><b> </b></text>
<text top="704" left="697" width="137" height="20" font="7"><b>1</b>°<b> endpoint:</b> First major </text>
<text top="722" left="697" width="141" height="20" font="0">cardiovascular event (MI, </text>
<text top="739" left="697" width="139" height="20" font="0">stroke, hospitalization for </text>
<text top="756" left="697" width="135" height="20" font="0">unstable angina, arterial </text>
<text top="703" left="879" width="130" height="20" font="7"><b>Secondary Endpoints </b></text>
<text top="722" left="879" width="11" height="18" font="0">• </text>
<text top="722" left="906" width="192" height="20" font="0">Fatal or nonfatal MI: 0.17 and 0.37 </text>
<text top="739" left="906" width="174" height="20" font="0">per 100 person-y for rosuva vs. </text>
<text top="756" left="906" width="211" height="20" font="0">placebo (HR: for rosuva 0.46; 95% CI: </text>
<text top="773" left="906" width="131" height="20" font="0">0.30 to 0.70; p=0.0002) </text>
</page>
<page number="171" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">171 </text>
<text top="107" left="215" width="57" height="20" font="0">first major </text>
<text top="124" left="215" width="126" height="20" font="0">cardiovascular events. </text>
<text top="141" left="215" width="3" height="20" font="0"> </text>
<text top="159" left="215" width="102" height="20" font="7"><b>Study Type: </b>RCT </text>
<text top="176" left="215" width="3" height="20" font="0"> </text>
<text top="193" left="215" width="124" height="20" font="7"><b>Size: </b>17,802 men and </text>
<text top="210" left="215" width="43" height="20" font="0">women </text>
<text top="109" left="360" width="11" height="18" font="0">• </text>
<text top="108" left="387" width="96" height="20" font="0">TG &lt; 500 mg/dL. </text>
<text top="125" left="360" width="3" height="20" font="7"><b> </b></text>
<text top="143" left="360" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="162" left="360" width="11" height="18" font="0">• </text>
<text top="161" left="387" width="152" height="20" font="0">Prior history of CAD, stroke </text>
<text top="178" left="387" width="40" height="20" font="0">or DM  </text>
<text top="197" left="360" width="11" height="18" font="0">• </text>
<text top="196" left="387" width="120" height="20" font="0">ALT &gt; twice the ULN  </text>
<text top="215" left="360" width="11" height="18" font="0">• </text>
<text top="215" left="387" width="106" height="20" font="0">CK &gt; 3 times ULN  </text>
<text top="233" left="360" width="11" height="18" font="0">• </text>
<text top="233" left="387" width="128" height="20" font="0">Creatinine &gt; 2.0 mg/dL </text>
<text top="252" left="360" width="11" height="18" font="0">• </text>
<text top="251" left="387" width="105" height="20" font="0">Uncontrolled HTN  </text>
<text top="270" left="360" width="11" height="18" font="0">• </text>
<text top="269" left="387" width="98" height="20" font="0">Cancer within 5 y </text>
<text top="288" left="360" width="11" height="18" font="0">• </text>
<text top="287" left="387" width="72" height="20" font="0">Uncontrolled </text>
<text top="305" left="387" width="86" height="20" font="0">hypothyroidism </text>
<text top="324" left="360" width="11" height="18" font="0">• </text>
<text top="323" left="387" width="152" height="20" font="0">Recent history of alcohol or </text>
<text top="340" left="387" width="68" height="20" font="0">drug abuse  </text>
<text top="359" left="360" width="11" height="18" font="0">• </text>
<text top="358" left="387" width="133" height="20" font="0">Inflammatory conditions </text>
<text top="375" left="387" width="143" height="20" font="0">such as arthritis, lupus, or </text>
<text top="393" left="387" width="159" height="20" font="0">inflammatory bowel disease  </text>
<text top="412" left="360" width="11" height="18" font="0">• </text>
<text top="411" left="387" width="133" height="20" font="0">Current use of hormone </text>
<text top="428" left="387" width="44" height="20" font="0">therapy </text>
<text top="447" left="360" width="11" height="18" font="0">• </text>
<text top="447" left="387" width="144" height="20" font="0">Previous or current use of </text>
<text top="464" left="387" width="120" height="20" font="0">lipid-lowering therapy </text>
<text top="483" left="360" width="11" height="18" font="0">• </text>
<text top="482" left="387" width="152" height="20" font="0">Immunosuppresent agents. </text>
<text top="499" left="360" width="3" height="20" font="7"><b> </b></text>
<text top="107" left="555" width="125" height="20" font="7"><b>Comparator:</b> Placebo </text>
<text top="124" left="555" width="112" height="20" font="0">(3375 women; 5526 </text>
<text top="141" left="555" width="31" height="20" font="0">men)<b> </b></text>
<text top="107" left="697" width="99" height="20" font="0">revascularization, </text>
<text top="124" left="697" width="121" height="20" font="0">cardiovascular death) </text>
<text top="143" left="697" width="11" height="18" font="0">• </text>
<text top="143" left="724" width="139" height="20" font="0">After 1.9 y median follow-</text>
<text top="160" left="724" width="142" height="20" font="0">up; maximal follow-up 5 y </text>
<text top="179" left="697" width="11" height="18" font="0">• </text>
<text top="178" left="724" width="140" height="20" font="0">Rosuva 142 events (0.77 </text>
<text top="195" left="724" width="104" height="20" font="0">per 100 person-y), </text>
<text top="212" left="724" width="123" height="20" font="0">placebo 251 (1.36 per </text>
<text top="230" left="724" width="79" height="20" font="0">100 person-y) </text>
<text top="249" left="697" width="11" height="18" font="0">• </text>
<text top="248" left="724" width="141" height="20" font="0">HR: for rosuva 0.56; 95% </text>
<text top="265" left="724" width="140" height="20" font="0">CI: 0.46-0.69; p&lt;0.00001 </text>
<text top="284" left="697" width="11" height="18" font="0">• </text>
<text top="283" left="724" width="89" height="20" font="0">Relative hazard </text>
<text top="300" left="724" width="94" height="20" font="0">reductions in the </text>
<text top="318" left="724" width="135" height="20" font="0">rosuvastatin group were </text>
<text top="335" left="724" width="136" height="20" font="0">similar for women (46%) </text>
<text top="352" left="724" width="87" height="20" font="0">and men (42%) </text>
<text top="369" left="697" width="3" height="20" font="7"><b> </b></text>
<text top="387" left="697" width="3" height="20" font="0"> </text>
<text top="404" left="697" width="3" height="20" font="0"> </text>
<text top="421" left="697" width="3" height="20" font="7"><b> </b></text>
<text top="109" left="879" width="11" height="18" font="0">• </text>
<text top="108" left="906" width="211" height="20" font="0">Fatal or nonfatal stroke: 0.18 and 0.34 </text>
<text top="125" left="906" width="174" height="20" font="0">per 100 person-y for rosuva vs. </text>
<text top="143" left="906" width="194" height="20" font="0">placebo (HR: 0.52; 95% CI: 0.34 to </text>
<text top="160" left="906" width="83" height="20" font="0">0.70; p=0.002) </text>
<text top="179" left="879" width="11" height="18" font="0">• </text>
<text top="178" left="906" width="202" height="20" font="0">Arterial revascularization or unstable </text>
<text top="195" left="906" width="168" height="20" font="0">angina: 0.41 and 0.77 per 100 </text>
<text top="212" left="906" width="204" height="20" font="0">person-y for rosuva vs. placebo (HR: </text>
<text top="230" left="906" width="150" height="20" font="0">0.53; 95% CI: 0.40 to 0.70; </text>
<text top="247" left="906" width="66" height="20" font="0">p&lt;0.00001) </text>
<text top="266" left="879" width="11" height="18" font="0">• </text>
<text top="265" left="906" width="206" height="20" font="0">Nonfatal MI, nonfatal stroke, or death </text>
<text top="282" left="906" width="208" height="20" font="0">from cardiovascular causes: 0.45 and </text>
<text top="300" left="906" width="201" height="20" font="0">0.85 per 100 person-y for rosuva vs. </text>
<text top="317" left="906" width="194" height="20" font="0">placebo (HR: 0.53; 95% CI: 0.40 to </text>
<text top="334" left="906" width="97" height="20" font="0">0.69; p&lt;0.00001) </text>
<text top="351" left="879" width="3" height="20" font="7"><b> </b></text>
<text top="368" left="879" width="3" height="20" font="7"><b> </b></text>
<text top="386" left="879" width="3" height="20" font="7"><b> </b></text>
<text top="403" left="879" width="120" height="20" font="7"><b>Potential limitations </b></text>
<text top="420" left="879" width="3" height="20" font="0"> </text>
<text top="439" left="879" width="11" height="18" font="0">• </text>
<text top="438" left="906" width="172" height="20" font="0">Did not include people with low </text>
<text top="455" left="906" width="210" height="20" font="0">hsCRP along with low LDL-C (unlikely </text>
<text top="473" left="906" width="104" height="20" font="0">to show a benefit). </text>
<text top="492" left="879" width="11" height="18" font="0">• </text>
<text top="491" left="906" width="178" height="20" font="0">Trial was stopped early (median </text>
<text top="508" left="906" width="200" height="20" font="0">follow up &lt;2 y); effect of longer-term </text>
<text top="525" left="906" width="120" height="20" font="0">therapy is not known. </text>
<text top="544" left="879" width="11" height="18" font="0">• </text>
<text top="544" left="906" width="211" height="20" font="0">Trial evaluated the use of rosuvastatin </text>
<text top="561" left="906" width="200" height="20" font="0">for the prevention of first CV events; </text>
<text top="578" left="906" width="196" height="20" font="0">absolute event rates are lower than </text>
<text top="595" left="906" width="166" height="20" font="0">expected among patients with </text>
<text top="612" left="906" width="204" height="20" font="0">vascular disease; must consider cost </text>
<text top="630" left="906" width="187" height="20" font="0">effectiveness of statins in patients </text>
<text top="647" left="906" width="202" height="20" font="0">with low LDL-C but elevated hsCRP. </text>
<text top="664" left="879" width="3" height="20" font="0"> </text>
<text top="681" left="879" width="96" height="20" font="7"><b>Adverse Events </b></text>
<text top="700" left="879" width="11" height="18" font="0">• </text>
<text top="699" left="906" width="174" height="20" font="0">Similar total number of adverse </text>
<text top="717" left="906" width="176" height="20" font="0">events in the rosuva (1352) and </text>
<text top="734" left="906" width="171" height="20" font="0">placebo (1377) groups; p=0.60 </text>
<text top="753" left="879" width="11" height="18" font="0">• </text>
<text top="752" left="906" width="212" height="20" font="0">19 myopathic events in rosuva vs. 9 in </text>
<text top="769" left="906" width="132" height="20" font="0">placebo groups; p=0.82 </text>
</page>
<page number="172" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">172 </text>
<text top="109" left="879" width="11" height="18" font="0">• </text>
<text top="108" left="906" width="206" height="20" font="0">One nonfatal case of rhabdomyolysis </text>
<text top="125" left="906" width="109" height="20" font="0">in the rosuva group </text>
<text top="144" left="879" width="11" height="18" font="0">• </text>
<text top="144" left="906" width="207" height="20" font="0">No sign between-group differences in </text>
<text top="161" left="906" width="165" height="20" font="0">newly diagnosed cancer, ALT </text>
<text top="178" left="906" width="152" height="20" font="0">elevation &gt; 3 times ULN, or </text>
<text top="195" left="906" width="133" height="20" font="0">intracranial hemorrhage </text>
<text top="214" left="879" width="11" height="18" font="0">• </text>
<text top="213" left="906" width="181" height="20" font="0">Physician-reported diabetes was </text>
<text top="231" left="906" width="182" height="20" font="0">more frequent in the rosuva (270 </text>
<text top="248" left="906" width="194" height="20" font="0">cases) vs. the placebo (216 cases) </text>
<text top="265" left="906" width="83" height="20" font="0">group; p=0.01. </text>
<text top="283" left="89" width="55" height="20" font="7"><b>JUPITER </b></text>
<text top="300" left="89" width="80" height="20" font="0">Mora S, et al., </text>
<text top="317" left="89" width="63" height="20" font="0">2010 <a href="data supplement.html#248">(199)</a> </text>
<text top="335" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20176986">20176986</a></text>
<text top="335" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20176986"> </a></text>
<text top="283" left="215" width="119" height="20" font="7"><b>AIM:</b> 1) To conduct a </text>
<text top="300" left="215" width="93" height="20" font="0">prespecified sex-</text>
<text top="317" left="215" width="105" height="20" font="0">specific analysis in </text>
<text top="335" left="215" width="115" height="20" font="0">JUPITER comparing </text>
<text top="352" left="215" width="126" height="20" font="0">the efficacy and safety </text>
<text top="369" left="215" width="128" height="20" font="0">of rosuvastatin therapy </text>
<text top="386" left="215" width="120" height="20" font="0">in women vs. men; 2) </text>
<text top="404" left="215" width="112" height="20" font="0">Perform an updated </text>
<text top="421" left="215" width="119" height="20" font="0">met-analysis of statin </text>
<text top="438" left="215" width="127" height="20" font="0">therapy for the primary </text>
<text top="455" left="215" width="104" height="20" font="0">prevention of CVD </text>
<text top="472" left="215" width="90" height="20" font="0">events and total </text>
<text top="490" left="215" width="106" height="20" font="0">mortality in women </text>
<text top="507" left="215" width="3" height="20" font="0"> </text>
<text top="524" left="215" width="122" height="20" font="7"><b>Study type</b>: RCT and </text>
<text top="541" left="215" width="79" height="20" font="0">meta-analysis </text>
<text top="558" left="215" width="3" height="20" font="0"> </text>
<text top="576" left="215" width="109" height="20" font="7"><b>Size</b>: 6801 women, </text>
<text top="593" left="215" width="75" height="20" font="0">11,0001 men </text>
<text top="283" left="360" width="55" height="20" font="7"><b>JUPITER </b></text>
<text top="300" left="360" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="319" left="360" width="11" height="18" font="0">• </text>
<text top="319" left="387" width="125" height="20" font="0">Women ≥ 60 y of age  </text>
<text top="337" left="360" width="11" height="18" font="0">• </text>
<text top="337" left="387" width="69" height="20" font="0">Men ≥ 50 y  </text>
<text top="356" left="360" width="11" height="18" font="0">• </text>
<text top="355" left="387" width="114" height="20" font="0">LDL-C &lt; 130 mg/dL  </text>
<text top="374" left="360" width="11" height="18" font="0">• </text>
<text top="373" left="387" width="109" height="20" font="0">hsCRP ≥ 2.0 mg/L  </text>
<text top="392" left="360" width="11" height="18" font="0">• </text>
<text top="391" left="387" width="96" height="20" font="0">TG &lt; 500 mg/dL. </text>
<text top="409" left="360" width="3" height="20" font="7"><b> </b></text>
<text top="426" left="360" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="445" left="360" width="11" height="18" font="0">• </text>
<text top="444" left="387" width="152" height="20" font="0">Prior history of CAD, stroke </text>
<text top="461" left="387" width="40" height="20" font="0">or DM  </text>
<text top="480" left="360" width="11" height="18" font="0">• </text>
<text top="480" left="387" width="120" height="20" font="0">ALT &gt; twice the ULN  </text>
<text top="499" left="360" width="11" height="18" font="0">• </text>
<text top="498" left="387" width="106" height="20" font="0">CK &gt; 3 times ULN  </text>
<text top="517" left="360" width="11" height="18" font="0">• </text>
<text top="516" left="387" width="128" height="20" font="0">Creatinine &gt; 2.0 mg/dL </text>
<text top="535" left="360" width="11" height="18" font="0">• </text>
<text top="534" left="387" width="105" height="20" font="0">Uncontrolled HTN  </text>
<text top="553" left="360" width="11" height="18" font="0">• </text>
<text top="553" left="387" width="98" height="20" font="0">Cancer within 5 y </text>
<text top="571" left="360" width="11" height="18" font="0">• </text>
<text top="571" left="387" width="72" height="20" font="0">Uncontrolled </text>
<text top="588" left="387" width="86" height="20" font="0">hypothyroidism </text>
<text top="607" left="360" width="11" height="18" font="0">• </text>
<text top="606" left="387" width="152" height="20" font="0">Recent history of alcohol or </text>
<text top="623" left="387" width="68" height="20" font="0">drug abuse  </text>
<text top="642" left="360" width="11" height="18" font="0">• </text>
<text top="642" left="387" width="133" height="20" font="0">Inflammatory conditions </text>
<text top="659" left="387" width="143" height="20" font="0">such as arthritis, lupus, or </text>
<text top="676" left="387" width="159" height="20" font="0">inflammatory bowel disease  </text>
<text top="695" left="360" width="11" height="18" font="0">• </text>
<text top="694" left="387" width="133" height="20" font="0">Current use of hormone </text>
<text top="712" left="387" width="44" height="20" font="0">therapy </text>
<text top="731" left="360" width="11" height="18" font="0">• </text>
<text top="730" left="387" width="144" height="20" font="0">Previous or current use of </text>
<text top="747" left="387" width="120" height="20" font="0">lipid-lowering therapy </text>
<text top="766" left="360" width="11" height="18" font="0">• </text>
<text top="765" left="387" width="152" height="20" font="0">Immunosuppresent agents. </text>
<text top="782" left="360" width="3" height="20" font="0"> </text>
<text top="283" left="555" width="55" height="20" font="7"><b>JUPITER </b></text>
<text top="300" left="555" width="78" height="20" font="7"><b>Intervention:</b> </text>
<text top="317" left="555" width="112" height="20" font="0">Rosuvastatin 20 mg </text>
<text top="335" left="555" width="110" height="20" font="0">daily (3426 women; </text>
<text top="352" left="555" width="62" height="20" font="0">5475 men) </text>
<text top="369" left="555" width="3" height="20" font="7"><b> </b></text>
<text top="386" left="555" width="125" height="20" font="7"><b>Comparator:</b> Placebo </text>
<text top="404" left="555" width="112" height="20" font="0">(3375 women; 5526 </text>
<text top="421" left="555" width="31" height="20" font="0">men) </text>
<text top="438" left="555" width="3" height="20" font="0"> </text>
<text top="455" left="555" width="84" height="20" font="7"><b>Meta-analysis </b></text>
<text top="472" left="555" width="101" height="20" font="0">Statin vs. placebo </text>
<text top="283" left="697" width="55" height="20" font="7"><b>JUPITER </b></text>
<text top="301" left="697" width="137" height="20" font="7"><b>1</b>°<b> endpoint:</b> First major </text>
<text top="319" left="697" width="141" height="20" font="0">cardiovascular event (MI, </text>
<text top="336" left="697" width="139" height="20" font="0">stroke, hospitalization for </text>
<text top="353" left="697" width="135" height="20" font="0">unstable angina, arterial </text>
<text top="370" left="697" width="99" height="20" font="0">revascularization, </text>
<text top="387" left="697" width="121" height="20" font="0">cardiovascular death) </text>
<text top="406" left="697" width="11" height="18" font="0">• </text>
<text top="406" left="724" width="122" height="20" font="0">Women: 0.56 per 100 </text>
<text top="423" left="724" width="128" height="20" font="0">person-y for rosuva vs. </text>
<text top="440" left="724" width="92" height="20" font="0">1.04 for placebo </text>
<text top="459" left="697" width="11" height="18" font="0">• </text>
<text top="458" left="724" width="103" height="20" font="0">Men: 0.88 per 100 </text>
<text top="476" left="724" width="128" height="20" font="0">person-y for rosuva vs. </text>
<text top="493" left="724" width="92" height="20" font="0">1.54 for placebo </text>
<text top="512" left="697" width="11" height="18" font="0">• </text>
<text top="511" left="724" width="133" height="20" font="0">Women<b>: </b>HR: 0.54; 95% </text>
<text top="528" left="724" width="139" height="20" font="0">CI: 0.37 to 0.80; p=0.002 </text>
<text top="547" left="697" width="11" height="18" font="0">• </text>
<text top="547" left="724" width="133" height="20" font="0">Men: HR: 0.58; 95% CI: </text>
<text top="564" left="724" width="120" height="20" font="0">0.45 to 0.73; p&lt;0.001 </text>
<text top="583" left="697" width="11" height="18" font="0">• </text>
<text top="582" left="724" width="100" height="20" font="0">Treatment-by-sex </text>
<text top="599" left="724" width="126" height="20" font="0">interaction using a sex-</text>
<text top="616" left="724" width="75" height="20" font="0">stratified Cox </text>
<text top="634" left="724" width="116" height="20" font="0">proportional-hazards </text>
<text top="651" left="724" width="141" height="20" font="0">model was nonsignificant </text>
<text top="668" left="724" width="53" height="20" font="0">(p=0.80). </text>
<text top="685" left="697" width="3" height="20" font="7"><b> </b></text>
<text top="702" left="697" width="84" height="20" font="7"><b>Meta-analysis </b></text>
<text top="720" left="697" width="150" height="20" font="0">CVD in exclusively primary </text>
<text top="737" left="697" width="104" height="20" font="0">prevention women </text>
<text top="754" left="697" width="160" height="20" font="0">(AFCAPS/TexCAPS, MEGA, </text>
<text top="771" left="697" width="59" height="20" font="0">JUPITER) </text>
<text top="283" left="879" width="55" height="20" font="7"><b>JUPITER </b></text>
<text top="300" left="879" width="130" height="20" font="7"><b>Secondary Endpoints </b></text>
<text top="317" left="879" width="3" height="20" font="0"> </text>
<text top="335" left="879" width="191" height="20" font="0">Revascularization/unstable angina </text>
<text top="354" left="879" width="11" height="18" font="0">• </text>
<text top="353" left="906" width="193" height="20" font="0">Women:<b> </b>HR: 0.24; 95% CI: 0.11 to </text>
<text top="370" left="906" width="27" height="20" font="0">0.51 </text>
<text top="389" left="879" width="11" height="18" font="0">• </text>
<text top="388" left="906" width="209" height="20" font="0">Men: HR: 0.63; 95% CI: 0.46 to 0.85;  </text>
<text top="407" left="879" width="11" height="18" font="0">• </text>
<text top="407" left="906" width="125" height="20" font="0">Heterogeneity, p=0.01 </text>
<text top="424" left="879" width="86" height="20" font="0">Nonfatal stroke </text>
<text top="443" left="879" width="11" height="18" font="0">• </text>
<text top="442" left="906" width="193" height="20" font="0">Women:<b> </b>HR: 0.84; 95% CI: 0.45 to </text>
<text top="459" left="906" width="27" height="20" font="0">1.58 </text>
<text top="478" left="879" width="11" height="18" font="0">• </text>
<text top="478" left="906" width="202" height="20" font="0">Men: HR: 0.33; 95% CI: 0.17 to 0.63 </text>
<text top="497" left="879" width="11" height="18" font="0">• </text>
<text top="496" left="906" width="129" height="20" font="0">Heterogeneity, p=0.04) </text>
<text top="513" left="879" width="88" height="20" font="0">All-cause death </text>
<text top="532" left="879" width="11" height="18" font="0">• </text>
<text top="531" left="906" width="193" height="20" font="0">Women:<b> </b>HR: 0.77; 95% CI: 0.55 to </text>
<text top="548" left="906" width="27" height="20" font="0">1.06 </text>
<text top="567" left="879" width="11" height="18" font="0">• </text>
<text top="567" left="906" width="202" height="20" font="0">Men: HR: 0.82; 95% CI: 0.66 to 1.03 </text>
<text top="586" left="879" width="11" height="18" font="0">• </text>
<text top="585" left="906" width="170" height="20" font="0">Significant only when men and </text>
<text top="602" left="906" width="130" height="20" font="0">women were combined </text>
<text top="619" left="879" width="3" height="20" font="0"> </text>
<text top="636" left="879" width="90" height="20" font="0">Adverse Events </text>
<text top="655" left="879" width="11" height="18" font="0">• </text>
<text top="655" left="906" width="186" height="20" font="13"><i>Muscle weakness, stiffness, pain, </i></text>
<text top="672" left="906" width="198" height="20" font="13"><i>myopathy – </i>no difference in women </text>
<text top="689" left="906" width="176" height="20" font="0">vs. men regardless of treatment </text>
<text top="706" left="906" width="66" height="20" font="0">assignment </text>
<text top="725" left="879" width="11" height="18" font="0">• </text>
<text top="725" left="906" width="166" height="20" font="13"><i>Newly diagnosed cancer </i>-- no </text>
<text top="742" left="906" width="160" height="20" font="0">difference in women vs. men </text>
<text top="759" left="906" width="196" height="20" font="0">regardless of treatment assignment </text>
</page>
<page number="173" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">173 </text>
<text top="107" left="360" width="84" height="20" font="7"><b>Meta-analysis </b></text>
<text top="124" left="360" width="105" height="20" font="7"><b>Inclusion criteria</b>: </text>
<text top="143" left="360" width="11" height="18" font="0">• </text>
<text top="143" left="387" width="111" height="20" font="0">RCTs through 2009 </text>
<text top="162" left="360" width="11" height="18" font="0">• </text>
<text top="161" left="387" width="96" height="20" font="0">Predominantly or </text>
<text top="178" left="387" width="107" height="20" font="0">exclusively primary </text>
<text top="195" left="387" width="122" height="20" font="0">prevention individuals </text>
<text top="214" left="360" width="11" height="18" font="0">• </text>
<text top="213" left="387" width="117" height="20" font="0">Mean follow-up &gt; 1 y </text>
<text top="233" left="360" width="11" height="18" font="0">• </text>
<text top="232" left="387" width="110" height="20" font="0">Sex-specific clinical </text>
<text top="249" left="387" width="144" height="20" font="0">outcomes on CVD or total </text>
<text top="266" left="387" width="50" height="20" font="0">mortality </text>
<text top="283" left="360" width="3" height="20" font="7"><b> </b></text>
<text top="109" left="697" width="11" height="18" font="0">• </text>
<text top="108" left="724" width="127" height="20" font="0">RR 0.63; 95% CI: 0.49-</text>
<text top="125" left="724" width="79" height="20" font="0">0.82; p&lt;0.001 </text>
<text top="144" left="697" width="11" height="18" font="0">• </text>
<text top="144" left="724" width="125" height="20" font="0">Heterogeneity, p=0.56 </text>
<text top="161" left="697" width="3" height="20" font="0"> </text>
<text top="178" left="697" width="147" height="20" font="0">CVD in predominantly and </text>
<text top="195" left="697" width="168" height="20" font="0">exclusively primary prevention </text>
<text top="212" left="697" width="136" height="20" font="0">women (+ ALLHAT-LLT, </text>
<text top="230" left="697" width="76" height="20" font="0">ASCOT-LLA) </text>
<text top="249" left="697" width="11" height="18" font="0">• </text>
<text top="248" left="724" width="130" height="20" font="0">RR: 0.79; 95% CI: 0.59-</text>
<text top="265" left="724" width="72" height="20" font="0">1.05; p=0.11 </text>
<text top="284" left="697" width="11" height="18" font="0">• </text>
<text top="283" left="724" width="125" height="20" font="0">Heterogeneity, p=0.05 </text>
<text top="300" left="697" width="3" height="20" font="0"> </text>
<text top="318" left="697" width="156" height="20" font="0">Total mortality in exclusively </text>
<text top="335" left="697" width="152" height="20" font="0">primary prevention women  </text>
<text top="354" left="697" width="11" height="18" font="0">• </text>
<text top="353" left="724" width="130" height="20" font="0">RR: 0.78; 95% CI: 0.53-</text>
<text top="370" left="724" width="72" height="20" font="0">1.15; p=0.21 </text>
<text top="390" left="697" width="11" height="18" font="0">• </text>
<text top="389" left="724" width="125" height="20" font="0">Heterogeneity, p=0.20 </text>
<text top="406" left="697" width="3" height="20" font="0"> </text>
<text top="423" left="697" width="94" height="20" font="0">Total mortality in </text>
<text top="440" left="697" width="167" height="20" font="0">predominantly and exclusively </text>
<text top="457" left="697" width="152" height="20" font="0">primary prevention women  </text>
<text top="476" left="697" width="11" height="18" font="0">• </text>
<text top="476" left="724" width="130" height="20" font="0">RR: 0.86; 95% CI: 0.67-</text>
<text top="493" left="724" width="72" height="20" font="0">1.12; p=0.27 </text>
<text top="512" left="697" width="11" height="18" font="0">• </text>
<text top="511" left="724" width="128" height="20" font="0">Heterogeneity, p=0.13. </text>
<text top="109" left="879" width="11" height="18" font="0">• </text>
<text top="108" left="906" width="181" height="20" font="13"><i>Cancer deaths </i>– no difference in </text>
<text top="125" left="906" width="152" height="20" font="0">women based on treatment </text>
<text top="143" left="906" width="201" height="20" font="0">assignment; more deaths in placebo </text>
<text top="160" left="906" width="130" height="20" font="0">group for men (p=0.03) </text>
<text top="179" left="879" width="11" height="18" font="0">• </text>
<text top="178" left="906" width="192" height="20" font="13"><i>Hepatic disorder </i>-- no difference in </text>
<text top="195" left="906" width="152" height="20" font="0">women based on treatment </text>
<text top="212" left="906" width="201" height="20" font="0">assignment; more adverse events in </text>
<text top="230" left="906" width="208" height="20" font="0">men assigned to rosuva than placebo </text>
<text top="247" left="906" width="49" height="20" font="0">(p=0.02) </text>
<text top="266" left="879" width="11" height="18" font="0">• </text>
<text top="265" left="906" width="205" height="20" font="13"><i>Physician reported diabetes </i>– Higher </text>
<text top="282" left="906" width="211" height="20" font="0">in women on rosuva vs. placebo (1.53 </text>
<text top="300" left="906" width="202" height="20" font="0">vs. 1.03 per 100 person-y; HR: 1.49; </text>
<text top="317" left="906" width="175" height="20" font="0">95% CI: 1.11 to 2.01; p=0.008). </text>
<text top="334" left="879" width="215" height="20" font="0">    Men on rosuva vs. placebo (1.36 vs. </text>
<text top="351" left="879" width="229" height="20" font="0">1.20 per 100 person-y; HR: 1.14; 95% CI: </text>
<text top="368" left="879" width="166" height="20" font="0">0.91 to 1.43; p=0.24). Test for </text>
<text top="386" left="879" width="199" height="20" font="0">heterogeneity of DM by sex was not </text>
<text top="403" left="879" width="193" height="20" font="0">significant (heterogeneity, p=0.16). </text>
<text top="529" left="89" width="95" height="20" font="0">Kostis WJ, et al., </text>
<text top="546" left="89" width="63" height="20" font="0">2012 <a href="data supplement.html#248">(200)</a> </text>
<text top="564" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22300691">22300691</a></text>
<text top="564" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22300691"> </a></text>
<text top="581" left="89" width="3" height="20" font="0"> </text>
<text top="529" left="215" width="124" height="20" font="7"><b>Aim:</b> Meta-analysis of </text>
<text top="546" left="215" width="124" height="20" font="0">sex-specific outcomes </text>
<text top="564" left="215" width="70" height="20" font="0">in controlled </text>
<text top="581" left="215" width="108" height="20" font="0">randomized clinical </text>
<text top="598" left="215" width="120" height="20" font="0">trials of statin therapy </text>
<text top="615" left="215" width="3" height="20" font="0"> </text>
<text top="632" left="215" width="102" height="20" font="7"><b>Study type:</b> Meta-</text>
<text top="650" left="215" width="51" height="20" font="0">analysis  </text>
<text top="667" left="215" width="3" height="20" font="0"> </text>
<text top="684" left="215" width="106" height="20" font="7"><b>Size: </b>18 studies (8 </text>
<text top="701" left="215" width="126" height="20" font="0">primary prevention, 10 </text>
<text top="718" left="215" width="128" height="20" font="0">secondary prevention); </text>
<text top="736" left="215" width="116" height="20" font="0">5 primary prevention </text>
<text top="753" left="215" width="91" height="20" font="0">studies included </text>
<text top="770" left="215" width="108" height="20" font="0">patients with CVD.  </text>
<text top="787" left="215" width="94" height="20" font="0">Overall, 141,235 </text>
<text top="529" left="360" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="548" left="360" width="11" height="18" font="0">• </text>
<text top="547" left="387" width="131" height="20" font="0">Controlled, randomized </text>
<text top="564" left="387" width="29" height="20" font="0">trials </text>
<text top="583" left="360" width="11" height="18" font="0">• </text>
<text top="583" left="387" width="136" height="20" font="0">Investigator- and patient-</text>
<text top="600" left="387" width="43" height="20" font="0">blinded </text>
<text top="619" left="360" width="11" height="18" font="0">• </text>
<text top="618" left="387" width="130" height="20" font="0">Data presented by sex. </text>
<text top="635" left="360" width="3" height="20" font="0"> </text>
<text top="653" left="360" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="672" left="360" width="11" height="18" font="0">• </text>
<text top="671" left="387" width="154" height="20" font="0">Studies with fewer than 100 </text>
<text top="688" left="387" width="50" height="20" font="0">patients  </text>
<text top="707" left="360" width="11" height="18" font="0">• </text>
<text top="706" left="387" width="127" height="20" font="0">Fewer than deaths per </text>
<text top="724" left="387" width="103" height="20" font="0">randomized group </text>
<text top="529" left="555" width="81" height="20" font="7"><b>Intervention:</b>  </text>
<text top="548" left="555" width="11" height="18" font="0">• </text>
<text top="547" left="582" width="35" height="20" font="0">Statin </text>
<text top="566" left="555" width="11" height="18" font="0">• </text>
<text top="566" left="582" width="84" height="20" font="0">Analyses were </text>
<text top="583" left="582" width="91" height="20" font="0">done separately </text>
<text top="600" left="582" width="62" height="20" font="0">for primary </text>
<text top="617" left="582" width="85" height="20" font="0">prevention and </text>
<text top="634" left="582" width="60" height="20" font="0">secondary </text>
<text top="652" left="582" width="94" height="20" font="0">prevention trials, </text>
<text top="669" left="582" width="59" height="20" font="0">by level of </text>
<text top="686" left="582" width="96" height="20" font="0">baseline risk and </text>
<text top="703" left="582" width="57" height="20" font="0">by type of </text>
<text top="721" left="582" width="54" height="20" font="0">endpoint. </text>
<text top="738" left="555" width="7" height="20" font="0">  </text>
<text top="755" left="555" width="77" height="20" font="7"><b>Comparator: </b></text>
<text top="530" left="697" width="130" height="20" font="7"><b>1</b>°<b> endpoint:</b> All-cause </text>
<text top="548" left="697" width="163" height="20" font="0">mortality and the primary end-</text>
<text top="565" left="697" width="127" height="20" font="0">point as defined by the </text>
<text top="582" left="697" width="152" height="20" font="0">investigators of each study. </text>
<text top="601" left="697" width="11" height="18" font="0">• </text>
<text top="600" left="724" width="138" height="20" font="0">Women -- OR 0.81; 95% </text>
<text top="617" left="724" width="91" height="20" font="0">CI: 0.75 to 0.89, </text>
<text top="634" left="724" width="55" height="20" font="0">p&lt;0.0001 </text>
<text top="654" left="697" width="11" height="18" font="0">• </text>
<text top="653" left="724" width="141" height="20" font="0">Men – OR: 0.77; 95% CI: </text>
<text top="670" left="724" width="117" height="20" font="0">0.71-0.83, p&lt;0.0001  </text>
<text top="689" left="697" width="11" height="18" font="0">• </text>
<text top="688" left="724" width="94" height="20" font="0">Interaction effect </text>
<text top="705" left="724" width="55" height="20" font="0">p=0.1837 </text>
<text top="724" left="697" width="11" height="18" font="0">• </text>
<text top="724" left="724" width="109" height="20" font="0">Women, secondary </text>
<text top="741" left="724" width="126" height="20" font="0">prevention trials – OR: </text>
<text top="758" left="724" width="137" height="20" font="0">0.78; 95% CI: 0.70-0.88; </text>
<text top="775" left="724" width="55" height="20" font="0">p&lt;0.0001 </text>
<text top="529" left="879" width="21" height="20" font="0">NA </text>
</page>
<page number="174" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">174 </text>
<text top="107" left="215" width="129" height="20" font="0">patients were included, </text>
<text top="124" left="215" width="129" height="20" font="0">21,468 primary events, </text>
<text top="141" left="215" width="116" height="20" font="0">13,710 events (3898 </text>
<text top="159" left="215" width="121" height="20" font="0">deaths in studies with </text>
<text top="176" left="215" width="117" height="20" font="0">sex-specific mortality </text>
<text top="193" left="215" width="35" height="20" font="0">data). </text>
<text top="109" left="555" width="11" height="18" font="0">• </text>
<text top="108" left="582" width="95" height="20" font="0">Placebo or lower </text>
<text top="125" left="582" width="81" height="20" font="0">intensity statin </text>
<text top="109" left="697" width="11" height="18" font="0">• </text>
<text top="108" left="724" width="94" height="20" font="0">Women, primary </text>
<text top="125" left="724" width="130" height="20" font="0">prevention trials --: OR: </text>
<text top="143" left="724" width="137" height="20" font="0">0.85; 95% CI: 0.75-0.98; </text>
<text top="160" left="724" width="55" height="20" font="0">p=0.0209 </text>
<text top="179" left="697" width="11" height="18" font="0">• </text>
<text top="178" left="724" width="123" height="20" font="0">Interaction, p=0.3397. </text>
<text top="195" left="697" width="3" height="20" font="0"> </text>
<text top="212" left="697" width="153" height="20" font="7"><b>Women, Meta-analysis by </b></text>
<text top="230" left="697" width="75" height="20" font="7"><b>level of risk: </b></text>
<text top="249" left="697" width="11" height="18" font="0">• </text>
<text top="248" left="724" width="117" height="20" font="0">High risk – OR: 0.88; </text>
<text top="265" left="724" width="106" height="20" font="0">95% CI: 0.81-0.95; </text>
<text top="282" left="724" width="55" height="20" font="0">p=0.0014 </text>
<text top="301" left="697" width="11" height="18" font="0">• </text>
<text top="301" left="724" width="136" height="20" font="0">Medium risk – OR: 0.75; </text>
<text top="318" left="724" width="106" height="20" font="0">95% CI: 0.64-0.89; </text>
<text top="335" left="724" width="55" height="20" font="0">p=0.0011 </text>
<text top="354" left="697" width="11" height="18" font="0">• </text>
<text top="353" left="724" width="115" height="20" font="0">Low risk – OR: 0.59; </text>
<text top="370" left="724" width="106" height="20" font="0">95% CI: 0.41-0.87; </text>
<text top="388" left="724" width="52" height="20" font="0">p=0.006.<b> </b></text>
<text top="406" left="89" width="85" height="20" font="0">Taylor F, et al., </text>
<text top="423" left="89" width="63" height="20" font="0">2013 <a href="data supplement.html#248">(201)</a> </text>
<text top="440" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23440795">23440795</a></text>
<text top="440" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23440795"> </a></text>
<text top="406" left="215" width="111" height="20" font="7"><b>Aim:</b> To assess the </text>
<text top="423" left="215" width="108" height="20" font="0">effects, both harms </text>
<text top="440" left="215" width="126" height="20" font="0">and benefits, of statins </text>
<text top="457" left="215" width="96" height="20" font="0">in people with no </text>
<text top="474" left="215" width="83" height="20" font="0">history of CVD </text>
<text top="492" left="215" width="3" height="20" font="0"> </text>
<text top="509" left="215" width="71" height="20" font="7"><b>Study type: </b></text>
<text top="526" left="215" width="103" height="20" font="0">Systematic review </text>
<text top="543" left="215" width="3" height="20" font="0"> </text>
<text top="560" left="215" width="128" height="20" font="7"><b>Size: </b>18 RCTs, 15,934 </text>
<text top="578" left="215" width="46" height="20" font="0">patients<b> </b></text>
<text top="406" left="360" width="106" height="20" font="7"><b>Inclusion criteria: </b></text>
<text top="425" left="360" width="11" height="18" font="0">• </text>
<text top="424" left="387" width="151" height="20" font="0">RCTs comparing treatment </text>
<text top="441" left="387" width="142" height="20" font="0">with statins for at least 12 </text>
<text top="458" left="387" width="139" height="20" font="0">mo with placebo or usual </text>
<text top="475" left="387" width="27" height="20" font="0">care </text>
<text top="494" left="360" width="11" height="18" font="0">• </text>
<text top="494" left="387" width="146" height="20" font="0">Men and women (aged 18 </text>
<text top="511" left="387" width="155" height="20" font="0">or more) with no restrictions </text>
<text top="528" left="387" width="115" height="20" font="0">on total, low- or high-</text>
<text top="545" left="387" width="102" height="20" font="0">density lipoprotein </text>
<text top="563" left="387" width="98" height="20" font="0">cholesterol levels </text>
<text top="582" left="360" width="11" height="18" font="0">• </text>
<text top="581" left="387" width="127" height="20" font="0">RCTs with less than or </text>
<text top="598" left="387" width="135" height="20" font="0">equal to 10% of patients </text>
<text top="615" left="387" width="139" height="20" font="0">with a previous history of </text>
<text top="632" left="387" width="29" height="20" font="0">CVD </text>
<text top="650" left="360" width="3" height="20" font="0"> </text>
<text top="667" left="360" width="110" height="20" font="7"><b>Exclusion criteria: </b></text>
<text top="684" left="360" width="180" height="20" font="0">Trials in which statins were used </text>
<text top="701" left="360" width="140" height="20" font="0">to treat or control chronic </text>
<text top="718" left="360" width="154" height="20" font="0">conditions (e.g. Alzheimer’s </text>
<text top="736" left="360" width="161" height="20" font="0">disease, rheumatoid arthritis, </text>
<text top="753" left="360" width="127" height="20" font="0">renal disease, macular </text>
<text top="770" left="360" width="165" height="20" font="0">degeneration, aortic stenosis)<b> </b></text>
<text top="406" left="555" width="78" height="20" font="7"><b>Intervention: </b></text>
<text top="423" left="555" width="41" height="20" font="0">Statins </text>
<text top="440" left="555" width="3" height="20" font="7"><b> </b></text>
<text top="457" left="555" width="77" height="20" font="7"><b>Comparator: </b></text>
<text top="474" left="555" width="122" height="20" font="0">Placebo or usual care<b> </b></text>
<text top="407" left="697" width="83" height="20" font="7"><b>1</b>°<b> endpoints: </b></text>
<text top="426" left="697" width="11" height="18" font="0">• </text>
<text top="425" left="724" width="116" height="20" font="0">Total mortality – OR: </text>
<text top="442" left="724" width="133" height="20" font="0">0.86; 95% CI: 0.79-0.94 </text>
<text top="461" left="697" width="11" height="18" font="0">• </text>
<text top="460" left="724" width="135" height="20" font="0">Total CHD events – RR: </text>
<text top="478" left="724" width="133" height="20" font="0">0.73; 95% CI: 0.67-0.80 </text>
<text top="497" left="697" width="11" height="18" font="0">• </text>
<text top="496" left="724" width="119" height="20" font="0">Total number of CVD </text>
<text top="513" left="724" width="133" height="20" font="0">events – RR: 0.75; 95% </text>
<text top="530" left="724" width="75" height="20" font="0">CI: 0.70-0.81 </text>
<text top="549" left="697" width="11" height="18" font="0">• </text>
<text top="549" left="724" width="127" height="20" font="0">Total number of stroke </text>
<text top="566" left="724" width="133" height="20" font="0">events – RR: 0.78; 95% </text>
<text top="583" left="724" width="75" height="20" font="0">CI: 0.68-0.89 </text>
<text top="602" left="697" width="11" height="18" font="0">• </text>
<text top="601" left="724" width="140" height="20" font="0">Total number of fatal and </text>
<text top="618" left="724" width="134" height="20" font="0">nonfatal CHD, CVD and </text>
<text top="636" left="724" width="139" height="20" font="0">stroke events –RR: 0.65; </text>
<text top="653" left="724" width="103" height="20" font="0">95% CI: 0.58-0.73 </text>
<text top="672" left="697" width="11" height="18" font="0">• </text>
<text top="671" left="724" width="94" height="20" font="0">Number of study </text>
<text top="688" left="724" width="92" height="20" font="0">participants who </text>
<text top="705" left="724" width="61" height="20" font="0">underwent </text>
<text top="723" left="724" width="130" height="20" font="0">revascularization – RR: </text>
<text top="740" left="724" width="133" height="20" font="0">0.62; 95% CI: 0.54-0.72 </text>
<text top="757" left="697" width="3" height="20" font="0"> </text>
<text top="406" left="879" width="98" height="20" font="7"><b>Adverse events: </b></text>
<text top="425" left="879" width="11" height="18" font="0">• </text>
<text top="424" left="906" width="176" height="20" font="0">No difference in adverse events </text>
<text top="441" left="906" width="198" height="20" font="0">between groups (RR: 1.00; 95% CI: </text>
<text top="458" left="906" width="68" height="20" font="0">0.97 to 1.03 </text>
<text top="477" left="879" width="11" height="18" font="0">• </text>
<text top="477" left="906" width="182" height="20" font="0">No difference in participants who </text>
<text top="494" left="906" width="187" height="20" font="0">stopped treatment due to adverse </text>
<text top="511" left="906" width="187" height="20" font="0">events (RR: 0.86; 95% CI: 0.65 to </text>
<text top="528" left="906" width="27" height="20" font="0">1.12 </text>
<text top="547" left="879" width="11" height="18" font="0">• </text>
<text top="546" left="906" width="189" height="20" font="0">No difference in study participants </text>
<text top="564" left="906" width="186" height="20" font="0">who developed cancer (RR: 1.01; </text>
<text top="581" left="906" width="116" height="20" font="0">95% CI: 0.93 to 1.10 </text>
<text top="600" left="879" width="11" height="18" font="0">• </text>
<text top="599" left="906" width="189" height="20" font="0">No difference in study participants </text>
<text top="616" left="906" width="192" height="20" font="0">who developed myalgia (RR: 1.03; </text>
<text top="633" left="906" width="112" height="20" font="0">95% CI: 0.97 to1.09 </text>
<text top="652" left="879" width="11" height="18" font="0">• </text>
<text top="652" left="906" width="189" height="20" font="0">No difference in study participants </text>
<text top="669" left="906" width="187" height="20" font="0">who developed rhabdo (RR: 1.00; </text>
<text top="686" left="906" width="116" height="20" font="0">95% CI: 0.23 to 4.38 </text>
<text top="705" left="879" width="11" height="18" font="0">• </text>
<text top="704" left="906" width="189" height="20" font="0">No difference in study participants </text>
<text top="721" left="906" width="196" height="20" font="0">who developed diabetes (RR: 1.18; </text>
<text top="739" left="906" width="112" height="20" font="0">95% CI: 1.01 to1.39 </text>
</page>
<page number="175" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">175 </text>
<text top="107" left="697" width="152" height="20" font="0">** <b>Analyses based on sex </b></text>
<text top="124" left="697" width="169" height="20" font="7"><b>were initially considered but </b></text>
<text top="141" left="697" width="152" height="20" font="7"><b>abandoned due to lack of </b></text>
<text top="159" left="697" width="115" height="20" font="7"><b>adequate reporting </b></text>
<text top="176" left="697" width="3" height="20" font="7"><b> </b></text>
<text top="109" left="879" width="11" height="18" font="0">• </text>
<text top="108" left="906" width="189" height="20" font="0">No difference in study participants </text>
<text top="125" left="906" width="195" height="20" font="0">who developed hemorrhagic stroke </text>
<text top="143" left="906" width="172" height="20" font="0">(RR: 0.97; 95% CI: 0.54 to1.75 </text>
<text top="160" left="879" width="215" height="20" font="0">No difference in study participants who </text>
<text top="177" left="879" width="217" height="20" font="0">developed elevated liver enzymes (RR: </text>
<text top="194" left="879" width="143" height="20" font="0">1.16; 95% CI: 0.87 to1.54<b> </b></text>
<text top="212" left="89" width="107" height="20" font="0">CTT Collaboration  </text>
<text top="229" left="89" width="91" height="20" font="0">Fulcher J, et.al., </text>
<text top="247" left="89" width="63" height="20" font="0">2015 <a href="data supplement.html#248">(202)</a> </text>
<text top="264" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25579834">25579834</a></text>
<text top="264" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25579834"> </a></text>
<text top="281" left="89" width="3" height="20" font="0"> </text>
<text top="212" left="215" width="103" height="20" font="7"><b>Aim:</b> To provide a </text>
<text top="229" left="215" width="78" height="20" font="0">more detailed </text>
<text top="247" left="215" width="103" height="20" font="0">assessment of the </text>
<text top="264" left="215" width="131" height="20" font="0">effects of statin therapy </text>
<text top="281" left="215" width="120" height="20" font="0">on particular vascular </text>
<text top="298" left="215" width="98" height="20" font="0">and non-vascular </text>
<text top="315" left="215" width="121" height="20" font="0">outcomes in men and </text>
<text top="333" left="215" width="122" height="20" font="0">women in the settings </text>
<text top="350" left="215" width="109" height="20" font="0">of both primary and </text>
<text top="367" left="215" width="124" height="20" font="0">secondary prevention. </text>
<text top="384" left="215" width="3" height="20" font="0"> </text>
<text top="401" left="215" width="105" height="20" font="7"><b>Study type:</b>  Meta-</text>
<text top="419" left="215" width="48" height="20" font="0">analysis </text>
<text top="436" left="215" width="3" height="20" font="0"> </text>
<text top="453" left="215" width="130" height="20" font="7"><b>Size:</b> 27 trials; 174,149 </text>
<text top="470" left="215" width="89" height="20" font="0">patients (26.8% </text>
<text top="487" left="215" width="47" height="20" font="0">women) </text>
<text top="212" left="360" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="231" left="360" width="11" height="18" font="0">• </text>
<text top="230" left="387" width="155" height="20" font="0">Studies reported up to 2010 </text>
<text top="249" left="360" width="11" height="18" font="0">• </text>
<text top="249" left="387" width="143" height="20" font="0">Trials of statin therapy vs. </text>
<text top="266" left="387" width="154" height="20" font="0">control and trials comparing </text>
<text top="283" left="387" width="148" height="20" font="0">statin regimens of differing </text>
<text top="300" left="387" width="49" height="20" font="0">intensity </text>
<text top="319" left="360" width="11" height="18" font="0">• </text>
<text top="319" left="387" width="144" height="20" font="0">Main effect of at least one </text>
<text top="336" left="387" width="131" height="20" font="0">of the trial interventions </text>
<text top="353" left="387" width="145" height="20" font="0">was to reduce LDL-C; trial </text>
<text top="370" left="387" width="132" height="20" font="0">was unconfounded with </text>
<text top="387" left="387" width="147" height="20" font="0">respect to this intervention </text>
<text top="406" left="360" width="11" height="18" font="0">• </text>
<text top="406" left="387" width="150" height="20" font="0">Trial investigators aimed to </text>
<text top="423" left="387" width="114" height="20" font="0">recruit 1000 or more </text>
<text top="440" left="387" width="66" height="20" font="0">participants </text>
<text top="459" left="360" width="11" height="18" font="0">• </text>
<text top="458" left="387" width="135" height="20" font="0">Treatment duration of at </text>
<text top="475" left="387" width="53" height="20" font="0">least 2 y. </text>
<text top="493" left="360" width="3" height="20" font="0"> </text>
<text top="510" left="360" width="3" height="20" font="0"> </text>
<text top="212" left="555" width="127" height="20" font="7"><b>Intervention:</b> Statin or </text>
<text top="229" left="555" width="109" height="20" font="0">high-intensity statin </text>
<text top="247" left="555" width="3" height="20" font="7"><b> </b></text>
<text top="264" left="555" width="128" height="20" font="7"><b>Comparator:</b> <b> </b>Placebo </text>
<text top="281" left="555" width="128" height="20" font="0">or lower intensity statin<b> </b></text>
<text top="213" left="697" width="159" height="20" font="7"><b>1</b>°<b> endpoint:</b> Major vascular </text>
<text top="230" left="697" width="168" height="20" font="0">events, major coronary events </text>
<text top="248" left="697" width="138" height="20" font="0">(non-fatal MI or coronary </text>
<text top="265" left="697" width="93" height="20" font="0">death), coronary </text>
<text top="282" left="697" width="165" height="20" font="0">revascularization (angioplasty </text>
<text top="299" left="697" width="149" height="20" font="0">or bypass grafting), stroke, </text>
<text top="317" left="697" width="154" height="20" font="0">site-specific cancers, cause-</text>
<text top="334" left="697" width="98" height="20" font="0">specific mortality. </text>
<text top="351" left="697" width="3" height="20" font="0"> </text>
<text top="368" left="697" width="155" height="20" font="7"><b>Overall Result for Primary </b></text>
<text top="385" left="697" width="159" height="20" font="7"><b>and Secondary Prevention </b></text>
<text top="403" left="697" width="120" height="20" font="7"><b>Trials (</b>irrespective of </text>
<text top="420" left="697" width="146" height="20" font="0">vascular risk or subtype of </text>
<text top="437" left="697" width="111" height="20" font="0">vascular outcome)<b>:  </b></text>
<text top="456" left="697" width="11" height="18" font="0">• </text>
<text top="455" left="724" width="127" height="20" font="0">Women -- Proportional </text>
<text top="473" left="724" width="101" height="20" font="0">reduction in major </text>
<text top="490" left="724" width="131" height="20" font="0">vascular events per 1.0 </text>
<text top="507" left="724" width="137" height="20" font="0">mmol/L LDL-C reduction </text>
<text top="524" left="724" width="130" height="20" font="0">(RR 0.84; 99% CI: 0.78 </text>
<text top="541" left="724" width="49" height="20" font="0">to 0.91)  </text>
<text top="560" left="697" width="11" height="18" font="0">• </text>
<text top="560" left="724" width="109" height="20" font="0">Men -- Proportional </text>
<text top="577" left="724" width="101" height="20" font="0">reduction in major </text>
<text top="594" left="724" width="131" height="20" font="0">vascular events per 1.0 </text>
<text top="611" left="724" width="137" height="20" font="0">mmol/L LDL-C reduction </text>
<text top="628" left="724" width="130" height="20" font="0">(RR 0.78; 99% CI: 0.75 </text>
<text top="646" left="724" width="41" height="20" font="0">to 0.81 </text>
<text top="663" left="697" width="3" height="20" font="7"><b> </b></text>
<text top="212" left="879" width="133" height="20" font="7"><b>Secondary endpoints: </b></text>
<text top="229" left="879" width="3" height="20" font="7"><b> </b></text>
<text top="247" left="879" width="200" height="20" font="0">Major vascular events (% annum) in </text>
<text top="264" left="879" width="190" height="20" font="0">women and men without history of </text>
<text top="281" left="879" width="95" height="20" font="0">vascular disease </text>
<text top="300" left="879" width="11" height="18" font="0">• </text>
<text top="299" left="906" width="197" height="20" font="0">Women -- 593 (1.3%) statin vs. 669 </text>
<text top="316" left="906" width="180" height="20" font="0">(1.4%) control (RR per 1 mmol/L </text>
<text top="334" left="906" width="194" height="20" font="0">reduction in LDL-C = 0.85; 99% CI: </text>
<text top="351" left="906" width="68" height="20" font="0">0.72 to 1.00<b> </b></text>
<text top="370" left="879" width="11" height="18" font="0">• </text>
<text top="369" left="906" width="192" height="20" font="0">Men -- 1313 (1.5%) statin vs. 1756 </text>
<text top="386" left="906" width="180" height="20" font="0">(2.1%) control (RR per 1 mmol/L </text>
<text top="404" left="906" width="194" height="20" font="0">reduction in LDL-C = 0.72; 99% CI: </text>
<text top="421" left="906" width="60" height="20" font="0">0.66-0.80) </text>
<text top="440" left="879" width="11" height="18" font="0">• </text>
<text top="439" left="906" width="174" height="20" font="0">Adjusted heterogeneity, p=0.02 </text>
<text top="456" left="879" width="3" height="20" font="7"><b> </b></text>
<text top="473" left="879" width="232" height="20" font="0">All women -- RR per 1.0 mmol/L reduction </text>
<text top="490" left="879" width="192" height="20" font="0">in LDL-C based on vascular risk at </text>
<text top="508" left="879" width="49" height="20" font="0">baseline </text>
<text top="527" left="906" width="11" height="18" font="0">• </text>
<text top="526" left="933" width="144" height="20" font="0">&lt; 10 % = 0.74 (0.59-0.93) </text>
<text top="545" left="906" width="11" height="18" font="0">• </text>
<text top="544" left="933" width="178" height="20" font="0">10 to &lt;20% =    0.88 (0.77-1.00) </text>
<text top="561" left="879" width="3" height="20" font="0"> </text>
<text top="579" left="879" width="230" height="20" font="0">Major Coronary Events in all women --RR </text>
<text top="596" left="879" width="228" height="20" font="0">per 1.0 mmol/L reduction in LDL-C based </text>
<text top="613" left="879" width="152" height="20" font="0">on vascular risk at baseline </text>
<text top="632" left="906" width="11" height="18" font="0">• </text>
<text top="631" left="933" width="144" height="20" font="0">&lt; 10 % = 0.72 (0.49-1.06) </text>
<text top="650" left="906" width="11" height="18" font="0">• </text>
<text top="650" left="933" width="164" height="20" font="0">10 to &lt;20%   0.85 (0.70-1.03) </text>
<text top="667" left="879" width="3" height="20" font="0"> </text>
<text top="684" left="879" width="233" height="20" font="0">Coronary revascularization in all women -- </text>
<text top="701" left="879" width="213" height="20" font="0">RR per 1.0 mmol/L reduction in LDL-C </text>
<text top="718" left="879" width="189" height="20" font="0">based on vascular risk at baseline </text>
<text top="737" left="879" width="11" height="18" font="0">• </text>
<text top="737" left="906" width="144" height="20" font="0">&lt; 10 % = 0.58 (0.38-0.89) </text>
<text top="756" left="879" width="11" height="18" font="0">• </text>
<text top="755" left="906" width="155" height="20" font="0">10-&lt;20% = 0.83 (0.67-1.04) </text>
<text top="772" left="879" width="3" height="20" font="0"> </text>
</page>
<page number="176" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">176 </text>
<text top="107" left="879" width="235" height="20" font="0">Ischemic stroke in all Women --RR per 1.0 </text>
<text top="124" left="879" width="204" height="20" font="0">mmol/L reduction in LDL-C based on </text>
<text top="141" left="879" width="135" height="20" font="0">vascular risk at baseline </text>
<text top="160" left="879" width="11" height="18" font="0">• </text>
<text top="160" left="906" width="144" height="20" font="0">&lt; 10 % = 0.73 (0.50-1.07) </text>
<text top="179" left="879" width="11" height="18" font="0">• </text>
<text top="178" left="906" width="155" height="20" font="0">10-&lt;20% = 0.92 (0.67-1.25) </text>
<text top="195" left="879" width="3" height="20" font="0"> </text>
<text top="212" left="879" width="218" height="20" font="0">All-cause mortality in combined primary </text>
<text top="230" left="879" width="192" height="20" font="0">and secondary prevention studies) </text>
<text top="249" left="879" width="11" height="18" font="0">• </text>
<text top="248" left="906" width="212" height="20" font="0">Women -- 9% reduction with statin per </text>
<text top="265" left="906" width="199" height="20" font="0">1.0 mmol/L reduction in LDL-C (RR: </text>
<text top="282" left="906" width="150" height="20" font="0">0.91; 99% CI: 0.84 to 0.99) </text>
<text top="301" left="879" width="11" height="18" font="0">• </text>
<text top="301" left="906" width="201" height="20" font="0">Men -- 10% (RR: 0.90; 99% CI: 0.86 </text>
<text top="318" left="906" width="45" height="20" font="0">to 0.95) </text>
<text top="335" left="879" width="3" height="20" font="7"><b> </b></text>
<text top="352" left="879" width="107" height="20" font="7"><b>Study Limitations </b></text>
<text top="369" left="879" width="3" height="20" font="0"> </text>
<text top="388" left="879" width="11" height="18" font="0">• </text>
<text top="388" left="906" width="204" height="20" font="0">Fewer women than men recruited for </text>
<text top="405" left="906" width="70" height="20" font="0">clinical trials </text>
<text top="424" left="879" width="11" height="18" font="0">• </text>
<text top="423" left="906" width="185" height="20" font="0">Primary prevention trials/subjects </text>
<text top="440" left="906" width="207" height="20" font="0">were difficult to tease out in this meta-</text>
<text top="457" left="906" width="48" height="20" font="0">analysis </text>
<text top="476" left="879" width="11" height="18" font="0">• </text>
<text top="476" left="906" width="200" height="20" font="0">Fewer events in women, particularly </text>
<text top="493" left="906" width="88" height="20" font="0">low-risk women </text>
<text top="510" left="879" width="3" height="20" font="0"> </text>
<text top="528" left="89" width="49" height="20" font="7"><b>HOPE-3 </b></text>
<text top="545" left="89" width="83" height="20" font="0">Yusuf S, et al., </text>
<text top="562" left="89" width="81" height="20" font="0">2016 (a) <a href="data supplement.html#248">(203)</a> </text>
<text top="580" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27039945">27039945</a></text>
<text top="580" left="144" width="3" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27039945"><b> </b></a></text>
<text top="597" left="89" width="3" height="20" font="7"><b> </b></text>
<text top="528" left="215" width="119" height="20" font="7"><b>Aim: </b>To evaluate the </text>
<text top="545" left="215" width="119" height="20" font="0">effects of a moderate </text>
<text top="562" left="215" width="124" height="20" font="0">dose of a potent statin </text>
<text top="580" left="215" width="72" height="20" font="0">(without lipid </text>
<text top="597" left="215" width="105" height="20" font="0">monitoring) versus </text>
<text top="614" left="215" width="89" height="20" font="0">placebo, a fixed </text>
<text top="631" left="215" width="83" height="20" font="0">combination of </text>
<text top="649" left="215" width="122" height="20" font="0">moderate doses of an </text>
<text top="666" left="215" width="116" height="20" font="0">angiotensin-receptor </text>
<text top="683" left="215" width="122" height="20" font="0">blocker plus a diuretic </text>
<text top="700" left="215" width="131" height="20" font="0">(without blood pressure </text>
<text top="718" left="215" width="85" height="20" font="0">targets) versus </text>
<text top="735" left="215" width="94" height="20" font="0">placebo, and the </text>
<text top="752" left="215" width="111" height="20" font="0">combination of both </text>
<text top="769" left="215" width="128" height="20" font="0">treatments versus dual </text>
<text top="786" left="215" width="84" height="20" font="0">placebo on the </text>
<text top="528" left="360" width="106" height="20" font="7"><b>Inclusion criteria: </b></text>
<text top="547" left="360" width="11" height="18" font="0">• </text>
<text top="546" left="387" width="140" height="20" font="0">Men 55 y of age or older, </text>
<text top="564" left="387" width="152" height="20" font="0">women 65 y of age or older </text>
<text top="583" left="360" width="11" height="18" font="0">• </text>
<text top="582" left="387" width="151" height="20" font="0">No cardiovascular disease  </text>
<text top="601" left="360" width="11" height="18" font="0">• </text>
<text top="600" left="387" width="133" height="20" font="0">At least 1 additional risk </text>
<text top="617" left="387" width="104" height="20" font="0">factor besides age </text>
<text top="634" left="387" width="151" height="20" font="0">(elevated waist-to-hip ratio, </text>
<text top="652" left="387" width="120" height="20" font="0">history of low HDL-C, </text>
<text top="669" left="387" width="140" height="20" font="0">current or recent tobacco </text>
<text top="686" left="387" width="137" height="20" font="0">use, dysglycemia, family </text>
<text top="703" left="387" width="113" height="20" font="0">history of premature </text>
<text top="721" left="387" width="126" height="20" font="0">coronary disease, mild </text>
<text top="738" left="387" width="100" height="20" font="0">renal dysfunction) </text>
<text top="757" left="360" width="11" height="18" font="0">• </text>
<text top="756" left="387" width="155" height="20" font="0">Women 60 y of age or older </text>
<text top="773" left="387" width="153" height="20" font="0">were included if they had at </text>
<text top="528" left="555" width="74" height="20" font="7"><b>Intervention </b></text>
<text top="547" left="555" width="11" height="18" font="0">• </text>
<text top="546" left="582" width="91" height="20" font="0">Candesartan 16 </text>
<text top="564" left="582" width="88" height="20" font="0">mg- HCTZ 12.5 </text>
<text top="581" left="582" width="91" height="20" font="0">mg per day plus </text>
<text top="598" left="582" width="87" height="20" font="0">rosuvastatin 10 </text>
<text top="615" left="582" width="65" height="20" font="0">mg per day </text>
<text top="632" left="582" width="85" height="20" font="0">(N=3180, 1465 </text>
<text top="650" left="582" width="47" height="20" font="0">women) </text>
<text top="669" left="555" width="11" height="18" font="0">• </text>
<text top="668" left="582" width="91" height="20" font="0">Rosuvastatin 10 </text>
<text top="685" left="582" width="91" height="20" font="0">mg per day plus </text>
<text top="702" left="582" width="101" height="20" font="0">placebo (N=3181) </text>
<text top="721" left="555" width="11" height="18" font="0">• </text>
<text top="721" left="582" width="91" height="20" font="0">Candesartan 16 </text>
<text top="738" left="582" width="85" height="20" font="0">mg-HCTZ 12.5 </text>
<text top="755" left="582" width="91" height="20" font="0">mg per day plus </text>
<text top="772" left="582" width="101" height="20" font="0">placebo (N=3176) </text>
<text top="789" left="555" width="3" height="20" font="7"><b> </b></text>
<text top="528" left="697" width="126" height="20" font="7"><b>Primary endpoint #1: </b></text>
<text top="545" left="697" width="138" height="20" font="0">Composite of death from </text>
<text top="562" left="697" width="128" height="20" font="0">cardiovascular causes, </text>
<text top="580" left="697" width="170" height="20" font="0">nonfatal MI, or nonfatal stroke  </text>
<text top="599" left="697" width="11" height="18" font="0">• </text>
<text top="598" left="724" width="101" height="20" font="0">3.6% in combined </text>
<text top="615" left="724" width="130" height="20" font="0">therapy group vs. 5.0% </text>
<text top="632" left="724" width="121" height="20" font="0">in dual placebo group </text>
<text top="651" left="697" width="11" height="18" font="0">• </text>
<text top="651" left="724" width="99" height="20" font="0">HR: for combined </text>
<text top="668" left="724" width="122" height="20" font="0">therapy 0.71, 95% CI: </text>
<text top="685" left="724" width="120" height="20" font="0">0.56 to 0.90, p=0.005 </text>
<text top="704" left="697" width="11" height="18" font="0">• </text>
<text top="703" left="724" width="91" height="20" font="0">Women:<b> </b>HR: for </text>
<text top="721" left="724" width="132" height="20" font="0">combined therapy 0.70; </text>
<text top="738" left="724" width="116" height="20" font="0">95% CI: 0.48 to 1.03 </text>
<text top="528" left="879" width="201" height="20" font="7"><b>Secondary outcome: </b>Composite of<b> </b></text>
<text top="545" left="879" width="235" height="20" font="0">cardiovascular death, nonfatal MI, nonfatal </text>
<text top="562" left="879" width="223" height="20" font="0">stroke, resuscitated cardiac arrest, heart </text>
<text top="580" left="879" width="219" height="20" font="0">failure, revascularization, or angina with </text>
<text top="597" left="879" width="170" height="20" font="0">objective evidence of ischemia </text>
<text top="616" left="879" width="11" height="18" font="0">• </text>
<text top="615" left="906" width="200" height="20" font="0">4.6% in combined therapy group vs. </text>
<text top="632" left="906" width="126" height="20" font="0">6.5% in placebo group </text>
<text top="651" left="879" width="11" height="18" font="0">• </text>
<text top="651" left="906" width="202" height="20" font="0">HR: for combined therapy 0.71; 95% </text>
<text top="668" left="906" width="139" height="20" font="0">CI: 0.57 to 0.87, p=0.001 </text>
<text top="685" left="879" width="3" height="20" font="0"> </text>
<text top="702" left="879" width="98" height="20" font="7"><b>Adverse events: </b></text>
<text top="721" left="879" width="11" height="18" font="0">• </text>
<text top="721" left="906" width="209" height="20" font="0">Muscle weakness and dizziness were </text>
<text top="738" left="906" width="172" height="20" font="0">more common in the combined </text>
<text top="755" left="906" width="178" height="20" font="0">therapy than in the dual placebo </text>
<text top="772" left="906" width="35" height="20" font="0">group </text>
</page>
<page number="177" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">177 </text>
<text top="107" left="215" width="109" height="20" font="0">prevention of major </text>
<text top="124" left="215" width="126" height="20" font="0">cardiovascular events. </text>
<text top="141" left="215" width="3" height="20" font="0"> </text>
<text top="159" left="215" width="124" height="20" font="7"><b>Study type: </b>RCT with </text>
<text top="176" left="215" width="127" height="20" font="0">a 2 x 2 factorial design </text>
<text top="193" left="215" width="3" height="20" font="0"> </text>
<text top="210" left="215" width="120" height="20" font="7"><b>Size:</b> 12,705 (women </text>
<text top="227" left="215" width="96" height="20" font="0">5874, men 6831) </text>
<text top="245" left="215" width="3" height="20" font="7"><b> </b></text>
<text top="107" left="387" width="133" height="20" font="0">least 2 of the above risk </text>
<text top="124" left="387" width="44" height="20" font="0">factors. </text>
<text top="141" left="360" width="3" height="20" font="0"> </text>
<text top="159" left="360" width="114" height="20" font="7"><b>Exclusion criteria:  </b></text>
<text top="178" left="360" width="11" height="18" font="0">• </text>
<text top="177" left="387" width="131" height="20" font="0">Cardiovascular disease </text>
<text top="196" left="360" width="11" height="18" font="0">• </text>
<text top="195" left="387" width="106" height="20" font="0">An indication for or </text>
<text top="212" left="387" width="145" height="20" font="0">contraindication to statins, </text>
<text top="230" left="387" width="116" height="20" font="0">angiotensin-receptor </text>
<text top="247" left="387" width="119" height="20" font="0">blockers, angiotensin-</text>
<text top="264" left="387" width="107" height="20" font="0">converting enzyme </text>
<text top="281" left="387" width="116" height="20" font="0">inhibitors, or thiazide </text>
<text top="298" left="387" width="53" height="20" font="0">diuretics. </text>
<text top="107" left="555" width="76" height="20" font="7"><b>Comparator</b>  </text>
<text top="126" left="555" width="11" height="18" font="0">• </text>
<text top="125" left="582" width="74" height="20" font="0">Placebo plus </text>
<text top="143" left="582" width="101" height="20" font="0">placebo (N=3168, </text>
<text top="160" left="582" width="78" height="20" font="0">1478 women)<b> </b></text>
<text top="109" left="697" width="11" height="18" font="0">• </text>
<text top="108" left="724" width="130" height="20" font="0">Men:<b> </b>HR: for combined </text>
<text top="125" left="724" width="122" height="20" font="0">therapy 0.71; 95% CI: </text>
<text top="143" left="724" width="68" height="20" font="0">0.52 to 0.97 </text>
<text top="160" left="697" width="3" height="20" font="0"> </text>
<text top="179" left="697" width="11" height="18" font="0">• </text>
<text top="178" left="724" width="109" height="20" font="0">Subgroup analyses </text>
<text top="195" left="724" width="121" height="20" font="0">showed no significant </text>
<text top="212" left="724" width="111" height="20" font="0">heterogeneity in the </text>
<text top="230" left="724" width="123" height="20" font="0">effects of combination </text>
<text top="247" left="724" width="137" height="20" font="0">therapy according to sex </text>
<text top="264" left="724" width="60" height="20" font="0">(p=0.980). </text>
<text top="281" left="697" width="3" height="20" font="7"><b> </b></text>
<text top="298" left="697" width="126" height="20" font="7"><b>Primary endpoint #2: </b></text>
<text top="316" left="697" width="133" height="20" font="0">Composite of the above </text>
<text top="333" left="697" width="135" height="20" font="0">events plus resuscitated </text>
<text top="350" left="697" width="164" height="20" font="0">cardiac arrest, heart failure or </text>
<text top="367" left="697" width="96" height="20" font="0">revascularization </text>
<text top="386" left="697" width="11" height="18" font="0">• </text>
<text top="386" left="724" width="101" height="20" font="0">4.3% in combined </text>
<text top="403" left="724" width="130" height="20" font="0">therapy group vs. 5.9% </text>
<text top="420" left="724" width="121" height="20" font="0">in dual placebo group </text>
<text top="439" left="697" width="11" height="18" font="0">• </text>
<text top="438" left="724" width="99" height="20" font="0">HR: for combined </text>
<text top="455" left="724" width="122" height="20" font="0">therapy 0.72; 95% CI: </text>
<text top="473" left="724" width="120" height="20" font="0">0.57 to 0.89, p=0.003 </text>
<text top="492" left="697" width="11" height="18" font="0">• </text>
<text top="491" left="724" width="91" height="20" font="0">Women:<b> </b>HR: for </text>
<text top="508" left="724" width="132" height="20" font="0">combined therapy 0.71; </text>
<text top="525" left="724" width="116" height="20" font="0">95% CI: 0.49 to 1.01 </text>
<text top="544" left="697" width="11" height="18" font="0">• </text>
<text top="544" left="724" width="130" height="20" font="0">Men:<b> </b>HR: for combined </text>
<text top="561" left="724" width="122" height="20" font="0">therapy 0.72; 95% CI: </text>
<text top="578" left="724" width="68" height="20" font="0">0.54 to 0.95 </text>
<text top="597" left="697" width="11" height="18" font="0">• </text>
<text top="596" left="724" width="109" height="20" font="0">Subgroup analyses </text>
<text top="613" left="724" width="121" height="20" font="0">showed no significant </text>
<text top="631" left="724" width="111" height="20" font="0">heterogeneity in the </text>
<text top="648" left="724" width="123" height="20" font="0">effects of combination </text>
<text top="665" left="724" width="137" height="20" font="0">therapy according to sex </text>
<text top="682" left="724" width="56" height="20" font="0">(p=0.936) </text>
<text top="700" left="697" width="3" height="20" font="0"> </text>
<text top="717" left="697" width="107" height="20" font="7"><b>Safety endpoints: </b></text>
<text top="736" left="697" width="11" height="18" font="0">• </text>
<text top="735" left="724" width="133" height="20" font="0">No difference in cancer, </text>
<text top="752" left="724" width="101" height="20" font="0">myopathy, or total </text>
<text top="769" left="724" width="137" height="20" font="0">hospitalizations between </text>
<text top="109" left="879" width="11" height="18" font="0">• </text>
<text top="108" left="906" width="197" height="20" font="0">Rates of permanent discontinuation </text>
<text top="125" left="906" width="203" height="20" font="0">for any reason did not differ between </text>
<text top="143" left="906" width="203" height="20" font="0">the combined therapy group (26.3%) </text>
<text top="160" left="906" width="199" height="20" font="0">and the dual placebo group (28.8%) </text>
<text top="177" left="879" width="3" height="20" font="0"> </text>
</page>
<page number="178" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">178 </text>
<text top="107" left="724" width="122" height="20" font="0">the combined therapy </text>
<text top="124" left="724" width="138" height="20" font="0">and dual placebo groups </text>
<text top="143" left="697" width="11" height="18" font="0">• </text>
<text top="143" left="724" width="107" height="20" font="0">Hospitalizations for </text>
<text top="160" left="724" width="125" height="20" font="0">cardiovascular causes </text>
<text top="177" left="724" width="128" height="20" font="0">were higher in the dual </text>
<text top="194" left="724" width="140" height="20" font="0">placebo group (6.0%) vs. </text>
<text top="211" left="724" width="101" height="20" font="0">combined therapy </text>
<text top="229" left="724" width="91" height="20" font="0">(4.4%); p=0.005 </text>
<text top="246" left="697" width="3" height="20" font="7"><b> </b></text>
<text top="264" left="89" width="49" height="20" font="7"><b>HOPE-3 </b></text>
<text top="281" left="89" width="83" height="20" font="0">Yusuf S, et al., </text>
<text top="298" left="89" width="75" height="20" font="0">2016 (b) <a href="data supplement.html#236">(12)</a> </text>
<text top="315" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27040132">27040132</a></text>
<text top="315" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27040132"> </a></text>
<text top="264" left="215" width="119" height="20" font="7"><b>Aim: </b>To evaluate the </text>
<text top="281" left="215" width="109" height="20" font="0">long-term effects of </text>
<text top="298" left="215" width="128" height="20" font="0">rosuvastatin 10 mg per </text>
<text top="315" left="215" width="100" height="20" font="0">day (without dose </text>
<text top="333" left="215" width="103" height="20" font="0">adjustment or lipid </text>
<text top="350" left="215" width="86" height="20" font="0">targets) among </text>
<text top="367" left="215" width="104" height="20" font="0">persons of various </text>
<text top="384" left="215" width="127" height="20" font="0">ethnic backgrounds on </text>
<text top="401" left="215" width="124" height="20" font="0">six continents who did </text>
<text top="419" left="215" width="51" height="20" font="0">not have </text>
<text top="436" left="215" width="128" height="20" font="0">cardiovascular disease </text>
<text top="453" left="215" width="68" height="20" font="0">and were at </text>
<text top="470" left="215" width="100" height="20" font="0">intermediate risk.  </text>
<text top="487" left="215" width="3" height="20" font="0"> </text>
<text top="505" left="215" width="124" height="20" font="7"><b>Study type: </b>RCT with </text>
<text top="522" left="215" width="126" height="20" font="0">a 2 x 2 factorial design </text>
<text top="539" left="215" width="83" height="20" font="0">(including both </text>
<text top="556" left="215" width="112" height="20" font="0">cholesterol lowering </text>
<text top="573" left="215" width="109" height="20" font="0">and blood pressure </text>
<text top="591" left="215" width="84" height="20" font="0">lowering arms) </text>
<text top="608" left="215" width="3" height="20" font="0"> </text>
<text top="625" left="215" width="120" height="20" font="7"><b>Size:</b> 12,705 (women </text>
<text top="642" left="215" width="96" height="20" font="0">5874, men 6831) </text>
<text top="660" left="215" width="3" height="20" font="7"><b> </b></text>
<text top="264" left="360" width="106" height="20" font="7"><b>Inclusion criteria: </b></text>
<text top="283" left="360" width="11" height="18" font="0">• </text>
<text top="282" left="387" width="140" height="20" font="0">Men 55 y of age or older, </text>
<text top="299" left="387" width="152" height="20" font="0">women 65 y of age or older </text>
<text top="318" left="360" width="11" height="18" font="0">• </text>
<text top="318" left="387" width="151" height="20" font="0">No cardiovascular disease  </text>
<text top="337" left="360" width="11" height="18" font="0">• </text>
<text top="336" left="387" width="133" height="20" font="0">At least 1 additional risk </text>
<text top="353" left="387" width="104" height="20" font="0">factor besides age </text>
<text top="370" left="387" width="151" height="20" font="0">(elevated waist-to-hip ratio, </text>
<text top="387" left="387" width="120" height="20" font="0">history of low HDL-C, </text>
<text top="404" left="387" width="140" height="20" font="0">current or recent tobacco </text>
<text top="422" left="387" width="137" height="20" font="0">use, dysglycemia, family </text>
<text top="439" left="387" width="113" height="20" font="0">history of premature </text>
<text top="456" left="387" width="126" height="20" font="0">coronary disease, mild </text>
<text top="473" left="387" width="100" height="20" font="0">renal dysfunction) </text>
<text top="492" left="360" width="11" height="18" font="0">• </text>
<text top="492" left="387" width="155" height="20" font="0">Women 60 y of age or older </text>
<text top="509" left="387" width="153" height="20" font="0">were included if they had at </text>
<text top="526" left="387" width="133" height="20" font="0">least 2 of the above risk </text>
<text top="543" left="387" width="44" height="20" font="0">factors. </text>
<text top="561" left="360" width="3" height="20" font="0"> </text>
<text top="578" left="360" width="114" height="20" font="7"><b>Exclusion criteria:  </b></text>
<text top="597" left="360" width="11" height="18" font="0">• </text>
<text top="596" left="387" width="131" height="20" font="0">Cardiovascular disease </text>
<text top="615" left="360" width="11" height="18" font="0">• </text>
<text top="614" left="387" width="106" height="20" font="0">An indication for or </text>
<text top="631" left="387" width="145" height="20" font="0">contraindication to statins, </text>
<text top="649" left="387" width="116" height="20" font="0">angiotensin-receptor </text>
<text top="666" left="387" width="119" height="20" font="0">blockers, angiotensin-</text>
<text top="683" left="387" width="107" height="20" font="0">converting enzyme </text>
<text top="700" left="387" width="116" height="20" font="0">inhibitors, or thiazide </text>
<text top="717" left="387" width="53" height="20" font="0">diuretics.<b> </b></text>
<text top="264" left="555" width="78" height="20" font="7"><b>Intervention:</b> </text>
<text top="281" left="555" width="112" height="20" font="0">Rosuvastatin 10 mg </text>
<text top="298" left="555" width="100" height="20" font="0">per day (N=6361) </text>
<text top="315" left="555" width="3" height="20" font="0"> </text>
<text top="333" left="555" width="125" height="20" font="7"><b>Comparator:</b> Placebo </text>
<text top="350" left="555" width="55" height="20" font="0">(N=6344) </text>
<text top="264" left="697" width="126" height="20" font="7"><b>Primary endpoint #1: </b></text>
<text top="281" left="697" width="138" height="20" font="0">Composite of death from </text>
<text top="298" left="697" width="128" height="20" font="0">cardiovascular causes, </text>
<text top="315" left="697" width="170" height="20" font="0">nonfatal MI, or nonfatal stroke  </text>
<text top="334" left="697" width="11" height="18" font="0">• </text>
<text top="334" left="724" width="139" height="20" font="0">3.7% in rosuva group vs. </text>
<text top="351" left="724" width="126" height="20" font="0">4.8% in placebo group<b> </b></text>
<text top="370" left="697" width="11" height="18" font="0">• </text>
<text top="369" left="724" width="141" height="20" font="0">HR: for rosuva 0.76; 95% </text>
<text top="386" left="724" width="139" height="20" font="0">CI: 0.64 to 0.91, p=0.002 </text>
<text top="405" left="697" width="11" height="18" font="0">• </text>
<text top="405" left="724" width="132" height="20" font="0">Women:<b> </b>HR: for rosuva </text>
<text top="422" left="724" width="119" height="20" font="0">0.83; 95% CI: 0.64 to </text>
<text top="439" left="724" width="27" height="20" font="0">1.09 </text>
<text top="458" left="697" width="11" height="18" font="0">• </text>
<text top="457" left="724" width="113" height="20" font="0">Men: HR: for rosuva </text>
<text top="474" left="724" width="119" height="20" font="0">0.72; 95% CI: 0.58 to </text>
<text top="492" left="724" width="27" height="20" font="0">0.90 </text>
<text top="511" left="697" width="11" height="18" font="0">• </text>
<text top="510" left="724" width="109" height="20" font="0">Subgroup analyses </text>
<text top="527" left="724" width="121" height="20" font="0">showed no significant </text>
<text top="544" left="724" width="111" height="20" font="0">heterogeneity in the </text>
<text top="561" left="724" width="94" height="20" font="0">effects of rosuva </text>
<text top="579" left="724" width="93" height="20" font="0">according to sex </text>
<text top="596" left="724" width="60" height="20" font="0">(p=0.427). </text>
<text top="613" left="697" width="3" height="20" font="7"><b> </b></text>
<text top="630" left="697" width="126" height="20" font="7"><b>Primary endpoint #2: </b></text>
<text top="647" left="697" width="133" height="20" font="0">Composite of the above </text>
<text top="665" left="697" width="135" height="20" font="0">events plus resuscitated </text>
<text top="682" left="697" width="164" height="20" font="0">cardiac arrest, heart failure or </text>
<text top="699" left="697" width="96" height="20" font="0">revascularization </text>
<text top="718" left="697" width="11" height="18" font="0">• </text>
<text top="717" left="724" width="101" height="20" font="0">4.4% in combined </text>
<text top="735" left="724" width="130" height="20" font="0">therapy group vs. 5.7% </text>
<text top="752" left="724" width="121" height="20" font="0">in dual placebo group </text>
<text top="771" left="697" width="11" height="18" font="0">• </text>
<text top="770" left="724" width="141" height="20" font="0">HR: for rosuva 0.75; 95% </text>
<text top="787" left="724" width="139" height="20" font="0">CI: 0.64 to 0.88, p&lt;0.001 </text>
<text top="264" left="879" width="201" height="20" font="7"><b>Secondary outcome: </b>Composite of<b> </b></text>
<text top="281" left="879" width="235" height="20" font="0">cardiovascular death, nonfatal MI, nonfatal </text>
<text top="298" left="879" width="223" height="20" font="0">stroke, resuscitated cardiac arrest, heart </text>
<text top="315" left="879" width="219" height="20" font="0">failure, revascularization, or angina with </text>
<text top="333" left="879" width="170" height="20" font="0">objective evidence of ischemia </text>
<text top="352" left="879" width="11" height="18" font="0">• </text>
<text top="351" left="906" width="183" height="20" font="0">4.8% in rosuva group vs. 6.2% in </text>
<text top="368" left="906" width="81" height="20" font="0">placebo group </text>
<text top="387" left="879" width="11" height="18" font="0">• </text>
<text top="386" left="906" width="202" height="20" font="0">HR: for rosuva 0.77; 95% CI: 0.66 to </text>
<text top="404" left="906" width="79" height="20" font="0">0.89; p&lt;0.001 </text>
<text top="421" left="879" width="3" height="20" font="7"><b> </b></text>
<text top="438" left="879" width="73" height="20" font="7"><b>Limitations: </b></text>
<text top="457" left="879" width="11" height="18" font="0">• </text>
<text top="456" left="906" width="183" height="20" font="0">Relatively short mean duration of </text>
<text top="473" left="906" width="205" height="20" font="0">treatment (5.6 y); may underestimate </text>
<text top="490" left="906" width="180" height="20" font="0">the benefits of longer-term statin </text>
<text top="508" left="906" width="59" height="20" font="0">treatment. </text>
<text top="525" left="879" width="3" height="20" font="0"> </text>
<text top="542" left="879" width="3" height="20" font="7"><b> </b></text>
<text top="559" left="879" width="98" height="20" font="7"><b>Adverse events: </b></text>
<text top="578" left="879" width="11" height="18" font="0">• </text>
<text top="578" left="906" width="209" height="20" font="0">Muscle pain or weakness were higher </text>
<text top="595" left="906" width="209" height="20" font="0">in the rosuva group (5.8%) than in the </text>
<text top="612" left="906" width="173" height="20" font="0">placebo group (4.7%); p=0.005 </text>
<text top="631" left="879" width="11" height="18" font="0">• </text>
<text top="630" left="906" width="197" height="20" font="0">Rates of permanent discontinuation </text>
<text top="647" left="906" width="208" height="20" font="0">due to muscle symptoms were similar </text>
<text top="665" left="906" width="207" height="20" font="0">in both groups (rosuva 1.3%, placebo </text>
<text top="682" left="906" width="80" height="20" font="0">1.2%; p=0.63) </text>
<text top="701" left="879" width="11" height="18" font="0">• </text>
<text top="700" left="906" width="202" height="20" font="0">Rates of rhabdo and myopathy were </text>
<text top="717" left="906" width="42" height="20" font="0">similar  </text>
<text top="737" left="879" width="11" height="18" font="0">• </text>
<text top="736" left="906" width="209" height="20" font="0">Rates of cataract surgery were higher </text>
<text top="753" left="906" width="209" height="20" font="0">in the rosuva group (3.8%) than in the </text>
<text top="770" left="906" width="166" height="20" font="0">placebo group (3.1%); p=0.02 </text>
<text top="787" left="879" width="3" height="20" font="0"> </text>
</page>
<page number="179" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="21" size="12" family="Times" color="#535353"/>
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">179 </text>
<text top="701" left="81" width="799" height="20" font="7"><b>Abbreviations: </b>AFCAPS/TexCAPS indicates Air Force/Texas Atherosclerosis Prevention Study; AHA, American Heart Association; ALLHAT-LLT, </text>
<text top="701" left="880" width="202" height="20" font="21">Antihypertensive and Lipid-Lowering </text>
<text top="718" left="81" width="332" height="20" font="21">Treatment to Prevent Heart Attack Trial--Lipid Lowering Trial;</text>
<text top="718" left="413" width="657" height="20" font="0"> ALT, alanine aminotransferase; ASCOT-LLA, Anglo-Scandinavian Cardiac Outcomes Trial--Lipid-Lowering Arm; atorva, </text>
<text top="736" left="81" width="980" height="20" font="0">atorvastatin; CARDS, Collaborative Atorvastatin Diabetes Study; CHD, coronary heart disease; CI, confidence interval; CK, creatinine kinase; CVA, cerebrovascular accident; CVD, </text>
<text top="753" left="81" width="1014" height="20" font="0">cardiovascular disease; CTT, Cholesterol Treatment Trialists’ Collaboration; DM, diabetes mellitus; HbA1C, hemoglobin A1C; HDL-C, high density lipoprotein cholesterol; HOPE-3 , Heart </text>
<text top="770" left="81" width="1016" height="20" font="0">Outcomes Prevention Evaluation-3; HR, hazard ratio; hsCRP, high sensitivity C-reactive protein; HTN, hypertension; IDDM, insulin dependent diabetes mellitus; JUPITER, Justification for </text>
<text top="787" left="81" width="975" height="20" font="0">the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin; LDL-C, low density lipoprotein cholesterol; LFT, liver function tests; lova, lovastatin; MEGA, Primary </text>
<text top="109" left="697" width="11" height="18" font="0">• </text>
<text top="108" left="724" width="132" height="20" font="0">Women<b>: </b>HR: for rosuva<b> </b></text>
<text top="125" left="724" width="105" height="20" font="0">0.82; 95% CI: 0.64 </text>
<text top="143" left="724" width="38" height="20" font="0">to1.06 </text>
<text top="162" left="697" width="11" height="18" font="0">• </text>
<text top="161" left="724" width="114" height="20" font="0">Men<b>: </b>HR: for rosuva<b> </b></text>
<text top="178" left="724" width="119" height="20" font="0">0.72; 95% CI: 0.59 to </text>
<text top="195" left="724" width="27" height="20" font="0">0.87 </text>
<text top="214" left="697" width="11" height="18" font="0">• </text>
<text top="213" left="724" width="109" height="20" font="0">Subgroup analyses </text>
<text top="231" left="724" width="121" height="20" font="0">showed no significant </text>
<text top="248" left="724" width="111" height="20" font="0">heterogeneity in the </text>
<text top="265" left="724" width="94" height="20" font="0">effects of rosuva </text>
<text top="282" left="724" width="93" height="20" font="0">according to sex </text>
<text top="300" left="724" width="56" height="20" font="0">(p=0.404) </text>
<text top="317" left="697" width="3" height="20" font="0"> </text>
<text top="334" left="697" width="166" height="20" font="7"><b>Safety endpoints for rosuva </b></text>
<text top="351" left="697" width="75" height="20" font="7"><b>vs. placebo: </b></text>
<text top="370" left="697" width="11" height="18" font="0">• </text>
<text top="370" left="724" width="133" height="20" font="0">No difference in cancer, </text>
<text top="387" left="724" width="101" height="20" font="0">myopathy, or total </text>
<text top="404" left="724" width="137" height="20" font="0">hospitalizations between </text>
<text top="421" left="724" width="111" height="20" font="0">rosuva and placebo </text>
<text top="438" left="724" width="41" height="20" font="0">groups </text>
<text top="457" left="697" width="11" height="18" font="0">• </text>
<text top="456" left="724" width="107" height="20" font="0">Hospitalizations for </text>
<text top="474" left="724" width="125" height="20" font="0">cardiovascular causes </text>
<text top="491" left="724" width="101" height="20" font="0">were higher in the </text>
<text top="508" left="724" width="140" height="20" font="0">placebo group (5.8%) vs. </text>
<text top="525" left="724" width="118" height="20" font="0">rosuva group (4.4%); </text>
<text top="543" left="724" width="55" height="20" font="0">p=0.0004 </text>
<text top="562" left="697" width="11" height="18" font="0">• </text>
<text top="561" left="724" width="124" height="20" font="0">No difference in death </text>
<text top="578" left="724" width="87" height="20" font="0">from any cause </text>
<text top="597" left="697" width="11" height="18" font="0">• </text>
<text top="596" left="724" width="140" height="20" font="0">No different in new-onset </text>
<text top="613" left="724" width="50" height="20" font="0">diabetes </text>
<text top="632" left="697" width="11" height="18" font="0">• </text>
<text top="632" left="724" width="106" height="20" font="0">CHD was higher in </text>
<text top="649" left="724" width="121" height="20" font="0">placebo group (2.2%) </text>
<text top="666" left="724" width="116" height="20" font="0">than in rosuva group </text>
<text top="683" left="724" width="84" height="20" font="0">(1.7%); p=0.02 </text>
<text top="107" left="879" width="3" height="20" font="0"> </text>
<text top="124" left="879" width="3" height="20" font="7"><b> </b></text>
</page>
<page number="180" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">180 </text>
<text top="106" left="81" width="1016" height="20" font="0">Prevention of Cardiovascular Disease with Pravastatin in Japan; mg/dL, milligram per deciliter; MI, myocardial infarction; mmol/L, millimole per liter; NCEP, National Cholesterol Education </text>
<text top="123" left="81" width="1026" height="20" font="0">Program; PAD, peripheral arterial disease; patient-y, patient-years; prava, pravastatin; RCT, randomized controlled trial; rhabdo, rhabdomyolosis; rosuva, rosuvastatin; RR, relative risk; TC, </text>
<text top="141" left="81" width="343" height="20" font="0">total cholesterol; TG, triglycerides; ULN, upper limit of normal.  </text>
<text top="158" left="81" width="3" height="20" font="0"> </text>
<text top="175" left="81" width="3" height="20" font="0"> </text>
<text top="192" left="81" width="787" height="24" font="4"><b>Data Supplement 34. Nonrandomized Studies of the Utility of Coronary Artery Calcium in Women (Section 4.5.3) </b></text>
<text top="214" left="103" width="94" height="20" font="7"><b>Study Acronym </b></text>
<text top="231" left="129" width="44" height="20" font="7"><b>Author </b></text>
<text top="248" left="104" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="214" left="252" width="114" height="20" font="7"><b>Study Type/Design </b></text>
<text top="231" left="276" width="66" height="20" font="7"><b>Study Size </b></text>
<text top="214" left="442" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="214" left="645" width="183" height="20" font="7"><b>Primary Endpoint and Results  </b></text>
<text top="231" left="646" width="176" height="20" font="7"><b>(P values; OR or RR &amp; 95% CI </b></text>
<text top="214" left="907" width="130" height="20" font="7"><b>Summary/Conclusion </b></text>
<text top="231" left="939" width="67" height="20" font="7"><b>Comments </b></text>
<text top="266" left="89" width="39" height="20" font="7"><b>MESA </b></text>
<text top="283" left="89" width="120" height="20" font="0">McClelland RL, et al., </text>
<text top="301" left="89" width="63" height="20" font="0">2006<a href="data supplement.html#248"> (204)</a> </text>
<text top="318" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16365194">16365194</a></text>
<text top="318" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=16365194"> </a></text>
<text top="335" left="89" width="3" height="20" font="0"> </text>
<text top="268" left="224" width="11" height="18" font="0">• </text>
<text top="267" left="251" width="138" height="20" font="0">Prospective cohort study </text>
<text top="284" left="251" width="129" height="20" font="0">designed to investigate </text>
<text top="302" left="251" width="113" height="20" font="0">subclinical CVD in a </text>
<text top="319" left="251" width="138" height="20" font="0">multiethnic cohort free of </text>
<text top="336" left="251" width="70" height="20" font="0">clinical CVD </text>
<text top="355" left="224" width="11" height="18" font="0">• </text>
<text top="354" left="251" width="128" height="20" font="0">6110 participants, 53% </text>
<text top="371" left="251" width="142" height="20" font="0">female, average age 62 y </text>
<text top="266" left="406" width="95" height="20" font="0">Inclusion Criteria </text>
<text top="285" left="406" width="11" height="18" font="0">• </text>
<text top="285" left="433" width="95" height="20" font="0">45 to 84 y of age </text>
<text top="303" left="406" width="11" height="18" font="0">• </text>
<text top="303" left="433" width="130" height="20" font="0">Self-identified as white, </text>
<text top="320" left="433" width="152" height="20" font="0">black, Hispanic, or Chinese </text>
<text top="339" left="406" width="11" height="18" font="0">• </text>
<text top="338" left="433" width="143" height="20" font="0">Free of clinically apparent </text>
<text top="355" left="433" width="29" height="20" font="0">CVD </text>
<text top="372" left="406" width="3" height="20" font="0"> </text>
<text top="390" left="406" width="99" height="20" font="0">Exclusion Criteria </text>
<text top="409" left="406" width="11" height="18" font="0">• </text>
<text top="408" left="433" width="96" height="20" font="0">Treated diabetes </text>
<text top="427" left="406" width="11" height="18" font="0">• </text>
<text top="426" left="433" width="62" height="20" font="0">Pregnancy </text>
<text top="445" left="406" width="11" height="18" font="0">• </text>
<text top="445" left="433" width="150" height="20" font="0">Active treatment for cancer </text>
<text top="463" left="406" width="11" height="18" font="0">• </text>
<text top="463" left="433" width="120" height="20" font="0">Weight &gt; 300 pounds </text>
<text top="482" left="406" width="11" height="18" font="0">• </text>
<text top="481" left="433" width="156" height="20" font="0">Cognitive inability as judged </text>
<text top="498" left="433" width="79" height="20" font="0">by interviewer </text>
<text top="517" left="406" width="11" height="18" font="0">• </text>
<text top="516" left="433" width="137" height="20" font="0">Living in a nursing home </text>
<text top="535" left="406" width="11" height="18" font="0">• </text>
<text top="535" left="433" width="101" height="20" font="0">Plans to leave the </text>
<text top="552" left="433" width="118" height="20" font="0">community within 5 y </text>
<text top="571" left="406" width="11" height="18" font="0">• </text>
<text top="570" left="433" width="97" height="20" font="0">Language barrier </text>
<text top="589" left="406" width="11" height="18" font="0">• </text>
<text top="588" left="433" width="130" height="20" font="0">CT scan of chest within </text>
<text top="606" left="433" width="54" height="20" font="0">past year </text>
<text top="625" left="406" width="11" height="18" font="0">• </text>
<text top="624" left="433" width="113" height="20" font="0">Any serious medical </text>
<text top="641" left="433" width="156" height="20" font="0">condition that would prohibit </text>
<text top="658" left="433" width="125" height="20" font="0">long-term participation </text>
<text top="266" left="602" width="219" height="20" font="0">CAC measured by either EBT or MDCT </text>
<text top="285" left="602" width="11" height="18" font="0">• </text>
<text top="285" left="629" width="192" height="20" font="0">Men had higher CAC than women, </text>
<text top="302" left="629" width="161" height="20" font="0">greatest difference for whites </text>
<text top="321" left="602" width="11" height="18" font="0">• </text>
<text top="320" left="629" width="192" height="20" font="0">Amount and prevalence of calcium </text>
<text top="337" left="629" width="106" height="20" font="0">increased with age </text>
<text top="356" left="602" width="11" height="18" font="0">• </text>
<text top="355" left="629" width="228" height="20" font="0">Women – whites had highest percentiles, </text>
<text top="372" left="629" width="119" height="20" font="0">Hispanics had lowest </text>
<text top="391" left="602" width="11" height="18" font="0">• </text>
<text top="391" left="629" width="184" height="20" font="0">Distribution curves are presented </text>
<text top="408" left="629" width="200" height="20" font="0">according to age, sex, race/ethnicity </text>
<text top="266" left="880" width="175" height="20" font="0">Substantial differences for CAC </text>
<text top="283" left="880" width="147" height="20" font="0">distribution were observed </text>
<text top="301" left="880" width="148" height="20" font="0">among the 4 race/ethnicity </text>
<text top="318" left="880" width="160" height="20" font="0">groups, as well as significant </text>
<text top="335" left="880" width="159" height="20" font="0">interactions for both age and </text>
<text top="352" left="880" width="146" height="20" font="0">gender with race/ethnicity. </text>
<text top="676" left="89" width="39" height="20" font="7"><b>MESA </b></text>
<text top="693" left="89" width="75" height="20" font="0">Jain A, et al., </text>
<text top="710" left="89" width="63" height="20" font="0">2011<a href="data supplement.html#248"> (205)</a> </text>
<text top="728" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21068189">21068189</a></text>
<text top="728" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21068189"> </a></text>
<text top="678" left="224" width="11" height="18" font="0">• </text>
<text top="677" left="251" width="138" height="20" font="0">Prospective cohort study </text>
<text top="694" left="251" width="75" height="20" font="0">to compare 3 </text>
<text top="712" left="251" width="115" height="20" font="0">noninvasive imaging </text>
<text top="729" left="251" width="107" height="20" font="0">tests (CAC, carotid </text>
<text top="746" left="251" width="132" height="20" font="0">intima-media thickness, </text>
<text top="763" left="251" width="137" height="20" font="0">left ventricular mass and </text>
<text top="780" left="251" width="104" height="20" font="0">geometry) for their </text>
<text top="676" left="406" width="95" height="20" font="0">Inclusion Criteria </text>
<text top="695" left="406" width="11" height="18" font="0">• </text>
<text top="694" left="433" width="156" height="20" font="0">Men and women aged 45 to </text>
<text top="712" left="433" width="27" height="20" font="0">84 y </text>
<text top="731" left="406" width="11" height="18" font="0">• </text>
<text top="730" left="433" width="155" height="20" font="0">Free of clinically recognized </text>
<text top="747" left="433" width="104" height="20" font="0">CVD at enrollment </text>
<text top="676" left="602" width="242" height="20" font="0">CVD events considered separately: all CHD </text>
<text top="693" left="602" width="262" height="20" font="0">(MI, resuscitated cardiac arrest, definite angina, </text>
<text top="710" left="602" width="166" height="20" font="0">probable angina if followed by </text>
<text top="728" left="602" width="243" height="20" font="0">revascularization, CHD death), stroke, heart </text>
<text top="745" left="602" width="85" height="20" font="0">failure, all CVD </text>
<text top="676" left="880" width="175" height="20" font="0">Compared with carotid IMT and </text>
<text top="693" left="880" width="163" height="20" font="0">LV mass and geometry, CAC </text>
<text top="710" left="880" width="185" height="20" font="0">was the most strongly associated </text>
<text top="728" left="880" width="176" height="20" font="0">with CHD and CVD in both men </text>
<text top="745" left="880" width="70" height="20" font="0">and women. </text>
</page>
<page number="181" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">181 </text>
<text top="107" left="251" width="131" height="20" font="0">overall and sex-specific </text>
<text top="124" left="251" width="122" height="20" font="0">ability to predict CVD. </text>
<text top="143" left="224" width="11" height="18" font="0">• </text>
<text top="143" left="251" width="131" height="20" font="0">4965 participants, 2600 </text>
<text top="160" left="251" width="47" height="20" font="0">women) </text>
<text top="109" left="406" width="11" height="18" font="0">• </text>
<text top="108" left="433" width="124" height="20" font="0">Available measures of </text>
<text top="125" left="433" width="143" height="20" font="0">CAC, carotid IMT, and LV </text>
<text top="143" left="433" width="100" height="20" font="0">mass and volume </text>
<text top="109" left="602" width="11" height="18" font="0">• </text>
<text top="108" left="629" width="215" height="20" font="0">Men had a higher burden of subclinical </text>
<text top="125" left="629" width="195" height="20" font="0">disease at baseline (p&lt;0.001 for all </text>
<text top="143" left="629" width="62" height="20" font="0">measures) </text>
<text top="162" left="602" width="11" height="18" font="0">• </text>
<text top="161" left="629" width="238" height="20" font="0">297 incident CVD events occurred over 5.8 </text>
<text top="178" left="629" width="211" height="20" font="0">y follow-up; men experienced a higher </text>
<text top="195" left="629" width="206" height="20" font="0">incidence of CHD, HF, and CVD than </text>
<text top="212" left="629" width="93" height="20" font="0">women (p&lt;0.05) </text>
<text top="231" left="602" width="11" height="18" font="0">• </text>
<text top="231" left="629" width="219" height="20" font="0">CAC was most strongly associated with </text>
<text top="248" left="629" width="222" height="20" font="0">CHD in men (HR: 2.4 per 1 SD; 95% CI: </text>
<text top="265" left="629" width="230" height="20" font="0">1.9 to 2.9) and women (HR: 2.2 per 1 SD; </text>
<text top="282" left="629" width="159" height="20" font="0">95% CI: 1.5 to 3.1); p≤0.001 </text>
<text top="301" left="602" width="11" height="18" font="0">• </text>
<text top="301" left="629" width="234" height="20" font="0">CAC was most strongly associated with all </text>
<text top="318" left="629" width="221" height="20" font="0">CVD in men (HR: 1.9 per 1 SD; 95% CI: </text>
<text top="335" left="629" width="230" height="20" font="0">1.6 to 2.3) and women (HR: 1.5 per 1 SD; </text>
<text top="352" left="629" width="159" height="20" font="0">95% CI: 1.2 to 1.8); p≤0.001 </text>
<text top="371" left="602" width="11" height="18" font="0">• </text>
<text top="370" left="629" width="208" height="20" font="0">No significant interactions for imaging </text>
<text top="388" left="629" width="178" height="20" font="0">measures with sex and ethnicity </text>
<text top="407" left="602" width="11" height="18" font="0">• </text>
<text top="406" left="629" width="231" height="20" font="0">For women, compared with traditional risk </text>
<text top="423" left="629" width="235" height="20" font="0">factors alone, CAC added most to AUC for </text>
<text top="440" left="629" width="227" height="20" font="0">CHD prediction (0.805 vs. 0.835; p=0.04) </text>
<text top="458" left="89" width="95" height="20" font="0">Kelkar AA, et al., </text>
<text top="475" left="89" width="63" height="20" font="0">2016<a href="data supplement.html#248"> (206)</a> </text>
<text top="493" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27072301">27072301</a></text>
<text top="493" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27072301"> </a></text>
<text top="460" left="224" width="11" height="18" font="0">• </text>
<text top="459" left="251" width="138" height="20" font="0">Prospective cohort study </text>
<text top="476" left="251" width="127" height="20" font="0">to determine long-term </text>
<text top="494" left="251" width="139" height="20" font="0">prognostic use of CAC in </text>
<text top="511" left="251" width="122" height="20" font="0">asymptomatic women </text>
<text top="528" left="251" width="109" height="20" font="0">and men with a low-</text>
<text top="545" left="251" width="71" height="20" font="0">intermediate </text>
<text top="563" left="251" width="135" height="20" font="0">Framingham Risk Score </text>
<text top="580" left="251" width="36" height="20" font="0">(FRS) </text>
<text top="599" left="224" width="11" height="18" font="0">• </text>
<text top="598" left="251" width="131" height="20" font="0">2363 participants, 1072 </text>
<text top="615" left="251" width="43" height="20" font="0">women </text>
<text top="458" left="406" width="95" height="20" font="0">Inclusion Criteria </text>
<text top="477" left="406" width="11" height="18" font="0">• </text>
<text top="477" left="433" width="141" height="20" font="0">Patients referred for CAC </text>
<text top="494" left="433" width="53" height="20" font="0">scanning </text>
<text top="513" left="406" width="11" height="18" font="0">• </text>
<text top="512" left="433" width="144" height="20" font="0">Without CAD diagnosis or </text>
<text top="529" left="433" width="135" height="20" font="0">symptoms suggestive of </text>
<text top="546" left="433" width="29" height="20" font="0">CAD </text>
<text top="565" left="406" width="11" height="18" font="0">• </text>
<text top="565" left="433" width="155" height="20" font="0">Calculated low-intermediate </text>
<text top="582" left="433" width="150" height="20" font="0">FRS (10-y risk of CAD, 6%-</text>
<text top="599" left="433" width="36" height="20" font="0">9.9%) </text>
<text top="458" left="602" width="147" height="20" font="0">Time to all-cause mortality </text>
<text top="477" left="602" width="11" height="18" font="0">• </text>
<text top="477" left="629" width="212" height="20" font="0">Women were older than men (55.6 vs. </text>
<text top="494" left="629" width="100" height="20" font="0">46.7 y; p&lt;0.0001) </text>
<text top="513" left="602" width="11" height="18" font="0">• </text>
<text top="512" left="629" width="224" height="20" font="0"> CAC scores ≥ 100 occurred in 18.8% of </text>
<text top="529" left="629" width="146" height="20" font="0">women and 15.1% of men </text>
<text top="548" left="602" width="11" height="18" font="0">• </text>
<text top="547" left="629" width="217" height="20" font="0">Cumulative 15-y mortality was 8.8% for </text>
<text top="564" left="629" width="231" height="20" font="0">women and 6.0% for men; p&lt;0.0001 (HR: </text>
<text top="582" left="629" width="144" height="20" font="0">for women 1.44, p=0.022) </text>
<text top="601" left="602" width="11" height="18" font="0">• </text>
<text top="600" left="629" width="193" height="20" font="0">Mortality in relation to CAC scores: </text>
<text top="617" left="629" width="231" height="20" font="7"><b>women </b>5% for CAC score of 0, 23.5% for </text>
<text top="635" left="629" width="236" height="20" font="0">CAC score ≥ 400 (p&lt;0.001); <b>men </b>3.5% for </text>
<text top="652" left="629" width="221" height="20" font="0">CAC score of 0, 18.0% for CAC score ≥ </text>
<text top="669" left="629" width="80" height="20" font="0">400 (p&lt;0.001) </text>
<text top="688" left="602" width="11" height="18" font="0">• </text>
<text top="687" left="629" width="230" height="20" font="0">Multivariate model for <b>women</b> (covariates </text>
<text top="704" left="629" width="180" height="20" font="0">include age, family history, HTN, </text>
<text top="721" left="629" width="221" height="20" font="0">dyslipidemia, smoking, DM) – HR: (95% </text>
<text top="739" left="629" width="154" height="20" font="0">CI:; p-value) for CAC score: </text>
<text top="756" left="629" width="195" height="20" font="0">1-10         1.92: (0.82-4.47; p=0.13) </text>
<text top="773" left="629" width="201" height="20" font="0">11-99       2.37: (1.29-4.35; p=0.005) </text>
<text top="458" left="880" width="176" height="20" font="0">CAC may effectively risk stratify </text>
<text top="475" left="880" width="161" height="20" font="0">women who are classified as </text>
<text top="493" left="880" width="134" height="20" font="0">low- to intermediate-risk </text>
<text top="510" left="880" width="179" height="20" font="0">according to FRS. In this cohort, </text>
<text top="527" left="880" width="183" height="20" font="0">women had a greater prevalence </text>
<text top="544" left="880" width="167" height="20" font="0">of CAC, an elevated mortality, </text>
<text top="561" left="880" width="182" height="20" font="0">and an increased relative hazard </text>
<text top="579" left="880" width="170" height="20" font="0">for 15-y death when compared </text>
<text top="596" left="880" width="56" height="20" font="0">with men. </text>
</page>
<page number="182" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">182 </text>
<text top="107" left="602" width="229" height="20" font="0">        100-399   2.99: (1.60-5.60; p=0.001) </text>
<text top="124" left="602" width="233" height="20" font="0">         ≥ 400      6.53 (3.50-12.21; p&lt;0.001) </text>
<text top="142" left="89" width="101" height="20" font="0">Kavousi M, et al.,  </text>
<text top="159" left="89" width="56" height="20" font="0">2016<a href="data supplement.html#241"> (92)</a> </text>
<text top="177" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27846641">27846641</a></text>
<text top="177" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27846641"> </a></text>
<text top="144" left="224" width="11" height="18" font="0">• </text>
<text top="143" left="251" width="103" height="20" font="0">Meta-analysis of 5 </text>
<text top="161" left="251" width="118" height="20" font="0">cohorts: Dallas Heart </text>
<text top="178" left="251" width="111" height="20" font="0">Study, Framingham </text>
<text top="195" left="251" width="107" height="20" font="0">Heart Study, Heinz </text>
<text top="212" left="251" width="118" height="20" font="0">Nixdorf Recall Study, </text>
<text top="229" left="251" width="137" height="20" font="0">MESA, Rotterdam Study </text>
<text top="248" left="224" width="11" height="18" font="0">• </text>
<text top="248" left="251" width="130" height="20" font="0">To assess the potential </text>
<text top="265" left="251" width="132" height="20" font="0">utility of CAC testing for </text>
<text top="282" left="251" width="135" height="20" font="0">CVD risk estimation and </text>
<text top="299" left="251" width="132" height="20" font="0">stratification among low-</text>
<text top="316" left="251" width="66" height="20" font="0">risk women </text>
<text top="335" left="224" width="11" height="18" font="0">• </text>
<text top="335" left="251" width="132" height="20" font="0">6739 women mean age </text>
<text top="352" left="251" width="57" height="20" font="0">44 to 63 y </text>
<text top="142" left="406" width="95" height="20" font="0">Inclusion Criteria </text>
<text top="161" left="406" width="11" height="18" font="0">• </text>
<text top="161" left="433" width="132" height="20" font="0">Availability of CAC data </text>
<text top="180" left="406" width="11" height="18" font="0">• </text>
<text top="179" left="433" width="144" height="20" font="0">Women with 10-y ASCVD </text>
<text top="196" left="433" width="65" height="20" font="0">risk &lt; 7.5% </text>
<text top="213" left="406" width="3" height="20" font="0"> </text>
<text top="230" left="406" width="99" height="20" font="0">Exclusion Criteria </text>
<text top="249" left="406" width="11" height="18" font="0">• </text>
<text top="249" left="433" width="137" height="20" font="0">Previous history of CAD, </text>
<text top="266" left="433" width="122" height="20" font="0">stroke, chronic kidney </text>
<text top="283" left="433" width="46" height="20" font="0">disease </text>
<text top="302" left="406" width="11" height="18" font="0">• </text>
<text top="301" left="433" width="118" height="20" font="0">Treatment with statin </text>
<text top="320" left="406" width="11" height="18" font="0">• </text>
<text top="320" left="433" width="116" height="20" font="0">LDL-C ≥ 190 mg/dL  </text>
<text top="339" left="406" width="11" height="18" font="0">• </text>
<text top="338" left="433" width="75" height="20" font="0">&gt; 79 y of age </text>
<text top="142" left="602" width="237" height="20" font="0">Incident ASCVD (composite of nonfatal MI, </text>
<text top="159" left="602" width="146" height="20" font="0">death due to CHD, stroke) </text>
<text top="178" left="602" width="11" height="18" font="0">• </text>
<text top="178" left="629" width="222" height="20" font="0">CAC was present (CAC &gt; 0) in 36.1% of </text>
<text top="195" left="629" width="104" height="20" font="0">all low-risk women </text>
<text top="214" left="602" width="11" height="18" font="0">• </text>
<text top="213" left="629" width="235" height="20" font="0">165 ASCVD events occurred in 7.0 to 11.6 </text>
<text top="230" left="629" width="219" height="20" font="0">y follow-up (total ASCVD incidence rate </text>
<text top="247" left="629" width="158" height="20" font="0">1.5 to 6.0 per 1000 person-y </text>
<text top="267" left="602" width="11" height="18" font="0">• </text>
<text top="266" left="629" width="220" height="20" font="0">CAC presence = ASCVD incidence rate </text>
<text top="283" left="629" width="229" height="20" font="0">4.33 per 1000 person-y vs. CAC absence </text>
<text top="300" left="629" width="216" height="20" font="0">= ASCVD incidence rate 1.41 per 1000 </text>
<text top="318" left="629" width="219" height="20" font="0">person-y (difference 2.92; 95% CI: 2.02-</text>
<text top="335" left="629" width="31" height="20" font="0">3.83) </text>
<text top="354" left="602" width="11" height="18" font="0">• </text>
<text top="353" left="629" width="212" height="20" font="0">HR for CAC &gt; 100 vs. CAC absence = </text>
<text top="370" left="629" width="211" height="20" font="0">4.02; 95% CI: 2.61-6.19 (fixed effects) </text>
<text top="389" left="602" width="11" height="18" font="0">• </text>
<text top="388" left="629" width="219" height="20" font="0">Addition of CAC to the base model (risk </text>
<text top="406" left="629" width="201" height="20" font="0">factors from pooled cohort equation) </text>
<text top="423" left="629" width="236" height="20" font="0">resulted in an increase in C statistic in all 5 </text>
<text top="440" left="629" width="229" height="20" font="0">cohorts (overall C statistic increased from </text>
<text top="457" left="629" width="228" height="20" font="0">0.73; 95% CI: 0.69-0.77, to 0.77; 95% CI: </text>
<text top="474" left="629" width="55" height="20" font="0">0.74-0.81 </text>
<text top="142" left="880" width="153" height="20" font="0">CAC was present in a large </text>
<text top="159" left="880" width="178" height="20" font="0">proportion of women with a 10-y </text>
<text top="177" left="880" width="157" height="20" font="0">risk &lt; 7.5%. The hazard of a </text>
<text top="194" left="880" width="179" height="20" font="0">woman having an ASCVD event </text>
<text top="211" left="880" width="150" height="20" font="0">was higher when CAC was </text>
<text top="228" left="880" width="185" height="20" font="0">present. CAC has the potential to </text>
<text top="246" left="880" width="180" height="20" font="0">further risk stratify asymptomatic </text>
<text top="263" left="880" width="166" height="20" font="0">women categorized as having </text>
<text top="280" left="880" width="124" height="20" font="0">low 10-y ASCVD risk.  </text>
<text top="492" left="89" width="107" height="20" font="0">Nakanishi R, et al., </text>
<text top="510" left="89" width="63" height="20" font="0">2016<a href="data supplement.html#248"> (207)</a> </text>
<text top="527" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26705490">26705490</a></text>
<text top="527" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26705490"> </a></text>
<text top="494" left="224" width="11" height="18" font="0">• </text>
<text top="494" left="251" width="138" height="20" font="0">Prospective cohort study </text>
<text top="511" left="251" width="84" height="20" font="0">to examine the </text>
<text top="528" left="251" width="116" height="20" font="0">relationship between </text>
<text top="545" left="251" width="106" height="20" font="0">CAC and all-cause </text>
<text top="562" left="251" width="110" height="20" font="0">mortality, used as a </text>
<text top="579" left="251" width="130" height="20" font="0">proxy for CVD risk, in a </text>
<text top="597" left="251" width="117" height="20" font="0">cohort with a median </text>
<text top="614" left="251" width="139" height="20" font="0">follow-up of at least 10 y. </text>
<text top="633" left="224" width="11" height="18" font="0">• </text>
<text top="632" left="251" width="141" height="20" font="0">13,092 participants, 4379 </text>
<text top="649" left="251" width="133" height="20" font="0">women, mean age 58 ± </text>
<text top="667" left="251" width="27" height="20" font="0">11 y </text>
<text top="492" left="406" width="95" height="20" font="0">Inclusion Criteria </text>
<text top="511" left="406" width="11" height="18" font="0">• </text>
<text top="511" left="433" width="87" height="20" font="0">No known CAD </text>
<text top="530" left="406" width="11" height="18" font="0">• </text>
<text top="529" left="433" width="138" height="20" font="0">Referred for a CAC scan </text>
<text top="546" left="406" width="3" height="20" font="0"> </text>
<text top="563" left="406" width="99" height="20" font="0">Exclusion Criteria </text>
<text top="582" left="406" width="11" height="18" font="0">• </text>
<text top="582" left="433" width="63" height="20" font="0">Age &lt; 20 y </text>
<text top="600" left="406" width="11" height="18" font="0">• </text>
<text top="600" left="433" width="62" height="20" font="0">Chest pain </text>
<text top="619" left="406" width="11" height="18" font="0">• </text>
<text top="618" left="433" width="98" height="20" font="0">Prior known CVD </text>
<text top="637" left="406" width="11" height="18" font="0">• </text>
<text top="636" left="433" width="116" height="20" font="0">Follow-up of ≤ 365 d </text>
<text top="492" left="602" width="104" height="20" font="0">All-cause mortality </text>
<text top="511" left="602" width="11" height="18" font="0">• </text>
<text top="511" left="629" width="209" height="20" font="0">Compared to men, women were older </text>
<text top="528" left="629" width="232" height="20" font="0">(58.7 ± 11.3 vs. 57.7 ± 11.5 y, p=0.0001). </text>
<text top="547" left="602" width="11" height="18" font="0">• </text>
<text top="546" left="629" width="204" height="20" font="0">Women had a greater number of risk </text>
<text top="563" left="629" width="200" height="20" font="0">factors (1.77 ± 0.99 vs. 1.64 ± 1.01, </text>
<text top="580" left="629" width="63" height="20" font="0">p=0.0001). </text>
<text top="600" left="602" width="11" height="18" font="0">• </text>
<text top="599" left="629" width="210" height="20" font="0">Compared to women, men had higher </text>
<text top="616" left="629" width="138" height="20" font="0">CAC across age groups. </text>
<text top="635" left="602" width="11" height="18" font="0">• </text>
<text top="634" left="629" width="224" height="20" font="0">Among both genders, patients with more </text>
<text top="651" left="629" width="218" height="20" font="0">risk factors had increased CAC burden. </text>
<text top="670" left="602" width="11" height="18" font="0">• </text>
<text top="670" left="629" width="229" height="20" font="0">522 (4%) died; no significant difference in </text>
<text top="687" left="629" width="220" height="20" font="0">mortality risk between men and women. </text>
<text top="706" left="602" width="11" height="18" font="0">• </text>
<text top="705" left="629" width="206" height="20" font="0">Mortality rate was low in patients with </text>
<text top="722" left="629" width="235" height="20" font="0">CAC=0 for men (1.6%) and women (1.8%) </text>
<text top="739" left="629" width="234" height="20" font="0">and increased with each CAC category for </text>
<text top="757" left="629" width="182" height="20" font="0">both men and women (p&lt;0.001). </text>
<text top="492" left="880" width="161" height="20" font="0">Increasing CAC was strongly </text>
<text top="510" left="880" width="172" height="20" font="0">associated with increased long-</text>
<text top="527" left="880" width="174" height="20" font="0">term mortality risk in young and </text>
<text top="544" left="880" width="169" height="20" font="0">middle-aged men and women. </text>
<text top="561" left="880" width="165" height="20" font="0">Long-term risk stratification of </text>
<text top="578" left="880" width="181" height="20" font="0">CAC was lower in older patients, </text>
<text top="596" left="880" width="174" height="20" font="0">however even in older patients, </text>
<text top="613" left="880" width="180" height="20" font="0">those with 0 or lower CAC had a </text>
<text top="630" left="880" width="167" height="20" font="0">lower risk of mortality than the </text>
<text top="647" left="880" width="170" height="20" font="0">general population. This was a </text>
<text top="665" left="880" width="109" height="20" font="0">single center study. </text>
</page>
<page number="183" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">183 </text>
<text top="109" left="602" width="11" height="18" font="0">• </text>
<text top="108" left="629" width="230" height="20" font="0">HR: (95% CI:) for men 45-74 y: <i>CAC 1-99</i> </text>
<text top="125" left="629" width="226" height="20" font="0">1.8 (1.1-2.8), <i>CAC 100-399</i> 2.5 (1.5-4.0), </text>
<text top="143" left="629" width="135" height="20" font="13"><i>CAC ≥ 400</i> 4.5 (2.8-7.1) </text>
<text top="162" left="602" width="11" height="18" font="0">• </text>
<text top="161" left="629" width="229" height="20" font="0">HR: (95% CI:) for women 55-74 y: <i>CAC 1-</i></text>
<text top="178" left="629" width="215" height="20" font="13"><i>99</i> 2.4 (1.2-4.8), <i>CAC 100-399</i> 3.8 (1.8-</text>
<text top="195" left="629" width="170" height="20" font="0">7.9), <i>CAC ≥ 400</i> 5.8 (2.8-12.4) </text>
<text top="214" left="602" width="11" height="18" font="0">• </text>
<text top="213" left="629" width="204" height="20" font="0">In men and women, CAC showed an </text>
<text top="231" left="629" width="187" height="20" font="0">incremental prognostic value over </text>
<text top="248" left="629" width="228" height="20" font="0">traditional risk factors alone at 15 y (men: </text>
<text top="265" left="629" width="225" height="20" font="0">AUC 0.723 vs. 0.656, p&lt;0.0001; women: </text>
<text top="282" left="629" width="183" height="20" font="0">AUC 0.690 vs. 0.624, p&lt;0.0001). </text>
<text top="300" left="89" width="39" height="20" font="7"><b>MESA </b></text>
<text top="317" left="89" width="120" height="20" font="0">Mortensen MB, et al., </text>
<text top="335" left="89" width="56" height="20" font="0">2017<a href="data supplement.html#240"> (80)</a> </text>
<text top="352" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28624395">28624395</a></text>
<text top="352" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28624395"> </a></text>
<text top="302" left="224" width="11" height="18" font="0">• </text>
<text top="301" left="251" width="138" height="20" font="0">Prospective cohort study </text>
<text top="318" left="251" width="119" height="20" font="0">to determine whether </text>
<text top="336" left="251" width="123" height="20" font="0">CAC could be used to </text>
<text top="353" left="251" width="137" height="20" font="0">optimize statin allocation </text>
<text top="370" left="251" width="120" height="20" font="0">among individuals for </text>
<text top="387" left="251" width="97" height="20" font="0">whom trial-based </text>
<text top="404" left="251" width="103" height="20" font="0">evidence supports </text>
<text top="422" left="251" width="139" height="20" font="0">efficacy of statin therapy. </text>
<text top="441" left="224" width="11" height="18" font="0">• </text>
<text top="440" left="251" width="131" height="20" font="0">5600 participants, 2965 </text>
<text top="457" left="251" width="124" height="20" font="0">women, ages 53-69 y, </text>
<text top="474" left="251" width="80" height="20" font="0">10-y follow-up </text>
<text top="300" left="406" width="95" height="20" font="0">Inclusion Criteria </text>
<text top="319" left="406" width="11" height="18" font="0">• </text>
<text top="319" left="433" width="128" height="20" font="0">Free of clinical ASCVD </text>
<text top="337" left="406" width="11" height="18" font="0">• </text>
<text top="337" left="433" width="82" height="20" font="0">45-84 y of age </text>
<text top="300" left="602" width="261" height="20" font="0">ASCVD events (MI, resuscitated cardiac arrest, </text>
<text top="317" left="602" width="109" height="20" font="0">CHD death, stroke) </text>
<text top="337" left="602" width="11" height="18" font="0">• </text>
<text top="336" left="629" width="232" height="20" font="0">1929 women (65%) were eligible for statin </text>
<text top="353" left="629" width="144" height="20" font="0">therapy based on 7 RCTs </text>
<text top="372" left="602" width="11" height="18" font="0">• </text>
<text top="371" left="629" width="206" height="20" font="0">Of statin eligible women, 54% had no </text>
<text top="388" left="629" width="228" height="20" font="0">CAC, 27% had CAC score of 1-100, 20% </text>
<text top="406" left="629" width="121" height="20" font="0">had CAC score &gt; 100 </text>
<text top="425" left="602" width="11" height="18" font="0">• </text>
<text top="424" left="629" width="222" height="20" font="0">Event rate per 1000 person-y in women: </text>
<text top="441" left="629" width="236" height="20" font="0">CAC=0, 3.77 (2.72-5.23); CAC 1-100, 9.37 </text>
<text top="458" left="629" width="214" height="20" font="0">(6.95-12.63); CAC &gt; 100, 17.89 (13.74-</text>
<text top="475" left="629" width="38" height="20" font="0">23.31) </text>
<text top="494" left="602" width="11" height="18" font="0">• </text>
<text top="494" left="629" width="238" height="20" font="0">HR: for ASCVD event when CAC &gt; 100 vs. </text>
<text top="511" left="629" width="164" height="20" font="0">0 in women: 4.99 (3.27-7.62)  </text>
<text top="300" left="880" width="131" height="20" font="0">CAC=0 at baseline was </text>
<text top="317" left="880" width="155" height="20" font="0">associated with low ASCVD </text>
<text top="335" left="880" width="165" height="20" font="0">event rates for at least 10 y in </text>
<text top="352" left="880" width="160" height="20" font="0">women, whereas CAC &gt; 100 </text>
<text top="369" left="880" width="183" height="20" font="0">was associated with a high event </text>
<text top="386" left="880" width="178" height="20" font="0">rate. Since evidence from RCTs </text>
<text top="404" left="880" width="181" height="20" font="0">supports primary prevention with </text>
<text top="421" left="880" width="175" height="20" font="0">statins in nearly all women &gt; 55 </text>
<text top="438" left="880" width="182" height="20" font="0">y of age, and over half of women </text>
<text top="455" left="880" width="177" height="20" font="0">eligible for statin therapy have a </text>
<text top="472" left="880" width="176" height="20" font="0">CAC score of 0 and a low event </text>
<text top="490" left="880" width="167" height="20" font="0">rate, having a CAC score may </text>
<text top="507" left="880" width="164" height="20" font="0">help patients and providers in </text>
<text top="524" left="880" width="133" height="20" font="0">shared decision-making </text>
<text top="541" left="880" width="179" height="20" font="0">regarding treatment with statins. </text>
<text top="559" left="89" width="103" height="20" font="7"><b>FHS, MESA, CHS </b></text>
<text top="576" left="89" width="84" height="20" font="0">Yano Y, et al.,  </text>
<text top="594" left="89" width="63" height="20" font="0">2017<a href="data supplement.html#248"> (208)</a> </text>
<text top="611" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28746709">28746709</a></text>
<text top="611" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28746709"> </a></text>
<text top="561" left="224" width="11" height="18" font="0">• </text>
<text top="560" left="251" width="138" height="20" font="0">Prospective cohort study </text>
<text top="577" left="251" width="128" height="20" font="0">using pooled individual </text>
<text top="595" left="251" width="126" height="20" font="0">participant data from 3 </text>
<text top="612" left="251" width="141" height="20" font="0">US cohorts (FHS, MESA, </text>
<text top="629" left="251" width="114" height="20" font="0">CHS), examined the </text>
<text top="646" left="251" width="134" height="20" font="0">predictive ability of CAC </text>
<text top="663" left="251" width="94" height="20" font="0">score vs. age for </text>
<text top="681" left="251" width="131" height="20" font="0">ASCVD, including CHD </text>
<text top="698" left="251" width="64" height="20" font="0">and stroke. </text>
<text top="717" left="224" width="11" height="18" font="0">• </text>
<text top="716" left="251" width="131" height="20" font="0">4778 participants, 2582 </text>
<text top="733" left="251" width="116" height="20" font="0">women, aged ≥ 60 y </text>
<text top="559" left="406" width="95" height="20" font="0">Inclusion Criteria </text>
<text top="578" left="406" width="11" height="18" font="0">• </text>
<text top="577" left="433" width="122" height="20" font="0">Adults older than 60 y </text>
<text top="596" left="406" width="11" height="18" font="0">• </text>
<text top="596" left="433" width="127" height="20" font="0">Without known CVD at </text>
<text top="613" left="433" width="49" height="20" font="0">baseline </text>
<text top="632" left="406" width="11" height="18" font="0">• </text>
<text top="631" left="433" width="147" height="20" font="0">Participant in FHS, MESA, </text>
<text top="648" left="433" width="44" height="20" font="0">or CHS </text>
<text top="665" left="406" width="3" height="20" font="0"> </text>
<text top="683" left="406" width="103" height="20" font="0">Exclusion Criteria: </text>
<text top="702" left="406" width="11" height="18" font="0">• </text>
<text top="701" left="433" width="142" height="20" font="0">Younger than 60 y of age </text>
<text top="720" left="406" width="11" height="18" font="0">• </text>
<text top="719" left="433" width="129" height="20" font="0">Known CHD, stroke, or </text>
<text top="736" left="433" width="131" height="20" font="0">heart failure at baseline </text>
<text top="559" left="602" width="238" height="20" font="0">Incident ASCVD during follow-up, including </text>
<text top="576" left="602" width="91" height="20" font="0">CHD and stroke </text>
<text top="595" left="602" width="11" height="18" font="0">• </text>
<text top="595" left="629" width="228" height="20" font="0">598 ASCVD events during median 10.7 y </text>
<text top="612" left="629" width="53" height="20" font="0">follow-up </text>
<text top="631" left="602" width="11" height="18" font="0">• </text>
<text top="630" left="629" width="226" height="20" font="0">Event rates increased across CAC strata </text>
<text top="649" left="602" width="11" height="18" font="0">• </text>
<text top="648" left="629" width="228" height="20" font="0">11% of ASCVD events (8% of CHD, 16% </text>
<text top="665" left="629" width="220" height="20" font="0">of stroke) occurred with CAC=0; 42% of </text>
<text top="683" left="629" width="206" height="20" font="0">ASCVD events (45% of CHD, 38% of </text>
<text top="700" left="629" width="183" height="20" font="0">stroke) occurred with CAC ≥ 300 </text>
<text top="719" left="602" width="11" height="18" font="0">• </text>
<text top="718" left="629" width="237" height="20" font="0">CAC score vs. age had greater association </text>
<text top="735" left="629" width="219" height="20" font="0">with incident CHD (C statistic, 0.733 vs. </text>
<text top="753" left="629" width="234" height="20" font="0">0.690; C statistics difference, +0.043; 95% </text>
<text top="770" left="629" width="223" height="20" font="0">CI: 0.009-0.075) and modestly improved </text>
<text top="787" left="629" width="111" height="20" font="0">prediction of stroke. </text>
<text top="559" left="880" width="162" height="20" font="0">In older adults without known </text>
<text top="576" left="880" width="152" height="20" font="0">CVD, CAC score instead of </text>
<text top="594" left="880" width="150" height="20" font="0">chronological age provided </text>
<text top="611" left="880" width="177" height="20" font="0">better discrimination for incident </text>
<text top="628" left="880" width="185" height="20" font="0">ASCVD, especially CHD, over an </text>
<text top="645" left="880" width="156" height="20" font="0">11-y follow-up period. When </text>
<text top="662" left="880" width="179" height="20" font="0">deciding to initiate statin therapy </text>
<text top="680" left="880" width="180" height="20" font="0">for primary prevention, obtaining </text>
<text top="697" left="880" width="147" height="20" font="0">a CAC score may assist in </text>
<text top="714" left="880" width="151" height="20" font="0">shared decision-making for </text>
<text top="731" left="880" width="126" height="20" font="0">patients ≥ 60 y of age. </text>
</page>
<page number="184" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">184 </text>
<text top="109" left="602" width="11" height="18" font="0">• </text>
<text top="108" left="629" width="228" height="20" font="0">Cox analysis including CAC score and all </text>
<text top="125" left="629" width="180" height="20" font="0">risk factors including age and an </text>
<text top="143" left="629" width="224" height="20" font="0">interaction term suggested no significant </text>
<text top="160" left="629" width="223" height="20" font="0">interaction between CAC score and sex. </text>
<text top="177" left="629" width="230" height="20" font="0">Sex-specific C statistics analyses showed </text>
<text top="194" left="629" width="82" height="20" font="0">similar results. </text>
<text top="212" left="89" width="120" height="20" font="0">Catov JM et al., 2007 </text>
<text top="229" left="89" width="32" height="20" font="0"><a href="data supplement.html#248">(209)</a> </text>
<text top="247" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17917602">17917602</a></text>
<text top="247" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17917602"> </a></text>
<text top="264" left="89" width="7" height="20" font="0">  </text>
<text top="212" left="224" width="165" height="20" font="7"><b>Study type:</b>   Cross-sectional </text>
<text top="229" left="224" width="56" height="20" font="0">sub study </text>
<text top="247" left="224" width="3" height="20" font="0"> </text>
<text top="264" left="224" width="145" height="20" font="7"><b>Size:</b>    446 women in this </text>
<text top="281" left="224" width="48" height="20" font="0">analysis </text>
<text top="212" left="406" width="170" height="20" font="7"><b>Inclusion criteria:</b>  Age 70-79 </text>
<text top="229" left="406" width="174" height="20" font="0">years, self-report of no difficulty </text>
<text top="247" left="406" width="152" height="20" font="0">walking one-quarter mile or </text>
<text top="264" left="406" width="141" height="20" font="0">climbing 10 steps without </text>
<text top="281" left="406" width="171" height="20" font="0">resting, no difficulty performing </text>
<text top="298" left="406" width="177" height="20" font="0">basic activities of daily living, no </text>
<text top="315" left="406" width="146" height="20" font="0">use of assistive devices to </text>
<text top="333" left="406" width="163" height="20" font="0">ambulate, no history of active </text>
<text top="350" left="406" width="174" height="20" font="0">treatment for cancer in the past </text>
<text top="367" left="406" width="178" height="20" font="0">3 years, no plans to move out of </text>
<text top="384" left="406" width="159" height="20" font="0">the area in the subsequent 3 </text>
<text top="401" left="406" width="37" height="20" font="0">years. </text>
<text top="419" left="406" width="3" height="20" font="0"> </text>
<text top="436" left="406" width="146" height="20" font="7"><b>Exclusion criteria:</b>  None </text>
<text top="453" left="406" width="52" height="20" font="0">specified </text>
<text top="213" left="602" width="219" height="20" font="7"><b>1</b>°<b> endpoint:</b>  CVD status at the time of </text>
<text top="230" left="602" width="52" height="20" font="0">interview </text>
<text top="248" left="602" width="3" height="20" font="0"> </text>
<text top="265" left="602" width="59" height="20" font="7"><b>Results:</b>   </text>
<text top="284" left="629" width="11" height="18" font="0">• </text>
<text top="283" left="656" width="194" height="20" font="0">6% of women reported delivering a </text>
<text top="300" left="656" width="174" height="20" font="0">preterm infant and 9% reported </text>
<text top="318" left="656" width="189" height="20" font="0">having a term infant weighing less </text>
<text top="335" left="656" width="72" height="20" font="0">than 2500 g. </text>
<text top="354" left="629" width="11" height="18" font="0">• </text>
<text top="353" left="656" width="180" height="20" font="0">Compared with delivering a term </text>
<text top="370" left="656" width="192" height="20" font="0">infant ≥ 2500 g, a preterm delivery </text>
<text top="387" left="656" width="161" height="20" font="0">was associated with a higher </text>
<text top="405" left="656" width="207" height="20" font="0">prevalence of CVD (OR 2.05; 95% CI </text>
<text top="422" left="656" width="187" height="20" font="0">0.93-4.52); adjusted OR was 2.85 </text>
<text top="439" left="656" width="107" height="20" font="0">(95% CI 1.10-6.85) </text>
<text top="458" left="629" width="11" height="18" font="0">• </text>
<text top="457" left="656" width="199" height="20" font="0">Delivery of a small term infant -- OR </text>
<text top="475" left="656" width="148" height="20" font="0">of CVD of 1.33 (0.66-2.70) </text>
<text top="493" left="629" width="11" height="18" font="0">• </text>
<text top="493" left="656" width="193" height="20" font="0">Delivery of a preterm and &lt; 2500 g </text>
<text top="510" left="656" width="203" height="20" font="0">infant – OR of CVD 2.55 (0.99-6.60); </text>
<text top="527" left="656" width="170" height="20" font="0">adjusted OR 3.31 (1.06-10.37) </text>
<text top="214" left="880" width="7" height="18" font="0">•</text>
<text top="213" left="887" width="177" height="20" font="0">Women who reported delivering </text>
<text top="230" left="880" width="148" height="20" font="0">a preterm first birth had an </text>
<text top="248" left="880" width="163" height="20" font="0">increased prevalence of CVD </text>
<text top="265" left="880" width="183" height="20" font="0">after adjusting for demographics, </text>
<text top="282" left="880" width="108" height="20" font="0">smoking, and other </text>
<text top="299" left="880" width="149" height="20" font="0">cardiovascular risk factors. </text>
<text top="318" left="880" width="7" height="18" font="0">•</text>
<text top="318" left="887" width="141" height="20" font="0">This effect was greater in </text>
<text top="335" left="880" width="182" height="20" font="0">women who delivered both small </text>
<text top="352" left="880" width="162" height="20" font="0">and preterm infants.  Authors </text>
<text top="369" left="880" width="154" height="20" font="0">suggest that earlier preterm </text>
<text top="387" left="880" width="159" height="20" font="0">delivery or preterm birth with </text>
<text top="404" left="880" width="180" height="20" font="0">growth restriction are associated </text>
<text top="421" left="880" width="133" height="20" font="0">with a greater CVD risk. </text>
<text top="440" left="880" width="7" height="18" font="0">•</text>
<text top="439" left="887" width="148" height="20" font="0">These results suggest that </text>
<text top="456" left="880" width="165" height="20" font="0">women who deliver a preterm </text>
<text top="474" left="880" width="159" height="20" font="0">infant may benefit from early </text>
<text top="491" left="880" width="132" height="20" font="0">CVD risk screening and </text>
<text top="508" left="880" width="77" height="20" font="0">intervention.   </text>
<text top="525" left="880" width="3" height="20" font="0"> </text>
<text top="545" left="89" width="96" height="20" font="0">Grandi SM et al., </text>
<text top="562" left="89" width="63" height="20" font="0">2017 <a href="data supplement.html#248">(210)</a> </text>
<text top="580" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28816365">28816365</a></text>
<text top="580" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28816365"> </a></text>
<text top="597" left="89" width="7" height="20" font="0">  </text>
<text top="545" left="224" width="139" height="20" font="7"><b>Study type:</b>   Population-</text>
<text top="562" left="224" width="167" height="20" font="0">based cohort study using data </text>
<text top="580" left="224" width="141" height="20" font="0">extracted from the United </text>
<text top="597" left="224" width="152" height="20" font="0">Kingdom’s Clinical Practice </text>
<text top="614" left="224" width="104" height="20" font="0">Research Datalink </text>
<text top="631" left="224" width="3" height="20" font="0"> </text>
<text top="648" left="224" width="137" height="20" font="7"><b>Size:</b>    146,748 women  </text>
<text top="545" left="406" width="155" height="20" font="7"><b>Inclusion criteria:</b>  Women </text>
<text top="562" left="406" width="183" height="20" font="0">between 15 and 45 years of age; </text>
<text top="580" left="406" width="171" height="20" font="0">first recorded delivery between </text>
<text top="597" left="406" width="169" height="20" font="0">January, 1990 and December, </text>
<text top="614" left="406" width="31" height="20" font="0">2013 </text>
<text top="631" left="406" width="3" height="20" font="0"> </text>
<text top="648" left="406" width="180" height="20" font="7"><b>Exclusion criteria:</b>  Record of a </text>
<text top="666" left="406" width="168" height="20" font="0">previous delivery; diagnosis of </text>
<text top="683" left="406" width="167" height="20" font="0">hypertension before 18 weeks </text>
<text top="700" left="406" width="179" height="20" font="0">gestation for the first pregnancy; </text>
<text top="717" left="406" width="132" height="20" font="0">history of CVD; had ≥ 2 </text>
<text top="734" left="406" width="174" height="20" font="0">measures of SBP ≥ 140 mmHg </text>
<text top="752" left="406" width="170" height="20" font="0">or DBP ≥ 90 mmHg prior to 18 </text>
<text top="769" left="406" width="158" height="20" font="0">weeks gestation; had a DBP </text>
<text top="786" left="406" width="169" height="20" font="0">≥110 mmHg prior to 18 weeks </text>
<text top="546" left="602" width="257" height="20" font="7"><b>1</b>°<b> endpoint:</b>  Incident CVD – any diagnosis of </text>
<text top="564" left="602" width="226" height="20" font="0">cerebrovascular disease, coronary artery </text>
<text top="581" left="602" width="262" height="20" font="0">disease, coronary revascularization, myocardial </text>
<text top="598" left="602" width="256" height="20" font="0">infarction, peripheral arterial disease, transient </text>
<text top="615" left="602" width="128" height="20" font="0">ischemic attack, stroke </text>
<text top="632" left="602" width="3" height="20" font="0"> </text>
<text top="650" left="602" width="59" height="20" font="7"><b>Results:</b>   </text>
<text top="669" left="629" width="11" height="18" font="0">• </text>
<text top="668" left="656" width="161" height="20" font="0">1.8% (6433 women) had one </text>
<text top="685" left="656" width="198" height="20" font="0">pregnancy affected by hypertensive </text>
<text top="702" left="656" width="166" height="20" font="0">disorders of pregnancy (HDP) </text>
<text top="721" left="629" width="11" height="18" font="0">• </text>
<text top="721" left="656" width="204" height="20" font="0">997 women had incident CVD during </text>
<text top="738" left="656" width="189" height="20" font="0">902,897 person-years of follow-up </text>
<text top="757" left="629" width="11" height="18" font="0">• </text>
<text top="756" left="656" width="153" height="20" font="0">In women with HDP, rate of </text>
<text top="773" left="656" width="193" height="20" font="0">subsequent CVD was 2-fold higher </text>
<text top="547" left="880" width="7" height="18" font="0">•</text>
<text top="546" left="887" width="172" height="20" font="0">Women who experienced HDP </text>
<text top="564" left="880" width="146" height="20" font="0">had an approximate 2-fold </text>
<text top="581" left="880" width="170" height="20" font="0">increased rate of incident CVD </text>
<text top="598" left="880" width="163" height="20" font="0">and a 5-fold increased rate of </text>
<text top="615" left="880" width="77" height="20" font="0">hypertension. </text>
<text top="634" left="880" width="7" height="18" font="0">•</text>
<text top="634" left="887" width="152" height="20" font="0">As a result of a higher CVD </text>
<text top="651" left="880" width="150" height="20" font="0">risk, women with HDP may </text>
<text top="668" left="880" width="178" height="20" font="0">warrant a close long-term follow-</text>
<text top="685" left="880" width="122" height="20" font="0">up for early risk factor </text>
<text top="702" left="880" width="174" height="20" font="0">identification and management. </text>
<text top="720" left="880" width="3" height="20" font="0"> </text>
<text top="737" left="880" width="3" height="20" font="0"> </text>
</page>
<page number="185" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">185 </text>
<text top="107" left="406" width="163" height="20" font="0">gestation; younger than 15 or </text>
<text top="124" left="406" width="146" height="20" font="0">older than 45 years at first </text>
<text top="141" left="406" width="135" height="20" font="0">pregnancy; used an anti-</text>
<text top="159" left="406" width="174" height="20" font="0">hypertensive medication before </text>
<text top="176" left="406" width="109" height="20" font="0">18 weeks gestation </text>
<text top="107" left="656" width="208" height="20" font="0">than in women with no history of HDP </text>
<text top="124" left="656" width="141" height="20" font="0">(HR 2.2, 95% CI 1.7, 2.7) </text>
<text top="143" left="629" width="11" height="18" font="0">• </text>
<text top="143" left="656" width="163" height="20" font="0">In women with a HDP, rate of </text>
<text top="160" left="656" width="180" height="20" font="0">hypertension was 5 times that of </text>
<text top="177" left="656" width="208" height="20" font="0">women without HDP (HR 5.6, 95% CI </text>
<text top="194" left="656" width="49" height="20" font="0">5.1, 6.3) </text>
<text top="213" left="629" width="11" height="18" font="0">• </text>
<text top="213" left="656" width="190" height="20" font="0">In the time-fixed analyses for CVD </text>
<text top="230" left="656" width="166" height="20" font="0">and hypertension, none of the </text>
<text top="247" left="656" width="199" height="20" font="0">potential confounders were found to </text>
<text top="264" left="656" width="203" height="20" font="0">change the point estimate more than </text>
<text top="281" left="656" width="28" height="20" font="0">10% </text>
<text top="304" left="602" width="4" height="13" font="0"> </text>
<text top="316" left="89" width="111" height="20" font="0">Shostrom DC et al., </text>
<text top="334" left="89" width="63" height="20" font="0">2017 <a href="data supplement.html#248">(211)</a> </text>
<text top="351" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28694789">28694789</a></text>
<text top="351" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28694789"> </a></text>
<text top="368" left="89" width="3" height="20" font="7"><b> </b></text>
<text top="316" left="224" width="139" height="20" font="7"><b>Study type:</b>   Population-</text>
<text top="334" left="224" width="165" height="20" font="0">based cross-sectional survey: </text>
<text top="351" left="224" width="55" height="20" font="0">NHANES </text>
<text top="368" left="224" width="3" height="20" font="0"> </text>
<text top="385" left="224" width="117" height="20" font="7"><b>Size:</b>    8127 women </text>
<text top="316" left="406" width="157" height="20" font="7"><b>Inclusion criteria:</b>  Female, </text>
<text top="334" left="406" width="158" height="20" font="0">aged 20 years or older, prior </text>
<text top="351" left="406" width="114" height="20" font="0">history of pregnancy </text>
<text top="368" left="406" width="3" height="20" font="0"> </text>
<text top="385" left="406" width="175" height="20" font="7"><b>Exclusion criteria:</b>  Individuals </text>
<text top="402" left="406" width="154" height="20" font="0">who reported a diagnosis of </text>
<text top="420" left="406" width="176" height="20" font="0">CVD or diabetes present before </text>
<text top="437" left="406" width="149" height="20" font="0">or during the same time as </text>
<text top="454" left="406" width="182" height="20" font="0">diagnosis of gestational diabetes </text>
<text top="471" left="406" width="41" height="20" font="0">(GDM) </text>
<text top="317" left="602" width="222" height="20" font="7"><b>1</b>°<b> endpoint:</b>  CVD, self-reported during </text>
<text top="335" left="602" width="241" height="20" font="0">interview: congestive heart failure, coronary </text>
<text top="352" left="602" width="233" height="20" font="0">heart disease, angina, heart attack, stroke </text>
<text top="369" left="602" width="3" height="20" font="0"> </text>
<text top="386" left="602" width="59" height="20" font="7"><b>Results:</b>   </text>
<text top="405" left="629" width="11" height="18" font="0">• </text>
<text top="405" left="656" width="198" height="20" font="0">787 women developed CVD among </text>
<text top="422" left="656" width="180" height="20" font="0">7572 women without a history of </text>
<text top="439" left="656" width="185" height="20" font="0">GDM; 42 women developed CVD </text>
<text top="456" left="656" width="197" height="20" font="0">among 555 women with a history of </text>
<text top="474" left="656" width="32" height="20" font="0">GDM </text>
<text top="493" left="629" width="11" height="18" font="0">• </text>
<text top="492" left="656" width="210" height="20" font="0">Compared to women without a history </text>
<text top="509" left="656" width="181" height="20" font="0">of GDM, women with a history of </text>
<text top="526" left="656" width="182" height="20" font="0">GDM were more lifely to develop </text>
<text top="543" left="656" width="209" height="20" font="0">CVD (multivariable-adjusted OR 1.63, </text>
<text top="561" left="656" width="204" height="20" font="0">95% CI 1.02, 2.62).  <i>Association was </i></text>
<text top="578" left="656" width="157" height="20" font="13"><i>attenuated and became non-</i></text>
<text top="595" left="656" width="196" height="20" font="13"><i>significant after adjustment for BMI. </i></text>
<text top="618" left="602" width="4" height="13" font="0"> </text>
<text top="318" left="880" width="7" height="18" font="0">•</text>
<text top="317" left="887" width="167" height="20" font="0">Women with a history of GDM </text>
<text top="335" left="880" width="176" height="20" font="0">are at greater risk of developing </text>
<text top="352" left="880" width="159" height="20" font="0">CVD later in life than women </text>
<text top="369" left="880" width="141" height="20" font="0">without a history of GDM, </text>
<text top="386" left="880" width="181" height="20" font="0">however this association may be </text>
<text top="404" left="880" width="146" height="20" font="0">explained, in part, by BMI. </text>
<text top="423" left="880" width="7" height="18" font="0">•</text>
<text top="422" left="887" width="170" height="20" font="0">Targeted interventions may be </text>
<text top="439" left="880" width="180" height="20" font="0">implemented to reduce CVD risk </text>
<text top="456" left="880" width="181" height="20" font="0">at a young age for women with a </text>
<text top="474" left="880" width="89" height="20" font="0">history of GDM. </text>
<text top="493" left="880" width="7" height="18" font="0">•</text>
<text top="492" left="887" width="3" height="20" font="0"> </text>
<text top="511" left="880" width="7" height="18" font="0">•</text>
<text top="510" left="887" width="3" height="20" font="0"> </text>
<text top="630" left="81" width="3" height="20" font="7"><b> </b></text>
<text top="647" left="81" width="1008" height="20" font="7"><b>Abbreviations: </b>ASCVD, atherosclerotic cardiovascular disease; AUC, area under the curve; CAC, coronary artery calcium; CAD, coronary artery disease; CHD, coronary heart disease; </text>
<text top="665" left="81" width="981" height="20" font="0">CHS, Cardiovascular Health Study; CI, confidence interval; CT, computed tomography; CVD, cardiovascular disease; DM, diabetes mellitus; EBT, electron beam tomography; FHS, </text>
<text top="682" left="81" width="1019" height="20" font="0">Framingham Heart Study; FRS, Framingham Risk Score; HR, hazard ratio; HTN, hypertension; IMT, intima-media thickness; LDL-C, low density lipoprotein cholesterol; LV, left ventricular; </text>
<text top="699" left="81" width="811" height="20" font="0">MDCT, multidetector computed tomography; MESA, Multi-Ethnic Study of Atherosclerosis; person-y, person-years; RCT, randomized controlled trial. </text>
<text top="716" left="81" width="3" height="20" font="0"> </text>
<text top="740" left="81" width="5" height="16" font="15"> </text>
<text top="760" left="81" width="5" height="16" font="15"> </text>
<text top="781" left="81" width="5" height="16" font="15"> </text>
</page>
<page number="186" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">186 </text>
<text top="106" left="81" width="409" height="24" font="4"><b>Data Supplement 35. CAC to guide therapy (Section 4.5.3) </b></text>
<text top="133" left="81" width="5" height="16" font="15"> </text>
<text top="756" left="81" width="5" height="16" font="15"> </text>
<text top="776" left="81" width="5" height="16" font="15"> </text>
<text top="162" left="118" width="38" height="20" font="7"><b>Study </b></text>
<text top="179" left="106" width="61" height="20" font="7"><b>Acronym; </b></text>
<text top="197" left="113" width="48" height="20" font="7"><b>Author; </b></text>
<text top="214" left="91" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="162" left="244" width="83" height="20" font="7"><b>Aim of Study; </b></text>
<text top="179" left="248" width="74" height="20" font="7"><b>Study Type; </b></text>
<text top="197" left="242" width="86" height="20" font="7"><b>Study Size (N) </b></text>
<text top="162" left="388" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="162" left="533" width="126" height="20" font="7"><b>Study Intervention (# </b></text>
<text top="179" left="550" width="92" height="20" font="7"><b>patients)/Study </b></text>
<text top="197" left="527" width="137" height="20" font="7"><b>comparator (#patients) </b></text>
<text top="162" left="846" width="105" height="20" font="7"><b>Endpoint Results </b></text>
<text top="179" left="734" width="329" height="20" font="7"><b>(Absolute Event Rates, p values, OR or RR, and 95% CI) </b></text>
<text top="232" left="89" width="59" height="20" font="7"><b>BioImage </b></text>
<text top="249" left="89" width="87" height="20" font="0">Mortensen MB, </text>
<text top="266" left="89" width="90" height="20" font="0">et al., 2016 <a href="data supplement.html#241">(95)</a> </text>
<text top="283" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27561760">27561760</a></text>
<text top="283" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27561760"> </a></text>
<text top="232" left="197" width="34" height="20" font="7"><b>Aim:  </b></text>
<text top="249" left="197" width="173" height="20" font="0">Disease-guided reclassification </text>
<text top="266" left="197" width="3" height="20" font="0"> </text>
<text top="283" left="197" width="74" height="20" font="7"><b>Study Type: </b></text>
<text top="301" left="197" width="143" height="20" font="0">prospective observational </text>
<text top="318" left="197" width="41" height="20" font="0">cohort  </text>
<text top="335" left="197" width="3" height="20" font="0"> </text>
<text top="352" left="197" width="103" height="20" font="7"><b>Size:</b> 5,805 adults </text>
<text top="370" left="197" width="145" height="20" font="0">men and women 55–80 y; </text>
<text top="387" left="197" width="77" height="20" font="0">mean 68.9±6 </text>
<text top="404" left="197" width="170" height="20" font="0">Follow-up: median follow-up of </text>
<text top="421" left="197" width="33" height="20" font="0">2.7 y. </text>
<text top="232" left="386" width="106" height="20" font="7"><b>Inclusion criteria: </b></text>
<text top="249" left="386" width="81" height="20" font="0">without known </text>
<text top="266" left="386" width="109" height="20" font="0">ASCVD at baseline </text>
<text top="283" left="386" width="70" height="20" font="0">examination </text>
<text top="301" left="386" width="3" height="20" font="0"> </text>
<text top="232" left="514" width="78" height="20" font="7"><b>Intervention: </b></text>
<text top="249" left="514" width="159" height="20" font="0">those with an estimated 10 y </text>
<text top="266" left="514" width="68" height="20" font="0">ASCVD risk </text>
<text top="283" left="514" width="157" height="20" font="0">≥7.5% were down-classified </text>
<text top="301" left="514" width="116" height="20" font="0">from statin eligible to </text>
<text top="318" left="514" width="158" height="20" font="0">ineligible if imaging revealed </text>
<text top="335" left="514" width="43" height="20" font="0">CAC=0 </text>
<text top="352" left="514" width="3" height="20" font="0"> </text>
<text top="370" left="514" width="156" height="20" font="0">Intermediate-risk individuals </text>
<text top="387" left="514" width="130" height="20" font="0">were up-classified from </text>
<text top="404" left="514" width="152" height="20" font="0">optional to statin eligibility if </text>
<text top="421" left="514" width="90" height="20" font="0">CAC was ≥100  </text>
<text top="234" left="689" width="11" height="18" font="0">• </text>
<text top="233" left="709" width="77" height="20" font="7"><b>1° Endpoint: </b></text>
<text top="252" left="689" width="11" height="18" font="0">• </text>
<text top="251" left="709" width="389" height="20" font="0">With CAC-guided reclassification, specificity for coronary heart disease </text>
<text top="268" left="709" width="94" height="20" font="0">events improved </text>
<text top="287" left="689" width="11" height="18" font="0">• </text>
<text top="287" left="709" width="369" height="20" font="0">22% (p&lt;0.0001) without any significant loss in sensitivity, yielding a </text>
<text top="304" left="709" width="248" height="20" font="0">binary net reclassification index (NRI) of 0.20 </text>
<text top="323" left="689" width="11" height="18" font="0">• </text>
<text top="322" left="709" width="70" height="20" font="0">(p&lt;0.0001).  </text>
<text top="341" left="689" width="11" height="18" font="0">• </text>
<text top="340" left="709" width="234" height="20" font="0">CAC scores of 0 were common (32%) and </text>
<text top="359" left="689" width="11" height="18" font="0">• </text>
<text top="359" left="709" width="198" height="20" font="0">were associated with low event rate </text>
<text top="439" left="89" width="39" height="20" font="7"><b>MESA</b> </text>
<text top="456" left="89" width="84" height="20" font="0">Nasir, K, et al., </text>
<text top="474" left="89" width="56" height="20" font="0">2015 <a href="data supplement.html#240">(82)</a> </text>
<text top="491" left="89" width="58" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26449135">26449135 </a></text>
<text top="491" left="148" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26449135"> </a></text>
<text top="439" left="197" width="150" height="20" font="7"><b>Aim: </b>to determine whether </text>
<text top="456" left="197" width="152" height="20" font="0">quantification of CAC score </text>
<text top="474" left="197" width="131" height="20" font="0">may discriminate risk in </text>
<text top="491" left="197" width="173" height="20" font="0">subjects with and without statin </text>
<text top="508" left="197" width="126" height="20" font="0">indication according to </text>
<text top="525" left="197" width="117" height="20" font="0">AHA/ACC guidelines </text>
<text top="542" left="197" width="3" height="20" font="0"> </text>
<text top="560" left="197" width="74" height="20" font="7"><b>Study Type: </b></text>
<text top="577" left="197" width="164" height="20" font="0">population-based prospective </text>
<text top="594" left="197" width="66" height="20" font="0">longitudinal </text>
<text top="611" left="197" width="70" height="20" font="0">cohort study </text>
<text top="628" left="197" width="3" height="20" font="0"> </text>
<text top="646" left="197" width="171" height="20" font="7"><b>Size:</b> 4758 subjects (59±9 y of </text>
<text top="663" left="197" width="87" height="20" font="0">age, 47% men) </text>
<text top="439" left="386" width="106" height="20" font="7"><b>Inclusion criteria: </b></text>
<text top="456" left="386" width="61" height="20" font="0">MESA is a </text>
<text top="474" left="386" width="66" height="20" font="0">prospective </text>
<text top="491" left="386" width="114" height="20" font="0">observational cohort </text>
<text top="508" left="386" width="99" height="20" font="0">of 6,814 men and </text>
<text top="525" left="386" width="107" height="20" font="0">women, 45–84 y of </text>
<text top="542" left="386" width="109" height="20" font="0">age, without known </text>
<text top="560" left="386" width="107" height="20" font="0">CVD at enrollment. </text>
<text top="577" left="386" width="3" height="20" font="0"> </text>
<text top="439" left="514" width="102" height="20" font="7"><b>Intervention: </b>N/A </text>
<text top="456" left="514" width="3" height="20" font="7"><b> </b></text>
<text top="474" left="514" width="101" height="20" font="7"><b>Comparator:</b> N/A<b> </b></text>
<text top="491" left="514" width="3" height="20" font="0"> </text>
<text top="508" left="514" width="3" height="20" font="0"> </text>
<text top="525" left="514" width="3" height="20" font="0"> </text>
<text top="542" left="514" width="3" height="20" font="0"> </text>
<text top="560" left="514" width="3" height="20" font="0"> </text>
<text top="577" left="514" width="3" height="20" font="0"> </text>
<text top="594" left="514" width="3" height="20" font="0"> </text>
<text top="611" left="514" width="3" height="20" font="0"> </text>
<text top="628" left="514" width="3" height="20" font="0"> </text>
<text top="646" left="514" width="3" height="20" font="0"> </text>
<text top="663" left="514" width="3" height="20" font="0"> </text>
<text top="680" left="514" width="3" height="20" font="0"> </text>
<text top="697" left="514" width="3" height="20" font="0"> </text>
<text top="714" left="514" width="3" height="20" font="0"> </text>
<text top="732" left="514" width="3" height="20" font="0"> </text>
<text top="441" left="689" width="11" height="18" font="0">• </text>
<text top="440" left="709" width="116" height="20" font="0">A total of 247 (5.2%) </text>
<text top="459" left="689" width="11" height="18" font="0">• </text>
<text top="458" left="709" width="381" height="20" font="0">ASCVD and 155 (3.3%) hard coronary heart disease events occurred </text>
<text top="476" left="709" width="286" height="20" font="0">over a median (interquartile range) follow-up of 10.3 </text>
<text top="495" left="689" width="11" height="18" font="0">• </text>
<text top="494" left="709" width="68" height="20" font="0">9.7–10.8 y.  </text>
<text top="513" left="689" width="11" height="18" font="0">• </text>
<text top="512" left="709" width="386" height="20" font="0">The absence of CAC reclassifies approximately one-half of candidates </text>
<text top="529" left="709" width="174" height="20" font="0">as not eligible for statin therapy </text>
<text top="548" left="689" width="11" height="18" font="0">• </text>
<text top="548" left="709" width="358" height="20" font="0">The new ACC/AHA guidelines recommended 2,377 (50%) MESA </text>
<text top="565" left="709" width="378" height="20" font="0">participants for moderate- to high intensity statins; the majority (77%) </text>
<text top="582" left="709" width="386" height="20" font="0">was eligible because of a 10-y estimated ASCVD risk ≥7.5%. Of those </text>
<text top="599" left="709" width="334" height="20" font="0">recommended statins, 41% had CAC=0 and had 5.2 ASCVD </text>
<text top="616" left="709" width="379" height="20" font="0">events/1,000 person-y. Among 589 participants (12%) considered for </text>
<text top="634" left="709" width="370" height="20" font="0">moderate-intensity statin, 338 (57%) had a CAC=0, with an ASCVD </text>
<text top="651" left="709" width="392" height="20" font="0">event rate of 1.5/1,000 person-y. Of participants eligible (recommended </text>
<text top="668" left="709" width="391" height="20" font="0">or considered) for statins, 44% (1,316 of 2,966) had CAC=0 at baseline </text>
<text top="685" left="709" width="352" height="20" font="0">and an observed 10 y ASCVD event rate of 4.2 /1,000 person-y. </text>
</page>
<page number="187" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">187 </text>
<text top="106" left="81" width="969" height="24" font="4"><b>Data Supplement 36. Nonrandomized Trials, Observational Studies, and/or Registries of Chronic Kidney Disease and Cardiovascular Risk </b></text>
<text top="127" left="81" width="104" height="24" font="4"><b>(Section 4.5.4) </b></text>
<text top="148" left="105" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="166" left="131" width="48" height="20" font="7"><b>Author; </b></text>
<text top="183" left="108" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="157" left="239" width="118" height="20" font="7"><b>Study Type/Design; </b></text>
<text top="174" left="266" width="66" height="20" font="7"><b>Study Size </b></text>
<text top="166" left="412" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="157" left="644" width="179" height="20" font="7"><b>Primary Endpoint and Results </b></text>
<text top="174" left="642" width="184" height="20" font="7"><b>(P values; OR or RR; &amp; 95% CI) </b></text>
<text top="157" left="950" width="130" height="20" font="7"><b>Summary/Conclusion </b></text>
<text top="174" left="977" width="75" height="20" font="7"><b>Comment(s) </b></text>
<text top="201" left="91" width="121" height="20" font="0">Tonelli M, et al., 2012 </text>
<text top="218" left="91" width="32" height="20" font="0"><a href="data supplement.html#243">(125)</a> </text>
<text top="235" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22717317">22717317</a></text>
<text top="235" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22717317"> </a></text>
<text top="201" left="231" width="71" height="20" font="7"><b>Study type:</b> </text>
<text top="218" left="231" width="120" height="20" font="0">Observational cohort; </text>
<text top="235" left="231" width="124" height="20" font="0">medical claims data in </text>
<text top="252" left="231" width="92" height="20" font="0">Alberta, Canada </text>
<text top="270" left="231" width="3" height="20" font="0"> </text>
<text top="287" left="231" width="90" height="20" font="7"><b>Size:</b> 1,268,029 </text>
<text top="304" left="231" width="120" height="20" font="0">DM and CKD: 15,368 </text>
<text top="321" left="231" width="74" height="20" font="0">CKD: 59,117 </text>
<text top="201" left="379" width="154" height="20" font="7"><b>Inclusion criteria:</b> Persons </text>
<text top="218" left="379" width="156" height="20" font="0">with measures of eGFR and </text>
<text top="235" left="379" width="167" height="20" font="0">proteinuria in Alberta, Canada </text>
<text top="252" left="379" width="164" height="20" font="0">between 2002-2009, age &gt;18 </text>
<text top="270" left="379" width="3" height="20" font="0"> </text>
<text top="287" left="379" width="166" height="20" font="7"><b>Exclusion criteria:</b> no kidney </text>
<text top="304" left="379" width="159" height="20" font="0">measures, ESRD, eGFR&lt;15 </text>
<text top="202" left="568" width="215" height="20" font="7"><b>1</b>°<b> endpoint:</b> hospital admission for MI </text>
<text top="219" left="568" width="3" height="20" font="0"> </text>
<text top="236" left="568" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="255" left="568" width="7" height="18" font="0">•</text>
<text top="255" left="575" width="215" height="20" font="0"> 11340 admitted with MI (1% of cohort) </text>
<text top="274" left="568" width="7" height="18" font="0">•</text>
<text top="273" left="575" width="173" height="20" font="0"> Rates of MI per 1000-person y </text>
<text top="292" left="568" width="7" height="18" font="0">•</text>
<text top="291" left="575" width="81" height="20" font="0"> Prior MI: 18.5 </text>
<text top="310" left="568" width="7" height="18" font="0">•</text>
<text top="310" left="575" width="97" height="20" font="0"> With no prior MI: </text>
<text top="327" left="568" width="209" height="20" font="0">Diabetes and no CKD: 5.4 (5.2 to 5.7) </text>
<text top="344" left="568" width="187" height="20" font="0">CKD no diabetes: 6.9 (6.6. to 7.2) </text>
<text top="363" left="568" width="7" height="18" font="0">•</text>
<text top="363" left="575" width="210" height="20" font="0"> When eGFR &lt;45 used to define CKD </text>
<text top="380" left="568" width="172" height="20" font="0">Diabetes no CKD: (approx.7.5) </text>
<text top="397" left="568" width="90" height="20" font="0">CKD no DM: 10 </text>
<text top="416" left="568" width="7" height="18" font="0">•</text>
<text top="415" left="575" width="300" height="20" font="0"> Absolute rates of MI increased with more severe CKD </text>
<text top="433" left="568" width="288" height="20" font="0">(especially if also had proteinuria). Risks higher than </text>
<text top="450" left="568" width="122" height="20" font="0">diabetes without CKD </text>
<text top="469" left="568" width="7" height="18" font="0">•</text>
<text top="468" left="575" width="159" height="20" font="0"> Specific data on proteinuria: </text>
<text top="485" left="568" width="296" height="20" font="0">Moderate proteinuria (ACR &gt;=30 or trace on dipstick); </text>
<text top="503" left="568" width="267" height="20" font="0">Severe proteinuria (ACR&gt;=300 or dipstick &gt;=2+) </text>
<text top="522" left="568" width="7" height="18" font="0">•</text>
<text top="521" left="575" width="312" height="20" font="0"> Figure appendix eFigure3: CKD stage 1-4 (Rate about 5 </text>
<text top="538" left="568" width="251" height="20" font="0">per 1000PY)- similar to diabetes with no CKD </text>
<text top="555" left="568" width="328" height="20" font="0">If egfr &lt;60 and severe proteinuria and no diabetes, rate &gt;10 </text>
<text top="573" left="568" width="314" height="20" font="0">per 1000PY and this is higher than diabetes with no CKD </text>
<text top="590" left="568" width="29" height="20" font="0">(5.4) </text>
<text top="609" left="568" width="7" height="18" font="0">•</text>
<text top="608" left="575" width="271" height="20" font="0"> Note: from same cohort, published in the KDIGO </text>
<text top="626" left="568" width="96" height="20" font="0">guideline, table 3 </text>
<text top="643" left="568" width="314" height="20" font="0">CKD stage g1-g2, rates of coronary death or non-fatal MI </text>
<text top="660" left="568" width="308" height="20" font="0">9.7 per 1000 PY (higher for age &gt;50; rate 12.9 age &gt;50) </text>
<text top="203" left="913" width="7" height="18" font="0">•</text>
<text top="202" left="919" width="184" height="20" font="0"> Among persons with no prior MI: </text>
<text top="219" left="913" width="190" height="20" font="0">Rates of hospitalized MI higher for </text>
<text top="236" left="913" width="183" height="20" font="0">persons with CKD-absolute rates </text>
<text top="254" left="913" width="167" height="20" font="0">even higher than persons with </text>
<text top="271" left="913" width="132" height="20" font="0">diabetes (and no CKD)  </text>
<text top="678" left="91" width="111" height="20" font="0">Matsushita K, et al., </text>
<text top="695" left="91" width="63" height="20" font="0">2010 <a href="data supplement.html#248">(212)</a> </text>
<text top="712" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20483451">20483451</a></text>
<text top="712" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20483451"> </a></text>
<text top="678" left="231" width="71" height="20" font="7"><b>Study type:</b> </text>
<text top="695" left="231" width="117" height="20" font="0">Observational cohort </text>
<text top="712" left="231" width="79" height="20" font="0">Meta-analysis </text>
<text top="730" left="231" width="3" height="20" font="0"> </text>
<text top="747" left="231" width="36" height="20" font="7"><b>Size:</b>  </text>
<text top="766" left="231" width="7" height="18" font="0">•</text>
<text top="765" left="238" width="100" height="20" font="0"> 1,128,310 from 7 </text>
<text top="782" left="231" width="112" height="20" font="0">studies with dipstick </text>
<text top="678" left="379" width="139" height="20" font="7"><b>Inclusion criteria:</b> study </text>
<text top="695" left="379" width="152" height="20" font="0">N≥1000 participants from a </text>
<text top="712" left="379" width="166" height="20" font="0">general population with eGFR </text>
<text top="730" left="379" width="101" height="20" font="0">and urine albumin </text>
<text top="747" left="379" width="142" height="20" font="0">concentrations or dipstick </text>
<text top="764" left="379" width="170" height="20" font="0">proteinuria, and information on </text>
<text top="679" left="568" width="284" height="20" font="7"><b>1</b>°<b> endpoint:</b> all cause and cardiovascular mortality </text>
<text top="696" left="568" width="3" height="20" font="0"> </text>
<text top="713" left="568" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="733" left="568" width="7" height="18" font="0">•</text>
<text top="732" left="575" width="287" height="20" font="0"> HR for CVD mortality elevated starting at eGFR 75- </text>
<text top="749" left="568" width="310" height="20" font="0">associations stronger with more severely reduced eGFR </text>
<text top="768" left="568" width="7" height="18" font="0">•</text>
<text top="767" left="575" width="267" height="20" font="0"> HR for CVD mortality linearly increases for ACR </text>
<text top="680" left="913" width="7" height="18" font="0">•</text>
<text top="679" left="919" width="170" height="20" font="0"> egfr and albuminuria are each </text>
<text top="696" left="913" width="183" height="20" font="0">independently associated with all </text>
<text top="713" left="913" width="143" height="20" font="0">cause and CVD mortality, </text>
<text top="731" left="913" width="194" height="20" font="0">independent of traditional CVD risk </text>
<text top="748" left="913" width="183" height="20" font="0">factors (and independent of each </text>
<text top="765" left="913" width="36" height="20" font="0">other) </text>
</page>
<page number="188" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">188 </text>
<text top="107" left="231" width="131" height="20" font="0">information- (4,732,110 </text>
<text top="124" left="231" width="59" height="20" font="0">person-y)  </text>
<text top="143" left="231" width="7" height="18" font="0">•</text>
<text top="143" left="238" width="118" height="20" font="0"> 105,872 participants </text>
<text top="160" left="231" width="135" height="20" font="0">(730,577 person-y) from </text>
<text top="177" left="231" width="115" height="20" font="0">14 studies with urine </text>
<text top="194" left="231" width="29" height="20" font="0">ACR </text>
<text top="107" left="379" width="117" height="20" font="0">all-cause mortality or </text>
<text top="124" left="379" width="133" height="20" font="0">cardiovascular mortality </text>
<text top="141" left="379" width="3" height="20" font="0"> </text>
<text top="159" left="379" width="154" height="20" font="7"><b>Exclusion criteria:</b> Studies </text>
<text top="176" left="379" width="156" height="20" font="0">that selected participants on </text>
<text top="193" left="379" width="149" height="20" font="0">the basis of cardiovascular </text>
<text top="210" left="379" width="141" height="20" font="0">disease or risk factors for </text>
<text top="228" left="379" width="129" height="20" font="0">cardiovascular disease </text>
<text top="109" left="568" width="7" height="18" font="0">•</text>
<text top="108" left="575" width="313" height="20" font="0"> For example, compared with eGFR ≥95, HR: 1.5, 2, and </text>
<text top="125" left="568" width="308" height="20" font="0">about 3 for eGFR 60, 45 and 15, respectively (these are </text>
<text top="143" left="568" width="137" height="20" font="0">estimated from Figure 2) </text>
<text top="162" left="568" width="7" height="18" font="0">•</text>
<text top="161" left="575" width="311" height="20" font="0"> Compared with ACR &lt;5, HR: 1.5, 2, 2.5 for ACR 10, 30, </text>
<text top="178" left="568" width="24" height="20" font="0">300 </text>
<text top="197" left="568" width="7" height="18" font="0">•</text>
<text top="197" left="575" width="305" height="20" font="0"> eGFR and albuminuria were multiplicatively associated </text>
<text top="214" left="568" width="331" height="20" font="0">with risk of mortality and CVD mortality, with no evidence for </text>
<text top="231" left="568" width="60" height="20" font="0">interaction </text>
<text top="250" left="568" width="7" height="18" font="0">•</text>
<text top="249" left="575" width="246" height="20" font="0"> Notes on albuminuria with preserved eGFR  </text>
<text top="268" left="568" width="7" height="18" font="0">•</text>
<text top="268" left="575" width="303" height="20" font="0"> For CVD mortality: among persons with eGFR 90-104, </text>
<text top="285" left="568" width="311" height="20" font="0">compared with ACR &lt;10 ACR 30-330 HR: 1.8; HR: 4.7 if </text>
<text top="302" left="568" width="62" height="20" font="0">ACR ≥300 </text>
<text top="113" left="940" width="9" height="12" font="0">o</text>
<text top="112" left="949" width="4" height="14" font="0"> </text>
<text top="107" left="967" width="114" height="20" font="0">Association appears </text>
<text top="127" left="967" width="131" height="20" font="0">around eGFR 75 and is </text>
<text top="147" left="967" width="135" height="20" font="0">linear and monotonic for </text>
<text top="166" left="967" width="67" height="20" font="0">albuminuria </text>
<text top="203" left="913" width="7" height="18" font="0">•</text>
<text top="202" left="919" width="156" height="20" font="0"> Association is multiplicative </text>
<text top="320" left="91" width="110" height="20" font="0">van der Velde M, et </text>
<text top="337" left="91" width="83" height="20" font="0">al., 2011 <a href="data supplement.html#248">(213)</a> </text>
<text top="355" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21307840">21307840</a></text>
<text top="355" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21307840"> </a></text>
<text top="320" left="231" width="102" height="20" font="7"><b>Study type:</b> Meta-</text>
<text top="337" left="231" width="61" height="20" font="0">analysis of </text>
<text top="355" left="231" width="120" height="20" font="0">observational cohorts </text>
<text top="372" left="231" width="3" height="20" font="0"> </text>
<text top="389" left="231" width="126" height="20" font="7"><b>Size:</b> 266,975 patients </text>
<text top="406" left="231" width="89" height="20" font="0">from 10 cohorts </text>
<text top="320" left="379" width="152" height="20" font="7"><b>Inclusion criteria:</b> patients </text>
<text top="337" left="379" width="141" height="20" font="0">from 10 cohorts, selected </text>
<text top="355" left="379" width="161" height="20" font="0">because of increased risk for </text>
<text top="372" left="379" width="175" height="20" font="0">chronic kidney disease, defined </text>
<text top="389" left="379" width="157" height="20" font="0">as a history of hypertension, </text>
<text top="406" left="379" width="97" height="20" font="0">diabetes, or CVD </text>
<text top="423" left="379" width="3" height="20" font="0"> </text>
<text top="441" left="379" width="158" height="20" font="7"><b>Exclusion criteria:</b> Low risk </text>
<text top="458" left="379" width="47" height="20" font="0">persons </text>
<text top="321" left="568" width="284" height="20" font="7"><b>1</b>°<b> endpoint:</b> all cause and cardiovascular mortality </text>
<text top="339" left="568" width="3" height="20" font="0"> </text>
<text top="356" left="568" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="375" left="568" width="7" height="18" font="0">•</text>
<text top="374" left="575" width="293" height="20" font="0"> Compared with eGFr &gt;95, HR for all cause and CVD </text>
<text top="391" left="568" width="286" height="20" font="0">death increased at eGFRs of 60, 45, and 15 ml/min. </text>
<text top="410" left="568" width="7" height="18" font="0">•</text>
<text top="410" left="575" width="310" height="20" font="0"> Log albuminuria was linearly associated with log risk for </text>
<text top="427" left="568" width="330" height="20" font="0">all-cause and CVD mortality without thresholds. Albuminuria </text>
<text top="444" left="568" width="313" height="20" font="0">and eGFR were multiplicatively associated with all-cause </text>
<text top="461" left="568" width="233" height="20" font="0">mortality, without evidence for interaction.  </text>
<text top="322" left="913" width="7" height="18" font="0">•</text>
<text top="321" left="919" width="156" height="20" font="0"> In persons at high CVD risk </text>
<text top="339" left="913" width="204" height="20" font="0">(hypertension, DM, CVD), eGFR and </text>
<text top="356" left="913" width="196" height="20" font="0">ACR are independently association </text>
<text top="373" left="913" width="195" height="20" font="0">with all cause and CVD death. Risk </text>
<text top="390" left="913" width="168" height="20" font="0">is multiplicative by eGFR/ACR </text>
<text top="407" left="913" width="7" height="20" font="0">  </text>
<text top="479" left="91" width="112" height="20" font="0">Fox CS, et al., 2012 </text>
<text top="497" left="91" width="32" height="20" font="0"><a href="data supplement.html#248">(214)</a> </text>
<text top="514" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23013602">23013602</a></text>
<text top="514" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/23013602"> </a></text>
<text top="479" left="231" width="102" height="20" font="7"><b>Study type:</b> Meta-</text>
<text top="497" left="231" width="61" height="20" font="0">analysis of </text>
<text top="514" left="231" width="114" height="20" font="0">observational cohort </text>
<text top="531" left="231" width="42" height="20" font="0">studies </text>
<text top="548" left="231" width="3" height="20" font="0"> </text>
<text top="565" left="231" width="90" height="20" font="7"><b>Size:</b> 1,024,977 </text>
<text top="583" left="231" width="122" height="20" font="0">30 general population </text>
<text top="600" left="231" width="103" height="20" font="0">and high-risk CVD </text>
<text top="617" left="231" width="128" height="20" font="0">cohorts and 13 chronic </text>
<text top="634" left="231" width="132" height="20" font="0">kidney disease cohorts. </text>
<text top="479" left="379" width="175" height="20" font="7"><b>Inclusion criteria:</b> cohorts with </text>
<text top="497" left="379" width="149" height="20" font="0">&gt;1000 persons, at least 50 </text>
<text top="514" left="379" width="122" height="20" font="0">events of interest with </text>
<text top="531" left="379" width="141" height="20" font="0">information on eGFR and </text>
<text top="548" left="379" width="167" height="20" font="0">albuminuria (ACR or dipstick); </text>
<text top="565" left="379" width="50" height="20" font="0">Age &gt;18 </text>
<text top="583" left="379" width="3" height="20" font="0"> </text>
<text top="600" left="379" width="134" height="20" font="7"><b>Exclusion criteria:</b> N/A </text>
<text top="480" left="568" width="79" height="20" font="7"><b>1</b>°<b> endpoint:</b>  </text>
<text top="499" left="568" width="7" height="18" font="0">•</text>
<text top="499" left="575" width="132" height="20" font="0"> All cause death, ESRD </text>
<text top="516" left="568" width="219" height="20" font="0">CVD death in cohorts with this outcome </text>
<text top="535" left="568" width="7" height="18" font="0">•</text>
<text top="534" left="575" width="314" height="20" font="0"> CVD death included deaths due to myocardial infarction, </text>
<text top="552" left="568" width="248" height="20" font="0">heart failure, sudden cardiac death, or stroke </text>
<text top="569" left="568" width="3" height="20" font="0"> </text>
<text top="586" left="568" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="605" left="568" width="7" height="18" font="0">•</text>
<text top="604" left="575" width="304" height="20" font="0"> In the 23 studies with data for cardiovascular mortality, </text>
<text top="622" left="568" width="327" height="20" font="0">21,237 deaths occurred from cardiovascular disease during </text>
<text top="639" left="568" width="195" height="20" font="0">a mean follow-up of 9·2 y (SD 4·9). </text>
<text top="658" left="568" width="7" height="18" font="0">•</text>
<text top="657" left="575" width="305" height="20" font="0"> Finding #1-Persons with DM at higher risk than without </text>
<text top="674" left="568" width="319" height="20" font="0">diabetes across eGFr and ACR spectrum (HR: 1.2 to 1.9)  </text>
<text top="692" left="568" width="117" height="20" font="0">Finding #2 (figure 1)  </text>
<text top="709" left="568" width="310" height="20" font="0">-All-cause mortality and CVD death increased with lower </text>
<text top="726" left="568" width="286" height="20" font="0">eGFR and higher albuminuria categories in both the </text>
<text top="743" left="568" width="304" height="20" font="0">diabetes and no diabetes groups. No interaction by DM </text>
<text top="762" left="568" width="7" height="18" font="0">•</text>
<text top="762" left="575" width="133" height="20" font="0"> Examples from figure 1 </text>
<text top="481" left="913" width="7" height="18" font="0">•</text>
<text top="480" left="919" width="198" height="20" font="0"> Lower eGFR (threshold around 60) </text>
<text top="498" left="913" width="192" height="20" font="0">and albuminuria (no threshold) are </text>
<text top="515" left="913" width="167" height="20" font="0">independently associated with </text>
<text top="532" left="913" width="193" height="20" font="0">cardiovascular mortality in persons </text>
<text top="549" left="913" width="141" height="20" font="0">with and without diabetes </text>
<text top="568" left="913" width="7" height="18" font="0">•</text>
<text top="568" left="919" width="191" height="20" font="0"> The association of CKD with CVD </text>
<text top="585" left="913" width="187" height="20" font="0">death is similar magnitude as that </text>
<text top="602" left="913" width="189" height="20" font="0">seen in persons with diabetes and </text>
<text top="619" left="913" width="46" height="20" font="0">no CKD </text>
</page>
<page number="189" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">189 </text>
<text top="107" left="568" width="331" height="20" font="0">Compared with category eGFR &gt;95 and no diabetes, HR for </text>
<text top="124" left="568" width="329" height="20" font="0">CVD death for eGFR 60 no diabetes 1.3, eGFR 60 diabetes </text>
<text top="141" left="568" width="292" height="20" font="0">2.0, eGFR 45 no diabetes 1.5, eGFR 45 diabetes 2.0 </text>
<text top="160" left="568" width="7" height="18" font="0">•</text>
<text top="160" left="575" width="163" height="20" font="0"> Figure 2: Risk for ACR linear </text>
<text top="177" left="568" width="247" height="20" font="0">Compared with category no DM and ACR &lt;5 </text>
<text top="194" left="568" width="135" height="20" font="0">ACR 30 no DM: HR: 1.5 </text>
<text top="211" left="568" width="107" height="20" font="0">ACR 30 DM: HR: 3 </text>
<text top="231" left="568" width="7" height="18" font="0">•</text>
<text top="230" left="575" width="48" height="20" font="0"> Table 2 </text>
<text top="247" left="568" width="317" height="20" font="0">All-cause mortality and cardiovascular mortality increased </text>
<text top="264" left="568" width="323" height="20" font="0">with lower eGFR and higher albuminuria categories in both </text>
<text top="282" left="568" width="202" height="20" font="0">the diabetes and no diabetes groups </text>
<text top="299" left="568" width="101" height="20" font="0">Risk multiplicative </text>
<text top="318" left="568" width="7" height="18" font="0">•</text>
<text top="317" left="575" width="268" height="20" font="0"> Notes on albuminuria with preserved egFr (&gt;60) </text>
<text top="334" left="568" width="319" height="20" font="0">For example: Among persons with no diabetes, compared </text>
<text top="352" left="568" width="148" height="20" font="0">with egfr &gt;95 and ACR &lt;5: </text>
<text top="369" left="568" width="171" height="20" font="0">Acr 30-299 and egfr 75-89: 1.6 </text>
<text top="386" left="568" width="199" height="20" font="0">ACR &gt;300 and egfr 75-89 HR: 2.57  </text>
<text top="404" left="91" width="118" height="20" font="0">Colantonio LD, et al., </text>
<text top="421" left="91" width="63" height="20" font="0">2015 <a href="data supplement.html#249">(215)</a> </text>
<text top="438" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25395432">25395432</a></text>
<text top="438" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25395432"> </a></text>
<text top="404" left="231" width="71" height="20" font="7"><b>Study type:</b> </text>
<text top="421" left="231" width="117" height="20" font="0">Observational cohort </text>
<text top="438" left="231" width="3" height="20" font="0"> </text>
<text top="456" left="231" width="66" height="20" font="7"><b>Size:</b> 4,726 </text>
<text top="404" left="379" width="165" height="20" font="7"><b>Inclusion criteria:</b> age 50-79 </text>
<text top="421" left="379" width="163" height="20" font="0">with CKD (eGFR &lt;60 or ACR </text>
<text top="438" left="379" width="111" height="20" font="0">≥30) not on dialysis </text>
<text top="456" left="379" width="3" height="20" font="0"> </text>
<text top="473" left="379" width="155" height="20" font="7"><b>Exclusion criteria:</b> missing </text>
<text top="490" left="379" width="170" height="20" font="0">information on kidney function, </text>
<text top="507" left="379" width="169" height="20" font="0">CVD risk equation variables or </text>
<text top="524" left="379" width="57" height="20" font="0">outcomes </text>
<text top="405" left="568" width="281" height="20" font="7"><b>1</b>°<b> endpoint:</b> incident ASCVD events - adjudicated </text>
<text top="422" left="568" width="3" height="20" font="0"> </text>
<text top="440" left="568" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="459" left="568" width="7" height="18" font="0">•</text>
<text top="458" left="575" width="323" height="20" font="0"> Among 1,110 participants age 50-80 not already on statin, </text>
<text top="475" left="568" width="243" height="20" font="0">free of ASCVD and diabetes and LDL 70-89 </text>
<text top="494" left="568" width="7" height="18" font="0">•</text>
<text top="493" left="575" width="208" height="20" font="0"> 24% had pooled risk equation &lt;7.5% </text>
<text top="512" left="568" width="7" height="18" font="0">•</text>
<text top="512" left="575" width="255" height="20" font="0"> If eGFR &lt;60, 17.6% had &lt;7.5% predicted risk </text>
<text top="531" left="568" width="7" height="18" font="0">•</text>
<text top="530" left="575" width="187" height="20" font="0"> Pooled risk cohort well calibrated </text>
<text top="549" left="568" width="7" height="18" font="0">•</text>
<text top="549" left="575" width="166" height="20" font="0"> Incidence rate for ASCVD for </text>
<text top="566" left="568" width="326" height="20" font="0"> eGFR &lt;60 was 14.3 (9.4 to 19.2) per 1,000-person y, ACR </text>
<text top="583" left="568" width="129" height="20" font="0">≥30 15.8 (11.7 to 19.7) </text>
<text top="602" left="568" width="7" height="18" font="0">•</text>
<text top="601" left="575" width="302" height="20" font="0"> if ASCVD predicted risk &lt;7.5%, incidence rates &lt;5 per </text>
<text top="619" left="568" width="82" height="20" font="0">1000-person y </text>
<text top="638" left="568" width="7" height="18" font="0">•</text>
<text top="637" left="575" width="303" height="20" font="0"> if ASCVD predicted risk &gt;7.5%, persons with CKD had </text>
<text top="654" left="568" width="276" height="20" font="0">observed ASCVD rates &gt;15% per 1,000-person y  </text>
<text top="671" left="568" width="309" height="20" font="0">eGFR &lt;60 or ACR ≥30 17.7 per 1,000-person y (13.6 to </text>
<text top="689" left="568" width="303" height="20" font="0">21.7), eGFR &lt;60 17.3 per 1000-person y (11.4 to 23.2) </text>
<text top="708" left="568" width="7" height="18" font="0">•</text>
<text top="707" left="575" width="324" height="20" font="0"> ACC/AHA would recommend statin for 92% of participants </text>
<text top="724" left="568" width="234" height="20" font="0">for whom statins recommended by KDIGO </text>
<text top="743" left="568" width="7" height="18" font="0">•</text>
<text top="742" left="575" width="307" height="20" font="0"> The 8% with predicted risk &lt;7.5%, risk low even if CKD </text>
<text top="760" left="568" width="307" height="20" font="0">where not recommended low risk (&lt;0 to 4 depending on </text>
<text top="777" left="568" width="90" height="20" font="0">CKD definition)  </text>
<text top="406" left="913" width="7" height="18" font="0">•</text>
<text top="405" left="919" width="176" height="20" font="0"> Risk equation well calibrated in </text>
<text top="422" left="913" width="29" height="20" font="0">CKD </text>
<text top="441" left="913" width="7" height="18" font="0">•</text>
<text top="441" left="919" width="195" height="20" font="0"> Majority of persons with CKD have </text>
<text top="458" left="913" width="118" height="20" font="0">estimated risk &gt;7.5% </text>
<text top="477" left="913" width="7" height="18" font="0">•</text>
<text top="476" left="919" width="186" height="20" font="0"> If risk predicted &gt;7.5%, observed </text>
<text top="493" left="913" width="66" height="20" font="0">rates &gt;15% </text>
<text top="512" left="913" width="7" height="18" font="0">•</text>
<text top="512" left="919" width="186" height="20" font="0"> If predicted risk &lt;7.5%, observed </text>
<text top="529" left="913" width="57" height="20" font="0">risk is low </text>
<text top="548" left="913" width="7" height="18" font="0">•</text>
<text top="547" left="919" width="183" height="20" font="0"> The simpler guideline by KDIGO </text>
<text top="565" left="913" width="183" height="20" font="0">would potentially overtreat a very </text>
<text top="582" left="913" width="177" height="20" font="0">small proportion of persons with </text>
<text top="599" left="913" width="29" height="20" font="0">CKD </text>
<text top="618" left="913" width="7" height="18" font="0">•</text>
<text top="617" left="919" width="163" height="20" font="0"> No data on persons age &lt;50 </text>
<text top="635" left="913" width="160" height="20" font="0">Limited data on persons with </text>
<text top="652" left="913" width="122" height="20" font="0">estimated risk 5-7.5% </text>
</page>
<page number="190" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">190 </text>
<text top="106" left="81" width="4" height="22" font="1"> </text>
<text top="125" left="81" width="1001" height="24" font="4"><b>Data Supplement 37. RCTs Comparing PLACEBO VS. Statin (or Statin plus another agent) to reduce CVD events in persons with CKD (Section </b></text>
<text top="146" left="81" width="46" height="24" font="4"><b>4.5.4)  </b></text>
<text top="176" left="97" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="193" left="123" width="48" height="20" font="7"><b>Author; </b></text>
<text top="210" left="100" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="176" left="244" width="83" height="20" font="7"><b>Aim of Study; </b></text>
<text top="193" left="249" width="74" height="20" font="7"><b>Study Type; </b></text>
<text top="210" left="243" width="86" height="20" font="7"><b>Study Size (N) </b></text>
<text top="193" left="391" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="167" left="557" width="111" height="20" font="7"><b>Study Intervention </b></text>
<text top="184" left="574" width="76" height="20" font="7"><b>(# patients) / </b></text>
<text top="202" left="557" width="111" height="20" font="7"><b>Study Comparator </b></text>
<text top="219" left="578" width="69" height="20" font="7"><b>(# patients) </b></text>
<text top="176" left="751" width="105" height="20" font="7"><b>Endpoint Results </b></text>
<text top="193" left="735" width="137" height="20" font="7"><b>(Absolute Event Rates, </b></text>
<text top="210" left="713" width="181" height="20" font="7"><b>P values; OR or RR; &amp; 95% CI) </b></text>
<text top="176" left="932" width="175" height="20" font="7"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="194" left="964" width="111" height="20" font="7"><b>Study Limitations; </b></text>
<text top="211" left="971" width="96" height="20" font="7"><b>Adverse Events </b></text>
<text top="237" left="89" width="46" height="20" font="7"><b>SHARP </b></text>
<text top="254" left="89" width="94" height="20" font="0">Baigent C, et al., </text>
<text top="271" left="89" width="56" height="20" font="0">2011 <a href="data supplement.html#236">(13)</a> </text>
<text top="289" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21663949">21663949</a></text>
<text top="289" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21663949"> </a></text>
<text top="237" left="217" width="126" height="20" font="7"><b>Aim:</b> To assess safety </text>
<text top="254" left="217" width="133" height="20" font="0">and efficacy of reducing </text>
<text top="271" left="217" width="111" height="20" font="0">LDL in persons with </text>
<text top="289" left="217" width="29" height="20" font="0">CKD </text>
<text top="306" left="217" width="132" height="20" font="0">Placebo vs. simvastatin </text>
<text top="323" left="217" width="118" height="20" font="0">20mg + ezetimibe 10 </text>
<text top="340" left="217" width="49" height="20" font="0">mg daily </text>
<text top="357" left="217" width="3" height="20" font="0"> </text>
<text top="375" left="217" width="99" height="20" font="7"><b>Study type:</b> RCT </text>
<text top="392" left="217" width="3" height="20" font="0"> </text>
<text top="409" left="217" width="134" height="20" font="7"><b>Size:</b> 9,270 randomized </text>
<text top="426" left="217" width="106" height="20" font="0">Study duration: 4 y </text>
<text top="443" left="217" width="82" height="20" font="0">(median 4.9 y) </text>
<text top="237" left="368" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="256" left="368" width="7" height="18" font="0">•</text>
<text top="255" left="375" width="146" height="20" font="0"> Age ≥40, Cr 1.7 men, 1.5 </text>
<text top="272" left="368" width="131" height="20" font="0">women, With or without </text>
<text top="290" left="368" width="44" height="20" font="0">dialysis </text>
<text top="309" left="368" width="7" height="18" font="0">•</text>
<text top="308" left="375" width="140" height="20" font="0"> Total randomized: 9,438 </text>
<text top="325" left="368" width="3" height="20" font="0"> </text>
<text top="343" left="368" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="362" left="368" width="7" height="18" font="0">•</text>
<text top="361" left="375" width="130" height="20" font="0"> 6 wk run-in period with </text>
<text top="378" left="368" width="102" height="20" font="0">placebo to identify </text>
<text top="395" left="368" width="76" height="20" font="0">noncompliers </text>
<text top="414" left="368" width="7" height="18" font="0">•</text>
<text top="414" left="375" width="62" height="20" font="0"> Prior CVD </text>
<text top="433" left="368" width="7" height="18" font="0">•</text>
<text top="432" left="375" width="141" height="20" font="0"> Note re egfr: among non-</text>
<text top="449" left="368" width="143" height="20" font="0">dialysis, mean eGFR was </text>
<text top="467" left="368" width="152" height="20" font="0">26.6 (SD 13). 36% stage 3, </text>
<text top="484" left="368" width="150" height="20" font="0">43% stage 4, 20% stage 5  </text>
<text top="501" left="368" width="155" height="20" font="0">20% ACR &lt;30, 38% 30-300 </text>
<text top="518" left="368" width="83" height="20" font="0">and 42% &gt;300 </text>
<text top="537" left="368" width="7" height="18" font="0">•</text>
<text top="536" left="375" width="92" height="20" font="0"> 33% on dialysis </text>
<text top="556" left="368" width="7" height="18" font="0">•</text>
<text top="555" left="375" width="82" height="20" font="0"> 23% diabetes </text>
<text top="572" left="368" width="3" height="20" font="0"> </text>
<text top="237" left="539" width="126" height="20" font="7"><b>Intervention:</b> Placebo </text>
<text top="254" left="539" width="142" height="20" font="0">(N=4,620) vs. simvastatin </text>
<text top="271" left="539" width="138" height="20" font="0">20mg + ezetimibe 10 mg </text>
<text top="289" left="539" width="87" height="20" font="0">daily (N=4,650) </text>
<text top="306" left="539" width="7" height="20" font="0">  </text>
<text top="323" left="539" width="81" height="20" font="7"><b>Comparator:</b>  </text>
<text top="342" left="539" width="7" height="18" font="0">•</text>
<text top="341" left="546" width="102" height="20" font="0"> Placebo, N=4620 </text>
<text top="360" left="539" width="7" height="18" font="0">•</text>
<text top="360" left="546" width="131" height="20" font="0"> Duration: median 4.9 y </text>
<text top="238" left="698" width="79" height="20" font="7"><b>1</b>°<b> endpoint:</b>  </text>
<text top="257" left="698" width="7" height="18" font="0">•</text>
<text top="256" left="705" width="190" height="20" font="0"> major atherosclerotic events (non-</text>
<text top="274" left="698" width="172" height="20" font="0">fatal MI or coronary death, non-</text>
<text top="291" left="698" width="153" height="20" font="0">hemorrhagic stroke, arterial </text>
<text top="308" left="698" width="100" height="20" font="0">revascularization) </text>
<text top="327" left="698" width="7" height="18" font="0">•</text>
<text top="327" left="705" width="125" height="20" font="0"> Placebo: 619 (13.4%) </text>
<text top="346" left="698" width="7" height="18" font="0">•</text>
<text top="345" left="705" width="145" height="20" font="0"> Intervention: 526 (11.3%) </text>
<text top="364" left="698" width="7" height="18" font="0">•</text>
<text top="363" left="705" width="183" height="20" font="0"> RR 0.83 (0.74 to 0.94), p 0.0021 </text>
<text top="382" left="698" width="7" height="18" font="0">•</text>
<text top="382" left="705" width="201" height="20" font="0"> LDL chol. reduction for intervention: </text>
<text top="399" left="698" width="183" height="20" font="0">Overall, -1.08 y 1, -0.84 at 44 mo </text>
<text top="418" left="698" width="7" height="18" font="0">•</text>
<text top="417" left="705" width="197" height="20" font="0"> 1.1 mmol/ L for non-dialysis (39%), </text>
<text top="434" left="698" width="96" height="20" font="0">- 0.75 for dialysis </text>
<text top="453" left="698" width="7" height="18" font="0">•</text>
<text top="453" left="705" width="179" height="20" font="0"> Effects consistent across eGFR </text>
<text top="470" left="698" width="54" height="20" font="0">category  </text>
<text top="489" left="698" width="7" height="18" font="0">•</text>
<text top="488" left="705" width="144" height="20" font="0"> No statistically significant </text>
<text top="506" left="698" width="143" height="20" font="0">differences by CKD stage </text>
<text top="523" left="698" width="3" height="20" font="0"> </text>
<text top="540" left="698" width="114" height="20" font="7"><b>Dialysis subgroup: </b></text>
<text top="557" left="698" width="204" height="20" font="0">3023 on dialysis (2527 hemodialysis, </text>
<text top="574" left="698" width="129" height="20" font="0">496 peritoneal dialysis) </text>
<text top="592" left="698" width="3" height="20" font="0"> </text>
<text top="611" left="698" width="7" height="18" font="0">•</text>
<text top="610" left="705" width="135" height="20" font="0"> Intervention: 230 (15%) </text>
<text top="629" left="698" width="7" height="18" font="0">•</text>
<text top="628" left="705" width="125" height="20" font="0"> Placebo: 246 (16.5%) </text>
<text top="647" left="698" width="7" height="18" font="0">•</text>
<text top="647" left="705" width="129" height="20" font="0"> RR 0.90 (0.75 to 1.08) </text>
<text top="664" left="698" width="3" height="20" font="0"> </text>
<text top="681" left="698" width="173" height="20" font="7"><b>Safety endpoint (if relevant):</b>  </text>
<text top="698" left="698" width="103" height="20" font="7"><b>• </b>No differences in </text>
<text top="716" left="698" width="161" height="20" font="0">Cancer, cancer mortality, CK </text>
<text top="733" left="698" width="141" height="20" font="0">concentration, myopathy, </text>
<text top="750" left="698" width="195" height="20" font="0">rhabdomyolysis, persistently raised </text>
<text top="767" left="698" width="202" height="20" font="0">transaminases, hepatitis, gallstones, </text>
<text top="784" left="698" width="66" height="20" font="0">pancreatitis </text>
<text top="239" left="921" width="7" height="18" font="0">•</text>
<text top="238" left="928" width="141" height="20" font="0"> lack of power for dialysis </text>
<text top="255" left="921" width="55" height="20" font="0">subgroup </text>
<text top="274" left="921" width="7" height="18" font="0">•</text>
<text top="274" left="928" width="167" height="20" font="0"> Crossover: 33% discontinued </text>
<text top="291" left="921" width="158" height="20" font="0">intervention, 14% in placebo </text>
<text top="308" left="921" width="143" height="20" font="0">started non-statin therapy </text>
<text top="327" left="921" width="7" height="18" font="0">•</text>
<text top="327" left="928" width="152" height="20" font="0"> Few persons on peritoneal </text>
<text top="344" left="921" width="44" height="20" font="0">dialysis </text>
<text top="361" left="921" width="3" height="20" font="0"> </text>
<text top="378" left="921" width="196" height="20" font="0">Important Note: initially randomized </text>
<text top="395" left="921" width="165" height="20" font="0">3 ways (placebo, statin alone, </text>
<text top="413" left="921" width="185" height="20" font="0">ezetimibe plus simva) – the statin </text>
<text top="430" left="921" width="175" height="20" font="0">only was then re-randomized to </text>
<text top="447" left="921" width="181" height="20" font="0">intervention vs. placebo after 1 y </text>
<text top="464" left="921" width="3" height="20" font="0"> </text>
</page>
<page number="191" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">191 </text>
<text top="109" left="698" width="7" height="18" font="0">•</text>
<text top="108" left="705" width="183" height="20" font="0"> Note: 34% transitioned to ESRD </text>
<text top="125" left="698" width="81" height="20" font="0">during the trial<b> </b></text>
<text top="193" left="89" width="65" height="20" font="0">Cholesterol </text>
<text top="210" left="89" width="108" height="20" font="0">Treatment Trialists’ </text>
<text top="227" left="89" width="36" height="20" font="0">(CTT) </text>
<text top="244" left="89" width="81" height="20" font="0">Collaboration* </text>
<text top="262" left="89" width="102" height="20" font="0">Herrington WG, et </text>
<text top="279" left="89" width="83" height="20" font="0">al., 2016 <a href="data supplement.html#249">(216)</a> </text>
<text top="296" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27477773">27477773</a></text>
<text top="296" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27477773"> </a></text>
<text top="193" left="217" width="133" height="20" font="7"><b>Aim:</b> Compare Effect of </text>
<text top="210" left="217" width="138" height="20" font="0">statin by renal function -  </text>
<text top="227" left="217" width="127" height="20" font="0">Please check the ref is </text>
<text top="244" left="217" width="72" height="20" font="0">the following </text>
<text top="262" left="217" width="3" height="20" font="0"> </text>
<text top="279" left="217" width="102" height="20" font="7"><b>Study type:</b> Meta-</text>
<text top="296" left="217" width="48" height="20" font="0">analysis </text>
<text top="313" left="217" width="3" height="20" font="0"> </text>
<text top="330" left="217" width="82" height="20" font="7"><b>Size:</b> 28 trials, </text>
<text top="348" left="217" width="64" height="20" font="0">N=183,419 </text>
<text top="193" left="368" width="156" height="20" font="7"><b>Inclusion criteria:</b> Included </text>
<text top="210" left="368" width="158" height="20" font="0">all trials in renal populations, </text>
<text top="227" left="368" width="129" height="20" font="0">primary and secondary </text>
<text top="244" left="368" width="61" height="20" font="0">prevention </text>
<text top="262" left="368" width="3" height="20" font="0"> </text>
<text top="279" left="368" width="139" height="20" font="7"><b>Exclusion criteria:</b> trials </text>
<text top="296" left="368" width="124" height="20" font="0">with no information on </text>
<text top="313" left="368" width="96" height="20" font="0">kidney measures </text>
<text top="193" left="539" width="132" height="20" font="7"><b>Intervention:</b> Statin vs. </text>
<text top="210" left="539" width="46" height="20" font="0">placebo </text>
<text top="227" left="539" width="46" height="20" font="0">23 trials </text>
<text top="244" left="539" width="3" height="20" font="0"> </text>
<text top="262" left="539" width="130" height="20" font="0">5 trials compared statin </text>
<text top="279" left="539" width="30" height="20" font="0">dose </text>
<text top="296" left="539" width="7" height="20" font="0">  </text>
<text top="313" left="539" width="125" height="20" font="7"><b>Comparator:</b> Placebo<b> </b></text>
<text top="194" left="698" width="79" height="20" font="7"><b>1</b>°<b> endpoint:</b>  </text>
<text top="213" left="698" width="7" height="18" font="0">•</text>
<text top="212" left="705" width="202" height="20" font="0"> Major vascular events (non-fatal MI, </text>
<text top="230" left="698" width="181" height="20" font="0">coronary death, stroke, coronary </text>
<text top="247" left="698" width="100" height="20" font="0">revascularization) </text>
<text top="264" left="698" width="199" height="20" font="0">Note: able to readjudicate AURORA </text>
<text top="281" left="698" width="96" height="20" font="0">coronary deaths) </text>
<text top="300" left="698" width="7" height="18" font="0">•</text>
<text top="300" left="705" width="200" height="20" font="0"> Estimates as rate ratios per mmol/L </text>
<text top="317" left="698" width="89" height="20" font="0">of LDL lowering </text>
<text top="336" left="698" width="7" height="18" font="0">•</text>
<text top="335" left="705" width="174" height="20" font="0"> Overall, RR 0.79 (0.77 to 0.81) </text>
<text top="354" left="698" width="7" height="18" font="0">•</text>
<text top="354" left="705" width="177" height="20" font="0"> Smaller relative effects as GFR </text>
<text top="371" left="698" width="199" height="20" font="0">declined (p=0.008 for trend), benefit </text>
<text top="388" left="698" width="111" height="20" font="0">not seen on dialysis </text>
<text top="405" left="698" width="3" height="20" font="0"> </text>
<text top="422" left="698" width="183" height="20" font="0">N, % events per year, and RR by </text>
<text top="440" left="698" width="36" height="20" font="0">eGFR </text>
<text top="459" left="698" width="7" height="18" font="0">•</text>
<text top="458" left="705" width="140" height="20" font="0"> eGFR 45-60 (N=34,417) </text>
<text top="475" left="698" width="85" height="20" font="0"> 4.6% vs. 3.6% </text>
<text top="492" left="698" width="104" height="20" font="0">0.76 (0.70 to 0.81) </text>
<text top="511" left="698" width="7" height="18" font="0">•</text>
<text top="511" left="705" width="140" height="20" font="0"> eGFR 30-45 (N=10,634) </text>
<text top="528" left="698" width="71" height="20" font="0">5.2 vs. 4.5% </text>
<text top="545" left="698" width="107" height="20" font="0"> 0.85 (0.75 to 0.96) </text>
<text top="564" left="698" width="7" height="18" font="0">•</text>
<text top="564" left="705" width="106" height="20" font="0"> eGFR &lt;30 (5,368) </text>
<text top="581" left="698" width="60" height="20" font="0">3.5 vs. 3.0 </text>
<text top="598" left="698" width="104" height="20" font="0">0.85 (0.71 to 1.02) </text>
<text top="617" left="698" width="7" height="18" font="0">•</text>
<text top="617" left="705" width="104" height="20" font="0"> Dialysis (N=7053) </text>
<text top="634" left="698" width="60" height="20" font="0">5.0 vs. 4.7 </text>
<text top="651" left="698" width="104" height="20" font="0">0.94 (0.79 to 1.11) </text>
<text top="195" left="921" width="7" height="18" font="0">•</text>
<text top="194" left="928" width="166" height="20" font="0"> Particular strength: considers </text>
<text top="211" left="921" width="190" height="20" font="0">differences in achieved LDL levels </text>
<text top="228" left="921" width="183" height="20" font="0">across trials, uniform definition of </text>
<text top="246" left="921" width="192" height="20" font="0">outcome in dialysis trials (coronary </text>
<text top="263" left="921" width="38" height="20" font="0">death) </text>
<text top="280" left="921" width="3" height="20" font="0"> </text>
<text top="297" left="921" width="66" height="20" font="7"><b>Limitation:</b> </text>
<text top="316" left="921" width="7" height="18" font="0">•</text>
<text top="316" left="928" width="157" height="20" font="0"> Concern over agreement of </text>
<text top="333" left="921" width="139" height="20" font="0">causes of vascular death </text>
<text top="350" left="921" width="193" height="20" font="0">adjudication in patients with kidney </text>
<text top="367" left="921" width="46" height="20" font="0">disease </text>
<text top="384" left="921" width="3" height="20" font="0"> </text>
<text top="669" left="89" width="100" height="20" font="0">Palmer SC, et al., </text>
<text top="686" left="89" width="63" height="20" font="0">2012 <a href="data supplement.html#249">(217)</a> </text>
<text top="703" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22910937">22910937</a></text>
<text top="703" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22910937"> </a></text>
<text top="669" left="217" width="112" height="20" font="7"><b>Aim:</b> To summarize </text>
<text top="686" left="217" width="122" height="20" font="0">benefits and harms of </text>
<text top="703" left="217" width="120" height="20" font="0">statin therapy in CKD </text>
<text top="721" left="217" width="112" height="20" font="0">And whether effects </text>
<text top="738" left="217" width="106" height="20" font="0">vary by CKD stage </text>
<text top="755" left="217" width="3" height="20" font="0"> </text>
<text top="772" left="217" width="102" height="20" font="7"><b>Study type:</b> Meta-</text>
<text top="789" left="217" width="90" height="20" font="0">analysis of RCT </text>
<text top="669" left="368" width="135" height="20" font="7"><b>Inclusion criteria:</b> RCT </text>
<text top="686" left="368" width="134" height="20" font="0">statin vs. placebo (or no </text>
<text top="703" left="368" width="156" height="20" font="0">therapy or standard care) or </text>
<text top="721" left="368" width="78" height="20" font="0">another statin </text>
<text top="738" left="368" width="3" height="20" font="0"> </text>
<text top="755" left="368" width="146" height="20" font="7"><b>Exclusion criteria:</b> &lt;8 wk </text>
<text top="772" left="368" width="106" height="20" font="0">follow-up, pediatric </text>
<text top="669" left="539" width="113" height="20" font="7"><b>Intervention:</b> Statin </text>
<text top="686" left="539" width="7" height="20" font="0">  </text>
<text top="703" left="539" width="139" height="20" font="7"><b>Comparator:</b> Placebo or </text>
<text top="721" left="539" width="127" height="20" font="0">no treatment, standard </text>
<text top="738" left="539" width="126" height="20" font="0">care (86 comparisons) </text>
<text top="755" left="539" width="100" height="20" font="0">Vs. other statin (9 </text>
<text top="772" left="539" width="77" height="20" font="0">comparisons)<b> </b></text>
<text top="670" left="698" width="187" height="20" font="7"><b>1</b>°<b> endpoint:</b> Focus here on CVD </text>
<text top="687" left="698" width="170" height="20" font="0">mortality, major cardiovascular </text>
<text top="704" left="698" width="100" height="20" font="0">events, MI, stroke </text>
<text top="722" left="698" width="3" height="20" font="0"> </text>
<text top="739" left="698" width="180" height="20" font="0">Event Rates (Estimate of control </text>
<text top="756" left="698" width="110" height="20" font="0">group risk per year) </text>
<text top="775" left="698" width="7" height="18" font="0">•</text>
<text top="774" left="705" width="118" height="20" font="0"> CKD not on dialysis: </text>
<text top="671" left="921" width="7" height="18" font="0">•</text>
<text top="670" left="928" width="100" height="20" font="0"> Statins beneficial </text>
<text top="687" left="921" width="169" height="20" font="0">Benefit varies by CKD severity </text>
<text top="704" left="921" width="92" height="20" font="0">(dialysis vs. not) </text>
<text top="722" left="921" width="3" height="20" font="0"> </text>
<text top="739" left="921" width="73" height="20" font="7"><b>Limitations: </b></text>
<text top="758" left="921" width="7" height="18" font="0">•</text>
<text top="757" left="928" width="174" height="20" font="0"> Included secondary prevention </text>
<text top="774" left="921" width="29" height="20" font="0">trials </text>
</page>
<page number="192" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">192 </text>
<text top="107" left="217" width="3" height="20" font="0"> </text>
<text top="124" left="217" width="120" height="20" font="7"><b>Size:</b> 89 trials 56,857 </text>
<text top="141" left="217" width="93" height="20" font="0">participants total </text>
<text top="159" left="217" width="88" height="20" font="0">Size differed by </text>
<text top="176" left="217" width="91" height="20" font="0">comparison and </text>
<text top="193" left="217" width="114" height="20" font="0">outcome considered </text>
<text top="107" left="698" width="118" height="20" font="0">Major CV events: 2.0 </text>
<text top="124" left="698" width="102" height="20" font="0">CV mortality 1.5% </text>
<text top="143" left="698" width="7" height="18" font="0">•</text>
<text top="143" left="705" width="71" height="20" font="0"> On dialysis: </text>
<text top="160" left="698" width="148" height="20" font="0">Major vascular event: 15% </text>
<text top="177" left="698" width="86" height="20" font="0">CV death: 10% </text>
<text top="194" left="698" width="3" height="20" font="0"> </text>
<text top="213" left="698" width="7" height="18" font="0">•</text>
<text top="213" left="705" width="180" height="20" font="0"> CVD mortality: 27 comparisons, </text>
<text top="230" left="698" width="84" height="20" font="0">35417 patients </text>
<text top="249" left="698" width="7" height="18" font="0">•</text>
<text top="248" left="705" width="154" height="20" font="0"> CKD not dialysis- 8 studies </text>
<text top="266" left="698" width="129" height="20" font="0"> RR 0.78 (0.68 to 0.89) </text>
<text top="285" left="698" width="7" height="18" font="0">•</text>
<text top="284" left="705" width="109" height="20" font="0"> Dialysis 13 studies </text>
<text top="301" left="698" width="125" height="20" font="0">RR 0.94 (0.82 to 1.07) </text>
<text top="320" left="698" width="7" height="18" font="0">•</text>
<text top="320" left="705" width="175" height="20" font="0"> Major CV events 7899 patients </text>
<text top="337" left="698" width="159" height="20" font="0">(included data from SHARP) </text>
<text top="356" left="698" width="7" height="18" font="0">•</text>
<text top="355" left="705" width="190" height="20" font="0"> Stat significant difference by CKD </text>
<text top="372" left="698" width="89" height="20" font="0">stage p &lt;0.001: </text>
<text top="391" left="698" width="7" height="18" font="0">•</text>
<text top="391" left="705" width="188" height="20" font="0"> CKD not on dialysis 14 studies or </text>
<text top="408" left="698" width="46" height="20" font="0">subsets </text>
<text top="427" left="698" width="7" height="18" font="0">•</text>
<text top="426" left="705" width="162" height="20" font="0"> Statin 2525/17912 (14%) vs. </text>
<text top="443" left="698" width="115" height="20" font="0">3361/18121 (18.5%) </text>
<text top="462" left="698" width="7" height="18" font="0">•</text>
<text top="462" left="705" width="129" height="20" font="0"> RR 0.76 (0.73 to 0.80) </text>
<text top="481" left="698" width="7" height="18" font="0">•</text>
<text top="480" left="705" width="102" height="20" font="0"> Dialysis 4 studies </text>
<text top="499" left="698" width="7" height="18" font="0">•</text>
<text top="499" left="705" width="107" height="20" font="0"> 0.95 (0.87 to 1.03) </text>
<text top="518" left="698" width="7" height="18" font="0">•</text>
<text top="517" left="705" width="203" height="20" font="0"> LDL reduction: -43.1 (-49.5 to -36.7) </text>
<text top="534" left="698" width="3" height="20" font="0"> </text>
<text top="551" left="698" width="103" height="20" font="7"><b>Safety endpoint:</b>  </text>
<text top="570" left="698" width="7" height="18" font="0">•</text>
<text top="570" left="705" width="187" height="20" font="0"> Cancer, elevated CKD, abnormal </text>
<text top="587" left="698" width="165" height="20" font="0">liver function, withdrawal from </text>
<text top="604" left="698" width="139" height="20" font="0">treatment, LDL reduction </text>
<text top="623" left="698" width="7" height="18" font="0">•</text>
<text top="622" left="705" width="189" height="20" font="0"> Adverse events (33 comparisons, </text>
<text top="640" left="698" width="92" height="20" font="0">45,568 patients) </text>
<text top="659" left="698" width="7" height="18" font="0">•</text>
<text top="658" left="705" width="147" height="20" font="0"> No differences from statin </text>
<text top="675" left="698" width="147" height="20" font="0">Cancer 0.96 (0.89 to 1.04) </text>
<text top="692" left="698" width="176" height="20" font="0">Elevated CK 1.11 (0.80 to 1.56) </text>
<text top="109" left="921" width="7" height="18" font="0">•</text>
<text top="108" left="928" width="189" height="20" font="0"> Estimates for CKD not on dialysis </text>
<text top="125" left="921" width="192" height="20" font="0">includes posthoc subgroup of prior </text>
<text top="143" left="921" width="29" height="20" font="0">trials </text>
<text top="162" left="921" width="7" height="18" font="0">•</text>
<text top="161" left="928" width="157" height="20" font="0"> Risk of bias: highest risk for </text>
<text top="178" left="921" width="154" height="20" font="0">selective outcome reporting </text>
<text top="195" left="921" width="169" height="20" font="0">For CKD not on dialysis not all </text>
<text top="213" left="921" width="196" height="20" font="0">reported concealment, 8 trials were </text>
<text top="230" left="921" width="160" height="20" font="0">post hoc analyses of general </text>
<text top="247" left="921" width="60" height="20" font="0">population </text>
<text top="264" left="921" width="150" height="20" font="0">Overall related high-quality </text>
<text top="282" left="921" width="53" height="20" font="0">evidence </text>
<text top="301" left="921" width="7" height="18" font="0">•</text>
<text top="300" left="928" width="182" height="20" font="0"> Limited by not able to report risk </text>
<text top="317" left="921" width="187" height="20" font="0">reduction per unit of LDL lowering </text>
<text top="334" left="921" width="3" height="20" font="0"> </text>
<text top="710" left="89" width="59" height="20" font="0">Upadhyay </text>
<text top="728" left="89" width="66" height="20" font="0">2012  <a href="data supplement.html#249">(218)</a> </text>
<text top="745" left="89" width="55" height="20" font="8"><a href="">22910936</a></text>
<text top="745" left="144" width="3" height="20" font="0"><a href=""> </a></text>
<text top="762" left="89" width="3" height="20" font="0"> </text>
<text top="710" left="217" width="92" height="20" font="7"><b>Aim:</b> synthesize </text>
<text top="728" left="217" width="91" height="20" font="0">evidence of lipid </text>
<text top="745" left="217" width="107" height="20" font="0">lowering on clinical </text>
<text top="762" left="217" width="117" height="20" font="0">outcomes in persons </text>
<text top="779" left="217" width="55" height="20" font="0">with CKD </text>
<text top="710" left="368" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="729" left="368" width="7" height="18" font="0">•</text>
<text top="729" left="375" width="36" height="20" font="0"> RCT  </text>
<text top="746" left="368" width="130" height="20" font="0">1 or more lipid lowering </text>
<text top="763" left="368" width="140" height="20" font="0">agent vs. no treatment or </text>
<text top="780" left="368" width="106" height="20" font="0">other lipid lowering </text>
<text top="710" left="539" width="113" height="20" font="7"><b>Intervention:</b> Statin </text>
<text top="728" left="539" width="7" height="20" font="0">  </text>
<text top="745" left="539" width="139" height="20" font="7"><b>Comparator:</b> Placebo or </text>
<text top="762" left="539" width="136" height="20" font="0">no treatment, usual care<b> </b></text>
<text top="712" left="698" width="79" height="20" font="7"><b>1</b>°<b> endpoint:</b>  </text>
<text top="731" left="698" width="7" height="18" font="0">•</text>
<text top="730" left="705" width="150" height="20" font="0"> For Cardiovascular events </text>
<text top="747" left="698" width="201" height="20" font="0">9 trials composite fatal and non-fatal </text>
<text top="764" left="698" width="123" height="20" font="0">CV events or need for </text>
<text top="782" left="698" width="96" height="20" font="0">revascularization </text>
<text top="712" left="921" width="7" height="18" font="0">•</text>
<text top="712" left="928" width="176" height="20" font="0"> Mostly report across all studies </text>
<text top="729" left="921" width="140" height="20" font="0">(dialysis and not dialysis) </text>
<text top="748" left="921" width="7" height="18" font="0">•</text>
<text top="747" left="928" width="129" height="20" font="0"> Good quality evidence </text>
<text top="766" left="921" width="7" height="18" font="0">•</text>
<text top="766" left="928" width="154" height="20" font="0"> Not enough participants on </text>
<text top="783" left="921" width="101" height="20" font="0">peritoneal dialysis </text>
</page>
<page number="193" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">193 </text>
<text top="107" left="217" width="3" height="20" font="0"> </text>
<text top="124" left="217" width="102" height="20" font="7"><b>Study type:</b> Meta-</text>
<text top="141" left="217" width="48" height="20" font="0">analysis </text>
<text top="159" left="217" width="3" height="20" font="0"> </text>
<text top="176" left="217" width="79" height="20" font="7"><b>Size:</b> 18 trials </text>
<text top="107" left="368" width="133" height="20" font="0">Adults and children with </text>
<text top="124" left="368" width="100" height="20" font="0">CKD of any stage </text>
<text top="143" left="368" width="7" height="18" font="0">•</text>
<text top="143" left="375" width="105" height="20" font="0"> f/u minimum 6 mo </text>
<text top="160" left="368" width="142" height="20" font="0">&gt;100 with CKD per group </text>
<text top="177" left="368" width="54" height="20" font="0">for adults </text>
<text top="194" left="368" width="3" height="20" font="0"> </text>
<text top="211" left="368" width="153" height="20" font="7"><b>Exclusion criteria:</b> trials of </text>
<text top="229" left="368" width="117" height="20" font="0">dietary supplements, </text>
<text top="246" left="368" width="90" height="20" font="0">binders, sterols. </text>
<text top="109" left="698" width="7" height="18" font="0">•</text>
<text top="108" left="705" width="179" height="20" font="0"> RR 0.78 (0.71 to 0.86) estimate </text>
<text top="125" left="698" width="82" height="20" font="0">across studies </text>
<text top="143" left="698" width="208" height="20" font="0">Did not report for dialysis studies only </text>
<text top="162" left="698" width="7" height="18" font="0">•</text>
<text top="161" left="705" width="77" height="20" font="0"> 9 trials on MI </text>
<text top="178" left="698" width="125" height="20" font="0">RR 0.74 (0.67 to 0.81) </text>
<text top="195" left="698" width="159" height="20" font="0">Consistent across all studies </text>
<text top="214" left="698" width="7" height="18" font="0">•</text>
<text top="214" left="705" width="97" height="20" font="0"> 9 trials on stroke </text>
<text top="231" left="698" width="125" height="20" font="0">RR 0.90 (0.63 to 1.27) </text>
<text top="248" left="698" width="3" height="20" font="0"> </text>
<text top="265" left="698" width="188" height="20" font="7"><b>Safety endpoint:</b> Adverse events </text>
<text top="283" left="698" width="46" height="20" font="0">14 trials </text>
<text top="300" left="698" width="83" height="20" font="0">No differences<b> </b></text>
<text top="109" left="921" width="7" height="18" font="0">•</text>
<text top="108" left="928" width="129" height="20" font="0"> Heterogeneity in study </text>
<text top="125" left="921" width="66" height="20" font="0">populations </text>
<text top="144" left="921" width="7" height="18" font="0">•</text>
<text top="144" left="928" width="180" height="20" font="0"> Subgroup analyses are majority </text>
<text top="161" left="921" width="178" height="20" font="0">of CKD data- can introduce bias </text>
<text top="180" left="921" width="7" height="18" font="0">•</text>
<text top="179" left="928" width="168" height="20" font="0"> Combined LIPID, WOSCOPS </text>
<text top="197" left="921" width="152" height="20" font="0">AND CARE and used meta-</text>
<text top="214" left="921" width="155" height="20" font="0">analysis estimates for these </text>
<text top="231" left="921" width="147" height="20" font="0">studies published together </text>
<text top="248" left="921" width="3" height="20" font="0"> </text>
<text top="318" left="89" width="95" height="20" font="0">Major RW, et al., </text>
<text top="335" left="89" width="63" height="20" font="0">2015 <a href="data supplement.html#249">(219)</a> </text>
<text top="352" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25833405">25833405</a></text>
<text top="352" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25833405"> </a></text>
<text top="318" left="217" width="124" height="20" font="7"><b>Aim:</b> Meta-analysis of </text>
<text top="335" left="217" width="32" height="20" font="0">RCT  </text>
<text top="352" left="217" width="113" height="20" font="0">Focused on Primary </text>
<text top="370" left="217" width="105" height="20" font="0">Prevention in CKD </text>
<text top="387" left="217" width="3" height="20" font="0"> </text>
<text top="404" left="217" width="102" height="20" font="7"><b>Study type:</b> Meta-</text>
<text top="421" left="217" width="48" height="20" font="0">analysis </text>
<text top="438" left="217" width="3" height="20" font="0"> </text>
<text top="456" left="217" width="137" height="20" font="7"><b>Size:</b> 8,834 persons in 6 </text>
<text top="473" left="217" width="29" height="20" font="0">trials </text>
<text top="318" left="368" width="148" height="20" font="7"><b>Inclusion criteria:</b> RCT of </text>
<text top="335" left="368" width="154" height="20" font="0">lipid lowering, CKD patients </text>
<text top="352" left="368" width="129" height="20" font="0">usually seen in primary </text>
<text top="370" left="368" width="106" height="20" font="0">care, with no CVD, </text>
<text top="387" left="368" width="136" height="20" font="0">minimum 6 mo follow up </text>
<text top="404" left="368" width="3" height="20" font="0"> </text>
<text top="421" left="368" width="139" height="20" font="7"><b>Exclusion criteria:</b> trials </text>
<text top="438" left="368" width="137" height="20" font="0">that included persons on </text>
<text top="456" left="368" width="134" height="20" font="0">dialysis, or persons with </text>
<text top="473" left="368" width="134" height="20" font="0">macroalbuminuria (ACR </text>
<text top="490" left="368" width="126" height="20" font="0">≥300) or primary renal </text>
<text top="507" left="368" width="66" height="20" font="0">pathologies </text>
<text top="318" left="539" width="113" height="20" font="7"><b>Intervention:</b> Statin </text>
<text top="335" left="539" width="7" height="20" font="0">  </text>
<text top="352" left="539" width="125" height="20" font="7"><b>Comparator:</b> Placebo<b> </b></text>
<text top="319" left="698" width="79" height="20" font="7"><b>1</b>°<b> endpoint:</b>  </text>
<text top="338" left="698" width="7" height="18" font="0">•</text>
<text top="337" left="705" width="101" height="20" font="0"> In CKD stage 1-3 </text>
<text top="355" left="698" width="157" height="20" font="0">Major cardiovascular events </text>
<text top="372" left="698" width="125" height="20" font="0">RR 0.59 (0.48 to 0.72) </text>
<text top="391" left="698" width="7" height="18" font="0">•</text>
<text top="390" left="705" width="190" height="20" font="0"> Total events 409 32,846-person y </text>
<text top="407" left="698" width="31" height="20" font="0">of f/u </text>
<text top="426" left="698" width="7" height="18" font="0">•</text>
<text top="426" left="705" width="155" height="20" font="0"> No statistical heterogeneity </text>
<text top="320" left="921" width="7" height="18" font="0">•</text>
<text top="319" left="928" width="103" height="20" font="0"> Excluded SHARP </text>
<text top="338" left="921" width="7" height="18" font="0">•</text>
<text top="337" left="928" width="165" height="20" font="0"> Represents a lower CVD risk </text>
<text top="355" left="921" width="171" height="20" font="0">group of CKD patients but also </text>
<text top="372" left="921" width="169" height="20" font="0">those more likely to be seen in </text>
<text top="389" left="921" width="72" height="20" font="0">primary care </text>
<text top="525" left="89" width="94" height="20" font="0">Baigent C, et al., </text>
<text top="542" left="89" width="56" height="20" font="0">2010 <a href="data supplement.html#236">(13)</a> </text>
<text top="560" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21067804">21067804</a></text>
<text top="560" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21067804"> </a></text>
<text top="525" left="217" width="136" height="20" font="7"><b>Aim: </b>safety and efficacy </text>
<text top="542" left="217" width="123" height="20" font="0">of more intensive LDL </text>
<text top="560" left="217" width="49" height="20" font="0">lowering<b> </b></text>
<text top="577" left="217" width="3" height="20" font="7"><b> </b></text>
<text top="594" left="217" width="102" height="20" font="7"><b>Study type: </b>meta-</text>
<text top="611" left="217" width="90" height="20" font="0">analysis of RCT<b> </b></text>
<text top="628" left="217" width="3" height="20" font="7"><b> </b></text>
<text top="646" left="217" width="87" height="20" font="7"><b>Size: </b>&gt;170,000<b> </b></text>
<text top="525" left="368" width="109" height="20" font="7"><b>Inclusion criteria:  </b></text>
<text top="544" left="368" width="7" height="18" font="0">•</text>
<text top="543" left="375" width="105" height="20" font="0"> RCT that included </text>
<text top="561" left="368" width="104" height="20" font="0">&gt;1000 participants </text>
<text top="578" left="368" width="116" height="20" font="0">At least 2 y follow up </text>
<text top="597" left="368" width="7" height="18" font="0">•</text>
<text top="596" left="375" width="131" height="20" font="0"> More vs. less intensive </text>
<text top="614" left="368" width="84" height="20" font="0">statin (5 trials)  </text>
<text top="631" left="368" width="22" height="20" font="0">OR </text>
<text top="648" left="368" width="149" height="20" font="0">Statin vs. control (12 trials) </text>
<text top="667" left="368" width="7" height="18" font="0">•</text>
<text top="666" left="375" width="129" height="20" font="0"> Note: included trials of </text>
<text top="683" left="368" width="141" height="20" font="0">persons with known CVD </text>
<text top="701" left="368" width="3" height="20" font="7"><b> </b></text>
<text top="718" left="368" width="134" height="20" font="7"><b>Exclusion criteria: </b>N/A </text>
<text top="525" left="539" width="135" height="20" font="7"><b>Intervention: Statin (or </b></text>
<text top="542" left="539" width="77" height="20" font="7"><b>higher dose) </b></text>
<text top="560" left="539" width="7" height="20" font="7"><b>  </b></text>
<text top="577" left="539" width="81" height="20" font="7"><b>Comparator: </b> </text>
<text top="526" left="698" width="79" height="20" font="7"><b>1</b>°<b> endpoint: </b> </text>
<text top="545" left="698" width="7" height="18" font="0">•</text>
<text top="545" left="705" width="196" height="20" font="0"> (of relevance to this section) report </text>
<text top="562" left="698" width="56" height="20" font="0">by eGFR  </text>
<text top="579" left="698" width="208" height="20" font="0">Major vascular event (first occurrence </text>
<text top="596" left="698" width="196" height="20" font="0">of any major coronary event, stroke </text>
<text top="614" left="698" width="114" height="20" font="0">or revascularization) </text>
<text top="633" left="698" width="7" height="18" font="0">•</text>
<text top="632" left="705" width="64" height="20" font="0"> eGFR &lt;60 </text>
<text top="649" left="698" width="209" height="20" font="0">statin group 2712 events (4.1% per y) </text>
<text top="666" left="698" width="204" height="20" font="0">vs. 3354 (5.15 per y), RR: 0.77 (0.72-</text>
<text top="683" left="698" width="31" height="20" font="0">0.83) </text>
<text top="703" left="698" width="7" height="18" font="0">•</text>
<text top="702" left="705" width="198" height="20" font="0"> no heterogeneity when considering </text>
<text top="719" left="698" width="148" height="20" font="0">eGFR 60-90 or &gt;90; p=0.9 </text>
<text top="736" left="698" width="3" height="20" font="7"><b> </b></text>
<text top="753" left="698" width="187" height="20" font="7"><b>Safety endpoint: </b>not reported for </text>
<text top="771" left="698" width="84" height="20" font="0">CKD subgroup </text>
<text top="788" left="698" width="3" height="20" font="7"><b> </b></text>
<text top="525" left="921" width="186" height="20" font="0">Benefit of statin does not differ by </text>
<text top="542" left="921" width="188" height="20" font="0">GFR (when comparing egFR &gt;90, </text>
<text top="560" left="921" width="67" height="20" font="0">60-90, &lt;60) </text>
<text top="577" left="921" width="3" height="20" font="0"> </text>
</page>
<page number="194" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">194 </text>
<text top="107" left="89" width="96" height="20" font="0">Wanner C, et al., </text>
<text top="124" left="89" width="63" height="20" font="0">2005 <a href="data supplement.html#249">(220)</a> </text>
<text top="141" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16034009">16034009</a></text>
<text top="141" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/16034009"> </a></text>
<text top="107" left="217" width="131" height="20" font="7"><b>Aim:</b> Effectiveness and </text>
<text top="124" left="217" width="119" height="20" font="0">safety of statin use in </text>
<text top="141" left="217" width="109" height="20" font="0">persons with type 2 </text>
<text top="159" left="217" width="111" height="20" font="0">diabetes on dialysis </text>
<text top="176" left="217" width="3" height="20" font="0"> </text>
<text top="193" left="217" width="99" height="20" font="7"><b>Study type:</b> RCT </text>
<text top="210" left="217" width="137" height="20" font="0">Multicenter, double blind </text>
<text top="227" left="217" width="3" height="20" font="0"> </text>
<text top="245" left="217" width="66" height="20" font="7"><b>Size:</b> 1,255<b> </b></text>
<text top="107" left="368" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="126" left="368" width="7" height="18" font="0">•</text>
<text top="125" left="375" width="141" height="20" font="0"> 18-80 y, type 2 diabetes, </text>
<text top="143" left="368" width="106" height="20" font="0">on dialysis for &lt;2 y </text>
<text top="162" left="368" width="7" height="18" font="0">•</text>
<text top="161" left="375" width="84" height="20" font="0"> Total N= 1255 </text>
<text top="178" left="368" width="68" height="20" font="0">randomized </text>
<text top="195" left="368" width="3" height="20" font="0"> </text>
<text top="213" left="368" width="157" height="20" font="7"><b>Exclusion criteria:</b> LDL&lt;80 </text>
<text top="230" left="368" width="118" height="20" font="0">or &gt;190, triglycerides </text>
<text top="247" left="368" width="138" height="20" font="0">&gt;1000, LFTs &gt;3x normal </text>
<text top="264" left="368" width="114" height="20" font="0">limit, congestive HF, </text>
<text top="282" left="368" width="137" height="20" font="0">vascular intervention, MI </text>
<text top="299" left="368" width="143" height="20" font="0">within 3 mo, unsuccessful </text>
<text top="316" left="368" width="150" height="20" font="0">kidney transplant, resistant </text>
<text top="333" left="368" width="29" height="20" font="0">HTN<b> </b></text>
<text top="107" left="539" width="121" height="20" font="7"><b>Intervention:</b> N=619  </text>
<text top="124" left="539" width="130" height="20" font="0">Placebo run-in period 4 </text>
<text top="141" left="539" width="118" height="20" font="0">wk (discontinued any </text>
<text top="159" left="539" width="102" height="20" font="0">prior lipid lowering </text>
<text top="176" left="539" width="67" height="20" font="0">medication) </text>
<text top="193" left="539" width="134" height="20" font="0">Placebo vs. atorvastatin </text>
<text top="210" left="539" width="38" height="20" font="0">20 mg </text>
<text top="228" left="539" width="7" height="20" font="0">  </text>
<text top="245" left="539" width="144" height="20" font="7"><b>Comparator:</b> Placebo N= </text>
<text top="262" left="539" width="31" height="20" font="0">636  <b> </b></text>
<text top="108" left="698" width="79" height="20" font="7"><b>1</b>°<b> endpoint:</b>  </text>
<text top="127" left="698" width="7" height="18" font="0">•</text>
<text top="127" left="705" width="185" height="20" font="0"> Composite of death from cardiac </text>
<text top="144" left="698" width="192" height="20" font="0">causes, fatal stroke, nonfatal MI or </text>
<text top="161" left="698" width="176" height="20" font="0">stroke (only 1 event per patient) </text>
<text top="180" left="698" width="7" height="18" font="0">•</text>
<text top="179" left="705" width="172" height="20" font="0"> Secondary endpoint: all cause </text>
<text top="197" left="698" width="196" height="20" font="0">death, all cardiac events combined, </text>
<text top="214" left="698" width="203" height="20" font="0">all cerebrovascular events combined </text>
<text top="233" left="698" width="7" height="18" font="0">•</text>
<text top="232" left="705" width="195" height="20" font="0"> LDL reduction: 42% in intervention </text>
<text top="249" left="698" width="110" height="20" font="0">vs. 1.3% in placebo </text>
<text top="269" left="698" width="7" height="18" font="0">•</text>
<text top="268" left="705" width="182" height="20" font="0"> Cumulative incidence of primary </text>
<text top="285" left="698" width="195" height="20" font="0">outcome: 31.9 at 3 y in intervention </text>
<text top="302" left="698" width="190" height="20" font="0">vs. 30.5% in placebo 0.92 (0.77 to </text>
<text top="320" left="698" width="76" height="20" font="0">1.10), p=0.37 </text>
<text top="339" left="698" width="7" height="18" font="0">•</text>
<text top="338" left="705" width="189" height="20" font="0"> Secondary endpoint of all cardiac </text>
<text top="355" left="698" width="201" height="20" font="0">events combined 0.82 (0.68 to 0.99) </text>
<text top="372" left="698" width="208" height="20" font="0">but not significant for cerebrovascular </text>
<text top="390" left="698" width="203" height="20" font="0">events combined (RR: 1.12; 95% CI: </text>
<text top="407" left="698" width="209" height="20" font="0">0.81-1.55) or total mortality, RR: 0.93; </text>
<text top="424" left="698" width="106" height="20" font="0">95% CI: 0.79-1.08. </text>
<text top="441" left="698" width="3" height="20" font="0"> </text>
<text top="458" left="698" width="168" height="20" font="7"><b>Safety endpoint:</b> No cases of </text>
<text top="476" left="698" width="169" height="20" font="0">rhabdomyolysis or severe liver </text>
<text top="493" left="698" width="148" height="20" font="0">dysfunction in either group </text>
<text top="510" left="698" width="143" height="20" font="0"> No differences in cancer  </text>
<text top="527" left="698" width="202" height="20" font="0">No differences in myalgia, myopathy </text>
<text top="544" left="698" width="201" height="20" font="0">CK levels 3-5 x normal (3 in placebo </text>
<text top="562" left="698" width="82" height="20" font="0">vs. 11 in statin </text>
<text top="109" left="921" width="7" height="18" font="0">•</text>
<text top="108" left="928" width="186" height="20" font="0"> IF LDL fell below 50, atorvastatin </text>
<text top="125" left="921" width="129" height="20" font="0">dose reduced to 10 mg </text>
<text top="144" left="921" width="7" height="18" font="0">•</text>
<text top="144" left="928" width="131" height="20" font="0"> Higher rate of stroke in </text>
<text top="161" left="921" width="186" height="20" font="0">atorvastatin group RR: 2.03 (1.05-</text>
<text top="178" left="921" width="31" height="20" font="0">3.93) </text>
<text top="197" left="921" width="7" height="18" font="0">•</text>
<text top="197" left="928" width="190" height="20" font="0"> Revascularization procedures not </text>
<text top="214" left="921" width="157" height="20" font="0">included in primary outcome </text>
<text top="231" left="921" width="3" height="20" font="0"> </text>
<text top="580" left="89" width="57" height="20" font="7"><b>AURORA </b></text>
<text top="597" left="89" width="112" height="20" font="0">Fellstrӧm BC, et al., </text>
<text top="615" left="89" width="63" height="20" font="0">2009 <a href="data supplement.html#249">(221)</a> </text>
<text top="632" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19332456">19332456</a></text>
<text top="632" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19332456"> </a></text>
<text top="580" left="217" width="79" height="20" font="7"><b>Aim:</b> Effect of </text>
<text top="597" left="217" width="124" height="20" font="0">rosuvastatin to reduce </text>
<text top="614" left="217" width="137" height="20" font="0">CV events in patients on </text>
<text top="631" left="217" width="75" height="20" font="0">hemodialysis </text>
<text top="648" left="217" width="3" height="20" font="0"> </text>
<text top="666" left="217" width="137" height="20" font="7"><b>Study type:</b> multicenter, </text>
<text top="683" left="217" width="98" height="20" font="0">double blind RCT </text>
<text top="700" left="217" width="3" height="20" font="0"> </text>
<text top="717" left="217" width="66" height="20" font="7"><b>Size:</b> 2,776<b> </b></text>
<text top="580" left="368" width="149" height="20" font="7"><b>Inclusion criteria:</b> Age 50-</text>
<text top="597" left="368" width="17" height="20" font="0">80 </text>
<text top="614" left="368" width="148" height="20" font="0">On hemodialysis at least 3 </text>
<text top="631" left="368" width="21" height="20" font="0">mo </text>
<text top="648" left="368" width="3" height="20" font="0"> </text>
<text top="666" left="368" width="139" height="20" font="7"><b>Exclusion criteria:</b> Prior </text>
<text top="683" left="368" width="150" height="20" font="0">statin therapy within prior 6 </text>
<text top="700" left="368" width="21" height="20" font="0">mo </text>
<text top="717" left="368" width="151" height="20" font="0">Expected kidney transplant </text>
<text top="734" left="368" width="55" height="20" font="0">within 1 y </text>
<text top="752" left="368" width="118" height="20" font="0">Serious hematologic, </text>
<text top="769" left="368" width="152" height="20" font="0">neoplastic, gastrointestinal, </text>
<text top="786" left="368" width="126" height="20" font="0">infectious or metabolic </text>
<text top="580" left="539" width="78" height="20" font="7"><b>Intervention:</b> </text>
<text top="597" left="539" width="141" height="20" font="0">Rosuvastatin 10 mg daily </text>
<text top="614" left="539" width="7" height="20" font="0">  </text>
<text top="631" left="539" width="125" height="20" font="7"><b>Comparator:</b> Placebo<b> </b></text>
<text top="581" left="698" width="79" height="20" font="7"><b>1</b>°<b> endpoint:</b>  </text>
<text top="600" left="698" width="7" height="18" font="0">•</text>
<text top="599" left="705" width="192" height="20" font="0"> LDL reduction 43% in statin group </text>
<text top="618" left="698" width="7" height="18" font="0">•</text>
<text top="617" left="705" width="125" height="20" font="0"> Follow-up mean 3.2 y </text>
<text top="636" left="698" width="7" height="18" font="0">•</text>
<text top="636" left="705" width="192" height="20" font="0"> Time to major CV event (non-fatal </text>
<text top="653" left="698" width="165" height="20" font="0">MI or stroke or death from CV </text>
<text top="670" left="698" width="46" height="20" font="0">causes) </text>
<text top="687" left="698" width="203" height="20" font="0">Event rate: 9.2 statin vs. 9.5 placebo </text>
<text top="705" left="698" width="103" height="20" font="0">(per 100 patient y) </text>
<text top="722" left="698" width="116" height="20" font="0">HR: 0.96 (0.84-1.11) </text>
<text top="741" left="698" width="7" height="18" font="0">•</text>
<text top="740" left="705" width="174" height="20" font="0"> Selected Secondary endpoints </text>
<text top="757" left="698" width="166" height="20" font="0">(event rates per 100-person-y </text>
<text top="775" left="698" width="169" height="20" font="0">rosuvastatin vs. placebo): total </text>
<text top="581" left="921" width="7" height="18" font="0">•</text>
<text top="581" left="928" width="165" height="20" font="0"> Excluded patients already on </text>
<text top="598" left="921" width="146" height="20" font="0">statins (and so could have </text>
<text top="615" left="921" width="192" height="20" font="0">recruited lower risk HD population) </text>
<text top="634" left="921" width="7" height="18" font="0">•</text>
<text top="633" left="928" width="181" height="20" font="0"> Lower event rate than 4D, lower </text>
<text top="651" left="921" width="178" height="20" font="0">than observed in population and </text>
<text top="668" left="921" width="117" height="20" font="0">lower than expected  </text>
<text top="687" left="921" width="7" height="18" font="0">•</text>
<text top="686" left="928" width="153" height="20" font="0"> Relatively high rate of drug </text>
<text top="703" left="921" width="85" height="20" font="0">discontinuation </text>
<text top="722" left="921" width="7" height="18" font="0">•</text>
<text top="722" left="928" width="169" height="20" font="0"> Uncertainty on adjudication of </text>
<text top="739" left="921" width="90" height="20" font="0">vascular deaths </text>
</page>
<page number="195" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">195 </text>
<text top="107" left="368" width="154" height="20" font="0">disease, malignancy, active </text>
<text top="124" left="368" width="141" height="20" font="0">liver disease, elevation in </text>
<text top="141" left="368" width="21" height="20" font="0">CK<b> </b></text>
<text top="107" left="698" width="189" height="20" font="0">mortality (13.5 vs. 14), nonfatal MI </text>
<text top="124" left="698" width="176" height="20" font="0">(2.1 vs. 2.5), stroke 1.2 vs. 1.1), </text>
<text top="141" left="698" width="209" height="20" font="0">procedures for stenosis or thrombosis </text>
<text top="159" left="698" width="180" height="20" font="0">(10.9 vs. 10) of vascular access, </text>
<text top="176" left="698" width="187" height="20" font="0">death from cardiovascular causes </text>
<text top="193" left="698" width="72" height="20" font="0">(7.2 vs. 7.3). </text>
<text top="210" left="698" width="3" height="20" font="0"> </text>
<text top="227" left="698" width="103" height="20" font="7"><b>Safety endpoint:</b>  </text>
<text top="247" left="698" width="7" height="18" font="0">•</text>
<text top="246" left="705" width="187" height="20" font="0"> Serious adverse events requiring </text>
<text top="263" left="698" width="189" height="20" font="0">permanent discontinuation of drug </text>
<text top="280" left="698" width="127" height="20" font="0">(31.5 vs. 32.1), p=0.78 </text>
<text top="298" left="698" width="3" height="20" font="0"> </text>
<text top="317" left="698" width="7" height="18" font="0">•</text>
<text top="316" left="705" width="178" height="20" font="0"> No significant differences in CK </text>
<text top="333" left="698" width="162" height="20" font="0">levels, LFTs, rhabdomyolysis </text>
<text top="351" left="81" width="4" height="22" font="1"> </text>
<text top="370" left="81" width="1023" height="24" font="4"><b>Data Supplement 38. RCTs Comparing PLACEBO VS. Statin (or Statin plus another agent) to reduce CVD events in persons with Albuminuria and </b></text>
<text top="390" left="81" width="222" height="24" font="4"><b>preserved eGFR (Section 4.5.4) </b></text>
<text top="421" left="97" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="438" left="123" width="48" height="20" font="7"><b>Author; </b></text>
<text top="455" left="100" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="421" left="244" width="83" height="20" font="7"><b>Aim of Study; </b></text>
<text top="438" left="249" width="74" height="20" font="7"><b>Study Type; </b></text>
<text top="455" left="243" width="86" height="20" font="7"><b>Study Size (N) </b></text>
<text top="438" left="391" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="412" left="557" width="111" height="20" font="7"><b>Study Intervention </b></text>
<text top="429" left="574" width="76" height="20" font="7"><b>(# patients) / </b></text>
<text top="447" left="557" width="111" height="20" font="7"><b>Study Comparator </b></text>
<text top="464" left="578" width="69" height="20" font="7"><b>(# patients) </b></text>
<text top="421" left="751" width="105" height="20" font="7"><b>Endpoint Results </b></text>
<text top="438" left="735" width="137" height="20" font="7"><b>(Absolute Event Rates, </b></text>
<text top="455" left="713" width="181" height="20" font="7"><b>P values; OR or RR; &amp; 95% CI) </b></text>
<text top="421" left="932" width="175" height="20" font="7"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="438" left="964" width="111" height="20" font="7"><b>Study Limitations; </b></text>
<text top="456" left="971" width="96" height="20" font="7"><b>Adverse Events </b></text>
<text top="482" left="89" width="109" height="20" font="0">Colhoun HM, et al., </text>
<text top="499" left="89" width="63" height="20" font="0">2009 <a href="data supplement.html#249">(222)</a> </text>
<text top="516" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19540640">19540640</a></text>
<text top="516" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19540640"> </a></text>
<text top="482" left="217" width="135" height="20" font="7"><b>Aim:</b> Subgroup analysis </text>
<text top="499" left="217" width="90" height="20" font="0">of major RCT to </text>
<text top="516" left="217" width="133" height="20" font="0">evaluate whether eGFR </text>
<text top="533" left="217" width="118" height="20" font="0">or albuminuria status </text>
<text top="551" left="217" width="133" height="20" font="0">modify effect of statin to </text>
<text top="568" left="217" width="70" height="20" font="0">reduce CVD </text>
<text top="585" left="217" width="3" height="20" font="0"> </text>
<text top="602" left="217" width="118" height="20" font="7"><b>Study type:</b> Posthoc </text>
<text top="619" left="217" width="97" height="20" font="0">subgroup of RCT </text>
<text top="637" left="217" width="3" height="20" font="0"> </text>
<text top="654" left="217" width="66" height="20" font="7"><b>Size:</b> 2,838 </text>
<text top="482" left="368" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="501" left="368" width="7" height="18" font="0">•</text>
<text top="500" left="375" width="134" height="20" font="0"> Type 2 diabetes +1 risk </text>
<text top="517" left="368" width="116" height="20" font="0">factor (hypertension, </text>
<text top="534" left="368" width="138" height="20" font="0">retinopathy, albuminuria, </text>
<text top="552" left="368" width="53" height="20" font="0">smoking) </text>
<text top="571" left="368" width="7" height="18" font="0">•</text>
<text top="570" left="375" width="80" height="20" font="0"> No prior CVD </text>
<text top="587" left="368" width="3" height="20" font="0"> </text>
<text top="604" left="368" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="623" left="368" width="7" height="18" font="0">•</text>
<text top="623" left="375" width="48" height="20" font="0"> Cr &gt;1.7 </text>
<text top="642" left="368" width="7" height="18" font="0">•</text>
<text top="641" left="375" width="86" height="20" font="0"> HgbA1c &gt;12% </text>
<text top="660" left="368" width="7" height="18" font="0">•</text>
<text top="660" left="375" width="91" height="20" font="0"> LD &gt;160 mg/dL </text>
<text top="677" left="368" width="3" height="20" font="0"> </text>
<text top="482" left="539" width="78" height="20" font="7"><b>Intervention:</b> </text>
<text top="499" left="539" width="106" height="20" font="0">Atorvastatin 10 mg </text>
<text top="516" left="539" width="7" height="20" font="0">  </text>
<text top="533" left="539" width="125" height="20" font="7"><b>Comparator:</b> Placebo<b> </b></text>
<text top="483" left="698" width="79" height="20" font="7"><b>1</b>°<b> endpoint:</b>  </text>
<text top="502" left="698" width="7" height="18" font="0">•</text>
<text top="501" left="705" width="104" height="20" font="0"> Major CVD event  </text>
<text top="518" left="698" width="72" height="20" font="0">(median 4 y) </text>
<text top="537" left="698" width="7" height="18" font="0">•</text>
<text top="537" left="705" width="202" height="20" font="0"> No difference in CVD reduction with </text>
<text top="554" left="698" width="148" height="20" font="0">statin by eGFR at baseline </text>
<text top="573" left="698" width="7" height="18" font="0">•</text>
<text top="572" left="705" width="198" height="20" font="0"> No difference in treatment effect by </text>
<text top="590" left="698" width="67" height="20" font="0">albuminuria </text>
<text top="607" left="698" width="94" height="20" font="0">Major CV events </text>
<text top="624" left="698" width="202" height="20" font="0">Albuminuria 13.8 vs. 8.7%, HR: 0.59 </text>
<text top="641" left="698" width="111" height="20" font="0">(95% CI: 0.36-0.99) </text>
<text top="658" left="698" width="189" height="20" font="0">No albuminuria: 7.8 vs. 5.1%, HR: </text>
<text top="676" left="698" width="135" height="20" font="0">0.64 (95% CI:0.46-0.89) </text>
<text top="482" left="921" width="188" height="20" font="0">Note: eGFR&lt;60 had no increased </text>
<text top="499" left="921" width="178" height="20" font="0">incidence of CV events or death </text>
<text top="516" left="921" width="147" height="20" font="0">compared with eGFR &gt;60  </text>
<text top="695" left="89" width="104" height="20" font="0">Asselbergs FW, et </text>
<text top="712" left="89" width="83" height="20" font="0">al., 2004 <a href="data supplement.html#249">(223)</a> </text>
<text top="729" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15492322">15492322</a></text>
<text top="729" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=15492322"> </a></text>
<text top="695" left="217" width="121" height="20" font="7"><b>Aim:</b> assess ability of </text>
<text top="712" left="217" width="76" height="20" font="0">fosinopril and </text>
<text top="729" left="217" width="118" height="20" font="0">pravastatin to reduce </text>
<text top="746" left="217" width="129" height="20" font="0">CVD events in persons </text>
<text top="764" left="217" width="122" height="20" font="0">with microalbuminuria </text>
<text top="781" left="217" width="3" height="20" font="0"> </text>
<text top="695" left="368" width="106" height="20" font="7"><b>Inclusion criteria:</b> </text>
<text top="712" left="368" width="155" height="20" font="0">Persistent microalbuminuria </text>
<text top="729" left="368" width="113" height="20" font="0">(15 to 300 mg/24 H) </text>
<text top="746" left="368" width="75" height="20" font="0">BP &lt;160/100 </text>
<text top="764" left="368" width="149" height="20" font="0">No use of antihypertensive </text>
<text top="781" left="368" width="63" height="20" font="0">medication </text>
<text top="695" left="539" width="101" height="20" font="7"><b>Intervention:</b> 2x2 </text>
<text top="712" left="539" width="46" height="20" font="0">factorial </text>
<text top="729" left="539" width="103" height="20" font="0">Pravastatin 40 mg </text>
<text top="746" left="539" width="57" height="20" font="0">Fosinopril </text>
<text top="764" left="539" width="48" height="20" font="0">Placebo </text>
<text top="781" left="539" width="7" height="20" font="0">  </text>
<text top="696" left="698" width="79" height="20" font="7"><b>1</b>°<b> endpoint:</b>  </text>
<text top="715" left="698" width="7" height="18" font="0">•</text>
<text top="714" left="705" width="183" height="20" font="0"> Combined incident CV mortality, </text>
<text top="731" left="698" width="202" height="20" font="0">hospitalization for CV morbidity (non-</text>
<text top="749" left="698" width="199" height="20" font="0">fatal MI or ischemia, congestive HF, </text>
<text top="766" left="698" width="76" height="20" font="0">PAD or CVA) </text>
<text top="785" left="698" width="7" height="18" font="0">•</text>
<text top="784" left="705" width="150" height="20" font="0"> In pravastatin vs. placebo  </text>
<text top="695" left="921" width="158" height="20" font="0">Fewer events than expected </text>
<text top="712" left="921" width="164" height="20" font="0">Study powered to detect 35% </text>
<text top="729" left="921" width="176" height="20" font="0">reduction in events for statin vs. </text>
<text top="746" left="921" width="196" height="20" font="0">placebo assuming incidence rate of </text>
<text top="764" left="921" width="91" height="20" font="0">15% in placebo  </text>
</page>
<page number="196" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">196 </text>
<text top="107" left="217" width="94" height="20" font="7"><b>Study type:</b> 2x2 </text>
<text top="124" left="217" width="79" height="20" font="0">factorial RCT  </text>
<text top="141" left="217" width="75" height="20" font="0">Single center </text>
<text top="159" left="217" width="72" height="20" font="0">Double blind </text>
<text top="176" left="217" width="3" height="20" font="0"> </text>
<text top="193" left="217" width="112" height="20" font="7"><b>Size:</b> 864, &lt;3% had </text>
<text top="210" left="217" width="50" height="20" font="0">diabetes </text>
<text top="107" left="368" width="130" height="20" font="0">No use of lipid lowering </text>
<text top="124" left="368" width="33" height="20" font="0">meds </text>
<text top="141" left="368" width="159" height="20" font="0">Cholesterol &lt;8.0 mmol/L (&lt;5 </text>
<text top="159" left="368" width="59" height="20" font="0">if prior MI) </text>
<text top="176" left="368" width="3" height="20" font="0"> </text>
<text top="193" left="368" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="212" left="368" width="7" height="18" font="0">•</text>
<text top="211" left="375" width="128" height="20" font="0"> Crl Cl &lt;60% or normal </text>
<text top="229" left="368" width="135" height="20" font="0">age adjusted and use of </text>
<text top="246" left="368" width="57" height="20" font="0">ACE/ARB </text>
<text top="265" left="368" width="7" height="18" font="0">•</text>
<text top="264" left="375" width="94" height="20" font="0"> Duration: 46 mo </text>
<text top="281" left="368" width="3" height="20" font="0"> </text>
<text top="107" left="539" width="125" height="20" font="7"><b>Comparator:</b> Placebo<b> </b></text>
<text top="107" left="698" width="192" height="20" font="0">LDL reduction in pravastatin group </text>
<text top="124" left="698" width="168" height="20" font="0">4.1 to 3.1 (25%) mmol/L at 4 y </text>
<text top="143" left="698" width="7" height="18" font="0">•</text>
<text top="143" left="705" width="103" height="20" font="0"> Primary endpoint: </text>
<text top="160" left="698" width="183" height="20" font="0">Rate of events 5.2% (N=45) over </text>
<text top="177" left="698" width="75" height="20" font="0">mean 46 mo. </text>
<text top="196" left="698" width="7" height="18" font="0">•</text>
<text top="195" left="705" width="178" height="20" font="0"> 4.8% in statin vs. 5.6% placebo </text>
<text top="214" left="698" width="7" height="18" font="0">•</text>
<text top="214" left="705" width="129" height="20" font="0"> RR 0.87 (0.49 to 1.57) </text>
<text top="231" left="698" width="3" height="20" font="0"> </text>
<text top="248" left="698" width="183" height="20" font="7"><b>Safety endpoint:</b> Intolerability of </text>
<text top="265" left="698" width="207" height="20" font="0">statin (5.1 in placebo vs. 3.0 in statin) </text>
<text top="283" left="698" width="3" height="20" font="7"><b> </b></text>
<text top="300" left="81" width="4" height="22" font="1"> </text>
<text top="319" left="81" width="4" height="22" font="1"> </text>
<text top="338" left="81" width="4" height="22" font="1"> </text>
<text top="357" left="81" width="921" height="24" font="4"><b>Data Supplement 39. Nonrandomized Trials, Observational Studies, and/or Registries of HIV/Inflammatory Diseases (Section 4.5.5)  </b></text>
<text top="379" left="119" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="396" left="144" width="48" height="20" font="7"><b>Author; </b></text>
<text top="413" left="122" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="387" left="274" width="118" height="20" font="7"><b>Study Type/Design; </b></text>
<text top="405" left="300" width="66" height="20" font="7"><b>Study Size </b></text>
<text top="396" left="460" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="387" left="656" width="179" height="20" font="7"><b>Primary Endpoint and Results </b></text>
<text top="405" left="653" width="184" height="20" font="7"><b>(P values; OR or RR; &amp; 95% CI) </b></text>
<text top="387" left="934" width="130" height="20" font="7"><b>Summary/Conclusion </b></text>
<text top="405" left="962" width="75" height="20" font="7"><b>Comment(s) </b></text>
<text top="431" left="91" width="119" height="20" font="0">Mantel A, et al., 2015 </text>
<text top="448" left="91" width="29" height="20" font="0"><a href="data supplement.html#249">(224)</a></text>
<text top="448" left="120" width="55" height="20" font="16"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28279294">28279294</a></text>
<text top="448" left="174" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28279294"> </a></text>
<text top="466" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="483" left="91" width="7" height="20" font="0"> <b> </b></text>
<text top="500" left="91" width="3" height="20" font="0"> </text>
<text top="431" left="259" width="136" height="20" font="7"><b>Study type:</b>  Population-</text>
<text top="448" left="259" width="135" height="20" font="0">based cohort of patients </text>
<text top="466" left="259" width="134" height="20" font="0">with rheumatoid arthritis </text>
<text top="483" left="259" width="104" height="20" font="0">(RA) with matched </text>
<text top="500" left="259" width="105" height="20" font="0">general population </text>
<text top="517" left="259" width="98" height="20" font="0">comparators who </text>
<text top="534" left="259" width="106" height="20" font="0">developed an ACS </text>
<text top="552" left="259" width="3" height="20" font="0"> </text>
<text top="569" left="259" width="3" height="20" font="0"> </text>
<text top="586" left="259" width="139" height="20" font="7"><b>Size:</b>  1,135 with RA and </text>
<text top="603" left="259" width="81" height="20" font="0">3184 matched </text>
<text top="621" left="259" width="75" height="20" font="0">comparators  </text>
<text top="431" left="420" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="450" left="420" width="11" height="18" font="0">• </text>
<text top="450" left="430" width="142" height="20" font="0">Age &gt;18 living in Sweden </text>
<text top="468" left="420" width="11" height="18" font="0">• </text>
<text top="468" left="430" width="155" height="20" font="0">with &gt;2 medical visits with a </text>
<text top="485" left="430" width="172" height="20" font="0">diagnosis of actively monitored </text>
<text top="502" left="430" width="21" height="20" font="0">RA </text>
<text top="521" left="420" width="11" height="18" font="0">• </text>
<text top="521" left="430" width="162" height="20" font="0">developed an acute coronary </text>
<text top="538" left="430" width="94" height="20" font="0">syndrome (ACS) </text>
<text top="557" left="420" width="11" height="18" font="0">• </text>
<text top="556" left="430" width="133" height="20" font="0">Population comparators </text>
<text top="573" left="430" width="178" height="20" font="0">matched for age, sex, education </text>
<text top="590" left="430" width="154" height="20" font="0">level, and area of residency </text>
<text top="608" left="420" width="3" height="20" font="0"> </text>
<text top="625" left="420" width="185" height="20" font="7"><b>Exclusion criteria:</b> If clinical visit </text>
<text top="642" left="420" width="147" height="20" font="0">did not occur from 2006-9  </text>
<text top="432" left="623" width="191" height="20" font="7"><b>1</b>°<b> endpoint:</b> Short-term mortality  </text>
<text top="450" left="623" width="3" height="20" font="0"> </text>
<text top="467" left="623" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="486" left="623" width="11" height="18" font="0">• </text>
<text top="485" left="631" width="212" height="20" font="0">Within first wk after ACS, 10.4% of RA </text>
<text top="502" left="631" width="222" height="20" font="0">cases vs. 6.7% of population cases died </text>
<text top="519" left="631" width="228" height="20" font="0">(age/sex-adjusted HR:1.65; 95% CI: 1.32-</text>
<text top="537" left="631" width="27" height="20" font="0">2.08 </text>
<text top="556" left="623" width="11" height="18" font="0">• </text>
<text top="555" left="631" width="229" height="20" font="0">Rates of deaths within 1 month after ACS </text>
<text top="572" left="631" width="232" height="20" font="0">was 15.7% among RA cases vs. 10.7% of </text>
<text top="589" left="631" width="197" height="20" font="0">population cases (age/sex-adjusted </text>
<text top="607" left="631" width="166" height="20" font="0">HR:=1.57; 95% CI: 1.30-1.89) </text>
<text top="626" left="623" width="11" height="18" font="0">• </text>
<text top="625" left="631" width="218" height="20" font="0">After adjustment for prior comorbidities, </text>
<text top="642" left="631" width="222" height="20" font="0">demographics, education, 7-d (HR:1.50; </text>
<text top="659" left="631" width="221" height="20" font="0">95% CI: 1.19-1.90;, 30-d HR: 1.43; 95% </text>
<text top="676" left="631" width="79" height="20" font="0">CI: 1.18-1.72) </text>
<text top="433" left="881" width="7" height="18" font="0">•</text>
<text top="432" left="888" width="225" height="20" font="0"> Patients with RA sustained more severe </text>
<text top="450" left="881" width="237" height="20" font="0">ACS with increased short-term mortality as </text>
<text top="467" left="881" width="192" height="20" font="0">compared with general population. </text>
<text top="484" left="881" width="214" height="20" font="0">They have worse outcomes after ACS, </text>
<text top="501" left="881" width="219" height="20" font="0">and this can only partly be explained by </text>
<text top="518" left="881" width="139" height="20" font="0">increased event severity. </text>
<text top="537" left="881" width="7" height="18" font="0">•</text>
<text top="537" left="888" width="201" height="20" font="0"> RA patients may have an increased </text>
<text top="554" left="881" width="235" height="20" font="0">frequency of vulnerable plaques as well as </text>
<text top="571" left="881" width="200" height="20" font="0">markers of endothelial damage, and </text>
<text top="588" left="881" width="126" height="20" font="0">prothrombotic factors.  </text>
<text top="607" left="881" width="7" height="18" font="0">•</text>
<text top="607" left="888" width="226" height="20" font="0">RA patients have an increased incidence </text>
<text top="624" left="881" width="42" height="20" font="0">of ACS </text>
<text top="694" left="91" width="124" height="20" font="0">Westerweel PE, et al., </text>
<text top="712" left="91" width="63" height="20" font="0">2007 <a href="data supplement.html#249">(225)</a> </text>
<text top="729" left="91" width="55" height="20" font="16"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17469095">17469095</a></text>
<text top="729" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17469095"> </a></text>
<text top="746" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="763" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="694" left="259" width="123" height="20" font="7"><b>Study type:</b> review of </text>
<text top="712" left="259" width="90" height="20" font="0">prospective and </text>
<text top="729" left="259" width="116" height="20" font="0">retrospective studies </text>
<text top="746" left="259" width="142" height="20" font="0">looking at CVD endpoints </text>
<text top="763" left="259" width="126" height="20" font="0">in adults with systemic </text>
<text top="694" left="420" width="174" height="20" font="7"><b>Inclusion criteria:</b> Studies that </text>
<text top="712" left="420" width="144" height="20" font="0">reported CV endpoints for </text>
<text top="729" left="420" width="182" height="20" font="0">populations with SLE vs. general </text>
<text top="746" left="420" width="170" height="20" font="0">population or those vs. healthy </text>
<text top="763" left="420" width="46" height="20" font="0">controls </text>
<text top="780" left="420" width="3" height="20" font="0"> </text>
<text top="695" left="623" width="175" height="20" font="7"><b>1</b>°<b> endpoint:</b> Incidence of CVD </text>
<text top="713" left="623" width="3" height="20" font="0"> </text>
<text top="730" left="623" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="749" left="623" width="11" height="18" font="0">• </text>
<text top="748" left="638" width="222" height="20" font="0">Incidence of MI was considerably higher </text>
<text top="765" left="638" width="228" height="20" font="0">in all age groups of women with SLE with </text>
<text top="696" left="881" width="7" height="18" font="0">•</text>
<text top="695" left="888" width="208" height="20" font="0">The increased CVD risk in adults with </text>
<text top="713" left="881" width="213" height="20" font="0">SLE is likely related to a propensity for </text>
<text top="730" left="881" width="230" height="20" font="0">thrombotic complications and accelerated </text>
<text top="747" left="881" width="93" height="20" font="0">atherosclerosis.  </text>
</page>
<page number="197" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">197 </text>
<text top="107" left="259" width="117" height="20" font="0">lupus erythematosus </text>
<text top="124" left="259" width="35" height="20" font="0">(SLE) </text>
<text top="141" left="259" width="3" height="20" font="0"> </text>
<text top="159" left="259" width="145" height="20" font="7"><b>Size:</b> 14,421 patients with </text>
<text top="176" left="259" width="27" height="20" font="0">SLE </text>
<text top="107" left="420" width="134" height="20" font="7"><b>Exclusion criteria:</b> N/A </text>
<text top="107" left="638" width="171" height="20" font="0">a 7-fold higher incidence in the </text>
<text top="124" left="638" width="110" height="20" font="0">Framingham cohort </text>
<text top="143" left="623" width="11" height="18" font="0">• </text>
<text top="143" left="638" width="215" height="20" font="0">Longer disease duration and treatment </text>
<text top="160" left="638" width="223" height="20" font="0">with glucocorticoids was associated with </text>
<text top="177" left="638" width="120" height="20" font="0">a higher MI incidence </text>
<text top="109" left="881" width="7" height="18" font="0">•</text>
<text top="108" left="888" width="177" height="20" font="0">Adults with SLE tend to develop </text>
<text top="125" left="881" width="215" height="20" font="0">subclinical atherosclerosis at an earlier </text>
<text top="143" left="881" width="27" height="20" font="0">age. </text>
<text top="162" left="881" width="7" height="18" font="0">•</text>
<text top="161" left="888" width="226" height="20" font="0">Hypertension and Dyslipidemia are more </text>
<text top="178" left="881" width="162" height="20" font="0">prevalent in adults with SLE.  </text>
<text top="196" left="91" width="126" height="20" font="0">Mehat NN, et al., 2010 </text>
<text top="213" left="91" width="32" height="20" font="0"><a href="data supplement.html#249">(226)</a> </text>
<text top="231" left="91" width="55" height="20" font="16"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20037179">20037179</a></text>
<text top="231" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20037179"> </a></text>
<text top="248" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="265" left="91" width="7" height="20" font="0"> <b> </b></text>
<text top="282" left="91" width="3" height="20" font="0"> </text>
<text top="196" left="259" width="147" height="20" font="7"><b>Study type:</b>  Cohort study </text>
<text top="213" left="259" width="148" height="20" font="0">using the General Practice </text>
<text top="231" left="259" width="112" height="20" font="0">Research Database </text>
<text top="248" left="259" width="3" height="20" font="0"> </text>
<text top="265" left="259" width="128" height="20" font="7"><b>Size:</b> 3,603 adults with </text>
<text top="282" left="259" width="147" height="20" font="0">severe psoriasis and up to </text>
<text top="299" left="259" width="99" height="20" font="0">4 patients without </text>
<text top="317" left="259" width="134" height="20" font="0">psoriasis from the same </text>
<text top="334" left="259" width="143" height="20" font="0">United Kingdom practices </text>
<text top="351" left="259" width="133" height="20" font="0">and start dates for each </text>
<text top="368" left="259" width="107" height="20" font="0">adult with psoriasis </text>
<text top="196" left="420" width="179" height="20" font="7"><b>Inclusion criteria:</b> Patients with </text>
<text top="213" left="420" width="182" height="20" font="0">severe psoriasis who were &gt;18 y </text>
<text top="231" left="420" width="150" height="20" font="0">of age between 1987-2002 </text>
<text top="248" left="420" width="3" height="20" font="0"> </text>
<text top="265" left="420" width="163" height="20" font="7"><b>Exclusion criteria:</b> Psoriasis </text>
<text top="282" left="420" width="156" height="20" font="0">patients who did not receive </text>
<text top="299" left="420" width="96" height="20" font="0">systemic therapy </text>
<text top="197" left="623" width="191" height="20" font="7"><b>1</b>°<b> endpoint:</b> CV death defined as </text>
<text top="215" left="623" width="228" height="20" font="0">diagnoses consistent with MI, CVA, PVD, </text>
<text top="232" left="623" width="214" height="20" font="0">arrhythmia, or left ventricular thrombus </text>
<text top="249" left="623" width="3" height="20" font="0"> </text>
<text top="266" left="623" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="285" left="623" width="11" height="18" font="0">• </text>
<text top="285" left="638" width="186" height="20" font="0">When adjusting for age, smoking, </text>
<text top="302" left="638" width="180" height="20" font="0">diabetes, sex, hypertension, and </text>
<text top="319" left="638" width="221" height="20" font="0">hyperlipidemia, severe psoriasis was an </text>
<text top="336" left="638" width="216" height="20" font="0">independent risk factor for CV mortality </text>
<text top="353" left="638" width="166" height="20" font="0">(HR: 1.57; 95% CI: 1.26-1.96) </text>
<text top="372" left="623" width="11" height="18" font="0">• </text>
<text top="372" left="638" width="207" height="20" font="0">Severe psoriasis patients sustained 1 </text>
<text top="389" left="638" width="217" height="20" font="0">extra CVD death per 283 patients per y </text>
<text top="406" left="638" width="195" height="20" font="0">after adjusting for major risk factors </text>
<text top="198" left="881" width="7" height="18" font="0">•</text>
<text top="197" left="888" width="196" height="20" font="0">Adults with severe psoriasis have a </text>
<text top="215" left="881" width="233" height="20" font="0">higher risk of CV mortality, independent of </text>
<text top="232" left="881" width="144" height="20" font="0">traditional CV risk factors. </text>
<text top="251" left="881" width="7" height="18" font="0">•</text>
<text top="250" left="888" width="230" height="20" font="0">Counselling and aggressive management </text>
<text top="267" left="881" width="202" height="20" font="0">of risk factors in patients with severe </text>
<text top="285" left="881" width="126" height="20" font="0">psoriasis is warranted. </text>
<text top="302" left="881" width="3" height="20" font="0"> </text>
<text top="424" left="91" width="128" height="20" font="0">Hanna DB, et al., 2016 </text>
<text top="441" left="91" width="32" height="20" font="0"><a href="data supplement.html#249">(227)</a><b> </b></text>
<text top="458" left="91" width="55" height="20" font="16"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27444412">27444412</a></text>
<text top="458" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27444412"> </a></text>
<text top="476" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="493" left="91" width="3" height="20" font="0"> </text>
<text top="424" left="259" width="144" height="20" font="7"><b>Study type:</b>  Surveillance </text>
<text top="441" left="259" width="44" height="20" font="0">registry </text>
<text top="458" left="259" width="3" height="20" font="0"> </text>
<text top="476" left="259" width="104" height="20" font="7"><b>Size:</b> 145,845 HIV-</text>
<text top="493" left="259" width="83" height="20" font="0">infected adults </text>
<text top="424" left="420" width="167" height="20" font="7"><b>Inclusion criteria:</b> Individuals </text>
<text top="441" left="420" width="172" height="20" font="0">diagnosed with HIV infection in </text>
<text top="458" left="420" width="126" height="20" font="0">the New York City HIV </text>
<text top="476" left="420" width="177" height="20" font="0">Surveillance Registry compared </text>
<text top="493" left="420" width="187" height="20" font="0">with those without HIV In the New </text>
<text top="510" left="420" width="182" height="20" font="0">York City Vital Statistics Registry </text>
<text top="527" left="420" width="3" height="20" font="0"> </text>
<text top="544" left="420" width="167" height="20" font="7"><b>Exclusion criteria:</b> If persons </text>
<text top="562" left="420" width="84" height="20" font="0">were &lt;13 y old </text>
<text top="425" left="623" width="195" height="20" font="7"><b>1</b>°<b> endpoint:</b> Age-specific and age-</text>
<text top="442" left="623" width="226" height="20" font="0">standardized mortality rates due to major </text>
<text top="460" left="623" width="69" height="20" font="0">CVD events </text>
<text top="477" left="623" width="3" height="20" font="0"> </text>
<text top="494" left="623" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="513" left="623" width="11" height="18" font="0">• </text>
<text top="512" left="638" width="217" height="20" font="0">10% of the 29,588 deaths were caused </text>
<text top="529" left="638" width="228" height="20" font="0">by CVD; 42% were due to ischemic heart </text>
<text top="547" left="638" width="220" height="20" font="0">disease, 27% to hypertension, and 10% </text>
<text top="564" left="638" width="208" height="20" font="0">were due to cerebrovascular disease. </text>
<text top="583" left="623" width="11" height="18" font="0">• </text>
<text top="582" left="638" width="194" height="20" font="0">Proportionate mortality due to CVD </text>
<text top="599" left="638" width="225" height="20" font="0">among HIV+ persons increased from 6% </text>
<text top="617" left="638" width="129" height="20" font="0">in 2001 to 15% in 2012 </text>
<text top="636" left="623" width="11" height="18" font="0">• </text>
<text top="635" left="638" width="213" height="20" font="0">CVD mortality rate was highest among </text>
<text top="652" left="638" width="227" height="20" font="0">viremic persons (adjusted rate ratio [RR], </text>
<text top="669" left="638" width="182" height="20" font="0">3.53; 95% CI: 3.21-3.87), but still </text>
<text top="686" left="638" width="228" height="20" font="0">elevated among virally suppressed (&lt;400 </text>
<text top="704" left="638" width="216" height="20" font="0">copies/ml) persons (adjusted RR, 1.53; </text>
<text top="721" left="638" width="225" height="20" font="0">95% CI: ?! <a href="data supplement.html#249">(227)</a>) compared with general </text>
<text top="738" left="638" width="60" height="20" font="0">population </text>
<text top="424" left="881" width="223" height="20" font="0">Clinicians who care for patients with HIV </text>
<text top="441" left="881" width="216" height="20" font="0">should aggressively manage traditional </text>
<text top="458" left="881" width="208" height="20" font="0">CVD risk factors and focus on viremic </text>
<text top="476" left="881" width="94" height="20" font="0">control via ART.  </text>
<text top="493" left="881" width="3" height="20" font="0"> </text>
</page>
<page number="198" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">198 </text>
<text top="107" left="91" width="122" height="20" font="0">Triant VA, et al., 2007 </text>
<text top="124" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17456578">17456578</a></text>
<text top="124" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=17456578"> </a></text>
<text top="141" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="159" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="107" left="259" width="144" height="20" font="7"><b>Study type:</b> Cohort study </text>
<text top="124" left="259" width="3" height="20" font="0"> </text>
<text top="141" left="259" width="117" height="20" font="7"><b>Size:</b>  3,851 HIV and </text>
<text top="159" left="259" width="107" height="20" font="0">1,044,589 non-HIV </text>
<text top="176" left="259" width="128" height="20" font="0">patients in a large data </text>
<text top="193" left="259" width="44" height="20" font="0">registry </text>
<text top="107" left="420" width="180" height="20" font="7"><b>Inclusion criteria:</b> Patients who </text>
<text top="124" left="420" width="186" height="20" font="0">were seen at one of two hospitals </text>
<text top="141" left="420" width="149" height="20" font="0">in the Partners HealthCare </text>
<text top="159" left="420" width="134" height="20" font="0">System at least 2 times  </text>
<text top="176" left="420" width="3" height="20" font="0"> </text>
<text top="193" left="420" width="171" height="20" font="7"><b>Exclusion criteria:</b> Individuals </text>
<text top="210" left="420" width="154" height="20" font="0">who were not billed for their </text>
<text top="227" left="420" width="58" height="20" font="0">encounter </text>
<text top="108" left="623" width="182" height="20" font="7"><b>1</b>°<b> endpoint:</b> Occurrence of AMI </text>
<text top="125" left="623" width="3" height="20" font="0"> </text>
<text top="143" left="623" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="162" left="623" width="11" height="18" font="0">• </text>
<text top="161" left="638" width="189" height="20" font="0">AMI rates per 1000 person-y were </text>
<text top="178" left="638" width="208" height="20" font="0">increased in HIV vs. non-HIV patients </text>
<text top="195" left="638" width="205" height="20" font="0">(11.13; 95% CI: 9.58-12.68) vs. 6.98; </text>
<text top="213" left="638" width="107" height="20" font="0">95% CI: 6.89-7.06) </text>
<text top="232" left="623" width="11" height="18" font="0">• </text>
<text top="231" left="638" width="202" height="20" font="0">RRs (for HIV vs. non-HIV) were 2.98 </text>
<text top="248" left="638" width="223" height="20" font="0">(95% CI: 2.33-3.75) for women and 1.40 </text>
<text top="265" left="638" width="184" height="20" font="0">(95% CI: 1.16-1.67) for men after </text>
<text top="282" left="638" width="217" height="20" font="0">adjustment for age, race, hypertension, </text>
<text top="299" left="638" width="193" height="20" font="0">gender, diabetes, and dyslipidemia </text>
<text top="107" left="881" width="193" height="20" font="0">AMI rates and CVD risk factors are </text>
<text top="124" left="881" width="218" height="20" font="0">increased in HIV + patients vs. non-HIV </text>
<text top="141" left="881" width="198" height="20" font="0">patients, especially among women.  </text>
<text top="159" left="881" width="3" height="20" font="0"> </text>
<text top="317" left="91" width="146" height="20" font="0">Fernandez-Montero JV, et </text>
<text top="335" left="91" width="83" height="20" font="0">al., 2016 <a href="data supplement.html#249">(228)</a> </text>
<text top="352" left="91" width="55" height="20" font="16"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26390144">26390144</a></text>
<text top="352" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26390144"> </a></text>
<text top="369" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="386" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="317" left="259" width="74" height="20" font="7"><b>Study type:</b>  </text>
<text top="335" left="259" width="82" height="20" font="0">Retrospective, </text>
<text top="352" left="259" width="123" height="20" font="0">observational study of </text>
<text top="369" left="259" width="148" height="20" font="0">individuals with HIV and/or </text>
<text top="386" left="259" width="79" height="20" font="0">HCV infection </text>
<text top="404" left="259" width="3" height="20" font="0"> </text>
<text top="421" left="259" width="80" height="20" font="7"><b>Size:</b> 567 HIV-</text>
<text top="438" left="259" width="128" height="20" font="0">monoinfected, 70 HCV-</text>
<text top="455" left="259" width="129" height="20" font="0">monoinfected, and 499 </text>
<text top="472" left="259" width="113" height="20" font="0">HIV/HCV-coinfected </text>
<text top="490" left="259" width="36" height="20" font="0">adults </text>
<text top="317" left="420" width="177" height="20" font="7"><b>Inclusion criteria:</b> Consecutive </text>
<text top="335" left="420" width="178" height="20" font="0">individuals with HIV and/or HCV </text>
<text top="352" left="420" width="189" height="20" font="0">seen at outpatient clinic in Madrid, </text>
<text top="369" left="420" width="174" height="20" font="0">Spain as compared to a control </text>
<text top="386" left="420" width="170" height="20" font="0">group with HCV monoinfection </text>
<text top="404" left="420" width="3" height="20" font="0"> </text>
<text top="421" left="420" width="183" height="20" font="7"><b>Exclusion criteria:</b> Patients with </text>
<text top="438" left="420" width="152" height="20" font="0">HCV who had been treated </text>
<text top="319" left="623" width="202" height="20" font="7"><b>1</b>°<b> endpoint:</b> Composite endpoint of </text>
<text top="336" left="623" width="174" height="20" font="0">angina, MI, CVA, or CVD death </text>
<text top="353" left="623" width="3" height="20" font="0"> </text>
<text top="370" left="623" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="389" left="623" width="11" height="18" font="0">• </text>
<text top="389" left="638" width="194" height="20" font="0">HIV/HCV-coinfected patients had a </text>
<text top="406" left="638" width="214" height="20" font="0">higher incidence of CVD events and/or </text>
<text top="423" left="638" width="225" height="20" font="0">death than HIV-monoinfected adults (4% </text>
<text top="440" left="638" width="160" height="20" font="0">vs. 1.2%, p=0.004) and HCV-</text>
<text top="457" left="638" width="204" height="20" font="0">monoinfected persons (4% vs. 1.4%, </text>
<text top="475" left="638" width="39" height="20" font="0">p=0.5) </text>
<text top="494" left="623" width="11" height="18" font="0">• </text>
<text top="493" left="638" width="201" height="20" font="0">After adjustments for demographics, </text>
<text top="510" left="638" width="202" height="20" font="0">traditional CVD risk factors, and viral </text>
<text top="527" left="638" width="212" height="20" font="0">parameters, both HIV/HCV coinfection </text>
<text top="544" left="638" width="190" height="20" font="0">(HR: 2.91; 95% CI: 1.19-7.12) and </text>
<text top="562" left="638" width="212" height="20" font="0">hypertension (HR: 3.65;  95% CI: 1.34-</text>
<text top="579" left="638" width="229" height="20" font="0">9.94) were independently associated with </text>
<text top="596" left="638" width="225" height="20" font="0">CVD events and/or death in HIV+ adults  </text>
<text top="319" left="881" width="7" height="18" font="0">•</text>
<text top="319" left="888" width="226" height="20" font="0">Chronic hepatitis C and hypertension are </text>
<text top="336" left="881" width="224" height="20" font="0">independently associated with increased </text>
<text top="353" left="881" width="154" height="20" font="0">CVD risk in adults with HIV. </text>
<text top="372" left="881" width="7" height="18" font="0">•</text>
<text top="371" left="888" width="217" height="20" font="0">Treatment of chronic hepatitis C should </text>
<text top="389" left="881" width="200" height="20" font="0">be prioritized in HIV/HCV-coinfected </text>
<text top="406" left="881" width="213" height="20" font="0">patients regardless of any liver fibrosis </text>
<text top="423" left="881" width="50" height="20" font="0">staging.  </text>
<text top="440" left="881" width="3" height="20" font="0"> </text>
<text top="614" left="91" width="146" height="20" font="0">Dregan A,Chowienczyk P, </text>
<text top="631" left="91" width="124" height="20" font="0">and Molokhia M. 2017 </text>
<text top="649" left="91" width="32" height="20" font="0"><a href="data supplement.html#249">(229)</a> </text>
<text top="666" left="91" width="55" height="20" font="16"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28601812">28601812</a></text>
<text top="666" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28601812"> </a></text>
<text top="683" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="700" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="614" left="259" width="110" height="20" font="7"><b>Study type:</b>  Cross-</text>
<text top="631" left="259" width="148" height="20" font="0">sectional study to estimate </text>
<text top="649" left="259" width="146" height="20" font="0">cardiometabolic risk and a </text>
<text top="666" left="259" width="137" height="20" font="0">prospective cohort study </text>
<text top="683" left="259" width="139" height="20" font="0">to estimate mortality risk  </text>
<text top="700" left="259" width="3" height="20" font="0"> </text>
<text top="717" left="259" width="109" height="20" font="7"><b>Size:</b> 19,082 with a </text>
<text top="735" left="259" width="117" height="20" font="0">chronic inflammatory </text>
<text top="752" left="259" width="119" height="20" font="0">disorder out of a total </text>
<text top="769" left="259" width="107" height="20" font="0">study population of </text>
<text top="786" left="259" width="48" height="20" font="0">502,641 </text>
<text top="614" left="420" width="187" height="20" font="7"><b>Inclusion criteria:</b> Participants in </text>
<text top="631" left="420" width="183" height="20" font="0">the UK Biobank with diagnosis of </text>
<text top="649" left="420" width="184" height="20" font="0">RA, SLE, psoriasis, AS, systemic </text>
<text top="666" left="420" width="190" height="20" font="0">vasculitis, and inflammatory bowel </text>
<text top="683" left="420" width="176" height="20" font="0">disease composed the exposed </text>
<text top="700" left="420" width="175" height="20" font="0">group; those with none of these </text>
<text top="717" left="420" width="172" height="20" font="0">disorders were the comparison </text>
<text top="735" left="420" width="42" height="20" font="0">group.  </text>
<text top="752" left="420" width="3" height="20" font="0"> </text>
<text top="769" left="420" width="134" height="20" font="7"><b>Exclusion criteria:</b> N/A </text>
<text top="615" left="623" width="231" height="20" font="7"><b>1</b>°<b> endpoint:</b> MI, type 2 diabetes mellitus, </text>
<text top="632" left="623" width="229" height="20" font="0">PAD, and VTE events; all-cause mortality </text>
<text top="650" left="623" width="152" height="20" font="0">and CVD-related mortality.  </text>
<text top="667" left="623" width="3" height="20" font="0"> </text>
<text top="684" left="623" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="703" left="623" width="11" height="18" font="0">• </text>
<text top="703" left="638" width="215" height="20" font="0">SLE had the strongest association with </text>
<text top="720" left="638" width="200" height="20" font="0">risk of cardiometabolic disease (RR: </text>
<text top="737" left="638" width="226" height="20" font="0">6.36; 95% CI: 4.37-9.25), followed by RA </text>
<text top="754" left="638" width="218" height="20" font="0">(RR: 1.70; 95% CI: 1.59-1.83), AS (RR: </text>
<text top="771" left="638" width="223" height="20" font="0">1.28; 95% CI: 1.09-1.52), vasculitis (RR: </text>
<text top="616" left="881" width="7" height="18" font="0">•</text>
<text top="615" left="888" width="215" height="20" font="0">Inflammatory disorders increase risk of </text>
<text top="632" left="881" width="122" height="20" font="0">cardiovascular events </text>
<text top="652" left="881" width="7" height="18" font="0">•</text>
<text top="651" left="888" width="188" height="20" font="0">Excess risk varies with use of anti-</text>
<text top="668" left="881" width="224" height="20" font="0">inflammatory therapy and duration of the </text>
<text top="685" left="881" width="185" height="20" font="0">underlying inflammatory disorder  </text>
<text top="704" left="881" width="7" height="18" font="0">•</text>
<text top="704" left="888" width="167" height="20" font="0">Increased risk associated with </text>
<text top="721" left="881" width="230" height="20" font="0">inflammatory disorders is similar to that of </text>
<text top="738" left="881" width="196" height="20" font="0">diabetes or chronic kidney disease  </text>
<text top="755" left="881" width="3" height="20" font="0"> </text>
</page>
<page number="199" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">199 </text>
<text top="107" left="638" width="217" height="20" font="0">1.64; 95% CI: 1.42-1.90), and psoriasis </text>
<text top="124" left="638" width="170" height="20" font="0">(RR: 1.25; 95% CI: 1.16-1.35). </text>
<text top="143" left="623" width="11" height="18" font="0">• </text>
<text top="143" left="638" width="203" height="20" font="0">Magnitude of association was higher </text>
<text top="160" left="638" width="226" height="20" font="0">among adults on anti-inflammatory drugs </text>
<text top="177" left="638" width="206" height="20" font="0">or corticosteroids with risk greatest in </text>
<text top="194" left="638" width="215" height="20" font="0">SLE patients (RR: 12.35; 95% CI: 7.18-</text>
<text top="211" left="638" width="230" height="20" font="0">21.24) followed by RA patients (RR: 3.06; </text>
<text top="229" left="638" width="107" height="20" font="0">95% CI: 2.44-3.85) </text>
<text top="248" left="623" width="11" height="18" font="0">• </text>
<text top="247" left="638" width="187" height="20" font="0">Patients with SLE had the highest </text>
<text top="264" left="638" width="223" height="20" font="0">adjusted HR: for all-cause mortality (HR: </text>
<text top="281" left="638" width="224" height="20" font="0">2.06; 95% CI: 1.37-3.10) vs. comparison </text>
<text top="298" left="638" width="42" height="20" font="0">group.  </text>
<text top="316" left="91" width="132" height="20" font="0">Bartels CM, et al., 2011 </text>
<text top="334" left="91" width="32" height="20" font="0"><a href="data supplement.html#249">(230)</a> </text>
<text top="351" left="91" width="55" height="20" font="16"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21305507">21305507</a></text>
<text top="351" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21305507"> </a></text>
<text top="368" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="385" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="316" left="259" width="74" height="20" font="7"><b>Study type:</b>  </text>
<text top="334" left="259" width="116" height="20" font="0">Retrospective cohort </text>
<text top="351" left="259" width="33" height="20" font="0">study </text>
<text top="368" left="259" width="3" height="20" font="0"> </text>
<text top="385" left="259" width="133" height="20" font="7"><b>Size:</b> 3,298 RA patients </text>
<text top="402" left="259" width="114" height="20" font="0">enrolled in Medicare </text>
<text top="316" left="420" width="185" height="20" font="7"><b>Inclusion criteria:</b> Age &gt; 65 who </text>
<text top="334" left="420" width="176" height="20" font="0">were alive from 1/1/04-12/31/06 </text>
<text top="351" left="420" width="174" height="20" font="0">and had a diagnosis of RA who </text>
<text top="368" left="420" width="178" height="20" font="0">were considered eligible for lipid </text>
<text top="385" left="420" width="57" height="20" font="0">screening </text>
<text top="402" left="420" width="3" height="20" font="0"> </text>
<text top="420" left="420" width="176" height="20" font="7"><b>Exclusion criteria:</b> no baseline </text>
<text top="437" left="420" width="145" height="20" font="0">CVD, diabetes mellitus, or </text>
<text top="454" left="420" width="83" height="20" font="0">hyperlipidemia </text>
<text top="317" left="623" width="240" height="20" font="7"><b>1</b>°<b> endpoint:</b> Primary lipid screening by the </text>
<text top="335" left="623" width="210" height="20" font="0">relative frequency of primary care and </text>
<text top="352" left="623" width="245" height="20" font="0">rheumatology visits or seeing a primary care </text>
<text top="369" left="623" width="203" height="20" font="0">provider (PCP) at least once a year.  </text>
<text top="386" left="623" width="3" height="20" font="0"> </text>
<text top="404" left="623" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="423" left="623" width="11" height="18" font="0">• </text>
<text top="422" left="638" width="226" height="20" font="0">Primary lipid screening was performed in </text>
<text top="439" left="638" width="204" height="20" font="0">just 45% of RA patients. Any primary </text>
<text top="456" left="638" width="222" height="20" font="0">care predicted more lipid screening than </text>
<text top="474" left="638" width="212" height="20" font="0">care by a rheumatology practice alone </text>
<text top="491" left="638" width="81" height="20" font="0">(26% [21-32]). </text>
<text top="510" left="623" width="11" height="18" font="0">• </text>
<text top="509" left="638" width="194" height="20" font="0">Not seeing a PCP at least annually </text>
<text top="526" left="638" width="188" height="20" font="0">decreased lipid screening by 22% </text>
<text top="543" left="638" width="210" height="20" font="0">(adjusted risk ratio 0.78; 95% CI: 0.71-</text>
<text top="560" left="638" width="31" height="20" font="0">0.84) </text>
<text top="318" left="881" width="7" height="18" font="0">•</text>
<text top="317" left="888" width="213" height="20" font="0"> Lipid screening was performed in less </text>
<text top="335" left="881" width="195" height="20" font="0">than half of eligible adults with RA.  </text>
<text top="354" left="881" width="7" height="18" font="0">•</text>
<text top="353" left="888" width="204" height="20" font="0">Annual visits to a PCP improved lipid </text>
<text top="370" left="881" width="194" height="20" font="0">screening; there needs to be better </text>
<text top="388" left="881" width="235" height="20" font="0">partnerships between rheumatologists and </text>
<text top="405" left="881" width="163" height="20" font="0">PCPs for assessing CVD risk </text>
<text top="422" left="881" width="3" height="20" font="0"> </text>
<text top="578" left="91" width="141" height="20" font="0">Feinstein MJ, et al., 2017 </text>
<text top="596" left="91" width="25" height="20" font="0"><a href="data supplement.html#240">(72)</a> </text>
<text top="613" left="91" width="55" height="20" font="16"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28002550">28002550</a></text>
<text top="613" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28002550"> </a></text>
<text top="630" left="91" width="3" height="20" font="0"> </text>
<text top="647" left="91" width="3" height="20" font="0"> </text>
<text top="578" left="259" width="137" height="20" font="7"><b>Study type:</b>  Multicenter </text>
<text top="596" left="259" width="108" height="20" font="0">cohort study of HIV </text>
<text top="613" left="259" width="46" height="20" font="0">patients </text>
<text top="630" left="259" width="3" height="20" font="0"> </text>
<text top="647" left="259" width="109" height="20" font="7"><b>Size</b>: 11,288 adults </text>
<text top="578" left="420" width="177" height="20" font="7"><b>Inclusion criteria</b>: Patients age </text>
<text top="596" left="420" width="171" height="20" font="0">18 or older with HIV enrolled in </text>
<text top="613" left="420" width="152" height="20" font="0">Centers for AIDS Research </text>
<text top="630" left="420" width="164" height="20" font="0">Network of Integrated Clinical </text>
<text top="647" left="420" width="103" height="20" font="0">Systems 9CNICS) </text>
<text top="665" left="420" width="3" height="20" font="0"> </text>
<text top="682" left="420" width="184" height="20" font="7"><b>Exclusion criteria</b>: Prior ASCVD </text>
<text top="580" left="623" width="234" height="20" font="7"><b>1</b>°<b> endpoint:</b> MI rates and accuracy of the </text>
<text top="597" left="623" width="227" height="20" font="0">2013 Pooled Cohort Equations (PCE) vs. </text>
<text top="614" left="623" width="230" height="20" font="0">two data-derived model incorporating HIV-</text>
<text top="631" left="623" width="104" height="20" font="0">specific covariates </text>
<text top="649" left="623" width="3" height="20" font="0"> </text>
<text top="666" left="623" width="55" height="20" font="7"><b>Results</b>:  </text>
<text top="685" left="623" width="11" height="18" font="0">• </text>
<text top="684" left="638" width="207" height="20" font="0">MI rates were increased in black men </text>
<text top="701" left="638" width="206" height="20" font="0">(6.9/1000 person-y and black women </text>
<text top="718" left="638" width="199" height="20" font="0">(7.2/1000 person-y) as compared to </text>
<text top="736" left="638" width="217" height="20" font="0">white men and women (4.4 and 3.3 per </text>
<text top="753" left="638" width="182" height="20" font="0">1000 person-y, respectively) and </text>
<text top="770" left="638" width="227" height="20" font="0">subjects who were not virally suppressed </text>
<text top="787" left="638" width="185" height="20" font="0">(6.3 vs. 4.7 per 1000 person-y for </text>
<text top="580" left="881" width="7" height="18" font="0">•</text>
<text top="580" left="888" width="226" height="20" font="0"> The PCE discriminated MI risk and were </text>
<text top="597" left="881" width="213" height="20" font="0">only moderately calibrated in this multi-</text>
<text top="614" left="881" width="99" height="20" font="0">center HIV cohort </text>
<text top="633" left="881" width="7" height="18" font="0">•</text>
<text top="632" left="888" width="214" height="20" font="0">The addition of HIV-specific factors did </text>
<text top="650" left="881" width="184" height="20" font="0">not improve model performance.  </text>
<text top="669" left="881" width="7" height="18" font="0">•</text>
<text top="668" left="888" width="211" height="20" font="0">As more ASCVD events accrue in this </text>
<text top="685" left="881" width="235" height="20" font="0">cohort, HIV-specific risk estimation models </text>
<text top="703" left="881" width="224" height="20" font="0">should be compared again to the PCE in </text>
<text top="720" left="881" width="83" height="20" font="0">this population </text>
<text top="737" left="881" width="3" height="20" font="0"> </text>
</page>
<page number="200" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">200 </text>
<text top="107" left="638" width="208" height="20" font="0">persons with and with detectable viral </text>
<text top="124" left="638" width="106" height="20" font="0">load, respectively.) </text>
<text top="143" left="623" width="11" height="18" font="0">• </text>
<text top="143" left="638" width="224" height="20" font="0">PCE adequately discriminated MI risk (C </text>
<text top="160" left="638" width="216" height="20" font="0">statistic 0.75 [95% CI: 0.71-0.78], while </text>
<text top="177" left="638" width="187" height="20" font="0">two data-derived models with HIV-</text>
<text top="194" left="638" width="213" height="20" font="0">specific covariates did not discriminate </text>
<text top="211" left="638" width="84" height="20" font="0">risk any better. </text>
<text top="230" left="623" width="11" height="18" font="0">• </text>
<text top="230" left="638" width="225" height="20" font="0">The PCE predicted consistently lower MI </text>
<text top="247" left="638" width="146" height="20" font="0">rates than what occurred.  </text>
<text top="265" left="91" width="145" height="20" font="0">Arts EE, et al., 2015 <a href="data supplement.html#249">(231)</a> </text>
<text top="282" left="91" width="55" height="20" font="16"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24389293">24389293</a></text>
<text top="282" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24389293"> </a></text>
<text top="299" left="91" width="3" height="20" font="0"> </text>
<text top="265" left="259" width="73" height="20" font="7"><b>Study type</b>:  </text>
<text top="282" left="259" width="116" height="20" font="0">Retrospective cohort </text>
<text top="299" left="259" width="87" height="20" font="0">study based on </text>
<text top="316" left="259" width="127" height="20" font="0">prospectively collected </text>
<text top="334" left="259" width="27" height="20" font="0">data </text>
<text top="351" left="259" width="3" height="20" font="0"> </text>
<text top="368" left="259" width="134" height="20" font="7"><b>Size</b>: 1050 patients with </text>
<text top="385" left="259" width="21" height="20" font="0">RA </text>
<text top="265" left="420" width="189" height="20" font="7"><b>Inclusion criteria:</b> Adults with RA </text>
<text top="282" left="420" width="169" height="20" font="0">enrolled in Nijmegen, early RA </text>
<text top="299" left="420" width="128" height="20" font="0">inception cohort in The </text>
<text top="316" left="420" width="70" height="20" font="0">Netherlands </text>
<text top="334" left="420" width="3" height="20" font="0"> </text>
<text top="351" left="420" width="184" height="20" font="7"><b>Exclusion criteria:</b> Patients who </text>
<text top="368" left="420" width="183" height="20" font="0">had a CV event before they were </text>
<text top="385" left="420" width="106" height="20" font="0">diagnosed with RA </text>
<text top="266" left="623" width="233" height="20" font="7"><b>1</b>°<b> endpoint:</b> First CV event – either ACS, </text>
<text top="283" left="623" width="225" height="20" font="0">MI, angina pectoris, CVA, TIA, PVD, and </text>
<text top="300" left="623" width="244" height="20" font="0">heart failure and discriminatory ability for CV </text>
<text top="318" left="623" width="208" height="20" font="0">risk prediction was estimated by ROC </text>
<text top="335" left="623" width="243" height="20" font="0">curves; calibration, sensitivity and specificity </text>
<text top="352" left="623" width="122" height="20" font="0">were also calculated.  </text>
<text top="369" left="623" width="3" height="20" font="7"><b> </b></text>
<text top="386" left="623" width="55" height="20" font="7"><b>Results</b>:  </text>
<text top="405" left="623" width="11" height="18" font="0">• </text>
<text top="405" left="638" width="213" height="20" font="0">Areas under the ROC curve were 0.78-</text>
<text top="422" left="638" width="220" height="20" font="0">0.80, indicating moderate discrimination </text>
<text top="439" left="638" width="215" height="20" font="0">between those with and without a CVD </text>
<text top="456" left="638" width="206" height="20" font="0">event. The Systematic Coronary Risk </text>
<text top="474" left="638" width="215" height="20" font="0">Evaluation (SCORE), Framingham risk </text>
<text top="491" left="638" width="215" height="20" font="0">score (FRS), and Reynolds Risk Score </text>
<text top="508" left="638" width="222" height="20" font="0">(RRS) generally underestimated CV risk </text>
<text top="525" left="638" width="221" height="20" font="0">and low and middle observed risk levels </text>
<text top="542" left="638" width="217" height="20" font="0">and mostly overestimated risk at higher </text>
<text top="560" left="638" width="115" height="20" font="0">observed risk levels. </text>
<text top="579" left="623" width="11" height="18" font="0">• </text>
<text top="578" left="638" width="213" height="20" font="0">Depending on the model, up to 32% of </text>
<text top="595" left="638" width="208" height="20" font="0">observed CVD events occurred in RA </text>
<text top="612" left="638" width="217" height="20" font="0">patients who were classified as low risk </text>
<text top="629" left="638" width="51" height="20" font="0">for CVD. </text>
<text top="267" left="881" width="7" height="18" font="0">•</text>
<text top="266" left="888" width="175" height="20" font="0">Established risk models like the </text>
<text top="283" left="881" width="209" height="20" font="0">Systematic Coronary Risk Evaluation, </text>
<text top="300" left="881" width="209" height="20" font="0">Framingham Risk, and Reynolds Risk </text>
<text top="318" left="881" width="228" height="20" font="0">Scores generally underestimate CVD risk </text>
<text top="335" left="881" width="230" height="20" font="0">in RA patients, especially in the lower two-</text>
<text top="352" left="881" width="127" height="20" font="0">thirds of predicted risk. </text>
<text top="371" left="881" width="7" height="18" font="0">•</text>
<text top="370" left="888" width="215" height="20" font="0">The QRisk II score is the only standard </text>
<text top="388" left="881" width="231" height="20" font="0">algorithm tends to overestimate CV risk in </text>
<text top="405" left="881" width="74" height="20" font="0">RA patients.  </text>
<text top="424" left="881" width="7" height="18" font="0">•</text>
<text top="423" left="888" width="222" height="20" font="0">Underestimation of risk would likely lead </text>
<text top="440" left="881" width="234" height="20" font="0">to suboptimal implementation of statin and </text>
<text top="458" left="881" width="164" height="20" font="0">aspirin therapy in RA patients </text>
<text top="477" left="881" width="7" height="18" font="0">•</text>
<text top="476" left="888" width="207" height="20" font="0">There is a need to develop and test a </text>
<text top="493" left="881" width="146" height="20" font="0">RA-specific CV risk model </text>
<text top="647" left="91" width="139" height="20" font="0">Yu HH, et al., 2015 <a href="data supplement.html#250">(232)</a> </text>
<text top="665" left="91" width="55" height="20" font="16"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26342937">26342937</a></text>
<text top="665" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=26342937"> </a></text>
<text top="682" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="699" left="91" width="7" height="20" font="0"> <b> </b></text>
<text top="647" left="259" width="138" height="20" font="7"><b>Study type:</b>  Nationwide </text>
<text top="665" left="259" width="135" height="20" font="0">population-based cohort </text>
<text top="682" left="259" width="33" height="20" font="0">study </text>
<text top="699" left="259" width="3" height="20" font="0"> </text>
<text top="716" left="259" width="128" height="20" font="7"><b>Size:</b> 4,095 adults with </text>
<text top="733" left="259" width="133" height="20" font="0">SLE and hyperlipidemia </text>
<text top="751" left="259" width="132" height="20" font="0">and 935 who had never </text>
<text top="768" left="259" width="122" height="20" font="0">been on lipid lowering </text>
<text top="785" left="259" width="44" height="20" font="0">therapy </text>
<text top="647" left="420" width="169" height="20" font="7"><b>Inclusion criteria:</b> Adults with </text>
<text top="665" left="420" width="157" height="20" font="0">SLE and hyperlipidemia and </text>
<text top="682" left="420" width="183" height="20" font="0">matching set of patients who had </text>
<text top="699" left="420" width="139" height="20" font="0">never used lipid-lowering </text>
<text top="716" left="420" width="189" height="20" font="0">medications and a separate group </text>
<text top="733" left="420" width="76" height="20" font="0">of statin uses </text>
<text top="751" left="420" width="3" height="20" font="0"> </text>
<text top="649" left="623" width="217" height="20" font="7"><b>1</b>°<b> endpoint:</b> Development of coronary </text>
<text top="666" left="623" width="210" height="20" font="0">artery disease (CAD), CVD, ESRD, or </text>
<text top="683" left="623" width="50" height="20" font="0">mortality </text>
<text top="700" left="623" width="3" height="20" font="0"> </text>
<text top="717" left="623" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="736" left="623" width="11" height="18" font="0">• </text>
<text top="736" left="638" width="194" height="20" font="0">Multivariate adjusted HRs for statin </text>
<text top="753" left="638" width="217" height="20" font="0">users, as compared with patients never </text>
<text top="770" left="638" width="212" height="20" font="0">on lipid lowering medication were 0.67 </text>
<text top="787" left="638" width="205" height="20" font="0">[0.54-0.83] for death from any cause. </text>
<text top="649" left="881" width="7" height="18" font="0">•</text>
<text top="649" left="888" width="192" height="20" font="0">Statin therapy in SLE patients may </text>
<text top="666" left="881" width="225" height="20" font="0">reduce risk of mortality, CVD, and ESRD </text>
<text top="685" left="881" width="7" height="18" font="0">•</text>
<text top="684" left="888" width="156" height="20" font="0">This hypothesis needs to be </text>
<text top="701" left="881" width="198" height="20" font="0">demonstrated and proven in a large </text>
<text top="719" left="881" width="232" height="20" font="0">prospective study with long-term follow-up </text>
<text top="736" left="881" width="3" height="20" font="0"> </text>
</page>
<page number="201" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">201 </text>
<text top="107" left="420" width="186" height="20" font="7"><b>Exclusion criteria:</b> SLE that was </text>
<text top="124" left="420" width="168" height="20" font="0">not diagnosed between 1/1/97 </text>
<text top="141" left="420" width="75" height="20" font="0">and 12/31/08 </text>
<text top="109" left="623" width="11" height="18" font="0">• </text>
<text top="108" left="638" width="220" height="20" font="0">High dose statin for &gt;1 y reduced risk of </text>
<text top="125" left="638" width="205" height="20" font="0">mortality (HR: 0.44 [0.32-0.60]); CAD </text>
<text top="143" left="638" width="227" height="20" font="0">(HR: 0.20; 95% CI: 0.13-0.31); CVD (HR: </text>
<text top="160" left="638" width="202" height="20" font="0">0.14; 95% CI: 0.08-0.25) with similar </text>
<text top="177" left="638" width="204" height="20" font="0">results in the nested matched study.  </text>
<text top="195" left="91" width="139" height="20" font="0">Ou HT, et al., 2017 <a href="data supplement.html#250">(233)</a> </text>
<text top="212" left="91" width="55" height="20" font="16"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28062146">28062146</a></text>
<text top="212" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28062146"> </a></text>
<text top="229" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="247" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="195" left="259" width="135" height="20" font="7"><b>Study type:</b> Nationwide </text>
<text top="212" left="259" width="139" height="20" font="0">longitudinal cohort study  </text>
<text top="229" left="259" width="3" height="20" font="0"> </text>
<text top="247" left="259" width="127" height="20" font="7"><b>Size:</b> 945 HIV-infected </text>
<text top="264" left="259" width="46" height="20" font="0">patients </text>
<text top="195" left="420" width="180" height="20" font="7"><b>Inclusion criteria:</b> Patients who </text>
<text top="212" left="420" width="163" height="20" font="0">had started on a statin after a </text>
<text top="229" left="420" width="163" height="20" font="0">diagnosis of HIV; 801 without </text>
<text top="247" left="420" width="184" height="20" font="0">history of CVD and 144 with prior </text>
<text top="264" left="420" width="33" height="20" font="0">CVD. </text>
<text top="281" left="420" width="3" height="20" font="0"> </text>
<text top="298" left="420" width="174" height="20" font="7"><b>Exclusion criteria:</b> Those who </text>
<text top="315" left="420" width="186" height="20" font="0">had used statin therapy within 1 y </text>
<text top="333" left="420" width="187" height="20" font="0">before the index date (date of first </text>
<text top="350" left="420" width="144" height="20" font="0">statin treatment) after HIV </text>
<text top="367" left="420" width="55" height="20" font="0">diagnosis </text>
<text top="196" left="623" width="239" height="20" font="7"><b>1</b>°<b> endpoint:</b> Composite of hospitalizations </text>
<text top="213" left="623" width="225" height="20" font="0">with diagnosis of ischemic CVA, CAD, or </text>
<text top="230" left="623" width="75" height="20" font="0">heart failure.  </text>
<text top="248" left="623" width="3" height="20" font="0"> </text>
<text top="265" left="623" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="284" left="623" width="11" height="18" font="0">• </text>
<text top="283" left="638" width="227" height="20" font="0">In HIV + persons with history of CVD, the </text>
<text top="300" left="638" width="221" height="20" font="0">high-dose statin group had a lower CVD </text>
<text top="318" left="638" width="205" height="20" font="0">risk compared to that of the low-dose </text>
<text top="335" left="638" width="204" height="20" font="0">group (HR: 0.88; 95% CI: 0.39-1.99). </text>
<text top="354" left="623" width="11" height="18" font="0">• </text>
<text top="353" left="638" width="222" height="20" font="0">The high-potency group showed a lower </text>
<text top="370" left="638" width="204" height="20" font="0">CVD risk compared to that of the low-</text>
<text top="387" left="638" width="216" height="20" font="0">potency group (HR: 0.42; 95% CI: 0.06-</text>
<text top="405" left="638" width="35" height="20" font="0">3.13). </text>
<text top="424" left="623" width="11" height="18" font="0">• </text>
<text top="423" left="638" width="215" height="20" font="0">For those without a history of CVD, the </text>
<text top="440" left="638" width="228" height="20" font="0">HR values were 0.64 (95% CI: 0.30-1.35) </text>
<text top="457" left="638" width="190" height="20" font="0">and HR: 0.67 (95% CI: 0.16-2.87). </text>
<text top="476" left="623" width="11" height="18" font="0">• </text>
<text top="476" left="638" width="217" height="20" font="0">No muscle complaints or dementia was </text>
<text top="493" left="638" width="140" height="20" font="0">observed in statin users.  </text>
<text top="512" left="623" width="11" height="18" font="0">• </text>
<text top="511" left="638" width="203" height="20" font="0">New-onset diabetes in the high-dose </text>
<text top="528" left="638" width="214" height="20" font="0">statin group was higher than in the low-</text>
<text top="545" left="638" width="198" height="20" font="0">dose statin group (15.3% vs. 8.3%). </text>
<text top="197" left="881" width="7" height="18" font="0">•</text>
<text top="196" left="888" width="230" height="20" font="0">There is a strong trend for lower CVD risk </text>
<text top="213" left="881" width="230" height="20" font="0">in HIV patients on intensive statin therapy </text>
<text top="232" left="881" width="7" height="18" font="0">•</text>
<text top="232" left="888" width="228" height="20" font="0">The results observed with intensive statin </text>
<text top="249" left="881" width="218" height="20" font="0">regimens in HIV + adults are consistent </text>
<text top="266" left="881" width="187" height="20" font="0">with those in non-HIV populations </text>
<text top="285" left="881" width="7" height="18" font="0">•</text>
<text top="284" left="888" width="212" height="20" font="0">It is important to monitor the metabolic </text>
<text top="302" left="881" width="219" height="20" font="0">profiles in HIV patients on high intensity </text>
<text top="319" left="881" width="226" height="20" font="0">statin therapy. Weight loss and improved </text>
<text top="336" left="881" width="224" height="20" font="0">exercise habits should be encouraged in </text>
<text top="353" left="881" width="127" height="20" font="0">overweight individuals. </text>
<text top="370" left="881" width="3" height="20" font="0"> </text>
<text top="563" left="91" width="151" height="20" font="0">Klein DB, et al., 2015 <a href="data supplement.html#250">(234)</a> </text>
<text top="581" left="91" width="55" height="20" font="16"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25595743">25595743</a></text>
<text top="581" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25595743"> </a></text>
<text top="598" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="615" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="563" left="259" width="147" height="20" font="7"><b>Study type:</b>  Cohort study </text>
<text top="581" left="259" width="107" height="20" font="0">of Kaiser members </text>
<text top="598" left="259" width="3" height="20" font="0"> </text>
<text top="615" left="259" width="128" height="20" font="7"><b>Size:</b> 24,768 HIV+ and </text>
<text top="632" left="259" width="131" height="20" font="0">257,600 HIV– subjects  </text>
<text top="563" left="420" width="185" height="20" font="7"><b>Inclusion criteria:</b> Enrollees age </text>
<text top="581" left="420" width="159" height="20" font="0">&gt;18 in Kaiser Permanente in </text>
<text top="598" left="420" width="184" height="20" font="0">Southern and Northern California </text>
<text top="615" left="420" width="3" height="20" font="0"> </text>
<text top="632" left="420" width="177" height="20" font="7"><b>Exclusion criteria:</b> HIV+ adults </text>
<text top="649" left="420" width="117" height="20" font="0">who were not in care </text>
<text top="564" left="623" width="174" height="20" font="7"><b>1</b>°<b> endpoint:</b> Occurrence of MI </text>
<text top="582" left="623" width="3" height="20" font="0"> </text>
<text top="599" left="623" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="618" left="623" width="11" height="18" font="0">• </text>
<text top="617" left="638" width="221" height="20" font="0">The adjusted MI rate ratio for HIV status </text>
<text top="634" left="638" width="227" height="20" font="0">declined over time and reached 1.0 [95% </text>
<text top="652" left="638" width="220" height="20" font="0">CI: 0.7-1.4] in 2011; this was down from </text>
<text top="669" left="638" width="189" height="20" font="0">1.8 [95% CI: 1.3-2.6] from 1996-9. </text>
<text top="688" left="623" width="11" height="18" font="0">• </text>
<text top="687" left="638" width="213" height="20" font="0">There were 320 MIs among HIV+ (268 </text>
<text top="704" left="638" width="220" height="20" font="0">cases/100,000 person-y) and 2,483 MIs </text>
<text top="721" left="638" width="227" height="20" font="0">among HIV-negative (165 cases/100,000 </text>
<text top="739" left="638" width="221" height="20" font="0">person-y) with an adjusted RR:1.4 [95% </text>
<text top="756" left="638" width="68" height="20" font="0">CI: 1.2-1.6]. </text>
<text top="565" left="881" width="7" height="18" font="0">•</text>
<text top="564" left="888" width="190" height="20" font="0">The improved rate of CVD in HIV+ </text>
<text top="582" left="881" width="224" height="20" font="0">positive patients is likely related to better </text>
<text top="599" left="881" width="226" height="20" font="0">access to care and broadly disseminated </text>
<text top="616" left="881" width="232" height="20" font="0">CVD risk reduction initiatives in the Kaiser </text>
<text top="633" left="881" width="42" height="20" font="0">system </text>
<text top="652" left="881" width="7" height="18" font="0">•</text>
<text top="652" left="888" width="228" height="20" font="0">The increased use of more tolerable ART </text>
<text top="669" left="881" width="229" height="20" font="0">regimens has also contributed to reduced </text>
<text top="686" left="881" width="162" height="20" font="0">risk of CVD in HIV+ subjects. </text>
<text top="703" left="881" width="3" height="20" font="0"> </text>
<text top="721" left="881" width="3" height="20" font="0"> </text>
</page>
<page number="202" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">202 </text>
<text top="109" left="623" width="11" height="18" font="0">• </text>
<text top="108" left="638" width="212" height="20" font="0">Prescriptions for lipid-lowering therapy </text>
<text top="125" left="638" width="226" height="20" font="0">increased for HIV+ subjects from 5.5% in </text>
<text top="143" left="638" width="162" height="20" font="0">1996-9 to 31.5% in 2010-11.  </text>
<text top="161" left="91" width="152" height="20" font="0">Myasoedova E, et al., 2011 </text>
<text top="178" left="91" width="32" height="20" font="0"><a href="data supplement.html#250">(235)</a> </text>
<text top="195" left="91" width="55" height="20" font="16"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21216812">21216812</a></text>
<text top="195" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21216812"> </a></text>
<text top="212" left="91" width="3" height="20" font="0"> </text>
<text top="229" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="247" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="161" left="259" width="136" height="20" font="7"><b>Study type:</b>  Population-</text>
<text top="178" left="259" width="130" height="20" font="0">based incidence cohort </text>
<text top="195" left="259" width="3" height="20" font="0"> </text>
<text top="212" left="259" width="138" height="20" font="7"><b>Size:</b> 651 adults with RA </text>
<text top="161" left="420" width="178" height="20" font="7"><b>Inclusion criteria:</b> Residents of </text>
<text top="178" left="420" width="185" height="20" font="0">Olmstead County, MN at least 18 </text>
<text top="195" left="420" width="93" height="20" font="0">y of age with RA </text>
<text top="212" left="420" width="3" height="20" font="0"> </text>
<text top="229" left="420" width="174" height="20" font="7"><b>Exclusion criteria:</b> Those who </text>
<text top="247" left="420" width="187" height="20" font="0">did fulfill the 1987 ACR criteria for </text>
<text top="264" left="420" width="21" height="20" font="0">RA </text>
<text top="162" left="623" width="224" height="20" font="7"><b>1</b>°<b> endpoint:</b> Interactions between lipids </text>
<text top="179" left="623" width="90" height="20" font="0">and risk of CVD </text>
<text top="196" left="623" width="3" height="20" font="0"> </text>
<text top="213" left="623" width="239" height="20" font="7"><b>Results:</b> There was a significant non-linear </text>
<text top="230" left="623" width="226" height="20" font="0">association for TC with CVD risk with 3.3-</text>
<text top="248" left="623" width="234" height="20" font="0">fold increased risk for TC &lt;4 mmol/l and in </text>
<text top="265" left="623" width="220" height="20" font="0">increased risk of CVD for TC &gt;4 mmol/l. </text>
<text top="282" left="623" width="218" height="20" font="0">There was no increased risk of CVD for </text>
<text top="299" left="623" width="96" height="20" font="0">LDL-C &gt;2 mmol/l </text>
<text top="162" left="881" width="7" height="18" font="0">•</text>
<text top="162" left="888" width="230" height="20" font="0">Lipids may have paradoxical associations </text>
<text top="179" left="881" width="229" height="20" font="0">with CVD risk in RA; lower TC and LDL-C </text>
<text top="196" left="881" width="221" height="20" font="0">are associated with increased CVD risk. </text>
<text top="215" left="881" width="7" height="18" font="0">•</text>
<text top="214" left="888" width="223" height="20" font="0">Patients with lower TC and LDL-C levels </text>
<text top="232" left="881" width="142" height="20" font="0">have increased CVD risk. </text>
<text top="251" left="881" width="7" height="18" font="0">•</text>
<text top="250" left="888" width="229" height="20" font="0">The associations of lipids with CVD in RA </text>
<text top="267" left="881" width="188" height="20" font="0">likely confounded by inflammation </text>
<text top="284" left="881" width="3" height="20" font="0"> </text>
<text top="317" left="91" width="151" height="20" font="0">Post WS, et al., 2014 <a href="data supplement.html#250">(236)</a> </text>
<text top="334" left="91" width="55" height="20" font="16"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24687069">24687069</a></text>
<text top="334" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24687069"> </a></text>
<text top="352" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="369" left="91" width="7" height="20" font="0">  </text>
<text top="317" left="259" width="110" height="20" font="7"><b>Study type:</b>  Cross-</text>
<text top="334" left="259" width="88" height="20" font="0">sectional study  </text>
<text top="352" left="259" width="3" height="20" font="0"> </text>
<text top="369" left="259" width="94" height="20" font="7"><b>Size:</b>  1001 men </text>
<text top="386" left="259" width="133" height="20" font="0">underwent non-contrast </text>
<text top="403" left="259" width="142" height="20" font="0">CT and 759 has coronary </text>
<text top="420" left="259" width="127" height="20" font="0">CT angiography (CTA) </text>
<text top="317" left="420" width="177" height="20" font="7"><b>Inclusion criteria:</b> HIV-infected </text>
<text top="334" left="420" width="184" height="20" font="0">and uninfected men who had sex </text>
<text top="352" left="420" width="56" height="20" font="0">with men, </text>
<text top="369" left="420" width="179" height="20" font="0">Age: 40-70 y, weighed &lt;300 lbs. </text>
<text top="386" left="420" width="3" height="20" font="0"> </text>
<text top="403" left="420" width="139" height="20" font="7"><b>Exclusion criteria:</b> Prior </text>
<text top="420" left="420" width="147" height="20" font="0">coronary revascularization </text>
<text top="318" left="623" width="219" height="20" font="7"><b>1</b>°<b> endpoint:</b> Presence of any coronary </text>
<text top="336" left="623" width="226" height="20" font="0">atherosclerotic plaque and degree of any </text>
<text top="353" left="623" width="97" height="20" font="0">stenosis on CTA. </text>
<text top="370" left="623" width="3" height="20" font="0"> </text>
<text top="387" left="623" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="406" left="623" width="11" height="18" font="0">• </text>
<text top="406" left="638" width="216" height="20" font="0">After adjustments for age, race, center, </text>
<text top="423" left="638" width="198" height="20" font="0">and cohort, HIV-infected men had a </text>
<text top="440" left="638" width="218" height="20" font="0">greater prevalence of CAC (Prevalence </text>
<text top="457" left="638" width="213" height="20" font="0">ratio (PR): 1.21; 95% CI: 1.08-1.35) as </text>
<text top="474" left="638" width="220" height="20" font="0">well as any plaque (PR=1.14), including </text>
<text top="492" left="638" width="200" height="20" font="0">non-calcified plaque (PR =1.28) and </text>
<text top="509" left="638" width="188" height="20" font="0">mixed plaque (PR=1.45) than HIV-</text>
<text top="526" left="638" width="91" height="20" font="0">uninfected men. </text>
<text top="545" left="623" width="11" height="18" font="0">• </text>
<text top="544" left="638" width="201" height="20" font="0">HIV-infected men also had a greater </text>
<text top="561" left="638" width="221" height="20" font="0">extent of non-calcified plaque after CAD </text>
<text top="579" left="638" width="180" height="20" font="0">risk factor adjustment (p=0.026). </text>
<text top="598" left="623" width="11" height="18" font="0">• </text>
<text top="597" left="638" width="219" height="20" font="0">Longer duration of ART and lower nadir </text>
<text top="614" left="638" width="220" height="20" font="0">CD4+ T-cell count were associated with </text>
<text top="631" left="638" width="190" height="20" font="0">coronary stenosis diameter &gt;50%. </text>
<text top="319" left="881" width="7" height="18" font="0">•</text>
<text top="318" left="888" width="195" height="20" font="0">Independent of traditional CHD risk </text>
<text top="336" left="881" width="180" height="20" font="0">factors, coronary arterial plaque, </text>
<text top="353" left="881" width="217" height="20" font="0">especially non-calcified plaque, is more </text>
<text top="370" left="881" width="217" height="20" font="0">extensive and prevalent in HIV-infected </text>
<text top="387" left="881" width="31" height="20" font="0">men. </text>
<text top="406" left="881" width="7" height="18" font="0">•</text>
<text top="406" left="888" width="214" height="20" font="0">Men with more advanced HIV infection </text>
<text top="423" left="881" width="231" height="20" font="0">(lower nadir CD4+ T cell count and higher </text>
<text top="440" left="881" width="215" height="20" font="0">number of years on ART have a higher </text>
<text top="457" left="881" width="198" height="20" font="0">prevalence of more advanced CAD. </text>
<text top="474" left="881" width="3" height="20" font="0"> </text>
<text top="649" left="91" width="146" height="20" font="0">Kao AH, et al., 2008 <a href="data supplement.html#250">(237)</a> </text>
<text top="667" left="91" width="55" height="20" font="16"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18774002">18774002</a></text>
<text top="667" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18774002"> </a></text>
<text top="649" left="259" width="110" height="20" font="7"><b>Study type:</b>  Cross-</text>
<text top="667" left="259" width="52" height="20" font="0">sectional </text>
<text top="684" left="259" width="3" height="20" font="0"> </text>
<text top="701" left="259" width="124" height="20" font="7"><b>Size:</b> 157 women with </text>
<text top="718" left="259" width="146" height="20" font="0">SLE, 181 women with RA, </text>
<text top="735" left="259" width="138" height="20" font="0">and 157 healthy controls </text>
<text top="649" left="420" width="177" height="20" font="7"><b>Inclusion criteria:</b> Women with </text>
<text top="667" left="420" width="140" height="20" font="0">SLE or RA in the Univ. of </text>
<text top="684" left="420" width="152" height="20" font="0">Pittsburgh Arthritis Network </text>
<text top="701" left="420" width="3" height="20" font="0"> </text>
<text top="718" left="420" width="182" height="20" font="7"><b>Exclusion criteria:</b> No history of </text>
<text top="735" left="420" width="150" height="20" font="0">a CVD event or diabetes in </text>
<text top="753" left="420" width="75" height="20" font="0">control group </text>
<text top="650" left="623" width="239" height="20" font="7"><b>1</b>°<b> endpoint:</b> Presence of CAC in age- and </text>
<text top="668" left="623" width="228" height="20" font="0">race-matched women with SLE, RA, or in </text>
<text top="685" left="623" width="230" height="20" font="0">controls and its relationship with CHD risk </text>
<text top="702" left="623" width="40" height="20" font="0">factors </text>
<text top="719" left="623" width="3" height="20" font="0"> </text>
<text top="737" left="623" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="756" left="623" width="11" height="18" font="0">• </text>
<text top="755" left="638" width="217" height="20" font="0">The prevalence of any CAC was higher </text>
<text top="772" left="638" width="221" height="20" font="0">in asymptomatic women with either SLE </text>
<text top="651" left="881" width="7" height="18" font="0">•</text>
<text top="650" left="888" width="205" height="20" font="0">There is generally a higher burden of </text>
<text top="668" left="881" width="231" height="20" font="0">CAC in patients with chronic inflammatory </text>
<text top="685" left="881" width="55" height="20" font="0">diseases. </text>
<text top="704" left="881" width="7" height="18" font="0">•</text>
<text top="703" left="888" width="183" height="20" font="0">Inflammation and endothelial cell </text>
<text top="721" left="881" width="203" height="20" font="0">activation may play significant role in </text>
<text top="738" left="881" width="223" height="20" font="0">excess risk of CVD in women with RA or </text>
<text top="755" left="881" width="33" height="20" font="0">SLE.  </text>
<text top="772" left="881" width="3" height="20" font="0"> </text>
<text top="789" left="881" width="3" height="20" font="0"> </text>
</page>
<page number="203" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">203 </text>
<text top="107" left="638" width="228" height="20" font="0">or RA (both 48%) compared with controls </text>
<text top="124" left="638" width="40" height="20" font="0">(35%). </text>
<text top="143" left="623" width="11" height="18" font="0">• </text>
<text top="143" left="638" width="209" height="20" font="0">Independent of traditional risk factors, </text>
<text top="160" left="638" width="222" height="20" font="0">women with SLE or RA were more likely </text>
<text top="177" left="638" width="185" height="20" font="0">to have any CAC as well as more </text>
<text top="194" left="638" width="225" height="20" font="0">extensive CAC as compared to age- and </text>
<text top="211" left="638" width="128" height="20" font="0">race-matched controls. </text>
<text top="230" left="623" width="11" height="18" font="0">• </text>
<text top="230" left="638" width="225" height="20" font="0">After adjustments for levels of C-reactive </text>
<text top="247" left="638" width="192" height="20" font="0">protein and /or soluble intercellular </text>
<text top="264" left="638" width="223" height="20" font="0">adhesion molecule-1, women with RA or </text>
<text top="281" left="638" width="206" height="20" font="0">SLE no longer had increased odds of </text>
<text top="298" left="638" width="229" height="20" font="0">having any CAC compared with controls.  </text>
<text top="316" left="91" width="124" height="20" font="0">Kawai VK, et al., 2015 </text>
<text top="334" left="91" width="32" height="20" font="0"><a href="data supplement.html#250">(238)</a> </text>
<text top="351" left="91" width="55" height="20" font="16"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25371313">25371313</a></text>
<text top="351" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25371313"> </a></text>
<text top="368" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="385" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="316" left="259" width="147" height="20" font="7"><b>Study type:</b> Cohort study  </text>
<text top="334" left="259" width="3" height="20" font="0"> </text>
<text top="351" left="259" width="131" height="20" font="7"><b>Size:</b> 98 adults with RA </text>
<text top="316" left="420" width="176" height="20" font="7"><b>Inclusion criteria:</b> Ages 40-75, </text>
<text top="334" left="420" width="111" height="20" font="0">LDL-C &lt; 190 mg/dL </text>
<text top="351" left="420" width="3" height="20" font="0"> </text>
<text top="368" left="420" width="169" height="20" font="7"><b>Exclusion criteria:</b> Prior CVD </text>
<text top="385" left="420" width="150" height="20" font="0">event, statin use, history of </text>
<text top="402" left="420" width="50" height="20" font="0">diabetes </text>
<text top="317" left="623" width="195" height="20" font="7"><b>1</b>°<b> endpoint:</b> Accuracy of the 2013 </text>
<text top="335" left="623" width="240" height="20" font="0">ACC/AHA PCE compared to FRS and RRS </text>
<text top="352" left="623" width="204" height="20" font="0">to identify RA patients with high CAC </text>
<text top="369" left="623" width="3" height="20" font="0"> </text>
<text top="386" left="623" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="405" left="623" width="11" height="18" font="0">• </text>
<text top="405" left="631" width="217" height="20" font="0">All 3 risk scores were higher in patients </text>
<text top="422" left="631" width="223" height="20" font="0">with high CAC (&gt;300 Agatston units or &gt; </text>
<text top="439" left="631" width="14" height="20" font="0">75</text>
<text top="441" left="645" width="7" height="13" font="9">th</text>
<text top="439" left="652" width="202" height="20" font="0"> percentile of expected CAC for age, </text>
<text top="456" left="631" width="143" height="20" font="0">sex, and ethnicity, p&lt;0.05 </text>
<text top="475" left="623" width="11" height="18" font="0">• </text>
<text top="475" left="631" width="231" height="20" font="0">The percentage of patients with high CAC </text>
<text top="492" left="631" width="209" height="20" font="0">correctly assigned to the elevated risk </text>
<text top="509" left="631" width="226" height="20" font="0">category was similar among the 3 scores </text>
<text top="526" left="631" width="178" height="20" font="0">(FRS 32%, RRS 32, PCE 41%). </text>
<text top="545" left="623" width="11" height="18" font="0">• </text>
<text top="544" left="631" width="226" height="20" font="0">The C-statistics for each score predicting </text>
<text top="562" left="631" width="235" height="20" font="0">high CAC were nearly identical (0.65-0.66) </text>
<text top="318" left="881" width="7" height="18" font="0">•</text>
<text top="317" left="888" width="219" height="20" font="0">The PCE did not outperform the FRS or </text>
<text top="335" left="881" width="232" height="20" font="0">RR in the identification of RA patients with </text>
<text top="352" left="881" width="59" height="20" font="0">high CAC. </text>
<text top="371" left="881" width="7" height="18" font="0">•</text>
<text top="370" left="888" width="213" height="20" font="0">Standard risk prediction models do not </text>
<text top="388" left="881" width="228" height="20" font="0">accurately identify many RA patients with </text>
<text top="405" left="881" width="56" height="20" font="0">high CAC </text>
<text top="422" left="881" width="3" height="20" font="0"> </text>
<text top="580" left="91" width="130" height="20" font="0">Lerman JB, et al., 2017 </text>
<text top="597" left="91" width="32" height="20" font="0"><a href="data supplement.html#250">(239)</a> </text>
<text top="614" left="91" width="55" height="20" font="16"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28483812">28483812</a></text>
<text top="614" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28483812"> </a></text>
<text top="631" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="580" left="259" width="141" height="20" font="7"><b>Study type:</b>  Prospective </text>
<text top="597" left="259" width="147" height="20" font="0">observational cohort study </text>
<text top="614" left="259" width="3" height="20" font="0"> </text>
<text top="631" left="259" width="121" height="20" font="7"><b>Size:</b>  105 adults with </text>
<text top="648" left="259" width="141" height="20" font="0">psoriasis, 100 adults with </text>
<text top="666" left="259" width="127" height="20" font="0">hyperlipidemia, and 25 </text>
<text top="683" left="259" width="107" height="20" font="0">healthy volunteers  </text>
<text top="580" left="420" width="167" height="20" font="7"><b>Inclusion criteria:</b> adults with </text>
<text top="597" left="420" width="117" height="20" font="0">psoriasis, adults with </text>
<text top="614" left="420" width="175" height="20" font="0">hyperlipidemia eligible for statin </text>
<text top="631" left="420" width="146" height="20" font="0">Rx by ATP III, and healthy </text>
<text top="648" left="420" width="175" height="20" font="0">volunteers matched by age and </text>
<text top="666" left="420" width="150" height="20" font="0">sex to those with psoriasis. </text>
<text top="683" left="420" width="3" height="20" font="0"> </text>
<text top="700" left="420" width="165" height="20" font="7"><b>Exclusion criteria:</b> age &lt; 18, </text>
<text top="717" left="420" width="181" height="20" font="0">eGFR &lt; 30, pregnancy, lactating </text>
<text top="734" left="420" width="43" height="20" font="0">women </text>
<text top="581" left="623" width="211" height="20" font="7"><b>1</b>°<b> endpoint:</b> Assessment of coronary </text>
<text top="598" left="623" width="127" height="20" font="0">plaque burden on CTA </text>
<text top="615" left="623" width="3" height="20" font="0"> </text>
<text top="632" left="623" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="651" left="623" width="11" height="18" font="0">• </text>
<text top="651" left="631" width="208" height="20" font="0">Subjects with psoriasis had increased </text>
<text top="668" left="631" width="202" height="20" font="0">noncalcified coronary plaque burden </text>
<text top="685" left="631" width="227" height="20" font="0">(NCB) (1.18+0.33 vs. 1.11+0.32, p=0.02) </text>
<text top="702" left="631" width="230" height="20" font="0">and similar prevalence of high-risk plaque </text>
<text top="719" left="631" width="215" height="20" font="0">(HRP) (p=0.58), despite being younger </text>
<text top="737" left="631" width="181" height="20" font="0">with lower traditional risk factors. </text>
<text top="756" left="623" width="11" height="18" font="0">• </text>
<text top="755" left="631" width="230" height="20" font="0">Compared to healthy volunteers, subjects </text>
<text top="772" left="631" width="236" height="20" font="0">with psoriasis had increased total coronary </text>
<text top="789" left="631" width="230" height="20" font="0">plaque burden (1.22+0.31 vs. 1.04+0.22), </text>
<text top="581" left="881" width="7" height="18" font="0">•</text>
<text top="581" left="888" width="193" height="20" font="0">As assessed by CTA, patients with </text>
<text top="598" left="881" width="222" height="20" font="0">psoriasis tend to have greater volume of </text>
<text top="615" left="881" width="235" height="20" font="0">NCB and HRP prevalence as compared to </text>
<text top="632" left="881" width="216" height="20" font="0">healthy volunteers and equivalent HRP </text>
<text top="650" left="881" width="185" height="20" font="0">prevalence as older subjects with </text>
<text top="667" left="881" width="86" height="20" font="0">hyperlipidemia. </text>
<text top="686" left="881" width="7" height="18" font="0">•</text>
<text top="685" left="888" width="202" height="20" font="0">Reductions in skin inflammation was </text>
<text top="702" left="881" width="227" height="20" font="0">associated with decreases in NCB at 1 y. </text>
<text top="720" left="881" width="237" height="20" font="0">This suggests that changes in remote sites </text>
<text top="737" left="881" width="190" height="20" font="0">of inflammation may correlate with </text>
<text top="754" left="881" width="122" height="20" font="0">changes in CAD risk.  </text>
</page>
<page number="204" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">204 </text>
<text top="107" left="631" width="233" height="20" font="0">p=0.001), NCB (1.18+0.33 vs. 1.03+0.21), </text>
<text top="124" left="631" width="230" height="20" font="0">p=0.001), and prevalence of HRP beyond </text>
<text top="141" left="631" width="83" height="20" font="0">traditional risk. </text>
<text top="160" left="623" width="11" height="18" font="0">• </text>
<text top="160" left="631" width="210" height="20" font="0">After a year, improvement in psoriasis </text>
<text top="177" left="631" width="233" height="20" font="0">severity was associated with improvement </text>
<text top="194" left="631" width="226" height="20" font="0">in total coronary plaque burden and NCB </text>
<text top="211" left="631" width="170" height="20" font="0">beyond traditional risk factors.  </text>
<text top="109" left="881" width="7" height="18" font="0">•</text>
<text top="108" left="888" width="205" height="20" font="0">Aggressive management of CVD risk </text>
<text top="125" left="881" width="229" height="20" font="0">factors in person with moderate to severe </text>
<text top="143" left="881" width="129" height="20" font="0">psoriasis is warranted.  </text>
<text top="160" left="881" width="3" height="20" font="0"> </text>
<text top="229" left="91" width="127" height="20" font="0">Navarro-Millan I,  et. al </text>
<text top="247" left="91" width="63" height="20" font="0">2013<a href="data supplement.html#250"> (240)</a><b> </b></text>
<text top="264" left="91" width="7" height="20" font="7"><b>  </b></text>
<text top="281" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23460074">23460074</a></text>
<text top="281" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23460074"> </a></text>
<text top="298" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="315" left="91" width="7" height="20" font="0"> <b> </b></text>
<text top="333" left="91" width="3" height="20" font="0"> </text>
<text top="229" left="259" width="77" height="20" font="7"><b>Study type:</b>   </text>
<text top="247" left="259" width="139" height="20" font="0">Data from TEAR RCT: a  </text>
<text top="264" left="259" width="110" height="22" font="0">2‐year, investigator‐</text>
<text top="282" left="259" width="132" height="22" font="0">initiated, randomized, 4‐</text>
<text top="299" left="259" width="133" height="22" font="0">arm, placebo‐controlled </text>
<text top="316" left="259" width="132" height="20" font="0">trial of 755 patients with </text>
<text top="334" left="259" width="120" height="20" font="0">early RA and no prior </text>
<text top="351" left="259" width="127" height="20" font="0">treatment with disease-</text>
<text top="368" left="259" width="137" height="20" font="0">modifying anti-rheumatic </text>
<text top="385" left="259" width="34" height="20" font="0">drugs </text>
<text top="403" left="259" width="3" height="20" font="0"> </text>
<text top="420" left="259" width="109" height="20" font="7"><b>Size:</b>   459 patients </text>
<text top="437" left="259" width="117" height="20" font="0">RA disease duration: </text>
<text top="454" left="259" width="123" height="20" font="0">(mean ± SD 3.8 ± 1.1 </text>
<text top="471" left="259" width="51" height="20" font="0">months)  </text>
<text top="489" left="259" width="70" height="20" font="0">White:  80% </text>
<text top="506" left="259" width="146" height="20" font="0">Female:  73.6%; 76.9% &amp;  </text>
<text top="523" left="259" width="124" height="20" font="0">70.8% in three groups </text>
<text top="540" left="259" width="128" height="20" font="0">DAS28-ESR  5.8 ± 1.1 </text>
<text top="557" left="259" width="135" height="20" font="0">On prednisone:   40% in </text>
<text top="575" left="259" width="120" height="20" font="0">each treatment group </text>
<text top="592" left="259" width="7" height="20" font="0">  </text>
<text top="609" left="259" width="126" height="20" font="0">No significant baseline </text>
<text top="626" left="259" width="113" height="20" font="0">differences between </text>
<text top="644" left="259" width="103" height="20" font="0">treatment groups.  </text>
<text top="661" left="259" width="3" height="20" font="0"> </text>
<text top="229" left="420" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="248" left="420" width="11" height="18" font="0">• </text>
<text top="248" left="430" width="173" height="20" font="0"> Participants naive to treatment </text>
<text top="265" left="430" width="128" height="22" font="0">with disease‐modifying </text>
<text top="282" left="430" width="178" height="20" font="0">antirheumatic drugs (DMARDs). </text>
<text top="300" left="420" width="187" height="20" font="0">Patients randomized to 4 different </text>
<text top="317" left="420" width="96" height="20" font="0">treatment groups </text>
<text top="346" left="424" width="55" height="20" font="0">MTX plus </text>
<text top="363" left="424" width="62" height="20" font="0">etanercept </text>
<text top="380" left="424" width="53" height="20" font="0">(n = 155) </text>
<text top="337" left="486" width="41" height="20" font="0">Triple   </text>
<text top="355" left="486" width="44" height="20" font="0">therapy </text>
<text top="372" left="486" width="25" height="20" font="0">(n = </text>
<text top="389" left="486" width="21" height="20" font="0">78) </text>
<text top="337" left="532" width="29" height="20" font="0">MTX </text>
<text top="355" left="532" width="75" height="20" font="0">monotherapy </text>
<text top="372" left="532" width="53" height="20" font="0">(n = 226) </text>
<text top="389" left="532" width="3" height="24" font="0">  </text>
<text top="409" left="420" width="111" height="20" font="0">And a Placebo arm; </text>
<text top="427" left="420" width="3" height="20" font="0"> </text>
<text top="444" left="420" width="3" height="20" font="0"> </text>
<text top="461" left="420" width="136" height="20" font="0">Two arms included MTX </text>
<text top="478" left="420" width="188" height="20" font="0">monotherapy aggressively titrated </text>
<text top="496" left="420" width="179" height="22" font="0">to 20 mg/week, with “step‐up” to </text>
<text top="513" left="420" width="187" height="20" font="0">MTX plus etanercept 50 mg/week </text>
<text top="530" left="420" width="188" height="20" font="0">or to triple therapy at 6 months for </text>
<text top="548" left="420" width="169" height="20" font="0">patients who did not achieve a </text>
<text top="565" left="420" width="178" height="20" font="0">low Disease Activity Score in 28 </text>
<text top="582" left="420" width="150" height="20" font="0">joints using the erythrocyte </text>
<text top="599" left="420" width="185" height="22" font="0">sedimentation rate (DAS28‐ESR; </text>
<text top="617" left="420" width="106" height="20" font="0">&lt;3.2 at 6 months).  </text>
<text top="634" left="420" width="169" height="20" font="0">The other two arms were MTX </text>
<text top="651" left="420" width="147" height="20" font="0">plus etanercept initiated at </text>
<text top="669" left="420" width="148" height="20" font="0">baseline and triple therapy </text>
<text top="686" left="420" width="116" height="20" font="0">initiated at baseline.  </text>
<text top="703" left="420" width="3" height="20" font="0"> </text>
<text top="720" left="420" width="82" height="20" font="0">Triple therapy: </text>
<text top="737" left="420" width="180" height="20" font="0">1) MTX (titrated to 20 mg/week)  </text>
<text top="755" left="420" width="155" height="20" font="0">2) SSZ 500 mg twice a day. </text>
<text top="772" left="420" width="143" height="20" font="0"> If this was tolerated, then </text>
<text top="789" left="420" width="166" height="20" font="0">escalated to 1,000 mg twice a </text>
<text top="230" left="623" width="79" height="20" font="7"><b>1</b>°<b> endpoint:</b>  </text>
<text top="248" left="623" width="137" height="20" font="0">Lipid levels at 24 weeks. </text>
<text top="265" left="623" width="3" height="20" font="0"> </text>
<text top="282" left="623" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="299" left="623" width="216" height="20" font="0">Significant changes in total cholesterol, </text>
<text top="317" left="623" width="146" height="20" font="0">HDL-C, and LDL-C levels  </text>
<text top="334" left="623" width="75" height="20" font="0">(all in mg/dL) </text>
<text top="351" left="623" width="195" height="20" font="0">compared to baseline (p&lt;0.0001)    </text>
<text top="368" left="623" width="240" height="20" font="0">Mean decrease in Total Cholesterol to HDL-</text>
<text top="385" left="623" width="197" height="20" font="0">C compared to baseline (p&lt;0.0001) </text>
<text top="432" left="627" width="33" height="20" font="0">MTX  </text>
<text top="449" left="627" width="26" height="20" font="0">plus </text>
<text top="466" left="627" width="62" height="20" font="0">etanercept </text>
<text top="483" left="627" width="46" height="20" font="0">LDL-C   </text>
<text top="501" left="627" width="27" height="20" font="0">31.4 </text>
<text top="432" left="689" width="41" height="20" font="0">Triple   </text>
<text top="449" left="689" width="44" height="20" font="0">therapy </text>
<text top="466" left="689" width="3" height="20" font="0"> </text>
<text top="483" left="689" width="39" height="20" font="0">LDL-C </text>
<text top="501" left="689" width="41" height="20" font="0">28.7     </text>
<text top="406" left="735" width="3" height="20" font="0"> </text>
<text top="423" left="735" width="108" height="20" font="0">MTX monotherapy  </text>
<text top="440" left="735" width="27" height="20" font="0">        </text>
<text top="458" left="735" width="3" height="20" font="0"> </text>
<text top="475" left="735" width="39" height="20" font="0">LDL-C </text>
<text top="492" left="735" width="27" height="20" font="0">30.0 </text>
<text top="509" left="735" width="10" height="20" font="0">   </text>
<text top="526" left="735" width="3" height="24" font="0">  </text>
<text top="547" left="623" width="188" height="20" font="7"><b>TC/HDL-C  TC/HDL-C TC/HDL-C </b></text>
<text top="564" left="623" width="190" height="20" font="0"> −0.1.                 -0.3.               -0.2 </text>
<text top="581" left="623" width="230" height="20" font="0">(<i>P</i> = 0.012 versus baseline) for first group </text>
<text top="599" left="623" width="204" height="20" font="0">(<i>P</i> &lt; 0.0001 versus baseline for each </text>
<text top="616" left="623" width="78" height="20" font="0">comparison) 2</text>
<text top="618" left="701" width="9" height="13" font="9">nd</text>
<text top="616" left="710" width="34" height="20" font="0"> and 3</text>
<text top="618" left="744" width="7" height="13" font="9">rd</text>
<text top="616" left="752" width="44" height="20" font="0"> groups </text>
<text top="633" left="623" width="3" height="20" font="0"> </text>
<text top="650" left="623" width="235" height="20" font="0">Within each treatment group, the changes  </text>
<text top="668" left="623" width="193" height="20" font="0">in lipid levels at 24 weeks were not </text>
<text top="685" left="623" width="241" height="20" font="0">significantly different comparing  those with  </text>
<text top="702" left="623" width="227" height="22" font="0">DAS28‐ESR &lt;3.2 and those with DAS28‐</text>
<text top="719" left="623" width="68" height="20" font="0">ESR ≥3.2    </text>
<text top="737" left="623" width="3" height="20" font="0"> </text>
<text top="754" left="623" width="3" height="20" font="0"> </text>
<text top="771" left="623" width="3" height="20" font="0"> </text>
<text top="229" left="881" width="187" height="20" font="0">Although lipid levels increase with </text>
<text top="247" left="881" width="225" height="20" font="0">intensive treatment of RA with 3 different </text>
<text top="264" left="881" width="234" height="20" font="0">protocols, the ratio of TC/HDL-C, a robust  </text>
<text top="281" left="881" width="219" height="20" font="0">lipid measure of risk actually decreased </text>
<text top="298" left="881" width="156" height="20" font="0">slightly in all treatment arms </text>
<text top="315" left="881" width="3" height="20" font="0"> </text>
<text top="333" left="881" width="66" height="20" font="0">Comments: </text>
<text top="350" left="881" width="215" height="20" font="0">Strength of study was use of a  blinded </text>
<text top="367" left="881" width="232" height="20" font="0">(TEAR) study comparing various rgimens  </text>
<text top="384" left="881" width="147" height="20" font="0">for  patients with early RA. </text>
<text top="401" left="881" width="3" height="20" font="0"> </text>
<text top="419" left="881" width="53" height="20" font="0">Caution:  </text>
<text top="436" left="881" width="182" height="20" font="0">Significant number of patients on </text>
<text top="453" left="881" width="235" height="20" font="0">prednisone that increases all lipid fractions </text>
<text top="470" left="881" width="93" height="20" font="0">including HDL-C </text>
<text top="487" left="881" width="3" height="20" font="0"> </text>
<text top="505" left="881" width="226" height="20" font="0">Study suggests that lipid levels are worth </text>
<text top="522" left="881" width="231" height="20" font="0">watching, although in these patients there </text>
<text top="539" left="881" width="232" height="20" font="0">can be multiple factors that can affect lipid </text>
<text top="556" left="881" width="38" height="20" font="0">levels. </text>
</page>
<page number="205" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">205 </text>
<text top="107" left="420" width="169" height="20" font="0">day, plus HCQ 200 mg twice a </text>
<text top="124" left="420" width="23" height="20" font="0">day </text>
<text top="141" left="420" width="3" height="20" font="0"> </text>
<text top="159" left="420" width="3" height="20" font="0"> </text>
<text top="177" left="81" width="89" height="20" font="7"><b>Abbreviations: </b></text>
<text top="194" left="81" width="1017" height="20" font="0">RA = rheumatoid arthritis, ACS = acute coronary syndrome, HR = hazard ratio, CVD = cardiovascular disease, CI = confidence interval, MI = myocardial infarction; CVA = cerebrovascular </text>
<text top="211" left="81" width="1016" height="20" font="0">accident, PVD = peripheral vascular disease, VTE = venous thromboembolic, PCP = primary care provider, ROC = Receiver Operator Characteristic, SCORE = Systematic Coronary Risk </text>
<text top="228" left="81" width="1000" height="20" font="0">Evaluation; FRS = Framingham Risk Score; RRS = Reynold’s Risk Score, ESRD = end stage renal disease, CTA = Computed Tomographic Angiography, NCB = noncalcified coronary </text>
<text top="246" left="81" width="82" height="20" font="0">plaque burden </text>
<text top="263" left="81" width="4" height="22" font="1"> </text>
<text top="281" left="81" width="4" height="22" font="1"> </text>
<text top="300" left="81" width="4" height="22" font="1"> </text>
<text top="319" left="81" width="4" height="22" font="1"> </text>
<text top="338" left="81" width="694" height="24" font="4"><b>Data Supplement 40. RCTs Comparing Statin Safety and Statin Associated Side Effects (Section 5) </b></text>
<text top="369" left="102" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="386" left="127" width="48" height="20" font="7"><b>Author; </b></text>
<text top="403" left="105" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="369" left="253" width="83" height="20" font="7"><b>Aim of Study; </b></text>
<text top="386" left="258" width="74" height="20" font="7"><b>Study Type; </b></text>
<text top="403" left="252" width="86" height="20" font="7"><b>Study Size (N) </b></text>
<text top="386" left="410" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="360" left="582" width="111" height="20" font="7"><b>Study Intervention </b></text>
<text top="378" left="599" width="76" height="20" font="7"><b>(# patients) / </b></text>
<text top="395" left="582" width="111" height="20" font="7"><b>Study Comparator </b></text>
<text top="412" left="603" width="69" height="20" font="7"><b>(# patients) </b></text>
<text top="369" left="778" width="105" height="20" font="7"><b>Endpoint Results </b></text>
<text top="386" left="761" width="137" height="20" font="7"><b>(Absolute Event Rates, </b></text>
<text top="403" left="740" width="181" height="20" font="7"><b>P values; OR or RR; &amp; 95% CI) </b></text>
<text top="361" left="964" width="143" height="20" font="7"><b>Relevant 2</b>°<b> Endpoint (if </b></text>
<text top="378" left="1019" width="33" height="20" font="7"><b>any); </b></text>
<text top="395" left="980" width="111" height="20" font="7"><b>Study Limitations; </b></text>
<text top="413" left="987" width="96" height="20" font="7"><b>Adverse Events </b></text>
<text top="431" left="89" width="52" height="20" font="7"><b>HOPE 3  </b></text>
<text top="448" left="89" width="114" height="20" font="0">Yusuf S, et al., 2016 </text>
<text top="465" left="89" width="25" height="20" font="0"><a href="data supplement.html#236">(12)</a> </text>
<text top="482" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27040132">27040132</a></text>
<text top="482" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27040132"> </a></text>
<text top="499" left="89" width="80" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00468923">NCT00468923</a></text>
<text top="499" left="169" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00468923"> </a></text>
<text top="431" left="226" width="111" height="20" font="7"><b>Aim:</b> Determine net </text>
<text top="448" left="226" width="40" height="20" font="0">benefit </text>
<text top="465" left="226" width="3" height="20" font="0"> </text>
<text top="482" left="226" width="102" height="20" font="7"><b>Study type:</b> RCT  </text>
<text top="499" left="226" width="3" height="20" font="0"> </text>
<text top="517" left="226" width="76" height="20" font="7"><b>Size:</b>  12,705 </text>
<text top="534" left="226" width="66" height="20" font="0">participants </text>
<text top="551" left="226" width="98" height="20" font="0">46.4% female G1 </text>
<text top="568" left="226" width="102" height="20" font="0">46.1% female G2  </text>
<text top="431" left="376" width="144" height="20" font="7"><b>Inclusion criteria:</b> Men &gt; </text>
<text top="448" left="376" width="159" height="20" font="0">55yrs, Women &gt; 65 y with at </text>
<text top="465" left="376" width="179" height="20" font="0">least 1 CVRF; Women &gt; 60 with </text>
<text top="482" left="376" width="36" height="20" font="0">2 RFs </text>
<text top="499" left="376" width="3" height="20" font="0"> </text>
<text top="517" left="376" width="143" height="20" font="0">Worldwide recruitment 21 </text>
<text top="534" left="376" width="53" height="20" font="0">countries </text>
<text top="551" left="376" width="3" height="20" font="0"> </text>
<text top="568" left="376" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="587" left="376" width="11" height="18" font="0">• </text>
<text top="587" left="403" width="76" height="20" font="0">Pts with CVD </text>
<text top="604" left="376" width="172" height="20" font="0">Indications or contraindications </text>
<text top="621" left="376" width="145" height="20" font="0">to statins, ARBs, ACE-I or </text>
<text top="638" left="376" width="95" height="20" font="0">thiazide diuretics </text>
<text top="431" left="568" width="81" height="20" font="7"><b>Intervention:</b>  </text>
<text top="448" left="568" width="115" height="20" font="0">G1: Rosuvastatin 10 </text>
<text top="465" left="568" width="70" height="20" font="0">mg/d (6361) </text>
<text top="482" left="568" width="3" height="20" font="0"> </text>
<text top="499" left="568" width="7" height="20" font="0">  </text>
<text top="517" left="568" width="77" height="20" font="7"><b>Comparator: </b></text>
<text top="534" left="568" width="112" height="20" font="0">G2: placebo (6344) <b> </b></text>
<text top="432" left="720" width="210" height="20" font="7"><b>1</b>°<b> endpoint:</b> Composite of CV death, </text>
<text top="449" left="720" width="204" height="20" font="0">nonfatal MI/nonfatal stroke (G1:3.7% </text>
<text top="466" left="720" width="208" height="20" font="0">vs. G2: 4.8%; HR: 0.76; 95% CI: 0.64-</text>
<text top="483" left="720" width="136" height="20" font="0">0.91; p=0.002; NNT=91) </text>
<text top="501" left="720" width="3" height="20" font="0"> </text>
<text top="519" left="720" width="219" height="20" font="7"><b>Second co- 1</b>°<b> endpoint: </b>composite of </text>
<text top="536" left="720" width="189" height="20" font="0">CV death, MI, stroke, resuscitated </text>
<text top="553" left="720" width="164" height="20" font="0">cardiac arrest, heart failure or </text>
<text top="571" left="720" width="190" height="20" font="0">revascularization (G1 4.4% vs. G2 </text>
<text top="588" left="720" width="196" height="20" font="0">5.7%; HR: 0.75; 95% CI: 0.64-0.88; </text>
<text top="605" left="720" width="105" height="20" font="0">p&lt;0.001; NNT=73) </text>
<text top="622" left="720" width="7" height="20" font="0">  </text>
<text top="640" left="720" width="181" height="20" font="0">LDL-C with G1 lower than G2 at  </text>
<text top="657" left="720" width="86" height="20" font="0">1 y: 39.6 (1.02) </text>
<text top="674" left="720" width="86" height="20" font="0">3 y: 34.7 (0.90) </text>
<text top="691" left="720" width="200" height="20" font="0">Overall mean Diff: 34.6 (0.9) 26.5%; </text>
<text top="708" left="720" width="48" height="20" font="0">p=0.001 </text>
<text top="726" left="720" width="3" height="20" font="0"> </text>
<text top="743" left="720" width="125" height="20" font="0">ASCVD Risk G2 (%/y) </text>
<text top="760" left="720" width="118" height="20" font="0">PO1=4.8%/5.6 y=8.6 </text>
<text top="777" left="720" width="125" height="20" font="0">PO2=5.7%/5.6 y=10.1 </text>
<text top="432" left="953" width="7" height="18" font="0">•</text>
<text top="432" left="960" width="151" height="20" font="7"><b>Muscle pain or weakness</b> </text>
<text top="449" left="953" width="132" height="20" font="0">G1: 5.8% vs. G2: 4.7%; </text>
<text top="466" left="953" width="48" height="20" font="0">p=0.005 </text>
<text top="485" left="953" width="7" height="18" font="0">•</text>
<text top="485" left="960" width="94" height="20" font="0">Cataract surgery </text>
<text top="502" left="953" width="125" height="20" font="0">G1:3.8% vs. G2 3.1%; </text>
<text top="519" left="953" width="41" height="20" font="0">p=0.02 </text>
<text top="536" left="953" width="3" height="20" font="0"> </text>
<text top="554" left="953" width="3" height="20" font="0"> </text>
<text top="571" left="953" width="83" height="20" font="7"><b>No excess of: </b></text>
<text top="590" left="953" width="7" height="18" font="0">•</text>
<text top="589" left="960" width="139" height="20" font="0">New-onset DM: G1:3.9% </text>
<text top="606" left="953" width="95" height="20" font="0">vs. 3.8%, p=0.82 </text>
<text top="625" left="953" width="7" height="18" font="0">•</text>
<text top="625" left="960" width="145" height="20" font="0">Muscle symptoms leading </text>
<text top="642" left="953" width="113" height="20" font="0">to discontinuation of </text>
<text top="659" left="953" width="59" height="20" font="0">treatment: </text>
<text top="676" left="953" width="132" height="20" font="0">G1: 1.3% vs. G2: 1.2%, </text>
<text top="694" left="953" width="41" height="20" font="0">p=0.63 </text>
<text top="713" left="953" width="7" height="18" font="0">•</text>
<text top="712" left="960" width="108" height="20" font="0">Rhabdomyolysis or </text>
<text top="729" left="953" width="145" height="20" font="0">myopathy: G1 2 cases vs. </text>
<text top="746" left="953" width="60" height="20" font="0">G2:1 case </text>
<text top="765" left="953" width="7" height="18" font="0">•</text>
<text top="765" left="960" width="47" height="20" font="0">Cancer: </text>
<text top="782" left="953" width="107" height="20" font="0">G1 267 vs. G2 286 </text>
</page>
<page number="206" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">206 </text>
<text top="109" left="953" width="7" height="18" font="0">•</text>
<text top="108" left="960" width="153" height="20" font="0">No excess risk of functional </text>
<text top="125" left="953" width="150" height="20" font="0">abnormalities of the liver in </text>
<text top="143" left="953" width="27" height="20" font="0">G1.  </text>
<text top="160" left="953" width="3" height="20" font="0"> </text>
<text top="193" left="89" width="47" height="20" font="7"><b>STOMP </b></text>
<text top="210" left="89" width="96" height="20" font="0">Parker BA, et al., </text>
<text top="227" left="89" width="63" height="20" font="0">2013 <a href="data supplement.html#250">(241)</a> </text>
<text top="244" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23183941">23183941</a></text>
<text top="244" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23183941"> </a></text>
<text top="262" left="89" width="80" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00609063">NCT00609063</a></text>
<text top="262" left="169" width="7" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00609063">  </a></text>
<text top="193" left="226" width="135" height="20" font="7"><b>Aim:</b> To study the effect </text>
<text top="210" left="226" width="112" height="20" font="0">of statins on muscle </text>
<text top="227" left="226" width="135" height="20" font="0">symptoms, strength and </text>
<text top="244" left="226" width="122" height="20" font="0">exercise performance </text>
<text top="262" left="226" width="3" height="20" font="0"> </text>
<text top="279" left="226" width="99" height="20" font="7"><b>Study type:</b> RCT </text>
<text top="296" left="226" width="3" height="20" font="0"> </text>
<text top="313" left="226" width="60" height="20" font="7"><b>Size:</b> 420  </text>
<text top="330" left="226" width="75" height="20" font="0">51% women  </text>
<text top="193" left="376" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="210" left="376" width="166" height="20" font="0">Healthy, statin-naive men and </text>
<text top="227" left="376" width="43" height="20" font="0">women </text>
<text top="244" left="376" width="3" height="20" font="0"> </text>
<text top="262" left="376" width="3" height="20" font="0"> </text>
<text top="279" left="376" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="296" left="376" width="101" height="20" font="0">Cancer within 5 y, </text>
<text top="313" left="376" width="172" height="20" font="0">baseline ALT&gt;2x ULN, Cr level </text>
<text top="330" left="376" width="154" height="20" font="0">&gt;2 mg/dL, abnormal thyroid </text>
<text top="348" left="376" width="109" height="20" font="0">function, CVD, DM, </text>
<text top="365" left="376" width="178" height="20" font="0">pretreatment muscle symptoms, </text>
<text top="382" left="376" width="141" height="20" font="0">disability limiting exercise </text>
<text top="399" left="376" width="40" height="20" font="0">testing </text>
<text top="193" left="568" width="78" height="20" font="7"><b>Intervention:</b> </text>
<text top="210" left="568" width="133" height="20" font="0">atorvastatin 80 mg for 6 </text>
<text top="227" left="568" width="56" height="20" font="0">mo (203)  </text>
<text top="244" left="568" width="7" height="20" font="0">  </text>
<text top="262" left="568" width="124" height="20" font="7"><b>Comparator:</b> placebo </text>
<text top="279" left="568" width="81" height="20" font="0">for 6 mo (217)<b> </b></text>
<text top="194" left="720" width="210" height="20" font="7"><b>1</b>°<b> endpoint:</b> incidence of myalgias in </text>
<text top="211" left="720" width="214" height="20" font="0">atorvastatin vs. placebo groups (19 vs. </text>
<text top="228" left="720" width="66" height="20" font="0">10; p=0.05) </text>
<text top="246" left="720" width="3" height="20" font="0"> </text>
<text top="263" left="720" width="129" height="20" font="7"><b>Secondary endpoint:  </b></text>
<text top="282" left="720" width="7" height="18" font="0">•</text>
<text top="281" left="726" width="212" height="20" font="0">Change in serologic markers including </text>
<text top="298" left="720" width="193" height="20" font="0">creatine kinase levels (average CK </text>
<text top="316" left="720" width="204" height="20" font="0">increase of 20.8 U/L from baseline in </text>
<text top="333" left="720" width="194" height="20" font="0">atorvastatin group; p&lt;0.0001), liver </text>
<text top="350" left="720" width="194" height="20" font="0">enzymes (average ALT increase of </text>
<text top="367" left="720" width="189" height="20" font="0">15.7 U/L in the atorvastatin group; </text>
<text top="384" left="720" width="63" height="20" font="0">p&lt;0.0001). </text>
<text top="403" left="720" width="7" height="18" font="0">•</text>
<text top="403" left="726" width="208" height="20" font="0">Muscle strength and performance (no </text>
<text top="420" left="720" width="178" height="20" font="0">effect of atorvastatin or placebo; </text>
<text top="437" left="720" width="46" height="20" font="0">p&gt;0.17)<b> </b></text>
<text top="195" left="953" width="7" height="18" font="0">•</text>
<text top="194" left="960" width="146" height="20" font="0">No subject on atorvastatin </text>
<text top="211" left="953" width="134" height="20" font="0">had CK levels&gt;10x ULN </text>
<text top="230" left="953" width="7" height="18" font="0">•</text>
<text top="230" left="960" width="124" height="20" font="0">No effect on vitamin D </text>
<text top="247" left="953" width="83" height="20" font="0">levels at 6 mo  </text>
<text top="264" left="953" width="3" height="20" font="0"> </text>
<text top="281" left="953" width="3" height="20" font="0"> </text>
<text top="455" left="89" width="58" height="20" font="7"><b>GAUSS-3 </b></text>
<text top="472" left="89" width="101" height="20" font="0">Nissen SE, et al.,  </text>
<text top="490" left="89" width="63" height="20" font="0">2016<a href="data supplement.html#250"> (242)</a> </text>
<text top="507" left="89" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27039291"> </a></text>
<text top="507" left="93" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27039291">27039291</a></text>
<text top="507" left="148" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27039291"> </a></text>
<text top="524" left="89" width="80" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01984424">NCT01984424</a></text>
<text top="524" left="169" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01984424"> </a></text>
<text top="455" left="226" width="120" height="20" font="7"><b>Aim:</b> Identify patients </text>
<text top="472" left="226" width="104" height="20" font="0">with statin induced </text>
<text top="490" left="226" width="127" height="20" font="0">muscle symptoms with </text>
<text top="507" left="226" width="128" height="20" font="0">statin re-challenge and </text>
<text top="524" left="226" width="126" height="20" font="0">compare effectiveness </text>
<text top="541" left="226" width="107" height="20" font="0">of evolocumab and </text>
<text top="559" left="226" width="115" height="20" font="0">ezetimibe in patients </text>
<text top="576" left="226" width="109" height="20" font="0">with muscle related </text>
<text top="593" left="226" width="96" height="20" font="0">statin intolerance </text>
<text top="610" left="226" width="3" height="20" font="0"> </text>
<text top="627" left="226" width="131" height="20" font="7"><b>Study type:</b> Two-stage </text>
<text top="645" left="226" width="32" height="20" font="0">RCT  </text>
<text top="662" left="226" width="3" height="20" font="0"> </text>
<text top="679" left="226" width="60" height="20" font="7"><b>Size:</b> 491  </text>
<text top="455" left="376" width="106" height="20" font="7"><b>Inclusion criteria: </b></text>
<text top="474" left="376" width="7" height="18" font="0">•</text>
<text top="474" left="383" width="171" height="20" font="0">Phase A: pts 18 to 80 y unable </text>
<text top="491" left="376" width="101" height="20" font="0">to tolerate a statin </text>
<text top="508" left="376" width="169" height="20" font="0">Phase B: Patients with muscle </text>
<text top="525" left="376" width="135" height="20" font="0">related symptoms or CK </text>
<text top="525" left="511" width="8" height="20" font="14">≥</text>
<text top="525" left="519" width="23" height="20" font="0">10x </text>
<text top="542" left="376" width="149" height="20" font="0">ULN on statin re-challenge </text>
<text top="560" left="376" width="90" height="20" font="0">during phase A: </text>
<text top="579" left="376" width="7" height="18" font="0">•</text>
<text top="578" left="383" width="35" height="20" font="0">LDL-C</text>
<text top="578" left="418" width="135" height="20" font="14">≥100 mg/dl with CHD or </text>
<text top="595" left="376" width="176" height="20" font="14">≥130 mg/dl with ≥2 risk factors, </text>
<text top="613" left="376" width="170" height="20" font="14">≥160 mg/dl with ≥1 risk factor, </text>
<text top="630" left="376" width="145" height="20" font="14">or ≥190 mg/dl with no risk </text>
<text top="647" left="376" width="37" height="20" font="14">factors</text>
<text top="647" left="413" width="3" height="20" font="0"> </text>
<text top="664" left="376" width="3" height="20" font="0"> </text>
<text top="681" left="376" width="110" height="20" font="7"><b>Exclusion criteria: </b></text>
<text top="700" left="376" width="7" height="18" font="0">•</text>
<text top="700" left="383" width="165" height="20" font="0">MI, unstable angina, coronary </text>
<text top="717" left="376" width="147" height="20" font="0">revascularization or stroke </text>
<text top="734" left="376" width="104" height="20" font="0">within 3 mo before </text>
<text top="751" left="376" width="81" height="20" font="0">randomization </text>
<text top="770" left="376" width="7" height="18" font="0">•</text>
<text top="770" left="383" width="143" height="20" font="0">NYHA class III or IV heart </text>
<text top="787" left="376" width="37" height="20" font="0">failure </text>
<text top="455" left="568" width="81" height="20" font="7"><b>Intervention:</b>  </text>
<text top="472" left="568" width="139" height="20" font="0">Phase A: Atorvastatin 20 </text>
<text top="490" left="568" width="124" height="20" font="0">mg for first 10 wk then </text>
<text top="507" left="568" width="120" height="20" font="0">cross over to placebo </text>
<text top="524" left="568" width="124" height="20" font="0">Phase B: Evolocumab </text>
<text top="541" left="568" width="123" height="20" font="0">420 mg monthly (145) </text>
<text top="559" left="568" width="7" height="20" font="0">  </text>
<text top="576" left="568" width="81" height="20" font="7"><b>Comparator:</b>  </text>
<text top="593" left="568" width="119" height="20" font="0">Phase A: Placebo for </text>
<text top="610" left="568" width="119" height="20" font="0">first 10 wk then cross </text>
<text top="627" left="568" width="111" height="20" font="0">over to atorvastatin  </text>
<text top="645" left="568" width="126" height="20" font="0">Phase B: ezetimibe 10 </text>
<text top="662" left="568" width="75" height="20" font="0">mg daily (73) </text>
<text top="679" left="568" width="3" height="20" font="7"><b> </b></text>
<text top="456" left="720" width="79" height="20" font="7"><b>1</b>°<b> endpoint:</b>  </text>
<text top="475" left="720" width="7" height="18" font="0">•</text>
<text top="475" left="726" width="172" height="20" font="0">Mean % change in LDL-C from </text>
<text top="492" left="720" width="213" height="20" font="0">baseline to wk 24 with evolocumab vs. </text>
<text top="509" left="720" width="220" height="20" font="0">ezetimibe (-52.8% vs. -16.7%, p&lt;0.001) </text>
<text top="528" left="720" width="7" height="18" font="0">•</text>
<text top="528" left="726" width="204" height="20" font="0"> % change in LDL-C from baseline to </text>
<text top="545" left="720" width="156" height="20" font="0">means of wk 22 and 24 with </text>
<text top="562" left="720" width="214" height="20" font="0">evolocumab vs. ezetimibe (-54.5% vs. -</text>
<text top="579" left="720" width="94" height="20" font="0">16.7%, p&lt;0.001) </text>
<text top="597" left="720" width="3" height="20" font="0"> </text>
<text top="614" left="720" width="3" height="20" font="7"><b> </b></text>
<text top="457" left="953" width="7" height="18" font="0">•</text>
<text top="456" left="960" width="153" height="20" font="0">Muscle symptoms occurred </text>
<text top="474" left="953" width="135" height="20" font="0">in 209 of 491 (42.6%) of </text>
<text top="491" left="953" width="162" height="20" font="0">patients while on atorvastatin </text>
<text top="508" left="953" width="142" height="20" font="0">but not on placebo during </text>
<text top="525" left="953" width="49" height="20" font="0">phase A </text>
<text top="544" left="953" width="7" height="18" font="0">•</text>
<text top="544" left="960" width="156" height="20" font="0">Muscle related symptoms in </text>
<text top="561" left="953" width="148" height="20" font="0">evolocumab vs. ezetimibe: </text>
<text top="578" left="953" width="138" height="20" font="0">20.7% vs. 28.8% P&gt;0.05 </text>
<text top="597" left="953" width="7" height="18" font="0">•</text>
<text top="597" left="960" width="153" height="20" font="0">Drug discontinuation due to </text>
<text top="614" left="953" width="115" height="20" font="0">muscle symptoms in </text>
<text top="631" left="953" width="148" height="20" font="0">evolocumab vs. ezetimibe: </text>
<text top="648" left="953" width="82" height="20" font="0">0.7% vs. 6.8% </text>
<text top="667" left="953" width="7" height="18" font="0">•</text>
<text top="667" left="960" width="20" height="20" font="0">CK </text>
<text top="667" left="980" width="8" height="20" font="14">≥</text>
<text top="667" left="989" width="76" height="20" font="0">10x ULN with </text>
<text top="684" left="953" width="148" height="20" font="0">evolocumab vs. ezetimibe: </text>
<text top="701" left="953" width="128" height="20" font="0">2.8% vs. 1.4%, P&gt;0.05 </text>
<text top="718" left="953" width="3" height="20" font="0"> </text>
<text top="735" left="953" width="3" height="20" font="0"> </text>
</page>
<page number="207" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">207 </text>
<text top="109" left="376" width="7" height="18" font="0">•</text>
<text top="108" left="383" width="161" height="20" font="0">Uncontrolled hypertension or </text>
<text top="125" left="376" width="105" height="20" font="0">cardiac arrhythmia </text>
<text top="144" left="376" width="7" height="18" font="0">•</text>
<text top="144" left="383" width="64" height="20" font="0">Type 1 DM </text>
<text top="163" left="376" width="7" height="18" font="0">•</text>
<text top="162" left="383" width="159" height="20" font="0">Poorly controlled Type II DM </text>
<text top="181" left="376" width="7" height="18" font="0">•</text>
<text top="181" left="383" width="162" height="20" font="0">Uncontrolled thyroid disease  </text>
<text top="199" left="89" width="63" height="20" font="7"><b>ODYSSEY </b></text>
<text top="216" left="89" width="89" height="20" font="7"><b>ALTERNATIVE </b></text>
<text top="233" left="89" width="107" height="20" font="0">Moriarty PM, et al., </text>
<text top="250" left="89" width="63" height="20" font="0">2015 <a href="data supplement.html#250">(243)</a> </text>
<text top="267" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25499937">25499937</a></text>
<text top="267" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25499937"> </a></text>
<text top="285" left="89" width="80" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01709513">NCT01709513</a></text>
<text top="285" left="169" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01709513"> </a></text>
<text top="199" left="226" width="120" height="20" font="7"><b>Aim:</b> study the safety </text>
<text top="216" left="226" width="121" height="20" font="0">and efficacy of LDL-C </text>
<text top="233" left="226" width="79" height="20" font="0">reduction with </text>
<text top="250" left="226" width="83" height="20" font="0">alirocumab vs. </text>
<text top="267" left="226" width="115" height="20" font="0">ezetimibe in patients </text>
<text top="285" left="226" width="121" height="20" font="0">with statin intolerance </text>
<text top="302" left="226" width="68" height="20" font="0">and primary </text>
<text top="319" left="226" width="120" height="20" font="0">hypercholesterolemia </text>
<text top="336" left="226" width="3" height="20" font="0"> </text>
<text top="353" left="226" width="102" height="20" font="7"><b>Study type:</b> RCT  </text>
<text top="371" left="226" width="3" height="20" font="0"> </text>
<text top="388" left="226" width="60" height="20" font="7"><b>Size:</b> 314  </text>
<text top="199" left="376" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="218" left="376" width="7" height="18" font="0">•</text>
<text top="217" left="383" width="161" height="20" font="0">Statin intolerance (inability to </text>
<text top="234" left="376" width="174" height="20" font="0">tolerate at least 2 statins due to </text>
<text top="251" left="376" width="146" height="20" font="0">muscle related symptoms, </text>
<text top="269" left="376" width="148" height="20" font="0">including one at the lowest </text>
<text top="286" left="376" width="165" height="20" font="0">dose) with LDL-C ≥ 70 mg/dL </text>
<text top="303" left="376" width="154" height="20" font="0">(very high CV risk) or ≥ 100 </text>
<text top="320" left="376" width="174" height="20" font="0">mg/dL (moderate/high CV risk). </text>
<text top="337" left="376" width="3" height="20" font="0"> </text>
<text top="355" left="376" width="110" height="20" font="7"><b>Exclusion criteria: </b></text>
<text top="374" left="376" width="7" height="18" font="0">•</text>
<text top="373" left="383" width="143" height="20" font="0">Non-statin related muscle </text>
<text top="390" left="376" width="163" height="20" font="0">symptoms during single-blind </text>
<text top="407" left="376" width="119" height="20" font="0">placebo run-in period </text>
<text top="426" left="376" width="7" height="18" font="0">•</text>
<text top="426" left="383" width="159" height="20" font="0">Uncontrolled thyroid disease </text>
<text top="445" left="376" width="7" height="18" font="0">•</text>
<text top="444" left="383" width="141" height="20" font="0">Use of fibrates other than </text>
<text top="461" left="376" width="163" height="20" font="0">fenofibrate within 6 wk before </text>
<text top="479" left="376" width="60" height="20" font="0">screening. </text>
<text top="498" left="376" width="7" height="18" font="0">•</text>
<text top="497" left="383" width="135" height="20" font="0">Hx of rhabdomyolysis or </text>
<text top="514" left="376" width="154" height="20" font="0">known myopathy other than </text>
<text top="531" left="376" width="156" height="20" font="0">statin-associated myopathy. </text>
<text top="199" left="568" width="78" height="20" font="7"><b>Intervention:</b> </text>
<text top="216" left="568" width="122" height="20" font="0">alirocumab 75 mg SQ </text>
<text top="233" left="568" width="128" height="20" font="0">Q2W plus oral placebo </text>
<text top="250" left="568" width="36" height="20" font="0">(126)  </text>
<text top="267" left="568" width="3" height="20" font="0"> </text>
<text top="285" left="568" width="133" height="20" font="7"><b>Comparator: </b>ezetimibe </text>
<text top="302" left="568" width="113" height="20" font="0">10 mg daily plus SQ </text>
<text top="319" left="568" width="124" height="20" font="0">placebo Q2W (125) or </text>
<text top="336" left="568" width="133" height="20" font="0">atorvastatin 20 mg daily </text>
<text top="354" left="568" width="125" height="20" font="0">plus SQ placebo Q2W </text>
<text top="371" left="568" width="29" height="20" font="0">(63)  </text>
<text top="388" left="568" width="3" height="20" font="7"><b> </b></text>
<text top="200" left="720" width="79" height="20" font="7"><b>1</b>°<b> endpoint:</b>  </text>
<text top="217" left="720" width="206" height="20" font="0">% LDL-C change from baseline to wk </text>
<text top="234" left="720" width="212" height="20" font="0">24 in alirocumab vs. ezetimibe group (-</text>
<text top="251" left="720" width="206" height="20" font="0">45% vs. -14.6%, difference of 30.4%, </text>
<text top="269" left="720" width="59" height="20" font="0">p&lt;0.0001) </text>
<text top="286" left="720" width="3" height="20" font="0"> </text>
<text top="303" left="720" width="3" height="20" font="7"><b> </b></text>
<text top="200" left="953" width="7" height="18" font="0">•</text>
<text top="200" left="960" width="149" height="20" font="0">Muscle related side effects </text>
<text top="217" left="953" width="158" height="20" font="0">were lower in alirocumab vs. </text>
<text top="234" left="953" width="137" height="20" font="0">atorvastatin groups (HR: </text>
<text top="251" left="953" width="137" height="20" font="0">0.61, 95% CI: 0.38-0.99, </text>
<text top="269" left="953" width="52" height="20" font="0">p=0.042) </text>
<text top="286" left="953" width="3" height="20" font="0"> </text>
<text top="305" left="953" width="7" height="18" font="0">•</text>
<text top="304" left="960" width="139" height="20" font="0">27% had myalgias, 6.3% </text>
<text top="321" left="953" width="148" height="20" font="0">had muscle weakness and </text>
<text top="339" left="953" width="163" height="20" font="0">11.1% had muscle spasms in </text>
<text top="356" left="953" width="122" height="20" font="0">the atorvastatin group </text>
<text top="373" left="953" width="3" height="20" font="0"> </text>
<text top="390" left="953" width="3" height="20" font="0"> </text>
<text top="549" left="89" width="68" height="20" font="7"><b>N-of-1 Trial </b></text>
<text top="567" left="89" width="110" height="20" font="0">Joy TR, et al., 2014 </text>
<text top="584" left="89" width="32" height="20" font="0"><a href="data supplement.html#250">(244)</a> </text>
<text top="601" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24737272">24737272</a></text>
<text top="601" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24737272"> </a></text>
<text top="618" left="89" width="80" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01259791">NCT01259791</a></text>
<text top="618" left="169" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01259791"> </a></text>
<text top="549" left="226" width="129" height="20" font="7"><b>Aim:</b> compare effect of </text>
<text top="567" left="226" width="113" height="20" font="0">statin rechallenge in </text>
<text top="584" left="226" width="104" height="20" font="0">patients with Hx of </text>
<text top="601" left="226" width="124" height="20" font="0">statin-related myalgia  </text>
<text top="618" left="226" width="3" height="20" font="0"> </text>
<text top="635" left="226" width="113" height="20" font="7"><b>Study type:</b> RCT, 3 </text>
<text top="653" left="226" width="130" height="20" font="0">double-blind, crossover </text>
<text top="670" left="226" width="73" height="20" font="0">comparisons </text>
<text top="687" left="226" width="3" height="20" font="0"> </text>
<text top="704" left="226" width="46" height="20" font="7"><b>Size:</b> 8  </text>
<text top="549" left="376" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="567" left="376" width="107" height="20" font="0">pts ≥ 18 y age with </text>
<text top="584" left="376" width="144" height="20" font="0">hypercholesterolemia and </text>
<text top="601" left="376" width="163" height="20" font="0">statin-related myalgia without </text>
<text top="618" left="376" width="173" height="20" font="0">clinically significant elevation in </text>
<text top="635" left="376" width="169" height="20" font="0">CK levels (&lt;3x ULN or &lt;3x the </text>
<text top="653" left="376" width="86" height="20" font="0">baseline value) </text>
<text top="670" left="376" width="3" height="20" font="0"> </text>
<text top="687" left="376" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="706" left="376" width="7" height="18" font="0">•</text>
<text top="705" left="383" width="124" height="20" font="0">Hx of rhabdomyolysis, </text>
<text top="723" left="376" width="144" height="20" font="0">metabolic or inflammatory </text>
<text top="740" left="376" width="136" height="20" font="0">myopathy or neuropathy </text>
<text top="757" left="376" width="3" height="20" font="0"> </text>
<text top="549" left="568" width="81" height="20" font="7"><b>Intervention:</b>  </text>
<text top="567" left="568" width="101" height="20" font="0">Re-challenge with </text>
<text top="584" left="568" width="113" height="20" font="0">previously intolerant </text>
<text top="601" left="568" width="58" height="20" font="0">statin (80) </text>
<text top="618" left="568" width="3" height="20" font="0"> </text>
<text top="635" left="568" width="124" height="20" font="7"><b>Comparator:</b> placebo </text>
<text top="653" left="568" width="25" height="20" font="0">(80)<b> </b></text>
<text top="550" left="720" width="215" height="20" font="7"><b>1</b>°<b> endpoint:</b> difference in mean visual </text>
<text top="568" left="720" width="202" height="20" font="0">analogue scale (VAS) myalgia score </text>
<text top="585" left="720" width="209" height="20" font="0">between statin treatment and placebo </text>
<text top="602" left="720" width="215" height="20" font="0">(No statistically significant difference in </text>
<text top="619" left="720" width="200" height="20" font="0">VAS myalgia score between the two </text>
<text top="636" left="720" width="90" height="20" font="0">groups, p&gt;0.05) </text>
<text top="654" left="720" width="3" height="20" font="0"> </text>
<text top="671" left="720" width="217" height="20" font="7"><b>Secondary outcome: </b>mean difference </text>
<text top="688" left="720" width="202" height="20" font="0">in symptom specific VAS score, pain </text>
<text top="705" left="720" width="166" height="20" font="0">severity score (PSS) and pain </text>
<text top="723" left="720" width="219" height="20" font="0">interference score (PIS) (No statistically </text>
<text top="740" left="720" width="204" height="20" font="0">significant differences between statin </text>
<text top="757" left="720" width="219" height="20" font="0">treatment and placebo groups, p&gt;0.05).<b> </b></text>
<text top="551" left="953" width="7" height="18" font="0">•</text>
<text top="550" left="960" width="140" height="20" font="0">No statistically significant </text>
<text top="568" left="953" width="131" height="20" font="0">difference in CK or liver </text>
<text top="585" left="953" width="164" height="20" font="0">enzyme levels between statin </text>
<text top="602" left="953" width="126" height="20" font="0">treatment and placebo </text>
<text top="619" left="953" width="41" height="20" font="0">groups </text>
<text top="636" left="953" width="3" height="20" font="0"> </text>
<text top="654" left="953" width="3" height="20" font="0"> </text>
<text top="671" left="953" width="3" height="20" font="0"> </text>
</page>
<page number="208" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">208 </text>
<text top="107" left="89" width="94" height="20" font="0">Taylor BA, et al., </text>
<text top="124" left="89" width="63" height="20" font="0">2015<a href="data supplement.html#250"> (245)</a> </text>
<text top="141" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25545331">25545331</a></text>
<text top="141" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25545331"> </a></text>
<text top="159" left="89" width="80" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01140308">NCT01140308</a></text>
<text top="159" left="169" width="3" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01140308"><b> </b></a></text>
<text top="107" left="226" width="131" height="20" font="7"><b>Aim: </b>to study the effect </text>
<text top="124" left="226" width="100" height="20" font="0">of coenzyme Q10 </text>
<text top="141" left="226" width="51" height="20" font="0">(CoQ10) </text>
<text top="159" left="226" width="111" height="20" font="0">supplementation on </text>
<text top="176" left="226" width="95" height="20" font="0">statin associated </text>
<text top="193" left="226" width="105" height="20" font="0">muscle symptoms, </text>
<text top="210" left="226" width="72" height="20" font="0">strength and </text>
<text top="228" left="226" width="76" height="20" font="0">performance  </text>
<text top="245" left="226" width="3" height="20" font="7"><b> </b></text>
<text top="262" left="226" width="99" height="20" font="7"><b>Study type: </b>RCT </text>
<text top="279" left="226" width="3" height="20" font="7"><b> </b></text>
<text top="296" left="226" width="56" height="20" font="7"><b>Size: </b>41<b>   </b></text>
<text top="107" left="376" width="109" height="20" font="7"><b>Inclusion criteria:  </b></text>
<text top="124" left="376" width="166" height="20" font="0">Pts ≥ 20 y age with confirmed </text>
<text top="141" left="376" width="161" height="20" font="0">statin myalgia on simvastatin </text>
<text top="159" left="376" width="101" height="20" font="0">during lead-in trial </text>
<text top="176" left="376" width="3" height="20" font="7"><b> </b></text>
<text top="193" left="376" width="110" height="20" font="7"><b>Exclusion criteria: </b></text>
<text top="212" left="376" width="7" height="18" font="0">•</text>
<text top="211" left="383" width="163" height="20" font="0"> subjects with muscle pain on </text>
<text top="229" left="376" width="151" height="20" font="0">placebo during lead-in trial<b>  </b></text>
<text top="248" left="376" width="7" height="18" font="0">•</text>
<text top="247" left="383" width="109" height="20" font="0">cancer within 5 y of </text>
<text top="264" left="376" width="65" height="20" font="0">recruitment<b> </b></text>
<text top="283" left="376" width="7" height="18" font="0">•</text>
<text top="283" left="383" width="139" height="20" font="0">hypo- or hyperthyroidism </text>
<text top="302" left="376" width="7" height="18" font="0">•</text>
<text top="301" left="383" width="157" height="20" font="0">liver disease (ALT &gt;2x ULN) </text>
<text top="320" left="376" width="7" height="18" font="0">•</text>
<text top="319" left="383" width="156" height="20" font="0">renal disease (Cr &gt;2 mg/dL) </text>
<text top="339" left="376" width="7" height="18" font="0">•</text>
<text top="338" left="383" width="155" height="20" font="0">medications known to affect </text>
<text top="355" left="376" width="109" height="20" font="0">muscle metabolism </text>
<text top="372" left="376" width="91" height="20" font="0">(corticosteroids) </text>
<text top="389" left="376" width="3" height="20" font="0"> </text>
<text top="407" left="376" width="7" height="20" font="7"><b> </b> </text>
<text top="107" left="568" width="78" height="20" font="7"><b>Intervention: </b></text>
<text top="124" left="568" width="137" height="20" font="0">simvastatin 20 mg/d and </text>
<text top="141" left="568" width="122" height="20" font="0">CoQ10 600 mg/d (20) </text>
<text top="159" left="568" width="7" height="20" font="7"><b>  </b></text>
<text top="176" left="568" width="77" height="20" font="7"><b>Comparator: </b></text>
<text top="193" left="568" width="137" height="20" font="0">simvastatin 20 mg/d and </text>
<text top="210" left="568" width="72" height="20" font="0">placebo (18) </text>
<text top="108" left="720" width="217" height="20" font="7"><b>1</b>°<b> endpoint: </b>muscle pain assessed by </text>
<text top="125" left="720" width="200" height="20" font="0">Pain Severity Score (PSS) and Pain </text>
<text top="143" left="720" width="139" height="20" font="0">Interference Score (PIS)  </text>
<text top="162" left="720" width="7" height="18" font="0">•</text>
<text top="161" left="727" width="189" height="20" font="0">More subjects reported pain in the </text>
<text top="178" left="720" width="215" height="20" font="0">CoQ10 vs. placebo group (70% vs. 39; </text>
<text top="195" left="720" width="46" height="20" font="0">p=0.05) </text>
<text top="214" left="720" width="7" height="18" font="0">•</text>
<text top="214" left="727" width="179" height="20" font="0">Increase in PSS and PIS in both </text>
<text top="231" left="720" width="193" height="20" font="0">groups (p&lt;0.01) with statin therapy </text>
<text top="248" left="720" width="206" height="20" font="0">however no difference with CoQ10 or </text>
<text top="265" left="720" width="161" height="20" font="0">placebo (p=0.53 and p=0.56) </text>
<text top="283" left="720" width="3" height="20" font="7"><b> </b></text>
<text top="300" left="720" width="129" height="20" font="7"><b>Secondary endpoint:  </b></text>
<text top="319" left="720" width="7" height="18" font="0">•</text>
<text top="318" left="727" width="204" height="20" font="0">No change in CK, muscle strength or </text>
<text top="335" left="720" width="166" height="20" font="0">aerobic performance between </text>
<text top="353" left="720" width="181" height="20" font="0">statin+CoQ10 vs. statin+placebo </text>
<text top="370" left="720" width="106" height="20" font="0">groups (all p&gt;0.10) </text>
<text top="389" left="720" width="7" height="18" font="0">•</text>
<text top="388" left="727" width="203" height="20" font="0">No difference in time to pain onset in </text>
<text top="406" left="720" width="206" height="20" font="0">CoQ10 vs. placebo groups (3.0 ± 2.0 </text>
<text top="423" left="720" width="158" height="20" font="0">wk vs. 2.4 ± 2.1 wk; p=0.55)<b> </b></text>
<text top="109" left="953" width="7" height="18" font="0">•</text>
<text top="108" left="960" width="154" height="20" font="0">Of the 120 patients enrolled </text>
<text top="125" left="953" width="118" height="20" font="0">in the lead-in phase,  </text>
<text top="143" left="953" width="139" height="20" font="7"><b>   -</b>35.8% had myalgia on </text>
<text top="160" left="953" width="123" height="20" font="0">simvastatin but not on </text>
<text top="177" left="953" width="50" height="20" font="0">placebo  </text>
<text top="194" left="953" width="153" height="20" font="7"><b>   -</b>17.5% had no symptoms </text>
<text top="211" left="953" width="143" height="20" font="0">on simvastatin or placebo </text>
<text top="229" left="953" width="150" height="20" font="7"><b>   -</b>29.2% experienced pain </text>
<text top="246" left="953" width="122" height="20" font="0">on placebo but not on </text>
<text top="263" left="953" width="65" height="20" font="0">simvastatin </text>
<text top="280" left="953" width="150" height="20" font="7"><b>   -</b>17.5% experienced pain </text>
<text top="298" left="953" width="133" height="20" font="0">on both simvastatin and </text>
<text top="315" left="953" width="46" height="20" font="0">placebo </text>
<text top="332" left="953" width="137" height="20" font="7"><b>  -</b>time to pain onset was </text>
<text top="349" left="953" width="113" height="20" font="0">shorter in those with </text>
<text top="367" left="953" width="136" height="20" font="0">confirmed statin myalgia </text>
<text top="384" left="953" width="142" height="20" font="0">compared to non-myalgia </text>
<text top="401" left="953" width="159" height="20" font="0">patients who developed pain </text>
<text top="418" left="953" width="157" height="20" font="0">on simvastatin (1.7 ± 1.4 wk </text>
<text top="435" left="953" width="139" height="20" font="0">vs. 3.0 ± 1.8 wk; p&lt;0.01) </text>
<text top="453" left="953" width="3" height="20" font="7"><b> </b></text>
<text top="470" left="953" width="3" height="20" font="0"> </text>
<text top="488" left="89" width="111" height="20" font="7"><b>JUPITER-Diabetes </b></text>
<text top="505" left="89" width="25" height="20" font="7"><b>risk </b></text>
<text top="522" left="89" width="98" height="20" font="0">Ridker PM, et al., </text>
<text top="539" left="89" width="63" height="20" font="0">2012<a href="data supplement.html#250"> (246)</a> </text>
<text top="557" left="89" width="75" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=PMC3774022">PMC3774022</a></text>
<text top="557" left="165" width="3" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=PMC3774022"><b> </b></a></text>
<text top="488" left="226" width="115" height="20" font="7"><b>Aim: </b>to evaluate the </text>
<text top="505" left="226" width="117" height="20" font="0">balance between net </text>
<text top="522" left="226" width="100" height="20" font="0">CV benefit versus </text>
<text top="539" left="226" width="116" height="20" font="0">incident DM risk with </text>
<text top="557" left="226" width="128" height="20" font="0">rosuvastatin in pts with </text>
<text top="574" left="226" width="130" height="20" font="0">none or ≥ 1 risk factors </text>
<text top="591" left="226" width="130" height="20" font="0">for DM (fasting glucose </text>
<text top="608" left="226" width="120" height="20" font="0">&gt;100 mg/dL but &lt;126 </text>
<text top="625" left="226" width="97" height="20" font="0">mg/dL, metabolic </text>
<text top="643" left="226" width="115" height="20" font="0">syndrome, BMI ≥ 30 </text>
<text top="660" left="226" width="27" height="20" font="0">kg/m</text>
<text top="661" left="253" width="7" height="13" font="9">2 </text>
<text top="660" left="260" width="64" height="20" font="0">or glycated </text>
<text top="677" left="226" width="128" height="20" font="0">hemoglobin A1c &gt;6%)  </text>
<text top="694" left="226" width="3" height="20" font="7"><b> </b></text>
<text top="711" left="226" width="99" height="20" font="7"><b>Study type: </b>RCT </text>
<text top="729" left="226" width="3" height="20" font="7"><b> </b></text>
<text top="746" left="226" width="77" height="20" font="7"><b>Size:</b>17,603<b>   </b></text>
<text top="488" left="376" width="109" height="20" font="7"><b>Inclusion criteria:  </b></text>
<text top="505" left="376" width="155" height="20" font="0">Healthy men ≥50 y age and </text>
<text top="522" left="376" width="169" height="20" font="0">women ≥ 60 y age with LDL-C </text>
<text top="539" left="376" width="176" height="20" font="0">&lt;130 mg/dL and high sensitivity </text>
<text top="557" left="376" width="173" height="20" font="0">C-reactive protein (hsCRP) ≥ 2 </text>
<text top="574" left="376" width="34" height="20" font="0">mg/L  </text>
<text top="591" left="376" width="3" height="20" font="0"> </text>
<text top="608" left="376" width="110" height="20" font="7"><b>Exclusion criteria: </b></text>
<text top="627" left="376" width="7" height="18" font="0">•</text>
<text top="626" left="383" width="79" height="20" font="0"> history of DM </text>
<text top="646" left="376" width="7" height="18" font="0">•</text>
<text top="645" left="383" width="86" height="20" font="7"><b> </b>history of CVD </text>
<text top="664" left="376" width="7" height="18" font="0">•</text>
<text top="663" left="383" width="146" height="20" font="7"><b> </b>previous or current use of </text>
<text top="680" left="376" width="120" height="20" font="0">lipid-lowering therapy </text>
<text top="699" left="376" width="7" height="18" font="0">•</text>
<text top="699" left="383" width="109" height="20" font="0"> current use of post-</text>
<text top="716" left="376" width="103" height="20" font="0">menopausal HR:T </text>
<text top="735" left="376" width="7" height="18" font="0">•</text>
<text top="734" left="383" width="152" height="20" font="0"> liver dysfunction (ALT &gt; 2x </text>
<text top="752" left="376" width="32" height="20" font="0">ULN) </text>
<text top="771" left="376" width="7" height="18" font="0">•</text>
<text top="770" left="383" width="69" height="20" font="0">CK&gt;3x ULN </text>
<text top="789" left="376" width="7" height="18" font="0">•</text>
<text top="788" left="383" width="82" height="20" font="0">Cr &gt;2.0 mg/dL </text>
<text top="488" left="568" width="78" height="20" font="7"><b>Intervention: </b></text>
<text top="505" left="568" width="107" height="20" font="0">rosuvastatin 20 mg </text>
<text top="522" left="568" width="7" height="20" font="7"><b>  </b></text>
<text top="539" left="568" width="124" height="20" font="7"><b>Comparator: </b>placebo<b> </b></text>
<text top="489" left="720" width="218" height="20" font="7"><b>1</b>°<b> endpoint: </b>MI, stroke, hospitalization </text>
<text top="506" left="720" width="211" height="20" font="0">for unstable angina, revascularization, </text>
<text top="523" left="720" width="69" height="20" font="0">or CV death </text>
<text top="540" left="720" width="3" height="20" font="0"> </text>
<text top="558" left="720" width="219" height="20" font="0">Individuals without major risk factors for </text>
<text top="575" left="720" width="170" height="20" font="0">DM (rosuvastatin vs. placebo): </text>
<text top="594" left="720" width="7" height="18" font="0">•</text>
<text top="593" left="727" width="190" height="20" font="0">52% reduction in 1° endpoint (HR: </text>
<text top="610" left="720" width="196" height="20" font="0">0.48; 95% CI: 0.33-0.68; p=0.0001) </text>
<text top="628" left="720" width="3" height="20" font="0"> </text>
<text top="645" left="720" width="206" height="20" font="0">Individuals with ≥ 1 risk factor for DM </text>
<text top="662" left="720" width="147" height="20" font="0">(rosuvastatin vs. placebo): </text>
<text top="681" left="720" width="7" height="18" font="0">•</text>
<text top="680" left="727" width="194" height="20" font="7"><b> </b>39% reduction in 1° endpoint (HR: </text>
<text top="698" left="720" width="196" height="20" font="0">0.61; 95% CI: 0.47-0.79; p=0.0001) </text>
<text top="715" left="720" width="3" height="20" font="0"> </text>
<text top="732" left="720" width="129" height="20" font="7"><b>Secondary endpoint:</b>  </text>
<text top="749" left="720" width="219" height="20" font="0">Individuals without major risk factors for </text>
<text top="766" left="720" width="170" height="20" font="0">DM (rosuvastatin vs. placebo): </text>
<text top="489" left="953" width="7" height="18" font="0">•</text>
<text top="489" left="960" width="148" height="20" font="0">More frequent incident DM </text>
<text top="506" left="953" width="148" height="20" font="0">in rosuvastatin vs. placebo </text>
<text top="523" left="953" width="134" height="20" font="0">group (270 vs. 216, HR: </text>
<text top="540" left="953" width="137" height="20" font="0">1.25; 95% CI: 1.05-1.49; </text>
<text top="558" left="953" width="46" height="20" font="0">p=0.01) </text>
<text top="577" left="953" width="7" height="18" font="0">•</text>
<text top="576" left="960" width="112" height="20" font="0">Average time to DM </text>
<text top="593" left="953" width="162" height="20" font="0">diagnosis for rosuvastatin vs. </text>
<text top="610" left="953" width="152" height="20" font="0">placebo group was 84.3 wk </text>
<text top="628" left="953" width="137" height="20" font="0">vs. 89.7 wk respectively  </text>
<text top="647" left="953" width="7" height="18" font="0">•</text>
<text top="646" left="960" width="147" height="20" font="7"><b> </b>for every 54 new cases of </text>
<text top="663" left="953" width="137" height="20" font="0">diabetes diagnosed, 134 </text>
<text top="680" left="953" width="143" height="20" font="0">vascular events or deaths </text>
<text top="698" left="953" width="154" height="20" font="0">avoided with rosuvastatin in </text>
<text top="715" left="953" width="162" height="20" font="0">those with risk factors for DM </text>
<text top="734" left="953" width="7" height="18" font="0">•</text>
<text top="733" left="960" width="143" height="20" font="0">for individuals without risk </text>
<text top="750" left="953" width="150" height="20" font="0">factors for DM, 86 vascular </text>
<text top="768" left="953" width="141" height="20" font="0">events or deaths avoided </text>
<text top="785" left="953" width="163" height="20" font="0">without any new cases of DM </text>
</page>
<page number="209" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">209 </text>
<text top="109" left="376" width="7" height="18" font="0">•</text>
<text top="108" left="383" width="144" height="20" font="0">uncontrolled hypertension </text>
<text top="125" left="376" width="177" height="20" font="0">(SBP &gt;190 mmHg or DBP &gt;100 </text>
<text top="143" left="376" width="44" height="20" font="0">mmHg) </text>
<text top="162" left="376" width="7" height="18" font="0">•</text>
<text top="161" left="383" width="136" height="20" font="0">Cancer within 5 y before </text>
<text top="178" left="376" width="61" height="20" font="0">enrollment </text>
<text top="197" left="376" width="7" height="18" font="0">•</text>
<text top="197" left="383" width="159" height="20" font="0">Uncontrolled hypothyroidism </text>
<text top="216" left="376" width="7" height="18" font="0">•</text>
<text top="215" left="383" width="154" height="20" font="0">Hx of alcohol or drug abuse </text>
<text top="234" left="376" width="7" height="18" font="0">•</text>
<text top="233" left="383" width="120" height="20" font="0">Pts with inflammatory </text>
<text top="251" left="376" width="157" height="20" font="0">conditions (arthritis, lupus or </text>
<text top="268" left="376" width="159" height="20" font="0">inflammatory bowel disease) </text>
<text top="287" left="376" width="7" height="18" font="0">•</text>
<text top="286" left="383" width="171" height="20" font="0">Pts taking immunosuppressant </text>
<text top="303" left="376" width="120" height="20" font="0">agents (cyclosporine, </text>
<text top="321" left="376" width="163" height="20" font="0">tacrolimus, azathioprine, long </text>
<text top="338" left="376" width="141" height="20" font="0">term oral glucocorticoids)<b> </b></text>
<text top="109" left="720" width="7" height="18" font="0">•</text>
<text top="108" left="727" width="213" height="20" font="0"> 53% reduction in VTE (HR: 0.47; 95% </text>
<text top="125" left="720" width="123" height="20" font="0">CI: 0.21-1.03; p=0.05) </text>
<text top="144" left="720" width="7" height="18" font="0">•</text>
<text top="144" left="727" width="204" height="20" font="0"> 22% reduction in total mortality (HR: </text>
<text top="161" left="720" width="182" height="20" font="0">0.78; 95% CI: 0.59-1.03; p=0.08) </text>
<text top="180" left="720" width="7" height="18" font="0">•</text>
<text top="179" left="727" width="213" height="20" font="0">No increase in incident DM (0.99; 95% </text>
<text top="197" left="720" width="123" height="20" font="0">CI: 0.45-2.21; p=0.99) </text>
<text top="214" left="720" width="3" height="20" font="0"> </text>
<text top="231" left="720" width="206" height="20" font="0">Individuals with ≥ 1 risk factor for DM </text>
<text top="248" left="720" width="147" height="20" font="0">(rosuvastatin vs. placebo): </text>
<text top="267" left="720" width="7" height="18" font="0">•</text>
<text top="267" left="727" width="210" height="20" font="0">36% reduction in VTE (HR: 0.64; 95% </text>
<text top="284" left="720" width="123" height="20" font="0">CI: 0.39-1.06; p=0.08) </text>
<text top="303" left="720" width="7" height="18" font="0">•</text>
<text top="302" left="727" width="200" height="20" font="0">17% reduction in total mortality (HR: </text>
<text top="319" left="720" width="182" height="20" font="0">0.83; 95% CI: 0.64-1.07; p=0.15) </text>
<text top="339" left="720" width="7" height="18" font="0">•</text>
<text top="338" left="727" width="191" height="20" font="7"><b> </b>28% increase in incident DM (HR: </text>
<text top="355" left="720" width="183" height="20" font="0">1.28 (95% CI: 1.07-1.54; p=0.01) </text>
<text top="372" left="720" width="3" height="20" font="0"> </text>
<text top="389" left="720" width="7" height="20" font="0"> <b> </b></text>
<text top="407" left="89" width="101" height="20" font="7"><b>St. Francis Heart </b></text>
<text top="425" left="89" width="66" height="20" font="7"><b>Study RCT </b></text>
<text top="442" left="89" width="117" height="20" font="0">Foster T, et al., 2011 </text>
<text top="459" left="89" width="32" height="20" font="0"><a href="data supplement.html#250">(247)</a> </text>
<text top="476" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20842109">20842109</a></text>
<text top="476" left="144" width="3" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20842109"><b> </b></a></text>
<text top="407" left="226" width="115" height="20" font="7"><b>Aim:</b> to evaluate the </text>
<text top="425" left="226" width="121" height="20" font="0">effectiveness of statin </text>
<text top="442" left="226" width="87" height="20" font="0">therapy for non-</text>
<text top="459" left="226" width="104" height="20" font="0">alcoholic fatty liver </text>
<text top="476" left="226" width="101" height="20" font="0">disease (NAFLD)  </text>
<text top="493" left="226" width="3" height="20" font="7"><b> </b></text>
<text top="511" left="226" width="99" height="20" font="7"><b>Study type: </b>RCT </text>
<text top="528" left="226" width="3" height="20" font="7"><b> </b></text>
<text top="545" left="226" width="56" height="20" font="7"><b>Size:</b>455<b>  </b></text>
<text top="407" left="376" width="109" height="20" font="7"><b>Inclusion criteria:  </b></text>
<text top="425" left="376" width="139" height="20" font="0">Healthy men and women </text>
<text top="442" left="376" width="125" height="20" font="0">between ages 50-70 y </text>
<text top="459" left="376" width="110" height="20" font="7"><b>Exclusion criteria: </b></text>
<text top="478" left="376" width="7" height="18" font="0">•</text>
<text top="477" left="383" width="128" height="20" font="0"> history of CAD, insulin </text>
<text top="495" left="376" width="137" height="20" font="0">dependent DM, bleeding </text>
<text top="512" left="376" width="139" height="20" font="0">diathesis, severe anemia </text>
<text top="531" left="376" width="7" height="18" font="0">•</text>
<text top="530" left="383" width="137" height="20" font="0">cancer within 5 y prior to </text>
<text top="547" left="376" width="61" height="20" font="0">enrollment </text>
<text top="566" left="376" width="7" height="18" font="0">•</text>
<text top="566" left="383" width="171" height="20" font="0">condition likely to lead to death </text>
<text top="583" left="376" width="129" height="20" font="0">within 5 y of enrollment </text>
<text top="602" left="376" width="7" height="18" font="0">•</text>
<text top="601" left="383" width="134" height="20" font="0">use of anticoagulants or </text>
<text top="619" left="376" width="72" height="20" font="0">cyclosporine </text>
<text top="638" left="376" width="7" height="18" font="0">•</text>
<text top="637" left="383" width="171" height="20" font="0">LDL &gt;174 mg/dL or &lt;90 mg/dL </text>
<text top="656" left="376" width="7" height="18" font="0">•</text>
<text top="655" left="383" width="161" height="20" font="0">Systolic blood pressure &gt;180 </text>
<text top="672" left="376" width="40" height="20" font="0">mmHg </text>
<text top="691" left="376" width="7" height="18" font="0">•</text>
<text top="691" left="383" width="164" height="20" font="0">diastolic blood pressure &gt;100 </text>
<text top="708" left="376" width="40" height="20" font="0">mmHg<b> </b></text>
<text top="727" left="376" width="7" height="18" font="0">•</text>
<text top="726" left="383" width="167" height="20" font="0">elevated transaminases &gt;1.5x </text>
<text top="744" left="376" width="28" height="20" font="0">ULN </text>
<text top="763" left="376" width="7" height="18" font="0">•</text>
<text top="762" left="383" width="153" height="20" font="0">pts without both visible liver </text>
<text top="779" left="376" width="127" height="20" font="0">and spleen on imaging </text>
<text top="407" left="568" width="78" height="20" font="7"><b>Intervention: </b></text>
<text top="425" left="568" width="108" height="20" font="0">atorvastatin 20 mg, </text>
<text top="442" left="568" width="138" height="20" font="0">vitamin C 1g and vitamin </text>
<text top="459" left="568" width="104" height="20" font="0">E 1000 IU (n=229) </text>
<text top="476" left="568" width="7" height="20" font="7"><b>  </b></text>
<text top="493" left="568" width="124" height="20" font="7"><b>Comparator: </b>placebo </text>
<text top="511" left="568" width="46" height="20" font="0">(n=226)<b> </b></text>
<text top="409" left="720" width="193" height="20" font="7"><b>1</b>°<b> endpoint:</b> effect of atorvastatin, </text>
<text top="426" left="720" width="217" height="20" font="0">vitamin C and Vitamin E vs. placebo on </text>
<text top="443" left="720" width="47" height="20" font="0">NAFLD  </text>
<text top="462" left="720" width="7" height="18" font="0">•</text>
<text top="461" left="727" width="169" height="20" font="0">reduced odds of NAFLD in the </text>
<text top="479" left="720" width="219" height="20" font="0">intervention group vs. placebo (70% vs. </text>
<text top="496" left="720" width="140" height="20" font="0">34%, OR: 0.29; p&lt;0.001) </text>
<text top="513" left="720" width="3" height="20" font="7"><b> </b></text>
<text top="409" left="953" width="7" height="18" font="0">•</text>
<text top="409" left="960" width="109" height="20" font="0">Only 3 patients had </text>
<text top="426" left="953" width="153" height="20" font="0">transaminase elevation &gt;2x </text>
<text top="443" left="953" width="154" height="20" font="0">ULN that resolved on follow </text>
<text top="460" left="953" width="17" height="20" font="0">up </text>
</page>
<page number="210" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">210 </text>
<text top="106" left="81" width="4" height="22" font="1"> </text>
<text top="125" left="81" width="1012" height="24" font="4"><b>Data Supplement 41. Nonrandomized Trials, Observational Studies, Meta-analyses and/or Registries of Statin Safety and Statin-Associated Side </b></text>
<text top="146" left="81" width="133" height="24" font="4"><b>Effects (Section 5) </b></text>
<text top="167" left="121" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="184" left="147" width="48" height="20" font="7"><b>Author; </b></text>
<text top="202" left="124" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="176" left="280" width="118" height="20" font="7"><b>Study Type/Design; </b></text>
<text top="193" left="306" width="66" height="20" font="7"><b>Study Size </b></text>
<text top="184" left="458" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="176" left="667" width="179" height="20" font="7"><b>Primary Endpoint and Results </b></text>
<text top="193" left="664" width="184" height="20" font="7"><b>(P values; OR or RR; &amp; 95% CI) </b></text>
<text top="176" left="950" width="130" height="20" font="7"><b>Summary/Conclusion </b></text>
<text top="193" left="977" width="75" height="20" font="7"><b>Comment(s) </b></text>
<text top="220" left="91" width="75" height="20" font="7"><b>ASCOT-LLA </b></text>
<text top="237" left="91" width="148" height="20" font="0">Gupta A, et al., 2017<a href="data supplement.html#250"> (248)</a> </text>
<text top="254" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28476288">28476288</a></text>
<text top="254" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28476288"> </a></text>
<text top="220" left="263" width="144" height="20" font="7"><b>Study type:</b> Non-blinded, </text>
<text top="237" left="263" width="148" height="20" font="0">non-randomized extension </text>
<text top="254" left="263" width="118" height="20" font="0">of ASCOT-LLA RCT  </text>
<text top="271" left="263" width="3" height="20" font="0"> </text>
<text top="289" left="263" width="109" height="20" font="7"><b>Size: </b>9899 patients </text>
<text top="308" left="263" width="7" height="18" font="0">•</text>
<text top="307" left="270" width="83" height="20" font="0"> 6409 (65%) in </text>
<text top="324" left="263" width="129" height="20" font="0">atorvastatin user group </text>
<text top="343" left="263" width="7" height="18" font="0">•</text>
<text top="343" left="270" width="95" height="20" font="0"> 3490 (35%) non-</text>
<text top="360" left="263" width="129" height="20" font="0">atorvastatin user group </text>
<text top="377" left="263" width="3" height="20" font="0"> </text>
<text top="220" left="428" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="239" left="428" width="7" height="18" font="0">•</text>
<text top="238" left="435" width="123" height="20" font="0">pts aged 40–79 y with </text>
<text top="255" left="428" width="144" height="20" font="0">hypertension and three or </text>
<text top="273" left="428" width="124" height="20" font="0">more CVD risk factors </text>
<text top="292" left="428" width="7" height="18" font="0">•</text>
<text top="291" left="435" width="129" height="20" font="0">fasting total cholesterol </text>
<text top="308" left="428" width="163" height="20" font="0">concentrations 6·5 mmol/L or </text>
<text top="325" left="428" width="171" height="20" font="0">lower and not taking a statin or </text>
<text top="343" left="428" width="38" height="20" font="0">fibrate </text>
<text top="362" left="428" width="7" height="18" font="0">•</text>
<text top="361" left="435" width="142" height="20" font="0"> no hx of MI and were not </text>
<text top="378" left="428" width="137" height="20" font="0">being treated for angina  </text>
<text top="395" left="428" width="3" height="20" font="0"> </text>
<text top="413" left="428" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="432" left="428" width="7" height="18" font="0">•</text>
<text top="431" left="435" width="47" height="20" font="0">Prior MI </text>
<text top="450" left="428" width="7" height="18" font="0">•</text>
<text top="449" left="435" width="163" height="20" font="0">currently on angina treatment </text>
<text top="467" left="428" width="169" height="20" font="0">cerebrovascular event within 3 </text>
<text top="484" left="428" width="21" height="20" font="0">mo </text>
<text top="503" left="428" width="7" height="18" font="0">•</text>
<text top="502" left="435" width="128" height="20" font="0">fasting TG&gt;4.5 mmol/L </text>
<text top="521" left="428" width="7" height="18" font="0">•</text>
<text top="520" left="435" width="68" height="20" font="0">heart failure </text>
<text top="539" left="428" width="7" height="18" font="0">•</text>
<text top="539" left="435" width="138" height="20" font="0">uncontrolled arrhythmias </text>
<text top="558" left="428" width="7" height="18" font="0">•</text>
<text top="557" left="435" width="104" height="20" font="0">clinically important </text>
<text top="574" left="428" width="162" height="20" font="0">hematological or biochemical </text>
<text top="592" left="428" width="141" height="20" font="0">abnormality on screening </text>
<text top="221" left="613" width="273" height="20" font="7"><b>1</b>°<b> endpoint:</b> compare rates of AEs in blinded vs. </text>
<text top="238" left="613" width="172" height="20" font="0">non-blinded phase of the study </text>
<text top="255" left="613" width="3" height="20" font="0"> </text>
<text top="272" left="613" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="290" left="613" width="92" height="20" font="7"><b>Blinded phase: </b></text>
<text top="309" left="613" width="7" height="18" font="0">•</text>
<text top="308" left="619" width="228" height="20" font="0">Muscle related AEs were similar between </text>
<text top="325" left="613" width="284" height="20" font="0">atorvastatin and placebo groups (2.03% vs. 2.0%/y, </text>
<text top="343" left="613" width="207" height="20" font="0">HR: 1.03; 95% CI: 0.88-1.21; p=0.72) </text>
<text top="362" left="613" width="7" height="18" font="0">•</text>
<text top="361" left="619" width="278" height="20" font="0">Erectile dysfunction (1.86% vs. 2.14%/y, HR: 0.88; </text>
<text top="378" left="613" width="152" height="20" font="0">95% CI: 0.75-1.04; p=0.13) </text>
<text top="397" left="613" width="7" height="18" font="0">•</text>
<text top="397" left="619" width="269" height="20" font="0">Sleep disturbance lower in atorvastatin group vs. </text>
<text top="414" left="613" width="273" height="20" font="0">placebo (1.0% vs. 1.46%, HR: 0.69, 95% CI: 0.56-</text>
<text top="431" left="613" width="90" height="20" font="0">0.85; p=0.0005) </text>
<text top="450" left="613" width="7" height="18" font="0">•</text>
<text top="449" left="619" width="266" height="20" font="0">Few cases of reported cognitive impairment (not </text>
<text top="467" left="613" width="241" height="20" font="0">statistically reliable for analysis per authors) </text>
<text top="484" left="613" width="7" height="20" font="0">  </text>
<text top="501" left="613" width="106" height="20" font="7"><b>Unblinded phase</b>: </text>
<text top="520" left="613" width="7" height="18" font="0">•</text>
<text top="519" left="619" width="224" height="20" font="0">Muscle related AEs higher in patients on </text>
<text top="537" left="613" width="273" height="20" font="0">atorvastatin vs. those not on it (1.26% vs. 1.0%/y, </text>
<text top="554" left="613" width="214" height="20" font="0">HR: 1.41; 95% CI: 1.10-1.79; p=0.006) </text>
<text top="573" left="613" width="7" height="18" font="0">•</text>
<text top="572" left="619" width="272" height="20" font="0">No significant differences between statin and non-</text>
<text top="589" left="613" width="229" height="20" font="0">statin users for erectile dysfunction, sleep </text>
<text top="606" left="613" width="198" height="20" font="0">disturbance or cognitive impairment </text>
<text top="222" left="913" width="7" height="18" font="0">•</text>
<text top="221" left="919" width="174" height="20" font="0"> muscle related adverse effects </text>
<text top="238" left="913" width="177" height="20" font="0">were higher when patients were </text>
<text top="255" left="913" width="197" height="20" font="0">unblinded suggesting nocebo effect </text>
<text top="624" left="91" width="159" height="20" font="0">Banach M, et al., 2015 <a href="data supplement.html#251">(249)</a> </text>
<text top="642" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25440725">25440725</a></text>
<text top="642" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25440725"> </a></text>
<text top="624" left="263" width="105" height="20" font="7"><b>Study type:</b>  Meta-</text>
<text top="642" left="263" width="96" height="20" font="0">analysis of RCTs </text>
<text top="659" left="263" width="3" height="20" font="0"> </text>
<text top="676" left="263" width="134" height="20" font="7"><b>Size:</b> 6 studies with 302 </text>
<text top="693" left="263" width="132" height="20" font="0">patients receiving statin </text>
<text top="710" left="263" width="150" height="20" font="0">therapy, 5 studies with 226 </text>
<text top="728" left="263" width="146" height="20" font="0">participants evaluating the </text>
<text top="745" left="263" width="150" height="20" font="0">effect of CoQ10 on plasma </text>
<text top="762" left="263" width="150" height="20" font="0">CK, and 5 studies with 253 </text>
<text top="779" left="263" width="145" height="20" font="0">participants assessing the </text>
<text top="624" left="428" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="642" left="428" width="123" height="20" font="0">Randomized, placebo-</text>
<text top="659" left="428" width="118" height="20" font="0">controlled, parallel or </text>
<text top="676" left="428" width="170" height="20" font="0">crossover trial; adults 18 y and </text>
<text top="693" left="428" width="136" height="20" font="0">older; intervention group </text>
<text top="710" left="428" width="116" height="20" font="0">received CoQ10 and </text>
<text top="728" left="428" width="152" height="20" font="0">comparison group received </text>
<text top="745" left="428" width="168" height="20" font="0">placebo; availability of data on </text>
<text top="762" left="428" width="129" height="20" font="0">CK levels or severity of </text>
<text top="779" left="428" width="86" height="20" font="0">myopathic pain </text>
<text top="626" left="613" width="252" height="20" font="7"><b>1</b>°<b> endpoint:</b> impact of CoQ10 on plasma CK </text>
<text top="643" left="613" width="138" height="20" font="0">activity and muscle pain  </text>
<text top="660" left="613" width="3" height="20" font="0"> </text>
<text top="677" left="613" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="696" left="613" width="7" height="18" font="0">•</text>
<text top="696" left="619" width="256" height="20" font="0"> Non-significant increase in plasma CK activity </text>
<text top="713" left="613" width="259" height="20" font="0">increased after CoQ10 supplementation (mean </text>
<text top="730" left="613" width="277" height="20" font="0">difference 11.69 U/L; 95% CI: -14.25 to 37.63 U/L; </text>
<text top="747" left="613" width="49" height="20" font="0">p=0.38)  </text>
<text top="764" left="613" width="3" height="20" font="0"> </text>
<text top="626" left="913" width="7" height="18" font="0">•</text>
<text top="626" left="919" width="177" height="20" font="0"> No significant benefit of CoQ10 </text>
<text top="643" left="913" width="197" height="20" font="0">supplementation in improving statin-</text>
<text top="660" left="913" width="103" height="20" font="0">induced myopathy </text>
<text top="677" left="913" width="3" height="20" font="0"> </text>
</page>
<page number="211" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">211 </text>
<text top="107" left="263" width="149" height="20" font="0">effect of CoQ10 on muscle </text>
<text top="124" left="263" width="27" height="20" font="0">pain </text>
<text top="107" left="428" width="3" height="20" font="0"> </text>
<text top="124" left="428" width="117" height="20" font="7"><b>Exclusion criteria:</b>   </text>
<text top="141" left="428" width="171" height="20" font="0">Not conducted in statin-treated </text>
<text top="159" left="428" width="138" height="20" font="0">individuals; no numerical </text>
<text top="176" left="428" width="138" height="20" font="0">values; no control group; </text>
<text top="193" left="428" width="138" height="20" font="0">ongoing trial; inadequate </text>
<text top="210" left="428" width="150" height="20" font="0">details of study methods or </text>
<text top="227" left="428" width="47" height="20" font="0">results<b>:</b>  </text>
<text top="109" left="613" width="7" height="18" font="0">•</text>
<text top="108" left="619" width="252" height="20" font="0"> Non-significant decrease in muscle pain after </text>
<text top="125" left="613" width="248" height="20" font="0">CoQ10 supplementation (standardized mean </text>
<text top="143" left="613" width="272" height="20" font="0">difference =-0.53; 95% CI: -1.33 to 0.28; p=0.20)  </text>
<text top="160" left="613" width="3" height="20" font="0"> </text>
<text top="177" left="613" width="3" height="20" font="0"> </text>
<text top="245" left="91" width="150" height="20" font="0">Preiss D, et al., 2011 <a href="data supplement.html#251">(250)</a> </text>
<text top="263" left="91" width="58" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21693744">21693744 </a></text>
<text top="263" left="149" width="7" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21693744"> </a> </text>
<text top="245" left="263" width="150" height="20" font="7"><b>Study type:</b> Meta-analysis </text>
<text top="263" left="263" width="49" height="20" font="0">of RCTs </text>
<text top="280" left="263" width="3" height="20" font="0"> </text>
<text top="297" left="263" width="126" height="20" font="7"><b>Size:</b> 5 trials of 32,752 </text>
<text top="314" left="263" width="66" height="20" font="0">participants </text>
<text top="245" left="428" width="149" height="20" font="7"><b>Inclusion criteria:</b> trials of </text>
<text top="263" left="428" width="143" height="20" font="0">1000 or more participants </text>
<text top="280" left="428" width="128" height="20" font="0">without DM exposed to </text>
<text top="297" left="428" width="152" height="20" font="0">moderate or intensive dose </text>
<text top="314" left="428" width="166" height="20" font="0">statin therapy with a minimum </text>
<text top="332" left="428" width="120" height="20" font="0">mean follow-up of 1 y </text>
<text top="349" left="428" width="3" height="20" font="0"> </text>
<text top="366" left="428" width="159" height="20" font="7"><b>Exclusion criteria:</b> Placebo-</text>
<text top="383" left="428" width="161" height="20" font="0">controlled trials, patients with </text>
<text top="400" left="428" width="140" height="20" font="0">diabetes, other agents or </text>
<text top="418" left="428" width="62" height="20" font="0">treatments </text>
<text top="435" left="428" width="7" height="20" font="0">  </text>
<text top="247" left="613" width="79" height="20" font="7"><b>1</b>°<b> endpoint:</b>  </text>
<text top="266" left="613" width="7" height="18" font="0">•</text>
<text top="265" left="619" width="251" height="20" font="0">incident DM, determined by an adverse event </text>
<text top="282" left="613" width="276" height="20" font="0">report of new diagnosis during the trial, participant </text>
<text top="300" left="613" width="284" height="20" font="0">starting glucose-lowering medication during the trial </text>
<text top="317" left="613" width="282" height="20" font="0">or 2 fasting plasma glucose values of 126 mg/dL or </text>
<text top="334" left="613" width="127" height="20" font="0">greater during the trial  </text>
<text top="353" left="613" width="7" height="18" font="0">•</text>
<text top="352" left="619" width="267" height="20" font="0"> composite of CV events (CV death, nonfatal MI, </text>
<text top="370" left="613" width="168" height="20" font="0">nonfatal stroke, CABG or PCI) </text>
<text top="387" left="613" width="3" height="20" font="0"> </text>
<text top="404" left="613" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="423" left="613" width="7" height="18" font="0">•</text>
<text top="422" left="619" width="265" height="20" font="0">Participants receiving intensive dose statin were </text>
<text top="440" left="613" width="263" height="20" font="0">more likely to develop new-onset DM compared </text>
<text top="457" left="613" width="279" height="20" font="0">with moderate-dose statin (OR: 1.12; 95% CI: 1.04-</text>
<text top="474" left="613" width="34" height="20" font="0">1.22; I</text>
<text top="476" left="647" width="4" height="13" font="9">2</text>
<text top="474" left="651" width="32" height="20" font="0">=0%) </text>
<text top="493" left="613" width="7" height="18" font="0">•</text>
<text top="492" left="619" width="258" height="20" font="0"> Participants receiving intensive dose statin vs. </text>
<text top="510" left="613" width="273" height="20" font="0">moderate dose statin had OR: 0.84; 95% CI: 0.75-</text>
<text top="527" left="613" width="34" height="20" font="0">0.94; I</text>
<text top="528" left="647" width="4" height="13" font="9">2</text>
<text top="527" left="651" width="116" height="20" font="0">=74% for CV events. </text>
<text top="247" left="913" width="7" height="18" font="0">•</text>
<text top="247" left="919" width="186" height="20" font="0">Intensive-dose statin therapy was </text>
<text top="264" left="913" width="198" height="20" font="0">associated with an increased risk of </text>
<text top="281" left="913" width="182" height="20" font="0">new-onset diabetes compared to </text>
<text top="298" left="913" width="163" height="20" font="0">moderate-dose statin therapy </text>
<text top="317" left="913" width="7" height="18" font="0">•</text>
<text top="317" left="919" width="190" height="20" font="0">2 additional cases of DM per 1000 </text>
<text top="334" left="913" width="193" height="20" font="0">patient-y vs. 6.5 fewer cases of CV </text>
<text top="351" left="913" width="176" height="20" font="0">events per 1000 patient-y in the </text>
<text top="368" left="913" width="164" height="20" font="0">intensive statin therapy group </text>
<text top="387" left="913" width="7" height="18" font="0">•</text>
<text top="387" left="919" width="182" height="20" font="0">NNH=498 for new onset DM and </text>
<text top="404" left="913" width="200" height="20" font="0">NNT=155 for CV events in intensive-</text>
<text top="421" left="913" width="142" height="20" font="0">dose statin therapy group </text>
<text top="438" left="913" width="3" height="20" font="0"> </text>
<text top="545" left="91" width="143" height="20" font="0">Navarese EP, et al., 2013 </text>
<text top="562" left="91" width="32" height="20" font="0"><a href="data supplement.html#251">(251)</a><b> </b></text>
<text top="579" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23352266">23352266</a></text>
<text top="579" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23352266"> </a></text>
<text top="545" left="263" width="150" height="20" font="7"><b>Study type:</b> Meta-analysis </text>
<text top="562" left="263" width="52" height="20" font="0">of RCTs  </text>
<text top="579" left="263" width="3" height="20" font="0"> </text>
<text top="596" left="263" width="150" height="20" font="7"><b>Size:</b>  17 RCTs including a </text>
<text top="614" left="263" width="135" height="20" font="0">total of 113,394 patients </text>
<text top="545" left="428" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="562" left="428" width="140" height="20" font="0">RCTs comparing either a </text>
<text top="579" left="428" width="170" height="20" font="0">statin vs. placebo or high-dose </text>
<text top="596" left="428" width="138" height="20" font="0">vs. moderate-dose statin </text>
<text top="614" left="428" width="48" height="20" font="0">therapy  </text>
<text top="631" left="428" width="3" height="20" font="0"> </text>
<text top="648" left="428" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="665" left="428" width="161" height="20" font="0">Trials investigating surrogate </text>
<text top="682" left="428" width="141" height="20" font="0">markers, patients already </text>
<text top="700" left="428" width="138" height="20" font="0">diagnosed with DM, new-</text>
<text top="717" left="428" width="163" height="20" font="0">onset DM data not published, </text>
<text top="734" left="428" width="157" height="20" font="0">different follow-up per group </text>
<text top="546" left="613" width="273" height="20" font="7"><b>1</b>°<b> endpoint:</b> the incidence of new-onset DM with </text>
<text top="563" left="613" width="191" height="20" font="0">different type and doses of statins  </text>
<text top="580" left="613" width="3" height="20" font="0"> </text>
<text top="597" left="613" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="616" left="613" width="7" height="18" font="0">•</text>
<text top="616" left="619" width="246" height="20" font="0">Pravastatin 40 mg/d was associated with the </text>
<text top="633" left="613" width="276" height="20" font="0">lowest risk of new-onset DM compared to placebo </text>
<text top="650" left="613" width="170" height="20" font="0">(OR: 1.07; 95% CI: 0.86-1.30)  </text>
<text top="669" left="613" width="7" height="18" font="0">•</text>
<text top="669" left="619" width="263" height="20" font="0">Rosuvastatin 20mg/d associated with increased </text>
<text top="686" left="613" width="271" height="20" font="0">risk for new-onset DM compared to placebo (OR: </text>
<text top="703" left="613" width="133" height="20" font="0">1.25; 95% CI: 0.82-1.90 </text>
<text top="722" left="613" width="7" height="18" font="0">•</text>
<text top="721" left="619" width="226" height="20" font="0">Atorvastatin 80mg/d was associated with </text>
<text top="739" left="613" width="263" height="20" font="0">increased risk of DM compared to placebo (OR: </text>
<text top="756" left="613" width="138" height="20" font="0">1.15; 95% CI: 0.90-1.50) </text>
<text top="546" left="913" width="7" height="18" font="0">•</text>
<text top="546" left="919" width="193" height="20" font="0"> Various doses of different types of </text>
<text top="563" left="913" width="178" height="20" font="0">statins show varying potential to </text>
<text top="580" left="913" width="165" height="20" font="0">increase the incidence of DM  </text>
<text top="597" left="913" width="3" height="20" font="0"> </text>
</page>
<page number="212" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">212 </text>
<text top="107" left="91" width="148" height="20" font="0">Sattar N, et al., 2010 <a href="data supplement.html#251">(252)</a><b> </b></text>
<text top="124" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20167359">20167359</a></text>
<text top="124" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20167359"> </a></text>
<text top="141" left="91" width="3" height="20" font="0"> </text>
<text top="107" left="263" width="77" height="20" font="7"><b>Study type:</b>   </text>
<text top="124" left="263" width="131" height="20" font="0">Meta-analysis of RCTs  </text>
<text top="141" left="263" width="3" height="20" font="0"> </text>
<text top="159" left="263" width="39" height="20" font="7"><b>Size:</b>   </text>
<text top="176" left="263" width="109" height="20" font="0">13 trials with 91140 </text>
<text top="193" left="263" width="70" height="20" font="0">participants  </text>
<text top="107" left="428" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="124" left="428" width="138" height="20" font="0">RCTs of more than 1000 </text>
<text top="141" left="428" width="164" height="20" font="0">patients, identical follow-up in </text>
<text top="159" left="428" width="157" height="20" font="0">both groups, and duration of </text>
<text top="176" left="428" width="79" height="20" font="0">more than 1 y </text>
<text top="193" left="428" width="3" height="20" font="0"> </text>
<text top="210" left="428" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="227" left="428" width="154" height="20" font="0">Trials of patients with organ </text>
<text top="245" left="428" width="122" height="20" font="0">transplants or needed </text>
<text top="262" left="428" width="75" height="20" font="0">hemodialysis </text>
<text top="279" left="428" width="3" height="20" font="0"> </text>
<text top="108" left="613" width="148" height="20" font="7"><b>1</b>°<b> endpoint:</b> Incident DM  </text>
<text top="125" left="613" width="3" height="20" font="0"> </text>
<text top="143" left="613" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="162" left="613" width="7" height="18" font="0">•</text>
<text top="161" left="619" width="263" height="20" font="0">Statin therapy associated with an increased risk </text>
<text top="178" left="613" width="278" height="20" font="0">for incident DM (OR: 1.09; 95% CI: 0.02-1.17) with </text>
<text top="195" left="613" width="190" height="20" font="0">little heterogeneity between trials (I</text>
<text top="197" left="803" width="4" height="13" font="9">2</text>
<text top="195" left="807" width="39" height="20" font="0">=11%) </text>
<text top="214" left="613" width="7" height="18" font="0">•</text>
<text top="214" left="619" width="250" height="20" font="0"> one case of DM for every 255 patients (0.4% </text>
<text top="231" left="613" width="248" height="20" font="0">absolute increase) treated with statins for 4 y </text>
<text top="250" left="613" width="7" height="18" font="0">•</text>
<text top="249" left="619" width="278" height="20" font="0"> Incidence of DM was 12.3 cases/1000 patient-y in </text>
<text top="267" left="613" width="276" height="20" font="0">the statin group and 11.25 cases/1000 patient-y in </text>
<text top="284" left="613" width="96" height="20" font="0">the control group </text>
<text top="109" left="913" width="7" height="18" font="0">•</text>
<text top="108" left="919" width="192" height="20" font="0">Statin therapy was associated with </text>
<text top="125" left="913" width="194" height="20" font="0">a slightly increased risk of diabetes </text>
<text top="143" left="913" width="81" height="20" font="0">development.  </text>
<text top="162" left="913" width="7" height="18" font="0">•</text>
<text top="161" left="919" width="187" height="20" font="0"> Absolute risk of DM development </text>
<text top="178" left="913" width="194" height="20" font="0">is low and low-risk when compared </text>
<text top="195" left="913" width="207" height="20" font="0">with the reduction in coronary events  </text>
<text top="213" left="913" width="3" height="20" font="0"> </text>
<text top="302" left="91" width="148" height="20" font="0">Taylor F, et al., 2013 <a href="data supplement.html#248">(201)</a><b> </b></text>
<text top="319" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21249663">21249663</a></text>
<text top="319" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21249663"> </a></text>
<text top="336" left="91" width="3" height="20" font="0"> </text>
<text top="302" left="263" width="137" height="20" font="7"><b>Study type:</b>  Systematic </text>
<text top="319" left="263" width="148" height="20" font="0">Review and Meta-Analysis </text>
<text top="336" left="263" width="3" height="20" font="0"> </text>
<text top="353" left="263" width="130" height="20" font="7"><b>Size:</b>  18 RCTs with 19 </text>
<text top="371" left="263" width="152" height="20" font="0">groups; 56,934 participants </text>
<text top="302" left="428" width="113" height="20" font="7"><b>Inclusion criteria:</b>   </text>
<text top="319" left="428" width="167" height="20" font="0">RCTs of statins vs. placebo or </text>
<text top="336" left="428" width="148" height="20" font="0">usual care in adults ≥ 18 y </text>
<text top="353" left="428" width="170" height="20" font="0">age; with treatment duration of </text>
<text top="371" left="428" width="148" height="20" font="0">≥ 12 mo and follow-up ≥ 6 </text>
<text top="388" left="428" width="165" height="20" font="0">mo; 10% or less had a history </text>
<text top="405" left="428" width="43" height="20" font="0">of CVD </text>
<text top="422" left="428" width="3" height="20" font="0"> </text>
<text top="440" left="428" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="457" left="428" width="141" height="20" font="0">Studies in which &gt;10% of </text>
<text top="474" left="428" width="150" height="20" font="0">patients had previous CVD </text>
<text top="491" left="428" width="150" height="20" font="0">Studies where statins were </text>
<text top="508" left="428" width="155" height="20" font="0">used to control/treat chronic </text>
<text top="526" left="428" width="62" height="20" font="0">conditions  </text>
<text top="303" left="613" width="285" height="20" font="7"><b>1</b>°<b> endpoint:</b> All-cause mortality, fatal and non-fatal </text>
<text top="320" left="613" width="271" height="20" font="0">CHD, CVD and stroke, combined endpoints (fatal </text>
<text top="337" left="613" width="206" height="20" font="0">and non-fatal CHD, CVD and stroke), </text>
<text top="355" left="613" width="96" height="20" font="0">revascularization </text>
<text top="374" left="613" width="7" height="18" font="0">•</text>
<text top="373" left="619" width="270" height="20" font="0"> Adverse events <a href="data supplement.html#251">(253)</a> included cancer, DM Type </text>
<text top="390" left="613" width="17" height="20" font="0">2.  </text>
<text top="407" left="613" width="3" height="20" font="0"> </text>
<text top="425" left="613" width="180" height="20" font="7"><b>Results: AEs</b> (statin vs. control) </text>
<text top="444" left="613" width="7" height="18" font="0">•</text>
<text top="443" left="619" width="247" height="20" font="0"> Pooled event rates from 12 trials showed no </text>
<text top="460" left="613" width="264" height="20" font="0">difference in overall rate of AEs (RR: 1; 95% CI: </text>
<text top="477" left="613" width="63" height="20" font="0">0.97-1.03). </text>
<text top="496" left="613" width="7" height="18" font="0">•</text>
<text top="496" left="619" width="256" height="20" font="0">No excess risk of cancer from pooled estimate </text>
<text top="513" left="613" width="263" height="20" font="0">from 11 trials (RR: 1.01; 95% 0.93-1.10) and no </text>
<text top="530" left="613" width="81" height="20" font="0">heterogeneity. </text>
<text top="549" left="613" width="7" height="18" font="0">•</text>
<text top="549" left="619" width="256" height="20" font="0">No excess risk of myalgia and rhabdomyolysis </text>
<text top="566" left="613" width="278" height="20" font="0">from pooled estimate of 9 trials (RR: 1.03; 95% CI: </text>
<text top="583" left="613" width="204" height="20" font="0">0.97-1.09) with some heterogeneity (I</text>
<text top="585" left="816" width="7" height="13" font="9">2 </text>
<text top="583" left="823" width="32" height="20" font="0">41%) </text>
<text top="602" left="613" width="7" height="18" font="0">•</text>
<text top="601" left="619" width="273" height="20" font="0">Excess risk of Type 2 DM observed from only two </text>
<text top="619" left="613" width="199" height="20" font="0">trials (RR: 1.18; 95% CI: 1.01-1.39). </text>
<text top="638" left="613" width="7" height="18" font="0">•</text>
<text top="637" left="619" width="278" height="20" font="0"> No excess risk of hemorrhagic stroke from pooled </text>
<text top="654" left="613" width="245" height="20" font="0">estimate of 2 trials (RR: 0.97; CI: 0.54-1.75). </text>
<text top="673" left="613" width="7" height="18" font="0">•</text>
<text top="672" left="619" width="254" height="20" font="0">Weak evidence for elevation in transaminases </text>
<text top="690" left="613" width="279" height="20" font="0">from pooled estimate of 10 studies (RR: 1.16; 95% </text>
<text top="707" left="613" width="82" height="20" font="0">CI: 0.87-1.54). </text>
<text top="726" left="613" width="7" height="18" font="0">•</text>
<text top="725" left="619" width="270" height="20" font="0">Weak evidence for renal dysfunction from pooled </text>
<text top="743" left="613" width="286" height="20" font="0">estimate of 4 studies (RR: 1.11; 95% CI: 0.99-1.26). </text>
<text top="762" left="613" width="7" height="18" font="0">•</text>
<text top="761" left="619" width="271" height="20" font="0"> Weak evidence for arthritis from pooled estimate </text>
<text top="778" left="613" width="233" height="20" font="0">of 2 studies (RR: 1.2; 95% CI: 0.82-1.75) . </text>
<text top="304" left="913" width="7" height="18" font="0">•</text>
<text top="303" left="919" width="174" height="20" font="0">In patients without CVD, statins </text>
<text top="320" left="913" width="181" height="20" font="0">reduce all-cause mortality, major </text>
<text top="337" left="913" width="113" height="20" font="0">vascular events and </text>
<text top="355" left="913" width="148" height="20" font="0">revascularization without a </text>
<text top="372" left="913" width="154" height="20" font="0">significant increase in AEs.  </text>
</page>
<page number="213" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">213 </text>
<text top="107" left="91" width="145" height="20" font="0">Richardson K, et al., 2013 </text>
<text top="124" left="91" width="32" height="20" font="0"><a href="data supplement.html#251">(254)</a><b> </b></text>
<text top="141" left="91" width="55" height="20" font="8"><a href="">24247674</a></text>
<text top="141" left="146" width="3" height="20" font="0"><a href=""> </a></text>
<text top="107" left="263" width="137" height="20" font="7"><b>Study type:</b>  Systematic </text>
<text top="124" left="263" width="148" height="20" font="0">Review and Meta-Analysis </text>
<text top="141" left="263" width="3" height="20" font="0"> </text>
<text top="159" left="263" width="144" height="20" font="7"><b>Size:</b> 27 studies (3 RCTs, </text>
<text top="176" left="263" width="145" height="20" font="0">16 cohort, 4 case–control, </text>
<text top="193" left="263" width="124" height="20" font="0">and 4 cross-sectional) </text>
<text top="210" left="263" width="124" height="20" font="0">were included in meta-</text>
<text top="228" left="263" width="48" height="20" font="0">analysis </text>
<text top="107" left="428" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="124" left="428" width="156" height="20" font="0">Studies evaluating cognitive </text>
<text top="141" left="428" width="148" height="20" font="0">function in adults receiving </text>
<text top="159" left="428" width="39" height="20" font="0">statins </text>
<text top="176" left="428" width="7" height="20" font="0">  </text>
<text top="108" left="613" width="270" height="20" font="7"><b>1</b>°<b> endpoint:</b> Incidence of dementia, Alzheimer’s </text>
<text top="125" left="613" width="271" height="20" font="0">disease, or mild cognitive impairment in statin vs. </text>
<text top="143" left="613" width="135" height="20" font="0">placebo treated patients </text>
<text top="160" left="613" width="3" height="20" font="0"> </text>
<text top="177" left="613" width="3" height="20" font="0"> </text>
<text top="194" left="613" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="213" left="613" width="7" height="18" font="0">•</text>
<text top="213" left="619" width="276" height="20" font="0">Moderate-strength evidence showed no increased </text>
<text top="230" left="613" width="162" height="20" font="0">risk for dementia with statins  </text>
<text top="247" left="640" width="260" height="20" font="0">-  One RCT of statin vs. placebo – RR: 1.00; </text>
<text top="264" left="667" width="103" height="20" font="0">95% CI: 0.61-1.64 </text>
<text top="282" left="640" width="226" height="20" font="0">-  pooled analysis of 10 cohort studies </text>
<text top="299" left="667" width="202" height="20" font="0">showed statins were associated with </text>
<text top="316" left="667" width="215" height="20" font="0">decreased risk for dementia (RR: 0.87; </text>
<text top="333" left="667" width="79" height="20" font="0">CI: 0.82-0.92) </text>
<text top="352" left="613" width="7" height="18" font="0">•</text>
<text top="352" left="619" width="226" height="20" font="0"> Low-strength evidence demonstrates no </text>
<text top="369" left="613" width="271" height="20" font="0">association between statins and increased risk of </text>
<text top="386" left="613" width="104" height="20" font="0">Alzheimer disease </text>
<text top="403" left="640" width="227" height="20" font="0">-  Pooled analysis of 10 cohort studies </text>
<text top="420" left="667" width="194" height="20" font="0">suggest statins are associated with </text>
<text top="438" left="667" width="230" height="20" font="0">decreased risk of Alzheimer disease (RR: </text>
<text top="455" left="667" width="113" height="20" font="0">0.79; CI: 0.63-0.99)  </text>
<text top="474" left="613" width="7" height="18" font="0">•</text>
<text top="473" left="619" width="276" height="20" font="0">Moderate-strength evidence suggests no increase </text>
<text top="490" left="613" width="240" height="20" font="0">in risk of mild cognitive impairment (MCI) or </text>
<text top="508" left="613" width="277" height="20" font="0">cognitive impairment without dementia with statins </text>
<text top="525" left="640" width="203" height="20" font="0">-  One RCT showed no significant </text>
<text top="542" left="667" width="224" height="20" font="0">difference in incidence of MCI with statin </text>
<text top="559" left="667" width="217" height="20" font="0">therapy vs. placebo (RR: 0.98; 95% CI: </text>
<text top="576" left="667" width="60" height="20" font="0">0.93-1.03) </text>
<text top="594" left="640" width="221" height="20" font="0">-  Pooled analysis of 4 cohort studies </text>
<text top="611" left="667" width="204" height="20" font="0">showed a decrease in risk with statin </text>
<text top="628" left="667" width="183" height="20" font="0">therapy (RR: 0.66; CI: 0.51-0.86) </text>
<text top="109" left="913" width="7" height="18" font="0">•</text>
<text top="108" left="919" width="176" height="20" font="0"> Lack of large RCTs to evaluate </text>
<text top="125" left="913" width="193" height="20" font="0">effect of statin therapy on cognitive </text>
<text top="143" left="913" width="46" height="20" font="0">function </text>
<text top="162" left="913" width="7" height="18" font="0">•</text>
<text top="161" left="919" width="184" height="20" font="0"> currently available data does not </text>
<text top="178" left="913" width="197" height="20" font="0">suggest adverse effect of statins on </text>
<text top="195" left="913" width="102" height="20" font="0">cognitive function  </text>
<text top="213" left="913" width="3" height="20" font="0"> </text>
<text top="646" left="91" width="128" height="20" font="0">Ganga HV, et al., 2014 </text>
<text top="663" left="91" width="32" height="20" font="0"><a href="data supplement.html#251">(255)</a> </text>
<text top="680" left="91" width="55" height="20" font="8"><a href="">24952854</a></text>
<text top="680" left="146" width="3" height="20" font="0"><a href=""> </a></text>
<text top="646" left="263" width="137" height="20" font="7"><b>Study type:</b>  Systematic </text>
<text top="663" left="263" width="44" height="20" font="0">Review </text>
<text top="680" left="263" width="3" height="20" font="0"> </text>
<text top="698" left="263" width="134" height="20" font="7"><b>Size:</b>  42 trials (113,695 </text>
<text top="715" left="263" width="51" height="20" font="0">patients)<b> </b></text>
<text top="646" left="428" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="663" left="428" width="147" height="20" font="0">Placebo controlled studies </text>
<text top="680" left="428" width="165" height="20" font="0">with a minimum follow-up of 6 </text>
<text top="698" left="428" width="163" height="20" font="0">mo. and published from 1990 </text>
<text top="715" left="428" width="143" height="20" font="0">through November 2012.  </text>
<text top="732" left="428" width="3" height="20" font="0"> </text>
<text top="749" left="428" width="110" height="20" font="7"><b>Exclusion criteria:</b> </text>
<text top="766" left="428" width="121" height="20" font="0">nonrandomized trials, </text>
<text top="784" left="428" width="152" height="20" font="0">observational studies, case </text>
<text top="647" left="613" width="79" height="20" font="7"><b>1</b>°<b> endpoint:</b>  </text>
<text top="664" left="613" width="273" height="20" font="0">Incidence of muscle symptoms in patients treated </text>
<text top="682" left="613" width="124" height="20" font="0">with statin vs. placebo </text>
<text top="699" left="613" width="3" height="20" font="0"> </text>
<text top="716" left="613" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="735" left="613" width="7" height="18" font="0">•</text>
<text top="734" left="619" width="278" height="20" font="0">Incidence of any muscle problems was 12.7% (n = </text>
<text top="752" left="613" width="278" height="20" font="0">7,544) in 59,237 statin treatment group and 12.4% </text>
<text top="769" left="613" width="248" height="20" font="0">(n = 6,735) in 54,458 placebo group (p=0.06) </text>
<text top="648" left="913" width="7" height="18" font="0">•</text>
<text top="647" left="919" width="187" height="20" font="0"> incidence of muscle symptoms is </text>
<text top="664" left="913" width="158" height="20" font="0">almost identical in statin and </text>
<text top="682" left="913" width="189" height="20" font="0">placebo-treated patients in clinical </text>
<text top="699" left="913" width="204" height="20" font="0">trials (about 13% of the participants)  </text>
<text top="718" left="913" width="7" height="18" font="0">•</text>
<text top="717" left="919" width="185" height="20" font="0"> statin related adverse effects are </text>
<text top="734" left="913" width="156" height="20" font="0">less frequent in clinical trials </text>
<text top="752" left="913" width="159" height="20" font="0">compared to clinical practice </text>
</page>
<page number="214" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">214 </text>
<text top="107" left="428" width="124" height="20" font="0">series, review articles, </text>
<text top="124" left="428" width="139" height="20" font="0">editorials, and duplicates<b> </b></text>
<text top="109" left="613" width="7" height="18" font="0">•</text>
<text top="108" left="619" width="269" height="20" font="0">CK&gt;3 times ULN reported in 0.5% (63/13,734) of </text>
<text top="125" left="613" width="265" height="20" font="0">statin group vs. 0.3% (42/13,740) of the placebo </text>
<text top="143" left="613" width="84" height="20" font="0">group (p=0.04) </text>
<text top="162" left="613" width="7" height="18" font="0">•</text>
<text top="161" left="619" width="279" height="20" font="0">CK &gt;10 times ULN reported in 0.2% (77/39,893) of </text>
<text top="178" left="613" width="246" height="20" font="0">the statin group vs. 0.16% (55/34,499) of the </text>
<text top="195" left="613" width="131" height="20" font="0">placebo group (p=0.28) </text>
<text top="214" left="613" width="7" height="18" font="0">•</text>
<text top="214" left="619" width="276" height="20" font="0">Rhabdomyolysis occurred in 0.03% (15/49,691) of </text>
<text top="231" left="613" width="246" height="20" font="0">the statin group vs. 0.02% (12/52,301) of the </text>
<text top="248" left="613" width="131" height="20" font="0">placebo group (p=0.48) </text>
<text top="266" left="91" width="56" height="20" font="7"><b>GREACE </b></text>
<text top="283" left="91" width="159" height="20" font="0">Athyros VG, et al., 2010<a href="data supplement.html#237"> (23)</a> </text>
<text top="301" left="91" width="55" height="20" font="8"><a href="">21109302</a></text>
<text top="301" left="146" width="3" height="20" font="0"><a href=""> </a></text>
<text top="266" left="263" width="126" height="20" font="7"><b>Study type:</b>  Post-hoc </text>
<text top="283" left="263" width="137" height="20" font="0">analysis of the GREACE </text>
<text top="301" left="263" width="141" height="20" font="0">population randomized to </text>
<text top="318" left="263" width="111" height="20" font="0">statin or usual care  </text>
<text top="335" left="263" width="3" height="20" font="0"> </text>
<text top="352" left="263" width="113" height="20" font="7"><b>Size:</b>  1600 patients<b> </b></text>
<text top="266" left="428" width="154" height="20" font="7"><b>Inclusion criteria:</b> Patients </text>
<text top="283" left="428" width="161" height="20" font="0">with coronary artery disease, </text>
<text top="301" left="428" width="157" height="20" font="0">aged &lt;75 y, with LDL-C&gt;2·6 </text>
<text top="318" left="428" width="165" height="20" font="0">mmol/L and triglycerides &lt;4·5 </text>
<text top="335" left="428" width="44" height="20" font="0">mmol/L<b> </b></text>
<text top="267" left="613" width="258" height="20" font="7"><b>1</b>°<b> endpoint:</b> safety and effectiveness of statin </text>
<text top="285" left="613" width="282" height="20" font="0">therapy in risk reduction for first recurrent CV event </text>
<text top="302" left="613" width="195" height="20" font="0">in patients with abnormal liver tests </text>
<text top="319" left="613" width="3" height="20" font="0"> </text>
<text top="336" left="613" width="59" height="20" font="7"><b>Results:</b>   </text>
<text top="355" left="613" width="7" height="18" font="0">•</text>
<text top="355" left="619" width="276" height="20" font="0"> 227patients with abnormal liver tests, treated with </text>
<text top="372" left="613" width="244" height="20" font="0">a statin had improvements in liver tests from </text>
<text top="389" left="613" width="112" height="20" font="0">baseline (p&lt;0.0001) </text>
<text top="408" left="613" width="7" height="18" font="0">•</text>
<text top="407" left="619" width="271" height="20" font="0">210 patients with abnormal liver tests, not treated </text>
<text top="425" left="613" width="278" height="20" font="0">with statin had increase in liver tests from baseline </text>
<text top="442" left="613" width="63" height="20" font="0">(p&lt;0.0001) </text>
<text top="461" left="613" width="7" height="18" font="0">•</text>
<text top="460" left="619" width="210" height="20" font="0">&lt;1% (7/880 pts) who received a statin </text>
<text top="477" left="613" width="283" height="20" font="0">discontinued due to elevation in transaminases &gt;3x </text>
<text top="495" left="613" width="28" height="20" font="0">ULN </text>
<text top="514" left="613" width="7" height="18" font="0">•</text>
<text top="513" left="619" width="238" height="20" font="0">CV events occurred in 10% of patients with </text>
<text top="530" left="613" width="267" height="20" font="0">abnormal liver tests receiving statin compared to </text>
<text top="547" left="613" width="244" height="20" font="0">30% of patients with abnormal liver tests not </text>
<text top="565" left="613" width="159" height="20" font="0">receiving a statin (p&lt;0.0001)<b> </b></text>
<text top="268" left="913" width="7" height="18" font="0">•</text>
<text top="267" left="919" width="196" height="20" font="0">Statin treatment appears to be safe </text>
<text top="285" left="913" width="195" height="20" font="0">in patients with abnormal liver tests </text>
<text top="302" left="913" width="141" height="20" font="0">and reduces CV mortality </text>
<text top="583" left="91" width="156" height="20" font="0">Kralis DG, et al., 2016 <a href="data supplement.html#251">(256)</a> </text>
<text top="600" left="91" width="55" height="20" font="8"><a href="">27678424</a></text>
<text top="600" left="146" width="3" height="20" font="0"><a href=""> </a></text>
<text top="583" left="263" width="137" height="20" font="7"><b>Study type:</b>  Systematic </text>
<text top="600" left="263" width="44" height="20" font="0">Review </text>
<text top="617" left="263" width="3" height="20" font="0"> </text>
<text top="634" left="263" width="139" height="20" font="7"><b>Size:</b>  16 studies (5 case </text>
<text top="651" left="263" width="143" height="20" font="0">series, 3 cohort studies, 3 </text>
<text top="669" left="263" width="137" height="20" font="0">registry-based studies, 1 </text>
<text top="686" left="263" width="124" height="20" font="0">RCT and 4 systematic </text>
<text top="703" left="263" width="49" height="20" font="0">reviews)<b> </b></text>
<text top="583" left="428" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="600" left="428" width="140" height="20" font="0">English language studies </text>
<text top="617" left="428" width="165" height="20" font="0">related to statin exposure and </text>
<text top="634" left="428" width="64" height="20" font="0">pregnancy  </text>
<text top="651" left="428" width="3" height="20" font="0"> </text>
<text top="669" left="428" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="686" left="428" width="109" height="20" font="0">Single case reports </text>
<text top="703" left="428" width="83" height="20" font="0">Animal studies </text>
<text top="720" left="428" width="139" height="20" font="0">Studies only published in </text>
<text top="737" left="428" width="171" height="20" font="0">abstract form, and non-English </text>
<text top="755" left="428" width="57" height="20" font="0">language <b> </b></text>
<text top="584" left="613" width="276" height="20" font="7"><b>1</b>°<b> endpoint:</b> Teratogenicity associated with statin </text>
<text top="601" left="613" width="23" height="20" font="0">use </text>
<text top="618" left="613" width="3" height="20" font="0"> </text>
<text top="635" left="613" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="653" left="613" width="273" height="20" font="0">No clear relationship in congenital anomalies with </text>
<text top="670" left="613" width="130" height="20" font="0">statin use in pregnancy<b> </b></text>
<text top="584" left="913" width="7" height="18" font="0">•</text>
<text top="584" left="919" width="165" height="20" font="0">No clear relationship between </text>
<text top="601" left="913" width="199" height="20" font="0">statin use and congenital anomalies </text>
<text top="618" left="913" width="74" height="20" font="0">in pregnancy </text>
<text top="637" left="913" width="7" height="18" font="0">•</text>
<text top="636" left="919" width="153" height="20" font="0">More studies are needed to </text>
<text top="654" left="913" width="180" height="20" font="0">determine the safety of statins in </text>
<text top="671" left="913" width="61" height="20" font="0">pregnancy </text>
<text top="772" left="81" width="4" height="22" font="1"> </text>
</page>
<page number="215" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">215 </text>
<text top="106" left="81" width="4" height="22" font="1"> </text>
<text top="125" left="81" width="607" height="24" font="4"><b>Data Supplement 42. RCTs Comparing Patient Interventions to Usual Care (Section 6)  </b></text>
<text top="155" left="97" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="172" left="123" width="48" height="20" font="7"><b>Author; </b></text>
<text top="190" left="100" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="155" left="244" width="83" height="20" font="7"><b>Aim of Study; </b></text>
<text top="172" left="249" width="74" height="20" font="7"><b>Study Type; </b></text>
<text top="190" left="243" width="86" height="20" font="7"><b>Study Size (N) </b></text>
<text top="172" left="391" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="147" left="557" width="111" height="20" font="7"><b>Study Intervention </b></text>
<text top="164" left="574" width="76" height="20" font="7"><b>(# patients) / </b></text>
<text top="181" left="557" width="111" height="20" font="7"><b>Study Comparator </b></text>
<text top="198" left="578" width="69" height="20" font="7"><b>(# patients) </b></text>
<text top="155" left="751" width="105" height="20" font="7"><b>Endpoint Results </b></text>
<text top="172" left="735" width="137" height="20" font="7"><b>(Absolute Event Rates, </b></text>
<text top="190" left="713" width="181" height="20" font="7"><b>P values; OR or RR; &amp; 95% CI) </b></text>
<text top="156" left="932" width="175" height="20" font="7"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="173" left="964" width="111" height="20" font="7"><b>Study Limitations; </b></text>
<text top="190" left="971" width="96" height="20" font="7"><b>Adverse Events </b></text>
<text top="216" left="89" width="85" height="20" font="0">Park LG, et al., </text>
<text top="233" left="89" width="63" height="20" font="0">2014<a href="data supplement.html#251"> (257)</a> </text>
<text top="251" left="89" width="58" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24321403">24321403 </a></text>
<text top="251" left="148" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24321403"> </a></text>
<text top="268" left="89" width="3" height="20" font="0"> </text>
<text top="216" left="217" width="127" height="20" font="7"><b>Aim:</b> To determine the </text>
<text top="233" left="217" width="99" height="20" font="0">effectiveness of a </text>
<text top="251" left="217" width="126" height="20" font="0">mobile text messaging </text>
<text top="268" left="217" width="137" height="20" font="0">intervention in improving </text>
<text top="285" left="217" width="138" height="20" font="0">adherence to antiplatelet </text>
<text top="302" left="217" width="133" height="20" font="0">and statin medications.  </text>
<text top="319" left="217" width="3" height="20" font="0"> </text>
<text top="337" left="217" width="115" height="20" font="7"><b>Study type: </b>Parallel </text>
<text top="354" left="217" width="124" height="20" font="0">randomized controlled </text>
<text top="371" left="217" width="70" height="20" font="0">clinical trial   </text>
<text top="388" left="217" width="3" height="20" font="0"> </text>
<text top="406" left="217" width="36" height="20" font="7"><b>Size:</b>  </text>
<text top="423" left="217" width="91" height="20" font="0">N recruited = 90 </text>
<text top="440" left="217" width="108" height="20" font="0">N randomized = 90 </text>
<text top="457" left="217" width="129" height="20" font="0">N reported outcomes = </text>
<text top="474" left="217" width="17" height="20" font="0">84 </text>
<text top="492" left="217" width="3" height="20" font="0"> </text>
<text top="216" left="368" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="235" left="368" width="7" height="18" font="0">•</text>
<text top="235" left="375" width="79" height="20" font="0"> ≥ 21 y of age </text>
<text top="254" left="368" width="7" height="18" font="0">•</text>
<text top="253" left="375" width="135" height="20" font="0"> Hospitalized for non-ST </text>
<text top="270" left="368" width="145" height="20" font="0">elevation MI, ST elevation </text>
<text top="287" left="368" width="59" height="20" font="0">MI, or PCI </text>
<text top="306" left="368" width="7" height="18" font="0">•</text>
<text top="306" left="375" width="146" height="20" font="0"> Prescribed an antiplatelet </text>
<text top="323" left="368" width="63" height="20" font="0">medication </text>
<text top="342" left="368" width="7" height="18" font="0">•</text>
<text top="341" left="375" width="109" height="20" font="0"> Prescribed a statin </text>
<text top="359" left="368" width="66" height="20" font="0">medication  </text>
<text top="378" left="368" width="7" height="18" font="0">•</text>
<text top="377" left="375" width="148" height="20" font="0"> Owned mobile phone with </text>
<text top="394" left="368" width="141" height="20" font="0">text messaging capability </text>
<text top="413" left="368" width="7" height="18" font="0">•</text>
<text top="413" left="375" width="116" height="20" font="0"> Able to speak, read, </text>
<text top="430" left="368" width="109" height="20" font="0">understand English </text>
<text top="447" left="368" width="3" height="20" font="0"> </text>
<text top="464" left="368" width="3" height="20" font="0"> </text>
<text top="481" left="368" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="501" left="368" width="7" height="18" font="0">•</text>
<text top="500" left="375" width="146" height="20" font="0"> Cognitive impairment that </text>
<text top="517" left="368" width="152" height="20" font="0">limited ability to understand </text>
<text top="534" left="368" width="77" height="20" font="0">and complete </text>
<text top="551" left="368" width="83" height="20" font="0">questionnaires </text>
<text top="570" left="368" width="7" height="18" font="0">•</text>
<text top="570" left="375" width="118" height="20" font="0"> Inability to operate a </text>
<text top="587" left="368" width="77" height="20" font="0">mobile phone </text>
<text top="604" left="368" width="7" height="20" font="0">  </text>
<text top="216" left="539" width="81" height="20" font="7"><b>Intervention:</b>  </text>
<text top="235" left="539" width="7" height="18" font="0">•</text>
<text top="235" left="546" width="105" height="20" font="0"> TM for medication </text>
<text top="252" left="539" width="139" height="20" font="0">reminders and education </text>
<text top="269" left="539" width="46" height="20" font="0">(n = 30) </text>
<text top="288" left="539" width="7" height="18" font="0">•</text>
<text top="287" left="546" width="133" height="20" font="0"> Educational TM only (n </text>
<text top="305" left="539" width="32" height="20" font="0">= 30) </text>
<text top="322" left="539" width="3" height="20" font="0"> </text>
<text top="339" left="539" width="84" height="20" font="7"><b>Comparator:</b> <b>  </b></text>
<text top="358" left="539" width="7" height="18" font="0">•</text>
<text top="357" left="546" width="90" height="20" font="0"> No TM (n = 30)<b> </b></text>
<text top="217" left="698" width="159" height="20" font="7"><b>1</b>°<b> endpoint:</b> Comparison of </text>
<text top="235" left="698" width="178" height="20" font="0">medication adherence using TM </text>
<text top="252" left="698" width="204" height="20" font="0">response rates and MEMS data over </text>
<text top="269" left="698" width="136" height="20" font="0">30-d intervention period. </text>
<text top="286" left="698" width="3" height="20" font="0"> </text>
<text top="305" left="698" width="7" height="18" font="0">•</text>
<text top="305" left="705" width="194" height="20" font="0"> Patients receiving educational and </text>
<text top="322" left="698" width="152" height="20" font="0">reminder text messages for </text>
<text top="339" left="698" width="206" height="20" font="0">antiplatelets had a higher percentage </text>
<text top="356" left="698" width="198" height="20" font="0">of correct doses taken (p=0.02) and </text>
<text top="373" left="698" width="209" height="20" font="0">percentage of prescribed doses taken </text>
<text top="391" left="698" width="191" height="20" font="0">on schedule (p=0.01) compared to </text>
<text top="408" left="698" width="103" height="20" font="0">the No TM group.  </text>
<text top="425" left="698" width="3" height="20" font="0"> </text>
<text top="444" left="698" width="7" height="18" font="0">•</text>
<text top="444" left="705" width="139" height="20" font="0"> TM response rates were </text>
<text top="461" left="698" width="195" height="20" font="0">significantly higher for anti-platelets </text>
<text top="478" left="698" width="206" height="20" font="0">than statins (p=0.005), which authors </text>
<text top="495" left="698" width="190" height="20" font="0">attribute to the fact that statins are </text>
<text top="512" left="698" width="152" height="20" font="0">prescribed for the evening. <b> </b></text>
<text top="216" left="921" width="151" height="20" font="7"><b>Study limitations: </b>(1) Low </text>
<text top="233" left="921" width="174" height="20" font="0">frequency of analyzable MEMS </text>
<text top="251" left="921" width="193" height="20" font="0">data caused by poor usage among </text>
<text top="268" left="921" width="191" height="20" font="0">patients recruited in acute-settings </text>
<text top="285" left="921" width="148" height="20" font="0">and/or patients resistant to </text>
<text top="302" left="921" width="148" height="20" font="0">changing habit of using pill </text>
<text top="320" left="921" width="189" height="20" font="0">organizers. (2) Small convenience </text>
<text top="337" left="921" width="185" height="20" font="0">sample could undermine external </text>
<text top="354" left="921" width="176" height="20" font="0">validity of the findings to a more </text>
<text top="371" left="921" width="185" height="20" font="0">diverse group. (3) Short follow-up </text>
<text top="388" left="921" width="137" height="20" font="0">period does not allow for </text>
<text top="406" left="921" width="148" height="20" font="0">measurement of long-term </text>
<text top="423" left="921" width="154" height="20" font="0">adherence trends or clinical </text>
<text top="440" left="921" width="185" height="20" font="0">outcomes. (4) Use of MEMS may </text>
<text top="457" left="921" width="132" height="20" font="0">have added attention to </text>
<text top="475" left="921" width="191" height="20" font="0">medication-taking habits across all </text>
<text top="492" left="921" width="48" height="20" font="0">groups.  </text>
<text top="509" left="921" width="3" height="20" font="0"> </text>
<text top="622" left="89" width="58" height="20" font="7"><b>ORBITAL </b></text>
<text top="639" left="89" width="96" height="20" font="0">Willich SN, et al., </text>
<text top="657" left="89" width="63" height="20" font="0">2009<a href="data supplement.html#251"> (258)</a> </text>
<text top="674" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19174696">19174696</a></text>
<text top="674" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19174696"> </a></text>
<text top="691" left="89" width="3" height="20" font="0"> </text>
<text top="622" left="217" width="120" height="20" font="7"><b>Aim:</b> To measure the </text>
<text top="639" left="217" width="124" height="20" font="0">effect of a compliance-</text>
<text top="657" left="217" width="127" height="20" font="0">enhancing program on </text>
<text top="674" left="217" width="128" height="20" font="0">the level of lipid control </text>
<text top="691" left="217" width="100" height="20" font="0">for patients taking </text>
<text top="708" left="217" width="73" height="20" font="0">rosuvastatin. </text>
<text top="725" left="217" width="3" height="20" font="0"> </text>
<text top="743" left="217" width="115" height="20" font="7"><b>Study type:</b> Parallel </text>
<text top="760" left="217" width="124" height="20" font="0">randomized controlled </text>
<text top="777" left="217" width="64" height="20" font="0">clinical trial </text>
<text top="622" left="368" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="641" left="368" width="7" height="18" font="0">•</text>
<text top="641" left="375" width="121" height="20" font="0"> LDL-C ≥ 115 mg/dl if </text>
<text top="658" left="368" width="66" height="20" font="0">statin naïve </text>
<text top="677" left="368" width="7" height="18" font="0">•</text>
<text top="676" left="375" width="111" height="20" font="0"> LDL-C ≥ 125 mg/dl </text>
<text top="693" left="368" width="56" height="20" font="0">otherwise </text>
<text top="712" left="368" width="7" height="18" font="0">•</text>
<text top="712" left="375" width="132" height="20" font="0"> Participants had one of </text>
<text top="729" left="368" width="138" height="20" font="0">the following risk factors: </text>
<text top="746" left="368" width="129" height="20" font="0">history of CHD or other </text>
<text top="763" left="368" width="150" height="20" font="0">atherosclerotic disease, 10-</text>
<text top="622" left="539" width="78" height="20" font="7"><b>Intervention:</b> </text>
<text top="639" left="539" width="129" height="20" font="0">Rosuvastatin 10/20 mg </text>
<text top="657" left="539" width="140" height="20" font="0">with compliance program </text>
<text top="674" left="539" width="131" height="20" font="0">(videotape, educational </text>
<text top="691" left="539" width="138" height="20" font="0">leaflet, information about </text>
<text top="708" left="539" width="103" height="20" font="0">free phone patient </text>
<text top="725" left="539" width="118" height="20" font="0">helpline and website, </text>
<text top="743" left="539" width="126" height="20" font="0">labels with reminder to </text>
<text top="760" left="539" width="119" height="20" font="0">take medication) (n = </text>
<text top="777" left="539" width="35" height="20" font="0">4064) </text>
<text top="623" left="698" width="204" height="20" font="7"><b>1</b>°<b> endpoint:</b> Medication adherence, </text>
<text top="641" left="698" width="149" height="20" font="0">expressed as proportion of </text>
<text top="658" left="698" width="202" height="20" font="0">participants who were adherent at 3, </text>
<text top="675" left="698" width="75" height="20" font="0">6, and 12 mo </text>
<text top="692" left="698" width="3" height="20" font="0"> </text>
<text top="711" left="698" width="7" height="18" font="0">•</text>
<text top="711" left="705" width="170" height="20" font="0"> Compliance program effective </text>
<text top="728" left="698" width="199" height="20" font="0">among statin-naïve patients at 3 mo </text>
<text top="745" left="698" width="183" height="20" font="0">(80% vs. 76%, p&lt;0.01) and 6 mo </text>
<text top="762" left="698" width="164" height="20" font="0">(78% vs. 73%, p&lt;0.01), when </text>
<text top="622" left="921" width="107" height="20" font="7"><b>Study limitations:</b> </text>
<text top="639" left="921" width="3" height="20" font="0"> </text>
</page>
<page number="216" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">216 </text>
<text top="107" left="217" width="3" height="20" font="0"> </text>
<text top="124" left="217" width="39" height="20" font="7"><b>Size:</b>   </text>
<text top="141" left="217" width="105" height="20" font="0">N recruited = 8108 </text>
<text top="159" left="217" width="121" height="20" font="0">N randomized = 8108 </text>
<text top="176" left="217" width="129" height="20" font="0">N reported outcomes = </text>
<text top="193" left="217" width="31" height="20" font="0">6872 </text>
<text top="107" left="368" width="115" height="20" font="0">y CHD risk Z20%, or </text>
<text top="124" left="368" width="50" height="20" font="0">diabetes </text>
<text top="141" left="368" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="160" left="368" width="7" height="18" font="0">•</text>
<text top="160" left="375" width="151" height="20" font="0"> Fasting triglycerides &gt; 400 </text>
<text top="177" left="368" width="33" height="20" font="0">mg/dl </text>
<text top="196" left="368" width="7" height="18" font="0">•</text>
<text top="195" left="375" width="124" height="20" font="0"> Familial or secondary </text>
<text top="213" left="368" width="120" height="20" font="0">hypercholesterolemia </text>
<text top="232" left="368" width="7" height="18" font="0">•</text>
<text top="231" left="375" width="112" height="20" font="0"> Active liver disease </text>
<text top="248" left="368" width="131" height="20" font="0">(elevations of aspartate </text>
<text top="265" left="368" width="156" height="20" font="0">aminotransferase or alanine </text>
<text top="283" left="368" width="103" height="20" font="0">aminotransferase) </text>
<text top="107" left="539" width="7" height="20" font="0">  </text>
<text top="124" left="539" width="77" height="20" font="7"><b>Comparator:</b> </text>
<text top="141" left="539" width="129" height="20" font="0">Rosuvastatin 10/20 mg </text>
<text top="159" left="539" width="108" height="20" font="0">without compliance </text>
<text top="176" left="539" width="109" height="20" font="0">program (n = 4044) </text>
<text top="193" left="539" width="7" height="20" font="7"><b>  </b></text>
<text top="107" left="698" width="206" height="20" font="0">compared with control group, but had </text>
<text top="124" left="698" width="167" height="20" font="0">no significant effect at 12 mo.  </text>
<text top="141" left="698" width="3" height="20" font="7"><b> </b></text>
<text top="301" left="89" width="100" height="20" font="0">Ma Y, et al., 2010 </text>
<text top="318" left="89" width="32" height="20" font="0"><a href="data supplement.html#251">(259)</a> </text>
<text top="335" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21490915">21490915</a></text>
<text top="335" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21490915"> </a></text>
<text top="352" left="89" width="3" height="20" font="0"> </text>
<text top="301" left="217" width="119" height="20" font="7"><b>Aim:</b> To evaluate the </text>
<text top="318" left="217" width="133" height="20" font="0">efficacy of a pharmacist-</text>
<text top="335" left="217" width="133" height="20" font="0">delivered intervention in </text>
<text top="352" left="217" width="122" height="20" font="0">improving LDL-C goal </text>
<text top="370" left="217" width="64" height="20" font="0">attainment. </text>
<text top="387" left="217" width="3" height="20" font="0"> </text>
<text top="404" left="217" width="115" height="20" font="7"><b>Study type:</b> Parallel </text>
<text top="421" left="217" width="124" height="20" font="0">randomized controlled </text>
<text top="438" left="217" width="64" height="20" font="0">clinical trial </text>
<text top="456" left="217" width="3" height="20" font="0"> </text>
<text top="473" left="217" width="32" height="20" font="7"><b>Size:</b> </text>
<text top="490" left="217" width="98" height="20" font="0">N recruited = 689 </text>
<text top="507" left="217" width="114" height="20" font="0">N randomized = 689 </text>
<text top="524" left="217" width="129" height="20" font="0">N reported outcomes = </text>
<text top="542" left="217" width="24" height="20" font="0">559 </text>
<text top="301" left="368" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="320" left="368" width="7" height="18" font="0">•</text>
<text top="319" left="375" width="86" height="20" font="0"> 30-85 y of age </text>
<text top="338" left="368" width="7" height="18" font="0">•</text>
<text top="337" left="375" width="120" height="20" font="0"> CHD (defined as ≥ 1 </text>
<text top="355" left="368" width="140" height="20" font="0">coronary lesion ≥ 50% at </text>
<text top="372" left="368" width="112" height="20" font="0">the time of coronary </text>
<text top="389" left="368" width="70" height="20" font="0">angioplasty) </text>
<text top="406" left="368" width="3" height="20" font="0"> </text>
<text top="423" left="368" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="442" left="368" width="7" height="18" font="0">•</text>
<text top="442" left="375" width="150" height="20" font="0"> Unable or unwilling to give </text>
<text top="459" left="368" width="155" height="20" font="0">informed consent in English </text>
<text top="478" left="368" width="7" height="18" font="0">•</text>
<text top="477" left="375" width="136" height="20" font="0"> History of intolerance to </text>
<text top="495" left="368" width="135" height="20" font="0">two or more statin drugs </text>
<text top="514" left="368" width="7" height="18" font="0">•</text>
<text top="513" left="375" width="133" height="20" font="0"> Planned to move out of </text>
<text top="530" left="368" width="117" height="20" font="0">the area within 1 y of </text>
<text top="547" left="368" width="68" height="20" font="0">recruitment  </text>
<text top="566" left="368" width="7" height="18" font="0">•</text>
<text top="566" left="375" width="146" height="20" font="0"> Estimated life expectancy </text>
<text top="583" left="368" width="30" height="20" font="0">&lt; 5 y </text>
<text top="602" left="368" width="7" height="18" font="0">•</text>
<text top="601" left="375" width="137" height="20" font="0"> Major psychiatric illness </text>
<text top="620" left="368" width="7" height="18" font="0">•</text>
<text top="620" left="375" width="80" height="20" font="0"> No telephone </text>
<text top="301" left="539" width="78" height="20" font="7"><b>Intervention:</b> </text>
<text top="318" left="539" width="119" height="20" font="0">Pharmacist-delivered </text>
<text top="335" left="539" width="126" height="20" font="0">intervention (PI). Initial </text>
<text top="352" left="539" width="127" height="20" font="0">inpatient contact and 5 </text>
<text top="370" left="539" width="92" height="20" font="0">patient-centered </text>
<text top="387" left="539" width="118" height="20" font="0">pharmacist-delivered </text>
<text top="404" left="539" width="120" height="20" font="0">telephone counseling </text>
<text top="421" left="539" width="138" height="20" font="0">calls after discharge (n = </text>
<text top="438" left="539" width="28" height="20" font="0">338) </text>
<text top="456" left="539" width="7" height="20" font="0">  </text>
<text top="473" left="539" width="123" height="20" font="7"><b>Comparator: </b>Routine </text>
<text top="490" left="539" width="125" height="20" font="0">care as determined by </text>
<text top="507" left="539" width="130" height="20" font="0">provider (UC) (n = 331)<b> </b></text>
<text top="302" left="698" width="202" height="20" font="7"><b>1</b>°<b> endpoint:</b> Percentage of patients </text>
<text top="319" left="698" width="201" height="20" font="0">with serum LDL-C &lt; 100 mg/dl at 12 </text>
<text top="336" left="698" width="27" height="20" font="0">mo.  </text>
<text top="353" left="698" width="3" height="20" font="0"> </text>
<text top="373" left="698" width="7" height="18" font="0">•</text>
<text top="372" left="705" width="153" height="20" font="0"> There was not a significant </text>
<text top="389" left="698" width="180" height="20" font="0">difference between patients who </text>
<text top="406" left="698" width="180" height="20" font="0">received the intervention (64.51) </text>
<text top="423" left="698" width="191" height="20" font="0">when compared to those receiving </text>
<text top="441" left="698" width="197" height="20" font="0">routine care (60.15) (p=0.293, FET) </text>
<text top="458" left="698" width="171" height="20" font="0">in terms of meeting cholesterol </text>
<text top="475" left="698" width="44" height="20" font="0">targets. </text>
<text top="492" left="698" width="3" height="20" font="7"><b> </b></text>
<text top="302" left="921" width="157" height="20" font="7"><b>2</b>°<b> endpoint:</b> CMA for statin </text>
<text top="319" left="921" width="174" height="20" font="0">medication use was 0.88 (SD = </text>
<text top="336" left="921" width="174" height="20" font="0">0.3) for PI group vs. 0.90 (SD = </text>
<text top="354" left="921" width="127" height="20" font="0">0.03) for UC (p=0.51).  </text>
<text top="371" left="921" width="3" height="20" font="0"> </text>
<text top="388" left="921" width="159" height="20" font="7"><b>Study limitations: </b>(1) Small </text>
<text top="405" left="921" width="177" height="20" font="0">sample size available for LDL-C </text>
<text top="422" left="921" width="177" height="20" font="0">outcome limited power to detect </text>
<text top="440" left="921" width="161" height="20" font="0">level of LDL-C difference; (2) </text>
<text top="457" left="921" width="192" height="20" font="0">Limitations of using pharmacy refill </text>
<text top="474" left="921" width="178" height="20" font="0">data – no information to indicate </text>
<text top="491" left="921" width="176" height="20" font="0">whether dispensed medications </text>
<text top="508" left="921" width="192" height="20" font="0">were actually taken by patients, no </text>
<text top="526" left="921" width="195" height="20" font="0">information for patients who did not </text>
<text top="543" left="921" width="174" height="20" font="0">fill prescriptions; (3) No data on </text>
<text top="560" left="921" width="174" height="20" font="0">cost of medication or insurance </text>
<text top="577" left="921" width="161" height="20" font="0">coverage; (4) Study does not </text>
<text top="594" left="921" width="135" height="20" font="0">account for effects of co-</text>
<text top="612" left="921" width="196" height="20" font="0">management (e.g., by pharmacists, </text>
<text top="629" left="921" width="169" height="20" font="0">cardiologists, etc.); (5) No lipid </text>
<text top="646" left="921" width="196" height="20" font="0">levels at baseline to account for the </text>
<text top="663" left="921" width="195" height="20" font="0">drop in LDL-C following acute CHD </text>
<text top="680" left="921" width="195" height="20" font="0">event; (6) Majority of study patients </text>
<text top="698" left="921" width="195" height="20" font="0">Caucasian, limiting generalizability; </text>
<text top="715" left="921" width="172" height="20" font="0">(7) Possibility of selection bias, </text>
<text top="732" left="921" width="185" height="20" font="0">explaining high adherence rate in </text>
<text top="749" left="921" width="79" height="20" font="0">control group. </text>
<text top="766" left="921" width="3" height="20" font="0"> </text>
</page>
<page number="217" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="22" size="12" family="Times" color="#ff0000"/>
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">217 </text>
<text top="107" left="89" width="97" height="20" font="0">Nieuwkerk PT, et </text>
<text top="124" left="89" width="83" height="20" font="0">al., 2012<a href="data supplement.html#251"> (253)</a> </text>
<text top="141" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=nieuwkerk+2012+intervention+to+improve+adherence">22621795</a></text>
<text top="141" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=nieuwkerk+2012+intervention+to+improve+adherence"> </a></text>
<text top="159" left="89" width="7" height="20" font="0">  </text>
<text top="176" left="89" width="3" height="20" font="0"> </text>
<text top="193" left="89" width="3" height="20" font="0"> </text>
<text top="107" left="217" width="119" height="20" font="7"><b>Aim:</b> To evaluate the </text>
<text top="124" left="217" width="122" height="20" font="0">potential for nurse-led </text>
<text top="141" left="217" width="123" height="20" font="0">counseling to improve </text>
<text top="159" left="217" width="118" height="20" font="0">statin adherence and </text>
<text top="176" left="217" width="102" height="20" font="0">lipid levels without </text>
<text top="193" left="217" width="102" height="20" font="0">increasing anxiety </text>
<text top="210" left="217" width="38" height="20" font="0">levels. </text>
<text top="227" left="217" width="3" height="20" font="0"> </text>
<text top="245" left="217" width="115" height="20" font="7"><b>Study type:</b> Parallel </text>
<text top="262" left="217" width="124" height="20" font="0">randomized controlled </text>
<text top="279" left="217" width="67" height="20" font="0">clinical trial  </text>
<text top="296" left="217" width="3" height="20" font="0"> </text>
<text top="314" left="217" width="39" height="20" font="7"><b>Size:</b>   </text>
<text top="331" left="217" width="98" height="20" font="0">N recruited = 201 </text>
<text top="348" left="217" width="114" height="20" font="0">N randomized = 201 </text>
<text top="365" left="217" width="129" height="20" font="0">N reported outcomes = </text>
<text top="382" left="217" width="24" height="20" font="0">181 </text>
<text top="107" left="368" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="126" left="368" width="7" height="18" font="0">•</text>
<text top="125" left="375" width="79" height="20" font="0"> ≥ 18 y of age </text>
<text top="144" left="368" width="7" height="18" font="0">•</text>
<text top="144" left="375" width="133" height="20" font="0"> Indication for statin use </text>
<text top="161" left="368" width="125" height="20" font="0">(1° or 2° prevention of </text>
<text top="178" left="368" width="120" height="20" font="0">cardiovascular event) </text>
<text top="195" left="368" width="3" height="20" font="0"> </text>
<text top="213" left="368" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="232" left="368" width="7" height="18" font="0">•</text>
<text top="231" left="375" width="85" height="20" font="0"> Severe fasting </text>
<text top="248" left="368" width="102" height="20" font="0">dyslipidemia (total </text>
<text top="265" left="368" width="149" height="20" font="0">cholesterol &gt;9.0 mmol/L or </text>
<text top="283" left="368" width="138" height="20" font="0">triglyceride &gt;4.0 mmol/L) </text>
<text top="302" left="368" width="7" height="18" font="0">•</text>
<text top="301" left="375" width="138" height="20" font="0"> Statin use &gt;3 mo before </text>
<text top="318" left="368" width="51" height="20" font="0">inclusion </text>
<text top="337" left="368" width="7" height="18" font="0">•</text>
<text top="337" left="375" width="125" height="20" font="0"> History of drug and/or </text>
<text top="354" left="368" width="79" height="20" font="0">alcohol abuse </text>
<text top="373" left="368" width="7" height="18" font="0">•</text>
<text top="372" left="375" width="149" height="20" font="0"> Pregnant or breastfeeding </text>
<text top="390" left="368" width="3" height="20" font="0"> </text>
<text top="107" left="539" width="133" height="20" font="7"><b>Intervention:</b> Extended </text>
<text top="124" left="539" width="110" height="20" font="0">Care (EC). Patients </text>
<text top="141" left="539" width="122" height="20" font="0">received multifactorial </text>
<text top="159" left="539" width="112" height="20" font="0">(modifiable and non-</text>
<text top="176" left="539" width="121" height="20" font="0">modifiable) risk-factor </text>
<text top="193" left="539" width="105" height="20" font="0">counselling by NP. </text>
<text top="210" left="539" width="131" height="20" font="0">Counselling focused on </text>
<text top="228" left="539" width="122" height="20" font="0">increasing medication </text>
<text top="245" left="539" width="116" height="20" font="0">adherence, reducing </text>
<text top="262" left="539" width="115" height="20" font="0">overweight, smoking </text>
<text top="279" left="539" width="142" height="20" font="0">cessation, and increasing </text>
<text top="296" left="539" width="121" height="20" font="0">physical activity. Data </text>
<text top="314" left="539" width="138" height="20" font="0">summarized in “personal </text>
<text top="331" left="539" width="126" height="20" font="0">risk-factor passport,” a </text>
<text top="348" left="539" width="138" height="20" font="0">graphical presentation of </text>
<text top="365" left="539" width="136" height="20" font="0">10-y CVD risk. (n = 100) </text>
<text top="382" left="539" width="3" height="20" font="0"> </text>
<text top="400" left="539" width="7" height="20" font="0">  </text>
<text top="417" left="539" width="123" height="20" font="7"><b>Comparator:</b> Routine </text>
<text top="434" left="539" width="141" height="20" font="0">Care (RC). Measurement </text>
<text top="451" left="539" width="120" height="20" font="0">of body weight, blood </text>
<text top="469" left="539" width="128" height="20" font="0">pressure, capillary lipid </text>
<text top="486" left="539" width="126" height="20" font="0">profile at each visit. All </text>
<text top="503" left="539" width="134" height="20" font="0">patients received 10 mg </text>
<text top="520" left="539" width="109" height="20" font="0">atorvastatin, unless </text>
<text top="537" left="539" width="112" height="20" font="0">baseline cholesterol </text>
<text top="555" left="539" width="119" height="20" font="0">levels indicated more </text>
<text top="572" left="539" width="111" height="20" font="0">aggressive therapy. </text>
<text top="589" left="539" width="99" height="20" font="0">Subsequent dose </text>
<text top="606" left="539" width="132" height="20" font="0">escalation was allowed, </text>
<text top="623" left="539" width="94" height="20" font="0">as deemed fit by </text>
<text top="641" left="539" width="111" height="20" font="0">providers. (n = 101) </text>
<text top="658" left="539" width="3" height="20" font="7"><b> </b></text>
<text top="108" left="698" width="152" height="20" font="7"><b>1</b>°<b> endpoints:</b> Serum LDL; </text>
<text top="125" left="698" width="151" height="20" font="0">Adherence to lipid lowering </text>
<text top="143" left="698" width="181" height="20" font="0">medication (subjects asked what </text>
<text top="160" left="698" width="193" height="20" font="0">percentage of their prescribed lipid-</text>
<text top="177" left="698" width="209" height="20" font="0">lowering medications they took during </text>
<text top="194" left="698" width="168" height="20" font="0">the past month, 1 = &lt;30%, 9 = </text>
<text top="212" left="698" width="159" height="20" font="0">100%). Both measures were </text>
<text top="229" left="698" width="187" height="20" font="0">averaged over follow-up (mo 3, 9, </text>
<text top="246" left="698" width="52" height="20" font="0">and 18).  </text>
<text top="263" left="698" width="3" height="20" font="0"> </text>
<text top="282" left="698" width="7" height="18" font="0">•</text>
<text top="281" left="705" width="199" height="20" font="0"> Among 1° prevention patients, LDL </text>
<text top="299" left="698" width="203" height="20" font="0">levels were significantly lower for EC </text>
<text top="316" left="698" width="187" height="20" font="0">group (3.0 ± 0.10 mmol/L) vs. RC </text>
<text top="333" left="698" width="210" height="20" font="0">group (2.66 ± 0.10 mmol/L) (p&lt;0.05).  </text>
<text top="350" left="698" width="3" height="20" font="0"> </text>
<text top="369" left="698" width="7" height="18" font="0">•</text>
<text top="369" left="705" width="144" height="20" font="0"> Adherence to statins was </text>
<text top="386" left="698" width="186" height="20" font="0">significantly higher for EC (4.90 ± </text>
<text top="403" left="698" width="199" height="20" font="0">0.05) vs. RC (4.60 ± 0.05) (p&lt;0.01). </text>
<text top="420" left="698" width="3" height="20" font="0"> </text>
<text top="438" left="698" width="3" height="20" font="7"><b> </b></text>
<text top="108" left="921" width="151" height="20" font="7"><b>2</b>°<b> endpoints</b>: Anxiety was </text>
<text top="125" left="921" width="183" height="20" font="0">significantly lower (p&lt;0.01) in the </text>
<text top="143" left="921" width="109" height="20" font="0">intervention group.  </text>
<text top="160" left="921" width="3" height="20" font="0"> </text>
<text top="177" left="921" width="3" height="20" font="0"> </text>
<text top="194" left="921" width="186" height="20" font="7"><b>Study limitations: </b>(1) Self-report </text>
<text top="211" left="921" width="186" height="20" font="0">was used to assess adherence to </text>
<text top="229" left="921" width="167" height="20" font="0">statin, known to over-estimate </text>
<text top="246" left="921" width="166" height="20" font="0">adherence when compared to </text>
<text top="263" left="921" width="190" height="20" font="0">more objective measures. Authors </text>
<text top="280" left="921" width="150" height="20" font="0">note significant association </text>
<text top="298" left="921" width="184" height="20" font="0">between self-reported adherence </text>
<text top="315" left="921" width="169" height="20" font="0">and LDL cholesterol, however, </text>
<text top="332" left="921" width="188" height="20" font="0">which supports the validity of their </text>
<text top="349" left="921" width="168" height="20" font="0">measure. (2) Framingham risk </text>
<text top="367" left="921" width="163" height="20" font="0">score may not be appropriate </text>
<text top="384" left="921" width="196" height="20" font="0">estimate for cardiovascular disease </text>
<text top="401" left="921" width="185" height="20" font="0">among patients with known CVD. </text>
<text top="418" left="921" width="194" height="20" font="0">(3) Multiple comparisons may have </text>
<text top="435" left="921" width="192" height="20" font="0">produced false-positive results. (4) </text>
<text top="453" left="921" width="180" height="20" font="0">Target levels for LDL cholesterol </text>
<text top="470" left="921" width="189" height="20" font="0">are currently lower than they were </text>
<text top="487" left="921" width="135" height="20" font="0">at the time of the study.  </text>
<text top="676" left="89" width="91" height="20" font="0">Kooy MJ,  et al., </text>
<text top="693" left="89" width="63" height="20" font="0">2013<a href="data supplement.html#251"> (260)</a> </text>
<text top="710" left="89" width="48" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665928/">3665928</a></text>
<text top="710" left="137" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665928/"> </a></text>
<text top="727" left="89" width="3" height="20" font="22"> </text>
<text top="745" left="89" width="3" height="20" font="22"> </text>
<text top="745" left="93" width="3" height="20" font="0"> </text>
<text top="676" left="217" width="119" height="20" font="7"><b>Aim:</b> To evaluate the </text>
<text top="693" left="217" width="135" height="20" font="0">ability of an ERD with or </text>
<text top="710" left="217" width="118" height="20" font="0">without counseling to </text>
<text top="727" left="217" width="127" height="20" font="0">improve adherence for </text>
<text top="745" left="217" width="126" height="20" font="0">statin treatment in non-</text>
<text top="762" left="217" width="105" height="20" font="0">adherent patients.  </text>
<text top="676" left="368" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="695" left="368" width="7" height="18" font="0">•</text>
<text top="694" left="375" width="79" height="20" font="0"> ≥ 65 y of age </text>
<text top="713" left="368" width="7" height="18" font="0">•</text>
<text top="713" left="375" width="137" height="20" font="0"> Started statin therapy at </text>
<text top="730" left="368" width="124" height="20" font="0">least 1 y prior to study </text>
<text top="749" left="368" width="7" height="18" font="0">•</text>
<text top="748" left="375" width="143" height="20" font="0"> Non-adherent in the year </text>
<text top="765" left="368" width="129" height="20" font="0">prior to study (refill rate </text>
<text top="783" left="368" width="103" height="20" font="0">between 50-80%). </text>
<text top="676" left="539" width="81" height="20" font="7"><b>Intervention:</b>  </text>
<text top="695" left="539" width="7" height="18" font="0">•</text>
<text top="694" left="546" width="134" height="20" font="0"> ERD: Patients received </text>
<text top="711" left="539" width="137" height="20" font="0">ERD by mail with written </text>
<text top="729" left="539" width="139" height="20" font="0">instructions for use. ERD </text>
<text top="746" left="539" width="139" height="20" font="0">beeped at the same time </text>
<text top="763" left="539" width="123" height="20" font="0">every day until patient </text>
<text top="780" left="539" width="121" height="20" font="0">turned it off. (n = 131) </text>
<text top="677" left="698" width="186" height="20" font="7"><b>1</b>°<b> endpoint:</b> Refill adherence for </text>
<text top="694" left="698" width="207" height="20" font="0">statin treatment for 360-d period after </text>
<text top="711" left="698" width="209" height="20" font="0">inclusion (refill rate ≥ 80% considered </text>
<text top="729" left="698" width="56" height="20" font="0">adherent) </text>
<text top="746" left="698" width="3" height="20" font="0"> </text>
<text top="765" left="698" width="7" height="18" font="0">•</text>
<text top="764" left="705" width="199" height="20" font="0"> The proportion of adherent patients </text>
<text top="781" left="698" width="184" height="20" font="0">was not significantly higher in the </text>
<text top="676" left="921" width="160" height="20" font="7"><b>Study limitations</b>: (1) Some </text>
<text top="693" left="921" width="178" height="20" font="0">pharmacists did not follow study </text>
<text top="710" left="921" width="194" height="20" font="0">protocol. Only 54 of the 116 invited </text>
<text top="727" left="921" width="162" height="20" font="0">patients actually received the </text>
<text top="745" left="921" width="187" height="20" font="0">counseling; (2) Small sample size </text>
<text top="762" left="921" width="180" height="20" font="0">could limit power to demonstrate </text>
<text top="779" left="921" width="158" height="20" font="0">statistically significant effect; </text>
</page>
<page number="218" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">218 </text>
<text top="107" left="217" width="115" height="20" font="7"><b>Study type:</b> Parallel </text>
<text top="124" left="217" width="124" height="20" font="0">randomized controlled </text>
<text top="141" left="217" width="64" height="20" font="0">clinical trial </text>
<text top="159" left="217" width="3" height="20" font="0"> </text>
<text top="176" left="217" width="36" height="20" font="7"><b>Size:</b>  </text>
<text top="193" left="217" width="98" height="20" font="0">N recruited = 399 </text>
<text top="210" left="217" width="114" height="20" font="0">N randomized = 399 </text>
<text top="228" left="217" width="129" height="20" font="0">N reported outcomes = </text>
<text top="245" left="217" width="27" height="20" font="0">381  </text>
<text top="107" left="368" width="7" height="20" font="0">  </text>
<text top="124" left="368" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="143" left="368" width="7" height="18" font="0">•</text>
<text top="143" left="375" width="132" height="20" font="0"> Persons not personally </text>
<text top="160" left="368" width="147" height="20" font="0">responsible for medication </text>
<text top="177" left="368" width="36" height="20" font="0">intake </text>
<text top="196" left="368" width="7" height="18" font="0">•</text>
<text top="195" left="375" width="123" height="20" font="0"> Life expectancy &lt; 5 y </text>
<text top="214" left="368" width="7" height="18" font="0">•</text>
<text top="214" left="375" width="78" height="20" font="0"> &lt; 65 y of age </text>
<text top="233" left="368" width="7" height="18" font="0">•</text>
<text top="232" left="375" width="152" height="20" font="0"> Patients who had changed </text>
<text top="249" left="368" width="145" height="20" font="0">statins in the 540 d before </text>
<text top="267" left="368" width="55" height="20" font="0">inclusion  </text>
<text top="109" left="539" width="7" height="18" font="0">•</text>
<text top="108" left="546" width="125" height="20" font="0"> ERD and Counseling: </text>
<text top="125" left="539" width="128" height="20" font="0">Patients participated in </text>
<text top="143" left="539" width="103" height="20" font="0">10-min counseling </text>
<text top="160" left="539" width="134" height="20" font="0">session with pharmacist </text>
<text top="177" left="539" width="107" height="20" font="0">based on stages of </text>
<text top="194" left="539" width="132" height="20" font="0">change model. Patients </text>
<text top="212" left="539" width="142" height="20" font="0">received ERD device and </text>
<text top="229" left="539" width="135" height="20" font="0">instructions for use. (n = </text>
<text top="246" left="539" width="28" height="20" font="0">134) </text>
<text top="263" left="539" width="7" height="20" font="0">  </text>
<text top="280" left="539" width="142" height="20" font="7"><b>Comparator:</b> Usual Care </text>
<text top="298" left="539" width="130" height="20" font="0">(UC). Patients received </text>
<text top="315" left="539" width="143" height="20" font="0">information about therapy </text>
<text top="332" left="539" width="141" height="20" font="0">and medication at start of </text>
<text top="349" left="539" width="101" height="20" font="0">therapy. (n = 134) </text>
<text top="366" left="539" width="3" height="20" font="7"><b> </b></text>
<text top="107" left="698" width="190" height="20" font="0">ERD group (72.4%, p=0.18) or the </text>
<text top="124" left="698" width="196" height="20" font="0">ERD and counseling group (69.2%, </text>
<text top="141" left="698" width="174" height="20" font="0">p=0.55), when compared to the </text>
<text top="159" left="698" width="125" height="20" font="0">control group (64.8%). </text>
<text top="178" left="698" width="7" height="18" font="0">•</text>
<text top="177" left="705" width="174" height="20" font="0"> For women using statins for 2° </text>
<text top="194" left="698" width="151" height="20" font="0">prevention, adherence was </text>
<text top="211" left="698" width="192" height="20" font="0">significantly higher among those in </text>
<text top="229" left="698" width="167" height="20" font="0">the ERD group (86.1%), when </text>
<text top="246" left="698" width="168" height="20" font="0">compared to the control group </text>
<text top="263" left="698" width="110" height="20" font="0">(52.6%) (p&lt;0.005).  </text>
<text top="280" left="698" width="3" height="20" font="0"> </text>
<text top="298" left="698" width="3" height="20" font="7"><b> </b></text>
<text top="107" left="921" width="188" height="20" font="0">(3) Some patients may have been </text>
<text top="124" left="921" width="168" height="20" font="0">selected as non-adherent who </text>
<text top="141" left="921" width="162" height="20" font="0">were actually more than 80% </text>
<text top="159" left="921" width="177" height="20" font="0">adherent; (4) Researchers were </text>
<text top="176" left="921" width="193" height="20" font="0">unaware of whether or not patients </text>
<text top="193" left="921" width="151" height="20" font="0">who received ERD with the </text>
<text top="210" left="921" width="173" height="20" font="0">instructions actually utilized the </text>
<text top="228" left="921" width="121" height="20" font="0">device; (5) Odds ratio </text>
<text top="245" left="921" width="192" height="20" font="0">overestimates the effect size when </text>
<text top="262" left="921" width="151" height="20" font="0">interpreted as relative risk.  </text>
<text top="279" left="921" width="3" height="20" font="0"> </text>
<text top="384" left="89" width="104" height="20" font="0">Pladevall M, et al., </text>
<text top="402" left="89" width="63" height="20" font="0">2015<a href="data supplement.html#251"> (261)</a> </text>
<text top="419" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722813/">28000212</a></text>
<text top="419" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722813/"> </a></text>
<text top="436" left="89" width="3" height="20" font="0"> </text>
<text top="453" left="89" width="3" height="20" font="22"> </text>
<text top="470" left="89" width="3" height="20" font="22"> </text>
<text top="488" left="89" width="3" height="20" font="7"><b> </b></text>
<text top="384" left="217" width="107" height="20" font="7"><b>Aim: </b>To determine </text>
<text top="402" left="217" width="134" height="20" font="0">whether the provision of </text>
<text top="419" left="217" width="126" height="20" font="0">adherence information </text>
<text top="436" left="217" width="82" height="20" font="0">with or without </text>
<text top="453" left="217" width="128" height="20" font="0">motivation interviewing </text>
<text top="470" left="217" width="129" height="20" font="0">has a positive effect on </text>
<text top="488" left="217" width="99" height="20" font="0">diabetes and lipid </text>
<text top="505" left="217" width="44" height="20" font="0">control. </text>
<text top="522" left="217" width="3" height="20" font="7"><b> </b></text>
<text top="539" left="217" width="115" height="20" font="7"><b>Study type: </b>Parallel </text>
<text top="557" left="217" width="124" height="20" font="0">randomized controlled </text>
<text top="574" left="217" width="67" height="20" font="0">clinical trial  </text>
<text top="591" left="217" width="3" height="20" font="7"><b> </b></text>
<text top="608" left="217" width="36" height="20" font="7"><b>Size:  </b></text>
<text top="625" left="217" width="105" height="20" font="0">N recruited = 3799 </text>
<text top="643" left="217" width="121" height="20" font="0">N randomized = 1692 </text>
<text top="660" left="217" width="129" height="20" font="0">N reported outcomes = </text>
<text top="677" left="217" width="31" height="20" font="0">1692<b> </b></text>
<text top="384" left="368" width="109" height="20" font="7"><b>Inclusion criteria:  </b></text>
<text top="403" left="368" width="7" height="18" font="0">•</text>
<text top="403" left="375" width="79" height="20" font="0"> ≥ 18 y of age </text>
<text top="422" left="368" width="7" height="18" font="0">•</text>
<text top="421" left="375" width="129" height="20" font="0"> Member of health plan </text>
<text top="438" left="368" width="146" height="20" font="0">with prescription coverage </text>
<text top="457" left="368" width="7" height="18" font="0">•</text>
<text top="457" left="375" width="144" height="20" font="0"> ≥ 1 HbA1c measurement </text>
<text top="474" left="368" width="138" height="20" font="0">with the last value ≥ 7%  </text>
<text top="493" left="368" width="7" height="18" font="0">•</text>
<text top="492" left="375" width="143" height="20" font="0"> ≥ 1 LDL-C measurement </text>
<text top="510" left="368" width="137" height="20" font="0">with the last value ≥ 100 </text>
<text top="527" left="368" width="38" height="20" font="0">mg/dL </text>
<text top="546" left="368" width="7" height="18" font="0">•</text>
<text top="545" left="375" width="139" height="20" font="0"> ≥ 1 Prescription for both </text>
<text top="562" left="368" width="154" height="20" font="0">an oral diabetes medication </text>
<text top="580" left="368" width="109" height="20" font="0">and a lipid-lowering </text>
<text top="597" left="368" width="70" height="20" font="0">medication.  </text>
<text top="614" left="368" width="3" height="20" font="7"><b> </b></text>
<text top="631" left="368" width="3" height="20" font="7"><b> </b></text>
<text top="648" left="368" width="114" height="20" font="7"><b>Exclusion criteria:  </b></text>
<text top="667" left="368" width="7" height="18" font="0">•</text>
<text top="667" left="375" width="93" height="20" font="0"> Hospice care or </text>
<text top="684" left="368" width="107" height="20" font="0">hospitalized ≥ 90 d </text>
<text top="703" left="368" width="7" height="18" font="0">•</text>
<text top="702" left="375" width="142" height="20" font="0"> Participation in any other </text>
<text top="719" left="368" width="134" height="20" font="0">study involving diabetes </text>
<text top="737" left="368" width="152" height="20" font="0">management or medication </text>
<text top="754" left="368" width="62" height="20" font="0">adherence </text>
<text top="773" left="368" width="7" height="18" font="0">•</text>
<text top="772" left="375" width="144" height="20" font="0"> Primary care provider did </text>
<text top="789" left="368" width="144" height="20" font="0">not consent to participate <b> </b></text>
<text top="384" left="539" width="81" height="20" font="7"><b>Intervention:  </b></text>
<text top="403" left="539" width="7" height="18" font="0">•</text>
<text top="403" left="546" width="131" height="20" font="0"> Adherence information </text>
<text top="420" left="539" width="131" height="20" font="0">provided to clinicians to </text>
<text top="437" left="539" width="143" height="20" font="0">discuss with patients (AI). </text>
<text top="454" left="539" width="53" height="20" font="0">(n = 569) </text>
<text top="473" left="539" width="7" height="18" font="0">•</text>
<text top="473" left="546" width="131" height="20" font="0"> Adherence information </text>
<text top="490" left="539" width="141" height="20" font="0">provided to clinicians and </text>
<text top="507" left="539" width="137" height="20" font="0">motivational interviewing </text>
<text top="524" left="539" width="130" height="20" font="0">provided to patients via </text>
<text top="542" left="539" width="134" height="20" font="0">nurses and pharmacists </text>
<text top="559" left="539" width="143" height="20" font="0">in “adherence clinic” (AI + </text>
<text top="576" left="539" width="78" height="20" font="0">MI). (n = 556)<b> </b></text>
<text top="593" left="539" width="7" height="20" font="7"><b>  </b></text>
<text top="610" left="539" width="139" height="20" font="7"><b>Comparator: </b>Usual care </text>
<text top="628" left="539" width="82" height="20" font="0">(UC) (n = 567) </text>
<text top="645" left="539" width="3" height="20" font="7"><b> </b></text>
<text top="386" left="698" width="196" height="20" font="7"><b>1</b>°<b> endpoints: </b>HbA1c; LDL-C at 18 </text>
<text top="403" left="698" width="24" height="20" font="0">mo. </text>
<text top="420" left="698" width="3" height="20" font="0"> </text>
<text top="439" left="698" width="7" height="18" font="0">•</text>
<text top="438" left="705" width="197" height="20" font="0"> HbA1c not significantly different for </text>
<text top="456" left="698" width="198" height="20" font="0">AI (7.91 ± 1.53, p=0.763) or AI + MI </text>
<text top="473" left="698" width="163" height="20" font="0">(7.79 ± 1.34, p=0.285), when </text>
<text top="490" left="698" width="179" height="20" font="0">compared with UC (7.88 ± 1.53) </text>
<text top="507" left="698" width="3" height="20" font="0"> </text>
<text top="526" left="698" width="7" height="18" font="0">•</text>
<text top="526" left="705" width="196" height="20" font="0"> LDL-C not significantly different for </text>
<text top="543" left="698" width="195" height="20" font="0">AI (87.27 ± 35.67, p=0.380) or AI + </text>
<text top="560" left="698" width="193" height="20" font="0">MI (85.56 ± 32.86, p=0.084), when </text>
<text top="577" left="698" width="193" height="20" font="0">compared with UC (89.02 ± 32.11) </text>
<text top="594" left="698" width="3" height="20" font="7"><b> </b></text>
<text top="384" left="921" width="196" height="20" font="7"><b>Study limitations</b>: (1) Possibility of </text>
<text top="402" left="921" width="179" height="20" font="0">selection bias toward individuals </text>
<text top="419" left="921" width="180" height="20" font="0">already motivated to change; (2) </text>
<text top="436" left="921" width="145" height="20" font="0">Study carried out in single </text>
<text top="453" left="921" width="188" height="20" font="0">integrated health system, may not </text>
<text top="470" left="921" width="191" height="20" font="0">be generalizable to other systems; </text>
<text top="488" left="921" width="192" height="20" font="0">(3) Significant baseline differences </text>
<text top="505" left="921" width="162" height="20" font="0">between randomized groups, </text>
<text top="522" left="921" width="196" height="20" font="0">although not thought to be clinically </text>
<text top="539" left="921" width="172" height="20" font="0">significant; (4) Measurement of </text>
<text top="557" left="921" width="153" height="20" font="0">primary laboratory outcome </text>
<text top="574" left="921" width="177" height="20" font="0">measures was not standardized </text>
<text top="591" left="921" width="187" height="20" font="0">and relied on PCPs ordering tests </text>
<text top="608" left="921" width="113" height="20" font="0">during routine care.  </text>
<text top="625" left="921" width="3" height="20" font="7"><b> </b></text>
</page>
<page number="219" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">219 </text>
<text top="106" left="88" width="1013" height="20" font="7"><b>Abbreviations: </b>1° indicated primary; 2° indicated secondary; CHD, coronary heart disease; CMA, continuous multiple interval; ERD, electronic reminder device; FET, Fisher’s exact test; </text>
<text top="123" left="88" width="1015" height="20" font="0">HbA1c, hemoglobin A1c; LDL-C, low density lipoprotein cholesterol; MEMS, medication event monitoring system; MI, myocardial infarction; N/A, not available; NP, nurse practitioner; PCI, </text>
<text top="141" left="88" width="721" height="20" font="0">percutaneous coronary intervention; PI, pharmacist-delivered intervention; RCT, randomized controlled trial; and TM, text message.  </text>
<text top="158" left="88" width="292" height="20" font="7"><b>Search Terms: </b>Cholesterol, adherence, compliance  </text>
<text top="175" left="88" width="120" height="20" font="7"><b>Date of Search</b>: 9/17 </text>
<text top="192" left="81" width="4" height="22" font="1"> </text>
<text top="211" left="81" width="4" height="22" font="1"> </text>
<text top="230" left="81" width="606" height="24" font="4"><b>Data Supplement 43. RCTs Comparing System Interventions to Usual Care (Section 6) </b></text>
<text top="260" left="97" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="277" left="123" width="48" height="20" font="7"><b>Author; </b></text>
<text top="295" left="100" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="260" left="244" width="83" height="20" font="7"><b>Aim of Study; </b></text>
<text top="277" left="249" width="74" height="20" font="7"><b>Study Type; </b></text>
<text top="295" left="243" width="86" height="20" font="7"><b>Study Size (N) </b></text>
<text top="277" left="391" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="252" left="557" width="111" height="20" font="7"><b>Study Intervention </b></text>
<text top="269" left="574" width="76" height="20" font="7"><b>(# patients) / </b></text>
<text top="286" left="557" width="111" height="20" font="7"><b>Study Comparator </b></text>
<text top="303" left="578" width="69" height="20" font="7"><b>(# patients) </b></text>
<text top="260" left="751" width="105" height="20" font="7"><b>Endpoint Results </b></text>
<text top="277" left="735" width="137" height="20" font="7"><b>(Absolute Event Rates, </b></text>
<text top="295" left="713" width="181" height="20" font="7"><b>P values; OR or RR; &amp; 95% CI) </b></text>
<text top="261" left="932" width="175" height="20" font="7"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="278" left="964" width="111" height="20" font="7"><b>Study Limitations; </b></text>
<text top="295" left="971" width="96" height="20" font="7"><b>Adverse Events </b></text>
<text top="321" left="89" width="100" height="20" font="0">Tamblyn R, et al., </text>
<text top="338" left="89" width="66" height="20" font="0">2010<a href="data supplement.html#251"> (262)</a>  </text>
<text top="356" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19675319">19675319</a></text>
<text top="356" left="144" width="7" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/19675319">  </a></text>
<text top="373" left="89" width="3" height="20" font="0"> </text>
<text top="390" left="89" width="3" height="20" font="0"> </text>
<text top="321" left="217" width="107" height="20" font="7"><b>Aim: </b>To determine </text>
<text top="338" left="217" width="118" height="20" font="0">whether integrating a </text>
<text top="356" left="217" width="83" height="20" font="0">cardiovascular </text>
<text top="373" left="217" width="133" height="20" font="0">medication tracking and </text>
<text top="390" left="217" width="93" height="20" font="0">alert system into </text>
<text top="407" left="217" width="102" height="20" font="0">electronic medical </text>
<text top="424" left="217" width="130" height="20" font="0">records would increase </text>
<text top="442" left="217" width="120" height="20" font="0">drug profile review by </text>
<text top="459" left="217" width="137" height="20" font="0">PCP, increase likelihood </text>
<text top="476" left="217" width="120" height="20" font="0">of therapy change, or </text>
<text top="493" left="217" width="116" height="20" font="0">improve adherence<b>. </b> </text>
<text top="511" left="217" width="3" height="20" font="7"><b> </b></text>
<text top="528" left="217" width="115" height="20" font="7"><b>Study type: </b>Parallel </text>
<text top="545" left="217" width="108" height="20" font="0">cluster-randomized </text>
<text top="562" left="217" width="83" height="20" font="0">controlled trial  </text>
<text top="579" left="217" width="3" height="20" font="7"><b> </b></text>
<text top="597" left="217" width="36" height="20" font="7"><b>Size:  </b></text>
<text top="614" left="217" width="111" height="20" font="0">N screened = 2138  </text>
<text top="631" left="217" width="121" height="20" font="0">N randomized = 2004 </text>
<text top="648" left="217" width="129" height="20" font="0">N reported outcomes = </text>
<text top="665" left="217" width="31" height="20" font="0">1921 </text>
<text top="683" left="217" width="3" height="20" font="0"> </text>
<text top="321" left="368" width="109" height="20" font="7"><b>Inclusion criteria:  </b></text>
<text top="340" left="368" width="7" height="18" font="0">•</text>
<text top="340" left="375" width="129" height="20" font="0"> Insured with provincial </text>
<text top="357" left="368" width="134" height="20" font="0">drug insurance program </text>
<text top="376" left="368" width="7" height="18" font="0">•</text>
<text top="375" left="375" width="150" height="20" font="0"> ≥ 1 active lipid-lowering or </text>
<text top="392" left="368" width="121" height="20" font="0">antihypertensive drug </text>
<text top="410" left="368" width="110" height="20" font="0">prescribed by study </text>
<text top="427" left="368" width="143" height="20" font="0">physician in 3 mo. prior to </text>
<text top="444" left="368" width="64" height="20" font="0">index visit.  </text>
<text top="461" left="368" width="3" height="20" font="0"> </text>
<text top="478" left="368" width="3" height="20" font="0"> </text>
<text top="496" left="368" width="114" height="20" font="7"><b>Exclusion criteria:  </b></text>
<text top="515" left="368" width="7" height="18" font="0">•</text>
<text top="514" left="375" width="31" height="20" font="0"> N/A  </text>
<text top="321" left="539" width="106" height="20" font="7"><b>Intervention</b>: PCP </text>
<text top="338" left="539" width="122" height="20" font="0">provided with detailed </text>
<text top="356" left="539" width="96" height="20" font="0">drug profile (total </text>
<text top="373" left="539" width="110" height="20" font="0">medication cost per </text>
<text top="390" left="539" width="115" height="20" font="0">month, out of pocket </text>
<text top="407" left="539" width="129" height="20" font="0">expenditure for patient, </text>
<text top="424" left="539" width="140" height="20" font="0">graphic representation of </text>
<text top="442" left="539" width="143" height="20" font="0">unfilled prescriptions, and </text>
<text top="459" left="539" width="130" height="20" font="0">days of supply for each </text>
<text top="476" left="539" width="111" height="20" font="0">medication); patient </text>
<text top="493" left="539" width="134" height="20" font="0">adherence calculated at </text>
<text top="511" left="539" width="113" height="20" font="0">each visit; physician </text>
<text top="528" left="539" width="108" height="20" font="0">alerted to check for </text>
<text top="545" left="539" width="111" height="20" font="0">potential adherence </text>
<text top="562" left="539" width="119" height="20" font="0">problems if treatment </text>
<text top="579" left="539" width="125" height="20" font="0">adherence &lt; 80% (n = </text>
<text top="597" left="539" width="38" height="20" font="0">1002). </text>
<text top="614" left="539" width="3" height="20" font="0"> </text>
<text top="631" left="539" width="130" height="20" font="7"><b>Comparator: </b>PCP had </text>
<text top="648" left="539" width="141" height="20" font="0">access only to current list </text>
<text top="665" left="539" width="98" height="20" font="0">of prescribed and </text>
<text top="683" left="539" width="132" height="20" font="0">dispensed drugs; PCPs </text>
<text top="700" left="539" width="135" height="20" font="0">did not receive alerts for </text>
<text top="717" left="539" width="108" height="20" font="0">low adherence (n = </text>
<text top="734" left="539" width="38" height="20" font="0">1002).<b> </b></text>
<text top="322" left="698" width="205" height="20" font="7"><b>1</b>°<b> endpoints: </b>Review of drug profile </text>
<text top="340" left="698" width="204" height="20" font="0">by physician; change in drug therapy </text>
<text top="357" left="698" width="167" height="20" font="0">(increase or discontinuation of </text>
<text top="374" left="698" width="52" height="20" font="0">therapy)  </text>
<text top="391" left="698" width="3" height="20" font="0"> </text>
<text top="410" left="698" width="7" height="18" font="0">•</text>
<text top="410" left="705" width="172" height="20" font="0"> Participants in the intervention </text>
<text top="427" left="698" width="198" height="20" font="0">group were more likely to have their </text>
<text top="444" left="698" width="209" height="20" font="0">drug profile reviewed when compared </text>
<text top="461" left="698" width="171" height="20" font="0">to the control group (44.5% vs. </text>
<text top="478" left="698" width="200" height="20" font="0">35.5%, OR: 1.4; 95% CI: 1.21- 1.76; </text>
<text top="496" left="698" width="63" height="20" font="0">p&lt;0.0001)  </text>
<text top="513" left="698" width="3" height="20" font="0"> </text>
<text top="532" left="698" width="7" height="18" font="0">•</text>
<text top="531" left="705" width="176" height="20" font="0"> The intervention did not have a </text>
<text top="548" left="698" width="194" height="20" font="0">significant effect on increased drug </text>
<text top="566" left="698" width="204" height="20" font="0">therapy (28.5% vs. 29.1%; OR: 0.98; </text>
<text top="583" left="698" width="179" height="20" font="0">95% CI: 0.80 to 1.21; p=0.86) or </text>
<text top="600" left="698" width="198" height="20" font="0">discontinuation of therapy (2.3% vs. </text>
<text top="617" left="698" width="210" height="20" font="0">2.0%; OR: 1.18; 95% CI: 0.63 to 2.19; </text>
<text top="635" left="698" width="49" height="20" font="0">p=0.61). </text>
<text top="652" left="698" width="3" height="20" font="7"><b> </b></text>
<text top="322" left="921" width="183" height="20" font="7"><b>2</b>°<b> endpoint: </b>Adherence rates to </text>
<text top="340" left="921" width="196" height="20" font="0">cardiovascular medications in the 6 </text>
<text top="357" left="921" width="131" height="20" font="0">mo before and after the </text>
<text top="374" left="921" width="145" height="20" font="0">intervention. Measured as </text>
<text top="391" left="921" width="185" height="20" font="0">difference in post-pre-compliance </text>
<text top="408" left="921" width="38" height="20" font="0">rates.  </text>
<text top="426" left="921" width="3" height="20" font="0"> </text>
<text top="445" left="921" width="7" height="18" font="0">•</text>
<text top="444" left="928" width="176" height="20" font="0"> The intervention did not have a </text>
<text top="461" left="921" width="178" height="20" font="0">significant effect on adherence (-</text>
<text top="478" left="921" width="181" height="20" font="0">6.2 vs. -6.4; SD = 24.1; 95% CI: -</text>
<text top="496" left="921" width="101" height="20" font="0">1.8, - 2.1; p=0.90) </text>
<text top="513" left="921" width="3" height="20" font="0"> </text>
<text top="530" left="921" width="186" height="20" font="7"><b>Study limitations</b>: (1) Insufficient </text>
<text top="547" left="921" width="182" height="20" font="0">number of new users to evaluate </text>
<text top="564" left="921" width="187" height="20" font="0">whether there is greater benefit of </text>
<text top="582" left="921" width="195" height="20" font="0">adherence monitoring tools for new </text>
<text top="599" left="921" width="172" height="20" font="0">users; (2) Insufficient statistical </text>
<text top="616" left="921" width="196" height="20" font="0">power to assess clinically important </text>
<text top="633" left="921" width="171" height="20" font="0">changes to therapy; (3) Risk of </text>
<text top="651" left="921" width="190" height="20" font="0">contamination due to study design </text>
<text top="668" left="921" width="172" height="20" font="0">(i.e., physicians reviewing drug </text>
<text top="685" left="921" width="184" height="20" font="0">profiles for non-adherent patients </text>
<text top="702" left="921" width="96" height="20" font="0">in control group). </text>
<text top="719" left="921" width="7" height="20" font="0">  </text>
</page>
<page number="220" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">220 </text>
<text top="107" left="89" width="114" height="20" font="0">Choudhry NK, et al., </text>
<text top="124" left="89" width="63" height="20" font="0">2011<a href="data supplement.html#251"> (263)</a> </text>
<text top="141" left="89" width="55" height="20" font="8"><a href="">22080794</a></text>
<text top="141" left="144" width="3" height="20" font="0"><a href=""> </a></text>
<text top="159" left="89" width="3" height="20" font="0"> </text>
<text top="107" left="217" width="107" height="20" font="7"><b>Aim: </b>To determine </text>
<text top="124" left="217" width="130" height="20" font="0">whether eliminating the </text>
<text top="141" left="217" width="120" height="20" font="0">costs associated with </text>
<text top="159" left="217" width="126" height="20" font="0">prescriptions improves </text>
<text top="176" left="217" width="131" height="20" font="0">medication adherence.  </text>
<text top="193" left="217" width="3" height="20" font="7"><b> </b></text>
<text top="210" left="217" width="115" height="20" font="7"><b>Study type: </b>Parallel </text>
<text top="227" left="217" width="124" height="20" font="0">randomized controlled </text>
<text top="245" left="217" width="67" height="20" font="0">clinical trial  </text>
<text top="262" left="217" width="3" height="20" font="7"><b> </b></text>
<text top="279" left="217" width="36" height="20" font="7"><b>Size:  </b></text>
<text top="296" left="217" width="108" height="20" font="0">N recruited = 6768  </text>
<text top="314" left="217" width="121" height="20" font="0">N randomized = 5855 </text>
<text top="331" left="217" width="129" height="20" font="0">N reported outcomes = </text>
<text top="348" left="217" width="31" height="20" font="0">5216 </text>
<text top="365" left="217" width="3" height="20" font="0"> </text>
<text top="107" left="368" width="109" height="20" font="7"><b>Inclusion criteria:  </b></text>
<text top="126" left="368" width="7" height="18" font="0">•</text>
<text top="125" left="375" width="115" height="20" font="0"> Patients discharged </text>
<text top="143" left="368" width="68" height="20" font="0">following MI </text>
<text top="162" left="368" width="7" height="18" font="0">•</text>
<text top="161" left="375" width="147" height="20" font="0"> Patients received medical </text>
<text top="178" left="368" width="119" height="20" font="0">and prescription drug </text>
<text top="195" left="368" width="120" height="20" font="0">benefits tough Aetna. </text>
<text top="213" left="368" width="3" height="20" font="0"> </text>
<text top="230" left="368" width="114" height="20" font="7"><b>Exclusion criteria:  </b></text>
<text top="249" left="368" width="7" height="18" font="0">•</text>
<text top="248" left="375" width="27" height="20" font="0"> N/A </text>
<text top="107" left="539" width="77" height="20" font="7"><b>Intervention</b>: </text>
<text top="124" left="539" width="128" height="20" font="0">Participants’ pharmacy </text>
<text top="141" left="539" width="143" height="20" font="0">benefits were changed so </text>
<text top="159" left="539" width="118" height="20" font="0">that they had no cost </text>
<text top="176" left="539" width="127" height="20" font="0">sharing for any statins, </text>
<text top="193" left="539" width="105" height="20" font="0">betablockers, ACE </text>
<text top="210" left="539" width="133" height="20" font="0">inhibitors, or ARBs after </text>
<text top="228" left="539" width="101" height="20" font="0">randomization. All </text>
<text top="245" left="539" width="141" height="20" font="0">copayments were waived </text>
<text top="262" left="539" width="113" height="20" font="0">at point of care. (n = </text>
<text top="279" left="539" width="38" height="20" font="0">2845). </text>
<text top="296" left="539" width="3" height="20" font="0"> </text>
<text top="314" left="539" width="112" height="20" font="7"><b>Comparator: </b>Usual </text>
<text top="331" left="539" width="143" height="20" font="0">copayment arrangements </text>
<text top="348" left="539" width="60" height="20" font="0">(n = 3010)<b> </b></text>
<text top="108" left="698" width="168" height="20" font="7"><b>1</b>°<b> endpoint: </b>Fatal or nonfatal </text>
<text top="125" left="698" width="199" height="20" font="0">vascular event or revascularizations </text>
<text top="143" left="698" width="111" height="20" font="0">(rate/100 person-y). </text>
<text top="160" left="698" width="3" height="20" font="0"> </text>
<text top="179" left="698" width="7" height="18" font="0">•</text>
<text top="178" left="705" width="181" height="20" font="0"> The rate of total fatal or nonfatal </text>
<text top="195" left="698" width="180" height="20" font="0">vascular events was lower in the </text>
<text top="213" left="698" width="198" height="20" font="0">intervention group (21.5) than in the </text>
<text top="230" left="698" width="198" height="20" font="0">control group (23.3) (HR: 0.89, 95% </text>
<text top="247" left="698" width="140" height="20" font="0">CI: 0.80 to 0.99; p=0.03). </text>
<text top="264" left="698" width="3" height="20" font="0"> </text>
<text top="282" left="698" width="3" height="20" font="7"><b> </b></text>
<text top="299" left="698" width="3" height="20" font="7"><b> </b></text>
<text top="108" left="921" width="139" height="20" font="7"><b>2</b>°<b> endpoint: </b>Medication </text>
<text top="125" left="921" width="177" height="20" font="0">adherence rates (full adherence </text>
<text top="143" left="921" width="163" height="20" font="0">defined as having a supply of </text>
<text top="160" left="921" width="192" height="20" font="0">medications available on ≥ 80% of </text>
<text top="177" left="921" width="169" height="20" font="0">days during follow-up); Cost of </text>
<text top="194" left="921" width="70" height="20" font="0">intervention. </text>
<text top="194" left="991" width="3" height="20" font="22"> </text>
<text top="211" left="921" width="3" height="20" font="22"> </text>
<text top="231" left="921" width="7" height="18" font="0">•</text>
<text top="230" left="928" width="151" height="20" font="0"> Rates of full adherence for </text>
<text top="247" left="921" width="187" height="20" font="0">statins were significantly higher in </text>
<text top="264" left="921" width="176" height="20" font="0">the full-coverage group (49.3%) </text>
<text top="282" left="921" width="190" height="20" font="0">than the usual care group (41.9%) </text>
<text top="299" left="921" width="179" height="20" font="0">(OR: 1.36; 95% CI: 1.18 to 1.56; </text>
<text top="316" left="921" width="59" height="20" font="0">p&lt;0.001).  </text>
<text top="333" left="921" width="3" height="20" font="0"> </text>
<text top="352" left="921" width="7" height="18" font="0">•</text>
<text top="352" left="928" width="178" height="20" font="0"> The elimination of co-payments </text>
<text top="369" left="921" width="160" height="20" font="0">for intervention group did not </text>
<text top="386" left="921" width="189" height="20" font="0">increase the total spending for the </text>
<text top="403" left="921" width="187" height="20" font="0">health system (USD 66,008 in full-</text>
<text top="420" left="921" width="196" height="20" font="0">coverage group vs. USD 71,778 for </text>
<text top="438" left="921" width="181" height="20" font="0">usual coverage group). (Relative </text>
<text top="455" left="921" width="172" height="20" font="0">spending 0.89; 95% CI: 0.50 to </text>
<text top="472" left="921" width="83" height="20" font="0">1.56; p=0.68).  </text>
<text top="489" left="921" width="3" height="20" font="0"> </text>
<text top="508" left="921" width="7" height="18" font="0">•</text>
<text top="508" left="928" width="178" height="20" font="0"> Participants in the full coverage </text>
<text top="525" left="921" width="172" height="20" font="0">group paid significantly less for </text>
<text top="542" left="921" width="190" height="20" font="0">drugs and other services (Relative </text>
<text top="559" left="921" width="172" height="20" font="0">spending 0.75; 95% CI: 0.68 to </text>
<text top="576" left="921" width="87" height="20" font="0">0.80; p&lt;0.001). </text>
<text top="594" left="921" width="3" height="20" font="22"> </text>
<text top="611" left="921" width="193" height="20" font="7"><b>Study limitations</b>: (1) Reliance on </text>
<text top="628" left="921" width="174" height="20" font="0">administrative claims to identify </text>
<text top="645" left="921" width="177" height="20" font="0">patients and evaluate outcomes </text>
<text top="663" left="921" width="194" height="20" font="0">may have diminished the observed </text>
<text top="680" left="921" width="157" height="20" font="0">effect of the intervention. (2) </text>
<text top="697" left="921" width="190" height="20" font="0">Nature of sample (relatively young </text>
<text top="714" left="921" width="187" height="20" font="0">patients, insured by large national </text>
<text top="731" left="921" width="195" height="20" font="0">insurer) may limit generalizability to </text>
<text top="749" left="921" width="76" height="20" font="0">other groups. </text>
<text top="766" left="921" width="3" height="20" font="0"> </text>
<text top="783" left="921" width="3" height="20" font="0"> </text>
</page>
<page number="221" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">221 </text>
<text top="106" left="88" width="1012" height="20" font="7"><b>Abbreviations: </b>ACE, angiotensin-converting-enzyme; ARB, angiotensin-receptor blocker; CI, confidence interval; HR, hazard ratio; N/A, not available; OR, odds ratio; PCP, primary care </text>
<text top="123" left="88" width="393" height="20" font="0">provider; RCT, randomized controlled trial; and SD, standard deviation.  </text>
<text top="141" left="88" width="292" height="20" font="7"><b>Search Terms: </b>Cholesterol, adherence, compliance  </text>
<text top="158" left="88" width="120" height="20" font="7"><b>Date of Search</b>: 9/17 </text>
<text top="175" left="594" width="4" height="22" font="1"> </text>
<text top="194" left="81" width="747" height="24" font="4"><b>Data Supplement 44. RCTs Comparing Small Number of Pills/Day to Large Number of Pills/Day (Section 6) </b></text>
<text top="224" left="97" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="241" left="123" width="48" height="20" font="7"><b>Author; </b></text>
<text top="258" left="100" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="224" left="244" width="83" height="20" font="7"><b>Aim of Study; </b></text>
<text top="241" left="249" width="74" height="20" font="7"><b>Study Type; </b></text>
<text top="258" left="243" width="86" height="20" font="7"><b>Study Size (N) </b></text>
<text top="241" left="391" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="215" left="557" width="111" height="20" font="7"><b>Study Intervention </b></text>
<text top="233" left="574" width="76" height="20" font="7"><b>(# patients) / </b></text>
<text top="250" left="557" width="111" height="20" font="7"><b>Study Comparator </b></text>
<text top="267" left="578" width="69" height="20" font="7"><b>(# patients) </b></text>
<text top="224" left="751" width="105" height="20" font="7"><b>Endpoint Results </b></text>
<text top="241" left="735" width="137" height="20" font="7"><b>(Absolute Event Rates, </b></text>
<text top="258" left="713" width="181" height="20" font="7"><b>P values; OR or RR; &amp; 95% CI) </b></text>
<text top="225" left="932" width="175" height="20" font="7"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="242" left="964" width="111" height="20" font="7"><b>Study Limitations; </b></text>
<text top="259" left="971" width="96" height="20" font="7"><b>Adverse Events </b></text>
<text top="285" left="89" width="96" height="20" font="0">Brown BG, et al., </text>
<text top="302" left="89" width="63" height="20" font="0">1997<a href="data supplement.html#251"> (264)</a> </text>
<text top="319" left="89" width="48" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/9230143">9230143</a></text>
<text top="319" left="137" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/9230143"> </a></text>
<text top="337" left="89" width="3" height="20" font="0"> </text>
<text top="354" left="89" width="3" height="20" font="22"> </text>
<text top="354" left="93" width="3" height="20" font="0"> </text>
<text top="285" left="217" width="119" height="20" font="7"><b>Aim: </b>To evaluate the </text>
<text top="302" left="217" width="112" height="20" font="0">efficacy, safety, and </text>
<text top="319" left="217" width="138" height="20" font="0">tolerability of a moderate </text>
<text top="337" left="217" width="98" height="20" font="0">dose, 3-drug lipid-</text>
<text top="354" left="217" width="100" height="20" font="0">lowering regimen. </text>
<text top="371" left="217" width="3" height="20" font="7"><b> </b></text>
<text top="388" left="217" width="134" height="20" font="7"><b>Study type: </b>Cross-over </text>
<text top="406" left="217" width="124" height="20" font="0">randomized controlled </text>
<text top="423" left="217" width="64" height="20" font="0">clinical trial </text>
<text top="440" left="217" width="3" height="20" font="7"><b> </b></text>
<text top="457" left="217" width="32" height="20" font="7"><b>Size: </b></text>
<text top="474" left="217" width="91" height="20" font="0">N recruited = 31 </text>
<text top="492" left="217" width="108" height="20" font="0">N randomized = 31 </text>
<text top="509" left="217" width="129" height="20" font="0">N reported outcomes = </text>
<text top="526" left="217" width="17" height="20" font="0">29 </text>
<text top="543" left="217" width="3" height="20" font="0"> </text>
<text top="285" left="368" width="109" height="20" font="7"><b>Inclusion criteria:  </b></text>
<text top="304" left="368" width="7" height="18" font="0">•</text>
<text top="303" left="375" width="33" height="20" font="0"> Male </text>
<text top="322" left="368" width="7" height="18" font="0">•</text>
<text top="322" left="375" width="79" height="20" font="0"> ≤ 65 y of age </text>
<text top="341" left="368" width="7" height="18" font="0">•</text>
<text top="340" left="375" width="150" height="20" font="0"> High risk for future cardiac </text>
<text top="357" left="368" width="152" height="20" font="0">events (apoprotein B ≥ 125 </text>
<text top="375" left="368" width="157" height="20" font="0">mg/dl; ≥ 1 coronary lesion ≥ </text>
<text top="392" left="368" width="154" height="20" font="0">50% stenosis or 2 lesions ≥ </text>
<text top="409" left="368" width="155" height="20" font="0">30% stenosis; family history </text>
<text top="426" left="368" width="156" height="20" font="0">of premature cardiovascular </text>
<text top="444" left="368" width="51" height="20" font="0">events).  </text>
<text top="461" left="368" width="3" height="20" font="0"> </text>
<text top="478" left="368" width="114" height="20" font="7"><b>Exclusion criteria:  </b></text>
<text top="497" left="368" width="7" height="18" font="0">•</text>
<text top="496" left="375" width="27" height="20" font="0"> N/A </text>
<text top="285" left="539" width="146" height="20" font="0">Preliminary treatment: For </text>
<text top="302" left="539" width="127" height="20" font="0">first 12 mo, all enrolled </text>
<text top="319" left="539" width="135" height="20" font="0">patients received 3-drug </text>
<text top="337" left="539" width="91" height="20" font="0">regimen (niacin, </text>
<text top="354" left="539" width="136" height="20" font="0">lovastatin, colestipol). At </text>
<text top="371" left="539" width="118" height="20" font="0">12 mo, patients were </text>
<text top="388" left="539" width="120" height="20" font="0">randomly assigned to </text>
<text top="406" left="539" width="107" height="20" font="0">intervention/control </text>
<text top="423" left="539" width="100" height="20" font="0">groups. At 20 mo, </text>
<text top="440" left="539" width="128" height="20" font="0">intervention status was </text>
<text top="457" left="539" width="58" height="20" font="0">reversed.  </text>
<text top="474" left="539" width="3" height="20" font="0"> </text>
<text top="492" left="539" width="81" height="20" font="7"><b>Intervention</b>:  </text>
<text top="509" left="539" width="128" height="20" font="0">Reduced daily dosage: </text>
<text top="526" left="539" width="103" height="20" font="0">Intervention group </text>
<text top="543" left="539" width="122" height="20" font="0">changed to controlled-</text>
<text top="561" left="539" width="83" height="20" font="0">release niacin, </text>
<text top="578" left="539" width="137" height="20" font="0">administered twice daily, </text>
<text top="595" left="539" width="145" height="20" font="0">rather than 4 times/d. (n = </text>
<text top="612" left="539" width="21" height="20" font="0">31) </text>
<text top="629" left="539" width="3" height="20" font="0"> </text>
<text top="647" left="539" width="137" height="20" font="7"><b>Comparator: </b>Continued </text>
<text top="664" left="539" width="135" height="20" font="0">regular niacin at dosage </text>
<text top="681" left="539" width="143" height="20" font="0">established during first 12 </text>
<text top="698" left="539" width="70" height="20" font="0">mo. (n = 31)<b> </b></text>
<text top="286" left="698" width="143" height="20" font="7"><b>1</b>°<b> endpoint: </b>Lipid levels  </text>
<text top="303" left="698" width="3" height="20" font="0"> </text>
<text top="322" left="698" width="7" height="18" font="0">•</text>
<text top="322" left="705" width="175" height="20" font="0"> Target LDL of &lt; 100 mg/dl was </text>
<text top="339" left="698" width="155" height="20" font="0">achieved at 8 mo by 83% of </text>
<text top="356" left="698" width="185" height="20" font="0">participants on controlled-release </text>
<text top="373" left="698" width="149" height="20" font="0">niacin compared to 52% of </text>
<text top="391" left="698" width="161" height="20" font="0">participants on regular niacin </text>
<text top="408" left="698" width="53" height="20" font="0">(p&lt;0.01) <b> </b></text>
<text top="286" left="921" width="139" height="20" font="7"><b>2</b>°<b> endpoint: </b>Medication </text>
<text top="303" left="921" width="65" height="20" font="0">adherence  </text>
<text top="321" left="921" width="3" height="20" font="7"><b> </b></text>
<text top="340" left="921" width="7" height="18" font="0">•</text>
<text top="339" left="928" width="186" height="20" font="0"> Reducing medication intake from </text>
<text top="356" left="921" width="174" height="20" font="0">4 times/d to 2 times/d improved </text>
<text top="373" left="921" width="178" height="20" font="0">mean medication intake by 11% </text>
<text top="391" left="921" width="172" height="20" font="0">(96% in intervention vs. 85% in </text>
<text top="408" left="921" width="89" height="20" font="0">control; p=0.01) </text>
<text top="425" left="921" width="3" height="20" font="7"><b> </b></text>
<text top="442" left="921" width="183" height="20" font="7"><b>Study limitations</b>: Small sample </text>
<text top="460" left="921" width="172" height="20" font="0">size limits statistical power and </text>
<text top="477" left="921" width="151" height="20" font="0">generalizability of findings.  </text>
<text top="716" left="89" width="46" height="20" font="7"><b>FOCUS </b></text>
<text top="733" left="89" width="98" height="20" font="0">Castellano JM, et </text>
<text top="751" left="89" width="83" height="20" font="0">al., 2014 <a href="data supplement.html#251">(265)</a> </text>
<text top="768" left="89" width="58" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25193393">25193393 </a></text>
<text top="768" left="148" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/25193393"> </a></text>
<text top="785" left="89" width="3" height="20" font="0"> </text>
<text top="716" left="217" width="120" height="20" font="7"><b>Aim: </b>To compare the </text>
<text top="733" left="217" width="99" height="20" font="0">effects of an FDC </text>
<text top="751" left="217" width="88" height="20" font="0">polypill (aspirin, </text>
<text top="768" left="217" width="116" height="20" font="0">simvastatin, rampiril) </text>
<text top="716" left="368" width="106" height="20" font="7"><b>Inclusion criteria: </b></text>
<text top="733" left="368" width="126" height="20" font="0">Participants previously </text>
<text top="751" left="368" width="148" height="20" font="0">included in Phase 1 (cross-</text>
<text top="768" left="368" width="149" height="20" font="0">sectional study of FOCUS) </text>
<text top="716" left="539" width="106" height="20" font="7"><b>Intervention</b>: FDC </text>
<text top="733" left="539" width="140" height="20" font="0">polypill containing aspirin </text>
<text top="751" left="539" width="130" height="20" font="0">100 mg, simvastatin 40 </text>
<text top="768" left="539" width="144" height="20" font="0">mg, and rampiril 2.5, 5, or </text>
<text top="717" left="698" width="207" height="20" font="7"><b>1</b>°<b> endpoint: </b>Attending final visit with </text>
<text top="735" left="698" width="197" height="20" font="0">MAQ of 20 and high pill count (80% </text>
<text top="752" left="698" width="56" height="20" font="0">to 110%)<b> </b> </text>
<text top="769" left="698" width="3" height="20" font="0"> </text>
<text top="717" left="921" width="86" height="20" font="7"><b> 2</b>°<b> endpoints: </b></text>
<text top="736" left="921" width="7" height="18" font="0">•</text>
<text top="736" left="928" width="169" height="20" font="0"> Among study participants, the </text>
<text top="753" left="921" width="193" height="20" font="0">risk of being non-adherent (MAQ &lt; </text>
<text top="770" left="921" width="182" height="20" font="0">20) was associated with younger </text>
<text top="787" left="921" width="143" height="20" font="0">age, depression, complex </text>
</page>
<page number="222" position="absolute" top="0" left="0" height="918" width="1188">
	<fontspec id="23" size="12" family="Times" color="#0070c0"/>
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">222 </text>
<text top="107" left="89" width="3" height="20" font="22"> </text>
<text top="107" left="93" width="3" height="20" font="0"> </text>
<text top="107" left="217" width="132" height="20" font="0">with administering the 3 </text>
<text top="124" left="217" width="98" height="20" font="0">drugs separately. </text>
<text top="141" left="217" width="3" height="20" font="7"><b> </b></text>
<text top="159" left="217" width="115" height="20" font="7"><b>Study type: </b>Parallel </text>
<text top="176" left="217" width="124" height="20" font="0">randomized controlled </text>
<text top="193" left="217" width="67" height="20" font="0">clinical trial  </text>
<text top="210" left="217" width="3" height="20" font="7"><b> </b></text>
<text top="227" left="217" width="36" height="20" font="7"><b>Size:  </b></text>
<text top="245" left="217" width="98" height="20" font="0">N recruited = 695 </text>
<text top="262" left="217" width="114" height="20" font="0">N randomized = 695 </text>
<text top="279" left="217" width="129" height="20" font="0">N reported outcomes = </text>
<text top="296" left="217" width="135" height="20" font="0">695 for intention-to-treat </text>
<text top="314" left="217" width="135" height="20" font="0">analysis; 458 completed </text>
<text top="331" left="217" width="132" height="20" font="0">all visits for per protocol </text>
<text top="348" left="217" width="51" height="20" font="0">analysis  </text>
<text top="365" left="217" width="3" height="20" font="0"> </text>
<text top="107" left="368" width="149" height="20" font="0">but not in Phase 2 (RCT of </text>
<text top="124" left="368" width="51" height="20" font="0">FOCUS) </text>
<text top="141" left="368" width="3" height="20" font="0"> </text>
<text top="159" left="368" width="114" height="20" font="7"><b>Exclusion criteria:  </b></text>
<text top="178" left="368" width="7" height="18" font="0">•</text>
<text top="177" left="375" width="137" height="20" font="0"> Secondary dyslipidemia </text>
<text top="196" left="368" width="7" height="18" font="0">•</text>
<text top="195" left="375" width="150" height="20" font="0"> Contraindication to polypill </text>
<text top="214" left="368" width="7" height="18" font="0">•</text>
<text top="214" left="375" width="133" height="20" font="0"> Participation in another </text>
<text top="231" left="368" width="23" height="20" font="0">trial </text>
<text top="250" left="368" width="7" height="18" font="0">•</text>
<text top="249" left="375" width="132" height="20" font="0"> Previous percutaneous </text>
<text top="267" left="368" width="121" height="20" font="0">transluminal coronary </text>
<text top="284" left="368" width="158" height="20" font="0">angioplasty with drug eluting </text>
<text top="301" left="368" width="142" height="20" font="0">stent within previous year </text>
<text top="320" left="368" width="7" height="18" font="0">•</text>
<text top="320" left="375" width="140" height="20" font="0"> Severe congestive heart </text>
<text top="337" left="368" width="37" height="20" font="0">failure </text>
<text top="356" left="368" width="7" height="18" font="0">•</text>
<text top="355" left="375" width="121" height="20" font="0"> Serum creatinine &gt; 2 </text>
<text top="372" left="368" width="37" height="20" font="0">mg/dl  </text>
<text top="391" left="368" width="7" height="18" font="0">•</text>
<text top="391" left="375" width="126" height="20" font="0"> Life expectancy &lt; 2 y  </text>
<text top="410" left="368" width="7" height="18" font="0">•</text>
<text top="409" left="375" width="69" height="20" font="0"> Pregnancy  </text>
<text top="428" left="368" width="7" height="18" font="0">•</text>
<text top="427" left="375" width="96" height="20" font="0"> Premenopausal  </text>
<text top="445" left="368" width="3" height="20" font="0"> </text>
<text top="462" left="368" width="3" height="20" font="0"> </text>
<text top="107" left="539" width="139" height="20" font="0">10 mg, given once daily.  </text>
<text top="124" left="539" width="53" height="20" font="0">(n = 350) </text>
<text top="141" left="539" width="3" height="20" font="0"> </text>
<text top="159" left="539" width="131" height="20" font="7"><b>Comparator</b>: Received </text>
<text top="176" left="539" width="135" height="20" font="0">aspirin, simvastatin, and </text>
<text top="193" left="539" width="122" height="20" font="0">rampiril as 3 separate </text>
<text top="210" left="539" width="141" height="20" font="0">drugs, administered once </text>
<text top="228" left="539" width="82" height="20" font="0">daily (n = 345)<b> </b></text>
<text top="109" left="698" width="7" height="18" font="0">•</text>
<text top="108" left="705" width="176" height="20" font="0"> The intervention group showed </text>
<text top="125" left="698" width="204" height="20" font="0">improved adherence over the control </text>
<text top="143" left="698" width="206" height="20" font="0">group at 9 mo in the intention-to-treat </text>
<text top="160" left="698" width="163" height="20" font="0">population (50.8% vs. 41.0%; </text>
<text top="177" left="698" width="208" height="20" font="0">p=0.019) and per protocol population  </text>
<text top="194" left="698" width="159" height="20" font="0">(65.7% vs. 55.7%; p=0.012)  </text>
<text top="211" left="698" width="3" height="20" font="0"> </text>
<text top="229" left="698" width="3" height="20" font="7"><b> </b></text>
<text top="107" left="921" width="190" height="20" font="0">medication regimen, poorer health </text>
<text top="124" left="921" width="171" height="20" font="0">insurance coverage, and lower </text>
<text top="141" left="921" width="135" height="20" font="0">levels of social support.  </text>
<text top="159" left="921" width="3" height="20" font="0"> </text>
<text top="178" left="921" width="7" height="18" font="0">•</text>
<text top="177" left="928" width="174" height="20" font="0"> No significant differences were </text>
<text top="194" left="921" width="171" height="20" font="0">seen between intervention and </text>
<text top="211" left="921" width="196" height="20" font="0">control for mean LDL-C (89.9 mg/dl </text>
<text top="229" left="921" width="161" height="20" font="0">vs. 91.7 mg/dl) or mean SBP </text>
<text top="246" left="921" width="178" height="20" font="0">(129.6 mmHg vs. 129.6 mmHg). </text>
<text top="263" left="921" width="3" height="20" font="0"> </text>
<text top="280" left="921" width="188" height="20" font="7"><b>Adverse events:</b> No difference in </text>
<text top="298" left="921" width="192" height="20" font="0">adverse events or serious adverse </text>
<text top="315" left="921" width="187" height="20" font="0">events in groups receiving polypill </text>
<text top="332" left="921" width="161" height="20" font="0">(35.4%, 6.0%) or the 3 drugs </text>
<text top="349" left="921" width="180" height="20" font="0">separately (32.5%, 6.6%). There </text>
<text top="366" left="921" width="183" height="20" font="0">was 1 death in each group (0.3% </text>
<text top="384" left="921" width="58" height="20" font="0">vs. 0.3%). </text>
<text top="401" left="921" width="3" height="20" font="0"> </text>
<text top="480" left="89" width="111" height="20" font="0">Patel A, et al., 2015 </text>
<text top="497" left="89" width="32" height="20" font="0"><a href="data supplement.html#251">(266)</a> </text>
<text top="514" left="89" width="62" height="20" font="23"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24676715">24676715  </a></text>
<text top="531" left="89" width="3" height="20" font="0"> </text>
<text top="549" left="89" width="3" height="20" font="22"> </text>
<text top="549" left="93" width="3" height="20" font="0"> </text>
<text top="480" left="217" width="107" height="20" font="7"><b>Aim: </b>To determine </text>
<text top="497" left="217" width="137" height="20" font="0">whether FDC polypills of </text>
<text top="514" left="217" width="113" height="20" font="0">generic drugs would </text>
<text top="531" left="217" width="85" height="20" font="0">promote use of </text>
<text top="549" left="217" width="112" height="20" font="0">preventive drugs for </text>
<text top="566" left="217" width="137" height="20" font="0">individuals at high risk of </text>
<text top="583" left="217" width="36" height="20" font="0">CVD.  </text>
<text top="600" left="217" width="3" height="20" font="7"><b> </b></text>
<text top="617" left="217" width="115" height="20" font="7"><b>Study type: </b>Parallel </text>
<text top="635" left="217" width="124" height="20" font="0">randomized controlled </text>
<text top="652" left="217" width="64" height="20" font="0">clinical trial </text>
<text top="669" left="217" width="3" height="20" font="0"> </text>
<text top="686" left="217" width="36" height="20" font="7"><b>Size:  </b></text>
<text top="703" left="217" width="98" height="20" font="0">N recruited = 731 </text>
<text top="721" left="217" width="114" height="20" font="0">N randomized = 623 </text>
<text top="738" left="217" width="129" height="20" font="0">N reported outcomes = </text>
<text top="755" left="217" width="24" height="20" font="0">623 </text>
<text top="772" left="217" width="3" height="20" font="0"> </text>
<text top="480" left="368" width="109" height="20" font="7"><b>Inclusion criteria:  </b></text>
<text top="499" left="368" width="7" height="18" font="0">•</text>
<text top="498" left="375" width="79" height="20" font="0"> ≥ 18 y of age </text>
<text top="517" left="368" width="7" height="18" font="0">•</text>
<text top="516" left="375" width="84" height="20" font="0"> High CVD risk </text>
<text top="534" left="368" width="113" height="20" font="0">(established CVD or </text>
<text top="551" left="368" width="150" height="20" font="0">estimated 5-y Framingham </text>
<text top="568" left="368" width="98" height="20" font="0">CVD risk of 15%) </text>
<text top="587" left="368" width="7" height="18" font="0">•</text>
<text top="586" left="375" width="137" height="20" font="0">Indications for all and no </text>
<text top="604" left="368" width="132" height="20" font="0">contraindications to any </text>
<text top="621" left="368" width="155" height="20" font="0">component of at least 1 of 2 </text>
<text top="638" left="368" width="47" height="20" font="0">polypills<b> </b></text>
<text top="655" left="368" width="3" height="20" font="0"> </text>
<text top="672" left="368" width="114" height="20" font="7"><b>Exclusion criteria:  </b></text>
<text top="691" left="368" width="7" height="18" font="0">•</text>
<text top="691" left="375" width="135" height="20" font="0"> Participants for whom it </text>
<text top="708" left="368" width="150" height="20" font="0">was clinically inappropriate </text>
<text top="725" left="368" width="114" height="20" font="0">to alter medications <b> </b></text>
<text top="742" left="368" width="3" height="20" font="0"> </text>
<text top="480" left="539" width="145" height="20" font="7"><b>Intervention</b>: Intervention </text>
<text top="497" left="539" width="136" height="20" font="0">group received a polypill </text>
<text top="514" left="539" width="140" height="20" font="0">containing aspirin 75 mg, </text>
<text top="531" left="539" width="106" height="20" font="0">simvastatin 40 mg, </text>
<text top="549" left="539" width="113" height="20" font="0">lisinopril 10 mg, and </text>
<text top="566" left="539" width="133" height="20" font="0">either atenolol 50 mg or </text>
<text top="583" left="539" width="137" height="20" font="0">hydrochlorothiazide 12.5 </text>
<text top="600" left="539" width="77" height="20" font="0">mg. (n = 311) </text>
<text top="617" left="539" width="3" height="20" font="0"> </text>
<text top="635" left="539" width="139" height="20" font="7"><b>Comparator </b>Usual care. </text>
<text top="652" left="539" width="143" height="20" font="0">Medications administered </text>
<text top="669" left="539" width="124" height="20" font="0">as separate doses, as </text>
<text top="686" left="539" width="135" height="20" font="0">prescribed by physician. </text>
<text top="703" left="539" width="56" height="20" font="0">(n = 312) <b> </b></text>
<text top="481" left="698" width="198" height="20" font="7"><b>1</b>°<b> endpoint: </b>Use of treatment after </text>
<text top="498" left="698" width="102" height="20" font="0">median of 18 mo.  </text>
<text top="517" left="698" width="7" height="18" font="0">•</text>
<text top="516" left="705" width="172" height="20" font="0"> Participants in the intervention </text>
<text top="534" left="698" width="193" height="20" font="0">group demonstrated greater use of </text>
<text top="551" left="698" width="187" height="20" font="0">treatment compared to those who </text>
<text top="568" left="698" width="208" height="20" font="0">received the drugs as separate doses </text>
<text top="585" left="698" width="185" height="20" font="0">(70% vs. 47%; RR: 1.49, 95% CI: </text>
<text top="603" left="698" width="134" height="20" font="0">1.30 to 1.72; p&lt;0.0001). </text>
<text top="620" left="698" width="7" height="20" font="0"> <b> </b></text>
<text top="481" left="921" width="76" height="20" font="7"><b>2</b>°<b> endpoint: </b></text>
<text top="500" left="921" width="7" height="18" font="0">•</text>
<text top="499" left="928" width="144" height="20" font="0"> No significant differences </text>
<text top="516" left="921" width="181" height="20" font="0">between intervention and control </text>
<text top="534" left="921" width="174" height="20" font="0">for total cholesterol levels (0.08 </text>
<text top="551" left="921" width="195" height="20" font="0">mmol/l; 95% CI: 0.06-0.22; p=0.26) </text>
<text top="568" left="921" width="178" height="20" font="0">or SBP (1.5 mmHg; 95% CI: 4.0-</text>
<text top="585" left="921" width="73" height="20" font="0">1.0; p=0.24).<b> </b></text>
<text top="603" left="921" width="3" height="20" font="7"><b> </b></text>
<text top="620" left="921" width="163" height="20" font="7"><b>Adverse events: </b>≥ 1 serious </text>
<text top="637" left="921" width="195" height="20" font="0">adverse event reported in 46.3% of </text>
<text top="654" left="921" width="195" height="20" font="0">intervention participants and 40.7% </text>
<text top="671" left="921" width="170" height="20" font="0">of control participants (p=0.16) </text>
</page>
<page number="223" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">223 </text>
<text top="107" left="89" width="95" height="20" font="0">Pill Collaborative </text>
<text top="124" left="89" width="109" height="20" font="0">Group,  et al., 2011 </text>
<text top="141" left="89" width="32" height="20" font="0"><a href="data supplement.html#251">(267)</a> </text>
<text top="159" left="89" width="58" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21647425">21647425 </a></text>
<text top="159" left="148" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21647425"> </a></text>
<text top="176" left="89" width="3" height="20" font="0"> </text>
<text top="193" left="89" width="3" height="20" font="22"> </text>
<text top="193" left="93" width="3" height="20" font="0"> </text>
<text top="107" left="217" width="119" height="20" font="7"><b>Aim: </b>To evaluate the </text>
<text top="124" left="217" width="115" height="20" font="0">effect of a polypill on </text>
<text top="141" left="217" width="133" height="20" font="0">systolic BP, LDL-C, and </text>
<text top="159" left="217" width="66" height="20" font="0">tolerability.  </text>
<text top="176" left="217" width="3" height="20" font="7"><b> </b></text>
<text top="193" left="217" width="115" height="20" font="7"><b>Study type: </b>Parallel </text>
<text top="210" left="217" width="124" height="20" font="0">randomized controlled </text>
<text top="227" left="217" width="67" height="20" font="0">clinical trial<b> </b> </text>
<text top="245" left="217" width="3" height="20" font="7"><b> </b></text>
<text top="262" left="217" width="32" height="20" font="7"><b>Size: </b></text>
<text top="279" left="217" width="98" height="20" font="0">N recruited = 859 </text>
<text top="296" left="217" width="114" height="20" font="0">N randomized = 378 </text>
<text top="314" left="217" width="129" height="20" font="0">N reported outcomes = </text>
<text top="331" left="217" width="24" height="20" font="0">373 </text>
<text top="348" left="217" width="3" height="20" font="0"> </text>
<text top="107" left="368" width="109" height="20" font="7"><b>Inclusion criteria:  </b></text>
<text top="126" left="368" width="7" height="18" font="0">•</text>
<text top="125" left="375" width="150" height="20" font="0"> Raised cardiovascular risk </text>
<text top="143" left="368" width="141" height="20" font="0">(7.5% using Framingham </text>
<text top="160" left="368" width="81" height="20" font="0">risk equation)  </text>
<text top="179" left="368" width="7" height="18" font="0">•</text>
<text top="178" left="375" width="126" height="20" font="0"> No contraindication to </text>
<text top="195" left="368" width="44" height="20" font="0">polypill  </text>
<text top="215" left="368" width="7" height="18" font="0">•</text>
<text top="214" left="375" width="79" height="20" font="0"> ≥ 18 y of age<b> </b></text>
<text top="231" left="368" width="3" height="20" font="0"> </text>
<text top="248" left="368" width="114" height="20" font="7"><b>Exclusion criteria:  </b></text>
<text top="267" left="368" width="7" height="18" font="0">•</text>
<text top="267" left="375" width="119" height="20" font="0"> Patients taking other </text>
<text top="284" left="368" width="151" height="20" font="0">antiplatelet, blood pressure </text>
<text top="301" left="368" width="130" height="20" font="0">lowering, or cholesterol </text>
<text top="318" left="368" width="105" height="20" font="0">lowering medicine  </text>
<text top="337" left="368" width="7" height="18" font="0">•</text>
<text top="337" left="375" width="126" height="20" font="0"> Patients with diabetes </text>
<text top="354" left="368" width="49" height="20" font="0">mellitus  </text>
<text top="371" left="368" width="3" height="20" font="0"> </text>
<text top="107" left="539" width="145" height="20" font="7"><b>Intervention</b>: Intervention </text>
<text top="124" left="539" width="126" height="20" font="0">group received polypill </text>
<text top="141" left="539" width="140" height="20" font="0">containing aspirin 75 mg, </text>
<text top="159" left="539" width="89" height="20" font="0">lisinopril 10 mg, </text>
<text top="176" left="539" width="137" height="20" font="0">hydrochlorothiazide 12.5 </text>
<text top="193" left="539" width="130" height="20" font="0">mg, and simvastatin 20 </text>
<text top="210" left="539" width="77" height="20" font="0">mg. (n = 189) </text>
<text top="227" left="539" width="3" height="20" font="0"> </text>
<text top="245" left="539" width="139" height="20" font="7"><b>Comparator: </b>Placebo (n </text>
<text top="262" left="539" width="39" height="20" font="0">= 189)<b> </b></text>
<text top="108" left="698" width="200" height="20" font="7"><b>1</b>°<b> endpoints: </b>Change in SBP, LDL-</text>
<text top="125" left="698" width="192" height="20" font="0">C, and tolerability (withdrawal from </text>
<text top="143" left="698" width="151" height="20" font="0">study) measured at 12 wk.  </text>
<text top="160" left="698" width="3" height="20" font="0"> </text>
<text top="179" left="698" width="7" height="18" font="0">•</text>
<text top="178" left="705" width="194" height="20" font="0"> There was a reduction in SBP (9.9 </text>
<text top="195" left="698" width="206" height="20" font="0">mmHg; 95% CI: 7.7-12.1) and LDL-C </text>
<text top="213" left="698" width="197" height="20" font="0">(0.8 mmol/L; 95% CI: 7.7-12.1) with </text>
<text top="230" left="698" width="174" height="20" font="0">the polypill, as compared to the </text>
<text top="247" left="698" width="50" height="20" font="0">placebo. </text>
<text top="264" left="698" width="3" height="20" font="0"> </text>
<text top="283" left="698" width="7" height="18" font="0">•</text>
<text top="283" left="705" width="203" height="20" font="0"> Discontinuation rates were higher in </text>
<text top="300" left="698" width="206" height="20" font="0">polypill group (23%) than the placebo </text>
<text top="317" left="698" width="206" height="20" font="0">group (18%) (RR: 1.33; 95% CI: 0.89-</text>
<text top="334" left="698" width="66" height="20" font="0">2.0; p=0.2). </text>
<text top="352" left="698" width="3" height="20" font="7"><b> </b></text>
<text top="108" left="921" width="79" height="20" font="7"><b>2</b>°<b> endpoint:</b>  </text>
<text top="127" left="921" width="7" height="18" font="0">•</text>
<text top="127" left="928" width="156" height="20" font="0"> Treatment adherence (% of </text>
<text top="144" left="921" width="187" height="20" font="0">prescribed treatment according to </text>
<text top="161" left="921" width="174" height="20" font="0">pill counts) was 82% for polypill </text>
<text top="178" left="921" width="180" height="20" font="0">group and 86% for control group </text>
<text top="195" left="921" width="46" height="20" font="0">(p=0.1). </text>
<text top="213" left="921" width="3" height="20" font="0"> </text>
<text top="230" left="921" width="158" height="20" font="7"><b>Study limitations: </b>(1) Short </text>
<text top="247" left="921" width="180" height="20" font="0">follow-up period did not allow for </text>
<text top="264" left="921" width="187" height="20" font="0">assessment of long-term drop-out </text>
<text top="282" left="921" width="191" height="20" font="0">rates. (2) Narrow sample may limit </text>
<text top="299" left="921" width="151" height="20" font="0">generalizability of findings.  </text>
<text top="316" left="921" width="3" height="20" font="7"><b> </b></text>
<text top="333" left="921" width="140" height="20" font="7"><b>Adverse events: </b>58% of </text>
<text top="350" left="921" width="167" height="20" font="0">participants in the intervention </text>
<text top="368" left="921" width="171" height="20" font="0">group reported adverse events </text>
<text top="385" left="921" width="188" height="20" font="0">compared to 42% in control group </text>
<text top="402" left="921" width="157" height="20" font="0">(p=0.001). Authors note that </text>
<text top="419" left="921" width="145" height="20" font="0">reported side effects were </text>
<text top="437" left="921" width="189" height="20" font="0">consistent with known side effects </text>
<text top="454" left="921" width="182" height="20" font="0">of medications within the polypill. </text>
<text top="471" left="921" width="159" height="20" font="0">Within each group, 4 serious </text>
<text top="488" left="921" width="166" height="20" font="0">adverse events were reported </text>
<text top="505" left="921" width="146" height="20" font="0">(polypill: chest pain, newly </text>
<text top="523" left="921" width="154" height="20" font="0">diagnosed Type II diabetes, </text>
<text top="540" left="921" width="193" height="20" font="0">removal of wisdom teeth, syncope; </text>
<text top="557" left="921" width="169" height="20" font="0">placebo: syncope, depression, </text>
<text top="574" left="921" width="161" height="20" font="0">transient ischemic attack; hip </text>
<text top="591" left="921" width="56" height="20" font="0">fracture).  </text>
<text top="609" left="921" width="3" height="20" font="0"> </text>
<text top="627" left="89" width="113" height="20" font="0">Selak V, et al., 2014 </text>
<text top="644" left="89" width="32" height="20" font="0"><a href="data supplement.html#252">(268)</a> </text>
<text top="661" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/labs/articles/24868083/">24868083</a></text>
<text top="661" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/labs/articles/24868083/"> </a></text>
<text top="678" left="89" width="3" height="20" font="0"> </text>
<text top="695" left="89" width="3" height="20" font="22"> </text>
<text top="695" left="93" width="3" height="20" font="0"> </text>
<text top="627" left="217" width="119" height="20" font="7"><b>Aim: </b>To evaluate the </text>
<text top="644" left="217" width="117" height="20" font="0">effectiveness of FDC </text>
<text top="661" left="217" width="125" height="20" font="0">treatment in improving </text>
<text top="678" left="217" width="108" height="20" font="0">adherence and risk </text>
<text top="695" left="217" width="116" height="20" font="0">factor control among </text>
<text top="713" left="217" width="132" height="20" font="0">high risk cardiovascular </text>
<text top="730" left="217" width="53" height="20" font="0">patients.  </text>
<text top="747" left="217" width="3" height="20" font="7"><b> </b></text>
<text top="627" left="368" width="109" height="20" font="7"><b>Inclusion criteria:  </b></text>
<text top="646" left="368" width="7" height="18" font="0">•</text>
<text top="645" left="375" width="86" height="20" font="0"> 18-79 y of age </text>
<text top="664" left="368" width="7" height="18" font="0">•</text>
<text top="663" left="375" width="98" height="20" font="0"> High risk of CVD </text>
<text top="680" left="368" width="124" height="20" font="0">(established coronary, </text>
<text top="698" left="368" width="109" height="20" font="0">cerebrovascular, or </text>
<text top="715" left="368" width="156" height="20" font="0">peripheral vascular disease; </text>
<text top="732" left="368" width="111" height="20" font="0">or ≥ 15% 5-y risk of </text>
<text top="749" left="368" width="120" height="20" font="0">cardiovascular event) </text>
<text top="768" left="368" width="7" height="18" font="0">•</text>
<text top="768" left="375" width="147" height="20" font="0"> PCP determined all drugs </text>
<text top="785" left="368" width="111" height="20" font="0">in at least 1 of the 2 </text>
<text top="627" left="539" width="106" height="20" font="7"><b>Intervention</b>: FDC </text>
<text top="644" left="539" width="81" height="20" font="0">treatment was </text>
<text top="661" left="539" width="122" height="20" font="0">administered by PCP. </text>
<text top="678" left="539" width="111" height="20" font="0">PCPs could choose </text>
<text top="695" left="539" width="117" height="20" font="0">between 2 FDCs: (1) </text>
<text top="713" left="539" width="145" height="20" font="0">aspirin 75 mg, simvastatin </text>
<text top="730" left="539" width="130" height="20" font="0">40 mg, lisinopril 10 mg, </text>
<text top="747" left="539" width="120" height="20" font="0">atenolol 50 mg; or (2) </text>
<text top="764" left="539" width="145" height="20" font="0">aspirin 75 mg, simvastatin </text>
<text top="781" left="539" width="130" height="20" font="0">40 mg, lisinopril 10 mg, </text>
<text top="628" left="698" width="194" height="20" font="7"><b>1</b>°<b> endpoint: </b>Adherence rate at 12 </text>
<text top="645" left="698" width="21" height="20" font="0">mo </text>
<text top="662" left="698" width="3" height="20" font="7"><b> </b></text>
<text top="681" left="698" width="7" height="18" font="0">•</text>
<text top="680" left="705" width="183" height="20" font="0"> FDC was associated with higher </text>
<text top="698" left="698" width="194" height="20" font="0">adherence compared to usual care </text>
<text top="715" left="698" width="185" height="20" font="0">(81% vs. 46%; RR: 1.75, 95% CI: </text>
<text top="732" left="698" width="131" height="20" font="0">1.52 to 2.03; p&lt;0.001). <b> </b></text>
<text top="628" left="921" width="167" height="20" font="7"><b>2</b>°<b> endpoint:</b> Mean change in </text>
<text top="645" left="921" width="70" height="20" font="0">LDL-C, SBP </text>
<text top="662" left="921" width="3" height="20" font="0"> </text>
<text top="681" left="921" width="7" height="18" font="0">•</text>
<text top="680" left="928" width="153" height="20" font="0"> There was not a significant </text>
<text top="698" left="921" width="194" height="20" font="0">difference in LDL-C levels between </text>
<text top="715" left="921" width="193" height="20" font="0">the intervention and control groups </text>
<text top="732" left="921" width="195" height="20" font="0">(-0.05 mmol/L; 95% CI: -0.17, 0.08; </text>
<text top="749" left="921" width="52" height="20" font="0">p=0.46).  </text>
<text top="766" left="921" width="3" height="20" font="0"> </text>
</page>
<page number="224" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">224 </text>
<text top="107" left="217" width="115" height="20" font="7"><b>Study type: </b>Parallel </text>
<text top="124" left="217" width="124" height="20" font="0">randomized controlled </text>
<text top="141" left="217" width="67" height="20" font="0">clinical trial  </text>
<text top="159" left="217" width="3" height="20" font="7"><b> </b></text>
<text top="176" left="217" width="32" height="20" font="7"><b>Size: </b></text>
<text top="193" left="217" width="98" height="20" font="0">N recruited = 513 </text>
<text top="210" left="217" width="114" height="20" font="0">N randomized = 513 </text>
<text top="228" left="217" width="129" height="20" font="0">N reported outcomes = </text>
<text top="245" left="217" width="24" height="20" font="0">513 </text>
<text top="262" left="217" width="3" height="20" font="0"> </text>
<text top="107" left="368" width="112" height="20" font="0">versions of the FDC </text>
<text top="124" left="368" width="85" height="20" font="0">treatment were </text>
<text top="141" left="368" width="85" height="20" font="0">recommended  </text>
<text top="160" left="368" width="7" height="18" font="0">•</text>
<text top="160" left="375" width="116" height="20" font="0"> Patients had started </text>
<text top="177" left="368" width="112" height="20" font="0">statins ≥ 1 y prior to </text>
<text top="194" left="368" width="133" height="20" font="0">inclusion, and were non-</text>
<text top="211" left="368" width="155" height="20" font="0">adherent in the year prior to </text>
<text top="229" left="368" width="156" height="20" font="0">inclusion (refill rate between </text>
<text top="246" left="368" width="87" height="20" font="0">50% and 80%) <b> </b></text>
<text top="263" left="368" width="3" height="20" font="0"> </text>
<text top="280" left="368" width="114" height="20" font="7"><b>Exclusion criteria:  </b></text>
<text top="299" left="368" width="7" height="18" font="0">•</text>
<text top="299" left="375" width="139" height="20" font="0"> Contraindications to any </text>
<text top="316" left="368" width="113" height="20" font="0">components of FDC </text>
<text top="335" left="368" width="7" height="18" font="0">•</text>
<text top="334" left="375" width="140" height="20" font="0"> Congestive heart failure, </text>
<text top="352" left="368" width="148" height="20" font="0">hemorrhagic stroke, active </text>
<text top="369" left="368" width="152" height="20" font="0">stomach or duodenal ulcer, </text>
<text top="386" left="368" width="155" height="20" font="0">receipt of oral anticoagulant </text>
<text top="405" left="368" width="7" height="18" font="0">•</text>
<text top="404" left="375" width="136" height="20" font="0"> Concerns of PCP about </text>
<text top="422" left="368" width="73" height="20" font="0">risk of study  </text>
<text top="441" left="368" width="7" height="18" font="0">•</text>
<text top="440" left="375" width="123" height="20" font="0"> Participant unlikely to </text>
<text top="457" left="368" width="124" height="20" font="0">complete the trial (i.e., </text>
<text top="474" left="368" width="92" height="20" font="0">terminal illness) <b> </b></text>
<text top="492" left="368" width="3" height="20" font="0"> </text>
<text top="107" left="539" width="137" height="20" font="0">hydrochlorothiazide 12.5 </text>
<text top="124" left="539" width="77" height="20" font="0">mg. (n = 256) </text>
<text top="141" left="539" width="3" height="20" font="0"> </text>
<text top="159" left="539" width="77" height="20" font="7"><b>Comparator: </b></text>
<text top="176" left="539" width="113" height="20" font="0">Cardiovascular drug </text>
<text top="193" left="539" width="134" height="20" font="0">regimen was prescribed </text>
<text top="210" left="539" width="141" height="20" font="0">according to PCP’s usual </text>
<text top="228" left="539" width="101" height="20" font="0">method. (n = 257)<b> </b></text>
<text top="109" left="921" width="7" height="18" font="0">•</text>
<text top="108" left="928" width="187" height="20" font="0"> There was a significant reduction </text>
<text top="125" left="921" width="181" height="20" font="0">in SBP for the intervention group </text>
<text top="143" left="921" width="196" height="20" font="0">compared to the control group (-2.6 </text>
<text top="160" left="921" width="186" height="20" font="0">mmHg; 95% CI: -4.0, -1.1 mmHg; </text>
<text top="177" left="921" width="59" height="20" font="0">p&lt;0.001).  </text>
<text top="194" left="921" width="3" height="20" font="0"> </text>
<text top="211" left="921" width="3" height="20" font="0"> </text>
<text top="229" left="921" width="181" height="20" font="7"><b>Study limitations: </b>(1) Moderate </text>
<text top="246" left="921" width="195" height="20" font="0">statistical power limits ability to rule </text>
<text top="263" left="921" width="196" height="20" font="0">out small increases or decreases in </text>
<text top="280" left="921" width="164" height="20" font="0">risk factor levels. (2) Baseline </text>
<text top="298" left="921" width="181" height="20" font="0">treatment rates were higher than </text>
<text top="315" left="921" width="194" height="20" font="0">national averages, limiting ability to </text>
<text top="332" left="921" width="190" height="20" font="0">test FDC among patients currently </text>
<text top="349" left="921" width="188" height="20" font="0">taking few or no preventive drugs. </text>
<text top="366" left="921" width="171" height="20" font="0">(3) Open label trial design may </text>
<text top="384" left="921" width="168" height="20" font="0">have contributed to differential </text>
<text top="401" left="921" width="172" height="20" font="0">treatment or reporting between </text>
<text top="418" left="921" width="48" height="20" font="0">groups.  </text>
<text top="435" left="921" width="3" height="20" font="7"><b> </b></text>
<text top="452" left="921" width="190" height="20" font="7"><b>Adverse events: </b>There was not a </text>
<text top="470" left="921" width="172" height="20" font="0">significant difference in serious </text>
<text top="487" left="921" width="157" height="20" font="0">adverse events between the </text>
<text top="504" left="921" width="172" height="20" font="0">intervention group (99) and the </text>
<text top="521" left="921" width="189" height="20" font="0">control group (93) (p=0.56). There </text>
<text top="539" left="921" width="181" height="20" font="0">were 4 deaths in the intervention </text>
<text top="556" left="921" width="163" height="20" font="0">group and 6 in the usual care </text>
<text top="573" left="921" width="84" height="20" font="0">group (p=0.75) </text>
<text top="590" left="921" width="3" height="20" font="0"> </text>
<text top="608" left="89" width="114" height="20" font="0">Thom S, et al., 2013 </text>
<text top="625" left="89" width="32" height="20" font="0"><a href="data supplement.html#252">(269)</a> </text>
<text top="643" left="89" width="58" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24002278">24002278 </a></text>
<text top="643" left="148" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/24002278"> </a></text>
<text top="660" left="89" width="3" height="20" font="0"> </text>
<text top="677" left="89" width="3" height="20" font="7"><b> </b></text>
<text top="608" left="217" width="107" height="20" font="7"><b>Aim:</b> To determine </text>
<text top="625" left="217" width="120" height="20" font="0">whether FDC therapy </text>
<text top="643" left="217" width="109" height="20" font="0">improves long-term </text>
<text top="660" left="217" width="120" height="20" font="0">adherence, SBP, and </text>
<text top="677" left="217" width="130" height="20" font="0">LDL-C when compared </text>
<text top="694" left="217" width="81" height="20" font="0">to usual care.  </text>
<text top="711" left="217" width="3" height="20" font="7"><b> </b></text>
<text top="729" left="217" width="115" height="20" font="7"><b>Study type: </b>Parallel </text>
<text top="746" left="217" width="124" height="20" font="0">randomized controlled </text>
<text top="763" left="217" width="64" height="20" font="0">clinical trial </text>
<text top="780" left="217" width="3" height="20" font="7"><b> </b></text>
<text top="608" left="368" width="109" height="20" font="7"><b>Inclusion criteria:  </b></text>
<text top="627" left="368" width="7" height="18" font="0">•</text>
<text top="626" left="375" width="79" height="20" font="0"> ≥ 18 y of age </text>
<text top="646" left="368" width="7" height="18" font="0">•</text>
<text top="645" left="375" width="137" height="20" font="0"> High cardiovascular risk </text>
<text top="662" left="368" width="140" height="20" font="0">(history of coronary heart </text>
<text top="679" left="368" width="100" height="20" font="0">disease, ischemic </text>
<text top="697" left="368" width="154" height="20" font="0">cerebrovascular disease, or </text>
<text top="714" left="368" width="156" height="20" font="0">peripheral vascular disease; </text>
<text top="731" left="368" width="155" height="20" font="0">or estimated 5-y CVD risk ≥ </text>
<text top="748" left="368" width="32" height="20" font="0">15%)<b> </b></text>
<text top="765" left="368" width="3" height="20" font="0"> </text>
<text top="783" left="368" width="114" height="20" font="7"><b>Exclusion criteria:  </b></text>
<text top="608" left="539" width="125" height="20" font="7"><b>Intervention</b>: Patients </text>
<text top="625" left="539" width="142" height="20" font="0">were assigned to an FDC </text>
<text top="643" left="539" width="123" height="20" font="0">of either (1) aspirin 75 </text>
<text top="660" left="539" width="130" height="20" font="0">mg, simvastatin 40 mg, </text>
<text top="677" left="539" width="113" height="20" font="0">lisinopril 10 mg, and </text>
<text top="694" left="539" width="120" height="20" font="0">atenolol 50 mg; or (2) </text>
<text top="711" left="539" width="145" height="20" font="0">aspirin 75 mg, simvastatin </text>
<text top="729" left="539" width="130" height="20" font="0">40 mg, lisinopril 10 mg, </text>
<text top="746" left="539" width="134" height="20" font="0">and hydrochlorothiazide </text>
<text top="763" left="539" width="91" height="20" font="0">12.5. (n = 1002) </text>
<text top="780" left="539" width="3" height="20" font="0"> </text>
<text top="609" left="698" width="150" height="20" font="7"><b>1</b>°<b> endpoint: </b>Self-reported </text>
<text top="627" left="698" width="162" height="20" font="0">adherence (defined as taking </text>
<text top="644" left="698" width="183" height="20" font="0">medication for ≤ 4 d during week </text>
<text top="661" left="698" width="187" height="20" font="0">preceding visit); mean changes in </text>
<text top="678" left="698" width="142" height="20" font="0">LDL-C and SBP at 15 mo </text>
<text top="695" left="698" width="3" height="20" font="0"> </text>
<text top="714" left="698" width="7" height="18" font="0">•</text>
<text top="714" left="705" width="201" height="20" font="0"> Adherence was significantly greater </text>
<text top="731" left="698" width="182" height="20" font="0">for patients receiving FDC, when </text>
<text top="748" left="698" width="204" height="20" font="0">compared to the usual care (86% vs. </text>
<text top="765" left="698" width="206" height="20" font="0">65%, RR: 1.33, 95% CI: 1.26 to 1.41; </text>
<text top="783" left="698" width="56" height="20" font="0">p&lt;0.001). </text>
<text top="608" left="921" width="193" height="20" font="7"><b>Study limitations: </b>(1) Participants </text>
<text top="625" left="921" width="131" height="20" font="0">selected based on their </text>
<text top="643" left="921" width="182" height="20" font="0">willingness/ability to attend study </text>
<text top="660" left="921" width="141" height="20" font="0">visits, which may limit the </text>
<text top="677" left="921" width="187" height="20" font="0">generalizability of the findings. (2) </text>
<text top="694" left="921" width="196" height="20" font="0">High level of adherence reported at </text>
<text top="711" left="921" width="186" height="20" font="0">baseline findings when compared </text>
<text top="729" left="921" width="157" height="20" font="0">with the general population.  </text>
<text top="746" left="921" width="3" height="20" font="0"> </text>
<text top="763" left="921" width="176" height="20" font="7"><b>Adverse events: </b>There was no </text>
<text top="780" left="921" width="166" height="20" font="0">significant different in adverse </text>
</page>
<page number="225" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">225 </text>
<text top="107" left="217" width="32" height="20" font="7"><b>Size: </b></text>
<text top="124" left="217" width="105" height="20" font="0">N recruited = 2138 </text>
<text top="141" left="217" width="121" height="20" font="0">N randomized = 2004 </text>
<text top="159" left="217" width="129" height="20" font="0">N reported outcomes = </text>
<text top="176" left="217" width="31" height="20" font="0">1921<b> </b></text>
<text top="109" left="368" width="7" height="18" font="0">•</text>
<text top="108" left="375" width="135" height="20" font="0"> Low cardiovascular risk </text>
<text top="127" left="368" width="7" height="18" font="0">•</text>
<text top="127" left="375" width="115" height="20" font="0"> Contraindications to </text>
<text top="144" left="368" width="120" height="20" font="0">switching medication  </text>
<text top="163" left="368" width="7" height="18" font="0">•</text>
<text top="162" left="375" width="139" height="20" font="0"> Inability to complete trial </text>
<text top="179" left="368" width="3" height="20" font="7"><b> </b></text>
<text top="107" left="539" width="139" height="20" font="7"><b>Comparator: </b>Usual care<b> </b></text>
<text top="124" left="539" width="53" height="20" font="0">(n=1002)<b> </b></text>
<text top="107" left="698" width="3" height="20" font="0"> </text>
<text top="126" left="698" width="7" height="18" font="0">•</text>
<text top="125" left="705" width="203" height="20" font="0"> There was a significant difference in </text>
<text top="143" left="698" width="206" height="20" font="0">LDL-C, favoring the intervention (-4.2 </text>
<text top="160" left="698" width="154" height="20" font="0">mg/dL, 95% CI: -6.6 to -1.9; </text>
<text top="177" left="698" width="59" height="20" font="0">p&lt;0.001).  </text>
<text top="194" left="698" width="3" height="20" font="0"> </text>
<text top="213" left="698" width="7" height="18" font="0">•</text>
<text top="213" left="705" width="203" height="20" font="0"> There was a significant difference in </text>
<text top="230" left="698" width="195" height="20" font="0">SBP, favoring the intervention (-2.6 </text>
<text top="247" left="698" width="196" height="20" font="0">mmHg, 95% CI: -4.0 to -1.1 mmHg; </text>
<text top="264" left="698" width="52" height="20" font="0">p&lt;0.001) </text>
<text top="281" left="698" width="3" height="20" font="7"><b> </b></text>
<text top="107" left="921" width="174" height="20" font="0">events between the FDC group </text>
<text top="124" left="921" width="169" height="20" font="0">(5%) and the usual care group </text>
<text top="141" left="921" width="175" height="20" font="0">(3.5%) (p=0.09). There were 17 </text>
<text top="159" left="921" width="195" height="20" font="0">deaths in the FDC group compared </text>
<text top="176" left="921" width="159" height="20" font="0">to 15 in the usual care group </text>
<text top="193" left="921" width="56" height="20" font="0">(p=0.72). <b> </b></text>
<text top="301" left="88" width="1029" height="20" font="7"><b>Abbreviations:</b> 1° indicated primary; CI, confidence interval; CVD, cardiovascular disease; FDC, fixed-dose combination; HR, hazard ratio; LDL-C, low density lipoprotein cholesterol; MAQ, </text>
<text top="318" left="88" width="997" height="20" font="0">Morisky Green questionnaire; N/A, not available; OR, odds ratio; PCP, primary care provider; RCT, randomized controlled trial; and RR, relative risk; and SBP, systolic blood pressure. </text>
<text top="335" left="88" width="206" height="20" font="7"><b>Search Terms and Date of Search</b>:  </text>
<text top="352" left="81" width="4" height="22" font="1"> </text>
<text top="371" left="81" width="4" height="22" font="1"> </text>
<text top="390" left="81" width="409" height="24" font="4"><b>Data Supplement 45. RCTs for Implementation (Section 6) </b></text>
<text top="412" left="107" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="429" left="132" width="48" height="20" font="7"><b>Author; </b></text>
<text top="447" left="110" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="412" left="276" width="83" height="20" font="7"><b>Aim of Study; </b></text>
<text top="429" left="281" width="74" height="20" font="7"><b>Study Type; </b></text>
<text top="447" left="275" width="86" height="20" font="7"><b>Study Size (N) </b></text>
<text top="429" left="450" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="412" left="683" width="105" height="20" font="7"><b>Endpoint Results </b></text>
<text top="429" left="667" width="137" height="20" font="7"><b>(Absolute Event Rates, </b></text>
<text top="447" left="645" width="181" height="20" font="7"><b>P values; OR or RR; &amp; 95% CI) </b></text>
<text top="413" left="899" width="175" height="20" font="7"><b>Relevant 2</b>°<b> Endpoint (if any); </b></text>
<text top="430" left="931" width="111" height="20" font="7"><b>Study Limitations; </b></text>
<text top="447" left="939" width="96" height="20" font="7"><b>Adverse Events </b></text>
<text top="465" left="89" width="117" height="20" font="0">Choudhry, NK, et al., </text>
<text top="482" left="89" width="63" height="20" font="0">2011 <a href="data supplement.html#251">(263)</a> </text>
<text top="499" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22080794">22080794</a></text>
<text top="499" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22080794"> </a></text>
<text top="517" left="89" width="3" height="20" font="0"> </text>
<text top="465" left="236" width="77" height="20" font="7"><b>Study type:</b>   </text>
<text top="482" left="236" width="156" height="20" font="0">investigator-initiated, cluster-</text>
<text top="499" left="236" width="128" height="20" font="0">randomized, controlled </text>
<text top="517" left="236" width="68" height="20" font="0">policy study </text>
<text top="534" left="236" width="144" height="20" font="7"><b>Size:</b> 5855 patients (2845 </text>
<text top="551" left="236" width="143" height="20" font="0">full prescription coverage; </text>
<text top="568" left="236" width="135" height="20" font="0">3010 patients with usual </text>
<text top="586" left="236" width="125" height="20" font="0">prescription coverage) </text>
<text top="465" left="412" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="482" left="412" width="171" height="20" font="0">Patients received both medical </text>
<text top="499" left="412" width="119" height="20" font="0">and prescription drug </text>
<text top="517" left="412" width="130" height="20" font="0">benefits through Aetna, </text>
<text top="534" left="412" width="183" height="20" font="0">discharged from the hospital with </text>
<text top="551" left="412" width="134" height="20" font="0">a principal or secondary </text>
<text top="568" left="412" width="170" height="20" font="0">diagnosis code of International </text>
<text top="586" left="412" width="167" height="20" font="0">Classification of Diseases, 9th </text>
<text top="603" left="412" width="166" height="20" font="0">Revision, Clinical Modification </text>
<text top="620" left="412" width="167" height="20" font="0">(ICD-9-CM) 410 (except when </text>
<text top="637" left="412" width="184" height="20" font="0">the fifth digit was 2), and a length </text>
<text top="655" left="412" width="115" height="20" font="0">of stay of 3 to 180 d. </text>
<text top="672" left="412" width="3" height="20" font="7"><b> </b></text>
<text top="689" left="412" width="154" height="20" font="7"><b>Exclusion criteria </b>Patients </text>
<text top="706" left="412" width="152" height="20" font="0">enrolled in a health savings </text>
<text top="723" left="412" width="182" height="20" font="0">account offering full coverage for </text>
<text top="741" left="412" width="122" height="20" font="0">the study medications </text>
<text top="758" left="412" width="18" height="20" font="0">or  </text>
<text top="466" left="612" width="79" height="20" font="7"><b>1</b>°<b> endpoint:</b>  </text>
<text top="483" left="612" width="159" height="20" font="0">First major vascular event or </text>
<text top="501" left="612" width="99" height="20" font="0">revascularization. </text>
<text top="518" left="612" width="3" height="20" font="0"> </text>
<text top="535" left="612" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="552" left="612" width="182" height="20" font="0">Primary endpoint - no difference  </text>
<text top="569" left="612" width="231" height="20" font="0">17.6 per 100 person-y in the full-coverage </text>
<text top="587" left="612" width="240" height="20" font="0">group vs. 18.8 in the usual coverage group; </text>
<text top="604" left="612" width="206" height="20" font="0">HR: 0.93; 95% CI: 0.82-1.04; p=0.21. </text>
<text top="621" left="612" width="3" height="20" font="0"> </text>
<text top="640" left="612" width="11" height="18" font="0">• </text>
<text top="640" left="623" width="191" height="20" font="0">Secondary endpoints better for full-</text>
<text top="659" left="623" width="218" height="20" font="0">coverage total major vascular events or </text>
<text top="679" left="623" width="232" height="20" font="0">revascularization (21.5 vs. 23.3; HR: 0.89; </text>
<text top="699" left="623" width="165" height="20" font="0">95% CI: 0.90 to 0.99; p=0.03) </text>
<text top="720" left="612" width="11" height="18" font="0">• </text>
<text top="720" left="623" width="198" height="20" font="0">Rate of first major vascular event or </text>
<text top="739" left="623" width="232" height="20" font="0">revascularization (11.0 vs. 12.8; HR: 0.93; </text>
<text top="759" left="623" width="113" height="20" font="0">95% CI: 0.82–1.04). </text>
<text top="467" left="871" width="7" height="18" font="0">•</text>
<text top="466" left="878" width="204" height="20" font="0"> Elimination of copayments improved </text>
<text top="483" left="871" width="206" height="20" font="0">adherence and secondary outcomes. </text>
<text top="502" left="871" width="7" height="18" font="0">•</text>
<text top="502" left="878" width="197" height="20" font="0"> Although out-of-pocket costs to the </text>
<text top="519" left="871" width="222" height="20" font="0">patient were reduced, total spending did </text>
<text top="536" left="871" width="74" height="20" font="0">not increase. </text>
</page>
<page number="226" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">226 </text>
<text top="107" left="412" width="175" height="20" font="0">&gt; 65 y of age at time of hospital </text>
<text top="124" left="412" width="171" height="20" font="0">discharge, since Medicare was </text>
<text top="141" left="412" width="122" height="20" font="0">primary health insurer </text>
<text top="109" left="612" width="11" height="18" font="0">• </text>
<text top="108" left="623" width="217" height="20" font="0">Adherence rates statins, beta-blockers, </text>
<text top="128" left="623" width="177" height="20" font="0">ACE inhibitors, and ARBs for all </text>
<text top="148" left="623" width="130" height="20" font="0">comparisons (p&lt;0.001) </text>
<text top="182" left="612" width="219" height="20" font="0">No difference in total spending between </text>
<text top="200" left="612" width="240" height="20" font="0">groups ($66,008 for the full-coverage group </text>
<text top="217" left="612" width="231" height="20" font="0">vs. $71,778 for the usual-coverage group; </text>
<text top="234" left="612" width="237" height="20" font="0">relative spending, 0.89; 95% CI: 0.50-1.56; </text>
<text top="251" left="612" width="49" height="20" font="0">p=0.68). </text>
<text top="270" left="88" width="921" height="20" font="7"><b>Abbreviations:</b> 1° indicated primary; CI, confidence interval; HR, hazard ratio; N/A, not available; OR, odds ratio; RCT, randomized controlled trial; and RR, relative risk. </text>
<text top="288" left="88" width="297" height="20" font="7"><b>Search Terms and Date of Search</b>: Author to provide</text>
<text top="286" left="384" width="4" height="22" font="1"> </text>
</page>
<page number="227" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">227 </text>
<text top="106" left="81" width="818" height="24" font="4"><b>Data Supplement 46. Nonrandomized Trials, Observational Studies, and/or Registries for Implementation (Section 6</b>) </text>
<text top="128" left="115" width="98" height="20" font="7"><b>Study Acronym; </b></text>
<text top="145" left="141" width="48" height="20" font="7"><b>Author; </b></text>
<text top="162" left="118" width="92" height="20" font="7"><b>Year Published </b></text>
<text top="136" left="263" width="118" height="20" font="7"><b>Study Type/Design; </b></text>
<text top="154" left="289" width="66" height="20" font="7"><b>Study Size </b></text>
<text top="145" left="462" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="136" left="667" width="179" height="20" font="7"><b>Primary Endpoint and Results </b></text>
<text top="154" left="665" width="184" height="20" font="7"><b>(P values; OR or RR; &amp; 95% CI) </b></text>
<text top="136" left="936" width="130" height="20" font="7"><b>Summary/Conclusion </b></text>
<text top="154" left="963" width="75" height="20" font="7"><b>Comment(s) </b></text>
<text top="180" left="91" width="145" height="20" font="0">ACC/AHA Special Report: </text>
<text top="197" left="91" width="146" height="20" font="0">Clinical Practice Guideline </text>
<text top="215" left="91" width="87" height="20" font="0">Implementation </text>
<text top="232" left="91" width="125" height="20" font="0">Strategies, 2017<a href="data supplement.html#252"> (270)</a><b> </b></text>
<text top="249" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28132746">28132746</a></text>
<text top="249" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28132746"> </a></text>
<text top="180" left="251" width="140" height="20" font="7"><b>Study type:</b> Summary of </text>
<text top="197" left="251" width="135" height="20" font="0">systematic reviews (SR) </text>
<text top="215" left="251" width="3" height="20" font="0"> </text>
<text top="232" left="251" width="39" height="20" font="7"><b>Size:</b>   </text>
<text top="249" left="251" width="38" height="20" font="0">39 SR </text>
<text top="266" left="251" width="109" height="20" font="0">16 overviews of SR </text>
<text top="180" left="406" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="197" left="406" width="197" height="20" font="0">For critical questions (CQ) 1,2: SRs </text>
<text top="215" left="406" width="223" height="20" font="0">focused on implementation of guidelines </text>
<text top="232" left="406" width="193" height="20" font="0">or clinical practice directly affecting </text>
<text top="249" left="406" width="203" height="20" font="0">patient care   + aimed at clinicians [4 </text>
<text top="266" left="406" width="80" height="20" font="0">interventions:  </text>
<text top="285" left="417" width="11" height="18" font="0">• </text>
<text top="285" left="428" width="189" height="20" font="0">audit and feedback (any summary </text>
<text top="304" left="428" width="164" height="20" font="0">of clinical performance over a </text>
<text top="324" left="428" width="189" height="20" font="0">specified time period; may include </text>
<text top="344" left="428" width="159" height="20" font="0">recommendations for clinical </text>
<text top="364" left="428" width="46" height="20" font="0">active);  </text>
<text top="385" left="417" width="11" height="18" font="0">• </text>
<text top="384" left="428" width="148" height="20" font="0">educational outreach visits </text>
<text top="404" left="428" width="161" height="20" font="0">(academic detailing = trained </text>
<text top="424" left="428" width="185" height="20" font="0">person met with providers in their </text>
<text top="444" left="428" width="190" height="20" font="0">practice setting to give information </text>
<text top="464" left="428" width="196" height="20" font="0">with the intent of changing practice; </text>
<text top="483" left="428" width="191" height="20" font="0">the information may have included </text>
<text top="503" left="428" width="150" height="20" font="0">feedback on performance); </text>
<text top="525" left="417" width="11" height="18" font="0">• </text>
<text top="524" left="428" width="179" height="20" font="0"> reminders (patient or encounter </text>
<text top="544" left="428" width="202" height="20" font="0">specific information given verbally or </text>
<text top="564" left="428" width="185" height="20" font="0">on paper/computer screen, which </text>
<text top="583" left="428" width="198" height="20" font="0">was designed to prompt information </text>
<text top="603" left="428" width="174" height="20" font="0">recall; computer-aided decision </text>
<text top="623" left="428" width="154" height="20" font="0">support and drug doses are </text>
<text top="643" left="428" width="60" height="20" font="0">included);  </text>
<text top="664" left="417" width="11" height="18" font="0">• </text>
<text top="664" left="428" width="151" height="20" font="0">provider incentives (pay for </text>
<text top="683" left="428" width="174" height="20" font="0">performance = direct or indirect </text>
<text top="703" left="428" width="164" height="20" font="0">financial reward/benefit to the </text>
<text top="723" left="428" width="161" height="20" font="0">individual for doing a specific </text>
<text top="743" left="428" width="44" height="20" font="0">action). </text>
<text top="778" left="406" width="3" height="20" font="0"> </text>
<text top="181" left="643" width="79" height="20" font="7"><b>1</b>°<b> endpoint:</b>  </text>
<text top="199" left="643" width="124" height="20" font="0">Critical questions 1,2:  </text>
<text top="218" left="653" width="11" height="18" font="0">• </text>
<text top="217" left="664" width="206" height="20" font="0">Generally effective: &gt; 2/3 studies had </text>
<text top="236" left="664" width="152" height="20" font="0">positive intervention effects </text>
<text top="258" left="653" width="11" height="18" font="0">• </text>
<text top="257" left="664" width="169" height="20" font="0">Mixed effectiveness: 1/3 to 2/3 </text>
<text top="277" left="664" width="178" height="20" font="0">studies had positive intervention </text>
<text top="297" left="664" width="40" height="20" font="0">effects </text>
<text top="319" left="653" width="11" height="18" font="0">• </text>
<text top="318" left="664" width="192" height="20" font="0">Generally ineffective: &lt; 1/3 studies </text>
<text top="338" left="664" width="176" height="20" font="0">had positive intervention effects </text>
<text top="372" left="643" width="3" height="20" font="0"> </text>
<text top="389" left="643" width="216" height="20" font="0">Critical questions 3, 4: Conclusions are </text>
<text top="407" left="643" width="190" height="20" font="0">drawn from contractor's qualitative </text>
<text top="424" left="643" width="185" height="20" font="0">coding of included reviews during </text>
<text top="441" left="643" width="192" height="20" font="0">abstraction process for a variety of </text>
<text top="458" left="643" width="226" height="20" font="0">categories of contextual factors identified </text>
<text top="476" left="643" width="44" height="20" font="0">a priori. </text>
<text top="493" left="643" width="3" height="20" font="0"> </text>
<text top="510" left="643" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="527" left="643" width="226" height="20" font="0">Generally effective for improving process </text>
<text top="544" left="643" width="165" height="20" font="0">of care and clinical outcomes: </text>
<text top="564" left="653" width="11" height="18" font="0">• </text>
<text top="563" left="664" width="159" height="20" font="0">audit and feedback (15 of 21 </text>
<text top="582" left="664" width="142" height="20" font="0">reviews; 7 of 12 reviews)  </text>
<text top="604" left="653" width="11" height="18" font="0">• </text>
<text top="603" left="664" width="200" height="20" font="0">educational outreach visits (12 of 13 </text>
<text top="623" left="664" width="132" height="20" font="0">reviews; 3 of 5 reviews) </text>
<text top="658" left="643" width="206" height="20" font="0">Generally effective for cost reduction: </text>
<text top="677" left="653" width="11" height="18" font="0">• </text>
<text top="676" left="664" width="170" height="20" font="0">outreach visits (2 of 2 reviews) </text>
<text top="698" left="653" width="11" height="18" font="0">• </text>
<text top="697" left="664" width="146" height="20" font="0">reminders (3 of 4 reviews) </text>
<text top="718" left="653" width="11" height="18" font="0">• </text>
<text top="718" left="664" width="187" height="20" font="0">provider incentives (1 of 1 review) </text>
<text top="753" left="643" width="225" height="20" font="0">Generally effective for cost-effectiveness </text>
<text top="770" left="643" width="64" height="20" font="0">outcomes:  </text>
<text top="182" left="884" width="7" height="18" font="0">•</text>
<text top="181" left="891" width="165" height="20" font="0"> Gaps exist in the evidence of </text>
<text top="199" left="884" width="176" height="20" font="0">effectiveness of implementation </text>
<text top="216" left="884" width="64" height="20" font="0">strategies.  </text>
<text top="235" left="884" width="7" height="18" font="0">•</text>
<text top="234" left="891" width="203" height="20" font="0"> Audit and feedback and educational </text>
<text top="251" left="884" width="228" height="20" font="0">outreach visits were generally effective in </text>
<text top="269" left="884" width="208" height="20" font="0">improving process of care and clinical </text>
<text top="286" left="884" width="60" height="20" font="0">outcomes. </text>
<text top="305" left="884" width="7" height="18" font="0">•</text>
<text top="304" left="891" width="183" height="20" font="0"> Educational outreach visits were </text>
<text top="321" left="884" width="224" height="20" font="0">generally effective for cost reduction and </text>
<text top="339" left="884" width="161" height="20" font="0">cost effectiveness outcomes. </text>
<text top="358" left="884" width="7" height="18" font="0">•</text>
<text top="357" left="891" width="196" height="20" font="0"> Reminders and provider incentives </text>
<text top="374" left="884" width="176" height="20" font="0">were generally effective for cost </text>
<text top="391" left="884" width="57" height="20" font="0">reduction. </text>
<text top="410" left="884" width="7" height="18" font="0">•</text>
<text top="410" left="891" width="196" height="20" font="0"> Reminders and provider incentives </text>
<text top="427" left="884" width="232" height="20" font="0">showed mixed effectiveness for improving </text>
<text top="444" left="884" width="94" height="20" font="0">process of care.  </text>
<text top="463" left="884" width="7" height="18" font="0">•</text>
<text top="462" left="891" width="212" height="20" font="0"> Implementation strategies may not be </text>
<text top="480" left="884" width="204" height="20" font="0">effective across all practice settings.  </text>
<text top="499" left="884" width="7" height="18" font="0">•</text>
<text top="498" left="891" width="183" height="20" font="0"> It may take multiple strategies to </text>
<text top="515" left="884" width="222" height="20" font="0">implement guidelines in clinical practice. </text>
</page>
<page number="228" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">228 </text>
<text top="107" left="406" width="221" height="20" font="0">For critical questions (CQ) 3,4: SRs and </text>
<text top="124" left="406" width="222" height="20" font="0">overviews of SRs focused on contextual </text>
<text top="141" left="406" width="141" height="20" font="0">issues affecting guideline </text>
<text top="159" left="406" width="94" height="20" font="0">implementation.  </text>
<text top="176" left="406" width="3" height="20" font="0"> </text>
<text top="193" left="406" width="218" height="20" font="7"><b>Exclusion criteria:</b> Studies focused on </text>
<text top="210" left="406" width="199" height="20" font="0">interventions targeting patients (e.g. </text>
<text top="227" left="406" width="163" height="20" font="0">patient education/reminders). </text>
<text top="109" left="653" width="11" height="18" font="0">• </text>
<text top="108" left="664" width="187" height="20" font="0">educational outreach visits (1 of 1 </text>
<text top="128" left="664" width="201" height="20" font="0">review) and provider incentives (1 of </text>
<text top="148" left="664" width="60" height="20" font="0">1 review) . </text>
<text top="182" left="643" width="186" height="20" font="0">Mixed effectiveness for improving </text>
<text top="200" left="643" width="212" height="20" font="0">process of care and clinical outcomes: </text>
<text top="219" left="653" width="11" height="18" font="0">• </text>
<text top="218" left="664" width="203" height="20" font="0">provider incentives (3 of 4 reviews; 3 </text>
<text top="238" left="664" width="198" height="20" font="0">reviews equally distributed between </text>
<text top="258" left="664" width="169" height="20" font="0">generally effective, mixed, and </text>
<text top="277" left="664" width="120" height="20" font="0">generally ineffective). </text>
<text top="312" left="643" width="186" height="20" font="0">Mixed effectiveness for improving </text>
<text top="329" left="643" width="224" height="20" font="0">process of care and generally ineffective </text>
<text top="346" left="643" width="118" height="20" font="0">for clinical outcomes: </text>
<text top="366" left="653" width="11" height="18" font="0">• </text>
<text top="365" left="664" width="203" height="20" font="0">reminders (27 reviews with 11 mixed </text>
<text top="385" left="664" width="206" height="20" font="0">and 3 generally ineffective results; 18 </text>
<text top="404" left="664" width="204" height="20" font="0">reviews with 6 mixed and 9 generally </text>
<text top="424" left="664" width="109" height="20" font="0">ineffective results).  </text>
<text top="459" left="643" width="3" height="20" font="0"> </text>
<text top="476" left="643" width="116" height="20" font="0">Facilitating factors to </text>
<text top="493" left="643" width="119" height="20" font="0">adoption/adherence:  </text>
<text top="512" left="653" width="11" height="18" font="0">• </text>
<text top="512" left="664" width="204" height="20" font="0">guideline characteristics, e.g. format, </text>
<text top="532" left="664" width="206" height="20" font="0">resources, and end-user involvement </text>
<text top="551" left="664" width="125" height="20" font="0">(6 reviews/overviews). </text>
<text top="573" left="653" width="11" height="18" font="0">• </text>
<text top="572" left="664" width="139" height="20" font="0">involving stakeholders (5 </text>
<text top="592" left="664" width="111" height="20" font="0">reviews/overviews). </text>
<text top="613" left="653" width="11" height="18" font="0">• </text>
<text top="613" left="664" width="119" height="20" font="0">leadership support (5 </text>
<text top="632" left="664" width="157" height="20" font="0">reviews/overviews) scope of </text>
<text top="652" left="664" width="101" height="20" font="0">implementation (5 </text>
<text top="672" left="664" width="111" height="20" font="0">reviews/overviews). </text>
<text top="694" left="653" width="11" height="18" font="0">• </text>
<text top="693" left="664" width="166" height="20" font="0">organizational culture such as </text>
<text top="713" left="664" width="173" height="20" font="0">multidisciplinary teams and low-</text>
<text top="732" left="664" width="125" height="20" font="0">baseline adherence (9 </text>
<text top="752" left="664" width="111" height="20" font="0">reviews/overviews). </text>
</page>
<page number="229" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">229 </text>
<text top="109" left="653" width="11" height="18" font="0">• </text>
<text top="108" left="664" width="178" height="20" font="0">electronic guidelines systems (3 </text>
<text top="128" left="664" width="53" height="20" font="0">reviews). </text>
<text top="163" left="643" width="3" height="20" font="0"> </text>
<text top="180" left="643" width="179" height="20" font="0">Barriers to adoption/ adherence: </text>
<text top="199" left="653" width="11" height="18" font="0">• </text>
<text top="198" left="664" width="104" height="20" font="0">time constraints (8 </text>
<text top="218" left="664" width="189" height="20" font="0">reviews/overviews) limited staffing </text>
<text top="238" left="664" width="137" height="20" font="0">resources (2 overviews). </text>
<text top="259" left="653" width="11" height="18" font="0">• </text>
<text top="259" left="664" width="158" height="20" font="0">timing (5 reviews/overviews) </text>
<text top="280" left="653" width="11" height="18" font="0">• </text>
<text top="280" left="664" width="122" height="20" font="0">clinician skepticism (5 </text>
<text top="299" left="664" width="111" height="20" font="0">reviews/overviews). </text>
<text top="321" left="653" width="11" height="18" font="0">• </text>
<text top="320" left="664" width="197" height="20" font="0">clinician knowledge of guidelines (4 </text>
<text top="340" left="664" width="111" height="20" font="0">reviews/overviews). </text>
<text top="361" left="653" width="11" height="18" font="0">• </text>
<text top="361" left="664" width="157" height="20" font="0">higher age of the clinician (1 </text>
<text top="381" left="664" width="59" height="20" font="0">overview). </text>
<text top="416" left="91" width="126" height="20" font="0">Fischer, F, et al., 2016 </text>
<text top="433" left="91" width="32" height="20" font="0"><a href="data supplement.html#252">(271)</a><b> </b></text>
<text top="450" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27417624">27417624</a></text>
<text top="450" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27417624"> </a></text>
<text top="467" left="91" width="7" height="20" font="0">  </text>
<text top="416" left="251" width="118" height="20" font="7"><b>Study type:</b> Scoping </text>
<text top="433" left="251" width="42" height="20" font="0">review  </text>
<text top="450" left="251" width="113" height="20" font="7"><b>Size:</b> 69 articles (42 </text>
<text top="467" left="251" width="112" height="20" font="0">studies, 27 reviews) </text>
<text top="416" left="406" width="204" height="20" font="7"><b>Inclusion criteria:</b> articles published </text>
<text top="433" left="406" width="194" height="20" font="0">through 2015 and listed in PubMed </text>
<text top="450" left="406" width="107" height="20" font="0">(English, German). </text>
<text top="467" left="406" width="3" height="20" font="0"> </text>
<text top="485" left="406" width="210" height="20" font="7"><b>Exclusion criteria:</b> If did not include:  </text>
<text top="504" left="417" width="11" height="18" font="0">• </text>
<text top="503" left="428" width="133" height="20" font="0">generalizable strategies </text>
<text top="525" left="417" width="11" height="18" font="0">• </text>
<text top="524" left="428" width="103" height="20" font="0">direct reference to </text>
<text top="544" left="428" width="172" height="20" font="0">strategies/barriers for guideline </text>
<text top="563" left="428" width="87" height="20" font="0">implementation </text>
<text top="585" left="417" width="11" height="18" font="0">• </text>
<text top="584" left="428" width="99" height="20" font="0">clinical guidelines </text>
<text top="606" left="417" width="11" height="18" font="0">• </text>
<text top="605" left="428" width="167" height="20" font="0">comparability (e.g. developing </text>
<text top="625" left="428" width="57" height="20" font="0">countries) </text>
<text top="646" left="417" width="11" height="18" font="0">• </text>
<text top="646" left="428" width="80" height="20" font="0">study protocol </text>
<text top="416" left="643" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="433" left="643" width="96" height="20" font="0">Physician factors </text>
<text top="452" left="653" width="11" height="18" font="0">• </text>
<text top="451" left="664" width="155" height="20" font="0">Barriers: knowledge (lack of </text>
<text top="471" left="664" width="190" height="20" font="0">awareness or familiarity); attitudes </text>
<text top="491" left="664" width="180" height="20" font="0">(lack of agreement, self-efficacy, </text>
<text top="511" left="664" width="175" height="20" font="0">skills, learning culture, outcome </text>
<text top="531" left="664" width="150" height="20" font="0">expectancy, or motivation). </text>
<text top="552" left="653" width="11" height="18" font="0">• </text>
<text top="551" left="664" width="141" height="20" font="0">Strategies: dissemination </text>
<text top="571" left="664" width="183" height="20" font="0">(standardize notification process, </text>
<text top="591" left="664" width="158" height="20" font="0">training material), continuing </text>
<text top="611" left="664" width="196" height="20" font="0">education/meetings, active learning </text>
<text top="630" left="664" width="153" height="20" font="0">with expert opinion leaders, </text>
<text top="650" left="664" width="188" height="20" font="0">individualized audit and feedback, </text>
<text top="670" left="664" width="180" height="20" font="0">group performance audit, quality </text>
<text top="690" left="664" width="176" height="20" font="0">circle, financial, standing orders </text>
<text top="725" left="643" width="138" height="20" font="0">Guideline-related factors </text>
<text top="744" left="653" width="11" height="18" font="0">• </text>
<text top="743" left="664" width="145" height="20" font="0">Barriers: lack of evidence, </text>
<text top="763" left="664" width="182" height="20" font="0">applicability, or clear intervention </text>
<text top="783" left="664" width="110" height="20" font="0">goals; plausibility of </text>
<text top="418" left="884" width="7" height="18" font="0">•</text>
<text top="417" left="891" width="183" height="20" font="0"> Publication and dissemination of </text>
<text top="434" left="884" width="203" height="20" font="0">guidelines does not ensure guideline </text>
<text top="451" left="884" width="90" height="20" font="0">implementation. </text>
<text top="470" left="884" width="7" height="18" font="0">•</text>
<text top="470" left="891" width="174" height="20" font="0"> An implementation strategy for </text>
<text top="487" left="884" width="119" height="20" font="0">guidelines is needed. </text>
<text top="506" left="884" width="7" height="18" font="0">•</text>
<text top="505" left="891" width="203" height="20" font="0"> Barriers to guideline implementation </text>
<text top="523" left="884" width="213" height="20" font="0">and adherence need to be analyzed in </text>
<text top="540" left="884" width="213" height="20" font="0">advance, so implementation strategies </text>
<text top="557" left="884" width="220" height="20" font="0">may be tailored to the setting and target </text>
<text top="574" left="884" width="38" height="20" font="0">group. </text>
<text top="591" left="884" width="3" height="20" font="0"> </text>
<text top="609" left="884" width="3" height="20" font="0"> </text>
</page>
<page number="230" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">230 </text>
<text top="107" left="664" width="174" height="20" font="0">recommendations; complex/too </text>
<text top="127" left="664" width="185" height="20" font="0">theoretical; focus on patients with </text>
<text top="147" left="664" width="148" height="20" font="0">single disease or excludes </text>
<text top="166" left="664" width="198" height="20" font="0">comorbidities, difficult to implement. </text>
<text top="188" left="653" width="11" height="18" font="0">• </text>
<text top="187" left="664" width="176" height="20" font="0">Strategies: use evidence-based </text>
<text top="207" left="664" width="196" height="20" font="0">medicine in guideline development, </text>
<text top="227" left="664" width="204" height="20" font="0">communication strategies, marketing </text>
<text top="247" left="664" width="163" height="20" font="0">outreach visits, computerized </text>
<text top="267" left="664" width="207" height="20" font="0">decision-support systems, reminders, </text>
<text top="286" left="664" width="76" height="20" font="0">pilot projects. </text>
<text top="321" left="643" width="89" height="20" font="0">External factors </text>
<text top="340" left="653" width="11" height="18" font="0">• </text>
<text top="339" left="664" width="196" height="20" font="0">Barriers: organizational constraints, </text>
<text top="359" left="664" width="187" height="20" font="0">lack of resources or collaboration, </text>
<text top="379" left="664" width="140" height="20" font="0">social and clinical norms. </text>
<text top="400" left="653" width="11" height="18" font="0">• </text>
<text top="400" left="664" width="154" height="20" font="0">Strategies: standing orders, </text>
<text top="420" left="664" width="178" height="20" font="0">improvements in organization of </text>
<text top="439" left="664" width="172" height="20" font="0">care, local adaption/consensus </text>
<text top="459" left="664" width="142" height="20" font="0">groups, incorporation into </text>
<text top="479" left="664" width="127" height="20" font="0">established structures. </text>
<text top="514" left="91" width="124" height="20" font="0">Stacey D, et al., 2017  </text>
<text top="532" left="91" width="32" height="20" font="0"><a href="data supplement.html#252">(272)</a> </text>
<text top="549" left="91" width="55" height="20" font="8"><a href="">28402085</a></text>
<text top="549" left="146" width="3" height="20" font="0"><a href=""> </a></text>
<text top="514" left="251" width="77" height="20" font="7"><b>Study type:</b>   </text>
<text top="532" left="251" width="139" height="20" font="0">Updated search (2012 to </text>
<text top="549" left="251" width="140" height="20" font="0">April 2015) in CENTRAL; </text>
<text top="566" left="251" width="113" height="20" font="0">MEDLINE; Embase; </text>
<text top="583" left="251" width="114" height="20" font="0">PsycINFO; and grey </text>
<text top="600" left="251" width="103" height="20" font="0">literature; includes </text>
<text top="618" left="251" width="62" height="20" font="0">CINAHL to </text>
<text top="635" left="251" width="98" height="20" font="0">September 2008. </text>
<text top="652" left="251" width="3" height="20" font="0"> </text>
<text top="669" left="251" width="105" height="20" font="7"><b> Size:</b> 105 studies, </text>
<text top="686" left="251" width="107" height="20" font="0">34,043 participants<b> </b></text>
<text top="514" left="406" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="532" left="406" width="217" height="20" font="0">RCTs comparing decision aids to usual </text>
<text top="549" left="406" width="202" height="20" font="0">care and/or alternative interventions. </text>
<text top="566" left="406" width="3" height="20" font="7"><b> </b></text>
<text top="583" left="406" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="600" left="406" width="192" height="20" font="0">Studies comparing detailed versus </text>
<text top="618" left="406" width="117" height="20" font="0">simple decision aids. </text>
<text top="635" left="406" width="3" height="20" font="7"><b> </b></text>
<text top="515" left="643" width="79" height="20" font="7"><b>1</b>°<b> endpoint:</b>  </text>
<text top="533" left="643" width="213" height="20" font="0">Difference in attributes of choice made </text>
<text top="550" left="643" width="187" height="20" font="0">and the decision-making process. </text>
<text top="567" left="643" width="3" height="20" font="7"><b> </b></text>
<text top="584" left="643" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="602" left="643" width="218" height="20" font="0">Decision aids improved these attributes </text>
<text top="619" left="643" width="135" height="20" font="0">compared to usual care: </text>
<text top="636" left="643" width="3" height="20" font="0"> </text>
<text top="653" left="643" width="80" height="20" font="7"><b>Choice made </b></text>
<text top="672" left="653" width="11" height="18" font="0">• </text>
<text top="672" left="664" width="169" height="20" font="0">participants’ knowledge (mean </text>
<text top="691" left="664" width="200" height="20" font="0">difference 13.27/100; 95% CI: 11.32 </text>
<text top="711" left="664" width="203" height="20" font="0">- 15.23; 52 studies; N = 13,316; high-</text>
<text top="731" left="664" width="99" height="20" font="0">quality evidence), </text>
<text top="752" left="653" width="11" height="18" font="0">• </text>
<text top="752" left="664" width="182" height="20" font="0">accuracy of risk perceptions (risk </text>
<text top="771" left="664" width="188" height="20" font="0">ratio 2.10; 95% CI: 1.66 - 2.66; 17 </text>
<text top="514" left="884" width="144" height="20" font="0">After using a decision aid, </text>
<text top="533" left="895" width="11" height="18" font="0">• </text>
<text top="533" left="906" width="116" height="20" font="0">knowledge improved </text>
<text top="554" left="895" width="11" height="18" font="0">• </text>
<text top="553" left="906" width="175" height="20" font="0">patients had more accurate risk </text>
<text top="573" left="906" width="61" height="20" font="0">perception </text>
<text top="595" left="895" width="11" height="18" font="0">• </text>
<text top="594" left="906" width="196" height="20" font="0">More patients were willing to start a </text>
<text top="614" left="906" width="92" height="20" font="0">new medication. </text>
<text top="649" left="884" width="3" height="20" font="0"> </text>
<text top="666" left="884" width="192" height="20" font="0">Decision aids added 2.6 min to the </text>
<text top="683" left="884" width="99" height="20" font="0">consultation time. </text>
<text top="700" left="884" width="3" height="20" font="0"> </text>
</page>
<page number="231" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">231 </text>
<text top="107" left="664" width="198" height="20" font="0">studies; N = 5096; moderate-quality </text>
<text top="127" left="664" width="57" height="20" font="0">evidence) </text>
<text top="148" left="653" width="11" height="18" font="0">• </text>
<text top="148" left="664" width="207" height="20" font="0">congruency between informed values </text>
<text top="168" left="664" width="181" height="20" font="0">and care choices (risk ratio 2.06; </text>
<text top="187" left="664" width="47" height="20" font="0">95% CI: </text>
<text top="209" left="653" width="11" height="18" font="0">• </text>
<text top="208" left="664" width="192" height="20" font="0">1.46 to 2.91; 10 studies; N = 4626; </text>
<text top="228" left="664" width="122" height="20" font="0">low-quality evidence) <b> </b></text>
<text top="263" left="643" width="144" height="20" font="0">Decision-making process  </text>
<text top="282" left="653" width="11" height="18" font="0">• </text>
<text top="281" left="664" width="194" height="20" font="0">decisional conflict related to feeling </text>
<text top="301" left="664" width="161" height="20" font="0">uninformed (mean difference </text>
<text top="321" left="664" width="202" height="20" font="0">−9.28/100; 95% CI: −12.20 to −6.36; </text>
<text top="340" left="664" width="186" height="20" font="0">27 studies; N = 5707; high-quality </text>
<text top="360" left="664" width="57" height="20" font="0">evidence) </text>
<text top="382" left="653" width="11" height="18" font="0">• </text>
<text top="381" left="664" width="182" height="20" font="0">indecision about personal values </text>
<text top="401" left="664" width="205" height="20" font="0">(mean difference −8.81/100; 95% CI: </text>
<text top="420" left="664" width="203" height="20" font="0">−11.99, −5.63; 23 studies; N = 5068; </text>
<text top="440" left="664" width="123" height="20" font="0">high-quality evidence) </text>
<text top="462" left="653" width="11" height="18" font="0">• </text>
<text top="461" left="664" width="174" height="20" font="0"> Proportion of people who were </text>
<text top="481" left="664" width="204" height="20" font="0">passive in decision making (risk ratio </text>
<text top="501" left="664" width="200" height="20" font="0">0.68; 95% CI: 0.55-0.83; 16 studies; </text>
<text top="521" left="664" width="152" height="20" font="0">N = 3180; moderate-quality </text>
<text top="540" left="664" width="60" height="20" font="0">evidence).<b> </b></text>
<text top="575" left="643" width="169" height="20" font="0">Relevant secondary outcomes </text>
<text top="594" left="653" width="11" height="18" font="0">• </text>
<text top="593" left="664" width="184" height="20" font="0">increased those choosing to start </text>
<text top="613" left="664" width="189" height="20" font="0">new medications for diabetes (risk </text>
<text top="633" left="664" width="184" height="20" font="0">ratio1.65; 95% CI: 1.06 to 2.56; 4 </text>
<text top="653" left="664" width="97" height="20" font="0">studies; N =447). </text>
<text top="674" left="653" width="11" height="18" font="0">• </text>
<text top="674" left="664" width="183" height="20" font="0">median effect of decision aids on </text>
<text top="693" left="664" width="189" height="20" font="0">length of consultation was 2.6 min </text>
<text top="713" left="664" width="150" height="20" font="0">longer (24 versus 21; 7.5% </text>
<text top="733" left="664" width="57" height="20" font="0">increase). </text>
<text top="768" left="643" width="3" height="20" font="0"> </text>
</page>
<page number="232" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">232 </text>
<text top="107" left="91" width="136" height="20" font="0">Michelis,KC, et al., 2011 </text>
<text top="124" left="91" width="32" height="20" font="0"><a href="data supplement.html#252">(273)</a><b> </b></text>
<text top="141" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21462218">21462218</a></text>
<text top="141" left="146" width="3" height="20" font="7"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21462218"><b> </b></a></text>
<text top="159" left="91" width="3" height="20" font="0"> </text>
<text top="107" left="251" width="77" height="20" font="7"><b>Study type:</b>   </text>
<text top="124" left="251" width="111" height="20" font="0">retrospective cohort </text>
<text top="141" left="251" width="33" height="20" font="0">study </text>
<text top="159" left="251" width="3" height="20" font="0"> </text>
<text top="176" left="251" width="128" height="20" font="7"><b>Size:</b> 796 patients with </text>
<text top="193" left="251" width="122" height="20" font="0">baseline LDL-C not at </text>
<text top="210" left="251" width="27" height="20" font="0">goal </text>
<text top="107" left="406" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="124" left="406" width="211" height="20" font="0">&gt;18 y old; &gt; 2 patient encounters, with </text>
<text top="141" left="406" width="206" height="20" font="0">primary care provider, cardiologist, or </text>
<text top="159" left="406" width="215" height="20" font="0">endocrinologist, and lipid panels drawn </text>
<text top="176" left="406" width="47" height="20" font="0">in 2007. </text>
<text top="193" left="406" width="3" height="20" font="0"> </text>
<text top="210" left="406" width="114" height="20" font="7"><b>Exclusion criteria:</b>  </text>
<text top="227" left="406" width="174" height="20" font="0">LDL-C could not be determined </text>
<text top="245" left="406" width="218" height="20" font="0">(triglycerides &gt; 400 mg/dL); LDL-C goal </text>
<text top="262" left="406" width="139" height="20" font="0">could not be determined. </text>
<text top="108" left="643" width="79" height="20" font="7"><b>1</b>°<b> endpoint:</b>  </text>
<text top="125" left="643" width="163" height="20" font="0">LDL-C goal attainment with e-</text>
<text top="143" left="643" width="195" height="20" font="0">prescription with formulary decision </text>
<text top="160" left="643" width="164" height="20" font="0">support (FDS) versus manual </text>
<text top="177" left="643" width="70" height="20" font="0">prescription. </text>
<text top="194" left="643" width="3" height="20" font="0"> </text>
<text top="211" left="643" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="229" left="643" width="212" height="20" font="0">Patients with e-prescription using FDS </text>
<text top="246" left="643" width="212" height="20" font="0">reached LDL-C goal more often (51%) </text>
<text top="263" left="643" width="210" height="20" font="0">than patients with manual prescription </text>
<text top="280" left="643" width="206" height="20" font="0">(44%), OR: 1.59 (95% CI: 1.12-2.25). </text>
<text top="109" left="884" width="7" height="18" font="0">•</text>
<text top="108" left="891" width="200" height="20" font="0"> Use of e-prescription with formulary </text>
<text top="125" left="884" width="231" height="20" font="0">decision support may increase adherence </text>
<text top="143" left="884" width="150" height="20" font="0">and LDL-C goal attainment </text>
<text top="162" left="884" width="7" height="18" font="0">•</text>
<text top="161" left="891" width="206" height="20" font="0"> Generic statin prescribed more often </text>
<text top="178" left="884" width="209" height="20" font="0">with an e-prescription using FDS than </text>
<text top="195" left="884" width="197" height="20" font="0">with a manual prescription (38% vs. </text>
<text top="213" left="884" width="101" height="20" font="0">22.9%; p=0.0004) </text>
<text top="232" left="884" width="7" height="18" font="0">•</text>
<text top="231" left="891" width="209" height="20" font="0"> For each $10 increase in prescription </text>
<text top="248" left="884" width="196" height="20" font="0">price, the likelihood of being at goal </text>
<text top="265" left="884" width="206" height="20" font="0">decreased by 5% (OR: 0.95; 95% CI: </text>
<text top="283" left="884" width="63" height="20" font="0">0.93-0.98). </text>
<text top="301" left="91" width="144" height="20" font="0">Watanabe JH, 2014 <a href="data supplement.html#252">(274)</a> </text>
<text top="318" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24372459">24372459</a></text>
<text top="318" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24372459"> </a></text>
<text top="335" left="91" width="3" height="20" font="7"><b> </b></text>
<text top="352" left="91" width="3" height="20" font="0"> </text>
<text top="301" left="251" width="77" height="20" font="7"><b>Study type:</b>   </text>
<text top="318" left="251" width="111" height="20" font="0">retrospective cohort </text>
<text top="335" left="251" width="33" height="20" font="0">study </text>
<text top="352" left="251" width="113" height="20" font="7"><b>Size:</b> 4886 patients  </text>
<text top="301" left="406" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="318" left="406" width="204" height="20" font="0">New users of statins (no active statin </text>
<text top="335" left="406" width="217" height="20" font="0">prescription in 6 mo prior), dyslipidemia </text>
<text top="352" left="406" width="222" height="20" font="0">(International Classification of Diseases, </text>
<text top="370" left="406" width="198" height="20" font="0">Ninth Revision, Clinical Modification </text>
<text top="387" left="406" width="176" height="20" font="0">ICD-9-CM code 272), within the </text>
<text top="404" left="406" width="222" height="20" font="0">Veterans Integrated Service Network 22 </text>
<text top="421" left="406" width="192" height="20" font="0">for at least 2 y prior, and initiated a </text>
<text top="438" left="406" width="222" height="20" font="0">statin between November 30, 2006, and </text>
<text top="456" left="406" width="205" height="20" font="0">December 2, 2007. Required to have </text>
<text top="473" left="406" width="174" height="20" font="0">medical and pharmacy benefits </text>
<text top="490" left="406" width="192" height="20" font="0">throughout the study period. Study </text>
<text top="507" left="406" width="214" height="20" font="0">subjects were required to have at least </text>
<text top="524" left="406" width="212" height="20" font="0">1 primary care visit prior to index date, </text>
<text top="542" left="406" width="217" height="20" font="0">at least 2 primary care visits after index </text>
<text top="559" left="406" width="217" height="20" font="0">date, and at least 1 prescription prior to </text>
<text top="576" left="406" width="194" height="20" font="0">index date. Patients included in the </text>
<text top="593" left="406" width="170" height="20" font="0">analysis were required to have </text>
<text top="610" left="406" width="210" height="20" font="0">complete data for exposure, outcome, </text>
<text top="628" left="406" width="204" height="20" font="0">and regression adjustment variables. </text>
<text top="645" left="406" width="3" height="20" font="0"> </text>
<text top="662" left="406" width="134" height="20" font="7"><b>Exclusion criteria:</b> N\A </text>
<text top="302" left="643" width="79" height="20" font="7"><b>1</b>°<b> endpoint:</b>  </text>
<text top="319" left="643" width="196" height="20" font="0">Adherence rate [determined via the </text>
<text top="336" left="643" width="198" height="20" font="0">medication possession ratio (MPR), </text>
<text top="354" left="643" width="223" height="20" font="0">defined as number of days supplied with </text>
<text top="371" left="643" width="218" height="20" font="0">prescription medication divided by days </text>
<text top="388" left="643" width="87" height="20" font="0">of observation]. </text>
<text top="405" left="643" width="3" height="20" font="0"> </text>
<text top="422" left="643" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="440" left="643" width="215" height="20" font="0">Patients with copayment for their statin </text>
<text top="457" left="643" width="217" height="20" font="0">had higher adherence rates (≥0.8 MPR </text>
<text top="474" left="643" width="187" height="20" font="0">and ≥0.9 MPR) than patients with </text>
<text top="491" left="643" width="208" height="20" font="0">copayments, odds ratios (OR) of 1.19 </text>
<text top="508" left="643" width="213" height="20" font="0">(95% CI: 1.03-1.37) and 1.28 (95% CI: </text>
<text top="526" left="643" width="63" height="20" font="0">1.11-1.48). </text>
<text top="543" left="643" width="3" height="20" font="0"> </text>
<text top="560" left="643" width="3" height="20" font="0"> </text>
<text top="303" left="884" width="7" height="18" font="0">•</text>
<text top="302" left="891" width="207" height="20" font="0"> Elimination of copayments increased </text>
<text top="319" left="884" width="90" height="20" font="0">adherence rate. </text>
<text top="336" left="884" width="3" height="20" font="0"> </text>
<text top="680" left="91" width="126" height="20" font="0">Navar AM, et al., 2017 </text>
<text top="697" left="91" width="32" height="20" font="0"><a href="data supplement.html#252">(275)</a><b> </b></text>
<text top="714" left="91" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28973087">28973087</a></text>
<text top="714" left="146" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28973087"> </a></text>
<text top="680" left="251" width="77" height="20" font="7"><b>Study type:</b>   </text>
<text top="697" left="251" width="120" height="20" font="0">Retrospective, cohort </text>
<text top="714" left="251" width="123" height="20" font="0">study using pharmacy </text>
<text top="732" left="251" width="139" height="20" font="0">claims transactional data </text>
<text top="749" left="251" width="3" height="20" font="0"> </text>
<text top="766" left="251" width="123" height="20" font="7"><b>Size:</b>  45,029 patients </text>
<text top="680" left="406" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="697" left="406" width="213" height="20" font="0">New PCSK9 inhibitor prescription from </text>
<text top="714" left="406" width="96" height="20" font="0">8/1/15 to 7/31/16 </text>
<text top="732" left="406" width="3" height="20" font="0"> </text>
<text top="749" left="406" width="134" height="20" font="7"><b>Exclusion criteria:</b> N\A </text>
<text top="681" left="643" width="79" height="20" font="7"><b>1</b>°<b> endpoint:</b>  </text>
<text top="698" left="643" width="164" height="20" font="0">Proportion of PCSK9 inhibitor </text>
<text top="716" left="643" width="217" height="20" font="0">prescriptions approved and abandoned </text>
<text top="733" left="643" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="752" left="653" width="11" height="18" font="0">• </text>
<text top="751" left="664" width="198" height="20" font="0">20.8% approved on first day; 47.2% </text>
<text top="771" left="664" width="128" height="20" font="0">ever received approval </text>
<text top="682" left="884" width="7" height="18" font="0">•</text>
<text top="681" left="891" width="219" height="20" font="0"> About 1/3 of approved prescriptions for </text>
<text top="698" left="884" width="226" height="20" font="0">PCSK9 inhibitors were not filled because </text>
<text top="716" left="884" width="43" height="20" font="0">of cost. </text>
<text top="733" left="884" width="3" height="20" font="0"> </text>
</page>
<page number="233" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">233 </text>
<text top="109" left="653" width="11" height="18" font="0">• </text>
<text top="108" left="664" width="196" height="20" font="0">Of those approved, 65.3% filled the </text>
<text top="128" left="664" width="67" height="20" font="0">prescription </text>
<text top="150" left="653" width="11" height="18" font="0">• </text>
<text top="149" left="664" width="190" height="20" font="0">30.9% of those prescribed PCSK9 </text>
<text top="168" left="664" width="168" height="20" font="0">inhibitor ever received therapy </text>
<text top="203" left="643" width="3" height="20" font="0"> </text>
<text top="220" left="643" width="210" height="20" font="0">Prescription abandonment by patients </text>
<text top="238" left="643" width="114" height="20" font="0">associated with cost </text>
<text top="257" left="653" width="11" height="18" font="0">• </text>
<text top="256" left="664" width="121" height="20" font="0">7.5% with copay = $0 </text>
<text top="277" left="653" width="11" height="18" font="0">• </text>
<text top="277" left="664" width="131" height="20" font="0">75% with copay &gt; $350 </text>
<text top="312" left="91" width="120" height="20" font="0">Hess GP, et al., 2017 </text>
<text top="330" left="91" width="36" height="20" font="0"> <a href="data supplement.html#252">(276)</a> </text>
<text top="347" left="91" width="3" height="20" font="11"><a href=""> </a></text>
<text top="347" left="94" width="55" height="20" font="8"><a href="">29084735</a></text>
<text top="347" left="149" width="3" height="20" font="11"><a href=""> </a></text>
<text top="364" left="91" width="3" height="20" font="0"> </text>
<text top="312" left="251" width="77" height="20" font="7"><b>Study type:</b>   </text>
<text top="330" left="251" width="82" height="20" font="0">Retrospective, </text>
<text top="347" left="251" width="132" height="20" font="0">descriptive cohort study </text>
<text top="364" left="251" width="128" height="20" font="0">using pharmacy claims </text>
<text top="381" left="251" width="105" height="20" font="0">linked to electronic </text>
<text top="398" left="251" width="118" height="20" font="0">medical records from </text>
<text top="416" left="251" width="89" height="20" font="0">nationwide data </text>
<text top="433" left="251" width="67" height="20" font="0">warehouse  </text>
<text top="450" left="251" width="123" height="20" font="7"><b>Size:</b>  51,446 patients </text>
<text top="467" left="251" width="140" height="20" font="0">who had PCSK9 inhibitor </text>
<text top="484" left="251" width="124" height="20" font="0">prescription submitted </text>
<text top="502" left="251" width="120" height="20" font="0">(451 individual health </text>
<text top="519" left="251" width="37" height="20" font="0">plans)<b> </b></text>
<text top="312" left="406" width="109" height="20" font="7"><b>Inclusion criteria:</b>  </text>
<text top="330" left="406" width="181" height="20" font="0">&gt;18 y old; &gt;1 submitted claim for </text>
<text top="347" left="406" width="176" height="20" font="0">PCSK9 inhibitors from 7/1/15 to </text>
<text top="364" left="406" width="198" height="20" font="0">8/31/2016, &gt;1 private practitioner or </text>
<text top="381" left="406" width="215" height="20" font="0">facility medical claims from 1/1/2010 to </text>
<text top="398" left="406" width="200" height="20" font="0">7/31/15, and &gt;1 LDL-C test result (&lt; </text>
<text top="416" left="406" width="179" height="20" font="0">400 mg/dL) from 7/1/2015 to the </text>
<text top="433" left="406" width="116" height="20" font="0">patient's index date.<b>  </b></text>
<text top="450" left="406" width="3" height="20" font="7"><b> </b></text>
<text top="467" left="406" width="134" height="20" font="7"><b>Exclusion criteria:</b> N\A<b> </b></text>
<text top="313" left="643" width="79" height="20" font="7"><b>1</b>°<b> endpoint:</b>  </text>
<text top="331" left="643" width="196" height="20" font="0">Percentage of patients approved or </text>
<text top="348" left="643" width="159" height="20" font="0">rejected for PCSK9 inhibitor  </text>
<text top="365" left="643" width="3" height="20" font="7"><b> </b></text>
<text top="382" left="643" width="55" height="20" font="7"><b>Results:</b>  </text>
<text top="401" left="653" width="11" height="18" font="0">• </text>
<text top="401" left="664" width="205" height="20" font="0">47% of PCSK9 inhibitor prescriptions </text>
<text top="420" left="664" width="207" height="20" font="0">were approved for coverage by payer </text>
<text top="455" left="643" width="3" height="20" font="0"> </text>
<text top="472" left="643" width="186" height="20" font="0">Variables associated with PCSK9 </text>
<text top="490" left="643" width="100" height="20" font="0">inhibitor approval: </text>
<text top="509" left="653" width="11" height="18" font="0">• </text>
<text top="508" left="664" width="125" height="20" font="0">&gt; 65 y of age (p&lt;0.01) </text>
<text top="529" left="653" width="11" height="18" font="0">• </text>
<text top="529" left="664" width="149" height="20" font="0">history of ASCVD (p&lt;0.01) </text>
<text top="550" left="653" width="11" height="18" font="0">• </text>
<text top="550" left="664" width="175" height="20" font="0">prescription from cardiologist or </text>
<text top="569" left="664" width="190" height="20" font="0">nonprimary care provider (p&lt;0.01) </text>
<text top="591" left="653" width="11" height="18" font="0">• </text>
<text top="590" left="664" width="146" height="20" font="0">statin intolerance (p=0.03) </text>
<text top="612" left="653" width="11" height="18" font="0">• </text>
<text top="611" left="664" width="168" height="20" font="0">longer statin duration (p=0.01) </text>
<text top="632" left="653" width="11" height="18" font="0">• </text>
<text top="632" left="664" width="177" height="20" font="0">noncommercial payers (p&lt;0.01) </text>
<text top="652" left="664" width="3" height="20" font="0"> </text>
<text top="686" left="643" width="83" height="20" font="0">Approval rates </text>
<text top="705" left="653" width="11" height="18" font="0">• </text>
<text top="705" left="664" width="149" height="20" font="0">Highest: Medicare (60.9%) </text>
<text top="726" left="653" width="11" height="18" font="0">• </text>
<text top="725" left="664" width="171" height="20" font="0">Lowest: commercial third-party </text>
<text top="745" left="664" width="90" height="20" font="0">payers (24.4%)  </text>
<text top="312" left="884" width="182" height="20" font="0">Cost to the patient (mean patient </text>
<text top="330" left="884" width="182" height="20" font="0">responsibility) influenced therapy </text>
<text top="347" left="884" width="168" height="20" font="0">possession and abandonment </text>
<text top="366" left="884" width="7" height="18" font="0">•</text>
<text top="365" left="891" width="212" height="20" font="0"> Approved/possessed: $202.87±12.92 </text>
<text top="384" left="884" width="7" height="18" font="0">•</text>
<text top="383" left="891" width="215" height="20" font="0"> Approved/abandoned: $478.83±27.32 </text>
<text top="782" left="88" width="921" height="20" font="7"><b>Abbreviations:</b> 1° indicated primary; CI, confidence interval; HR, hazard ratio; N/A, not available; OR, odds ratio; RCT, randomized controlled trial; and RR, relative risk. </text>
</page>
<page number="234" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">234 </text>
<text top="106" left="88" width="297" height="20" font="7"><b>Search Terms and Date of Search</b>: Author to provide</text>
<text top="105" left="384" width="4" height="22" font="1"> </text>
<text top="123" left="81" width="4" height="22" font="1"> </text>
<text top="142" left="81" width="741" height="24" font="4"><b>Data Supplement 47. Cost-Effectiveness Models of PCKS9 Inhibitors in Secondary Prevention (Section 7) </b></text>
<text top="164" left="108" width="38" height="20" font="7"><b>Study </b></text>
<text top="164" left="199" width="44" height="20" font="7"><b>Design </b></text>
<text top="164" left="311" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="164" left="485" width="73" height="20" font="7"><b>Incremental </b></text>
<text top="181" left="480" width="81" height="20" font="7"><b>Lifetime Cost </b></text>
<text top="164" left="612" width="73" height="20" font="7"><b>Incremental </b></text>
<text top="181" left="607" width="83" height="20" font="7"><b>Effectiveness </b></text>
<text top="164" left="763" width="36" height="20" font="7"><b>Value </b></text>
<text top="164" left="882" width="137" height="20" font="7"><b>Summary/Conclusions </b></text>
<text top="199" left="89" width="65" height="20" font="0">Kazi DS, et </text>
<text top="216" left="89" width="51" height="20" font="0">al., 2016 </text>
<text top="233" left="89" width="32" height="20" font="0"><a href="data supplement.html#252">(277)</a> </text>
<text top="251" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27533159">27533159</a></text>
<text top="251" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27533159"> </a></text>
<text top="199" left="177" width="86" height="20" font="0">State-transition </text>
<text top="216" left="177" width="81" height="20" font="0">Markov Model </text>
<text top="233" left="177" width="70" height="20" font="0">(CVD Policy </text>
<text top="251" left="177" width="41" height="20" font="0">Model) </text>
<text top="199" left="278" width="168" height="20" font="0">ASCVD with LDL&gt;=70 despite </text>
<text top="216" left="278" width="142" height="20" font="0">maximally tolerated statin </text>
<text top="233" left="278" width="161" height="20" font="0">therapy (including individuals </text>
<text top="251" left="278" width="138" height="20" font="0">who are statin intolerant) </text>
<text top="199" left="467" width="68" height="20" font="0">$ 3,282 x 10</text>
<text top="201" left="535" width="7" height="13" font="9">9 </text>
<text top="199" left="541" width="25" height="20" font="0">(US </text>
<text top="216" left="467" width="66" height="20" font="0">Population) </text>
<text top="199" left="588" width="51" height="20" font="0">7.92 x 10</text>
<text top="201" left="638" width="7" height="13" font="9">6 </text>
<text top="199" left="645" width="42" height="20" font="0">Quality </text>
<text top="216" left="588" width="110" height="20" font="0">Adjusted Life Years </text>
<text top="233" left="588" width="90" height="20" font="0">(US Population) </text>
<text top="199" left="722" width="91" height="20" font="0">$414,000/QALY </text>
<text top="216" left="722" width="98" height="20" font="0">added (relative to </text>
<text top="233" left="722" width="60" height="20" font="0">ezetimibe) </text>
<text top="251" left="722" width="3" height="20" font="0"> </text>
<text top="268" left="722" width="91" height="20" font="0">$316,000/QALY </text>
<text top="285" left="722" width="94" height="20" font="0">(relative to statin </text>
<text top="302" left="722" width="96" height="20" font="0">standard of care) </text>
<text top="199" left="853" width="159" height="20" font="0">“Assuming 2015 [US] prices, </text>
<text top="216" left="853" width="194" height="20" font="0">PSCK9 inhibitor use…did not meet </text>
<text top="233" left="853" width="174" height="20" font="0">generally accepted incremental </text>
<text top="251" left="853" width="166" height="20" font="0">cost-effectiveness thresholds” </text>
<text top="352" left="89" width="65" height="20" font="0">Kazi DS, et </text>
<text top="370" left="89" width="61" height="20" font="0">al., update </text>
<text top="387" left="89" width="32" height="20" font="0"><a href="data supplement.html#252">(278)</a> </text>
<text top="404" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28829863">28829863</a></text>
<text top="404" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28829863"> </a></text>
<text top="421" left="89" width="3" height="20" font="0"> </text>
<text top="352" left="177" width="86" height="20" font="0">State-transition </text>
<text top="370" left="177" width="81" height="20" font="0">Markov Model </text>
<text top="387" left="177" width="70" height="20" font="0">(CVD Policy </text>
<text top="404" left="177" width="41" height="20" font="0">Model) </text>
<text top="352" left="278" width="168" height="20" font="0">ASCVD with LDL&gt;=70 despite </text>
<text top="370" left="278" width="142" height="20" font="0">maximally tolerated statin </text>
<text top="387" left="278" width="161" height="20" font="0">therapy (including individuals </text>
<text top="404" left="278" width="138" height="20" font="0">who are statin intolerant) </text>
<text top="352" left="467" width="68" height="20" font="0">$ 2,500 x 10</text>
<text top="354" left="535" width="7" height="13" font="9">9 </text>
<text top="352" left="541" width="25" height="20" font="0">(US </text>
<text top="370" left="467" width="66" height="20" font="0">Population) </text>
<text top="352" left="588" width="51" height="20" font="0">5.56 x 10</text>
<text top="354" left="638" width="7" height="13" font="9">6 </text>
<text top="352" left="645" width="42" height="20" font="0">Quality </text>
<text top="370" left="588" width="110" height="20" font="0">Adjusted Life Years </text>
<text top="387" left="588" width="90" height="20" font="0">(US Population) </text>
<text top="352" left="722" width="91" height="20" font="0">$450,000/QALY </text>
<text top="370" left="722" width="98" height="20" font="0">added (relative to </text>
<text top="387" left="722" width="60" height="20" font="0">ezetimibe) </text>
<text top="404" left="722" width="3" height="20" font="0"> </text>
<text top="421" left="722" width="91" height="20" font="0">$339,000/QALY </text>
<text top="438" left="722" width="94" height="20" font="0">(relative to statin </text>
<text top="456" left="722" width="96" height="20" font="0">standard of care) </text>
<text top="352" left="853" width="177" height="20" font="0">“PCSK9 inhibitor use in patients </text>
<text top="370" left="853" width="193" height="20" font="0">with ASCVD was not cost-effective </text>
<text top="387" left="853" width="120" height="20" font="0">at 2017 [US] prices… </text>
<text top="404" left="853" width="172" height="20" font="0">Reducing annual drug costs by </text>
<text top="421" left="853" width="193" height="20" font="0">71% (to ≤$4215) would be needed </text>
<text top="438" left="853" width="171" height="20" font="0">for PCSK9 inhibitors to be cost-</text>
<text top="456" left="853" width="172" height="20" font="0">effective at a threshold of $100 </text>
<text top="473" left="853" width="64" height="20" font="0">000/QALY” </text>
<text top="491" left="89" width="68" height="20" font="0">Gandra SR, </text>
<text top="508" left="89" width="68" height="20" font="0">et al., 2016  </text>
<text top="525" left="89" width="32" height="20" font="0"><a href="data supplement.html#252">(279)</a> </text>
<text top="542" left="89" width="55" height="20" font="8"><a href="">27092712</a></text>
<text top="542" left="144" width="7" height="20" font="0"><a href=""> </a> </text>
<text top="491" left="177" width="86" height="20" font="0">State-transition </text>
<text top="508" left="177" width="81" height="20" font="0">Markov Model </text>
<text top="491" left="278" width="155" height="20" font="0">ASCVD with LDL &gt;70 mg/dl </text>
<text top="508" left="278" width="152" height="20" font="0">despite maximally tolerated </text>
<text top="525" left="278" width="77" height="20" font="0">statin therapy </text>
<text top="491" left="467" width="80" height="20" font="0">$158,307 (per </text>
<text top="508" left="467" width="44" height="20" font="0">patient) </text>
<text top="491" left="588" width="120" height="20" font="0">1.12 Quality Adjusted </text>
<text top="508" left="588" width="84" height="20" font="0">Life Years (per </text>
<text top="525" left="588" width="44" height="20" font="0">patient) </text>
<text top="491" left="722" width="91" height="20" font="0">$141,700/QALY </text>
<text top="508" left="722" width="94" height="20" font="0">(relative to statin </text>
<text top="525" left="722" width="96" height="20" font="0">standard of care) </text>
<text top="491" left="853" width="192" height="20" font="0">“Evolocumab added to standard of </text>
<text top="508" left="853" width="184" height="20" font="0">care may provide a cost-effective </text>
<text top="525" left="853" width="186" height="20" font="0">treatment option for lowering LDL-</text>
<text top="542" left="853" width="16" height="20" font="0">C” </text>
<text top="560" left="89" width="65" height="20" font="0">Toth PP, et </text>
<text top="577" left="89" width="51" height="20" font="0">al., 2017 </text>
<text top="595" left="89" width="32" height="20" font="0"><a href="data supplement.html#252">(280)</a> </text>
<text top="612" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28097904">28097904</a></text>
<text top="612" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28097904"> </a></text>
<text top="560" left="177" width="86" height="20" font="0">State-transition </text>
<text top="577" left="177" width="81" height="20" font="0">Markov Model </text>
<text top="560" left="278" width="167" height="20" font="0">ASCVD with a prior CV event, </text>
<text top="577" left="278" width="134" height="20" font="0">LDL &gt;=70 mg/dl despite </text>
<text top="595" left="278" width="142" height="20" font="0">maximally tolerated statin </text>
<text top="612" left="278" width="44" height="20" font="0">therapy </text>
<text top="560" left="467" width="80" height="20" font="0">$127,088 (per </text>
<text top="577" left="467" width="44" height="20" font="0">patient) </text>
<text top="560" left="588" width="120" height="20" font="0">0.68 Quality Adjusted </text>
<text top="577" left="588" width="84" height="20" font="0">Life Years (per </text>
<text top="595" left="588" width="44" height="20" font="0">patient) </text>
<text top="560" left="722" width="91" height="20" font="0">$190,400/QALY </text>
<text top="577" left="722" width="94" height="20" font="0">(relative to statin </text>
<text top="595" left="722" width="96" height="20" font="0">standard of care) </text>
<text top="560" left="853" width="182" height="20" font="0">“The expected value-based price </text>
<text top="577" left="853" width="180" height="20" font="0">for evolocumab is higher than its </text>
<text top="595" left="853" width="192" height="20" font="0">current annual cost, as long as the </text>
<text top="612" left="853" width="161" height="20" font="0">payer discount off list price is </text>
<text top="629" left="853" width="102" height="20" font="0">greater than 20%” </text>
<text top="647" left="89" width="51" height="20" font="0">Fonarow </text>
<text top="664" left="89" width="59" height="20" font="0">GC, et al., </text>
<text top="681" left="89" width="63" height="20" font="0">2017 <a href="data supplement.html#252">(281)</a> </text>
<text top="699" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28832867">28832867</a></text>
<text top="699" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28832867"> </a></text>
<text top="647" left="177" width="86" height="20" font="0">State-transition </text>
<text top="664" left="177" width="81" height="20" font="0">Markov Model </text>
<text top="647" left="278" width="167" height="20" font="0">ASCVD with a prior CV event, </text>
<text top="664" left="278" width="134" height="20" font="0">LDL &gt;=70 mg/dl despite </text>
<text top="681" left="278" width="142" height="20" font="0">maximally tolerated statin </text>
<text top="699" left="278" width="44" height="20" font="0">therapy </text>
<text top="647" left="467" width="80" height="20" font="0">$105,398 (per </text>
<text top="664" left="467" width="44" height="20" font="0">patient) </text>
<text top="647" left="588" width="120" height="20" font="0">0.39 Quality Adjusted </text>
<text top="664" left="588" width="84" height="20" font="0">Life Years (per </text>
<text top="681" left="588" width="44" height="20" font="0">patient) </text>
<text top="647" left="722" width="91" height="20" font="0">$268,600/QALY </text>
<text top="664" left="722" width="94" height="20" font="0">(relative to statin </text>
<text top="681" left="722" width="96" height="20" font="0">standard of care) </text>
<text top="647" left="853" width="190" height="20" font="0">“At its current list price of $14 523, </text>
<text top="664" left="853" width="164" height="20" font="0">the addition of evolocumab to </text>
<text top="681" left="853" width="176" height="20" font="0">standard background therapy in </text>
<text top="699" left="853" width="155" height="20" font="0">patients with atherosclerotic </text>
<text top="716" left="853" width="178" height="20" font="0">cardiovascular disease exceeds </text>
<text top="733" left="853" width="133" height="20" font="0">generally accepted cost-</text>
<text top="750" left="853" width="143" height="20" font="0">effectiveness thresholds.” </text>
</page>
<page number="235" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">235 </text>
<text top="107" left="89" width="68" height="20" font="0">Arrieta A, et </text>
<text top="124" left="89" width="52" height="20" font="0">al., <a href="data supplement.html#252">(282)</a> </text>
<text top="141" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28081164">28081164</a></text>
<text top="141" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28081164"> </a></text>
<text top="107" left="177" width="86" height="20" font="0">State-transition </text>
<text top="124" left="177" width="81" height="20" font="0">Markov Model </text>
<text top="107" left="278" width="139" height="20" font="0">Patients who would have </text>
<text top="124" left="278" width="138" height="20" font="0">been eligible the OSLER </text>
<text top="141" left="278" width="152" height="20" font="0">(Open-Label Study of Long-</text>
<text top="159" left="278" width="162" height="20" font="0">Term Evaluation against LDL </text>
<text top="176" left="278" width="103" height="20" font="0">Cholesterol) study </text>
<text top="107" left="467" width="80" height="20" font="0">$231,918 (per </text>
<text top="124" left="467" width="44" height="20" font="0">patient) </text>
<text top="107" left="588" width="120" height="20" font="0">0.66 Quality Adjusted </text>
<text top="124" left="588" width="84" height="20" font="0">Life Years (per </text>
<text top="141" left="588" width="44" height="20" font="0">patient) </text>
<text top="107" left="722" width="91" height="20" font="0">$348,800/QALY </text>
<text top="124" left="722" width="94" height="20" font="0">(relative to statin </text>
<text top="141" left="722" width="96" height="20" font="0">standard of care) </text>
<text top="107" left="853" width="154" height="20" font="0">“At current prices, our study </text>
<text top="124" left="853" width="190" height="20" font="0">suggests that PCSK9 inhibitors do </text>
<text top="141" left="853" width="176" height="20" font="0">not add value to the U.S. health </text>
<text top="159" left="853" width="178" height="20" font="0">system…to be the breakthrough </text>
<text top="176" left="853" width="131" height="20" font="0">drug in the fight against </text>
<text top="193" left="853" width="152" height="20" font="0">cardiovascular disease, the </text>
<text top="210" left="853" width="182" height="20" font="0">current price of PCSK9 inhibitors </text>
<text top="228" left="853" width="170" height="20" font="0">must be reduced by more than </text>
<text top="245" left="853" width="32" height="20" font="0">70%” </text>
<text top="263" left="89" width="68" height="20" font="0">Arrieta A, et </text>
<text top="280" left="89" width="61" height="20" font="0">al., update </text>
<text top="297" left="89" width="32" height="20" font="0"><a href="data supplement.html#252">(282)</a> </text>
<text top="314" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=29049467">29049467</a></text>
<text top="314" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=29049467"> </a></text>
<text top="263" left="177" width="86" height="20" font="0">State-transition </text>
<text top="280" left="177" width="81" height="20" font="0">Markov Model </text>
<text top="263" left="278" width="139" height="20" font="0">Patients who would have </text>
<text top="280" left="278" width="152" height="20" font="0">been eligible the FOURIER </text>
<text top="297" left="278" width="133" height="20" font="0">(Further Cardiovascular </text>
<text top="314" left="278" width="141" height="20" font="0">Outcomes Research with </text>
<text top="332" left="278" width="160" height="20" font="0">PCSK9 Inhibition in Subjects </text>
<text top="349" left="278" width="25" height="20" font="0">with </text>
<text top="366" left="278" width="106" height="20" font="0">Elevated Risk) trial </text>
<text top="263" left="467" width="80" height="20" font="0">$136,101 (per </text>
<text top="280" left="467" width="44" height="20" font="0">patient) </text>
<text top="263" left="588" width="120" height="20" font="0">0.36 Quality Adjusted </text>
<text top="280" left="588" width="84" height="20" font="0">Life Years (per </text>
<text top="297" left="588" width="44" height="20" font="0">patient) </text>
<text top="263" left="722" width="91" height="20" font="0">$337,700/QALY </text>
<text top="280" left="722" width="94" height="20" font="0">(relative to statin </text>
<text top="297" left="722" width="96" height="20" font="0">standard of care) </text>
<text top="263" left="853" width="181" height="20" font="0">“At current prices, the addition of </text>
<text top="280" left="853" width="194" height="20" font="0">PCSK9 inhibitor to statin therapy is </text>
<text top="297" left="853" width="187" height="20" font="0">estimated to provide an additional </text>
<text top="314" left="853" width="154" height="20" font="0">quality-adjusted life year for </text>
<text top="332" left="853" width="174" height="20" font="0">$337,729. Significant discounts </text>
<text top="349" left="853" width="125" height="20" font="0">are necessary to meet </text>
<text top="366" left="853" width="174" height="20" font="0">conventional cost-effectiveness </text>
<text top="383" left="853" width="65" height="20" font="0">standards.” </text>
<text top="407" left="81" width="5" height="16" font="15"> </text>
<text top="422" left="81" width="947" height="24" font="4"><b>Data Supplement 48. Cost-Effectiveness Models of PCKS9 Inhibitors in Primary Prevention (Familial Hypercholesterolemia) (Section 7) </b></text>
<text top="443" left="108" width="38" height="20" font="7"><b>Study </b></text>
<text top="443" left="206" width="44" height="20" font="7"><b>Design </b></text>
<text top="443" left="318" width="111" height="20" font="7"><b>Patient Population </b></text>
<text top="443" left="473" width="123" height="20" font="7"><b>Incremental Lifetime </b></text>
<text top="460" left="520" width="31" height="20" font="7"><b>Cost </b></text>
<text top="443" left="644" width="73" height="20" font="7"><b>Incremental </b></text>
<text top="460" left="638" width="83" height="20" font="7"><b>Effectiveness </b></text>
<text top="443" left="801" width="36" height="20" font="7"><b>Value </b></text>
<text top="443" left="930" width="137" height="20" font="7"><b>Summary/Conclusions </b></text>
<text top="478" left="89" width="65" height="20" font="0">Kazi DS, et </text>
<text top="496" left="89" width="51" height="20" font="0">al., 2016 </text>
<text top="513" left="89" width="32" height="20" font="0"><a href="data supplement.html#252">(277)</a> </text>
<text top="530" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27533159">27533159</a></text>
<text top="530" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27533159"> </a></text>
<text top="478" left="176" width="86" height="20" font="0">State-transition </text>
<text top="496" left="176" width="81" height="20" font="0">Markov Model </text>
<text top="513" left="176" width="70" height="20" font="0">(CVD Policy </text>
<text top="530" left="176" width="41" height="20" font="0">Model) </text>
<text top="478" left="294" width="121" height="20" font="0">Heterozygous familial </text>
<text top="496" left="294" width="145" height="20" font="0">hypercholesterolemia with </text>
<text top="513" left="294" width="34" height="20" font="0">either:</text>
<text top="513" left="328" width="3" height="20" font="19"> </text>
<text top="513" left="331" width="118" height="20" font="0">(1) a family history of </text>
<text top="530" left="294" width="152" height="20" font="0">premature CHD and LDL-C </text>
<text top="547" left="294" width="154" height="20" font="0">&gt;= 190 mg/dL without statin </text>
<text top="564" left="294" width="138" height="20" font="0">therapy or &gt;= 150 mg/dL </text>
<text top="582" left="294" width="160" height="20" font="0">with statin therapy OR (2) no </text>
<text top="599" left="294" width="148" height="20" font="0">family history of premature </text>
<text top="616" left="294" width="134" height="20" font="0">CHD and LDL-C &gt;= 250 </text>
<text top="633" left="294" width="157" height="20" font="0">mg/dL without statin therapy </text>
<text top="651" left="294" width="152" height="20" font="0">or &gt;= 200 mg/dL with statin </text>
<text top="668" left="294" width="44" height="20" font="0">therapy </text>
<text top="478" left="467" width="57" height="20" font="0">$ 316 x 10</text>
<text top="480" left="524" width="7" height="13" font="9">9 </text>
<text top="478" left="531" width="25" height="20" font="0">(US </text>
<text top="496" left="467" width="66" height="20" font="0">Population) </text>
<text top="478" left="616" width="47" height="20" font="0">628 x 10</text>
<text top="480" left="663" width="7" height="13" font="9">3 </text>
<text top="478" left="670" width="42" height="20" font="0">Quality </text>
<text top="496" left="616" width="110" height="20" font="0">Adjusted Life Years </text>
<text top="513" left="616" width="90" height="20" font="0">(US Population) </text>
<text top="478" left="757" width="91" height="20" font="0">$503,000/QALY </text>
<text top="496" left="757" width="98" height="20" font="0">added (relative to </text>
<text top="513" left="757" width="60" height="20" font="0">ezetimibe) </text>
<text top="530" left="757" width="3" height="20" font="0"> </text>
<text top="547" left="757" width="3" height="20" font="0"> </text>
<text top="478" left="894" width="203" height="20" font="0">“Assuming 2015 [US] prices, PSCK9 </text>
<text top="496" left="894" width="203" height="20" font="0">inhibitor use…did not meet generally </text>
<text top="513" left="894" width="147" height="20" font="0">accepted incremental cost-</text>
<text top="530" left="894" width="139" height="20" font="0">effectiveness thresholds” </text>
<text top="686" left="89" width="68" height="20" font="0">Gandra SR, </text>
<text top="703" left="89" width="69" height="20" font="0">et al., <a href="data supplement.html#252">(279)</a>  </text>
<text top="720" left="89" width="55" height="20" font="8"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27092712">27092712</a></text>
<text top="720" left="144" width="3" height="20" font="0"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27092712"> </a></text>
<text top="686" left="176" width="86" height="20" font="0">State-transition </text>
<text top="703" left="176" width="81" height="20" font="0">Markov Model </text>
<text top="686" left="294" width="121" height="20" font="0">Heterozygous familial </text>
<text top="703" left="294" width="145" height="20" font="0">hypercholesterolemia with </text>
<text top="720" left="294" width="94" height="20" font="0">LDL &gt; 100 md/dl </text>
<text top="686" left="467" width="125" height="20" font="0">$153,289 (per patient) </text>
<text top="686" left="616" width="120" height="20" font="0">2.02 Quality Adjusted </text>
<text top="703" left="616" width="84" height="20" font="0">Life Years (per </text>
<text top="720" left="616" width="44" height="20" font="0">patient) </text>
<text top="686" left="757" width="84" height="20" font="0">$75,900/QALY </text>
<text top="703" left="757" width="94" height="20" font="0">(relative to statin </text>
<text top="720" left="757" width="96" height="20" font="0">standard of care) </text>
<text top="686" left="894" width="192" height="20" font="0">“Evolocumab added to standard of </text>
<text top="703" left="894" width="184" height="20" font="0">care may provide a cost-effective </text>
<text top="720" left="894" width="202" height="20" font="0">treatment option for lowering LDL-C” </text>
<text top="738" left="81" width="4" height="22" font="1"> </text>
<text top="757" left="81" width="4" height="22" font="1"> </text>
</page>
<page number="236" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">236 </text>
<text top="106" left="81" width="84" height="24" font="4"><b>References </b></text>
<text top="127" left="81" width="4" height="24" font="4"><b> </b></text>
<text top="149" left="81" width="16" height="21" font="1">1. </text>
<text top="149" left="135" width="919" height="21" font="1">Collaboration ERF, Erqou S, Kaptoge S, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular </text>
<text top="169" left="81" width="238" height="21" font="1">mortality. JAMA. 2009;302:412-23. </text>
<text top="189" left="81" width="16" height="21" font="1">2. </text>
<text top="189" left="135" width="972" height="21" font="1">Doran B, Guo Y, Xu J, et al. Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: insight </text>
<text top="209" left="81" width="712" height="21" font="1">from the National Health and Nutrition Examination Survey III (NHANES-III). Circulation. 2014;130:546-53. </text>
<text top="230" left="81" width="16" height="21" font="1">3. </text>
<text top="230" left="135" width="884" height="21" font="1">Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, </text>
<text top="250" left="81" width="558" height="21" font="1">apolipoproteins, and cardiovascular risk prediction. Circulation. 2008;118:2047-56. </text>
<text top="270" left="81" width="16" height="21" font="1">4. </text>
<text top="270" left="135" width="952" height="21" font="1">Langsted A, Nordestgaard BG. Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58 434 individuals </text>
<text top="290" left="81" width="511" height="21" font="1">from the Copenhagen General Population Study. Clin Chem. 2011;57:482-9. </text>
<text top="310" left="81" width="16" height="21" font="1">5. </text>
<text top="310" left="135" width="928" height="21" font="1">Mora S, Rifai N, Buring JE, et al. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. </text>
<text top="330" left="81" width="219" height="21" font="1">Circulation. 2008;118:993-1001. </text>
<text top="350" left="81" width="16" height="21" font="1">6. </text>
<text top="350" left="135" width="959" height="21" font="1">Mora S, Rifai N, Buring JE, et al. Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to </text>
<text top="370" left="81" width="462" height="21" font="1">cardiovascular events in 27,331 women. Clin Chem. 2009;55:888-94. </text>
<text top="391" left="81" width="16" height="21" font="1">7. </text>
<text top="391" left="135" width="963" height="21" font="1">Sidhu D, Naugler C. Fasting time and lipid levels in a community-based population: a cross-sectional study. Arch Intern Med. 2012;172:1707-10. </text>
<text top="411" left="81" width="16" height="21" font="1">8. </text>
<text top="411" left="135" width="939" height="21" font="1">Chronic Kidney Disease Prognosis Consortium, Matsushima T, Nakaya N, et al. The effect of low-dose pravastatin in metabolic syndrome for </text>
<text top="431" left="81" width="935" height="21" font="1">primary prevention of cardiovascular disease in Japan: a post hoc analysis of the MEGA study. J Cardiovasc Pharmacol Ther. 2012;17:153-8. </text>
<text top="451" left="81" width="16" height="21" font="1">9. </text>
<text top="451" left="135" width="958" height="21" font="1">Clearfield M, Downs JR, Lee M, et al. Implications from the Air Force/Texas Coronary Atherosclerosis Prevention Study for the Adult Treatment </text>
<text top="471" left="81" width="346" height="21" font="1">Panel III guidelines. Am J Cardiol. 2005;96:1674-80. </text>
<text top="491" left="81" width="25" height="21" font="1">10. </text>
<text top="491" left="135" width="943" height="21" font="1">Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and </text>
<text top="512" left="81" width="604" height="21" font="1">diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414-9. </text>
<text top="532" left="81" width="25" height="21" font="1">11. </text>
<text top="532" left="135" width="968" height="21" font="1">Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl </text>
<text top="552" left="81" width="187" height="21" font="1">J Med. 2008;359:2195-207. </text>
<text top="572" left="81" width="25" height="21" font="1">12. </text>
<text top="572" left="135" width="877" height="21" font="1">Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. </text>
<text top="592" left="81" width="130" height="21" font="1">2016;374:2021-31. </text>
<text top="612" left="81" width="25" height="21" font="1">13. </text>
<text top="612" left="135" width="898" height="21" font="1">Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL </text>
<text top="632" left="81" width="764" height="21" font="1">cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-81. </text>
<text top="652" left="81" width="25" height="21" font="1">14. </text>
<text top="652" left="135" width="929" height="21" font="1">Bohula EA, Morrow DA, Giugliano RP, et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. J Am Coll Cardiol. </text>
<text top="673" left="81" width="114" height="21" font="1">2017;69:911-21. </text>
<text top="693" left="81" width="25" height="21" font="1">15. </text>
<text top="693" left="135" width="958" height="21" font="1">Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of </text>
<text top="713" left="81" width="732" height="21" font="1">treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-45. </text>
<text top="733" left="81" width="25" height="21" font="1">16. </text>
<text top="733" left="135" width="945" height="21" font="1">Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. </text>
<text top="753" left="81" width="486" height="21" font="1">Experience from the Helsinki Heart Study. Circulation. 1995;92:1779-85. </text>
</page>
<page number="237" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">237 </text>
<text top="108" left="81" width="25" height="21" font="1">17. </text>
<text top="108" left="135" width="969" height="21" font="1">Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus </text>
<text top="128" left="81" width="495" height="21" font="1">(the FIELD study): randomised controlled trial. Lancet. 2005;366:1849-61. </text>
<text top="148" left="81" width="25" height="21" font="1">18. </text>
<text top="148" left="135" width="921" height="21" font="1">Ginsberg HN, Kris-Etherton P, Dennis B, et al. Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy </text>
<text top="168" left="81" width="570" height="21" font="1">subjects: the DELTA Study, protocol 1. Arterioscler Thromb Vasc Biol. 1998;18:441-9. </text>
<text top="188" left="81" width="25" height="21" font="1">19. </text>
<text top="188" left="135" width="855" height="21" font="1">Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248-61. </text>
<text top="208" left="81" width="25" height="21" font="1">20. </text>
<text top="208" left="135" width="957" height="21" font="1">Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-</text>
<text top="228" left="81" width="381" height="21" font="1">blind, placebo-controlled trial. Lancet. 2008;372:1231-9. </text>
<text top="249" left="81" width="25" height="21" font="1">21. </text>
<text top="249" left="135" width="949" height="21" font="1">Feinstein MJ, Jhund P, Kang J, et al. Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level </text>
<text top="269" left="81" width="466" height="21" font="1">reanalysis of CORONA and GISSI-HF. Eur J Heart Fail. 2015;17:434-41. </text>
<text top="289" left="81" width="25" height="21" font="1">22. </text>
<text top="289" left="135" width="972" height="21" font="1">Amarenco P, Bogousslavsky J, Callahan Ar, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-59. </text>
<text top="309" left="81" width="25" height="21" font="1">23. </text>
<text top="309" left="135" width="942" height="21" font="1">Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus </text>
<text top="329" left="81" width="1019" height="21" font="1">“usual” care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med </text>
<text top="349" left="81" width="173" height="21" font="1">Res Opin. 2002;18:220-8. </text>
<text top="370" left="81" width="25" height="21" font="1">24. </text>
<text top="370" left="135" width="974" height="21" font="1">Taguchi I, Iimuro S, Iwata H, et al. High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): </text>
<text top="390" left="81" width="442" height="21" font="1">A Randomized Superiority Trial. Circulation. 2018;137:1997-2009. </text>
<text top="410" left="81" width="25" height="21" font="1">25. </text>
<text top="410" left="135" width="948" height="21" font="1">Zwald ML, Akinbami LJ, Fakhouri TH, et al. Prevalence of Low High-density Lipoprotein Cholesterol Among Adults, by Physical Activity: United </text>
<text top="430" left="81" width="312" height="21" font="1">States, 2011-2014. NCHS Data Brief. 2017;1-8. </text>
<text top="450" left="81" width="25" height="21" font="1">26. </text>
<text top="450" left="135" width="960" height="21" font="1">Cannon CP, Khan I, Klimchak AC, et al. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular </text>
<text top="470" left="81" width="262" height="21" font="1">Disease. JAMA Cardiol. 2017;2:959-66. </text>
<text top="490" left="81" width="25" height="21" font="1">27. </text>
<text top="490" left="135" width="974" height="21" font="1">Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089-99. </text>
<text top="510" left="81" width="25" height="21" font="1">28. </text>
<text top="510" left="135" width="925" height="21" font="1">Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. </text>
<text top="531" left="81" width="122" height="21" font="1">2015;372:1500-9. </text>
<text top="551" left="81" width="25" height="21" font="1">29. </text>
<text top="551" left="135" width="930" height="21" font="1">Schwartz GG, Steg PG, Szarek M. Alirocumab and Cardiovascular Outcomes After Acute Coronary Syndrome. N Engl J Med (In press). 2018; </text>
<text top="571" left="81" width="25" height="21" font="1">30. </text>
<text top="571" left="135" width="838" height="21" font="1">Giugliano RP, Mach F, Zavitz K, et al. Cognitive function in a randomized trial of evolocumab. N Engl J Med. 2017;377:633-43. </text>
<text top="591" left="81" width="25" height="21" font="1">31. </text>
<text top="591" left="135" width="954" height="21" font="1">Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431-</text>
<text top="611" left="81" width="25" height="21" font="1">43. </text>
<text top="631" left="81" width="25" height="21" font="1">32. </text>
<text top="631" left="135" width="971" height="21" font="1">Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387-97. </text>
<text top="651" left="81" width="25" height="21" font="1">33. </text>
<text top="651" left="135" width="927" height="21" font="1">Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic </text>
<text top="671" left="81" width="539" height="21" font="1">interventions: a systematic review and meta-analysis. JAMA. 2016;316:1289-97. </text>
<text top="692" left="81" width="25" height="21" font="1">34. </text>
<text top="692" left="135" width="961" height="21" font="1">Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland </text>
<text top="712" left="81" width="451" height="21" font="1">Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-7. </text>
<text top="732" left="81" width="25" height="21" font="1">35. </text>
<text top="732" left="135" width="955" height="21" font="1">Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-</text>
<text top="752" left="81" width="554" height="21" font="1">2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:331-40. </text>
</page>
<page number="238" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">238 </text>
<text top="108" left="81" width="25" height="21" font="1">36. </text>
<text top="108" left="135" width="889" height="21" font="1">Kastelein JJP, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with </text>
<text top="128" left="81" width="529" height="21" font="1">heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36:2996-3003. </text>
<text top="148" left="81" width="25" height="21" font="1">37. </text>
<text top="148" left="135" width="967" height="21" font="1">Ross S, D’Mello M, Anand SS, et al. Effect of bile acid sequestrants on the risk of cardiovascular events: a mendelian randomization analysis. Circ </text>
<text top="168" left="81" width="231" height="21" font="1">Cardiovasc Genet. 2015;8:618-27. </text>
<text top="188" left="81" width="25" height="21" font="1">38. </text>
<text top="188" left="135" width="901" height="21" font="1">Huijgen R, Abbink EJ, Bruckert E, et al. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial </text>
<text top="208" left="81" width="787" height="21" font="1">hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. Clin Ther. 2010;32:615-25. </text>
<text top="228" left="81" width="25" height="21" font="1">39. </text>
<text top="228" left="135" width="838" height="21" font="1">Perak AM, Ning H, de Ferranti SD, et al. Long-term risk of atherosclerotic cardiovascular disease in US adults with the familial </text>
<text top="249" left="81" width="417" height="21" font="1">hypercholesterolemia phenotype. Circulation. 2016;134:9-19. </text>
<text top="269" left="81" width="25" height="21" font="1">40. </text>
<text top="269" left="135" width="938" height="21" font="1">Khera AV, Won H-H, Peloso GM, et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with </text>
<text top="289" left="81" width="444" height="21" font="1">severe hypercholesterolemia. J Am Coll Cardiol. 2016;67:2578-89. </text>
<text top="309" left="81" width="25" height="21" font="1">41. </text>
<text top="309" left="135" width="938" height="21" font="1">Nanchen D, Gencer B, Muller O, et al. Prognosis of patients with familial hypercholesterolemia after acute coronary syndromes. Circulation. </text>
<text top="329" left="81" width="130" height="21" font="1">2016;134:698-709. </text>
<text top="349" left="81" width="25" height="21" font="1">42. </text>
<text top="349" left="135" width="919" height="21" font="1">Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. </text>
<text top="370" left="81" width="117" height="21" font="1">2008;337:a2423. </text>
<text top="390" left="81" width="25" height="21" font="1">43. </text>
<text top="390" left="135" width="922" height="21" font="1">Besseling J, Hovingh GK, Huijgen R, et al. Statins in familial hypercholesterolemia: consequences for coronary artery disease and all-cause </text>
<text top="410" left="81" width="303" height="21" font="1">mortality. J Am Coll Cardiol. 2016;68:252-60. </text>
<text top="430" left="81" width="25" height="21" font="1">44. </text>
<text top="430" left="135" width="933" height="21" font="1">Pérez de Isla L, Alonso R, Mata N, et al. Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART Registry (Spanish </text>
<text top="450" left="81" width="519" height="21" font="1">Familial Hypercholesterolemia Cohort Study). Circulation. 2017;135:2133-44. </text>
<text top="470" left="81" width="25" height="21" font="1">45. </text>
<text top="470" left="135" width="927" height="21" font="1">Wong ND, Glovaci D, Wong K, et al. Global cardiovascular disease risk assessment in United States adults with diabetes. Diab Vasc Dis Res. </text>
<text top="490" left="81" width="105" height="21" font="1">2012;9:146-52. </text>
<text top="510" left="81" width="25" height="21" font="1">46. </text>
<text top="510" left="135" width="960" height="21" font="1">Rana JS, Liu JY, Moffet HH, et al. Diabetes and prior coronary heart disease are not necessarily risk equivalent for future coronary heart disease </text>
<text top="531" left="81" width="290" height="21" font="1">events. J Gen Intern Med. 2016;31:387-93. </text>
<text top="551" left="81" width="25" height="21" font="1">47. </text>
<text top="551" left="135" width="954" height="21" font="1">Malik S, Budoff MJ, Katz R, et al. Impact of subclinical atherosclerosis on cardiovascular disease events in individuals with metabolic syndrome </text>
<text top="571" left="81" width="595" height="21" font="1">and diabetes: the multi-ethnic study of atherosclerosis. Diabetes care. 2011;34:2285-90. </text>
<text top="591" left="81" width="25" height="21" font="1">48. </text>
<text top="591" left="135" width="957" height="21" font="1">Mulnier HE, Seaman HE, Raleigh VS, et al. Risk of myocardial infarction in men and women with type 2 diabetes in the UK: a cohort study using </text>
<text top="611" left="81" width="491" height="21" font="1">the General Practice Research Database. Diabetologia. 2008;51:1639-45. </text>
<text top="631" left="81" width="25" height="21" font="1">49. </text>
<text top="631" left="135" width="959" height="21" font="1">Soedamah-Muthu SS, Fuller JH, Mulnier HE, et al. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study </text>
<text top="651" left="81" width="529" height="21" font="1">using the general practice research database. Diabetes care. 2006;29:798-804. </text>
<text top="671" left="81" width="25" height="21" font="1">50. </text>
<text top="671" left="135" width="948" height="21" font="1">Huo X, Gao L, Guo L, et al. Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross-sectional </text>
<text top="692" left="81" width="340" height="21" font="1">study. Lancet Diabetes Endocrinol. 2016;4:115-24. </text>
<text top="712" left="81" width="25" height="21" font="1">51. </text>
<text top="712" left="135" width="960" height="21" font="1">Constantino MI, Molyneaux L, Limacher-Gisler F, et al. Long-term complications and mortality in young-onset diabetes: type 2 diabetes is more </text>
<text top="732" left="81" width="502" height="21" font="1">hazardous and lethal than type 1 diabetes. Diabetes care. 2013;36:3863-9. </text>
</page>
<page number="239" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">239 </text>
<text top="108" left="81" width="25" height="21" font="1">52. </text>
<text top="108" left="135" width="944" height="21" font="1">Svensson MK, Cederholm J, Eliasson B, et al. Albuminuria and renal function as predictors of cardiovascular events and mortality in a general </text>
<text top="128" left="81" width="956" height="21" font="1">population of patients with type 2 diabetes: a nationwide observational study from the Swedish National Diabetes Register. Diab Vasc Dis Res. </text>
<text top="148" left="81" width="105" height="21" font="1">2013;10:520-9. </text>
<text top="168" left="81" width="25" height="21" font="1">53. </text>
<text top="168" left="135" width="946" height="21" font="1">Guo VY, Cao B, Wu X, et al. Prospective association between diabetic retinopathy and cardiovascular disease—a systematic review and meta-</text>
<text top="188" left="81" width="470" height="21" font="1">analysis of cohort studies. J Stroke Cerebrovasc Dis. 2016;25:1688-95. </text>
<text top="208" left="81" width="25" height="21" font="1">54. </text>
<text top="208" left="135" width="970" height="21" font="1">Brownrigg JRW, de Lusignan S, McGovern A, et al. Peripheral neuropathy and the risk of cardiovascular events in type 2 diabetes mellitus. Heart. </text>
<text top="228" left="81" width="130" height="21" font="1">2014;100:1837-43. </text>
<text top="249" left="81" width="25" height="21" font="1">55. </text>
<text top="249" left="135" width="904" height="21" font="1">Nordestgaard BG, Langsted A, Mora S, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory </text>
<text top="269" left="81" width="980" height="21" font="1">implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and </text>
<text top="289" left="81" width="665" height="21" font="1">European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J. 2016;37:1944-58. </text>
<text top="309" left="81" width="25" height="21" font="1">56. </text>
<text top="309" left="135" width="969" height="21" font="1">Pang X-H, Han J, Ye W-L, et al. Lower extremity peripheral arterial disease is an independent predictor of coronary heart disease and stroke risks </text>
<text top="329" left="81" width="587" height="21" font="1">in patients with type 2 diabetes mellitus in China. Int J Endocrinol. 2017;2017:9620513. </text>
<text top="349" left="81" width="25" height="21" font="1">57. </text>
<text top="349" left="135" width="954" height="21" font="1">Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a </text>
<text top="370" left="81" width="431" height="21" font="1">randomised placebo-controlled trial. Lancet. 2003;361:2005-16. </text>
<text top="390" left="81" width="25" height="21" font="1">58. </text>
<text top="390" left="135" width="919" height="21" font="1">Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the </text>
<text top="410" left="81" width="855" height="21" font="1">Collaborative AtoRvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-96. </text>
<text top="430" left="81" width="25" height="21" font="1">59. </text>
<text top="430" left="135" width="906" height="21" font="1">Sever PS, Poulter NR, Dahlöf B, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-</text>
<text top="450" left="81" width="689" height="21" font="1">Scandinavian Cardiac Outcomes Tria—lipid-lowering arm (ASCOT-LLA). Diabetes care. 2005;28:1151-7. </text>
<text top="470" left="81" width="25" height="21" font="1">60. </text>
<text top="470" left="135" width="966" height="21" font="1">Knopp RH, d’Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 </text>
<text top="490" left="81" width="1021" height="21" font="1">diabetes: the Atorvastatin Study for Prevention of coronary heart disease Endpoints in Non-insulin-dependent diabetes mellitus (ASPEN). Diabetes care. </text>
<text top="510" left="81" width="122" height="21" font="1">2006;29:1478-85. </text>
<text top="531" left="81" width="25" height="21" font="1">61. </text>
<text top="531" left="135" width="969" height="21" font="1">de Vries FM, Denig P, Pouwels KB, et al. Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: </text>
<text top="551" left="81" width="281" height="21" font="1">a meta-analysis. Drugs. 2012;72:2365-73. </text>
<text top="571" left="81" width="25" height="21" font="1">62. </text>
<text top="571" left="135" width="943" height="21" font="1">Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-</text>
<text top="591" left="81" width="446" height="21" font="1">analysis of longitudinal studies. J Am Coll Cardiol. 2007;49:403-14. </text>
<text top="611" left="81" width="25" height="21" font="1">63. </text>
<text top="611" left="135" width="859" height="21" font="1">Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med. 2006;119:812-9. </text>
<text top="631" left="81" width="25" height="21" font="1">64. </text>
<text top="631" left="135" width="916" height="21" font="1">Andersson C, Enserro D, Larson MG, et al. Implications of the US cholesterol guidelines on eligibility for statin therapy in the community: </text>
<text top="651" left="81" width="870" height="21" font="1">comparison of observed and predicted risks in the Framingham Heart Study Offspring Cohort. J Am Heart Assoc. 2015;4:e001888. </text>
<text top="671" left="81" width="25" height="21" font="1">65. </text>
<text top="671" left="135" width="941" height="21" font="1">Chia YC, Lim HM, Ching SM. Validation of the pooled cohort risk score in an Asian population - a retrospective cohort study. BMC Cardiovasc </text>
<text top="692" left="81" width="143" height="21" font="1">Disord. 2014;14:163. </text>
<text top="712" left="81" width="25" height="21" font="1">66. </text>
<text top="712" left="135" width="948" height="21" font="1">Colantonio LD, Richman JS, Carson AP, et al. Performance of the atherosclerotic cardiovascular disease pooled cohort risk equations by social </text>
<text top="732" left="81" width="369" height="21" font="1">deprivation status. J Am Heart Assoc. 2017;6:e005676. </text>
<text top="752" left="81" width="25" height="21" font="1">67. </text>
<text top="752" left="135" width="975" height="21" font="1">Cook NR, Ridker PM. Further insight into the cardiovascular risk calculator: the roles of statins, revascularizations, and underascertainment in the </text>
<text top="772" left="81" width="418" height="21" font="1">Women’s Health Study. JAMA Intern Med. 2014;174:1964-71. </text>
</page>
<page number="240" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">240 </text>
<text top="108" left="81" width="25" height="21" font="1">68. </text>
<text top="108" left="135" width="914" height="21" font="1">Crowson CS, Gabriel SE, Semb AG, et al. Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a </text>
<text top="128" left="81" width="639" height="21" font="1">validation analysis of patients from seven countries. Rheumatology (Oxford). 2017;56:1102-10. </text>
<text top="148" left="81" width="25" height="21" font="1">69. </text>
<text top="148" left="135" width="885" height="21" font="1">Dalton JE, Perzynski AT, Zidar DA, et al. Accuracy of cardiovascular risk prediction varies by neighborhood socioeconomic position: a </text>
<text top="168" left="81" width="422" height="21" font="1">retrospective cohort study. Ann Intern Med. 2017;167:456-64. </text>
<text top="188" left="81" width="25" height="21" font="1">70. </text>
<text top="188" left="135" width="949" height="21" font="1">DeFilippis AP, Young R, Carrubba CJ, et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern </text>
<text top="208" left="81" width="369" height="21" font="1">multiethnic cohort. Ann Intern Med. 2015;162:266-75. </text>
<text top="228" left="81" width="25" height="21" font="1">71. </text>
<text top="228" left="135" width="970" height="21" font="1">DeFilippis AP, Young R, McEvoy JW, et al. Risk score overestimation: the impact of individual cardiovascular risk factors and preventive therapies </text>
<text top="249" left="81" width="1002" height="21" font="1">on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern </text>
<text top="269" left="81" width="341" height="21" font="1">multi-ethnic cohort. Eur Heart J. 2017;38:598-608. </text>
<text top="289" left="81" width="25" height="21" font="1">72. </text>
<text top="289" left="135" width="870" height="21" font="1">Feinstein MJ, Nance RM, Drozd DR, et al. Assessing and refining myocardial infarction risk estimation among patients with human </text>
<text top="309" left="81" width="915" height="21" font="1">immunodeficiency virus: a study by the Centers for AIDS Research Network of Integrated Clinical Systems. JAMA Cardiol. 2017;2:155-62. </text>
<text top="329" left="81" width="25" height="21" font="1">73. </text>
<text top="329" left="135" width="922" height="21" font="1">Flueckiger P, Qureshi W, Michos ED, et al. Guideline-based statin/lipid-lowering therapy eligibility for primary prevention and accuracy of </text>
<text top="349" left="81" width="922" height="21" font="1">coronary artery calcium and clinical cardiovascular events: The Multi-Ethnic Study of Atherosclerosis (MESA). Clin Cardiol. 2017;40:163-9. </text>
<text top="370" left="81" width="25" height="21" font="1">74. </text>
<text top="370" left="135" width="921" height="21" font="1">Jung KJ, Jang Y, Oh DJ, et al. The ACC/AHA 2013 pooled cohort equations compared to a Korean Risk Prediction Model for atherosclerotic </text>
<text top="390" left="81" width="391" height="21" font="1">cardiovascular disease. Atherosclerosis. 2015;242:367-75. </text>
<text top="410" left="81" width="25" height="21" font="1">75. </text>
<text top="410" left="135" width="932" height="21" font="1">Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and </text>
<text top="430" left="81" width="864" height="21" font="1">European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA. 2014;311:1416-23. </text>
<text top="450" left="81" width="25" height="21" font="1">76. </text>
<text top="450" left="135" width="952" height="21" font="1">Khalili D, Asgari S, Hadaegh F, et al. A new approach to test validity and clinical usefulness of the 2013 ACC/AHA guideline on statin therapy: A </text>
<text top="470" left="81" width="375" height="21" font="1">population-based study. Int J Cardiol. 2015;184:587-94. </text>
<text top="490" left="81" width="25" height="21" font="1">77. </text>
<text top="490" left="135" width="923" height="21" font="1">Lee CH, Woo YC, Lam JK, et al. Validation of the Pooled Cohort equations in a long-term cohort study of Hong Kong Chinese. J Clin Lipidol. </text>
<text top="510" left="81" width="118" height="21" font="1">2015;9:640-6.e2. </text>
<text top="531" left="81" width="25" height="21" font="1">78. </text>
<text top="531" left="135" width="907" height="21" font="1">Loprinzi PD, Addoh O. Predictive validity of the American College of Cardiology/American Heart Association pooled cohort equations in </text>
<text top="551" left="81" width="1006" height="21" font="1">predicting all-cause and cardiovascular disease-specific mortality in a national prospective cohort study of adults in the United States. Mayo Clin Proc. </text>
<text top="571" left="81" width="105" height="21" font="1">2016;91:763-9. </text>
<text top="591" left="81" width="25" height="21" font="1">79. </text>
<text top="591" left="135" width="968" height="21" font="1">Mortensen MB, Afzal S, Nordestgaard BG, et al. Primary prevention with statins: ACC/AHA risk-based approach versus trial-based approaches to </text>
<text top="611" left="81" width="393" height="21" font="1">guide statin therapy. J Am Coll Cardiol. 2015;66:2699-709. </text>
<text top="631" left="81" width="25" height="21" font="1">80. </text>
<text top="631" left="135" width="954" height="21" font="1">Mortensen MB, Nordestgaard BG, Afzal S, et al. ACC/AHA guidelines superior to ESC/EAS guidelines for primary prevention with statins in non-</text>
<text top="651" left="81" width="624" height="21" font="1">diabetic Europeans: the Copenhagen General Population Study. Eur Heart J. 2017;38:586-94. </text>
<text top="671" left="81" width="25" height="21" font="1">81. </text>
<text top="671" left="135" width="928" height="21" font="1">Muntner P, Colantonio LD, Cushman M, et al. Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations. JAMA. </text>
<text top="692" left="81" width="130" height="21" font="1">2014;311:1406-15. </text>
<text top="712" left="81" width="25" height="21" font="1">82. </text>
<text top="712" left="135" width="961" height="21" font="1">Nasir K, Bittencourt MS, Blaha MJ, et al. Implications of coronary artery calcium testing among statin candidates according to American College </text>
<text top="732" left="81" width="967" height="21" font="1">of Cardiology/American Heart Association Cholesterol Management Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. </text>
<text top="752" left="81" width="122" height="21" font="1">2015;66:1657-68. </text>
</page>
<page number="241" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">241 </text>
<text top="108" left="81" width="25" height="21" font="1">83. </text>
<text top="108" left="135" width="924" height="21" font="1">Rana JS, Tabada GH, Solomon MD, et al. Accuracy of the atherosclerotic cardiovascular risk equation in a large contemporary, multiethnic </text>
<text top="128" left="81" width="323" height="21" font="1">population. J Am Coll Cardiol. 2016;67:2118-30. </text>
<text top="148" left="81" width="25" height="21" font="1">84. </text>
<text top="148" left="135" width="961" height="21" font="1">Ungprasert P, Matteson EL, Crowson CS. Reliability of Cardiovascular risk calculators to estimate accurately the risk of cardiovascular disease in </text>
<text top="168" left="81" width="386" height="21" font="1">patients with sarcoidosis. Am J Cardiol. 2017;120:868-73. </text>
<text top="188" left="81" width="25" height="21" font="1">85. </text>
<text top="188" left="135" width="951" height="21" font="1">Wolfson J, Vock DM, Bandyopadhyay S, et al. Use and customization of risk scores for predicting cardiovascular events using electronic health </text>
<text top="208" left="81" width="326" height="21" font="1">record data. J Am Heart Assoc. 2017;6:e003670. </text>
<text top="228" left="81" width="25" height="21" font="1">86. </text>
<text top="228" left="135" width="936" height="21" font="1">Yang X, Li J, Hu D, et al. Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese Population: The China-PAR Project </text>
<text top="249" left="81" width="458" height="21" font="1">(Prediction for ASCVD Risk in China). Circulation. 2016;134:1430-40. </text>
<text top="269" left="81" width="25" height="21" font="1">87. </text>
<text top="269" left="135" width="953" height="21" font="1">Carr JJ, Jacobs DR, Jr., Terry JG, et al. Association of coronary artery calcium in adults aged 32 to 46 years with incident coronary heart disease </text>
<text top="289" left="81" width="270" height="21" font="1">and death. JAMA Cardiol. 2017;2:391-9. </text>
<text top="309" left="81" width="25" height="21" font="1">88. </text>
<text top="309" left="135" width="970" height="21" font="1">Fudim M, Zalawadiya S, Patel DK, et al. Data on coronary artery calcium score performance and cardiovascular risk reclassification across gender </text>
<text top="329" left="81" width="287" height="21" font="1">and ethnicities. Data Brief. 2016;6:578-81. </text>
<text top="349" left="81" width="25" height="21" font="1">89. </text>
<text top="349" left="135" width="973" height="21" font="1">Gupta A, Lau E, Varshney R, et al. The identification of calcified coronary plaque is associated with initiation and continuation of pharmacological </text>
<text top="370" left="81" width="784" height="21" font="1">and lifestyle preventive therapies: a systematic review and meta-analysis. JACC Cardiovasc Imaging. 2017;10:833-42. </text>
<text top="390" left="81" width="25" height="21" font="1">90. </text>
<text top="390" left="135" width="937" height="21" font="1">Han BH, Sutin D, Williamson JD, et al. Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults: The </text>
<text top="410" left="81" width="498" height="21" font="1">ALLHAT-LLT randomized clinical trial. JAMA Intern Med. 2017;177:955-65. </text>
<text top="430" left="81" width="25" height="21" font="1">91. </text>
<text top="430" left="135" width="956" height="21" font="1">Hong JC, Blankstein R, Blaha M, et al. Cost-effectiveness of coronary artery calcium testing among statin candidates according to the American </text>
<text top="450" left="81" width="933" height="21" font="1">College of Cardiology and American Heart Association cholesterol guidelines. Journal of the American College of Cardiology. 2017;69:1828. </text>
<text top="470" left="81" width="25" height="21" font="1">92. </text>
<text top="470" left="135" width="955" height="21" font="1">Kavousi M, Desai CS, Ayers C, et al. Prevalence and prognostic implications of coronary artery calcification in low-risk women: a meta-analysis. </text>
<text top="490" left="81" width="177" height="21" font="1">JAMA. 2016;316:2126-34. </text>
<text top="510" left="81" width="25" height="21" font="1">93. </text>
<text top="510" left="135" width="921" height="21" font="1">Mahabadi AA, Möhlenkamp S, Lehmann N, et al. CAC score improves coronary and CV risk assessment above statin indication by ESC and </text>
<text top="531" left="81" width="566" height="21" font="1">AHA/ACC Primary Prevention Guidelines. JACC Cardiovasc Imaging. 2017;10:143-53. </text>
<text top="551" left="81" width="25" height="21" font="1">94. </text>
<text top="551" left="135" width="958" height="21" font="1">McClelland RL, Jorgensen NW, Budoff M, et al. 10-year coronary heart disease risk prediction using coronary artery calcium and traditional risk </text>
<text top="571" left="81" width="1020" height="21" font="1">factors: derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) with validation in the HNR (Heinz Nixdorf Recall) Study and the DHS (Dallas Heart </text>
<text top="591" left="81" width="292" height="21" font="1">Study). J Am Coll Cardiol. 2015;66:1643-53. </text>
<text top="611" left="81" width="25" height="21" font="1">95. </text>
<text top="611" left="135" width="941" height="21" font="1">Mortensen MB, Fuster V, Muntendam P, et al. A simple disease-guided approach to personalize ACC/AHA-recommended statin allocation in </text>
<text top="631" left="81" width="476" height="21" font="1">elderly people: the BioImage Study. J Am Coll Cardiol. 2016;68:881-91. </text>
<text top="651" left="81" width="25" height="21" font="1">96. </text>
<text top="651" left="135" width="933" height="21" font="1">Pursnani A, Massaro JM, D’Agostino RB, Sr., et al. Guideline-based statin eligibility, coronary artery calcification, and cardiovascular events. </text>
<text top="671" left="81" width="168" height="21" font="1">JAMA. 2015;314:134-41. </text>
<text top="692" left="81" width="25" height="21" font="1">97. </text>
<text top="692" left="135" width="916" height="21" font="1">Qureshi WT, Rana JS, Yeboah J, et al. Risk stratification for primary prevention of coronary artery disease: roles of C-reactive protein and </text>
<text top="712" left="81" width="377" height="21" font="1">coronary artery calcium. Curr Cardiol Rep. 2015;17:110. </text>
<text top="732" left="81" width="25" height="21" font="1">98. </text>
<text top="732" left="135" width="921" height="21" font="1">Shah RV, Spahillari A, Mwasongwe S, et al. Subclinical atherosclerosis, statin eligibility, and outcomes in African American individuals: the </text>
<text top="752" left="81" width="345" height="21" font="1">Jackson Heart Study. JAMA Cardiol. 2017;2:644-52. </text>
</page>
<page number="242" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">242 </text>
<text top="108" left="81" width="25" height="21" font="1">99. </text>
<text top="108" left="135" width="970" height="21" font="1">Waheed S, Pollack S, Roth M, et al. Collective impact of conventional cardiovascular risk factors and coronary calcium score on clinical outcomes </text>
<text top="128" left="81" width="618" height="21" font="1">with or without statin therapy: The St Francis Heart Study. Atherosclerosis. 2016;255:193-9. </text>
<text top="148" left="81" width="981" height="21" font="1">100.  Yeboah J, Polonsky TS, Young R, et al. Utility of nontraditional risk markers in individuals ineligible for statin therapy according to the 2013 </text>
<text top="168" left="81" width="767" height="21" font="1">American College of Cardiology/American Heart Association Cholesterol Guidelines. Circulation. 2015;132:916-22. </text>
<text top="188" left="81" width="1022" height="21" font="1">101.  Yeboah J, Young R, McClelland RL, et al. Utility of nontraditional risk markers in atherosclerotic cardiovascular disease risk assessment. J Am Coll </text>
<text top="208" left="81" width="169" height="21" font="1">Cardiol. 2016;67:139-47. </text>
<text top="228" left="81" width="1014" height="21" font="1">102.  Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol </text>
<text top="249" left="81" width="816" height="21" font="1">levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-22. </text>
<text top="269" left="81" width="1002" height="21" font="1">103.  Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective </text>
<text top="289" left="81" width="374" height="21" font="1">randomised controlled trial. Lancet. 2006;368:1155-63. </text>
<text top="309" left="81" width="1003" height="21" font="1">104.  Benner JS, Tierce JC, Ballantyne CM, et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. </text>
<text top="329" left="81" width="315" height="21" font="1">Pharmacoeconomics. 2004;22 (suppl 3):13-23. </text>
<text top="349" left="81" width="1005" height="21" font="1">105.  Chiavaroli L, Nishi SK, Khan TA, et al. Portfolio dietary pattern and cardiovascular disease: a systematic review and meta-analysis of controlled </text>
<text top="370" left="81" width="285" height="21" font="1">trials. Prog Cardiovasc Dis. 2018;61:43-53. </text>
<text top="390" left="81" width="960" height="21" font="1">106.  Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic </text>
<text top="410" left="81" width="1012" height="21" font="1">cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. </text>
<text top="430" left="81" width="113" height="21" font="1">2014;129:S1-45. </text>
<text top="450" left="81" width="983" height="21" font="1">107.  Qi K, Reeve E, Hilmer SN, et al. Older peoples’ attitudes regarding polypharmacy, statin use and willingness to have statins deprescribed in </text>
<text top="470" left="81" width="293" height="21" font="1">Australia. Int J Clin Pharm. 2015;37:949-57. </text>
<text top="490" left="81" width="966" height="21" font="1">108.  Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing </text>
<text top="510" left="81" width="352" height="21" font="1">polypharmacy. Arch Intern Med. 2010;170:1648-54. </text>
<text top="531" left="81" width="1021" height="21" font="1">109.  Todd A, Holmes H, Pearson S, et al. 'I don't think I'd be frightened if the statins went': a phenomenological qualitative study exploring medicines </text>
<text top="551" left="81" width="651" height="21" font="1">use in palliative care patients, carers and healthcare professionals. BMC Palliat Care. 2016;15:13. </text>
<text top="571" left="81" width="1011" height="21" font="1">110.  Kutner JS, Blatchford PJ, Taylor DH, Jr., et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a </text>
<text top="591" left="81" width="424" height="21" font="1">randomized clinical trial. JAMA Intern Med. 2015;175:691-700. </text>
<text top="611" left="81" width="940" height="21" font="1">111.  Tjia J, Kutner JS, Ritchie CS, et al. Perceptions of Statin Discontinuation among Patients with Life-Limiting Illness. J Palliat Med. 2017; </text>
<text top="631" left="81" width="1004" height="21" font="1">112.  Glynn RJ, Koenig W, Nordestgaard BG, et al. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to </text>
<text top="651" left="81" width="911" height="21" font="1">average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med. 2010;152:488-96, W174. </text>
<text top="671" left="81" width="1005" height="21" font="1">113.  Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. </text>
<text top="692" left="81" width="183" height="21" font="1">Lancet. 2002;360:1623-30. </text>
<text top="712" left="81" width="1002" height="21" font="1">114.  Orkaby AR, Gaziano JM, Djousse L, et al. Statins for primary prevention of cardiovascular events and mortality in older men. J Am Geriatr Soc. </text>
<text top="732" left="81" width="114" height="21" font="1">2017;65:2362-8. </text>
<text top="752" left="81" width="977" height="21" font="1">115.  Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk </text>
<text top="772" left="81" width="506" height="21" font="1">individuals: a randomised placebo-controlled trial. Lancet. 2002;360:23-33. </text>
</page>
<page number="243" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">243 </text>
<text top="108" left="81" width="1017" height="21" font="1">116.  Neil HA, Hawkins MM, Durrington PN, et al. Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous </text>
<text top="128" left="81" width="633" height="21" font="1">familial hypercholesterolaemia: a prospective registry study. Atherosclerosis. 2005;179:293-7. </text>
<text top="148" left="81" width="1016" height="21" font="1">117.  Lemaitre RN, Psaty BM, Heckbert SR, et al. Therapy with hydroxymethylglutaryl coenzyme a reductase inhibitors (statins) and associated risk of </text>
<text top="168" left="81" width="891" height="21" font="1">incident cardiovascular events in older adults: evidence from the Cardiovascular Health Study. Arch Intern Med. 2002;162:1395-400. </text>
<text top="188" left="81" width="1017" height="21" font="1">118.  Ridker PM, Lonn E, Paynter NP, et al. Primary prevention with statin therapy in the elderly: new Meta-analyses from the contemporary JUPITER </text>
<text top="208" left="81" width="420" height="21" font="1">and HOPE-3 randomized trials. Circulation. 2017;135:1979-81. </text>
<text top="228" left="81" width="1028" height="21" font="1">119.  Savarese G, Gotto AM, Jr., Paolillo S, et al. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. J Am </text>
<text top="249" left="81" width="198" height="21" font="1">Coll Cardiol. 2013;62:2090-9. </text>
<text top="269" left="81" width="1005" height="21" font="1">120.  Teng M, Lin L, Zhao YJ, et al. Statins for primary prevention of cardiovascular disease in elderly patients: systematic review and meta-analysis. </text>
<text top="289" left="81" width="215" height="21" font="1">Drugs &amp; aging. 2015;32:649-61. </text>
<text top="309" left="81" width="1029" height="21" font="1">121.  Cholesterol Treatment Trialists’ (CTT) Collaborators, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in </text>
<text top="329" left="81" width="828" height="21" font="1">people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581-90. </text>
<text top="349" left="81" width="881" height="21" font="1">122.  Ademi Z, Watts GF, Juniper A, et al. A systematic review of economic evaluations of the detection and treatment of familial </text>
<text top="370" left="81" width="363" height="21" font="1">hypercholesterolemia. Int J Cardiol. 2013;167:2391-6. </text>
<text top="390" left="81" width="1001" height="21" font="1">123.  Group AOaCftACR. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The </text>
<text top="410" left="81" width="809" height="21" font="1">Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998-3007. </text>
<text top="430" left="81" width="1026" height="21" font="1">124.  Ademi Z, Watts GF, Pang J, et al. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care </text>
<text top="450" left="81" width="434" height="21" font="1">for familial hypercholesterolemia. J Clin Lipidol. 2014;8:390-400. </text>
<text top="470" left="81" width="970" height="21" font="1">125.  Tonelli M, Muntner P, Lloyd A, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a </text>
<text top="490" left="81" width="380" height="21" font="1">population-level cohort study. Lancet. 2012;380:807-14. </text>
<text top="510" left="81" width="1027" height="21" font="1">126.  Chen CX, Hay JW. Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in </text>
<text top="531" left="81" width="333" height="21" font="1">the United States. Int J Cardiol. 2015;181:417-24. </text>
<text top="551" left="81" width="992" height="21" font="1">127.  Marang-van de Mheen PJ, ten Asbroek AH, Bonneux L, et al. Cost-effectiveness of a family and DNA based screening programme on familial </text>
<text top="571" left="81" width="497" height="21" font="1">hypercholesterolaemia in The Netherlands. Eur Heart J. 2002;23:1922-30. </text>
<text top="591" left="81" width="1022" height="21" font="1">128.  Marks D, Wonderling D, Thorogood M, et al. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. </text>
<text top="611" left="81" width="145" height="21" font="1">BMJ. 2002;324:1303. </text>
<text top="631" left="81" width="982" height="21" font="1">129.  Marks D, Thorogood M, Neil HA, et al. Comparing costs and benefits over a 10 year period of strategies for familial hypercholesterolaemia </text>
<text top="651" left="81" width="318" height="21" font="1">screening. J Public Health Med. 2003;25:47-52. </text>
<text top="671" left="81" width="981" height="21" font="1">130.  Nherera L, Marks D, Minhas R, et al. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using </text>
<text top="692" left="81" width="511" height="21" font="1">alternative diagnostic and identification strategies. Heart. 2011;97:1175-81. </text>
<text top="712" left="81" width="1008" height="21" font="1">131.  Oliva J, Lopez-Bastida J, Moreno SG, et al. [Cost-effectiveness analysis of a genetic screening program in the close relatives of Spanish patients </text>
<text top="732" left="81" width="462" height="21" font="1">with familial hypercholesterolemia]. Rev Esp Cardiol. 2009;62:57-65. </text>
<text top="752" left="81" width="915" height="21" font="1">132.  Wonderling D, Umans-Eckenhausen MA, Marks D, et al. Cost-effectiveness analysis of the genetic screening program for familial </text>
<text top="772" left="81" width="510" height="21" font="1">hypercholesterolemia in The Netherlands. Semin Vasc Med. 2004;4:97-104. </text>
</page>
<page number="244" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">244 </text>
<text top="108" left="81" width="968" height="21" font="1">133.  Kusters DM, Caceres M, Coll M, et al. Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial </text>
<text top="128" left="81" width="384" height="21" font="1">hypercholesterolemia. J Pediatr. 2015;166:1377-84.e1-3. </text>
<text top="148" left="81" width="1020" height="21" font="1">134.  Schanberg LE, Sandborg C, Barnhart HX, et al. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum. </text>
<text top="168" left="81" width="114" height="21" font="1">2012;64:285-96. </text>
<text top="188" left="81" width="1014" height="21" font="1">135.  Ardoin SP, Schanberg LE, Sandborg CI, et al. Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in </text>
<text top="208" left="81" width="591" height="21" font="1">pubertal lupus patients with higher C reactive protein. Ann Rheum Dis. 2014;73:557-66. </text>
<text top="228" left="81" width="993" height="21" font="1">136.  Niinikoski H, Lagström H, Jokinen E, et al. Impact of repeated dietary counseling between infancy and 14 years of age on dietary intakes and </text>
<text top="249" left="81" width="525" height="21" font="1">serum lipids and lipoproteins: the STRIP study. Circulation. 2007;116:1032-40. </text>
<text top="269" left="81" width="974" height="21" font="1">137.  Pahkala K, Hietalampi H, Laitinen TT, et al. Ideal cardiovascular health in adolescence: effect of lifestyle intervention and association with </text>
<text top="289" left="81" width="979" height="21" font="1">vascular intima-media thickness and elasticity (the Special Turku Coronary Risk Factor Intervention Project for Children [STRIP] study). Circulation. </text>
<text top="309" left="81" width="130" height="21" font="1">2013;127:2088-96. </text>
<text top="329" left="81" width="980" height="21" font="1">138.  Iannuzzi A, Licenziati MR, Vacca M, et al. Comparison of two diets of varying glycemic index on carotid subclinical atherosclerosis in obese </text>
<text top="349" left="81" width="274" height="21" font="1">children. Heart Vessels. 2009;24:419-24. </text>
<text top="370" left="81" width="1003" height="21" font="1">139.  Murphy EC-S, Carson L, Neal W, et al. Effects of an exercise intervention using Dance Dance Revolution on endothelial function and other risk </text>
<text top="390" left="81" width="439" height="21" font="1">factors in overweight children. Int J Pediatr Obes. 2009;4:205-14. </text>
<text top="410" left="81" width="945" height="21" font="1">140.  Farpour-Lambert NJ, Aggoun Y, Marchand LM, et al. Physical activity reduces systemic blood pressure and improves early markers of </text>
<text top="430" left="81" width="566" height="21" font="1">atherosclerosis in pre-pubertal obese children. J Am Coll Cardiol. 2009;54:2396-406. </text>
<text top="450" left="81" width="981" height="21" font="1">141.  Velazquez-Lopez L, Santiago-Diaz G, Nava-Hernandez J, et al. Mediterranean-style diet reduces metabolic syndrome components in obese </text>
<text top="470" left="81" width="445" height="21" font="1">children and adolescents with obesity. BMC Pediatr. 2014;14:175. </text>
<text top="490" left="81" width="982" height="21" font="1">142.  Singhal A, Lanigan J, Storry C, et al. Docosahexaenoic acid supplementation, vascular function and risk factors for cardiovascular disease: a </text>
<text top="510" left="81" width="537" height="21" font="1">randomized controlled trial in young adults. J Am Heart Assoc. 2013;2:e000283. </text>
<text top="531" left="81" width="1019" height="21" font="1">143.  Vuorio A, Kuoppala J, Kovanen PT, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev. 2017;7:CD006401. </text>
<text top="551" left="81" width="997" height="21" font="1">144.  Lozano P, Henrikson NB, Dunn J, et al. Lipid screening in childhood and adolescence for detection of familial hypercholesterolemia: evidence </text>
<text top="571" left="81" width="652" height="21" font="1">report and systematic review for the US Preventive Services Task Force. JAMA. 2016;316:645-55. </text>
<text top="591" left="81" width="979" height="21" font="1">145.  Obarzanek E, Kimm SY, Barton BA, et al. Long-term safety and efficacy of a cholesterol-lowering diet in children with elevated low-density </text>
<text top="611" left="81" width="832" height="21" font="1">lipoprotein cholesterol: seven-year results of the Dietary Intervention Study in Children (DISC). Pediatrics. 2001;107:256-64. </text>
<text top="631" left="81" width="999" height="21" font="1">146.  Efficacy and safety of lowering dietary intake of fat and cholesterol in children with elevated low-density lipoprotein cholesterol. The Dietary </text>
<text top="651" left="81" width="850" height="21" font="1">Intervention Study in Children (DISC). The Writing Group for the DISC Collaborative Research Group. JAMA. 1995;273:1429-35. </text>
<text top="671" left="81" width="969" height="21" font="1">147.  Obarzanek E, Hunsberger SA, Van Horn L, et al. Safety of a fat-reduced diet: the Dietary Intervention Study in Children (DISC). Pediatrics. </text>
<text top="692" left="81" width="105" height="21" font="1">1997;100:51-9. </text>
<text top="712" left="81" width="1025" height="21" font="1">148.  Lavigne JV, Brown KM, Gidding S, et al. A cholesterol-lowering diet does not produce adverse psychological effects in children: three-year results </text>
<text top="732" left="81" width="540" height="21" font="1">from the dietary intervention study in children. Health Psychol. 1999;18:604-13. </text>
<text top="752" left="81" width="1027" height="21" font="1">149.  Dorgan JF, Liu L, Barton BA, et al. Adolescent diet and metabolic syndrome in young women: results of the Dietary Intervention Study in Children </text>
<text top="772" left="81" width="469" height="21" font="1">(DISC) follow-up study. J Clin Endocrinol Metab. 2011;96:E1999-2008. </text>
</page>
<page number="245" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">245 </text>
<text top="108" left="81" width="955" height="21" font="1">150.  Shivakumar S, Ilango K, Dubey GP, et al. Evaluation of plant based formulation on adolescent obesity and its associated bio-markers: a </text>
<text top="128" left="81" width="631" height="21" font="1">randomized, double blind, placebo controlled study. Complement Ther Med. 2015;23:157-64. </text>
<text top="148" left="81" width="1005" height="21" font="1">151.  Kelishadi R, Hashemipour M, Adeli K, et al. Effect of zinc supplementation on markers of insulin resistance, oxidative stress, and inflammation </text>
<text top="168" left="81" width="668" height="21" font="1">among prepubescent children with metabolic syndrome. Metab Syndr Relat Disord. 2010;8:505-10. </text>
<text top="188" left="81" width="1016" height="21" font="1">152.  Horner K, Kuk JL, Barinas-Mitchell E, et al. Effect of Aerobic versus Resistance Exercise on Pulse Wave Velocity, Intima Media Thickness and Left </text>
<text top="208" left="81" width="509" height="21" font="1">Ventricular Mass in Obese Adolescents. Pediatr Exerc Sci. 2015;27:494-502. </text>
<text top="228" left="81" width="978" height="21" font="1">153.  de Ferranti SD, Milliren CE, Denhoff ER, et al. Providing food to treat adolescents at risk for cardiovascular disease. Obesity (Silver Spring). </text>
<text top="249" left="81" width="122" height="21" font="1">2015;23:2109-17. </text>
<text top="269" left="81" width="992" height="21" font="1">154.  Gidding SS, Prospero C, Hossain J, et al. A double-blind randomized trial of fish oil to lower triglycerides and improve cardiometabolic risk in </text>
<text top="289" left="81" width="304" height="21" font="1">adolescents. J Pediatr. 2014;165:497-503 e2. </text>
<text top="309" left="81" width="1020" height="21" font="1">155.  de Ferranti SD, Milliren CE, Denhoff ER, et al. Using high-dose omega-3 fatty acid supplements to lower triglyceride levels in 10- to 19-year-olds. </text>
<text top="329" left="81" width="245" height="21" font="1">Clin Pediatr (Phila). 2014;53:428-38. </text>
<text top="349" left="81" width="975" height="21" font="1">156.  Gunnarsdottir T, Einarsson SM, Njardvik U, et al. [Family-based behavioral treatment for obese children - results and two year follow up]. </text>
<text top="370" left="81" width="219" height="21" font="1">Laeknabladid. 2014;100:139-45. </text>
<text top="390" left="81" width="996" height="21" font="1">157.  Viitasalo A, Lakka TA, Laaksonen DE, et al. Validation of metabolic syndrome score by confirmatory factor analysis in children and adults and </text>
<text top="410" left="81" width="536" height="21" font="1">prediction of cardiometabolic outcomes in adults. Diabetologia. 2014;57:940-9. </text>
<text top="430" left="81" width="987" height="21" font="1">158.  Benson M, Hossain J, Caulfield MP, et al. Lipoprotein subfractions by ion mobility in lean and obese children. J Pediatr. 2012;161:997-1003. </text>
<text top="450" left="81" width="989" height="21" font="1">159.  Elkiran O, Yilmaz E, Koc M, et al. The association between intima media thickness, central obesity and diastolic blood pressure in obese and </text>
<text top="470" left="81" width="602" height="21" font="1">overweight children: a cross-sectional school-based study. Int J Cardiol. 2013;165:528-32. </text>
<text top="490" left="81" width="947" height="21" font="1">160.  Dalili S, Mohammadi H, Rezvany SM, et al. The relationship between blood pressure, anthropometric indices and metabolic profile in </text>
<text top="510" left="81" width="539" height="21" font="1">adolescents: a cross sectional study. Indian journal of pediatrics. 2015;82:445-9. </text>
<text top="531" left="81" width="1010" height="21" font="1">161.  de Jong M, Cranendonk A, van Weissenbruch MM. Components of the metabolic syndrome in early childhood in very-low-birth-weight infants </text>
<text top="551" left="81" width="642" height="21" font="1">and term small and appropriate for gestational age infants. Pediatric research. 2015;78:457-61. </text>
<text top="571" left="81" width="1004" height="21" font="1">162.  Thompson PDM, R.J.; Levine, B.D.; Udelson, J.E.; Kovacs, R.J.; American Heart Association Electrocardiography and Arrhythmias Committee of </text>
<text top="591" left="81" width="964" height="21" font="1">Council on Clinical Cardiology; Council on Cardiovascular Disease in Young; Council on Cardiovascular and Stroke Nursing; Council on Functional </text>
<text top="611" left="81" width="996" height="21" font="1">Genomics and Translational Biology; American College of Cardiology. Eligibility and Disqualification Recommendations for Competitive Athletes with </text>
<text top="631" left="81" width="1020" height="21" font="1">Cardiovascular Abnormalities: Task Force 8: Coronary Artery Disease: A Scientific Statement from the American Heart Association and American College </text>
<text top="651" left="81" width="299" height="21" font="1">of Cardiology. Circulation. 2015;132:e310-4. </text>
<text top="671" left="81" width="1022" height="21" font="1">163.  de Lima Sanches P, de Mello MT, Elias N, et al. Improvement in HOMA-IR is an independent predictor of reduced carotid intima-media thickness </text>
<text top="692" left="81" width="967" height="21" font="1">in obese adolescents participating in an interdisciplinary weight-loss program. Hypertension research : official journal of the Japanese Society of </text>
<text top="712" left="81" width="204" height="21" font="1">Hypertension. 2011;34:232-8. </text>
<text top="732" left="81" width="995" height="21" font="1">164.  Bauer KW, Marcus MD, El ghormli L, et al. Cardio-metabolic risk screening among adolescents: understanding the utility of body mass index, </text>
<text top="752" left="81" width="545" height="21" font="1">waist circumference and waist to height ratio. Pediatric obesity. 2015;10:329-37. </text>
</page>
<page number="246" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">246 </text>
<text top="108" left="81" width="1024" height="21" font="1">165.  Braamskamp MJ, Kusters DM, Wiegman A, et al. Gonadal steroids, gonadotropins and DHEAS in young adults with familial hypercholesterolemia </text>
<text top="128" left="81" width="543" height="21" font="1">who had initiated statin therapy in childhood. Atherosclerosis. 2015;241:427-32. </text>
<text top="148" left="81" width="1002" height="21" font="1">166.  Pratt RE, Kavey R-E, Quinzi D. Combined dyslipidemia in obese children: response to a focused lifestyle approach. J Clin Lipidol. 2014;8:181-6. </text>
<text top="168" left="81" width="1027" height="21" font="1">167.  Zachariah JP, Chan J, Mendelson MM, et al. Adolescent dyslipidemia and standardized lifestyle modification: benchmarking real-world practice. J </text>
<text top="188" left="81" width="224" height="21" font="1">Am Coll Cardiol. 2016;68:2122-3. </text>
<text top="208" left="81" width="995" height="21" font="1">168.  Fox ER, Samdarshi TE, Musani SK, et al. Development and Validation of Risk Prediction Models for Cardiovascular Events in Black Adults: The </text>
<text top="228" left="81" width="387" height="21" font="1">Jackson Heart Study Cohort. JAMA Cardiol. 2016;1:15-25. </text>
<text top="249" left="81" width="1012" height="21" font="1">169.  George MD, McGill N-K, Baker JF. Creatine kinase in the U.S. population: Impact of demographics, comorbidities, and body composition on the </text>
<text top="269" left="81" width="356" height="21" font="1">normal range. Medicine (Baltimore). 2016;95:e4344. </text>
<text top="289" left="81" width="1018" height="21" font="1">170.  Paixao AR, Ayers CR, El Sabbagh A, et al. Coronary Artery Calcium Improves Risk Classification in Younger Populations. JACC Cardiovasc Imaging. </text>
<text top="309" left="81" width="114" height="21" font="1">2015;8:1285-93. </text>
<text top="329" left="81" width="979" height="21" font="1">171.  Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the </text>
<text top="349" left="81" width="472" height="21" font="1">MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711-8. </text>
<text top="370" left="81" width="996" height="21" font="1">172.  Cho YK, Jung CH, Kang YM, et al. 2013 ACC/AHA cholesterol guideline versus 2004 NCEP ATP III guideline in the prediction of coronary artery </text>
<text top="390" left="81" width="566" height="21" font="1">calcification progression in a Korean population. J Am Heart Assoc. 2016;5:e003410. </text>
<text top="410" left="81" width="1014" height="21" font="1">173.  Kandula NR, Kanaya AM, Liu K, et al. Association of 10-year and lifetime predicted cardiovascular disease risk with subclinical atherosclerosis in </text>
<text top="430" left="81" width="988" height="21" font="1">South Asians: findings from the Mediators of Atherosclerosis in South Asians Living in America (MASALA) study. J Am Heart Assoc. 2014;3:e001117. </text>
<text top="450" left="81" width="1006" height="21" font="1">174.  Qureshi WT, Michos ED, Flueckiger P, et al. Impact of Replacing the Pooled Cohort Equation With Other Cardiovascular Disease Risk Scores on </text>
<text top="470" left="81" width="964" height="21" font="1">Atherosclerotic Cardiovascular Disease Risk Assessment (from the Multi-Ethnic Study of Atherosclerosis [MESA]). Am J Cardiol. 2016;118:691-6. </text>
<text top="490" left="81" width="1024" height="21" font="1">175.  Mercado C, DeSimone AK, Odom E, et al. Prevalence of Cholesterol Treatment Eligibility and Medication Use Among Adults--United States, 2005-</text>
<text top="510" left="81" width="485" height="21" font="1">2012. MMWR Morbidity and mortality weekly report. 2015;64:1305-11. </text>
<text top="531" left="81" width="958" height="21" font="1">176.  Qureshi WT, Kaplan RC, Swett K, et al. American College of Cardiology/American Heart Association (ACC/AHA) class I guidelines for the </text>
<text top="551" left="81" width="968" height="21" font="1">treatment of cholesterol to reduce atherosclerotic cardiovascular risk: implications for US Hispanics/Latinos based on findings from the Hispanic </text>
<text top="571" left="81" width="611" height="21" font="1">Community Health Study/Study of Latinos (HCHS/SOL). J Am Heart Assoc. 2017;6:e005045. </text>
<text top="591" left="81" width="991" height="21" font="1">177.  Mattei J, Sotres-Alvarez D, Daviglus ML, et al. Diet Quality and Its Association with Cardiometabolic Risk Factors Vary by Hispanic and Latino </text>
<text top="611" left="81" width="816" height="21" font="1">Ethnic Background in the Hispanic Community Health Study/Study of Latinos. The Journal of nutrition. 2016;146:2035-44. </text>
<text top="631" left="81" width="1010" height="21" font="1">178.  Daviglus ML, Pirzada A, Durazo-Arvizu R, et al. Prevalence of low cardiovascular risk profile among diverse Hispanic/Latino adults in the United </text>
<text top="651" left="81" width="920" height="21" font="1">States by age, sex, and level of acculturation: the Hispanic Community Health Study/Study of Latinos. J Am Heart Assoc. 2016;5:e003929. </text>
<text top="671" left="81" width="974" height="21" font="1">179.  Kershaw KN, Greenlund KJ, Stamler J, et al. Understanding ethnic and nativity-related differences in low cardiovascular risk status among </text>
<text top="692" left="81" width="506" height="21" font="1">Mexican-Americans and non-Hispanic Whites. Prev Med. 2012;55:597-602. </text>
<text top="712" left="81" width="1007" height="21" font="1">180.  Yoshida YX, Simonsen N, Chen L, et al. Sociodemographic Factors, Acculturation, and Nutrition Management among Hispanic American Adults </text>
<text top="732" left="81" width="545" height="21" font="1">with Self-reported Diabetes. J Health Care Poor Underserved. 2016;27:1592-607. </text>
<text top="752" left="81" width="1021" height="21" font="1">181.  Rivera-Hernandez M, Leyva B, Keohane LM, et al. Quality of Care for White and Hispanic Medicare Advantage Enrollees in the United States and </text>
<text top="772" left="81" width="334" height="21" font="1">Puerto Rico. JAMA Intern Med. 2016;176:787-94. </text>
</page>
<page number="247" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">247 </text>
<text top="108" left="81" width="995" height="21" font="1">182.  Adedinsewo D, Taka N, Agasthi P, et al. Prevalence and Factors Associated With Statin Use Among a Nationally Representative Sample of US </text>
<text top="128" left="81" width="663" height="21" font="1">Adults: National Health and Nutrition Examination Survey, 2011-2012. Clin Cardiol. 2016;39:491-6. </text>
<text top="148" left="81" width="938" height="21" font="1">183.  Daviglus ML, Talavera GA, Aviles-Santa ML, et al. Prevalence of major cardiovascular risk factors and cardiovascular diseases among </text>
<text top="168" left="81" width="660" height="21" font="1">Hispanic/Latino individuals of diverse backgrounds in the United States. JAMA. 2012;308:1775-84. </text>
<text top="188" left="81" width="1026" height="21" font="1">184.  Schneiderman N, Chirinos DA, Avilés-Santa ML, et al. Challenges in preventing heart disease in Hispanics: early lessons learned from the Hispanic </text>
<text top="208" left="81" width="624" height="21" font="1">Community Health Study/Study of Latinos (HCHS/SOL). Prog Cardiovasc Dis. 2014;57:253-61. </text>
<text top="228" left="81" width="1002" height="21" font="1">185.  Arguelles W, Llabre MM, Sacco RL, et al. Characterization of metabolic syndrome among diverse Hispanics/Latinos living in the United States: </text>
<text top="249" left="81" width="832" height="21" font="1">Latent class analysis from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). Int J Cardiol. 2015;184:373-9. </text>
<text top="269" left="81" width="1013" height="21" font="1">186.  Nicholls SJ, Brandrup-Wognsen G, Palmer M, et al. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin </text>
<text top="289" left="81" width="717" height="21" font="1">versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol. 2010;105:69-76. </text>
<text top="309" left="81" width="989" height="21" font="1">187.  Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels </text>
<text top="329" left="81" width="982" height="21" font="1">(from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. </text>
<text top="349" left="81" width="122" height="21" font="1">2011;108:682-90. </text>
<text top="370" left="81" width="1014" height="21" font="1">188.  Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol </text>
<text top="390" left="81" width="641" height="21" font="1">level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213-9. </text>
<text top="410" left="81" width="995" height="21" font="1">189.  Emerging Risk Factors C, Kaptoge S, Di Angelantonio E, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and </text>
<text top="430" left="81" width="510" height="21" font="1">mortality: an individual participant meta-analysis. Lancet. 2010;375:132-40. </text>
<text top="450" left="81" width="1017" height="21" font="1">190.  Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men </text>
<text top="470" left="81" width="264" height="21" font="1">and women. JAMA. 2007;298:299-308. </text>
<text top="490" left="81" width="941" height="21" font="1">191.  Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, et al. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA. </text>
<text top="510" left="81" width="130" height="21" font="1">2008;300:2142-52. </text>
<text top="531" left="81" width="1010" height="21" font="1">192.  Karlson BW, Palmer MK, Nicholls SJ, et al. A VOYAGER meta-analysis of the impact of statin therapy on low-density lipoprotein cholesterol and </text>
<text top="551" left="81" width="589" height="21" font="1">triglyceride levels in patients with hypertriglyceridemia. Am J Cardiol. 2016;117:1444-8. </text>
<text top="571" left="81" width="1020" height="21" font="1">193.  Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med. </text>
<text top="591" left="81" width="130" height="21" font="1">2016;176:1834-42. </text>
<text top="611" left="81" width="1005" height="21" font="1">194.  Rhodes KS, Weintraub M, Marchlewicz EH, et al. Medical nutrition therapy is the essential cornerstone for effective treatment of “refractory” </text>
<text top="631" left="81" width="968" height="21" font="1">severe hypertriglyceridemia regardless of pharmaceutical treatment: evidence from a Lipid Management Program. J Clin Lipidol. 2015;9:559-67. </text>
<text top="651" left="81" width="1025" height="21" font="1">195.  Christian JB, Arondekar B, Buysman EK, et al. Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg/dL </text>
<text top="671" left="81" width="499" height="21" font="1">in patients with severe hypertriglyceridemia. J Clin Lipidol. 2012;6:450-61. </text>
<text top="692" left="81" width="1016" height="21" font="1">196.  Clearfield M, Downs JR, Weis S, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of </text>
<text top="712" left="81" width="677" height="21" font="1">long-term treatment with lovastatin in women. J Womens Health Gend Based Med. 2001;10:971-81. </text>
<text top="732" left="81" width="963" height="21" font="1">197.  Mizuno K, Nakaya N, Ohashi Y, et al. Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the </text>
<text top="752" left="81" width="909" height="21" font="1">Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study). Circulation. 2008;117:494-502. </text>
</page>
<page number="248" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">248 </text>
<text top="108" left="81" width="996" height="21" font="1">198.  Ridker PM, Paynter NP, Rifai N, et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk </text>
<text top="128" left="81" width="424" height="21" font="1">Score for men. Circulation. 2008;118:2243-51, 4p following 51. </text>
<text top="148" left="81" width="997" height="21" font="1">199.  Mora S, Glynn RJ, Hsia J, et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive </text>
<text top="168" left="81" width="1003" height="21" font="1">protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and </text>
<text top="188" left="81" width="590" height="21" font="1">meta-analysis of women from primary prevention trials. Circulation. 2010;121:1069-77. </text>
<text top="208" left="81" width="931" height="21" font="1">200.  Kostis WJ, Cheng JQ, Dobrzynski JM, et al. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol. 2012;59:572-82. </text>
<text top="228" left="81" width="935" height="21" font="1">201.  Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. </text>
<text top="249" left="81" width="115" height="21" font="1">2013;CD004816. </text>
<text top="269" left="81" width="1001" height="21" font="1">202.  Cholesterol Treatment Trialists’ (CTT) Collaborators, Fulcher J, O’Connell R, et al. Efficacy and safety of LDL-lowering therapy among men and </text>
<text top="289" left="81" width="805" height="21" font="1">women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385:1397-405. </text>
<text top="309" left="81" width="1017" height="21" font="1">203.  Yusuf S, Lonn E, Pais P, et al. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. N Engl J Med. 2016;374:2032-</text>
<text top="329" left="81" width="25" height="21" font="1">43. </text>
<text top="349" left="81" width="1026" height="21" font="1">204.  McClelland RL, Chung H, Detrano R, et al. Distribution of coronary artery calcium by race, gender, and age: results from the Multi-Ethnic Study of </text>
<text top="370" left="81" width="350" height="21" font="1">Atherosclerosis (MESA). Circulation. 2006;113:30-7. </text>
<text top="390" left="81" width="997" height="21" font="1">205.  Jain A, McClelland RL, Polak JF, et al. Cardiovascular imaging for assessing cardiovascular risk in asymptomatic men versus women: the multi-</text>
<text top="410" left="81" width="521" height="21" font="1">ethnic study of atherosclerosis (MESA). Circ Cardiovasc Imaging. 2011;4:8-15. </text>
<text top="430" left="81" width="1007" height="21" font="1">206.  Kelkar AA, Schultz WM, Khosa F, et al. Long-Term Prognosis After Coronary Artery Calcium Scoring Among Low-Intermediate Risk Women and </text>
<text top="450" left="81" width="322" height="21" font="1">Men. Circ Cardiovasc Imaging. 2016;9:e003742. </text>
<text top="470" left="81" width="1027" height="21" font="1">207.  Nakanishi R, Li D, Blaha MJ, et al. All-cause mortality by age and gender based on coronary artery calcium scores. Eur Heart J Cardiovasc Imaging. </text>
<text top="490" left="81" width="122" height="21" font="1">2016;17:1305-14. </text>
<text top="510" left="81" width="999" height="21" font="1">208.  Yano Y, O’Donnell CJ, Kuller L, et al. Association of coronary artery calcium score vs age with cardiovascular risk in older adults: an analysis of </text>
<text top="531" left="81" width="431" height="21" font="1">pooled population-based studies. JAMA Cardiol. 2017;2:986-94. </text>
<text top="551" left="81" width="968" height="21" font="1">209.  Catov JM, Newman AB, Roberts JM, et al. Preterm delivery and later maternal cardiovascular disease risk. Epidemiology. 2007;18:733-9. </text>
<text top="571" left="81" width="1003" height="21" font="1">210.  Grandi SM, Vallée-Pouliot K, Reynier P, et al. Hypertensive disorders in pregnancy and the risk of subsequent cardiovascular disease. Paediatr </text>
<text top="591" left="81" width="241" height="21" font="1">Perinat Epidemiol. 2017;31:412-21. </text>
<text top="611" left="81" width="1025" height="21" font="1">211.  Shostrom DCV, Sun Y, Oleson JJ, et al. History of gestational diabetes mellitus in relation to cardiovascular disease and cardiovascular risk factors </text>
<text top="631" left="81" width="377" height="21" font="1">in US women. Front Endocrinol (Lausanne). 2017;8:144. </text>
<text top="651" left="81" width="948" height="21" font="1">212.  Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and </text>
<text top="671" left="81" width="757" height="21" font="1">cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073-81. </text>
<text top="692" left="81" width="1011" height="21" font="1">213.  van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause </text>
<text top="712" left="81" width="811" height="21" font="1">and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79:1341-52. </text>
<text top="732" left="81" width="1027" height="21" font="1">214.  Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with </text>
<text top="752" left="81" width="445" height="21" font="1">and without diabetes: a meta-analysis. Lancet. 2012;380:1662-73. </text>
</page>
<page number="249" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">249 </text>
<text top="108" left="81" width="1020" height="21" font="1">215.  Colantonio LD, Baber U, Banach M, et al. Contrasting Cholesterol Management Guidelines for Adults with CKD. J Am Soc Nephrol. 2015;26:1173-</text>
<text top="128" left="81" width="25" height="21" font="1">80. </text>
<text top="148" left="81" width="1026" height="21" font="1">216.  Herrington WG, Emberson J, Mihaylova B, et al. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a </text>
<text top="168" left="81" width="770" height="21" font="1">meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol. 2016;4:829-39. </text>
<text top="188" left="81" width="1002" height="21" font="1">217.  Palmer SC, Craig JC, Navaneethan SD, et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review </text>
<text top="208" left="81" width="366" height="21" font="1">and meta-analysis. Ann Intern Med. 2012;157:263-75. </text>
<text top="228" left="81" width="1002" height="21" font="1">218.  Upadhyay A, Earley A, Lamont JL, et al. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. </text>
<text top="249" left="81" width="236" height="21" font="1">Ann Intern Med. 2012;157:251-62. </text>
<text top="269" left="81" width="937" height="21" font="1">219.  Major RW, Cheung CK, Gray LJ, et al. Statins and Cardiovascular Primary Prevention in CKD: A Meta-Analysis. Clin J Am Soc Nephrol. </text>
<text top="289" left="81" width="105" height="21" font="1">2015;10:732-9. </text>
<text top="309" left="81" width="1012" height="21" font="1">220.  Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238-</text>
<text top="329" left="81" width="25" height="21" font="1">48. </text>
<text top="349" left="81" width="974" height="21" font="1">221.  Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. </text>
<text top="370" left="81" width="139" height="21" font="1">2009;360:1395-407. </text>
<text top="390" left="81" width="967" height="21" font="1">222.  Colhoun HM, Betteridge DJ, Durrington PN, et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with </text>
<text top="410" left="81" width="769" height="21" font="1">diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis. 2009;54:810-9. </text>
<text top="430" left="81" width="1007" height="21" font="1">223.  Asselbergs FW, Diercks GFH, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. </text>
<text top="450" left="81" width="211" height="21" font="1">Circulation. 2004;110:2809-16. </text>
<text top="470" left="81" width="1008" height="21" font="1">224.  Mantel Ä, Holmqvist M, Jernberg T, et al. Rheumatoid arthritis is associated with a more severe presentation of acute coronary syndrome and </text>
<text top="490" left="81" width="392" height="21" font="1">worse short-term outcome. Eur Heart J. 2015;36:3413-22. </text>
<text top="510" left="81" width="1020" height="21" font="1">225.  Westerweel PE, Luyten RKMAC, Koomans HA, et al. Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. Arthritis </text>
<text top="531" left="81" width="178" height="21" font="1">Rheum. 2007;56:1384-96. </text>
<text top="551" left="81" width="1029" height="21" font="1">226.  Mehta NN, Azfar RS, Shin DB, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General </text>
<text top="571" left="81" width="387" height="21" font="1">Practice Research Database. Eur Heart J. 2010;31:1000-6. </text>
<text top="591" left="81" width="1024" height="21" font="1">227.  Hanna DB, Ramaswamy C, Kaplan RC, et al. Trends in cardiovascular disease mortality among persons with HIV in New York City, 2001-2012. Clin </text>
<text top="611" left="81" width="184" height="21" font="1">Infect Dis. 2016;63:1122-9. </text>
<text top="631" left="81" width="1014" height="21" font="1">228.  Fernández-Montero JV, Barreiro P, de Mendoza C, et al. Hepatitis C virus coinfection independently increases the risk of cardiovascular disease </text>
<text top="651" left="81" width="361" height="21" font="1">in HIV-positive patients. J Viral Hepat. 2016;23:47-52. </text>
<text top="671" left="81" width="939" height="21" font="1">229.  Dregan A, Chowienczyk P, Molokhia M. Cardiovascular and type 2 diabetes morbidity and all-cause mortality among diverse chronic </text>
<text top="692" left="81" width="341" height="21" font="1">inflammatory disorders. Heart. 2017;103:1867-73. </text>
<text top="712" left="81" width="996" height="21" font="1">230.  Bartels CM, Kind AJH, Everett C, et al. Low frequency of primary lipid screening among medicare patients with rheumatoid arthritis. Arthritis </text>
<text top="732" left="81" width="178" height="21" font="1">Rheum. 2011;63:1221-30. </text>
<text top="752" left="81" width="1003" height="21" font="1">231.  Arts EEA, Popa C, Den Broeder AA, et al. Performance of four current risk algorithms in predicting cardiovascular events in patients with early </text>
<text top="772" left="81" width="368" height="21" font="1">rheumatoid arthritis. Ann Rheum Dis. 2015;74:668-74. </text>
</page>
<page number="250" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">250 </text>
<text top="108" left="81" width="965" height="21" font="1">232.  Yu HH, Chen PC, Yang YH, et al. Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: A </text>
<text top="128" left="81" width="510" height="21" font="1">nationwide population-based cohort study. Atherosclerosis. 2015;243:11-8. </text>
<text top="148" left="81" width="979" height="21" font="1">233.  Ou HT, Chang KC, Li CY, et al. Intensive statin regimens for reducing risk of cardiovascular diseases among human immunodeficiency virus-</text>
<text top="168" left="81" width="690" height="21" font="1">infected population: A nation-wide longitudinal cohort study 2000-2011. Int J Cardiol. 2017;230:592-8. </text>
<text top="188" left="81" width="997" height="21" font="1">234.  Klein DB, Leyden WA, Xu L, et al. Declining relative risk for myocardial infarction among HIV-positive compared with HIV-negative individuals </text>
<text top="208" left="81" width="357" height="21" font="1">with access to care. Clin Infect Dis. 2015;60:1278-80. </text>
<text top="228" left="81" width="961" height="21" font="1">235.  Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic </text>
<text top="249" left="81" width="560" height="21" font="1">inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70:482-7. </text>
<text top="269" left="81" width="1025" height="21" font="1">236.  Post WS, Budoff M, Kingsley L, et al. Associations between HIV infection and subclinical coronary atherosclerosis. Ann Intern Med. 2014;160:458-</text>
<text top="289" left="81" width="25" height="21" font="1">67. </text>
<text top="309" left="81" width="961" height="21" font="1">237.  Kao AH, Wasko MC, Krishnaswami S, et al. C-reactive protein and coronary artery calcium in asymptomatic women with systemic lupus </text>
<text top="329" left="81" width="479" height="21" font="1">erythematosus or rheumatoid arthritis. Am J Cardiol. 2008;102:755-60. </text>
<text top="349" left="81" width="1019" height="21" font="1">238.  Kawai VK, Chung CP, Solus JF, et al. The ability of the 2013 American College of Cardiology/American Heart Association cardiovascular risk score </text>
<text top="370" left="81" width="825" height="21" font="1">to identify rheumatoid arthritis patients with high coronary artery calcification scores. Arthritis Rheumatol. 2015;67:381-5. </text>
<text top="390" left="81" width="1022" height="21" font="1">239.  Lerman JB, Joshi AA, Chaturvedi A, et al. Coronary Plaque Characterization in Psoriasis Reveals High-Risk Features That Improve After Treatment </text>
<text top="410" left="81" width="456" height="21" font="1">in a Prospective Observational Study. Circulation. 2017;136:263-76. </text>
<text top="430" left="81" width="985" height="21" font="1">240.  Navarro-Millán I, Charles-Schoeman C, Yang S, et al. Changes in lipoproteins associated with methotrexate or combination therapy in early </text>
<text top="450" left="81" width="784" height="21" font="1">rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. Arthritis Rheum. 2013;65:1430-8. </text>
<text top="470" left="81" width="825" height="21" font="1">241.  Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation. 2013;127:96-103. </text>
<text top="490" left="81" width="1026" height="21" font="1">242.  Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: </text>
<text top="510" left="81" width="434" height="21" font="1">the GAUSS-3 randomized clinical trial. JAMA. 2016;315:1580-90. </text>
<text top="531" left="81" width="957" height="21" font="1">243.  Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin </text>
<text top="551" left="81" width="618" height="21" font="1">rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9:758-69. </text>
<text top="571" left="81" width="873" height="21" font="1">244.  Joy TR, Monjed A, Zou GY, et al. N-of-1 (single-patient) trials for statin-related myalgia. Ann Intern Med. 2014;160:301-10. </text>
<text top="591" left="81" width="959" height="21" font="1">245.  Taylor BA, Lorson L, White CM, et al. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis. </text>
<text top="611" left="81" width="122" height="21" font="1">2015;238:329-35. </text>
<text top="631" left="81" width="1016" height="21" font="1">246.  Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from </text>
<text top="651" left="81" width="292" height="21" font="1">the JUPITER trial. Lancet. 2012;380:565-71. </text>
<text top="671" left="81" width="1013" height="21" font="1">247.  Foster T, Budoff MJ, Saab S, et al. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study </text>
<text top="692" left="81" width="410" height="21" font="1">randomized clinical trial. Am J Gastroenterol. 2011;106:71-7. </text>
<text top="712" left="81" width="967" height="21" font="1">248.  Gupta A, Thompson D, Whitehouse A, et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-</text>
<text top="732" left="81" width="1018" height="21" font="1">Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-</text>
<text top="752" left="81" width="337" height="21" font="1">blind extension phase. Lancet. 2017;389:2473-81. </text>
</page>
<page number="251" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">251 </text>
<text top="108" left="81" width="1006" height="21" font="1">249.  Banach M, Serban C, Sahebkar A, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. </text>
<text top="128" left="81" width="214" height="21" font="1">Mayo Clin Proc. 2015;90:24-34. </text>
<text top="148" left="81" width="975" height="21" font="1">250.  Preiss D, Seshasai SRK, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-</text>
<text top="168" left="81" width="237" height="21" font="1">analysis. JAMA. 2011;305:2556-64. </text>
<text top="188" left="81" width="1007" height="21" font="1">251.  Navarese EP, Buffon A, Andreotti F, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J </text>
<text top="208" left="81" width="186" height="21" font="1">Cardiol. 2013;111:1123-30. </text>
<text top="228" left="81" width="981" height="21" font="1">252.  Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. </text>
<text top="249" left="81" width="122" height="21" font="1">2010;375:735-42. </text>
<text top="269" left="81" width="1012" height="21" font="1">253.  Nieuwkerk PT, Nierman MC, Vissers MN, et al. Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with </text>
<text top="289" left="81" width="433" height="21" font="1">an increased cardiovascular risk. Am J Cardiol. 2012;110:666-72. </text>
<text top="309" left="81" width="910" height="21" font="1">254.  Richardson K, Schoen M, French B, et al. Statins and cognitive function: a systematic review. Ann Intern Med. 2013;159:688-97. </text>
<text top="329" left="81" width="955" height="21" font="1">255.  Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J. 2014;168:6-15. </text>
<text top="349" left="81" width="881" height="21" font="1">256.  Karalis DG, Hill AN, Clifton S, et al. The risks of statin use in pregnancy: A systematic review. J Clin Lipidol. 2016;10:1081-90. </text>
<text top="370" left="81" width="1002" height="21" font="1">257.  Park LG, Howie-Esquivel J, Chung ML, et al. A text messaging intervention to promote medication adherence for patients with coronary heart </text>
<text top="390" left="81" width="503" height="21" font="1">disease: a randomized controlled trial. Patient Educ Couns. 2014;94:261-8. </text>
<text top="410" left="81" width="1018" height="21" font="1">258.  Willich SN, Englert H, Sonntag F, et al. Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 </text>
<text top="430" left="81" width="544" height="21" font="1">patients treated with rosuvastatin. Eur J Cardiovasc Prev Rehabil. 2009;16:180-7. </text>
<text top="450" left="81" width="1015" height="21" font="1">259.  Ma Y, Ockene IS, Rosal MC, et al. Randomized Trial of a Pharmacist-Delivered Intervention for Improving Lipid-Lowering Medication Adherence </text>
<text top="470" left="81" width="526" height="21" font="1">among Patients with Coronary Heart Disease. Cholesterol. 2010;2010:383281. </text>
<text top="490" left="81" width="1012" height="21" font="1">260.  Kooy MJ, van Wijk BL, Heerdink ER, et al. Does the use of an electronic reminder device with or without counseling improve adherence to lipid-</text>
<text top="510" left="81" width="634" height="21" font="1">lowering treatment? The results of a randomized controlled trial. Front Pharmacol. 2013;4:69. </text>
<text top="531" left="81" width="1020" height="21" font="1">261.  Pladevall M, Divine G, Wells KE, et al. A randomized controlled trial to provide adherence information and motivational interviewing to improve </text>
<text top="551" left="81" width="395" height="21" font="1">diabetes and lipid control. Diabetes Educ. 2015;41:136-46. </text>
<text top="571" left="81" width="1001" height="21" font="1">262.  Tamblyn R, Reidel K, Huang A, et al. Increasing the detection and response to adherence problems with cardiovascular medication in primary </text>
<text top="591" left="81" width="824" height="21" font="1">care through computerized drug management systems: a randomized controlled trial. Med Decis Making. 2010;30:176-88. </text>
<text top="611" left="81" width="997" height="21" font="1">263.  Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365:2088-97. </text>
<text top="631" left="81" width="1027" height="21" font="1">264.  Brown BG, Bardsley J, Poulin D, et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein </text>
<text top="651" left="81" width="762" height="21" font="1">cholesterol &lt;100 mg/dl in patients with hyperlipidemia and coronary artery disease. Am J Cardiol. 1997;80:111-5. </text>
<text top="671" left="81" width="938" height="21" font="1">265.  Castellano JM, Sanz G, Penalvo JL, et al. A polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol. </text>
<text top="692" left="81" width="122" height="21" font="1">2014;64:2071-82. </text>
<text top="712" left="81" width="997" height="21" font="1">266.  Patel A, Cass A, Peiris D, et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in </text>
<text top="732" left="81" width="523" height="21" font="1">people at high cardiovascular disease risk. Eur J Prev Cardiol. 2015;22:920-30. </text>
<text top="752" left="81" width="1022" height="21" font="1">267.  Rodgers A, Patel A, Berwanger O, et al. An international randomised placebo-controlled trial of a four-component combination pill (&#34;polypill&#34;) in </text>
<text top="772" left="81" width="440" height="21" font="1">people with raised cardiovascular risk. PLoS One. 2011;6:e19857. </text>
</page>
<page number="252" position="absolute" top="0" left="0" height="918" width="1188">
<text top="54" left="81" width="4" height="21" font="1"> </text>
<text top="54" left="432" width="4" height="21" font="1"> </text>
<text top="54" left="783" width="4" height="21" font="1"> </text>
<text top="54" left="837" width="4" height="21" font="1"> </text>
<text top="54" left="891" width="4" height="21" font="1"> </text>
<text top="54" left="945" width="4" height="21" font="1"> </text>
<text top="825" left="81" width="542" height="19" font="0">© American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="844" left="81" width="29" height="21" font="1">252 </text>
<text top="108" left="81" width="1014" height="21" font="1">268.  Selak V, Elley CR, Bullen C, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of </text>
<text top="128" left="81" width="605" height="21" font="1">cardiovascular disease: randomised controlled trial in primary care. Bmj. 2014;348:g3318. </text>
<text top="148" left="81" width="1027" height="21" font="1">269.  Thom S, Poulter N, Field J, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: </text>
<text top="168" left="81" width="421" height="21" font="1">the UMPIRE randomized clinical trial. JAMA. 2013;310:918-29. </text>
<text top="188" left="81" width="1024" height="21" font="1">270.  Chan WV, Pearson TA, Bennett GC, et al. ACC/AHA special report: clinical practice guideline implementation strategies: a summary of systematic </text>
<text top="208" left="81" width="1006" height="21" font="1">reviews by the NHLBI Implementation Science Work Group: a report of the American College of Cardiology/American Heart Association Task Force on </text>
<text top="228" left="81" width="398" height="21" font="1">Clinical Practice Guidelines. Circulation. 2017;135:e122-37. </text>
<text top="249" left="81" width="936" height="21" font="1">271.  Fischer F, Lange K, Klose K, et al. Barriers and strategies in guideline implementation—a scoping review. Healthcare (Basel). 2016;4: </text>
<text top="269" left="81" width="957" height="21" font="1">272.  Stacey D, Légaré F, Lewis K, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. </text>
<text top="289" left="81" width="128" height="21" font="1">2017;4:CD001431. </text>
<text top="309" left="81" width="976" height="21" font="1">273.  Michelis KC, Hassouna B, Owlia M, et al. Effect of electronic prescription on attainment of cholesterol goals. Clin Cardiol. 2011;34:254-60. </text>
<text top="329" left="81" width="959" height="21" font="1">274.  Watanabe JH, Kazerooni R, Bounthavong M. Association of copayment with likelihood and level of adherence in new users of statins: a </text>
<text top="349" left="81" width="436" height="21" font="1">retrospective cohort study. J Manag Care Pharm. 2014;20:43-50. </text>
<text top="370" left="81" width="1020" height="21" font="1">275.  Navar AM, Taylor B, Mulder H, et al. Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy. </text>
<text top="390" left="81" width="211" height="21" font="1">JAMA Cardiol. 2017;2:1217-25. </text>
<text top="410" left="81" width="987" height="21" font="1">276.  Hess GP, Natarajan P, Faridi KF, et al. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and </text>
<text top="430" left="81" width="535" height="21" font="1">Patient Characteristics for Successful Prescribing. Circulation. 2017;136:2210-9. </text>
<text top="450" left="81" width="1013" height="21" font="1">277.  Kazi DS, Moran AE, Coxson PG, et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia </text>
<text top="470" left="81" width="449" height="21" font="1">or atherosclerotic cardiovascular disease. JAMA. 2016;316:743-53. </text>
<text top="490" left="81" width="991" height="21" font="1">278.  Kazi DS, Penko J, Coxson PG, et al. Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial. Jama. </text>
<text top="510" left="81" width="122" height="21" font="1">2017;318:748-50. </text>
<text top="531" left="81" width="987" height="21" font="1">279.  Gandra SR, Villa G, Fonarow GC, et al. Cost-effectiveness of LDL-C lowering with evolocumab in patients with high cardiovascular risk in the </text>
<text top="551" left="81" width="296" height="21" font="1">United States. Clin Cardiol. 2016;39:313-20. </text>
<text top="571" left="81" width="967" height="21" font="1">280.  Toth PP, Danese M, Villa G, et al. Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, </text>
<text top="591" left="81" width="712" height="21" font="1">secondary-prevention population in the US payer context. Journal of medical economics. 2017;20:555-64. </text>
<text top="611" left="81" width="971" height="21" font="1">281.  Fonarow GC, Keech AC, Pedersen TR, et al. Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with </text>
<text top="631" left="81" width="474" height="21" font="1">atherosclerotic cardiovascular disease. JAMA Cardiol. 2017;2:1069-78. </text>
<text top="651" left="81" width="995" height="21" font="1">282.  Arrieta A, Page TF, Veledar E, et al. Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private </text>
<text top="671" left="81" width="339" height="21" font="1">Payer Perspectives. PLoS One. 2017;12:e0169761. </text>
<text top="690" left="81" width="4" height="24" font="4"><b> </b></text>
</page>
<outline>
<item page="4">Data Supplement 1. Nonrandomized Trials, Observational Studies, and/or Registries of Q3: Evidence regarding the difference in lipid levels measured in fasting and non-fasting individuals, and associations with outcomes (Section 2.2)</item>
<item page="12">Data Supplement 2. RCTs of Statin Therapy for Primary Prevention of ASCVD Among Patients with the Metabolic Syndrome or its Subcomponents (Section 3.1.2)</item>
<item page="15">Data Supplement 3. Meta-analyses comparing statins versus placebo or various intensities of statin therapy (Section 3.2)</item>
<item page="17">Data Supplement 4. Risk stratification among patients with ASCVD to identify those most likely to benefit from non-statin therapy (Section 3.2.2)</item>
<item page="20">Data Supplement 5. RCTs of Non-Statin or Combination Lipid Lowering Therapy for Primary Prevention of ASCVD Among Patients with the Metabolic Syndrome or its Subcomponents (Section 3.2.3)</item>
<item page="22">Data Supplement 6. Evidence Tables for Statin initiation in patients with heart failure meta-analysis of CORONA and GISSI HF trials (Section 4.1)</item>
<item page="26">Data Supplement 7. Meta-analysis of CORONA and GISSI HF trials (Section 4.1)</item>
<item page="32">Data Supplement 8. Evidence Tables for Secondary Prevention (Section 4.1)</item>
<item page="39">Data Supplement 9. RCTs comparing evidence on Severe Hypercholesterolemia (Section 4.2)</item>
<item page="46">Data Supplement 10. Non-randomized Trials, Observational Studies and/or Registries for Severe Hypercholesterolemia (Section 4.2)</item>
<item page="51">Data Supplement 11. Nonrandomized Trials, Observational Studies, and/or Registries of Diabetes Mellitus 40-75 Years (Section 4.3)</item>
<item page="58">Data Supplement 12. RCTs Comparing Diabetes Mellitus 40-75 Years (Section 4.3)</item>
<item page="64">Data Supplement 13. Nonrandomized Trials, Observational Studies, and/or Registries of ASCVD Risk Associated with the Metabolic Syndrome (Section 4.4.1)</item>
<item page="65">Data Supplement 14. Nonrandomized Trials, Observational Studies, and/or Registries of Q1: Performance of the Pooled Cohort Equations (PCE) when used for the prediction of first incident atherosclerotic cardiovascular disease (ASCVD) events in diverse ...</item>
<item page="84">Data Supplement 15. Nonrandomized Trials, Observational Studies, and/or Registries of Q2: Performance of coronary artery calcium screening to reclassify risk appropriately for atherosclerotic cardiovascular disease (ASCVD) events when used for the pre...</item>
<item page="101">Data Supplement 16. Evidence Tables for Borderline and Intermediate Risk Group (5-&lt;7.5%; 7.5 to 20%) (Section 4.4.2)</item>
<item page="104">Data Supplement 17. Evidence Tables Monitoring in Response to LDL-C–Lowering Therapy (Section 4.4.3)</item>
<item page="107">Data Supplement 18. Evidence Table to discontinue therapy (Section 4.4.4.1)</item>
<item page="109">Data Supplement 19. Evidence Table for Statin therapy for adults &gt;75 years (Section 4.4.4.1)</item>
<item page="115">Data Supplement 20. Nonrandomized Trials, Observational Studies, and/or Registries of Q4: Evidence regarding the cost-effectiveness of screening for familial hypercholesterolemia (Section 4.4.4.3)</item>
<item page="121">Data Supplement 21. RCTs Comparing Screening of Children and Adolescents (Section 4.4.4.3)</item>
<item page="131">Data Supplement 22. Nonrandomized Trials, Observational Studies, and/or Registries of Metabolic Syndrome of Children and Adolescents (Section 4.4.4.3)</item>
<item page="134">Data Supplement 23. Nonrandomized Trials, Observational Studies, and/or Registries of Treatment (Section 4.4.4.3)</item>
<item page="135">Data Supplement 24. Nonrandomized Trials, observational studies and / Registries for African Americans. (Section 4.5.1)</item>
<item page="138">Data Supplement 25. Nonrandomized Trials, Observational Studies, and/or Registries of Pooled Cohorts Equation Risk Estimation in Adults of Asian Descent (Section 4.5.1)</item>
<item page="141">Data Supplement 26. Nonrandomized Trials, Observational Studies, and/or Registries of Hispanic (Section 4.5.1)</item>
<item page="143">Data Supplement 27. Nonrandomized Trials, Observational Studies, and/or Registries of Hispanic (Section 4.5.1)</item>
<item page="148">Data Supplement 28. Nonrandomized Trials, Observational Studies, and/or Registries of Hispanic (Section 4.5.1)</item>
<item page="151">Data Supplement 29. Nonrandomized Trials, Observational Studies, and/or Registries of Hispanics (Section 4.5.1)</item>
<item page="153">Data Supplement 30 Nonrandomized Trials, Observational Studies, and/or Registries of Hispanic (Section 4.5.1)</item>
<item page="155">Data Supplement 31. Hypertriglyceridemia: RCT, Meta Analyses (4.5.2)</item>
<item page="161">Data Supplement 32. Hypertriglyceridemia: Observational Studies (Section 4.5.2)</item>
<item page="166">Data Supplement 33. Randomized Trials of Statins in Women for Primary Prevention of CVD (Section 4.5.3.)</item>
<item page="180">Data Supplement 34. Nonrandomized Studies of the Utility of Coronary Artery Calcium in Women (Section 4.5.3)</item>
<item page="186">Data Supplement 35. CAC to guide therapy (Section 4.5.3)</item>
<item page="187">Data Supplement 36. Nonrandomized Trials, Observational Studies, and/or Registries of Chronic Kidney Disease and Cardiovascular Risk (Section 4.5.4)</item>
<item page="190">Data Supplement 37. RCTs Comparing PLACEBO VS. Statin (or Statin plus another agent) to reduce CVD events in persons with CKD (Section 4.5.4)</item>
<item page="195">Data Supplement 38. RCTs Comparing PLACEBO VS. Statin (or Statin plus another agent) to reduce CVD events in persons with Albuminuria and preserved eGFR (Section 4.5.4)</item>
<item page="196">Data Supplement 39. Nonrandomized Trials, Observational Studies, and/or Registries of HIV/Inflammatory Diseases (Section 4.5.5)</item>
<item page="205">Data Supplement 40. RCTs Comparing Statin Safety and Statin Associated Side Effects (Section 5)</item>
<item page="210">Data Supplement 41. Nonrandomized Trials, Observational Studies, Meta-analyses and/or Registries of Statin Safety and Statin-Associated Side Effects (Section 5)</item>
<item page="215">Data Supplement 42. RCTs Comparing Patient Interventions to Usual Care (Section 6)</item>
<item page="219">Data Supplement 43. RCTs Comparing System Interventions to Usual Care (Section 6)</item>
<item page="221">Data Supplement 44. RCTs Comparing Small Number of Pills/Day to Large Number of Pills/Day (Section 6)</item>
<item page="225">Data Supplement 45. RCTs for Implementation (Section 6)</item>
<item page="227">Data Supplement 46. Nonrandomized Trials, Observational Studies, and/or Registries for Implementation (Section 6)</item>
<item page="234">Data Supplement 47. Cost-Effectiveness Models of PCKS9 Inhibitors in Secondary Prevention (Section 7)</item>
<item page="235">Data Supplement 48. Cost-Effectiveness Models of PCKS9 Inhibitors in Primary Prevention (Familial Hypercholesterolemia) (Section 7)</item>
<item page="236">References</item>
</outline>
</pdf2xml>
